pmid	doi	year	title	Hugo_Symbol
35255429	10.1016/j.anndiagpath.2021.151886	2022	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.	ACTB
35344115	10.1007/s11033-022-07337-w	2022	Identification and validation of suitable housekeeping genes for gene expression studies in BCR-ABL1 positive B-lineage acute lymphoblastic leukemia.	ACTB
35765478	10.14202/vetworld.2022.1333-1340	2022	Investigation of proteomic profiles in canine lymphoma using tandem mass tag-based quantitative proteomics approach.	ACTB
33404293	10.1080/15548627.2020.1871204	2021	BNIP3L-mediated mitophagy is required for mitochondrial remodeling during the differentiation of optic nerve oligodendrocytes.	ACTB
33952317	10.1186/s13148-021-01091-9	2021	Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors.	ACTB
34598060	10.1016/j.ctarc.2021.100465	2021	Prioritising breast cancer theranostics: A current medical longing in oncology.	ACTB
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	ACTB
31242129	10.1080/15548627.2019.1635380	2020	<i>MIR145-3p</i> promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting <i>HDAC4</i>.	ACTB
32349449	10.3390/ijms21093093	2020	Prevalence of Cytoplasmic Actin Mutations in Diffuse Large B-Cell Lymphoma and Multiple Myeloma: A Functional Assessment Based on Actin Three-Dimensional Structures.	ACTB
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	ACTB
31108950	10.3390/genes10050376	2019	Identification and Validation of Novel Reference Genes in Acute Lymphoblastic Leukemia for Droplet Digital PCR.	ACTB
29433359	10.1080/15548627.2017.1390636	2018	Piperlongumine restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models.	ACTB
27868373	10.1002/ajmg.a.38057	2017	Acute myeloid leukemia in Baraitser-Winter cerebrofrontofacial syndrome.	ACTB
28807016	10.1186/s12885-017-3536-6	2017	Endogenous controls of gene expression in N-methyl-N-nitrosourea-induced T-cell lymphoma in p53-deficient mice.	ACTB
26852652	10.1016/j.bcmd.2015.11.006	2016	ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia.	ACTB
25052316	10.1038/ejhg.2014.95	2015	Baraitser-Winter cerebrofrontofacial syndrome: delineation of the spectrum in 42 cases.	ACTB
25696013	NA	2015	Selection of superior reference genes' combination for quantitative real-time PCR in B-cell lymphomas.	ACTB
25715028	10.1080/15548627.2015.1017191	2015	BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy.	ACTB
25984893	10.1080/15548627.2015.1034402	2015	The GST-BHMT assay reveals a distinct mechanism underlying proteasome inhibition-induced macroautophagy in mammalian cells.	ACTB
26043155	10.1080/15548627.2015.1055439	2015	TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy.	ACTB
24275555	10.1016/j.bbadis.2013.11.021	2014	Peri-conceptional obesogenic exposure induces sex-specific programming of disease susceptibilities in adult mouse offspring.	ACTB
24418552	10.1016/j.virol.2013.11.022	2014	HTLV-1 infects human mesenchymal stromal cell in vitro and modifies their phenotypic characteristics.	ACTB
23266771	10.1016/j.cca.2012.12.012	2013	ACTB in cancer.	ACTB
23326330	10.1371/journal.pone.0052384	2013	Activated ERM protein plays a critical role in drug resistance of MOLT4 cells induced by CCL25.	ACTB
23849470	10.1186/1756-8722-6-52	2013	Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner.	ACTB
22343534	10.1073/pnas.1121343109	2012	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	ACTB
19309015	10.1002/elps.200800508	2009	2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma.	ACTB
20031021	10.1016/j.rbmo.2009.09.024	2009	Apoptosis in normal ovaries of women with and without endometriosis.	ACTB
17823310	10.1182/blood-2007-04-087775	2007	HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration.	ACTB
16105984	10.1182/blood-2005-03-1204	2005	p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.	ACTB
1505215	10.1159/000133336	1992	Sublocalization of an invasion-inducing locus and other genes on human chromosome 7.	ACTB
34265801	10.1097/PAS.0000000000001780	2022	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.	ARID1A
34560683	10.1097/PAS.0000000000001813	2022	A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients.	ARID1A
34649275	10.1182/bloodadvances.2021005316	2022	Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity.	ARID1A
34791836	10.1002/cam4.4422	2022	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.	ARID1A
35038193	10.1111/his.14617	2022	Incidence, clinicopathological features and genetics of in-situ follicular neoplasia: a comprehensive screening study in a Japanese cohort.	ARID1A
35054466	10.3390/life12010073	2022	The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma.	ARID1A
35172382	10.1002/JLB.5A0721-361R	2022	Genomic heterogeneity contributed to different prognosis between adult and pediatric acute lymphoblastic.	ARID1A
35317330	10.14740/wjon1436	2022	Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis.	ARID1A
35454811	10.3390/cancers14081904	2022	Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.	ARID1A
35727053	10.1002/cncr.34348	2022	Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.	ARID1A
35794096	10.1038/s41467-022-31355-8	2022	Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.	ARID1A
35879731	10.1186/s40364-022-00401-4	2022	Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma.	ARID1A
36001451	10.1097/PAS.0000000000001956	2022	Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.	ARID1A
33431788	10.1038/s41392-020-00437-8	2021	CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.	ARID1A
33829512	10.1111/his.14378	2021	Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma.	ARID1A
34039950	10.1038/s41408-021-00493-5	2021	Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.	ARID1A
34070951	10.3390/diagnostics11060999	2021	Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma.	ARID1A
34348985	10.1136/jclinpath-2021-207441	2021	Clinicopathological characteristics and genetic variations of uterine tumours resembling ovarian sex cord tumours.	ARID1A
31423576	10.1111/bjh.16159	2020	M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.	ARID1A
32083995	10.1200/JCO.19.02314	2020	Genomic Landscape of Waldenstr√∂m Macroglobulinemia and Its Impact on Treatment Strategies.	ARID1A
32918521	10.1002/pbc.28704	2020	Aggressive Langerhans cell histiocytosis following T-cell acute lymphoblastic leukemia.	ARID1A
32978169	10.1158/0008-5472.CAN-20-2147	2020	EZH2-Targeted Therapies in Cancer: Hype or a Reality.	ARID1A
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	ARID1A
33376237	10.1038/s41392-020-00331-3	2020	Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.	ARID1A
30886885	10.1016/j.gore.2019.02.007	2019	Endometrial cancer arising after complete remission of uterine malignant lymphoma: A case report and mutation analysis.	ARID1A
31123138	10.1136/jclinpath-2019-205727	2019	Intravascular NK/T-cell lymphoma: clinicopathological and integrated molecular analysis of two cases provides a clue to disease pathogenesis.	ARID1A
31300419	10.1182/bloodadvances.2018029546	2019	Sporadic and endemic Burkitt lymphoma have frequent <i>FOXO1</i> mutations but distinct hotspots in the AKT recognition motif.	ARID1A
31747604	10.1016/j.celrep.2019.10.083	2019	Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.	ARID1A
29307627	10.1016/j.humpath.2017.12.025	2018	Dedifferentiated liposarcoma composed predominantly of rhabdoid/epithelioid cells: a frequently misdiagnosed highly aggressive variant.	ARID1A
29486633	10.1177/1533034618754475	2018	Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma.	ARID1A
29669287	10.1016/j.celrep.2018.03.078	2018	ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.	ARID1A
29989027	10.18632/oncotarget.25601	2018	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	ARID1A
30134235	10.1159/000492835	2018	Frequent Mutations in Natural Killer/T Cell Lymphoma.	ARID1A
30190015	10.1016/j.hoc.2018.05.007	2018	Working Toward a Genomic Prognostic Classification of Waldenstr√∂m Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.	ARID1A
27872090	10.1158/0008-5472.CAN-16-1303	2017	Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia.	ARID1A
28401006	NA	2017	Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.	ARID1A
29025291	10.1556/650.2017.30868	2017	[Waldenstr√∂m's macroglobulinemia and its individualized therapy options].	ARID1A
29222279	10.1182/asheducation-2017.1.358	2017	Follicular lymphoma: are we ready for a risk-adapted approach?	ARID1A
26839360	10.1136/thoraxjnl-2015-207950	2016	A patient with complex multiple genomic ALK alterations.	ARID1A
27102345	10.1038/modpathol.2016.79	2016	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.	ARID1A
27590521	10.18632/oncotarget.11773	2016	Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.	ARID1A
27729836	10.5808/GI.2016.14.3.78	2016	Mutational Analysis of Extranodal NK/T-Cell Lymphoma Using Targeted Sequencing with a Comprehensive Cancer Panel.	ARID1A
25444907	10.1016/j.canlet.2014.11.024	2015	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	ARID1A
25779943	10.1158/1078-0432.CCR-14-2759	2015	Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.	ARID1A
25918285	10.1200/JCO.2014.59.2444	2015	Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing.	ARID1A
26192917	10.1038/ng.3358	2015	Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.	ARID1A
26256760	10.1016/S1470-2045(15)00169-2	2015	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	ARID1A
26415585	10.1038/ncomms9470	2015	Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in S√©zary syndrome.	ARID1A
26446488	10.1038/ncomms9325	2015	LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair.	ARID1A
26468873	10.1371/journal.ppat.1005158	2015	Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma.	ARID1A
26473533	10.1038/bcj.2015.89	2015	Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.	ARID1A
26551670	10.1038/ng.3444	2015	Genomic profiling of S√©zary syndrome identifies alterations of key T cell signaling and differentiation genes.	ARID1A
24366360	10.1182/blood-2013-09-525808	2014	The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.	ARID1A
24435047	10.1182/blood-2013-05-500264	2014	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	ARID1A
23292937	10.1073/pnas.1205299110	2013	Genetic heterogeneity of diffuse large B-cell lymphoma.	ARID1A
22585168	10.1158/2159-8290.CD-11-0208	2012	Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.	ARID1A
22915242	10.1007/s00428-012-1303-2	2012	ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability.	ARID1A
22931316	10.1056/NEJMoa1200710	2012	MYD88 L265P somatic mutation in Waldenstr√∂m's macroglobulinemia.	ARID1A
23091298	10.1182/blood-2012-06-437624	2012	Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in antiapoptotic and chromatin-remodeling genes.	ARID1A
23143597	10.1038/ng.2468	2012	The genetic landscape of mutations in Burkitt lymphoma.	ARID1A
21590771	10.1002/path.2911	2011	Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.	ARID1A
19066270	10.1093/jnci/djn416	2008	The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.	ARID1A
33788417	10.1002/pbc.29036	2021	Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene.	ARID5B
33891562	10.18632/aging.202903	2021	Age-related differences of genetic susceptibility to patients with acute lymphoblastic leukemia.	ARID5B
31573954	10.1158/1078-0432.CCR-19-0190	2020	<i>ARID5B</i> Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia.	ARID5B
31704777	10.1136/jmedgenet-2019-106339	2020	Novel phenotypes observed in patients with <i>ETV6</i>-linked leukaemia/familial thrombocytopenia syndrome and a biallelic <i>ARID5B</i> risk allele as leukaemogenic cofactor.	ARID5B
31870219	10.1080/08880018.2019.1705949	2020	Association of <i>ABCC2</i> with levels and toxicity of methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL).	ARID5B
32488880	10.1002/jcla.23414	2020	Association of TLX1 gene polymorphisms with the risk of acute lymphoblastic leukemia and B lineage acute lymphoblastic leukemia in Han Chinese children.	ARID5B
30770347	10.1158/1055-9965.EPI-18-0801	2019	Is There Etiologic Heterogeneity between Subtypes of Childhood Acute Lymphoblastic Leukemia? A Review of Variation in Risk by Subtype.	ARID5B
30810385	10.1089/gtmb.2018.0283	2019	Association of ARID5B and IKZF1 Variants with Leukemia from Northern India.	ARID5B
31076442	10.1182/blood.2018874503	2019	The enhancer RNA <i>ARIEL</i> activates the oncogenic transcriptional program in T-cell acute lymphoblastic leukemia.	ARID5B
31111395	10.1007/s12185-019-02658-2	2019	ARID5B gene polymorphisms and the risk of childhood acute lymphoblastic leukemia: a meta-analysis.	ARID5B
31221981	10.1038/s12276-019-0230-6	2019	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.	ARID5B
31227872	10.1007/s00277-019-03730-x	2019	Variants in ARID5B gene are associated with the development of acute lymphoblastic leukemia in Mexican children.	ARID5B
31274788	10.1097/JCMA.0000000000000038	2019	Genetic polymorphisms of ARID5B rs7089424 and rs10994982 are associated with B-lineage ALL susceptibility in Chinese pediatric population.	ARID5B
31350265	10.1182/blood.2018890764	2019	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome.	ARID5B
31424309	10.1080/08880018.2019.1649333	2019	<i>ARID5B</i> rs10821936 and rs10994982 gene polymorphisms and acute lymphoblastic leukemia: relation to disease susceptibility and outcome.	ARID5B
31800538	10.1097/JCMA.0000000000000197	2019	ARID5B rs7089424 and rs10994982 and association with B-lineage ALL susceptibility.	ARID5B
31800539	10.1097/JCMA.0000000000000198	2019	Reply to ARID5B rs7089424 and rs10994982 and association with B-lineage ALL susceptibility.	ARID5B
29335448	10.1038/s41598-017-19127-7	2018	Regional evaluation of childhood acute lymphoblastic leukemia genetic susceptibility loci among Japanese.	ARID5B
29504848	10.1080/08916934.2018.1446525	2018	Signalling pathways identified in salivary glands from primary Sj√∂gren's syndrome patients reveal enhanced adipose tissue development.	ARID5B
29654272	10.1038/s41375-018-0110-4	2018	Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia.	ARID5B
28256501	10.1038/ncomms14616	2017	Genetic and regulatory mechanism of susceptibility to high-hyperdiploid acute lymphoblastic leukaemia at 10p21.2.	ARID5B
28381164	10.1177/1010428317697573	2017	Association of ARID5B gene variants with acute lymphoblastic leukemia in Yemeni children.	ARID5B
28751478	10.1158/1055-9965.EPI-17-0360	2017	Novel Gene and Network Associations Found for Acute Lymphoblastic Leukemia Using Case-Control and Family-Based Studies in Multiethnic Populations.	ARID5B
28817678	10.1371/journal.pone.0180488	2017	Family-based exome-wide association study of childhood acute lymphoblastic leukemia among Hispanics confirms role of ARID5B in susceptibility.	ARID5B
28905228	10.1007/s12032-017-1038-7	2017	Genetic susceptibility in childhood acute lymphoblastic leukemia.	ARID5B
29326336	10.1101/gad.302646.117	2017	ARID5B as a critical downstream target of the TAL1 complex that activates the oncogenic transcriptional program and promotes T-cell leukemogenesis.	ARID5B
26941364	10.1158/1055-9965.EPI-15-0528	2016	Pathway Analysis of Genome-wide Association Study in Childhood Leukemia among Hispanics.	ARID5B
27184773	10.3109/08880018.2016.1161685	2016	Association of genetic variation in IKZF1, ARID5B, CDKN2A, and CEBPE with the risk of acute lymphoblastic leukemia in Tunisian children and their contribution to racial differences in leukemia incidence.	ARID5B
27644650	NA	2016	Association of Genetic Variants in ARID5B, IKZF1 and CEBPE with Risk of Childhood de novo B-Lineage Acute Lymphoblastic Leukemia in India.	ARID5B
28476190	10.1016/j.arcmed.2016.12.003	2016	ARID5B, CEBPE and PIP4K2A Germline Genetic Polymorphisms and Risk of Childhood Acute Lymphoblastic Leukemia in Mexican Patients: A¬†MIGICCL Study.	ARID5B
24707947	10.3109/10428194.2014.910662	2015	Genetic markers in a multi-ethnic sample for childhood acute lymphoblastic leukemia risk.	ARID5B
25005032	10.3109/10428194.2014.933479	2015	Childhood acute lymphoblastic leukemia-associated risk-loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin-Frankfurt-M√ºnster Study Group.	ARID5B
25150625	10.1016/j.bcmd.2014.07.011	2015	Concordant B-cell precursor acute lymphoblastic leukemia in non-twinned siblings.	ARID5B
25761407	10.1007/s10552-015-0550-3	2015	Association of genetic variation in IKZF1, ARID5B, and CEBPE and surrogates for early-life infections with the risk of acute lymphoblastic leukemia in Hispanic children.	ARID5B
25806972	10.1371/journal.pone.0121348	2015	ARID5B, IKZF1 and non-genetic factors in the etiology of childhood acute lymphoblastic leukemia: the ESCALE study.	ARID5B
26104880	10.1038/ncomms8553	2015	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children.	ARID5B
26575185	10.1371/journal.pone.0143343	2015	Somatic Mutation Allelic Ratio Test Using ddPCR (SMART-ddPCR): An Accurate Method for Assessment of Preferential Allelic Imbalance in Tumor DNA.	ARID5B
23975371	10.1007/s13277-013-1097-0	2014	ARID5B gene rs10821936 polymorphism is associated with childhood acute lymphoblastic leukemia: a meta-analysis based on 39,116 subjects.	ARID5B
24200646	10.1016/j.bcmd.2013.10.003	2014	High-resolution melting analyses for genetic variants in ARID5B and IKZF1 with childhood acute lymphoblastic leukemia susceptibility loci in Taiwan.	ARID5B
24497567	10.3324/haematol.2013.090720	2014	Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group.	ARID5B
24712521	10.1111/bjh.12886	2014	Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.	ARID5B
24753091	10.1002/ajh.23727	2014	Genomic ancestry and somatic alterations correlate with age at diagnosis in Hispanic children with B-cell acute lymphoblastic leukemia.	ARID5B
25096228	10.1159/000363660	2014	A new system identification approach to identify genetic variants in sequencing studies for a binary phenotype.	ARID5B
25124600	10.7314/apjcp.2014.15.15.6211	2014	Associations between AT-rich interactive domain 5B gene polymorphisms and risk of childhood acute lymphoblastic leukemia: a meta-analysis.	ARID5B
25297793	NA	2014	Genomic evaluations of childhood acute lymphoblastic leukemia susceptibility across race/ethnicities.	ARID5B
25310577	10.1371/journal.pone.0110255	2014	Confirmation of childhood acute lymphoblastic leukemia variants, ARID5B and IKZF1, and interaction with parental environmental exposures.	ARID5B
22422485	10.1002/pbc.24131	2013	Genetic variants modify susceptibility to leukemia in infants: a Children's Oncology Group report.	ARID5B
23382691	10.1371/journal.pgen.1003225	2013	Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers.	ARID5B
23512250	10.1093/jnci/djt042	2013	Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.	ARID5B
23608171	10.1016/j.gene.2013.04.028	2013	Association of three polymorphisms in ARID5B, IKZF1 and CEBPE with the risk of childhood acute lymphoblastic leukemia in a Chinese population.	ARID5B
23692655	10.1016/j.leukres.2013.04.022	2013	ARID5B and IKZF1 variants, selected demographic factors, and childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.	ARID5B
23836053	10.1007/s10552-013-0256-3	2013	Genetic variants in ARID5B and CEBPE are childhood ALL susceptibility loci in Hispanics.	ARID5B
23996088	10.1182/blood-2013-03-491316	2013	Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype.	ARID5B
24013273	10.1007/s00432-013-1512-3	2013	Intron 3 of the ARID5B gene: a hot spot for acute lymphoblastic leukemia susceptibility.	ARID5B
22076464	10.1038/leu.2011.302	2012	Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia.	ARID5B
22291082	10.1200/JCO.2011.38.0345	2012	ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.	ARID5B
22660188	10.1038/leu.2012.148	2012	Genetic polymorphisms and childhood acute lymphoblastic leukemia: GWAS of the ESCALE study (SFCE).	ARID5B
23016962	10.1111/bjh.12063	2012	Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study.	ARID5B
23021489	10.1186/1755-8794-5-42	2012	Candidate gene association study in pediatric acute lymphoblastic leukemia evaluated by Bayesian network based Bayesian multilevel analysis of relevance.	ARID5B
23114164	NA	2012	[Research advances on correlation of ARID5B gene with childhood acute lymphoblastic leukemia - review].	ARID5B
21889209	10.1016/j.leukres.2011.07.034	2011	Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population.	ARID5B
20042726	10.1182/blood-2009-09-241513	2010	Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood.	ARID5B
20054350	10.1038/leu.2009.277	2010	ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence.	ARID5B
20189245	10.1016/j.leukres.2010.02.001	2010	Genome-wide association study of childhood acute lymphoblastic leukemia in Korea.	ARID5B
20460642	10.3324/haematol.2010.022459	2010	Replication analysis confirms the association of ARID5B with childhood B-cell acute lymphoblastic leukemia.	ARID5B
20538337	10.1016/j.leukres.2010.05.013	2010	Genetic variation and the risk of acute lymphoblastic leukemia.	ARID5B
21098271	10.1073/pnas.1006981107	2010	Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.	ARID5B
19684603	10.1038/ng.432	2009	Germline genomic variants associated with childhood acute lymphoblastic leukemia.	ARID5B
19684604	10.1038/ng.430	2009	Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia.	ARID5B
19710713	10.1038/ng0909-957	2009	Inherited susceptibility to pediatric acute lymphoblastic leukemia.	ARID5B
34791836	10.1002/cam4.4422	2022	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.	ATP6AP1
35482846	10.1080/15548627.2022.2071382	2022	Mutations in V-ATPase in follicular lymphoma activate autophagic flux creating a targetable dependency.	ATP6AP1
26691987	10.1038/ng.3473	2016	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.	ATP6AP1
25713363	10.1073/pnas.1501199112	2015	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.	ATP6AP1
35482846	10.1080/15548627.2022.2071382	2022	Mutations in V-ATPase in follicular lymphoma activate autophagic flux creating a targetable dependency.	ATP6V1B2
30720463	10.1172/JCI98288	2019	Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR.	ATP6V1B2
26691987	10.1038/ng.3473	2016	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.	ATP6V1B2
25713363	10.1073/pnas.1501199112	2015	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.	ATP6V1B2
34560683	10.1097/PAS.0000000000001813	2022	A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients.	B2M
34614146	10.1182/blood.2020010263	2022	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials.	B2M
34664256	10.1111/bjh.17894	2022	Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.	B2M
35075971	10.1080/10428194.2021.2010060	2022	Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study.	B2M
35368100	10.1002/hon.2994	2022	A novel clinical immune-related prognostic model predicts the overall survival of mantle cell lymphoma.	B2M
35611992	10.1002/gcc.23069	2022	Primary mediastinal large B-cell lymphoma is characterized by large-scale copy-neutral loss of heterozygosity.	B2M
35795062	10.3389/fonc.2022.870487	2022	Plasma Concentrations and Cancer-Associated Mutations in Cell-Free Circulating DNA of Treatment-Naive Follicular Lymphoma for Improved Non-Invasive Diagnosis and Prognosis.	B2M
35885481	10.3390/diagnostics12071575	2022	Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma.	B2M
36001451	10.1097/PAS.0000000000001956	2022	Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.	B2M
36055572	10.1016/j.clim.2022.109105	2022	A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.	B2M
32079702	10.3324/haematol.2019.237719	2021	Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study.	B2M
32961552	10.1182/blood.2020007507	2021	Mutational landscape of gray zone lymphoma.	B2M
32964767	10.1080/10428194.2020.1821011	2021	Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas.	B2M
33311649	10.1038/s41379-020-00720-7	2021	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.	B2M
33332932	10.4143/crt.2020.1060	2021	Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum Œ≤2-microglobulin Levels.	B2M
33567641	10.3390/cancers13040682	2021	Genomic Landscape of Hodgkin Lymphoma.	B2M
33569430	10.21037/atm-20-7574	2021	Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity.	B2M
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	B2M
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	B2M
33964277	10.1016/j.humpath.2021.04.014	2021	Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma.	B2M
34050029	10.1073/pnas.2104504118	2021	Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma.	B2M
34050261	10.1038/s41375-021-01284-4	2021	Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young age.	B2M
34312841	10.1111/bjh.17719	2021	Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.	B2M
34374220	10.1002/cjp2.223	2021	c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.	B2M
34478526	10.1182/bloodadvances.2021005215	2021	Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.	B2M
35008340	10.3390/cancers14010176	2021	Recent Advances in the Genetic of MALT Lymphomas.	B2M
31242129	10.1080/15548627.2019.1635380	2020	<i>MIR145-3p</i> promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting <i>HDAC4</i>.	B2M
31782146	10.1111/bjh.16263	2020	New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).	B2M
31804029	10.1111/ejh.13364	2020	Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era.	B2M
31822802	10.1038/s41379-019-0428-0	2020	Diagnostic utility of STAT6<sup>YE361</sup> expression in classical Hodgkin lymphoma and related entities.	B2M
32172489	10.1007/s10637-020-00916-3	2020	Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.	B2M
32304999	10.1016/j.ebiom.2020.102731	2020	Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.	B2M
32399964	10.1002/ijc.33049	2020	Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.	B2M
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	B2M
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	B2M
30108156	10.1634/theoncologist.2018-0058	2019	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.	B2M
30591526	10.1182/blood-2018-08-862292	2019	Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints.	B2M
30792096	10.1016/j.clml.2019.01.003	2019	Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.	B2M
30942640	10.1080/10428194.2019.1594212	2019	Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma.	B2M
31006875	10.1002/ajh.25493	2019	Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma.	B2M
31205619	10.1016/j.csbj.2019.03.006	2019	Application of PD-1 Blockade in Cancer Immunotherapy.	B2M
31211907	10.1111/ejh.13274	2019	The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma.	B2M
31292115	10.1182/blood.2019001126	2019	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.	B2M
31324639	10.1182/bloodadvances.2018026591	2019	IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia.	B2M
31423206	10.3892/ol.2019.10410	2019	Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.	B2M
31597848	10.11406/rinketsu.60.1229	2019	[The immune microenvironment in malignant lymphoma].	B2M
31631675	10.2217/bmm-2019-0303	2019	Systemic immune-inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma.	B2M
31697821	10.1182/blood.2019002067	2019	Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.	B2M
31816062	10.1182/bloodadvances.2019001012	2019	Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.	B2M
29289361	10.1016/j.blre.2017.12.001	2018	The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.	B2M
29394125	10.1200/JCO.2017.77.3994	2018	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.	B2M
29625928	10.1016/j.clml.2018.03.005	2018	Serum Free Light Chain Difference and Œ≤<sub>2</sub> Microglobulin Levels Are Risk Factors for Thromboembolic Events in Patients With AL¬†Amyloidosis.	B2M
29657120	10.1016/j.canrad.2017.11.005	2018	Breast lymphoma occurring after an invasive ductal breast carcinoma developed in the same area: A case report and literature review.	B2M
29857068	10.1016/j.jid.2018.04.038	2018	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.	B2M
29872358	10.1177/1179299X18776974	2018	Clean Colorectum at Diagnostic Colonoscopy: Subsequent Detection of Extracolonic Malignancies by Plasma Protein Biomarkers?	B2M
30087457	10.1038/s41374-018-0096-6	2018	Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues.	B2M
28302137	10.1186/s13045-017-0438-7	2017	Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.	B2M
28372509	10.1080/10428194.2017.1307981	2017	FcŒ≥RIIb expression in early stage chronic lymphocytic leukemia.	B2M
28398499	10.1093/annonc/mdx128	2017	Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.	B2M
28419429	10.1111/bjh.14633	2017	Mutational landscape of B-cell post-transplant lymphoproliferative disorders.	B2M
28807016	10.1186/s12885-017-3536-6	2017	Endogenous controls of gene expression in N-methyl-N-nitrosourea-induced T-cell lymphoma in p53-deficient mice.	B2M
29228708	10.18632/oncotarget.21963	2017	Blood biomarkers in adults with lymph node enlargement contribute to diagnostic significance of malignancy.	B2M
25689467	10.1002/hon.2188	2016	Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.	B2M
26268515	10.1179/1607845415Y.0000000042	2016	Evaluation of serum and urine fetuin-A levels in children with acute lymphoblastic leukemia during and after high-dose methotrexate therapy: Relation to toxicity.	B2M
26732125	10.3109/10428194.2015.1137291	2016	Evaluation of serum markers in the LRF CLL4 trial: Œ≤2-microglobulin but not serum free light chains, is an independent marker of overall survival.	B2M
26752561	10.1371/journal.pone.0146624	2016	Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas.	B2M
27110054	10.1155/2016/1523959	2016	The Prognostic Significance of Beta2 Microglobulin in Patients with Hemophagocytic Lymphohistiocytosis.	B2M
27276707	10.18632/oncotarget.9793	2016	Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.	B2M
27389058	10.1038/leu.2016.161	2016	Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.	B2M
27835906	10.18632/oncotarget.13239	2016	Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.	B2M
27959929	10.1371/journal.pmed.1002197	2016	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.	B2M
24913511	10.3109/10428194.2014.917640	2015	Prognostic impact of Œ≤‚ÇÇ-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma.	B2M
25488972	10.1182/blood-2014-11-610436	2015	Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.	B2M
25577449	10.1016/j.transci.2014.12.007	2015	Beta-2 microglobulin predicts the outcome after autologous stem cell transplantation in non-Hodgkin lymphoma.	B2M
25622250	10.3390/ijms16022307	2015	Gentamicin arrests cancer cell growth: the intriguing involvement of nuclear sphingomyelin metabolism.	B2M
25981322	10.1016/j.bulcan.2015.03.013	2015	[Endocrine sequelae after treatment of pediatric cancer: From childhood to adulthood].	B2M
25991819	10.1158/1078-0432.CCR-14-2116	2015	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.	B2M
26068922	10.1371/journal.pone.0129298	2015	Plasma Hsp90 Level as a Marker of Early Acute Lymphoblastic Leukemia Engraftment and Progression in Mice.	B2M
26291013	10.1097/JTO.0000000000000624	2015	PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer.	B2M
26350140	10.1016/j.leukres.2015.08.016	2015	Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy.	B2M
24180329	10.3109/10428194.2013.850167	2014	Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.	B2M
24413734	10.1038/ng.2873	2014	Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.	B2M
24441948	10.1007/s00277-014-2015-2	2014	Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma.	B2M
24454777	10.1371/journal.pone.0084999	2014	Correlations between functional imaging markers derived from PET/CT and diffusion-weighted MRI in diffuse large B-cell lymphoma and follicular lymphoma.	B2M
24885312	10.1186/1471-2164-15-390	2014	In silico analyses reveal common cellular pathways affected by loss of heterozygosity (LOH) events in the lymphomagenesis of Non-Hodgkin's lymphoma (NHL).	B2M
24969158	10.1159/000362670	2014	Prognostic significance of serum beta-2 microglobulin in patients with non-Hodgkin lymphoma.	B2M
25171927	10.1182/blood-2013-12-546309	2014	Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients.	B2M
25292288	10.1186/1471-2407-14-750	2014	Characterization of Œ≤2-microglobulin expression in different types of breast cancer.	B2M
23331211	10.1111/ejh.12075	2013	Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era.	B2M
23717383	10.1371/journal.pone.0059868	2013	Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sj√∂gren's syndrome. Data at enrollment in the prospective ASSESS cohort.	B2M
23859015	10.1139/bcb-2012-0110	2013	Low expression of dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin-related protein in non-Hodgkin lymphoma and significant correlations with lactic acid dehydrogenase and Œ≤2-microglobulin.	B2M
23898101	NA	2013	Beta-2 microglobulin as a diagnostic parameter in non-Hodgkin lymphoma: a comparative study with FDG-PET.	B2M
22373550	10.1007/s00277-012-1434-1	2012	Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma.	B2M
22475215	10.3109/10428194.2012.666662	2012	Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia.	B2M
22585868	10.1158/2159-8290.CD-RW2011-64	2012	Gene inactivation promotes immune escape in DLBCL.	B2M
23033288	NA	2012	Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma.	B2M
23226803	10.3892/ol.2012.913	2012	Detection of the Epstein-Barr virus in blood and bone marrow mononuclear cells of patients with aggressive B-cell non-Hodgkin's lymphoma is not associated with prognosis.	B2M
20828817	10.1016/j.leukres.2010.08.006	2011	Different prognostic factors for survival in acute and lymphomatous adult T-cell leukemia/lymphoma.	B2M
22137796	10.1016/j.ccr.2011.11.006	2011	Combined genetic inactivation of Œ≤2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.	B2M
20437868	NA	2010	Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin.	B2M
20629733	10.1111/j.1600-0625.2010.01138.x	2010	A novel xenograft model of cutaneous T-cell lymphoma.	B2M
19265139	10.4049/jimmunol.0802316	2009	Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells.	B2M
19286254	10.1016/j.leukres.2009.02.015	2009	Prognostic [corrected] significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature.	B2M
19874554	10.1111/j.1365-3083.2009.02313.x	2009	Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.	B2M
18688847	10.1002/ijc.23772	2008	Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains.	B2M
17325847	10.1080/10428190601001904	2007	An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma.	B2M
17499801	10.1016/j.juro.2007.03.007	2007	Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma.	B2M
18024396	10.3324/haematol.11502	2007	Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.	B2M
16085553	10.1080/10428190500102845	2005	Malignant pleural effusion of multiple myeloma: prognostic factors and outcome.	B2M
12454016	10.1074/jbc.M208381200	2003	A dominant negative mutant beta 2-microglobulin blocks the extracellular folding of a major histocompatibility complex class I heavy chain.	B2M
12471623	10.1002/ijc.10824	2003	Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system.	B2M
12759931	10.1002/gcc.10214	2003	Evidence for whole chromosome 6 loss and duplication of the remaining chromosome in acute lymphoblastic leukemia.	B2M
12401828	10.1136/jcp.55.11.865	2002	A reliable method for total RNA extraction from frozen human bone marrow samples taken at diagnosis of acute leukaemia.	B2M
11712809	NA	2001	Beta-2-microglobulin levels in patients with extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type: a retrospective analysis.	B2M
12004151	NA	2001	[Renal function in children after treatment of acute lymphoblastic leukaemia (ALL)].	B2M
10790290	10.1667/0033-7587(2000)153[0663:eodctl]2.0.co;2	2000	Exposure of Daudi cells to low-frequency magnetic fields does not elevate MYC steady-state mRNA levels.	B2M
9789607	10.1023/a:1008418727472	1998	Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification.	B2M
9067691	NA	1997	Increased beta 2-microglobulin (B2M) is useful in the detection of post-transplant lymphoproliferative disease (PTLD).	B2M
8726404	10.3109/10428199209067605	1996	Effects of alpha-interferon on serum beta-2-microglobulin.	B2M
8580834	10.3109/10428199509064927	1995	Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase.	B2M
7959371	NA	1994	Report on a 3-year follow-up zidovudine (AZT) treatment in a group of HIV-positive patients with congenital clotting disorders.	B2M
1575009	10.1111/j.1600-0404.1992.tb04033.x	1992	Cerebrospinal fluid beta-2-microglobulin in adult patients with acute leukemia or lymphoma: a useful marker in early diagnosis and monitoring of CNS-involvement.	B2M
1627535	10.1111/j.1744-313x.1992.tb00053.x	1992	Damage in B2m genes and DNA methylation of H-2 genes are involved in loss of expression of class I MHC products on the membrane of LR.4, a cell line derivative of the T-cell lymphoma L5178Y.	B2M
2194155	10.3109/00313029009061421	1990	Cerebrospinal fluid B2-microglobulin levels in meningeal involvement by malignancy.	B2M
2450918	NA	1988	Specific associations of fluorescent beta-2-microglobulin with cell surfaces. The affinity of different H-2 and HLA antigens for beta-2-microglobulin.	B2M
2846212	10.1016/0009-8981(88)90311-7	1988	A method to detect the in vitro modification of serum beta-2-microglobulin in health and disease.	B2M
3141196	10.1016/0277-5379(88)90218-0	1988	Alteration of beta-2-microglobulin level in malignant lymphoproliferative diseases after a high dose of alpha-2-recombinant interferon.	B2M
3285553	NA	1988	Serum beta 2-microglobulin in malignant lymphoproliferative disorders.	B2M
11894933	10.1002/j.1460-2075.1983.tb01412.x	1983	The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon.	B2M
6180821	10.1002/1097-0142(19821101)50:9&lt;1783::aid-cncr2820500923&gt;3.0.co;2-v	1982	Diagnostic value of tumoral markers in serous effusions: carcinoembryonic antigen, alpha1-acidglycoprotein, alpha-fetoprotein, phosphohexose isomerase, and beta 2-microglobulin.	B2M
6185038	NA	1982	Beta-2 microglobulin--an immunogenetic marker of inflammatory and malignant origin.	B2M
6154490	NA	1980	The behaviour of beta-2-microglobulin in acute and chronic leukaemias.	B2M
7212634	NA	1980	The identification of testis-organizing H-Y antigen of man as hydrophobic polymers of a M.W. 18,000 subunit.	B2M
82455	NA	1978	Serial measurement of beta2 microglobulin, acute phase reactant proteins and the ESR in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.	B2M
15154230	NA	1965	[Immunologic phenomena in guinea pigs injected with homologous ganglia extracts].	B2M
34753803	10.1158/1541-7786.MCR-21-0208	2022	MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer.	BCL10
34783281	10.1080/10428194.2021.1999444	2022	Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.	BCL10
34906687	10.1016/j.fsi.2021.12.009	2022	BCL10 regulates the production of proinflammatory cytokines by activating MAPK-NF-Œ∫B/Rel signaling pathway in oysters.	BCL10
35099607	10.1007/s00018-022-04154-z	2022	A20 and ABIN-1 cooperate in balancing CBM complex-triggered NF-Œ∫B signaling in activated T cells.	BCL10
35192832	10.1016/j.scitotenv.2022.153990	2022	Effects of gestational exposure to bisphenol A on the hepatic transcriptome and lipidome of rat dams: Intergenerational comparison of effects in the offspring.	BCL10
35218741	10.1016/j.bcp.2022.114977	2022	Post-translational modification of MALT1 and its role in B cell- and T cell-related diseases.	BCL10
35230873	10.1126/scisignal.abk3083	2022	Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells.	BCL10
35255409	10.1016/j.jbior.2022.100890	2022	CARD11 signaling in regulatory T cell development and function.	BCL10
35406516	10.3390/cancers14071742	2022	Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment.	BCL10
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	BCL10
35540095	10.1016/j.jacbts.2022.02.004	2022	CARD9-Mediated Signaling and Cardiovascular Diseases.	BCL10
35600392	10.3389/fonc.2022.881801	2022	SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer.	BCL10
35658124	10.1158/2159-8290.CD-21-1566	2022	BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.	BCL10
35727133	10.7554/eLife.79826	2022	A nucleation barrier spring-loads the CBM signalosome for binary activation.	BCL10
35750252	10.1016/j.clim.2022.109067	2022	BCL10 loss-of-function novel mutation leading to atypical severe combined immunodeficiency.	BCL10
35929131	10.1158/2159-8290.CD-22-0614	2022	BCL10 Mutants: Architects of Oncogenic Signaling Provide a Blueprint for Precision Medicine.	BCL10
35981904	10.1016/j.jaci.2022.06.023	2022	The role of the CBM complex in allergic inflammation and disease.	BCL10
36094731	10.1007/s12104-022-10105-3	2022	Assignment of IVL-Methyl side chain of the ligand-free monomeric human MALT1 paracaspase-IgL<sub>3</sub> domain in solution.	BCL10
31595055	10.1038/s41423-019-0297-y	2021	Bcl10 is required for the development and suppressive function of Foxp3<sup>+</sup> regulatory T cells.	BCL10
32790937	10.1111/febs.15522	2021	Defining the combinatorial space of PKC::CARD-CC signal transduction nodes.	BCL10
32838054	10.1016/j.coemr.2020.07.011	2021	Subcellular hot spots of GPCR signaling promote vascular inflammation.	BCL10
32855441	10.1038/s41379-020-00660-2	2021	Deciphering the genetic landscape of pulmonary lymphomas.	BCL10
32927162	10.1016/j.ecoenv.2020.111272	2021	Augmented autophagy suppresses thymocytes development via Bcl10/p-p65 pathway in prenatal nicotine exposed fetal mice.	BCL10
33419765	10.4049/jimmunol.2001031	2021	Intrinsic Abnormalities of Keratinocytes Initiate Skin Inflammation through the IL-23/T17 Axis in a MALT1-Dependent Manner.	BCL10
33640899	10.1038/s41392-021-00477-8	2021	TRIM41 is required to innate antiviral response by polyubiquitinating BCL10 and recruiting NEMO.	BCL10
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	BCL10
33872653	10.1016/j.jaci.2021.04.006	2021	Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency.	BCL10
33941870	10.1038/s41418-021-00787-y	2021	USP12 promotes CD4<sup>+</sup> T cell responses through deubiquitinating and stabilizing BCL10.	BCL10
34014917	10.1371/journal.pcbi.1007986	2021	Signaling through polymerization and degradation: Analysis and simulations of T cell activation mediated by Bcl10.	BCL10
34192836	10.1515/hsz-2021-0250	2021	The paracaspase MALT1 in psoriasis.	BCL10
34236636	10.1007/978-1-0716-1669-7_8	2021	Methods to Study CARD11-BCL10-MALT1 Dependent Canonical NF-Œ∫B Activation in Jurkat T Cells.	BCL10
34412631	10.1186/s12935-021-02143-z	2021	Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-Œ∫B-related signaling.	BCL10
34481211	10.1016/j.prp.2021.153593	2021	Bcl-10, trypsin and synaptophysin helps recognize acinar cell and mixed acinar neuroendocrine cell carcinoma of the pancreas on both preoperative cytological samples and needle biopsy specimens.	BCL10
34499781	10.1111/pin.13164	2021	Primary pure pancreatic-type acinar cell carcinoma of the stomach.	BCL10
34826258	10.1126/sciimmunol.abi4425	2021	Keratinocyte-intrinsic BCL10/MALT1 activity initiates and amplifies psoriasiform skin inflammation.	BCL10
34868072	10.3389/fimmu.2021.786572	2021	Clinical and Immunological Features of Human BCL10 Deficiency.	BCL10
34879060	10.1371/journal.pntd.0010029	2021	Deep resequencing identifies candidate functional genes in leprosy GWAS loci.	BCL10
34928543	10.1002/iub.2581	2021	BCL10 correlates with bad prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.	BCL10
31241148	10.1093/cvr/cvz169	2020	B-cell lymphoma/leukaemia 10 and angiotensin II-induced kidney injury.	BCL10
31751629	10.1016/j.dci.2019.103555	2020	The signaling relations between three adaptors of porcine C-type lectin receptor pathway.	BCL10
31757436	10.1016/j.pathol.2019.08.012	2020	Marginal zone B-cell lymphoma: lessons from Western and Eastern diagnostic approaches.	BCL10
31774199	10.15252/embj.2019102030	2020	Paracaspase MALT1 regulates glioma cell survival by controlling endo-lysosome homeostasis.	BCL10
31808815	10.1093/cvr/cvz320	2020	A complex role for Bcl10 in kidney injury.	BCL10
31883669	10.1016/j.pathol.2019.09.014	2020	The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.	BCL10
31961340	10.1172/JCI97040	2020	GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.	BCL10
32008135	10.1007/s10875-020-00760-3	2020	Human BCL10 Deficiency due to Homozygosity for a Rare Allele.	BCL10
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	BCL10
32164050	10.4143/crt.2019.606	2020	Caspase Recruitment Domain Containing Protein 9 Suppresses Non-Small Cell Lung Cancer Proliferation and Invasion via Inhibiting MAPK/p38 Pathway.	BCL10
32179489	10.1016/j.cancergen.2020.02.005	2020	Integrating transcriptome-wide association study and copy number variation study identifies candidate genes and pathways for diffuse non-Hodgkin's lymphoma.	BCL10
32343482	10.15252/embr.201949237	2020	MALT1 targeting suppresses CARD14-induced psoriatic dermatitis in mice.	BCL10
32388054	10.1016/j.cellimm.2020.104115	2020	TAK1 lessens the activity of the paracaspase MALT1 during T cell receptor signaling.	BCL10
32450431	10.1016/j.cellimm.2020.104133	2020	The LUBAC participates in lysophosphatidic acid-induced NF-Œ∫B activation.	BCL10
32574386	10.1111/ejh.13467	2020	MALT-1 as a novel therapeutic target for adult T-cell leukemia.	BCL10
32593012	10.1016/j.cellimm.2020.104147	2020	Regulation and dysregulation of CARD14 signalling and its physiological consequences in inflammatory skin disease.	BCL10
32683230	10.1016/j.jtemb.2020.126615	2020	Zinc homeostasis plays an important role in the prevention of obesity-induced cardiac inflammation, remodeling and dysfunction.	BCL10
32721634	10.1016/j.cellimm.2020.104158	2020	Critical protein-protein interactions within the CARMA1-BCL10-MALT1 complex: Take-home points for the cell biologist.	BCL10
32768663	10.1016/j.cellimm.2020.104161	2020	Bcl10 is associated with actin dynamics at the T cell immune synapse.	BCL10
32771677	10.1016/j.cellimm.2020.104189	2020	The CBM complex: A growing multiplicity of cellular functions, regulatory mechanisms and connections to human disease.	BCL10
33052237	10.7150/thno.47533	2020	Targeting BCL10 by small peptides for the treatment of B cell lymphoma.	BCL10
33202260	10.1016/j.ajhg.2020.10.015	2020	Multiplexed Functional Assessment of Genetic Variants in CARD11.	BCL10
33297339	10.3390/nu12123755	2020	Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.	BCL10
33329596	10.3389/fimmu.2020.601926	2020	Cellular and Mathematical Analyses of LUBAC Involvement in T Cell Receptor-Mediated NF-Œ∫B Activation Pathway.	BCL10
30514565	10.1016/j.cellimm.2018.11.001	2019	Ubiquitination and phosphorylation of the CARD11-BCL10-MALT1 signalosome in T cells.	BCL10
30660642	10.1016/j.jaci.2018.12.1000	2019	Double-strand break repair through homologous recombination in autosomal-recessive BCL10 deficiency.	BCL10
30773504	10.5582/bst.2018.01291	2019	By regulating miR-182-5p/BCL10/CYCS, sufentanil reduces the apoptosis of umbilical cord mesenchymal stem cells caused by ropivacaine.	BCL10
31047877	10.1016/j.cca.2019.04.077	2019	BCL10 in cell survival after DNA damage.	BCL10
31060714	10.1016/j.jaci.2019.03.009	2019	Germline CBM-opathies: From immunodeficiency to atopy.	BCL10
31077220	10.1186/s13000-019-0815-3	2019	Gastric mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) with pancreatic acinar differentiation: a case report.	BCL10
31092922	10.1038/s41586-019-1215-2	2019	Targeting the CBM complex causes T<sub>reg</sub> cells to prime tumours for immune checkpoint therapy.	BCL10
31138793	10.1038/s41467-019-10203-2	2019	Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells.	BCL10
31178130	10.1016/j.bbrc.2019.06.004	2019	ZNF436 promotes tumor cell proliferation through transcriptional activation of BCL10 in glioma.	BCL10
31179345	10.1155/2019/9582714	2019	Distinct Effects of Carrageenan and High-Fat Consumption on the Mechanisms of Insulin Resistance in Nonobese and Obese Models of Type 2 Diabetes.	BCL10
31296852	10.1038/s41467-019-10953-z	2019	Structures of autoinhibited and polymerized forms of CARD9 reveal mechanisms of CARD9 and CARD11 activation.	BCL10
31391255	10.1074/jbc.RA119.009551	2019	Coordinated regulation of scaffold opening and enzymatic activity during CARD11 signaling.	BCL10
31420608	10.1038/s41388-019-0958-4	2019	MALT1 is a critical mediator of PAR1-driven NF-Œ∫B activation and metastasis in multiple tumor types.	BCL10
31427546	NA	2019	Characterisation of immunogenotypes of diffuse large B-cell lymphoma.	BCL10
31554683	10.1128/JVI.01499-19	2019	Host CARD11 Inhibits Newcastle Disease Virus Replication by Suppressing Viral Polymerase Activity in Neurons.	BCL10
31644910	10.1016/j.celrep.2019.09.040	2019	MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.	BCL10
31658764	10.3390/ijms20205022	2019	B-Cell Activating Factor Enhances Hepatocyte-Driven Angiogenesis via B-Cell CLL/Lymphoma 10/Nuclear Factor-KappaB Signaling during Liver Regeneration.	BCL10
28886618	10.1111/cmi.12788	2018	Bcl10 synergistically links CEACAM3 and TLR-dependent inflammatory signalling.	BCL10
29259013	10.1158/0008-5472.CAN-17-1089	2018	The CARMA3-Bcl10-MALT1 Signalosome Drives NFŒ∫B Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer.	BCL10
29289361	10.1016/j.blre.2017.12.001	2018	The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.	BCL10
29358699	10.1038/s41598-018-19822-z	2018	GSK3Œ≤ modulates NF-Œ∫B activation and RelB degradation through site-specific phosphorylation of BCL10.	BCL10
29382759	10.1073/pnas.1721967115	2018	Assembly mechanism of the CARMA1-BCL10-MALT1-TRAF6 signalosome.	BCL10
29649481	10.1016/j.bbrc.2018.04.057	2018	Role of IŒ∫B kinase Œ≤ in regulating the remodeling of the CARMA1-Bcl10-MALT1 complex.	BCL10
29765142	10.1038/s41379-018-0064-0	2018	Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement.	BCL10
29881386	10.3389/fimmu.2018.01136	2018	Ancient Origin of the CARD-Coiled Coil/Bcl10/MALT1-Like Paracaspase Signaling Complex Indicates Unknown Critical Functions.	BCL10
29925955	10.1038/s41586-018-0290-0	2018	A multiprotein supercomplex controlling oncogenic signalling in lymphoma.	BCL10
29953499	10.1371/journal.pone.0199779	2018	Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-Œ∫B signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells.	BCL10
30022982	10.3389/fimmu.2018.01539	2018	BCL10 - Bridging CARDs to Immune Activation.	BCL10
30206119	10.1074/jbc.RA118.004821	2018	Picomolar zinc binding modulates formation of Bcl10-nucleating assemblies of the caspase recruitment domain (CARD) of CARD9.	BCL10
30214442	10.3389/fimmu.2018.01927	2018	Holding All the CARDs: How MALT1 Controls CARMA/CARD-Dependent Signaling.	BCL10
30279415	10.1038/s41467-018-06573-8	2018	Molecular architecture and regulation of BCL10-MALT1 filaments.	BCL10
30283440	10.3389/fimmu.2018.02078	2018	The CBM-opathies-A Rapidly Expanding Spectrum of Human Inborn Errors of Immunity Caused by Mutations in the CARD11-BCL10-MALT1 Complex.	BCL10
30283447	10.3389/fimmu.2018.02105	2018	Mechanisms of Regulated and Dysregulated CARD11 Signaling in Adaptive Immunity and Disease.	BCL10
30336982	10.1016/j.bbrc.2018.10.029	2018	MALT1 activation by TRAF6 needs neither BCL10 nor CARD11.	BCL10
30386326	10.3389/fimmu.2018.02239	2018	Clinical and Genetic Heterogeneity of <i>CARD14</i> Mutations in Psoriatic Skin Disease.	BCL10
30401751	10.1182/bloodadvances.2018022962	2018	Insights into the genomic landscape of MYD88 wild-type Waldenstr√∂m macroglobulinemia.	BCL10
30429846	10.3389/fimmu.2018.02366	2018	A <i>CARD9</i> Founder Mutation Disrupts NF-Œ∫B Signaling by Inhibiting BCL10 and MALT1 Recruitment and Signalosome Formation.	BCL10
30446641	10.1038/s41467-018-07215-9	2018	Cellular metabolism constrains innate immune responses in early human ontogeny.	BCL10
30474008	10.3389/fonc.2018.00498	2018	Post-translational Modifications of the CARMA1-BCL10-MALT1 Complex in Lymphocytes and Activated B-Cell Like Subtype of Diffuse Large B-Cell Lymphoma.	BCL10
30515170	10.3389/fimmu.2018.02695	2018	BCL10-CARD11 Fusion Mimics an Active CARD11 Seed That Triggers Constitutive BCL10 Oligomerization and Lymphocyte Activation.	BCL10
30553470	10.1016/j.cancergen.2018.08.001	2018	Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases.	BCL10
26354285	10.1002/hon.2251	2017	Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma.	BCL10
27860444	10.1002/dc.23634	2017	Cytological findings and BCL10 expression in pancreatic acinar cell carcinoma: A Case Report.	BCL10
27864294	10.1182/blood-2016-05-718775	2017	B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.	BCL10
27873317	10.1002/path.4852	2017	The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21).	BCL10
27939769	10.1016/j.jid.2016.09.031	2017	CARD14-Mediated Activation of Paracaspase MALT1 in Keratinocytes: Implications for Psoriasis.	BCL10
28052131	10.1371/journal.pone.0169026	2017	Two Antagonistic MALT1 Auto-Cleavage Mechanisms Reveal a Role for TRAF6 to Unleash MALT1 Activation.	BCL10
28158919	10.1111/jcmm.13050	2017	Zinc rescues obesity-induced cardiac hypertrophy via stimulating metallothionein to suppress oxidative stress-activated BCL10/CARD9/p38 MAPK pathway.	BCL10
28163398	10.1155/2017/8634865	2017	<i>Œ∫</i>-Carrageenan Enhances Lipopolysaccharide-Induced Interleukin-8 Secretion by Stimulating the Bcl10-NF-<i>Œ∫</i>B Pathway in HT-29 Cells and Aggravates <i>C</i>. <i>freundii</i>-Induced Inflammation in Mice.	BCL10
28230860	10.1038/cddis.2017.51	2017	CARMA2sh and ULK2 control pathogen-associated molecular patterns recognition in human keratinocytes: psoriasis-linked CARMA2sh mutants escape ULK2 censorship.	BCL10
28288707	10.1016/j.beha.2016.09.002	2017	MALT lymphoma: Genetic abnormalities, immunological stimulation and molecular mechanism.	BCL10
28672935	10.3892/etm.2017.4464	2017	Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.	BCL10
28717989	10.1007/s13238-017-0441-3	2017	The CARMA3-BCL10-MALT1 (CBM) complex contributes to DNA damage-induced NF-Œ∫B activation and cell survival.	BCL10
28765954	10.3892/mmr.2017.7116	2017	In¬†vitro reconstitution of interactions in the CARD9 signalosome.	BCL10
29084984	10.1038/s41598-017-14102-8	2017	First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma.	BCL10
29194363	10.3390/ijms18122581	2017	The E3 Ubiquitin Ligase RNF7 Negatively Regulates CARD14/CARMA2sh Signaling.	BCL10
29225710	10.1007/s12308-017-0302-2	2017	Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma.	BCL10
29340061	10.18632/oncotarget.22799	2017	Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.	BCL10
26392569	10.1158/1541-7786.MCR-15-0229-T	2016	The CBM Complex Underwrites NF-Œ∫B Activation to Promote HER2-Associated Tumor Malignancy.	BCL10
26521038	10.1016/j.jaci.2015.09.016	2016	Impaired RASGRF1/ERK-mediated GM-CSF response characterizes CARD9 deficiency in French-Canadians.	BCL10
26767426	10.1016/j.jid.2015.12.027	2016	MALT1 Protease Activity Controls the Expression of Inflammatory Genes in Keratinocytes upon Zymosan Stimulation.	BCL10
26771713	10.1080/15384101.2015.1121322	2016	BCL10 is recruited to sites of DNA damage to facilitate DNA double-strand break repair.	BCL10
26774590	10.1016/j.clim.2016.01.003	2016	Actin polymerisation after FCŒ≥R stimulation of human fibroblasts is BCL10 independent.	BCL10
26776161	10.1038/onc.2015.493	2016	Oncogenic CARMA1 couples NF-Œ∫B and Œ≤-catenin signaling in diffuse large B-cell lymphomas.	BCL10
26884334	10.1074/jbc.M116.717322	2016	Intramolecular Interactions and Regulation of Cofactor Binding by the Four Repressive Elements in the Caspase Recruitment Domain-containing Protein 11 (CARD11) Inhibitory Domain.	BCL10
26936881	10.4049/jimmunol.1403165	2016	Usp9X Is Required for Lymphocyte Activation and Homeostasis through Its Control of ZAP70 Ubiquitination and PKCŒ≤ Kinase Activity.	BCL10
26947079	10.1016/j.celrep.2016.02.031	2016	CARMA3 Is a Host Factor Regulating the Balance of Inflammatory and Antiviral Responses against Viral Infection.	BCL10
27006117	10.1242/jcs.185025	2016	The paracaspase MALT1 cleaves the LUBAC subunit HOIL1 during antigen receptor signaling.	BCL10
27070692	10.1016/j.ccell.2016.03.018	2016	Killing Lymphoma with Smac-Mimetics: As Easy as ABC?	BCL10
27070702	10.1016/j.ccell.2016.03.006	2016	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.	BCL10
27071417	10.1042/BCJ20160270	2016	Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-Œ∫B activation.	BCL10
27092298	10.3389/fcimb.2016.00039	2016	Mechanistic Insights into the Role of C-Type Lectin Receptor/CARD9 Signaling in Human Antifungal Immunity.	BCL10
27109639	10.1016/j.clim.2016.04.011	2016	Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation.	BCL10
27113748	10.15252/embr.201642109	2016	The paracaspase MALT1 mediates CARD14-induced signaling in keratinocytes.	BCL10
27135977	10.1097/MOH.0000000000000257	2016	Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies.	BCL10
27452667	10.1016/j.semcancer.2016.07.003	2016	MALT lymphoma: A paradigm of NF-Œ∫B dysregulation.	BCL10
27509941	NA	2016	E1/E2 of Hepatitis C Virus Genotype4 and Apoptosis.	BCL10
27566587	10.18632/oncotarget.11548	2016	Recurrent mutations in NF-Œ∫B pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.	BCL10
27681433	10.1016/j.celrep.2016.08.080	2016	MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage.	BCL10
27777308	10.1074/jbc.M116.754028	2016	Molecular Determinants of Scaffold-induced Linear Ubiquitinylation of B Cell Lymphoma/Leukemia 10 (Bcl10) during T Cell Receptor and Oncogenic Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling.	BCL10
24681956	10.1038/onc.2014.43	2015	B-cell lymphoma/leukemia 10 promotes oral cancer progression through STAT1/ATF4/S100P signaling pathway.	BCL10
25391967	10.1007/s11060-014-1655-3	2015	Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.	BCL10
25556945	10.1016/j.chembiol.2014.10.021	2015	Activity-based probes for detection of active MALT1 paracaspase in immune cells and lymphomas.	BCL10
25569716	10.1038/ncomms6908	2015	Conversion of the LIMA1 tumour suppressor into an oncogenic LMO-like protein by API2-MALT1 in MALT lymphoma.	BCL10
25736751	10.1007/978-1-4939-2422-6_12	2015	Visualizing TCR-induced POLKADOTS formation and NF-Œ∫B activation in the D10 T-cell clone and mouse primary effector T cells.	BCL10
25748427	10.1371/journal.pone.0119363	2015	MALT1-ubiquitination triggers non-genomic NF-Œ∫B/IKK signaling upon platelet activation.	BCL10
25849213	10.1371/journal.pone.0122365	2015	Functional characterization of zebrafish (Danio rerio) Bcl10.	BCL10
25956014	10.1016/j.jaci.2015.02.037	2015	Advances in basic and clinical immunology in 2014.	BCL10
25965667	10.1371/journal.pone.0127083	2015	MALT1 Protease Activity Is Required for Innate and Adaptive Immune Responses.	BCL10
25973362	10.1016/j.fob.2015.04.011	2015	Oligomerized CARD16 promotes caspase-1 assembly and IL-1Œ≤ processing.	BCL10
26038114	10.15252/msb.20145880	2015	Systems-wide analysis of BCR signalosomes and downstream phosphorylation and ubiquitylation.	BCL10
26043155	10.1080/15548627.2015.1055439	2015	TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy.	BCL10
26202083	10.3892/ijmm.2015.2290	2015	Bcl10 crucially nucleates the pro-apoptotic complexes comprising PDK1, PKCŒ∂ and caspase-3 at the nuclear envelope of etoposide-treated human cervical carcinoma C4-I cells.	BCL10
26277595	10.1016/j.jaci.2015.06.031	2015	Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity.	BCL10
26287604	10.18632/oncotarget.4467	2015	Immunodeficiency and CARD-BCL10-MALT1.	BCL10
26525107	10.1038/ncomms9777	2015	The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-Œ∫B signalling.	BCL10
26615705	10.1016/j.anndiagpath.2015.10.001	2015	Antisecretory medication is associated with decreased Helicobacter pylori detection in gastric marginal zone lymphoma.	BCL10
26668357	10.1073/pnas.1507459112	2015	Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-Œ∫B and JNK activation.	BCL10
26711259	10.1128/MCB.00876-15	2015	Negative Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181.	BCL10
23846624	10.14670/HH-29.77	2014	BCL10 expression and localization in ocular adnexa MALT lymphomas: a comparative cytogenetic and immunohistochemical study.	BCL10
23886693	10.1016/j.imbio.2013.06.013	2014	Activation of NF-Œ∫B and respiratory burst following Aspergillus fumigatus stimulation of macrophages.	BCL10
24329526	10.1089/dna.2013.2199	2014	The TCR Œ≥Œ¥ repertoire and relative gene expression characteristics of T-ALL cases with biclonal malignant VŒ¥1 and VŒ¥2 T cells.	BCL10
24375035	10.1002/jcp.24543	2014	The three CARMA sisters: so different, so similar: a portrait of the three CARMA proteins and their involvement in human disorders.	BCL10
24383645	10.1111/imm.12207	2014	N-Ethyl-N-nitrosourea mutagenesis in the mouse provides strong genetic and in vivo evidence for the role of the Caspase Recruitment Domain (CARD) of CARD-MAGUK1 in T regulatory cell development.	BCL10
24411492	10.1016/j.cytogfr.2013.12.008	2014	The CBM signalosome: potential therapeutic target for aggressive lymphoma?	BCL10
24443940	10.1111/cei.12275	2014	CARD11 blockade suppresses murine collagen-induced arthritis via inhibiting CARD11/Bcl10 assembly and T helper type 17 response.	BCL10
24491438	10.1158/2159-8290.CD-13-0915	2014	Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.	BCL10
24497531	10.1182/blood-2013-05-504019	2014	A catalytic-independent role for the LUBAC in NF-Œ∫B activation upon antigen receptor engagement and in lymphoma cells.	BCL10
24548923	10.1016/j.molimm.2014.01.011	2014	Phosphorylation of Carma1, but not Bcl10, by Akt regulates TCR/CD28-mediated NF-Œ∫B induction and cytokine production.	BCL10
24560716	10.1016/j.imlet.2014.02.002	2014	1999-2014: 15 years of BCL10.	BCL10
24633921	10.1007/s13277-014-1791-6	2014	CARMA3 is upregulated in human pancreatic carcinoma, and its depletion inhibits tumor proliferation, migration, and invasion.	BCL10
24641824	10.1016/j.bbagen.2014.03.011	2014	Degraded Œª-carrageenan activates NF-Œ∫B and AP-1 pathways in macrophages and enhances LPS-induced TNF-Œ± secretion through AP-1.	BCL10
24702227	10.3109/00016489.2013.878474	2014	Increased expression of Dec-205, Bcl-10, Tim-3, and Trem-1 mRNA in chronic otitis media with cholesteatoma.	BCL10
24732096	10.4161/cc.28707	2014	BCL10 regulates RNF8/RNF168-mediated ubiquitination in the DNA damage response.	BCL10
24777530	10.1038/ni.2888	2014	Rad50-CARD9 interactions link cytosolic DNA sensing to IL-1Œ≤ production.	BCL10
24792914	10.1016/j.immuni.2014.04.007	2014	Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation.	BCL10
24806599	10.1038/ncomms4755	2014	An ITAM-Syk-CARD9 signalling axis triggers contact hypersensitivity by stimulating IL-1 production in dendritic cells.	BCL10
24825920	10.1126/scisignal.2004882	2014	T cell receptor signals to NF-Œ∫B are transmitted by a cytosolic p62-Bcl10-Malt1-IKK signalosome.	BCL10
24917592	10.1126/scisignal.2005169	2014	T cell receptor-dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10.	BCL10
24958727	10.1074/jbc.M114.588723	2014	The adaptor CRADD/RAIDD controls activation of endothelial cells by proinflammatory stimuli.	BCL10
25011391	10.1007/s00418-014-1244-8	2014	Combining immunofluorescence with in situ proximity ligation assay: a novel imaging approach to monitor protein-protein interactions in relation to subcellular localization.	BCL10
25087226	10.1016/j.jaci.2014.06.015	2014	The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency.	BCL10
25105596	10.1371/journal.pone.0103774	2014	MALT1 auto-proteolysis is essential for NF-Œ∫B-dependent gene transcription in activated lymphocytes.	BCL10
25150998	10.1007/978-1-4939-1212-4_8	2014	Detection of NF-Œ∫B pathway activation in T helper cells.	BCL10
25185127	10.1161/HYPERTENSIONAHA.114.03900	2014	Bcl10 mediates angiotensin II-induced cardiac damage and electrical remodeling.	BCL10
25185129	10.1161/HYPERTENSIONAHA.114.04047	2014	Linking angiotensin II to nuclear factor-Œ∫ light chain enhancer of activated B cells-induced cardiovascular damage: bad CARMAs.	BCL10
25190756	10.1182/blood-2014-03-564609	2014	Inability to resolve specific infection generates innate immunodeficiency syndrome in Xiap-/- mice.	BCL10
25202022	10.1074/jbc.M114.588574	2014	C-type lectin receptor dectin-3 mediates trehalose 6,6'-dimycolate (TDM)-induced Mincle expression through CARD9/Bcl10/MALT1-dependent nuclear factor (NF)-Œ∫B activation.	BCL10
25245034	10.1186/s12964-014-0049-7	2014	AIP augments CARMA1-BCL10-MALT1 complex formation to facilitate NF-Œ∫B signaling upon T cell activation.	BCL10
25320244	10.1182/blood-2014-07-589689	2014	Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.	BCL10
25365219	10.1172/JCI77493	2014	Inherited BCL10 deficiency impairs hematopoietic and nonhematopoietic immunity.	BCL10
25384343	10.1186/s40001-014-0062-8	2014	Characteristics of CARMA1-BCL10-MALT1-A20-NF-Œ∫B expression in T cell-acute lymphocytic leukemia.	BCL10
25536807	10.2298/vsp130813035h	2014	BCL10 aberations and NF-kappa B activation involving p65 are absent or rare in primary gastric MALT lymphoma.	BCL10
23149938	10.1128/MCB.00850-12	2013	A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival.	BCL10
23252516	10.1111/bjh.12172	2013	Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.	BCL10
23297344	10.1128/MCB.06407-11	2013	Kinase-independent feedback of the TAK1/TAB1 complex on BCL10 turnover and NF-Œ∫B activation.	BCL10
23393199	10.1158/0008-5472.CAN-12-2362	2013	Hyperactivated JNK is a therapeutic target in pVHL-deficient renal cell carcinoma.	BCL10
23463379	10.1002/ijc.28148	2013	Ca2+/calmodulin-dependent kinase II contributes to inhibitor of nuclear factor-kappa B kinase complex activation in Helicobacter pylori infection.	BCL10
23525237	10.3892/ijmm.2013.1307	2013	Self-oligomerization of the CARD domain prevents complex formation in the CARMA1 signalosome.	BCL10
23530562	10.1111/pin.12045	2013	BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens.	BCL10
23545653	10.1107/S1744309113005642	2013	Crystallization and preliminary X-ray crystallographic studies of the CARD domain of human CARMA1.	BCL10
23616440	10.1002/glia.22502	2013	Amyloid beta deregulates astroglial mGluR5-mediated calcium signaling via calcineurin and Nf-kB.	BCL10
23632891	10.1182/blood-2012-12-470153	2013	Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-Œ∫B activation in diffuse large B-cell lymphoma.	BCL10
23661444	10.4238/2013.April.12.6	2013	Significance of Bcl10 gene mutations in the clinical diagnosis of MALT-type ocular adnexal lymphoma in the Chinese population.	BCL10
23677497	10.1007/s13105-013-0259-2	2013	Bcl10 is an essential regulator for A20 gene expression.	BCL10
23690623	10.1073/pnas.1221925110	2013	Regulation of T cell function by the ubiquitin-specific protease USP9X via modulating the Carma1-Bcl10-Malt1 complex.	BCL10
23766559	10.1155/2013/397642	2013	Carrageenan-induced colonic inflammation is reduced in Bcl10 null mice and increased in IL-10-deficient mice.	BCL10
23770291	10.1016/j.cellsig.2013.06.007	2013	Antagonistic crosstalk between NF-Œ∫B and SIRT1 in the regulation of inflammation and metabolic disorders.	BCL10
23784377	10.1093/hmg/ddt286	2013	An association study of TOLL and CARD with leprosy susceptibility in Chinese population.	BCL10
23827971	10.1016/j.pneurobio.2013.06.002	2013	Impaired autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome.	BCL10
23918355	10.1073/pnas.1303669110	2013	Inhibition of pluripotent stem cell-derived teratoma formation by small molecules.	BCL10
24004675	10.1158/1078-0432.CCR-12-3869	2013	Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.	BCL10
24036998	10.1038/ni.2708	2013	Signaling by Fyn-ADAP via the Carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells.	BCL10
24074955	10.1016/j.molcel.2013.08.032	2013	Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly.	BCL10
24145781	10.1038/ni.2737	2013	ADAPted secretion of cytokines in NK cells.	BCL10
21954216	10.1002/pbc.23331	2012	Inhibition of caspase-8 activity caused by overexpression of BCL10 contributes to the pathogenesis of high-grade MALT lymphoma.	BCL10
21988643	10.3109/10428194.2011.631157	2012	Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type.	BCL10
22079206	10.1016/j.jnutbio.2011.05.012	2012	Molecular signature of kappa-carrageenan mimics chondroitin-4-sulfate and dermatan sulfate and enables interaction with arylsulfatase B.	BCL10
22323537	10.4049/jimmunol.1101502	2012	Cutting edge: the death adaptor CRADD/RAIDD targets BCL10 and suppresses agonist-induced cytokine expression in T lymphocytes.	BCL10
22363141	10.3748/wjg.v18.i7.685	2012	Gastric mucosa-associated lymphoid tissue lymphomas and Helicobacter pylori infection: a Colombian perspective.	BCL10
22366302	10.1016/j.jmb.2012.02.018	2012	Structural determinants of MALT1 protease activity.	BCL10
22382892	10.1038/leu.2012.28	2012	Chlamydia psittaci-negative ocular adnexal marginal zone B-cell lymphomas have biased VH4-34 immunoglobulin gene expression and proliferate in a distinct inflammatory environment.	BCL10
22407319	10.1038/nature10894	2012	The Shigella flexneri effector OspI deamidates UBC13 to dampen the inflammatory response.	BCL10
22423967	10.1016/j.chom.2012.01.019	2012	The autophagy regulator Rubicon is a feedback inhibitor of CARD9-mediated host innate immunity.	BCL10
22474286	10.1074/jbc.M111.291708	2012	Forkhead transcription factor FOXO3a protein activates nuclear factor Œ∫B through B-cell lymphoma/leukemia 10 (BCL10) protein and promotes tumor cell survival in serum deprivation.	BCL10
22528498	10.1074/jbc.M111.335463	2012	Protein kinase C-Œ¥ negatively regulates T cell receptor-induced NF-Œ∫B activation by inhibiting the assembly of CARMA1 signalosome.	BCL10
22564715	10.1016/j.ygyno.2012.04.047	2012	Expression of BCL10 in cervical cancer has a role in the regulation of cell growth through the activation of NF-Œ∫B-dependent cyclin D1 signaling.	BCL10
22574776	10.1042/BJ20120414	2012	Protease activity of MALT1: a mystery unravelled.	BCL10
22579587	10.1016/j.bbadis.2012.05.001	2012	Prolongation of carrageenan-induced inflammation in human colonic epithelial cells by activation of an NFŒ∫B-BCL10 loop.	BCL10
22658522	10.1016/j.immuni.2012.04.008	2012	Selective autophagy of the adaptor protein Bcl10 modulates T cell receptor activation of NF-Œ∫B.	BCL10
22708078	10.1016/j.celrep.2012.04.006	2012	Bcl10 links saturated fat overnutrition with hepatocellular NF-kB activation and insulin resistance.	BCL10
22734454	10.3109/10520295.2012.695025	2012	BCL10 expression is unrelated to clinico-pathological parameters or prognoses for oral squamous cell carcinomas.	BCL10
22812606	10.1021/pr3000464	2012	Role-shifting PKCŒ∂ fosters its own proapoptotic destruction by complexing with Bcl10 at the nuclear envelope of human cervical carcinoma cells: a proteomic and biochemical study.	BCL10
22818167	10.1016/j.humpath.2012.03.024	2012	BCL10 down-regulation in peripheral T-cell lymphomas.	BCL10
22842723	10.3892/or.2012.1942	2012	Breast MALT lymphomas: a clinicopathological and cytogenetic study of 9 cases.	BCL10
22880103	10.1371/journal.pone.0042775	2012	Structural insights into the assembly of CARMA1 and BCL10.	BCL10
23035874	10.1186/1423-0127-19-85	2012	BCL10GFP fusion protein as a substrate for analysis of determinants required for mucosa-associated lymphoid tissue 1 (MALT1)-mediated cleavage.	BCL10
23087406	10.4049/jimmunol.1102952	2012	Critical role of B cell lymphoma 10 in BAFF-regulated NF-Œ∫B activation and survival of anergic B cells.	BCL10
23153494	10.1016/j.devcel.2012.09.021	2012	The NF-Œ∫B signaling protein Bcl10 regulates actin dynamics by controlling AP1 and OCRL-bearing vesicles.	BCL10
23238011	10.1016/j.ccr.2012.11.011	2012	A new brew of MALT1 inhibitors.	BCL10
20830719	10.1002/ijc.25663	2011	BCL6 gene rearrangement and protein expression are associated with large cell presentation of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.	BCL10
21187856	10.1038/cr.2010.182	2011	NF-Œ∫B signaling pathways regulated by CARMA family of scaffold proteins.	BCL10
21199863	10.1074/jbc.M110.155895	2011	The Ca2+-dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-kappaB activation.	BCL10
21261681	10.1111/j.1365-2559.2010.03699.x	2011	MALT lymphoma: many roads lead to nuclear factor-Œ∫b activation.	BCL10
21283787	10.1371/journal.ppat.1001259	2011	Selective C-Rel activation via Malt1 controls anti-fungal T(H)-17 immunity by dectin-1 and dectin-2.	BCL10
21396111	10.1186/1478-811X-9-6	2011	B cell antigen receptor-induced activation of an IRAK4-dependent signaling pathway revealed by a MALT1-IRAK4 double knockout mouse model.	BCL10
21406399	10.1158/0008-5472.CAN-10-3626	2011	CARMA3 is crucial for EGFR-Induced activation of NF-Œ∫B and tumor progression.	BCL10
21489413	10.1016/j.cellimm.2011.03.025	2011	CD4 ligation excludes the Carma1-Bcl10-MALT1 complex from GM1-positive membrane rafts in CD3/CD28 activated T cells.	BCL10
21513986	10.1016/j.molimm.2011.03.020	2011	CaMKII targets Bcl10 in T-cell receptor induced activation of NF-Œ∫B.	BCL10
21674474	10.1002/eji.201041052	2011	Dephosphorylation of Bcl-10 by calcineurin is essential for canonical NF-Œ∫B activation in Th cells.	BCL10
21700900	10.1152/ajpgi.00071.2011	2011	Specific effects of BCL10 Serine mutations on phosphorylations in canonical and noncanonical pathways of NF-Œ∫B activation following carrageenan.	BCL10
21745165	10.3109/10428194.2011.596968	2011	Thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a clinicopathological and genetic analysis of six cases.	BCL10
21750409	10.4161/cc.10.15.16923	2011	From MALT lymphoma to the CBM signalosome: three decades of discovery.	BCL10
21837708	10.1002/gcc.20910	2011	Establishment of a novel MALT lymphoma cell line, ma-1, from a patient with t(14;18)(q32;q21)-positive Helicobacter pylori-independent gastric MALT lymphoma.	BCL10
21862580	10.1074/jbc.M111.259549	2011	Akt fine-tunes NF-Œ∫B-dependent gene expression during T cell activation.	BCL10
21896478	10.1074/jbc.M111.263384	2011	The E3 ubiquitin ligase mind bomb-2 (MIB2) protein controls B-cell CLL/lymphoma 10 (BCL10)-dependent NF-Œ∫B activation.	BCL10
22158899	10.1073/pnas.1111708108	2011	Crystal structure of the mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) paracaspase region.	BCL10
19714753	10.1002/ibd.21092	2010	Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent.	BCL10
19864123	10.1016/j.jnutbio.2009.07.002	2010	Carrageenan-induced innate immune response is modified by enzymes that hydrolyze distinct galactosidic bonds.	BCL10
19897484	10.1074/jbc.M109.050815	2010	B-cell CLL/lymphoma 10 (BCL10) is required for NF-kappaB production by both canonical and noncanonical pathways and for NF-kappaB-inducing kinase (NIK) phosphorylation.	BCL10
19950170	10.1002/eji.200939445	2010	c-Rel phenocopies PKCtheta but not Bcl-10 in regulating CD8+ T-cell activation versus tolerance.	BCL10
20193035	10.1111/j.1744-313X.2010.00898.x	2010	BCL10 as a new candidate gene for immune response in pigs: cloning, expression and association analysis.	BCL10
20235165	10.1002/path.2699	2010	Interleukin-2 induces NF-kappaB activation through BCL10 and affects its subcellular localization in natural killer lymphoma cells.	BCL10
20439115	10.1016/j.molimm.2010.04.005	2010	Interaction of calmodulin with Bcl10 modulates NF-kappaB activation.	BCL10
20466000	10.1016/j.yexcr.2010.05.004	2010	Lipopolysaccharide-induced activation of NF-Œ∫B non-canonical pathway requires BCL10 serine 138 and NIK phosphorylations.	BCL10
20507572	10.1186/1471-2172-11-26	2010	Differential cytokine regulation by NF-kappaB and AP-1 in Jurkat T-cells.	BCL10
20516126	10.1101/cshperspect.a000109	2010	Oncogenic activation of NF-kappaB.	BCL10
20520640	10.1038/leu.2010.118	2010	Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism.	BCL10
20538615	10.1074/jbc.M110.131300	2010	CARD9 mediates dectin-2-induced IkappaBalpha kinase ubiquitination leading to activation of NF-kappaB in response to stimulation by the hyphal form of Candida albicans.	BCL10
20551178	10.1242/jcs.069476	2010	Interplay between BCL10, MALT1 and IkappaBalpha during T-cell-receptor-mediated NFkappaB activation.	BCL10
20605784	10.1074/jbc.C110.109421	2010	The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis.	BCL10
20679053	NA	2010	[Orbital and ocular adnexal lymphomas. Clinico-pathological correlation in 25 cases].	BCL10
20685844	10.1101/cshperspect.a003004	2010	Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1.	BCL10
20799731	10.1021/bi101052d	2010	Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain.	BCL10
20937806	10.1074/jbc.M110.159681	2010	Tumor necrosis factor alpha-induced inflammation is increased but apoptosis is inhibited by common food additive carrageenan.	BCL10
21041303	10.1074/jbc.M110.158949	2010	Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3¬∑Bcl10¬∑MALT1 signalosome.	BCL10
21084243	10.1684/bdc.2010.1214	2010	[Molecular abnormalities in lymphomas].	BCL10
22282688	10.2147/JBM.S9772	2010	L-CBM signaling in lymphocyte development and function.	BCL10
18775860	10.1167/iovs.08-2539	2009	Extranodal marginal zone lymphoma in the ocular region: clinical, immunophenotypical, and cytogenetical characteristics.	BCL10
18952491	10.1016/j.oraloncology.2008.08.003	2009	Expression of BCL10 is significantly associated with the progression and prognosis of oral squamous cell carcinomas in Taiwan.	BCL10
19066953	10.1007/s00428-008-0710-x	2009	The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia.	BCL10
19085995	10.1002/ibd.20821	2009	ROS, Hsp27, and IKKbeta mediate dextran sodium sulfate (DSS) activation of IkappaBa, NFkappaB, and IL-8.	BCL10
19112107	10.1074/jbc.C800207200	2009	CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex.	BCL10
19118383	10.1038/nature07613	2009	Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival.	BCL10
19124758	10.4049/jimmunol.182.2.1146	2009	Differential use of CARD9 by dectin-1 in macrophages and dendritic cells.	BCL10
19136564	10.1074/jbc.M806650200	2009	Phospholipase Cgamma2 is critical for Dectin-1-mediated Ca2+ flux and cytokine production in dendritic cells.	BCL10
19139169	10.1084/jem.20081445	2009	Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation.	BCL10
19144384	10.1016/j.humpath.2008.06.032	2009	BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.	BCL10
19279678	10.1371/journal.pone.0004822	2009	Auto-ubiquitination-induced degradation of MALT1-API2 prevents BCL10 destabilization in t(11;18)(q21;q21)-positive MALT lymphoma.	BCL10
19298243	10.1111/j.1600-0714.2009.00757.x	2009	Nuclear BCL10 in primary Sj√∂gren's syndrome.	BCL10
19309400	10.1111/j.1365-2559.2009.03250.x	2009	Bcl-10 protein highly correlates with the expression of phosphorylated p65 NF-kappaB in peripheral T-cell lymphomas and is associated with clinical outcome.	BCL10
19336552	10.1158/1055-9965.EPI-08-1037	2009	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.	BCL10
19359218	10.1016/j.it.2009.03.002	2009	CARD9 versus CARMA1 in innate and adaptive immunity.	BCL10
19366357	10.1111/j.1747-0285.2009.00805.x	2009	Protein-protein interactions: a simple strategy to identify binding sites and peptide antagonists.	BCL10
19385974	10.1111/j.1349-7006.2009.01139.x	2009	Antibodies to Helicobacter pylori and CagA protein are associated with the response to antibacterial therapy in patients with H. pylori-positive API2-MALT1-negative gastric MALT lymphoma.	BCL10
19428562	10.1016/j.imlet.2009.03.005	2009	Barley-derived beta-D-glucan induces immunostimulation via a dectin-1-mediated pathway.	BCL10
19444310	10.1038/embor.2009.64	2009	COP9 signalosome controls the Carma1-Bcl10-Malt1 complex upon T-cell stimulation.	BCL10
19454668	10.4049/jimmunol.0900498	2009	CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells.	BCL10
19480824	10.1051/medsci/2009255454	2009	[Role of CK1alpha in adaptive immunity and lymphomagenesis].	BCL10
19494296	10.4049/jimmunol.0803313	2009	A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains.	BCL10
19535128	10.1016/j.humpath.2009.02.018	2009	Primary mucosa-associated lymphoid tissue lymphoma of the gallbladder: report of a case harboring API2/MALT1 gene fusion.	BCL10
19538180	10.1042/BJ20090055	2009	Generation and functional characterization of a BCL10-inhibitory peptide that represses NF-kappaB activation.	BCL10
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	BCL10
19576081	NA	2009	[A clinical study of chromosome translocations in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Chinese patients].	BCL10
19608748	10.1182/blood-2009-03-208215	2009	Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma.	BCL10
19690445	10.1159/000235603	2009	BCL10 single nucleotide polymorphism and its association with CSF dissemination of primary intracranial germ cell tumors.	BCL10
19696203	10.1182/blood-2008-12-192583	2009	Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma.	BCL10
19709433	10.1186/1476-4598-8-67	2009	STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells.	BCL10
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	BCL10
19841089	10.1084/jem.20091167	2009	Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.	BCL10
19860212	NA	2009	[Crucial roles of Helicobacter pylori infection in the pathogenesis of gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma].	BCL10
19897720	10.1073/pnas.0907511106	2009	Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.	BCL10
19915361	NA	2009	[Recent progress in lymphoma genomics and biology].	BCL10
20431728	10.5009/gnl.2009.3.2.81	2009	Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Updated Review of Clinical Outcomes and the Molecular Pathogenesis.	BCL10
20695076	10.4248/IJOS.09059	2009	CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex.	BCL10
17893875	10.1002/ijc.23071	2008	Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype.	BCL10
18175935	10.1248/bpb.31.13	2008	Dissociation of Toll-like receptor 2-mediated innate immune response to Zymosan by organic solvent-treatment without loss of Dectin-1 reactivity.	BCL10
18192506	10.1182/blood-2007-11-123513	2008	Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-kappaB and MAPK activation to selectively control cytokine production.	BCL10
18223652	10.1038/ni1561	2008	T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20.	BCL10
18227156	10.1128/MCB.01505-07	2008	T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b.	BCL10
18231929	10.1080/10428190701784722	2008	Analysis of CARMA1/BCL10/MALT1 expression in Reed-Sternberg cells of classical Hodgkin lymphoma.	BCL10
18245662	10.3324/haematol.11950	2008	Rare occurrence of IgVH gene translocations and restricted IgVH gene repertoire in ocular MALT-type lymphoma.	BCL10
18252714	10.1074/jbc.M708833200	2008	Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells.	BCL10
18264101	10.1038/ni1568	2008	The proteolytic activity of the paracaspase MALT1 is key in T cell activation.	BCL10
18287044	10.1073/pnas.0712313105	2008	NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation.	BCL10
18316375	10.1074/jbc.M707988200	2008	Sequestration of NF-kappaB signaling complexes in lipid rafts contributes to repression of NF-kappaB in T lymphocytes under hyperthermia stress.	BCL10
18349075	10.1242/jcs.021105	2008	A20 is a negative regulator of BCL10- and CARMA3-mediated activation of NF-kappaB.	BCL10
18445693	10.1158/1078-0432.CCR-07-4946	2008	Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma.	BCL10
18452717	10.1016/j.bbagen.2008.03.019	2008	Carrageenan-induced NFkappaB activation depends on distinct pathways mediated by reactive oxygen species and Hsp27 or by Bcl10.	BCL10
18550498	10.3724/sp.j.1005.2008.00747	2008	[In silico identification, molecular cloning and verification of a novel pig gene homologous to human BCL10 of innate immunity and its preliminary expression profiles in pigs].	BCL10
18575460	10.1038/nri2338	2008	Multifunctional roles for MALT1 in T-cell activation.	BCL10
18583339	10.1074/jbc.M802344200	2008	T cell receptor-mediated activation of CD4+CD44hi T cells bypasses Bcl10: an implication of differential NF-kappaB dependence of na√Øve and memory T cells during T cell receptor-mediated responses.	BCL10
18606643	10.4049/jimmunol.181.2.918	2008	Cell type-specific regulation of ITAM-mediated NF-kappaB activation by the adaptors, CARMA1 and CARD9.	BCL10
18625728	10.1128/MCB.00418-08	2008	The protein kinase C-responsive inhibitory domain of CARD11 functions in NF-kappaB activation to regulate the association of multiple signaling cofactors that differentially depend on Bcl10 and MALT1 for association.	BCL10
18628489	10.1182/blood-2008-02-137513	2008	Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma.	BCL10
18718996	10.1152/ajpgi.90434.2008	2008	Lipopolysaccharide activates NF-kappaB by TLR4-Bcl10-dependent and independent pathways in colonic epithelial cells.	BCL10
18802088	10.4049/jimmunol.181.7.4840	2008	Distinct regulation of integrin-dependent T cell conjugate formation and NF-kappa B activation by the adapter protein ADAP.	BCL10
18806265	10.1074/jbc.M800670200	2008	Multiple protein domains mediate interaction between Bcl10 and MALT1.	BCL10
18829987	10.1093/intimm/dxn108	2008	CD28 stimulation triggers NF-kappaB activation through the CARMA1-PKCtheta-Grb2/Gads axis.	BCL10
18833938	NA	2008	[Molecular genetics in primary gastrointestinal lymphomas].	BCL10
18927281	10.1158/1078-0432.CCR-08-0702	2008	Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3.	BCL10
18941215	10.4049/jimmunol.181.9.6244	2008	Loss of protein kinase C theta, Bcl10, or Malt1 selectively impairs proliferation and NF-kappa B activation in the CD4+ T cell subset.	BCL10
18949449	10.1007/s12185-008-0187-z	2008	BCL10 nuclear expression and t(11;18)(q21;q21) indicate nonresponsiveness to Helicobacter pylori eradication of Chinese primary gastric MALT lymphoma.	BCL10
19035248	NA	2008	[Abnormal BCL10 nuclear expression and chromosomal translocation in ocular adnexal mucosa-associated lymphoid tissue lymphomas].	BCL10
19080537	NA	2008	[High incidence of t (11; 18)/API2-MALT1 and BCL10 aberrant nuclear expression in pulmonary mucosa-associated lymphoid tissue lymphomas].	BCL10
19174606	10.1159/000195698	2008	Methylation of p16INK4A and mitotic arrest defective protein 2 (MAD2) genes in gastric marginal-zone B-cell lymphomas.	BCL10
17052756	10.1016/j.molimm.2006.09.012	2007	Bcl10 is phosphorylated on Ser138 by Ca2+/calmodulin-dependent protein kinase II.	BCL10
17095601	10.1073/pnas.0608388103	2007	Bcl10 and Malt1 control lysophosphatidic acid-induced NF-kappaB activation and cytokine production.	BCL10
17095757	10.1152/ajpgi.00380.2006	2007	Carrageenan induces interleukin-8 production through distinct Bcl10 pathway in normal human colonic epithelial cells.	BCL10
17098884	10.1136/jcp.2006.041012	2007	Pulmonary mucosa-associated lymphoid tissue lymphoma with strong nuclear B-cell CLL/lymphoma 10 (BCL10) expression and novel translocation t(1;2)(p22;p12)/immunoglobulin kappa chain-BCL10.	BCL10
17101977	10.1073/pnas.0601947103	2007	CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells.	BCL10
17167822	10.1002/path.2117	2007	Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression.	BCL10
17179215	10.1073/pnas.0601894104	2007	Bcl10 plays a critical role in NF-kappaB activation induced by G protein-coupled receptors.	BCL10
17182539	10.4049/jimmunol.178.1.49	2007	B cell lymphoma 10 is essential for FcepsilonR-mediated degranulation and IL-6 production in mast cells.	BCL10
17199743	10.1111/j.1440-1827.2007.02056.x	2007	MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas.	BCL10
17202357	10.4049/jimmunol.178.2.953	2007	Bcl10/Malt1 signaling is essential for TCR-induced NF-kappaB activation in thymocytes but dispensable for positive or negative selection.	BCL10
17213322	10.1073/pnas.0606982104	2007	Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10.	BCL10
17287209	10.1074/jbc.M611038200	2007	A Novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappaB activation by API2middle dotMALT1 fusions.	BCL10
17317796	10.1354/vp.44-2-196	2007	High-throughput immunophenotyping of 43 ferret lymphomas using tissue microarray technology.	BCL10
17356384	10.1097/01.jnen.0000248553.45456.96	2007	Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression.	BCL10
17363905	10.1038/sj.emboj.7601622	2007	Phosphorylation and ubiquitination of the IkappaB kinase complex by two distinct signaling pathways.	BCL10
17371994	10.4049/jimmunol.178.7.4373	2007	Bcl10 controls TCR- and FcgammaR-induced actin polymerization.	BCL10
17433222	10.1051/medsci/2007234353	2007	[New Bcl10 regulation mechanisms: a step in the comprehension of what has occurred in MALT lymphomas?].	BCL10
17438001	10.1101/gad.1502507	2007	CARMA3 deficiency abrogates G protein-coupled receptor-induced NF-{kappa}B activation.	BCL10
17462996	10.1074/jbc.M610610200	2007	Caspase-8 and c-FLIPL associate in lipid rafts with NF-kappaB adaptors during T cell activation.	BCL10
17468049	10.1016/j.it.2007.04.004	2007	Post-translational modifications regulate distinct functions of CARMA1 and BCL10.	BCL10
17473310	10.1126/stke.3842007pe21	2007	CARD-Bcl10-Malt1 signalosomes: missing link to NF-kappaB.	BCL10
17478723	10.1126/science.1137895	2007	Regulation of NF-kappaB activation in T cells via association of the adapter proteins ADAP and CARMA1.	BCL10
17502353	10.1128/MCB.01645-06	2007	Phosphorylation of Bcl10 negatively regulates T-cell receptor-mediated NF-kappaB activation.	BCL10
17525089	10.1136/gut.2007.123729	2007	Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation.	BCL10
17540779	10.1152/ajpgi.00149.2007	2007	Bcl10 mediates LPS-induced activation of NF-kappaB and IL-8 in human intestinal epithelial cells.	BCL10
17613665	10.1080/15321810701454573	2007	Development, evaluation, and application of a highly sensitive microtiter plate ELISA for human Bcl10 protein.	BCL10
17660823	10.1038/ni1493	2007	MALT1 directs B cell receptor-induced canonical nuclear factor-kappaB signaling selectively to the c-Rel subunit.	BCL10
17785812	10.4049/jimmunol.179.6.3752	2007	Bcl10 plays a divergent role in NK cell-mediated cytotoxicity and cytokine generation.	BCL10
17845767	NA	2007	[Detection of t (11; 18) and rearrangement of bcl-10 in paraffin-embedded samples using interphase fluorescence in-situ hybridization].	BCL10
17852708	10.1080/10428190701606818	2007	Higher rates of t(11;18) in Chinese patients with transformed type of MALT lymphoma suggest novel pathways for progression of the disease.	BCL10
17948050	10.1038/sj.emboj.7601897	2007	Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation.	BCL10
18040143	10.3960/jslrt.47.31	2007	MALT lymphoma : recent advances in aetiology and molecular genetics.	BCL10
18086859	10.1084/jem.20070379	2007	IkappaB kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells.	BCL10
18307876	NA	2007	[Clonal relationship between transformed and non-transformed components in mucosa-associated lymphoid tissue lymphoma].	BCL10
18307945	NA	2007	[Significance of detection of Bcl-10 novel mutation in ocular adnexal mucosa-associated lymphoid tissue lymphoma].	BCL10
18346354	NA	2007	[Abnormal expression of bcl-10 protein in extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue lymphoma type].	BCL10
16229939	10.1016/j.canlet.2005.08.019	2006	Association of BCL10 germ line polymorphisms on chromosome 1p with advanced stage testicular germ cell tumor patients.	BCL10
16280327	10.1074/jbc.M511014200	2006	A pathway for tumor necrosis factor-alpha-induced Bcl10 nuclear translocation. Bcl10 is up-regulated by NF-kappaB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus.	BCL10
16323006	10.1007/s00428-005-0122-0	2006	Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases.	BCL10
16341151	10.1038/modpathol.3800523	2006	MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of BCL10 in the tumour cells.	BCL10
16344587	10.1136/gut.2005.081117	2006	Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication.	BCL10
16395405	10.1172/JCI25641	2006	cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas.	BCL10
16432253	10.1084/jem.20051982	2006	The Bcl10-Malt1 complex segregates Fc epsilon RI-mediated nuclear factor kappa B activation and cytokine production from mast cell degranulation.	BCL10
16495340	10.1091/mbc.e05-10-0985	2006	POLKADOTS are foci of functional interactions in T-Cell receptor-mediated signaling to NF-kappaB.	BCL10
16508008	10.1128/MCB.26.6.2327-2336.2006	2006	CARMA1 is required for Akt-mediated NF-kappaB activation in T cells.	BCL10
16512826	10.1111/j.1365-2141.2006.05969.x	2006	Distinct comparative genomic hybridisation profiles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21).	BCL10
16572121	10.1038/nature04687	2006	A loss-of-function RNA interference screen for molecular targets in cancer.	BCL10
16572204	10.1038/sj.leu.2404192	2006	Molecular pathogenesis of MALT lymphoma: two signaling pathways underlying the antiapoptotic effect of API2-MALT1 fusion protein.	BCL10
16636337	10.1200/JCO.2006.05.6150	2006	Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.	BCL10
16636680	10.1038/modpathol.3800609	2006	Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenstr√∂m macroglobulinemia and does not correlate with p65 NF-kappaB activation.	BCL10
16648871	10.1038/modpathol.3800597	2006	Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival.	BCL10
16672958	10.1038/441032a	2006	Cell biology: divining cancer cell weaknesses.	BCL10
16775419	10.4161/cc.5.13.2866	2006	CIAP2 inhibits anigen receptor signaling by targeting Bcl10 for degredation.	BCL10
16776985	NA	2006	[Mucosa-associated lymphoid tissue lymphoma].	BCL10
16784987	10.1016/j.humpath.2006.02.012	2006	Aberrant nuclear BCL10 expression and lack of t(11;18)(q21;q21) in primary cutaneous marginal zone B-cell lymphoma.	BCL10
16785131	NA	2006	BCL10 gene amplification associated with strong nuclear BCL10 expression in a diffuse large B cell lymphoma with IGH-BCL2 fusion.	BCL10
16799010	10.1167/iovs.05-1312	2006	Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma.	BCL10
16809782	10.1128/MCB.02469-05	2006	Ca2+/calmodulin-dependent protein kinase II is a modulator of CARMA1-mediated NF-kappaB activation.	BCL10
16818229	10.1016/j.molcel.2006.05.027	2006	Essential role for IkappaB kinase beta in remodeling Carma1-Bcl10-Malt1 complexes upon T cell activation.	BCL10
16830336	10.1002/gcc.20352	2006	Quantitative microsatellite analysis to delineate the commonly deleted region 1p22.3 in mantle cell lymphomas.	BCL10
16831874	10.1074/jbc.M513057200	2006	The IRAK-1-BCL10-MALT1-TRAF6-TAK1 cascade mediates signaling to NF-kappaB from Toll-like receptor 4.	BCL10
16862125	10.1038/nature04926	2006	Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity.	BCL10
16863911	10.1016/j.exphem.2006.06.003	2006	The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics.	BCL10
16917511	10.1038/modpathol.3800668	2006	MALT1 gene rearrangements and NF-kappaB activation involving p65 and p50 are absent or rare in primary MALT lymphomas of the breast.	BCL10
16920630	10.1016/j.cub.2006.06.062	2006	Caspase-8 regulation by direct interaction with TRAF6 in T cell receptor-induced NF-kappaB activation.	BCL10
17043017	NA	2006	CARMA1 and chromosomal translocations in extranodal marginal zone B-cell lymphomas of MALT type or diffuse large B-cell lymphomas.	BCL10
17073595	10.2174/138945006778559256	2006	The Bcl10/Malt1 signaling pathway as a drug target in lymphoma.	BCL10
17099876	10.1002/cncr.22326	2006	Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment.	BCL10
17122510	10.1097/01.pas.0000213275.60962.2a	2006	The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.	BCL10
17274374	NA	2006	[Expression of BCL-10 protein and the relationship with API2-MALT1 fusion gene in extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue].	BCL10
15598810	10.1182/blood-2004-06-2297	2005	MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells.	BCL10
15682432	10.1002/path.1711	2005	FISH analysis of MALT lymphoma-specific translocations and aneuploidy in primary cutaneous marginal zone lymphoma.	BCL10
15682443	10.1002/path.1715	2005	MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression.	BCL10
15694184	10.1016/j.beha.2004.08.003	2005	Update on MALT lymphomas.	BCL10
15703784	10.1038/sj.leu.2403644	2005	T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma.	BCL10
15711920	10.1007/s10495-005-6059-6	2005	Anti-apoptotic action of API2-MALT1 fusion protein involved in t(11;18)(q21;q21) MALT lymphoma.	BCL10
15802594	10.1126/science.1110902	2005	Cell biology. Kinasing and clipping down the NF-kappa B trail.	BCL10
15802604	10.1126/science.1107107	2005	PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation.	BCL10
15845895	10.1182/blood-2005-01-0004	2005	Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21).	BCL10
15878976	10.1182/blood-2004-04-1248	2005	Bcl10 can promote survival of antigen-stimulated B lymphocytes.	BCL10
15989914	10.1016/j.amjmed.2005.02.004	2005	Idiopathic retroperitoneal fibrosis associated with immunohematological abnormalities.	BCL10
16123224	10.1182/blood-2004-12-4785	2005	MALT1 contains nuclear export signals and regulates cytoplasmic localization of BCL10.	BCL10
16127295	10.1159/000086789	2005	Accumulation of BCL10 at the perinuclear region is required for the BCL10-mediated nuclear factor-kappa B activation.	BCL10
16155022	10.1200/JCO.2005.05.011	2005	Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma.	BCL10
16177990	10.1002/cncr.21421	2005	Overexpression of caspase recruitment domain (CARD) membrane-associated guanylate kinase 1 (CARMA1) and CARD9 in primary gastric B-cell lymphoma.	BCL10
16310461	10.1016/j.ajo.2005.05.038	2005	BCL10 expression in ocular adnexal lymphomas.	BCL10
16440771	NA	2005	[Long-term remission after CHOP therapy in a case of multifocal extranodal diffuse large B-cell lymphoma with t(1 ; 14) (p22 ; q32) and rearrangement of bcl-10].	BCL10
16545185	NA	2005	[Expression of bcl-10 protein in MALT lymphoma].	BCL10
14574335	10.1038/sj.leu.2403185	2004	Primary pulmonary MALT lymphomas show frequent and heterogeneous cytogenetic abnormalities, including aneuploidy and translocations involving API2 and MALT1 and IGH and MALT1.	BCL10
14638696	10.1074/jbc.C300460200	2004	Rip2 participates in Bcl10 signaling and T-cell receptor-mediated NF-kappaB activation.	BCL10
14657271	10.1242/jcs.00904	2004	NF-kappaB signaling in lymphocytes: a new cast of characters.	BCL10
14673152	10.1128/MCB.24.1.164-171.2003	2004	CD3/CD28 costimulation-induced NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkappaB kinase beta to the immunological synapse through CARMA1.	BCL10
14674990	10.1111/j.1440-1827.2004.01580.x	2004	No evidence of a correlation between BCL10 expression and API2-MALT1 gene rearrangement in ocular adnexal MALT lymphoma.	BCL10
14695475	10.1038/nature02273	2004	Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO.	BCL10
14724296	10.1073/pnas.0307858100	2004	Complex and dynamic redistribution of NF-kappaB signaling intermediates in response to T cell receptor stimulation.	BCL10
14754896	10.1074/jbc.M310599200	2004	MALT1/paracaspase is a signaling component downstream of CARMA1 and mediates T cell receptor-induced NF-kappaB activation.	BCL10
14989765	NA	2004	[Expression of t(11;18) and bcl-10 in gastrointestinal MALT lymphoma].	BCL10
15049289	10.1016/j.it.2003.12.007	2004	New roles for Bcl10 in B-cell development and LPS response.	BCL10
15070758	10.1073/pnas.0400885101	2004	Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation.	BCL10
15082780	10.1128/MCB.24.9.3860-3873.2004	2004	Degradation of Bcl10 induced by T-cell activation negatively regulates NF-kappa B signaling.	BCL10
15100327	10.1093/jnci/djh138	2004	Common threads of mucosa-associated lymphoid tissue lymphoma pathogenesis: from infection to translocation.	BCL10
15122200	10.1038/nri1352	2004	CARMA1, BCL-10 and MALT1 in lymphocyte development and activation.	BCL10
15125833	10.1016/s1097-2765(04)00236-9	2004	The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes.	BCL10
15143341	10.1038/modpathol.3800164	2004	t(1;14) and t(11;18) in the differential diagnosis of Waldenstr√∂m's macroglobulinemia.	BCL10
15184390	10.1074/jbc.M402244200	2004	Physical and functional interaction of CARMA1 and CARMA3 with Ikappa kinase gamma-NFkappaB essential modulator.	BCL10
15207693	10.1016/j.bbrc.2004.05.112	2004	Characterization of Bcl10 as a potential transcriptional activator that interacts with general transcription factor TFIIB.	BCL10
15210867	10.112/4.3.3	2004	Ubiquitination for activation: new directions in the NF-kappaB roadmap.	BCL10
15213237	10.1074/jbc.M400241200	2004	BCL10 mediates lipopolysaccharide/toll-like receptor-4 signaling through interaction with Pellino2.	BCL10
15337797	10.1200/JCO.2004.10.087	2004	Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas.	BCL10
15539155	10.1016/j.immuni.2004.09.012	2004	SAP regulates T(H)2 differentiation and PKC-theta-mediated activation of NF-kappaB1.	BCL10
15540895	10.1532/ijh97.04101	2004	Nuclear factor kappaB activation and antiapoptosis in mucosa-associated lymphoid tissue lymphoma.	BCL10
15541657	10.1016/j.smim.2004.08.022	2004	The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling.	BCL10
15577674	10.1097/00000478-200412000-00003	2004	Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion.	BCL10
15634591	NA	2004	[Expression of BCL-10 in gastrointestinal mucosa-associated lymphoid tissue lymphoma].	BCL10
15637807	10.1016/j.febslet.2004.10.094	2004	Inhibition of Bcl10-mediated activation of NF-kappa B by BinCARD, a Bcl10-interacting CARD protein.	BCL10
12393483	10.1182/blood-2002-07-2009	2003	Cell cycle deregulation in B-cell lymphomas.	BCL10
12517817	10.1182/blood-2002-10-3167	2003	High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma.	BCL10
12589800	10.1016/s0006-291x(03)00063-9	2003	UV-light induces p38 MAPK-dependent phosphorylation of Bcl10.	BCL10
12651604	10.1016/S0002-9440(10)63908-9	2003	API2-MALT1 fusion defines a distinctive clinicopathologic subtype in pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.	BCL10
12676782	10.1182/blood-2002-11-3502	2003	Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma.	BCL10
12692046	10.1136/gut.52.5.641	2003	Distinct methylated profiles in Helicobacter pylori dependent and independent gastric MALT lymphomas.	BCL10
12720128	10.1053/sonc.2003.50049	2003	Dysregulation of apoptosis in Waldenstrom's macroglobulinemia does not involve nuclear factor kappa B activation.	BCL10
12766579	10.1097/00000478-200306000-00006	2003	Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases.	BCL10
12835267	10.1093/bioinformatics/btg148	2003	Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values.	BCL10
12841349	NA	2003	Bcl10 protein can act as a transcription activator in yeast.	BCL10
12867038	10.1016/s0960-9822(03)00491-3	2003	Requirement for CARMA1 in antigen receptor-induced NF-kappa B activation and lymphocyte proliferation.	BCL10
12883238	10.1097/00000478-200308000-00003	2003	Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases.	BCL10
12900354	10.1182/blood-2003-04-1286	2003	Aberrant BCL10 nuclear expression in nasal NK/T-cell lymphoma.	BCL10
12909454	10.1016/s1471-4906(03)00177-7	2003	TCR-induced NF-kappaB activation: a crucial role for Carma1, Bcl10 and MALT1.	BCL10
12910267	10.1038/ni963	2003	Defective development and function of Bcl10-deficient follicular, marginal zone and B1 B cells.	BCL10
12950026	10.1002/path.1426	2003	Infrequent somatic Fas mutations but no evidence of Bcl10 mutations or t(11;18) in primary cutaneous MALT-type lymphoma.	BCL10
12960515	10.1097/00001622-200309000-00001	2003	Update: gastric MALT lymphoma.	BCL10
14502259	10.1038/sj.thj.6200295	2003	T(11;18)(q21;q21) in gastric MALT lymphoma and diffuse large B-cell lymphoma of Chinese patients.	BCL10
14523480	10.1038/sj.leu.2403128	2003	BCL10 mutations are irrelevant to its aberrant nuclear localization in nasal NK/T-cell lymphoma.	BCL10
14576442	10.1126/science.1090769	2003	Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase.	BCL10
14614861	10.1016/s1074-7613(03)00293-0	2003	Differential requirement for Malt1 in T and B cell antigen receptor signaling.	BCL10
14634131	10.4049/jimmunol.171.11.6154	2003	Apoptosis-associated speck-like protein containing a caspase recruitment domain is a regulator of procaspase-1 activation.	BCL10
14645834	10.1126/science.1092951	2003	Immunology. The paracaspase connection.	BCL10
14681324	10.1097/01.MP.0000097283.47637.58	2003	API2-MALT1 fusion gene in colorectal lymphoma.	BCL10
14716524	10.1007/s10120-003-0260-5	2003	Colliding gastric and intestinal phenotype well-differentiated adenocarcinoma of the stomach developing in an area of MALT-type lymphoma.	BCL10
15202520	10.1080/10428190310001623793	2003	Molecular pathogenesis of mucosal-associated lymphoid tissue (MALT) lymphoma.	BCL10
11748643	10.1002/path.1015	2002	BCL10 in malignant lymphomas--an evaluation using fluorescence in situ hybridization.	BCL10
11753078	10.1097/00062752-200201000-00009	2002	Mucosa-associated lymphoid tissue lymphoma.	BCL10
11818074	10.1016/s0960-9822(01)00668-6	2002	Bcl10.	BCL10
11830492	10.1182/blood.v99.4.1398	2002	BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression.	BCL10
11836626	NA	2002	Lack of Bcl10 mutations in malignant cartilaginous tumors.	BCL10
11850073	10.1016/s0165-4608(01)00548-9	2002	Cytogenetic characterization of diffuse large cell lymphoma using multi-color fluorescence in situ hybridization.	BCL10
11960389	10.1038/sj.thj.6200146	2002	Genetic alterations underlying the pathogenesis of MALT lymphoma.	BCL10
12017308	NA	2002	Lack of BCL10 mRNA mutation in lymphold malignancies.	BCL10
12091384	10.1074/jbc.M202222200	2002	Protein kinase C-associated kinase (PKK) mediates Bcl10-independent NF-kappa B activation induced by phorbol ester.	BCL10
12154356	10.1038/ni824	2002	A requirement for CARMA1 in TCR-induced NF-kappa B activation.	BCL10
12154360	10.1038/ni830	2002	CARMA1 is a critical lipid raft-associated regulator of TCR-induced NF-kappa B activation.	BCL10
12389689	10.1258/00222150260171605	2002	Lack of Bcl10 gene mutations in laryngeal squamous cell carcinoma.	BCL10
14993411	10.1124/mi.2.6.356	2002	Determining the destiny of NF-kappa B after TCR ligation: it's CARMA1.	BCL10
11163238	10.1016/s0092-8674(01)00189-1	2001	Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure.	BCL10
11238466	10.1083/jcb.152.5.1115	2001	Equine herpesvirus protein E10 induces membrane recruitment and phosphorylation of its cellular homologue, bcl-10.	BCL10
11259443	10.1074/jbc.M102488200	2001	Card10 is a novel caspase recruitment domain/membrane-associated guanylate kinase family member that interacts with BCL10 and activates NF-kappa B.	BCL10
11262391	10.1074/jbc.M009984200	2001	Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway.	BCL10
11278692	10.1074/jbc.M010512200	2001	CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B.	BCL10
11356195	10.1016/s0014-5793(01)02414-0	2001	Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaB activation.	BCL10
11387339	10.1074/jbc.M103824200	2001	Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-kappaB induction.	BCL10
11466612	10.1038/sj.onc.1204576	2001	Interchangeable binding of Bcl10 to TRAF2 and cIAPs regulates apoptosis signaling.	BCL10
11605060	10.3892/or.8.6.1333	2001	Absence of Bcl10 gene mutations in Ewing's sarcomas.	BCL10
11707622	10.1097/00125480-200111000-00001	2001	Marginal-zone B-cell lymphoma of extranodal mucosa-associated lymphoid tissue type: molecular genetics provides new insights into pathogenesis.	BCL10
11722987	10.1182/asheducation-2001.1.241	2001	MALT Lymphomas.	BCL10
11780342	NA	2001	bcl 10 gene mutation in hepatocellular carcinoma.	BCL10
10753917	10.1074/jbc.275.15.11114	2000	Regulatory mechanisms of TRAF2-mediated signal transduction by Bcl10, a MALT lymphoma-associated protein.	BCL10
11021819	10.1016/S0002-9440(10)64630-5	2000	BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma.	BCL10
11053425	10.1074/jbc.C000726200	2000	CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B.	BCL10
11090634	10.1016/s1097-2765(00)00094-0	2000	Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma.	BCL10
11701542	10.1182/asheducation-2000.1.180	2000	Non-Hodgkin's Lymphoma: Molecular Features of B Cell Lymphoma.	BCL10
10187770	10.1074/jbc.274.15.9955	1999	CIPER, a novel NF kappaB-activating protein containing a caspase recruitment domain with homology to Herpesvirus-2 protein E10.	BCL10
10187771	10.1074/jbc.274.15.9962	1999	Equine herpesvirus-2 E10 gene product, but not its cellular homologue, activates NF-kappaB transcription factor and c-Jun N-terminal kinase.	BCL10
10187815	10.1074/jbc.274.15.10287	1999	mE10, a novel caspase recruitment domain-containing proapoptotic molecule.	BCL10
10364242	10.1074/jbc.274.25.17946	1999	CLAP, a novel caspase recruitment domain-containing protein in the tumor necrosis factor receptor pathway, regulates NF-kappaB activation and apoptosis.	BCL10
10400625	10.1074/jbc.274.29.20127	1999	c-E10 is a caspase-recruiting domain-containing protein that interacts with components of death receptors signaling pathway and activates nuclear factor-kappaB.	BCL10
9989495	10.1016/s0092-8674(00)80957-5	1999	Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types.	BCL10
35143940	10.1016/j.gene.2022.146289	2022	Reactivation of Œ≥-globin expression using a minicircle DNA system to treat Œ≤-thalassemia.	BCL11A
35300055	10.2147/PGPM.S351599	2022	Association Between Selected Single Nucleotide Polymorphisms in Globin and Related Genes and Response to Hydroxyurea Therapy in Ghanaian Children with Sickle Cell Disease.	BCL11A
35504960	10.1038/s41598-022-11247-z	2022	A retrospective study on the clinicopathological and molecular features of 22 cases of natural killer/T-cell lymphoma in children and adolescents.	BCL11A
35805190	10.3390/cells11132106	2022	Selective Ablation of BCL11A in Epidermal Keratinocytes Alters Skin Homeostasis and Accelerates Excisional Wound Healing In Vivo.	BCL11A
35806029	10.3390/ijms23137025	2022	LRF Promotes Indirectly Advantageous Chromatin Conformation via <i>BGLT3</i>-lncRNA Expression and Switch from Fetal to Adult Hemoglobin.	BCL11A
35909289	10.2174/1568009622666220728123748	2022	BCL11A Facilitates Cell Proliferation and Metastasis in Neuroblastoma via Regulating the PI3K/Akt Signaling Pathway.	BCL11A
32882024	10.1093/jnci/djaa133	2021	Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children.	BCL11A
33910976	10.1126/scitranslmed.abb0411	2021	Sustained fetal hemoglobin induction in vivo is achieved by <i>BCL11A</i> interference and coexpressed truncated erythropoietin receptor.	BCL11A
33959502	10.3389/fonc.2021.638897	2021	c-Rel Is the Pivotal NF-Œ∫B Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.	BCL11A
34592153	10.1016/j.celrep.2021.109759	2021	Structural basis for human ZBTB7A action at the fetal globin promoter.	BCL11A
34611409	10.2147/OTT.S319845	2021	Identification of a Novel SLC8A1-ALK Fusion and Non-Canonical Expression Significantly Responding to ALK-TKIs in Lung Adenocarcinoma: A Case Report.	BCL11A
30853596	10.1016/j.ygeno.2019.03.002	2020	Identification of deleterious SNPs and their effects on BCL11A, the master regulator of fetal hemoglobin expression.	BCL11A
32013807	10.1177/1010428319901061	2020	Antiproliferative and proapoptotic effects of <i>Inula viscosa</i> extract on Burkitt lymphoma cell line.	BCL11A
32085444	10.3390/ani10020317	2020	Metabolic and Biomolecular Changes Induced by Incremental Long-Term Training in Young Thoroughbred Racehorses during First Workout Season.	BCL11A
32218847	10.3892/ol.2020.11383	2020	BCL11A confers cell invasion and migration in androgen receptor-positive triple-negative breast cancer.	BCL11A
32266150	10.3389/fonc.2020.00375	2020	BCL11A Promotes the Progression of Laryngeal Squamous Cell Carcinoma.	BCL11A
32319565	10.3892/ijo.2020.4995	2020	miR‚Äë574‚Äë5p attenuates proliferation, migration and EMT in triple‚Äënegative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.	BCL11A
32576660	10.1074/jbc.RA120.014018	2020	The transcriptional repressor BCL11A promotes breast cancer metastasis.	BCL11A
32625084	10.3389/fphar.2020.00820	2020	BCL11A Is Oncogenic and Predicts Poor Outcomes in Natural Killer/T-Cell Lymphoma.	BCL11A
32878504	10.1080/03630269.2020.1811117	2020	Association Between Genetic Polymorphisms and Hb F Levels in Heterozygous Œ≤-Thalassemia 3.5‚Äâkb Deletions.	BCL11A
32903878	10.1159/000508566	2020	A Novel de novo Frameshift Mutation in the <i>BCL11A</i> Gene in a Patient with Intellectual Disability Syndrome and Epilepsy.	BCL11A
33073380	10.1111/bjh.17102	2020	F cell numbers are associated with an X-linked genetic polymorphism and correlate with haematological parameters in patients with sickle cell disease.	BCL11A
33154494	10.1038/s41598-020-76157-4	2020	The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolution.	BCL11A
30124006	10.22074/cellj.2019.5589	2019	Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction.	BCL11A
30520249	10.1111/1753-0407.12882	2019	Role of metabolic syndrome and its components as mediators of the genetic effect on type 2 diabetes: A family-based study in China.	BCL11A
30768627	10.1371/journal.pone.0212492	2019	The rs61742690 (S783N) single nucleotide polymorphism is a suitable target for disrupting BCL11A-mediated foetal-to-adult globin switching.	BCL11A
30870006	10.1096/fj.201802252R	2019	Long noncoding RNA CDKN2B-AS1 interacts with transcription factor BCL11A to regulate progression of cerebral infarction through mediating MAP4K1 transcription.	BCL11A
31000522	10.1158/0008-5472.CAN-18-3438	2019	MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.	BCL11A
31039344	10.1016/j.ejphar.2019.04.042	2019	Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.	BCL11A
31277480	10.3390/cancers11070941	2019	The Unsolved Puzzle of c-Rel in B Cell Lymphoma.	BCL11A
31312380	NA	2019	Molecular simulation studies on B-cell lymphoma/leukaemia 11A (BCL11A).	BCL11A
31362654	10.2174/1389450120666190726155733	2019	Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia.	BCL11A
31410080	10.3906/biy-1810-2	2019	Systematic analysis of the frequently amplified 2p15-p16.1 locus reveals PAPOLG as a potential proto-oncogene in follicular and transformed follicular lymphoma.	BCL11A
31654056	10.1042/BSR20190604	2019	BCL11A: a potential diagnostic biomarker and therapeutic target in human diseases.	BCL11A
28544358	10.1111/ajco.12690	2018	The expression pattern of Bcl11a, Mdm2 and Pten genes in B-cell acute lymphoblastic leukemia.	BCL11A
29581848	10.18632/oncotarget.24512	2018	Aberrant expression of NKL homeobox gene HLX in Hodgkin lymphoma.	BCL11A
29975921	10.1159/000491526	2018	MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.	BCL11A
30289070	10.2174/1566524018666181004121604	2018	Genetic Modifiers of Fetal Haemoglobin (HbF) and Phenotypic Severity in Œ≤-Thalassemia Patients.	BCL11A
30821197	10.1080/03630269.2018.1515774	2018	BCL11A Down-Regulation Induces Œ≥-Globin in Human Œ≤-Thalassemia Major Erythroid Cells.	BCL11A
31938433	NA	2018	Clinical significance of BCL11A expression in ER-negative and PR-negative endometrial carcinoma.	BCL11A
27786413	10.1002/pbc.26251	2017	DNA methylation profiling of pediatric B-cell lymphoblastic leukemia with KMT2A rearrangement identifies hypomethylation at enhancer sites.	BCL11A
28225775	10.1371/journal.pone.0171116	2017	Genetic polymorphisms and plasma levels of BCL11A contribute to the development of laryngeal squamous cell carcinoma.	BCL11A
28404650	10.1183/13993003.02149-2016	2017	Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient.	BCL11A
28493377	10.1002/eji.201646621	2017	Neonatal myeloid derived suppressor cells show reduced apoptosis and immunosuppressive activity upon infection with Escherichia coli.	BCL11A
29018799	10.3389/fmed.2017.00153	2017	TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform.	BCL11A
26862517	10.22074/cellj.2016.3808	2016	MicroRNA Expression in Œ≤-Thalassemia and Sickle Cell Disease: A Role in The Induction of Fetal Hemoglobin.	BCL11A
27340226	10.1093/hmg/ddw170	2016	Hemoglobin genetics: recent contributions of GWAS and gene editing.	BCL11A
27653684	10.1016/j.celrep.2016.08.064	2016	Bcl11a Deficiency Leads to Hematopoietic Stem Cell Defects with an Aging-like Phenotype.	BCL11A
27774950	NA	2016	[Knock-down of BCL11A expression in breast cancer cells promotes MDA-MB-231 cell apoptosis].	BCL11A
27835906	10.18632/oncotarget.13239	2016	Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.	BCL11A
24796653	10.1111/1753-0407.12163	2015	Decreased miR-146 expression in peripheral blood mononuclear cells is correlated with ongoing islet autoimmunity in type 1 diabetes patients 1miR-146.	BCL11A
25979662	10.1016/j.ejmg.2015.04.006	2015	Brain malformations in a patient with deletion 2p16.1: A refinement of¬†the phenotype to BCL11A.	BCL11A
26342260	10.1016/j.exphem.2015.08.011	2015	Development and characterization of K562 cell clones expressing BCL11A-XL: Decreased hemoglobin production with fetal hemoglobin inducers and its rescue with mithramycin.	BCL11A
26487345	10.1038/srep15215	2015	Transcription factor and miRNA co-regulatory network reveals shared and specific regulators in the development of B cell and T cell.	BCL11A
23432949	10.1179/1607845413Y.0000000078	2014	Concurrent rearrangements of BCL2, BCL3, and BCL11A genes in atypical chronic lymphocytic leukemia.	BCL11A
24344258	10.1073/pnas.1321704111	2014	Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A.	BCL11A
24832791	10.1002/gcc.22184	2014	Amplification of 2p as a genomic marker for transformation in lymphoma.	BCL11A
24961604	10.1186/2047-783X-19-34	2014	Combination of BCL11A siRNA with vincristine increases the apoptosis of SUDHL6 cells.	BCL11A
25044937	10.1002/cbin.10332	2014	Gene expression profile analysis of SUDHL6 cells with siRNA-mediated BCL11A downregulation.	BCL11A
25364581	10.7497/j.issn.2095-3941.2014.03.006	2014	The gene expression patterns of BMPR2, EP300, TGFŒ≤2, and TNFAIP3 in B-Lymphoma cells.	BCL11A
22890838	10.1002/ijc.27774	2013	High-resolution genomic profiling reveals clonal evolution and competition in gastrointestinal marginal zone B-cell lymphoma and its large cell variant.	BCL11A
23361909	10.1182/blood-2012-06-434530	2013	Erythropoiesis and globin switching in compound Klf1::Bcl11a mutant mice.	BCL11A
23758992	10.1186/1476-4598-12-61	2013	BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification.	BCL11A
23815911	10.7534/j.issn.1009-2137.2013.03.018	2013	[Effect of BCL11A gene on transcription of Œ≥-globin gene].	BCL11A
24648892	10.3892/br.2012.9	2013	Downregulation of BCL11A by siRNA induces apoptosis in B lymphoma cell lines.	BCL11A
22582156	10.1007/s13205-011-0026-4	2012	Comparative studies of glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1: evidence for a eutherian mammalian origin for the GPIHBP1 gene from an LY6-like gene.	BCL11A
21366467	10.5858/2009-0463-RSR.1	2011	Primary mediastinal (thymic) large B-cell lymphoma: a short review with brief discussion of mediastinal gray zone lymphoma.	BCL11A
21429398	NA	2011	[Preliminary study of gene expression profile associated with risk classification of childhood patients with acute lymphoblastic leukemia].	BCL11A
21772954	10.4081/pr.2011.e17	2011	Recent advances in Œ≤-thalassemias.	BCL11A
21822207	10.1038/modpathol.2011.116	2011	Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations.	BCL11A
20534004	10.1111/j.1471-4159.2010.06852.x	2010	Bcl11A/CTIP1 mediates the effect of the glutamate receptor on axon branching and dendrite outgrowth.	BCL11A
20578197	10.1002/ajh.21758	2010	14q32/miRNA clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up-regulation of BCL11a.	BCL11A
20623620	10.1002/jnr.22407	2010	X-linked mental retardation gene CASK interacts with Bcl11A/CTIP1 and regulates axon branching and outgrowth.	BCL11A
19096012	10.1182/blood-2008-07-168096	2009	Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.	BCL11A
19369625	10.1309/AJCPXLY46UPFLISC	2009	Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes.	BCL11A
18367492	10.3324/haematol.12221	2008	Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia.	BCL11A
18940474	10.1016/j.cancergencyto.2008.06.007	2008	BCL2 and BCL3 are recurrent translocation partners of the IGH locus.	BCL11A
17230227	10.1038/sj.leu.2404529	2007	Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas.	BCL11A
17638669	10.1309/21TN2RUWKR827UW2	2007	Chronic lymphocytic leukemia FISH panel: impact on diagnosis.	BCL11A
18253030	10.1159/000112062	2007	U-HO1, a new cell line derived from a primary refractory classical Hodgkin lymphoma.	BCL11A
16704730	10.1186/1476-4598-5-18	2006	Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells.	BCL11A
16734728	10.1111/j.1349-7006.2006.00209.x	2006	Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma.	BCL11A
16871282	10.1038/sj.leu.2404324	2006	Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A(XL) protein are frequent in primary mediastinal B-cell lymphoma.	BCL11A
16091750	10.1038/sj.onc.1208904	2005	BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter.	BCL11A
16147992	10.1074/mcp.M500112-MCP200	2005	Analysis of BCL6-interacting proteins by tandem mass spectrometry.	BCL11A
15241441	10.1038/labinvest.3700152	2004	Epstein-Barr virus is integrated between REL and BCL-11A in American Burkitt lymphoma cell line (NAB-2).	BCL11A
15313894	10.1158/0008-5472.CAN-04-1253	2004	Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in S√©zary syndrome identified by gene expression analysis.	BCL11A
15337798	10.1200/JCO.2004.11.025	2004	Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas.	BCL11A
15496980	10.1038/sj.leu.2403500	2004	Rapid amplification of immunoglobulin heavy chain switch (IGHS) translocation breakpoints using long-distance inverse PCR.	BCL11A
12406872	10.1182/blood-2002-07-2119	2003	Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations.	BCL11A
12774917	10.1007/BF02982637	2003	The pathogenetic role of oncogenes deregulated by chromosomal translocation in B-cell malignancies.	BCL11A
11830502	10.1182/blood.v99.4.1474	2002	Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.	BCL11A
11986957	10.1038/sj.leu.2402480	2002	Lack of somatic hypermutation of IG V(H) genes in lymphoid malignancies with t(2;14)(p13;q32) translocation involving the BCL11A gene.	BCL11A
12040429	10.1038/sj.leu.2402528	2002	The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia.	BCL11A
11719382	10.1182/blood.v98.12.3413	2001	The BCL11 gene family: involvement of BCL11A in lymphoid malignancies.	BCL11A
34060394	10.1080/01635581.2021.1931700	2022	Britannin a Sesquiterpene Lactone from <i>Inula aucheriana</i> Exerted an Anti-leukemic Effect in Acute Lymphoblastic Leukemia (ALL) Cells and Enhanced the Sensitivity of the Cells to Vincristine.	BCL2
34082607	10.1177/11206721211023309	2022	Follicular lymphoma of the ocular adnexa: Clinicopathological findings with flow cytometry analysis of eight cases.	BCL2
34180720	10.1177/10668969211027409	2022	Aggressive Cyclin D1 Negative Blastoid Variant Mantle Cell Lymphoma-A Case Report.	BCL2
34184213	10.1007/s12011-021-02802-2	2022	Borax Pentahydrate and Disodium Pentaborate Decahydrate Are Candidates as Anti-leukemic Drug Components by Inducing Apoptosis and Changing Bax/Bcl-2 Ratio in HL-60 Cell Line.	BCL2
34236820	10.21470/1678-9741-2020-0549	2022	The Protective Effect of Kaempferol Against Ischemia/Reperfusion Injury Through Activating SIRT3 to Inhibit Oxidative Stress.	BCL2
34265801	10.1097/PAS.0000000000001780	2022	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.	BCL2
34289655	10.3324/haematol.2021.278638	2022	Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.	BCL2
34304248	10.1038/s41375-021-01347-6	2022	Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.	BCL2
34314292	10.1080/15321819.2021.1954948	2022	Expression of Friend Leukemia Integration-1 (Fli-1) and the Apoptosis Regulator B Cell Lymphoma-2 (BCL-2) in Gastric Carcinoma; an Immunohistochemical Study.	BCL2
34332791	10.1016/j.pathol.2021.04.008	2022	Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.	BCL2
34353221	10.1080/15376516.2021.1965276	2022	Concerted hepatoprotective effect of bradykinin potentiating factor and low dose of Œ≥- radiation on <i>Naja haje</i> envenomed rats <i>via</i> Bax/Bcl2 pathway.	BCL2
34392269	10.1097/PAS.0000000000001750	2022	Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity.	BCL2
34411492	10.1139/cjpp-2021-0007	2022	Colchicine attenuates renal ischemia-reperfusion-induced liver damage: implication of TLR4/NF-Œ∫B, TGF-Œ≤, and <i>BAX</i> and <i>Bcl-2</i> gene expression.	BCL2
34417692	10.1007/s11356-021-15985-x	2022	Landfill soil leachates from Nigeria and India induced DNA damage and alterations in genes associated with apoptosis in Jurkat cell.	BCL2
34454850	10.1016/j.clml.2021.07.020	2022	Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.	BCL2
34456240	10.1097/PAI.0000000000000967	2022	Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting.	BCL2
34510996	10.1080/10428194.2021.1975189	2022	<i>BCL2</i> translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival.	BCL2
34515880	10.1007/s10238-021-00754-4	2022	Programmed cell death-ligand 1 (PD-L1)<sup>+</sup> tumour cells and low-reacting programmed cell death 1 (PD1)<sup>+</sup> tumour-infiltrating lymphocytes predict poor prognosis in Epstein-Barr virus<sup>+</sup> diffuse large B-cell lymphoma.	BCL2
34519021	10.1111/bjh.17815	2022	Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.	BCL2
34528680	10.1093/ajcp/aqab128	2022	Recurrent Chromosomal Abnormalities in Tissues Involved by Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.	BCL2
34530171	10.1016/j.bone.2021.116182	2022	Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through mediating Bcl2 stability via Ythdf1-mediated m<sup>6</sup>A modification.	BCL2
34532813	10.1007/s11010-021-04257-4	2022	Tanshinone I restrains osteosarcoma progression by regulating circ_0000376/miR-432-5p/BCL2 axis.	BCL2
34538551	10.1016/j.jfma.2021.08.015	2022	Mechanism of quercetin on the improvement of ovulation disorder and regulation of ovarian CNP/NPR2 in PCOS model rats.	BCL2
34601504	10.1038/s41379-021-00938-z	2022	Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation.	BCL2
34601571	10.1182/blood.2021013156	2022	Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.	BCL2
34605949	10.1007/s00277-021-04671-0	2022	Characterization of molecular genetics and clinicopathology in thymic MALT lymphoma.	BCL2
34608246	10.1038/s41379-021-00909-4	2022	Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge.	BCL2
34615723	10.1158/1078-0432.CCR-21-2183	2022	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.	BCL2
34617271	10.1111/bjh.17874	2022	Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.	BCL2
34624089	10.1182/blood.2021012327	2022	Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2+ diffuse large B-cell lymphomas.	BCL2
34632572	10.1111/bjh.17858	2022	Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.	BCL2
34632715	10.1002/1878-0261.13115	2022	Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma.	BCL2
34637146	10.1111/his.14585	2022	EBV<sup>+</sup> high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study.	BCL2
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	BCL2
34673010	10.1016/j.cbi.2021.109703	2022	The effects of agomelatine on endoplasmic reticulum stress related to mitochondrial dysfunction in hippocampus of aging rat model.	BCL2
34710243	10.1002/ajh.26390	2022	Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.	BCL2
34713475	10.1002/hon.2943	2022	Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.	BCL2
34727403	10.1111/pin.13182	2022	AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.	BCL2
34727633	10.5713/ab.21.0371	2022	Curcumin represses lipid accumulation through inhibiting ERK1/2-PPAR-Œ≥ signaling pathway and triggering apoptosis in porcine subcutaneous preadipocytes.	BCL2
34727830	10.1080/10428194.2021.1998480	2022	Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma.	BCL2
34728569	10.1158/1535-7163.MCT-21-0511	2022	Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas.	BCL2
34730059	10.1080/08916934.2021.1995861	2022	Circ_0114427 promotes LPS-induced septic acute kidney injury by modulating miR-495-3p/TRAF6 through the NF-Œ∫B pathway.	BCL2
34735897	10.1016/j.tranon.2021.101260	2022	A novel strategy for combination of clofarabine and pictilisib is synergistic in gastric cancer.	BCL2
34739417	10.1097/PAS.0000000000001830	2022	Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined With Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma.	BCL2
34747234	10.1177/00031348211054526	2022	Primary Parotid Non-Hodgkin's B-Cell Lymphoma in an Elderly Woman on Pembrolizumab for Metastatic Invasive Papillary Urothelial Cell Carcinoma of the Bladder.	BCL2
34752896	10.1016/j.cbpc.2021.109241	2022	Excessive manganese alters serum biochemical indices, induces histopathological alterations, and activates apoptosis in liver and cerebrum of Jianzhou Da'er goat (Capra hircus).	BCL2
34756435	10.3168/jds.2021-20364	2022	Acute and chronic effects of cortisol on milk yield, the expression of key receptors, and apoptosis of mammary epithelial cells in Saanen goats.	BCL2
34764434	10.1038/s41379-021-00962-z	2022	BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.	BCL2
34788985	10.3324/haematol.2021.279631	2022	Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing.	BCL2
34793256	10.1200/JCO.21.01194	2022	Venetoclax in Previously Treated Waldenstr√∂m Macroglobulinemia.	BCL2
34795418	10.1038/s41375-021-01470-4	2022	Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models.	BCL2
34802044	10.1038/s41379-021-00954-z	2022	A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform.	BCL2
34821081	10.1002/cnr2.1590	2022	Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data.	BCL2
34837284	10.1111/cas.15224	2022	Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.	BCL2
34842019	10.1080/10428194.2021.2008383	2022	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?	BCL2
34848360	10.1016/j.jep.2021.114873	2022	Crocetin ameliorates non-alcoholic fatty liver disease by modulating mitochondrial dysfunction in L02¬†cells and zebrafish model.	BCL2
34861556	10.1016/j.theriogenology.2021.11.017	2022	Expression of kisspeptin and its receptor in different functional classes of ovarian follicle in the buffalo (Bubalus bubalis).	BCL2
34861696	10.1182/bloodadvances.2021006211	2022	Single-cell sequencing demonstrates complex resistance landscape in¬†CLL and MCL treated with BTK and BCL2 inhibitors.	BCL2
34864562	10.1016/j.theriogenology.2021.11.022	2022	Protegrin-1 inhibits porcine ovarian granulosa cell apoptosis from H<sub>2</sub>O<sub>2</sub>-induced oxidative stress via the PERK/eIF2Œ±/CHOP signaling pathway in¬†vitro.	BCL2
34866456	10.1177/10668969211065110	2022	Endometrial Stromal Expression of ER, PR, and B-Catenin Toward Differentiating Hyperplasia Diagnoses.	BCL2
34872752	10.1016/j.pathol.2021.09.009	2022	EBV-positive low-grade follicular lymphoma transforming to EBV-negative high-grade B-cell lymphoma with MYC and BCL2 rearrangements.	BCL2
34878357	10.1080/14737159.2022.2016394	2022	Association between serum concentrations of anti-apoptotic B-cell lymphoma-2 protein and traumatic brain injury mortality.	BCL2
34896653	10.1016/j.jtct.2021.12.001	2022	Inhibition of IL-1 Receptor-Associated Kinase 1 Decreases Murine Acute Graft-versus-Host Disease While Preserving the Graft-versus-Lymphoma Effect.	BCL2
34896889	10.1016/j.anndiagpath.2021.151868	2022	Merkel cell carcinoma in the setting of hematologic disease is associated with unique features and potential pitfalls.	BCL2
34913064	10.3892/mmr.2021.12566	2022	Substance P prevents doxorubicin‚Äëinduced cardiomyocyte injury by regulating apoptosis and autophagy: <i>In¬†vitro</i> and <i>in¬†vivo</i> evidence.	BCL2
34913075	10.3892/or.2021.8241	2022	Niclosamide suppresses T‚Äëcell acute lymphoblastic leukemia growth through activation of apoptosis and autophagy.	BCL2
34913076	10.3892/ijo.2021.5292	2022	Synergism of a novel MCL‚Äë1 downregulator, acriflavine, with navitoclax (ABT‚Äë263) in triple‚Äënegative breast cancer, lung adenocarcinoma and glioblastoma multiforme.	BCL2
34920187	10.1016/j.anireprosci.2021.106908	2022	Silver nanoparticles induce oxidative stress, apoptosis and impaired steroidogenesis in ovarian granulosa cells of cattle.	BCL2
34922904	10.1016/j.cbi.2021.109779	2022	Diffuse large B-cell lymphoma-derived exosomes push macrophage polarization toward M2 phenotype via GP130/STAT3 signaling pathway.	BCL2
34932207	10.1007/s40265-021-01657-0	2022	Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.	BCL2
34932406	10.1139/cjpp-2021-0596	2022	Doxorubicin-induced apoptosis enhances monocyte infiltration and adverse cardiac remodeling in diabetic animals.	BCL2
34932839	10.1111/and.14348	2022	Explore the effects of pulmonary fibrosis on sperm quality and the role of the PI3K/Akt pathway based on rat model.	BCL2
34937946	10.1038/s41586-021-04244-1	2022	Valine tRNA levels and availability regulate complex I assembly in leukaemia.	BCL2
34951009	10.1111/bjh.17971	2022	Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.	BCL2
34957565	10.1002/path.5861	2022	Widespread in situ follicular neoplasia in patients who subsequently developed follicular lymphoma.	BCL2
34962105	10.1002/dc.24922	2022	Primary thyroid high-grade B-cell lymphoma with MYC and BCL2 rearrangements in Hashimoto's thyroiditis.	BCL2
34967008	10.1111/bjh.17990	2022	The molecular ontogeny of follicular lymphoma: gene mutations succeeding the BCL2 translocation define common precursor cells.	BCL2
34980601	10.1158/1078-0432.CCR-21-2949	2022	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.	BCL2
34984584	10.1007/s12035-021-02675-5	2022	Bax Contributes to Retinal Ganglion Cell Dendritic Degeneration During Glaucoma.	BCL2
34990302	10.1080/21655979.2021.2017590	2022	Propofol induces the apoptosis of neural stem cells via microRNA-9-5p / chemokine CXC receptor 4 signaling pathway.	BCL2
34994825	10.1007/s00210-021-02175-2	2022	Diacerein ameliorates induced polycystic ovary in female rats via modulation of inflammasome/caspase1/IL1Œ≤ and Bax/Bcl2 pathways.	BCL2
34994930	10.1007/s11356-021-18399-x	2022	Histopathological, Immunohistochemical, And Molecular Alterations In Brain Tissue And Submandibular Salivary Gland Of Atrazine-Induced Toxicity In Male Rats.	BCL2
34994989	10.1002/jcla.24227	2022	Association of B-cell lymphoma 2/microRNA-497 gene expression ratio score with metastasis in patients with colorectal cancer: A propensity-matched cohort analysis.	BCL2
34999394	10.1016/j.intimp.2021.108497	2022	Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway.	BCL2
35007655	10.1016/j.dci.2022.104349	2022	SpBAG3 assisted WSSV infection in mud crab (Scylla paramamosain) by inhibiting apoptosis.	BCL2
35013138	10.1038/s41420-021-00622-w	2022	Knockdown of NRMT enhances sensitivity of retinoblastoma cells to cisplatin through upregulation of the CENPA/Myc/Bcl2 axis.	BCL2
35028710	10.1007/s00428-021-03265-5	2022	Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.	BCL2
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	BCL2
35036912	10.1177/2632010X211070774	2022	Rare but Potentially Fatal Presentations of Diffuse Large B-cell Lymphoma: Leukemic Phase or Hemophagocytic Syndrome in Bone Marrow.	BCL2
35038193	10.1111/his.14617	2022	Incidence, clinicopathological features and genetics of in-situ follicular neoplasia: a comprehensive screening study in a Japanese cohort.	BCL2
35044826	10.1126/sciadv.abl4644	2022	Preneoplastic somatic mutations including <i>MYD88</i><sup>L265P</sup> in lymphoplasmacytic lymphoma.	BCL2
35045798	10.1080/10428194.2021.2024821	2022	High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.	BCL2
35045920	10.1691/ph.2022.1670	2022	Anti-TIM1 suppresses airway inflammation and hyperresponsiveness via the STAT6 /STAT1 pathways in mice with allergic asthma.	BCL2
35046056	10.1158/1078-0432.CCR-21-3617	2022	First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.	BCL2
35053500	10.3390/cancers14020338	2022	High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients.	BCL2
35058488	10.1038/s41598-022-04916-6	2022	Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.	BCL2
35062067	10.1016/j.biopha.2021.112601	2022	Genistein alleviates renin-angiotensin system mediated vascular and kidney alterations in renovascular hypertensive rats.	BCL2
35064305	10.1007/s00011-021-01535-1	2022	MiR-21 participates in LPS-induced myocardial injury by targeting Bcl-2 and CDK6.	BCL2
35067515	10.1097/PAS.0000000000001828	2022	Composite Classic Hodgkin Lymphoma and Follicular Lymphoma: A Clinicopathologic Study of 22 Cases With Review of 27 Additional Cases in the Literature.	BCL2
35068334	10.1080/21655979.2022.2026552	2022	Salvianolic acid B alleviates diabetic endothelial and mitochondrial dysfunction by down-regulating apoptosis and mitophagy of endothelial cells.	BCL2
35074718	10.1016/j.theriogenology.2022.01.017	2022	The opposite effects of VGLL1 and VGLL4 genes on granulosa cell proliferation and apoptosis of hen ovarian prehierarchical follicles.	BCL2
35076333	10.1080/10428194.2021.2010065	2022	Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.	BCL2
35089437	10.1007/s00018-022-04139-y	2022	A20 undermines alternative NF-Œ∫B activity and expression of anti-apoptotic genes in Helicobacter pylori infection.	BCL2
35132478	10.1007/s11064-022-03545-9	2022	Human Umbilical Cord Mesenchymal Stem Cells Derived Exosomes Promote Neurological Function Recovery in a Rat Spinal Cord Injury Model.	BCL2
35141965	10.1111/ejn.15622	2022	Sevoflurane protects mice from cerebral ischaemic injury by regulating microRNA-203-3p/HDAC4/Bcl-2 axis.	BCL2
35142981	10.1007/s11033-022-07203-9	2022	Apoptosis induction in human lung and colon cancer cells via impeding VEGF signaling pathways.	BCL2
35151528	10.1016/j.blre.2022.100930	2022	CLL update 2022: A continuing evolution in care.	BCL2
35152630	10.3760/cma.j.cn112151-20210826-00604	2022	[Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements].	BCL2
35153031	10.1016/j.carbpol.2022.119097	2022	Co-delivery of doxorubicin and siRNA by all-trans retinoic acid conjugated chitosan-based nanocarriers for multiple synergistic antitumor efficacy.	BCL2
35171311	10.1007/s00277-022-04785-z	2022	CD37 expression in follicular lymphoma.	BCL2
35176466	10.1016/j.jep.2022.115095	2022	Cinobufagin induces FOXO1-regulated apoptosis, proliferation, migration, and invasion by inhibiting G9a in non-small-cell lung cancer A549¬†cells.	BCL2
35178927	10.19540/j.cnki.cjcmm.20210902.701	2022	[Molecular mechanism of Ganoderma against gastric cancer based on network pharmacology and experimental test].	BCL2
35183824	10.1016/j.prp.2022.153804	2022	Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma.	BCL2
35185150	10.1038/s41392-021-00870-3	2022	Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.	BCL2
35188042	10.1080/10428194.2022.2042689	2022	Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells.	BCL2
35193595	10.1186/s12943-022-01516-w	2022	BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion.	BCL2
35198451	10.3389/fonc.2022.834288	2022	Prognostic Value of Radiomic Features of <sup>18</sup>F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells.	BCL2
35199915	10.1002/tox.23497	2022	Nimbolide retards T cell lymphoma progression by altering apoptosis, glucose metabolism, pH regulation, and ROS homeostasis.	BCL2
35205731	10.3390/cancers14040983	2022	Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart.	BCL2
35217188	10.1016/j.biocel.2022.106184	2022	Galactocerebrosidase deficiency induces an increase in lactosylceramide content: A new hallmark of Krabbe disease?	BCL2
35220171	10.1016/j.prp.2022.153812	2022	Prognostic value of Bcl2 and Bcl6 in primary cutaneous large B-cell lymphoma: A systematic review and meta-analysis.	BCL2
35222803	10.1155/2022/6933812	2022	Protection of Human Lens Epithelial Cells from Oxidative Stress Damage and Cell Apoptosis by KGF-2 through the Akt/Nrf2/HO-1 Pathway.	BCL2
35223094	10.1155/2022/7687154	2022	miR-197 Participates in Lipopolysaccharide-Induced Cardiomyocyte Injury by Modulating SIRT1.	BCL2
35223507	10.3389/fonc.2022.824632	2022	<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS.	BCL2
35225270	10.3791/62961	2022	Enhancing Tumor Content through Tumor Macrodissection.	BCL2
35231992	10.3760/cma.j.issn.0253-2727.2022.01.009	2022	[MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis].	BCL2
35233562	10.15212/amm-2021-0002	2022	The regulation of neuronal autophagy and cell survival by MCL1 in Alzheimer's disease.	BCL2
35234557	10.1080/1354750X.2022.2048892	2022	Phytochemical constituents and protective efficacy of <i>Schefflera arboricola</i> L. leaves extract against thioacetamide-induced hepatic encephalopathy in rats.	BCL2
35236331	10.1186/s12885-022-09237-5	2022	Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.	BCL2
35237395	10.1177/20406207221080738	2022	Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).	BCL2
35237907	10.1007/s10930-022-10046-9	2022	Multi-catalytic Sites Inhibition of Bcl2 Induces Expanding of Hydrophobic Groove: A New Avenue Towards Waldenstr√∂m Macroglobulinemia Therapy.	BCL2
35240234	10.1016/j.canlet.2022.215608	2022	DT7 peptide-modified lecithin nanoparticles co-loaded with Œ≥-secretase inhibitor and dexamethasone efficiently inhibit T-cell acute lymphoblastic leukemia and reduce gastrointestinal toxicity.	BCL2
35241367	10.1016/j.semcdb.2022.01.011	2022	Mitochondrial-apoptotic signaling involvement in remodeling during myogenesis and skeletal muscle atrophy.	BCL2
35255774	10.1080/15548627.2022.2048432	2022	TET2 regulates osteoclastogenesis by modulating autophagy in OVX-induced bone loss.	BCL2
35256453	10.1523/ENEURO.0434-21.2022	2022	Agmatine Alleviates Cisplatin-Induced Ototoxicity by Activating PI3K/AKT Signaling Pathway.	BCL2
35266562	10.1002/ajh.26523	2022	Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.	BCL2
35276693	10.1097/CAD.0000000000001282	2022	LncRNA ZFPM2-AS1 drives the progression of nasopharyngeal carcinoma via modulating the downstream miR-3612/DTL signaling.	BCL2
35277463	10.1136/jitc-2020-002029corr1	2022	Correction: MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	BCL2
35277788	10.1007/s11033-022-07221-7	2022	The relationship between B-cell lymphoma 2, interleukin-1Œ≤, interleukin-17, and interleukin-33 and the development of diabetic nephropathy.	BCL2
35279534	10.1016/j.theriogenology.2022.02.028	2022	Ascorbic acid regulates mouse spermatogonial stem cell proliferation in a Wnt/Œ≤-catenin/ROS signaling dependent manner.	BCL2
35286779	10.1002/jez.2592	2022	Effects of metformin on the uterus of d-galactose-induced aging mice: Histomorphometric, immunohistochemical localization (B-cell lymphoma 2, Bcl2-associated X protein, and active capase3), and oxidative stress study.	BCL2
35292420	10.1016/j.jphotobiol.2022.112426	2022	Blue light induces skin apoptosis and degeneration through activation of the endoplasmic reticulum stress-autophagy apoptosis axis: Protective role of hydrogen sulfide.	BCL2
35296646	10.1038/s41419-022-04684-1	2022	Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.	BCL2
35297566	10.1111/pin.13223	2022	Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements.	BCL2
35299080	10.1016/j.anndiagpath.2022.151913	2022	HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridisation to assess MYC gene copies.	BCL2
35303910	10.1186/s13045-022-01249-9	2022	Altered pathways and targeted therapy in double hit lymphoma.	BCL2
35308723	10.7759/cureus.22023	2022	Conjunctival Pediatric-Type Follicular Lymphoma in a Young Male: A Case Report and Literature Review.	BCL2
35313087	10.1111/cbdd.14041	2022	Ginsenoside Rg1 improves Alzheimer's disease by regulating oxidative stress, apoptosis, and neuroinflammation through Wnt/GSK-3Œ≤/Œ≤-catenin signaling pathway.	BCL2
35316462	10.1007/s11064-022-03544-w	2022	Transcription Factor HEY1 Improves Brain Vascular Endothelial Cell Function and Alleviates Ischemic Stroke by Upregulating NOTCH3.	BCL2
35317444	10.3892/etm.2022.11208	2022	Effects and early diagnostic value of lncRNA H19 on sepsis-induced acute lung injury.	BCL2
35320477	10.1007/s11356-022-19747-1	2022	Anticolitic activity of prodigiosin loaded with selenium nanoparticles on acetic acid-induced colitis in rats.	BCL2
35321563	10.1161/ATVBAHA.121.317018	2022	Plaque Evaluation by Ultrasound and Transcriptomics Reveals BCLAF1 as a Regulator of Smooth Muscle Cell Lipid Transdifferentiation in Atherosclerosis.	BCL2
35322932	10.1002/cam4.4692	2022	Patient-reported outcomes provide prognostic information for survival in patients with diffuse large B-cell lymphoma: Analysis of 1239 patients from the GOYA study.	BCL2
35324708	10.3390/toxins14030211	2022	Protective Effects of Taraxasterol against Deoxynivalenol-Induced Damage to Bovine Mammary Epithelial Cells.	BCL2
35331723	10.1016/j.ejphar.2022.174907	2022	Novel vandetanib derivative inhibited proliferation and promoted apoptosis of cancer cells under normoxia and hypoxia.	BCL2
35339405	10.1016/j.clml.2022.02.005	2022	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenstr√∂m Macroglobulinemia.	BCL2
35344084	10.1007/s00404-022-06531-2	2022	Diagnostic and prognostic value of Bcl-2 in uterine leiomyosarcoma.	BCL2
35346194	10.1186/s12951-022-01377-x	2022	Multifunctional nanoparticles co-loaded with Adriamycin and MDR-targeting siRNAs for treatment of chemotherapy-resistant esophageal cancer.	BCL2
35347000	10.21873/anticanres.15658	2022	Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies.	BCL2
35350909	10.1177/10781552221090869	2022	Real-world management of targeted therapies in chronic lymphocytic leukemia.	BCL2
35365988	NA	2022	[Protective effect of nuclear receptor related 1 (Nurr1) on nerves in rats with cerebral occlusion/reperfusion injury and its mechanism].	BCL2
35365989	NA	2022	[Inhibition of autophagy enhances apoptosis induced by doxorubicin hydrochloride in human colon cancer cells].	BCL2
35366141	10.1007/s10495-022-01723-2	2022	Targeting lysophosphatidic acid receptor with Ki16425 impedes T cell lymphoma progression through apoptosis induction, glycolysis inhibition, and activation of antitumor immune response.	BCL2
35368047	10.1038/s41375-022-01556-7	2022	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN).	BCL2
35370290	10.1038/s41392-022-00915-1	2022	Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies.	BCL2
35371331	10.7150/jca.69639	2022	Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma.	BCL2
35379357	10.1186/s40364-022-00357-5	2022	Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma.	BCL2
35381283	10.1016/j.ijbiomac.2022.03.212	2022	Molecular characterization, expression and anti-tumor function analysis of yak IFITM2 gene.	BCL2
35393909	10.1080/09513590.2022.2061454	2022	Effects of clinical and metabolic variables and hormones on the expression of immune protein biomarkers in the endometrium of women with polycystic ovary syndrome and normal-cycling controls.	BCL2
35411095	10.1038/s41375-022-01558-5	2022	JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia.	BCL2
35414044	10.1186/s13287-022-02832-0	2022	Melatonin treatment improves human umbilical cord mesenchymal stem cell therapy in a mouse model of type II diabetes mellitus via the PI3K/AKT signaling pathway.	BCL2
35414839	NA	2022	Primary ovarian Burkitt lymphoma: report of a case and review of literature.	BCL2
35422931	NA	2022	HGF induces oncoprotein HCCR-1 expression through the Wnt/Œ≤-catenin pathway in gastric cancer.	BCL2
35425994	10.3892/mmr.2022.12710	2022	Preparation of Nereid oligopeptide and investigation of the mechanism underlying the induction of apoptosis in human lung cancer H1299 cells.	BCL2
35432742	10.4253/wjge.v14.i3.176	2022	Mucosa-associated lymphoid tissue lymphoma in the terminal ileum: A case report.	BCL2
35435120	10.1080/21655979.2022.2061283	2022	CircSETD3 (hsa_circ_0000567) inhibits proliferation and induces apoptosis in cholangiocarcinoma cells via downregulation of microRNA-421 expression.	BCL2
35435617	10.1007/s11864-022-00953-5	2022	Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.	BCL2
35436854	10.1186/s12863-022-01041-1	2022	An alternative CYB5A transcript is expressed in aneuploid ALL and enriched in relapse.	BCL2
35444774	10.4084/MJHID.2022.018	2022	TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment.	BCL2
35448884	10.3390/toxins14040275	2022	Protective Effects of Ferulic Acid on Deoxynivalenol-Induced Toxicity in IPEC-J2 Cells.	BCL2
35452696	10.1016/j.humpath.2022.04.002	2022	B-cell lymphoma-2 downregulation is a useful feature supporting a neoplastic phenotype in mature T-cell lymphomas.	BCL2
35468679	10.31083/j.fbl2704120	2022	Phytochemical Profiling of Microalgae <i>Euglena tuba</i> and Its Anticancer Activity in Dalton's Lymphoma Cells.	BCL2
35481444	10.1080/10428194.2022.2064988	2022	Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.	BCL2
35482553	10.1002/hon.3010	2022	Targeting MYC and BCL2 by a natural compound for double-hit lymphoma.	BCL2
35483927	10.5045/br.2022.2022037	2022	Basic immunohistochemistry for lymphoma diagnosis.	BCL2
35484682	10.3324/haematol.2021.280557	2022	Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement.	BCL2
35489963	10.1016/j.blre.2022.100967	2022	ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma.	BCL2
35495111	10.1016/j.csbj.2022.03.023	2022	Integrating whole genome sequencing, methylation, gene expression, topological associated domain information in regulatory mutation prediction: A study of follicular lymphoma.	BCL2
35498426	10.3389/fendo.2022.846357	2022	Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.	BCL2
35504024	10.18632/aging.204041	2022	<i>In vitro</i> and <i>in vivo</i> anti-lymphoma effects of <i>Ophiorrhiza pumila</i> extract.	BCL2
35510016	10.7759/cureus.23681	2022	Incidental Pathogenic Fibrin-Associated Diffuse Large B-cell Lymphoma Found During Aorto-Biiliac Bypass.	BCL2
35511481	10.1080/09553002.2022.2074164	2022	<i>BAG1, MGMT, FOXO1</i>, and <i>DNAJA1</i> as potential drug targets for radiosensitizing cancer cell lines.	BCL2
35511691	10.1093/ajcp/aqac047	2022	A Combined Biomarker of Bright CD38 and MYC ‚â•55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma.	BCL2
35513284	10.1016/j.mce.2022.111653	2022	Exosomal miR-140-3p and miR-143-3p from TGF-Œ≤1-treated pancreatic stellate cells target BCL2 mRNA to increase Œ≤-cell apoptosis.	BCL2
35535226	10.1155/2022/1565094	2022	Analysis of the Role and Mechanism of ZEB1 in Regulating Cervical Carcinoma Progression via Modulating PD-1/PD-L1 Checkpoint.	BCL2
35538643	10.1002/cam4.4742	2022	Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.	BCL2
35539018	10.1016/j.lrr.2022.100318	2022	A very rare case of extranodal B-cell non-Hodgkin lymphoma presenting with adrenal and heart involvement.	BCL2
35549669	10.1164/rccm.202201-0033OC	2022	Tacrolimus Prevents Mechanical and Humoral Alterations in Brain Death-induced Lung Injury in Pigs.	BCL2
35566180	10.3390/molecules27092827	2022	Dioscin-Mediated Autophagy Alleviates MPP<sup>+</sup>-Induced Neuronal Degeneration: An In Vitro Parkinson's Disease Model.	BCL2
35568724	10.1038/s41394-022-00520-y	2022	Primary intradural extramedullary spinal Burkitt's lymphoma mimicking a nerve sheath tumor: a case report.	BCL2
35571331	10.1016/j.fochx.2022.100322	2022	Recent developments in <i>Moringa oleifera</i> Lam. polysaccharides: A review of the relationship between extraction methods, structural characteristics and functional activities.	BCL2
35571440	10.21037/atm-22-894	2022	Long non-coding RNA MEG3 regulates the progress of osteoarthritis by regulating the miR-34a/Klotho axis.	BCL2
35576104	10.1111/1440-1681.13667	2022	Glaucocalyxin A induces apoptosis of non-small cell lung carcinoma cells by inhibiting the PI3K/Akt/GSK3Œ≤ pathway.	BCL2
35576884	10.1016/j.jinorgbio.2022.111855	2022	Cyclometalated iridium(III) dithioformic acid complexes as mitochondria-targeted imaging and anticancer agents.	BCL2
35577753	10.1016/j.clml.2022.04.017	2022	SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.	BCL2
35578798	10.1002/jcp.30777	2022	Neddylation inactivation affects cell cycle and apoptosis in sheep follicular granulosa cells.	BCL2
35583405	10.1097/DAD.0000000000002053	2022	Histological Transformation and Clonal Relationship of Subcutaneous Marginal Zone B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma.	BCL2
35583555	10.1158/1078-0432.CCR-21-3811	2022	VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results.	BCL2
35583809	10.1002/ptr.7481	2022	Psoralidin protects against cerebral hypoxia/reoxygenation injury: Role of GAS6/Axl signaling.	BCL2
35584731	10.1016/j.tiv.2022.105386	2022	Paclitaxel is evidence to reduce growing ovarian follicle growth in mice model study.	BCL2
35592654	10.1155/2022/5707504	2022	Effect of miR-144-3p-Targeted Regulation of PTEN on Proliferation, Apoptosis, and Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells under Stretch.	BCL2
35595618	10.1016/j.clml.2022.04.010	2022	Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA.	BCL2
35601256	10.1016/j.aninu.2022.03.003	2022	Effects of fish meal replacement with <i>Chlorella</i> meal on growth performance, pigmentation, and liver health of largemouth bass (<i>Micropterus salmoides</i>).	BCL2
35603649	NA	2022	[Activation of JNK induces apoptosis to autophagy conversion and enhances the survival of oxygen-glycogen deprived rat neurons].	BCL2
35603962	10.1002/mgg3.1964	2022	Construction of three-gene-based prognostic signature and analysis of immune cells infiltration in children and young adults with B-acute lymphoblastic leukemia.	BCL2
35610180	10.1002/cbdv.202100845	2022	Co-Binding of JQ1 and Venetoclax Exhibited Synergetic Inhibitory Effect for Cancer Therapy; Potential Line of Treatment for the Waldenstr√∂m Macroglobulinemia Lymphoma.	BCL2
35616841	10.1007/s11356-022-20734-9	2022	Cadmium induces apoptosis by miR-9-5p targeting PTEN and regulates the PI3K/AKT pathway in the piglet adrenal gland.	BCL2
35621073	10.1039/d1fo03746c	2022	Nano-curcumin supplementation in critically ill patients with sepsis: a randomized clinical trial investigating the inflammatory biomarkers, oxidative stress indices, endothelial function, clinical outcomes and nutritional status.	BCL2
35622324	10.1007/978-1-0716-2115-8_8	2022	Targeted Locus Amplification as Marker Screening Approach to Detect Immunoglobulin (IG) Translocations in B-Cell Non-Hodgkin Lymphomas.	BCL2
35624736	10.3390/antiox11050872	2022	Dietary Tryptophan Supplementation Improves Antioxidant Status and Alleviates Inflammation, Endoplasmic Reticulum Stress, Apoptosis, and Pyroptosis in the Intestine of Piglets after Lipopolysaccharide Challenge.	BCL2
35625017	10.3390/brainsci12050631	2022	Preconditioned MSCs Alleviate Cerebral Ischemia-Reperfusion Injury in Rats by Improving the Neurological Function and the Inhibition of Apoptosis.	BCL2
35633553	10.31557/APJCP.2022.23.5.1679	2022	Relationship between Bax and Bcl-2 Protein Expression and Outcome of Induction Phase Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.	BCL2
35635742	10.1177/10781552221103820	2022	Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia.	BCL2
35640776	10.1016/j.lfs.2022.120675	2022	Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-Œ∫B pathways and LncRNA-AF085935/GPC3 axis.	BCL2
35646671	10.3389/fonc.2022.883141	2022	Case Report: Intravascular Large B-Cell Lymphoma: A Clinicopathologic Study of Four Cases With Review of Additional 331 Cases in the Literature.	BCL2
35652622	10.4149/neo_2022_220318N300	2022	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry.	BCL2
35653936	10.1016/j.jtemb.2022.127014	2022	Up-regulation of B-cell lymphoma factor-2 expression, inhibition of oxidative stress and down-regulation of pro-inflammatory cytokines are involved in the protective effect of cabbage (Brassica oleracea) juice in lead-induced endothelial dysfunction in rats.	BCL2
35657404	10.1007/s00428-022-03342-3	2022	Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.	BCL2
35659041	10.1186/s13045-022-01295-3	2022	Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination.	BCL2
35661922	10.1007/s00428-022-03347-y	2022	H3K27m3 overexpression as a new, BCL2 independent diagnostic tool in follicular and cutaneous follicle center lymphomas.	BCL2
35662912	10.1155/2022/9569226	2022	Nanoemulsion and Encapsulation Strategy of Hydrophobic Oregano Essential Oil Increased Human Prostate Cancer Cell Death via Apoptosis by Attenuating Lipid Metabolism.	BCL2
35673965	10.1002/1878-0261.13264	2022	The SKP2-p27 axis defines susceptibility to cell death upon CHK1 inhibition.	BCL2
35674932	10.1007/s12105-022-01461-6	2022	Extranodal MALT Lymphoma in the Oral Cavity: A Series of Three Cases with Review of Literature.	BCL2
35678255	10.1111/jcmm.17358	2022	LncRNA SNHG1 promotes sepsis-induced myocardial injury by inhibiting Bcl-2 expression via DNMT1.	BCL2
35685242	10.3389/fmolb.2022.864874	2022	Structural Details of BH3 Motifs and BH3-Mediated Interactions: an Updated Perspective.	BCL2
35687213	10.1007/s10753-022-01696-z	2022	PTX3 Protects Intestinal Mucosal Barrier Damage in Sepsis Through Toll-Like Receptor Signaling Pathway.	BCL2
35701534	10.1038/s41388-022-02372-0	2022	BCL-2 isoform Œ≤ promotes angiogenesis by TRiC-mediated upregulation of VEGF-A in lymphoma.	BCL2
35704690	10.1182/blood.2021014304	2022	Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.	BCL2
35705274	10.2169/internalmedicine.9711-22	2022	Biclonal diffuse large B-cell lymphoma commonly characterized by partial trisomy 18q involving MALT1 and BCL2.	BCL2
35709931	10.1016/j.drudis.2022.06.002	2022	BCL2 G quadruplex-binding small molecules: Current status and prospects for the development of next-generation anticancer therapeutics.	BCL2
35715938	10.1002/cjp2.283	2022	Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.	BCL2
35716968	10.1016/j.fsi.2022.06.017	2022	Dietary chlorella (Chlorella vulgaris) supplementation effectively improves body color, alleviates muscle inflammation and inhibits apoptosis in largemouth bass (Micropterus salmoides).	BCL2
35749795	10.1097/MCP.0000000000000879	2022	Senescence in pulmonary arterial hypertension: is there a link?	BCL2
35759728	10.1182/blood.2022015926	2022	Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma.	BCL2
35760783	10.1038/s41419-022-05021-2	2022	IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma.	BCL2
35762155	10.1080/10520295.2022.2083685	2022	Effects of long term diabetogenic high fat diet on bone in ovariectomized female rats.	BCL2
35770040	10.2147/TCRM.S338655	2022	Zanubrutinib in Treating Waldenstr√∂m Macroglobulinemia, the Last Shall Be the First.	BCL2
35774514	10.3389/fgene.2022.827840	2022	A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma.	BCL2
35782651	10.1093/toxres/tfac024	2022	Isorhamnetin: a flavonoid, attenuated doxorubicin-induced testicular injury via regulation of steroidogenic enzymes and apoptotic signaling gene expression in male rats.	BCL2
35783530	10.1155/2022/9100056	2022	LINC00461 Regulates the Recurrence of Large B Cell Lymphoma through the miR-411-5p/BNIP3 Pathway.	BCL2
35787399	10.1016/j.jid.2022.06.005	2022	The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ŒîNp73 Depletion.	BCL2
35792817	10.1080/10790268.2022.2088498	2022	Warm acupuncture therapy alleviates neuronal apoptosis after spinal cord injury via inhibition of the ERK signaling pathway.	BCL2
35794096	10.1038/s41467-022-31355-8	2022	Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.	BCL2
35794478	10.1038/s41586-022-04906-8	2022	Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.	BCL2
35795062	10.3389/fonc.2022.870487	2022	Plasma Concentrations and Cancer-Associated Mutations in Cell-Free Circulating DNA of Treatment-Naive Follicular Lymphoma for Improved Non-Invasive Diagnosis and Prognosis.	BCL2
35800619	10.1016/j.bbrep.2022.101303	2022	CA10 is associated with HBV-related hepatocarcinogenesis.	BCL2
35804999	10.3390/cancers14133229	2022	Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.	BCL2
35816682	10.1182/bloodadvances.2022008355	2022	Genomic and microenvironmental landscape of stage I follicular lymphoma, compared to stage III/IV.	BCL2
35830966	10.1111/ijlh.13928	2022	Downregulation of hsa-miR-548d-3p and overexpression of HOXA9 in diffuse large B-cell lymphoma patients and the risk of R-CHOP chemotherapy resistance and disease progression.	BCL2
35846201	10.1002/jha2.310	2022	Redefining the high-grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report.	BCL2
35846216	10.1002/jha2.364	2022	Primary cutaneous diffuse large B-cell lymphoma, leg type with <i>MYC/BCL2/BCL6</i> overexpression.	BCL2
35847946	10.3389/fonc.2022.864430	2022	Hymeglusin Enhances the Pro-Apoptotic Effects of Venetoclax in Acute Myeloid Leukemia.	BCL2
35848706	10.4103/aja202242	2022	The protective effects and underlying mechanisms of dapagliflozin on diabetes-induced testicular dysfunction.	BCL2
35851082	NA	2022	[Paeoniflorin inhibits Wnt1/Œ≤-catenin pathway and promotes apoptosis of fibroblast-like synoviocytes in patients with rheumatoid arthritis by upregulating lncRNA MALAT1].	BCL2
35856441	10.3892/or.2022.8375	2022	Administration of 4‚Äëhexylresorcinol increases p53‚Äëmediated transcriptional activity in oral cancer cells with the p53 mutation.	BCL2
35857625	10.1126/scitranslmed.abl5654	2022	Phenotypic screening with deep learning identifies HDAC6 inhibitors as cardioprotective in a BAG3 mouse model of dilated cardiomyopathy.	BCL2
35857791	10.1080/15548627.2022.2100105	2022	Lack of COL6/collagen VI causes megakaryocyte dysfunction by impairing autophagy and inducing apoptosis.	BCL2
35861049	10.1002/jsfa.12141	2022	Research on apoptotic mechanism and related pathways involving in postmortem grass carp (Ctenopharyngodon idellus) muscle.	BCL2
35869021	10.1016/j.clml.2022.06.011	2022	Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.	BCL2
35879400	10.1038/s41598-022-16943-4	2022	Promising anti-leukemic effect of Zataria multiflora extract in combination with doxorubicin to combat acute lymphoblastic leukemia cells (Nalm-6) (in vitro and in silico).	BCL2
35884496	10.3390/cancers14143434	2022	Classifying Germinal Center Derived Lymphomas-Navigate a Complex Transcriptional Landscape.	BCL2
35885931	10.3390/genes13071144	2022	Targeting a Novel G-Quadruplex in the <i>CARD11</i> Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group.	BCL2
35893891	10.3390/nu14153037	2022	Shibi Tea (<i>Adinandra nitida</i>) and Camellianin A Alleviate CCl<sub>4</sub>-Induced Liver Injury in C57BL-6J Mice by Attenuation of Oxidative Stress, Inflammation, and Apoptosis.	BCL2
35900563	10.4103/jcrt.JCRT_676_19	2022	Signet ring cell lymphoma of follicular type with BCL2 gene rearrangement: A rare case with a short review of literature.	BCL2
35916333	10.1002/dc.25027	2022	HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.	BCL2
35916644	10.1097/QAI.0000000000003069	2022	Diffuse Large B-cell Lymphoma in the public-sector of Johannesburg, South Africa, in the era of widescale Anti-retroviral therapy use.	BCL2
35919815	10.7150/ijms.73077	2022	[6]-Gingerol induces Caspase-Dependent Apoptosis in Bladder Cancer cells via MAPK and ROS Signaling.	BCL2
35920412	10.1002/jbt.23185	2022	Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro.	BCL2
35932211	10.1002/hon.3061	2022	Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification.	BCL2
35933930	10.1016/j.ctrv.2022.102443	2022	Treatment strategies for patients with diffuse large B-cell lymphoma.	BCL2
35936524	10.18502/ijph.v51i4.9251	2022	The Effect of <i>B-Cell Lymphoma 2</i> and <i>BCL2-Associated X</i> Polymorphisms on the Survival of Acute Lymphoblastic Leukemia Patients: Application of Frailty Survival Models.	BCL2
35952327	10.1200/JCO.22.00597	2022	Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.	BCL2
35953760	10.1631/jzus.B2200016	2022	HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.	BCL2
35955467	10.3390/ijms23158334	2022	Synovial Fluid Regulates the Gene Expression of a Pattern of microRNA via the NF-Œ∫B Pathway: An In Vitro Study on Human Osteoarthritic Chondrocytes.	BCL2
35962819	10.1007/s00280-022-04460-0	2022	Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia.	BCL2
35968590	10.3760/cma.j.issn.0253-2727.2022.06.006	2022	[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review].	BCL2
35970756	10.1016/j.clml.2022.07.013	2022	Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukaemia and Potential Future Therapeutic Directions.	BCL2
35974958	10.1097/HS9.0000000000000767	2022	Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular Lymphomas.	BCL2
35979721	10.3324/haematol.2022.280631	2022	Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes.	BCL2
35982976	10.3389/fonc.2022.934008	2022	Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation.	BCL2
35983732	10.1080/10428194.2022.2098291	2022	Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.	BCL2
36001789	10.46883/2022.25920970	2022	Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas.	BCL2
36014833	10.3390/nu14163327	2022	The Protective Effect of Œ±-Lipoic Acid against Gold Nanoparticles (AuNPs)-Mediated Liver Damage Is Associated with Upregulating Nrf2 and Suppressing NF-Œ∫B.	BCL2
36029292	10.1111/bcpt.13788	2022	The therapeutic effects of cycloastragenol in ulcerative colitis by modulating SphK/MIP-1Œ±/miR-143 signalling.	BCL2
36035812	10.1016/j.jobcr.2022.07.009	2022	Expression and bioinformatics analyses show HSP70 complements BCL2 action in oral carcinogenesis.	BCL2
36048893	10.1093/ajcp/aqac104	2022	Systemic Presentation of Somatic TET2 Mutated B-Cell Lymphoma in a Child With Kabuki Syndrome and a Germline KMT2D Variant.	BCL2
36051027	10.1002/jha2.489	2022	Inactivating <i>BTK</i> mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with <i>BCL2</i> translocation.	BCL2
36051039	10.1002/jha2.513	2022	Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement.	BCL2
36051055	10.1002/jha2.457	2022	An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.	BCL2
36054886	10.1097/SCS.0000000000008519	2022	Influence of Experimental Skull Defects on Brain.	BCL2
36056803	10.1111/and.14579	2022	Asprosin promotes steroidogenesis and spermatogenesis with improved glucose metabolism in adult mice testis.	BCL2
36057749	10.1007/s00428-022-03404-6	2022	Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma.	BCL2
36062172	10.1155/2022/1932777	2022	Ethyl Acetate Fraction of <i>Hedyotis diffusa Willd</i> Induces Apoptosis via JNK/Nur77 Pathway in Hepatocellular Carcinoma Cells.	BCL2
36081566	10.3389/fonc.2022.941347	2022	Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.	BCL2
36082710	NA	2022	[Homocysteine induces glomerular podocyte apoptosis via up-regulation of miR-488-3p expression in MPC-5 mice].	BCL2
36092159	10.1155/2022/3737137	2022	Ginsenoside Rg1 Ameliorates Acute Renal Ischemia/Reperfusion Injury via Upregulating AMPK<i>Œ±</i>1 Expression.	BCL2
36092554	10.1021/acsomega.2c02796	2022	Lycopene Effects on Metabolic Syndrome and Kidney Injury in Rats Fed a High-Fat Diet: An Experimental Study.	BCL2
36098711	10.1111/cbdd.14144	2022	The expression of miR-181b, CYLD, CBX-7, BCL2, and p53 in osteosarcoma patients and correlation with clinicopathological factors.	BCL2
36100068	10.1016/j.fsi.2022.09.005	2022	Molecular characterization and expression analysis of B-cell lymphoma-2 protein in Amphiprion clarkii and its role in virus infections.	BCL2
32515262	10.1089/neu.2020.7028	2021	B-Cell Lymphoma 2 (Bcl-2) Gene Is Associated with Intracranial Hypertension after Severe Traumatic Brain Injury.	BCL2
32749680	10.1002/jcp.29943	2021	Light-emitting diode irradiation induces AKT/mTOR-mediated apoptosis in human pancreatic cancer cells and xenograft mouse model.	BCL2
32912960	10.1136/jclinpath-2020-206767	2021	<i>BCL2</i> and <i>BCL6</i> atypical/unbalanced gene rearrangements in diffuse large B-cell lymphoma are indicators of an aggressive clinical course.	BCL2
33120427	10.1182/blood.2020007193	2021	The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC.	BCL2
33356554	10.2217/epi-2020-0189	2021	Epigenetic targeting of Waldenstr√∂m macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.	BCL2
33423045	10.1038/s41419-020-03311-1	2021	GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner.	BCL2
33480087	10.1002/hon.2839	2021	High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup.	BCL2
33495811	10.3892/ijmm.2021.4858	2021	Effects of Smad4 on the expression of caspase‚Äë3 and Bcl‚Äë2 in human gingival fibroblasts cultured on 3D¬†PLGA scaffolds induced by compressive force.	BCL2
33580459	10.1007/s11033-021-06161-y	2021	Increased level of long non coding RNA H19 is correlated with the downregulation of miR-326 and BCL-2 genes in pediatric acute lymphoblastic leukemia, a possible hallmark for leukemogenesis.	BCL2
33605072	10.1111/jcmm.16373	2021	Cyclic stretching boosts microRNA-499 to regulate Bcl-2 via microRNA-208a in atrial fibroblasts.	BCL2
33689920	10.1016/j.leukres.2021.106552	2021	Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.	BCL2
33799592	10.3390/ijms22062841	2021	Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer.	BCL2
33858042	10.3760/cma.j.issn.0253-2727.2021.02.006	2021	[The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma].	BCL2
33910828	10.21873/invivo.12403	2021	Depletion of NK Cells Resistant to Ionizing Radiation Increases Mutations in Mice After Whole-body Irradiation.	BCL2
33912159	10.3389/fimmu.2021.627602	2021	The <i>Traf2</i>DNx<i>BCL2-tg</i> Mouse Model of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recapitulates the Biased IGHV Gene Usage, Stereotypy, and Antigen-Specific HCDR3 Selection of Its Human Counterpart.	BCL2
33912563	10.3389/fcell.2021.647522	2021	Expression Level of ADAMTS1 in Granulosa Cells of PCOS Patients Is Related to Granulosa Cell Function, Oocyte Quality, and Embryo Development.	BCL2
33914737	10.1371/journal.pone.0237830	2021	Loss-of-function of Fbxo10, encoding a post-translational regulator of BCL2 in lymphomas, has no discernible effect on BCL2 or B lymphocyte accumulation in mice.	BCL2
33917107	10.3390/ijms22083829	2021	Quercetin Attenuates Brain Oxidative Alterations Induced by Iron Oxide Nanoparticles in Rats.	BCL2
33934404	10.1002/jcla.23784	2021	PCR array analysis identified hyperproliferation but not autophagy or apoptosis in fibrous epulis.	BCL2
33938687	10.36849/JDD.5373	2021	A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.	BCL2
33938816	10.4103/CJP.CJP_79_20	2021	Tau phosphorylation and cochlear apoptosis cause hearing loss in 3√óTg-AD Mouse Model of Alzheimer's Disease.	BCL2
33939407	10.1021/acs.jmedchem.0c02200	2021	Pharmacological Targeting of Executioner Proteins: Controlling Life and Death.	BCL2
33945543	10.1371/journal.pone.0248886	2021	Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.	BCL2
33946435	10.3390/cancers13092167	2021	Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma.	BCL2
33955654	10.1111/jcmm.16558	2021	Exosomes derived from MSC pre-treated with oridonin alleviates myocardial IR injury by suppressing apoptosis via regulating autophagy activation.	BCL2
33959502	10.3389/fonc.2021.638897	2021	c-Rel Is the Pivotal NF-Œ∫B Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.	BCL2
33962620	10.1186/s12957-021-02216-3	2021	A new pathological classification of intrahepatic cholangiocarcinoma according to protein expression of SSTR2 and Bcl2.	BCL2
33964277	10.1016/j.humpath.2021.04.014	2021	Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma.	BCL2
33973992	NA	2021	Cryopreservation of Dog Spermatozoa Using Essential and Non-Essential Amino Acids Solutions in An Egg Yolk-Free Polyvinyl Alcohol Extender.	BCL2
33974882	10.1016/j.ejphar.2021.174167	2021	Effects of trans-resveratrol on type 1 diabetes-induced up-regulation of apoptosis and mitogen-activated protein kinase signaling in retinal pigment epithelium of Dark Agouti rats.	BCL2
33978190	10.1093/jn/nxab116	2021	Dietary n-3 PUFA Deficiency Increases Vulnerability to Scopolamine-Induced Cognitive Impairment in Male C57BL/6 Mice.	BCL2
33980772	10.1507/endocrj.EJ20-0739	2021	Circular RNA circ_0000712 regulates high glucose-induced apoptosis, inflammation, oxidative stress, and fibrosis in (DN) by targeting the miR-879-5p/SOX6 axis.	BCL2
33988072	10.1080/10428194.2021.1927020	2021	Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates with <i>MYC</i> and <i>MYC</i>/<i>BCL2</i> rearrangements, especially in germinal center cell-type tumors.	BCL2
33997750	10.1016/j.jhepr.2021.100276	2021	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury.	BCL2
34007050	10.1038/s41375-021-01291-5	2021	MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.	BCL2
34007370	10.14740/jh818	2021	<i>MYC</i>-Positive Diffuse Large B-Cell Lymphoma in Leukemic Phase at Presentation: A Diagnostic and Therapeutic Challenge.	BCL2
34012033	10.1038/s41416-021-01434-6	2021	A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.	BCL2
34012594	10.21037/jtd-21-551	2021	Anticancer mechanism of breviscapine in non-small cell lung cancer A549 cells acts via ROS-mediated upregulation of IGFBP4.	BCL2
34017010	10.1038/s41597-021-00915-w	2021	DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set.	BCL2
34027047	10.1080/23723556.2021.1911290	2021	The importance of transmembrane domain interactions in the viral control of apoptosis.	BCL2
34027766	10.1080/08916934.2021.1919878	2021	MiR-429 prohibited NF-Œ∫B signalling to alleviate contrast-induced acute kidney injury via targeting PDCD4.	BCL2
34031842	10.1007/s11064-021-03353-7	2021	The Effect of NeuroAid (MLC901) on Cholestasis-Induced Spatial Memory Impairment with Respect to the Expression of BAX, BCL-2, BAD, PGC-1Œ± and TFAM Genes in the Hippocampus of Male Wistar Rats.	BCL2
34044633	10.1177/03000605211019187	2021	Association of <i>BCL2</i> polymorphisms and the <i>IL19</i> single nucleotide polymorphism rs2243188 with systemic lupus erythematosus.	BCL2
34046322	NA	2021	Cytotoxic effects of hydroalcoholic extract of <i>Cuscuta chinensis</i> on PC3 and MCF7 cancer cell lines.	BCL2
34051685	10.1016/j.ejrad.2021.109784	2021	Differentiation between primary CNS lymphoma and atypical glioblastoma according to major genomic alterations using diffusion and susceptibility-weighted MR imaging.	BCL2
34059487	10.1016/j.clml.2021.04.004	2021	A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.	BCL2
34060449	NA	2021	[Chronic venous disease increases placental villous angiogenesis and lymphangiogenesis and villous cell apoptosis].	BCL2
34061027	10.7554/eLife.67336	2021	Contingency and chance erase necessity in the experimental evolution of ancestral proteins.	BCL2
34078654	10.1136/jitc-2020-002029	2021	MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	BCL2
34097157	10.1007/s11864-021-00857-w	2021	Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma.	BCL2
34099597	10.4014/jmb.2102.02010	2021	LINC01272 Suppressed Cell Multiplication and Induced Apoptosis Via Regulating MiR-7-5p/CRLS1 Axis in Lung Cancer.	BCL2
34101913	10.1111/jop.13208	2021	Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: A systematic review with meta-analysis.	BCL2
34105411	10.1177/15347354211021920	2021	Antitumor and Radiosensitizing Effects of Zinc Oxide-Caffeic Acid Nanoparticles against Solid Ehrlich Carcinoma in Female Mice.	BCL2
34105893	10.1002/cam4.4062	2021	Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.	BCL2
34106911	NA	2021	Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?	BCL2
34107971	10.1186/s13018-021-02504-4	2021	Raloxifene retards the progression of adjacent segmental intervertebral disc degeneration by inhibiting apoptosis of nucleus pulposus in ovariectomized rats.	BCL2
34113336	10.3389/fimmu.2021.599493	2021	<i>PiggyBac</i>-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.	BCL2
34123811	10.3389/fonc.2021.656219	2021	Case Report: Concurrent Occurrence of Abdominal Double Expressor Lymphoma and Jejunum Follicular Lymphoma.	BCL2
34139193	10.1016/j.ajpath.2021.06.004	2021	Rictor/Mammalian Target of Rapamycin Complex 2 Signaling Protects Colonocytes from Apoptosis and Prevents Epithelial Barrier Breakdown.	BCL2
34151288	10.1038/s43018-020-00167-4	2021	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.	BCL2
34159086	10.21037/tau-21-280	2021	The protective effects of exogenous spermine on renal ischemia-reperfusion injury in rats.	BCL2
34165702	10.1007/s12282-021-01266-5	2021	Biology of primary breast cancer in older women beyond routine biomarkers.	BCL2
34166762	10.1016/j.neuroscience.2021.06.021	2021	Phosphatase and Tensin Homolog Deleted on Chromosome Ten Knockdown Attenuates Cognitive Deficits by Inhibiting Neuroinflammation in a Mouse Model of Perioperative Neurocognitive Disorder.	BCL2
34171161	10.1111/pin.13131	2021	Fluorescent nanoparticle-mediated semiquantitative MYC protein expression analysis in morphologically diffuse large B-cell lymphoma.	BCL2
34174694	10.1016/j.jss.2021.05.004	2021	Sulforaphane Ameliorates the Liver Injury of Traumatic Hemorrhagic Shock Rats.	BCL2
34176492	10.1186/s13256-021-02949-5	2021	A young girl with chronic isolated cervical lymphadenopathy found to have lupus lymphadenopathy, progressing to develop lupus nephritis: a case report.	BCL2
34178461	10.7717/peerj.11577	2021	Expression of autophagy and apoptosis-related factors in the periodontal tissue of experimental diabetic rats: a histomorphometric, microtomographic and immunohistochemical study.	BCL2
34180401	10.14411/fp.2021.016	2021	Toxoplasma gondii ROP17 promotes autophagy via the Bcl-2-Beclin 1 pathway.	BCL2
34185336	10.1002/ajh.26284	2021	BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.	BCL2
34199936	10.3390/ijms22116084	2021	Suppression of TRPV1/TRPM8/P2Y Nociceptors by Withametelin via Downregulating MAPK Signaling in Mouse Model of Vincristine-Induced Neuropathic Pain.	BCL2
34202528	10.3390/cancers13133155	2021	Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types.	BCL2
34204385	10.3390/cancers13123032	2021	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing.	BCL2
34210682	10.1158/1078-0432.CCR-21-0553	2021	Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.	BCL2
34219464	10.1139/bcb-2021-0045	2021	Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway.	BCL2
34221962	10.3389/fonc.2021.638154	2021	Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.	BCL2
34224392	10.1530/REP-21-0157	2021	PIWIs maintain testis apoptosis to remove abnormal germ cells in Eriocheir sinensis.	BCL2
34226167	10.1016/j.clml.2021.05.018	2021	Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.	BCL2
34243771	10.1186/s12958-021-00791-4	2021	Characterization of the effects of heat stress on autophagy induction in the pig oocyte.	BCL2
34251414	10.1182/bloodadvances.2021004233	2021	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).	BCL2
34259934	10.1007/s12032-021-01513-x	2021	Computational study on novel natural inhibitors targeting BCL2.	BCL2
34269703	10.1097/FJC.0000000000001031	2021	Circ-PRKCI Alleviates Lipopolysaccharide-induced Human Kidney 2 Cell Injury by Regulating miR-106b-5p/GAB1 Axis.	BCL2
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	BCL2
34276389	10.3389/fphys.2021.603848	2021	Expression of Autophagy-Related Factors LC3A and Beclin 1 and Apoptosis-Related Factors Bcl-2 and BAX in Osteoblasts Treated With Sodium Fluoride.	BCL2
34277781	10.21037/atm-21-2574	2021	A novel peptide promotes human trophoblast proliferation and migration through PI3K/Akt/mTOR signaling pathway.	BCL2
34282785	10.3390/cancers13133367	2021	Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma.	BCL2
34282799	10.3390/cancers13133369	2021	The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.	BCL2
34284777	10.1186/s12958-021-00799-w	2021	Effects of low intensity pulsed ultrasound on expression of B-cell lymphoma-2 and BCL2-Associated X in premature ovarian failure mice induced by 4-vinylcyclohexene diepoxide.	BCL2
34295778	10.21037/tp-21-39	2021	Effect of SOCS3 on apoptosis of human trophoblasts via adjustment of the JAK2/STAT3 signaling pathway in preterm birth.	BCL2
34295921	10.3389/fmolb.2021.681849	2021	Novel Nanoliposomes Alleviate Contrast-Induced Nephropathy by Mediating Apoptosis Response in New Zealand Rabbits.	BCL2
34302428	10.1111/jcmm.16793	2021	Novel polysaccharide extracted from Sipunculus nudus inhibits HepG2 tumour growth in vivo by enhancing immune function and inducing tumour cell apoptosis.	BCL2
34302634	10.1007/s13258-021-01142-8	2021	Lactucin induces apoptosis through reactive oxygen species-mediated BCL-2 and CFLAR<sub>L</sub> downregulation in Caki-1 cells.	BCL2
34307232	10.4322/acr.2021.278	2021	De novo double-hit B-cell precursor leukemia/lymphoma - an unusual presentation as peritoneal lymphomatosis.	BCL2
34313135	10.2217/fon-2021-0370	2021	Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing.	BCL2
34323626	10.1080/10428194.2021.1957870	2021	TAp63 and BCL2 expression are co-affected by cell-extrinsic signals in chronic lymphocytic leukemia.	BCL2
34328190	10.3892/mmr.2021.12327	2021	Heat shock protein 70 attenuates hypoxia‚Äëinduced apoptosis of pulmonary microvascular endothelial¬†cells isolated from neonatal rats.	BCL2
34334687	10.1097/PAS.0000000000001726	2021	High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B.	BCL2
34339901	10.1016/j.clineuro.2021.106838	2021	MYC, BCL2, and BCL6 expression as prognostic indicators in primary central nervous system lymphoma: A systematic review and meta-analysis.	BCL2
34343635	10.1016/j.canlet.2021.07.045	2021	Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance.	BCL2
34346845	10.1080/21655979.2021.1950282	2021	Long non-coding RNA MCM3AP antisense RNA 1 promotes non-small cell lung cancer progression through targeting microRNA-195-5p.	BCL2
34353509	10.1016/j.eimce.2020.06.017	2021	Circulating Bcl-2 concentrations and septic patient mortality.	BCL2
34359500	10.3390/foods10071630	2021	Transcriptional Changes after Enniatins A, A1, B and B1 Ingestion in Rat Stomach, Liver, Kidney and Lower Intestine.	BCL2
34369229	10.1080/10428194.2021.1957873	2021	Thiostrepton inhibits growth and induces apoptosis by targeting FoxM1/SKP2/MTH1 axis in B-precursor acute lymphoblastic leukemia cells.	BCL2
34374220	10.1002/cjp2.223	2021	c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.	BCL2
34378195	10.1111/bjh.17765	2021	Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.	BCL2
34380369	10.1080/10428194.2021.1964021	2021	Whole genome sequencing demonstrates substantial pathophysiological differences of <i>MYC</i> rearrangements in patients with plasma cell myeloma and B-cell lymphoma.	BCL2
34382859	10.1089/jmf.2021.K.0059	2021	Ginkgolic Acid Suppresses Nasopharyngeal Carcinoma Growth by Inducing Apoptosis and Inhibiting <i>AKT/NF-Œ∫B</i> Signaling.	BCL2
34384155	10.3760/cma.j.issn.0253-2727.2021.06.008	2021	[Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].	BCL2
34386317	10.1016/j.apsb.2020.10.018	2021	Natural compounds modulate the autophagy with potential implication of stroke.	BCL2
34388250	10.1093/jnen/nlab080	2021	Expression of STAT6 and Phosphorylated STAT6 in Primary Central Nervous System Lymphomas.	BCL2
34389272	10.1016/j.clml.2021.07.012	2021	SOHO State of the Art Updates and Next Questions: The Past, Present and Future of Venetoclax-Based Therapies in AML.	BCL2
34400859	10.1016/j.jsps.2021.04.027	2021	Effects of neoadjuvant therapies on genetic regulation of targeted pathways in ER+¬†primary ductal breast carcinoma: A meta-analysis of microarray datasets.	BCL2
34400968	10.22037/ijpr.2019.14907.12738	2021	Evaluation of Nrf2, Keap1 and Apoptotic Pathway Genes Expression in Acute Myeloid Leukemia Patients.	BCL2
34402163	10.1111/jcmm.16822	2021	BAG1 down-regulation increases chemo-sensitivity of acute lymphoblastic leukaemia cells.	BCL2
34404436	10.1186/s13027-021-00396-x	2021	Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China.	BCL2
34406351	10.1093/ajcp/aqab043	2021	Light Chain-Restricted Plasmacytoid Cells in Hyperplastic Germinal CentersA Clinicopathologic Investigation.	BCL2
34406846	10.1089/gtmb.2021.0009	2021	<i>miR-1</i> Targeted Downregulation of <i>Bcl-2</i> Increases Chemosensitivity of Lung Cancer Cells.	BCL2
34417162	10.1016/j.clml.2021.07.016	2021	A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies.	BCL2
34424320	10.1182/bloodadvances.2020003276	2021	The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia.	BCL2
34424958	10.1182/blood.2021012052	2021	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior.	BCL2
34425193	10.1016/j.ijpharm.2021.121034	2021	Transferrin-conjugated liposomes loaded with carnosic acid inhibit liver cancer growth by inducing mitochondria-mediated apoptosis.	BCL2
34438040	10.1016/j.annonc.2021.08.1991	2021	SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status.	BCL2
34438219	10.1016/j.jinorgbio.2021.111580	2021	DNA binding and evaluation of anticancer activity in vitro and in vivo of iridium(III) polypyridyl complexes.	BCL2
34440193	10.3390/biomedicines9080990	2021	Nanonutraceuticals: Anti-Cancer Activity and Improved Safety of Chemotherapy by Costunolide and Its Nanoformulation against Colon and Breast Cancer.	BCL2
34445685	10.3390/ijms22168980	2021	A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes.	BCL2
34465079	10.4132/jptm.2021.07.25	2021	Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution.	BCL2
34477080	NA	2021	Indurated Plaques on the Legs: Think Lymphoma.	BCL2
34478505	10.1182/bloodadvances.2021005083	2021	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.	BCL2
34479596	10.1186/s13005-021-00287-x	2021	Influences of cold atmospheric plasma on apoptosis related molecules in osteoblast-like cells in vitro.	BCL2
34488262	10.3760/cma.j.cn121094-20201010-00568	2021	[Changes and significance of autophagy in rat lung injury induced by gas explosion].	BCL2
34489160	10.1016/j.jjcc.2021.08.018	2021	LncRNA MIAT knockdown alleviates oxygen-glucose deprivation‚Äëinduced cardiomyocyte injury by regulating JAK2/STAT3 pathway via miR-181a-5p.	BCL2
34490824	10.1177/15347354211035450	2021	Thymoquinone and Costunolide Induce Apoptosis of Both Proliferative and Doxorubicin-Induced-Senescent Colon and Breast Cancer Cells.	BCL2
34497195	10.11406/rinketsu.62.1085	2021	[Molecular pathogenesis and treatment of chronic lymphocytic leukemia].	BCL2
34500469	10.1182/bloodadvances.2021004635	2021	Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma.	BCL2
34520298	10.1177/15330338211041193	2021	miR-342-3p Regulates the Proliferation and Apoptosis of NSCLC Cells by Targeting <i>BCL-2</i>.	BCL2
34528238	10.1111/bjh.17729	2021	Quadruple-hit pleomorphic mantle cell lymphoma with MYC, BCL2, BCL6, and CCND1 gene rearrangements.	BCL2
34534532	10.1016/j.ejphar.2021.174505	2021	7-[[(4-methyl-2-pyridinyl)amino](2-pyridinyl)methyl]-8-quinolinol (compound 30666) inhibits enhancer activity and reduces B-cell lymphoma growth - A question of specificity.	BCL2
34551886	10.1016/j.clml.2021.07.029	2021	A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.	BCL2
34555842	10.1182/bloodadvances.2020003949	2021	A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival.	BCL2
34563576	10.1016/j.ijbiomac.2021.09.095	2021	The crystal structure of the domain-swapped dimer of onconase highlights some catalytic and antitumor activity features of the enzyme.	BCL2
34568060	10.3389/fonc.2021.729106	2021	Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia.	BCL2
34576095	10.3390/ijms22189924	2021	Titanium Dioxide Nanoparticles Exacerbate Allergic Airway Inflammation via TXNIP Upregulation in a Mouse Model of Asthma.	BCL2
34576319	10.3390/ijms221810157	2021	BH3 Mimetics in Hematologic Malignancies.	BCL2
34581757	10.1182/bloodadvances.2021004619	2021	Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.	BCL2
34610523	10.1016/j.oraloncology.2021.105552	2021	Blastoid variant of mantle cell lymphoma in palatine tonsil.	BCL2
34625994	10.1002/ajh.26367	2021	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.	BCL2
34633547	10.1007/s00894-021-04924-9	2021	Difference in the binding mechanisms of ABT-263/43b with Bcl-xL/Bcl-2: computational perspective on the accurate binding free energy analysis.	BCL2
34634256	10.1016/S2352-3026(21)00273-8	2021	Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.	BCL2
34638779	10.3390/ijms221910442	2021	B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy.	BCL2
34669537	10.1177/09603271211051597	2021	Vinpocetine attenuates fluoxetine-induced liver damage in rats; Role of Nrf2 and PPAR-Œ≥.	BCL2
34669944	10.1093/mtomcs/mfab058	2021	Maternal selenium deficiency suppresses proliferation, induces autophagy dysfunction and apoptosis in the placenta of mice.	BCL2
34671837	10.1007/s00292-021-01011-x	2021	[Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].	BCL2
34680290	10.3390/cancers13205141	2021	Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents.	BCL2
34685497	10.3390/cells10102517	2021	The Dual Role of Autophagy in Crizotinib-Treated ALK<sup>+</sup> ALCL: From the Lymphoma Cells Drug Resistance to Their Demise.	BCL2
34698437	10.1111/jcmm.16999	2021	Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma.	BCL2
34706861	10.1136/bjophthalmol-2021-319580	2021	Prevalence and prognostic value of <i>MYD88</i> and <i>CD79B</i> mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.	BCL2
34707037	10.3960/jslrt.21025	2021	t(9;14)(p13;q32)/PAX5-IGH translocation as a secondary cytogenetic abnormality in diffuse large B-cell lymphoma.	BCL2
34708625	10.19852/j.cnki.jtcm.2021.05.003	2021	Mechanism of total glucosides from Chishao (Radix Paeoniae Rubra) on proliferation and apoptosis of hepatocellular carcinoma cells via phosphatase and tensin homolog deleted on chromosome ten / phosphatidylinositol 3-kinase / protein kinase B signaling pathway.	BCL2
34712389	10.1155/2021/9013280	2021	Effect of Maternal Marginal Zinc Deficiency on Development, Redox Status, and Gene Expression Related to Oxidation and Apoptosis in an Avian Embryo Model.	BCL2
34718250	10.1097/WNR.0000000000001739	2021	Neuroprotective effect of paeoniflorin in the mouse model of Parkinson's disease through Œ±-synuclein/protein kinase C Œ¥ subtype signaling pathway.	BCL2
34722836	10.1016/j.reth.2021.09.005	2021	Xeno-free workflow exhibits comparable efficiency and quality of keratinocytes isolated from human skin biopsies.	BCL2
34732441	10.21873/anticanres.15384	2021	Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma.	BCL2
34732719	10.1038/s41467-021-26400-x	2021	Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia.	BCL2
34733114	10.1155/2021/2255017	2021	Increased Death of Peripheral Blood Mononuclear Cells after TLR4 Inhibition in Sepsis Is Not via TNF/TNF Receptor-Mediated Apoptotic Pathway.	BCL2
34733270	10.3389/fimmu.2021.703256	2021	Cytomegalovirus in Haematological Tumours.	BCL2
34736967	10.1016/j.ejphar.2021.174612	2021	Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells.	BCL2
34758330	10.1016/j.celrep.2021.109979	2021	TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change.	BCL2
34782660	10.1038/s41598-021-01693-6	2021	Primary central nervous system lymphomas express immunohistochemical factors of autophagy.	BCL2
34789674	10.1097/APO.0000000000000447	2021	Potential Protective Role of TRPM7 and Involvement of PKC/ERK Pathway in Blue Light-Induced Apoptosis in Retinal Pigment Epithelium Cells in Vitro.	BCL2
34791478	10.1093/rpd/ncab163	2021	EVALUATION OF BCL2 AND ITS REGULATORY MIRS, MIR-15-B AND MIR-16 EXPRESSION CHANGES UNDER THE EXPOSURE OF EXTREMELY LOW-FREQUENCY ELECTROMAGNETIC FIELDS ON HUMAN GASTRIC CANCER CELL LINE.	BCL2
34796352	10.5187/jast.2021.e93	2021	Enhanced supply of methionine regulates protein synthesis in bovine mammary epithelial cells under hyperthermia condition.	BCL2
34799660	10.1038/s41388-021-02117-5	2021	Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer.	BCL2
34806851	10.20892/j.issn.2095-3941.2021.0193	2021	Prognostic value of <i>BCL2</i> and <i>TP53</i> genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP.	BCL2
34821362	10.1042/BSR20211885	2021	LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis.	BCL2
34829668	10.3390/antiox10111797	2021	Impact of Fennel Essential Oil as an Antibiotic Alternative in Rabbit Diet on Antioxidant Enzymes Levels, Growth Performance, and Meat Quality.	BCL2
34830747	10.3390/cancers13225592	2021	Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era.	BCL2
34831318	10.3390/cells10113095	2021	Multi-Target Effects of Novel Synthetic Coumarin Derivatives Protecting AŒ≤-GFP SH-SY5Y Cells against AŒ≤ Toxicity.	BCL2
34837933	10.31557/APJCP.2021.22.11.3723	2021	Investigation the Cytotoxicity of 5-AZA on Acute Lymphoblastic Leukemia Cell Line In Vitro and Characterization the Underlying Molecular Mechanisms of Cell Death and Motility.	BCL2
34839787	10.1080/21655979.2021.2010315	2021	Hsp22 ameliorates lipopolysaccharide-induced myocardial injury by inhibiting inflammation, oxidative stress, and apoptosis.	BCL2
34859100	10.1155/2021/4579850	2021	A Network Pharmacology-Based Study on Irritable Bowel Syndrome Prevention and Treatment Utilizing Shenling Baizhu Powder.	BCL2
34889402	10.1182/hematology.2021000247	2021	Double-hit lymphoma: optimizing therapy.	BCL2
34889425	10.1182/hematology.2021000312	2021	Does MRD have a role in the management of iNHL?	BCL2
34900354	10.1155/2021/6843103	2021	Rare Presentation of Hypoglycemia in a Patient with Anaplastic Large-Cell Lymphoma.	BCL2
34906296	NA	2021	[Naringin inhibits the proliferation and invasion of Eca109 esophageal cancer cells and promotes its apoptosis by blocking JAK/STAT signal pathway].	BCL2
34907175	10.1038/s41467-021-27197-5	2021	Interleukin-7 receptor Œ± mutational activation can initiate precursor B-cell acute lymphoblastic leukemia.	BCL2
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	BCL2
34938664	10.3389/fonc.2021.789891	2021	Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.	BCL2
34940336	10.3390/gels7040276	2021	Development, Optimization, and In Vitro Evaluation of Novel Oral Long-Acting Resveratrol Nanocomposite In-Situ Gelling Film in the Treatment of Colorectal Cancer.	BCL2
34945004	10.3390/cancers13246384	2021	Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel.	BCL2
34945817	10.3390/jpm11121345	2021	Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies.	BCL2
34945856	10.3390/jpm11121384	2021	Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma.	BCL2
34956871	10.3389/fonc.2021.746577	2021	Clinical Features and Prognostic Significance of <i>NOTCH1</i> Mutations in Diffuse Large B-Cell Lymphoma.	BCL2
34963222	10.3760/cma.j.cn115330-20210125-00036	2021	[The role of RUNX1 in the apoptosis of epithelial cells in nasal polyps].	BCL2
34970357	10.1155/2021/4933194	2021	MiR-126-HMGB1-HIF-1 Axis Regulates Endothelial Cell Inflammation during Exposure to Hypoxia-Acidosis.	BCL2
34988210	10.21037/atm-21-5975	2021	Andrographolide inhibits non-small cell lung cancer cell proliferation through the activation of the mitochondrial apoptosis pathway and by reprogramming host glucose metabolism.	BCL2
35003920	10.7717/peerj.12571	2021	Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway.	BCL2
35004320	10.3389/fonc.2021.795330	2021	Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With <i>MYC</i> and <i>BCL6</i> Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?	BCL2
35077634	NA	2021	Burkitt Lymphoma With Aberrant Immunophenotype Imposing Diagnostic Challenge.	BCL2
35116484	10.21037/tcr-20-2748	2021	Double hit B-lymphoblastic lymphoma with concurrent <i>IGH</i>/<i>BCL2</i> and 8q24/<i>MYC</i> translocations: a case report.	BCL2
35116524	10.21037/tcr-20-3018	2021	Procyanidins mediates antineoplastic effects against non-small cell lung cancer via the JAK2/STAT3 pathway.	BCL2
35124663	NA	2021	An uncommon clinical presentation of primary pancreatic lymphoma: Bleeding. Case report and literature review.	BCL2
35127485	10.3389/fonc.2021.780191	2021	Neutralizing Anti-IL-17A Antibody Demonstrates Preclinical Activity Enhanced by Vinblastine in Langerhans Cell Histiocytosis.	BCL2
35155650	10.3389/fvets.2021.817183	2021	The Protective Impact of <i>Salsola imbricata</i> Leaf Extract From Taif Against Acrylamide-Induced Hepatic Inflammation and Oxidative Damage: The Role of Antioxidants, Cytokines, and Apoptosis-Associated Genes.	BCL2
35546979	10.22092/ari.2021.356202.1803	2021	Renoprotective Potential of the Ultra-Pure Lipopolysaccharide from¬†Rhodobacter Sphaeroides on Acutely Injured Kidneys in an Animal Model.	BCL2
31838216	10.1016/j.ijid.2019.12.004	2020	Do genetic polymorphisms of B-cell CLL/lymphoma 2 confer susceptibility to anti-tuberculous therapy-associated drug-induced liver injury?	BCL2
31844144	10.1038/s41375-019-0691-6	2020	Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.	BCL2
31880257	10.2174/1389203721666191227122252	2020	Role of BCL-2 Family Proteins in Apoptosis and its Regulation by Nutrients.	BCL2
31889428	10.1002/kjm2.12181	2020	miR-636 represses cell survival by targeting CDK6/Bcl-2 in cervical cancer.	BCL2
31954371	10.1016/j.redox.2019.101403	2020	Superoxide induced inhibition of death receptor signaling is mediated via induced expression of apoptosis inhibitory protein cFLIP.	BCL2
32100014	10.1093/jnen/nlaa006	2020	Anti-HMGCR Antibody-Positive Myopathy Shows Bcl-2-Positive Inflammation and Lymphocytic Accumulations.	BCL2
32101329	10.1002/hon.2727	2020	Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.	BCL2
32334477	10.31557/APJCP.2020.21.4.1103	2020	The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.	BCL2
32364682	10.1111/ijlh.13222	2020	Significance of CD10 protein expression in the diagnostics of follicular lymphoma: A comparison of conventional immunohistochemistry with flow cytometry supported by the establishment of BCL2 and BCL6 rearrangements.	BCL2
32566654	10.1155/2020/1350820	2020	Prognostic Value of Concurrent Expression of C-MYC and BCL2 in Intravascular Large B-Cell Lymphoma: A 10-Year Retrospective Study.	BCL2
32580907	10.1016/j.clbc.2020.05.005	2020	p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.	BCL2
32632899	10.1007/s12253-020-00866-4	2020	A Clinicopathological Approach to Odontogenic Cysts: the Role of Cytokeratin 17 and bcl2 Immunohistochemistry in Identifying Odontogenic Keratocysts.	BCL2
32648768	10.1139/bcb-2019-0336	2020	MiR-448 targets BLC2 and inhibits the growth of pituitary adenoma cells.	BCL2
32680911	10.1136/jclinpath-2020-206725	2020	Incidence of single hit Bcl-2 and Bcl-6 rearrangements in DLBCL: the Irish experience.	BCL2
32722781	10.1182/bloodadvances.2020001551	2020	Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.	BCL2
32921221	10.1080/10428194.2020.1815017	2020	Clinicopathological and prognostic significance of <i>BCL2</i>, <i>BCL6</i>, <i>MYC</i>, and <i>IRF4</i> copy number gains and translocations in follicular lymphoma: a study by FISH analysis.	BCL2
32991338	10.1097/PAS.0000000000001577	2020	High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.	BCL2
33031695	NA	2020	A Study Investigating the Role of 2 Candidate SNPs in Bax and Bcl-2 Genes in Alzheimer's Disease.	BCL2
33168821	10.1038/s41408-020-00382-3	2020	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients.	BCL2
33233721	10.3390/ijms21228795	2020	Identification of Recurrent Mutations in the microRNA-Binding Sites of B-Cell Lymphoma-Associated Genes in Follicular Lymphoma.	BCL2
33280526	10.1177/1533033820980098	2020	microRNA-214 Prevents Traits of Cutaneous Squamous Cell Carcinoma via VEGFA and Bcl-2.	BCL2
34171048	10.47162/RJME.61.4.01	2020	Ovarian ectopic pregnancy: the role of complex morphopathological assay. Review and case presentation.	BCL2
29930300	10.1038/s41375-018-0176-z	2019	The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.	BCL2
30075095	10.1016/j.hemonc.2018.07.005	2019	BCL-2 overexpression overcomes cell of origin stratification in diffuse large B-cell lymphoma.	BCL2
30304559	10.1002/jcb.27655	2019	LINC00152 promotes the proliferation of gastric cancer cells by regulating B-cell lymphoma-2.	BCL2
30306208	10.1007/s00277-018-3498-z	2019	MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.	BCL2
30460680	10.1111/bjh.15653	2019	Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.	BCL2
30535471	10.3892/ijmm.2018.4019	2019	MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2.	BCL2
30569090	10.3892/mmr.2018.9738	2019	miR‚Äë15a‚Äë3p affects the proliferation, migration and apoptosis of lens epithelial cells.	BCL2
30575108	10.1002/ajh.25385	2019	IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.	BCL2
30623427	10.1002/jcp.28091	2019	The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.	BCL2
30681073	10.12659/MSM.912082	2019	Berberine Promotes Apoptosis of Colorectal Cancer via Regulation of the Long Non-Coding RNA (lncRNA) Cancer Susceptibility Candidate 2 (CASC2)/AU-Binding Factor 1 (AUF1)/B-Cell CLL/Lymphoma 2 (Bcl-2) Axis.	BCL2
30741252	10.12659/MSM.912148	2019	microRNA-205 and microRNA-338-3p Reduces Cell Apoptosis in Prostate Carcinoma Tissue and LNCaP Prostate Carcinoma Cells by Directly Targeting the B-Cell Lymphoma 2 (Bcl-2) Gene.	BCL2
30747219	10.3892/or.2019.6980	2019	Stanniocalcin‚Äë1 promotes cell proliferation, chemoresistance and metastasis in hypoxic gastric cancer cells via Bcl‚Äë2.	BCL2
30747227	10.3892/mmr.2019.9883	2019	Long noncoding RNA GAS5 promotes apoptosis in primary nucleus pulposus cells derived from the human intervertebral disc via Bcl‚Äë2 downregulation and caspase‚Äë3 upregulation.	BCL2
30801855	10.1111/odi.13070	2019	Bcl-2 is a prognostic marker and its silencing inhibits recurrence in ameloblastomas.	BCL2
30842155	10.21873/anticanres.13235	2019	Digital Analysis of BCL2 Expression in Laryngeal Squamous Cell Carcinoma.	BCL2
30940629	10.1124/dmd.118.085605	2019	Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy.	BCL2
31036603	10.1042/BSR20182321	2019	miR-1915-3p inhibits Bcl-2 expression in the development of gastric cancer.	BCL2
31103719	10.1016/j.canlet.2019.05.009	2019	A feedforward relationship between active Rac1 and phosphorylated Bcl-2 is critical for sustaining Bcl-2 phosphorylation and promoting cancer progression.	BCL2
31127909	10.31557/APJCP.2019.20.5.1463	2019	C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma	BCL2
31145521	10.1111/cas.14083	2019	Cysteine-rich protein 61 regulates the chemosensitivity of chronic myeloid leukemia to imatinib mesylate through the nuclear factor kappa B/Bcl-2 pathway.	BCL2
31160589	10.1038/s41467-019-10363-1	2019	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.	BCL2
31203382	10.1007/s00411-019-00802-4	2019	Hypoxia inducible factor-1Œ±/B-cell lymphoma 2 signaling impacts radiosensitivity of H1299 non-small cell lung cancer cells in a normoxic environment.	BCL2
31218746	10.1002/jcb.29207	2019	miR-34a-5p was involved in chronic intermittent hypoxia-induced autophagy of human coronary artery endothelial cells via Bcl-2/beclin 1 signal transduction pathway.	BCL2
31234236	10.1111/bjh.16069	2019	Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.	BCL2
31315646	10.1186/s13000-019-0856-7	2019	Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.	BCL2
31337422	10.1186/s13148-019-0706-1	2019	Suv39h1 promotes facet joint chondrocyte proliferation by targeting miR-15a/Bcl2 in idiopathic scoliosis patients.	BCL2
31358732	10.1038/s41419-019-1801-0	2019	Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.	BCL2
31379128	10.15252/embr.201847026	2019	Checkpoint kinase 1 is essential for fetal and adult hematopoiesis.	BCL2
31397599	10.1139/cjpp-2018-0743	2019	Inhibition of microRNA-34a mediates protection of thymosin beta 4 in endothelial progenitor cells against advanced glycation endproducts by targeting B-cell lymphoma 2.	BCL2
31410188	10.7150/thno.36254	2019	Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy.	BCL2
31417030	10.4103/ijmr.IJMR_1455_17	2019	Apoptosis gene reprograming of human peripheral blood mononuclear cells induced by radioiodine-131 (<sup>131</sup>I) irradiation.	BCL2
31485613	10.3892/mmr.2019.10610	2019	Rsf‚Äë1 regulates malignant melanoma cell viability and chemoresistance via NF‚ÄëŒ∫B/Bcl‚Äë2 signaling.	BCL2
31644584	10.1371/journal.pone.0224247	2019	Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.	BCL2
31683398	10.3760/cma.j.issn.0253-9624.2019.11.009	2019	[The association of <i>Bcl</i>-2 gene polymorphism with the esophageal cancer and gastric cardia adenocarcinoma in Hebei Province].	BCL2
31702637	10.1097/MD.0000000000017827	2019	Immunohistochemical overexpression of BCL-2 protein predicts an inferior survival in patients with primary central nervous system diffuse large B-cell lymphoma.	BCL2
31737898	10.1042/BSR20191773	2019	MicroRNA-15a modulates lens epithelial cells apoptosis and proliferation through targeting B-cell lymphoma-2 and E2F transcription factor 3 in age-related cataracts.	BCL2
31825969	10.1371/journal.pcbi.1007485	2019	Alterations of the interactome of Bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level.	BCL2
28701032	10.4143/crt.2017.134	2018	BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database.	BCL2
28718205	10.1002/cyto.b.21541	2018	Bcl-2 maturation pattern in T-cells distinguishes thymic neoplasm/hyperplasia, T-lymphoblastic lymphoma, and reactive lymph nodes.	BCL2
28777433	10.5301/ijbm.5000291	2018	Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.	BCL2
28805013	10.1002/mabi.201700196	2018	Drug-Free Macromolecular Therapeutics Induce Apoptosis via Calcium Influx and Mitochondrial Signaling Pathway.	BCL2
28824170	10.1038/leu.2017.270	2018	Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing.	BCL2
28875547	10.1111/bjh.14912	2018	Immunohistochemical double hit score enhances NCCN-IPI and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma.	BCL2
28914671	10.1097/PGP.0000000000000442	2018	Endometrial Polyps and Benign Endometrial Hyperplasia Have Increased Prevalence of DNA Fragmentation Factors 40 and 45 (DFF40 and DFF45) Together With the Antiapoptotic B-Cell Lymphoma (Bcl-2) Protein Compared With Normal Human Endometria.	BCL2
29131545	10.1111/febs.14324	2018	A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.	BCL2
29207009	10.3892/ijmm.2017.3260	2018	TAT‚Äëfused IP3R‚Äëderived peptide enhances cisplatin sensitivity of ovarian cancer cells by increasing ER Ca2+ release.	BCL2
29246583	10.1016/j.bbagen.2017.12.003	2018	DNA structural basis for fragility at peak III of BCL2 major breakpoint region associated with t(14;18) translocation.	BCL2
29328455	10.3892/mmr.2018.8381	2018	Role of miR-21 in the growth and metastasis of human salivary adenoid cystic carcinoma.	BCL2
29422088	10.1186/s13195-018-0344-4	2018	Associations of Bcl-2 rs956572 genotype groups in the structural covariance network in early-stage Alzheimer's disease.	BCL2
29484432	10.3892/ijo.2018.4285	2018	miR‚Äë15a represses cancer cell migration and invasion under conditions of hypoxia by targeting and downregulating Bcl‚Äë2 expression in human osteosarcoma cells.	BCL2
29666157	10.1136/jclinpath-2018-205039	2018	CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.	BCL2
29669301	10.1016/j.biopha.2018.04.002	2018	LIN28B promotes the progression of colon cancer by increasing B-cell lymphoma 2 expression.	BCL2
29680307	10.1016/j.arcmed.2018.04.006	2018	Prognostic Value of CD95, Active Caspase-3, and Bcl-2 Expression in Adult Patients with De Novo Acute Lymphoblastic Leukemia.	BCL2
29708579	10.5146/tjpath.2018.01430	2018	Evaluation of the Prognostic Importance of c-Myc and Bcl-2 Expressions and the Presence of Epstein-Barr Virus in Classical Hodgkin Lymphoma.	BCL2
29747654	10.1186/s13045-018-0608-2	2018	BCL-2 as therapeutic target for hematological malignancies.	BCL2
29801406	10.22034/APJCP.2018.19.5.1229	2018	Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience	BCL2
29902576	10.1016/j.humpath.2018.06.006	2018	Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.	BCL2
29983382	10.1016/j.clml.2018.06.010	2018	Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL.	BCL2
30015962	10.3892/or.2018.6581	2018	Knockdown of metadherin inhibits cell proliferation and migration in colorectal cancer.	BCL2
30043475	10.1002/dc.24038	2018	Triple hit lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.	BCL2
30058688	10.26355/eurrev_201807_15502	2018	Expressions and effects of G250, Bax and Bcl-2 in rats with renal clear cell carcinoma.	BCL2
30152851	10.3892/mmr.2018.9428	2018	Estrogen restricts the apoptosis of endometrial stromal cells by promoting TSLP secretion.	BCL2
30168854	10.1111/aogs.13452	2018	Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: A specific marker of precancer and novel indication for treatment: A systematic review and meta-analysis.	BCL2
30297390	10.1136/jim-2018-000804	2018	Prostate cancer aggressiveness and age: Impact of p53, BCL-2 and microvessel density.	BCL2
30687320	10.3389/fimmu.2018.03114	2018	Dysregulated TRAF3 and BCL2 Expression Promotes Multiple Classes of Mature Non-hodgkin B Cell Lymphoma in Mice.	BCL2
27098707	10.1111/bjh.14089	2017	Association of BAX G(-248)A and BCL2 C(-717)A polymorphisms with outcome in diffuse large B-cell lymphoma patients.	BCL2
27696517	10.1002/ajh.24571	2017	CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?	BCL2
27840321	10.1016/j.freeradbiomed.2016.11.010	2017	Pro-apoptotic effects of lipid oxidation products: HNE at the crossroads of NF-Œ∫B pathway and anti-apoptotic Bcl-2.	BCL2
28079890	10.1038/cddis.2016.469	2017	Structural insight into an evolutionarily ancient programmed cell death regulator - the crystal structure of marine sponge BHP2 bound to LB-Bak-2.	BCL2
28154089	10.3324/haematol.2016.159087	2017	Genetic polymorphism at <i>BCL2</i> as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma.	BCL2
28212447	10.1371/journal.pone.0172364	2017	Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence.	BCL2
28260044	10.3892/mmr.2017.6233	2017	microRNA-125b reverses the multidrug resistance of nasopharyngeal carcinoma cells via targeting of Bcl-2.	BCL2
28280358	10.2147/OTT.S128819	2017	miR-204-5p acts as a tumor suppressor by targeting matrix metalloproteinases-9 and B-cell lymphoma-2 in malignant melanoma.	BCL2
28327893	10.1093/annonc/mdx022	2017	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.	BCL2
28351336	10.1177/1010428317695965	2017	B-cell lymphoma 2 inhibitor ABT-737 induces Beclin1- and reactive oxygen species-dependent autophagy in Adriamycin-resistant human hepatocellular carcinoma cells.	BCL2
28351934	10.1182/blood-2016-11-747022	2017	Genetic profiling of <i>MYC</i> and <i>BCL2</i> in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.	BCL2
28379541	10.1093/molehr/gax022	2017	Resistance to apoptosis and autophagy leads to enhanced survival in Sertoli cells.	BCL2
28393810	10.4103/ijdr.IJDR_158_16	2017	Expression of E-cadherin and B-cell lymphoma 2 in oral cancer: A ratio-based planning for targeted therapy.	BCL2
28396899	10.1007/s00066-017-1126-9	2017	BCL2¬†genotypes and prostate cancer survival.	BCL2
28428442	10.1158/1535-7163.MCT-16-0555	2017	Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.	BCL2
28514780	10.1159/000474926	2017	Two Distinct BCL2 Rearrangements, Each Observed in 2 Independent Subclones, Evolving from a Founder Clone with Trisomy 12 in a Unique Case of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.	BCL2
28522442	10.1182/blood-2016-12-759621	2017	BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.	BCL2
28586007	10.3892/ijo.2017.4028	2017	APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells.	BCL2
28716711	10.1016/j.gene.2017.07.043	2017	Epigenetic silencing of miRNA-143 regulates apoptosis by targeting BCL2 in human intervertebral disc degeneration.	BCL2
28849107	10.3892/mmr.2017.7369	2017	GATA4 is highly expressed in childhood acute lymphoblastic leukemia, promotes cell proliferation and inhibits apoptosis by activating BCL2 and MDM2.	BCL2
28862228	10.4103/0973-1482.183197	2017	A study of the distribution of B-cell lymphoma/leukemia-2 in odontogenic cyst and tumors: Histochemical study.	BCL2
28888575	10.1016/j.gene.2017.09.009	2017	Fascaplysin inhibit ovarian cancer cell proliferation and metastasis through inhibiting CDK4.	BCL2
28952038	10.1007/s11912-017-0629-y	2017	Double-Hit Large B Cell Lymphoma.	BCL2
28972015	10.1182/blood-2017-06-792150	2017	Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.	BCL2
29020630	10.1016/j.celrep.2017.09.052	2017	Degradation of Bcl-2 by XIAP and ARTS Promotes Apoptosis.	BCL2
29044419	10.1093/jnen/nlx083	2017	MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL.	BCL2
29061914	10.1042/BCJ20170080	2017	Therapeutics targeting Bcl-2 in hematological malignancies.	BCL2
29088292	10.1371/journal.pone.0186983	2017	Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.	BCL2
29198442	10.1016/j.trecan.2017.09.008	2017	Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma.	BCL2
29254309	NA	2017	Association of BCL-2 with oxidative stress and total antioxidant status in pediatric acute lymphoblastic leukemia.	BCL2
25843436	10.3109/15622975.2015.1019360	2016	CACNA1C SNP rs1006737 associates with bipolar I disorder independent of the Bcl-2 SNP rs956572 variant and its associated effect on intracellular calcium homeostasis.	BCL2
26311051	10.1007/s13277-015-3934-9	2016	Association of the functional BCL-2 rs2279115 genetic variant and small cell lung cancer.	BCL2
26350953	10.1177/1535370215600548	2016	Hypoxia promotes apoptosis of neuronal cells through hypoxia-inducible factor-1Œ±-microRNA-204-B-cell lymphoma-2 pathway.	BCL2
26390147	10.3109/10428194.2015.1096352	2016	Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.	BCL2
26421520	10.3109/10428194.2015.1101099	2016	Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma.	BCL2
26448193	10.1097/PAS.0000000000000542	2016	High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.	BCL2
26467384	10.1158/1078-0432.CCR-15-1191	2016	Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.	BCL2
26565895	10.1002/cncr.29781	2016	Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.	BCL2
26621338	10.1038/leu.2015.330	2016	Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus.	BCL2
26639348	10.1056/NEJMoa1513257	2016	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.	BCL2
26658664	10.1097/PAS.0000000000000567	2016	Primary Cutaneous Follicle Center Lymphomas Expressing BCL2 Protein Frequently Harbor BCL2 Gene Break and May Present 1p36 Deletion: A Study of 20 Cases.	BCL2
26662799	10.1007/s13277-015-4554-0	2016	Influence of BCL2-938 C&gt;A promoter polymorphism and BCL2 gene expression on the progression of breast cancer.	BCL2
26725534	10.1016/j.prp.2015.12.001	2016	Partial lack of BCL2 in follicular lymphoma: An unusual immunohistochemical staining pattern explained by ongoing BCL2 mutation.	BCL2
26795455	10.1016/j.bbamcr.2016.01.006	2016	Histone demethylase Jmjd3 regulates osteoblast apoptosis through targeting anti-apoptotic protein Bcl-2 and pro-apoptotic protein Bim.	BCL2
26878773	10.1016/j.freeradbiomed.2016.02.009	2016	Antioxidant tert-butylhydroquinone ameliorates arsenic-induced intracellular damages and apoptosis through induction of Nrf2-dependent antioxidant responses as well as stabilization of anti-apoptotic factor Bcl-2 in human keratinocytes.	BCL2
26905515	10.1007/s00296-016-3443-1	2016	Fas/FasL, Bcl2 and Caspase-8 gene polymorphisms in Chinese patients with rheumatoid arthritis.	BCL2
26919255	10.18632/oncotarget.7687	2016	Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice.	BCL2
27008505	10.1371/journal.pone.0152142	2016	RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.	BCL2
27016043	10.1002/bip.22839	2016	Exploring the conformational and binding properties of unphosphorylated/phosphorylated monomeric and trimeric Bcl-2 through docking and molecular dynamics simulations.	BCL2
27071312	10.3109/10428194.2016.1167205	2016	Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.	BCL2
27129202	10.1074/jbc.M116.715235	2016	Orphan Nuclear Receptor NR4A1 Binds a Novel Protein Interaction Site on Anti-apoptotic B Cell Lymphoma Gene 2 Family Proteins.	BCL2
27134111	10.1016/j.humpath.2016.04.004	2016	Two cases of histiocytic sarcoma with BCL2 translocations and occult or subsequent follicular lymphoma.	BCL2
27157620	10.1038/onc.2016.155	2016	FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.	BCL2
27159593	10.1002/art.39744	2016	Bcl-2 as a Therapeutic Target in Human Tubulointerstitial Inflammation.	BCL2
27176117	10.3892/mmr.2016.5255	2016	MicroRNA-34a inhibits cell proliferation and induces cell apoptosis of glioma cells via targeting of Bcl-2.	BCL2
27286976	10.1186/s12885-016-2397-8	2016	MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.	BCL2
27391453	10.1097/DAD.0000000000000607	2016	Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.	BCL2
27509922	10.3892/mmr.2016.5608	2016	Investigation of the association between miR‚Äë181b, Bcl‚Äë2 and LRIG1 in oral verrucous carcinoma.	BCL2
27524613	10.1016/j.celrep.2016.07.053	2016	Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer Polymorphism.	BCL2
27543313	10.1016/j.mrrev.2016.06.001	2016	Functional Implications of the spectrum of BCL2 mutations in Lymphoma.	BCL2
27544800	10.1016/j.humpath.2016.07.025	2016	Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature.	BCL2
27578251	10.1038/srep32189	2016	The long noncoding RNA ASNR regulates degradation of Bcl-2 mRNA through its interaction with AUF1.	BCL2
27633052	10.3892/mmr.2016.5733	2016	Upregulation of DAPK contributes to homocysteine-induced endothelial apoptosis via the modulation of Bcl2/Bax and activation of caspase¬†3.	BCL2
27748813	10.3892/mmr.2016.5808	2016	Protocadherin Œ≥ A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth.	BCL2
27773559	10.1016/j.jfma.2016.09.006	2016	Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan.	BCL2
23925400	10.1177/1076029613498816	2015	VEGFR-1, Bcl-2, and HO-1 Ratios in Pregnant Women With Hypertension.	BCL2
24496723	10.1002/hon.2132	2015	BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma.	BCL2
24679006	10.3109/10428194.2014.907896	2015	TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.	BCL2
25103070	10.1038/modpathol.2014.95	2015	B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.	BCL2
25257838	10.1007/s12094-014-1226-2	2015	CC genotype of anti-apoptotic gene BCL-2 (-938 C/A) is an independent prognostic marker of unfavorable clinical outcome in patients with non-small-cell lung cancer.	BCL2
25284491	10.3109/10428194.2014.970550	2015	Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.	BCL2
25284608	10.1111/bjh.13149	2015	Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.	BCL2
25311206	10.1007/s12035-014-8908-1	2015	Bcl-2 Decreases the Affinity of SQSTM1/p62 to Poly-Ubiquitin Chains and Suppresses the Aggregation of Misfolded Protein in Neurodegenerative Disease.	BCL2
25336632	10.1182/blood-2014-05-576470	2015	Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.	BCL2
25342468	10.1038/cdd.2014.176	2015	Transformer 2Œ≤ and miR-204 regulate apoptosis through competitive binding to 3' UTR of BCL2 mRNA.	BCL2
25381338	10.1158/1078-0432.CCR-14-1913	2015	Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.	BCL2
25384499	10.3892/or.2014.3595	2015	Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.	BCL2
25388617	10.1007/s00109-014-1221-7	2015	BCL2 protein signalling determines acute responses to neoadjuvant chemoradiotherapy in rectal cancer.	BCL2
25449296	10.1007/s12013-014-0139-6	2015	LRIG1 improves chemosensitivity through inhibition of BCL-2 and MnSOD in glioblastoma.	BCL2
25452615	10.1182/blood-2014-04-571786	2015	BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.	BCL2
25484022	10.3892/or.2014.3655	2015	Lactate promotes resistance to glucose starvation via upregulation of Bcl-2 mediated by mTOR activation.	BCL2
25549806	10.3109/10428194.2014.999324	2015	Risk of follicular lymphoma associated with BCL2 translocations in peripheral blood.	BCL2
25563670	10.1016/j.psychres.2014.12.020	2015	Bcl-2 associated with severity of manic symptoms in bipolar patients in a manic phase.	BCL2
25604244	10.1179/1973947814Y.0000000234	2015	TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2.	BCL2
25631043	10.1074/jbc.M114.627679	2015	The viral restriction factor tetherin prevents leucine-rich pentatricopeptide repeat-containing protein (LRPPRC) from association with beclin 1 and B-cell CLL/lymphoma 2 (Bcl-2) and enhances autophagy and mitophagy.	BCL2
25648135	10.1007/s10549-015-3288-4	2015	Bcl2 and Ki67 refine prognostication in luminal breast cancers.	BCL2
25682076	10.1007/s10549-015-3305-7	2015	Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.	BCL2
25687653	10.1038/leu.2015.43	2015	Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.	BCL2
25715028	10.1080/15548627.2015.1017191	2015	BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy.	BCL2
25738398	10.3892/mmr.2015.3385	2015	B-cell lymphoma 2 and Œ≤-catenin expression in colorectal cancer and their prognostic role following surgery.	BCL2
25741152	10.3748/wjg.v21.i8.2433	2015	Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.	BCL2
25748272	10.1016/j.tem.2015.02.004	2015	Regulation of mitochondrial nutrient and energy metabolism by BCL-2 family proteins.	BCL2
25815462	10.3892/mmr.2015.3534	2015	Apoptosis of HL-60 human leukemia cells induced by Asiatic acid through modulation of B-cell lymphoma 2 family proteins and the mitogen-activated protein kinase signaling pathway.	BCL2
25828389	10.1097/PAS.0000000000000433	2015	MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.	BCL2
25828391	10.1097/PAS.0000000000000434	2015	Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.	BCL2
25854572	NA	2015	[Expressions and significance of NDRG2 and Bcl-2 in human gastric cancer tissues].	BCL2
25862909	NA	2015	miR-7 expression in serous ovarian carcinomas.	BCL2
25867342	10.4238/2015.March.20.6	2015	Effect of TIEG1 on apoptosis and expression of Bcl-2/Bax and Pten in leukemic cell lines.	BCL2
25882699	10.1038/leu.2015.99	2015	Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.	BCL2
25957473	10.1016/j.bbrc.2015.04.131	2015	Regulation of the ryanodine receptor by anti-apoptotic Bcl-2 is independent of its BH3-domain-binding properties.	BCL2
25957891	10.1007/s13277-015-3457-4	2015	Influence of BCL2-938C&gt;A and BAX-248G&gt;A promoter polymorphisms in the development of AML: case-control study from South India.	BCL2
25975837	10.3324/haematol.2014.118828	2015	ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2.	BCL2
25982455	10.1007/s00432-015-1982-6	2015	Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients' poor response to treatment and short-term relapse.	BCL2
25984893	10.1080/15548627.2015.1034402	2015	The GST-BHMT assay reveals a distinct mechanism underlying proteasome inhibition-induced macroautophagy in mammalian cells.	BCL2
26009182	10.1042/BST20140298	2015	Bcl-2 and FKBP12 bind to IP3 and ryanodine receptors at overlapping sites: the complexity of protein-protein interactions for channel regulation.	BCL2
26035796	10.3892/or.2015.4011	2015	Hypoxia-induced apoptosis is blocked by adrenomedullin via upregulation of Bcl-2 in human osteosarcoma cells.	BCL2
26081683	10.3892/mmr.2015.3939	2015	Quantitative analysis of the mRNA expression levels of BCL2 and BAX genes in human osteoarthritis and normal articular cartilage: An investigation into their differential expression.	BCL2
26091803	10.1186/s12885-015-1485-5	2015	Constitutive expression of Bcl-2 induces epithelial-Mesenchymal transition in mammary epithelial cells.	BCL2
26110568	10.18632/oncotarget.4230	2015	Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.	BCL2
26132559	10.1038/srep11833	2015	Functional BCL-2 regulatory genetic variants contribute to susceptibility of esophageal squamous cell carcinoma.	BCL2
26158410	10.18632/oncotarget.4073	2015	MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.	BCL2
26172269	10.1371/journal.pone.0132926	2015	BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?	BCL2
26214636	NA	2015	BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.	BCL2
26239087	10.1182/blood-2015-03-630012	2015	Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.	BCL2
26431330	10.18632/oncotarget.5901	2015	Subcellular localization of PUMA regulates its pro-apoptotic activity in Burkitt's lymphoma B cells.	BCL2
26458963	10.3892/mmr.2015.4363	2015	Aberrantly regulated dysadherin and B-cell lymphoma 2/B-cell lymphoma 2-associated X enhances tumorigenesis and DNA targeting drug resistance of liver cancer stem cells.	BCL2
26475474	10.1186/s12885-015-1778-8	2015	P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.	BCL2
26482649	10.1186/s13000-015-0427-5	2015	Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas?	BCL2
26515759	10.1186/s13045-015-0218-1	2015	Establishment and characterization of a novel MYC/BCL2 double-hit diffuse large B cell lymphoma cell line, RC.	BCL2
26546525	NA	2015	Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor Proliferation.	BCL2
26558423	10.3109/08880018.2015.1087611	2015	De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis.	BCL2
26634708	10.1007/s11864-015-0374-0	2015	Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.	BCL2
26638586	NA	2015	The Expressions of P53, Bcl-2, and P-Glycoprotein and Prognostic Impact in Patients with Peripheral T-Cell Lymphoma (PTCL).	BCL2
26717387	10.1097/MD.0000000000002388	2015	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.	BCL2
26782527	10.4238/2015.December.28.26	2015	Effect of transvaginal ultrasound on human chorionic villus cell apoptosis during pregnancy.	BCL2
26823859	NA	2015	B-cell lymphoma 2 rs17757541 C&gt;G polymorphism was associated with an increased risk of coronary artery disease in a Chinese population.	BCL2
23975374	10.1007/s13277-013-1115-2	2014	MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2.	BCL2
24024471	10.3109/10428194.2013.842992	2014	Role of polymorphisms in BCL-2 and BAX genes in modulating the risk of developing non-Hodgkin lymphoma.	BCL2
24028527	10.1080/07391102.2013.833858	2014	A study of the structural properties and thermal stability of human Bcl-2 by molecular dynamics simulations.	BCL2
24038028	10.3324/haematol.2013.085340	2014	Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia.	BCL2
24118498	10.1111/ejh.12212	2014	MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations.	BCL2
24190693	10.1007/s00404-013-3060-0	2014	Epigenetic and expression analysis of TRAIL-R2 and BCL2: on the TRAIL to knowledge of apoptosis in ovarian tumors.	BCL2
24232982	10.1007/s10120-013-0313-3	2014	Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.	BCL2
24280866	10.1038/leu.2013.361	2014	Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia.	BCL2
24287948	10.1007/s13277-013-1299-5	2014	Association of BCL2-938C&gt;A genetic polymorphism with glioma risk in Chinese Han population.	BCL2
24321200	10.1016/j.jad.2013.11.010	2014	Influence of BCL2 gene in major depression susceptibility and antidepressant treatment outcome.	BCL2
24338002	10.1007/s10555-013-9450-8	2014	Why anti-Bcl-2 clinical trials fail: a solution.	BCL2
24387269	10.1186/1471-2490-14-2	2014	Cyclooxygenase-2 and B-cell lymphoma-2 expression in cystitis glandularis and primary vesicle adenocarcinoma.	BCL2
24397922	10.1016/j.mce.2013.10.024	2014	Up-regulation of Bcl-2 during adipogenesis mediates apoptosis resistance in human adipocytes.	BCL2
24496564	10.1007/s12032-014-0872-0	2014	Phase II study of low-dose fixed-rate infusion of gemcitabine combined with cisplatin and dexamethasone in resistant non-Hodgkin lymphoma and correlation with Bcl-2 and MDR expression.	BCL2
24503222	10.1016/j.tibs.2013.12.006	2014	Many players in BCL-2 family affairs.	BCL2
24621205	10.3109/00365513.2014.891257	2014	Association of BH3 interacting domain death agonist (BID) gene polymorphisms with proteinuria of immunoglobulin A nephropathy.	BCL2
24626299	10.1371/journal.pone.0091782	2014	BEX1 promotes imatinib-induced apoptosis by binding to and antagonizing BCL-2.	BCL2
24762814	10.1242/jcs.150011	2014	Bcl-2 binds to and inhibits ryanodine receptors.	BCL2
24768714	10.1016/j.bbamcr.2014.04.017	2014	A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum.	BCL2
24786774	10.1182/blood-2014-03-560284	2014	Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.	BCL2
25016705	10.7754/clin.lab.2013.130517	2014	Bcl-2/IgH expression of diffuse large B-cell lymphoma cells in minimal bone marrow infiltration.	BCL2
25031780	NA	2014	miR-21 inhibitor suppresses proliferation and migration of nasopharyngeal carcinoma cells through down-regulation of BCL2 expression.	BCL2
25066397	10.1016/S1995-7645(14)60077-8	2014	Expression heterogeneity research of ITGB3 and BCL-2 in lung adenocarcinoma tissue and adenocarcinoma cell line.	BCL2
25086254	10.1016/j.bbagen.2014.07.014	2014	A newly identified G-quadruplex as a potential target regulating Bcl-2 expression.	BCL2
25090026	10.1371/journal.pone.0104068	2014	MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.	BCL2
25177684	10.1155/2014/234370	2014	Bcl-2 family proteins are involved in the signal crosstalk between endoplasmic reticulum stress and mitochondrial dysfunction in tumor chemotherapy resistance.	BCL2
25179840	10.1007/s13277-014-2534-4	2014	Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy.	BCL2
25279986	10.1016/j.ajhg.2014.09.004	2014	Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region.	BCL2
25301704	10.1182/blood-2014-05-574566	2014	ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.	BCL2
25362242	10.18632/oncotarget.2605	2014	Dysregulation of autophagy in human follicular lymphoma is independent of overexpression of BCL-2.	BCL2
25384217	10.1172/JCI72415	2014	Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression.	BCL2
25430556	10.1038/srep07241	2014	Role of Bcl-2 -938 C&gt;A polymorphism in susceptibility and prognosis of cancer: a meta-analysis.	BCL2
22484426	10.1038/onc.2012.117	2013	Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.	BCL2
22929980	10.3324/haematol.2012.066209	2013	Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.	BCL2
22933114	10.2337/db11-1464	2013	Bcl-2 and Bcl-xL suppress glucose signaling in pancreatic Œ≤-cells.	BCL2
23072837	10.1038/npp.2012.203	2013	Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder.	BCL2
23076250	10.3892/mmr.2012.1131	2013	Correlation between SATB1 and Bcl-2 expression in human glioblastoma multiforme.	BCL2
23126236	10.1111/jop.12020	2013	Relationship between anti-apoptotic proteins survivin and Bcl-2, and response to treatment in patients undergoing post-operative RT for laryngeal cancer: a pilot study.	BCL2
23135964	10.1002/alr.21107	2013	Upregulation of Bcl-2 in nasal polyps from patients with cystic fibrosis.	BCL2
23263985	10.1128/MCB.01436-12	2013	Both CpG methylation and activation-induced deaminase are required for the fragility of the human bcl-2 major breakpoint region: implications for the timing of the breaks in the t(14;18) translocation.	BCL2
23335369	10.1182/blood-2012-06-435842	2013	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.	BCL2
23359021	10.4238/2013.January.16.6	2013	Assessment of BCL2/J(H) translocation in healthy individuals exposed to low-level radiation of 137CsCl in Goi√¢nia, Goi√°s, Brazil.	BCL2
23363601	10.1091/mbc.E12-10-0747	2013	Regulation of apoptosis by Bcl-2 cysteine oxidation in human lung epithelial cells.	BCL2
23403511	10.1093/abbs/gmt002	2013	Rapamycin increases pCREB, Bcl-2, and VEGF-A through ERK under normoxia.	BCL2
23422486	NA	2013	No compensation in CD44 stem cell marker following BCL-2 suppression by antisense oligonucleotides.	BCL2
23431138	10.1073/pnas.1217271110	2013	Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma.	BCL2
23437205	10.1371/journal.pone.0056663	2013	Effect of Bcl-2 rs956572 polymorphism on age-related gray matter volume changes.	BCL2
23449635	10.1182/blood-2012-10-460063	2013	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.	BCL2
23471820	10.1158/2159-8290.CD-12-0504	2013	TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.	BCL2
23479509	10.1593/neo.121392	2013	Removal of the BH4 domain from Bcl-2 protein triggers an autophagic process that impairs tumor growth.	BCL2
23494176	10.1007/s13277-013-0647-9	2013	High levels of bcl-2 protein expression do not correlate with genetic abnormalities but predict worse prognosis in patients with lymphoblastic lymphoma.	BCL2
23509938	10.1111/his.12076	2013	Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups.	BCL2
23511489	10.1097/MPH.0b013e318286d29b	2013	The BCL-2 protein in precursor B acute lymphoblastic leukemia in children.	BCL2
23613627	10.3748/wjg.v19.i15.2340	2013	Depletion of telomerase RNA inhibits growth of gastrointestinal tumors transplanted in mice.	BCL2
23770605	10.1038/ng.2652	2013	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.	BCL2
23784204	10.3892/or.2013.2539	2013	Bcl-2 gene silencing by RNA interference inhibits the growth of the human gallbladder carcinoma cell line GBC-SD in vitro and in vivo.	BCL2
23851330	10.1097/PAS.0b013e31828b6ad3	2013	Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma.	BCL2
23939148	10.1097/PAP.0b013e3182a289f2	2013	MYC/BCL2 double-hit high-grade B-cell lymphoma.	BCL2
23953419	10.1016/j.oooo.2013.06.014	2013	Oral follicular lymphomas. A short report of 8 cases with assessment of the IGH/BCL2 gene fusion with fluorescence in situ hybridization.	BCL2
23991993	10.7314/apjcp.2013.14.7.4301	2013	B-cell Lymphoma 2 rs17757541 C&gt;G polymorphism was associated with an increased risk of gastric cardiac adenocarcinoma in a Chinese population.	BCL2
23998360	10.1016/j.psychres.2013.08.032	2013	Bcl-2 associated with positive symptoms of schizophrenic patients in an acute phase.	BCL2
24088574	10.1186/1471-2407-13-452	2013	The BCL2-938 C‚Äâ&gt;‚ÄâA promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.	BCL2
20981461	10.1007/s10006-010-0254-5	2012	Diffuse swelling of the buccal mucosa and palate as first and only manifestation of an extranodal non-Hodgkin 'double-hit' lymphoma: report of a case.	BCL2
21618512	10.1002/ijc.26183	2012	Cisplatin increases B-cell-lymphoma-2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells.	BCL2
21793937	10.1111/j.1600-0714.2011.01066.x	2012	The expression and significance of MRP1, LRP, TOPOIIŒ≤, and BCL2 in tongue squamous cell carcinoma.	BCL2
21855110	10.1016/j.humpath.2011.05.018	2012	Molecular and immunohistochemical characterization of B-cell lymphoma-2-negative follicular lymphomas.	BCL2
21988644	10.3109/10428194.2011.631158	2012	The effect of lentivirus-mediated expression of tumor necrosis factor related apoptosis-inducing ligand and shRNA against Bcl-2 on the growth of lymphoma cells.	BCL2
22002575	10.1038/modpathol.2011.147	2012	B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.	BCL2
22037714	10.1016/j.yexmp.2011.09.004	2012	Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy.	BCL2
22054286	10.3109/10428194.2011.637212	2012	Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.	BCL2
22081075	10.1038/onc.2011.508	2012	Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression.	BCL2
22138435	10.1016/j.canlet.2011.11.030	2012	Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.	BCL2
22187149	10.1007/s12032-011-0135-2	2012	The -938A/A genotype of BCL2 gene is associated with esophageal cancer.	BCL2
22189900	10.1038/leu.2011.378	2012	BCL2 mutations in diffuse large B-cell lymphoma.	BCL2
22262057	10.1002/jcp.24057	2012	Inactivation of Bcl-2 through IŒ∫B kinase (IKK)-dependent phosphorylation mediates apoptosis upon exposure to 4-hydroxynonenal (HNE).	BCL2
22275374	10.1074/jbc.M111.307363	2012	Mechanism of fragility at BCL2 gene minor breakpoint cluster region during t(14;18) chromosomal translocation.	BCL2
22322190	10.1038/modpathol.2012.1	2012	BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma.	BCL2
22393362	10.1371/journal.pone.0031366	2012	Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia.	BCL2
22395507	NA	2012	Immunologic and cytogenetic markers expressed in non-Hodgkin lymphoma of head and neck.	BCL2
22406486	10.1097/PAT.0b013e3283513fb2	2012	Variation in BCL2 protein expression in follicular lymphomas without t(14;18) chromosomal translocations.	BCL2
22517702	NA	2012	The predictive role of Bcl-2 expression in operable locally advanced or metastatic gastric carcinoma.	BCL2
22562364	10.3892/or.2012.1800	2012	Expression and correlation of Bcl-2 with pathological grades in human glioma stem cells.	BCL2
22591684	10.1016/j.leukres.2012.03.020	2012	Src, Akt, NF-Œ∫B, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia.	BCL2
22666341	10.1371/journal.pone.0037045	2012	Multifunctional role of Bcl-2 in malignant transformation and tumorigenesis of Cr(VI)-transformed lung cells.	BCL2
22732796	NA	2012	Study of molecular prognostic factors Bcl-2 and EGFR in rectal mucinous carcinomas.	BCL2
22804688	10.1111/j.1365-2559.2012.04301.x	2012	High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis.	BCL2
22851565	10.1200/JCO.2011.41.0985	2012	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	BCL2
22855608	10.1182/blood-2012-05-429514	2012	Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement.	BCL2
22949148	10.1200/JCO.2012.44.4729	2012	Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.	BCL2
22951829	10.1128/JVI.01136-12	2012	Hepatitis C virus activates Bcl-2 and MMP-2 expression through multiple cellular signaling pathways.	BCL2
22953646	NA	2012	Clinical value of serum hepatocyte growth factor, B-cell lymphoma-2 and nitric oxide in primary breast cancer patients.	BCL2
22968395	10.1097/PDM.0b013e3182585c3c	2012	Frequencies of BCL2 and BCL6 translocations in representative Chinese follicular lymphoma patients: morphologic, immunohistochemical, and FISH analyses.	BCL2
23018213	10.1097/PGP.0b013e31824df26b	2012	ATF5 is overexpressed in epithelial ovarian carcinomas and interference with its function increases apoptosis through the downregulation of Bcl-2 in SKOV-3 cells.	BCL2
23207618	10.1159/000343664	2012	Prognostic significance of Bcl-2, tumor-associated macrophages, and total neoplastic and inflammatory lymph node involvement in advanced stage classical Hodgkin's lymphoma.	BCL2
23324193	NA	2012	[Expression and significance of bcl-2, bax and ER in foci of adenomyosis].	BCL2
20836993	10.1016/j.bcp.2010.09.002	2011	Anti-apoptotic Bcl-2 fails to form efficient complexes with pro-apoptotic Bak to protect from Celecoxib-induced apoptosis.	BCL2
20952062	10.1016/j.leukres.2010.09.011	2011	Cryptic IGH/BCL2 rearrangements with variant FISH patterns in follicular lymphoma.	BCL2
21167476	10.1016/j.biopsych.2010.10.019	2011	The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder.	BCL2
21233846	10.1038/cdd.2010.175	2011	Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells.	BCL2
21320251	10.1111/j.1399-5618.2011.00897.x	2011	Bcl-2 SNP rs956572 associates with disrupted intracellular calcium homeostasis in bipolar I disorder.	BCL2
21412927	10.1002/gcc.20863	2011	A BACH2-BCL2L1 fusion gene resulting from a t(6;20)(q15;q11.2) chromosomal translocation in the lymphoma cell line BLUE-1.	BCL2
21442307	10.1007/s10495-011-0593-1	2011	Nonlinear regulation of commitment to apoptosis by simultaneous inhibition of Bcl-2 and XIAP in leukemia and lymphoma cells.	BCL2
21444675	10.1158/0008-5472.CAN-10-3119	2011	Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes.	BCL2
21454712	10.1074/jbc.M110.189092	2011	Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells.	BCL2
21457555	10.1186/1471-2350-12-48	2011	BCL-2 (-938C &gt; A) polymorphism is associated with breast cancer susceptibility.	BCL2
21474673	10.1182/blood-2010-08-301283	2011	The small GTPase Rac1 is a novel binding partner of Bcl-2 and stabilizes its antiapoptotic activity.	BCL2
21508398	NA	2011	Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.	BCL2
21518495	NA	2011	[Expression and significance of B cell-activating factor of TNF family (BAFF) and B cell lymphoma/leukemia-2 (BCL-2) in multiple myeloma].	BCL2
21560251	10.1002/cncy.20156	2011	Cytomorphologic findings of B-cell lymphomas with concurrent IGH/BCL2 and MYC rearrangements (dual-translocation lymphomas).	BCL2
21560252	10.1002/cncy.20160	2011	Cytopathology of double-hit non-Hodgkin lymphoma.	BCL2
21622563	10.1074/jbc.M110.212944	2011	Novel mechanism of anti-apoptotic function of 78-kDa glucose-regulated protein (GRP78): endocrine resistance factor in breast cancer, through release of B-cell lymphoma 2 (BCL-2) from BCL-2-interacting killer (BIK).	BCL2
21628855	10.3960/jslrt.51.7	2011	BCL2 and MYC dual-hit lymphoma/leukemia.	BCL2
21640157	10.1016/j.exphem.2011.05.002	2011	Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent¬†Bcl-2 and c-Myc overexpression.	BCL2
21640710	10.1016/j.bbrc.2011.05.118	2011	MicroRNAs expression in ox-LDL treated HUVECs: MiR-365 modulates apoptosis and Bcl-2 expression.	BCL2
21658611	10.1016/j.beha.2011.02.003	2011	Pathology, pathogenesis and molecular genetics of follicular NHL.	BCL2
21680733	10.1074/jbc.M111.235689	2011	Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathway.	BCL2
21738398	NA	2011	Expression of cell proliferation and apoptosis biomarkers in pterygia and normal conjunctiva.	BCL2
21914345	NA	2011	[Mechanism and clinical significance of anti-apoptotic gene bcl-2 expression in diffuse large B-cell lymphoma].	BCL2
21933893	10.1158/1078-0432.CCR-11-0267	2011	BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.	BCL2
21940310	10.5754/hge10765	2011	Cyclopamine blocked the growth of colorectal cancer SW116 cells by modulating some target genes of Gli1 in vitro.	BCL2
22022968	10.1134/S0006297911080104	2011	Mitogen-activated protein kinases mediate the production of B-cell lymphoma 2 protein by Mycobacterium tuberculosis in monocytes.	BCL2
22194861	10.1371/journal.pone.0028585	2011	EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas.	BCL2
24048795	10.1002/cncr.25811	2011	Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma: correlation with clinicopathologic features in 48 patients.	BCL2
19925052	10.3109/10428190903370338	2010	Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores.	BCL2
19968497	10.3109/07357900903095714	2010	Prognostic assessment of three single-nucleotide polymorphisms (GNB3 825C&gt;T, BCL2-938C&gt;A, MCL1-386C&gt;G) in extrahepatic cholangiocarcinoma.	BCL2
20001236	10.3109/10428190903350421	2010	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia.	BCL2
20045442	10.1016/j.exphem.2009.12.005	2010	Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.	BCL2
20087644	10.1007/s10552-010-9504-y	2010	Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma.	BCL2
20118770	10.1097/PAS.0b013e3181cd3aeb	2010	B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.	BCL2
20181625	NA	2010	Molecular profiling using tissue microarrays as a tool to identify predictive biomarkers in laryngeal cancer treated with radiotherapy.	BCL2
20350212	10.3109/00313021003631296	2010	Pseudonegative BCL2 protein expression in a t(14;18) translocation positive lymphoma cell line: a need for an alternative BCL2 antibody.	BCL2
20352431	10.1007/s00277-010-0945-x	2010	Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.	BCL2
20368567	10.1200/JCO.2009.25.0852	2010	BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.	BCL2
20415745	10.1111/j.1600-0781.2010.00496.x	2010	Bcl-2 expression in mycosis fungoides before and after PUVA therapy.	BCL2
20459572	10.1111/j.1365-2559.2010.03524.x	2010	The expression of Bcl-2 by proliferating cells varies in different categories of B-cell lymphoma.	BCL2
20564216	10.1002/jcb.22635	2010	Poly (ADP-ribose) polymerase-1 binds to BCL2 major breakpoint region and regulates BCL2 expression.	BCL2
20723300	NA	2010	[Effect of bortezomib on lymphoma cell line CA46 and its relative mechanisms].	BCL2
20855536	10.1158/1055-9965.EPI-10-0581	2010	Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma.	BCL2
20951945	10.1016/j.ccr.2010.09.009	2010	T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation.	BCL2
21131755	10.4103/0019-509X.73576	2010	Detection of B cell lymphoma 2, tumor protein 53, and FAS gene transcripts in blood cells of patients with breast cancer.	BCL2
18929412	10.1016/j.leukres.2008.09.007	2009	High levels of BACH2 associated with lower levels of BCL2 transcript abundance in t(14;18)(q21;q34) translocation positive non-Hodgkin's lymphoma.	BCL2
19141121	10.1111/j.1600-0609.2009.01222.x	2009	Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.	BCL2
19152170	10.1080/10428190802626616	2009	Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP.	BCL2
19196738	10.1093/annonc/mdn763	2009	The regulatory BCL2 promoter polymorphism (-938C&gt;A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma.	BCL2
19276283	10.1158/1078-0432.CCR-08-1588	2009	Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.	BCL2
19336552	10.1158/1055-9965.EPI-08-1037	2009	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.	BCL2
19417623	10.1097/PAI.0b013e3181a20307	2009	FOXP1 and BCL2 show similar immunoenzymatic pattern in bone marrow trephines of chronic lymphocytic leukemia patients.	BCL2
19448593	10.1038/modpathol.2009.73	2009	Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.	BCL2
19452318	10.1080/10428190902803677	2009	Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia.	BCL2
19460716	NA	2009	[Expressions of proliferating cell nuclear antigen, Bcl-2, and Bax in lymphocytes of patients with oral lichen planus].	BCL2
19520857	10.1074/jbc.M109.023721	2009	B cell lymphoma (Bcl)-2 protein is the major determinant in bcl-2 adenine-uridine-rich element turnover overcoming HuR activity.	BCL2
19535347	10.3324/haematol.2008.005355	2009	Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations.	BCL2
19537891	NA	2009	Frequency of bcl-2 gene rearrangement in B-cell Non-Hodgkin's lymphoma.	BCL2
19549844	10.1073/pnas.0903854106	2009	BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.	BCL2
19550126	NA	2009	Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.	BCL2
19557638	10.1080/10428190902943069	2009	Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737.	BCL2
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	BCL2
19597184	10.1182/blood-2009-03-212191	2009	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.	BCL2
19656156	10.1111/j.1349-7006.2009.01268.x	2009	Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.	BCL2
19717648	10.1182/blood-2009-01-201111	2009	C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.	BCL2
19725224	10.3727/096504009789735413	2009	Bcl-2 in combination to myeloid antigen expression in adult acute lymphoblastic leukemia and prognostic outcome.	BCL2
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	BCL2
19783718	10.1136/jcp.2009.066597	2009	BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.	BCL2
19883311	10.3109/10428190903207530	2009	BCL2-938C&gt;A polymorphism and disease progression in chronic lymphocytic leukemia.	BCL2
19996270	10.1158/1535-7163.MCT-09-0408	2009	Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells.	BCL2
20032416	NA	2009	BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH/BCL2.	BCL2
20034411	NA	2009	Oocyte in-vitro maturation: BCL2 mRNA content in cumulus cells reflects oocyte competency.	BCL2
20160358	10.4103/0973-1482.59901	2009	Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma.	BCL2
17893875	10.1002/ijc.23071	2008	Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype.	BCL2
18046449	10.1038/sj.leu.2405039	2008	The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia.	BCL2
18203018	10.1080/10428190701742472	2008	Frequency of BCL2 and BCL6 translocations in follicular lymphoma: relation with histological and clinical features.	BCL2
18367485	10.3324/haematol.12057	2008	Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma.	BCL2
18375822	10.1158/1535-7163.MCT-07-0302	2008	Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels.	BCL2
18426731	10.1309/CMPGPYTMFRM6RVQR	2008	Primary diffuse large B-cell lymphoma of bone displays preferential rearrangements of the c-MYC or BCL2 gene.	BCL2
18474261	10.1016/j.niox.2008.04.019	2008	Role of S-nitrosylation in apoptosis resistance and carcinogenesis.	BCL2
18493992	10.1002/pbc.21619	2008	Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group.	BCL2
18508827	10.1183/09031936.00064508	2008	Haem oxygenase-1 plays a central role in NNK-mediated lung carcinogenesis.	BCL2
18538438	10.1016/j.jhep.2008.03.031	2008	Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas.	BCL2
18622426	10.1038/onc.2008.214	2008	A novel fusion 5'AFF3/3'BCL2 originated from a t(2;18)(q11.2;q21.33) translocation in follicular lymphoma.	BCL2
18633450	10.2119/2008.00061.McCarthy	2008	Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18).	BCL2
18636124	10.1371/journal.pone.0002816	2008	Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.	BCL2
18695675	10.1038/onc.2008.286	2008	Functional long-range interactions of the IgH 3' enhancers with the bcl-2 promoter region in t(14;18) lymphoma cells.	BCL2
18752503	10.1111/j.1365-2559.2008.03076.x	2008	MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.	BCL2
18758641	NA	2008	Bcl-2 expression in Hodgkin's lymphoma progression.	BCL2
18806751	NA	2008	Expression of MDR1, LRP, BCRP and Bcl-2 genes at diagnosis of childhood all: comparison with MRD status after induction therapy.	BCL2
18940474	10.1016/j.cancergencyto.2008.06.007	2008	BCL2 and BCL3 are recurrent translocation partners of the IGH locus.	BCL2
18957415	10.1074/jbc.M800951200	2008	PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells.	BCL2
16949642	10.1016/j.humpath.2006.06.017	2007	Expression of bcl2 family proteins and active caspase 3 in classical Hodgkin's lymphomas.	BCL2
17200714	10.1172/JCI28281	2007	Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.	BCL2
17290286	10.1038/sj.cdd.4402091	2007	Failure of stress-induced downregulation of Bcl-2 contributes to apoptosis resistance in senescent human diploid fibroblasts.	BCL2
17363905	10.1038/sj.emboj.7601622	2007	Phosphorylation and ubiquitination of the IkappaB kinase complex by two distinct signaling pathways.	BCL2
17434928	10.1093/carcin/bgm093	2007	Bcl-2 over-expression promotes genomic instability by inhibiting apoptosis of cells exposed to hydrogen peroxide.	BCL2
17473827	10.1038/sj.bjc.6603762	2007	Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma.	BCL2
17652637	10.2353/jmoldx.2007.070038	2007	''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases.	BCL2
17692808	10.1016/j.ccr.2007.07.001	2007	BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.	BCL2
17693666	10.1093/carcin/bgm172	2007	Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck.	BCL2
17852408	10.1080/08977190701345515	2007	Lack of BCL-2 confers interferon-alpha sensitivity to B-cell lymphomas.	BCL2
17875758	10.1158/1078-0432.CCR-07-0283	2007	ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia.	BCL2
18055344	10.1532/IJH97.A20709	2007	High frequency of BCL2 translocation in Thai patients with follicular lymphomas.	BCL2
18073527	10.4161/cc.6.24.5023	2007	Staurosporine sensitizes T lymphoma cells to glucocorticoid-induced apoptosis: role of Nur77 and Bcl-2.	BCL2
16186795	10.1038/sj.onc.1209127	2006	Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression.	BCL2
16690525	10.1080/10428190500361128	2006	Expression of ice, bcl-2, c-myc and p53 in different bone marrow cell populations from patients with diffuse large B-cell lymphoma.	BCL2
16777355	10.1016/j.gene.2006.05.002	2006	The bcl-2 major breakpoint region (mbr) possesses transcriptional regulatory function.	BCL2
16799010	10.1167/iovs.05-1312	2006	Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma.	BCL2
16840204	10.1080/10428190500404498	2006	Preferential survival of acute lymphoblastic leukemia cells at 33 degrees C is associated with up-regulation of bcl-2.	BCL2
17074584	10.1016/j.cancergencyto.2006.05.016	2006	Association between telomere length and BCL2 gene rearrangements in low- and high-grade non-Hodgkin lymphomas.	BCL2
17097560	10.1016/j.ccr.2006.10.006	2006	Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.	BCL2
15367432	10.1182/blood-2004-07-2548	2005	Immunogenicity of Bcl-2 in patients with cancer.	BCL2
15657349	NA	2005	Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.	BCL2
15716988	10.1038/sj.leu.2403661	2005	Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas.	BCL2
15720419	10.1111/j.1365-2559.2005.02099.x	2005	CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses.	BCL2
16166262	10.1073/pnas.0506654102	2005	miR-15 and miR-16 induce apoptosis by targeting BCL2.	BCL2
16194898	10.1080/10428190500125648	2005	Translocation of BCL2 and BCL6 to the same immunoglobulin heavy chain locus in a case of follicular lymphoma.	BCL2
16215945	NA	2005	[BCL-2/IgH translocation in peripheral blood cells of healthy Chinese individuals of Han nationality located in Zhejiang area].	BCL2
14724650	10.1038/sj.leu.2403231	2004	Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation.	BCL2
14737118	10.1038/sj.onc.1207141	2004	Divergence of Genbank and human tumor Bcl-2 sequences and implications for binding affinity to key apoptotic proteins.	BCL2
14764541	10.1182/blood-2003-04-1011	2004	Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells.	BCL2
15061204	10.1080/1042819031000147009	2004	Lack of prognostic significance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry.	BCL2
15196944	10.1016/j.febslet.2004.05.020	2004	Overexpression of GD3 synthase induces apoptosis of vascular endothelial ECV304 cells through downregulation of Bcl-2.	BCL2
15203866	10.1080/1024533042000205496	2004	Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia.	BCL2
15561778	NA	2004	Bcl-2 overexpression leads to increases in suppressor of cytokine signaling-3 expression in B cells and de novo follicular lymphoma.	BCL2
12477721	10.1074/jbc.M210202200	2003	Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial Ras.	BCL2
12749011	10.1002/ajh.10333	2003	Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.	BCL2
12835724	10.1038/sj.leu.2402982	2003	NF- kappa B2/p100 induces Bcl-2 expression.	BCL2
12879322	10.1007/s00240-003-0324-3	2003	The expression of bcl-2 and bcl-6 protein in normal and malignant transitional epithelium.	BCL2
12960134	NA	2003	Association between glutathione S-transferase genotypes and Hodgkin's lymphoma risk and prognosis.	BCL2
12970736	10.1038/sj.onc.1206639	2003	Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells.	BCL2
14689061	NA	2003	Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.	BCL2
11877266	10.1182/blood.v99.6.1959	2002	Clinicopathologic analysis of follicular lymphoma occurring in children.	BCL2
11908736	10.1080/10428190210195	2002	Survival and cell cycle control in early hematopoiesis: role of bcl-2, and the cyclin dependent kinase inhibitors P27 and P21.	BCL2
11999565	10.1080/1042819029000611610	2002	Expression of P53 and bcl-2 proteins in T-cell lymphoblastic lymphoma: prognostic implications.	BCL2
12032828	10.1038/sj.onc.1205483	2002	NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells.	BCL2
12036852	10.1182/blood.v99.12.4265	2002	Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation.	BCL2
12036886	10.1182/blood.v99.12.4540	2002	Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma.	BCL2
12036888	10.1182/blood.v99.12.4554	2002	Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.	BCL2
12217802	NA	2002	Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement.	BCL2
12481899	10.1080/1042819021000015961	2002	Antisense oligonucleotides complementary to Bax transcripts reduce the susceptibility of B-cell chronic lymphocytic leukaemia cells to apoptosis in a bcl-2 independent manner.	BCL2
12533044	10.1080/1042819021000033024	2002	Chemotherapy induces bcl-2 cleavage in lymphoid leukemic cell lines.	BCL2
12613529	10.1080/1042819021000040107	2002	Absence of somatic hypermutation in the open reading frame of the bcl-2 gene participating in the t(14;18) chromosomal translocation in follicular lymphoma.	BCL2
11325850	NA	2001	Tumor necrosis factor alpha polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers.	BCL2
11368354	10.1038/sj.leu.2402090	2001	Phosphorylation of Bcl2 and regulation of apoptosis.	BCL2
11804283	10.1023/a:1012946812930	2001	Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type.	BCL2
11855781	10.1163/15685590152763737	2001	Induction of apoptosis and bcl-2 expression in acute lymphoblastic leukaemia and non-Hodgkin's lymphoma in children.	BCL2
11877091	NA	2001	[Clinical study of P-gp, and bcl-2 protein expression in non-Hodgkin's lymphomas patients].	BCL2
11949843	NA	2001	Expression of p53 and bcl-2 proteins in acute leukemias: an immunocytochemical study.	BCL2
9645350	10.1002/(sici)1097-0215(19980619)79:3&lt;273::aid-ijc11&gt;3.0.co;2-9	1998	Mutational analysis of Bax and Bcl-2 in childhood acute lymphoblastic leukaemia.	BCL2
9031086	10.3109/10428199609054864	1996	The human immunodeficiency virus type-1 (HIV-1) Tat protein and Bcl-2 gene expression.	BCL2
7772249	10.1089/dna.1994.13.679	1994	Evolutionary conservation of function among mammalian, avian, and viral homologs of the Bcl-2 oncoprotein.	BCL2
8022822	10.1073/pnas.91.14.6569	1994	Evidence that BCL-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes.	BCL2
8090743	10.1073/pnas.91.19.8910	1994	BCL2 translocation frequency rises with age in humans.	BCL2
8183370	10.1038/369321a0	1994	BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax.	BCL2
8402648	NA	1993	Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes.	BCL2
1286168	NA	1992	The bcl-2 oncogene and apoptosis.	BCL2
1339299	NA	1992	Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas.	BCL2
1373874	NA	1992	Bcl-2 confers growth and survival advantage to interleukin 7-dependent early pre-B cells which become factor independent by a multistep process in culture.	BCL2
1453000	10.1177/40.12.1453000	1992	Ultrastructural localization of bcl-2 protein.	BCL2
1508712	10.1093/nar/20.16.4187	1992	Isolation and characterization of the chicken bcl-2 gene: expression in a variety of tissues including lymphoid and neuronal organs in adult and embryo.	BCL2
2250705	10.1038/348334a0	1990	Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.	BCL2
2834197	10.1002/j.1460-2075.1988.tb02791.x	1988	Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma.	BCL2
3285301	NA	1988	Consequences of the t(14;18) chromosomal translocation in follicular lymphoma: deregulated expression of a chimeric and mutated BCL-2 gene.	BCL2
3523487	10.1073/pnas.83.14.5214	1986	Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma.	BCL2
3924412	10.1016/s0092-8674(85)80070-2	1985	Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18.	BCL2
32393046	10.1080/09603123.2020.1757043	2022	The expression of microRNAs and exposure to environmental contaminants related to human health: a review.	BCL6
33779481	10.1080/01676830.2021.1904426	2022	Double-hit and triple-hit high-grade B-cell lymphoma of the ocular adnexa.	BCL6
34180720	10.1177/10668969211027409	2022	Aggressive Cyclin D1 Negative Blastoid Variant Mantle Cell Lymphoma-A Case Report.	BCL6
34265801	10.1097/PAS.0000000000001780	2022	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.	BCL6
34374890	10.1007/s12029-021-00662-6	2022	Primary ALK-Positive Large B Cell Lymphoma of Pancreas.	BCL6
34392269	10.1097/PAS.0000000000001750	2022	Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity.	BCL6
34456240	10.1097/PAI.0000000000000967	2022	Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting.	BCL6
34519021	10.1111/bjh.17815	2022	Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.	BCL6
34559466	10.1111/ijlh.13709	2022	Discordant high-grade B-cell lymphoma with MYC and BCL6 rearrangements presenting as a pericardial effusion.	BCL6
34601504	10.1038/s41379-021-00938-z	2022	Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation.	BCL6
34608246	10.1038/s41379-021-00909-4	2022	Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge.	BCL6
34617271	10.1111/bjh.17874	2022	Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.	BCL6
34637146	10.1111/his.14585	2022	EBV<sup>+</sup> high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study.	BCL6
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	BCL6
34698964	10.1007/s10637-021-01196-1	2022	FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells.	BCL6
34707034	10.3960/jslrt.21017	2022	Clinicopathological analysis of diffuse large B-cell lymphoma lacking surface immunoglobulin light chain restriction on flow cytometry.	BCL6
34727403	10.1111/pin.13182	2022	AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.	BCL6
34727830	10.1080/10428194.2021.1998480	2022	Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma.	BCL6
34774129	10.1016/j.str.2021.10.010	2022	Structural basis of Apt48 inhibition of the BCL6 BTB domain.	BCL6
34788750	10.1159/000519074	2022	Application of Hans Algorithm for Subcategorization of Diffuse Large B-Cell Lymphoma in Fine-Needle Aspiration Biopsy Cytology.	BCL6
34788985	10.3324/haematol.2021.279631	2022	Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing.	BCL6
34809978	10.1016/j.fertnstert.2021.09.036	2022	B-cell lymphoma 6 expression is not associated with live birth in a normal responder in¬†vitro fertilization population.	BCL6
34842019	10.1080/10428194.2021.2008383	2022	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?	BCL6
34861697	10.1182/bloodadvances.2021006156	2022	Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo.	BCL6
34907996	10.1097/PAS.0000000000001852	2022	Human Germinal Center-associated Lymphoma (HGAL) Is a Reliable Marker of Normal and Neoplastic Follicular Helper T Cells Including Angioimmunoblastic T-Cell Lymphoma.	BCL6
34910327	10.1111/jop.13269	2022	Oral versus extra-oral plasmablastic lymphoma: A comparative analysis of 101 cases.	BCL6
34917911	10.1016/j.jhepr.2021.100386	2022	ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis.	BCL6
34951009	10.1111/bjh.17971	2022	Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.	BCL6
34990752	10.1016/j.canlet.2021.12.035	2022	An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.	BCL6
35036912	10.1177/2632010X211070774	2022	Rare but Potentially Fatal Presentations of Diffuse Large B-cell Lymphoma: Leukemic Phase or Hemophagocytic Syndrome in Bone Marrow.	BCL6
35045798	10.1080/10428194.2021.2024821	2022	High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.	BCL6
35046056	10.1158/1078-0432.CCR-21-3617	2022	First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.	BCL6
35067515	10.1097/PAS.0000000000001828	2022	Composite Classic Hodgkin Lymphoma and Follicular Lymphoma: A Clinicopathologic Study of 22 Cases With Review of 27 Additional Cases in the Literature.	BCL6
35091546	10.1038/s41420-022-00833-9	2022	Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma.	BCL6
35152630	10.3760/cma.j.cn112151-20210826-00604	2022	[Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements].	BCL6
35183824	10.1016/j.prp.2022.153804	2022	Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma.	BCL6
35220171	10.1016/j.prp.2022.153812	2022	Prognostic value of Bcl2 and Bcl6 in primary cutaneous large B-cell lymphoma: A systematic review and meta-analysis.	BCL6
35256863	10.2147/CMAR.S345745	2022	MUM1 Expression versus Hans Algorithm to Predict Prognosis in Indonesian Diffuse Large B-Cell Lymphoma Patients Receiving R-CHOP.	BCL6
35277463	10.1136/jitc-2020-002029corr1	2022	Correction: MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	BCL6
35297566	10.1111/pin.13223	2022	Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements.	BCL6
35303910	10.1186/s13045-022-01249-9	2022	Altered pathways and targeted therapy in double hit lymphoma.	BCL6
35308723	10.7759/cureus.22023	2022	Conjunctival Pediatric-Type Follicular Lymphoma in a Young Male: A Case Report and Literature Review.	BCL6
35327381	10.3390/biomedicines10030579	2022	Macrophage Infiltration Correlates with Genomic Instability in Classic Hodgkin Lymphoma.	BCL6
35357654	10.1007/s13402-022-00663-y	2022	BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.	BCL6
35371331	10.7150/jca.69639	2022	Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma.	BCL6
35414839	NA	2022	Primary ovarian Burkitt lymphoma: report of a case and review of literature.	BCL6
35436984	10.1038/s41419-022-04812-x	2022	B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36.	BCL6
35444774	10.4084/MJHID.2022.018	2022	TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment.	BCL6
35481444	10.1080/10428194.2022.2064988	2022	Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.	BCL6
35484682	10.3324/haematol.2021.280557	2022	Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement.	BCL6
35489963	10.1016/j.blre.2022.100967	2022	ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma.	BCL6
35495111	10.1016/j.csbj.2022.03.023	2022	Integrating whole genome sequencing, methylation, gene expression, topological associated domain information in regulatory mutation prediction: A study of follicular lymphoma.	BCL6
35503721	10.7554/eLife.69255	2022	The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress.	BCL6
35511691	10.1093/ajcp/aqac047	2022	A Combined Biomarker of Bright CD38 and MYC ‚â•55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma.	BCL6
35521914	10.1177/10668969221099627	2022	ALK-positive Large B-Cell Lymphoma Presenting as a Circumscribed Breast Mass with Germinal Center Immunophenotype.	BCL6
35539018	10.1016/j.lrr.2022.100318	2022	A very rare case of extranodal B-cell non-Hodgkin lymphoma presenting with adrenal and heart involvement.	BCL6
35568724	10.1038/s41394-022-00520-y	2022	Primary intradural extramedullary spinal Burkitt's lymphoma mimicking a nerve sheath tumor: a case report.	BCL6
35583405	10.1097/DAD.0000000000002053	2022	Histological Transformation and Clonal Relationship of Subcutaneous Marginal Zone B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma.	BCL6
35586895	10.1111/his.14674	2022	RNAseq identification of FISH-cryptic BCL6::TP63 rearrangement in ALK-negative anaplastic large-cell lymphoma.	BCL6
35600178	10.1016/j.amsu.2022.103786	2022	Immunohistochemical expression of transcription factors PAX5, OCT2, BCL6 and transcription regulator P53 in Non-Hodgkin lymphomas: A diagnostic cross-sectional study.	BCL6
35607925	10.17235/reed.2022.8765/2022	2022	Intestinal occlusion due to Burkitt lymphoma: an unusual cause.	BCL6
35640966	10.1093/humupd/dmac027	2022	BCL6, a key oncogene, in the placenta, pre-eclampsia and endometriosis.	BCL6
35646671	10.3389/fonc.2022.883141	2022	Case Report: Intravascular Large B-Cell Lymphoma: A Clinicopathologic Study of Four Cases With Review of Additional 331 Cases in the Literature.	BCL6
35652622	10.4149/neo_2022_220318N300	2022	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry.	BCL6
35653645	10.1021/acs.jmedchem.1c02175	2022	Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 <i>In Vivo</i>.	BCL6
35657291	10.1021/acs.jmedchem.1c02174	2022	Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors.	BCL6
35657404	10.1007/s00428-022-03342-3	2022	Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.	BCL6
35664405	10.7759/cureus.24592	2022	Primary Endometrial Diffuse Large B-cell Lymphoma: A Rare Disease and Diagnostic Challenge in an Asymptomatic Postmenopausal Woman.	BCL6
35696785	10.1016/j.biomaterials.2022.121607	2022	Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma.	BCL6
35697533	10.1016/j.fertnstert.2022.05.027	2022	Reply of the Authors: B-cell lymphoma 6 (BCL6) testing before in vitro fertilization as a predictor of failure.	BCL6
35705274	10.2169/internalmedicine.9711-22	2022	Biclonal diffuse large B-cell lymphoma commonly characterized by partial trisomy 18q involving MALT1 and BCL2.	BCL6
35713502	10.1093/rheumatology/keac304	2022	TOX promotes follicular helper T cell differentiation in patients with primary Sj√∂gren's syndrome.	BCL6
35715938	10.1002/cjp2.283	2022	Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.	BCL6
35717285	10.1016/j.fertnstert.2022.05.028	2022	B-cell lymphoma 6 (BCL6) testing before in vitro fertilization as a predictor of failure.	BCL6
35794478	10.1038/s41586-022-04906-8	2022	Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.	BCL6
35846201	10.1002/jha2.310	2022	Redefining the high-grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report.	BCL6
35846216	10.1002/jha2.364	2022	Primary cutaneous diffuse large B-cell lymphoma, leg type with <i>MYC/BCL2/BCL6</i> overexpression.	BCL6
35869021	10.1016/j.clml.2022.06.011	2022	Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.	BCL6
35873103	NA	2022	Neoplasms of follicular helper T-cells: an insight into the pathobiology.	BCL6
35883106	10.1186/s12935-022-02661-4	2022	DSF/Cu induces antitumor effect against diffuse large B-cell lymphoma through suppressing NF-Œ∫B/BCL6 pathways.	BCL6
35895386	10.1111/bjd.21791	2022	Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.	BCL6
35900784	10.1182/blood.2022016280	2022	EBV-positive high-grade B-cell lymphoma with MYC and BCL6 rearrangements.	BCL6
35916066	10.1111/imcb.12578	2022	CD137L and CD4 T cells limit BCL6-expressing pre-germinal center B cell expansion and BCL6-driven B cell malignancy.	BCL6
35916333	10.1002/dc.25027	2022	HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.	BCL6
35916644	10.1097/QAI.0000000000003069	2022	Diffuse Large B-cell Lymphoma in the public-sector of Johannesburg, South Africa, in the era of widescale Anti-retroviral therapy use.	BCL6
35932211	10.1002/hon.3061	2022	Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification.	BCL6
35938041	10.3389/fgene.2022.940513	2022	Case Report: Immune Microenvironment and Mutation Features in a Patient With Epstein-Barr Virus Positive Large B-Cell Lymphoma Secondary to Angioimmunoblastic T-Cell Lymphoma.	BCL6
35957990	10.3389/fphys.2022.946282	2022	Molecular mechanism of hyperactive tooth root formation in oculo-facio-cardio-dental syndrome.	BCL6
35968590	10.3760/cma.j.issn.0253-2727.2022.06.006	2022	[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review].	BCL6
35982974	10.3389/fonc.2022.822805	2022	iRGD-modified exosomes-delivered BCL6 siRNA inhibit the progression of diffuse large B-cell lymphoma.	BCL6
35997599	10.1089/vim.2021.0224	2022	Expression Pattern of Inflammatory and Anti-Inflammatory Cytokines and Key Differential Transcription Factors in Peripheral Blood Mononuclear Cells of Iranian Coronavirus Disease 2019 Patients with Different Disease Severity.	BCL6
36001789	10.46883/2022.25920970	2022	Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas.	BCL6
36057749	10.1007/s00428-022-03404-6	2022	Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma.	BCL6
36091937	10.3389/pore.2022.1610588	2022	Clinicopathologic Features and Treatment of CD10-Positive Mantle Cell Lymphoma: A Case Report and Review of Literature.	BCL6
32356355	10.1002/ajh.25848	2021	Triple hit SOX11<sup>-</sup> , MME<sup>+</sup> , TP53 mutated high-grade pleomorphic mantle cell lymphoma.	BCL6
32590454	10.1097/PAI.0000000000000863	2021	Aberrant Cytoplasmic Terminal Deoxynucleotidyl Transferase (TdT) Immunostaining on Previously Frozen, Formalin-fixed Paraffin-embedded Tissue: Cryotomy-induced Antigen Diffusion (CIAD).	BCL6
32675470	10.1097/DAD.0000000000001737	2021	Atypical BCL6/GATA3+ Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma: A Diagnostic Challenge.	BCL6
32731312	10.1111/odi.13578	2021	Clinicopathological and genetic characteristics of diffuse large B-cell lymphoma of the oropharyngeal and maxillofacial region.	BCL6
32863365	10.2169/internalmedicine.5429-20	2021	Multiple Malignant Lymphomas of the Bile Duct Developing after Spontaneous Regression of an Autoimmune Pancreatitis-like Mass.	BCL6
32911532	10.1182/blood.2019001745	2021	BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.	BCL6
32911592	10.12701/yujm.2020.00675	2021	Metachronous extranodal natural killer/T-cell lymphoma of nasal type and primary testicular lymphoma.	BCL6
32912960	10.1136/jclinpath-2020-206767	2021	<i>BCL2</i> and <i>BCL6</i> atypical/unbalanced gene rearrangements in diffuse large B-cell lymphoma are indicators of an aggressive clinical course.	BCL6
32961552	10.1182/blood.2020007507	2021	Mutational landscape of gray zone lymphoma.	BCL6
32973328	10.1038/s41379-020-00685-7	2021	The clinicopathological and molecular features of sinusoidal large B-cell lymphoma.	BCL6
32979280	10.1002/hon.2811	2021	Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.	BCL6
33040061	10.1159/000509923	2021	Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry.	BCL6
33058525	10.1002/dc.24642	2021	Fungating anterior chest wall mass in an adult: Cytologic diagnosis of a rare presentation.	BCL6
33120427	10.1182/blood.2020007193	2021	The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC.	BCL6
33136585	10.1097/PAS.0000000000001609	2021	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.	BCL6
33150819	10.1080/08880018.2020.1838013	2021	<i>KMT2A</i>-rearranged diffuse large B-cell lymphoma in a child: a case report and molecular characterization.	BCL6
33199235	10.1016/j.intimp.2020.107137	2021	Agrimophol suppresses RANKL-mediated osteoclastogenesis through Blimp1-Bcl6 axis and prevents inflammatory bone loss in mice.	BCL6
33252276	10.1177/1066896920977690	2021	CD10-Negative Primary Breast Follicular Lymphoma: A Rare Case of Primary Breast Lymphoma With an Atypical Immunophenotype Mimicking Marginal Zone Lymphoma.	BCL6
33258912	10.1093/ajcp/aqaa185	2021	Simultaneous Identification of Cell of Origin, Translocations, and Hotspot Mutations in Diffuse Large B-Cell Lymphoma Using a Single RNA-Sequencing Assay.	BCL6
33283568	10.1080/10428194.2020.1855347	2021	Expression of germinal center cell markers by extranodal marginal zone lymphomas of MALT type within colonized follicles, a diagnostic pitfall with follicular lymphoma.	BCL6
33306213	10.1002/ajh.26068	2021	First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study.	BCL6
33360122	10.1016/j.cancergen.2020.12.004	2021	RNA-Based next generation sequencing complements but does not replace fluorescence in situ hybridization studies for the classification of aggressive B-Cell lymphomas.	BCL6
33392349	10.22038/AOJNMB.2020.48887.1332	2021	Incremental Value of FDG PET/CT in Aggressive High Grade B Cell lymphoma with TdT Expression.	BCL6
33393079	10.1111/his.14327	2021	Radiologically guided percutaneous core needle biopsy of the spleen: a reliable and safe diagnostic procedure for neoplastic and reactive conditions.	BCL6
33393503	10.1172/JCI133090	2021	BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.	BCL6
33398683	10.1007/s12105-020-01276-3	2021	Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase Negative Anaplastic Large Cell Lymphoma in a Geriatric Patient-Report of a Rare Case.	BCL6
33400146	10.1007/s11684-020-0821-6	2021	Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.	BCL6
33432228	10.1038/s41590-020-00827-8	2021	Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.	BCL6
33468080	10.1186/s12885-021-07806-8	2021	The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma.	BCL6
33479306	10.1038/s41598-020-80376-0	2021	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.	BCL6
33480087	10.1002/hon.2839	2021	High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup.	BCL6
33480830	10.1080/10428194.2020.1869965	2021	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.	BCL6
33504685	10.5045/br.2021.2020146	2021	Optimal panel of immunohistochemistry for the diagnosis of B-cell non-Hodgkin lymphoma using bone marrow biopsy: a tertiary care center study.	BCL6
33512466	10.1182/blood.2020010175	2021	OBF1 and Oct factors control the germinal center transcriptional program.	BCL6
33521119	10.12998/wjcc.v9.i2.482	2021	Double-hit lymphoma (rearrangements of MYC, BCL-2) during pregnancy: A case report.	BCL6
33530253	10.1097/MD.0000000000024449	2021	Prognostic value of lymphocyte-to-monocyte ratio and histone methyltransferase G9a histone methyltransferase in patients with double expression lymphoma: A retrospective observational study.	BCL6
33541426	10.1186/s40104-020-00541-3	2021	High expression of BCL6 inhibits the differentiation and development of hematopoietic stem cells and affects the growth and development of chickens.	BCL6
33548250	10.1016/j.humpath.2021.01.006	2021	Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes.	BCL6
33551436	10.3960/jslrt.20043	2021	DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.	BCL6
33568199	10.1186/s13148-021-01007-7	2021	UHRF1 downregulation promotes T follicular helper cell differentiation by increasing BCL6 expression in SLE.	BCL6
33591648	10.1002/brb3.2061	2021	New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).	BCL6
33610538	10.1016/j.oooo.2020.11.005	2021	Oral and oropharyngeal diffuse large B-cell lymphoma and high-grade B-cell lymphoma: A clinicopathologic and prognostic study of 69 cases.	BCL6
33619998	10.1177/1066896921995942	2021	Tiny but Mighty: Collision Tumor of a Superficial Adenocarcinoma Arising From a Tubulovillous Adenoma with Associated Low-Grade Follicular Lymphoma.	BCL6
33629212	10.1007/s12032-021-01470-5	2021	Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.	BCL6
33650043	10.1007/s00428-021-03071-z	2021	Clinicopathological characterization of follicular helper T-cell-derived peripheral T-cell lymphoma involving Waldeyer's ring.	BCL6
33655392	10.1007/s00428-021-03050-4	2021	The Burkitt-like immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.	BCL6
33663954	10.1016/j.it.2021.02.002	2021	Bcl6-Mediated Transcriptional Regulation of Follicular Helper T cells (T<sub>FH</sub>).	BCL6
33672644	10.3390/cancers13040887	2021	Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements.	BCL6
33683983	10.1177/1093526621999022	2021	EBV-Positive Plasmacytomas Involving a Nasopharyngeal Angiofibroma in an Adolescent.	BCL6
33685720	10.1016/j.pathol.2021.01.002	2021	New developments in non-Hodgkin lymphoid malignancies.	BCL6
33768318	10.1007/s00428-021-03084-8	2021	High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.	BCL6
33771538	10.1016/j.humpath.2021.03.006	2021	MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.	BCL6
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	BCL6
33786155	NA	2021	Primary hepatic mucosa-associated lymphoid tissue lymphoma: case report and literature review.	BCL6
33786907	10.1111/cup.14020	2021	Primary cutaneous follicle center lymphoma with extensive plasmacytic differentiation and t(14;18) in both the lymphoid and plasma cell components.	BCL6
33807449	10.3390/cancers13071620	2021	High-Grade B-Cell Lymphoma (HGBL) with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan.	BCL6
33811277	10.1007/s10689-021-00244-2	2021	Constitutional 2p16.3 deletion including MSH6 and FBXO11 in a boy with developmental delay and diffuse large B-cell lymphoma.	BCL6
33816589	10.3389/fvets.2021.647009	2021	Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma.	BCL6
33844535	10.1021/acs.jmedchem.0c01686	2021	Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.	BCL6
33858042	10.3760/cma.j.issn.0253-2727.2021.02.006	2021	[The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma].	BCL6
33932086	10.1002/1878-0261.12964	2021	An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer.	BCL6
33964277	10.1016/j.humpath.2021.04.014	2021	Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma.	BCL6
33965178	10.1016/j.jtct.2021.02.009	2021	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma.	BCL6
33991335	10.1111/bjh.17536	2021	In situ follicular neoplasia with translocation of BCL6 - a new variant with different immunohistochemical properties.	BCL6
34017010	10.1038/s41597-021-00915-w	2021	DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set.	BCL6
34025195	10.33160/yam.2021.05.014	2021	Role of Cell-Origin Profiling Using Immunohistochemistry to Predict the Survival of Patients with Diffuse Large B-Cell Lymphoma in Indonesia.	BCL6
34049715	10.1016/j.pathol.2021.02.013	2021	Expression of BCL6 in paediatric B-cell acute lymphoblastic leukaemia and association with prognosis.	BCL6
34050029	10.1073/pnas.2104504118	2021	Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma.	BCL6
34069564	10.3390/ijms22105352	2021	The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential.	BCL6
34078654	10.1136/jitc-2020-002029	2021	MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	BCL6
34091974	10.1111/jop.13209	2021	Burkitt lymphoma of the head and neck: An international collaborative study.	BCL6
34097157	10.1007/s11864-021-00857-w	2021	Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma.	BCL6
34099699	10.1038/s41467-021-23695-8	2021	Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing.	BCL6
34105464	10.19746/j.cnki.issn.1009-2137.2021.03.012	2021	[Analysis of the Predictive Value of EZH2 Expression Level on the Clinical Efficacy and Long-term Prognosis of Patients with Primary Gastrointestinal Diffuse Large B-cell Lymphoma].	BCL6
34113336	10.3389/fimmu.2021.599493	2021	<i>PiggyBac</i>-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.	BCL6
34123811	10.3389/fonc.2021.656219	2021	Case Report: Concurrent Occurrence of Abdominal Double Expressor Lymphoma and Jejunum Follicular Lymphoma.	BCL6
34171161	10.1111/pin.13131	2021	Fluorescent nanoparticle-mediated semiquantitative MYC protein expression analysis in morphologically diffuse large B-cell lymphoma.	BCL6
34195728	10.1039/d1ob00612f	2021	Diversity-orientated synthesis of macrocyclic heterocycles using a double S<sub>N</sub>Ar approach.	BCL6
34204385	10.3390/cancers13123032	2021	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing.	BCL6
34221962	10.3389/fonc.2021.638154	2021	Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.	BCL6
34236648	10.1007/978-1-0716-1669-7_20	2021	Generation and Surgical Analysis of Genetic Mouse Models to Study NF-Œ∫B-Driven Pathogenesis of Diffuse Large B Cell Lymphoma.	BCL6
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	BCL6
34274316	10.1016/j.jbc.2021.100928	2021	GSK137, a potent small-molecule BCL6 inhibitor with in¬†vivo activity, suppresses antibody responses in mice.	BCL6
34287839	10.1002/eji.202049150	2021	BCL6 BTB-specific inhibitor reversely represses T-cell activation, Tfh cells differentiation, and germinal center reaction in vivo.	BCL6
34318932	10.1111/bjh.17734	2021	MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.	BCL6
34334687	10.1097/PAS.0000000000001726	2021	High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B.	BCL6
34339901	10.1016/j.clineuro.2021.106838	2021	MYC, BCL2, and BCL6 expression as prognostic indicators in primary central nervous system lymphoma: A systematic review and meta-analysis.	BCL6
34341277	10.4103/IJPM.IJPM_324_20	2021	Intravascular large B cell lymphoma of prostate, a rare entity.	BCL6
34378195	10.1111/bjh.17765	2021	Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.	BCL6
34380369	10.1080/10428194.2021.1964021	2021	Whole genome sequencing demonstrates substantial pathophysiological differences of <i>MYC</i> rearrangements in patients with plasma cell myeloma and B-cell lymphoma.	BCL6
34381423	10.3389/fendo.2021.673908	2021	Case Report: Identification of Potential Prognosis-Related <i>TP53</i> Mutation and <i>BCL6-LPP</i> Fusion in Primary Pituitary Lymphoma by Next Generation Sequencing: Two Cases.	BCL6
34384155	10.3760/cma.j.issn.0253-2727.2021.06.008	2021	[Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].	BCL6
34388250	10.1093/jnen/nlab080	2021	Expression of STAT6 and Phosphorylated STAT6 in Primary Central Nervous System Lymphomas.	BCL6
34406351	10.1093/ajcp/aqab043	2021	Light Chain-Restricted Plasmacytoid Cells in Hyperplastic Germinal CentersA Clinicopathologic Investigation.	BCL6
34426436	10.1158/1078-0432.CCR-21-0573	2021	Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma.	BCL6
34438040	10.1016/j.annonc.2021.08.1991	2021	SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status.	BCL6
34449978	10.1002/dc.24861	2021	Angioimmunoblastic T-cell lymphoma diagnosed from pleural fluid by integration of morphologic, immunophenotypic, and molecular findings.	BCL6
34465079	10.4132/jptm.2021.07.25	2021	Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution.	BCL6
34484219	10.3389/fimmu.2021.716240	2021	Coupled Antigen and BLIMP1 Asymmetric Division With a Large Segregation Between Daughter Cells Recapitulates the Temporal Transition From Memory B Cells to Plasma Cells and a DZ-to-LZ Ratio in the Germinal Center.	BCL6
34500469	10.1182/bloodadvances.2021004635	2021	Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma.	BCL6
34528238	10.1111/bjh.17729	2021	Quadruple-hit pleomorphic mantle cell lymphoma with MYC, BCL2, BCL6, and CCND1 gene rearrangements.	BCL6
34558634	10.3892/mmr.2021.12458	2021	Knockdown of miR‚Äë205‚Äë5p alleviates the inflammatory response in allergic rhinitis by targeting B‚Äëcell lymphoma 6.	BCL6
34588837	10.2147/BLCTT.S330008	2021	Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission.	BCL6
34596020	10.55563/clinexprheumatol/yuj21y	2021	Differential Th follicular cell subsets in minor salivary glands of patients with primary Sj√∂gren's syndrome and systemic lupus erythematosus associated with Sj√∂gren's syndrome.	BCL6
34610523	10.1016/j.oraloncology.2021.105552	2021	Blastoid variant of mantle cell lymphoma in palatine tonsil.	BCL6
34625792	10.1182/bloodadvances.2021005682	2021	Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.	BCL6
34679437	10.3390/diagnostics11101739	2021	Dysregulation of miRNAs in DLBCL: Causative Factor for Pathogenesis, Diagnosis and Prognosis.	BCL6
34698105	10.3390/cimb43030096	2021	Evaluation of BCL6 and SIRT1 as Non-Invasive Diagnostic Markers of Endometriosis.	BCL6
34698437	10.1111/jcmm.16999	2021	Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma.	BCL6
34706861	10.1136/bjophthalmol-2021-319580	2021	Prevalence and prognostic value of <i>MYD88</i> and <i>CD79B</i> mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.	BCL6
34707037	10.3960/jslrt.21025	2021	t(9;14)(p13;q32)/PAX5-IGH translocation as a secondary cytogenetic abnormality in diffuse large B-cell lymphoma.	BCL6
34782660	10.1038/s41598-021-01693-6	2021	Primary central nervous system lymphomas express immunohistochemical factors of autophagy.	BCL6
34806851	10.20892/j.issn.2095-3941.2021.0193	2021	Prognostic value of <i>BCL2</i> and <i>TP53</i> genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP.	BCL6
34830747	10.3390/cancers13225592	2021	Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era.	BCL6
34877288	10.12998/wjcc.v9.i31.9542	2021	Clinical observation of pediatric-type follicular lymphomas in adult: Two case reports.	BCL6
34889402	10.1182/hematology.2021000247	2021	Double-hit lymphoma: optimizing therapy.	BCL6
34900354	10.1155/2021/6843103	2021	Rare Presentation of Hypoglycemia in a Patient with Anaplastic Large-Cell Lymphoma.	BCL6
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	BCL6
34945004	10.3390/cancers13246384	2021	Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel.	BCL6
35004320	10.3389/fonc.2021.795330	2021	Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With <i>MYC</i> and <i>BCL6</i> Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?	BCL6
35008187	10.3390/cancers14010023	2021	Low BACH2 Expression Predicts Adverse Outcome in Chronic Lymphocytic Leukaemia.	BCL6
30842630	10.1038/s41423-019-0219-z	2020	The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection.	BCL6
30968736	10.1080/07391102.2019.1606735	2020	Target prioritization of novel substituted 5-aryl-2-oxo-/thioxo-2,3-dihydro-1<i>H</i>-benzo[6,7]chromeno[2,3-<i>d</i>]pyrimidine-4,6,11(5<i>H</i>)-triones as anticancer agents using <i>in-silico</i> approach.	BCL6
31123031	10.3324/haematol.2018.214122	2020	<i>MYD88</i> mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.	BCL6
31197071	10.3324/haematol.2019.224121	2020	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.	BCL6
31399522	10.3324/haematol.2019.223891	2020	An increase in <i>MYC</i> copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens.	BCL6
31556696	10.5858/arpa.2019-0007-OA	2020	Bone Marrow Infiltration of Angioimmunoblastic T-Cell Lymphoma: Identification and Prognostic Impact of Histologic Patterns and Diagnostic Application of Ancillary Phenotypic and Molecular Analyses.	BCL6
31571234	10.1111/jmp.12438	2020	BCL6 BTB-specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque (Macaca mulatta).	BCL6
31585205	10.1016/j.prro.2019.09.013	2020	Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.	BCL6
31605845	10.1016/j.wneu.2019.09.158	2020	Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation.	BCL6
31615842	10.1136/jclinpath-2019-206199	2020	Clinical significance of 'double-hit' and 'double-expression' lymphomas.	BCL6
31631728	10.1080/10428194.2019.1675877	2020	The role of MYC in the transformation and aggressiveness of 'indolent' B-cell malignancies.	BCL6
31688139	10.1097/PAS.0000000000001390	2020	Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study.	BCL6
31705772	10.1002/gcc.22825	2020	Molecular characteristics of terminal deoxynucleotidyl transferase negative precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.	BCL6
31721454	10.1002/prca.201900091	2020	Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma.	BCL6
31728727	10.1007/s00795-019-00237-2	2020	Primary mediastinal large B cell lymphoma with coexisting aberrations of C-MYC and BCL-2: a case report and literature review.	BCL6
31734190	10.1016/j.humpath.2019.09.003	2020	Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.	BCL6
31735344	10.1016/j.pathol.2019.09.008	2020	High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification.	BCL6
31743519	10.1002/jcla.23122	2020	A long non-coding RNA LNBC3 facilitates non-small cell lung cancer progression by stabilizing BCL6.	BCL6
31751845	10.1016/j.anndiagpath.2019.151421	2020	The life and death of the germinal center.	BCL6
31776129	10.1101/mcs.a004614	2020	Dramatic increase in gene mutational burden after transformation of follicular lymphoma into TdT<sup>+</sup> B-lymphoblastic leukemia/lymphoma.	BCL6
31789821	10.1097/PAI.0000000000000820	2020	EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas.	BCL6
31849147	10.1111/cas.14286	2020	Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas.	BCL6
31868792	10.1097/IOP.0000000000001556	2020	Conjunctival Pediatric-Type Follicular Lymphoma.	BCL6
31870687	10.1053/j.semdp.2019.12.005	2020	Update on peripheral T-cell lymphomas with T-helper phenotype: ¬†Are there too many subtypes?	BCL6
31872861	10.1093/ajcp/aqz172	2020	Comparison Between Integrated Genomic DNA/RNA Profiling and Fluorescence In Situ Hybridization in the Detection of MYC, BCL-2, and BCL-6 Gene Rearrangements in Large B-Cell Lymphomas.	BCL6
31882486	10.21873/invivo.11768	2020	Laryngeal Diffuse Large B-Cell Lymphoma Presenting as Laryngeal Stenosis.	BCL6
31883669	10.1016/j.pathol.2019.09.014	2020	The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.	BCL6
31892985	10.7150/jca.36954	2020	<i>C-MYC, BCL2</i> and <i>BCL6</i> Translocation in B-cell Non-Hodgkin Lymphoma Cases.	BCL6
31895575	10.1021/acs.jmedchem.9b01618	2020	Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of <i>N</i>-Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth.	BCL6
31900295	10.1136/bcr-2019-231831	2020	Double-hit monomorphic B-cell lymphoma after liver transplantation.	BCL6
31903129	10.7150/thno.33482	2020	Extracellular vesicle-mediated delivery of miR-101 inhibits lung metastasis in osteosarcoma.	BCL6
31903146	10.7150/thno.39018	2020	Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma.	BCL6
31914056	10.1097/MD.0000000000018670	2020	Clinicopathologic features and prognostic analysis of Waldeyer ring B-cell lymphoma.	BCL6
31915197	10.1158/2159-8290.CD-19-0116	2020	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.	BCL6
31945157	10.1182/bloodadvances.2019000875	2020	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.	BCL6
31954378	10.1002/eji.201948299	2020	Bcl6 modulates innate immunity by controlling macrophage activity and plays critical role in experimental autoimmune encephalomyelitis.	BCL6
31955451	10.1002/hon.2716	2020	Diffuse large B-cell lymphoma carrying t(9;14)(p13;q32)/PAX5-immunoglobulin heavy chain gene is characterized by nuclear positivity of MUM1 and PAX5 by immunohistochemistry.	BCL6
31990228	10.5858/arpa.2019-0182-RA	2020	A Practical Approach to Diagnosis of B-Cell Lymphomas With Diffuse Large Cell Morphology.	BCL6
31991488	10.1111/apm.13029	2020	EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.	BCL6
31997133	10.1007/s12105-020-01135-1	2020	HIV-Associated Double-Hit Lymphoma of the Tonsil: A First Reported Case.	BCL6
32013324	10.4132/jptm.2019.12.17	2020	Morphologic variant of follicular lymphoma reminiscent of hyaline-vascular Castleman disease.	BCL6
32023600	10.11406/rinketsu.61.33	2020	[CD20-negative diffuse large B-cell lymphoma complicated by rheumatoid arthritis].	BCL6
32025812	10.1007/s00432-020-03137-6	2020	MYC/BCL2/BCL6 triple hit lymphoma of the pericardium: a case report and review of the literature.	BCL6
32038991	10.3389/fonc.2020.00023	2020	The Genetic and Molecular Basis for Canine Models of Human Leukemia and Lymphoma.	BCL6
32045477	10.1182/bloodadvances.2019000359	2020	Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies.	BCL6
32061875	10.1016/j.jim.2020.112753	2020	T follicular helper and T follicular regulatory cells in colorectal cancer: A complex interplay.	BCL6
32062068	10.1016/j.neo.2020.01.002	2020	AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines.	BCL6
32066288	10.1080/14656566.2020.1727445	2020	Perspectives on chemotherapy for the management of double-hit lymphoma.	BCL6
32074595	10.1159/000505892	2020	The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.	BCL6
32100426	10.1111/1756-185X.13800	2020	Characteristics of diffuse large B-cell lymphoma in patients with primary Sj√∂gren's syndrome.	BCL6
32112707	10.1093/ajcp/aqz208	2020	Double-Hit and Triple-Hit Follicular Lymphoma.	BCL6
32130407	10.1182/bloodadvances.2019001114	2020	Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk.	BCL6
32131762	10.1186/s12885-020-6650-9	2020	Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.	BCL6
32139607	10.1073/pnas.1920419117	2020	Distinct signaling and transcriptional pathways regulate peri-weaning development and cold-induced recruitment of beige adipocytes.	BCL6
32144513	10.1007/s11912-020-0898-8	2020	Burkitt and Burkitt-Like Lymphomas: a Systematic Review.	BCL6
32152442	10.1038/s41598-020-61378-4	2020	A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era.	BCL6
32180900	10.18632/oncotarget.27506	2020	Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis.	BCL6
32195944	10.1097/MD.0000000000019463	2020	Primary testicular diffuse large B-cell lymphoma: Case series.	BCL6
32210715	10.7150/ijms.41075	2020	Connective tissue growth factor (CTGF) regulates the fusion of osteoclast precursors by inhibiting Bcl6 in periodontitis.	BCL6
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	BCL6
32240660	10.1016/j.yexcr.2020.111986	2020	Establishment and characterization of a porcine B cell lymphoma cell line.	BCL6
32245492	10.1186/s13000-020-00932-0	2020	A rare face of follicular lymphoma: reverse variant of follicular lymphoma.	BCL6
32260556	10.3390/cancers12040884	2020	Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas.	BCL6
32275432	10.1021/acs.jmedchem.9b02076	2020	Achieving <i>In Vivo</i> Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders.	BCL6
32277518	10.1002/jcb.29650	2020	Hsa_circ_0031288/hsa-miR-139-3p/Bcl-6 regulatory feedback circuit influences the invasion and migration of cervical cancer HeLa cells.	BCL6
32281588	NA	2020	Classifying DLBCL according cell of origin using Hans algorithm and its association with clinicopathological parameters: A single centre experience.	BCL6
32287077	10.1097/PAI.0000000000000843	2020	Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified.	BCL6
32311849	10.3343/alm.2020.40.5.361	2020	Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.	BCL6
32320427	10.1371/journal.pone.0231470	2020	The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy.	BCL6
32334477	10.31557/APJCP.2020.21.4.1103	2020	The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.	BCL6
32363958	10.1177/0300060520918087	2020	CD56-positive diffuse large B-cell lymphoma/leukemia with <i>BCL6/MYC</i> double-hit and multiple gene mutations: an indicator of poor prognosis?	BCL6
32364682	10.1111/ijlh.13222	2020	Significance of CD10 protein expression in the diagnostics of follicular lymphoma: A comparison of conventional immunohistochemistry with flow cytometry supported by the establishment of BCL2 and BCL6 rearrangements.	BCL6
32424816	10.1111/jgh.15083	2020	Gastrointestinal: Inflammatory bowel disease therapy-induced triple-hit lymphoma.	BCL6
32491282	10.1002/dc.24477	2020	Anaplastic large cell lymphoma: Report of two cases with rare patterns (carcinomatous and sarcomatous) in fine needle aspiration cytology and histopathology.	BCL6
32497402	10.1002/cyto.b.21887	2020	Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.	BCL6
32507816	10.11406/rinketsu.61.503	2020	[Genetic alterations and lymphoma].	BCL6
32535543	10.1016/j.cancergen.2020.05.002	2020	Generation and characterization of the E¬µ-Irf8 mouse model.	BCL6
32541138	10.1159/000505715	2020	Comprehensive Genomic Analysis of Noonan Syndrome and Acute Myeloid Leukemia in Adults: A Review and Future Directions.	BCL6
32546802	10.1038/s41598-020-66539-z	2020	Liver-specific knockout of B cell lymphoma 6 suppresses progression of non-alcoholic steatohepatitis in mice.	BCL6
32551010	10.1021/acsmedchemlett.0c00111	2020	Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.	BCL6
32613279	10.1007/s00277-020-04124-0	2020	Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.	BCL6
32619424	10.1016/j.cell.2020.05.049	2020	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.	BCL6
32639587	10.1002/hon.2779	2020	Primary large B-cell lymphoma of the central nervous system with cyclin D1 expression and t(11;14) (IGH-CCND1): Diffuse large B-cell lymphoma with CCND1 rearrangement or mantle cell lymphoma?	BCL6
32648273	10.1111/pin.12981	2020	RHOA mutation in follicular T-cell lymphoma: Clinicopathological analysis of 16 cases.	BCL6
32679859	10.3390/cancers12071912	2020	Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type.	BCL6
32680911	10.1136/jclinpath-2020-206725	2020	Incidence of single hit Bcl-2 and Bcl-6 rearrangements in DLBCL: the Irish experience.	BCL6
32713346	10.1186/s13256-020-02433-6	2020	Transformation of a low-grade follicular lymphoma into a composite lymphoma combining a high-grade B-cell lymphoma and a lymphoblastic neoplasm expressing Terminal deoxynucleotidyl Transferase: a case report.	BCL6
32722781	10.1182/bloodadvances.2020001551	2020	Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.	BCL6
32736575	10.1186/s12885-020-07198-1	2020	Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.	BCL6
32780847	10.1182/bloodadvances.2020001727	2020	Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.	BCL6
32780869	10.1111/bjh.17038	2020	Indolent clinical behaviour of primary cutaneous diffuse large B-cell lymphoma, leg type, with double MYC and BCL6 gene rearrangement.	BCL6
32843454	10.1136/bcr-2020-235451	2020	High-grade B-cell lymphoma with MYC and BCL6 rearrangements presenting as a cervical mass.	BCL6
32843697	10.1038/s41598-020-71058-y	2020	Activation-induced cytidine deaminase overexpression in double-hit lymphoma: potential target for novel anticancer therapy.	BCL6
32851455	10.1007/s00277-020-04218-9	2020	A methotrexate-associated lymphoproliferative disorder expressing CD10 and BCL6 with the IGH/CCND1 translocation.	BCL6
32888407	10.1016/S0140-6736(20)31366-0	2020	Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.	BCL6
32889391	10.1016/j.anndiagpath.2020.151610	2020	Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.	BCL6
32909092	10.1007/s00292-020-00816-6	2020	[Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas].	BCL6
32921221	10.1080/10428194.2020.1815017	2020	Clinicopathological and prognostic significance of <i>BCL2</i>, <i>BCL6</i>, <i>MYC</i>, and <i>IRF4</i> copy number gains and translocations in follicular lymphoma: a study by FISH analysis.	BCL6
32947237	10.1016/j.tranon.2020.100855	2020	Identification of clinical molecular targets for childhood Burkitt lymphoma.	BCL6
32991338	10.1097/PAS.0000000000001577	2020	High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.	BCL6
33045225	10.1016/j.humpath.2020.09.014	2020	The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.	BCL6
33048405	10.1111/pin.13031	2020	The first reported case of primary extranodal counterpart of follicular T-cell lymphoma of submandibular gland.	BCL6
33065767	10.1111/bjh.17072	2020	Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.	BCL6
33066681	10.3390/diagnostics10100823	2020	Use of Liquid-based Cytology and Cell Block Combined Technique for an Accurate Diagnosis of Oral Diffuse Large B Cell Lymphoma: A Case Report.	BCL6
33082762	10.1159/000510362	2020	Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders, Diffuse Large B-Cell Lymphoma Type, in a Patient with Beh√ßet's Disease Treated with Cyclosporine A.	BCL6
33094287	10.1093/narcan/zcaa029	2020	Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphoma.	BCL6
33100703	10.1007/s12288-019-01248-w	2020	Double Hit and Double Expresser Diffuse Large B Cell Lymphoma Subtypes: Discrete Subtypes and Major Predictors of Overall Survival.	BCL6
33168821	10.1038/s41408-020-00382-3	2020	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients.	BCL6
33176509	10.1080/17474086.2020.1850252	2020	An analysis of genetic targets for guiding clinical management of follicular lymphoma.	BCL6
33180881	10.1371/journal.pone.0241634	2020	Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?	BCL6
33182312	10.3390/ijms21218393	2020	The Function of Oncogene B-Cell Lymphoma 6 in the Regulation of the Migration and Invasion of Trophoblastic Cells.	BCL6
33208943	10.1038/s41586-020-2925-1	2020	Small-molecule-induced polymerization triggers degradation of BCL6.	BCL6
33211828	10.1182/bloodadvances.2020002944	2020	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.	BCL6
33232656	10.1016/j.molcel.2020.10.036	2020	Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage.	BCL6
33275671	10.1182/hematology.2020000115	2020	Transformed lymphoma: what should I do now?	BCL6
33288562	10.21873/anticanres.14692	2020	EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment.	BCL6
33293491	NA	2020	FISH is Still an Excellent Tool to Monitor High-Grade Lymphomas.	BCL6
33304974	10.1016/j.jdcr.2020.08.041	2020	Primary cutaneous peripheral T-cell lymphoma, not otherwise specified with mammalian target of rapamycin mutation: A novel finding for targeted treatment.	BCL6
33318279	10.1136/bcr-2020-238626	2020	Primary intestinal follicular lymphoma presenting as multiple lymphomatous polyposis.	BCL6
33333642	10.3760/cma.j.cn112147-20200729-00859	2020	[Pulmonary mucosa-associated lymphoid tissue lymphoma concurrent with lung squamous cell carcinoma: a case report and literature review].	BCL6
33365186	10.25259/SNI_314_2020	2020	Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India.	BCL6
33376737	10.1155/2020/7467104	2020	Pyruvate Kinase M2 Knockdown Suppresses Migration, Invasion, and Epithelial-Mesenchymal Transition of Gastric Carcinoma via Hypoxia-Inducible Factor Alpha/B-Cell Lymphoma 6 Pathway.	BCL6
33425899	10.3389/fcell.2020.594785	2020	CircHmbox1 Targeting miRNA-1247-5p Is Involved in the Regulation of Bone Metabolism by TNF-Œ± in Postmenopausal Osteoporosis.	BCL6
33437697	10.4103/ajm.ajm_81_20	2020	High Ki67 proliferation index but not cell-of-origin subtypes is associated with shorter overall survival in diffuse large B-cell lymphoma.	BCL6
33463110	10.18502/ijaai.v19i4.4118	2020	Increased Expression of B Lymphocyte Induced Maturation Protein 1 (BLIMP1) in Patients with Common Variable Immunodeficiency (CVID).	BCL6
33550334	NA	2020	[Clinicopathological analysis of mucosa associated lymphoid tissue lymphoma secondary to Sj√∂gren' s syndrome in salivary gland].	BCL6
33613551	10.3389/fimmu.2020.620716	2020	Multiscale Modeling of Germinal Center Recapitulates the Temporal Transition From Memory B Cells to Plasma Cells Differentiation as Regulated by Antigen Affinity-Based Tfh Cell Help.	BCL6
33633728	10.3389/fimmu.2020.607626	2020	<i>In Situ</i> Characterization of Follicular Helper CD4 T Cells Using Multiplexed Imaging.	BCL6
34595452	10.2991/chi.d.200410.001	2020	Cost Analysis of R-CHOP <i>Versus</i> Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features.	BCL6
35847735	10.1002/jha2.28	2020	Relapse of follicular lymphoma arising from a non-t(14;18) clone.	BCL6
30105896	10.1002/jcp.27045	2019	Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).	BCL6
30179888	10.1097/PAI.0000000000000696	2019	nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin.	BCL6
30181564	10.1038/s41379-018-0112-9	2019	High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma.	BCL6
30210134	10.2169/internalmedicine.1686-18	2019	Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements.	BCL6
30277098	10.1080/10428194.2018.1508663	2019	Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.	BCL6
30277117	10.1080/10428194.2018.1516286	2019	Cytotoxic effect caspase activation dependent of a genetically engineered fusion protein with a CD154 peptide mimetic (OmpC-CD154<sub>p</sub>) on B-NHL cell lines is mediated by the inhibition of bcl-6 and YY1 through MAPK p38 activation.	BCL6
30279226	10.1182/blood-2018-03-839993	2019	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.	BCL6
30306208	10.1007/s00277-018-3498-z	2019	MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.	BCL6
30309852	10.3324/haematol.2018.198572	2019	Targeted next generation sequencing reveals high mutation frequency of <i>CREBBP, BCL2</i> and <i>KMT2D</i> in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements.	BCL6
30348636	10.1158/1078-0432.CCR-18-1153	2019	Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma.	BCL6
30355686	10.1128/JVI.01073-18	2019	BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation.	BCL6
30380402	10.1016/j.anndiagpath.2018.09.014	2019	Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues.	BCL6
30409904	10.1074/jbc.RA118.004204	2019	Reciprocal negative regulation between the tumor suppressor protein p53 and B cell CLL/lymphoma 6 (BCL6) via control of caspase-1 expression.	BCL6
30446717	10.1038/s41374-018-0152-2	2019	MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.	BCL6
30457458	10.1080/10428194.2018.1506586	2019	Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations.	BCL6
30460680	10.1111/bjh.15653	2019	Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.	BCL6
30496802	10.1016/j.humpath.2018.11.015	2019	p53 expression in large B-cell lymphomas with MYC extra copies and CD99 expression in large B-cell lymphomas in relation to MYC status.	BCL6
30523716	10.1200/JCO.18.01583	2019	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.	BCL6
30523719	10.1200/JCO.18.01314	2019	Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.	BCL6
30538335	10.1038/s41590-018-0273-1	2019	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis.	BCL6
30567732	10.4049/jimmunol.1800876	2019	BCL6-Mediated Silencing of PD-1 Ligands in Germinal Center B Cells Maintains Follicular T Cell Population.	BCL6
30573511	10.3324/haematol.2018.195834	2019	Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma.	BCL6
30608910	10.1097/DAD.0000000000001076	2019	Cutaneous Involvement in a High Grade B-Cell Lymphoma With Rearrangement of MYC, BCL2, and BCL6 Transformed From Follicular Lymphoma.	BCL6
30613837	10.1007/s00277-018-03590-x	2019	Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma.	BCL6
30636538	10.1177/0300985818823775	2019	Primary Colorectal Follicular Lymphoma in 3 Dogs.	BCL6
30653103	10.1097/MD.0000000000013985	2019	Colorectal follicular lymphoma: A case report.	BCL6
30680935	10.1002/jez.b.22843	2019	Bcl6aa and bcl6ab are ubiquitously expressed and are inducible by lipopolysaccharide and polyI:C in adult tissues of medaka Oryzias latipes.	BCL6
30719149	10.7150/jca.25732	2019	BCL6 Rearrangement Indicates Poor Prognosis in Diffuse Large B-cell Lymphoma Patients: A Meta-analysis of Cohort Studies.	BCL6
30732171	10.1097/MD.0000000000014367	2019	Diffuse large B-cell lymphoma of the central nervous system presenting as lymphomatosis cerebri and dementia in elderly man: Case report and review of the literature.	BCL6
30734478	10.1002/cyto.b.21770	2019	Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.	BCL6
30737994	10.1111/ejh.13219	2019	Stratification by MYC expression has prognostic impact in MYC translocated B-cell lymphoma-Identifies a subgroup of patients with poor outcome.	BCL6
30768141	10.1093/asj/sjz044	2019	The First Reported Case of Gluteal Implant-Associated Anaplastic Large Cell Lymphoma (ALCL).	BCL6
30788082	10.1016/j.csbj.2019.01.006	2019	Bivalent Ligands for Protein Degradation in Drug Discovery.	BCL6
30792929	10.1155/2019/3730915	2019	CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type.	BCL6
30805081	10.1155/2019/5018410	2019	BCL6 Attenuates Proliferation and Oxidative Stress of Vascular Smooth Muscle Cells in Hypertension.	BCL6
30809101	10.2147/CMAR.S192143	2019	Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with <i>MYC</i>, <i>BCL2/BCL6</i> gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study.	BCL6
30824609	10.1158/1535-7163.MCT-18-1068	2019	HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.	BCL6
30839349	10.1097/DAD.0000000000001368	2019	AL-Amyloidoma of the Skin-A Rare Manifestation of Primary Cutaneous Marginal Zone Lymphoma.	BCL6
30859597	10.1002/ajh.25460	2019	Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.	BCL6
30874346	10.1111/imr.12734	2019	MYC in Germinal Center-derived lymphomas: Mechanisms and therapeutic opportunities.	BCL6
30874354	10.1111/imr.12755	2019	Germinal center-derived lymphomas: The darkest side of humoral immunity.	BCL6
30917792	10.1186/s12885-019-5466-y	2019	The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis.	BCL6
30918199	10.2169/internalmedicine.2532-18	2019	Primary Chest Wall MYC/BCL6 Double-hit Lymphoma with t (3;7) (q27;p12) and t (8;14) (q24;q32) Translocations.	BCL6
30952970	10.1038/s41379-019-0254-4	2019	The pathological features of angioimmunoblastic T-cell lymphomas with IDH2<sup>R172</sup> mutations.	BCL6
30963474	10.1007/s12185-019-02646-6	2019	Double-hit pancreatic B-lymphoblastic lymphoma with a variant translocation t(2;18)(p11;q21).	BCL6
30980412	10.1111/cup.13475	2019	Cutaneous lesions of angioimmunoblastic T-cell lymphoma: Clinical, pathological, and immunophenotypic features.	BCL6
30983044	10.1111/cyt.12707	2019	The accuracy of diagnosing Burkitt lymphoma in serous effusion specimen: A cytological-histological correlation with ancillary studies.	BCL6
30983568	10.7554/eLife.43922	2019	Dynamic repression by BCL6 controls the genome-wide liver response to fasting and steatosis.	BCL6
30992267	10.1182/blood.2018864173	2019	Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background.	BCL6
31000603	10.1073/pnas.1901258116	2019	Transcription factors IRF8 and PU.1 are required for follicular B cell development and BCL6-driven germinal center responses.	BCL6
31024321	10.3389/fphar.2019.00367	2019	Inhibitory Effect of KP-A038 on Osteoclastogenesis and Inflammatory Bone Loss Is Associated With Downregulation of Blimp1.	BCL6
31025641	NA	2019	Diffuse large B-cell lymphoma of the small intestine in a patient with refractory coeliac disease.	BCL6
31030723	NA	2019	[T follicular helper cells and their related molecules in rheumatoid arthritis: A review].	BCL6
31042473	10.1016/j.celrep.2019.04.014	2019	Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation.	BCL6
31045473	10.1200/JGO.18.00203	2019	Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin.	BCL6
31063496	10.1371/journal.pone.0216470	2019	Generation and characterization of a monoclonal antibody against human BCL6 for immunohistochemical diagnosis.	BCL6
31068510	10.11406/rinketsu.60.155	2019	[MYC-associated B-cell lymphomas: pathophysiology and treatment].	BCL6
31072235	10.1080/16078454.2019.1614289	2019	Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.	BCL6
31095175	10.4067/s0034-98872019000200247	2019	[Triple expressor lymphoma in a kidney transplant patient].	BCL6
31109360	10.1186/s13000-019-0826-0	2019	Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.	BCL6
31150587	10.1080/17474086.2019.1624157	2019	High-grade B-cell lymphoma: how to diagnose and treat.	BCL6
31155767	10.1111/jpn.13110	2019	Dietary l-arginine supplementation influences growth performance and B-cell secretion of immunoglobulin in broiler chickens.	BCL6
31160360	10.1101/mcs.a004077	2019	Elucidating a false-negative <i>MYC</i> break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with <i>IGH/MYC</i> and <i>IGH/BCL2</i> rearrangements.	BCL6
31171907	10.7150/ijms.27610	2019	Clinical Significance of <i>BCL2</i>, C-<i>MYC</i>, and <i>BCL6</i> Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.	BCL6
31185999	10.1186/s12967-019-1951-y	2019	Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of DLBCL.	BCL6
31187528	10.1002/hon.2581	2019	Double-hit lymphoma: So what?	BCL6
31189479	10.1186/s13000-019-0833-1	2019	Treatment outcome and prognostic factors in PCNSL.	BCL6
31205728	10.1136/lupus-2019-000324	2019	Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival.	BCL6
31225766	10.1080/10428194.2019.1622099	2019	Survival outcomes of diffuse large B-cell lymphoma by association with concurrent or antecedent follicular lymphoma and double hit status.	BCL6
31229156	10.1016/j.hoc.2019.04.001	2019	Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and/or BCL6 Rearrangements.	BCL6
31281146	10.11406/rinketsu.60.570	2019	[BCL2, BCL6, and MYC-positive intravascular large B-cell lymphoma presenting with bilateral adrenal gland lesions].	BCL6
31283630	10.1097/PAS.0000000000001315	2019	Application of a 5 Marker Panel to the Routine Diagnosis of Peripheral T-Cell Lymphoma With T-Follicular Helper Phenotype.	BCL6
31285189	10.1182/bloodadvances.2019000251	2019	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.	BCL6
31285322	10.1073/pnas.1905305116	2019	Nbn-Mre11 interaction is required for tumor suppression and genomic integrity.	BCL6
31287161	10.1002/cncr.32145	2019	Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?	BCL6
31288832	10.1186/s13045-019-0761-2	2019	Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.	BCL6
31315646	10.1186/s13000-019-0856-7	2019	Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.	BCL6
31336593	10.3390/jcm8071074	2019	Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact.	BCL6
31365872	10.1016/j.celrep.2019.06.079	2019	CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation.	BCL6
31368914	10.1097/PAS.0000000000001338	2019	Indolent In Situ B-Cell Neoplasms With MYC Rearrangements Show Somatic Mutations in MYC and TNFRSF14 by Next-generation Sequencing.	BCL6
31375635	10.1073/pnas.1907308116	2019	BCL6 regulates brown adipocyte dormancy to maintain thermogenic reserve and fitness.	BCL6
31395741	10.1101/gad.327593.119	2019	Rationale for targeting BCL6 in <i>MLL</i>-rearranged acute lymphoblastic leukemia.	BCL6
31401377	10.1016/j.intimp.2019.105789	2019	BCL6 inhibitor FX1 attenuates inflammatory responses in murine sepsis through strengthening BCL6 binding affinity to downstream target gene promoters.	BCL6
31404445	10.1007/s12308-019-00354-y	2019	Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.	BCL6
31406071	10.11405/nisshoshi.116.660	2019	[Mucosa-associated lymphoid tissue lymphoma of the appendix concomitant with appendicitis:a case report].	BCL6
31408531	10.1002/hon.2664	2019	PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation.	BCL6
31416638	10.1016/j.annpat.2019.05.005	2019	[New entities and new tools in hematopathology as proposed by the 2016 WHO classification: Case 2].	BCL6
31419226	10.1371/journal.pone.0220681	2019	DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.	BCL6
31427546	NA	2019	Characterisation of immunogenotypes of diffuse large B-cell lymphoma.	BCL6
31440479	10.4322/acr.2019.090	2019	High-grade B-Cell lymphoma with <i>MYC</i> and <i>BCL6</i> rearrangements associated with Richter transformation of chronic lymphocytic leukemia.	BCL6
31498031	10.1200/JCO.19.00743	2019	Prognostic Significance of <i>MYC</i> Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.	BCL6
31518494	10.17219/acem/109200	2019	A large single-institution retrospective analysis of aggressive B-cell lymphomas according to the 2016/2017 WHO classification.	BCL6
31527075	10.1182/blood.2019002600	2019	The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.	BCL6
31558468	10.1182/blood.2019001880	2019	The whole-genome landscape of Burkitt lymphoma subtypes.	BCL6
31565620	10.7759/cureus.5217	2019	CD-20 Negative Plasmablastic Lymphoma Lurking in the Shadow of a Leiomyoma - Diagnosis and Management.	BCL6
31584842	10.5858/arpa.2019-0331-RA	2019	Ancillary Studies in the Diagnostic Evaluation of Large B-Cell Lymphoma.	BCL6
31586036	10.4049/jimmunol.1900326	2019	<i>Crlz-1</i> Controls Germinal Center Reaction by Relaying a Wnt Signal to the <i>Bcl-6</i> Expression in Centroblasts during Humoral Immune Responses.	BCL6
31586074	10.1038/s41467-019-12494-x	2019	Genetic modification of primary human B cells to model high-grade lymphoma.	BCL6
31611445	10.4103/IJPM.IJPM_849_18	2019	Primary epiglottic follicular variant of peripheral T-cell lymphoma.	BCL6
31666176	10.1016/j.pathol.2019.08.009	2019	TdT-positive high grade B-cell lymphoma transformed from grade 3B follicular lymphoma in an HIV-positive patient.	BCL6
31686194	10.1007/s00428-019-02681-y	2019	Novel markers in pediatric-type follicular lymphoma.	BCL6
31692510	10.2147/BLCTT.S216292	2019	Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens.	BCL6
31711493	10.1186/s12903-019-0936-9	2019	Follicular lymphoid hyperplasia of the posterior maxillary site presenting as uncommon entity: a case report and review of the literature.	BCL6
31712669	10.1038/s41598-019-52714-4	2019	Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.	BCL6
31748270	10.1073/pnas.1914163116	2019	A high-resolution landscape of mutations in the <i>BCL6</i> super-enhancer in normal human B cells.	BCL6
31752970	10.1186/s13045-019-0803-9	2019	Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma.	BCL6
31788471	10.3389/fcell.2019.00272	2019	Epigenetic Programing of B-Cell Lymphoma by BCL6 and Its Genetic Deregulation.	BCL6
31805190	10.1182/bloodadvances.2019000989	2019	Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray.	BCL6
31844420	10.7573/dic.2019-8-1	2019	Drug therapy for double-hit lymphoma.	BCL6
31934044	NA	2019	The impact of <i>BCL-2/MYC</i> protein expression and gene abnormality on primary central nervous system diffuse large B-cell lymphoma.	BCL6
31942539	10.1097/HS9.0000000000000284	2019	Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?	BCL6
31993568	10.1016/j.mayocpiqo.2019.08.004	2019	Quality Initiative in Clinical Practice: A Single-Institution Appraisal of Quality Metrics in the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma.	BCL6
32397023	10.3760/cma.j.issn.0253-2727.2019.07.010	2019	[Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL].	BCL6
32598736	10.26442/00403660.2019.07.000070	2019	[The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data].	BCL6
34468358	10.1158/2159-8290.CD-RW2018-216	2019	BCL6-Driven Lymphoma Is Dependent on LSD1 Corepression.	BCL6
28875547	10.1111/bjh.14912	2018	Immunohistochemical double hit score enhances NCCN-IPI and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma.	BCL6
29352142	10.1038/s41419-017-0066-8	2018	FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway.	BCL6
29510136	10.1016/j.bbrc.2018.03.010	2018	Interferon Œ≥ is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells.	BCL6
29510377	10.1159/000487372	2018	miR-519d-3p Inhibits Cell Proliferation and Invasion of Gastric Cancer by Downregulating B-Cell Lymphoma 6.	BCL6
29983382	10.1016/j.clml.2018.06.010	2018	Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL.	BCL6
30043475	10.1002/dc.24038	2018	Triple hit lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.	BCL6
30082494	10.1182/blood-2018-02-831438	2018	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.	BCL6
30089946	10.4103/JOC.JOC_42_18	2018	Contribution of Immunocytochemistry to the Diagnosis of Usual and Unusual Lymphoma Cases.	BCL6
30103201	10.1016/j.leukres.2018.08.002	2018	Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia.	BCL6
30109672	10.1007/s11060-018-2970-x	2018	Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.	BCL6
30111411	10.7534/j.issn.1009-2137.2018.04.023	2018	[Prognostic Value of Morphology and Hans Classification in Diffuse Large B Cell Lymphoma].	BCL6
30113335	10.1097/PAS.0000000000001132	2018	High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.	BCL6
30143009	10.1186/s12964-018-0258-6	2018	Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.	BCL6
30146835	10.7754/Clin.Lab.2018.180320	2018	Diffuse Large B Cell Lymphoma Coexistent with Follicular Cell Lymphoma.	BCL6
30158513	10.12659/AJCR.909400	2018	Double-Hit Lymphoma (MYC and BCL6) with Involvement of Skull and Adnexal Lesions: A Case Report and a Review of the Literature.	BCL6
30171453	10.1007/s11060-018-2990-6	2018	Characterization of genomic alterations in primary central nervous system lymphomas.	BCL6
30185437	10.1182/bloodadvances.2018021063	2018	STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.	BCL6
30195499	10.1016/j.acthis.2018.08.003	2018	Silymarin amplifies apoptosis in ectopic endometrial tissue in rats with endometriosis; implication on growth factor GDNF, ERK1/2 and Bcl-6b expression.	BCL6
30213388	10.1016/j.beha.2018.07.003	2018	Dissecting aggressive B-cell lymphoma through genomic analysis - What is clinically relevant?	BCL6
30213392	10.1016/j.beha.2018.07.012	2018	Double hit lymphoma: How do we define it and how do we treat it?	BCL6
30213394	10.1016/j.beha.2018.07.008	2018	An update in treating transformed lymphoma.	BCL6
30235749	10.1097/MD.0000000000012482	2018	Adrenal relapse of primary central nervous system diffuse large B-cell lymphoma: A case report.	BCL6
30245984	NA	2018	Mantle Cell Lymphoma of the Palatine Tonsil: A Rare Case Report.	BCL6
30252929	10.1002/cncr.31646	2018	Double hit and double expressors in lymphoma: Definition and treatment.	BCL6
30255584	10.1111/pin.12722	2018	Synchronous case of follicular lymphoma and Langerhans cell sarcoma in the same lymph node.	BCL6
30279867	10.1016/j.jccase.2017.11.002	2018	Primary cardiac MYC/BCL6 double hit non-Hodgkin lymphoma.	BCL6
30287880	10.1038/s41598-018-33230-3	2018	Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.	BCL6
30305516	10.11406/rinketsu.59.2109	2018	[Treatment strategy for high-grade B-cell lymphoma].	BCL6
30323893	10.18632/oncotarget.26060	2018	Generation and characteristics of a novel double-hit high grade B-cell lymphoma cell line DH-My6 with <i>MYC</i>/<i>IGH</i> and <i>BCL6</i>/<i>IGH</i> gene arrangements and potential molecular targeted therapies.	BCL6
30333862	10.3892/ol.2018.9376	2018	miR-339-5p inhibits lung adenocarcinoma invasion and migration by directly targeting BCL6.	BCL6
30335946	10.1021/acschembio.8b00698	2018	Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.	BCL6
30348671	10.1182/bloodadvances.2018023572	2018	High-resolution architecture and partner genes of <i>MYC</i> rearrangements in lymphoma with DLBCL morphology.	BCL6
30360879	10.1053/j.seminoncol.2018.07.005	2018	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	BCL6
30395539	10.1172/JCI124919	2018	PLK1: a promising and previously unexplored target in double-hit lymphoma.	BCL6
30498195	10.1038/s41467-018-06961-0	2018	Chromatin conformation analysis of primary patient tissue using a low input Hi-C method.	BCL6
30501868	10.1016/S2352-3026(18)30177-7	2018	Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.	BCL6
30504293	10.1182/asheducation-2018.1.69	2018	Genomics of aggressive B-cell lymphoma.	BCL6
30521492	NA	2018	Two Double-hit Lymphomas Cases: A Molecular Cytogenetic Approach.	BCL6
30553470	10.1016/j.cancergen.2018.08.001	2018	Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases.	BCL6
30564339	10.1002/ccr3.1871	2018	A double-hit High-grade B-cell lymphoma with three-way translocation t(3;8;14)(q27;q24;q32) involving BCL6, MYC, and IGH.	BCL6
30566857	10.1016/j.celrep.2018.11.074	2018	Loss of Transcriptional Repression by BCL6 Confers Insulin Sensitivity in the Setting of Obesity.	BCL6
30586419	10.1371/journal.pone.0210027	2018	Correction: MYC Expression in Concert With BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.	BCL6
30687256	10.3389/fmicb.2018.03253	2018	B-Cell Lymphoma 6 (BCL6) Is a Host Restriction Factor That Can Suppress HBV Gene Expression and Modulate Immune Responses.	BCL6
30949014	10.1080/08998280.2018.1460127	2018	RETRACTED ARTICLE: Primary central nervous system high-grade B-cell lymphoma, with rearrangements of <i>MYC</i> and <i>BCL6</i>.	BCL6
31007628	10.1080/08998280.2019.1578105	2018	RETRACTED ARTICLE: Primary central nervous system high-grade B-cell lymphoma, with rearrangements of <i>MYC</i> and <i>BCL6</i>.	BCL6
27921272	10.1007/s12185-016-2159-z	2017	BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma.	BCL6
28030830	10.18632/oncotarget.14038	2017	Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia.	BCL6
28256570	10.1038/modpathol.2017.12	2017	Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma.	BCL6
28628241	10.1111/his.13286	2017	Aberrant expression of CD10 and BCL6 in mantle cell lymphoma.	BCL6
28665415	10.1038/bcj.2017.59	2017	Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas.	BCL6
28952038	10.1007/s11912-017-0629-y	2017	Double-Hit Large B Cell Lymphoma.	BCL6
29056123	2721	2017	Immunohistochemical Expression of CD10, BCL6 and MUM1 in Differentiating Diffuse Large B Cell Lymphoma Subtypes.	BCL6
29072703	10.1038/cddis.2017.567	2017	BCL6 attenuates renal inflammation via negative regulation of NLRP3 transcription.	BCL6
29088292	10.1371/journal.pone.0186983	2017	Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.	BCL6
30802397	10.18821/0869-2084-2017-62-8-490-497	2017	[The complex morphologic diagnostic of marginal zone lymphoma.]	BCL6
26120879	10.1080/09168451.2015.1056512	2016	Development and function of follicular helper T cells.	BCL6
26414904	10.1002/cncy.21626	2016	CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.	BCL6
26448193	10.1097/PAS.0000000000000542	2016	High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.	BCL6
26553360	10.1007/s13277-015-4390-2	2016	miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6.	BCL6
26565895	10.1002/cncr.29781	2016	Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.	BCL6
26573234	10.18632/oncotarget.6262	2016	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.	BCL6
26710884	10.1038/leu.2015.355	2016	SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6.	BCL6
26728228	10.1038/srep18778	2016	Bcl6 Sets a Threshold for Antiviral Signaling by Restraining IRF7 Transcriptional Program.	BCL6
26986233	10.3892/ijmm.2016.2529	2016	Overexpression of miR-155 promotes the proliferation and invasion of oral squamous carcinoma cells by regulating BCL6/cyclin D2.	BCL6
27069113	10.1084/jem.20151724	2016	B cell IFN-Œ≥ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6.	BCL6
27268052	10.1074/jbc.M116.736868	2016	Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.	BCL6
27363279	NA	2016	[Increased expressions of Blimp-1 and Bcl-6 in the deciduas of patients with unexplained recurrent spontaneous abortion].	BCL6
27494852	10.18632/oncotarget.10993	2016	PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.	BCL6
27764808	10.18632/oncotarget.12680	2016	The feedback loop of LITAF and BCL6 is involved in regulating apoptosis in B cell non-Hodgkin's-lymphoma.	BCL6
27815824	10.1007/s13238-016-0316-z	2016	miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.	BCL6
24362533	10.1038/onc.2013.535	2015	Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus.	BCL6
24679006	10.3109/10428194.2014.907896	2015	TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.	BCL6
25543051	10.1093/toxsci/kfu257	2015	Suppression of human B cell activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin involves altered regulation of B cell lymphoma-6.	BCL6
25557390	10.1016/j.bbadis.2014.12.018	2015	The ITM2B (BRI2) gene is a target of BCL6 repression: Implications for lymphomas and neurodegenerative diseases.	BCL6
25596256	10.1309/AJCPUIDW2CPTA1JA	2015	Cyclin D1-positive diffuse large B-cell lymphoma with IGH-CCND1 translocation and BCL6 rearrangement: a report of two cases.	BCL6
25769544	10.3324/haematol.2014.120048	2015	BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.	BCL6
25828391	10.1097/PAS.0000000000000434	2015	Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.	BCL6
26049022	10.1016/j.canlet.2015.05.029	2015	BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells.	BCL6
26054109	NA	2015	Decreased Bcl-6 and increased Blimp-1 in the peritoneal cavity of patients with endometriosis.	BCL6
26214636	NA	2015	BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.	BCL6
26276666	10.1182/blood-2015-07-657999	2015	Convergent BCL6 and lncRNA promoters demarcate the major breakpoint region for BCL6 translocations.	BCL6
24114011	10.1007/s13277-013-1195-z	2014	BCL6 overexpression is associated with decreased p19 ARF expression and confers an independent prognosticator in gallbladder carcinoma.	BCL6
24678684	10.5858/arpa.2012-0663-OA	2014	Fluorescence immunophenotyping and interphase cytogenetics (FICTION) detects BCL6 abnormalities, including gene amplification, in most cases of nodular lymphocyte-predominant Hodgkin lymphoma.	BCL6
24698494	10.1016/j.molmed.2014.03.001	2014	Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis.	BCL6
24767250	10.1016/j.humpath.2014.02.002	2014	Targeted gene analysis: increased B-cell lymphoma 6 in preeclamptic placentas.	BCL6
24863065	10.1084/jem.20132267	2014	A negative feedback loop mediated by the Bcl6-cullin 3 complex limits Tfh cell differentiation.	BCL6
24878528	10.1016/j.bbrc.2014.05.096	2014	High concentrations of glucose suppress etoposide-induced cell death of B-cell lymphoma through BCL-6.	BCL6
24887457	10.1038/ncomms4904	2014	Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.	BCL6
24917186	10.1186/1471-2407-14-418	2014	B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cells.	BCL6
25038272	10.1016/j.canlet.2014.06.017	2014	Translocation of the proto-oncogene Bcl-6 in human glioblastoma multiforme.	BCL6
25090026	10.1371/journal.pone.0104068	2014	MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.	BCL6
25125624	10.1309/AJCPBWVHTF7RRSA4	2014	Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics.	BCL6
25234312	10.1152/ajprenal.00426.2014	2014	Transcriptional regulation of human organic anion transporter 1 by B-cell CLL/lymphoma 6.	BCL6
25245533	10.18632/oncotarget.2364	2014	Interleukin-32Œ± downregulates the activity of the B-cell CLL/lymphoma 6 protein by inhibiting protein kinase CŒµ-dependent SUMO-2 modification.	BCL6
25295537	10.1172/JCI75667	2014	Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination.	BCL6
25297597	10.3760/cma.j.issn.1003-9406.2014.01.020	2014	[Significance of BCL6, MYC, P53 genes abnormalities for the prognosis of diffuse large B-cell lymphoma].	BCL6
25490446	10.1016/j.ccell.2014.10.021	2014	A BCL6/BCOR/SIRT1 complex triggers neurogenesis and suppresses medulloblastoma by repressing Sonic Hedgehog signaling.	BCL6
22893614	10.1002/jbmr.1739	2013	Negative regulation of osteoclast precursor differentiation by CD11b and Œ≤2 integrin-B-cell lymphoma 6 signaling.	BCL6
23269799	10.1128/JVI.03081-12	2013	B cells in chronically hepatitis C virus-infected individuals lack a virus-induced mutation signature in the TP53, CTNNB1, and BCL6 genes.	BCL6
23335369	10.1182/blood-2012-06-435842	2013	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.	BCL6
23348205	10.1097/PAS.0b013e31826cebad	2013	Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.	BCL6
23476051	10.1182/blood-2012-10-464958	2013	BCL6 breaks occur at different AID sequence motifs in Ig-BCL6 and non-Ig-BCL6 rearrangements.	BCL6
23509938	10.1111/his.12076	2013	Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups.	BCL6
23716595	10.1128/MCB.01620-12	2013	STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.	BCL6
23749188	10.1038/ng.2666	2013	Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population.	BCL6
23852366	10.18632/oncotarget.1149	2013	STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL).	BCL6
23911289	10.1016/j.celrep.2013.06.016	2013	A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.	BCL6
23954399	10.1016/j.molimm.2013.07.001	2013	The zinc finger transcription factor ZXDC activates CCL2 gene expression by opposing BCL6-mediated repression.	BCL6
23974956	10.1038/ni.2688	2013	MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.	BCL6
24009228	10.1182/blood-2013-05-498329	2013	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.	BCL6
20981461	10.1007/s10006-010-0254-5	2012	Diffuse swelling of the buccal mucosa and palate as first and only manifestation of an extranodal non-Hodgkin 'double-hit' lymphoma: report of a case.	BCL6
21788950	10.1038/leu.2011.189	2012	Epstein-Barr virus microRNAs repress BCL6 expression in diffuse large B-cell lymphoma.	BCL6
21804610	10.1038/onc.2011.331	2012	The proto-oncoprotein KR-POK represses transcriptional activation of CDKN1A by MIZ-1 through competitive binding.	BCL6
21855110	10.1016/j.humpath.2011.05.018	2012	Molecular and immunohistochemical characterization of B-cell lymphoma-2-negative follicular lymphomas.	BCL6
22113614	10.1038/nature10688	2012	FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.	BCL6
22124122	10.4049/jimmunol.1102297	2012	Wnt5a is secreted by follicular dendritic cells to protect germinal center B cells via Wnt/Ca2+/NFAT/NF-Œ∫B-B cell lymphoma 6 signaling.	BCL6
22204827	10.1016/j.cyto.2011.12.001	2012	Type I interferons directly down-regulate BCL-6 in primary and transformed germinal center B cells: differential regulation in B cell lines derived from endemic or sporadic Burkitt's lymphoma.	BCL6
22387553	10.4049/jimmunol.1102899	2012	Downregulation of inflammatory microRNAs by Ig-like transcript 3 is essential for the differentiation of human CD8(+) T suppressor cells.	BCL6
22395507	NA	2012	Immunologic and cytogenetic markers expressed in non-Hodgkin lymphoma of head and neck.	BCL6
22451912	10.1073/pnas.1201168109	2012	PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas.	BCL6
22668559	10.1093/jb/mvs065	2012	Mediator CDK subunits are platforms for interactions with various chromatin regulatory complexes.	BCL6
22968395	10.1097/PDM.0b013e3182585c3c	2012	Frequencies of BCL2 and BCL6 translocations in representative Chinese follicular lymphoma patients: morphologic, immunohistochemical, and FISH analyses.	BCL6
22994707	10.7314/apjcp.2012.13.7.3037	2012	Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.	BCL6
23042398	10.3760/cma.j.issn.1003-9406.2012.05.017	2012	[Correlation of BCL-6, MYC and p53 gene abnormalities with immunological subtypes and prognosis of diffuse large B-cell lymphoma].	BCL6
20830719	10.1002/ijc.25663	2011	BCL6 gene rearrangement and protein expression are associated with large cell presentation of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.	BCL6
20966935	10.1038/leu.2010.230	2011	Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas.	BCL6
21390126	10.1038/nature09730	2011	Inactivating mutations of acetyltransferase genes in B-cell lymphoma.	BCL6
21424034	NA	2011	B-cell transcription factors Pax-5, Oct-2, BOB.1, Bcl-6, and MUM1 are useful markers for the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma.	BCL6
21623692	10.3109/10428194.2011.573032	2011	Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma.	BCL6
21783402	10.1016/j.oraloncology.2011.06.506	2011	Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas.	BCL6
21988858	10.1186/1746-1596-6-97	2011	Comparison of germinal center markers CD10, BCL6 and human germinal center-associated lymphoma (HGAL) in follicular lymphomas.	BCL6
22158496	10.1700/989.10724	2011	Immunohistochemical expression of Mum-1, Oct-2 and Bcl-6 in systemic anaplastic large cell lymphomas.	BCL6
19797315	10.1093/jmcb/mjp032	2010	An expanding job description for bcl6.	BCL6
19797725	10.3324/haematol.2009.007203	2010	Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.	BCL6
19925052	10.3109/10428190903370338	2010	Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores.	BCL6
20175752	10.1042/BJ20091578	2010	ZEB1 and CtBP form a repressive complex at a distal promoter element of the BCL6 locus.	BCL6
20299965	10.1097/QAD.0b013e328332d5b1	2010	Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study.	BCL6
20348878	10.1038/modpathol.2010.76	2010	Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas.	BCL6
20385356	10.1016/j.ccr.2010.03.012	2010	Anticancer therapy SMRT-ens up: targeting the BCL6-SMRT interaction in B cell lymphoma.	BCL6
20385364	10.1016/j.ccr.2009.12.050	2010	A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.	BCL6
20557674	10.1179/102453309X12583347113573	2010	CD56-positive diffuse large B-cell lymphoma: possible association with extranodal involvement and bcl-6 expression.	BCL6
20630860	10.1074/jbc.M110.121459	2010	A novel mechanism involving coordinated regulation of nuclear levels and acetylation of NF-YA and Bcl6 activates RGS4 transcription.	BCL6
20733034	10.1084/jem.20100204	2010	DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas.	BCL6
21041953	10.1172/JCI42869	2010	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.	BCL6
21055028	NA	2010	[Study on genetic aberrations of ocular mucosa-associated lymphoid tissue lymphomas occurring in southern China].	BCL6
21092586	NA	2010	[Acquired somatic mutations in non-coding region of bcl-6 gene in germinal center-type diffuse large B-cell lymphoma].	BCL6
19236753	NA	2009	[Expressions of bcl-6, lpp and miR-28 genes in diffuse large B cell lymphoma cell lines].	BCL6
19307668	10.1182/blood-2008-12-193037	2009	The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.	BCL6
19336552	10.1158/1055-9965.EPI-08-1037	2009	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.	BCL6
19367498	10.1080/10428190902842626	2009	BCL6: somatic mutations and expression in early-stage chronic lymphocytic leukemia.	BCL6
19448593	10.1038/modpathol.2009.73	2009	Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.	BCL6
19465899	10.1038/modpathol.2009.81	2009	t(14;18)-negative follicular lymphomas are associated with a high frequency of BCL6 rearrangement at the alternative breakpoint region.	BCL6
19525926	10.1038/modpathol.2009.87	2009	Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis.	BCL6
19549844	10.1073/pnas.0903854106	2009	BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.	BCL6
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	BCL6
19575892	NA	2009	[Expressions of CXCL13, CD10 and bcl-6 in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified].	BCL6
19656156	10.1111/j.1349-7006.2009.01268.x	2009	Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.	BCL6
19701248	10.1038/onc.2009.230	2009	Functional interaction of HTLV-1 tax protein with the POZ domain of the transcriptional repressor BCL6.	BCL6
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	BCL6
19787248	10.3892/ijo_00000409	2009	Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics.	BCL6
19855081	10.1182/blood-2009-02-204362	2009	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.	BCL6
19966776	10.1038/nm.2059	2009	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.	BCL6
20032416	NA	2009	BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH/BCL2.	BCL6
20160358	10.4103/0973-1482.59901	2009	Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma.	BCL6
17989715	10.1038/sj.leu.2405025	2008	T(3;7)(q27;q32) fuses BCL6 to a non-coding region at FRA7H near miR-29.	BCL6
17989722	10.1038/sj.leu.2404999	2008	Characterization of three t(3;8)(q27;q24) translocations from diffuse large B-cell lymphomas.	BCL6
18166802	10.3324/haematol.11927	2008	Chromosomal translocations involving BCL6 in MALT lymphoma.	BCL6
18203018	10.1080/10428190701742472	2008	Frequency of BCL2 and BCL6 translocations in follicular lymphoma: relation with histological and clinical features.	BCL6
18212045	10.1128/MCB.01400-07	2008	CtBP is an essential corepressor for BCL6 autoregulation.	BCL6
18256039	10.1093/intimm/dxn005	2008	Regulation of the plasma cell transcription factor Blimp-1 gene by Bach2 and Bcl6.	BCL6
18280243	10.1016/j.molcel.2007.12.026	2008	Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.	BCL6
18346918	10.1016/j.bcmd.2008.02.003	2008	BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells.	BCL6
18354204	10.4049/jimmunol.180.7.4805	2008	STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation.	BCL6
18500267	10.1038/modpathol.2008.75	2008	BCL6 gene amplification/3q27 gain is associated with unique clinicopathological characteristics among follicular lymphoma without BCL2 gene translocation.	BCL6
18604721	10.1080/10428190802087447	2008	Bcl-6 protein expression, and not the germinal centre immunophenotype, predicts favourable prognosis in a series of primary nodal diffuse large B-cell lymphomas: a single centre experience.	BCL6
18636124	10.1371/journal.pone.0002816	2008	Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.	BCL6
18801072	10.1111/j.1440-1827.2008.02273.x	2008	Clinical relevance of CD10, BCL-6 and multiple myeloma-1 expression in diffuse large B-cell lymphomas in Malaysia.	BCL6
19052359	10.1107/S1744309108036063	2008	Structure of the wild-type human BCL6 POZ domain.	BCL6
16815642	10.1016/j.patbio.2006.04.001	2007	The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis.	BCL6
16819511	10.1038/sj.onc.1209775	2007	STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.	BCL6
17151114	10.1128/JVI.01822-06	2007	EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.	BCL6
17210865	10.1182/blood-2006-07-038000	2007	BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?	BCL6
17296585	10.3324/haematol.10682	2007	MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes.	BCL6
17360630	10.1073/pnas.0611399104	2007	Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.	BCL6
17468402	10.1073/pnas.0701770104	2007	Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas.	BCL6
17476282	10.1038/sj.leu.2404706	2007	Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin.	BCL6
17542409	10.1177/147323000703500206	2007	BCL6 gene mutations in transitional cell carcinomas.	BCL6
17545502	10.1182/blood-2007-01-069575	2007	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.	BCL6
17558410	10.1038/ni1478	2007	Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR.	BCL6
17576390	10.1111/j.1365-2893.2006.00833.x	2007	Somatic hypermutation and mRNA expression levels of the BCL-6 gene in patients with hepatitis C virus-associated lymphoproliferative diseases.	BCL6
17625604	10.1038/sj.leu.2404856	2007	Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.	BCL6
17635238	10.1111/j.1600-0609.2007.00892.x	2007	Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.	BCL6
17785208	10.1016/j.ccr.2007.08.011	2007	A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.	BCL6
17889713	10.1016/j.cancergencyto.2007.06.003	2007	Diffuse large B-cell lymphoma with a novel translocation involving BCL6.	BCL6
16125304	10.1016/j.canlet.2005.07.015	2006	Single nucleotide polymorphism in 5'-flanking region of BCL6 is not associated with increased risk of non-Hodgkin's lymphoma.	BCL6
16249378	10.1182/blood-2005-04-1629	2006	BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma.	BCL6
16489068	10.1158/1078-0432.CCR-05-1699	2006	Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.	BCL6
16704730	10.1186/1476-4598-5-18	2006	Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells.	BCL6
16728698	10.1182/blood-2006-03-011536	2006	Association of Ig/BCL6 translocations with germinal center B lymphocytes in human lymphoid tissues: implications for malignant transformation.	BCL6
16733207	10.1016/j.humpath.2006.01.018	2006	BCL6 alternative breakpoint region break and homozygous deletion of 17q24 in the nodular lymphocyte predominance type of Hodgkin's lymphoma-derived cell line DEV.	BCL6
16772602	10.1182/blood-2006-05-022517	2006	High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma.	BCL6
16773719	10.3748/wjg.v12.i22.3602	2006	Roles of syndecan-1, bcl6 and p53 in diagnosis and prognostication of immunoproliferative small intestinal disease.	BCL6
16896311	10.1097/01.jnen.0000229988.48042.ae	2006	Chromosomal translocations fusing the BCL6 gene to different partner loci are recurrent in primary central nervous system lymphoma and may be associated with aberrant somatic hypermutation or defective class switch recombination.	BCL6
15609396	10.3748/wjg.v11.i1.51	2005	Point mutation of 5' noncoding region of BCL-6 gene in primary gastric lymphomas.	BCL6
16094416	10.1038/sj.leu.2403915	2005	Clinical and biological relevance of single-nucleotide polymorphisms and acquired somatic mutations of the BCL6 first intron in follicular lymphoma.	BCL6
16147992	10.1074/mcp.M500112-MCP200	2005	Analysis of BCL6-interacting proteins by tandem mass spectrometry.	BCL6
16194898	10.1080/10428190500125648	2005	Translocation of BCL2 and BCL6 to the same immunoglobulin heavy chain locus in a case of follicular lymphoma.	BCL6
16264183	10.1093/jnci/dji344	2005	A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphoma.	BCL6
14551142	10.1182/blood-2003-06-2081	2004	ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein.	BCL6
15024721	10.14670/HH-19.637	2004	Pathogenetic role of BCL6 translocation in B-cell non-Hodgkin's lymphoma.	BCL6
15191563	10.1111/j.0022-202X.2004.22720.x	2004	Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas.	BCL6
15277222	10.1016/S0002-9440(10)63313-5	2004	Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component.	BCL6
15339680	NA	2004	Heterogeneity of BCL6 rearrangements in nodular lymphocyte predominant Hodgkin's lymphoma.	BCL6
15377470	NA	2004	Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.	BCL6
15531890	10.1038/nm1134	2004	Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.	BCL6
15577913	10.1038/nature03147	2004	The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.	BCL6
12393409	10.1182/blood-2002-05-1592	2003	Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma.	BCL6
12507907	10.1016/s0002-9440(10)63815-1	2003	Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins.	BCL6
12515714	10.1182/blood-2002-11-3387	2003	Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.	BCL6
12555064	10.1038/sj.onc.1206152	2003	Ambivalent role of BCL6 in cell survival and transformation.	BCL6
12562237	10.5858/2003-127-208-EOPMOB	2003	Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.	BCL6
12775568	10.1182/blood-2002-12-3630	2003	Intronic BCL-6 mutations are preferentially targeted to the translocated allele in t(3;14)(q27;q32) non-Hodgkin B-cell lymphoma.	BCL6
12835729	10.1038/sj.leu.2402997	2003	The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene.	BCL6
12860928	10.1084/jem.20021395	2003	BCL6 controls the expression of the B7-1/CD80 costimulatory receptor in germinal center B cells.	BCL6
12879322	10.1007/s00240-003-0324-3	2003	The expression of bcl-2 and bcl-6 protein in normal and malignant transitional epithelium.	BCL6
12881702	10.1038/sj.onc.1206755	2003	BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells.	BCL6
14654791	10.1038/sj.onc.1206995	2003	Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha).	BCL6
14655758	10.1111/j.1750-3639.2003.tb00483.x	2003	Molecular characterization of BCL6 breakpoints in primary diffuse large B-cell lymphomas of the central nervous system identifies GAPD as novel translocation partner.	BCL6
14690607	10.1016/s1097-2765(03)00454-4	2003	Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.	BCL6
15202519	10.1080/10428190310001621588	2003	Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6.	BCL6
11821949	10.1038/sj.onc.1205099	2002	The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma.	BCL6
11854457	10.1073/pnas.042702599	2002	The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis.	BCL6
11914273	10.1101/gad.929302	2002	A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling.	BCL6
11929873	10.1074/jbc.M201736200	2002	Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor.	BCL6
12165517	10.4049/jimmunol.169.4.1922	2002	Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene.	BCL6
12217802	NA	2002	Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement.	BCL6
12389616	10.1080/10428190290033305	2002	Non-immunoglobulin/BCL6 gene fusion in diffuse large B-cell lymphoma: prognostic implications.	BCL6
12402037	10.1038/ng1018	2002	Acetylation inactivates the transcriptional repressor BCL6.	BCL6
12469325	10.1002/hon.689	2002	The proto-oncogene BCL-6 in normal and malignant B cell development.	BCL6
12477975	NA	2002	Transcriptional regulation of the BCL-6 gene: mechanistic dissection using mutant cell lines.	BCL6
11911418	10.3109/10428190109097762	2001	A polymorphism in the BCL-6 gene is associated with follicle center lymphoma.	BCL6
10898795	NA	2000	BCoR, a novel corepressor involved in BCL-6 repression.	BCL6
11175338	10.1038/sj.onc.1203976	2000	Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF.	BCL6
11920179	10.1038/sj.thj.6200002	2000	FISH analysis with a YAC probe improves detection of LAZ3/BCL6 rearrangement in non-Hodgkin's lymphoma.	BCL6
10490843	10.1038/sj.onc.1202892	1999	Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci.	BCL6
10611298	10.1073/pnas.96.26.14831	1999	Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B.	BCL6
9649500	10.1101/gad.12.13.1953	1998	Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor.	BCL6
9047392	10.1038/sj.onc.1200903	1997	Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation.	BCL6
9110977	10.1126/science.276.5312.589	1997	Control of inflammation, cytokine expression, and germinal center formation by BCL-6.	BCL6
9171827	10.1038/ng0697-161	1997	The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation.	BCL6
9380707	10.1073/pnas.94.20.10762	1997	Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.	BCL6
8692924	10.1073/pnas.93.14.6947	1996	BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.	BCL6
8758205	10.1002/(SICI)1096-9896(199606)179:2&lt;145::AID-PATH565&gt;3.0.CO;2-1	1996	BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas.	BCL6
7639334	NA	1995	A specific monoclonal antibody (PG-B6) detects expression of the BCL-6 protein in germinal center B cells.	BCL6
7795234	NA	1995	BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts.	BCL6
7795255	NA	1995	BCL-6 protein is expressed in germinal-center B cells.	BCL6
8618933	10.1073/pnas.92.26.12520	1995	Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma.	BCL6
8057668	NA	1994	The organization of the BCL6 gene.	BCL6
8274736	NA	1994	Molecular cloning of the breakpoint for 3q27 translocation in B-cell lymphomas and leukemias.	BCL6
8274740	NA	1994	Gene involved in the 3q27 translocation associated with B-cell lymphoma, BCL5, encodes a Kr√ºppel-like zinc-finger protein.	BCL6
8220427	10.1038/ng0993-66	1993	LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas.	BCL6
8235596	10.1126/science.8235596	1993	Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma.	BCL6
8506375	10.1073/pnas.90.11.5262	1993	Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas.	BCL6
35038193	10.1111/his.14617	2022	Incidence, clinicopathological features and genetics of in-situ follicular neoplasia: a comprehensive screening study in a Japanese cohort.	BCL7A
33306126	10.1093/jmcb/mjaa065	2021	BCL7C suppresses ovarian cancer growth by inactivating mutant p53.	BCL7A
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	BCL7A
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	BCL7A
32576963	10.1038/s41375-020-0919-5	2020	Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL.	BCL7A
31558468	10.1182/blood.2019001880	2019	The whole-genome landscape of Burkitt lymphoma subtypes.	BCL7A
28465297	10.1158/1541-7786.MCR-16-0305	2017	Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type-Specific Differences.	BCL7A
25626372	10.1007/s12275-015-4672-9	2015	Genipin as a novel chemical activator of EBV lytic cycle.	BCL7A
22856870	10.3109/10428194.2012.717695	2013	Loss of BCL7A expression correlates with poor disease prognosis in patients with early-stage cutaneous T-cell lymphoma.	BCL7A
23043359	10.1111/bjh.12080	2013	BCL7A protein expression in normal and malignant lymphoid tissues.	BCL7A
19336552	10.1158/1055-9965.EPI-08-1037	2009	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.	BCL7A
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	BCL7A
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	BCL7A
18663754	10.1002/gcc.20601	2008	Array-based comparative genomic hybridization in early-stage mycosis fungoides: recurrent deletion of tumor suppressor genes BCL7A, SMAC/DIABLO, and RHOF.	BCL7A
17888167	10.1186/1471-2164-8-332	2007	Unravelling the hidden heterogeneities of diffuse large B-cell lymphoma based on coupled two-way clustering.	BCL7A
19455257	NA	2007	Germinal center B cell-like (GCB) and activated B cell-like (ABC) type of diffuse large B cell lymphoma (DLBCL): analysis of molecular predictors, signatures, cell cycle state and patient survival.	BCL7A
15897551	10.1200/JCO.2005.11.353	2005	Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.	BCL7A
9931421	10.1016/s0378-1119(98)00514-9	1998	The BCL7 gene family: deletion of BCL7B in Williams syndrome.	BCL7A
8605326	NA	1996	Molecular cloning of complex chromosomal translocation t(8;14;12)(q24.1;q32.3;q24.1) in a Burkitt lymphoma cell line defines a new gene (BCL7A) with homology to caldesmon.	BCL7A
33735152	10.1097/MPH.0000000000002140	2022	Therapeutic Leukapheresis in Pediatric Leukemia: Utilization Trend and Early Outcomes in a US Nationwide Cohort.	BCR
33769465	10.5858/arpa.2020-0454-OA	2022	One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia.	BCR
33780164	10.1002/cyto.b.22002	2022	Lymphoid blasts with aberrant myeloid marker expression and BCR/ABL1: Is it mixed phenotype acute leukemia or B lymphoblastic leukemia?	BCR
34193976	10.1038/s41375-021-01326-x	2022	Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.	BCR
34379028	10.1080/10428194.2021.1961234	2022	Early prediction of stable MR<sup>4.5</sup> by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib.	BCR
34462243	10.1016/j.clml.2021.07.001	2022	Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors.	BCR
34486918	10.1080/10428194.2021.1975191	2022	Chronic myeloid leukemia with pure erythroid leukemia blast crisis.	BCR
34493150	10.1080/10428194.2021.1971219	2022	Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.	BCR
34561201	10.1016/j.clml.2021.08.003	2022	SOHO State of the Art Updates & Next Questions: Intensive and Non-Intensive Approaches for Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.	BCR
34582325	10.1080/08880018.2021.1966558	2022	Quantitative analysis of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia: higher levels are associated with a poorer prognosis.	BCR
34587720	10.3324/haematol.2021.279125	2022	Ikaros deficiency is associated with aggressive BCR-ABL1 B-cell precursor acute lymphoblastic leukemia independent of the lineage and developmental origin.	BCR
34617186	10.1007/s12185-021-03231-6	2022	Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.	BCR
34617433	10.4274/tjh.galenos.2021.2021.0326	2022	Characterization of Immunophenotypic Aberrancies with Respect to Common Fusion Transcripts in B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 986 Indian Patients	BCR
34624079	10.1182/blood.2021012081	2022	SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.	BCR
34657128	10.1038/s41375-021-01448-2	2022	Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.	BCR
34662891	10.1182/bloodadvances.2021005245	2022	VpreB surrogate light chain expression in B-lineage ALL: a report from the Children's Oncology Group.	BCR
34676543	10.1111/bjh.17869	2022	Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in¬†situ hybridisation and Multiplex Ligation-dependent Probe Amplification.	BCR
34711926	10.1038/s41375-021-01455-3	2022	Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia.	BCR
34758608	10.3324/haematol.2021.279807	2022	Detection of <i>ABL1</i> kinase domain mutations in therapy-na√Øve <i>BCR-ABL1</i>-positive acute lymphoblastic leukemia.	BCR
34775888	10.1080/10428194.2021.2002320	2022	Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.	BCR
34783280	10.1080/10428194.2021.1999439	2022	PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of <i>BCR-ABL1</i>-like acute lymphoblastic leukaemia in Indian patients.	BCR
34788984	10.3324/haematol.2021.279177	2022	Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.	BCR
34795418	10.1038/s41375-021-01470-4	2022	Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models.	BCR
34816424	10.1111/bjh.17966	2022	Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant.	BCR
34818644	10.1159/000519782	2022	BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.	BCR
34854546	10.1002/pbc.29441	2022	Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study.	BCR
34866312	10.1002/pbc.29490	2022	Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy.	BCR
34872441	10.1080/10428194.2021.2010059	2022	<i>SOCS-2</i> gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment.	BCR
34874488	10.1007/s11596-021-2477-0	2022	Cytogenetic Characteristics of Childhood Acute Lymphoblastic Leukemia: A Study of 1541 Chinese Patients Newly Diagnosed between 2001 and 2014.	BCR
34882582	10.1172/JCI153283	2022	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.	BCR
34902205	10.1111/cas.15239	2022	RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.	BCR
34903489	10.1016/j.clml.2021.11.007	2022	State-of-the-Art Review on Myelofibrosis Therapies.	BCR
34930078	10.1080/10428194.2021.2015590	2022	Prediction for sustained deep molecular response for treatment-free remission.	BCR
34933827	10.1016/j.clml.2021.11.012	2022	The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program.	BCR
34952433	10.1016/j.ejmech.2021.114051	2022	Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK).	BCR
34987015	10.1016/j.clml.2021.12.007	2022	'FLT3-ITD Mutation Does Not Influence Survival Outcome in Adult Acute Promyelocytic Leukemia Patients Treated With ATO and ATRA-Based Therapeutic Regimen: Experience From a North Indian Tertiary Care Centre'.	BCR
34991679	10.1186/s13045-021-01221-z	2022	Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.	BCR
35011712	10.3390/cells11010150	2022	The Molecular Subtype of Adult Acute Lymphoblastic Leukemia Samples Determines the Engraftment Site and Proliferation Kinetics in Patient-Derived Xenograft Models.	BCR
35022343	10.2169/internalmedicine.8392-21	2022	Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose.	BCR
35027410	10.1158/1078-0432.CCR-21-3959	2022	Progress in Transplants for Acute Lymphoblastic Leukemia.	BCR
35051110	10.3390/vetsci9010026	2022	Feline and Canine Cutaneous Lymphocytosis: Reactive Process or Indolent Neoplastic Disease?	BCR
35061886	10.1182/bloodadvances.2021006076	2022	SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia.	BCR
35075985	10.1080/10428194.2021.2018582	2022	Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.	BCR
35077445	10.1371/journal.pone.0261469	2022	T and NK cell lymphoma cell lines do not rely on ZAP-70 for survival.	BCR
35082399	10.1038/s41417-021-00415-4	2022	CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma.	BCR
35084434	10.1001/jamaoncol.2021.6826	2022	Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia.	BCR
35119131	10.1002/ajh.26487	2022	Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping.	BCR
35121370	10.1016/j.ejca.2021.12.029	2022	Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.	BCR
35123463	10.1186/s12920-022-01169-0	2022	A case report of pediatric acute lymphoblastic leukemia with e8a2 BCR/ABL1 fusion transcript.	BCR
35126963	10.1177/20406207211072839	2022	MYD88<sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy.	BCR
35142153	10.3324/haematol.2021.280433	2022	Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and <i>BCR-ABL</i>-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin.	BCR
35158410	10.1111/ejh.13755	2022	Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review.	BCR
35165777	10.1007/s00277-022-04791-1	2022	A case report of BCR-ABL1 rearrangement in de novo adult T-cell lymphoblastic leukemia/lymphoma with normal karyotype.	BCR
35171727	10.1080/10428194.2022.2025797	2022	MUC4 expression by immunohistochemistry is a specific marker for <i>BCR-ABL1+</i> and <i>BCR-ABL1</i>-like B-lymphoblastic leukemia.	BCR
35181934	10.1111/vcp.13062	2022	A challenging case of lymphoproliferative disease in a cat.	BCR
35195876	10.1007/s40265-022-01680-9	2022	Olverembatinib: First Approval.	BCR
35205606	10.3390/cancers14040860	2022	Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.	BCR
35205731	10.3390/cancers14040983	2022	Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart.	BCR
35210562	10.1038/s41409-022-01618-5	2022	Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study.	BCR
35218741	10.1016/j.bcp.2022.114977	2022	Post-translational modification of MALT1 and its role in B cell- and T cell-related diseases.	BCR
35230873	10.1126/scisignal.abk3083	2022	Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells.	BCR
35255496	10.1182/bloodadvances.2021006147	2022	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.	BCR
35256549	10.5045/br.2021.2021198	2022	Dasatinib-induced reversible pulmonary arterial hypertension in a pediatric patient with BCR/ABL1+ lymphoblastic lymphoma from chronic myeloid leukemia.	BCR
35257981	10.1016/j.drup.2022.100822	2022	Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma.	BCR
35259456	10.1016/j.cellsig.2022.110301	2022	Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL).	BCR
35266562	10.1002/ajh.26523	2022	Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.	BCR
35267003	10.1182/blood.2021014726	2022	Pseudo-Ch√©diak-Higashi inclusions in BCR::ABL1-like B-lymphoblastic leukemia with IGH::EPOR rearrangement.	BCR
35275990	10.1182/blood.2021015341	2022	Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia.	BCR
35290157	10.1080/10428194.2022.2047673	2022	Significance of <i>RUNX1</i> mutation in <i>BCR-ABL1</i> positive acute myeloid leukemia - a diagnostic dilemma in a young woman with persistent bleeding.	BCR
35295854	10.3389/fcell.2022.838871	2022	Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells.	BCR
35296646	10.1038/s41419-022-04684-1	2022	Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.	BCR
35306137	10.1016/j.cellsig.2022.110311	2022	B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells.	BCR
35319509	10.1097/MPH.0000000000002271	2022	Pediatric Chronic Myelogenous Leukemia in T-lineage Blast Crisis: A Reminder in Relevance.	BCR
35337248	10.1080/10428194.2022.2056180	2022	Making the case for the case report - informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients.	BCR
35344115	10.1007/s11033-022-07337-w	2022	Identification and validation of suitable housekeeping genes for gene expression studies in BCR-ABL1 positive B-lineage acute lymphoblastic leukemia.	BCR
35349077	10.1007/s12185-022-03329-5	2022	Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group.	BCR
35350909	10.1177/10781552221090869	2022	Real-world management of targeted therapies in chronic lymphocytic leukemia.	BCR
35358441	10.1016/S2352-3026(22)00038-2	2022	Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.	BCR
35358442	10.1016/S2352-3026(22)00036-9	2022	In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.	BCR
35359041	10.3760/cma.j.cn112151-20211028-00781	2022	[Characteristics of fusion gene expression in acute lymphoblastic leukemia].	BCR
35361036	10.1080/10428194.2022.2045599	2022	Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia.	BCR
35389507	10.1111/bjh.18175	2022	Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1.	BCR
35398488	10.1016/j.cellsig.2022.110331	2022	SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies.	BCR
35398858	10.1097/MPH.0000000000002456	2022	Mutational Analysis of the VPREB1 Gene of Pre-BCR Complex in a Cohort of Sporadic Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia.	BCR
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	BCR
35416325	10.1002/hon.3004	2022	LncRNA FIRRE stimulates PTBP1-induced Smurf2 decay, stabilizes B-cell receptor, and promotes the development of diffuse large B-cell lymphoma.	BCR
35435617	10.1007/s11864-022-00953-5	2022	Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.	BCR
35440579	10.1038/s41467-022-29835-y	2022	A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways.	BCR
35450208	10.1177/20406207221090886	2022	Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.	BCR
35472072	10.1371/journal.ppat.1010453	2022	Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells.	BCR
35478711	10.2147/CMAR.S353022	2022	Primary Testicular and Cutaneous Philadelphia Chromosome Positive B-Cell Lymphoblastic Lymphoma: A Rare Case and Review.	BCR
35482146	10.1007/s11307-022-01733-1	2022	[<sup>18</sup>F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton's Tyrosine Kinase.	BCR
35484080	10.1016/j.clml.2022.03.007	2022	Clinico-hematological and Outcome Profile of Pediatric B-other-ALL and BCR::ABL1-like pre-B-ALL: An Integrated Genomic Study From North India.	BCR
35484682	10.3324/haematol.2021.280557	2022	Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement.	BCR
35486832	10.1182/blood.2021013990	2022	Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment.	BCR
35523687	10.1016/j.anpede.2021.02.016	2022	Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic Hematopoietic stem cell Transplantation in Philadelphia acute lymphoblastic leukemia.	BCR
35548364	10.3389/fphar.2022.834113	2022	Effectiveness and Safety of Anti-CD19 Chimeric Antigen Receptor-T Cell Immunotherapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.	BCR
35570070	10.1016/j.blre.2022.100969	2022	Neoantigens - the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders.	BCR
35574218	10.18632/oncotarget.28228	2022	Proteomic analysis reveals dual requirement for Grb2 and PLCŒ≥1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation.	BCR
35577905	10.1038/s41375-022-01596-z	2022	Changing causes of death in persons with haematological cancers 1975-2016.	BCR
35588855	10.1016/j.ab.2022.114736	2022	Various types of electrochemical biosensors for leukemia detection and therapeutic approaches.	BCR
35597428	10.1016/j.cellsig.2022.110358	2022	BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.	BCR
35597806	10.1038/s41375-022-01598-x	2022	Inability to phosphorylate Y88 of p27<sup>Kip1</sup> enforces reduced p27 protein levels and accelerates leukemia progression.	BCR
35611214	10.2147/IJN.S355408	2022	Transcriptomics-Based Investigation of Molecular Mechanisms Underlying Apoptosis Induced by ZnO Nanoparticles in Human Diffuse Large B-Cell Lymphoma.	BCR
35641210	10.1093/oncolo/oyab052	2022	Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy.	BCR
35644195	10.7499/j.issn.1008-8830.2111108	2022	[Clinical features and prognosis of childhood B-lineage acute lymphoblastic leukemia expressing the <i>PRAME</i> gene].	BCR
35650206	10.1038/s41467-022-30651-7	2022	Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis.	BCR
35650277	10.1038/s41416-022-01806-6	2022	Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.	BCR
35681213	10.1186/s13058-022-01536-w	2022	Multiple roles for Bcl-3 in mammary gland branching, stromal collagen invasion, involution and tumor pathology.	BCR
35745866	10.3390/pharmaceutics14061294	2022	Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia.	BCR
35774848	10.1155/2022/3276925	2022	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.	BCR
35785180	10.3389/fonc.2022.901797	2022	Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.	BCR
35802654	10.1371/journal.pone.0270710	2022	Development and application of a next-generation sequencing protocol and bioinformatics pipeline for the comprehensive analysis of the canine immunoglobulin repertoire.	BCR
35804999	10.3390/cancers14133229	2022	Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.	BCR
35842355	10.1016/j.clml.2022.05.002	2022	Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China.	BCR
35884363	10.3390/cancers14143300	2022	Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia.	BCR
35885931	10.3390/genes13071144	2022	Targeting a Novel G-Quadruplex in the <i>CARD11</i> Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group.	BCR
35906470	10.1038/s41598-022-17271-3	2022	Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.	BCR
35916333	10.1002/dc.25027	2022	HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.	BCR
35920412	10.1002/jbt.23185	2022	Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro.	BCR
35922951	10.11406/rinketsu.63.799	2022	[Treatment strategy for Philadelphia chromosome-positive acute lymphoblastic leukemia in children].	BCR
35941532	10.1186/s10020-022-00518-0	2022	Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma.	BCR
35953718	10.1038/s41591-022-01927-8	2022	Detection of early seeding of Richter transformation in chronic lymphocytic leukemia.	BCR
35983732	10.1080/10428194.2022.2098291	2022	Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.	BCR
36011285	10.3390/genes13081374	2022	Commonly Assessed Markers in Childhood BCP-ALL Diagnostic Panels and Their Association with Genetic Aberrations and Outcome Prediction.	BCR
36029036	10.1111/bjh.18418	2022	Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.	BCR
36035991	10.3389/fcell.2022.935023	2022	Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.	BCR
36051037	10.1002/jha2.475	2022	B-cell receptors of EBV-negative Burkitt lymphoma bind modified isoforms of autoantigens.	BCR
36057522	10.1016/j.clml.2022.07.014	2022	Treatment of Ph-Negative Acute Lymphoblastic Leukemia in Adolescents and Young Adults with an Affordable Outpatient Pediatric Regimen.	BCR
36068158	10.1016/j.clml.2022.07.017	2022	Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review.	BCR
32068648	10.1097/MPH.0000000000001743	2021	B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.	BCR
32193251	10.3324/haematol.2019.242701	2021	The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma.	BCR
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	BCR
32467145	10.3324/haematol.2020.247973	2021	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.	BCR
32581286	10.1038/s41409-020-0982-6	2021	Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells.	BCR
32654389	10.1111/ajt.16194	2021	Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib.	BCR
32675219	10.3324/haematol.2020.252767	2021	Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice.	BCR
32675228	10.3324/haematol.2019.241653	2021	Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma.	BCR
32785655	10.1182/blood.2019004713	2021	Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.	BCR
32799601	10.1080/10428194.2020.1808205	2021	Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up.	BCR
32859541	10.1016/j.pedneo.2020.07.016	2021	Cytogenetic aberration in mixed-phenotype acute leukemia in children: A single-center retrospective review.	BCR
32871588	10.1182/blood.2020005514	2021	Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.	BCR
32898857	10.1182/blood.2020005655	2021	Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.	BCR
32910713	10.1080/15548627.2020.1821546	2021	TFG is required for autophagy flux and to prevent endoplasmic reticulum stress in CH12 B lymphoma cells.	BCR
32915195	10.1093/carcin/bgaa095	2021	Targeting of BCR-ABL1 and IRE1Œ± induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia.	BCR
32919926	10.1016/j.clml.2020.08.006	2021	BCR-ABL1-Negative Chronic Myeloproliferative Neoplasms and Pulmonary Hypertension: A Prospective Long-Term Follow-up Study of the Impact of Pulmonary Hypertension on Survival.	BCR
32951102	10.1007/s12185-020-03006-5	2021	Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.	BCR
32954738	10.21037/apm-20-469	2021	Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report.	BCR
32981690	10.1016/j.bulcan.2020.07.008	2021	[ALL in adult patients: Contribution and limits of pediatric management].	BCR
33021423	10.1080/10428194.2020.1827242	2021	Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.	BCR
33024996	10.1182/blood.2020004996	2021	Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice.	BCR
33089525	10.1111/ejh.13538	2021	A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.	BCR
33094664	10.1080/15476286.2020.1838783	2021	LncRNAs in adaptive immunity: role in physiological and pathological conditions.	BCR
33106061	10.1080/10428194.2020.1837366	2021	Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of differentiated Ph<sup>+</sup> B cells but not bone marrow stem/progenitors.	BCR
33125593	10.1007/s00411-020-00879-2	2021	Parameter perturbations in a post-treatment chronic myeloid leukemia model capture the essence of pre-diagnosis A-bomb survivor mysteries.	BCR
33150806	10.1080/10428194.2020.1842397	2021	Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.	BCR
33153332	10.1080/10428194.2020.1839655	2021	Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views.	BCR
33153355	10.1080/10428194.2020.1838509	2021	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia.	BCR
33153366	10.1080/10428194.2020.1839649	2021	Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study.	BCR
33161794	10.1080/10408363.2020.1829537	2021	The genomic and biological complexity of mixed phenotype acute leukemia.	BCR
33168949	10.1038/s41375-020-01082-4	2021	Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets.	BCR
33204013	10.1038/s41375-020-01090-4	2021	A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study.	BCR
33225446	10.1002/path.5592	2021	Classification of intestinal T-cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status.	BCR
33230570	10.1007/s00277-020-04354-2	2021	Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients.	BCR
33238261	10.1159/000510112	2021	Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.	BCR
33251904	10.1080/10428194.2020.1849679	2021	The regulation of bcr-abl in hypoxia is through the mTOR pathway.	BCR
33272709	10.1016/j.bioorg.2020.104385	2021	Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.	BCR
33283555	10.1080/10428194.2020.1855340	2021	Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees.	BCR
33283580	10.1080/10428194.2020.1849672	2021	Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.	BCR
33284042	10.1080/10428194.2020.1856834	2021	Development of <i>BCR-ABL1</i>-positive …§Œ¥ T-cell leukemia after treatment for thymoma type B1.	BCR
33303420	10.1016/j.clml.2020.10.009	2021	Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study.	BCR
33303632	10.1074/jbc.RA120.015285	2021	A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation.	BCR
33356699	10.1080/10428194.2020.1861274	2021	Evaluation of two CE-IVD tests for <i>BCR-ABL1</i> transcript monitoring of chronic myeloid leukemia patients.	BCR
33357483	10.1016/S2352-3026(20)30353-7	2021	Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.	BCR
33357484	10.1016/S2352-3026(20)30362-8	2021	Are we ABL to do better for children with BCR-ABL1-like acute lymphocytic leukaemia?	BCR
33367563	10.1093/ajcp/aqaa244	2021	Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.	BCR
33373915	10.1016/j.biopha.2020.111166	2021	Yishen-tongbi decoction inhibits excessive activation of B cells by activating the FcŒ≥RIIb/Lyn/SHP-1 pathway and attenuates the inflammatory response in CIA rats.	BCR
33390067	10.1080/10428194.2020.1861275	2021	<i>In-vitro</i> modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene <i>RANBP2-ABL1</i> - implications for targeted therapy.	BCR
33403687	10.1111/bjh.17301	2021	Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.	BCR
33414171	10.1158/0008-5472.CAN-20-1504	2021	CDK2-Mediated Upregulation of TNFŒ± as a Mechanism of Selective Cytotoxicity in Acute Leukemia.	BCR
33416167	10.3892/or.2020.7888	2021	Involvement of Blnk and Foxo1 in tumor suppression in BCR‚ÄëABL1‚Äëtransformed pro‚ÄëB cells.	BCR
33419778	10.1158/1078-0432.CCR-20-3741	2021	Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.	BCR
33427570	10.1080/10428194.2020.1864352	2021	Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.	BCR
33428808	10.1111/cas.14808	2021	Trends in survival of leukemia among children, adolescents, and young adults: A population-based study in Osaka, Japan.	BCR
33432783	10.1111/ijlh.13456	2021	Expression of CD304/neuropilin-1 in adult b-cell lymphoblastic leukemia/lymphoma and its utility for the measurable residual disease assessment.	BCR
33435587	10.3390/ijms22020592	2021	Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.	BCR
33443592	10.1007/s00277-021-04412-3	2021	Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia.	BCR
33477957	10.3390/cancers13020354	2021	Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells.	BCR
33478278	10.1080/10428194.2021.1872074	2021	<i>BCR-ABL1</i> kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib.	BCR
33485429	10.1016/j.clml.2020.08.011	2021	Philadelphia-Like Acute Lymphoblastic Leukemia: A Systematic Review.	BCR
33506273	10.1007/s00520-021-06016-z	2021	Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.	BCR
33513604	10.1182/blood.2020008835	2021	LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome.	BCR
33531346	10.1073/pnas.2016553118	2021	PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis.	BCR
33538150	10.3324/haematol.2020.260935	2021	A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol.	BCR
33542970	10.1200/PO.20.00360	2021	Acquired CARD11 mutation promotes BCR independence in Diffuse Large B Cell Lymphoma.	BCR
33554816	10.19746/j.cnki.issn.1009-2137.2021.01.028	2021	[Characteristic of 8p11 Myeloproliferative Syndrome with Rare Phenotype].	BCR
33560402	10.1182/bloodadvances.2020003768	2021	Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.	BCR
33570628	10.1182/bloodadvances.2020001665	2021	Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2.	BCR
33570732	10.1007/s12185-021-03094-x	2021	Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.	BCR
33591648	10.1002/brb3.2061	2021	New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).	BCR
33597098	10.1016/j.clml.2020.12.025	2021	Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome.	BCR
33616915	10.1002/cncr.33347	2021	Ethnic and border differences on blood cancer presentation and outcomes: A Texas population-based study.	BCR
33632667	10.1016/j.clml.2021.01.020	2021	Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia.	BCR
33639170	10.1016/j.jbc.2021.100465	2021	TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.	BCR
33646306	10.1182/bloodadvances.2020001844	2021	Genome-wide interference of ZNF423 with B-lineage transcriptional circuitries in acute lymphoblastic leukemia.	BCR
33648418	10.1080/10428194.2021.1885656	2021	Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates.	BCR
33653205	10.1080/10428194.2021.1889536	2021	The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study.	BCR
33653209	10.1080/08880018.2020.1843577	2021	Intracerebral hemorrhage as a rare complication of imatinib in a Philadelphia chromosome positive acute lymphoblastic leukemia pediatric patient.	BCR
33672947	10.3390/biology10020152	2021	HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases.	BCR
33674940	10.1007/s00277-021-04483-2	2021	Very rare lineage switch from acute myeloid leukemia with BCR-ABL1 to B-lymphoblastic leukemia.	BCR
33684941	10.1182/blood.2020010438	2021	Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation.	BCR
33688166	10.2147/DDDT.S250823	2021	Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.	BCR
33722147	10.1080/10428194.2021.1901094	2021	Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience.	BCR
33725318	10.1007/s12185-021-03116-8	2021	Clinical features and chromosomal/genetic aberration in adult acute lymphoblastic leukemia in Japan: results of Fukuoka Blood & Marrow Transplant Group Studies ALL MRD 2002 and 2008.	BCR
33728464	10.1182/blood.2020009855	2021	Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma.	BCR
33750258	10.1080/0284186X.2021.1900908	2021	Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on <i>BCR-ABL1</i>-like subtype.	BCR
33752626	10.1186/s12885-021-08015-z	2021	Establishment of a typing model for diffuse large B-cell lymphoma based on B-cell receptor repertoire sequencing.	BCR
33757770	10.1016/j.clml.2021.01.017	2021	Clinical and Molecular Attributes of Patients With BCR/ABL1-negative Myeloproliferative Neoplasms in India: Real-world Data and Challenges.	BCR
33758275	10.1038/s41598-021-86021-8	2021	Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines.	BCR
33762010	10.1186/s13256-021-02771-z	2021	Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.	BCR
33762097	10.1016/j.beha.2021.101242	2021	Have any strategies in Ph-like ALL been shown to be effective?	BCR
33768841	10.1002/ccr3.3770	2021	High-grade B-cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib.	BCR
33774681	10.1007/s00277-021-04504-0	2021	The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study.	BCR
33781217	10.1186/s12885-020-07781-6	2021	Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach - a population-based study.	BCR
33781551	10.1016/j.bulcan.2021.02.004	2021	COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE).	BCR
33786735	10.1007/s10815-021-02169-2	2021	Disease-inducing potential of two leukemic cell lines in a xenografting model.	BCR
33788182	10.1007/s40265-021-01507-z	2021	Ocular Toxicity of Targeted Anticancer Agents.	BCR
33808300	10.3390/curroncol28020131	2021	Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario.	BCR
33814500	10.2169/internalmedicine.7066-21	2021	BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy.	BCR
33823073	10.1002/cncr.33539	2021	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.	BCR
33851691	10.1358/dot.2021.57.4.3264113	2021	Tirabrutinib hydrochloride for B-cell lymphomas.	BCR
33853871	10.1128/mSphere.00093-21	2021	B Cell Receptor-Responsive miR-141 Enhances Epstein-Barr Virus Lytic Cycle via FOXO3 Inhibition.	BCR
33860589	10.1111/petr.14024	2021	Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell Transplantation in a Child with Philadelphia Chromosome-like Relapsed/Refractory acute lymphoblastic leukemia.	BCR
33878293	10.1016/j.molcel.2021.03.043	2021	Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer.	BCR
33890726	10.1002/cjp2.211	2021	CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways.	BCR
33895809	10.1182/blood.2020010144	2021	Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.	BCR
33896586	10.1016/j.bulcan.2021.01.014	2021	[Richter Syndrome: Diagnostic and Therapeutic Management].	BCR
33906825	10.1016/j.clml.2021.03.007	2021	IKZF1 Deletion Subtyping and Outcome Analysis in BCR-ABL1-Negative Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Institution Experience from North India.	BCR
33907977	10.1007/s12185-021-03156-0	2021	Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.	BCR
33912159	10.3389/fimmu.2021.627602	2021	The <i>Traf2</i>DNx<i>BCL2-tg</i> Mouse Model of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recapitulates the Biased IGHV Gene Usage, Stereotypy, and Antigen-Specific HCDR3 Selection of Its Human Counterpart.	BCR
33921415	10.3390/cancers13081837	2021	Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenstr√∂m Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells.	BCR
33941506	10.1016/j.clml.2021.03.008	2021	Outcomes of Adolescent Patients with Acute Lymphoblastic Leukemia: Long-term Follow-up of 335 Patients.	BCR
33942128	10.1007/s00277-021-04507-x	2021	Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.	BCR
33944660	10.1080/10428194.2021.1894652	2021	Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.	BCR
33949040	10.1111/cas.14939	2021	RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.	BCR
33950935	10.1097/MD.0000000000025579	2021	The role of E255K/V-inclusive mutations in a Philadelphia-positive acute lymphoblastic leukemia with mutation evolution during sequential TKIs therapies: A case report.	BCR
33988307	10.1111/ijlh.13580	2021	Systematic application of fluorescence in situ hybridization and immunophenotype profile for the identification of ZNF384 gene rearrangements in B cell acute lymphoblastic leukemia.	BCR
33990705	10.1038/s41379-021-00817-7	2021	Myeloid/lymphoid neoplasms with FLT3 rearrangement.	BCR
33991360	10.1002/ajh.26238	2021	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.	BCR
33993837	10.1080/10428194.2021.1919657	2021	3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance.	BCR
33999145	10.1182/bloodadvances.2020003566	2021	Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.	BCR
34000704	10.1016/j.bioorg.2021.104968	2021	Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.	BCR
34014290	10.1182/blood.2021011420	2021	Basophilic myeloblasts: a clue for CML blast phase.	BCR
34027795	10.1080/10428194.2021.1929964	2021	The frequency, hematological characteristics, and end-of induction residual disease in B-acute lymphoblastic leukemia with BCR-ABL1-like chimeric gene fusions in a high-risk cohort from India.	BCR
34038034	10.1111/ped.14474	2021	Suspected chronic myeloid leukemia-like BCR-ABL1-positive acute lymphoblastic leukemia.	BCR
34048072	10.1002/ajh.26253	2021	Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.	BCR
34049715	10.1016/j.pathol.2021.02.013	2021	Expression of BCL6 in paediatric B-cell acute lymphoblastic leukaemia and association with prognosis.	BCR
34052176	10.1016/j.clml.2021.04.005	2021	Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience.	BCR
34062932	10.3390/genes12050687	2021	Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia.	BCR
34078586	10.1016/j.clml.2021.04.014	2021	Genetic Heterogeneity in Chronic Myeloid Leukemia: How Clonal Hematopoiesis and Clonal Evolution May Influence Prognosis, Treatment Outcome, and Risk of Cardiovascular Events.	BCR
34102636	10.1159/000516593	2021	Durable Molecular Remission in an Elderly Patient Affected by Relapsed Ph&apos;+ Acute Lymphoblastic Leukemia with T315I and Concomitant p190 and p210 Expression Achieved by Inotuzumab and Ponatinib.	BCR
34106613	10.1097/MD.0000000000025786	2021	Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: A case report.	BCR
34106877	10.18632/aging.203116	2021	Identification of a nomogram based on an 8-lncRNA signature as a novel diagnostic biomarker for childhood acute lymphoblastic leukemia.	BCR
34110462	10.1007/s00277-020-04357-z	2021	Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1<sup>T315I</sup> and BCR-ABL1<sup>T315I-E255K</sup>.	BCR
34115047	10.1097/MD.0000000000026323	2021	Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review.	BCR
34118580	10.1016/j.anndiagpath.2021.151767	2021	From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia.	BCR
34120550	10.1080/14656566.2021.1941864	2021	Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma.	BCR
34130278	10.1159/000516003	2021	Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement.	BCR
34157051	10.1371/journal.pone.0251719	2021	Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL).	BCR
34158358	10.1158/1078-0432.CCR-20-5039	2021	SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma.	BCR
34158825	10.3332/ecancer.2021.1221	2021	T lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association.	BCR
34159401	10.1007/s00277-021-04574-0	2021	Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.	BCR
34160140	10.1002/adbi.202100220	2021	Functional Phenotype Flow Cytometry: On Chip Sorting of Individual Cells According to Responses to Stimuli.	BCR
34162990	10.1038/s41598-021-92647-5	2021	A microfluidic device enabling drug resistance analysis of leukemia cells via coupled dielectrophoretic detection and impedimetric counting.	BCR
34172894	10.1038/s41375-021-01277-3	2021	Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.	BCR
34177947	10.3389/fimmu.2021.689472	2021	Resistance Mutations to BTK Inhibitors Originate From the NF-Œ∫B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.	BCR
34189859	10.1002/cam4.4087	2021	Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population-based study.	BCR
34190698	10.22034/iji.2021.84496.1661	2021	Distinguishing Isolated Lymphoid Extramedullary Blast Crisis and Secondary Non-Hodgkin Lymphoma in Chronic Myelogenous Leukemia: a Case Report and Review of the Literature.	BCR
34195068	10.3389/fonc.2021.608238	2021	Alteration of Cholesterol Metabolism by Metformin Is Associated With Improved Outcome in Type II Diabetic Patients With Diffuse Large B-Cell Lymphoma.	BCR
34203891	10.3390/ijms22126411	2021	Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like-Recent Progress in Treatment.	BCR
34210682	10.1158/1078-0432.CCR-21-0553	2021	Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.	BCR
34217275	10.1186/s12920-021-01023-9	2021	Hypodiploidy in a pediatric patient of T-cell acute lymphoblastic leukemia: a case report.	BCR
34248965	10.3389/fimmu.2021.681984	2021	A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.	BCR
34250504	10.1158/2643-3230.BCD-20-0229	2021	Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.	BCR
34251066	10.1002/jcla.23583	2021	Correlation analysis of long non-coding RNA TUG1 with disease risk, clinical characteristics, treatment response, and survival profiles of adult Ph<sup>-</sup> Acute lymphoblastic leukemia.	BCR
34254886	10.1080/10428194.2021.1950709	2021	COVID-19 in chronic myeloid leukemia patients in Latin America.	BCR
34263144	10.1097/HS9.0000000000000620	2021	The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells.	BCR
34264564	10.20892/j.issn.2095-3941.2020.0291	2021	SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation.	BCR
34266412	10.1186/s12885-021-08545-6	2021	DNA index as prognostic factor in childhood acute lymphoblastic leukemia in the COG-TARGET database.	BCR
34314938	10.1016/j.bmc.2021.116275	2021	Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.	BCR
34320160	10.1182/blood.2020006784	2021	Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.	BCR
34323286	10.1002/eji.202048968	2021	Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.	BCR
34324199	10.1002/eji.202149235	2021	Heterogeneity of germinal center B cells: New insights from single-cell studies.	BCR
34325057	10.1016/j.jmoldx.2021.07.008	2021	Comparison of Two Quantitative PCR-Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts.	BCR
34325192	10.1016/j.leukres.2021.106647	2021	The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.	BCR
34326740	10.1159/000516270	2021	P190 <sup><i>BCR-ABL1</i></sup> in a Patient with Philadelphia Chromosome Positive T-Cell Acute Lymphoblastic Leukemia: A Rare Case Report and Review of Literature.	BCR
34335584	10.3389/fimmu.2021.683597	2021	Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models.	BCR
34340673	10.1186/s12885-021-08635-5	2021	Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia.	BCR
34348305	10.1159/000518280	2021	Cytogenetic and Fluorescence in situ Hybridization Profile of Pediatric Acute Lymphoblastic Leukemia in a University Hospital in South India.	BCR
34371436	10.1016/j.leukres.2021.106683	2021	Proposal and clinical application of molecular genetic risk scoring system, MRplus, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.	BCR
34371731	10.3390/pharmaceutics13071040	2021	mRNA-Based Anti-TCR CDR3 Tumour Vaccine for T-Cell Lymphoma.	BCR
34399819	10.1186/s40170-021-00263-8	2021	Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies.	BCR
34400115	10.1016/j.clml.2021.06.026	2021	Long-Term Outcome of Philadelphia Chromosome Positive Leukemia From Eastern Indian Subcontinent: An Experience in the Era of Tyrosine Kinase Inhibitor (TKI) Therapy.	BCR
34402088	10.1002/hon.2913	2021	Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.	BCR
34403880	10.1016/j.neo.2021.07.009	2021	Oncogene-independent resistance in Philadelphia chromosome - positive (Ph<sup>+</sup>) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway.	BCR
34404682	10.1158/1055-9965.EPI-21-0423	2021	Characterizing Trends in Cancer Patients' Survival Using the JPSurv Software.	BCR
34405773	10.1080/10428194.2021.1966787	2021	Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.	BCR
34406363	10.1084/jem.20202280	2021	Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice.	BCR
34406581	10.1007/s12185-021-03186-8	2021	Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph‚Äâ+‚ÄâALL.	BCR
34417955	10.1007/s11899-021-00648-y	2021	Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses.	BCR
34477034	10.1080/10428194.2021.1955878	2021	The diagnostic profile of rare acute myelomegakaryoblastic leukemia.	BCR
34477813	10.1182/bloodadvances.2021004430	2021	IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial.	BCR
34492682	10.1182/bloodadvances.2021004813	2021	Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.	BCR
34497196	10.11406/rinketsu.62.1094	2021	[B cell acute lymphoblastic leukemia therapy: an up to date overview].	BCR
34504101	10.1038/s41467-021-25622-3	2021	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth.	BCR
34511174	10.7499/j.issn.1008-8830.2105004	2021	Clinical features and prognosis of children with acute leukemias of ambiguous lineage under different diagnostic criteria.	BCR
34542753	10.1007/s10517-021-05268-3	2021	Changes in Bone Marrow Stromal Progenitor Cells in Patients with Hematoblastosis at the Onset of the Disease.	BCR
34551378	10.1016/j.cancergen.2021.09.001	2021	A rare case of atypical chronic myeloid leukemia associated with t(8;22)(p11.2;q11.2)/ BCR-FGFR1 rearrangement: A case report and literature review.	BCR
34573335	10.3390/genes12091355	2021	Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia.	BCR
34591424	10.32471/exp-oncology.2312-8852.vol-43-no-3.16548	2021	Evaluation of serum levels of selected cytokine receptors in adult B-cell precursor acute lymphoblastic leukemia and their association with prognostic factors and survival.	BCR
34625105	10.1186/s13256-021-03060-5	2021	Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: a case report.	BCR
34625709	10.1038/s41388-021-02025-8	2021	Calcium-dependent signalling in B-cell lymphomas.	BCR
34626353	10.1007/978-3-030-78311-2_2	2021	Genetics and Diagnostic Approach to Lymphoblastic Leukemia/Lymphoma.	BCR
34653294	10.1111/cas.15164	2021	C/EBPŒ≤ induces B-cell acute lymphoblastic leukemia and cooperates with BLNK mutations.	BCR
34655194	10.7754/Clin.Lab.2021.210122	2021	IL-10 as an Indicator for Predicting Clinical Progression in Acute Lymphoblastic Leukemia Patients.	BCR
34681663	10.3390/ijms222011004	2021	Proteomic Landscape of Extracellular Vesicles for Diffuse Large B-Cell Lymphoma Subtyping.	BCR
34711820	10.1038/s41467-021-26407-4	2021	Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy.	BCR
34722279	10.3389/fonc.2021.733848	2021	Protein Kinase CK1Œ± Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma.	BCR
34733777	10.3389/fonc.2021.701604	2021	Co-Occurrence of Myeloid and Lymphoid Neoplasms: Clinical Characterization and Impact on Outcome. A Single-Center Cohort Study.	BCR
34737376	10.1038/s41598-021-00950-y	2021	Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.	BCR
34763718	10.1186/s13046-021-02159-3	2021	ASB2 is a direct target of FLI1 that sustains NF-Œ∫B pathway activation in germinal center-derived diffuse large B-cell lymphoma.	BCR
34778802	10.1158/2643-3230.BCD-21-0063	2021	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.	BCR
34805008	10.4322/acr.2021.339	2021	Myeloid sarcoma: an uncommon presentation of myeloid neoplasms; a case series of 4 rare cases reported in a tertiary care institute.	BCR
34824268	10.1038/s41467-021-27232-5	2021	Single-cell analysis identifies dynamic gene expression networks that govern B cell development and transformation.	BCR
34830980	10.3390/cancers13225827	2021	Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions.	BCR
34865703	10.1016/j.beha.2021.101331	2021	Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?	BCR
34884478	10.3390/ijms222312673	2021	BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.	BCR
34940123	10.3390/cimb43030149	2021	Molecular Genetics of Pre-B Acute Lymphoblastic Leukemia Sister Cell Lines during Disease Progression.	BCR
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	BCR
34993136	10.3389/fonc.2021.771669	2021	The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia.	BCR
35015676	10.1158/2643-3230.BCD-21-0131	2021	Epigenetic Rewiring of BCR Signaling as a Novel Mechanism of Ibrutinib Resistance in ABC-DLBCL.	BCR
35028611	10.1016/j.xcrm.2021.100470	2021	Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system.	BCR
35158373	10.1182/hematology.2021000224	2021	MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	BCR
35186368	10.46234/ccdcw2021.269	2021	The Incidence of Lymphoma in Beijing: Comparing Results from MIS-CASS (2019) and Beijing Cancer Registry (2017).	BCR
35528192	10.1158/2767-9764.crc-21-0022	2021	The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways.	BCR
31980503	10.1101/mcs.a004838	2020	Functional characterization of two rare BCR-FGFR1<sup>+</sup> leukemias.	BCR
32047189	10.1038/s41598-020-59101-4	2020	Role of Vitamins A and D in BCR-ABL Arf<sup>-/-</sup> Acute Lymphoblastic Leukemia.	BCR
32052899	10.1002/jcla.23241	2020	T-cell blast crisis of chronic myelogenous leukemia presented with coexisting p210 and p190 BCR-ABL transcripts and t(10;11)(q11;p15).	BCR
32058318	10.1016/j.cancergen.2020.01.051	2020	Enrichment of atypical hyperdiploidy and IKZF1 deletions detected by SNP-microarray in high-risk Australian AIEOP-BFM B-cell acute lymphoblastic leukaemia cohort.	BCR
32077355	10.1080/10428194.2020.1728751	2020	Longitudinal clonal architecture of acute myeloid leukemia with <i>NPM1</i> driver insertion, early <i>TET2</i> mutations and secondary e6a2 <i>BCR-ABL1</i> rearrangement.	BCR
32078009	10.1007/s00277-020-03953-3	2020	Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.	BCR
32083012	10.3389/fonc.2020.00067	2020	B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making.	BCR
32090646	10.1080/10428194.2020.1713317	2020	Diffuse large B-cell lymphoma with low <sup>18</sup>F-fluorodeoxyglucose avidity features silent B-cell receptor signaling.	BCR
32107574	10.1007/s00277-020-03949-z	2020	T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.	BCR
32111748	10.21873/invivo.11802	2020	Targeting BCL-2 as a Therapeutic Strategy for Primary <i><sup>p210</sup>BCR-ABL1</i>-positive B-ALL Cells.	BCR
32122205	10.1080/10428194.2020.1734593	2020	Evidence of <i>BCR-ABL1</i>-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML).	BCR
32122281	10.1080/16078454.2020.1735670	2020	WT1 overexpression predicted good outcomes in adult B-cell acute lymphoblastic leukemia patients receiving chemotherapy.	BCR
32127472	10.1073/pnas.1921187117	2020	Regulation of B cell receptor-dependent NF-Œ∫B signaling by the tumor suppressor KLHL14.	BCR
32146103	10.1016/j.clml.2019.12.019	2020	Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI.	BCR
32146105	10.1016/j.clml.2019.09.606	2020	Halving Time of BCR-ABL1 in Chronic Myeloid Leukemia: Is It Better Than Day-90 Value-A Multicenter Study From South India.	BCR
32147612	10.11406/rinketsu.61.128	2020	[Mediastinal abscess due to Aspergillus in a patient with atypical chronic myeloid leukemia, BCR-ABL1-negative].	BCR
32150610	10.1182/bloodadvances.2019001008	2020	The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia.	BCR
32154668	10.1002/cam4.2946	2020	Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.	BCR
32154977	10.1111/vco.12588	2020	Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog.	BCR
32161170	10.1128/JVI.02123-19	2020	Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.	BCR
32163558	10.1182/blood.2019004674	2020	Sugar-coated BCR kept during FL clonal evolution.	BCR
32168755	10.3390/cancers12030650	2020	Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment.	BCR
32179412	10.1016/j.bcmd.2020.102420	2020	Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms.	BCR
32191635	10.1172/JCI134424	2020	Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL.	BCR
32192770	10.1016/j.bbrc.2020.03.006	2020	A regulatory SH2 domain-targeting protein binder effectively inhibits the activity of Bruton's tyrosine kinase and its drug-resistant variants.	BCR
32192976	10.1016/j.clml.2020.02.004	2020	Analysis of the Mortality of Russian Patients With Chronic Myeloid Leukemia in the Multicenter EUTOS ELN Population-based Study (EUTOS-PBS).	BCR
32194860	10.7150/thno.41362	2020	PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.	BCR
32199764	10.1016/j.clml.2020.01.008	2020	The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.	BCR
32201514	10.7150/jca.39083	2020	A novel classification based on B-cell receptor signal gene expression correlates with prognosis in primary breast diffuse large B-cell lymphoma.	BCR
32209331	10.1016/j.clml.2020.01.009	2020	Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center.	BCR
32210016	10.3390/ijms21062206	2020	VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects.	BCR
32219444	10.1182/blood.2019001417	2020	Integrin Œ±6 mediates the drug resistance of acute lymphoblastic B-cell leukemia.	BCR
32235787	10.3390/ijms21062193	2020	The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia.	BCR
32237084	10.1111/bjh.16627	2020	Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia.	BCR
32238402	10.1101/mcs.a004937	2020	The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and <i>ZBTB20-JAK2</i> gene fusion presenting as B-lymphoblastic leukemia.	BCR
32272636	10.3390/cancers12040894	2020	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.	BCR
32291235	10.1016/j.clml.2020.02.013	2020	Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review.	BCR
32311856	10.3343/alm.2020.40.5.417	2020	A Case of Preleukemic Chronic Myeloid Leukemia Following Chemotherapy and Autologous Transplantation for T-lymphoblastic Lymphoma.	BCR
32319365	10.19746/j.cnki.issn.1009-2137.2020.02.003	2020	[Epidemidogical Analysis of 982 Hospitalized Cases of Childhood Acute Lymphoblastic Leukemia].	BCR
32319419	10.19746/j.cnki.issn.1009-2137.2020.02.057	2020	[Research Progress on Pathogenic Genes of Ph-like Acute Lymphoblastic Leukemia--Review].	BCR
32330662	10.1016/j.anndiagpath.2020.151514	2020	From the archives of MD Anderson Cancer Center: BCR-ABL1-like B acute lymphoblastic leukemia with IGH/EPOR fusion.	BCR
32332702	10.1038/s41408-020-0308-3	2020	A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.	BCR
32341085	10.26508/lsa.202000700	2020	Immunoglobulin expression in the endoplasmic reticulum shapes the metabolic fitness of B lymphocytes.	BCR
32342278	10.1007/s13577-020-00367-1	2020	MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy.	BCR
32352166	10.1111/bjh.16718	2020	Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.	BCR
32362606	10.4103/jcrt.JCRT_137_17	2020	Interleukin 6 and disease transformation in chronic myeloid leukemia: A Northeast Indian population study.	BCR
32368831	10.1002/gcc.22858	2020	Impact of immunophenotypic characteristics on genetic subgrouping in childhood acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) study L04-16.	BCR
32370190	10.3390/cancers12051143	2020	Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells.	BCR
32376649	10.4049/jimmunol.2000172	2020	Rapid Death of Follicular B Cells and Burkitt Lymphoma Cells Effectuated by Xbp1s.	BCR
32378810	10.1002/cam4.3099	2020	High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.	BCR
32384445	10.1097/MD.0000000000019962	2020	Occurrence of lymphoplasmacytic lymphoma in a chronic myeloid leukemia patient following long-term treatment with tyrosine kinase inhibitors: A case report.	BCR
32404891	10.1038/s41408-020-0323-4	2020	Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century.	BCR
32424289	10.1038/s41467-020-16375-6	2020	Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma.	BCR
32445026	10.1007/s11899-020-00591-4	2020	Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia.	BCR
32452280	10.1080/10428194.2020.1768380	2020	Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes.	BCR
32453841	10.1182/bloodadvances.2020001466	2020	Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features.	BCR
32455989	10.3390/cancers12051328	2020	Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas.	BCR
32457305	10.1038/s41408-020-0329-y	2020	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.	BCR
32481267	10.1097/MD.0000000000020009	2020	Observation of the molecular genetics among children with acute lymphoblastic leukemia: A retrospective study based on the SEER database.	BCR
32481736	10.3390/cancers12061396	2020	Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies.	BCR
32503572	10.1186/s13045-020-00905-2	2020	Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.	BCR
32505444	10.1016/j.jiac.2020.05.001	2020	Clinical usefulness of very high serum soluble interleukin-2 receptor levels for the detection of tuberculous peritonitis in a patient with chronic myelogenous leukemia.	BCR
32508181	10.1080/10428194.2020.1762876	2020	Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL study.	BCR
32508223	10.1080/10428194.2020.1772476	2020	Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 <i>BCR-ABL1</i> transcripts in chronic myeloid leukemia.	BCR
32510610	10.1002/hon.2761	2020	On point in primary CNS lymphoma.	BCR
32552902	10.1186/s13045-020-00912-3	2020	Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.	BCR
32558932	10.1002/lipd.12254	2020	Low-Density Lipoproteins, High-Density Lipoproteins (HDL), and HDL-Associated Proteins Differentially Modulate Chronic Myelogenous Leukemia Cell Viability.	BCR
32565969	10.3892/ol.2020.11583	2020	Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments.	BCR
32571113	10.1080/10428194.2020.1775203	2020	Chronic myelogenous leukemia presenting as central retinal vein occlusion.	BCR
32581241	10.1038/s41467-020-16927-w	2020	Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.	BCR
32585766	10.1002/1878-0261.12753	2020	Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.	BCR
32594584	10.1111/petr.13728	2020	The impact of donor full-length KIR2DS4 in the development of acute and chronic GVHD after unrelated allogeneic HSCT.	BCR
32611574	10.3324/haematol.2020.252916	2020	ABL-class fusion positive acute lymphoblastic leukemia: can targeting ABL cure ALL?	BCR
32620617	10.21873/anticanres.14367	2020	Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma.	BCR
32653779	10.1016/j.canep.2020.101772	2020	Cancer incidence and treatment utilization patterns at a regional cancer center in Tanzania from 2008-2016: Initial report of 2,772 cases.	BCR
32654575	10.1080/10428194.2020.1791856	2020	Platelet function in patients with chronic myeloid leukemia treated with asciminib.	BCR
32659728	10.1016/j.advms.2020.06.002	2020	Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.	BCR
32662346	10.1080/10428194.2020.1783444	2020	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.	BCR
32672489	10.1080/10428194.2020.1786556	2020	No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group.	BCR
32681657	10.1111/cyt.12890	2020	Dasatinib-related effusion lymphoma in a patient treated for chronic myeloid leukaemia.	BCR
32691208	10.1007/s11060-020-03580-y	2020	Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.	BCR
32694049	10.1016/j.clml.2020.05.003	2020	De Novo CD5<sup>+</sup> Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances.	BCR
32696696	10.1080/10428194.2020.1797008	2020	Clonal evolution with acquisition of <i>BCR-ABL1</i> in refractory acute myeloid leukemia post therapy with FLT3-inhibitor.	BCR
32700989	10.1080/10428194.2020.1795160	2020	Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia.	BCR
32702393	10.1016/j.exphem.2020.07.005	2020	DEPTOR is a microRNA-155 target regulating migration and cytokine production in diffuse large B-cell lymphoma cells.	BCR
32768385	10.1016/j.clml.2020.07.004	2020	Surrogate Markers for Treatment-Free Remission in Patients With Chronic Myeloid Leukemia.	BCR
32784334	10.1097/CM9.0000000000000999	2020	TOSO interacts with SYK and enhances BCR pathway activation in chronic lymphocytic leukemia.	BCR
32803312	10.1007/s00277-020-04212-1	2020	The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.	BCR
32810963	10.3760/cma.j.issn.0253-2727.2020.07.006	2020	[Prognostic analysis of allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in complete remission in the era of tyrosine kinase inhibitors].	BCR
32812094	10.1007/s10561-020-09855-y	2020	Screening for pre-leukemia TEL-AML1 chromosomal translocation in banked cord blood units: cord blood bank perspective.	BCR
32812190	10.1007/s12185-020-02965-z	2020	JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).	BCR
32826247	NA	2020	Identification of Two Novel Truncated Transcripts of Janus Kinase 2 Gene.	BCR
32829325	10.1159/000509639	2020	Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.	BCR
32852239	10.1080/10428194.2020.1811272	2020	Prognostic value of MRD monitoring based on <i>BCR-ABL1</i> copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia.	BCR
32853380	10.1182/blood.2020006326	2020	Extramedullary early T-cell precursor acute lymphoblastic lymphoma presenting as blast crisis of CML.	BCR
32856506	10.1080/10428194.2020.1811269	2020	Let-7b regulates the adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells.	BCR
32862848	10.1016/S2152-2650(20)30477-8	2020	Update on CML-Like Disorders.	BCR
32862868	10.1016/S2152-2650(20)30460-2	2020	Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL: An Intensive Approach Is Still Standard of Care.	BCR
32902203	10.1002/cnr2.1290	2020	Recurrent genetic abnormalities detected by FISH in adult B ALL and association with hematological parameters.	BCR
32911643	10.3390/ijms21186556	2020	Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis.	BCR
32913188	10.1038/s41419-020-02949-1	2020	A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1<sup>-</sup> pre-B-ALL.	BCR
32924711	10.1080/10428194.2020.1817444	2020	Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected?	BCR
32946981	10.1016/j.exphem.2020.09.184	2020	Human pediatric B-cell acute lymphoblastic leukemias can be classified as B-1 or B-2-like based on a minimal transcriptional signature.	BCR
32955830	10.23736/S0026-4806.20.07031-7	2020	New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.	BCR
32955949	10.1080/14728214.2020.1822816	2020	Emerging drugs for the treatment of Waldenstr√∂m macroglobulinemia.	BCR
32974613	10.1158/0008-5472.BCD-19-0039	2020	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on <i>MIR300</i> Antiproliferative and PP2A-Activating Functions.	BCR
32983140	10.3389/fimmu.2020.01995	2020	Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia.	BCR
33004416	10.1101/gad.340216.120	2020	EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.	BCR
33004801	10.1038/s41419-020-03035-2	2020	BAFF-driven NLRP3 inflammasome activation in B cells.	BCR
33005100	10.1186/s12935-020-01518-y	2020	Ibrutinib in B-cell lymphoma: single fighter might be enough?	BCR
33016157	10.1080/14737140.2020.1832890	2020	Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse.	BCR
33020271	10.1073/pnas.2007946117	2020	Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A.	BCR
33050534	10.3390/cancers12102913	2020	Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice.	BCR
33054045	10.3324/haematol.2018.207019	2020	BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy.	BCR
33067949	10.19746/j.cnki.issn.1009-2137.2020.05.017	2020	[Analysis of Clinical Characteristics in De novo Chronic Myelogenous Leukemia Patients with Extramedullary T-Lymphoblastic Blast Crisis].	BCR
33091668	10.1016/j.bioorg.2020.104377	2020	HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.	BCR
33093447	10.1038/s41467-020-18998-1	2020	Targeting N-myristoylation for therapy of B-cell lymphomas.	BCR
33093947	10.12688/f1000research.22318.1	2020	ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.	BCR
33113607	10.3760/cma.j.issn.0253-2727.2020.09.008	2020	[Diagnosis of adult Philadelphia chromosome-like acute lymphoblastic leukemia by fluorescence in situ hybridization].	BCR
33122918	10.2147/OTT.S275334	2020	Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL.	BCR
33126303	10.1097/MD.0000000000022490	2020	A case report of lineage switch from T-cell acute leukemia to B-cell acute leukemia.	BCR
33126344	10.1097/MD.0000000000022904	2020	Clinical features and prognosis of duplex primary malignant neoplasms involving chronic myeloid leukemia.	BCR
33126415	10.3390/ijms21218006	2020	Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.	BCR
33134182	10.3389/fonc.2020.592205	2020	Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?	BCR
33149299	10.1038/s41586-020-2884-6	2020	IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B¬†cells.	BCR
33154951	10.3389/fonc.2020.591577	2020	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	BCR
33157925	10.1097/MD.0000000000022791	2020	Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: A case report.	BCR
33157999	10.1097/MD.0000000000023154	2020	AML, ALL, and CML classification and diagnosis based on bone marrow cell morphology combined with convolutional neural network: A STARD compliant diagnosis research.	BCR
33162520	10.11406/rinketsu.61.1227	2020	[Treatments for Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era].	BCR
33164984	10.1172/JCI140797	2020	Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo.	BCR
33194070	NA	2020	Evaluation of the clinicopathologic features of diffuse large B cell lymphoma after CD19-targeted CAR T-cell therapy emphasizing the potential diagnostic pitfalls.	BCR
33194762	10.3389/fonc.2020.595832	2020	ZAP-70 Shapes the Immune Microenvironment in B Cell Malignancies.	BCR
33206758	10.6061/clinics/2020/e2011	2020	Prognostic significance of a normal karyotype in adult patients with BCR-ABL1-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era.	BCR
33207194	10.1016/j.celrep.2020.108403	2020	Cyclin D3 Governs Clonal Expansion of Dark Zone Germinal Center B Cells.	BCR
33214594	10.1038/s41598-020-75860-6	2020	Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia.	BCR
33226961	10.18632/aging.104136	2020	Single cell sequencing reveals cell populations that predict primary resistance to imatinib in chronic myeloid leukemia.	BCR
33230098	10.1038/s41408-020-00388-x	2020	Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.	BCR
33242441	10.1016/S2352-3026(20)30369-0	2020	Targeted therapy or transplantation for paediatric ABL-class Ph-like acute lymphocytic leukaemia?	BCR
33256901	10.1053/j.seminhematol.2020.09.001	2020	New approaches to the treatment of older adults with acute lymphoblastic leukemia.	BCR
33277547	10.1038/s41598-020-78024-8	2020	Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia.	BCR
33282736	10.3389/fonc.2020.580364	2020	Integration of the B-Cell Receptor Antigen Neurabin-I/SAMD14 Into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma.	BCR
33283707	10.19746/j.cnki.issn.1009-2137.2020.06.008	2020	[Effect of the Risk Factors for Treatment-Related Death in Children with Acute Lymphoblastic Leukemia].	BCR
33283718	10.19746/j.cnki.issn.1009-2137.2020.06.019	2020	[Clinical Efficacy of ALL-2005 and ALL-2009 Regimen and Factors Influencing Prognosis of Newly Diagnosed ALL Patients Aged between 10-18 Years Old].	BCR
33322625	10.3390/cancers12123738	2020	Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients.	BCR
33323828	10.1097/CM9.0000000000001294	2020	R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms.	BCR
33324393	10.3389/fimmu.2020.560244	2020	Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies.	BCR
33338050	10.1371/journal.pone.0243657	2020	Role of BCR-ABL1 isoforms on the prognosis of Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A meta-analysis.	BCR
33343851	10.1155/2020/6648574	2020	IoMT-Based Automated Detection and Classification of Leukemia Using Deep Learning.	BCR
33356083	10.26444/aaem/115393	2020	Use of microarrays and MLPA for integrating diagnostics and personalizing treatment - Case report of a patient with Ph-like acute B-cell lymphoblastic leukemia.	BCR
33363034	10.3389/fonc.2020.604685	2020	Role of Specific B-Cell Receptor Antigens in Lymphomagenesis.	BCR
33419251	10.3390/ijms21249724	2020	Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation.	BCR
33445849	10.3760/cma.j.issn.0253-2727.2020.12.008	2020	[Dasatinib-related pulmonary adverse events in patients with chronic myeloid leukemia].	BCR
33552960	10.3389/fonc.2020.584149	2020	Case Report: A Case With Philadelphia Chromosome Positive T-Cell Lymphoblastic Lymphoma and a Review of Literature.	BCR
34661138	10.1158/2643-3249.BCD-20-0078	2020	<i>MEF2D</i> Fusions Drive Oncogenic Pre-BCR Signaling in B-ALL.	BCR
34661142	10.1158/2643-3230.BCD-19-0080	2020	Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia.	BCR
32568493	NA	2019	[Coexistence of mycosis fungoides and essential thrombocythemia with JAK2V617F].	BCR
28540759	10.1080/10428194.2017.1320711	2018	Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.	BCR
26607903	10.1016/j.canlet.2015.11.020	2016	Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells.	BCR
25769542	10.3324/haematol.2014.117424	2015	Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.	BCR
24856998	NA	2014	[Clinical characteristics of childhood leukemia with EVI1 gene and BCR/ABL gene co-expression].	BCR
23171834	10.1159/000341289	2013	A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation.	BCR
23289360	10.3109/10428194.2012.762649	2013	The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.	BCR
23974192	10.1182/blood-2012-10-462358	2013	Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.	BCR
22231445	10.1038/onc.2011.604	2012	STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.	BCR
22233112	10.3109/10428194.2012.656104	2012	BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.	BCR
22384256	10.1371/journal.pone.0032451	2012	Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.	BCR
22591684	10.1016/j.leukres.2012.03.020	2012	Src, Akt, NF-Œ∫B, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia.	BCR
22593461	NA	2012	T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports.	BCR
21504383	10.3109/10428194.2011.559670	2011	Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?	BCR
21960589	10.1182/blood-2011-07-366542	2011	Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia.	BCR
20038234	10.3109/10428190903503446	2010	Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.	BCR
20141430	10.3109/10428190903586326	2010	Co-expression of HoxA9 and bcr-abl genes in chronic myeloid leukemia.	BCR
19557636	10.1080/10428190902930496	2009	New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.	BCR
19608682	10.3324/haematol.2009.010900	2009	An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia.	BCR
18538733	10.1016/j.ccr.2008.04.018	2008	Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression.	BCR
18617057	10.1016/j.cancergencyto.2008.04.003	2008	Analysis of gene rearrangements using a fluorescence in situ hybridization method in Mexican patients with acute lymphoblastic leukemia: experience at a single institution.	BCR
18704194	10.1172/JCI33337	2008	Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.	BCR
18784740	10.1038/leu.2008.242	2008	Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.	BCR
18809762	10.1182/blood-2008-04-148791	2008	BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.	BCR
17638851	10.1182/blood-2007-01-068122	2007	Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells.	BCR
17762503	10.1097/MPH.0b013e3180f61bcf	2007	Frequency of BCR-ABL fusion oncogene in Pakistani childhood acute lymphoid leukemia (ALL) patients reflects ethnic differences in molecular genetics of ALL.	BCR
17768128	10.3324/haematol.11341	2007	Identification of a novel e8/a4 BCR/ABL fusion transcript in a case of a transformed S√©zary syndrome.	BCR
16966279	10.1080/10428190600709572	2006	Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.	BCR
15716990	10.1038/sj.leu.2403629	2005	Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia.	BCR
16116902	NA	2005	[Acute lymphoblastic leukemias with aberrations of BCR-ABL genes].	BCR
14993251	10.1084/jem.20031637	2004	The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells.	BCR
14534537	10.1038/sj.onc.1206747	2003	Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.	BCR
12408765	NA	2002	Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.	BCR
11069024	10.1038/sj.leu.2401923	2000	Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins.	BCR
10194128	10.3109/10428199909093732	1999	CRKL binding to BCR-ABL and BCR-ABL transformation.	BCR
2193202	NA	1990	A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia.	BCR
2407300	NA	1990	Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript.	BCR
32961552	10.1182/blood.2020007507	2021	Mutational landscape of gray zone lymphoma.	BIRC6
33809641	10.3390/cancers13061340	2021	Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms.	BIRC6
30931701	10.1080/15384101.2019.1601477	2019	circ-BIRC6, a circular RNA, promotes hepatocellular carcinoma progression by targeting the miR-3918/Bcl2 axis.	BIRC6
27614248	10.1016/j.jtho.2016.08.145	2017	Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events¬†in ALK Fusion Patterns in NSCLC that Responds¬†to Crizotinib Treatment.	BIRC6
27343444	10.1016/j.jtho.2016.06.001	2016	Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH¬†and IHC in Lung Adenocarcinoma.	BIRC6
26001147	10.1097/JTO.0000000000000467	2015	BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.	BIRC6
23678170	10.1128/JVI.03159-12	2013	Epstein-Barr virus-encoded microRNA BART15-3p promotes cell apoptosis partially by targeting BRUCE.	BIRC6
21902653	10.2174/156652411797536723	2011	Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies.	BIRC6
19759907	10.1371/journal.pone.0007089	2009	High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma.	BIRC6
33416167	10.3892/or.2020.7888	2021	Involvement of Blnk and Foxo1 in tumor suppression in BCR‚ÄëABL1‚Äëtransformed pro‚ÄëB cells.	BLNK
33570628	10.1182/bloodadvances.2020001665	2021	Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2.	BLNK
34653294	10.1111/cas.15164	2021	C/EBPŒ≤ induces B-cell acute lymphoblastic leukemia and cooperates with BLNK mutations.	BLNK
31882553	10.21873/cgp.20169	2020	BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach.	BLNK
32420699	10.1002/cam4.3136	2020	Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.	BLNK
32585766	10.1002/1878-0261.12753	2020	Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.	BLNK
33020271	10.1073/pnas.2007946117	2020	Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A.	BLNK
29931583	10.1007/s10637-018-0623-8	2019	Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.	BLNK
30872780	10.1038/s41375-019-0442-8	2019	Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.	BLNK
30890517	10.12122/j.issn.1673-4254.2019.02.20	2019	[Structure and function of B-cell linker and its role in the development of B cell-related diseases].	BLNK
30402490	10.1155/2018/6728128	2018	Gene Expression Profile Signature of Aggressive Waldenstr√∂m Macroglobulinemia with Chromosome 6q Deletion.	BLNK
26354285	10.1002/hon.2251	2017	Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma.	BLNK
28369050	10.1038/ni.3716	2017	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.	BLNK
28791394	10.3892/mmr.2017.7158	2017	Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis.	BLNK
28972016	10.1182/blood-2017-06-743252	2017	Philadelphia chromosome-like acute lymphoblastic leukemia.	BLNK
26522721	10.1038/onc.2015.385	2016	ZFP521 contributes to pre-B-cell lymphomagenesis through modulation of the pre-B-cell receptor signaling pathway.	BLNK
26703467	10.1074/jbc.M115.637835	2016	B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.	BLNK
27016671	10.1016/j.molimm.2016.03.007	2016	PAX5 promotes pre-B cell proliferation by regulating the expression of pre-B cell receptor and its downstream signaling.	BLNK
28476192	10.1016/j.arcmed.2016.12.005	2016	Gene Expression Profiling of Acute Lymphoblastic Leukemia in Children with¬†Very Early Relapse.	BLNK
25080849	10.1111/ejh.12427	2015	B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.	BLNK
25391967	10.1007/s11060-014-1655-3	2015	Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.	BLNK
24240734	10.1007/s00401-013-1202-x	2014	Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.	BLNK
24169826	10.1182/blood-2012-12-473090	2013	The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.	BLNK
22262777	10.1182/blood-2011-04-351965	2012	CIN85 is required for Cbl-mediated regulation of antigen receptor signaling in human B cells.	BLNK
22880054	10.1371/journal.pone.0042610	2012	Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas.	BLNK
22956576	10.4049/jimmunol.1201267	2012	Regulation of B cell linker protein transcription by PU.1 and Spi-B in murine B cell acute lymphoblastic leukemia.	BLNK
23066158	10.4049/jimmunol.1201440	2012	Highly restricted usage of Ig H chain VH14 family gene segments in Slp65-deficient pre-B cell leukemia in mice.	BLNK
19758698	10.1016/j.leukres.2009.08.030	2010	Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma.	BLNK
20876806	10.1158/0008-5472.CAN-10-1438	2010	Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia.	BLNK
19047679	10.1182/blood-2008-07-166355	2009	BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3.	BLNK
19150402	10.1016/j.cellsig.2008.12.006	2009	SAP binds to CD22 and regulates B cell inhibitory signaling and calcium flux.	BLNK
19850008	10.1016/j.bbrc.2009.10.070	2009	Phosphatidylinositol-3-kinase-dependent phosphorylation of SLP-76 by the lymphoma-associated ITK-SYK fusion-protein.	BLNK
19855081	10.1182/blood-2009-02-204362	2009	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.	BLNK
18006696	10.1182/blood-2007-07-100115	2008	SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.	BLNK
18172310	10.1158/0008-5472.CAN-07-2778	2008	PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.	BLNK
18426802	10.1074/jbc.M708459200	2008	Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling.	BLNK
18566961	10.1002/path.2384	2008	The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype.	BLNK
17717600	10.1172/JCI30842	2007	B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.	BLNK
16568084	10.1038/sj.onc.1209510	2006	The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells.	BLNK
16636677	10.1038/sj.onc.1209520	2006	SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells.	BLNK
16888096	10.1182/blood-2006-03-013821	2006	Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.	BLNK
15744341	10.1038/sj.leu.2403702	2005	Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma.	BLNK
12881301	10.1182/blood-2003-05-1487	2004	Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease.	BLNK
14984504	10.1111/j.1365-2141.2004.04802.x	2004	Intracellular signalling molecules as immunohistochemical markers of normal and neoplastic human leucocytes in routine biopsy samples.	BLNK
15029213	10.1038/sj.leu.2403349	2004	Expression of the adaptor protein BLNK/SLP-65 in childhood acute lymphoblastic leukemia.	BLNK
15231650	10.1158/0008-5472.CAN-03-3885	2004	High-throughput retroviral tagging for identification of genes involved in initiation and progression of mouse splenic marginal zone lymphomas.	BLNK
12436112	10.1038/ni862	2003	The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion.	BLNK
12761551	10.1038/nature01608	2003	Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia.	BLNK
11489945	10.1084/jem.194.3.255	2001	Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module.	BLNK
10498607	NA	1999	Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling.	BLNK
9341187	10.1074/jbc.272.43.27362	1997	Identification of two tyrosine phosphoproteins, pp70 and pp68, which interact with phospholipase Cgamma, Grb2, and Vav after B cell antigen receptor activation.	BLNK
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	BRAF
33722842	10.1136/jclinpath-2020-207205	2022	Clinicopathological characteristic of ciliated muconodular papillary tumour of the lung.	BRAF
33952592	10.1136/jclinpath-2021-207597	2022	Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.	BRAF
34015890	10.4143/crt.2021.218	2022	Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations.	BRAF
34309914	10.1111/jcpt.13489	2022	Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis.	BRAF
34687488	10.1002/gcc.23005	2022	Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.	BRAF
34704312	10.1111/cas.15176	2022	Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.	BRAF
34710243	10.1002/ajh.26390	2022	Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.	BRAF
34802044	10.1038/s41379-021-00954-z	2022	A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform.	BRAF
34843129	10.1111/his.14603	2022	ALK rearrangements in infantile fibrosarcoma-like spindle cell tumours of soft tissue and kidney.	BRAF
34952945	10.1038/s41379-021-01002-6	2022	Genomic landscape of Epstein-Barr virus-positive extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue.	BRAF
35012520	10.1186/s12890-021-01803-0	2022	Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study.	BRAF
35064935	10.1111/his.14619	2022	Parallel evolution of two distinct lymphoid proliferations in clonal haematopoiesis.	BRAF
35076701	10.1001/jamanetworkopen.2021.44923	2022	Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.	BRAF
35092381	10.31557/APJCP.2022.23.1.131	2022	Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.	BRAF
35147461	10.1177/00369330221078995	2022	Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.	BRAF
35189530	10.1016/j.ctarc.2022.100522	2022	Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.	BRAF
35205796	10.3390/cancers14041050	2022	Immunophenotypic Analysis of Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia-like (HCL-like) Disorders.	BRAF
35234079	10.1177/10668969221081432	2022	Hairy Cell Leukemia-Japanese Variant: Report of a Patient and Literature Review.	BRAF
35322197	10.1038/s41388-022-02266-1	2022	Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.	BRAF
35353542	10.1126/scitranslmed.abc7480	2022	Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.	BRAF
35356636	10.14740/jh942	2022	Concurrent Presentation of Hairy Cell Leukemia and Mantle Cell Lymphoma (Leukemic Non-Nodal Variant): An Extremely Rare Composite Lymphoma.	BRAF
35359040	10.3760/cma.j.cn112151-20211220-00915	2022	[Clinicopathological features and BRAF V600E and MYD88 L265P mutation status of nodal marginal zone lymphoma].	BRAF
35363510	10.1200/JCO.21.02840	2022	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.	BRAF
35373885	10.1002/pbc.29575	2022	Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas.	BRAF
35437610	10.1007/s00277-022-04795-x	2022	Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.	BRAF
35450208	10.1177/20406207221090886	2022	Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.	BRAF
35454811	10.3390/cancers14081904	2022	Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.	BRAF
35543076	10.1111/his.14680	2022	Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy.	BRAF
35582532	10.20517/cdr.2021.85	2022	Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study.	BRAF
35663079	10.12998/wjcc.v10.i14.4541	2022	Bronchiolar adenoma with unusual presentation: Two case reports.	BRAF
35669427	10.3389/fonc.2022.873111	2022	Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Na√Øve Metastatic Lung Adenocarcinoma.	BRAF
35739536	10.1186/s12920-022-01291-z	2022	A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.	BRAF
35748237	10.2217/pme-2021-0059	2022	Targeting molecular alterations in non-small-cell lung cancer: what's next?	BRAF
35774685	10.7759/cureus.25405	2022	A Rare Case of Metachronous Quadruple Primary Malignancies in a Single Patient: A Case Report and Comprehensive Literature Review.	BRAF
35789115	10.1111/his.14718	2022	Hodgkinoid histiocytosis: an atypical nodal CD30 and S100-positive histiocytosis with eosinophilia.	BRAF
35806042	10.3390/ijms23137037	2022	State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan.	BRAF
35870258	10.1016/j.lungcan.2022.07.011	2022	Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.	BRAF
35900506	10.4103/ijpm.ijpm_621_21	2022	Novel ALK-EML4 fusion with prominent mucous and hyaline stroma: Expanding the molecular genetic spectrum of S100 and CD34 positive spindle cell tumor.	BRAF
35900560	10.4103/jcrt.JCRT_559_20	2022	Primary pulmonary epithelial-myoepithelial carcinoma: Report of a rare and under-diagnosed low-grade malignancy.	BRAF
35980949	10.1371/journal.pone.0273207	2022	Various impacts of driver mutations on the PD-L1 expression of NSCLC.	BRAF
35984185	10.1097/MD.0000000000030094	2022	Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report.	BRAF
35988454	10.1016/j.esmoop.2022.100560	2022	Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries.	BRAF
36051021	10.1002/jha2.486	2022	Lymphoma-associated acquired von Willebrand syndrome responsive to splenectomy: A case report.	BRAF
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	BRAF
32638211	10.1007/s12020-020-02411-4	2021	Diagnostic and prognostic value of a 7-panel mutation testing in thyroid nodules with indeterminate cytology: the SWEETMAC study.	BRAF
32815748	10.1080/0284186X.2020.1806358	2021	Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990-2014.	BRAF
32915318	10.1007/s00262-020-02714-5	2021	Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer.	BRAF
32929178	10.1038/s41379-020-00673-x	2021	The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy.	BRAF
32943371	10.1016/j.clml.2020.08.007	2021	Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis.	BRAF
32954834	10.1080/17425247.2021.1825377	2021	Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I.	BRAF
32969291	10.1080/10428194.2020.1824070	2021	The triptych of mixed histiocytosis: a systematic review of 105 cases and proposed clinical classification.	BRAF
32970929	10.1111/ajco.13449	2021	Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance.	BRAF
33068418	10.1093/neuonc/noaa233	2021	Population-based estimates of survival among elderly patients with brain metastases.	BRAF
33237469	10.1007/s00428-020-02971-w	2021	ALK alterations in salivary gland carcinomas.	BRAF
33360690	10.1016/j.jss.2020.11.012	2021	Thyroid Cancer Identified After Positron Emission Tomography (PET) Shows Aggressive Histopathology.	BRAF
33387037	10.1007/s00432-020-03491-5	2021	Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer.	BRAF
33506327	10.1007/s00428-021-03032-6	2021	Undifferentiated large cell/rhabdoid carcinoma presenting in the intestines of patients with concurrent or recent non-small cell lung cancer (NSCLC): clinicopathologic and molecular analysis of 14 cases indicates an unusual pattern of dedifferentiated metastases.	BRAF
33552685	10.1080/2162402X.2020.1865653	2021	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ‚â•50%: real-world data.	BRAF
33591844	10.1200/JCO.20.03570	2021	Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.	BRAF
33637515	10.1136/bcr-2021-241815	2021	Rare case of <i>BRAF V600E</i> mutant anaplastic pleomorphic xanthroastrocytoma in a 5-year survivor of acute lymphoblastic leukaemia.	BRAF
33650659	10.3892/or.2020.7911	2021	Potentially life‚Äëthreatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).	BRAF
33663128	10.1097/MD.0000000000024917	2021	BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report.	BRAF
33671873	10.3390/cancers13040804	2021	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.	BRAF
33676171	10.1016/j.anndiagpath.2021.151720	2021	From the archives of MD Anderson Cancer Center: A case of concurrent follicular lymphoma and Langerhans cell sarcoma with a review of the literature.	BRAF
33685720	10.1016/j.pathol.2021.01.002	2021	New developments in non-Hodgkin lymphoid malignancies.	BRAF
33706747	10.1186/s12887-021-02590-7	2021	Giant congenital nodular melanoma in a newborn: a case report and literature review.	BRAF
33722699	10.1016/j.critrevonc.2021.103299	2021	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.	BRAF
33728131	10.7759/cureus.13112	2021	Pancoast-Tobias Syndrome: A Unique Presentation of Lung Cancer.	BRAF
33735913	10.1182/blood.2020010137	2021	A rapid genotyping panel for detection of primary central nervous system lymphoma.	BRAF
33777766	10.3389/fonc.2021.620435	2021	Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma.	BRAF
33807876	10.3390/ijms22052625	2021	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.	BRAF
33811006	10.1016/j.clml.2021.02.005	2021	Inhibitor of BRAF<sup>V600E</sup> Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications.	BRAF
33833885	10.1155/2021/6680635	2021	A Dose-Response Relationship to Radiotherapy for Cutaneous Lesions of Langerhans Cell Histiocytosis.	BRAF
33872472	10.1002/cncy.22434	2021	Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer.	BRAF
33889528	10.21037/tlcr-20-1113	2021	A narrative review of MET inhibitors in non-small cell lung cancer with <i>MET</i> exon 14 skipping mutations.	BRAF
33895683	10.1016/j.ejca.2021.03.026	2021	Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases.	BRAF
33898318	10.3389/fonc.2021.647598	2021	Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.	BRAF
33939500	10.1177/10668969211013402	2021	A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor.	BRAF
33979489	10.1056/NEJMoa2031298	2021	Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.	BRAF
34009369	10.1210/clinem/dgab304	2021	Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.	BRAF
34058070	10.1002/1878-0261.13033	2021	NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.	BRAF
34187757	10.1016/j.cllc.2021.05.006	2021	Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists.	BRAF
34198843	10.3390/ijms22116099	2021	Molecular Characterization of a Rare Case of Bilateral Vitreoretinal T Cell Lymphoma through Vitreous Liquid Biopsy.	BRAF
34275772	10.1016/j.clml.2021.06.007	2021	Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies.	BRAF
34298439	10.1016/j.prp.2021.153551	2021	Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis.	BRAF
34337566	10.1016/j.xcrm.2021.100350	2021	ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.	BRAF
34343999	10.1159/000514821	2021	Multigene Combined Detection by RT-qPCR Using Cytological Specimens.	BRAF
34353680	10.1016/j.lungcan.2021.06.002	2021	The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.	BRAF
34392186	10.1016/j.ejca.2021.06.043	2021	Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.	BRAF
34466010	10.2147/CCID.S323865	2021	Reactive Langerhans Cell Proliferation Mimicking Langerhans Cell Histiocytosis in Association with S√©zary Syndrome: A Case Report and Literature Review.	BRAF
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	BRAF
34593218	10.1016/j.bulcan.2021.06.009	2021	[Molecular genotyping in refractory thyroid cancers in 2021: When, how and why? A review from the TUTHYREF network].	BRAF
34804000	10.3389/fimmu.2021.686057	2021	Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.	BRAF
35116717	10.21037/tcr-21-1037	2021	Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects.	BRAF
36045702	10.37349/etat.2021.00056	2021	A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?	BRAF
31439678	10.3324/haematol.2019.230375	2020	Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.	BRAF
31598903	10.1007/s12094-019-02218-4	2020	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.	BRAF
31715289	10.1016/j.pharmthera.2019.107438	2020	Drug resistance to targeted therapeutic strategies in non-small cell lung cancer.	BRAF
31747139	10.1002/cam4.2670	2020	A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.	BRAF
31839532	10.1016/j.cllc.2019.11.006	2020	Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.	BRAF
31917616	10.1080/17476348.2020.1714441	2020	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.	BRAF
31924734	10.1158/1078-0432.CCR-19-3443	2020	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131).	BRAF
31989260	10.1007/s00428-020-02756-1	2020	Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.	BRAF
31993771	10.1007/s00428-020-02752-5	2020	ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology.	BRAF
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	BRAF
32037654	10.1002/pbc.28200	2020	Secondary histiocytic sarcoma with BRAF<sup>V600E</sup> mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib.	BRAF
32040482	10.1371/journal.pone.0227586	2020	Expression of the muscle-associated gene MYF6 in hairy cell leukemia.	BRAF
32045431	10.1371/journal.pone.0228188	2020	Precision medicine and actionable alterations in lung cancer: A single institution experience.	BRAF
32047535	10.1177/1758835919895756	2020	Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.	BRAF
32052529	10.1111/pin.12909	2020	Clinicopathological analysis of splenic red pulp low-grade B-cell lymphoma.	BRAF
32066856	10.1038/s41598-020-59744-3	2020	Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.	BRAF
32069373	10.1111/jcpt.13121	2020	Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer-An update.	BRAF
32132106	10.1136/esmoopen-2019-000626	2020	Genomic-guided precision therapy for soft tissue sarcoma.	BRAF
32143579	10.1186/s12885-020-6681-2	2020	An unusual hematopoietic stem cell transplantation for donor acute lymphoblastic leukemia: a case report.	BRAF
32186929	10.1080/14737140.2020.1744439	2020	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.	BRAF
32222087	10.1002/gcc.22844	2020	Novel PPP1CB-ALK fusion in spindle cell tumor defined by S100 and CD34 coexpression and distinctive stromal and perivascular hyalinization.	BRAF
32269611	10.3892/ol.2020.11460	2020	Emerging non-invasive detection methodologies for lung cancer.	BRAF
32283823	10.3390/ijms21072623	2020	Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with <i>ALK</i> Rearrangement.	BRAF
32315234	10.1200/GO.20.00030	2020	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.	BRAF
32319330	10.1080/10428194.2020.1753045	2020	Detection of an IGH-<i>BRAF</i> fusion in a patient with BRAF Val600Glu negative hairy cell leukemia.	BRAF
32325863	10.3390/ijms21082847	2020	Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition.	BRAF
32327174	10.1016/j.thorsurg.2020.01.004	2020	Molecular Targets Beyond the Big 3.	BRAF
32334988	10.1016/j.idc.2020.02.005	2020	Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors.	BRAF
32336065	10.3779/j.issn.1009-3419.2020.101.25	2020	[Analysis of Clinical Characteristics and Driver Genes in 405 Patients with Lung Cancer Complicated with Tuberculosis].	BRAF
32365229	10.1002/cncr.32876	2020	Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.	BRAF
32384767	10.3390/molecules25092174	2020	Multi-Targeting Bioactive Compounds Extracted from Essential Oils as Kinase Inhibitors.	BRAF
32402358	10.1016/j.ccm.2020.02.003	2020	Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy.	BRAF
32427409	10.1002/gcc.22861	2020	Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.	BRAF
32429639	10.3779/j.issn.1009-3419.2020.101.04	2020	[Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI].	BRAF
32450593	10.1055/s-0039-3399564	2020	Molecular Diagnostics in Non-Small Cell Lung Carcinoma.	BRAF
32450595	10.1055/s-0039-1700994	2020	Targeted Therapy for Non-Small Cell Lung Cancer.	BRAF
32458259	10.1007/s11033-020-05509-0	2020	BRAF V600E mutation detection in hairy cell leukemia-utility of archival DNA from bone marrow aspirate/imprint smear and amplification refractory mutation system.	BRAF
32521388	10.1016/j.lungcan.2020.05.018	2020	BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.	BRAF
32608295	10.1080/10428194.2020.1783447	2020	Low-dose vemurafenib monotherapy in <i>BRAF<sup>V600E</sup></i> -mutated Erdheim-Chester disease.	BRAF
32627042	10.3892/or.2020.7612	2020	Proline‚Äërich polypeptide‚Äë1 decreases cancer stem cell population by targeting BAFF chromatin‚Äëremodeling complexes in human chondrosarcoma JJ012 cells.	BRAF
32650968	10.1016/j.patol.2019.11.004	2020	[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].	BRAF
32657049	10.1002/mgg3.1398	2020	Genetic profile of non-small cell lung cancer (NSCLC): A hospital-based survey in Jinhua.	BRAF
32677947	10.1186/s12931-020-01437-6	2020	The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC.	BRAF
32747568	10.1073/pnas.2005052117	2020	Activating <i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.	BRAF
32756609	10.1371/journal.pone.0236580	2020	Molecular profiling of non-small cell lung cancer.	BRAF
32764384	10.3390/cancers12082182	2020	Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma.	BRAF
32804454	10.1097/PAS.0000000000001512	2020	Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature.	BRAF
32821125	10.2147/OTT.S258365	2020	<i>SET-CAN</i> Fusion Gene in Acute Leukemia and Myeloid Neoplasms: Report of Three Cases and a Literature Review.	BRAF
32892557	10.3760/cma.j.cn112151-20200601-00430	2020	[Clinicopathological characteristics of indeterminate dendritic cell tumor of four cases].	BRAF
32907612	10.1186/s12943-020-01254-x	2020	Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.	BRAF
32980422	10.1016/j.humpath.2020.09.004	2020	Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.	BRAF
32988155	10.3760/cma.j.cn112152-20200323-00248	2020	[Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].	BRAF
32991441	10.1097/MD.0000000000022322	2020	First case of bronchiolar adenoma lined purely by mucinous luminal cells with molecular analysis: A case report.	BRAF
33043062	10.36469/jheor.2020.17088	2020	Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.	BRAF
33053222	10.1111/bjh.17055	2020	Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V).	BRAF
33053439	10.1016/j.critrevonc.2020.103119	2020	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.	BRAF
33053749	10.3390/cancers12102936	2020	The In Vitro and In Vivo Anticancer Properties of Chalcone Flavokawain B through Induction of ROS-Mediated Apoptotic and Autophagic Cell Death in Human Melanoma Cells.	BRAF
33079606	10.1200/GO.20.00265	2020	Patterns of Biomarker Use in Cancer Treatment Among Medical Oncologists in the Philippines.	BRAF
33101670	10.1016/j.amsu.2020.10.024	2020	Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report.	BRAF
33162442	10.11406/rinketsu.61.1469	2020	[Marginal zone lymphoma-like primary bone marrow lymphoma with long-term pancytopenia preceding diagnosis].	BRAF
33269152	10.7759/cureus.11224	2020	Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation.	BRAF
33297339	10.3390/nu12123755	2020	Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.	BRAF
33327482	10.3390/cancers12123758	2020	Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer.	BRAF
33330555	10.3389/fmed.2020.594118	2020	Sarcoidosis and Cancer: A Complex Relationship.	BRAF
34589930	10.1016/j.jtocrr.2020.100023	2020	Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors¬†in¬†Patients With NSCLC: A Brief Report.	BRAF
35117356	10.21037/tcr-20-1675	2020	Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study.	BRAF
30003317	10.1007/s00277-018-3425-3	2019	Langerhans cell histiocytosis associated with classical Hodgkin lymphoma contains BRAF V600E mutation.	BRAF
30048416	10.1097/LBR.0000000000000534	2019	Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.	BRAF
30121320	10.1016/j.pharmthera.2018.08.007	2019	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities.	BRAF
30279110	10.1016/j.cllc.2018.08.020	2019	Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.	BRAF
30301660	10.1016/j.jgo.2018.09.008	2019	Treatment of older patients with advanced non-small cell lung cancer: A challenge.	BRAF
30320628	10.1097/PAS.0000000000001174	2019	An Immune Suppression-associated EBV-positive Anaplastic Large Cell Lymphoma With a BRAF V600E Mutation.	BRAF
30322325	10.1080/10428194.2018.1519809	2019	Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia.	BRAF
30526458	10.2174/1568009619666181210114559	2019	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.	BRAF
30548240	10.1002/cncr.31871	2019	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.	BRAF
30586141	10.1001/jamadermatol.2018.3662	2019	Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma.	BRAF
30611946	10.1016/j.wneu.2018.12.128	2019	The Radiological Imaging Features of Easily Misdiagnosed Epithelioid Glioblastoma in Seven Patients.	BRAF
30623224	10.1007/s00347-018-0840-8	2019	[New molecular pathological strategies for malignant iris tumors].	BRAF
30636374	10.1111/resp.13463	2019	Somatic mutations and immune checkpoint biomarkers.	BRAF
30642913	10.1158/1078-0432.CCR-18-3904	2019	Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.	BRAF
30653166	10.1097/MD.0000000000014180	2019	Simultaneous Hodgkin lymphoma and BRAFV600E-positive papillary thyroid carcinoma: A case report.	BRAF
30677225	10.1002/smll.201805285	2019	Developing a New qPCR-Based System for Screening Mutation.	BRAF
30734348	10.1111/cup.13440	2019	A rare pitfall in the molecular interpretation of BRAF V600E status in melanoma in the setting of BRAF V600E-mutated chronic lymphocytic leukemia/small lymphocytic lymphoma.	BRAF
30771009	10.1007/s11864-019-0618-5	2019	Current Treatment Options for Breast Cancer Brain Metastases.	BRAF
30775031	10.21037/jtd.2019.01.46	2019	Update on emerging biomarkers in lung cancer.	BRAF
30800314	10.1177/2050313X19830483	2019	Genetic and immunohistochemical analyses of ciliated muconodular papillary tumors of the lung: A report of five cases.	BRAF
30857967	10.1016/j.humpath.2019.03.002	2019	Fusion of ALK to the melanophilin gene MLPH in pediatric Spitz nevi.	BRAF
30865033	10.1097/MCP.0000000000000572	2019	Treatment of oncogene-driven non-small cell lung cancer.	BRAF
30869573	10.1089/thy.2018.0511	2019	Combination Treatment with the BRAF<sup>V600E</sup> Inhibitor Vemurafenib and the BH3 Mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma.	BRAF
30885850	10.1016/j.athoracsur.2019.02.010	2019	Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer.	BRAF
30886831	10.3389/fonc.2019.00099	2019	Targeting Molecular Pathways in Intracranial Metastatic Disease.	BRAF
30902917	10.1634/theoncologist.2018-0572	2019	Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.	BRAF
30914465	10.1634/theoncologist.2018-0112	2019	Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review.	BRAF
30917298	10.1177/0022034519837248	2019	Mutational Signatures in Mandibular Ameloblastoma Correlate with Smoking.	BRAF
30937513	10.1007/s00292-019-0586-3	2019	[Bronchoalveolar lavage in hairy cell leukemia with pulmonary infiltration].	BRAF
30946933	10.1016/j.humpath.2019.03.004	2019	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement.	BRAF
30975211	10.1186/s13046-019-1094-2	2019	Clinical development of targeted and immune based anti-cancer therapies.	BRAF
30982079	10.1007/s00018-019-03097-2	2019	Computational algorithms for in silico profiling of activating mutations in cancer.	BRAF
31016879	10.1002/cam4.2183	2019	Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.	BRAF
31036508	10.1016/j.clml.2019.03.017	2019	Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.	BRAF
31068044	10.1080/10428194.2019.1608536	2019	Hairy cell leukemia: present and future directions.	BRAF
31077558	10.1002/cyto.b.21785	2019	Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.	BRAF
31151782	10.1016/j.cllc.2019.04.009	2019	Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients.	BRAF
31172191	10.1093/ajcp/aqz056	2019	Histiocytic Sarcoma Following B-Lymphoblastic Leukemia/Lymphoma.	BRAF
31187521	10.1002/hon.2594	2019	New treatment options in hairy cell leukemia with focus on BRAF inhibitors.	BRAF
31202602	10.1016/j.rmr.2019.04.003	2019	[Management of non-small cell lung cancer patients harboring activating mutations and CNS progression].	BRAF
31229894	10.1016/j.isci.2019.06.001	2019	Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma.	BRAF
31242043	10.1200/CCI.19.00002	2019	Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer.	BRAF
31257073	10.1016/j.ccell.2019.05.015	2019	RAC1<sup>P29S</sup> Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.	BRAF
31280902	10.1016/j.cvsm.2019.05.002	2019	Novel Noninvasive Diagnostics.	BRAF
31281144	10.11406/rinketsu.60.559	2019	[Hairy cell leukemia complicated by bone marrow necrosis following cladribine administration].	BRAF
31297240	10.1136/esmoopen-2019-000498	2019	Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.	BRAF
31317311	10.1007/s00428-019-02608-7	2019	Clonal evolution of chronic lymphocytic leukemia to Langerhans cell histiocytosis: a case report.	BRAF
31354304	10.2147/OTT.S202061	2019	<i>BRAF</i> V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia.	BRAF
31412611	10.3390/ijms20163939	2019	Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (<i>ALK</i>) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects.	BRAF
31439588	10.1158/1078-0432.CCR-19-1176	2019	Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <i>ALK</i>-Rearranged Non-Small-Cell Lung Cancer.	BRAF
31443309	10.3390/medicina55080490	2019	Malignant Pleural Effusion and Its Current Management: A Review.	BRAF
31443496	10.3390/cancers11091229	2019	Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation.	BRAF
31447330	10.1016/j.lpm.2019.07.026	2019	[Hairy cell leukemia].	BRAF
31538423	10.3349/ymj.2019.60.10.890	2019	Hairiness is a Facsimile of Reorganized Cytoskeletons: A Cytopathic Effect of <i>Coxiella burnetii</i>.	BRAF
31551170	10.1016/j.clml.2019.08.010	2019	EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms.	BRAF
31591741	10.1002/ajh.25653	2019	Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.	BRAF
31711449	10.1186/s12890-019-0964-x	2019	EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.	BRAF
31737634	10.3389/fmed.2019.00233	2019	Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine.	BRAF
31768065	10.1038/s41591-019-0653-6	2019	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.	BRAF
31819518	10.2147/OTT.S230309	2019	Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer.	BRAF
32010591	10.21037/tlcr.2019.12.24	2019	The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.	BRAF
28280984	10.1007/s00595-017-1497-7	2018	Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.	BRAF
28544061	10.1111/imj.13491	2018	Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma.	BRAF
28756651	10.1111/crj.12670	2018	Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.	BRAF
28975389	10.1007/s00277-017-3145-0	2018	PET-positive bone lesion due to Langerhans cell histiocytosis after BEACOPP therapy for Hodgkin lymphoma: how anamnesis, histopathological accuracy, and molecular analysis could resolve a clinical dilemma.	BRAF
29046324	10.1530/EJE-17-0499	2018	<i>ETV6-NTRK3</i> and <i>STRN-ALK</i> kinase fusions are recurrent events in papillary thyroid cancer of adult population.	BRAF
29129559	10.1016/j.clcc.2017.10.006	2018	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study.	BRAF
29134959	10.1038/nrclinonc.2017.175	2018	Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.	BRAF
29165687	10.1093/jnci/djx209	2018	Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl Thyroid Cancer.	BRAF
29198034	10.1007/s00428-017-2268-y	2018	Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study.	BRAF
29361134	10.1093/annonc/mdx631	2018	Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.	BRAF
29364576	10.1002/cncy.21963	2018	Simultaneous detection of single-nucleotide variant, deletion/insertion, and fusion in lung and thyroid carcinoma using cytology specimen and an RNA-based next-generation sequencing assay.	BRAF
29398453	10.1016/j.jmoldx.2017.11.004	2018	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.	BRAF
29439113	10.1136/gutjnl-2016-312608	2018	Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.	BRAF
29507487	10.3747/co.25.3867	2018	Standardizing biomarker testing for Canadian patients with advanced lung cancer.	BRAF
29516752	10.1080/13696998.2018.1450261	2018	Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.	BRAF
29556019	10.1038/s41375-018-0082-4	2018	High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations.	BRAF
29565494	10.26355/eurrev_201803_14479	2018	Long non-coding RNA BANCR indicates poor prognosis for breast cancer and promotes cell proliferation and invasion.	BRAF
29588308	10.1158/1078-0432.CCR-18-0103	2018	Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.	BRAF
29600072	10.21037/jtd.2017.12.68	2018	Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.	BRAF
29618685	10.11406/rinketsu.59.281	2018	[Splenic diffuse red pulp small B-cell lymphoma diagnosed by splenectomy initially mimicking hairy cell leukemia-Japanese variant].	BRAF
29631966	10.1016/j.cllc.2018.03.010	2018	MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.	BRAF
29633575	10.1002/cjp2.102	2018	Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related human papillary thyroid carcinoma after the Chernobyl accident.	BRAF
29654269	10.1038/s41375-018-0108-y	2018	Kinase domain activation through gene rearrangement in multiple myeloma.	BRAF
29666969	10.1007/s10014-018-0316-1	2018	Three case reports of radiation-induced glioblastoma after complete remission of acute lymphoblastic leukemia.	BRAF
29702524	10.1097/MOH.0000000000000435	2018	Genetic convergence of rare lymphomas.	BRAF
29708356	10.14735/amko2018130	2018	MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.	BRAF
29764505	10.1186/s40880-018-0284-1	2018	Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.	BRAF
29807803	10.1016/j.clml.2018.05.008	2018	Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients.	BRAF
29846633	10.1210/jc.2017-01845	2018	Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.	BRAF
29854308	10.18632/oncotarget.25209	2018	Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel.	BRAF
29857068	10.1016/j.jid.2018.04.038	2018	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.	BRAF
29881714	10.3389/fonc.2018.00161	2018	Mechanisms and Therapy for Cancer Metastasis to the Brain.	BRAF
29895903	10.1038/s41408-018-0089-0	2018	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.	BRAF
29911108	10.21037/atm.2018.05.02	2018	Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.	BRAF
29920315	10.1016/j.jaad.2018.06.018	2018	Prevalence of ALK gene alterations among the spectrum of plexiform spitzoid lesions.	BRAF
29989027	10.18632/oncotarget.25601	2018	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	BRAF
29992751	10.1002/cam4.1667	2018	Emerging findings into molecular mechanism of brain metastasis.	BRAF
30035752	10.1097/DAD.0000000000001072	2018	Langerhans Cell Histiocytosis Associated With Underlying Hematolymphoid Disorders in Adults: Report of 2 Cases and Review of the Literature.	BRAF
30089719	10.1172/jci.insight.120858	2018	Personalized therapy for lung cancer: striking a moving target.	BRAF
30092236	10.1016/j.humpath.2018.07.029	2018	So-called non-classic ciliated muconodular papillary tumors: a comprehensive comparison of the clinicopathological and molecular features with classic ciliated muconodular papillary tumors.	BRAF
30121602	10.1136/bmjopen-2018-021642	2018	Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.	BRAF
30172272	10.3779/j.issn.1009-3419.2018.08.10	2018	[Research Progress of Targeted Therapy for BRAF Mutation in Advanced Non-small Cell Lung Cancer].	BRAF
30188361	10.1097/PAP.0000000000000206	2018	Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas.	BRAF
30198802	10.1080/14737140.2018.1521272	2018	Dabrafenib and trametinib for the treatment of non-small cell lung cancer.	BRAF
30228211	10.1136/jclinpath-2018-205396	2018	Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma.	BRAF
30231382	10.1200/EDBK_201331	2018	Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.	BRAF
30290811	10.1186/s12943-018-0886-x	2018	A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells.	BRAF
30334450	10.4149/neo_2018_171225N843	2018	PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center experience.	BRAF
30335863	10.1371/journal.pone.0206014	2018	Oncogenic mutations in IKKŒ≤ function through global changes induced by K63-linked ubiquitination and result in autocrine stimulation.	BRAF
30354850	10.1177/1753466618808660	2018	Biomarkers in the diagnosis of pleural diseases: a 2018 update.	BRAF
30359792	10.1016/j.ctrv.2018.10.006	2018	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?	BRAF
30474563	10.1186/s13000-018-0772-2	2018	Erdheim Chester disease in a patient with Burkitt lymphoma: a case report and review of literature.	BRAF
30504104	NA	2018	Distribution of molecular subtypes of advanced lung adenocarcinoma and clinical outcomes in a center of Argentina.	BRAF
30536772	10.1111/bpa.12666	2018	A 72-year old female with multiple supra- and infratentorial dural masses.	BRAF
30546443	10.3892/ol.2018.9560	2018	ALK expression favorably impacts the prognosis of <i>NRAS</i>-mutated metastatic melanomas.	BRAF
30622805	10.21037/jtd.2018.08.14	2018	Therapeutic bronchoscopy in the era of genotype directed lung cancer management.	BRAF
30680072	10.18632/oncotarget.26428	2018	Targeted therapies for advanced non-small cell lung cancer.	BRAF
25901525	10.2174/1389450116666150330114441	2017	Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?	BRAF
26882062	10.1097/IOP.0000000000000661	2017	Comparative Study of Clinical, Pathological, Radiological, and Genetic Features of Patients With Adult Ocular Adnexal Xanthogranulomatous Disease, Erdheim-Chester Disease, and IgG4-Related Disease of the Orbit/Ocular Adnexa.	BRAF
27347751	10.1080/10428194.2016.1196813	2017	Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies.	BRAF
27545333	10.1080/10428194.2016.1213830	2017	BRAF kinase domain mutations in de novo acute myeloid leukemia with monocytic differentiation.	BRAF
27575422	10.1016/j.jtho.2016.08.137	2017	High Prevalence of Concomitant Oncogene Mutations¬†in Prospectively Identified Patients with¬†ROS1-Positive Metastatic Lung Cancer.	BRAF
27776007	10.1097/PAS.0000000000000761	2017	A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms.	BRAF
27910030	10.1007/978-1-4939-6703-2_22	2017	Recurrent Cytogenetic Abnormalities in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.	BRAF
27912827	10.1016/j.hoc.2016.08.010	2017	New Targets in Non-Small Cell Lung Cancer.	BRAF
27980230	10.18632/oncotarget.13936	2017	A childhood acute lymphoblastic leukemia-specific lncRNA implicated in prednisolone resistance, cell proliferation, and migration.	BRAF
28084334	10.1038/modpathol.2016.235	2017	Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.	BRAF
28088073	10.1016/j.ctrv.2016.12.005	2017	Strategies to design clinical studies to identify predictive biomarkers in cancer research.	BRAF
28088512	10.1016/j.jtho.2017.01.004	2017	ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.	BRAF
28150468	10.1111/pin.12512	2017	Ciliated muconodular papillary tumor of the lung harboring ALK gene rearrangement: Case report and review of the literature.	BRAF
28194436	10.1172/jci.insight.89473	2017	Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.	BRAF
28203297	10.1177/1758834016670555	2017	Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.	BRAF
28212996	10.1016/j.lungcan.2016.12.005	2017	Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).	BRAF
28218040	10.1177/1010428317691413	2017	Comprehensive profiling and quantitation of oncogenic mutations in non-small cell lung carcinoma using single-molecule amplification and re-sequencing technology.	BRAF
28237660	10.1016/j.yexmp.2017.02.014	2017	Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis.	BRAF
28246485	10.3748/wjg.v23.i6.1106	2017	Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin.	BRAF
28280620	10.21037/jgo.2017.01.14	2017	Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.	BRAF
28297625	10.1200/JCO.2016.71.1556	2017	Genomics of Hairy Cell Leukemia.	BRAF
28351340	10.1089/thy.2016.0254	2017	Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.	BRAF
28376906	10.1186/s13256-017-1253-z	2017	BRAF <sup>V600E</sup> expression in histiocytic sarcoma associated with splenic marginal zone lymphoma: a case report.	BRAF
28399347	10.22608/APO.201710	2017	Conjunctival Tumors: Review of Clinical Features, Risks, Biomarkers, and Outcomes--The 2017 J. Donald M. Gass Lecture.	BRAF
28433076	10.1016/j.jmoldx.2016.11.005	2017	Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms.	BRAF
28487464	10.1634/theoncologist.2016-0458	2017	Targeting <i>BRAF</i>-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.	BRAF
28507204	10.1634/theoncologist.2016-0376	2017	Detection of an <i>ALK</i> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA.	BRAF
28550959	10.1016/j.cllc.2017.04.006	2017	Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a¬†Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.	BRAF
28592763	10.11406/rinketsu.58.480	2017	Malignant lymphoma: pathophysiology and current therapy.	BRAF
28608966	10.1002/cncr.30794	2017	Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.	BRAF
28609002	10.1002/cncy.21866	2017	Analytic inquiry: Molecular testing in lung cancer.	BRAF
28762087	10.1007/s11523-017-0520-7	2017	Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).	BRAF
28840016	10.21037/jtd.2017.06.20	2017	Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.	BRAF
28880462	10.1111/cup.13017	2017	Indeterminate dendritic cell neoplasm of the skin: A 2-case report and review of the literature.	BRAF
28883003	10.1158/0008-5472.CAN-16-2691	2017	Discovery of Human-Similar Gene Fusions in Canine Cancers.	BRAF
28892161	10.1002/path.4982	2017	A gene is known by the company it keeps: enrichment of TNFAIP3 gene aberrations in MALT lymphomas expressing IGHV4-34 antigen receptors.	BRAF
28976960	10.1038/nature24037	2017	Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.	BRAF
29068003	10.1038/nrc.2017.84	2017	Understanding and targeting resistance mechanisms in NSCLC.	BRAF
29110361	10.1002/ajh.24936	2017	Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.	BRAF
29167001	10.3779/j.issn.1009-3419.2017.11.02	2017	[Association between the ALK Gene Status and the Efficacy of First-line Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].	BRAF
29370427	10.1093/jnci/djx089	2017	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.	BRAF
29872694	10.1038/s41698-017-0009-y	2017	Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.	BRAF
26426381	10.1097/PAS.0000000000000523	2016	NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease.	BRAF
26566875	10.1158/2159-8290.CD-15-0913	2016	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.	BRAF
26618563	10.1586/14737140.2016.1126514	2016	Emerging targeted therapies in non-small cell lung cancer.	BRAF
26620497	10.1177/1753465815617871	2016	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.	BRAF
26646246	10.1007/s00432-015-2081-4	2016	Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations.	BRAF
26668120	10.1038/nrendo.2015.217	2016	Thyroid cancer in 2015: Molecular landscape of thyroid cancer continues to be deciphered.	BRAF
26695526	10.1002/cncr.29812	2016	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.	BRAF
26703797	10.1007/978-3-319-24932-2_2	2016	Emerging Biomarkers in Personalized Therapy of Lung Cancer.	BRAF
26711128	10.1007/s00595-015-1295-z	2016	Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.	BRAF
26720421	10.1001/jamaoncol.2015.4482	2016	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.	BRAF
26777916	10.1016/S0140-6736(16)00004-0	2016	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).	BRAF
26800678	10.1007/s00108-015-0006-6	2016	[Classification of malignant lymphomas. Current situation].	BRAF
26845116	10.1016/j.jtho.2015.10.005	2016	Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.	BRAF
26855057	10.1016/j.ejmg.2016.01.003	2016	Acute lymphoblastic leukemia in the context of RASopathies.	BRAF
26857243	10.1186/s13000-016-0458-6	2016	Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.	BRAF
26868143	10.1007/s00428-015-1881-x	2016	CD27-positive hairy cell leukemia-Japanese variant.	BRAF
26872010	10.1097/PAS.0000000000000611	2016	Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.	BRAF
26873340	10.1177/1066896916630375	2016	Spitz Tumors: Comparison of Histological Features in Relationship to Immunohistochemical Staining for ALK and NTRK1.	BRAF
26893860	10.3892/mco.2015.690	2016	Genetic alterations in lung adenocarcinoma with a micropapillary component.	BRAF
26901614	10.1016/j.ejca.2015.12.033	2016	Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.	BRAF
26925962	10.1038/nrclinonc.2016.19	2016	Evolving molecularly targeted therapies for advanced-stage thyroid cancers.	BRAF
26941398	10.1182/blood-2015-11-680074	2016	BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.	BRAF
26964771	10.1016/j.jtho.2016.02.018	2016	Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.	BRAF
26968843	10.1186/s12885-016-2249-6	2016	Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.	BRAF
27033383	10.3760/cma.j.issn.0529-5807.2016.04.002	2016	[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].	BRAF
27034005	10.18632/oncotarget.8427	2016	Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.	BRAF
27070758	10.1016/j.leukres.2016.03.002	2016	Risk stratification of T-cell Acute Lymphoblastic Leukemia patients based on gene expression, mutations and copy number variation.	BRAF
27073482	10.3892/ol.2016.4235	2016	<i>EGFR</i>, <i>ALK</i>, <i>RET</i>, <i>KRAS</i> and <i>BRAF</i> alterations in never-smokers with non-small cell lung cancer.	BRAF
27080983	10.1038/modpathol.2016.66	2016	Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.	BRAF
27099101	10.1111/resp.12737	2016	Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.	BRAF
27101528	10.1097/MOH.0000000000000256	2016	Histiocytic neoplasms in the era of personalized genomic medicine.	BRAF
27107327	10.1016/j.ejca.2016.03.012	2016	High co-expression of PD-L1 and HIF-1Œ± correlates with tumour necrosis in pulmonary pleomorphic carcinoma.	BRAF
27121112	10.3109/10428194.2016.1173212	2016	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.	BRAF
27126828	10.2146/ajhp150863	2016	Specialty pharmacy services for patients receiving oral medications for solid tumors.	BRAF
27135738	10.1038/nm.4092	2016	An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.	BRAF
27149123	NA	2016	Flavopiridol Induces Apoptosis via Mitochondrial Pathway in B16F10 Murine Melanoma Cells and a Subcutaneous Melanoma Tumor Model.	BRAF
27200298	10.3389/fonc.2016.00112	2016	Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.	BRAF
27249714	10.1200/EDBK_100006	2016	Targeted Therapy in Brain Metastases: Ready for Primetime?	BRAF
27262212	10.1016/j.jtho.2016.04.033	2016	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.	BRAF
27266901	10.1016/j.rmr.2016.01.007	2016	[Molecular epidemiology of the lung cancer].	BRAF
27275640	NA	2016	[Novelties in the diagnostics and therapy of hairy cell leukemia].	BRAF
27298405	10.1200/JCO.2016.67.2410	2016	Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.	BRAF
27343444	10.1016/j.jtho.2016.06.001	2016	Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH¬†and IHC in Lung Adenocarcinoma.	BRAF
27409166	10.18632/oncotarget.10464	2016	Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.	BRAF
27535394	10.1007/978-3-319-40389-2_8	2016	Targeted Therapies for Lung Cancer.	BRAF
27600764	10.1038/ncomms12602	2016	Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.	BRAF
27614521	10.1016/j.canrad.2016.07.082	2016	[Radiotherapy and targeted therapy/immunotherapy].	BRAF
27615396	10.1016/j.jtho.2016.08.142	2016	Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma.	BRAF
27659822	10.1007/s00381-016-3163-6	2016	An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update.	BRAF
27672108	10.1093/annonc/mdw282	2016	First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.	BRAF
27696251	10.1007/s12020-016-1080-9	2016	Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.	BRAF
27732995	10.1055/s-0036-1592111	2016	Metastatic Lung Cancer: Emerging Therapeutic Strategies.	BRAF
27769042	10.18632/oncotarget.12705	2016	ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.	BRAF
27775641	10.3390/ijms17101759	2016	Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma.	BRAF
27889782	10.1159/000453085	2016	Molecular Pathology: A Requirement for Precision Medicine in Cancer.	BRAF
30363424	10.1002/mdc3.12277	2016	Neurohistiocytosis of the Cerebellum: A Rare Cause of Ataxia.	BRAF
25029639	10.3109/10428194.2014.939966	2015	Second hematologic malignancies in hairy cell leukemia: report of two patients with dynamic mutations in the BRAF gene.	BRAF
25242093	10.3109/10428194.2014.946028	2015	BRAF V600E mutation-specific immunohistochemistry is a rare finding in dendritic cell- and histiocyte-derived tumors.	BRAF
25273224	10.1002/cncr.29042	2015	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.	BRAF
25357018	10.1097/DAD.0000000000000231	2015	Primary cutaneous small/medium CD4+ T-Cell lymphoma occurring during treatment with vemurafenib for advanced melanoma.	BRAF
25423572	10.1210/jc.2014-3250	2015	Oncogenic mutations and chromosomal aberrations in primary extranodal diffuse large B-cell lymphomas of the thyroid--a study of 21 cases.	BRAF
25468140	10.1016/j.metabol.2014.10.027	2015	Biomarkers for personalized oncology: recent advances and future challenges.	BRAF
25480661	10.1182/blood-2014-10-603100	2015	BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.	BRAF
25485910	10.1038/nm.3751	2015	Mutations in G protein Œ≤ subunits promote transformation and kinase inhibitor resistance.	BRAF
25501013	10.1097/PAS.0000000000000368	2015	A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma.	BRAF
25511147	10.1309/AJCPDN4Q1JTFGCFC	2015	Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia.	BRAF
25511150	10.1309/AJCPQLQ89VXTVWKN	2015	The utility of BRAF V600E mutation-specific antibody VE1 for the diagnosis of hairy cell leukemia.	BRAF
25527510	10.1530/ERC-14-0467	2015	Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer.	BRAF
25563425	10.3109/10428194.2014.1001988	2015	Novel therapeutic options for relapsed hairy cell leukemia.	BRAF
25587943	10.1080/15592294.2014.1003746	2015	Epigenetic regulation in human melanoma: past and future.	BRAF
25602801	10.1097/PAS.0000000000000387	2015	Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions.	BRAF
25629635	10.1097/JTO.0000000000000487	2015	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	BRAF
25657019	10.1183/09031936.00097214	2015	BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.	BRAF
25673595	10.4103/0377-4929.151190	2015	V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in hairy cell leukaemia.	BRAF
25675010	10.1097/PAS.0000000000000376	2015	Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome.	BRAF
25689095	10.1111/resp.12490	2015	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).	BRAF
25704901	10.1016/j.rmr.2014.08.014	2015	[Targeted therapies in non-small cell lung cancer in 2014].	BRAF
25729732	10.3343/alm.2015.35.2.257	2015	BRAF V600E and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone lymphoma cases.	BRAF
25735315	10.1093/annonc/mdv136	2015	Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).	BRAF
25738220	10.1097/JTO.0000000000000516	2015	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	BRAF
25745045	10.1183/09031936.00097314	2015	No impact of passive smoke on the somatic profile of lung cancers in never-smokers.	BRAF
25758902	10.1007/s40291-015-0133-8	2015	Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.	BRAF
25758903	10.1111/bjh.13291	2015	BRAF(V600E) mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients.	BRAF
25787243	10.1016/j.anndiagpath.2015.02.008	2015	Evidence of BRAF V600E in indeterminate cell tumor and interdigitating dendritic cell sarcoma.	BRAF
25807485	10.1038/nature14336	2015	Therapy-induced tumour secretomes promote resistance and tumour progression.	BRAF
25809821	10.1111/his.12694	2015	Lymphomatous variant of hairy cell leukaemia: a distinctive presentation mimicking low-grade B-cell lymphoma.	BRAF
25823918	10.1016/j.clinthera.2015.02.018	2015	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.	BRAF
25842168	10.1016/j.ctrv.2015.03.009	2015	Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.	BRAF
25843629	10.1016/j.cell.2015.02.043	2015	The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.	BRAF
25858127	10.1684/abc.2015.1037	2015	[Chronic B-cell lymphoproliferative disorders with hairy cells].	BRAF
25862146	10.1016/j.lungcan.2015.03.017	2015	PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.	BRAF
25925381	10.1016/j.neo.2015.03.004	2015	Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.	BRAF
25926053	10.1038/ncomms8002	2015	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.	BRAF
25960206	10.1002/gcc.22253	2015	NFkB is activated by multiple mechanisms in hairy cell leukemia.	BRAF
25989738	10.1007/s00115-015-4278-9	2015	[Therapeutic options for brain metastases].	BRAF
25995428	10.6004/jnccn.2015.0201	2015	Targeted/emerging therapies for metastatic non-small cell lung cancer.	BRAF
26011488	10.1038/nrclinonc.2015.92	2015	Adolescent and young adult patients with cancer: a milieu of unique features.	BRAF
26028064	10.7314/apjcp.2015.16.10.4147	2015	Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.	BRAF
26047060	10.1080/15384047.2015.1057359	2015	Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature.	BRAF
26058013	10.3390/md13063625	2015	Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation.	BRAF
26071465	10.1309/AJCP5WVXJ2KTLODO	2015	Immunohistochemistry for BRAF V600E in the Differential Diagnosis of Hairy Cell Leukemia vs Other Splenic B-Cell Lymphomas.	BRAF
26109403	10.1111/bjd.13958	2015	Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.	BRAF
26113587	10.1136/bcr-2015-209343	2015	Hodgkin's lymphoma in an adolescent previously treated with surgical resection of third ventricular juvenile pilocytic astrocytoma.	BRAF
26149886	10.1016/S1470-2045(15)00077-7	2015	Genomic alterations in lung adenocarcinoma.	BRAF
26154707	10.1097/CCO.0000000000000214	2015	New insights in the management of patients with hairy cell leukemia.	BRAF
26215190	10.1245/s10434-015-4704-z	2015	Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.	BRAF
26235020	10.3171/2015.5.FOCUS15143	2015	The genetic basis of intradural spinal tumors and its impact on clinical treatment.	BRAF
26281695	NA	2015	[Molecular target therapies for skin cancers].	BRAF
26339365	NA	2015	Cytologic, clinicopathologic, and molecular features of papillary thyroid carcinoma with prominent hobnail features: 10 case reports and systematic literature review.	BRAF
26345285	10.1186/s12885-015-1639-5	2015	A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cells.	BRAF
26350141	10.1016/j.leukres.2015.08.017	2015	BRAF<sup>V600E</sup> induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation.	BRAF
26358176	10.1038/cgt.2015.39	2015	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	BRAF
26371045	10.3390/cancers7030864	2015	The Evolution of Therapies in Non-Small Cell Lung Cancer.	BRAF
26373952	10.1186/s13000-015-0409-7	2015	Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.	BRAF
26422542	NA	2015	NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance.	BRAF
26551667	10.1038/ng.3442	2015	The mutational landscape of cutaneous T cell lymphoma and S√©zary syndrome.	BRAF
26579470	10.1016/j.apsb.2015.07.001	2015	Mechanisms of resistance to EGFR tyrosine kinase inhibitors.	BRAF
26581482	10.1186/s13104-015-1675-x	2015	Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.	BRAF
26614896	10.1016/j.beha.2015.10.017	2015	Clinical features and diagnosis of hairy cell leukemia.	BRAF
26614898	10.1016/j.beha.2015.10.019	2015	Bone marrow and splenic histology in hairy cell leukaemia.	BRAF
26615134	10.1053/j.seminoncol.2015.09.028	2015	Overcoming Resistance to Targeted Therapies in Cancer.	BRAF
26688666	10.4137/BIC.S29326	2015	Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells.	BRAF
26826484	10.1016/S0003-4266(16)30009-9	2015	Molecular perspectives in differentiated thyroid cancer.	BRAF
26887510	NA	2015	[Detection and significance of BRAF gene in mature T/NK cell lymphoma].	BRAF
23988776	10.1183/09031936.00018013	2014	EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.	BRAF
24296758	10.1158/1541-7786.MCR-13-0479-T	2014	ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.	BRAF
24297085	10.1093/annonc/mdt495	2014	Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.	BRAF
24346091	10.1097/JTO.0000000000000024	2014	Transbronchial biopsy needle rinse solution used for comprehensive biomarker testing in patients with lung cancer.	BRAF
24354593	10.1517/14728214.2014.873403	2014	Emerging protein kinase inhibitors for non-small cell lung cancer.	BRAF
24380695	10.1016/j.lungcan.2013.11.019	2014	On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.	BRAF
24397598	10.3109/10428194.2013.878461	2014	Absence of BRAF and KRAS hotspot mutations in primary mediastinal B-cell lymphoma.	BRAF
24420742	10.1007/s00428-014-1535-4	2014	Prognostic and predictive biomarkers in lung cancer. A review.	BRAF
24423920	10.1038/bjc.2013.794	2014	Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations.	BRAF
24433452	10.1111/bjh.12735	2014	Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias.	BRAF
24445188	10.1016/j.clml.2013.12.003	2014	BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.	BRAF
24471909	10.3109/10428194.2014.887713	2014	Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis.	BRAF
24481316	10.1097/JTO.0b013e3182a406d1	2014	Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.	BRAF
24503701	10.1371/journal.pone.0087456	2014	Immunohistochemistry for myc predicts survival in colorectal cancer.	BRAF
24531447	10.1038/bcj.2014.3	2014	Hairy cell leukemia: short review, today's recommendations and outlook.	BRAF
24548766	10.1016/j.ejca.2014.01.018	2014	Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.	BRAF
24552757	10.1016/j.lungcan.2014.01.023	2014	BRAF-mutations in non-small cell lung cancer.	BRAF
24629636	10.1016/j.lungcan.2014.02.007	2014	ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.	BRAF
24633422	10.1007/s00268-014-2485-3	2014	Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.	BRAF
24659662	NA	2014	Capsaicin induced apoptosis and gene expression dysregulation of human acute lymphoblastic leukemia CCRF-CEM cells.	BRAF
24689848	10.1111/cas.12408	2014	Disease-specific mutations in mature lymphoid neoplasms: recent advances.	BRAF
24691006	10.1371/journal.pone.0092147	2014	Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.	BRAF
24699316	10.1371/journal.pone.0092820	2014	High fidelity copy number analysis of formalin-fixed and paraffin-embedded tissues using Affymetrix Cytoscan HD chip.	BRAF
24700479	10.1002/cncr.28604	2014	Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.	BRAF
24727987	10.1159/000355902	2014	Successes and limitations of targeted cancer therapy in lung cancer.	BRAF
24729716	10.2147/OTT.S60122	2014	Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.	BRAF
24789721	10.1007/s12253-014-9783-9	2014	Treatment of refractory hairy cell leukemia with a BRAF-inhibitor: lessons to be learnt.	BRAF
24857124	10.14694/EdBook_AM.2014.34.e353	2014	Management and future directions in non-small cell lung cancer with known activating mutations.	BRAF
24878193	10.1016/j.bmcl.2014.05.030	2014	Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.	BRAF
24920406	10.3892/ijo.2014.2491	2014	Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).	BRAF
24994538	10.1007/s00277-014-2140-y	2014	Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.	BRAF
24997557	10.1016/j.clml.2014.06.004	2014	Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.	BRAF
25053603	10.1016/j.canrad.2014.05.007	2014	[Combination of stereotactic irradiation and chemotherapy or targeted therapies: state of the art and preliminary recommendations].	BRAF
25066006	10.1111/his.12515	2014	Multifocal synchronous mucinous adenocarcinomas arising in congenital pulmonary airway malformation: a case report with molecular study.	BRAF
25120816	NA	2014	Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia.	BRAF
25126481	10.1089/biores.2014.0011	2014	Establishment and characterization of a singaporean chinese lung adenocarcinoma cell line with four copies of the epidermal growth factor receptor gene.	BRAF
25133005	10.1155/2014/497027	2014	Primary hairy cell leukemia/lymphoma of the breast: a case report and review of the literature.	BRAF
25239585	10.1016/j.rmr.2013.11.004	2014	[An unusual mediastinal mass].	BRAF
25288236	10.1016/j.humpath.2014.08.005	2014	Molecular alterations in non-small cell lung carcinomas of the young.	BRAF
25302162	10.5306/wjco.v5.i4.576	2014	Review of the current targeted therapies for non-small-cell lung cancer.	BRAF
23009221	10.3109/10428194.2012.733878	2013	BRAF V600E mutation in adult acute lymphoblastic leukemia.	BRAF
23088640	10.3109/10428194.2012.742525	2013	BRAF mutations in chronic lymphocytic leukemia.	BRAF
23235345	10.1097/PAI.0b013e3182688e59	2013	Lack of BRAF V600E protein expression in primary central nervous system lymphoma.	BRAF
23349307	10.3324/haematol.2012.078071	2013	Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.	BRAF
23401445	10.1200/JCO.2012.42.9829	2013	New targetable oncogenes in non-small-cell lung cancer.	BRAF
23696960	10.5306/wjco.v4.i2.29	2013	Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma.	BRAF
23708073	10.1097/PPO.0b013e318297216a	2013	Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.	BRAF
23751074	10.1111/pcmr.12129	2013	Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas.	BRAF
23759932	10.1097/PAS.0b013e318283099f	2013	Clonally related follicular lymphomas and Langerhans cell neoplasms: expanding the spectrum of transdifferentiation.	BRAF
23841470	10.1164/rccm.201305-0843PP	2013	The impact of genomic changes on treatment of lung cancer.	BRAF
23885909	10.1016/j.jvir.2013.04.019	2013	Personalized oncology in interventional radiology.	BRAF
23923114	10.4103/1947-2714.114172	2013	Langerhans Cell Sarcoma Arising from Chronic Lymphocytic Lymphoma/Small Lymphocytic Leukemia: Lineage Analysis and BRAF V600E Mutation Study.	BRAF
23923507	10.1182/blood-2012-12-473181	2013	Collision of chronic lymphocytic leukemia/small lymphocytic lymphoma and melanoma.	BRAF
23930754	10.1517/14712598.2013.827657	2013	Targeted therapy for NSCLC with driver mutations.	BRAF
24041576	10.1182/blood-2013-08-460311	2013	Genome sequencing of lymphoid malignancies.	BRAF
24103785	10.1684/bdc.2013.1823	2013	[Molecular and therapeutic advances in Hairy cell leukemia].	BRAF
24159168	10.1182/blood-2013-07-513523	2013	BRAF V600E is also seen in unclassifiable splenic B-cell lymphoma/leukemia, a potential mimic of hairy cell leukemia.	BRAF
24206589	10.1016/j.pharma.2013.07.001	2013	[Characterization of principal predictive biomarkers of targeted therapies in thoracic cancer].	BRAF
24342286	10.1053/j.semdp.2013.11.007	2013	The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.	BRAF
22028477	10.1182/blood-2011-08-371179	2012	Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation.	BRAF
22072557	10.1182/blood-2011-08-368209	2012	The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms.	BRAF
22072743	10.1210/jc.2011-0484	2012	BAG3 down-modulation reduces anaplastic thyroid tumor growth by enhancing proteasome-mediated degradation of BRAF protein.	BRAF
22133769	10.3324/haematol.2011.054874	2012	Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders.	BRAF
22246856	10.1002/hon.1023	2012	Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia.	BRAF
22317764	10.1158/1078-0432.CCR-11-2511	2012	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.	BRAF
22339435	10.3109/10428194.2012.668188	2012	Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms.	BRAF
22531170	10.1097/PAS.0b013e3182549b50	2012	Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia.	BRAF
22639828	10.3109/10428194.2012.695777	2012	Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia.	BRAF
23161722	10.1309/AJCP5TWORA0TMXGL	2012	Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferative disorders.	BRAF
21625473	10.1371/journal.pone.0019861	2011	A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.	BRAF
21663470	10.1056/NEJMoa1014209	2011	BRAF mutations in hairy-cell leukemia.	BRAF
19626635	10.1002/hed.21178	2010	Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas.	BRAF
19551857	10.1002/ijc.24681	2009	The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms.	BRAF
17483702	10.1097/MPH.0b013e3180547136	2007	Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene.	BRAF
17525723	10.1038/sj.leu.2404761	2007	The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene.	BRAF
15538400	10.1038/sj.leu.2403589	2005	Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia.	BRAF
15705790	10.1182/blood-2004-09-3683	2005	B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells.	BRAF
15191558	10.1111/j.0022-202X.2004.22722.x	2004	BRAF point mutations in primary melanoma show different prevalences by subtype.	BRAF
14612909	10.1038/sj.bjc.6601371	2003	BRAF mutations in non-Hodgkin's lymphoma.	BRAF
34657128	10.1038/s41375-021-01448-2	2022	Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.	BTG1
34791836	10.1002/cam4.4422	2022	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.	BTG1
35401516	10.3389/fimmu.2022.842439	2022	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.	BTG1
35459639	10.1016/j.bpj.2022.04.023	2022	Conformational transitions in BTG1 antiproliferative protein and their modulation by disease mutants.	BTG1
35646048	10.3389/fgene.2022.878618	2022	Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	BTG1
35774514	10.3389/fgene.2022.827840	2022	A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma.	BTG1
35795062	10.3389/fonc.2022.870487	2022	Plasma Concentrations and Cancer-Associated Mutations in Cell-Free Circulating DNA of Treatment-Naive Follicular Lymphoma for Improved Non-Invasive Diagnosis and Prognosis.	BTG1
35880434	NA	2022	Emerging role of anti-proliferative protein BTG1 and BTG2.	BTG1
32467145	10.3324/haematol.2020.247973	2021	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.	BTG1
33021411	10.1080/10428194.2020.1827243	2021	Frequent loss of BTG1 activity and impaired interactions with the Caf1 subunit of the Ccr4-Not deadenylase in non-Hodgkin lymphoma.	BTG1
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	BTG1
34010787	10.1016/j.ejca.2021.03.034	2021	Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials.	BTG1
34371436	10.1016/j.leukres.2021.106683	2021	Proposal and clinical application of molecular genetic risk scoring system, MRplus, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.	BTG1
34599153	10.1038/s41419-021-04187-5	2021	Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.	BTG1
35116576	10.21037/tcr-20-2525	2021	Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database.	BTG1
32592278	10.1002/gcc.22882	2020	Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.	BTG1
32661308	10.1038/s41598-020-68311-9	2020	MLPA and DNA index improve the molecular diagnosis of childhood B-cell acute lymphoblastic leukemia.	BTG1
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	BTG1
33369444	10.31557/APJCP.2020.21.12.3493	2020	Frequency and Correlation of Common Genes Copy Number Alterations in Childhood Acute Lymphoblastic Leukemia with Prognosis.	BTG1
30350856	10.1002/jcp.27407	2019	Tumor suppressors BTG1 and BTG2: Beyond growth control.	BTG1
30854058	10.3892/ol.2019.9900	2019	Identification of B-cell translocation gene 1-controlled gene networks in diffuse large B-cell lymphoma: A study based on bioinformatics analysis.	BTG1
30874617	10.1038/s41598-019-41078-4	2019	Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.	BTG1
31112375	10.1111/ijlh.13052	2019	Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay.	BTG1
31228652	10.1016/j.leukres.2019.05.009	2019	Prognostic gene alterations and clonal changes in childhood B-ALL.	BTG1
29348129	10.1182/blood-2017-07-796862	2018	Genomic CDKN2A/2B deletions in adult Ph<sup>+</sup> ALL are adverse despite allogeneic stem cell transplantation.	BTG1
29407587	10.1016/j.leukres.2018.01.012	2018	High frequency of intermediate and poor risk copy number abnormalities in pediatric cohort of B-ALL correlate with high MRD post induction.	BTG1
29498923	10.1200/JCO.2017.74.3617	2018	IKZF1<sup>plus</sup> Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.	BTG1
29786757	10.1007/s12185-018-2474-7	2018	Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.	BTG1
30203896	10.1002/gcc.22664	2018	Improved cytogenetic characterization and risk stratification of pediatric acute lymphoblastic leukemia using single nucleotide polymorphism array analysis: A single center experience of 296 cases.	BTG1
27339065	10.1080/10428194.2016.1193855	2017	Gene copy number alteration profile and its clinical correlation in B-cell acute lymphoblastic leukemia.	BTG1
27979924	10.3324/haematol.2016.153023	2017	Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.	BTG1
28033648	10.1002/gcc.22439	2017	Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.	BTG1
28202519	10.1158/0008-5472.CAN-16-2571	2017	Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia.	BTG1
28401483	10.1007/s12032-017-0940-3	2017	Molecular profiling of gene copy number abnormalities in key regulatory genes in high-risk B-lineage acute lymphoblastic leukemia: frequency and their association with clinicopathological findings in Indian patients.	BTG1
28886309	10.14715/cmb/2017.63.8.4	2017	The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.	BTG1
28947432	10.1158/1940-6207.CAPR-17-0121	2017	<i>IKZF1</i> Gene in Childhood B-cell Precursor Acute Lymphoblastic Leukemia: Interplay between Genetic Susceptibility and Somatic Abnormalities.	BTG1
26657730	10.18632/oncotarget.6519	2016	Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress.	BTG1
26781410	NA	2016	[Detection of copy number variations in pediatric ETV6/RUNX1-positive acute lymphoblastic leukemia with multiplex ligation-dependent probe amplification].	BTG1
26957068	10.3760/cma.j.issn.0578-1310.2016.03.011	2016	[Copy number variations in pediatric ETV6/RUNX1 positive acute lymphoblastic leukemia].	BTG1
27036158	10.3324/haematol.2015.139675	2016	Tumor suppressors BTG1 and BTG2 regulate early mouse B-cell development.	BTG1
27151989	10.3324/haematol.2016.143875	2016	Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia.	BTG1
27229005	10.1182/blood-2016-03-704973	2016	Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.	BTG1
27959929	10.1371/journal.pmed.1002197	2016	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.	BTG1
25571854	10.3892/ijmm.2014.2058	2015	B cell translocation gene 1 reduces the biological outcome of kidney cancer through induction of cell proliferation, cell cycle arrest, cell apoptosis and cell metastasis.	BTG1
25710169	10.1371/journal.ppat.1004652	2015	HITS-CLIP analysis uncovers a link between the Kaposi's sarcoma-associated herpesvirus ORF57 protein and host pre-mRNA metabolism.	BTG1
25951811	10.1002/gcc.22251	2015	Identification of SPAG9 as a novel JAK2 fusion partner gene in pediatric acute lymphoblastic leukemia with t(9;17)(p24;q21).	BTG1
24366360	10.1182/blood-2013-09-525808	2014	The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.	BTG1
24957142	10.1182/blood-2014-03-562918	2014	A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.	BTG1
24998463	10.1016/j.cancergen.2014.05.003	2014	High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.	BTG1
25044358	10.1002/gcc.22201	2014	Gene alterations involving the CRLF2-JAK pathway and recurrent gene deletions in Down syndrome-associated acute lymphoblastic leukemia in Japan.	BTG1
25117713	10.1016/j.ccr.2014.06.014	2014	MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state.	BTG1
25173640	10.1007/s13277-014-2298-x	2014	Expression of BTG1 in hepatocellular carcinoma and its correlation with cell cycles, cell apoptosis, and cell metastasis.	BTG1
22868968	10.1038/leu.2012.199	2013	BTG1 deletions do not predict outcome in Down syndrome acute lymphoblastic leukemia.	BTG1
22072402	10.1002/gcc.20944	2012	High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with down syndrome.	BTG1
22343534	10.1073/pnas.1121343109	2012	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	BTG1
22359517	10.1371/journal.pgen.1002533	2012	The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution.	BTG1
22851563	10.1200/JCO.2011.40.3907	2012	IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia.	BTG1
20354172	10.1182/blood-2009-05-223081	2010	BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia.	BTG1
17374122	10.1111/j.1349-7006.2007.00443.x	2007	Genetic abnormalities involved in t(12;21) TEL-AML1 acute lymphoblastic leukemia: analysis by means of array-based comparative genomic hybridization.	BTG1
17466295	10.1016/j.yexcr.2007.03.021	2007	Role for Btg1 and Btg2 in growth arrest of WEHI-231 cells through arginine methylation following membrane immunoglobulin engagement.	BTG1
17485552	10.1182/blood-2006-12-064865	2007	Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors.	BTG1
11920564	10.1002/1521-4141(200204)32:4&lt;982::AID-IMMU982&gt;3.0.CO;2-I	2002	Expression profiling in transformed human B cells: influence of Btk mutations and comparison to B cell lymphomas using filter and oligonucleotide arrays.	BTG1
35053438	10.3390/cancers14020274	2022	The Antitumor Effect of Caffeic Acid Phenethyl Ester by Downregulating Mucosa-Associated Lymphoid Tissue 1 via AR/p53/NF-Œ∫B Signaling in Prostate Carcinoma Cells.	BTG2
35300216	10.2147/JIR.S341355	2022	The Mutation of <i>BTG2</i> Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma.	BTG2
35401516	10.3389/fimmu.2022.842439	2022	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.	BTG2
35646048	10.3389/fgene.2022.878618	2022	Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	BTG2
35880434	NA	2022	Emerging role of anti-proliferative protein BTG1 and BTG2.	BTG2
35928872	10.3389/fonc.2022.932674	2022	Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma.	BTG2
33021411	10.1080/10428194.2020.1827243	2021	Frequent loss of BTG1 activity and impaired interactions with the Caf1 subunit of the Ccr4-Not deadenylase in non-Hodgkin lymphoma.	BTG2
33206936	10.1182/blood.2020005650	2021	Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.	BTG2
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	BTG2
33945543	10.1371/journal.pone.0248886	2021	Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.	BTG2
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	BTG2
32059783	10.1016/j.cell.2020.01.029	2020	Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody.	BTG2
32457623	10.3389/fphar.2020.00630	2020	Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling.	BTG2
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	BTG2
30350856	10.1002/jcp.27407	2019	Tumor suppressors BTG1 and BTG2: Beyond growth control.	BTG2
30733272	10.3324/haematol.2018.207928	2019	Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.	BTG2
31220210	10.1093/carcin/bgz068	2019	Genomic pattern of intratumor heterogeneity predicts the risk of progression in early stage diffuse large B-cell lymphoma.	BTG2
30184526	10.1159/000492850	2018	MicroRNA High Throughput Loss-of-Function Screening Reveals an Oncogenic Role for miR-21-5p in Hodgkin Lymphoma.	BTG2
26757737	10.1007/s00401-016-1536-2	2016	Genomic characterization of primary central nervous system lymphoma.	BTG2
27036158	10.3324/haematol.2015.139675	2016	Tumor suppressors BTG1 and BTG2 regulate early mouse B-cell development.	BTG2
24140094	10.1016/j.metabol.2013.09.010	2014	Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.	BTG2
22323293	10.1091/mbc.E11-06-0524	2012	Intermediate progenitors are increased by lengthening of the cell cycle through calcium signaling and p53 expression in human neural progenitors.	BTG2
22808135	10.1371/journal.pone.0040332	2012	Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma.	BTG2
17466295	10.1016/j.yexcr.2007.03.021	2007	Role for Btg1 and Btg2 in growth arrest of WEHI-231 cells through arginine methylation following membrane immunoglobulin engagement.	BTG2
7768965	10.1007/BF01209594	1995	Differential expression of TIS21 and TIS1 genes in the various organs of Balb/c mice, thymic carcinoma tissues and human cancer cell lines.	BTG2
34319003	10.1002/cnr2.1524	2022	Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma.	BTK
34332791	10.1016/j.pathol.2021.04.008	2022	Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.	BTK
34615723	10.1158/1078-0432.CCR-21-2183	2022	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.	BTK
34638136	10.1182/bloodadvances.2020003698	2022	Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.	BTK
34679161	10.1182/blood.2021013326	2022	Therapeutic options for relapsed/refractory mantle cell lymphoma.	BTK
34713475	10.1002/hon.2943	2022	Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.	BTK
34714908	10.1182/bloodadvances.2021005486	2022	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.	BTK
34724705	10.1182/bloodadvances.2021005621	2022	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies.	BTK
34774461	10.1016/j.clml.2021.09.012	2022	SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds?	BTK
34783281	10.1080/10428194.2021.1999444	2022	Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.	BTK
34795418	10.1038/s41375-021-01470-4	2022	Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models.	BTK
34817087	10.1002/hon.2952	2022	Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre-CAR T-cell era.	BTK
34821081	10.1002/cnr2.1590	2022	Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data.	BTK
34838186	10.1016/j.ccell.2021.11.006	2022	Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.	BTK
34839996	10.1016/j.ejmech.2021.114009	2022	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.	BTK
34843717	10.1016/j.bcp.2021.114861	2022	Luxeptinib disables NLRP3 inflammasome-mediated IL-1Œ≤ release and pathways required for secretion of inflammatory cytokines IL-6 and TNFŒ±.	BTK
34861036	10.1182/blood.2021014085	2022	Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.	BTK
34861696	10.1182/bloodadvances.2021006211	2022	Single-cell sequencing demonstrates complex resistance landscape in¬†CLL and MCL treated with BTK and BCL2 inhibitors.	BTK
34905129	10.1007/s11523-021-00857-8	2022	Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.	BTK
34910982	10.1016/j.bioorg.2021.105541	2022	Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.	BTK
34932207	10.1007/s40265-021-01657-0	2022	Current Treatment of Chronic Lymphocytic Leukemia: The Diminishing Role of Chemoimmunotherapy.	BTK
34980578	10.1016/j.clml.2021.11.014	2022	SOHO State of the Art Updates and Next Questions: Waldenstr√∂m Macroglobulinemia - 2021 Update on Management and Future Directions.	BTK
35031886	10.1186/s43556-021-00066-9	2022	Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma.	BTK
35068379	10.1080/16078454.2021.2019363	2022	Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma.	BTK
35076567	10.3390/neurolint14010009	2022	Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.	BTK
35078814	10.1158/0008-5472.CAN-21-0218	2022	Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma.	BTK
35096069	10.1155/2022/1182384	2022	Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenstr√∂m's Macroglobulinemia).	BTK
35115740	10.1007/s12288-021-01433-w	2022	Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study.	BTK
35123927	10.1016/j.clml.2022.01.008	2022	SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.	BTK
35139644	10.2217/fon-2021-0602	2022	Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.	BTK
35149375	10.1016/j.ctarc.2022.100527	2022	Current approach to Waldenstr√∂m Macroglobulinemia.	BTK
35169086	10.11477/mf.1436204531	2022	[Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].	BTK
35184664	10.1080/17474086.2022.2044778	2022	Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy.	BTK
35188143	10.1358/dot.2022.58.2.3360405	2022	Research progress in overcoming ibrutinib drug resistance.	BTK
35196427	10.1056/NEJMoa2114110	2022	Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.	BTK
35205606	10.3390/cancers14040860	2022	Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.	BTK
35230873	10.1126/scisignal.abk3083	2022	Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells.	BTK
35237395	10.1177/20406207221080738	2022	Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).	BTK
35247223	10.1002/hon.2983	2022	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement.	BTK
35247800	10.1016/j.thromres.2022.02.020	2022	The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions.	BTK
35255496	10.1182/bloodadvances.2021006147	2022	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.	BTK
35266562	10.1002/ajh.26523	2022	Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.	BTK
35273899	10.1055/s-0042-1744128	2022	Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib.	BTK
35294723	10.1007/s11864-022-00973-1	2022	Novel Approaches for the Treatment of Patients with Richter's Syndrome.	BTK
35296646	10.1038/s41419-022-04684-1	2022	Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.	BTK
35303070	10.1182/blood.2021014162	2022	Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.	BTK
35306137	10.1016/j.cellsig.2022.110311	2022	B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells.	BTK
35306909	10.1177/10781552221087730	2022	A fatal disseminated cryptococcal infection in a patient treated with zanubrutinib for Waldenstr√∂m's macroglobulinemia.	BTK
35313381	10.1002/hon.2986	2022	Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group.	BTK
35326604	10.3390/cancers14061453	2022	DLBCL 1L-What to Expect beyond R-CHOP?	BTK
35330376	10.3390/jpm12030376	2022	Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.	BTK
35339405	10.1016/j.clml.2022.02.005	2022	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenstr√∂m Macroglobulinemia.	BTK
35341452	10.1080/10428194.2022.2056179	2022	Incidence of <i>Pneumocystis jirovecii</i> pneumonia (PJP) in patients receiving BTK inhibitors who did not receive PJP prophylaxis.	BTK
35350909	10.1177/10781552221090869	2022	Real-world management of targeted therapies in chronic lymphocytic leukemia.	BTK
35357653	10.1007/s11864-022-00974-0	2022	New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.	BTK
35379357	10.1186/s40364-022-00357-5	2022	Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma.	BTK
35383885	10.1111/bjh.18162	2022	A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies.	BTK
35403972	10.1007/s11912-022-01250-y	2022	Targeting The Tumor Microenvironment in Lymphomas: Emerging Biological Insights and Therapeutic Strategies.	BTK
35404729	10.1080/14737140.2022.2064849	2022	Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.	BTK
35411248	NA	2022	PIK-75 overcomes venetoclax resistance <i>via</i> blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma.	BTK
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	BTK
35435617	10.1007/s11864-022-00953-5	2022	Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.	BTK
35437106	10.1080/17474086.2022.2067526	2022	Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.	BTK
35440579	10.1038/s41467-022-29835-y	2022	A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways.	BTK
35450208	10.1177/20406207221090886	2022	Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.	BTK
35465824	10.1080/10428194.2022.2064995	2022	The role of BTK inhibitors on the tumor microenvironment in CLL.	BTK
35474969	10.1097/HS9.0000000000000715	2022	New Mechanisms of Genomic Escape From Noncovalent BTK Inhibitors.	BTK
35482146	10.1007/s11307-022-01733-1	2022	[<sup>18</sup>F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton's Tyrosine Kinase.	BTK
35510210	10.1177/20406207221093962	2022	Treatment paradigm in Waldenstr√∂m macroglobulinemia: frontline therapy and beyond.	BTK
35558005	10.1177/17588359221093745	2022	Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.	BTK
35561314	10.1182/bloodadvances.2022007247	2022	Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.	BTK
35571529	10.1155/2022/1930546	2022	Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse.	BTK
35577753	10.1016/j.clml.2022.04.017	2022	SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.	BTK
35596920	10.1007/s11912-022-01286-0	2022	BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.	BTK
35597428	10.1016/j.cellsig.2022.110358	2022	BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.	BTK
35628381	10.3390/ijms23105570	2022	<i>MYD88</i> Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies.	BTK
35639332	10.1007/s11912-022-01297-x	2022	Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.	BTK
35651781	10.1177/20406207221093980	2022	Zanubrutinib in lymphoproliferative disorders: a comprehensive review.	BTK
35658124	10.1158/2159-8290.CD-21-1566	2022	BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.	BTK
35670706	10.1358/dot.2022.58.6.3378055	2022	Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.	BTK
35671249	10.1021/acs.jmedchem.2c00324	2022	Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.	BTK
35680835	10.19746/j.cnki.issn.1009-2137.2022.03.049	2022	[Clinical Application of Zanubrutinib in B-Cell Lymphoma --Review].	BTK
35714675	10.6004/jnccn.2022.0031	2022	NCCN Guidelines¬Æ Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.	BTK
35721157	10.3389/fphar.2022.864194	2022	HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib.	BTK
35745866	10.3390/pharmaceutics14061294	2022	Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia.	BTK
35757723	10.3389/fimmu.2022.894787	2022	Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.	BTK
35770040	10.2147/TCRM.S338655	2022	Zanubrutinib in Treating Waldenstr√∂m Macroglobulinemia, the Last Shall Be the First.	BTK
35785180	10.3389/fonc.2022.901797	2022	Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series.	BTK
35804999	10.3390/cancers14133229	2022	Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.	BTK
35836543	10.21037/tcr-22-1375	2022	A case report of acquired immunodeficiency syndrome (AIDS)-related refractory Burkitt lymphoma got complete remission by multidisciplinary and multi-target combined therapy.	BTK
35852229	10.1080/10428194.2022.2098289	2022	Practical management of chronic lymphocytic leukemia with acalabrutinib.	BTK
35908982	10.1016/j.blre.2022.100992	2022	Follicular lymphoma: The long and winding road leading to your cure?	BTK
35911566	10.2147/BLCTT.S326627	2022	Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.	BTK
35937468	10.6004/jadpro.2022.13.5.14	2022	A Focus on Waldenstr√∂m Macroglobulinemia and AL Amyloidosis.	BTK
35941532	10.1186/s10020-022-00518-0	2022	Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma.	BTK
35956064	10.3390/jcm11154447	2022	Bing-Neel Syndrome, a Rare Presentation of Waldenstr√∂m Macroglobulinemia-A Multicenter Report by the Polish Lymphoma Research Group.	BTK
35957865	10.3389/fonc.2022.941633	2022	Case report: Zanubrutinib-induced dermatological toxicities: A single-center experience and review.	BTK
35973369	10.1016/j.intimp.2022.109138	2022	Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization.	BTK
35975476	10.1002/hon.3056	2022	Ibrutinib combined with low-dose histone deacetylases inhibitor chidamide synergistically enhances the anti-tumor effect in B-cell lymphoma.	BTK
35979372	10.3389/fimmu.2022.943354	2022	Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies.	BTK
35999205	10.1038/s41408-022-00720-7	2022	Determining drug dose in the era of targeted therapies: playing it (un)safe?	BTK
36003901	10.2147/BLCTT.S259860	2022	Differential Diagnosis of Waldenstr√∂m's Macroglobulinemia and Early Management: Perspectives from Clinical Practice.	BTK
36029036	10.1111/bjh.18418	2022	Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.	BTK
36029150	10.1002/cpdd.1153	2022	Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.	BTK
36035991	10.3389/fcell.2022.935023	2022	Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.	BTK
36051027	10.1002/jha2.489	2022	Inactivating <i>BTK</i> mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with <i>BCL2</i> translocation.	BTK
36051079	10.1002/jha2.428	2022	Targetable alterations in primary extranodal diffuse large B-cell lymphoma.	BTK
36068158	10.1016/j.clml.2022.07.017	2022	Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review.	BTK
36078155	10.3390/cells11172747	2022	Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.	BTK
32677095	10.1111/bjh.16946	2021	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.	BTK
32683672	10.1002/ijc.33212	2021	Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.	BTK
32855532	10.1038/s41401-020-00505-3	2021	Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.	BTK
32985902	10.2217/fon-2020-0794	2021	A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.	BTK
33011863	10.1007/s00428-020-02937-y	2021	ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib.	BTK
33089525	10.1111/ejh.13538	2021	A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.	BTK
33127325	10.1016/j.clml.2020.10.007	2021	Successful Long-Term Ibrutinib Treatment in a Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma.	BTK
33128020	10.1038/s41375-020-01074-4	2021	Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.	BTK
33140664	10.1080/10428194.2020.1832660	2021	Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3KŒ¥ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202).	BTK
33152104	10.1111/bjh.17197	2021	Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.	BTK
33199185	10.1016/j.clml.2020.10.012	2021	Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.	BTK
33216986	10.1111/bjh.17184	2021	Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.	BTK
33263441	10.1080/17474086.2021.1856652	2021	Development of molecular intervention strategies for B-cell lymphoma.	BTK
33272709	10.1016/j.bioorg.2020.104385	2021	Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.	BTK
33288483	10.1016/j.clml.2020.10.015	2021	Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.	BTK
33306268	10.1111/cts.12948	2021	Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.	BTK
33340912	10.1016/j.ejmech.2020.113094	2021	1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton's tyrosine kinase.	BTK
33419778	10.1158/1078-0432.CCR-20-3741	2021	Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.	BTK
33426371	10.1016/j.bioactmat.2020.12.010	2021	The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.	BTK
33427570	10.1080/10428194.2020.1864352	2021	Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.	BTK
33463471	10.2174/1568026621666210119112336	2021	A Multi-target Drug Designing for BTK, MMP9, Proteasome and TAK1 for the Clinical Treatment of Mantle Cell Lymphoma.	BTK
33477957	10.3390/cancers13020354	2021	Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells.	BTK
33512408	10.1182/blood.2020005964	2021	TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.	BTK
33515702	10.1016/j.critrevonc.2021.103238	2021	Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis.	BTK
33531153	10.1016/j.bulcan.2020.12.006	2021	[New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].	BTK
33552659	10.6004/jadpro.2021.12.1.2	2021	Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia.	BTK
33566715	10.1080/14712598.2021.1889510	2021	Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.	BTK
33569985	10.1080/10428194.2021.1881514	2021	Clinical application of genomics in Waldenstr√∂m macroglobulinemia.	BTK
33570649	10.1182/bloodadvances.2020003423	2021	Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.	BTK
33579791	10.1158/1078-0432.CCR-21-0140	2021	A Moving Target: Inactivating BTK Mutations as Drivers of Follicular Lymphoma.	BTK
33599764	10.1182/blood.2020009781	2021	Building on BTK inhibition in MCL.	BTK
33613932	10.1177/2040620721990553	2021	The role of acalabrutinib in adults with chronic lymphocytic leukemia.	BTK
33629212	10.1007/s12032-021-01470-5	2021	Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.	BTK
33639170	10.1016/j.jbc.2021.100465	2021	TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.	BTK
33645373	10.1080/14740338.2021.1897565	2021	Reducing treatment toxicity in Waldenstr√∂m macroglobulinemia.	BTK
33663302	10.1080/10428194.2021.1894643	2021	A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.	BTK
33676628	10.1016/S0140-6736(21)00224-5	2021	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.	BTK
33688166	10.2147/DDDT.S250823	2021	Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.	BTK
33704654	10.1007/s40265-021-01482-5	2021	Orelabrutinib: First Approval.	BTK
33711241	10.1080/14656566.2021.1902988	2021	Novel synthetic drugs for the treatment of non-Hodgkin lymphoma.	BTK
33718939	10.12703/r/10-22	2021	Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.	BTK
33730585	10.1016/j.celrep.2021.108870	2021	Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.	BTK
33735664	10.1016/j.neo.2021.02.002	2021	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr√∂m macroglobulinemia.	BTK
33740548	10.1016/j.ejmech.2021.113329	2021	Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.	BTK
33775465	10.1016/j.blre.2021.100824	2021	Revisiting Richter transformation in the era of novel CLL agents.	BTK
33812443	10.19746/j.cnki.issn.1009-2137.2021.02.052	2021	[New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review].	BTK
33827598	10.1186/s12935-021-01891-2	2021	Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma.	BTK
33851691	10.1358/dot.2021.57.4.3264113	2021	Tirabrutinib hydrochloride for B-cell lymphomas.	BTK
33869054	10.3389/fonc.2021.651057	2021	Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.	BTK
33896333	10.1080/10428194.2021.1913139	2021	Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies.	BTK
33902665	10.1186/s13045-021-01054-w	2021	Current and future treatment strategies in chronic lymphocytic leukemia.	BTK
33902692	10.1186/s40164-021-00222-5	2021	Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.	BTK
33912812	10.1097/HS9.0000000000000564	2021	Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia.	BTK
33946867	10.3390/cancers13092146	2021	Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma.	BTK
33981831	10.1016/j.omto.2021.03.015	2021	Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.	BTK
33996600	10.3389/fonc.2021.672052	2021	Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.	BTK
34000704	10.1016/j.bioorg.2021.104968	2021	Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.	BTK
34012272	10.2147/OTT.S300805	2021	Diagnosis and Individualized Treatment of Secondary Central Nervous System Lymphoma: A Case Report.	BTK
34021874	10.1007/s11899-021-00637-1	2021	Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.	BTK
34055635	10.3389/fonc.2021.668162	2021	Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.	BTK
34063667	10.3390/cancers13092198	2021	Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option.	BTK
34100025	10.1101/2021.06.02.21257804	2021	Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.	BTK
34108321	10.11406/rinketsu.62.398	2021	[Development and prospects of molecular targeted agents for malignant lymphoma].	BTK
34120550	10.1080/14656566.2021.1941864	2021	Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma.	BTK
34123480	10.6004/jadpro.2021.12.4.8	2021	A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.	BTK
34132782	10.1182/blood.2021011405	2021	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.	BTK
34137347	10.1080/14740338.2021.1945031	2021	Ibrutinib plus rituximab for the treatment of adult patients with Waldenstr√∂m's macroglobulinemia: a safety evaluation.	BTK
34159878	10.1080/10428194.2021.1929961	2021	Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.	BTK
34170207	10.1080/17474086.2021.1947236	2021	Managing complications secondary to Waldenstr√∂m's macroglobulinemia.	BTK
34174847	10.1186/s12885-021-08475-3	2021	Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma.	BTK
34174984	10.1016/j.hoc.2021.04.001	2021	The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.	BTK
34177947	10.3389/fimmu.2021.689472	2021	Resistance Mutations to BTK Inhibitors Originate From the NF-Œ∫B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.	BTK
34185336	10.1002/ajh.26284	2021	BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.	BTK
34214199	10.1111/ejh.13682	2021	MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.	BTK
34248972	10.3389/fimmu.2021.687458	2021	Targeting Bruton's Tyrosine Kinase in CLL.	BTK
34249912	10.3389/fcell.2021.655489	2021	Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK.	BTK
34263144	10.1097/HS9.0000000000000620	2021	The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells.	BTK
34264564	10.20892/j.issn.2095-3941.2020.0291	2021	SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation.	BTK
34268530	10.1358/dot.2021.57.7.3285932	2021	An update on acalabrutinib to treat chronic lymphocytic leukemia.	BTK
34269152	10.1080/10428194.2021.1938027	2021	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.	BTK
34277452	10.3389/fonc.2021.707285	2021	Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis.	BTK
34280258	10.1182/blood.2021011787	2021	BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.	BTK
34281758	10.1016/j.clml.2021.06.017	2021	A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy.	BTK
34293088	10.1182/blood.2021012039	2021	Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome.	BTK
34314938	10.1016/j.bmc.2021.116275	2021	Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.	BTK
34320163	10.1182/blood.2020006783	2021	Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.	BTK
34323286	10.1002/eji.202048968	2021	Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.	BTK
34327825	10.1111/jth.15367	2021	Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy.	BTK
34414843	10.1080/10428194.2021.1964020	2021	Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.	BTK
34447768	10.3389/fmed.2021.708071	2021	Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus.	BTK
34474146	10.1016/j.exphem.2021.08.010	2021	miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-Œ∫b signaling pathway in mantle cell lymphoma.	BTK
34478505	10.1182/bloodadvances.2021005083	2021	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.	BTK
34491123	10.1080/17512433.2021.1978288	2021	Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.	BTK
34497195	10.11406/rinketsu.62.1085	2021	[Molecular pathogenesis and treatment of chronic lymphocytic leukemia].	BTK
34497201	10.11406/rinketsu.62.1139	2021	[Therapeutic algorithm of Waldenstr√∂m's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].	BTK
34500472	10.1182/bloodadvances.2021004528	2021	Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.	BTK
34508613	10.18632/aging.203314	2021	Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.	BTK
34509879	10.1016/j.ejmech.2021.113820	2021	Discovery of novel BTK PROTACs for B-Cell lymphomas.	BTK
34534359	10.1111/imm.13416	2021	The role of Bruton's tyrosine kinase in the immune system and disease.	BTK
34551904	10.1158/1078-0432.CCR-21-1067	2021	Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma.	BTK
34557659	10.1016/j.isci.2021.102931	2021	The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma.	BTK
34599723	10.1007/s11899-021-00645-1	2021	BTK Inhibitors in Chronic Lymphocytic Leukemia.	BTK
34606736	10.1080/14728222.2021.1988927	2021	Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma.	BTK
34625994	10.1002/ajh.26367	2021	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.	BTK
34626359	10.1007/978-3-030-78311-2_8	2021	Chronic Lymphocytic Leukemia (CLL): Biology and Therapy.	BTK
34651869	10.1002/hon.2933	2021	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.	BTK
34710755	10.1016/j.phymed.2021.153802	2021	Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo.	BTK
34722279	10.3389/fonc.2021.733848	2021	Protein Kinase CK1Œ± Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma.	BTK
34732441	10.21873/anticanres.15384	2021	Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma.	BTK
34733270	10.3389/fimmu.2021.703256	2021	Cytomegalovirus in Haematological Tumours.	BTK
34739844	10.1016/j.ccell.2021.10.006	2021	Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.	BTK
34750354	10.1038/s41419-021-04353-9	2021	Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies.	BTK
34771535	10.3390/cancers13215372	2021	Update on Novel Therapeutics for Primary CNS Lymphoma.	BTK
34771616	10.3390/cancers13215453	2021	Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia.	BTK
34778802	10.1158/2643-3230.BCD-21-0063	2021	Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.	BTK
34858727	10.1080/2162402X.2021.2003533	2021	Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma.	BTK
34858810	10.3389/fonc.2021.720704	2021	Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice.	BTK
34884478	10.3390/ijms222312673	2021	BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.	BTK
34887877	10.3389/fimmu.2021.804735	2021	Editorial: New Insights on Bruton's Tyrosine Kinase Inhibitors.	BTK
34970462	10.1155/2021/3964465	2021	Reactivation of <i>Coccidioides immitis</i> in a Prosthetic Knee after Initiation of Chemotherapy.	BTK
34993136	10.3389/fonc.2021.771669	2021	The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia.	BTK
35003920	10.7717/peerj.12571	2021	Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway.	BTK
35087759	10.3389/fonc.2021.801124	2021	Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenstr√∂m Macroglobulinemia.	BTK
35116520	10.21037/tcr-21-50	2021	Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.	BTK
35356629	10.3389/fphar.2021.812565	2021	Target Specific Inhibition of Protein Tyrosine Kinase in Conjunction With Cancer and SARS-COV-2 by Olive Nutraceuticals.	BTK
31171645	10.3324/haematol.2019.220590	2020	Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma.	BTK
31316181	10.1038/s41401-019-0250-8	2020	Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.	BTK
31468508	10.1111/bjh.16168	2020	Ibrutinib monotherapy outside of clinical trial setting in Waldenstr√∂m macroglobulinaemia: practice patterns, toxicities and outcomes.	BTK
31685258	10.1016/j.bioorg.2019.103367	2020	Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.	BTK
31699386	10.1016/j.bioorg.2019.103361	2020	New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia.	BTK
31699465	10.1016/j.blre.2019.100635	2020	Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.	BTK
31738609	10.1080/14656566.2019.1689959	2020	An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.	BTK
31772331	10.1038/s41388-019-1122-x	2020	Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.	BTK
31782972	10.1002/hon.2694	2020	New responsibilities for aged kinases in B-lymphomas.	BTK
31831562	10.1158/1078-0432.CCR-19-2202	2020	Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.	BTK
31862225	10.1016/j.jocn.2019.11.013	2020	Bing-Neel syndrome presenting as isolated CNS lymphoplasmacytic lymphoma: A case report and review of the literature.	BTK
31865062	10.1016/j.leukres.2019.106286	2020	Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.	BTK
31866281	10.1016/S2352-3026(19)30210-8	2020	Acalabrutinib monotherapy in patients with Waldenstr√∂m macroglobulinemia: a single-arm, multicentre, phase 2 study.	BTK
31876911	10.1182/blood.2018884940	2020	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.	BTK
31918398	10.1016/j.bioorg.2019.103542	2020	JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma.	BTK
31931656	10.1080/15384047.2019.1700743	2020	Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma.	BTK
31933167	10.1007/s40265-019-01252-4	2020	Zanubrutinib: First Approval.	BTK
31992103	10.1080/10428194.2020.1719100	2020	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenstr√∂m macroglobulinemia.	BTK
32005797	10.1038/s41408-020-0277-6	2020	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.	BTK
32006301	10.1007/s11899-020-00559-4	2020	Novel Treatment Strategies in the Management of Waldenstr√∂m Macroglobulinemia.	BTK
32011729	10.1111/bjh.16416	2020	Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.	BTK
32014679	10.1016/j.ejmech.2020.112092	2020	Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.	BTK
32017058	10.1111/bjh.16406	2020	The Bruton's tyrosine¬†kinase¬†inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.	BTK
32027299	10.19746/j.cnki.issn.1009-2137.2020.01.056	2020	[Reaserch Advance on Bruton Tyrosine Kinase Inhibitors in the Treatment of B-Cell Tumors--Review].	BTK
32064588	10.1111/bjh.16407	2020	Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.	BTK
32083995	10.1200/JCO.19.02314	2020	Genomic Landscape of Waldenstr√∂m Macroglobulinemia and Its Impact on Treatment Strategies.	BTK
32093809	10.3727/096504020X15825405463920	2020	A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.	BTK
32103491	10.1111/bjh.16463	2020	Genomic evolution of ibrutinib-resistant clones in Waldenstr√∂m macroglobulinaemia.	BTK
32114502	10.1136/jitc-2020-000587	2020	Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.	BTK
32127472	10.1073/pnas.1921187117	2020	Regulation of B cell receptor-dependent NF-Œ∫B signaling by the tumor suppressor KLHL14.	BTK
32127939	10.7150/jca.34981	2020	Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma <i>in vivo and vitro</i>.	BTK
32162560	10.1080/14656566.2020.1737010	2020	Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.	BTK
32168755	10.3390/cancers12030650	2020	Mitochondrial Respiration Correlates with Prognostic Markers in Chronic Lymphocytic Leukemia and Is Normalized by Ibrutinib Treatment.	BTK
32186759	10.3892/mmr.2020.11022	2020	PDGFD induces ibrutinib resistance of diffuse large B‚Äëcell lymphoma through activation of EGFR.	BTK
32197990	10.1016/j.clml.2020.02.001	2020	Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes.	BTK
32198151	10.1158/1078-0432.CCR-19-3815	2020	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.	BTK
32207333	10.2217/fon-2019-0844	2020	ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.	BTK
32209572	10.1158/1078-0432.CCR-19-2856	2020	Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.	BTK
32239765	10.1002/ajh.25796	2020	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.	BTK
32242358	10.1056/NEJMoa1914347	2020	KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.	BTK
32253666	10.1007/s12185-020-02867-0	2020	Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?	BTK
32292084	10.1080/14656566.2020.1751123	2020	Duvelisib for the treatment of chronic lymphocytic leukemia.	BTK
32306816	10.1080/10428194.2020.1753043	2020	The effect of ibrutinib on neutrophil and Œ≥Œ¥ T cell functions.	BTK
32321318	10.1080/13543784.2020.1760245	2020	Novel agents for mantle cell lymphoma: molecular rational and clinical data.	BTK
32333154	10.1007/s00277-020-04005-6	2020	A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.	BTK
32345646	10.1158/1078-0432.CCR-20-1427	2020	BTK Inhibitors in Cancer Patients with COVID-19: The Winner Will be the One Who Controls That Chaos (Napoleon Bonaparte).	BTK
32370190	10.3390/cancers12051143	2020	Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells.	BTK
32382949	10.1007/s40265-020-01318-8	2020	Tirabrutinib: First Approval.	BTK
32385234	10.1038/s41467-020-16128-5	2020	Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms.	BTK
32393328	10.1186/s13045-020-00884-4	2020	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.	BTK
32400331	10.2174/1389557520666200513121524	2020	Irreversible Kinase Inhibitors Targeting Cysteine Residues and their Applications in Cancer Therapy.	BTK
32415780	10.1111/bjh.16738	2020	Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression.	BTK
32420699	10.1002/cam4.3136	2020	Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.	BTK
32452526	10.1111/bjh.16759	2020	Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.	BTK
32455989	10.3390/cancers12051328	2020	Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas.	BTK
32461234	10.1158/1078-0432.CCR-19-3703	2020	Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.	BTK
32481736	10.3390/cancers12061396	2020	Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies.	BTK
32484067	10.1177/1091581820918511	2020	Nonclinical Safety Assessment of Zanubrutinib: A Novel Irreversible BTK Inhibitor.	BTK
32489274	10.3747/co.27.6291	2020	Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-na√Øve chronic lymphocytic leukemia.	BTK
32508208	10.1080/10428194.2020.1772477	2020	Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.	BTK
32519423	10.1002/1878-0261.12742	2020	Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.	BTK
32552760	10.1186/s13045-020-00914-1	2020	Emerging therapies in mantle cell lymphoma.	BTK
32563910	10.1016/j.tranon.2020.100817	2020	Ibrutinib is not an effective drug in primografts of TCF3-PBX1.	BTK
32582577	10.2147/ITT.S240874	2020	Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?	BTK
32585766	10.1002/1878-0261.12753	2020	Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.	BTK
32586008	10.3390/biomedicines8060170	2020	ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells.	BTK
32598477	10.1182/bloodadvances.2019001350	2020	Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.	BTK
32603202	10.1080/14656566.2020.1770727	2020	An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.	BTK
32613545	10.1007/s40257-020-00535-x	2020	Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.	BTK
32631091	10.1080/14737140.2020.1791705	2020	The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.	BTK
32643971	10.1177/0300060520936053	2020	Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.	BTK
32644193	10.1002/cncr.33058	2020	US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.	BTK
32691208	10.1007/s11060-020-03580-y	2020	Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.	BTK
32698195	10.1182/blood.2020006449	2020	Zanubrutinib for the treatment of patients with Waldenstr√∂m macroglobulinemia: 3 years of follow-up.	BTK
32715803	10.1080/14740338.2020.1802424	2020	Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.	BTK
32731259	10.1182/blood.2020006844	2020	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr√∂m macroglobulinemia: the ASPEN study.	BTK
32753893	10.2147/OTT.S238832	2020	Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date.	BTK
32824276	10.3390/cancers12082303	2020	Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.	BTK
32848159	10.1038/s41467-020-17997-6	2020	Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry.	BTK
32861286	10.1016/j.hoc.2020.06.007	2020	Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.	BTK
32861287	10.1016/j.hoc.2020.06.008	2020	What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?	BTK
32861288	10.1016/j.hoc.2020.06.009	2020	Blastoid Mantle Cell Lymphoma.	BTK
32862855	10.1016/S2152-2650(20)30449-3	2020	BTK Inhibitors and Chemoimmunotherapy for CLL.	BTK
32862863	10.1016/S2152-2650(20)30456-0	2020	Waldenstr√∂m Macroglobulinemia - 2020 Update on Management and Future Directions.	BTK
32864130	10.1186/s40364-020-00214-3	2020	A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression.	BTK
32869675	10.1080/17474086.2020.1817735	2020	An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.	BTK
32899476	10.3390/cancers12092525	2020	Relevant Cytokines in the B Cell Lymphoma Micro-Environment.	BTK
32926124	10.1182/bloodadvances.2020001685	2020	Targeting phosphatidylinositol 3 kinase-Œ≤ and -Œ¥ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.	BTK
32929063	10.1038/s41392-020-00309-1	2020	Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma.	BTK
32955949	10.1080/14728214.2020.1822816	2020	Emerging drugs for the treatment of Waldenstr√∂m macroglobulinemia.	BTK
33005100	10.1186/s12935-020-01518-y	2020	Ibrutinib in B-cell lymphoma: single fighter might be enough?	BTK
33020271	10.1073/pnas.2007946117	2020	Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A.	BTK
33025948	10.1358/dot.2020.56.8.3158047	2020	Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.	BTK
33068336	10.1002/cam4.3499	2020	Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use.	BTK
33091356	10.1016/S2352-3026(20)30224-6	2020	Consensus treatment recommendations from the tenth International Workshop for Waldenstr√∂m Macroglobulinaemia.	BTK
33091668	10.1016/j.bioorg.2020.104377	2020	HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.	BTK
33091850	10.1016/j.bmc.2020.115815	2020	Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.	BTK
33093947	10.12688/f1000research.22318.1	2020	ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.	BTK
33109547	10.21873/anticanres.14630	2020	Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.	BTK
33126415	10.3390/ijms21218006	2020	Discovery of 5-Phenoxy-2-aminopyridine Derivatives as Potent and Selective Irreversible Inhibitors of Bruton's Tyrosine Kinase.	BTK
33134182	10.3389/fonc.2020.592205	2020	Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?	BTK
33154951	10.3389/fonc.2020.591577	2020	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	BTK
33188997	10.1016/j.ctarc.2020.100235	2020	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.	BTK
33214835	10.1021/acsmedchemlett.0c00378	2020	Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma.	BTK
33226337	10.7554/eLife.60470	2020	Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.	BTK
33273169	10.1212/CON.0000000000000936	2020	Central Nervous System Lymphomas.	BTK
33275726	10.1182/hematology.2020000121	2020	Management of Waldenstr√∂m macroglobulinemia in 2020.	BTK
33287742	10.1186/s12885-020-07678-4	2020	Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk.	BTK
33297772	10.1080/17474086.2020.1851184	2020	Zanubrutinib for the treatment of Waldenstr√∂m Macroglobulinemia.	BTK
33380880	10.3747/co.27.6795	2020	Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.	BTK
33489445	NA	2020	Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series.	BTK
34667996	10.21037/aol-20-20	2020	Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.	BTK
35117332	10.21037/tcr-20-72	2020	Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy.	BTK
29740811	10.1111/bjh.15271	2019	Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.	BTK
29978754	10.1080/10428194.2018.1480775	2019	Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.	BTK
30277101	10.1080/10428194.2018.1512710	2019	Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.	BTK
30381956	10.2217/fon-2018-0637	2019	Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.	BTK
30413649	10.1158/1535-7163.MCT-18-0478	2019	Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.	BTK
30423172	10.1093/neuonc/noy193	2019	Introduction of novel agents in the treatment of primary CNS lymphoma.	BTK
30442651	10.1124/dmd.118.084459	2019	Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans.	BTK
30453157	10.1016/j.jpba.2018.11.012	2019	Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats.	BTK
30508305	10.1002/cncr.31831	2019	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.	BTK
30522954	10.1016/j.bmcl.2018.11.051	2019	Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.	BTK
30545835	10.1182/blood-2018-07-862953	2019	Bruton tyrosine kinase degradation as a therapeutic strategy for cancer.	BTK
30546948	10.1080/2162402X.2018.1512455	2019	Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,<i>in-vitro</i> proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.	BTK
30556110	10.1007/s40262-018-0725-7	2019	Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.	BTK
30567753	10.1182/blood-2018-09-875732	2019	Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.	BTK
30638402	10.1080/17512433.2019.1568868	2019	Acalabrutinib for adults with mantle cell lymphoma.	BTK
30679329	10.3324/haematol.2018.214759	2019	The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.	BTK
30692121	10.1182/blood-2018-11-886457	2019	A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.	BTK
30693983	10.1002/mc.22983	2019	The HDAC6-selective inhibitor is effective against non-Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma.	BTK
30700840	10.1038/s41375-018-0366-8	2019	New roles for B cell receptor associated kinases: when the B cell is not the target.	BTK
30706214	10.1007/s12272-019-01124-1	2019	Development of BTK inhibitors for the treatment of B-cell malignancies.	BTK
30719267	10.1177/2040620718820510	2019	Novel treatment approaches and future perspectives in follicular lymphoma.	BTK
30723172	10.1126/scisignal.aat4105	2019	Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.	BTK
30760464	10.1182/bloodadvances.2018029058	2019	Resistance mechanism for ibrutinib in marginal zone lymphoma.	BTK
30777096	10.1186/s13046-019-1076-4	2019	Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.	BTK
30788082	10.1016/j.csbj.2019.01.006	2019	Bivalent Ligands for Protein Degradation in Drug Discovery.	BTK
30791947	10.1186/s40425-019-0529-9	2019	A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy.	BTK
30819916	10.3324/haematol.2018.212811	2019	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.	BTK
30821551	10.1080/10428194.2019.1569231	2019	Modulation of immune checkpoint molecule expression in mantle cell lymphoma.	BTK
30843894	NA	2019	Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.	BTK
30857748	10.1016/j.bmcl.2019.03.005	2019	Discovery of novel pyrazole derivatives as potential anticancer agents in MCL.	BTK
30858551	10.1038/s41375-019-0440-x	2019	Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.	BTK
30862686	10.1158/1541-7786.MCR-18-0256	2019	Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.	BTK
30872780	10.1038/s41375-019-0442-8	2019	Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.	BTK
30875504	10.1016/j.ejmech.2019.02.077	2019	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.	BTK
30878129	10.1016/j.critrevonc.2019.02.001	2019	Management of adverse effects/toxicity of ibrutinib.	BTK
30884247	10.1080/17474086.2019.1596793	2019	Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma.	BTK
30887112	10.1007/s00109-019-01777-x	2019	Activation of NF-Œ∫B in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IŒ∫B-Œ±.	BTK
30888232	10.1080/13543776.2019.1594777	2019	Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).	BTK
30907011	10.1002/cbf.3381	2019	TAK1 is a druggable kinase for diffuse large B-cell lymphoma.	BTK
30916599	10.1080/17474086.2019.1597703	2019	Ibrutinib for the treatment of chronic lymphocytic leukemia.	BTK
30927175	10.1007/s11523-019-00635-7	2019	Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.	BTK
30940906	10.1038/s41375-019-0463-3	2019	CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.	BTK
30963600	10.1002/ajh.25487	2019	Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.	BTK
30999237	10.1016/j.ejmech.2019.03.055	2019	Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).	BTK
31031018	10.1016/j.bioorg.2019.102943	2019	Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.	BTK
31043832	10.3747/co.26.4345	2019	Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.	BTK
31068044	10.1080/10428194.2019.1608536	2019	Hairy cell leukemia: present and future directions.	BTK
31105705	10.3389/fimmu.2019.00895	2019	Functional Antibody Responses Following Allogeneic Stem Cell Transplantation for <i>TP53</i> Mutant pre-B-ALL in a Patient With X-Linked Agammaglobulinemia.	BTK
31109313	10.1186/s12885-019-5717-y	2019	The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease.	BTK
31123343	10.1038/s41375-019-0489-6	2019	PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.	BTK
31187531	10.1002/hon.2596	2019	The modern approach to mantle cell lymphoma.	BTK
31188814	NA	2019	Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.	BTK
31189540	10.1136/jclinpath-2019-205837	2019	Diffuse large B-cell lymphoma in Southeast Asian cohort: expression patterns of B-cell receptor (BCR) repertoire and its linkage with molecular subtypes and response to R-CHOP therapy.	BTK
31217352	10.1172/jci.insight.127566	2019	Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.	BTK
31227358	10.1016/j.clml.2019.05.008	2019	Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.	BTK
31229160	10.1016/j.hoc.2019.03.004	2019	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.	BTK
31233483	10.1097/CCO.0000000000000556	2019	Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation.	BTK
31234030	10.1016/j.ejmech.2019.06.035	2019	Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.	BTK
31257351	10.3960/jslrt.19006	2019	Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.	BTK
31286638	10.1111/vco.12520	2019	Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.	BTK
31296529	10.1158/1078-0432.CCR-19-0273	2019	EŒº-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.	BTK
31327069	10.1007/s11912-019-0819-x	2019	How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.	BTK
31340982	10.1182/blood.2019001160	2019	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.	BTK
31355927	10.1111/bjh.16118	2019	Single and combined BTK and PI3KŒ¥ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.	BTK
31364164	10.1111/bph.14809	2019	A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk<sup>C481S</sup> mutation in B-cell malignancies.	BTK
31382969	10.1186/s12964-019-0391-x	2019	Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-Œ∫B, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.	BTK
31384539	10.1016/j.apsb.2019.01.001	2019	Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A).	BTK
31395509	10.1016/j.bmc.2019.07.043	2019	Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.	BTK
31406628	10.1186/s40164-019-0141-1	2019	Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide.	BTK
31420873	10.1002/hon.2667	2019	The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.	BTK
31432184	10.3892/or.2019.7282	2019	Disrupting myddosome assembly in diffuse large B‚Äëcell lymphoma cells using the MYD88 dimerization inhibitor ST2825.	BTK
31443360	10.3390/pathogens8030129	2019	Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment.	BTK
31481959	10.3389/fimmu.2019.01953	2019	A Novel <i>BTK</i> Gene Mutation in a Child With Atypical X-Linked Agammaglobulinemia and Recurrent Hemophagocytosis: A Case Report.	BTK
31508518	10.1016/j.heliyon.2019.e02290	2019	Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.	BTK
31511358	10.4049/jimmunol.1900321	2019	Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.	BTK
31527073	10.1182/blood.2019000725	2019	How I treat Waldenstr√∂m macroglobulinemia.	BTK
31534006	10.4049/jimmunol.1801327	2019	Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.	BTK
31558766	10.1038/s41375-019-0575-9	2019	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.	BTK
31591468	10.1038/s41375-019-0592-8	2019	What is new in the treatment of Waldenstrom macroglobulinemia?	BTK
31619091	10.1080/17474086.2020.1681962	2019	Contemporary management of nodal and primary splenic marginal zone lymphoma.	BTK
31624617	10.1002/ccr3.2257	2019	Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review.	BTK
31628288	10.3171/2019.7.JNS191376	2019	Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor.	BTK
31638169	10.3892/or.2019.7364	2019	Ibrutinib in CLL/SLL: From bench to bedside (Review).	BTK
31648477	10.3760/cma.j.issn.0253-2727.2019.09.008	2019	[Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review].	BTK
31676565	10.1158/2159-8290.CD-19-1135	2019	Correction: Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma.	BTK
31686856	10.2147/OTT.S155778	2019	Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy.	BTK
31688198	10.1097/QCO.0000000000000611	2019	Azole antifungals and new targeted therapies for hematological malignancy.	BTK
31708654	10.3747/co.26.4957	2019	Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.	BTK
31723816	10.1097/HS9.0000000000000175	2019	From Biology to Therapy: The CLL Success Story.	BTK
31764119	10.1097/PPO.0000000000000412	2019	Bruton Tyrosine Kinase Inhibitors: Present and Future.	BTK
31766355	10.3390/cancers11121834	2019	Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.	BTK
31801949	10.1038/s41419-019-2158-0	2019	Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.	BTK
31806993	10.2147/OTT.S227122	2019	Genomic Alterations In Primary Cardiac Diffuse Large B Cell Lymphoma: A Case Report And Literature Review.	BTK
31808904	10.1182/hematology.2019001321	2019	Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.	BTK
34468365	10.1158/2159-8290.CD-RW2019-016	2019	Ibrutinib plus Palbociclib Has Efficacy in Mantle Cell Lymphoma.	BTK
29452660	10.1016/j.beha.2017.10.010	2018	Novel therapies for relapsed/refractory mantle cell lymphoma.	BTK
29455639	10.1186/s12943-018-0779-z	2018	Role of Bruton's tyrosine kinase in B cells and malignancies.	BTK
29472356	10.3324/haematol.2017.184325	2018	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.	BTK
29476222	10.1007/s00280-018-3546-3	2018	Ibrutinib brain distribution: a preclinical study.	BTK
29483220	10.1158/1535-7163.MCT-17-0784	2018	p110Œ± Inhibition Overcomes Stromal Cell-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma.	BTK
29483358	10.4049/jimmunol.1701489	2018	Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages.	BTK
29484684	10.1002/hon.2502	2018	Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia.	BTK
29496671	10.1182/blood-2017-10-811752	2018	BTK<sup>Cys481Ser</sup> drives ibrutinib resistance via ERK1/2 and protects BTK<sup>wild-type</sup> MYD88-mutated cells by a paracrine mechanism.	BTK
29532266	10.1007/s10753-018-0745-3	2018	Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation.	BTK
29549872	10.1016/j.ctrv.2018.01.002	2018	Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.	BTK
29560128	10.18632/oncotarget.24310	2018	First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.	BTK
29567799	10.1182/blood-2017-10-809210	2018	Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.	BTK
29590547	10.1056/NEJMoa1715519	2018	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.	BTK
29615403	10.1182/blood-2018-02-832535	2018	SOX11 augments BCR signaling to drive MCL-like tumor development.	BTK
29637541	10.1111/bjh.15202	2018	How we manage patients with Waldenstr√∂m macroglobulinaemia.	BTK
29652138	10.1021/acs.bioconjchem.8b00137	2018	Development of a Selective Labeling Probe for Bruton's Tyrosine Kinase Quantification in Live Cells.	BTK
29669753	10.1182/bloodadvances.2017011916	2018	Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.	BTK
29690649	10.3390/cancers10040127	2018	Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.	BTK
29712895	10.1038/s41408-018-0076-5	2018	Waldenstr√∂m macroglobulinemia treatment algorithm 2018.	BTK
29715023	10.1021/acs.jmedchem.8b00441	2018	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.	BTK
29721381	10.1080/2162402X.2017.1423183	2018	FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.	BTK
29725548	10.1155/2018/5471368	2018	A Case Report of Nongerminal Center B-Cell Type Diffuse Large B-Cell Lymphoma Treated to Complete Response with Rituximab and Ibrutinib.	BTK
29735551	10.1158/0008-5472.CAN-17-4004	2018	Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.	BTK
29737219	10.1080/17474086.2018.1473030	2018	Use of acalabrutinib in patients with mantle cell lymphoma.	BTK
29741794	10.1002/ardp.201700369	2018	Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.	BTK
29768934	10.1080/14740338.2018.1477936	2018	A safety profile of medications used to treat Waldenstr√∂m's macroglobulinemia.	BTK
29781323	10.1080/14728214.2018.1479396	2018	Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.	BTK
29785709	10.1111/bjh.15411	2018	Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).	BTK
29808236	10.1007/s11864-018-0548-7	2018	Pitfalls of Combining Novel Agents in Lymphoma.	BTK
29855199	10.1080/13543784.2018.1482273	2018	Targeting the B cell receptor pathway in non-Hodgkin lymphoma.	BTK
29861875	10.18632/oncotarget.25011	2018	The B cell receptor signaling pathway in mantle cell lymphoma.	BTK
29873072	10.1111/bjh.15421	2018	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic¬†leukaemia treated with ibrutinib from 3 clinical trials.	BTK
29875397	10.1038/s41422-018-0055-1	2018	PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies.	BTK
29899297	10.3390/ijms19061758	2018	Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.	BTK
29912596	10.1080/10428194.2018.1457148	2018	Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.	BTK
29925955	10.1038/s41586-018-0290-0	2018	A multiprotein supercomplex controlling oncogenic signalling in lymphoma.	BTK
30006143	10.1016/j.bmc.2018.07.007	2018	Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.	BTK
30011241	10.1177/2472555218786165	2018	Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.	BTK
30013190	10.1038/s41388-018-0397-7	2018	Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.	BTK
30029202	10.1016/j.jchromb.2018.06.026	2018	Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.	BTK
30052472	10.1080/17474086.2018.1506327	2018	New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?	BTK
30069629	10.1007/978-3-319-91439-8_7	2018	Ibrutinib.	BTK
30072003	10.1016/j.jacc.2018.06.002	2018	Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.	BTK
30077608	10.1016/j.bmc.2018.07.047	2018	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3KŒ¥.	BTK
30077698	10.1016/j.clml.2018.07.287	2018	Risk of Major Bleeding with Ibrutinib.	BTK
30104685	10.1038/s41598-018-30509-3	2018	Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma.	BTK
30115641	10.1182/bloodadvances.2018016048	2018	Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.	BTK
30175400	10.1111/bjh.15567	2018	Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.	BTK
30190023	10.1016/j.hoc.2018.05.012	2018	First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenstr√∂m Macroglobulinemia.	BTK
30209121	10.1182/blood-2018-03-841015	2018	B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.	BTK
30231317	10.1200/EDBK_200829	2018	Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.	BTK
30280589	10.1080/1062936X.2018.1518927	2018	Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR.	BTK
30305939	10.1136/esmoopen-2018-000387	2018	BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance.	BTK
30390220	10.1007/s40265-018-1003-6	2018	Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.	BTK
30401751	10.1182/bloodadvances.2018022962	2018	Insights into the genomic landscape of MYD88 wild-type Waldenstr√∂m macroglobulinemia.	BTK
30510142	10.1158/1535-7163.MCT-17-0789-ATR	2018	XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IŒ∫B.	BTK
30534553	10.1155/2018/1042597	2018	Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.	BTK
30681658	NA	2018	In brief: Acalabrutinib (Calquence) for mantle cell lymphoma.	BTK
28428442	10.1158/1535-7163.MCT-16-0555	2017	Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.	BTK
26961147	10.1093/annonc/mdw131	2016	Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.	BTK
27157620	10.1038/onc.2016.155	2016	FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.	BTK
25189416	10.1038/leu.2014.263	2015	Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.	BTK
25284608	10.1111/bjh.13149	2015	Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.	BTK
25433814	10.1007/s00428-014-1698-z	2015	Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma.	BTK
25944695	10.18632/oncotarget.3824	2015	Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.	BTK
26540570	10.18632/oncotarget.6273	2015	Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.	BTK
23581641	10.3109/10428194.2013.794458	2014	Bruton's tyrosine kinase: potential target in human multiple myeloma.	BTK
24658273	10.1038/nrc3702	2014	Targeting Bruton's tyrosine kinase in B cell malignancies.	BTK
24970801	10.18632/oncotarget.2071	2014	Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.	BTK
23977012	10.1371/journal.pone.0071302	2013	Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase.	BTK
19212330	10.1038/leu.2009.23	2009	Identification of a Btk-BAG3 complex induced by oxidative stress.	BTK
18241233	10.1111/j.1365-2249.2008.03589.x	2008	Naturally occurring Bruton's tyrosine kinase mutations have no dominant negative effect in an X-linked agammaglobulinaemia cellular model.	BTK
15939795	10.1084/jem.20042101	2005	Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells.	BTK
16141323	10.1073/pnas.0505196102	2005	Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells.	BTK
12854903	10.1080/1042819031000067576	2003	Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia.	BTK
11920564	10.1002/1521-4141(200204)32:4&lt;982::AID-IMMU982&gt;3.0.CO;2-I	2002	Expression profiling in transformed human B cells: influence of Btk mutations and comparison to B cell lymphomas using filter and oligonucleotide arrays.	BTK
10068673	NA	1999	Involvement of wiskott-aldrich syndrome protein in B-cell cytoplasmic tyrosine kinase pathway.	BTK
10498607	NA	1999	Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK--functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling.	BTK
8688094	10.1126/science.273.5278.1096	1996	BTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cells.	BTK
8892607	NA	1996	Evidence that the Wiskott-Aldrich syndrome protein may be involved in lymphoid cell signaling pathways.	BTK
8283037	NA	1994	Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.	BTK
34605949	10.1007/s00277-021-04671-0	2022	Characterization of molecular genetics and clinicopathology in thymic MALT lymphoma.	CARD11
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	CARD11
34664256	10.1111/bjh.17894	2022	Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.	CARD11
34783281	10.1080/10428194.2021.1999444	2022	Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.	CARD11
34791836	10.1002/cam4.4422	2022	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.	CARD11
34837284	10.1111/cas.15224	2022	Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.	CARD11
35038193	10.1111/his.14617	2022	Incidence, clinicopathological features and genetics of in-situ follicular neoplasia: a comprehensive screening study in a Japanese cohort.	CARD11
35099607	10.1007/s00018-022-04154-z	2022	A20 and ABIN-1 cooperate in balancing CBM complex-triggered NF-Œ∫B signaling in activated T cells.	CARD11
35158799	10.3390/cancers14030531	2022	CARD9 Forms an Alternative CBM Complex in Richter Syndrome.	CARD11
35218741	10.1016/j.bcp.2022.114977	2022	Post-translational modification of MALT1 and its role in B cell- and T cell-related diseases.	CARD11
35230873	10.1126/scisignal.abk3083	2022	Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells.	CARD11
35240014	10.4143/crt.2022.017	2022	Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.	CARD11
35255409	10.1016/j.jbior.2022.100890	2022	CARD11 signaling in regulatory T cell development and function.	CARD11
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	CARD11
35651609	10.3389/fimmu.2022.878989	2022	Hyper-IgE and Carcinoma in CADINS Disease.	CARD11
35658124	10.1158/2159-8290.CD-21-1566	2022	BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.	CARD11
35734168	10.3389/fimmu.2022.922471	2022	m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment.	CARD11
35885931	10.3390/genes13071144	2022	Targeting a Novel G-Quadruplex in the <i>CARD11</i> Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group.	CARD11
35928872	10.3389/fonc.2022.932674	2022	Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma.	CARD11
35954378	10.3390/cancers14153716	2022	Mutations Affecting Genes in the Proximal T-Cell Receptor Signaling Pathway in Peripheral T-Cell Lymphoma.	CARD11
35981904	10.1016/j.jaci.2022.06.023	2022	The role of the CBM complex in allergic inflammation and disease.	CARD11
36051079	10.1002/jha2.428	2022	Targetable alterations in primary extranodal diffuse large B-cell lymphoma.	CARD11
32583848	10.1093/neuonc/noaa145	2021	Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.	CARD11
32790937	10.1111/febs.15522	2021	Defining the combinatorial space of PKC::CARD-CC signal transduction nodes.	CARD11
33034903	10.1002/hon.2816	2021	B cell receptor signaling related to resistance to Helicobacter pylori eradication therapy in gastric diffuse large B cell lymphoma.	CARD11
33098696	10.1111/ejh.13540	2021	RLTPR Q575E: A novel recurrent gain-of-function mutation in patients with adult T-cell leukemia/lymphoma.	CARD11
33232972	10.1182/blood.2020005244	2021	Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.	CARD11
33263441	10.1080/17474086.2021.1856652	2021	Development of molecular intervention strategies for B-cell lymphoma.	CARD11
33399078	10.1016/j.esmoop.2020.100012	2021	Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.	CARD11
33426772	10.1111/cas.14806	2021	Genetic profile of adult T-cell leukemia/lymphoma in Okinawa: Association with prognosis, ethnicity, and HTLV-1 strains.	CARD11
33479306	10.1038/s41598-020-80376-0	2021	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.	CARD11
33542970	10.1200/PO.20.00360	2021	Acquired CARD11 mutation promotes BCR independence in Diffuse Large B Cell Lymphoma.	CARD11
33561953	10.3390/cancers13040650	2021	Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies.	CARD11
33581493	10.1016/j.ctarc.2021.100310	2021	Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients.	CARD11
33872653	10.1016/j.jaci.2021.04.006	2021	Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency.	CARD11
33918793	10.3390/cancers13081801	2021	Clinical Applications of Genomic Alterations in ATLL: Predictive Markers and Therapeutic Targets.	CARD11
33951889	10.3324/haematol.2020.271957	2021	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.	CARD11
34177947	10.3389/fimmu.2021.689472	2021	Resistance Mutations to BTK Inhibitors Originate From the NF-Œ∫B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.	CARD11
34203889	10.3390/cancers13122993	2021	Genetic Characterization and Clinical Features of <i>Helicobacter pylori</i> Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.	CARD11
34223928	10.1007/s00109-021-02101-2	2021	CARMA1 is required for Notch1-induced NF-Œ∫B activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia.	CARD11
34236636	10.1007/978-1-0716-1669-7_8	2021	Methods to Study CARD11-BCL10-MALT1 Dependent Canonical NF-Œ∫B Activation in Jurkat T Cells.	CARD11
34236648	10.1007/978-1-0716-1669-7_20	2021	Generation and Surgical Analysis of Genetic Mouse Models to Study NF-Œ∫B-Driven Pathogenesis of Diffuse Large B Cell Lymphoma.	CARD11
34256839	10.1186/s40164-021-00232-3	2021	Progress in molecular feature of smoldering mantle cell lymphoma.	CARD11
34447369	10.3389/fimmu.2021.671755	2021	Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.	CARD11
34559885	10.1111/cei.13662	2021	Progressive B cell depletion in human MALT1 deficiency.	CARD11
34651869	10.1002/hon.2933	2021	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.	CARD11
34679437	10.3390/diagnostics11101739	2021	Dysregulation of miRNAs in DLBCL: Causative Factor for Pathogenesis, Diagnosis and Prognosis.	CARD11
34722279	10.3389/fonc.2021.733848	2021	Protein Kinase CK1Œ± Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma.	CARD11
34868072	10.3389/fimmu.2021.786572	2021	Clinical and Immunological Features of Human BCL10 Deficiency.	CARD11
31423576	10.1111/bjh.16159	2020	M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.	CARD11
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	CARD11
31883669	10.1016/j.pathol.2019.09.014	2020	The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.	CARD11
31961340	10.1172/JCI97040	2020	GRK2 suppresses lymphomagenesis by inhibiting the MALT1 proto-oncoprotein.	CARD11
31964218	10.1177/1078155219895079	2020	Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level.	CARD11
32059783	10.1016/j.cell.2020.01.029	2020	Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody.	CARD11
32473470	10.1016/j.cellimm.2020.104129	2020	Gain-of-function mutations in CARD11 promote enhanced aggregation and idiosyncratic signalosome assembly.	CARD11
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	CARD11
32574386	10.1111/ejh.13467	2020	MALT-1 as a novel therapeutic target for adult T-cell leukemia.	CARD11
32598477	10.1182/bloodadvances.2019001350	2020	Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.	CARD11
32721634	10.1016/j.cellimm.2020.104158	2020	Critical protein-protein interactions within the CARMA1-BCL10-MALT1 complex: Take-home points for the cell biologist.	CARD11
32770099	10.1038/s41598-020-70310-9	2020	Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.	CARD11
32771677	10.1016/j.cellimm.2020.104189	2020	The CBM complex: A growing multiplicity of cellular functions, regulatory mechanisms and connections to human disease.	CARD11
32779615	10.3960/jslrt.20019	2020	Clinical application of genomic aberrations in adult T-cell leukemia/lymphoma.	CARD11
33052237	10.7150/thno.47533	2020	Targeting BCL10 by small peptides for the treatment of B cell lymphoma.	CARD11
33154951	10.3389/fonc.2020.591577	2020	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	CARD11
33188997	10.1016/j.ctarc.2020.100235	2020	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.	CARD11
33202260	10.1016/j.ajhg.2020.10.015	2020	Multiplexed Functional Assessment of Genetic Variants in CARD11.	CARD11
33216547	10.1021/acs.jmedchem.0c01246	2020	Optimization of the <i>In Vivo</i> Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood.	CARD11
33329596	10.3389/fimmu.2020.601926	2020	Cellular and Mathematical Analyses of LUBAC Involvement in T Cell Receptor-Mediated NF-Œ∫B Activation Pathway.	CARD11
29734251	10.1097/PAI.0000000000000585	2019	MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.	CARD11
30360939	10.1016/j.leukres.2018.10.003	2019	Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns.	CARD11
30508305	10.1002/cncr.31831	2019	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.	CARD11
30514565	10.1016/j.cellimm.2018.11.001	2019	Ubiquitination and phosphorylation of the CARD11-BCL10-MALT1 signalosome in T cells.	CARD11
30986496	10.1016/j.exphem.2019.03.004	2019	ETV6-RUNX1 interacts with a region in SPIB intron 1 to regulate gene expression in pre-B-cell acute lymphoblastic leukemia.	CARD11
31000522	10.1158/0008-5472.CAN-18-3438	2019	MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.	CARD11
31060714	10.1016/j.jaci.2019.03.009	2019	Germline CBM-opathies: From immunodeficiency to atopy.	CARD11
31092922	10.1038/s41586-019-1215-2	2019	Targeting the CBM complex causes T<sub>reg</sub> cells to prime tumours for immune checkpoint therapy.	CARD11
31132650	10.1016/j.anndiagpath.2019.05.004	2019	TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.	CARD11
31138793	10.1038/s41467-019-10203-2	2019	Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells.	CARD11
31150604	10.1016/j.jid.2019.05.008	2019	Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.	CARD11
31296852	10.1038/s41467-019-10953-z	2019	Structures of autoinhibited and polymerized forms of CARD9 reveal mechanisms of CARD9 and CARD11 activation.	CARD11
31391255	10.1074/jbc.RA119.009551	2019	Coordinated regulation of scaffold opening and enzymatic activity during CARD11 signaling.	CARD11
31554683	10.1128/JVI.01499-19	2019	Host CARD11 Inhibits Newcastle Disease Virus Replication by Suppressing Viral Polymerase Activity in Neurons.	CARD11
31644910	10.1016/j.celrep.2019.09.040	2019	MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.	CARD11
31662757	10.1155/2019/9832956	2019	MicroRNA-181a Inhibits Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Progression by Repressing <i>CARD11</i>.	CARD11
29074501	10.1182/blood-2017-09-804641	2018	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.	CARD11
29382759	10.1073/pnas.1721967115	2018	Assembly mechanism of the CARMA1-BCL10-MALT1-TRAF6 signalosome.	CARD11
29587428	10.3390/biomedicines6020038	2018	NF-Œ∫B Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy.	CARD11
29649481	10.1016/j.bbrc.2018.04.057	2018	Role of IŒ∫B kinase Œ≤ in regulating the remodeling of the CARMA1-Bcl10-MALT1 complex.	CARD11
29891112	10.1016/j.critrevonc.2018.05.010	2018	Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.	CARD11
29899297	10.3390/ijms19061758	2018	Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.	CARD11
29925955	10.1038/s41586-018-0290-0	2018	A multiprotein supercomplex controlling oncogenic signalling in lymphoma.	CARD11
30022982	10.3389/fimmu.2018.01539	2018	BCL10 - Bridging CARDs to Immune Activation.	CARD11
30032036	10.1016/j.neo.2018.07.001	2018	Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma.	CARD11
30087457	10.1038/s41374-018-0096-6	2018	Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues.	CARD11
30127060	10.1084/jem.20180230	2018	Activated CARD11 accelerates germinal center kinetics, promoting mTORC1 and terminal differentiation.	CARD11
30214442	10.3389/fimmu.2018.01927	2018	Holding All the CARDs: How MALT1 Controls CARMA/CARD-Dependent Signaling.	CARD11
30279415	10.1038/s41467-018-06573-8	2018	Molecular architecture and regulation of BCL10-MALT1 filaments.	CARD11
30283440	10.3389/fimmu.2018.02078	2018	The CBM-opathies-A Rapidly Expanding Spectrum of Human Inborn Errors of Immunity Caused by Mutations in the CARD11-BCL10-MALT1 Complex.	CARD11
30283447	10.3389/fimmu.2018.02105	2018	Mechanisms of Regulated and Dysregulated CARD11 Signaling in Adaptive Immunity and Disease.	CARD11
30336982	10.1016/j.bbrc.2018.10.029	2018	MALT1 activation by TRAF6 needs neither BCL10 nor CARD11.	CARD11
30402490	10.1155/2018/6728128	2018	Gene Expression Profile Signature of Aggressive Waldenstr√∂m Macroglobulinemia with Chromosome 6q Deletion.	CARD11
30429846	10.3389/fimmu.2018.02366	2018	A <i>CARD9</i> Founder Mutation Disrupts NF-Œ∫B Signaling by Inhibiting BCL10 and MALT1 Recruitment and Signalosome Formation.	CARD11
30474008	10.3389/fonc.2018.00498	2018	Post-translational Modifications of the CARMA1-BCL10-MALT1 Complex in Lymphocytes and Activated B-Cell Like Subtype of Diffuse Large B-Cell Lymphoma.	CARD11
30515170	10.3389/fimmu.2018.02695	2018	BCL10-CARD11 Fusion Mimics an Active CARD11 Seed That Triggers Constitutive BCL10 Oligomerization and Lymphocyte Activation.	CARD11
26354285	10.1002/hon.2251	2017	Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma.	CARD11
27297871	10.1111/his.13015	2017	Recurrent mutations in genes involved in nuclear factor-Œ∫B signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.	CARD11
27698445	10.1038/leu.2016.272	2017	CARMA1 is a novel regulator of T-ALL disease and leukemic cell migration to the CNS.	CARD11
27864294	10.1182/blood-2016-05-718775	2017	B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.	CARD11
27915469	10.1002/cncr.30404	2017	MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.	CARD11
28052131	10.1371/journal.pone.0169026	2017	Two Antagonistic MALT1 Auto-Cleavage Mechanisms Reveal a Role for TRAF6 to Unleash MALT1 Activation.	CARD11
28073005	10.1016/j.ccell.2016.12.003	2017	Simultaneous Inhibition of PI3KŒ¥ and PI3KŒ± Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-Œ∫B and AKT.	CARD11
28115366	10.1182/blood-2016-09-692574	2017	Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells.	CARD11
28153771	10.1016/j.ebiom.2017.01.027	2017	B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.	CARD11
28235842	10.1182/blood-2017-01-761726	2017	Acquired mutations associated with ibrutinib resistance in Waldenstr√∂m macroglobulinemia.	CARD11
28319526	10.1097/PAS.0000000000000836	2017	Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features.	CARD11
28619981	10.1158/2159-8290.CD-17-0613	2017	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.	CARD11
28627735	10.1111/cas.13303	2017	Genetic alterations in adult T-cell leukemia/lymphoma.	CARD11
28664939	10.1038/modpathol.2017.58	2017	Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.	CARD11
28682481	10.1002/path.4933	2017	Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma.	CARD11
28993276	10.1016/j.humpath.2017.09.013	2017	A distinctive subgroup of oral EBV+ B-cell neoplasm with polymorphous features is potentially identical to EBV+ mucocutaneous ulcer.	CARD11
29222279	10.1182/asheducation-2017.1.358	2017	Follicular lymphoma: are we ready for a risk-adapted approach?	CARD11
29245897	10.18632/oncotarget.18502	2017	Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum.	CARD11
29262531	10.18632/oncotarget.21986	2017	Mutational profile of primary breast diffuse large B-cell lymphoma.	CARD11
29340061	10.18632/oncotarget.22799	2017	Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.	CARD11
26608593	10.1002/gcc.22328	2016	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.	CARD11
26747248	10.1182/blood-2015-07-655647	2016	CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.	CARD11
26752547	10.1097/PAS.0000000000000592	2016	Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.	CARD11
26773040	10.1182/blood-2015-09-672352	2016	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.	CARD11
26776161	10.1038/onc.2015.493	2016	Oncogenic CARMA1 couples NF-Œ∫B and Œ≤-catenin signaling in diffuse large B-cell lymphomas.	CARD11
26876250	10.3760/cma.j.issn.0253-2727.2016.01.006	2016	[Expression and prognostic value of CARD11 in diffuse large B cell lymphoma].	CARD11
26884334	10.1074/jbc.M116.717322	2016	Intramolecular Interactions and Regulation of Cofactor Binding by the Four Repressive Elements in the Caspase Recruitment Domain-containing Protein 11 (CARD11) Inhibitory Domain.	CARD11
26884335	10.1074/jbc.M115.683714	2016	Cooperative Control of Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling by an Unusual Array of Redundant Repressive Elements.	CARD11
26936881	10.4049/jimmunol.1403165	2016	Usp9X Is Required for Lymphocyte Activation and Homeostasis through Its Control of ZAP70 Ubiquitination and PKCŒ≤ Kinase Activity.	CARD11
27006117	10.1242/jcs.185025	2016	The paracaspase MALT1 cleaves the LUBAC subunit HOIL1 during antigen receptor signaling.	CARD11
27034408	10.1128/MCB.00106-16	2016	Correction for Pedersen et al., Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181.	CARD11
27070692	10.1016/j.ccell.2016.03.018	2016	Killing Lymphoma with Smac-Mimetics: As Easy as ABC?	CARD11
27070702	10.1016/j.ccell.2016.03.006	2016	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.	CARD11
27071417	10.1042/BCJ20160270	2016	Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-Œ∫B activation.	CARD11
27109639	10.1016/j.clim.2016.04.011	2016	Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation.	CARD11
27135977	10.1097/MOH.0000000000000257	2016	Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies.	CARD11
27169444	10.11406/rinketsu.57.417	2016	[Genetic landscape of adult T-cell leukemia/lymphoma].	CARD11
27224912	10.18632/oncotarget.9500	2016	Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.	CARD11
27262792	10.1016/j.semcancer.2016.05.002	2016	Mechanisms of NF-Œ∫B deregulation in lymphoid malignancies.	CARD11
27342034	10.1016/j.jid.2016.04.027	2016	S√©zary Syndrome: Translating Genetic Diversity into Personalized Medicine.	CARD11
27369867	10.1182/blood-2016-02-698977	2016	Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.	CARD11
27526684	10.1111/ejh.12792	2016	Rewired NFŒ∫B signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.	CARD11
27560392	10.1111/cas.13057	2016	Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.	CARD11
27777308	10.1074/jbc.M116.754028	2016	Molecular Determinants of Scaffold-induced Linear Ubiquitinylation of B Cell Lymphoma/Leukemia 10 (Bcl10) during T Cell Receptor and Oncogenic Caspase Recruitment Domain-containing Protein 11 (CARD11) Signaling.	CARD11
25030036	10.3109/10428194.2014.944522	2015	Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.	CARD11
25080849	10.1111/ejh.12427	2015	B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.	CARD11
25130477	10.3109/10428194.2014.941836	2015	Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.	CARD11
25391967	10.1007/s11060-014-1655-3	2015	Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.	CARD11
25428260	10.1038/leu.2014.330	2015	KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.	CARD11
25556945	10.1016/j.chembiol.2014.10.021	2015	Activity-based probes for detection of active MALT1 paracaspase in immune cells and lymphomas.	CARD11
25623213	10.1158/1078-0432.CCR-14-1561	2015	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.	CARD11
25748427	10.1371/journal.pone.0119363	2015	MALT1-ubiquitination triggers non-genomic NF-Œ∫B/IKK signaling upon platelet activation.	CARD11
25991819	10.1158/1078-0432.CCR-14-2116	2015	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.	CARD11
25996250	10.1111/febs.13325	2015	MALT1--a universal soldier: multiple strategies to ensure NF-Œ∫B activation and target gene expression.	CARD11
26245647	10.1038/ncomms8953	2015	MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation.	CARD11
26256760	10.1016/S1470-2045(15)00169-2	2015	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	CARD11
26277595	10.1016/j.jaci.2015.06.031	2015	Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: Molecular, immunologic, and clinical heterogeneity.	CARD11
26307535	10.1182/blood-2015-06-649905	2015	Cell of origin of transformed follicular lymphoma.	CARD11
26415585	10.1038/ncomms9470	2015	Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in S√©zary syndrome.	CARD11
26437031	10.1038/ng.3415	2015	Integrated molecular analysis of adult T cell leukemia/lymphoma.	CARD11
26525107	10.1038/ncomms9777	2015	The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-Œ∫B signalling.	CARD11
26540570	10.18632/oncotarget.6273	2015	Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.	CARD11
26551667	10.1038/ng.3442	2015	The mutational landscape of cutaneous T cell lymphoma and S√©zary syndrome.	CARD11
26551670	10.1038/ng.3444	2015	Genomic profiling of S√©zary syndrome identifies alterations of key T cell signaling and differentiation genes.	CARD11
26668357	10.1073/pnas.1507459112	2015	Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-Œ∫B and JNK activation.	CARD11
26711259	10.1128/MCB.00876-15	2015	Negative Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181.	CARD11
24240734	10.1007/s00401-013-1202-x	2014	Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.	CARD11
24327543	10.1002/gcc.22126	2014	Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.	CARD11
24362935	10.1038/nm.3435	2014	Pharmacological and genomic profiling identifies NF-Œ∫B-targeted treatment strategies for mantle cell lymphoma.	CARD11
24375035	10.1002/jcp.24543	2014	The three CARMA sisters: so different, so similar: a portrait of the three CARMA proteins and their involvement in human disorders.	CARD11
24383645	10.1111/imm.12207	2014	N-Ethyl-N-nitrosourea mutagenesis in the mouse provides strong genetic and in vivo evidence for the role of the Caspase Recruitment Domain (CARD) of CARD-MAGUK1 in T regulatory cell development.	CARD11
24411492	10.1016/j.cytogfr.2013.12.008	2014	The CBM signalosome: potential therapeutic target for aggressive lymphoma?	CARD11
24443940	10.1111/cei.12275	2014	CARD11 blockade suppresses murine collagen-induced arthritis via inhibiting CARD11/Bcl10 assembly and T helper type 17 response.	CARD11
24491438	10.1158/2159-8290.CD-13-0915	2014	Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.	CARD11
24548923	10.1016/j.molimm.2014.01.011	2014	Phosphorylation of Carma1, but not Bcl10, by Akt regulates TCR/CD28-mediated NF-Œ∫B induction and cytokine production.	CARD11
24792914	10.1016/j.immuni.2014.04.007	2014	Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation.	CARD11
24870942	10.1007/s00277-014-2116-y	2014	Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.	CARD11
24917592	10.1126/scisignal.2005169	2014	T cell receptor-dependent activation of mTOR signaling in T cells is mediated by Carma1 and MALT1, but not Bcl10.	CARD11
25087226	10.1016/j.jaci.2014.06.015	2014	The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency.	CARD11
25150998	10.1007/978-1-4939-1212-4_8	2014	Detection of NF-Œ∫B pathway activation in T helper cells.	CARD11
25245034	10.1186/s12964-014-0049-7	2014	AIP augments CARMA1-BCL10-MALT1 complex formation to facilitate NF-Œ∫B signaling upon T cell activation.	CARD11
25275047	NA	2014	Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.	CARD11
25320244	10.1182/blood-2014-07-589689	2014	Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.	CARD11
25365219	10.1172/JCI77493	2014	Inherited BCL10 deficiency impairs hematopoietic and nonhematopoietic immunity.	CARD11
25384343	10.1186/s40001-014-0062-8	2014	Characteristics of CARMA1-BCL10-MALT1-A20-NF-Œ∫B expression in T cell-acute lymphocytic leukemia.	CARD11
23149938	10.1128/MCB.00850-12	2013	A quantitative signaling screen identifies CARD11 mutations in the CARD and LATCH domains that induce Bcl10 ubiquitination and human lymphoma cell survival.	CARD11
23252516	10.1111/bjh.12172	2013	Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.	CARD11
23264041	10.1007/s13238-012-2120-8	2013	USP2a positively regulates TCR-induced NF-Œ∫B activation by bridging MALT1-TRAF6.	CARD11
23292937	10.1073/pnas.1205299110	2013	Genetic heterogeneity of diffuse large B-cell lymphoma.	CARD11
23378931	10.1155/2013/252318	2013	CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma.	CARD11
23508829	10.1002/gcc.22054	2013	Next-generation-sequencing-based risk stratification and identification of new genes involved in structural and sequence variations in near haploid lymphoblastic leukemia.	CARD11
23525237	10.3892/ijmm.2013.1307	2013	Self-oligomerization of the CARD domain prevents complex formation in the CARMA1 signalosome.	CARD11
23545653	10.1107/S1744309113005642	2013	Crystallization and preliminary X-ray crystallographic studies of the CARD domain of human CARMA1.	CARD11
23632891	10.1182/blood-2012-12-470153	2013	Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-Œ∫B activation in diffuse large B-cell lymphoma.	CARD11
23690623	10.1073/pnas.1221925110	2013	Regulation of T cell function by the ubiquitin-specific protease USP9X via modulating the Carma1-Bcl10-Malt1 complex.	CARD11
23720088	10.1002/ajh.23490	2013	Molecular and genomic aberrations in Chlamydophila psittaci negative ocular adnexal marginal zone lymphomas.	CARD11
24004675	10.1158/1078-0432.CCR-12-3869	2013	Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.	CARD11
24036998	10.1038/ni.2708	2013	Signaling by Fyn-ADAP via the Carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells.	CARD11
24060900	10.1016/j.semcancer.2013.09.001	2013	B-cell receptor signaling as a driver of lymphoma development and evolution.	CARD11
24074955	10.1016/j.molcel.2013.08.032	2013	Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly.	CARD11
24145781	10.1038/ni.2737	2013	ADAPted secretion of cytokines in NK cells.	CARD11
22102703	10.3324/haematol.2011.054080	2012	BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.	CARD11
22323537	10.4049/jimmunol.1101502	2012	Cutting edge: the death adaptor CRADD/RAIDD targets BCL10 and suppresses agonist-induced cytokine expression in T lymphocytes.	CARD11
22343534	10.1073/pnas.1121343109	2012	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	CARD11
22366302	10.1016/j.jmb.2012.02.018	2012	Structural determinants of MALT1 protease activity.	CARD11
22397314	10.3109/10428194.2012.668286	2012	Role of nuclear factor-Œ∫B regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.	CARD11
22528498	10.1074/jbc.M111.335463	2012	Protein kinase C-Œ¥ negatively regulates T cell receptor-induced NF-Œ∫B activation by inhibiting the assembly of CARMA1 signalosome.	CARD11
22698399	10.1016/j.ccr.2012.05.024	2012	Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.	CARD11
22808296	NA	2012	Mutation analysis of NF-Œ∫B signal pathway-related genes in ocular MALT lymphoma.	CARD11
22880103	10.1371/journal.pone.0042775	2012	Structural insights into the assembly of CARMA1 and BCL10.	CARD11
23027925	10.1084/jem.20112744	2012	Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production.	CARD11
23129749	10.1084/jem.20120831	2012	Congenital B cell lymphocytosis explained by novel germline CARD11 mutations.	CARD11
23238011	10.1016/j.ccr.2012.11.011	2012	A new brew of MALT1 inhibitors.	CARD11
23285191	10.1371/journal.pone.0052811	2012	VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type.	CARD11
20947507	10.1074/jbc.M110.177063	2011	NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway.	CARD11
21187856	10.1038/cr.2010.182	2011	NF-Œ∫B signaling pathways regulated by CARMA family of scaffold proteins.	CARD11
21199863	10.1074/jbc.M110.155895	2011	The Ca2+-dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-kappaB activation.	CARD11
21266526	10.1158/1078-0432.CCR-10-1859	2011	A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma.	CARD11
21324920	10.1158/0008-5472.CAN-10-2525	2011	Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.	CARD11
21396111	10.1186/1478-811X-9-6	2011	B cell antigen receptor-induced activation of an IRAK4-dependent signaling pathway revealed by a MALT1-IRAK4 double knockout mouse model.	CARD11
21489413	10.1016/j.cellimm.2011.03.025	2011	CD4 ligation excludes the Carma1-Bcl10-MALT1 complex from GM1-positive membrane rafts in CD3/CD28 activated T cells.	CARD11
21513986	10.1016/j.molimm.2011.03.020	2011	CaMKII targets Bcl10 in T-cell receptor induced activation of NF-Œ∫B.	CARD11
21569705	NA	2011	[Correlation between the expressions of CARMA1 gene and MUM1 and its significance in diffuse large B cell lymphoma].	CARD11
21862580	10.1074/jbc.M111.259549	2011	Akt fine-tunes NF-Œ∫B-dependent gene expression during T cell activation.	CARD11
22020631	10.1007/s00401-011-0891-2	2011	Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.	CARD11
20054396	10.1038/nature08638	2010	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.	CARD11
20439115	10.1016/j.molimm.2010.04.005	2010	Interaction of calmodulin with Bcl10 modulates NF-kappaB activation.	CARD11
20516126	10.1101/cshperspect.a000109	2010	Oncogenic activation of NF-kappaB.	CARD11
20544211	10.1007/s00401-010-0709-7	2010	Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma.	CARD11
20551178	10.1242/jcs.069476	2010	Interplay between BCL10, MALT1 and IkappaBalpha during T-cell-receptor-mediated NFkappaB activation.	CARD11
20668237	10.1073/pnas.1009209107	2010	T-cell regulation by casitas B-lineage lymphoma (Cblb) is a critical failsafe against autoimmune disease due to autoimmune regulator (Aire) deficiency.	CARD11
20685844	10.1101/cshperspect.a003004	2010	Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1.	CARD11
20799731	10.1021/bi101052d	2010	Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain.	CARD11
22282688	10.2147/JBM.S9772	2010	L-CBM signaling in lymphocyte development and function.	CARD11
19118383	10.1038/nature07613	2009	Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival.	CARD11
19359218	10.1016/j.it.2009.03.002	2009	CARD9 versus CARMA1 in innate and adaptive immunity.	CARD11
19412164	10.1038/nature07968	2009	Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.	CARD11
19444310	10.1038/embor.2009.64	2009	COP9 signalosome controls the Carma1-Bcl10-Malt1 complex upon T-cell stimulation.	CARD11
19454668	10.4049/jimmunol.0900498	2009	CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells.	CARD11
19480824	10.1051/medsci/2009255454	2009	[Role of CK1alpha in adaptive immunity and lymphomagenesis].	CARD11
19841088	10.1084/jem.20092160	2009	Masking MALT1: the paracaspase's potential for cancer therapy.	CARD11
19841089	10.1084/jem.20091167	2009	Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.	CARD11
19897720	10.1073/pnas.0907511106	2009	Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.	CARD11
18192506	10.1182/blood-2007-11-123513	2008	Multiple ITAM-coupled NK-cell receptors engage the Bcl10/Malt1 complex via Carma1 for NF-kappaB and MAPK activation to selectively control cytokine production.	CARD11
18227156	10.1128/MCB.01505-07	2008	T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b.	CARD11
18231929	10.1080/10428190701784722	2008	Analysis of CARMA1/BCL10/MALT1 expression in Reed-Sternberg cells of classical Hodgkin lymphoma.	CARD11
18323416	10.1126/science.1153629	2008	Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.	CARD11
18606643	10.4049/jimmunol.181.2.918	2008	Cell type-specific regulation of ITAM-mediated NF-kappaB activation by the adaptors, CARMA1 and CARD9.	CARD11
18625728	10.1128/MCB.00418-08	2008	The protein kinase C-responsive inhibitory domain of CARD11 functions in NF-kappaB activation to regulate the association of multiple signaling cofactors that differentially depend on Bcl10 and MALT1 for association.	CARD11
18633432	10.1038/leu.2008.191	2008	High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays.	CARD11
18806265	10.1074/jbc.M800670200	2008	Multiple protein domains mediate interaction between Bcl10 and MALT1.	CARD11
18829987	10.1093/intimm/dxn108	2008	CD28 stimulation triggers NF-kappaB activation through the CARMA1-PKCtheta-Grb2/Gads axis.	CARD11
19104039	10.1073/pnas.0806491106	2008	Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen.	CARD11
17052756	10.1016/j.molimm.2006.09.012	2007	Bcl10 is phosphorylated on Ser138 by Ca2+/calmodulin-dependent protein kinase II.	CARD11
17213322	10.1073/pnas.0606982104	2007	Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10.	CARD11
17356384	10.1097/01.jnen.0000248553.45456.96	2007	Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression.	CARD11
17363905	10.1038/sj.emboj.7601622	2007	Phosphorylation and ubiquitination of the IkappaB kinase complex by two distinct signaling pathways.	CARD11
17462996	10.1074/jbc.M610610200	2007	Caspase-8 and c-FLIPL associate in lipid rafts with NF-kappaB adaptors during T cell activation.	CARD11
17468049	10.1016/j.it.2007.04.004	2007	Post-translational modifications regulate distinct functions of CARMA1 and BCL10.	CARD11
17473310	10.1126/stke.3842007pe21	2007	CARD-Bcl10-Malt1 signalosomes: missing link to NF-kappaB.	CARD11
17478723	10.1126/science.1137895	2007	Regulation of NF-kappaB activation in T cells via association of the adapter proteins ADAP and CARMA1.	CARD11
17948050	10.1038/sj.emboj.7601897	2007	Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation.	CARD11
18086859	10.1084/jem.20070379	2007	IkappaB kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells.	CARD11
16484591	10.1182/blood-2005-09-3801	2006	Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma.	CARD11
16508008	10.1128/MCB.26.6.2327-2336.2006	2006	CARMA1 is required for Akt-mediated NF-kappaB activation in T cells.	CARD11
16572121	10.1038/nature04687	2006	A loss-of-function RNA interference screen for molecular targets in cancer.	CARD11
16672958	10.1038/441032a	2006	Cell biology: divining cancer cell weaknesses.	CARD11
16809782	10.1128/MCB.02469-05	2006	Ca2+/calmodulin-dependent protein kinase II is a modulator of CARMA1-mediated NF-kappaB activation.	CARD11
16818229	10.1016/j.molcel.2006.05.027	2006	Essential role for IkappaB kinase beta in remodeling Carma1-Bcl10-Malt1 complexes upon T cell activation.	CARD11
16920630	10.1016/j.cub.2006.06.062	2006	Caspase-8 regulation by direct interaction with TRAF6 in T cell receptor-induced NF-kappaB activation.	CARD11
17043017	NA	2006	CARMA1 and chromosomal translocations in extranodal marginal zone B-cell lymphomas of MALT type or diffuse large B-cell lymphomas.	CARD11
15802594	10.1126/science.1110902	2005	Cell biology. Kinasing and clipping down the NF-kappa B trail.	CARD11
15802604	10.1126/science.1107107	2005	PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation.	CARD11
16177990	10.1002/cncr.21421	2005	Overexpression of caspase recruitment domain (CARD) membrane-associated guanylate kinase 1 (CARMA1) and CARD9 in primary gastric B-cell lymphoma.	CARD11
14657271	10.1242/jcs.00904	2004	NF-kappaB signaling in lymphocytes: a new cast of characters.	CARD11
14673152	10.1128/MCB.24.1.164-171.2003	2004	CD3/CD28 costimulation-induced NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkappaB kinase beta to the immunological synapse through CARMA1.	CARD11
14754896	10.1074/jbc.M310599200	2004	MALT1/paracaspase is a signaling component downstream of CARMA1 and mediates T cell receptor-induced NF-kappaB activation.	CARD11
15122200	10.1038/nri1352	2004	CARMA1, BCL-10 and MALT1 in lymphocyte development and activation.	CARD11
15125833	10.1016/s1097-2765(04)00236-9	2004	The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes.	CARD11
15184390	10.1074/jbc.M402244200	2004	Physical and functional interaction of CARMA1 and CARMA3 with Ikappa kinase gamma-NFkappaB essential modulator.	CARD11
15210867	10.112/4.3.3	2004	Ubiquitination for activation: new directions in the NF-kappaB roadmap.	CARD11
15541657	10.1016/j.smim.2004.08.022	2004	The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling.	CARD11
12867038	10.1016/s0960-9822(03)00491-3	2003	Requirement for CARMA1 in antigen receptor-induced NF-kappa B activation and lymphocyte proliferation.	CARD11
12154356	10.1038/ni824	2002	A requirement for CARMA1 in TCR-induced NF-kappa B activation.	CARD11
12154360	10.1038/ni830	2002	CARMA1 is a critical lipid raft-associated regulator of TCR-induced NF-kappa B activation.	CARD11
14993411	10.1124/mi.2.6.356	2002	Determining the destiny of NF-kappa B after TCR ligation: it's CARMA1.	CARD11
11259443	10.1074/jbc.M102488200	2001	Card10 is a novel caspase recruitment domain/membrane-associated guanylate kinase family member that interacts with BCL10 and activates NF-kappa B.	CARD11
11278692	10.1074/jbc.M010512200	2001	CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B.	CARD11
11356195	10.1016/s0014-5793(01)02414-0	2001	Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaB activation.	CARD11
34472720	10.1002/cnr2.1545	2022	Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.	CCND3
34596253	10.1002/hon.2930	2022	Chronic lymphocytic leukemia with t(6;14) (p21;q32) CCND3-IGH: CCND3 rearrangement does not necessarily define a cyclin D1-negative mantle cell lymphoma.	CCND3
34605949	10.1007/s00277-021-04671-0	2022	Characterization of molecular genetics and clinicopathology in thymic MALT lymphoma.	CCND3
34617271	10.1111/bjh.17874	2022	Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.	CCND3
35359039	10.3760/cma.j.cn112151-20210904-00647	2022	[Clinicopathological and molecular genetic features of cyclin D1-negative mantle cell lymphoma].	CCND3
35687490	10.1182/bloodadvances.2021006654	2022	Genomic characterization of lymphomas in patients with inborn errors of immunity.	CCND3
35794096	10.1038/s41467-022-31355-8	2022	Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.	CCND3
35982976	10.3389/fonc.2022.934008	2022	Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation.	CCND3
33122824	10.1038/s41388-020-01532-4	2021	Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3.	CCND3
33332554	10.1084/jem.20201699	2021	Cyclin D3 drives inertial cell cycling in dark zone germinal center B cells.	CCND3
33399078	10.1016/j.esmoop.2020.100012	2021	Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.	CCND3
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	CCND3
33969276	10.1097/HS9.0000000000000563	2021	Acquisition of <i>TCF3</i> and <i>CCND3</i> Mutations and Transformation to Burkitt Lymphoma in a Case of B-Cell Prolymphocytic Leukemia.	CCND3
34058070	10.1002/1878-0261.13033	2021	NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.	CCND3
34098582	10.1182/blood.2020007591	2021	MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.	CCND3
34114641	10.14670/HH-18-351	2021	The pathologic diagnosis of mantle cell lymphoma.	CCND3
34627430	10.19746/j.cnki.issn.1009-2137.2021.05.019	2021	[Clinical Characteristics and Prognosis Affecting-Factors of the Patients with Burkitt Lymphoma].	CCND3
31688139	10.1097/PAS.0000000000001390	2020	Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study.	CCND3
31773249	10.1007/s00428-019-02704-8	2020	Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas.	CCND3
31849147	10.1111/cas.14286	2020	Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas.	CCND3
32059783	10.1016/j.cell.2020.01.029	2020	Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody.	CCND3
32449435	10.1080/15476286.2020.1772559	2020	Burkitt lymphoma-related <i>TCF3</i> mutations alter TCF3 alternative splicing by disrupting hnRNPH1 binding.	CCND3
32738175	10.1002/hon.2784	2020	Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis.	CCND3
33095873	10.1182/bloodadvances.2019001307	2020	Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia.	CCND3
33207194	10.1016/j.celrep.2020.108403	2020	Cyclin D3 Governs Clonal Expansion of Dark Zone Germinal Center B Cells.	CCND3
30538135	10.1182/blood-2018-07-862151	2019	<i>CCND2</i> and <i>CCND3</i> hijack immunoglobulin light-chain enhancers in cyclin D1<sup>-</sup> mantle cell lymphoma.	CCND3
30733272	10.3324/haematol.2018.207928	2019	Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.	CCND3
31557894	10.3390/cancers11101427	2019	FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma.	CCND3
29071477	10.1007/s12185-017-2360-8	2018	Enforced expression of MIR142, a target of chromosome translocation in human B-cell tumors, results in B-cell depletion.	CCND3
29295643	10.1080/10428194.2017.1413186	2018	The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples.	CCND3
29622548	10.1182/blood-2017-10-813576	2018	Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia.	CCND3
30381403	10.1182/bloodadvances.2018019398	2018	Recurrent <i>CCND3</i> mutations in <i>MLL</i>-rearranged acute myeloid leukemia.	CCND3
27493231	10.1136/jim-2016-000233	2017	Restoration of microRNA-212 causes a G0/G1 cell cycle arrest and apoptosis in adult T-cell leukemia/lymphoma cells by repressing CCND3 expression.	CCND3
27668411	10.1002/ijc.30444	2017	Synergy of interleukin 10 and toll-like receptor 9 signalling in B cell proliferation: Implications for lymphoma pathogenesis.	CCND3
28069605	10.1182/blood-2016-11-751024	2017	Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations.	CCND3
28148900	10.18632/oncotarget.14846	2017	Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling.	CCND3
28151717	10.1158/1078-0432.CCR-15-2869	2017	Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.	CCND3
28209658	10.3324/haematol.2016.156885	2017	Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-M√ºnster protocols.	CCND3
28607489	10.1038/nature22797	2017	The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.	CCND3
28671688	10.1038/ng.3909	2017	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.	CCND3
28883003	10.1158/0008-5472.CAN-16-2691	2017	Discovery of Human-Similar Gene Fusions in Canine Cancers.	CCND3
26522721	10.1038/onc.2015.385	2016	ZFP521 contributes to pre-B-cell lymphomagenesis through modulation of the pre-B-cell receptor signaling pathway.	CCND3
26647218	10.1158/1078-0432.CCR-15-2123	2016	Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.	CCND3
26887776	10.1111/bjh.13925	2016	Genetic differences between paediatric and adult Burkitt lymphomas.	CCND3
27440511	10.1373/clinchem.2016.255315	2016	Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.	CCND3
27750045	10.1016/j.ajpath.2016.07.027	2016	B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains.	CCND3
27888884	10.1016/j.hoc.2016.07.009	2016	Update on Burkitt Lymphoma.	CCND3
27959929	10.1371/journal.pmed.1002197	2016	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.	CCND3
25524659	10.3892/or.2014.3677	2015	Upregulation of AIOLOS induces apoptosis and enhances etoposide chemosensitivity in Jurkat leukemia cells.	CCND3
25529125	10.1016/j.humpath.2014.10.021	2015	Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients.	CCND3
25704763	10.1002/ijc.29494	2015	A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting.	CCND3
25839159	10.18632/oncotarget.3378	2015	Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.	CCND3
26173642	10.1002/gcc.22268	2015	The PCBP1 gene encoding poly(rC) binding protein I is recurrently mutated in Burkitt lymphoma.	CCND3
26485640	10.1016/j.yexcr.2015.10.012	2015	MicroRNA library screening identifies growth-suppressive microRNAs that regulate genes involved in cell cycle progression and apoptosis.	CCND3
24345752	10.1182/blood-2013-10-531509	2014	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.	CCND3
24492847	10.1101/cshperspect.a014282	2014	Oncogenic mechanisms in Burkitt lymphoma.	CCND3
25145835	10.1111/bjh.13079	2014	The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.	CCND3
23240690	10.1111/bjh.12161	2013	Gains of CCND3 gene in ocular adnexal MALT lymphomas: an integrated analysis.	CCND3
23255553	10.1182/blood-2012-08-452284	2013	CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.	CCND3
23422111	NA	2013	Prognostic value of clinical characteristics and immunophenotypic biomarkers in 115 patients with primary central nervous system lymphoma.	CCND3
23782073	10.1586/ehm.13.27	2013	Genetic sequencing studies in Burkitt's lymphoma: what can we learn about tumorigenesis?	CCND3
21479697	10.1007/s12032-011-9937-5	2012	The expression of SOX11, cyclin D1, cyclin D2, and cyclin D3 in B-cell lymphocytic proliferative diseases.	CCND3
22514694	10.1371/journal.pone.0034975	2012	3,3'-Diindolylmethane induces G1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia cells.	CCND3
22885699	10.1038/nature11378	2012	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.	CCND3
23079656	10.1016/j.ccr.2012.09.016	2012	Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.	CCND3
21504716	10.1016/j.cancergencyto.2010.08.016	2011	CD5-positive, cyclinD1-negative mantle cell lymphoma with a translocation involving the CCND2 gene and the IGL locus.	CCND3
21606168	10.3324/haematol.2011.041053	2011	Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells.	CCND3
21945515	10.1016/j.semcancer.2011.09.007	2011	The complex landscape of genetic alterations in mantle cell lymphoma.	CCND3
21965782	NA	2011	Immunohistochemical expression and prognostic significance of CCND3, MCM2 and MCM7 in Hodgkin lymhoma.	CCND3
20062012	10.1038/modpathol.2009.173	2010	Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes.	CCND3
20107311	10.4161/cc.9.4.10783	2010	Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: evidence for redundancy with cyclin E.	CCND3
20193116	10.5732/cjc.009.10552	2010	Significance of myeloid antigen expression in precursor T lymphoblastic lymphoma.	CCND3
20407034	10.1182/blood-2009-12-258822	2010	Pegylated arginase I: a potential therapeutic approach in T-ALL.	CCND3
20578819	10.3109/10428194.2010.496014	2010	Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.	CCND3
20956547	10.1084/jem.20091962	2010	Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases.	CCND3
19001083	10.1182/blood-2008-03-147967	2009	Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases.	CCND3
19639271	10.1007/s12185-009-0382-6	2009	Bone marrow large B cell lymphoma bearing cyclin D3 expression: clinical, morphologic, immunophenotypic, and genotypic analyses of seven patients.	CCND3
19704260	10.1097/PDM.0b013e31818935d2	2009	Improved diagnostic segregation of mantle cell lymphoma by determination of cyclin D1/D3 expression ratio in formalin-fixed tissue.	CCND3
18382684	10.1371/journal.pone.0001911	2008	p27 deficiency cooperates with Bcl-2 but not Bax to promote T-cell lymphoma.	CCND3
18391076	10.1182/blood-2007-10-118794	2008	Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas.	CCND3
18685613	10.1038/leu.2008.213	2008	Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2.	CCND3
17300668	10.1111/j.1440-1827.2006.02058.x	2007	Development-dependent expression of cyclin D3 in precursor T-cell lymphoblastic leukemia/lymphoma.	CCND3
17416736	10.1182/blood-2006-11-059451	2007	NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.	CCND3
16122798	10.1016/j.leukres.2005.06.025	2006	Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas.	CCND3
16270038	10.1038/sj.leu.2404008	2006	Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias.	CCND3
16614728	10.1038/sj.jid.5700224	2006	Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis.	CCND3
15389259	10.1038/modpathol.3800276	2005	Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma.	CCND3
15665120	10.1182/blood-2003-07-2558	2005	Posttranslational modifications of p27kip1 determine its binding specificity to different cyclins and cyclin-dependent kinases in vivo.	CCND3
15948116	10.1016/j.humpath.2005.03.004	2005	Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas.	CCND3
16084951	10.1016/j.humpath.2005.05.013	2005	Differential expression of cyclin D3 in ALK+ and ALK- anaplastic large cell lymphoma.	CCND3
16123218	10.1182/blood-2005-04-1753	2005	Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.	CCND3
16218953	10.1111/j.1742-4658.2005.04918.x	2005	Analysis of the contribution of changes in mRNA stability to the changes in steady-state levels of cyclin mRNA in the mammalian cell cycle.	CCND3
16322284	10.1158/1078-0432.CCR-05-1028	2005	Identification of CCND3 and BYSL as candidate targets for the 6p21 amplification in diffuse large B-cell lymphoma.	CCND3
16334487	10.1080/10428190500215100	2005	Expression of cyclins D1, D2, and D3 and Ki-67 in Leukemia.	CCND3
16620575	NA	2005	[Expression, localization and interrelationship of P27kip1 and cyclin D3 in non-Hodgkin's lymphoma].	CCND3
15096562	10.1016/S1525-1578(10)60494-1	2004	CyclinD1/CyclinD3 ratio by real-time PCR improves specificity for the diagnosis of mantle cell lymphoma.	CCND3
15098007	10.1038/modpathol.3800100	2004	Application of SELDI-TOF mass spectrometry for the identification of differentially expressed proteins in transformed follicular lymphoma.	CCND3
15305377	10.1002/ijc.20354	2004	Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index.	CCND3
15496980	10.1038/sj.leu.2403500	2004	Rapid amplification of immunoglobulin heavy chain switch (IGHS) translocation breakpoints using long-distance inverse PCR.	CCND3
12592386	10.1038/sj.onc.1206193	2003	Overexpression of Cdk6-cyclin D3 highly sensitizes cells to physical and chemical transformation.	CCND3
12647795	10.14670/HH-18.449	2003	Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferation and apoptosis in diffuse large B-cell lymphomas.	CCND3
12780788	10.1046/j.1365-2141.2003.04354.x	2003	Growth regulation by p27Kip1 is abrogated by multiple mechanisms in aggressive malignant lymphomas.	CCND3
12898595	10.1002/path.1384	2003	Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation.	CCND3
11895902	NA	2002	Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma.	CCND3
12036888	10.1182/blood.v99.12.4554	2002	Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.	CCND3
12107101	10.1016/S0002-9440(10)64168-5	2002	Expression of cyclin-dependent kinase inhibitor p27(Kip1) in AIDS-related diffuse large-cell lymphomas is associated with Epstein-Barr virus-encoded latent membrane protein 1.	CCND3
12383214	10.1046/j.1365-2559.2002.01506.x	2002	Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.	CCND3
12685840	10.1080/1042819021000006411	2002	Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.	CCND3
11242797	10.1309/8KF0-0Y0C-2F4L-UHXL	2001	Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features.	CCND3
11301189	10.1016/s0301-472x(01)00619-1	2001	Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors.	CCND3
11675358	10.1182/blood.v98.9.2837	2001	Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies.	CCND3
10803523	10.1038/sj.leu.2401761	2000	Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.	CCND3
10896950	10.1074/jbc.m001048200	2000	Glucocorticoid-mediated destabilization of cyclin D3 mRNA involves RNA-protein interactions in the 3'-untranslated region of the mRNA.	CCND3
10914560	10.1038/sj.leu.2401805	2000	Expression of cyclins D-type in B-chronic lymphoproliferative disorders.	CCND3
10225442	10.1002/(sici)1097-0215(19990517)81:4&lt;543::aid-ijc7&gt;3.0.co;2-3	1999	Expression of cyclin D2 and D3 in lymphoid lesions.	CCND3
10397744	NA	1999	Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells.	CCND3
10482983	10.1038/sj.leu.2401485	1999	Selective usage of D-type cyclins in lymphoid malignancies.	CCND3
10597239	10.1038/sj.onc.1203162	1999	Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells.	CCND3
11721429	NA	1999	[Expression and role of cyclin D3 in childhood acute leukemia].	CCND3
10037001	10.3109/10428199809059246	1998	The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features.	CCND3
9503147	10.1080/15216549800201052	1998	Prolactin-induced expression of TATA-less cyclin D3 gene is mediated by Sp1 and AP2.	CCND3
9697879	10.1038/sj.leu.2401100	1998	G1 arrest of U937 cells by onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF1/CIP1 and p27KIP and decreased pRb phosphorylation.	CCND3
9713342	10.1002/(SICI)1096-9896(199806)185:2&lt;159::AID-PATH73&gt;3.0.CO;2-0	1998	Cyclin D3 expression in normal, reactive and neoplastic tissues.	CCND3
9099742	10.1074/jbc.272.16.10859	1997	Elimination of cyclin D1 in vertebrate cells leads to an altered cell cycle phenotype, which is rescued by overexpression of murine cyclins D1, D2, or D3 but not by a mutant cyclin D1.	CCND3
9154817	10.1128/MCB.17.6.3181	1997	Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms.	CCND3
9376597	NA	1997	Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity.	CCND3
8668211	10.1128/MCB.16.7.3934	1996	Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest.	CCND3
8959341	NA	1996	Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines.	CCND3
7626688	10.1111/j.1365-2184.1995.tb00075.x	1995	Threshold expression of cyclin E but not D type cyclins characterizes normal and tumour cells entering S phase.	CCND3
7664296	NA	1995	c-Myc and cyclin D3 (CcnD3) genes are independent targets for glucocorticoid inhibition of lymphoid cell proliferation.	CCND3
7742549	NA	1995	Overexpression of cyclin D2 in chronic B-cell malignancies.	CCND3
8584027	10.1210/mend.9.11.8584027	1995	Glucocorticoid regulation of cyclin D3 gene transcription and mRNA stability in lymphoid cells.	CCND3
7926809	10.1016/0378-1119(94)90075-2	1994	Induction of D2 and D3 cyclin-encoding genes during promotion of the G1/S transition by prolactin in rat Nb2 cells.	CCND3
32401663	10.1080/15513815.2020.1764680	2022	PD-L1 and PD-L2 Mutations in Pediatric Hodgkin Lymphoma: Do They Have Any Prognostic Significance?	CD274
33722840	10.1136/jclinpath-2020-207280	2022	Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).	CD274
33870634	10.1111/ajco.13549	2022	Suitability of endobronchial ultrasound-guided transbronchial needle aspiration samples for programmed death ligand-1 testing in non-small cell lung cancer, the Bristol experience.	CD274
34520052	10.1111/bjh.17793	2022	9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.	CD274
34585994	10.1080/10428194.2021.1984454	2022	Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.	CD274
34841687	10.1111/1759-7714.14216	2022	Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue.	CD274
34842351	10.1002/cam4.4462	2022	PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders.	CD274
34862664	10.1111/apm.13195	2022	Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.	CD274
34903527	10.1101/gr.275911.121	2022	Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers.	CD274
34936940	10.1016/j.ejca.2021.11.013	2022	Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.	CD274
34959071	10.1016/j.molimm.2021.12.014	2022	HomA and HomB, outer membrane proteins of Helicobacter pylori down-regulate activation-induced cytidine deaminase (AID) and Ig switch germline transcription and thereby affect class switch recombination (CSR) of Ig genes in human B-cells.	CD274
34968160	10.1080/21655979.2021.2014617	2022	microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.	CD274
34996890	10.1038/s41598-021-02515-5	2022	The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.	CD274
35032188	10.1007/s00277-022-04760-8	2022	Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma.	CD274
35165282	10.1038/s41467-022-28479-2	2022	EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.	CD274
35194801	10.1111/bjd.21063	2022	Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and S√©zary syndrome: association with disease stage and clinical outcome.	CD274
35344582	10.1182/blood.2021014007	2022	Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies.	CD274
35359004	10.1182/bloodadvances.2022007104	2022	SIRPŒ±+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab.	CD274
35373781	10.23736/S2784-8671.22.07275-9	2022	PD-1 and PD-L1 expression in mycosis fungoides and S√©zary Syndrome.	CD274
35417939	10.3324/haematol.2021.280352	2022	Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.	CD274
35443604	10.7754/Clin.Lab.2021.210701	2022	Programmed Death Ligand-1 is Frequently Expressed in Primary Acute Myeloid Leukemia and B-Acute Lymphoblastic Leukemia.	CD274
35644823	10.1186/s43046-022-00121-8	2022	The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.	CD274
35655072	10.1038/s41598-022-13101-8	2022	Plasma extracellular vesicles bearing PD-L1, CD40, CD40L or TNF-RII are significantly reduced after treatment of AIDS-NHL.	CD274
35680804	10.19746/j.cnki.issn.1009-2137.2022.03.018	2022	[Inhibitory Effect of Interference with PD-L1 Expression on B-cell lymphoma in Mice].	CD274
35741318	10.3390/diagnostics12061507	2022	Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.	CD274
35764886	10.1038/s41598-022-15162-1	2022	Mutations in the miR-142 gene are not common in myeloproliferative neoplasms.	CD274
35767735	10.1182/bloodadvances.2022007046	2022	The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade.	CD274
35774848	10.1155/2022/3276925	2022	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.	CD274
35789115	10.1111/his.14718	2022	Hodgkinoid histiocytosis: an atypical nodal CD30 and S100-positive histiocytosis with eosinophilia.	CD274
35848760	10.1097/PAS.0000000000001899	2022	9p24.1 Genetic Alteration and PD-L1 Expression Are Characteristic of De Novo and Methotrexate-associated Epstein-Barr Virus-positive Hodgkin Lymphoma, But Not Methotrexate-associated Hodgkin-like Lesions.	CD274
35922773	10.1186/s12885-022-09803-x	2022	Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma.	CD274
31608729	10.1080/10428194.2019.1675880	2021	PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia.	CD274
32803453	10.1007/s00428-020-02901-w	2021	Clinicopathological analysis of neoplastic PD-L1-positive EBV<sup>+</sup> diffuse large B cell lymphoma, not otherwise specified, in a Japanese cohort.	CD274
32815748	10.1080/0284186X.2020.1806358	2021	Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990-2014.	CD274
32871584	10.1182/blood.2020006464	2021	Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.	CD274
32964767	10.1080/10428194.2020.1821011	2021	Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas.	CD274
33028589	10.1158/1078-0432.CCR-20-1457	2021	CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.	CD274
33091534	10.1016/j.canlet.2020.10.024	2021	NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.	CD274
33184699	10.1007/s00262-020-02787-2	2021	Epstein-Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma.	CD274
33196892	10.1007/s00432-020-03444-y	2021	Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world¬†study in China.	CD274
33232972	10.1182/blood.2020005244	2021	Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.	CD274
33247999	10.1111/cas.14752	2021	Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.	CD274
33277223	10.1016/j.clml.2020.11.009	2021	Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma.	CD274
33299141	10.1038/s41375-020-01105-0	2021	Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.	CD274
33369766	10.1002/hon.2836	2021	Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.	CD274
33389078	10.1007/s00432-020-03446-w	2021	Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma.	CD274
33454550	10.1016/j.ejmech.2021.113170	2021	Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.	CD274
33480087	10.1002/hon.2839	2021	High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup.	CD274
33512416	10.1182/blood.2020007245	2021	Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.	CD274
33517324	10.2967/jnumed.120.258384	2021	Synthesis and Preclinical Evaluation of a <sup>68</sup>Ga-Labeled Adnectin, <sup>68</sup>Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression.	CD274
33558066	10.1016/j.pathol.2020.11.004	2021	CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients.	CD274
33560388	10.1182/bloodadvances.2020002371	2021	Pembrolizumab in mycosis fungoides with PD-L1 structural variants.	CD274
33590326	10.1007/s00595-021-02236-2	2021	Immunotherapeutic advances in gastric cancer.	CD274
33620088	10.1111/bjh.17362	2021	Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma.	CD274
33655698	10.1002/cam4.3649	2021	Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.	CD274
33674274	10.1158/1078-0432.CCR-21-0133	2021	Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy.	CD274
33686666	10.1111/bjh.17366	2021	Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors.	CD274
33691262	10.1016/j.ejca.2021.01.020	2021	Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.	CD274
33721375	10.1111/ejh.13621	2021	Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.	CD274
33764958	10.12659/MSM.929431	2021	Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells.	CD274
33807678	10.3390/jof7030186	2021	Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.	CD274
33847923	10.1007/s12094-021-02579-9	2021	Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).	CD274
33889438	10.1080/2162402X.2021.1907059	2021	VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma.	CD274
33918793	10.3390/cancers13081801	2021	Clinical Applications of Genomic Alterations in ATLL: Predictive Markers and Therapeutic Targets.	CD274
33941556	NA	2021	PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.	CD274
33972504	10.1038/s41408-021-00477-5	2021	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.	CD274
34021249	10.1038/s41375-021-01289-z	2021	Thyroid MALT lymphoma: self-harm to gain potential T-cell help.	CD274
34060602	10.1042/BSR20204186	2021	Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.	CD274
34077007	NA	2021	Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings.	CD274
34078046	10.3760/cma.j.cn112151-20201223-00953	2021	[Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma].	CD274
34125179	10.1182/blood.2021011366	2021	Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations.	CD274
34130989	10.1136/jitc-2021-002558	2021	Pan-cancer analysis of <i>CD274</i> (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.	CD274
34153661	10.1016/j.intimp.2021.107870	2021	PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma.	CD274
34181355	10.31557/APJCP.2021.22.6.1943	2021	NFATc1 is Suppressed in Tumor Microenvironment of Hodgkin Lymphoma.	CD274
34257603	10.3389/pore.2021.637745	2021	Case Report: A Case Report of a Histological Transformation of <i>ALK</i>-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib.	CD274
34327781	10.1111/cas.15091	2021	Current progress and future perspectives of research on intravascular large B-cell lymphoma.	CD274
34363798	10.1016/j.humpath.2021.07.011	2021	Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.	CD274
34405609	10.3760/cma.j.cn112151-20210110-00023	2021	[Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation].	CD274
34534136	10.1097/PAS.0000000000001809	2021	Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells.	CD274
34543472	10.1002/hon.2926	2021	Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma.	CD274
34558414	10.5152/balkanmedj.2021.20086	2021	Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.	CD274
34584457	10.2147/CMAR.S317319	2021	Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma.	CD274
34600407	10.1016/j.lungcan.2021.09.011	2021	Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.	CD274
34615710	10.1073/pnas.2105822118	2021	Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.	CD274
34649362	10.1016/j.biopha.2021.112238	2021	An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1/PD-L1 drugs to treat cancers.	CD274
34661162	10.1158/2643-3230.BCD-21-0044	2021	Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1.	CD274
34742294	10.1186/s13000-021-01163-7	2021	Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.	CD274
34955650	10.2147/IJGM.S341557	2021	Combined Identification of Novel Markers for Diagnosis and Prognostic of Classic Hodgkin Lymphoma.	CD274
30225784	10.1007/s12253-018-0469-6	2020	The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.	CD274
31163235	10.1016/j.jaad.2019.05.077	2020	Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review.	CD274
31330525	10.1159/000500974	2020	Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.	CD274
31383967	10.1038/s41379-019-0336-3	2020	PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.	CD274
31493237	10.1007/s00535-019-01616-3	2020	Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.	CD274
31532724	10.1200/JCO.19.01056	2020	Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and S√©zary Syndrome: A Multicenter Phase II Study.	CD274
31598903	10.1007/s12094-019-02218-4	2020	Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.	CD274
31653980	10.1038/s41379-019-0392-8	2020	Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression.	CD274
31699300	10.1016/j.pathol.2019.09.005	2020	Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis.	CD274
31709594	10.1002/cbf.3463	2020	Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape.	CD274
31747139	10.1002/cam4.2670	2020	A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.	CD274
31752573	10.1080/10428194.2019.1691200	2020	New murine models of aggressive lymphoma.	CD274
31787352	10.1016/j.imbio.2019.11.007	2020	Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.	CD274
31790142	10.1182/blood.2019000847	2020	The immune landscape and response to immune checkpoint blockade therapy in lymphoma.	CD274
31809310	10.1097/PAI.0000000000000798	2020	Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment.	CD274
31811434	10.1007/s00428-019-02695-6	2020	Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.	CD274
31812554	10.1016/S1470-2045(19)30671-0	2020	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.	CD274
31825135	10.1002/1878-0261.12616	2020	High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination.	CD274
31829043	10.2217/fon-2019-0468	2020	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.	CD274
31879046	10.1016/j.prp.2019.152703	2020	TLR9 expression is associated with PD-L1 expression and indicates a poor prognosis in patients with peripheral T-cell lymphomas.	CD274
31894883	10.1111/pin.12891	2020	Diagnostic utility of programmed cell death ligand 1 (clone SP142) in mediastinal composite lymphoma: A report of two cases.	CD274
31894892	10.1111/pin.12888	2020	Syncytial variant of classic Hodgkin lymphoma: Four cases diagnosed with the aid of CD274/programmed cell death ligand 1 immunohistochemistry.	CD274
31903640	10.1002/jcla.23173	2020	Adrenal diffuse large B-cell lymphoma with high PD-L1 expression: Two case reports and literature review.	CD274
31911188	10.1016/j.semcancer.2020.01.001	2020	Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance.	CD274
31911474	10.1073/pnas.1908158117	2020	High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model.	CD274
31939183	10.1007/978-1-0716-0247-8_18	2020	Immunoblotting Analysis of Intracellular PD-L1 Levels in Interferon-Œ≥-Treated Ovarian Cancer Cells Stably Transfected with Bcl3 shRNA.	CD274
31959728	10.1136/jitc-2019-000376	2020	Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in <i>EGFR</i> <i>/</i> <i>ALK</i> wild-type advanced non-small cell lung cancer.	CD274
31977037	10.1093/ajcp/aqz198	2020	Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type.	CD274
31983543	10.1016/j.beem.2019.101370	2020	New insight in endocrine-related adverse events associated to immune checkpoint blockade.	CD274
31989260	10.1007/s00428-020-02756-1	2020	Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.	CD274
31992262	10.1186/s12885-020-6550-z	2020	Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis.	CD274
32030732	10.1111/bjh.16494	2020	Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.	CD274
32054467	10.1186/s12885-020-6612-2	2020	Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.	CD274
32066566	10.1158/0008-5472.CAN-19-2948	2020	Revisiting Immunotherapy: A Focus on Prostate Cancer.	CD274
32089543	10.1038/s41375-020-0737-9	2020	PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.	CD274
32108600	10.4103/lungindia.lungindia_488_19	2020	Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer.	CD274
32116068	10.1080/17474086.2020.1733405	2020	Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.	CD274
32143684	10.1186/s13104-020-04975-w	2020	Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.	CD274
32157792	10.1002/1878-0261.12664	2020	Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD-L1 and predicts poor prognosis in B-cell lymphoma.	CD274
32170448	10.1007/s00428-020-02790-z	2020	Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.	CD274
32227409	10.1111/cas.14397	2020	In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.	CD274
32248797	10.1186/s12885-020-06755-y	2020	PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.	CD274
32268011	10.1002/cyto.b.21879	2020	Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.	CD274
32295735	10.1016/j.clml.2019.11.021	2020	The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.	CD274
32327170	10.1016/j.thorsurg.2020.01.011	2020	Current Landscape of Personalized Therapy.	CD274
32366559	NA	2020	Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.	CD274
32367674	10.1002/cam4.3104	2020	PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.	CD274
32386255	10.1634/theoncologist.2020-0088	2020	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.	CD274
32394185	10.1007/s11899-020-00589-y	2020	PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.	CD274
32424876	10.1111/pin.12950	2020	PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: A clinicopathological study of 50 cases.	CD274
32515093	10.1002/hon.2758	2020	Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.	CD274
32558897	10.1084/jem.20191712	2020	Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.	CD274
32591311	10.1016/j.cllc.2020.05.004	2020	Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged¬†‚â• 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.	CD274
32623805	10.1111/pin.12982	2020	Nodal diffuse large B-cell lymphoma with neoplastic PD-L1 positivity, but without EBV association: Three cases highlighting an aspect of gray zone lymphoma.	CD274
32627031	10.3892/or.2020.7643	2020	Mechanistic insight of predictive biomarkers for antitumor PD‚Äë1/PD‚ÄëL1 blockade: A paradigm shift towards immunome evaluation (Review).	CD274
32649320	10.1097/PAS.0000000000001524	2020	PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.	CD274
32650968	10.1016/j.patol.2019.11.004	2020	[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].	CD274
32667831	10.1200/JCO.19.02103	2020	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.	CD274
32677947	10.1186/s12931-020-01437-6	2020	The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC.	CD274
32738861	10.31128/AJGP-11-19-5148	2020	Diagnosis and treatment of early lung cancer.	CD274
32751706	10.3390/ijms21155456	2020	Immune-Checkpoint Blockade Therapy in Lymphoma.	CD274
32759049	10.1016/j.intimp.2020.106852	2020	The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.	CD274
32778827	10.1038/s41591-020-1006-1	2020	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma.	CD274
32783303	10.1111/pin.13000	2020	Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.	CD274
32870581	10.1111/ijlh.13326	2020	Characteristics of immunological synapse in mature B-cell neoplasms.	CD274
32871472	10.1016/j.compbiolchem.2020.107362	2020	N-glycosylation and ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: A molecular modeling study.	CD274
32890601	10.1016/j.humpath.2020.08.008	2020	Comprehensive molecular genetic studies of Epstein-Barr virus-negative aggressive Natural killer-cell leukemia/lymphoma.	CD274
32992412	10.3760/cma.j.cn112151-20200205-00066	2020	[Expression of pSTAT3 and PD-L1 in extranodal NK/T cell lymphoma and its clinical significance].	CD274
33109533	10.21873/anticanres.14616	2020	EBV Positivity and Programmed Death-ligand 1 Expression in Diffuse Large B-cell Lymphoma: A Systematic Review.	CD274
33208970	10.1038/d41586-020-03154-y	2020	New lung-cancer drugs extend survival times.	CD274
33208971	10.1038/d41586-020-03155-x	2020	Better treatments for lung cancer that spreads to the brain.	CD274
33273548	10.1038/s41598-020-78152-1	2020	ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients.	CD274
33443026	10.4049/immunohorizons.2000089	2020	Enhanced Immunotherapeutic Efficacy of Anti-PD-L1 Antibody in Combination with an EP4 Antagonist.	CD274
33745258	NA	2020	PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population.	CD274
29946193	10.1038/s41375-018-0178-x	2019	Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.	CD274
30025443	10.4143/crt.2018.191	2019	Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‚ÄíPositive and ‚ÄíNegative Relapsed or Refractory Non-Hodgkin Lymphomas.	CD274
30028010	10.1111/bjh.15514	2019	PD-1 is highly expressed by neoplastic B-cells in Richter transformation.	CD274
30033844	10.1080/10428194.2018.1480767	2019	Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.	CD274
30132131	10.1007/s00428-018-2438-6	2019	Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.	CD274
30268773	10.1016/j.pharmthera.2018.09.008	2019	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.	CD274
30286249	10.1111/his.13765	2019	Integrative analysis of PD-L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B-cell lymphoma.	CD274
30321260	10.1093/ajcp/aqy130	2019	Lymphoepithelioma-Like Carcinoma of the Uterine Cervix: A Pathologic Study of Eight Cases With Emphasis on the Association With Human Papillomavirus.	CD274
30401947	10.1038/s41379-018-0173-9	2019	Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features.	CD274
30411330	10.1111/cei.13232	2019	Monocytes show immunoregulatory capacity on CD4<sup>+</sup> T cells in a human in-vitro model of extracorporeal photopheresis.	CD274
30450620	10.1111/pin.12738	2019	Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma arising in patient with a history of EBV-positive mucocutaneous ulcer and EBV-positive nodal polymorphous B-lymphoproliferative disorder.	CD274
30466764	10.1016/j.prp.2018.10.021	2019	Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia.	CD274
30475455	10.1111/1759-7714.12917	2019	PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.	CD274
30538305	10.1038/s41571-018-0138-4	2019	A banner year for immunotherapy and targeted therapy.	CD274
30540571	10.1097/PAS.0000000000001198	2019	Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.	CD274
30548240	10.1002/cncr.31871	2019	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.	CD274
30564891	10.1007/s00262-018-2282-1	2019	A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.	CD274
30567732	10.4049/jimmunol.1800876	2019	BCL6-Mediated Silencing of PD-1 Ligands in Germinal Center B Cells Maintains Follicular T Cell Population.	CD274
30601579	10.1111/pin.12742	2019	Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma.	CD274
30612418	10.3904/kjim.2018.179	2019	Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.	CD274
30630986	10.3324/haematol.2018.205567	2019	Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma.	CD274
30636374	10.1111/resp.13463	2019	Somatic mutations and immune checkpoint biomarkers.	CD274
30637917	10.1002/pbc.27571	2019	Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.	CD274
30642552	10.1016/j.lungcan.2018.11.025	2019	Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.	CD274
30642913	10.1158/1078-0432.CCR-18-3904	2019	Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.	CD274
30653748	10.4143/crt.2018.486	2019	Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.	CD274
30666052	10.1038/s41379-018-0193-5	2019	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.	CD274
30672338	10.5858/arpa.2018-0149-RS	2019	Pulmonary Lymphoepithelioma-like Carcinoma.	CD274
30683910	10.1038/s41375-019-0380-5	2019	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.	CD274
30688388	10.1111/pin.12757	2019	Divergence and heterogeneity of neoplastic PD-L1 expression: Two autopsy case reports of intravascular large B-cell lymphoma.	CD274
30723112	10.1182/bloodadvances.2018027672	2019	<i>MYD88</i> L265P mutation and <i>CDKN2A</i> loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.	CD274
30734108	10.1007/s00428-019-02528-6	2019	Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.	CD274
30745366	10.1158/2326-6066.CIR-18-0439	2019	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.	CD274
30770362	10.1182/bloodadvances.2018020602	2019	PD-L1 and tumor-associated macrophages in de novo DLBCL.	CD274
30783096	10.1038/s41408-019-0185-9	2019	Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.	CD274
30819446	10.1016/j.critrevonc.2019.01.003	2019	Programmed cell death protein receptor and ligands in haematological malignancies - Current status.	CD274
30821551	10.1080/10428194.2019.1569231	2019	Modulation of immune checkpoint molecule expression in mantle cell lymphoma.	CD274
30824609	10.1158/1535-7163.MCT-18-1068	2019	HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.	CD274
30827742	10.1016/j.currproblcancer.2019.01.008	2019	Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review.	CD274
30851544	10.1016/j.leukres.2019.02.010	2019	Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.	CD274
30860441	10.2217/imt-2018-0173	2019	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.	CD274
30861172	10.1111/his.13857	2019	Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.	CD274
30890046	10.1080/16078454.2019.1590965	2019	Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.	CD274
30898647	10.1016/j.lfs.2019.03.040	2019	LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.	CD274
30910787	10.1182/blood-2018-10-879015	2019	<i>PD-L1</i> gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.	CD274
30917792	10.1186/s12885-019-5466-y	2019	The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis.	CD274
30925928	10.1186/s12943-019-0977-3	2019	MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.	CD274
30938862	10.1111/his.13870	2019	A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features.	CD274
30942469	10.3892/or.2019.7096	2019	Effect and changes in PD‚Äë1 expression of CD19 CAR‚ÄëT¬†cells from T¬†cells highly expressing PD‚Äë1 combined with reduced‚Äëdose PD‚Äë1 inhibitor.	CD274
30955977	10.1016/S0140-6736(18)32409-7	2019	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.	CD274
30975638	10.1182/blood.2018889931	2019	PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.	CD274
30977285	10.1002/pbc.27757	2019	PD-L1 expression in pediatric Epstein-Barr virus positive classic Hodgkin lymphoma is not associated with 9p24.1 amplification.	CD274
31009388	10.1097/PAS.0000000000001254	2019	PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.	CD274
31017033	10.1080/10428194.2019.1602266	2019	The prognostic value of toll-like receptor5 and programmed cell death-ligand1 in patients with peripheral T-cell non-Hodgkin lymphoma.	CD274
31021376	10.1001/jamaoncol.2019.0393	2019	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.	CD274
31025831	10.1002/cncy.22140	2019	Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.	CD274
31039052	10.1200/JCO.18.02151	2019	Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.	CD274
31074879	10.1002/hon.2636	2019	Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.	CD274
31092922	10.1038/s41586-019-1215-2	2019	Targeting the CBM complex causes T<sub>reg</sub> cells to prime tumours for immune checkpoint therapy.	CD274
31098955	10.1007/s12539-019-00331-0	2019	PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation.	CD274
31107296	10.1097/LBR.0000000000000596	2019	Comparison of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration With Stylet Retracted Partially Versus Completely for Molecular Testing.	CD274
31123138	10.1136/jclinpath-2019-205727	2019	Intravascular NK/T-cell lymphoma: clinicopathological and integrated molecular analysis of two cases provides a clue to disease pathogenesis.	CD274
31125630	10.1016/j.humpath.2019.05.007	2019	Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas.	CD274
31130450	10.1016/j.cllc.2019.04.004	2019	Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.	CD274
31150165	10.1002/cam4.2316	2019	Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.	CD274
31151983	10.1182/blood.2019001043	2019	A novel model of controlling PD-L1 expression in ALK<sup>+</sup> anaplastic large cell lymphoma revealed by CRISPR screening.	CD274
31166373	10.1590/1806-3713/e20180181	2019	Molecular profile of non-small cell lung cancer in northeastern Brazil.	CD274
31189800	NA	2019	[Genetic Alterations Involving PD-L1/PD-L2 in Human Malignancies].	CD274
31197205	10.1038/s41374-019-0262-5	2019	PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma.	CD274
31206665	10.1002/jcp.28884	2019	Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death-ligand 1 by sponging microRNA-195-5p.	CD274
31253857	10.1038/s41598-019-45479-3	2019	Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL.	CD274
31269329	10.1002/cam4.2394	2019	PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories.	CD274
31292115	10.1182/blood.2019001126	2019	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.	CD274
31292525	10.1038/s41598-019-46473-5	2019	Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL.	CD274
31343834	10.1111/crj.13063	2019	Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer.	CD274
31382969	10.1186/s12964-019-0391-x	2019	Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-Œ∫B, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.	CD274
31394407	10.1016/j.virol.2019.07.024	2019	Expression of PD-1 and PD-Ls in Kaposi's sarcoma and regulation by oncogenic herpesvirus lytic reactivation.	CD274
31395597	10.1101/mcs.a004259	2019	Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma.	CD274
31408531	10.1002/hon.2664	2019	PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation.	CD274
31456438	10.1080/14712598.2019.1659777	2019	Pembrolizumab for the treatment of diffuse large B-cell lymphoma.	CD274
31503548	10.1172/JCI127721	2019	Myeloid loss of Beclin 1 promotes PD-L1hi precursor B cell lymphoma development.	CD274
31509890	10.1111/1759-7714.13195	2019	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.	CD274
31584451	10.1097/PAI.0000000000000800	2019	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP).	CD274
31640780	10.1186/s40425-019-0730-x	2019	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.	CD274
31644441	10.1097/COC.0000000000000608	2019	Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.	CD274
31655368	10.1016/j.lungcan.2019.10.017	2019	Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.	CD274
31679792	10.1016/j.prp.2019.152684	2019	Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.	CD274
31697809	10.1182/blood.2019002206	2019	The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative.	CD274
31844419	10.1186/s11658-019-0190-9	2019	MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.	CD274
31856276	10.1182/blood.2019000889	2019	EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.	CD274
31934533	10.1155/2019/8586354	2019	Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis.	CD274
27879989	10.1111/bjh.14432	2018	CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma.	CD274
28967040	10.1007/s00277-017-3146-z	2018	Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma.	CD274
29067721	10.1111/neup.12435	2018	The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.	CD274
29076134	10.1111/bjh.15009	2018	Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.	CD274
29112015	10.1097/PAS.0000000000000983	2018	PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.	CD274
29118007	10.1182/blood-2017-07-740993	2018	PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.	CD274
29122656	10.1016/j.humpath.2017.10.029	2018	Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.	CD274
29128997	10.1007/s00277-017-3176-6	2018	PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.	CD274
29132694	10.1016/j.jaad.2017.09.015	2018	Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study.	CD274
29153898	10.1016/j.cllc.2017.10.014	2018	The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.	CD274
29189264	10.1097/PAI.0000000000000615	2018	Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma.	CD274
29247952	10.1016/j.biopha.2017.11.146	2018	Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1.	CD274
29289361	10.1016/j.blre.2017.12.001	2018	The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.	CD274
29297942	10.1111/his.13461	2018	Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia/lymphoma.	CD274
29322203	10.1007/s00277-017-3226-0	2018	Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.	CD274
29338562	10.2217/nnm-2017-0296	2018	Targeted microbubbles with ultrasound irradiation and PD-1 inhibitor to increase antitumor activity in B-cell lymphoma.	CD274
29377256	10.1111/ejh.13033	2018	Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.	CD274
29380399	10.1111/his.13475	2018	Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.	CD274
29394125	10.1200/JCO.2017.77.3994	2018	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.	CD274
29415979	10.3960/jslrt.17037	2018	Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression.	CD274
29428449	10.1016/j.leukres.2018.01.014	2018	PD-1 /PD-L1 checkpoint in hematological malignancies.	CD274
29449276	10.1182/blood-2017-07-796342	2018	Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.	CD274
29464311	10.1007/s00277-018-3266-0	2018	High PD-L1 expression predicts poor prognosis in diffuse large B-cell lymphoma.	CD274
29476608	10.1002/dc.23900	2018	Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.	CD274
29510739	10.1186/s40425-018-0326-x	2018	Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis.	CD274
29540832	10.1038/s41388-018-0178-3	2018	miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy.	CD274
29545095	10.1016/S1470-2045(18)30144-X	2018	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.	CD274
29572000	10.1016/j.lungcan.2018.01.024	2018	PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.	CD274
29593668	10.3389/fmicb.2018.00380	2018	Simulation Study of cDNA Dataset to Investigate Possible Association of Differentially Expressed Genes of Human THP1-Monocytic Cells in Cancer Progression Affected by Bacterial Shiga Toxins.	CD274
29598887	10.1016/j.prp.2018.03.001	2018	Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.	CD274
29695237	10.1186/s12885-018-4266-0	2018	Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation.	CD274
29695766	10.1038/s41416-018-0076-z	2018	Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.	CD274
29748856	10.1007/s12185-018-2466-7	2018	CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.	CD274
29749542	10.3892/ijo.2018.4405	2018	The HDAC6 inhibitor ACY‚Äë1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells.	CD274
29762141	10.1097/PAS.0000000000001077	2018	PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.	CD274
29856861	10.1371/journal.pone.0198634	2018	Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.	CD274
29857068	10.1016/j.jid.2018.04.038	2018	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.	CD274
29863955	10.1056/NEJMoa1716948	2018	Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.	CD274
29876769	10.1007/s10238-018-0506-5	2018	Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients.	CD274
29877291	10.2169/internalmedicine.9884-17	2018	Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.	CD274
29880615	10.1182/blood-2018-04-843714	2018	Mass cytometry of Hodgkin lymphoma reveals a CD4<sup>+</sup> regulatory T-cell-rich and exhausted T-effector microenvironment.	CD274
29895574	10.1158/2326-6066.CIR-17-0270	2018	Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.	CD274
29895903	10.1038/s41408-018-0089-0	2018	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.	CD274
29902298	10.1001/jamaoncol.2018.1701	2018	Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.	CD274
29936139	10.1016/j.ebiom.2018.06.010	2018	Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies.	CD274
29950244	10.7534/j.issn.1009-2137.2018.03.049	2018	[PD-1/PD-L1 Signaling Pathway and Its Anti-Tumor Effect in Lymphoma -Review].	CD274
29970498	10.21873/anticanres.12662	2018	Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.	CD274
29998979	10.3960/jslrt.18001	2018	The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma.	CD274
30008296	10.1016/j.resinv.2018.04.004	2018	A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation.	CD274
30026337	10.3324/haematol.2018.197194	2018	PD-L1<sup>+</sup> tumor-associated macrophages and PD-1<sup>+</sup> tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.	CD274
30054295	10.1182/blood-2018-01-829424	2018	Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.	CD274
30104397	10.1182/bloodadvances.2018021113	2018	Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.	CD274
30116872	10.1007/s00277-018-3467-6	2018	Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome.	CD274
30135206	10.1074/jbc.RA118.004084	2018	The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.	CD274
30146693	10.1002/hon.2542	2018	Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma.	CD274
30209121	10.1182/blood-2018-03-841015	2018	B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.	CD274
30214445	10.3389/fimmu.2018.01955	2018	PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.	CD274
30247261	10.1097/PPO.0000000000000331	2018	Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.	CD274
30259911	NA	2018	Predictive markers in lung cancer: a few hints for the practicing pathologist.	CD274
30261066	10.1371/journal.pone.0204870	2018	Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma.	CD274
30290143	10.1016/j.cell.2018.09.007	2018	Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages.	CD274
30305518	10.11406/rinketsu.59.2127	2018	[Genetic analysis and its clinical implication in adult T-cell leukemia/lymphoma].	CD274
30327655	10.3389/fimmu.2018.02264	2018	Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.	CD274
30359792	10.1016/j.ctrv.2018.10.006	2018	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?	CD274
30389217	10.1016/j.pathol.2018.08.011	2018	EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.	CD274
30429043	10.1016/j.lungcan.2018.09.010	2018	Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.	CD274
30449068	10.1002/cam4.1875	2018	Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.	CD274
30458835	10.1186/s12967-018-1689-y	2018	Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.	CD274
30504313	10.1182/asheducation-2018.1.213	2018	Where does PD-1 blockade fit in HL therapy?	CD274
30541986	10.3960/jslrt.18034	2018	Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma.	CD274
30595199	10.1016/S0007-4551(18)30390-4	2018	NA	CD274
27667773	10.1007/s40291-016-0237-9	2017	An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.	CD274
27686004	10.1080/10428194.2016.1219903	2017	Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.	CD274
27696202	10.1007/s00277-016-2818-4	2017	Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.	CD274
27696517	10.1002/ajh.24571	2017	CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?	CD274
27881581	10.1158/1078-0432.CCR-16-1387	2017	Nivolumab in the Treatment of Hodgkin Lymphoma.	CD274
27966264	10.1002/hon.2375	2017	PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.	CD274
28104537	10.1016/j.jtho.2016.12.026	2017	Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ‚â•50% Expression in Lung Adenocarcinoma.	CD274
28114251	10.1097/PPO.0000000000000241	2017	Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy.	CD274
28125450	10.1097/PAS.0000000000000813	2017	Clinicopathological Study of 30 Cases of Peripheral T-cell Lymphoma with Hodgkin and Reed-Sternberg-like B-cells from Japan.	CD274
28132868	10.1016/j.jtho.2017.01.019	2017	LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.	CD274
28161001	10.1016/j.annpat.2016.12.005	2017	[Immune-checkpoint and hemopathies].	CD274
28188721	10.1016/j.cca.2017.02.005	2017	PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients.	CD274
28242522	10.1016/j.ctrv.2017.01.009	2017	Targeting the programmed death-1 pathway in lymphoid neoplasms.	CD274
28249162	10.1016/j.celrep.2017.02.011	2017	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.	CD274
28259530	10.1016/j.ejso.2017.02.008	2017	Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis.	CD274
28344319	10.1038/leu.2017.103	2017	PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.	CD274
28349165	10.1007/s00262-017-1987-x	2017	Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.	CD274
28402953	10.18632/oncotarget.16680	2017	Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.	CD274
28403071	10.1097/MD.0000000000006398	2017	The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.	CD274
28414300	10.1172/JCI94196	2017	PD-L1 serves as a double agent in separating GVL from GVHD.	CD274
28423587	10.18632/oncotarget.15627	2017	The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.	CD274
28476792	10.21873/anticanres.11564	2017	PD-L1 Expression in Patients with Non-small Cell Lung Cancer.	CD274
28482851	10.1186/s13045-017-0474-3	2017	Checkpoint inhibitors in hematological malignancies.	CD274
28504999	10.1097/PAS.0000000000000851	2017	Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.	CD274
28511816	10.1016/j.it.2017.04.004	2017	Mechanisms of Immune Tolerance in Leukemia and Lymphoma.	CD274
28514441	10.1038/nature22396	2017	PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.	CD274
28533311	10.1158/2326-6066.CIR-16-0221	2017	Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.	CD274
28561682	10.1200/EDBK_175265	2017	Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers.	CD274
28581487	10.1038/labinvest.2017.54	2017	EMMPRIN (CD147) is induced by C/EBPŒ≤ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.	CD274
28620848	10.1007/s40273-017-0527-z	2017	Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.	CD274
28624922	10.1007/s11523-017-0510-9	2017	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.	CD274
28659503	10.1183/16000617.0007-2017	2017	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series Pathology for the clinician Edited by Peter Dorfm√ºller and Alberto Cavazza.	CD274
28683452	10.1159/000471768	2017	Potential Role of the PD-1/PD-L1 Axis in the Immune Regulation of Chronic GVHD.	CD274
28685821	10.1111/imm.12788	2017	PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.	CD274
28688724	10.1016/j.pathol.2017.05.003	2017	PD-1 and PD-L1 expression in bone and soft tissue sarcomas.	CD274
28689001	10.1016/j.clml.2017.06.014	2017	Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.	CD274
28693793	10.1016/j.critrevonc.2017.06.001	2017	Biomarkers of response to PD-1/PD-L1 inhibition.	CD274
28760297	10.1016/j.clml.2017.02.022	2017	Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune¬†Checkpoints.	CD274
28778363	10.1053/j.ackd.2017.05.006	2017	Kidney Toxicities Associated With Novel Cancer Therapies.	CD274
28819821	10.1007/s40265-017-0796-z	2017	Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.	CD274
28822058	10.1007/s11899-017-0410-1	2017	Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.	CD274
28835513	10.1634/theoncologist.2017-0078	2017	FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.	CD274
28842748	10.1007/s00277-017-3115-6	2017	PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.	CD274
28883281	10.11406/rinketsu.58.957	2017	Novel mechanism of immune evasion in cancer via structural variations of the PD-L1 gene.	CD274
28893733	10.1182/blood-2017-03-770719	2017	Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.	CD274
28982883	10.21873/anticanres.12001	2017	Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.	CD274
29018115	10.1128/mBio.00917-17	2017	Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes.	CD274
29057919	10.1038/s41598-017-10946-2	2017	Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors.	CD274
29167175	10.1182/blood-2017-06-781989	2017	Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.	CD274
29190182	10.1080/08880018.2017.1383542	2017	Checkpoint inhibition in pediatric hematologic malignancies.	CD274
29222272	10.1182/asheducation-2017.1.310	2017	Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.	CD274
29246182	10.1186/s40880-017-0262-z	2017	Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.	CD274
29259344	10.1038/nrc.2017.124	2017	Targeted therapies: Strategies for mature T cell cancers.	CD274
26426431	10.1111/his.12882	2016	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.	CD274
26432723	10.1016/j.bbcan.2015.09.002	2016	Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.	CD274
26560962	10.1111/ejh.12697	2016	Checkpoint inhibitors in Hodgkin's lymphoma.	CD274
26678894	10.1007/s13277-015-4622-5	2016	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.	CD274
26807978	10.1111/febs.13668	2016	Immune checkpoint blockade in lymphoid malignancies.	CD274
26844985	10.1097/CCO.0000000000000272	2016	Experimental treatment strategies in primary cutaneous T-cell lymphomas.	CD274
26850007	10.1002/gcc.22345	2016	Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.	CD274
26901614	10.1016/j.ejca.2015.12.033	2016	Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.	CD274
26984449	10.1634/theoncologist.2015-0507	2016	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.	CD274
27026676	10.1634/theoncologist.2015-0498	2016	FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.	CD274
27030389	10.1182/blood-2015-12-686550	2016	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.	CD274
27045512	10.1016/j.humpath.2016.03.005	2016	Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.	CD274
27069084	10.1200/JCO.2016.66.4482	2016	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.	CD274
27070269	10.1080/13543784.2016.1175433	2016	Programming the immune checkpoint to treat hematologic malignancies.	CD274
27105512	10.18632/oncotarget.8847	2016	High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.	CD274
27107327	10.1016/j.ejca.2016.03.012	2016	High co-expression of PD-L1 and HIF-1Œ± correlates with tumour necrosis in pulmonary pleomorphic carcinoma.	CD274
27147575	10.18632/oncotarget.9061	2016	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.	CD274
27158757	10.1097/PAS.0000000000000653	2016	Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.	CD274
27225694	10.1158/1078-0432.CCR-15-3101	2016	EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.	CD274
27229745	10.1007/s40265-016-0588-x	2016	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?	CD274
27268263	10.1182/blood-2015-11-683003	2016	Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.	CD274
27269947	10.1200/JCO.2015.65.9789	2016	Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.	CD274
27281199	10.1038/nature18294	2016	Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.	CD274
27338100	10.1182/blood-2015-08-662783	2016	T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.	CD274
27341313	10.1111/bjh.14201	2016	The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.	CD274
27354476	10.1200/JCO.2016.67.3467	2016	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.	CD274
27376797	10.1007/s11596-016-1585-8	2016	A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer.	CD274
27418641	10.1182/blood-2016-02-698936	2016	PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.	CD274
27419920	10.1002/ajh.24485	2016	The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.	CD274
27473193	10.1007/s00277-016-2764-1	2016	Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety.	CD274
27564404	10.1111/cas.13065	2016	An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.	CD274
27595782	10.1007/s00428-016-2011-0	2016	Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.	CD274
27708232	10.18632/oncotarget.12363	2016	A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.	CD274
27737703	10.1186/s13045-016-0341-7	2016	PD-L1 is upregulated by EBV-driven LMP1 through NF-Œ∫B pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.	CD274
27737878	10.1158/2326-6066.CIR-16-0201	2016	Classical Hodgkin Lymphoma with Reduced Œ≤2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.	CD274
27753058	NA	2016	Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?	CD274
27753543	10.1080/15384101.2016.1245249	2016	STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.	CD274
27861156	10.18632/oncotarget.13411	2016	An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.	CD274
27861596	10.1371/journal.pone.0166266	2016	PD-L1 Status in Refractory Lymphomas.	CD274
28031823	10.1186/s40425-016-0201-6	2016	Challenges and opportunities¬†for checkpoint blockade in T-cell lymphoproliferative disorders.	CD274
25393674	10.3109/10428194.2014.985673	2015	Structural genomic alterations in primary mediastinal large B-cell lymphoma.	CD274
25482239	10.1056/NEJMoa1411087	2015	PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.	CD274
25712539	10.1002/path.4522	2015	Recurrent genomic rearrangements in primary testicular lymphoma.	CD274
25730880	10.1073/pnas.1500712112	2015	Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.	CD274
25823918	10.1016/j.clinthera.2015.02.018	2015	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.	CD274
25824455	10.1111/bjh.13397	2015	Immune checkpoint inhibition in lymphoid disease.	CD274
25862146	10.1016/j.lungcan.2015.03.017	2015	PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.	CD274
26004934	10.1007/s00277-015-2403-2	2015	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.	CD274
26019170	10.1158/1078-0432.CCR-15-0016	2015	Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.	CD274
26047524	10.1016/j.coph.2015.05.011	2015	PD-1/PD-L1 inhibitors.	CD274
26049755	10.1097/MOH.0000000000000158	2015	Targeting immune checkpoints in lymphoma.	CD274
26049756	10.1097/MOH.0000000000000155	2015	Genomic alterations underlying immune privilege in malignant lymphomas.	CD274
26135560	10.1097/PAS.0000000000000473	2015	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling.	CD274
26239088	10.1182/blood-2015-02-629600	2015	Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.	CD274
26254381	NA	2015	Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression.	CD274
26362649	10.1186/s13073-015-0218-3	2015	Gene expression meta-analysis reveals immune response convergence on the IFNŒ≥-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma.	CD274
26419961	10.1158/2326-6066.CIR-15-0089	2015	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.	CD274
26449653	10.1186/s13045-015-0213-6	2015	Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab.	CD274
26522856	10.1556/650.2015.30260	2015	[Novel treatment options in relapsed and refracter Hodgkin lymphomas].	CD274
26599546	10.1371/journal.pone.0139663	2015	Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines.	CD274
26686046	10.1016/S2352-3026(15)00150-7	2015	Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.	CD274
24359606	10.5414/np300698	2014	PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).	CD274
24497532	10.1182/blood-2013-10-535443	2014	Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.	CD274
24610827	10.1158/1078-0432.CCR-13-3007	2014	Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.	CD274
24732592	10.1038/leu.2014.137	2014	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial.	CD274
24780756	10.1158/0008-5472.CAN-13-3596	2014	Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.	CD274
23223433	10.1182/blood-2012-10-385591	2013	The role of B7 family molecules in hematologic malignancy.	CD274
23508008	10.3324/haematol.2012.071340	2013	Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.	CD274
23610619	10.1177/2040620712471553	2013	The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update.	CD274
23660624	10.1038/leu.2013.118	2013	Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells.	CD274
23966158	10.4161/cc.25922	2013	Histone H2AX suppresses translocations in lymphomas of EŒº-c-Myc transgenic mice that contain a germline amplicon of tumor-promoting genes.	CD274
24404580	10.1016/j.ajpath.2013.08.030	2013	The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.	CD274
22094231	10.1097/DAD.0b013e31821c35cb	2012	Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides.	CD274
22271878	10.1158/1078-0432.CCR-11-1942	2012	Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.	CD274
22462616	10.3109/10428194.2012.673228	2012	Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.	CD274
22547582	10.1182/blood-2012-02-411678	2012	Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.	CD274
22661084	10.4049/jimmunol.1102277	2012	B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels.	CD274
21368758	10.1038/nature09754	2011	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.	CD274
21540239	10.1158/1078-0432.CCR-10-2660	2011	Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.	CD274
21851845	10.1016/j.humimm.2011.07.308	2011	Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders.	CD274
22169317	NA	2011	[Research update on PD-1/PD-L1 pathway in hematological diseases].	CD274
20628145	10.1182/blood-2010-05-282780	2010	Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.	CD274
20639904	10.1038/onc.2010.280	2010	The stromal gene encoding the CD274 antigen as a genetic modifier controlling survival of mice with Œ≥-radiation-induced T-cell lymphoblastic lymphomas.	CD274
18830259	10.1038/leu.2008.272	2009	PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.	CD274
19393833	10.1053/j.seminoncol.2009.02.007	2009	Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.	CD274
19597183	10.1182/blood-2009-04-216671	2009	B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.	CD274
19703193	10.1111/j.1349-7006.2009.01302.x	2009	B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.	CD274
18203952	10.1182/blood-2007-05-085159	2008	PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.	CD274
19058313	10.3748/wjg.14.6853	2008	Hepatoma cells up-regulate expression of programmed cell death-1 on T cells.	CD274
19088198	10.1073/pnas.0810958105	2008	Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).	CD274
16403912	10.1182/blood-2005-08-3376	2006	Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.	CD274
34125957	10.1111/vox.13119	2022	A case of Philadelphia chromosome-positive acute lymphocytic leukaemia with type I CD36 deficiency.	CD36
35321563	10.1161/ATVBAHA.121.317018	2022	Plaque Evaluation by Ultrasound and Transcriptomics Reveals BCLAF1 as a Regulator of Smooth Muscle Cell Lipid Transdifferentiation in Atherosclerosis.	CD36
35436984	10.1038/s41419-022-04812-x	2022	B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36.	CD36
36040107	10.1002/JLB.6MA0822-720RR	2022	Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study.	CD36
34307504	10.3389/fcvm.2021.691336	2021	Plasma Purification Treatment Relieves the Damage of Hyperlipidemia to PBMCs.	CD36
34477034	10.1080/10428194.2021.1955878	2021	The diagnostic profile of rare acute myelomegakaryoblastic leukemia.	CD36
34478848	10.1016/j.nbd.2021.105495	2021	High-fat diet alters stress behavior, inflammatory parameters and gut microbiota in Tg APP mice in a sex-specific manner.	CD36
31919622	10.1007/s00262-019-02464-z	2020	Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas.	CD36
30579868	10.1016/j.ebiom.2018.12.020	2019	Associations between IgG reactivity to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) antigens and Burkitt lymphoma in Ghana and Uganda case-control studies.	CD36
31022903	10.3390/cancers11040576	2019	Deciphering the Elevated Lipid via CD36 in Mantle Cell Lymphoma with Bortezomib Resistance Using Synchrotron-Based Fourier Transform Infrared Spectroscopy of Single Cells.	CD36
31040105	10.1158/2159-8290.CD-18-1393	2019	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents.	CD36
31326577	10.1016/j.leukres.2019.106189	2019	Expression of platelet parameters and platelet membrane glycoproteins in childhood Burkitt lymphoma.	CD36
29552625	10.1016/j.jcmgh.2017.11.016	2018	Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are¬†Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).	CD36
28061439	10.18632/oncotarget.14494	2017	Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia.	CD36
28521628	10.1177/1093526616688753	2017	CD36-positive B-lymphoblasts Predict Poor Outcome in Children With B-lymphoblastic Leukemia.	CD36
29033373	10.1016/j.ebiom.2017.09.037	2017	Evaluating the Causal Link Between Malaria Infection and Endemic Burkitt Lymphoma in Northern Uganda: A Mendelian Randomization Study.	CD36
24188174	10.1111/cei.12231	2014	Integrin-driven monocyte to dendritic cell conversion in modified extracorporeal photochemotherapy.	CD36
24275555	10.1016/j.bbadis.2013.11.021	2014	Peri-conceptional obesogenic exposure induces sex-specific programming of disease susceptibilities in adult mouse offspring.	CD36
24307515	10.1007/s12185-013-1482-x	2014	inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman.	CD36
23452116	10.3109/10428194.2013.781167	2013	Immunophenotypic profile of nucleated erythroid progenitors during maturation in regenerating bone marrow.	CD36
25937841	10.1007/s12308-012-0166-4	2013	FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma.	CD36
19388928	10.1111/j.1365-2141.2009.07679.x	2009	Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia.	CD36
18622422	10.1038/bmt.2008.190	2008	Successful autologous hematopoietic progenitor cell transplantation in a patient with an isoantibody against CD36 (glycoprotein IV, Naka).	CD36
17490515	NA	2007	[CD36 expression in leukemia cells checked with multi-parameter flow cytometry and its significance].	CD36
16222707	10.1002/jcp.20517	2006	Unique human CD133+ leukemia cell line and its modulation towards a mesenchymal phenotype by FGF2 and TGFbeta1.	CD36
16896941	10.1007/s00125-006-0366-5	2006	BCL-6: a possible missing link for anti-inflammatory PPAR-delta signalling in pancreatic beta cells.	CD36
17071466	10.1080/10428190600763579	2006	CD36 - a marker for drug sensitive acute megakaryoblastic leukemia.	CD36
17071479	10.1080/10428190600773180	2006	CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome.	CD36
15737916	10.1016/j.meegid.2004.08.006	2005	Cell membrane proteins and quasispecies compartmentalization of CSF and plasma HIV-1 from aids patients with neurological disorders.	CD36
16029505	10.1186/1476-8518-3-4	2005	Rapid construction of a dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loading.	CD36
16211218	NA	2005	Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs.	CD36
25048671	10.1016/S1572-1000(05)00034-7	2005	Photopheresis up-regulates CD36 on monocytes and reduces CD25(+) and CD28(+) T cell numbers.	CD36
14767533	NA	2004	Pathway analysis of informative genes from microarray data reveals that metabolism and signal transduction genes distinguish different subtypes of lymphomas.	CD36
15339698	NA	2004	Type I CD36 deficiency in hematologic disorder.	CD36
15481137	10.1016/j.imbio.2004.02.001	2004	Macrophage chemotaxis to apoptotic Burkitt's lymphoma cells in vitro: role of CD14 and CD36.	CD36
12517778	NA	2003	Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas.	CD36
12579990	10.1309/HEFL-7KC4-35KF-WEX8	2003	Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry.	CD36
12008089	10.1016/s0145-2126(01)00198-9	2002	Cutaneous lymphoblastic lymphoma of putative plasmacytoid dendritic cell-precursor origin: two cases.	CD36
12452836	10.1046/j.1365-2249.2002.01998.x	2002	Murine glomerular mesangial cell uptake of apoptotic cells is inefficient and involves serum-mediated but complement-independent mechanisms.	CD36
11241503	10.1002/1097-0320(20010215)46:1&lt;23::aid-cyto1033&gt;3.0.co;2-z	2001	Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting.	CD36
10698208	10.1097/00000372-200002000-00001	2000	Nonlymphoid intraepidermal mononuclear cell collections (pseudo-Pautrier abscesses): a morphologic and immunophenotypical characterization.	CD36
10955685	10.1034/j.1600-0560.2000.027008392.x	2000	Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases.	CD36
10200002	10.1016/s0091-6749(99)70225-3	1999	Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis.	CD36
10329920	NA	1999	Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination.	CD36
10486527	NA	1999	Phenotyping of epidermal dendritic cells: clinical applications of a flow cytometric micromethod.	CD36
9594363	10.1007/s005990050017	1998	Primary ex vivo culture of keratinocytes isolated from hypertrophic scars as a means of biochemical characterization of CD36.	CD36
9820824	10.1042/bj3360451	1998	Cell proliferation, apoptosis and accumulation of lipid droplets in U937-1 cells incubated with eicosapentaenoic acid.	CD36
9094456	10.1159/000246076	1997	Extracorporeal photochemotherapy induces a significant increase in CD36+ circulating monocytes in patients with mycosis fungoides.	CD36
9322904	10.3109/10428199709051791	1997	CD4+ acute undifferentiated leukaemia, probably early monoblastic type, developing in a patient with myelodysplastic syndrome and bone marrow fibrosis.	CD36
9859781	NA	1997	Expression of thrombospondin receptor (CD36) in chronic B-cell lymphoproliferative disorders: a role in tumor metastasis?	CD36
8624153	NA	1996	Immunoregulatory events in the skin of patients with cutaneous T-cell lymphoma.	CD36
7658708	NA	1995	Acute leukemia and the transient myeloproliferative disorder associated with Down syndrome: morphologic, immunophenotypic and cytogenetic manifestations.	CD36
7718977	10.2169/internalmedicine.34.36	1995	B-cell lymphoma terminating in acute monoblastic leukemia.	CD36
7526582	10.2340/0001555574269272	1994	Expression of thrombospondin-1 (TSP1) and its receptor (CD36) in healthy and diseased human skin.	CD36
8069185	10.3109/10428199409049629	1994	Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers.	CD36
7688777	10.1111/j.1346-8138.1993.tb01295.x	1993	Expression of monocyte/macrophage markers (CD13, CD14, CD68) on human keratinocytes in healthy and diseased skin.	CD36
1337297	10.3109/10428199209049829	1992	Coexistence of acute monoblastic leukemia and adult T-cell leukemia: possible association with HTLV-I infection in both cases?	CD36
1371397	10.1111/j.1365-2141.1992.tb06413.x	1992	Expression of CD11B, CD14 and CD36 antigens by B-cell lymphoma.	CD36
1571092	10.1159/000163699	1992	Monoclonal antibodies defining shared human macrophage-endothelial antigens.	CD36
1722228	10.1111/j.1600-0560.1991.tb01543.x	1991	Reactivity of monoclonal antibody OKM5 with sebaceous carcinoma.	CD36
1835941	10.1159/000247666	1991	Expression of complement receptor CR2 (CD21) on human subcorneal keratinocytes in normal and diseased skin.	CD36
21269073	10.3109/10428199109068117	1991	Myelomonocytic associated antigens in B-chronic lymphocytic leukemia: analysis of clinical significance.	CD36
1697095	10.1111/j.1365-3083.1990.tb02900.x	1990	Phenotype, ultrastructure, and function of CD1+DR+ epidermal cells that express CD36 (OKM5) in cutaneous T-cell lymphoma.	CD36
2161182	10.1093/ajcp/93.6.822	1990	Additional evidence that plasmacytoid T-cell lymphoma associated with chronic myeloproliferative disorders is of macrophage/monocyte origin.	CD36
2294988	NA	1990	Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy.	CD36
27463821	10.3109/10428199009042472	1990	Early Erythroblastic Leukemia Presenting as De Novo Acute Leukemia.	CD36
2474314	10.1111/j.1365-2133.1989.tb01345.x	1989	Keratinocyte expression of OKM5 antigen in inflammatory cutaneous disease.	CD36
2452212	10.1111/1523-1747.ep13083836	1988	Expression of OKM5 antigen on epidermal cells in mycosis fungoides plaque stage.	CD36
3104684	NA	1987	Single cell studies on the immunological marker profile of plasmacytoid T-zone cells.	CD36
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	CD58
34560683	10.1097/PAS.0000000000001813	2022	A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients.	CD58
34727819	10.1080/10428194.2021.1992755	2022	Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.	CD58
35317330	10.14740/wjon1436	2022	Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis.	CD58
35491222	10.11406/rinketsu.63.313	2022	[Epigenetic modification as a therapeutic approach for B-cell lymphoma].	CD58
35622145	10.1007/s00428-022-03348-x	2022	CD2-negative lymphoma-associated T-cells: a potential mechanism of immune-evasion in diffuse large B-cell lymphoma.	CD58
35881486	10.1172/JCI159402	2022	Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses.	CD58
33340851	10.1016/j.leukres.2020.106491	2021	Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia.	CD58
33479306	10.1038/s41598-020-80376-0	2021	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.	CD58
33544565	10.1097/PAS.0000000000001658	2021	Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II.	CD58
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	CD58
34168659	10.3389/fimmu.2021.705260	2021	CD58 Immunobiology at a Glance.	CD58
34339834	10.1016/j.critrevonc.2021.103430	2021	Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review.	CD58
34470052	10.1182/bloodadvances.2020003534	2021	Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy.	CD58
34937829	10.3960/jslrt.21007	2021	Tumor microenvironment of adult T-cell leukemia/lymphoma.	CD58
31254446	10.1002/cyto.b.21834	2020	Immunophenotypic Characterization and Purification of Neoplastic Cells from Lymph Nodes Involved by T-Cell/Histiocyte-rich Large B-cell Lymphoma by Flow Cytometry and Flow Cytometric Cell Sorting.	CD58
31962268	10.1016/j.molimm.2020.01.006	2020	EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.	CD58
32027255	10.19746/j.cnki.issn.1009-2137.2020.01.012	2020	[Analysis of Clinical Characteristics and Therapeutic Efficacy of Patients with Adult Acute Lymphoblastic Leukemia].	CD58
32068791	10.1093/ajcp/aqaa007	2020	Improved Recognition of Hematogones From Precursor B-Lymphoblastic Leukemia by a Single Tube Flow Cytometric Analysis.	CD58
32281503	10.1080/10428194.2020.1742902	2020	Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.	CD58
32322878	10.1093/ibd/izaa065	2020	Propagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease.	CD58
32589698	10.1182/blood.2020005546	2020	Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58.	CD58
31292115	10.1182/blood.2019001126	2019	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.	CD58
31597848	10.11406/rinketsu.60.1229	2019	[The immune microenvironment in malignant lymphoma].	CD58
31934533	10.1155/2019/8586354	2019	Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis.	CD58
28888074	10.1002/cyto.b.21591	2018	Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.	CD58
29164976	10.1080/10428194.2017.1403598	2018	Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.	CD58
29500862	10.1111/ijlh.12795	2018	Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.	CD58
29564225	10.3389/fonc.2018.00054	2018	Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.	CD58
29857068	10.1016/j.jid.2018.04.038	2018	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.	CD58
29902581	10.1016/j.meegid.2018.06.010	2018	Low responsiveness to a hepatitis B virus vaccine in a Chinese population lacks association with ITGAL, CD58, TNFSF15, CCL15, TGFB3, and BCL6 gene variants.	CD58
29963520	10.5045/br.2018.53.2.138	2018	Leukemia propagating cells in Philadelphia chromosome-positive ALL: a resistant phenotype with an adverse prognosis.	CD58
30093402	10.1182/blood-2018-03-838524	2018	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with <i>DUSP22</i> rearrangements.	CD58
30113764	10.1111/ijlh.12912	2018	Easy discrimination of hematogones from lymphoblasts in B-cell progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio.	CD58
27998726	10.1016/j.ajpath.2016.10.007	2017	Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting.	CD58
28063722	10.1016/j.jfma.2016.12.002	2017	Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.	CD58
28245371	10.7534/j.issn.1009-2137.2017.01.005	2017	[Expression of CD146 in Adult and Children's Acute B Cell Lymphoblastic Leukemia and Its Significance].	CD58
28324281	10.1007/s12185-017-2206-4	2017	Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.	CD58
28446317	10.7534/j.issn.1009-2137.2017.02.051	2017	[Research Progress on Relationship between CD58 Molecule and ALL and Lymphoma -Review].	CD58
28627735	10.1111/cas.13303	2017	Genetic alterations in adult T-cell leukemia/lymphoma.	CD58
28694326	10.1182/blood-2017-02-768234	2017	Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).	CD58
28854975	10.1186/s12967-017-1286-5	2017	Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.	CD58
26930456	10.1016/j.leukres.2015.12.015	2016	CD38+ CD58- is an independent adverse prognostic factor in paediatric Philadelphia chromosome negative B cell acute lymphoblastic leukaemia patients.	CD58
27069035	10.1093/labmed/lmw009	2016	Hematogones With Lambda Light Chain Restriction in a 4-Year-Old Boy With Burkitt Lymphoma: A Potential Diagnostic Pitfall.	CD58
27276707	10.18632/oncotarget.9793	2016	Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.	CD58
27383875	10.1515/folmed-2016-0004	2016	Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.	CD58
27389058	10.1038/leu.2016.161	2016	Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.	CD58
27438018	10.1097/MPH.0000000000000624	2016	Key Markers of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.	CD58
27467287	10.1038/gene.2016.30	2016	CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse.	CD58
27825110	10.18632/oncotarget.13065	2016	Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.	CD58
25486581	10.1038/bmt.2014.274	2015	Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT.	CD58
25582824	10.1038/mt.2015.4	2015	Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.	CD58
25800755	10.1200/JCO.2014.57.7080	2015	Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis.	CD58
25991819	10.1158/1078-0432.CCR-14-2116	2015	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.	CD58
26106001	10.3960/jslrt.55.13	2015	Mutation Analysis for TP53 in Chronic-Type Adult T-Cell Leukemia/Lymphoma.	CD58
26194173	10.1002/gcc.22276	2015	Alterations of the CD58 gene in classical Hodgkin lymphoma.	CD58
26287347	NA	2015	[Expression of CD58 in childhood B-lineage acute lymphoblastic leukemia and its feasibility in minimal residual disease detection].	CD58
26550829	10.1159/000431058	2015	Molecular Pathology of Adult T-Cell Leukemia/Lymphoma.	CD58
24413734	10.1038/ng.2873	2014	Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.	CD58
25135692	10.1038/leu.2014.228	2014	CD34(+)CD38(-)CD58(-) cells are leukemia-propagating cells in Philadelphia chromosome-positive acute lymphoblastic leukemia.	CD58
25320005	10.1158/0008-5472.CAN-14-0643	2014	Molecular characterization of chronic-type adult T-cell leukemia/lymphoma.	CD58
22467604	10.1002/cyto.b.21017	2012	Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.	CD58
22585868	10.1158/2159-8290.CD-RW2011-64	2012	Gene inactivation promotes immune escape in DLBCL.	CD58
22713438	10.1177/120347541201600305	2012	Biologic therapy in psoriasis: perspectives on associated risks and patient management.	CD58
20634374	10.1182/blood-2008-01-130252	2011	Human CD14hi monocytes and myeloid dendritic cells provide a cell contact-dependent costimulatory signal for early CD40 ligand expression.	CD58
21669033	10.3727/096368911X580536	2011	Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.	CD58
22137796	10.1016/j.ccr.2011.11.006	2011	Combined genetic inactivation of Œ≤2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.	CD58
19854598	10.1016/j.anl.2009.08.004	2010	Maxillofacial mass as the first presentation of acute lymphoblastic leukemia in a nine-year-old girl.	CD58
20886718	NA	2010	[Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].	CD58
21344762	NA	2010	[Cells antigens' expression modulation during induction treatment of childhood acute lymphoblastic leukemia].	CD58
19573409	NA	2009	[Application of effective antigen combinations in childhood B lineage acute lymphoblastic leukemia].	CD58
18412874	10.1111/j.1365-4632.2008.03470.x	2008	Combining systemic retinoids with biologic agents for moderate to severe psoriasis.	CD58
18423260	10.1016/j.jaad.2008.02.039	2008	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.	CD58
18489039	10.1016/j.jaad.2006.05.074	2008	Patch-stage mycosis fungoides in remission after therapy with alefacept.	CD58
18809238	10.1016/j.exphem.2008.07.003	2008	Costimulation molecule expression and subset distribution of blood dendritic cells in normal children and newly diagnosed pediatric leukemia and lymphoma patients.	CD58
17349557	10.1016/j.sder.2006.12.002	2007	Complications and adverse reactions in the use of newer biologic agents.	CD58
17365261	10.1080/09546630601121045	2007	Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity.	CD58
16928307	NA	2006	[Prognostic significance of lymphocyte function associated anti-gen-3 (CD58) in childhood B cell-acute lymphocytic leukemia].	CD58
15538405	10.1038/sj.leu.2403559	2005	Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection.	CD58
15737916	10.1016/j.meegid.2004.08.006	2005	Cell membrane proteins and quasispecies compartmentalization of CSF and plasma HIV-1 from aids patients with neurological disorders.	CD58
15762287	10.1309/x5vv6fkjq6mublpx	2005	CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia.	CD58
16021141	10.1016/j.jaad.2005.02.043	2005	Transformed mycosis fungoides developing after treatment with alefacept.	CD58
16247429	10.1038/sj.bmt.1705185	2005	Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report.	CD58
15360006	10.1080/10428190310001643358	2004	Defective immune function of primary effusion lymphoma cells is associated with distinct KSHV gene expression profiles.	CD58
12393484	10.1182/blood-2002-07-1989	2003	T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.	CD58
12669246	10.1007/s00262-002-0364-5	2003	Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells.	CD58
12671023	10.1093/jnci/95.7.548	2003	Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.	CD58
12915579	10.1128/jvi.77.17.9669-9684.2003	2003	Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus.	CD58
14594504	10.1089/152581603322448187	2003	CD34+ cells and CD34+CD38- subset from mobilized blood show different patterns of adhesion molecules compared to those from steady-state blood, bone marrow, and cord blood.	CD58
14607753	NA	2003	Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.	CD58
14689062	NA	2003	Multiparametric flow cytometry in detection of minimal residual disease in acute lymphoblastic leukemia of early B-cell phenotype.	CD58
12008089	10.1016/s0145-2126(01)00198-9	2002	Cutaneous lymphoblastic lymphoma of putative plasmacytoid dendritic cell-precursor origin: two cases.	CD58
12215016	10.1007/BF02982580	2002	Establishment of a primary effusion lymphoma cell line (RM-P1) and in vivo growth system using SCID mice.	CD58
12357356	10.1038/sj.leu.2402672	2002	CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia.	CD58
11145841	10.1006/cyto.2000.0794	2001	Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression patterns of bone marrow blasts in relapsed childhood B cell precursor all.	CD58
11264179	10.1182/blood.v97.7.2115	2001	Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia.	CD58
11389007	10.1182/blood.v97.12.3713	2001	The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features.	CD58
11426534	10.3109/10428190109097660	2001	Adhesion molecule expression, clinical features and therapy outcome in childhood acute lymphoblastic leukemia.	CD58
10664622	10.1309/BFH5-NCNP-DK3J-DQBH	2000	Angiodestruction and tissue necrosis of skin-involving CD56+ NK/T-cell lymphoma are influenced by expression of cell adhesion molecules and cytotoxic granule and apoptosis-related proteins.	CD58
11061342	10.3727/000000001108747408	2000	CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG.	CD58
10089910	10.1016/s0301-472x(98)00059-9	1999	Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas.	CD58
10210778	NA	1999	Differential modulation of immune recognition molecules by interleukin-7 in human acute leukaemias.	CD58
10482995	10.1038/sj.leu.2401517	1999	Quantification of cellular adhesion molecules on malignant B cells from non-Hodgkin's lymphoma.	CD58
10485274	10.1111/j.1600-0609.1999.tb01767.x	1999	Different expression of adhesion molecules on CD34+ cells in AML and B-lineage ALL and their normal bone marrow counterparts.	CD58
10609780	10.1080/10428199909169607	1999	The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia.	CD58
10791904	10.1089/152581699319984	1999	Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.	CD58
9935206	10.1002/(sici)1097-0215(19990118)80:2&lt;240::aid-ijc13&gt;3.0.co;2-j	1999	Biologically relevant phenotypic changes and enhanced growth properties induced in B lymphocytes by an EBV strain derived from a histologically aggressive Hodgkin's disease.	CD58
9474747	10.1002/stem.160049	1998	Difference between expression of adhesion molecules on CD34+ cells from bone marrow and G-CSF-stimulated peripheral blood.	CD58
9517505	10.3109/10428199809092689	1998	Influence of malignant cell clonogenic capacities and position along the maturation pathway on their susceptibility to lymphokine-activated killer cell cytotoxicity.	CD58
9643566	10.3109/10428199809050912	1998	Dyshematopoiesis in de novo acute myeloid leukemia: cell biological features and prognostic significance.	CD58
9894758	NA	1998	Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.	CD58
9083889	10.1023/a:1027374331094	1997	A novel human monoclonal antibody rapidly induces homotypic cell aggregation and promotes antibody-secreting activity by human B lymphoblastoid cell line IM-9.	CD58
9208110	10.1038/sj.bmt.1700814	1997	GM-CSF-mobilized peripheral blood CD34+ cells differ from steady-state bone marrow CD34+ cells in adhesion molecule expression.	CD58
9498712	10.3109/10428199709058339	1997	Relationships between susceptibility to LAK cell-mediated lysis, conjugate formation and expression of adhesion molecules in B-cell derived non-Hodgkin's lymphomas.	CD58
11725077	10.1007/BF02253573	1996	Hodgkin's Disease and Anaplastic Large Cell Lymphoma Revisited. ii. from cytokines to cell lineage.	CD58
8636222	10.1083/jcb.132.3.465	1996	Visualization of CD2 interaction with LFA-3 and determination of the two-dimensional dissociation constant for adhesion receptors in a contact area.	CD58
8726400	10.3109/10428199209067601	1996	All-trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia.	CD58
8806537	10.1006/viro.1996.0452	1996	Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines.	CD58
8896174	10.1111/j.1399-0039.1996.tb02624.x	1996	A novel monoclonal antibody mNI-58A against the alpha-chain of leukocyte function-associated antigen-1 (LFA-1) blocks the homotypic cell aggregation and actively regulates morphological changes in the phorbol myristate acetate (PMA)-activated human monocyte-like cell line, U937.	CD58
8907282	10.3109/10428199609067592	1996	Expression of glycosyl-phosphatidylinositol-linked glycoproteins in blood cells from paroxysmal nocturnal haemoglobinuria patients: a flow cytometry study using CD55, CD58 and CD59 monoclonal antibodies.	CD58
8917708	10.1007/BF00192429	1996	Lack of adhesion molecules in testicular diffuse centroblastic and immunoblastic B cell lymphomas as a contributory factor in malignant behaviour.	CD58
8977276	10.1002/eji.1830261207	1996	Differential interaction of the CD2 extracellular and intracellular domains with the tyrosine phosphatase CD45 and the zeta chain of the TCR/CD3/zeta complex.	CD58
11725067	10.1007/BF02255217	1995	Hodgkin's Disease and Anaplastic Large Cell Lymphoma Revisited. 1. unique cytokine and cytokine receptor profile distinguished from that of non-hodgkin's lymphomas.	CD58
7490134	NA	1995	Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells. An analysis of the functional importance of complement inhibitors on the Raji cell line.	CD58
7543515	NA	1995	Costimulation of human CD4+ T cells with LFA-3 and B7 induce distinct effects on AP-1 and NF-kappa B transcription factors.	CD58
8580827	10.3109/10428199509064920	1995	The antigen-presenting cell function of Reed-Sternberg cells.	CD58
7519509	10.3109/10428199409056294	1994	Expression of adhesion molecules CD11/CD18 (Leu-CAMs, beta 2-integrins), CD54 (ICAM-1) and CD58 (LFA-3) in B-chronic lymphocytic leukemia.	CD58
7866283	10.3109/10428199409049732	1994	Kinetics of the pleiotropic effect of interleukin 4 on the surface properties of human B-lymphoma cells.	CD58
8035617	NA	1994	Modifications of leukemic blast cells induced by in vivo high-dose recombinant interleukin-2.	CD58
7504544	10.3109/10428199309047884	1993	Potential mechanisms of action of interferon-alpha in CML.	CD58
7681932	10.1016/0161-5890(93)90112-o	1993	Selective induction of allostimulatory capacity after 5-azaC treatment of EBV carrying but not EBV negative Burkitt lymphoma cell lines.	CD58
7682882	10.3109/10428199309148510	1993	Influence of Epstein-Barr virus encoded latent membrane protein 1 on the expression of CD23 antigen, ICAM-1 and LFA-3 in Hodgkin and Reed-Sternberg cells. A morphometric analysis.	CD58
7690510	NA	1993	CD10/common acute lymphoblastic leukemia-associated antigen and adhesion factor expression is predictive for lymphokine-activated killing sensitivity of adult B-lineage acute lymphoblastic leukemia.	CD58
7690630	10.3109/10428199309147353	1993	Biological response modifiers render tumor cells susceptible to autologous effector mechanisms by influencing adhesion receptors.	CD58
7694662	10.1007/BF01715049	1993	Expression of adhesion molecules on acute leukemic blast cells and sensitivity to normal LAK activity.	CD58
8214003	NA	1993	Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.	CD58
8344715	10.1016/0165-2478(93)90066-b	1993	The effect of IL-4 on the phenotype of a human B-cell lymphoma line (Farage) lacking immunoglobulin expression.	CD58
1282031	10.1093/intimm/4.11.1283	1992	Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.	CD58
1317364	10.1002/ijc.2910510319	1992	Expression of integrins and other adhesion molecules in Epstein-Barr virus-transformed B lymphoblastoid cells and Burkitt's lymphoma cells.	CD58
1370839	10.1083/jcb.116.4.997	1992	Micromanipulation of adhesion of a Jurkat cell to a planar bilayer membrane containing lymphocyte function-associated antigen 3 molecules.	CD58
1372880	10.1002/ijc.2910500605	1992	Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in Epstein-Barr-virus-positive nasopharyngeal carcinoma cells.	CD58
1375302	NA	1992	Expression of surface adhesion molecules CD54 (ICAM-1) and CD58 (LFA-3) in adult acute leukemia: relationship with initial characteristics and prognosis.	CD58
1378014	10.1002/eji.1830220712	1992	Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition.	CD58
1381563	NA	1992	Adhesion receptor profile of thymic B-cell lymphoma.	CD58
1384721	10.1007/BF01703110	1992	Adhesion molecules on CD34+ hematopoietic cells in normal human bone marrow and leukemia.	CD58
1490146	10.3109/10428199209054904	1992	The role of adhesion molecules in multiple myeloma.	CD58
1704356	10.1002/ijc.2910470328	1991	Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets.	CD58
1717480	10.1083/jcb.115.1.245	1991	Influence of receptor lateral mobility on adhesion strengthening between membranes containing LFA-3 and CD2.	CD58
1718496	NA	1991	Natural inhibitors of T-cell activation in Hodgkin's disease.	CD58
1721040	NA	1991	Expression of the CDw75 (beta-galactoside alpha 2,6-sialyltransferase) antigen on normal blood cells and in B-cell chronic lymphocytic leukaemia.	CD58
1722139	10.1007/BF01741347	1991	Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes.	CD58
1961038	NA	1991	Susceptibility of adult acute lymphoblastic leukemia blasts to lysis by lymphokine-activated killer cells.	CD58
27463481	10.3109/10428199109103380	1991	Expression of CD11a (LFA-1) on B-chronic Lymphocytic Leukemia and Lymphoma Cells: Correlation with Cell Surface Immunoglobulin Intensity and CD58 (LFA-3) Expression.	CD58
1691936	NA	1990	Low expression of lymphocyte function-associated antigen (LFA)-1 and LFA-3 adhesion molecules is a common trait in Burkitt's lymphoma associated with and not associated with Epstein-Barr virus.	CD58
1698024	NA	1990	Lymphocyte functional antigens stabilize agglutination between Reed-Sternberg cells and T cells, but are not responsible for homotypic binding of Hodgkin's Reed-Sternberg cells.	CD58
1698730	10.1002/ijc.2910460418	1990	Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV).	CD58
1973408	10.1111/j.1600-065x.1990.tb00562.x	1990	Leukocyte-cell adhesion: a molecular process fundamental in leukocyte physiology.	CD58
2474849	10.1111/j.1365-3083.1989.tb01197.x	1989	Leucocyte adhesion to cells. Molecular basis, physiological relevance, and abnormalities.	CD58
2572856	10.1016/s0140-6736(89)91498-0	1989	Leucocyte adhesion to cells in immune and inflammatory responses.	CD58
34318583	10.1111/aos.14993	2022	Vitreous proteomics, a gateway to improved understanding and stratification of diverse uveitis aetiologies.	CD70
34726773	10.1002/cncr.34005	2022	Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.	CD70
34872108	10.1182/bloodadvances.2021005714	2022	Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.	CD70
35041763	10.1111/bjd.21018	2022	Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in S√©zary syndrome.	CD70
35266562	10.1002/ajh.26523	2022	Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.	CD70
35317330	10.14740/wjon1436	2022	Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis.	CD70
35443163	10.1016/j.celrep.2022.110713	2022	A single-cell atlas of diffuse large B cell lymphoma.	CD70
35474464	10.1111/his.14670	2022	CD70 is a potential target biomarker in peripheral T-cell lymphomas.	CD70
35687490	10.1182/bloodadvances.2021006654	2022	Genomic characterization of lymphomas in patients with inborn errors of immunity.	CD70
35787399	10.1016/j.jid.2022.06.005	2022	The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ŒîNp73 Depletion.	CD70
36055572	10.1016/j.clim.2022.109105	2022	A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.	CD70
33666760	10.1007/s00262-021-02895-7	2021	Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.	CD70
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	CD70
33827115	10.1182/blood.2020009482	2021	CD27 is required for protective lytic EBV antigen-specific CD8+ T-cell expansion.	CD70
33996677	10.3389/fped.2021.615724	2021	Specific Immune Response and Cytokine Production in CD70 Deficiency.	CD70
33996698	10.3389/fped.2021.662645	2021	Different Apples, Same Tree: Visualizing Current Biological and Clinical Insights into CTLA-4 Insufficiency and LRBA and DEF6 Deficiencies.	CD70
34189576	10.1182/blood.2020010527	2021	SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma.	CD70
34267181	10.1038/s41408-021-00521-4	2021	Lack of intrafollicular memory CD4‚Äâ+‚ÄâT cells is predictive of early clinical failure in newly diagnosed follicular lymphoma.	CD70
34313014	10.1002/cac2.12201	2021	CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell Lymphoma.	CD70
34638238	10.3390/cancers13194752	2021	Epstein-Barr Virus in Inborn Immunodeficiency-More Than Infection.	CD70
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	CD70
32298986	10.1016/j.tranon.2020.100770	2020	Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma.	CD70
32380537	10.1182/bloodadvances.2019001079	2020	Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies.	CD70
32439996	10.1038/s41598-020-65463-6	2020	GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL.	CD70
32451662	10.1007/s10875-020-00790-x	2020	An Update on XMEN Disease.	CD70
32603431	10.1182/blood.2020006738	2020	Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency.	CD70
32620996	10.1007/s10875-020-00816-4	2020	Lymphoma Predisposing Gene in an Extended Family: CD70 Signaling Defect.	CD70
32727777	10.21873/anticanres.14452	2020	Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL).	CD70
33162537	10.11406/rinketsu.61.1365	2020	[Lymphoproliferative disorders and inborn errors of immunity].	CD70
29800648	10.1016/j.jaci.2018.04.030	2019	Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.	CD70
30132271	10.1007/s10637-018-0655-0	2019	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.	CD70
30784598	10.1016/j.celrep.2019.01.085	2019	Mass Cytometry Analysis Reveals that Specific Intratumoral CD4<sup>+</sup> T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma.	CD70
31014360	10.1186/s13045-019-0726-5	2019	Targeting CLL-1 for acute myeloid leukemia therapy.	CD70
31292525	10.1038/s41598-019-46473-5	2019	Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL.	CD70
31402499	10.1111/imr.12791	2019	Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.	CD70
31597848	10.11406/rinketsu.60.1229	2019	[The immune microenvironment in malignant lymphoma].	CD70
31652572	10.3390/cancers11101611	2019	Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method.	CD70
31678777	10.1016/j.scr.2019.101612	2019	Generation of a human induced pluripotent stem cell line (PHAi003) from a primary immunodeficient patient with CD70 mutation.	CD70
31867275	10.3389/fonc.2019.01350	2019	CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma.	CD70
29282224	10.15252/emmm.201708292	2018	Loss of RASGRP1 in humans impairs T-cell expansion leading to Epstein-Barr virus susceptibility.	CD70
29311309	10.1073/pnas.1713607115	2018	Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses.	CD70
29564225	10.3389/fonc.2018.00054	2018	Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.	CD70
28011863	10.1084/jem.20160784	2017	Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection.	CD70
28011864	10.1084/jem.20160849	2017	Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency.	CD70
28495792	10.1182/blood-2016-12-756585	2017	CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.	CD70
28729334	10.1182/blood-2017-06-786244	2017	CD70 turns on NK cells to attack lymphoma.	CD70
28783700	10.1126/sciimmunol.aan0291	2017	It's all in the family.	CD70
29158380	10.1073/pnas.1710877114	2017	Anti-SIRPŒ± antibody immunotherapy enhances neutrophil and macrophage antitumor activity.	CD70
26077361	10.3109/10428194.2015.1063140	2016	Clinical significance of CD70 expression on T cells in human T-lymphotropic virus type-1 carriers and adult T cell leukemia/ lymphoma patients.	CD70
26576779	10.1007/s00280-015-2909-2	2016	First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.	CD70
26914723	10.1517/14728222.2016.1158812	2016	Therapeutic targeting of CD70 and CD27.	CD70
27053012	10.3892/mmr.2016.5089	2016	Digital gene expression profiling analysis of childhood acute lymphoblastic leukemia.	CD70
27708227	10.18632/oncotarget.12357	2016	T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.	CD70
25582824	10.1038/mt.2015.4	2015	Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.	CD70
24569779	10.1038/leu.2014.84	2014	TGF-Œ≤ upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma.	CD70
25062112	10.1055/s-0034-1374640	2014	Significantly increased CD70 up regulation on TEL-AML positive B cell precursor acute lymphoblastic leukemia cells following CD40 stimulation.	CD70
25142258	10.1007/s10637-014-0151-0	2014	Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.	CD70
25171927	10.1182/blood-2013-12-546309	2014	Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients.	CD70
22801960	10.3324/haematol.2012.068791	2013	Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27.	CD70
23206232	10.1111/bjh.12136	2013	Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27.	CD70
23716461	10.1002/gcc.22072	2013	The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma.	CD70
23808985	10.1021/bc400217g	2013	A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.	CD70
21994111	10.1002/pbc.23352	2012	Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection.	CD70
22213068	10.1002/ijc.27416	2012	Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas.	CD70
21182090	10.1002/eji.201040905	2011	CD70-CD27 interactions provide survival and proliferative signals that regulate T cell receptor-driven activation of human Œ≥Œ¥ peripheral blood lymphocytes.	CD70
21304103	10.1182/blood-2010-04-278218	2011	T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies.	CD70
21606482	10.1182/blood-2010-09-307330	2011	RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia.	CD70
22065141	NA	2011	Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives.	CD70
19806404	10.1007/s11307-009-0264-6	2010	Two-step in vivo tumor targeting by biotin-conjugated antibodies and superparamagnetic nanoparticles assessed by magnetic resonance imaging at 1.5 T.	CD70
20048186	10.1200/JCO.2009.22.8254	2010	Investigational immunotherapeutics for B-cell malignancies.	CD70
19109206	10.4049/jimmunol.182.1.718	2009	The CD70/CD27 pathway is critical for stimulation of an effective cytotoxic T cell response against B cell precursor acute lymphoblastic leukemia.	CD70
19346216	10.1074/mcp.M800515-MCP200	2009	Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.	CD70
19362984	10.3816/CLM.2009.n.024	2009	Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenstr√∂m's macroglobulinemia.	CD70
19386499	10.1016/j.bmcl.2009.03.145	2009	Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.	CD70
19452318	10.1080/10428190902803677	2009	Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia.	CD70
19509224	10.1158/0008-5472.CAN-09-0266	2009	Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma.	CD70
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	CD70
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	CD70
18256142	10.1128/JVI.02013-07	2008	Highly enhanced expression of CD70 on human T-lymphotropic virus type 1-carrying T-cell lines and adult T-cell leukemia cells.	CD70
19047103	10.1158/1078-0432.CCR-08-0493	2008	Preclinical characterization of SGN-70, a humanized antibody directed against CD70.	CD70
17038522	10.1182/blood-2006-07-034017	2007	Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.	CD70
17311995	10.1182/blood-2006-11-057216	2007	Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.	CD70
17615291	10.1182/blood-2007-03-082578	2007	CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells.	CD70
17877845	10.3816/clm.2007.s.023	2007	Novel agents in the treatment of Waldenstr√∂m's macroglobulinemia.	CD70
16275070	10.1016/j.bmcl.2005.09.081	2006	Dipeptide-based highly potent doxorubicin antibody conjugates.	CD70
16704224	10.1021/bc0600214	2006	Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates.	CD70
18528464	NA	2006	Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.	CD70
16034459	10.1038/sj.gt.3302577	2005	Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.	CD70
16272354	10.4049/jimmunol.175.10.6940	2005	Proliferation response of leukemic cells to CD70 ligation oscillates with recurrent remission and relapse in a low-grade lymphoma.	CD70
16338493	10.1016/j.exphem.2005.10.005	2005	Expression of CD27-CD70 on early B cell progenitors in the bone marrow: implication for diagnosis and therapy of childhood ALL.	CD70
16373719	10.1158/1535-7163.MCT-05-0253	2005	Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas.	CD70
15359114	10.1023/B:JOCI.0000040926.37275.3b	2004	Resistance to cytotoxic chemotherapy is induced by NK cells in non-Hodgkin's Lymphoma Cells.	CD70
11743585	10.1038/ni746	2002	Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection.	CD70
12421908	10.4049/jimmunol.169.10.5377	2002	Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin.	CD70
12472567	10.1046/j.1365-2141.2002.03931.x	2002	Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma.	CD70
11333903	10.1128/JVI.75.11.5215-5221.2001	2001	Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody.	CD70
10800994	10.1097/00000478-200005000-00014	2000	CD70 expression in thymic carcinoma.	CD70
10221513	10.3109/10428199909058433	1999	Modulation of costimulatory molecules on follicular lymphoma cells by TNF and CD40.	CD70
10419648	10.1006/cyto.1998.0449	1999	CD27 signals through PKC in human B cell lymphomas.	CD70
10444164	10.1046/j.1365-2141.1999.01474.x	1999	Involvement of the CD27-CD70 co-stimulatory pathway in allogeneic T-cell response to follicular lymphoma cells.	CD70
10460611	10.1046/j.1365-2141.1999.01573.x	1999	Aberrant expression and reverse signalling of CD70 on malignant B cells.	CD70
10527687	10.1006/clim.1999.4782	1999	Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma.	CD70
10706444	10.3109/10428199909145724	1999	Plasma cell generation from B-lymphocytes via CD27/CD70 interaction.	CD70
9826582	10.1006/smim.1998.0154	1998	Control of lymphocyte function through CD27-CD70 interactions.	CD70
9850023	10.1200/JCO.1998.16.12.3788	1998	Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group.	CD70
9354461	NA	1997	B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules.	CD70
9366422	NA	1997	Characterization of murine CD70, the ligand of the TNF receptor family member CD27.	CD70
8691346	10.1002/(SICI)1096-9896(199605)179:1&lt;54::AID-PATH537&gt;3.0.CO;2-2	1996	Phenotypic modulation of Hodgkin and Reed-Sternberg cells by Epstein-Barr virus.	CD70
8922238	10.1016/s0950-3536(96)80019-9	1996	Pathophysiology of Hodgkin's disease: functional and molecular aspects.	CD70
11725067	10.1007/BF02255217	1995	Hodgkin's Disease and Anaplastic Large Cell Lymphoma Revisited. 1. unique cytokine and cytokine receptor profile distinguished from that of non-hodgkin's lymphomas.	CD70
8580081	10.1093/intimm/7.11.1827	1995	A T cell lymphoma can provide potent co-stimulatory effects to T cells that are not mediated by B7-1, B7-2, CD40, HSA or CD70.	CD70
8580829	10.3109/10428199509064922	1995	CD27-CD70 interaction: unravelling its implication in normal and neoplastic B-cell growth.	CD70
2163351	10.1111/j.1365-2559.1990.tb01143.x	1990	Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 + with a high content of reactive histiocytes).	CD70
27457195	10.3109/10428199009050972	1990	Detection of Activation Antigens on Chronic Lymphocytic Leukaemia Cells.	CD70
34216243	10.1007/s00277-021-04572-2	2022	Liquid biopsies of plasma and cerebrospinal fluid are useful for detection of intravascular lymphoma with central nervous system symptoms alone.	CD79B
34232979	10.1182/blood.2020010039	2022	The alternative RelB NF-Œ∫B subunit is a novel critical player in diffuse large B-cell lymphoma.	CD79B
34448823	10.1182/bloodadvances.2021004212	2022	The molecular hallmarks of primary and secondary vitreoretinal lymphoma.	CD79B
34638136	10.1182/bloodadvances.2020003698	2022	Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.	CD79B
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	CD79B
34672246	10.1080/10428194.2021.1980214	2022	Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy.	CD79B
34904799	10.1056/NEJMoa2115304	2022	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.	CD79B
34980599	10.1158/1078-0432.CCR-21-3261	2022	Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.	CD79B
35028710	10.1007/s00428-021-03265-5	2022	Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.	CD79B
35126963	10.1177/20406207211072839	2022	MYD88<sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy.	CD79B
35169086	10.11477/mf.1436204531	2022	[Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].	CD79B
35179642	10.1007/s00277-021-04394-2	2022	CD20/CD79a/PAX5/CD3-negative post-transplant lymphoma with aberrant actin and desmin co-expression-a potential differential diagnostic pitfall between PTLD and PTSMT.	CD79B
35210172	10.1016/j.preteyeres.2022.101053	2022	Challenges in the diagnosis and management of vitreoretinal lymphoma - Clinical and basic approaches.	CD79B
35223507	10.3389/fonc.2022.824632	2022	<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS.	CD79B
35236331	10.1186/s12885-022-09237-5	2022	Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.	CD79B
35240681	10.1182/bloodadvances.2021006801	2022	A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.	CD79B
35255429	10.1016/j.anndiagpath.2021.151886	2022	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.	CD79B
35326604	10.3390/cancers14061453	2022	DLBCL 1L-What to Expect beyond R-CHOP?	CD79B
35401516	10.3389/fimmu.2022.842439	2022	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.	CD79B
35484253	10.1007/s00277-022-04827-6	2022	Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature.	CD79B
35538064	10.1038/s41467-022-30050-y	2022	The genomic and transcriptional landscape of primary central nervous system lymphoma.	CD79B
35554927	10.1002/eji.202149746	2022	Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched diffuse large B-cell lymphomas.	CD79B
35646048	10.3389/fgene.2022.878618	2022	Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	CD79B
35663281	10.1016/j.lrr.2022.100325	2022	Immunotherapy in indolent Non-Hodgkin's Lymphoma.	CD79B
35726803	10.1080/14737140.2022.2093191	2022	Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.	CD79B
35759728	10.1182/blood.2022015926	2022	Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma.	CD79B
35764309	10.1111/bjh.18341	2022	The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.	CD79B
35807041	10.3390/jcm11133748	2022	BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL-A Pilot Study.	CD79B
35908982	10.1016/j.blre.2022.100992	2022	Follicular lymphoma: The long and winding road leading to your cure?	CD79B
35917107	10.1111/bjh.18384	2022	United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.	CD79B
35928872	10.3389/fonc.2022.932674	2022	Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma.	CD79B
35933930	10.1016/j.ctrv.2022.102443	2022	Treatment strategies for patients with diffuse large B-cell lymphoma.	CD79B
35937947	10.1155/2022/6441139	2022	Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis.	CD79B
35963895	10.1007/s00262-022-03267-5	2022	Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.	CD79B
36006771	10.1097/PAS.0000000000001957	2022	Clinicopathologic Features and Genomic Signature of De Novo CD5+ Diffuse Large B-Cell Lymphoma: A Multicenter Collaborative Study.	CD79B
36051079	10.1002/jha2.428	2022	Targetable alterations in primary extranodal diffuse large B-cell lymphoma.	CD79B
36059608	10.3389/fonc.2022.955080	2022	Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis.	CD79B
36081566	10.3389/fonc.2022.941347	2022	Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.	CD79B
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	CD79B
32500753	10.1080/14712598.2020.1777979	2021	Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.	CD79B
32583848	10.1093/neuonc/noaa145	2021	Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.	CD79B
32954807	10.2217/fon-2020-0675	2021	Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma.	CD79B
33202420	10.1182/blood.2020008520	2021	EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.	CD79B
33232972	10.1182/blood.2020005244	2021	Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.	CD79B
33273056	10.1158/1535-7163.MCT-20-0046	2021	An Anti-CD22-<i>seco</i>-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models.	CD79B
33314668	10.1111/ijlh.13420	2021	Downregulation of Lymphoid enhancer-binding factor 1 (LEF-1) expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features.	CD79B
33452395	10.1038/s41598-021-81000-5	2021	EBF1 drives hallmark B cell gene expression by enabling the interaction of PAX5 with the MLL H3K4 methyltransferase complex.	CD79B
33452446	10.1038/s42003-020-01591-z	2021	CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia.	CD79B
33479306	10.1038/s41598-020-80376-0	2021	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.	CD79B
33512416	10.1182/blood.2020007245	2021	Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.	CD79B
33561953	10.3390/cancers13040650	2021	Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies.	CD79B
33562532	10.3390/cancers13040630	2021	Large-Scale Proteomic Analysis of Follicular Lymphoma Reveals Extensive Remodeling of Cell Adhesion Pathway and Identifies Hub Proteins Related to the Lymphomagenesis.	CD79B
33581493	10.1016/j.ctarc.2021.100310	2021	Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients.	CD79B
33583077	10.1002/hon.2842	2021	Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.	CD79B
33639170	10.1016/j.jbc.2021.100465	2021	TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.	CD79B
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	CD79B
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	CD79B
33935029	10.5045/br.2021.2020320	2021	Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas.	CD79B
33940156	10.1016/j.ymthe.2021.04.038	2021	Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.	CD79B
33942442	10.1111/cas.14937	2021	A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.	CD79B
34061467	10.1002/cam4.3983	2021	A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia.	CD79B
34204385	10.3390/cancers13123032	2021	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing.	CD79B
34236648	10.1007/978-1-0716-1669-7_20	2021	Generation and Surgical Analysis of Genetic Mouse Models to Study NF-Œ∫B-Driven Pathogenesis of Diffuse Large B Cell Lymphoma.	CD79B
34254378	10.1111/neup.12739	2021	Primary central nervous system lymphomas with massive intratumoral hemorrhage: Clinical, radiological, pathological, and molecular features of six cases.	CD79B
34256851	10.1186/s40364-021-00309-5	2021	Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.	CD79B
34323286	10.1002/eji.202048968	2021	Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.	CD79B
34327781	10.1111/cas.15091	2021	Current progress and future perspectives of research on intravascular large B-cell lymphoma.	CD79B
34595463	10.2991/chi.k.210305.001	2021	Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma.	CD79B
34604075	10.3389/fonc.2021.737645	2021	Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.	CD79B
34657049	NA	2021	[Circulating Tumor DNA Analysis in Lymphomas].	CD79B
34706776	10.1186/s13256-021-03128-2	2021	Immunophenotypic challenges in diagnosis of CD79a negativity in a patient with¬†B acute lymphoblastic leukemia harboring intrachromosomal amplification of chromosome 21: a case report.	CD79B
34706861	10.1136/bjophthalmol-2021-319580	2021	Prevalence and prognostic value of <i>MYD88</i> and <i>CD79B</i> mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.	CD79B
34739844	10.1016/j.ccell.2021.10.006	2021	Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.	CD79B
34745101	10.3389/fimmu.2021.732006	2021	International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.	CD79B
34768899	10.3390/ijms222111470	2021	Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders.	CD79B
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	CD79B
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	CD79B
35116576	10.21037/tcr-20-2525	2021	Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database.	CD79B
29629945	10.1097/PAI.0000000000000655	2020	Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	CD79B
31123031	10.3324/haematol.2018.214122	2020	<i>MYD88</i> mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.	CD79B
31609782	10.1097/PAS.0000000000001386	2020	Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.	CD79B
31624374	10.1038/s41375-019-0607-5	2020	T cells redirected against IgŒ≤ for the immunotherapy of B cell lymphoma.	CD79B
31693429	10.1200/JCO.19.00172	2020	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.	CD79B
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	CD79B
31739126	10.1016/j.cancergen.2019.11.002	2020	Molecular and phenotypic characterization of an early T-cell precursor acute lymphoblastic lymphoma harboring PICALM-MLLT10 fusion with aberrant expression of B-cell antigens.	CD79B
31863183	10.1007/s00428-019-02698-3	2020	Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.	CD79B
31894255	10.3892/ijmm.2019.4418	2020	Precision medicine for human cancers with Notch signaling dysregulation (Review).	CD79B
32056332	10.1111/cas.14347	2020	Gene expression profiling of primary vitreoretinal lymphoma.	CD79B
32060403	10.1038/s41375-020-0743-y	2020	Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.	CD79B
32083995	10.1200/JCO.19.02314	2020	Genomic Landscape of Waldenstr√∂m Macroglobulinemia and Its Impact on Treatment Strategies.	CD79B
32127472	10.1073/pnas.1921187117	2020	Regulation of B cell receptor-dependent NF-Œ∫B signaling by the tumor suppressor KLHL14.	CD79B
32172360	10.1007/s11899-020-00572-7	2020	Polatuzumab Vedotin: a New Target for B Cell Malignancies.	CD79B
32201861	10.1093/noajnl/vdaa018	2020	Primary CNS lymphoma commonly expresses immune response biomarkers.	CD79B
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	CD79B
32309823	10.1358/dot.2020.56.4.3127026	2020	Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.	CD79B
32322395	10.1186/s40364-020-00189-1	2020	TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients.	CD79B
32399964	10.1002/ijc.33049	2020	Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.	CD79B
32420699	10.1002/cam4.3136	2020	Serine-227 in the N-terminal kinase domain of RSK2 is a potential therapeutic target for mantle cell lymphoma.	CD79B
32495161	10.1007/s11523-020-00729-7	2020	Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas.	CD79B
32497402	10.1002/cyto.b.21887	2020	Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.	CD79B
32510610	10.1002/hon.2761	2020	On point in primary CNS lymphoma.	CD79B
32606733	10.2147/OTT.S219449	2020	Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data.	CD79B
32641598	10.3960/jslrt.20010	2020	Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma.	CD79B
32695560	10.2176/nmccrj.cr.2019-0241	2020	Primary Central Nervous System Methotrexate-associated Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis: Case Report and Review of Literature.	CD79B
32700586	10.1080/17474086.2020.1795828	2020	An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.	CD79B
32700972	10.1080/13543784.2020.1800638	2020	Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.	CD79B
32736575	10.1186/s12885-020-07198-1	2020	Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.	CD79B
32745612	10.1016/j.jmoldx.2020.07.002	2020	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.	CD79B
32770353	10.1007/s00280-020-04119-8	2020	Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.	CD79B
32864130	10.1186/s40364-020-00214-3	2020	A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression.	CD79B
32932517	10.1182/blood.2020005857	2020	The dangers of d√©j√† vu: memory B cells as the cells of origin of ABC-DLBCLs.	CD79B
32985934	10.1080/17512433.2020.1826303	2020	Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.	CD79B
33050534	10.3390/cancers12102913	2020	Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice.	CD79B
33067267	10.1158/0008-5472.CAN-20-2425	2020	A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.	CD79B
33173488	10.1159/000510403	2020	High-Grade Epstein-Barr Virus-Negative Biphenotypic Lymphoma with Expression of B- and T-Cell Markers and Leukemia Presentation: Case Report and Literature Review.	CD79B
33188997	10.1016/j.ctarc.2020.100235	2020	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.	CD79B
33202794	10.3390/ijms21228553	2020	Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.	CD79B
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	CD79B
29734251	10.1097/PAI.0000000000000585	2019	MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.	CD79B
29931583	10.1007/s10637-018-0623-8	2019	Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.	CD79B
30390359	10.1111/ejh.13191	2019	CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.	CD79B
30623224	10.1007/s00347-018-0840-8	2019	[New molecular pathological strategies for malignant iris tumors].	CD79B
30683910	10.1038/s41375-019-0380-5	2019	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.	CD79B
30696890	10.1038/s41598-018-37273-4	2019	Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma.	CD79B
30723112	10.1182/bloodadvances.2018027672	2019	<i>MYD88</i> L265P mutation and <i>CDKN2A</i> loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.	CD79B
30797915	10.1016/j.wneu.2019.01.298	2019	Intracranial Cell Lymphomas That Mimic Meningiomas: Case Report To Understand Complex Genetic, Radiologic, and Histopathologic Entities.	CD79B
30815927	10.1111/cas.13983	2019	Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.	CD79B
30819916	10.3324/haematol.2018.212811	2019	A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.	CD79B
30859597	10.1002/ajh.25460	2019	Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.	CD79B
31077558	10.1002/cyto.b.21785	2019	Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.	CD79B
31101488	10.1016/S1470-2045(19)30182-2	2019	Targeted therapies make room, anti-CD79b agents are coming.	CD79B
31101489	10.1016/S1470-2045(19)30091-9	2019	Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.	CD79B
31150604	10.1016/j.jid.2019.05.008	2019	Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.	CD79B
31242994	10.1158/2159-8290.CD-NB2019-076	2019	Polatuzumab Vedotin Approved for DLBCL.	CD79B
31270798	10.1111/bph.14784	2019	Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.	CD79B
31292368	10.7888/juoeh.41.225	2019	[Two Resected Cases of Primary Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma, Differently Diagnosed in Chest Tomography Scan].	CD79B
31335415	10.1097/DAD.0000000000001347	2019	Cutaneous B-Cell Lymphoblastic Lymphoma.	CD79B
31352604	10.1007/s40265-019-01175-0	2019	Polatuzumab Vedotin: First Global Approval.	CD79B
31378966	10.1002/ajh.25600	2019	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.	CD79B
31403034	10.3389/fonc.2019.00683	2019	Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.	CD79B
31436356	10.1111/cas.14176	2019	Mutations found in cell-free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis.	CD79B
31439577	10.1158/1078-0432.CCR-19-1337	2019	Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.	CD79B
31522426	10.1007/978-1-4939-9650-6_17	2019	Clinical Flow-Cytometric Testing in Chronic Lymphocytic Leukemia.	CD79B
31565447	10.1155/2019/1586328	2019	Plasmablastic Lymphoma, a Rare Entity in Bone Marrow with Unusual Immunophenotype and Challenging Differential Diagnosis.	CD79B
31592789	10.1097/WCO.0000000000000759	2019	Molecular profiling of primary central nervous system lymphomas - predictive and prognostic value?	CD79B
31806993	10.2147/OTT.S227122	2019	Genomic Alterations In Primary Cardiac Diffuse Large B Cell Lymphoma: A Case Report And Literature Review.	CD79B
31872533	10.1111/pin.12871	2019	Anaplastic variant of diffuse large B-cell lymphoma: Reappraisal as a nodal disease with sinusoidal involvement.	CD79B
32063711	10.2147/OTT.S222189	2019	Prevalence And Clinical Significance Of Oncogenic <i>CD79B</i> And <i>MYD88</i> Mutations In Primary Testicular Diffuse Large B-Cell Lymphoma: A Retrospective Study In China.	CD79B
28109040	10.1002/cyto.b.21512	2018	Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.	CD79B
28187524	10.1002/cyto.b.21517	2018	Phenotypic Characterization of Trisomy 12 Monoclonal B-Cell Lymphocytosis.	CD79B
28713070	10.4274/tjh.2017.0085	2018	The Role of CD200 and CD43 Expression in Differential Diagnosis between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma.	CD79B
28868954	10.1080/10428194.2017.1370546	2018	Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.	CD79B
29220870	10.1002/cyto.b.21607	2018	Quantitative assessment of informative immunophenotypic markers increases the diagnostic value of immunophenotyping in mature CD5-positive B-cell neoplasms.	CD79B
29289361	10.1016/j.blre.2017.12.001	2018	The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.	CD79B
29472356	10.3324/haematol.2017.184325	2018	A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.	CD79B
29514783	10.1182/blood-2017-12-822817	2018	High prevalence of <i>MYD88</i> and <i>CD79B</i> mutations in intravascular large B-cell lymphoma.	CD79B
29568849	10.11622/smedj.2018030	2018	Intravascular large B-cell lymphoma presenting as panniculitis clinically: a case report.	CD79B
29641966	10.1056/NEJMoa1801445	2018	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.	CD79B
29642007	10.1016/j.celrep.2018.03.069	2018	How Biophysical Forces Regulate Human B Cell Lymphomas.	CD79B
29669863	10.15252/embj.201797980	2018	Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells.	CD79B
29807508	10.1177/0300985818777035	2018	Canine Splenic Nodular Lymphoid Lesions: Immunophenotyping, Proliferative Activity, and Clonality Assessment.	CD79B
29878045	10.1093/annonc/mdy133	2018	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.	CD79B
29891112	10.1016/j.critrevonc.2018.05.010	2018	Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.	CD79B
29895903	10.1038/s41408-018-0089-0	2018	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.	CD79B
29925955	10.1038/s41586-018-0290-0	2018	A multiprotein supercomplex controlling oncogenic signalling in lymphoma.	CD79B
29931605	10.1007/s11864-018-0555-8	2018	Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.	CD79B
29937999	10.18632/oncotarget.25463	2018	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma.	CD79B
29967210	10.1212/WNL.0000000000005735	2018	Teaching NeuroImages: Presentation of diffuse large B-cell lymphoma with bilateral sequential oculomotor neuropathy.	CD79B
30146835	10.7754/Clin.Lab.2018.180320	2018	Diffuse Large B Cell Lymphoma Coexistent with Follicular Cell Lymphoma.	CD79B
30171453	10.1007/s11060-018-2990-6	2018	Characterization of genomic alterations in primary central nervous system lymphomas.	CD79B
30190015	10.1016/j.hoc.2018.05.007	2018	Working Toward a Genomic Prognostic Classification of Waldenstr√∂m Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.	CD79B
30227305	10.1016/j.neo.2018.08.012	2018	Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.	CD79B
30243141	10.1016/j.legalmed.2018.09.001	2018	Sudden unexpected death with primary adrenal lymphoma.	CD79B
30294590	10.3389/fonc.2018.00382	2018	Detection of the <i>MYD88</i> p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma.	CD79B
27297871	10.1111/his.13015	2017	Recurrent mutations in genes involved in nuclear factor-Œ∫B signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.	CD79B
27549353	10.1111/vco.12262	2017	Evaluation of Pax5 expression and comparison with BLA.36 and CD79Œ±cy in feline non-Hodgkin lymphoma.	CD79B
27687087	10.1080/10428194.2016.1213836	2017	Nodal marginal zone lymphoma: mutation status analyses of CD79A, CD79B, and MYD88 reveal no specific recurrent lesions.	CD79B
27915469	10.1002/cncr.30404	2017	MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.	CD79B
27923841	10.1158/1078-0432.CCR-16-1922	2017	Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.	CD79B
28009435	10.1111/bph.13697	2017	Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.	CD79B
28011673	10.1182/blood-2016-05-718494	2017	Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.	CD79B
28073005	10.1016/j.ccell.2016.12.003	2017	Simultaneous Inhibition of PI3KŒ¥ and PI3KŒ± Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-Œ∫B and AKT.	CD79B
28153771	10.1016/j.ebiom.2017.01.027	2017	B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.	CD79B
28248816	10.1097/PAS.0000000000000828	2017	TdT-positive Infiltrate in Inflamed Pediatric Kidney: A Potential Diagnostic Pitfall.	CD79B
28319526	10.1097/PAS.0000000000000836	2017	Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features.	CD79B
28341730	10.3324/haematol.2016.161893	2017	Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant <i>MYD88</i> and wildtype <i>CD79</i>.	CD79B
28368423	10.1038/onc.2017.95	2017	Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.	CD79B
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	CD79B
28552327	10.1016/j.ccell.2017.04.012	2017	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.	CD79B
28612664	10.1177/1066896917714325	2017	Primary Central Nervous System T-Cell Lymphoma With Aberrant Expression of CD20 and CD79a: A Diagnostic Pitfall.	CD79B
28619981	10.1158/2159-8290.CD-17-0613	2017	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.	CD79B
28664939	10.1038/modpathol.2017.58	2017	Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.	CD79B
28682481	10.1002/path.4933	2017	Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma.	CD79B
28701369	10.1084/jem.20161454	2017	Synergistic cooperation and crosstalk between <i>MYD88<sup>L265P</sup></i> and mutations that dysregulate CD79B and surface IgM.	CD79B
28791394	10.3892/mmr.2017.7158	2017	Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis.	CD79B
28803429	10.1007/s00277-017-3094-7	2017	Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.	CD79B
28841204	10.1038/bcj.2017.72	2017	From Waldenstr√∂m's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.	CD79B
28856744	10.1111/neup.12405	2017	Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.	CD79B
28864640	10.1158/2159-8290.CD-17-0714	2017	Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.	CD79B
28884033	10.1155/2017/6891957	2017	High-Grade B-Cell Neoplasm with Surface Light Chain Restriction and Tdt Coexpression Evolved in a <i>MYC</i>-Rearranged Diffuse Large B-Cell Lymphoma: A Dilemma in Classification.	CD79B
28892912	10.7860/JCDR/2017/27149.10190	2017	Important Diagnostic Clues for Diagnosing Splenic Marginal Zone Lymphoma in Absence of Splenic Histology.	CD79B
28922238	10.1097/WCO.0000000000000492	2017	Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies?	CD79B
28993276	10.1016/j.humpath.2017.09.013	2017	A distinctive subgroup of oral EBV+ B-cell neoplasm with polymorphous features is potentially identical to EBV+ mucocutaneous ulcer.	CD79B
29025291	10.1556/650.2017.30868	2017	[Waldenstr√∂m's macroglobulinemia and its individualized therapy options].	CD79B
29035453	10.7754/Clin.Lab.2017.170406	2017	Immunophenotyping of Chronic Lymphocytic Leukemia.	CD79B
29062027	10.1038/s41467-017-01257-1	2017	Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.	CD79B
29125235	10.1002/cam4.1257	2017	Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.	CD79B
29245897	10.18632/oncotarget.18502	2017	Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum.	CD79B
29262531	10.18632/oncotarget.21986	2017	Mutational profile of primary breast diffuse large B-cell lymphoma.	CD79B
25612555	10.1002/cyto.b.21227	2016	The utility of multiparametric seven-color flow cytometry in the detection of double hit lymphoma in ascitic fluid samples.	CD79B
26111727	10.1111/nan.12259	2016	Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.	CD79B
26318093	10.1016/j.critrevonc.2015.08.014	2016	A review of monoclonal antibody therapies in lymphoma.	CD79B
26647218	10.1158/1078-0432.CCR-15-2123	2016	Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.	CD79B
26699656	10.3109/10428194.2015.1113276	2016	CD79B limits response of diffuse large B cell lymphoma to ibrutinib.	CD79B
26752547	10.1097/PAS.0000000000000592	2016	Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.	CD79B
26773040	10.1182/blood-2015-09-672352	2016	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.	CD79B
26826778	10.1016/j.gastrohep.2015.12.001	2016	[Intestinal infiltration of high-grade large T-cell non-Hodgkin lymphoma with cyclin-D1 overexpression and aberrant CD79a expression in a patient with a diagnosis of tumour stage mycosis fungoides].	CD79B
26879426	10.3760/cma.j.issn.0529-5807.2016.02.002	2016	[Diffuse large B-cell lymphoma with aberrant expression of CD56: a clinicopathologic and immunohistochemical study].	CD79B
27010137	NA	2016	Mutational status of EZH2 and CD79B hot spots in mature B-cell non-Hodgkin's lymphomas: novel CD79B variations have been revealed.	CD79B
27010357	10.1111/aos.13020	2016	Lacrimal gland extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue-type associated with massive amyloid deposition.	CD79B
27048211	10.1182/blood-2015-11-684183	2016	B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.	CD79B
27198204	10.1038/leu.2016.135	2016	Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.	CD79B
27262792	10.1016/j.semcancer.2016.05.002	2016	Mechanisms of NF-Œ∫B deregulation in lymphoid malignancies.	CD79B
27521317	10.1016/j.clml.2016.02.032	2016	Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia.	CD79B
27526684	10.1111/ejh.12792	2016	Rewired NFŒ∫B signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.	CD79B
27559941	10.1097/MD.0000000000004128	2016	Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia.	CD79B
27590508	10.18632/oncotarget.11740	2016	Transcriptomic and functional pathways analysis of ascorbate-induced cytotoxicity and resistance of Burkitt lymphoma.	CD79B
27600807	10.1007/s00428-016-2012-z	2016	Cellular-level characterization of B cells infiltrating pulmonary MALT lymphoma tissues.	CD79B
25030036	10.3109/10428194.2014.944522	2015	Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.	CD79B
25347427	10.3109/10428194.2014.979413	2015	Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.	CD79B
25391967	10.1007/s11060-014-1655-3	2015	Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.	CD79B
25414443	10.1182/blood-2014-07-587840	2015	Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.	CD79B
25417998	10.1002/ajh.23904	2015	CD20-negative diffuse large B-cell lymphoma presenting with lactic acidosis.	CD79B
25484043	10.4161/19420862.2014.979081	2015	Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.	CD79B
25529125	10.1016/j.humpath.2014.10.021	2015	Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients.	CD79B
25595795	10.1016/j.cgh.2015.01.003	2015	A Rare Case of Diffuse Polyps of Small Intestine With Abdominal Mass.	CD79B
25623213	10.1158/1078-0432.CCR-14-1561	2015	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.	CD79B
25639261	10.1002/eji.201545464	2015	Rehabilitation or the death penalty: autoimmune B cells in the dock.	CD79B
25643939	10.1111/bjh.13293	2015	Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma.	CD79B
25708834	10.1038/leu.2015.48	2015	Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.	CD79B
25807917	10.1002/cncy.21535	2015	Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation.	CD79B
25840969	10.1158/1078-0432.CCR-14-2035	2015	A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.	CD79B
25925618	10.1016/S1470-2045(15)70161-0	2015	Antibody-drug conjugates in non-Hodgkin lymphoma.	CD79B
25925619	10.1016/S1470-2045(15)70128-2	2015	Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.	CD79B
25933603	10.1186/s13104-015-1132-x	2015	Plasmablastic lymphoma of the oral cavity with breast recurrence: a case report.	CD79B
25991819	10.1158/1078-0432.CCR-14-2116	2015	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.	CD79B
26064133	10.1155/2015/953297	2015	Disseminated Gastric MALT Lymphoma with Monoclonal Gammopathy, t(11;18)(q21;q21), and Subsequent Development of T-Large Granular Lymphocytic Leukemia: A Case Report and Review of the Literature.	CD79B
26193343	10.1038/nm.3884	2015	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.	CD79B
26194424	10.1007/s11912-015-0466-9	2015	Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.	CD79B
26307535	10.1182/blood-2015-06-649905	2015	Cell of origin of transformed follicular lymphoma.	CD79B
26483459	10.1073/pnas.1514944112	2015	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.	CD79B
26515759	10.1186/s13045-015-0218-1	2015	Establishment and characterization of a novel MYC/BCL2 double-hit diffuse large B cell lymphoma cell line, RC.	CD79B
26517678	10.18632/oncotarget.5425	2015	Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.	CD79B
26540570	10.18632/oncotarget.6273	2015	Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.	CD79B
26588248	10.1371/journal.pone.0143216	2015	Conditional Expression of E2A-HLF Induces B-Cell Precursor Death and Myeloproliferative-Like Disease in Knock-In Mice.	CD79B
26639163	10.1038/srep17868	2015	Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma.	CD79B
23737093	10.1007/s00277-013-1810-5	2014	A mimicking multiple liver metastasis of breast cancer by recurrent B lymphoblastic leukemia.	CD79B
24169729	10.1007/s00431-013-2181-6	2014	The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.	CD79B
24240734	10.1007/s00401-013-1202-x	2014	Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.	CD79B
24253023	10.1038/leu.2013.348	2014	High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.	CD79B
24327543	10.1002/gcc.22126	2014	Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.	CD79B
24444466	10.1016/j.humpath.2013.10.023	2014	CD79B and MYD88 mutations in diffuse large B-cell lymphoma.	CD79B
24548411	10.1016/j.bbrc.2014.02.037	2014	IgG1 cytoplasmic tail is essential for cell surface expression in IgŒ≤ down-regulated cells.	CD79B
24576169	10.3109/10428194.2014.896006	2014	Auer rod-like inclusions in the cytoplasm of splenic lymphoma cells.	CD79B
24795275	10.1016/j.endonu.2014.03.005	2014	Hypothalamic evanescent lesion by diffuse large B-cell lymphoma.	CD79B
24841238	10.1371/journal.pone.0098315	2014	Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.	CD79B
24876818	10.5114/wo.2013.38570	2014	Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia.	CD79B
24970810	10.18632/oncotarget.2080	2014	Mutational analysis of primary central nervous system lymphoma.	CD79B
25194535	NA	2014	A case of t(14; 18)-negative follicular lymphoma with atypical immunophenotype: usefulness of immunoarchitecture of Ki67, CD79a and follicular dendritic cell meshwork in making the diagnosis.	CD79B
25275047	NA	2014	Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.	CD79B
25501023	10.1038/bcj.2014.87	2014	Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.	CD79B
26011976	NA	2014	Mantle cell lymphoma in a lacrimal gland in a female and a review of the literature.	CD79B
22296667	10.1111/j.1476-5829.2011.00317.x	2013	Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma.	CD79B
22776235	10.5732/cjc.012.10041	2013	Individualized leukemia cell-population profiles in common B-cell acute lymphoblastic leukemia patients.	CD79B
23174882	10.1038/leu.2012.280	2013	Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma.	CD79B
23361872	10.1002/cncy.21262	2013	EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.	CD79B
23372794	10.1371/journal.pone.0054938	2013	Cis and trans regulatory mechanisms control AP2-mediated B cell receptor endocytosis via select tyrosine-based motifs.	CD79B
23378931	10.1155/2013/252318	2013	CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma.	CD79B
23396434	10.1684/abc.2012.0782	2013	[Mantle cell lymphoma diagnosis].	CD79B
23405135	10.1371/journal.pone.0055324	2013	Horizontal transmission of malignancy: in-vivo fusion of human lymphomas with hamster stroma produces tumors retaining human genes and lymphoid pathology.	CD79B
23444036	10.1177/0300985813478210	2013	Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival.	CD79B
23558558	10.1007/s00251-013-0698-5	2013	Cloning of a hamster anti-mouse CD79B antibody sequences and identification of a new hamster immunoglobulin lambda constant IGLC gene region.	CD79B
23562349	10.1179/1607845412Y.0000000037	2013	Primary bone marrow T-cell/histiocyte-rich large B-cell lymphoma: a diagnostic challenge.	CD79B
23821660	10.1182/blood-2012-12-473744	2013	Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.	CD79B
24013661	10.1038/bcj.2013.28	2013	High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites.	CD79B
24060900	10.1016/j.semcancer.2013.09.001	2013	B-cell receptor signaling as a driver of lymphoma development and evolution.	CD79B
24447559	NA	2013	[Primary cutaneous follicle centre lymphoma: report of a case].	CD79B
21900543	10.1177/0300985811419531	2012	Neurolymphomatosis in a dog with B-cell lymphoma.	CD79B
22064604	10.2310/JIM.0b013e31823908f9	2012	CD200 expression in B-cell chronic lymphoproliferative disorders.	CD79B
22102703	10.3324/haematol.2011.054080	2012	BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.	CD79B
22170090	10.1007/s12032-011-0136-1	2012	Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study.	CD79B
22308233	10.1177/0300985811432352	2012	Cutaneous lymphomas in European pet rabbits (Oryctolagus cuniculus).	CD79B
22431545	10.1309/AJCP3FEPX5BEEKGX	2012	Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system.	CD79B
22567217	10.4081/hr.2012.e3	2012	Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry.	CD79B
22800526	10.3760/cma.j.issn.0529-5807.2012.04.013	2012	[Intracranial plasmablastic lymphoma: report of a case].	CD79B
22800529	10.3760/cma.j.issn.0529-5807.2012.04.016	2012	[Neoplastic counterpart of interfollicular dendritic large B cells: report of a case].	CD79B
22808296	NA	2012	Mutation analysis of NF-Œ∫B signal pathway-related genes in ocular MALT lymphoma.	CD79B
22844701	10.2478/v10181-011-0141-5	2012	High agreement of routine cytopathology and immunocytochemistry in canine lymphomas.	CD79B
22961721	10.1002/cyto.b.21038	2012	Flow cytometry CD45-negative B-NHL: a case report of a diffuse large B-cell lymphoma without extranodal involvement.	CD79B
23028900	10.1371/journal.pone.0045274	2012	Innate immunity and non-Hodgkin's lymphoma (NHL) related genes in a nested case-control study for gastric cancer risk.	CD79B
23032248	NA	2012	Random skin biopsy of intravascular large B-cell lymphoma: a case report.	CD79B
23037779	10.1292/jvms.12-0100	2012	Overexpression of interleukin 2 receptor, thymidine kinase and immunoglobulin-associated alpha-1 messenger RNA in a clinical case of enzootic bovine leukosis.	CD79B
23072591	10.1186/1471-2407-12-478	2012	Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.	CD79B
23141946	10.1016/j.annpat.2012.07.021	2012	[Pitfalls and update in haematopathology. Case 7. Nodular lymphocyte predominant Hodgkin lymphoma].	CD79B
23236245	10.3748/wjg.v18.i45.6677	2012	Plasmablastic lymphoma of the small intestine: case report and literature review.	CD79B
23285191	10.1371/journal.pone.0052811	2012	VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type.	CD79B
23302315	10.3760/cma.j.issn.0529-5807.2012.10.013	2012	[Clear cell renal carcinoma coexisting with primary renal lymphoma: report of a case].	CD79B
23610978	NA	2012	Difficulty in classifying a B cell chronic lymphoproliferative disorder CD5+.	CD79B
20337769	10.1111/j.1600-0560.2010.01538.x	2011	Cutaneous intravascular anaplastic large cell lymphoma.	CD79B
21145425	10.1016/j.cgh.2010.12.001	2011	Primary hepatic lymphoma: a large mass surrounding multiple intrahepatic vessels.	CD79B
21173233	10.1073/pnas.1008969108	2011	Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells.	CD79B
21275949	10.1111/j.1365-2141.2010.08445.x	2011	Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas.	CD79B
21324920	10.1158/0008-5472.CAN-10-2525	2011	Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.	CD79B
21337490	10.1002/cyto.b.20571	2011	Marginal zone B cell lymphomas with extensive plasmacytic differentiation are neoplasms of precursor plasma cells.	CD79B
21426801	NA	2011	[Primary lymphoma of breast: a clinicopathologic and prognostic study of 40 cases].	CD79B
21487112	10.1182/blood-2010-12-324004	2011	New markers for minimal residual disease detection in acute lymphoblastic leukemia.	CD79B
21597060	10.3382/ps.2010-01295	2011	Allele-specific expression analysis reveals CD79B has a cis-acting regulatory element that responds to Marek's disease virus infection in chickens.	CD79B
21626771	10.2298/sarh1104229c	2011	[Progression of nodal marginal zone lymphoma into diffuse large B cell lymphoma in a patient with Sj√∂gren's syndrome].	CD79B
21721452	NA	2011	Utilization of a scoring system for diagnosis of chronic lymphocytic leukemia in Thai patients.	CD79B
21865343	10.1182/blood-2011-01-333682	2011	ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation.	CD79B
21914354	NA	2011	[Diffuse large B-cell lymphoma of prostate: report of a case].	CD79B
21934229	10.4103/0377-4929.85103	2011	Primary lymphoma of the spermatic cord: a case report and review of the literature.	CD79B
21934679	10.1038/ni.2094	2011	Malignant pirates of the immune system.	CD79B
22124260	10.1097/PAT.0b013e32834c726f	2011	CD79a positive T cell lymphoma with bone marrow involvement.	CD79B
22177246	NA	2011	[Clinicopathological features of Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly].	CD79B
20054396	10.1038/nature08638	2010	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.	CD79B
20069343	10.1007/s11060-010-0112-1	2010	Immunohistological profiling by B-cell differentiation status of primary central nervous system lymphoma treated by high-dose methotrexate chemotherapy.	CD79B
20102401	10.1111/j.1365-2559.2009.03462.x	2010	BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma.	CD79B
20350661	10.1053/j.seminhematol.2010.01.004	2010	Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.	CD79B
20391985	10.1159/000325015	2010	Can kidney posttransplant lymphoproliferative disorder be detected in voided urine? A case report.	CD79B
20453211	10.1177/104063871002200306	2010	Optimized processing of fine-needle lymph node biopsies for automated immunostaining.	CD79B
20480837	NA	2010	Mucosa-associated lymphoid tissue lymphoma of the appendix vermiformis.	CD79B
20507729	10.5732/cjc.009.10573	2010	A liver-metastatic model of human primary gastric lymphoma in nude mice orthotopically constructed by using histologically intact patient specimens.	CD79B
20673534	NA	2010	A principal case of multiple lymphoid collision tumors involving both B-cell chronic lymphocytic leukemia and metastatic malignant melanoma.	CD79B
20728042	10.1016/j.ejogrb.2010.05.015	2010	Bilateral primary breast lymphoma masquerading as lactating mastitis.	CD79B
20804679	NA	2010	Cutaneous angiogenesis in patient with intravascular lymphoma (IVL): A case report.	CD79B
21055031	NA	2010	[Morphologic diversity of plasma cell neoplasms].	CD79B
21092597	NA	2010	[Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case].	CD79B
18838917	10.1097/PAI.0b013e3181845ef4	2009	Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffin-embedded tissues from lymphoid neoplasms.	CD79B
19136769	10.4103/0377-4929.44952	2009	CD20 positivity in classical Hodgkin's lymphoma: Diagnostic challenge or targeting opportunity.	CD79B
19179973	NA	2009	Meningeal relapse in a case of B acute lymphoblastic leukemia: the role of CD56 expression.	CD79B
19258515	10.1158/0008-5472.CAN-08-2250	2009	Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.	CD79B
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	CD79B
19575872	NA	2009	[Solitary plasmacytoma of spine: a clinical, radiologic and pathologic study of 13 cases].	CD79B
19633198	10.1182/blood-2009-02-205500	2009	Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.	CD79B
19665353	10.1016/j.ijom.2009.07.010	2009	B-cell lymphoblastic lymphoma in the maxilla of a child: a rare case report.	CD79B
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	CD79B
19808977	10.1158/1535-7163.MCT-09-0369	2009	In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.	CD79B
20067170	NA	2009	Splenectomy--a therapeutic option in splenic marginal zone cell lymphoma.	CD79B
20079010	NA	2009	[Lymphoplasmacytic lymphoma with Waldenstr√∂m's macroglobulinemia: a clinicopathological and immunophenotypic study of 40 Chinese patients].	CD79B
20079012	NA	2009	[Assessment of BIOMED-2 assays for detection of clonal Ig gene rearrangements in mature B-cell lymphomas].	CD79B
20079016	NA	2009	[Clinicopathologic and immunohistochemical study of intra-abdominal non-Hodgkin B-cell lymphoma occurring in children].	CD79B
20079018	NA	2009	[Clinicopathologic study of 15 splenectomy specimens of patients with hairy cell leukemia].	CD79B
17307369	10.1016/j.tvjl.2006.12.008	2008	Immunophenotyping of lymphosarcoma in South American camelids on six British premises.	CD79B
17628802	10.1007/s00277-007-0339-x	2008	Angiotropic large cell lymphoma presenting as intestinal obstruction.	CD79B
17629942	10.1016/j.leukres.2007.05.004	2008	The expression of cytoplasmic CD79a correlates with surface CD3 expression in childhood T-ALL lymphoblasts.	CD79B
18172310	10.1158/0008-5472.CAN-07-2778	2008	PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.	CD79B
18194817	10.1016/j.imlet.2007.11.023	2008	MHC class II structural requirements for the association with Igalpha/beta, and signaling of calcium mobilization and cell death.	CD79B
18288568	10.1007/s12185-008-0029-z	2008	B-Lymphoid and myeloid lineages biphenotypic acute leukemia with t(8;21)(q22;q22).	CD79B
18396780	NA	2008	Cutaneous T-cell lymphoma in an African hedgehog (Atelerix albiventris).	CD79B
18566961	10.1002/path.2384	2008	The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype.	CD79B
18670352	10.1097/PAS.0b013e3181758806	2008	Fluorescence immunophenotypic and interphase cytogenetic characterization of nodal lymphoplasmacytic lymphoma.	CD79B
18686384	NA	2008	[Burkitt's lymphoma of the spermatic cord: a case report and review of the literature].	CD79B
18712674	10.14670/HH-23.1223	2008	Immunophenotyping of acute lymphoblastic leukemia using immunohistochemistry in bone marrow biopsy specimens.	CD79B
18807227	10.1007/s12185-008-0153-9	2008	Primary hepatic marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type: case report and review of the literature.	CD79B
18928873	10.1016/j.annpat.2007.11.009	2008	[Hodgkin's disease variant of Richter's syndrome. Two cases and literature review].	CD79B
19031716	NA	2008	[Intravascular large B-cell lymphoma: report of two autopsy cases with literature review].	CD79B
17182546	10.4049/jimmunol.178.1.111	2007	Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.	CD79B
17300668	10.1111/j.1440-1827.2006.02058.x	2007	Development-dependent expression of cyclin D3 in precursor T-cell lymphoblastic leukemia/lymphoma.	CD79B
17317545	10.1016/j.carpath.2006.09.003	2007	Primary cardiac plasmablastic (diffuse large B-cell) lymphoma mimicking left ventricular aneurysm with mural thrombus.	CD79B
17317796	10.1354/vp.44-2-196	2007	High-throughput immunophenotyping of 43 ferret lymphomas using tissue microarray technology.	CD79B
17374736	10.1182/blood-2007-01-066704	2007	Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.	CD79B
17395398	10.1016/j.prp.2007.01.009	2007	Russell body gastritis: expanding the spectrum of Helicobacter pylori - related diseases?	CD79B
17413989	10.1097/01.pgp.0000228144.59677.5a	2007	Lymphoma-like lesion of the uterine cervix: report of 12 cases of a rare entity.	CD79B
17414444	10.1097/01.dad.0000246178.70768.81	2007	Cutaneous involvement with Burkitt-like lymphoma.	CD79B
17548964	10.1620/tjem.212.199	2007	Malignant lymphoma arising from heterotopic Warthin's tumor in the neck: case report and review of the literature.	CD79B
17550863	10.3324/haematol.11081	2007	Aberrant positivity for CD79a in erythroid lineage cells--a finding observed in a subset of re-staging bone marrow trephine biopsies after treatment cell pain.	CD79B
17555446	10.1111/j.1365-2141.2007.06620.x	2007	Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load.	CD79B
17577503	10.1016/j.joms.2005.12.039	2007	Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: a case report.	CD79B
17706135	NA	2007	[Distinction between lymphoma-like lesions and lymphoma of uterine cervix: a clinicopathologic study of 26 cases].	CD79B
17706154	NA	2007	[Primary cardiac lymphoma of non-Hodgkin's lymphoma located in the right atrium: report of a case].	CD79B
17707828	10.1016/j.beha.2007.02.005	2007	The normal counterpart to the chronic lymphocytic leukemia B cell.	CD79B
17825145	NA	2007	[Clinicopathologic features and treatment of primary splenic tumors].	CD79B
17883054	NA	2007	Primary non-Hodgkin's lymphoma of breast: a case report.	CD79B
17917091	10.1007/s12032-007-0029-5	2007	Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma.	CD79B
17969988	NA	2007	[Case of both T- and B-cell markers positive pyothorax-associated lymphoma].	CD79B
18019744	NA	2007	Primary hepatic low-grade B-cell lymphoma of MALT-type associated with Helicobacter pylori infection.	CD79B
18039900	10.1354/vp.44-6-875	2007	Immunohistochemical detection of multiple myeloma 1/interferon regulatory factor 4 (MUM1/IRF-4) in canine plasmacytoma: comparison with CD79a and CD20.	CD79B
18307875	NA	2007	[Mantle cell lymphoma: clinicopathologic features and prognostic factors of 102 cases occurring in Chinese patients].	CD79B
16304050	10.1182/blood-2005-09-3765	2006	Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma.	CD79B
16395706	10.1002/ijc.21762	2006	Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling.	CD79B
16468652	NA	2006	[Solitary plasmacytoma: a clinicopathologic and immunophenotypic analysis of 43 cases].	CD79B
16531332	10.1080/08820130500496878	2006	A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry.	CD79B
16800918	NA	2006	[Biological characteristics of hyperleukocytic acute leukemia].	CD79B
16877363	10.2353/ajpath.2006.060020	2006	Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma.	CD79B
16930333	10.1111/j.1440-1827.2006.02001.x	2006	Epstein-Barr virus-associated enteritis with multiple ulcers after stem cell transplantation: first histologically confirmed case.	CD79B
16938530	10.1016/j.humpath.2006.04.009	2006	Extra-oral plasmablastic lymphoma: report of a case and review of literature.	CD79B
16984613	10.1111/j.1440-1827.2006.02011.x	2006	Follicular lymphoma frequently originates in the salivary gland.	CD79B
16984625	10.1111/j.1440-1827.2006.02023.x	2006	Recurrent primary cutaneous large B-cell lymphoma after a long-term remission.	CD79B
17062357	NA	2006	[Primary diffuse large B-cell lymphoma of the heart: a clinicopathological study].	CD79B
17069714	NA	2006	[Diffuse large B-cell lymphoma of adrenal: report of a case].	CD79B
17134580	NA	2006	[Post-transplant lymphoproliferative disorders: a report of two cases].	CD79B
17147246	NA	2006	[Application of a four antibody (cMPO/cCD79aalpha/cCD3/CD45) combination to the diagnosis of acute leukemia expressing cross-lineage antigens].	CD79B
15693895	10.1111/j.1365-2559.2005.02046.x	2005	Composite marginal zone B-cell lymphoma and classical Hodgkin's lymphoma: a clinicopathological study of 12 cases.	CD79B
15743747	10.1309/FDGW-B5C2-MYRY-XH2E	2005	Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein.	CD79B
15949264	NA	2005	[A clinicopathological study of 96 cases of lymphoblastic lymphoma].	CD79B
15967459	10.1016/j.jmb.2005.05.032	2005	Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines.	CD79B
16042680	10.1111/j.1365-2141.2005.05506.x	2005	Lymphoma and malignant vasovagal syndrome.	CD79B
16045788	10.1111/j.1365-2559.2005.02079.x	2005	Nodal peripheral T-cell lymphoma associated with Warthin's tumour.	CD79B
16091170	NA	2005	[Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms].	CD79B
16105762	10.1532/IJH97.E0501	2005	Meningeal lymphomatosis as the first manifestation of splenic marginal zone lymphoma.	CD79B
16115242	10.1111/j.1365-2559.2005.02120.x	2005	Post-transplant lymphoproliferative disorder with Hodgkin's lymphoma and large B-cell lymphoma differentiation.	CD79B
16185500	NA	2005	[Expression of Oct2 and its significance in lymphoma diagnosis].	CD79B
16185515	NA	2005	[T cell/histiocyte-rich large B cell lymphoma].	CD79B
16191510	10.1309/3G1X-DX0D-VHBN-VKB4	2005	Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstr√∂m macroglobulinemia.	CD79B
16213517	10.1016/j.jcpa.2005.05.004	2005	Immunohistochemical diagnosis of alimentary lymphomas and severe intestinal inflammation in cats.	CD79B
16270275	10.1111/j.1939-165x.2005.tb00076.x	2005	Multilobulated flower cells in a subcutaneous mass aspirate from a cat.	CD79B
16271957	10.1016/j.cancergencyto.2005.06.002	2005	CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity.	CD79B
16403258	NA	2005	Comparative study of expressions of cytoplasmic CD79a and other B-lymphoid immunomarkers in acute leukemic cells.	CD79B
16545182	NA	2005	[T-cell/histiocyte-rich B-cell lymphoma: histology, immunophenotype and differential diagnosis].	CD79B
14989776	NA	2004	[Characteristic analysis of acute leukemia immunophenotyping in 180 cases by flow cytometry].	CD79B
15003483	10.1016/j.jcpa.2003.09.008	2004	The possible prognostic significance of immunophenotype in feline alimentary lymphoma: a pilot study.	CD79B
15166665	10.1097/01.pas.0000126781.87158.e3	2004	Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.	CD79B
15168595	10.1532/ijh97.03156	2004	Epstein-Barr virus-associated composite lymphoma composed of peripheral T-cell lymphoma and an anaplastic variant of a diffuse large B-cell type of non-Hodgkin's lymphoma and strongly expressing p53 protein.	CD79B
15229149	10.1373/clinchem.2003.030114	2004	Differentiation of acute myeloid leukemia from B- and T-lineage acute lymphoid leukemias by real-time quantitative reverse transcription-PCR of lineage marker mRNAs.	CD79B
15254666	NA	2004	Contribution of flow cytometric immunophenotyping and bone marrow trephine biopsy in the detection of lymphoid bone marrow infiltration in non-Hodgkin's lymphomas.	CD79B
15257313	10.1038/modpathol.3800227	2004	Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma.	CD79B
15265880	10.4049/jimmunol.173.3.1526	2004	Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells.	CD79B
15338374	10.1007/s00535-004-1374-1	2004	Primary, solitary, adult T-cell leukemia / lymphoma of the descending colon.	CD79B
15370213	10.1080/10428190410001683769	2004	Usefulness of bone marrow aspiration for definite diagnosis of Asian variant of intravascular lymphoma: four autopsied cases.	CD79B
15483677	10.1038/sj.leu.2403531	2004	IgH DJ rearrangements within T-ALL correlate with cCD79a expression, an immature/TCRgammadelta phenotype and absence of IL7Ralpha/CD127 expression.	CD79B
15492262	10.1158/0008-5472.CAN-04-1865	2004	PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.	CD79B
15544702	10.1186/1471-2407-4-80	2004	Neuroblastoma and pre-B lymphoma cells share expression of key transcription factors but display tissue restricted target gene expression.	CD79B
15551734	10.1097/00129039-200409000-00006	2004	Cutaneous immunocytoma: a clinical, histologic, and phenotypic study of 11 cases.	CD79B
15634450	NA	2004	[Application of flow cytometry in the differential diagnosis of lymphoma/leukemia with aberrant antigen expression].	CD79B
15650271	10.1196/annals.1322.054	2004	Flow cytometric immunophenotyping analysis of patterns of antigen expression in non-Hodgkin's B cell lymphoma in samples obtained from different anatomic sites.	CD79B
15738870	10.1016/s0242-6498(04)94000-x	2004	[A-leukemic caecal myeloid sarcoma: a difficult diagnosis].	CD79B
15884290	10.4314/eamj.v81i4.9159	2004	Recurrent chylothorax in a patient with non-Hodgkins lymphoma: case report.	CD79B
12580968	10.1046/j.1365-2141.2003.04071.x	2003	Cell surface CD43 determination improves diagnostic precision in late B-cell diseases.	CD79B
12651942	10.1073/pnas.0735266100	2003	Somatic hypermutation of the B cell receptor genes B29 (Igbeta, CD79b) and mb1 (Igalpha, CD79a).	CD79B
12653584	10.5858/2003-127-0356-BALWCO	2003	Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage.	CD79B
12720136	10.1053/sonc.2003.50046	2003	Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders.	CD79B
12786898	10.1046/j.1365-2559.2003.01636.x	2003	Plasmablastic lymphoma in HIV+ patients: an expanding spectrum.	CD79B
12859745	10.1034/j.1600-0560.2003.00078.x	2003	Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.	CD79B
12962571	NA	2003	Immunophenotypic characterization of normal peripheral blood B lymphocyte by flow cytometry: reference for diagnosis of chronic B cell leukemia/lymphoma.	CD79B
14579239	10.1002/hon.713	2003	Primary non-Hodgkin lymphoma of the humerus following traumatic injury: case report.	CD79B
14582135	10.1002/cyto.b.10049	2003	Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL).	CD79B
14608905	10.1309/YCH8-DWUF-FQBK-GPVB	2003	The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma.	CD79B
14614054	10.1097/01.MP.0000093627.51090.3F	2003	Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases.	CD79B
14644508	10.1016/j.gene.2003.08.021	2003	Disruption of the PU.1 gene in chicken B lymphoma DT40 cells and its effect on reported target gene expression.	CD79B
11940479	NA	2002	Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia.	CD79B
11950916	10.1038/modpathol.3880541	2002	Peripheral T-cell lymphoma mimicking marginal zone B-cell lymphoma.	CD79B
11970976	10.4049/jimmunol.168.9.4344	2002	Transmodulation of BCR signaling by transduction-incompetent antigen receptors: implications for impaired signaling in anergic B cells.	CD79B
12115880	10.1002/path.1126	2002	Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias.	CD79B
12354547	10.1053/jcpa.2002.0555	2002	Immunohistochemical characterization of lymphosarcoma in two alpacas (Lama pacos).	CD79B
12368180	NA	2002	Relevance of CD79a expression for T-cell lineage attribution in CD7+/CD3- acute lymphoblastic leukemia.	CD79B
12384401	10.1182/blood.V100.9.3068	2002	The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis.	CD79B
12429788	10.1097/01.MP.0000031710.32235.24	2002	Leukemic phase of B-cell lymphomas mimicking chronic lymphocytic leukemia and variants at presentation.	CD79B
12429796	10.1097/01.MP.0000032534.81894.B3	2002	MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas.	CD79B
11235901	10.1038/modpathol.3880265	2001	Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall.	CD79B
11241503	10.1002/1097-0320(20010215)46:1&lt;23::aid-cyto1033&gt;3.0.co;2-z	2001	Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting.	CD79B
11298107	10.1046/j.1365-2230.2001.00786.x	2001	Systemic B-cell lymphoma presenting as an isolated lesion on the ear.	CD79B
11368285	10.2165/00003495-200161050-00005	2001	Achieving optimal outcomes in chronic lymphocytic leukaemia.	CD79B
11372738	10.1007/BF02981944	2001	A Hodgkin's disease cell line, KM-H2, shows biphenotypic features of dendritic cells and B cells.	CD79B
11384666	10.1016/s0022-1759(01)00338-6	2001	Reference values for peripheral blood B-lymphocyte subpopulations: a basis for multiparametric immunophenotyping of abnormal lymphocytes.	CD79B
11396639	10.1097/00129039-200106000-00001	2001	CD79: a review.	CD79B
11419987	10.5858/2001-125-0958-CTCLLW	2001	CD79a(+) T-cell lymphoblastic lymphoma with coexisting Langerhans cell histiocytosis.	CD79B
11504918	10.1073/pnas.181206898	2001	CmC(A/T)GG DNA methylation in mature B cell lymphoma gene silencing.	CD79B
11553311	10.1034/j.1600-0560.2001.028009453.x	2001	Expression of cutaneous lymphocyte-associated antigen and TIA-1 by lymphocytes in pityriasis lichenoides et varioliformis acuta and lymphomatoid papulosis: immunohistochemical study.	CD79B
11564080	10.1046/j.1365-2141.2001.03019.x	2001	Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis.	CD79B
11697493	10.3109/10428190109099325	2001	Morphologically typical and atypical B-cell chronic lymphocytic leukemias display a different pattern of surface antigenic density.	CD79B
11697517	10.3109/10428190109099349	2001	Primary extramedullary plasmacytoma of the lacrimal gland.	CD79B
11706077	10.1038/modpathol.3880450	2001	Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma.	CD79B
11737305	10.1046/j.1365-2559.2001.01271.x	2001	Histological and immunohistochemical characterization of extranodal diffuse large-cell lymphomas with prominent spindle cell features.	CD79B
11778688	10.1023/a:1012904307579	2001	Molecular cytogenetic analysis of a novel high-grade canine T-lymphoblastic lymphoma demonstrating co-expression of CD3 and CD79a cell markers.	CD79B
11892366	NA	2001	[Cytoimmunofluorometry in the diagnosis of MALT lymphoma of the gastrointestinal tract].	CD79B
10674895	10.3109/10428190009148844	2000	Chronic lymphoproliferative disorders: an integrated point of view for the differential diagnosis.	CD79B
10757332	10.1038/modpathol.3880041	2000	Sinusoidal CD30-positive large B-cell lymphoma: a morphologic mimic of anaplastic large cell lymphoma.	CD79B
10818680	10.1016/s0065-230x(00)79005-1	2000	The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms.	CD79B
10821487	10.1053/hp.2000.6551	2000	Clonality assessment of lymphoproliferative disorders by multiparameter flow cytometry of paraffin-embedded tissue: an additional diagnostic tool in surgical pathology.	CD79B
10874881	10.1309/G689-2J36-KCTC-WD5N	2000	Usefulness of CD79b expression in the diagnosis of B-cell chronic lymphoproliferative disorders.	CD79B
10874883	10.1309/391R-93YF-DB4D-1L35	2000	Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemias.	CD79B
10886208	10.1046/j.1365-2141.2000.02045.x	2000	Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas.	CD79B
10903747	10.4049/jimmunol.165.3.1427	2000	Aberrant trafficking of the B cell receptor Ig-alpha beta subunit in a B lymphoma cell line.	CD79B
10912936	10.1038/modpathol.3880133	2000	Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas.	CD79B
11055871	10.1354/vp.37-5-465	2000	Progression of an orbital T-cell rich B-cell lymphoma to a B-cell lymphoma in a dog.	CD79B
11070128	10.1053/hupa.2000.18504	2000	Two cases of histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto's disease) following diffuse large B-cell lymphoma.	CD79B
11122144	NA	2000	An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome.	CD79B
11123762	10.1046/j.1440-1827.2000.01151.x	2000	Primary cutaneous B-cell lymphoma in Japanese patients.	CD79B
11131924	10.1007/s002770000200	2000	T-cell/natural killer cell lymphoblastic lymphoma with an unusual coexpression of B-cell antigens.	CD79B
11558462	10.1638/1042-7260(2000)031[0388:TCRBCL]2.0.CO;2	2000	T-cell-rich B-cell lymphoma in a ring-tailed lemur (Lemur catta).	CD79B
10048429	10.3109/10428199909058414	1999	Widespread B29 (CD79b) gene defects and loss of expression in chronic lymphocytic leukemia.	CD79B
10198699	NA	1999	[Role of Epstein-Barr virus in the pathogenesis of lymphogranulomatosis. Immunohistochemical and molecular-biological (hybridization in situ) research].	CD79B
10213673	10.1053/jcpa.1998.0244	1999	B-cell (CD79a+) lymphoma affecting the tarsal joint synovia in a sheep.	CD79B
10319379	NA	1999	B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstr√∂m's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders.	CD79B
10329919	NA	1999	Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders.	CD79B
10353002	NA	1999	Expression of CD79a antigen in acute lymphoblastic leukaemias in children.	CD79B
10397328	NA	1999	CD79a detected by ZL7.4 separates chronic lymphocytic leukemia from mantle cell lymphoma in the leukemic phase.	CD79B
10419594	10.1002/(SICI)1096-9896(199907)188:3&lt;267::AID-PATH357&gt;3.0.CO;2-N	1999	Gene rearrangements in T-cell lymphoblastic lymphoma.	CD79B
10587707	10.1093/ajcp/112.6.836	1999	Precursor B lymphoblastic lymphoma presenting as lytic bone lesions.	CD79B
11869528	NA	1999	[A clinico-pathological and immunohistochemical study on anaplastic large cell lymphoma].	CD79B
9531288	NA	1998	Asymmetrical phosphorylation and function of immunoreceptor tyrosine-based activation motif tyrosines in B cell antigen receptor signal transduction.	CD79B
9924428	10.1002/(SICI)1096-9896(1998100)186:2&lt;140::AID-PATH149&gt;3.0.CO;2-Y	1998	Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma.	CD79B
8656670	NA	1996	Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.	CD79B
7539038	10.1084/jem.181.6.2077	1995	Identification of the tyrosine phosphatase PTP1C as a B cell antigen receptor-associated protein involved in the regulation of B cell signaling.	CD79B
33620088	10.1111/bjh.17362	2021	Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma.	CD83
33684939	10.1182/blood.2020007683	2021	Characterization of DLBCL with a PMBL gene expression signature.	CD83
33945543	10.1371/journal.pone.0248886	2021	Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.	CD83
34173009	10.1007/s00262-021-02988-3	2021	The PI3KŒ¥ inhibitor idelalisib impairs the function of human dendritic cells.	CD83
32685149	10.1002/cti2.1156	2020	Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody.	CD83
33139544	10.1073/pnas.2014470117	2020	Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma.	CD83
31075666	10.1016/j.anndiagpath.2019.04.009	2019	The utility of CD83, fascin and CD23 in the differential diagnosis of primary mediastinal large B-cell lymphoma versus classic Hodgkin lymphoma.	CD83
29351987	10.3324/haematol.2017.178384	2018	CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.	CD83
29572346	10.3324/haematol.2018.188870	2018	CD83 in Hodgkin lymphoma.	CD83
29058460	10.1089/dna.2017.3923	2017	Ginsenoside Rg1 Activates Dendritic Cells and Acts as a Vaccine Adjuvant Inducing Protective Cellular Responses Against Lymphomas.	CD83
25867364	10.4238/2015.March.27.3	2015	Stimulation of dendritic cell maturation and induction of apoptosis in lymphoma cells by a stable lectin from buckwheat seeds.	CD83
26239360	10.3892/mmr.2015.4153	2015	Effect of thymosin Œ±‚ÇÅ on the phenotypic and functional maturation of dendritic cells from children with acute lymphoblastic leukemia.	CD83
26573001	10.1309/AJCPUJGMVV6ZF4GG	2015	High levels of regulatory T cells in blood are a poor prognostic factor in patients with diffuse large B-cell lymphoma.	CD83
24188174	10.1111/cei.12231	2014	Integrin-driven monocyte to dendritic cell conversion in modified extracorporeal photochemotherapy.	CD83
24633193	10.1038/modpathol.2014.44	2014	A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma.	CD83
24714353	10.1097/CJI.0000000000000014	2014	Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.	CD83
25470820	10.1371/journal.pone.0114345	2014	Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma.	CD83
23737309	NA	2013	Vaccination of diffuse large B- cell lymphoma patients with antigen-primed dendritic cells.	CD83
23958949	10.1182/blood-2012-09-456988	2013	Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.	CD83
22615251	10.1128/IAI.00381-12	2012	Comparative analysis of the interaction of Helicobacter pylori with human dendritic cells, macrophages, and monocytes.	CD83
22678564	10.2340/00015555-1220	2012	Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T-cell lymphoma: mycosis fungoides and S√©zary syndrome.	CD83
22739162	NA	2012	[Anti-tumor immune response of dendritic cells derived from lymphoma cells transduced with recombinant adenovirus encoding human P53].	CD83
22740445	10.1182/blood-2012-03-415380	2012	Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas.	CD83
20715107	10.1002/ijc.25597	2011	Specific infiltration of langerin-positive dendritic cells in EBV-infected tonsil, Hodgkin lymphoma and nasopharyngeal carcinoma.	CD83
20980519	10.1128/JVI.01007-10	2011	Activation of plasmacytoid dendritic cells by Kaposi's sarcoma-associated herpesvirus.	CD83
21479995	10.1007/s00262-011-1014-6	2011	The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.	CD83
21492747	10.1016/j.intimp.2011.03.022	2011	Preparation and identification of a novel immunomodulator composed of muramyl dipeptide and anti-CD10 monoclonal antibody for treatment of minimal residual disease in acute leukemia children.	CD83
21668308	10.2217/imt.11.56	2011	Broad-spectrum immunosuppression by classless monocytes in non-Hodgkin's lymphoma.	CD83
20420706	10.1186/1465-9921-11-45	2010	Cigarette smoke promotes dendritic cell accumulation in COPD; a Lung Tissue Research Consortium study.	CD83
19129484	10.1189/jlb.0808469	2009	Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia.	CD83
20514853	NA	2009	Dendritic cell distribution in lymphomas.	CD83
18464117	10.1080/10428190802007734	2008	Expression profiling reveals specific gene expression signatures in gastric MALT lymphomas.	CD83
18809238	10.1016/j.exphem.2008.07.003	2008	Costimulation molecule expression and subset distribution of blood dendritic cells in normal children and newly diagnosed pediatric leukemia and lymphoma patients.	CD83
18991097	10.1080/08820130802403358	2008	Development of immunogenic tumor-loaded dendritic cells through physical perturbation and apoptotic cell loading.	CD83
17212709	10.1111/j.1399-0039.2006.00706.x	2007	The expression analysis of ICOS-L on activated T cells and immature dendritic cells as well as malignant B cells and Grave's-disease-derived thyroid tissues by two novel mAbs against human ICOS-L.	CD83
17285277	10.1007/s00277-007-0256-z	2007	Upregulation of antigen-processing machinery components at mRNA level in acute lymphoblastic leukemia cells after CD40 stimulation.	CD83
17312329	10.1200/JCO.2006.09.3534	2007	Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.	CD83
17535098	10.2350/06-04-0082.1	2007	Anaplastic large cell lymphomas: a study of 75 pediatric patients.	CD83
17598863	10.1111/j.1600-0781.2007.00285.x	2007	Clinical-scale generation of strongly CD83-expressing dendritic cells using extracorporeal photopheresis.	CD83
17979570	10.1089/cbr.2007.356	2007	Human allogeneic and murine xenogeneic dendritic cells are cytotoxic to human tumor cells via two distinct pathways.	CD83
16517754	10.4049/jimmunol.176.6.3830	2006	Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity.	CD83
16733557	NA	2006	CD40 stimulation induces differentiation of acute lymphoblastic leukemia cells into dendritic cells.	CD83
16830056	NA	2006	Low expression of costimulatory molecules and mRNA for cytokines are important mechanisms of immunosuppression in acute lymphoblastic leukemia in children?	CD83
17101562	10.1080/00365510600931098	2006	Acute lymphoblastic leukaemia cells express CCR7 but not higher amounts of IL-10 after CD40 ligation.	CD83
15820064	NA	2005	[In vitro inducing differentiation of bone marrow mononuclear cells of chronic myeloid leukemia].	CD83
16029505	10.1186/1476-8518-3-4	2005	Rapid construction of a dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loading.	CD83
14681701	10.1038/sj.gt.3302141	2004	Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lentivectors.	CD83
14687618	10.1016/s0145-2126(03)00255-8	2004	The soluble form of CD83 is present at elevated levels in a number of hematological malignancies.	CD83
15183897	10.1016/j.exphem.2004.03.004	2004	Adhesion capacity and integrin expression by dendritic-like cells generated from acute myeloid leukemia blasts by calcium ionophore treatment.	CD83
15359643	10.1080/10428190310001653682	2004	Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy.	CD83
11843292	10.1007/BF02981980	2002	The generation of immunocompetent dendritic cells from CD34+ acute myeloid or lymphoid leukemia cells.	CD83
11904731	10.1007/s00262-001-0253-3	2002	Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia.	CD83
12006212	10.1080/146532402317381875	2002	Immune escape mechanisms of childhood ALL and a potential countering role for DC-like leukemia cells.	CD83
12408353	10.1080/0031302021000009469	2002	CD83 in Hodgkin and Reed-Sternberg cells.	CD83
12452867	10.1046/j.1365-2133.2002.04994.x	2002	Dendritic cells and apoptosis in mycosis fungoides.	CD83
11161986	10.1006/clim.2000.4968	2001	Replicative response, immunophenotype, and functional activity of monocyte-derived versus CD34(+)-derived dendritic cells following exposure to various expansion and maturational stimuli.	CD83
11372738	10.1007/BF02981944	2001	A Hodgkin's disease cell line, KM-H2, shows biphenotypic features of dendritic cells and B cells.	CD83
11587218	10.1038/sj.leu.2402273	2001	An optimised biphasic culture system for the generation of functional dendritic cells from patients with acute lymphoblastic leukaemia at presentation and in clinical remission.	CD83
11587221	10.1038/sj.leu.2402226	2001	CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells.	CD83
10698208	10.1097/00000372-200002000-00001	2000	Nonlymphoid intraepidermal mononuclear cell collections (pseudo-Pautrier abscesses): a morphologic and immunophenotypical characterization.	CD83
11342340	10.3109/10428190009113387	2000	Increased cytotoxicity against B-chronic lymphocytic leukemia by cellular manipulations: potentials for therapeutic use.	CD83
12042046	10.1080/146532400539099	2000	In vitro generation of dendritic cells derived from cryopreserved CD34+ cells mobilized into peripheral blood in lymphoma patients.	CD83
12058165	NA	2000	Expression of Human Soluble CD40 Ligand in Pichia pastoris and Its Effects on Dendritic Cells and Malignant B Cells.	CD83
10467329	10.1038/sj.bmt.1701916	1999	Simultaneous cord blood transplantation of ex vivo expanded together with non-expanded cells for high risk leukemia.	CD83
10477734	NA	1999	CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells.	CD83
9643561	10.3109/10428199809050907	1998	Developmental aspects of dendritic cells in vitro and in vivo.	CD83
9271021	10.1080/00313029700169125	1997	Hodgkin's cells express CD83, a dendritic cell lineage associated antigen.	CD83
8075582	10.3109/10428199409052677	1994	New CD from the B cell section of the Fifth International Workshop on Human Leukocyte Differentiation Antigens.	CD83
35106936	10.1002/cam4.4550	2022	SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.	CIITA
35760800	10.1038/s41467-022-31356-7	2022	Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.	CIITA
33777766	10.3389/fonc.2021.620435	2021	Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma.	CIITA
34360767	10.3390/ijms22158001	2021	HTLV-1 Infection and Pathogenesis: New Insights from Cellular and Animal Models.	CIITA
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	CIITA
32002294	10.1080/2162402X.2019.1683346	2020	Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression.	CIITA
32555149	10.1038/s41408-020-0335-0	2020	CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma.	CIITA
32649887	10.1016/j.ccell.2020.06.002	2020	Immunogenomic Landscape of Hematological Malignancies.	CIITA
32947237	10.1016/j.tranon.2020.100855	2020	Identification of clinical molecular targets for childhood Burkitt lymphoma.	CIITA
30211726	10.1097/PAS.0000000000001154	2019	Cyclin D1-positive Mediastinal Large B-Cell Lymphoma With Copy Number Gains of CCND1 Gene: A Study of 3 Cases With Nonmediastinal Disease.	CIITA
30540571	10.1097/PAS.0000000000001198	2019	Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.	CIITA
31292115	10.1182/blood.2019001126	2019	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.	CIITA
31704289	10.1016/j.intimp.2019.105999	2019	Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.	CIITA
31783769	10.1186/s12977-019-0498-6	2019	Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1.	CIITA
29289361	10.1016/j.blre.2017.12.001	2018	The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.	CIITA
29857068	10.1016/j.jid.2018.04.038	2018	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.	CIITA
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	CIITA
26500140	10.1038/leu.2015.299	2016	FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.	CIITA
26758422	10.3109/10428194.2015.1135431	2016	A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.	CIITA
26792751	10.1128/JVI.03000-15	2016	The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-Œ∫B by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein.	CIITA
26850007	10.1002/gcc.22345	2016	Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.	CIITA
25393674	10.3109/10428194.2014.985673	2015	Structural genomic alterations in primary mediastinal large B-cell lymphoma.	CIITA
25631773	10.1182/blood-2014-08-594689	2015	Epstein-Barr virus LMP2A suppresses MHC class II expression by regulating the B-cell transcription factors E47 and PU.1.	CIITA
25712539	10.1002/path.4522	2015	Recurrent genomic rearrangements in primary testicular lymphoma.	CIITA
25713363	10.1073/pnas.1501199112	2015	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.	CIITA
26049756	10.1097/MOH.0000000000000155	2015	Genomic alterations underlying immune privilege in malignant lymphomas.	CIITA
26135560	10.1097/PAS.0000000000000473	2015	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling.	CIITA
26229090	10.1158/2159-8290.CD-15-0370	2015	Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma.	CIITA
26314988	10.1038/bcj.2015.69	2015	Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.	CIITA
26549456	10.1016/j.celrep.2015.10.008	2015	Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression.	CIITA
26599546	10.1371/journal.pone.0139663	2015	Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines.	CIITA
23449805	10.1128/JVI.00250-13	2013	Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.	CIITA
23770291	10.1016/j.cellsig.2013.06.007	2013	Antagonistic crosstalk between NF-Œ∫B and SIRT1 in the regulation of inflammation and metabolic disorders.	CIITA
23789844	10.1111/imm.12136	2013	Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.	CIITA
22532676	10.1128/JVI.06908-11	2012	Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3.	CIITA
22808135	10.1371/journal.pone.0040332	2012	Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma.	CIITA
23251452	10.1371/journal.pone.0051203	2012	New fusion transcripts identified in normal karyotype acute myeloid leukemia.	CIITA
21345951	10.1128/JVI.02123-10	2011	Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression.	CIITA
21368758	10.1038/nature09754	2011	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.	CIITA
21664896	10.1016/j.bcp.2011.05.026	2011	Epigenetic regulation of CIITA expression in human T-cells.	CIITA
21822207	10.1038/modpathol.2011.116	2011	Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations.	CIITA
20363966	10.4049/jimmunol.1000079	2010	PU.1 binds to a distal regulatory element that is necessary for B cell-specific expression of CIITA.	CIITA
19081173	10.1016/j.exphem.2008.10.001	2009	Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).	CIITA
19229048	10.3324/haematol.2008.000752	2009	CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression.	CIITA
19814686	10.3109/10428190903297531	2009	Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV.	CIITA
19863170	10.3109/10428190903350454	2009	MHC class II as a therapeutic target in B-cell lymphomas: the CIITA road to paradise?	CIITA
17312329	10.1200/JCO.2006.09.3534	2007	Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.	CIITA
16239429	10.1182/blood-2005-04-1510	2006	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.	CIITA
16337482	10.1016/j.molimm.2005.03.008	2006	Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression.	CIITA
14563641	10.1182/blood-2003-05-1491	2004	Regulation of MHC class II expression in human T-cell malignancies.	CIITA
14973505	10.1038/sj.leu.2403315	2004	Defective class II transactivator expression in a B lymphoma cell line.	CIITA
15384976	10.1111/j.1365-2141.2004.05151.x	2004	Loss of heterozygosity, a frequent but a non-exclusive mechanism responsible for HLA dysregulation in non-Hodgkin's lymphomas.	CIITA
12738680	10.1182/blood-2002-08-2482	2003	BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma.	CIITA
12887826	NA	2003	[Cloning and biological activities of riboenzymes against major histocompatibility complex class II transactivator].	CIITA
11802213	10.1002/ijc.1623	2002	Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines.	CIITA
12218125	10.4049/jimmunol.169.6.3085	2002	DNA alkylating agents alleviate silencing of class II transactivator gene expression in L1210 lymphoma cells.	CIITA
12391224	10.4049/jimmunol.169.9.5078	2002	Modulation of gene expression by the MHC class II transactivator.	CIITA
12492813	10.1034/j.1399-0039.2002.600504.x	2002	Class II transactivator-induced expression of HLA-DO(beta) in HeLa cells.	CIITA
10637510	10.1038/sj.onc.1203293	1999	Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5'-RACE and LA - PCR analyses of biopsy samples.	CIITA
10725870	10.1002/(sici)1099-1069(199912)17:4&lt;149::aid-hon645&gt;3.0.co;2-f	1999	Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.	CIITA
9722631	10.1093/nar/26.18.4128	1998	The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element.	CIITA
9177216	10.1073/pnas.94.12.6324	1997	Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein.	CIITA
9177217	10.1073/pnas.94.12.6330	1997	Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5.	CIITA
9234682	10.1128/MCB.17.8.4249	1997	Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy.	CIITA
9352360	10.1093/intimm/9.10.1545	1997	Suppression of MHC class II expression by human class II trans-activator constructs lacking the N-terminal domain.	CIITA
8666795	NA	1996	Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells.	CIITA
20029944	10.1002/ajh.21580	2010	Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival.	CPS1
20438785	10.1016/j.humimm.2010.04.004	2010	Polymorphisms in innate immunity genes and risk of childhood leukemia.	CPS1
18636124	10.1371/journal.pone.0002816	2008	Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.	CPS1
34265801	10.1097/PAS.0000000000001780	2022	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.	CREBBP
34601504	10.1038/s41379-021-00938-z	2022	Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation.	CREBBP
34664256	10.1111/bjh.17894	2022	Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.	CREBBP
34837284	10.1111/cas.15224	2022	Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.	CREBBP
34957565	10.1002/path.5861	2022	Widespread in situ follicular neoplasia in patients who subsequently developed follicular lymphoma.	CREBBP
34967008	10.1111/bjh.17990	2022	The molecular ontogeny of follicular lymphoma: gene mutations succeeding the BCL2 translocation define common precursor cells.	CREBBP
34977845	10.1016/j.xjidi.2021.100068	2022	Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders.	CREBBP
35022084	10.1186/s13046-021-02234-9	2022	The follicular lymphoma epigenome regulates its microenvironment.	CREBBP
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	CREBBP
35038193	10.1111/his.14617	2022	Incidence, clinicopathological features and genetics of in-situ follicular neoplasia: a comprehensive screening study in a Japanese cohort.	CREBBP
35124168	10.1016/j.jsbmb.2022.106068	2022	Glucocorticoid receptor gene mutations confer glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.	CREBBP
35172382	10.1002/JLB.5A0721-361R	2022	Genomic heterogeneity contributed to different prognosis between adult and pediatric acute lymphoblastic.	CREBBP
35205765	10.3390/cancers14041018	2022	Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.	CREBBP
35240014	10.4143/crt.2022.017	2022	Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.	CREBBP
35255429	10.1016/j.anndiagpath.2021.151886	2022	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.	CREBBP
35317330	10.14740/wjon1436	2022	Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis.	CREBBP
35363872	10.1182/bloodadvances.2021005284	2022	Molecular subclusters of follicular lymphoma: a report from the UK's Haematological Malignancy Research Network.	CREBBP
35401516	10.3389/fimmu.2022.842439	2022	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.	CREBBP
35454811	10.3390/cancers14081904	2022	Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.	CREBBP
35734168	10.3389/fimmu.2022.922471	2022	m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment.	CREBBP
35816682	10.1182/bloodadvances.2022008355	2022	Genomic and microenvironmental landscape of stage I follicular lymphoma, compared to stage III/IV.	CREBBP
35870258	10.1016/j.lungcan.2022.07.011	2022	Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.	CREBBP
35908982	10.1016/j.blre.2022.100992	2022	Follicular lymphoma: The long and winding road leading to your cure?	CREBBP
35964234	10.1093/ajcp/aqac087	2022	Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma.	CREBBP
32855278	10.3324/haematol.2020.254854	2021	Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype.	CREBBP
32929178	10.1038/s41379-020-00673-x	2021	The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy.	CREBBP
32973328	10.1038/s41379-020-00685-7	2021	The clinicopathological and molecular features of sinusoidal large B-cell lymphoma.	CREBBP
33147938	10.3324/haematol.2020.259226	2021	Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations	CREBBP
33311649	10.1038/s41379-020-00720-7	2021	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.	CREBBP
33413063	10.2174/1568009620666210106122750	2021	Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).	CREBBP
33431788	10.1038/s41392-020-00437-8	2021	CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.	CREBBP
33479306	10.1038/s41598-020-80376-0	2021	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.	CREBBP
33560380	10.1182/bloodadvances.2020002469	2021	Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features.	CREBBP
33562694	10.3390/cancers13040641	2021	Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention.	CREBBP
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	CREBBP
33750258	10.1080/0284186X.2021.1900908	2021	Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on <i>BCR-ABL1</i>-like subtype.	CREBBP
33777766	10.3389/fonc.2021.620435	2021	Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma.	CREBBP
33829512	10.1111/his.14378	2021	Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma.	CREBBP
33911074	10.1038/s41419-021-03695-8	2021	Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.	CREBBP
33945543	10.1371/journal.pone.0248886	2021	Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.	CREBBP
33959502	10.3389/fonc.2021.638897	2021	c-Rel Is the Pivotal NF-Œ∫B Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.	CREBBP
34334687	10.1097/PAS.0000000000001726	2021	High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B.	CREBBP
34481935	10.1016/j.canlet.2021.09.002	2021	CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma.	CREBBP
34497221	10.11406/rinketsu.62.1308	2021	[Acute leukemia of infants and neonates].	CREBBP
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	CREBBP
34671837	10.1007/s00292-021-01011-x	2021	[Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].	CREBBP
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	CREBBP
35008340	10.3390/cancers14010176	2021	Recent Advances in the Genetic of MALT Lymphomas.	CREBBP
35071240	10.3389/fcell.2021.805195	2021	Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.	CREBBP
35528192	10.1158/2767-9764.crc-21-0022	2021	The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways.	CREBBP
31423576	10.1111/bjh.16159	2020	M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.	CREBBP
31697823	10.1182/blood.2019002220	2020	Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.	CREBBP
31752573	10.1080/10428194.2019.1691200	2020	New murine models of aggressive lymphoma.	CREBBP
31774495	10.1182/blood.2019001904	2020	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.	CREBBP
31807922	10.1007/s00428-019-02691-w	2020	Subsequent development of histiocytic sarcoma and follicular lymphoma: cytogenetics and next-generation sequencing analyses provide evidence for transdifferentiation of early common lymphoid precursor-a case report and review of literature.	CREBBP
31915197	10.1158/2159-8290.CD-19-0116	2020	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.	CREBBP
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	CREBBP
32251289	10.1038/s41419-020-2380-9	2020	mPGES-1/PGE2 promotes the growth of T-ALL cells in vitro and in vivo by regulating the expression of MTDH via the EP3/cAMP/PKA/CREB pathway.	CREBBP
32316399	10.3390/cancers12040986	2020	Identifying Genetic Lesions in Ocular Adnexal Extranodal Marginal Zone Lymphomas of the MALT Subtype by Whole Genome, Whole Exome and Targeted Sequencing.	CREBBP
32349779	10.1186/s13073-020-00739-0	2020	CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.	CREBBP
32459397	10.1111/jcmm.15425	2020	Establishment and characterization of a novel 'double-hit' follicular lymphoma cell line, FL-SJC.	CREBBP
32546039	10.1080/10428194.2020.1775216	2020	TBLR1 and CREBBP as potential novel prognostic immunohistochemical biomarkers in diffuse large B-cell lymphoma.	CREBBP
32555149	10.1038/s41408-020-0335-0	2020	CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma.	CREBBP
32576962	10.1038/s41375-020-0908-8	2020	CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.	CREBBP
32793890	10.1158/0008-5472.BCD-19-0041	2020	Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia.	CREBBP
32945392	10.3892/mmr.2020.11347	2020	Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells.	CREBBP
33045225	10.1016/j.humpath.2020.09.014	2020	The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.	CREBBP
33097085	10.1186/s13148-020-00948-9	2020	Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.	CREBBP
33160401	10.1186/s13148-020-00962-x	2020	Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.	CREBBP
33188997	10.1016/j.ctarc.2020.100235	2020	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.	CREBBP
33211828	10.1182/bloodadvances.2020002944	2020	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.	CREBBP
33283700	10.19746/j.cnki.issn.1009-2137.2020.06.001	2020	[Gene Mutation in Acute Lymphoblastic Leukemia by DNA Sequencing].	CREBBP
30213827	10.3324/haematol.2018.203224	2019	<i>JUNB</i>, <i>DUSP2</i>, <i>SGK1</i>, <i>SOCS1</i> and <i>CREBBP</i> are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma.	CREBBP
30307363	10.1080/15384047.2018.1523857	2019	Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).	CREBBP
30309852	10.3324/haematol.2018.198572	2019	Targeted next generation sequencing reveals high mutation frequency of <i>CREBBP, BCL2</i> and <i>KMT2D</i> in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements.	CREBBP
30348636	10.1158/1078-0432.CCR-18-1153	2019	Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma.	CREBBP
30446494	10.1182/blood-2018-07-865428	2019	Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.	CREBBP
30488325	10.1007/s00277-018-3565-5	2019	Primary hepatic marginal B cell lymphoma of mucosa-associated lymphoid tissue (MALT) and non-alcoholic steatohepatitis (NASH): more than a coincidence?	CREBBP
30567752	10.1182/blood-2018-07-864025	2019	The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.	CREBBP
30632835	10.1080/10428194.2018.1516878	2019	Descriptive analysis of genetic aberrations and cell of origin in Richter transformation.	CREBBP
30979734	10.1158/1078-0432.CCR-18-3989	2019	Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.	CREBBP
31096545	10.3390/ijms20102394	2019	Identification and Characterization of Novel Fusion Genes with Potential Clinical Applications in Mexican Children with Acute Lymphoblastic Leukemia.	CREBBP
31102422	10.1002/gcc.22765	2019	Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children.	CREBBP
31182547	10.1158/0008-5472.CAN-18-3622	2019	CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms.	CREBBP
31221981	10.1038/s12276-019-0230-6	2019	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.	CREBBP
31366566	10.1042/BSR20191162	2019	Genetic polymorphism and transcriptional regulation of <i>CREBBP</i> gene in patient with diffuse large B-cell lymphoma.	CREBBP
31403034	10.3389/fonc.2019.00683	2019	Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.	CREBBP
31475375	10.1002/hon.2674	2019	m7FLIPI and targeted sequencing in high-risk follicular lymphoma.	CREBBP
31489524	10.1007/s11899-019-00541-9	2019	Chromatin-Remodeled State in Lymphoma.	CREBBP
31519498	10.1016/j.immuni.2019.08.006	2019	Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.	CREBBP
31533053	10.1016/j.immuni.2019.08.018	2019	Scoring a HAT-Trick against Lymphoma.	CREBBP
31669559	10.1016/j.exphem.2019.10.004	2019	Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.	CREBBP
29158360	10.1182/blood-2017-08-737361	2018	Chromatin modifying gene mutations in follicular lymphoma.	CREBBP
29193015	10.1111/bjh.15041	2018	The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion.	CREBBP
29305415	10.3324/haematol.2017.182444	2018	Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.	CREBBP
29359884	10.1002/ajmg.a.38603	2018	Benign and malignant tumors in Rubinstein-Taybi syndrome.	CREBBP
29452662	10.1016/j.beha.2017.10.006	2018	Pathogenesis of follicular lymphoma.	CREBBP
29884215	10.1186/s13072-018-0197-x	2018	CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.	CREBBP
29895903	10.1038/s41408-018-0089-0	2018	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.	CREBBP
29989027	10.18632/oncotarget.25601	2018	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	CREBBP
30126979	10.1182/blood-2018-03-837252	2018	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.	CREBBP
30214692	10.18632/oncotarget.26080	2018	Correction: The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in <i>TNFAIP3</i> followed by mutations in <i>TBL1XR1</i> and <i>CREBBP</i>.	CREBBP
30227405	10.1159/000491013	2018	Microarray-Based Gene Expression Analysis Identifies Potential Diagnostic and Prognostic Biomarkers for Waldenstr√∂m Macroglobulinemia.	CREBBP
30262461	10.1158/0008-5472.CAN-18-1703	2018	CBP Modulates Sensitivity to Dasatinib in Pre-BCR<sup>+</sup> Acute Lymphoblastic Leukemia.	CREBBP
30274972	10.1158/2159-8290.CD-18-0657	2018	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.	CREBBP
30360879	10.1053/j.seminoncol.2018.07.005	2018	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	CREBBP
30401710	10.1182/blood-2018-03-837039	2018	<i>CREBBP</i> gene mutations are frequently detected in in situ follicular neoplasia.	CREBBP
27389057	10.1038/leu.2016.175	2017	Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.	CREBBP
27733359	10.1158/2159-8290.CD-16-0975	2017	CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.	CREBBP
27742770	10.3324/haematol.2016.144964	2017	Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.	CREBBP
27872090	10.1158/0008-5472.CAN-16-1303	2017	Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia.	CREBBP
27903646	10.1101/gr.209163.116	2017	Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.	CREBBP
27979926	10.3324/haematol.2016.145177	2017	CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.	CREBBP
28062671	10.1158/2159-8290.CD-16-1285	2017	Targeting HDAC3 in CREBBP-Mutant Lymphomas Counterstrikes Unopposed Enhancer Deacetylation of B-cell Signaling and Immune Response Genes.	CREBBP
28064239	10.1182/blood-2016-07-729954	2017	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.	CREBBP
28069569	10.1158/2159-8290.CD-16-1417	2017	The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.	CREBBP
28106467	10.1080/15592294.2017.1282587	2017	Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.	CREBBP
28116089	10.1186/s40425-016-0207-0	2017	It's a long way to the top (if you want to personalize immunotherapy).	CREBBP
28152507	10.18632/oncotarget.14928	2017	The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.	CREBBP
28253933	10.1186/s13045-017-0434-y	2017	Mutational profiling of acute lymphoblastic leukemia with testicular relapse.	CREBBP
28288979	10.1182/blood-2016-08-733469	2017	<i>Crebbp</i> loss cooperates with <i>Bcl2</i> overexpression to promote lymphoma in mice.	CREBBP
28302137	10.1186/s13045-017-0438-7	2017	Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.	CREBBP
28452416	10.1111/ejh.12897	2017	Low CREBBP expression is associated with adverse long-term outcomes in paediatric acute lymphoblastic leukaemia.	CREBBP
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	CREBBP
28825697	10.1038/ncb3597	2017	Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors.	CREBBP
28831000	10.1073/pnas.1619555114	2017	Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.	CREBBP
28856790	10.1111/ped.13365	2017	MSH2 deletion with CREBBP and KRAS mutations in pediatric high-hyperdiploid acute lymphoblastic leukemia.	CREBBP
29029550	10.18632/oncotarget.19271	2017	B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy.	CREBBP
29222279	10.1182/asheducation-2017.1.358	2017	Follicular lymphoma: are we ready for a risk-adapted approach?	CREBBP
29245897	10.18632/oncotarget.18502	2017	Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum.	CREBBP
29262531	10.18632/oncotarget.21986	2017	Mutational profile of primary breast diffuse large B-cell lymphoma.	CREBBP
26358273	10.1007/s00417-015-3158-0	2016	S100A4 gene silencing in oxygen-induced ischemic retinopathy inhibits retinal neovascularization via down-regulation of CREB expression.	CREBBP
26527318	10.18632/oncotarget.6259	2016	Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.	CREBBP
26631611	10.1158/1078-0432.CCR-15-2023	2016	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells.	CREBBP
26698557	10.2217/epi.15.96	2016	Epigenetic dysregulation in follicular lymphoma.	CREBBP
26773040	10.1182/blood-2015-09-672352	2016	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.	CREBBP
27086936	10.3109/10428194.2016.1165816	2016	Rubinstein-Taybi syndrome - a window into follicular lymphoma biology.	CREBBP
27163296	10.1002/gcc.22374	2016	Slower early response to treatment and distinct expression profile of childhood high hyperdiploid acute lymphoblastic leukaemia with DNA index &lt;‚Äâ1.16.	CREBBP
27325104	10.1182/blood-2015-12-682591	2016	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations.	CREBBP
27407063	10.1002/ijc.30263	2016	Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.	CREBBP
27663730	10.1073/pnas.1613836113	2016	Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.	CREBBP
25027518	10.1038/leu.2014.209	2015	Genomic and epigenomic co-evolution in follicular lymphomas.	CREBBP
25500291	10.1016/j.jtcvs.2014.11.011	2015	Erythropoietin activates the phosporylated cAMP [adenosine 3'5' cyclic monophosphate] response element-binding protein pathway and attenuates delayed paraplegia after ischemia-reperfusion injury.	CREBBP
25713363	10.1073/pnas.1501199112	2015	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.	CREBBP
25740345	10.1002/ardp.201400449	2015	MLL leukemia and future treatment strategies.	CREBBP
25790293	10.1038/ncomms7604	2015	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.	CREBBP
25917266	10.1038/leu.2015.107	2015	KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia.	CREBBP
26189108	10.1016/j.leukres.2015.06.005	2015	Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.	CREBBP
26206799	10.3324/haematol.2015.130179	2015	Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.	CREBBP
26256760	10.1016/S1470-2045(15)00169-2	2015	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	CREBBP
26473533	10.1038/bcj.2015.89	2015	Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.	CREBBP
26551667	10.1038/ng.3442	2015	The mutational landscape of cutaneous T cell lymphoma and S√©zary syndrome.	CREBBP
23728349	10.1038/onc.2013.169	2014	Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.	CREBBP
24035379	10.1016/j.jtcvs.2013.07.043	2014	Dexmedetomidine, an Œ±-2a adrenergic agonist, promotes ischemic tolerance in a murine model of spinal cord ischemia-reperfusion.	CREBBP
24362818	10.1038/ng.2856	2014	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.	CREBBP
24435047	10.1182/blood-2013-05-500264	2014	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	CREBBP
24662245	10.1038/ncomms4469	2014	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.	CREBBP
24710217	10.1038/ncomms4630	2014	The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes.	CREBBP
24870942	10.1007/s00277-014-2116-y	2014	Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.	CREBBP
24942941	10.3960/jslrt.54.3	2014	Pathology of follicular lymphoma.	CREBBP
24942943	10.3960/jslrt.54.23	2014	Molecular pathogenesis of follicular lymphoma.	CREBBP
25696852	10.1182/asheducation-2014.1.174	2014	The genomic landscape of acute lymphoblastic leukemia in children and young adults.	CREBBP
23297126	10.1182/blood-2012-09-457283	2013	Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.	CREBBP
23484726	10.7534/j.issn.1009-2137.2013.01.047	2013	[Research progress on mechanism of bone marrow relapse in pediatric acute lymphoblastic leukemia].	CREBBP
24052547	10.1182/blood-2013-04-496893	2013	EZH2 mutations are frequent and represent an early event in follicular lymphoma.	CREBBP
24349473	10.1371/journal.pone.0083244	2013	Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.	CREBBP
24377530	10.7314/apjcp.2013.14.11.6347	2013	Partial Least Squares Based Gene Expression Analysis in EBV- Positive and EBV-Negative Posttransplant Lymphoproliferative Disorders.	CREBBP
22287508	10.18632/oncotarget.436	2012	Histone modification defects in developmental disorders and cancer.	CREBBP
22343534	10.1073/pnas.1121343109	2012	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	CREBBP
22388726	10.1038/leu.2012.60	2012	CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia.	CREBBP
24371765	10.1016/j.lrr.2012.10.002	2012	Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones.	CREBBP
21244576	10.1111/j.1349-7006.2011.01873.x	2011	c-Maf suppresses human T-cell leukemia virus type 1 Tax by competing for CREB-binding protein.	CREBBP
21390126	10.1038/nature09730	2011	Inactivating mutations of acetyltransferase genes in B-cell lymphoma.	CREBBP
21390130	10.1038/nature09727	2011	CREBBP mutations in relapsed acute lymphoblastic leukaemia.	CREBBP
21493871	10.1158/1055-9965.EPI-11-0059	2011	Multilocus association of genetic variants in MLL, CREBBP, EP300, and TOP2A with childhood acute lymphoblastic leukemia in Hispanics from Texas.	CREBBP
21575156	10.1186/1756-8722-4-23	2011	Gene expression profiles in BCL11B-siRNA treated malignant T cells.	CREBBP
21680795	10.1182/blood-2011-03-341412	2011	Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.	CREBBP
21796119	10.1038/nature10351	2011	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.	CREBBP
22127311	10.1016/j.beha.2011.09.004	2011	Genomic profiling of B-progenitor acute lymphoblastic leukemia.	CREBBP
19948376	10.1016/j.canlet.2009.10.018	2010	Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8.	CREBBP
20048166	10.1074/jbc.M109.018838	2010	Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) beta expression by competing with IFN regulatory factor-3 for binding to IFNB promoter.	CREBBP
20072153	10.1038/leu.2009.282	2010	Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.	CREBBP
20413592	10.1074/jbc.M110.107607	2010	DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: potential involvement of direct inhibition of cAMP-responsive element (CRE)-binding protein/CRE modulator/activation transcription factor binding.	CREBBP
21080944	10.1186/1756-8722-3-44	2010	Analysis of the expression pattern of the BCL11B gene and its relatives in patients with T-cell acute lymphoblastic leukemia.	CREBBP
16843104	10.1016/j.cancergencyto.2006.02.013	2006	Infant acute lymphoblastic leukemia with t(11;16)(q23;p13.3) and lineage switch into acute monoblastic leukemia.	CREBBP
15722318	10.1136/bjo.2004.047092	2005	Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases.	CREBBP
15919945	10.1128/JVI.79.12.7899-7904.2005	2005	Epstein-Barr virus BZLF1 protein binds to mitotic chromosomes.	CREBBP
15994782	10.1128/JVI.79.14.8886-8893.2005	2005	Parvovirus nonstructural proteins induce an epigenetic modification through histone acetylation in host genes and revert tumor malignancy to benignancy.	CREBBP
14668346	10.1074/jbc.M309485200	2004	Kaposi's sarcoma-associated herpesvirus-encoded vIRF-3 stimulates the transcriptional activity of cellular IRF-3 and IRF-7.	CREBBP
14998493	10.1016/s1535-6108(04)00022-4	2004	Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency.	CREBBP
15467747	10.1038/sj.onc.1208059	2004	The Kaposi's sarcoma-associated herpesvirus K-bZIP protein represses transforming growth factor beta signaling through interaction with CREB-binding protein.	CREBBP
12730195	10.1074/jbc.M303518200	2003	Identification and characterization of BCL-3-binding protein: implications for transcription and DNA repair or recombination.	CREBBP
11313967	10.1038/sj.onc.1204081	2001	Downregulation of MLL-CBP fusion gene expression is associated with differentiation of SN-1 cells with t(11;16)(q23;p13).	CREBBP
10618435	10.1073/pnas.97.1.430	2000	Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter.	CREBBP
10679915	NA	2000	MLL-CBP fusion transcript in a therapy-related acute myeloid leukemia with the t(11;16)(q23;p13) which developed in an acute lymphoblastic leukemia patient with Fanconi anemia.	CREBBP
10815807	10.1038/sj.onc.1203536	2000	HTLV-I Tax transrepresses the human c-Myb promoter independently of its interaction with CBP or p300.	CREBBP
11091852	10.1136/mp.53.5.280	2000	Analysis of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) gene and promoter in Hodgkin's disease isolates: selection against EBV variants with mutations in the LMP-1 promoter ATF-1/CREB-1 binding site.	CREBBP
10497212	10.1074/jbc.274.40.28491	1999	Bcl3, an IkappaB protein, stimulates activating protein-1 transactivation and cellular proliferation.	CREBBP
9210395	10.1042/bj3240729	1997	Regulatory domains of the A-Myb transcription factor and its interaction with the CBP/p300 adaptor molecules.	CREBBP
9290955	NA	1997	Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation.	CREBBP
9376594	NA	1997	Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement.	CREBBP
9389684	NA	1997	Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13).	CREBBP
34272611	10.1007/s00467-021-05202-9	2022	Novel urine biomarkers to distinguish UTI from culture-negative pyuria.	CTSS
32330423	10.1016/j.celrep.2020.107522	2020	Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma.	CTSS
32330455	10.1016/j.ccell.2020.03.016	2020	Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma.	CTSS
32396854	10.1016/j.ccell.2020.04.008	2020	Genetic Alterations Impact Immune Microenvironment Interactions in Follicular Lymphoma.	CTSS
25907256	10.1007/s12253-015-9926-7	2015	Exploring the Molecular Mechanism and Biomakers of Liver Cancer Based on Gene Expression Microarray.	CTSS
33634586	10.1002/cyto.b.21995	2022	Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenstr√∂m macroglobulinemia.	CXCR4
34115701	10.1097/RLU.0000000000003750	2022	Burkitt Lymphoma/Leukemia Presented on 68Ga-Pentixafor and 18F-FDG PET/CT.	CXCR4
34525196	10.1182/blood.2021013239	2022	CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter¬†pylori eradication.	CXCR4
34651291	10.1007/s11307-021-01664-3	2022	CXCR4-Directed PET/CT with [<sup>68</sup>Ga]Pentixafor in Central Nervous System Lymphoma: A Comparison with [<sup>18</sup>F]FDG PET/CT.	CXCR4
34781809	10.1080/10428194.2021.2005045	2022	Plamotamab (XmAb<sup>¬Æ</sup>13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr√∂m macroglobulinemia.	CXCR4
34793256	10.1200/JCO.21.01194	2022	Venetoclax in Previously Treated Waldenstr√∂m Macroglobulinemia.	CXCR4
34980578	10.1016/j.clml.2021.11.014	2022	SOHO State of the Art Updates and Next Questions: Waldenstr√∂m Macroglobulinemia - 2021 Update on Management and Future Directions.	CXCR4
34990302	10.1080/21655979.2021.2017590	2022	Propofol induces the apoptosis of neural stem cells via microRNA-9-5p / chemokine CXC receptor 4 signaling pathway.	CXCR4
35020191	10.1111/bjh.18036	2022	Diagnosis and management of Waldenstr√∂m macroglobulinaemia-A British Society for Haematology guideline.	CXCR4
35037561	10.1080/10428194.2021.2020776	2022	Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.	CXCR4
35057088	10.3390/pharmaceutics14010192	2022	Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials.	CXCR4
35078860	10.1158/1078-0432.CCR-21-3284	2022	Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands.	CXCR4
35149375	10.1016/j.ctarc.2022.100527	2022	Current approach to Waldenstr√∂m Macroglobulinemia.	CXCR4
35149705	10.1038/s41598-022-05857-w	2022	Cell surface expression of GRP78 and CXCR4 is associated with childhood high-risk acute lymphoblastic leukemia at diagnostics.	CXCR4
35181615	NA	2022	Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications.	CXCR4
35241482	10.2967/jnumed.121.263693	2022	Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using <sup>68</sup>Ga-PentixaFor PET.	CXCR4
35255429	10.1016/j.anndiagpath.2021.151886	2022	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.	CXCR4
35316324	10.1182/blood.2021014723	2022	Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL.	CXCR4
35339405	10.1016/j.clml.2022.02.005	2022	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenstr√∂m Macroglobulinemia.	CXCR4
35358350	10.1002/ajh.26552	2022	First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenstr√∂m's Macroglobulinemia: A systematic review and meta-analysis.	CXCR4
35385630	NA	2022	Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?	CXCR4
35421785	10.1016/j.biopha.2022.112940	2022	A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4<sup>+</sup> lymphoma cells without toxicity in immunocompromised and immunocompetent mice.	CXCR4
35450208	10.1177/20406207221090886	2022	Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.	CXCR4
35454017	10.3390/diagnostics12040969	2022	Nucleic Acid Biomarkers in Waldenstr√∂m Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.	CXCR4
35510210	10.1177/20406207221093962	2022	Treatment paradigm in Waldenstr√∂m macroglobulinemia: frontline therapy and beyond.	CXCR4
35522562	10.1002/path.5924	2022	CXCR4 mediates leukemic cell migration and survival in the testicular microenvironment.	CXCR4
35608747	10.1007/s11033-022-07163-0	2022	Molecular effects of genistein, as a potential anticancer agent, on CXCR-4 and VEGF pathway in acute lymphoblastic leukemia.	CXCR4
35674738	10.1007/s00259-022-05849-y	2022	CXCR4-targeted theranostics in oncology.	CXCR4
35695746	10.1080/17474086.2022.2089110	2022	Positron emission tomography/magnetic resonance imaging (PET/MRI) vs. gastroscopy: Can it improve detection of extranodal marginal zone lymphomas of the stomach following <i>H. pylori</i> treatment?	CXCR4
35738903	10.2967/jnumed.122.264207	2022	C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Patients with Advanced T-Cell Lymphoma.	CXCR4
35770040	10.2147/TCRM.S338655	2022	Zanubrutinib in Treating Waldenstr√∂m Macroglobulinemia, the Last Shall Be the First.	CXCR4
35774848	10.1155/2022/3276925	2022	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.	CXCR4
35794478	10.1038/s41586-022-04906-8	2022	Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.	CXCR4
35802888	10.1080/10428194.2022.2074986	2022	CXCR4 expression of multiple myeloma as a dynamic process: influence of therapeutic agents.	CXCR4
35842683	10.1186/s13287-022-03011-x	2022	Prostaglandin E1 reduces apoptosis and improves the homing of mesenchymal stem cells in pulmonary arterial hypertension by regulating hypoxia-inducible factor 1 alpha.	CXCR4
35877223	10.3390/curroncol29070363	2022	Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation.	CXCR4
35884548	10.3390/cancers14143488	2022	Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review.	CXCR4
35954476	10.3390/cancers14153814	2022	The Role of [<sup>68</sup>Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review.	CXCR4
36030395	10.1111/ejh.13856	2022	A comparison of four leukapheresis methods to harvest an optimal dose of CD34+ cells: A single center experience.	CXCR4
36048893	10.1093/ajcp/aqac104	2022	Systemic Presentation of Somatic TET2 Mutated B-Cell Lymphoma in a Child With Kabuki Syndrome and a Germline KMT2D Variant.	CXCR4
32733009	10.1038/s41375-020-0999-2	2021	Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination.	CXCR4
32795528	10.1016/j.jid.2020.06.034	2021	Cancer-Associated Fibroblasts in Mycosis Fungoides Promote Tumor Cell Migration and Drug Resistance through CXCL12/CXCR4.	CXCR4
32810857	10.1159/000509286	2021	Current and Emerging Treatments for Waldenstr√∂m Macroglobulinemia.	CXCR4
33131073	10.1111/exd.14228	2021	The role of Dipeptidyl Peptidase-4 in cutaneous disease.	CXCR4
33206936	10.1182/blood.2020005650	2021	Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.	CXCR4
33208624	10.1097/RLU.0000000000003404	2021	Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI.	CXCR4
33253591	10.1021/acs.molpharmaceut.0c00785	2021	High-Contrast CXCR4-Targeted <sup>18</sup>F-PET Imaging Using a Potent and Selective Antagonist.	CXCR4
33391493	10.7150/thno.48620	2021	CXCR4 PET imaging of mantle cell lymphoma using [<sup>68</sup>Ga]Pentixafor: comparison with [<sup>18</sup>F]FDG-PET.	CXCR4
33555272	10.1172/JCI141566	2021	RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.	CXCR4
33569985	10.1080/10428194.2021.1881514	2021	Clinical application of genomics in Waldenstr√∂m macroglobulinemia.	CXCR4
33579803	10.2967/jnumed.120.257279	2021	Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT.	CXCR4
33604348	10.3389/fmed.2021.609116	2021	YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial.	CXCR4
33612450	10.1016/j.transci.2021.103070	2021	First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients.	CXCR4
33660512	10.1021/acs.jmedchem.1c00066	2021	Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors.	CXCR4
33716502	10.2147/IJN.S289733	2021	Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4<sup>+</sup> Diffuse Large B-Cell Lymphoma Cells.	CXCR4
33735664	10.1016/j.neo.2021.02.002	2021	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr√∂m macroglobulinemia.	CXCR4
33743810	10.1186/s13045-021-01060-y	2021	Targeting chemokines for acute lymphoblastic leukemia therapy.	CXCR4
33843403	10.1080/10428194.2021.1910684	2021	CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.	CXCR4
33856274	10.1080/10428194.2021.1913150	2021	Different chemokine profile between systemic and testicular diffuse large B-cell lymphoma.	CXCR4
33934404	10.1002/jcla.23784	2021	PCR array analysis identified hyperproliferation but not autophagy or apoptosis in fibrous epulis.	CXCR4
34050566	10.1111/cpr.13076	2021	Role of CXCR4 in the progression and therapy of acute leukaemia.	CXCR4
34083646	10.1038/s41598-021-91112-7	2021	DC-SIGN binding to mannosylated B-cell receptors in follicular lymphoma down-modulates receptor signaling capacity.	CXCR4
34093792	10.7150/jca.54952	2021	Aggregative Perivascular Tumor Cell Growth Pattern of Primary Central Nervous System Lymphomas Is Associated with Hypoxia-Related Endoplasmic Reticulum Stress.	CXCR4
34106998	10.1371/journal.ppat.1009618	2021	Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes.	CXCR4
34122453	10.3389/fimmu.2021.688747	2021	Knowledge From London and Berlin: Finding Threads to a Functional HIV Cure.	CXCR4
34172595	10.1097/RLU.0000000000003760	2021	Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenstr√∂m Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT.	CXCR4
34187383	10.1186/s12876-021-01844-z	2021	Tumor-to-tumor metastasis of diffuse large B cell lymphoma to gastric adenocarcinoma via CXCL12 (SDF-1)/CXCR4 axis: a case report.	CXCR4
34255748	10.1172/JCI143119	2021	Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia.	CXCR4
34269725	10.1097/RLU.0000000000003817	2021	CXCR4 Expression Demonstrated by 68Ga-Pentixafor PET/CT Imaging in a Case of Systemic Mastocytosis Mimicking Lymphoma.	CXCR4
34307181	10.3389/fonc.2021.710900	2021	Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes.	CXCR4
34340248	10.1111/bjh.17691	2021	Disease outcomes and biomarkers of progression in smouldering Waldenstr√∂m macroglobulinaemia.	CXCR4
34363012	10.1038/s41375-021-01376-1	2021	CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.	CXCR4
34396983	10.1172/JCI151295	2021	All in for nuclear PFKP-induced CXCR4 metastasis: a T cell acute lymphoblastic leukemia prognostic marker.	CXCR4
34404617	10.1016/j.transci.2021.103240	2021	An innovation in stem cell harvesting: Heparin use.	CXCR4
34490994	10.1002/pbc.29319	2021	Single-center results reporting improved hematopoietic stem cell mobilization success in pediatric and young adult patients with solid tumors and lymphoma.	CXCR4
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	CXCR4
34583709	10.1186/s12943-021-01419-2	2021	Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma.	CXCR4
34635806	10.1038/s41423-021-00775-9	2021	Posttransplant blockade of CXCR4 improves leukemia complete remission rates and donor stem cell engraftment without aggravating GVHD.	CXCR4
34714390	10.1186/s13550-021-00852-0	2021	Semi-quantitative measurements of chemokine receptor 4-targeted <sup>68</sup>Ga-pentixafor PET/CT in response assessment of Waldenstr√∂m macroglobulinemia/lymphoplasmacytic lymphoma.	CXCR4
34722241	10.3389/fonc.2021.692788	2021	Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.	CXCR4
34793563	10.1371/journal.pone.0260186	2021	Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach.	CXCR4
34990523	10.4143/crt.2021.944	2021	Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia During R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma.	CXCR4
35028611	10.1016/j.xcrm.2021.100470	2021	Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system.	CXCR4
35087759	10.3389/fonc.2021.801124	2021	Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenstr√∂m Macroglobulinemia.	CXCR4
31248974	10.3324/haematol.2018.211490	2020	A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.	CXCR4
31260155	10.1002/jmri.26848	2020	MRI and PET/MRI in hematologic malignancies.	CXCR4
31471373	10.3324/haematol.2019.216218	2020	CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.	CXCR4
31476465	10.1016/j.wneu.2019.08.140	2020	T140 Inhibits Apoptosis and Promotes Proliferation and Matrix Formation Through the SDF-1/CXC Receptor-4 Signaling Pathway in Endplate Chondrocytes of the Rat Intervertebral Discs.	CXCR4
31561267	10.1002/1873-3468.13623	2020	Single-cell RNA sequencing reveals chemokine self-feeding of myeloma cells promotes extramedullary metastasis.	CXCR4
31571524	10.1080/15384047.2019.1665405	2020	CXCR4-targeted PET imaging using <sup>64</sup>Cu-AMD3100 for detection of Waldenstr√∂m Macroglobulinemia.	CXCR4
31605845	10.1016/j.wneu.2019.09.158	2020	Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation.	CXCR4
31719683	10.1038/s41375-019-0628-0	2020	Physiological levels of the PTEN-PI3K-AKT axis activity are required for maintenance of Burkitt lymphoma.	CXCR4
31726164	10.1016/j.ijbiomac.2019.09.157	2020	Degraded fucoidan fractions and Œ≤-1,3-glucan sulfates inhibit CXCL12-induced Erk1/2 activation and chemotaxis in Burkitt lymphoma cells.	CXCR4
31768009	10.1038/s41409-019-0756-1	2020	The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.	CXCR4
31809874	10.1016/j.cellsig.2019.109492	2020	Ghrelin induces autophagy and CXCR4 expression via the SIRT1/AMPK axis in lymphoblastic leukemia cell lines.	CXCR4
31902622	10.1016/j.pathol.2019.11.002	2020	A practical guide to laboratory investigations at diagnosis and follow up in Waldenstr√∂m macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.	CXCR4
31960730	10.1080/10428194.2020.1711901	2020	Waldenstrom's macroglobulinemia in the era of immunotherapy.	CXCR4
31980558	10.1136/jclinpath-2019-206282	2020	Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenstr√∂m macroglobulinaemia and description of its mutational profiles by targeted NGS.	CXCR4
32006301	10.1007/s11899-020-00559-4	2020	Novel Treatment Strategies in the Management of Waldenstr√∂m Macroglobulinemia.	CXCR4
32083995	10.1200/JCO.19.02314	2020	Genomic Landscape of Waldenstr√∂m Macroglobulinemia and Its Impact on Treatment Strategies.	CXCR4
32265150	10.1016/j.clml.2020.02.016	2020	Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma.	CXCR4
32296856	10.1007/s00117-020-00676-4	2020	[Hybrid imaging in lymphoma].	CXCR4
32332145	10.2967/jnumed.120.241703	2020	CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma.	CXCR4
32370190	10.3390/cancers12051143	2020	Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells.	CXCR4
32373205	10.7150/thno.43231	2020	Selective delivery of T22-PE24-H6 to CXCR4<sup>+</sup> diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model.	CXCR4
32544428	10.1016/j.phrs.2020.105010	2020	CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent.	CXCR4
32581241	10.1038/s41467-020-16927-w	2020	Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.	CXCR4
32694049	10.1016/j.clml.2020.05.003	2020	De Novo CD5<sup>+</sup> Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances.	CXCR4
32723621	10.1016/j.clml.2020.06.025	2020	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis.	CXCR4
32724470	10.7150/thno.45537	2020	A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.	CXCR4
32757068	10.1186/s13550-020-00681-7	2020	Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [<sup>68</sup>Ga]pentixafor in non-Hodgkin lymphoma: comparison to [<sup>18</sup>F]FDG.	CXCR4
32766282	10.3389/fmolb.2020.00164	2020	High-Throughput Screening of a Functional Human CXCL12-CXCR4 Signaling Axis in a Genetically Modified <i>S. cerevisiae</i>: Discovery of a Novel Up-Regulator of CXCR4 Activity.	CXCR4
32913458	10.7150/jca.48748	2020	Safety, Efficacy, Pharmacokinetic and Pharmacodynamic evaluation of YF-H-2015005 for mobilizing Hematopoietic stem cells in Non-Hodgkin's Lymphoma Patients.	CXCR4
32955949	10.1080/14728214.2020.1822816	2020	Emerging drugs for the treatment of Waldenstr√∂m macroglobulinemia.	CXCR4
33085756	10.1182/bloodadvances.2020003087	2020	Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenstr√∂m macroglobulinemia.	CXCR4
33154951	10.3389/fonc.2020.591577	2020	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	CXCR4
33170753	10.1080/17474086.2020.1839885	2020	Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies.	CXCR4
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	CXCR4
33275726	10.1182/hematology.2020000121	2020	Management of Waldenstr√∂m macroglobulinemia in 2020.	CXCR4
33297772	10.1080/17474086.2020.1851184	2020	Zanubrutinib for the treatment of Waldenstr√∂m Macroglobulinemia.	CXCR4
34321159	10.1016/j.biopha.2020.110610	2020	Bone marrow mesenchymal stem cells in microenvironment transform into cancer-associated fibroblasts to promote the progression of B-cell acute lymphoblastic leukemia.	CXCR4
29363736	10.1111/bjh.15096	2019	Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy.	CXCR4
29777009	10.2967/jnumed.118.210997	2019	Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma.	CXCR4
29954928	10.3324/haematol.2017.180505	2019	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.	CXCR4
30227761	10.1080/10428194.2018.1508668	2019	Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenstr√∂m's macroglobulinemia.	CXCR4
30290030	10.1002/stem.2912	2019	Microvesicles Secreted by Nitric Oxide-Primed Mesenchymal Stromal Cells Boost the Engraftment Potential of Hematopoietic Stem Cells.	CXCR4
30333224	10.1158/1078-0432.CCR-18-1047	2019	Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.	CXCR4
30408147	10.1111/bjh.15670	2019	CXCR4 mutations in lymphoplasmacytic lymphoma lead to altered CXCR4 expression.	CXCR4
30623224	10.1007/s00347-018-0840-8	2019	[New molecular pathological strategies for malignant iris tumors].	CXCR4
30774774	10.18632/oncotarget.26588	2019	High CXCR4 expression impairs rituximab response and the prognosis of R-CHOP-treated diffuse large B-cell lymphoma patients.	CXCR4
30776910	10.1177/2040206619829382	2019	Mozobil¬Æ (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.	CXCR4
30828149	10.1007/s12288-018-0978-1	2019	MYD88 and CXCR4 Mutation Profiling in Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinaemia.	CXCR4
30829648	10.1172/JCI120654	2019	BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment.	CXCR4
30836379	10.1038/s41586-019-1027-4	2019	HIV-1 remission following CCR5Œî32/Œî32 haematopoietic stem-cell transplantation.	CXCR4
30850502	10.2967/jnumed.118.223420	2019	Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation.	CXCR4
30883140	10.1021/acs.molpharmaceut.9b00069	2019	Development and Evaluation of an <sup>18</sup>F-Radiolabeled Monocyclam Derivative for Imaging CXCR4 Expression.	CXCR4
30904045	10.1016/j.amjms.2019.01.008	2019	CXCR4 and CCR7 Expression in Primary Nodal Diffuse Large B-Cell Lymphoma-A Clinical and Immunohistochemical Study.	CXCR4
30966844	10.1080/21505594.2019.1605803	2019	The roles of apoptosis, autophagy and unfolded protein response in arbovirus, influenza virus, and HIV infections.	CXCR4
30985424	10.1097/RLU.0000000000002574	2019	68Ga CXCR-4 PET/CT Imaging in an Atypical Case of Extramedullary Plasmacytoma Mimicking as Renal Cell Carcinoma.	CXCR4
31004184	10.1007/s00259-019-04322-7	2019	[<sup>68</sup>Ga]Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery.	CXCR4
31096215	10.1159/000497430	2019	C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges.	CXCR4
31101745	10.2967/jnumed.119.226134	2019	<sup>68</sup>Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenstr√∂m Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to <sup>18</sup>F-FDG PET/CT.	CXCR4
31105032	10.1016/j.ebiom.2019.05.025	2019	LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML.	CXCR4
31106661	10.1080/15384101.2019.1617007	2019	Loss of Œ≤-arrestin-2 gene and possible functional consequences on Sezary Syndrome.	CXCR4
31202483	10.1016/j.pathol.2019.03.005	2019	MALT lymphoma with IgM paraprotein and bone marrow involvement mimicking Waldenstr√∂m macroglobulinaemia.	CXCR4
31221512	10.1016/j.clml.2019.03.009	2019	Characteristics of Waldenstr√∂m Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.	CXCR4
31229160	10.1016/j.hoc.2019.03.004	2019	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.	CXCR4
31281504	10.7150/thno.31032	2019	Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [<sup>68</sup>Ga]Ga-Pentixafor-PET/MRI.	CXCR4
31313940	10.1080/08880018.2019.1623354	2019	Bone marrow recovery of hematopoietic stem cells and microenvironment after chemotherapy in childhood acute lymphoblastic leukemia: consecutive observations according to chemotherapy schedule.	CXCR4
31346528	10.1155/2019/5601396	2019	Notch/CXCR4 Partnership in Acute Lymphoblastic Leukemia Progression.	CXCR4
31352850	10.1080/10428194.2019.1643463	2019	A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.	CXCR4
31358475	10.1016/j.ebiom.2019.07.053	2019	Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.	CXCR4
31368255	10.1002/pbc.27951	2019	Acute myeloid leukemia arising after Hodgkin lymphoma in a patient with WHIM syndrome.	CXCR4
31372333	10.1016/j.jbo.2019.100253	2019	The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond.	CXCR4
31378966	10.1002/ajh.25600	2019	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.	CXCR4
31545614	10.1021/acs.molpharmaceut.9b00808	2019	[<sup>68</sup>Ga]Ga/[<sup>177</sup>Lu]Lu-BL01, a Novel Theranostic Pair for Targeting C-X-C Chemokine Receptor 4.	CXCR4
31554271	10.3390/ijms20194740	2019	The <i>CXCR4-CXCL12</i>-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro.	CXCR4
31557894	10.3390/cancers11101427	2019	FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma.	CXCR4
31591468	10.1038/s41375-019-0592-8	2019	What is new in the treatment of Waldenstrom macroglobulinemia?	CXCR4
31695539	10.2147/JBM.S183997	2019	Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.	CXCR4
28631842	10.1002/jca.21563	2018	UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.	CXCR4
28830639	10.1016/j.blre.2017.08.006	2018	T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies.	CXCR4
28952842	10.1080/10428194.2017.1379077	2018	Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.	CXCR4
29272530	10.1093/molehr/gax067	2018	Formyl peptide receptor-2 is decreased in foetal growth restriction and contributes to placental dysfunction.	CXCR4
29435003	10.3892/ol.2017.7636	2018	Opposite response to hypoxia by breast cancer cells between cell proliferation and cell migration: A clue from microRNA expression profile.	CXCR4
29472546	10.1038/s41408-018-0056-9	2018	CXCR4 can induce PI3KŒ¥ inhibitor resistance in ABC DLBCL.	CXCR4
29485974	10.1172/JCI97454	2018	Redirection to the bone marrow improves T cell persistence and antitumor functions.	CXCR4
29603337	10.1002/ajh.25099	2018	CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion.	CXCR4
29642081	10.1097/RLI.0000000000000469	2018	[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results.	CXCR4
29662864	10.5045/br.2018.53.1.61	2018	Expression of adhesion molecules on CD34+ cells from steady-state bone marrow before and after mobilization and their association with the yield of CD34+ cells.	CXCR4
29693748	10.1002/jcb.26799	2018	MicroRNA-9 suppresses cancer proliferation and cell cycle progression in acute lymphoblastic leukemia with inverse association of neuropilin-1.	CXCR4
29856685	10.1056/NEJMoa1802917	2018	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstr√∂m's Macroglobulinemia.	CXCR4
29903571	10.1016/j.cyto.2018.02.020	2018	Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.	CXCR4
29911936	10.1080/10428194.2018.1455974	2018	Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells.	CXCR4
29916918	10.1097/RLU.0000000000002166	2018	Imaging of Chemokine Receptor CXCR4 in Mycosis Fungoides Using 68Ga-Pentixafor PET/CT.	CXCR4
29920526	10.1371/journal.pone.0198789	2018	CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis.	CXCR4
29982402	10.1093/annonc/mdy146	2018	Waldenstr√∂m's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.	CXCR4
29989027	10.18632/oncotarget.25601	2018	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	CXCR4
30005184	10.1016/j.leukres.2018.07.001	2018	Pediatric acute lymphoblastic leukemia-Conquering the CNS across the choroid plexus.	CXCR4
30038265	10.1038/s41388-018-0401-2	2018	Intrathymic Notch3 and CXCR4 combinatorial interplay facilitates T-cell leukemia propagation.	CXCR4
30190015	10.1016/j.hoc.2018.05.007	2018	Working Toward a Genomic Prognostic Classification of Waldenstr√∂m Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.	CXCR4
30194255	10.1182/blood-2018-04-845834	2018	Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.	CXCR4
30242208	10.1038/s41598-018-32634-5	2018	Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma.	CXCR4
30373149	10.3390/cancers10110402	2018	Calcium Independent Effect of Orai1 and STIM1 in Non-Hodgkin B Cell Lymphoma Dissemination.	CXCR4
30453100	10.1016/j.leukres.2018.11.001	2018	Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.	CXCR4
27461063	10.1038/leu.2016.202	2017	Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.	CXCR4
27686375	10.3324/haematol.2016.147744	2017	The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system.	CXCR4
27735212	10.1080/10428194.2016.1239261	2017	Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.	CXCR4
27840426	10.1038/leu.2016.330	2017	Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.	CXCR4
27905003	10.1007/s12185-016-2156-2	2017	New agents in HSC mobilization.	CXCR4
27909810	10.1007/s00432-016-2312-3	2017	Erratum to: Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin.	CXCR4
28064239	10.1182/blood-2016-07-729954	2017	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.	CXCR4
28157211	10.1038/srep41959	2017	Platelet activating factor-induced expression of p21 is correlated with histone acetylation.	CXCR4
28231592	10.1159/000455706	2017	CXCR4: A New Player in an Old Scene?	CXCR4
28235842	10.1182/blood-2017-01-761726	2017	Acquired mutations associated with ibrutinib resistance in Waldenstr√∂m macroglobulinemia.	CXCR4
28280994	10.1007/s00277-017-2968-z	2017	Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.	CXCR4
28281555	10.1038/modpathol.2017.5	2017	NF-Œ∫B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.	CXCR4
28282510	10.1016/j.hemonc.2017.01.002	2017	CXCR4 (CD184) expression on stem cell harvest and CD34<sup>+</sup> cells post-transplant.	CXCR4
28331368	10.2147/CMAR.S94059	2017	New developments in the management of Waldenstr√∂m macroglobulinemia.	CXCR4
28353016	10.1007/s11899-017-0380-3	2017	New Therapeutic Strategies in Acute Lymphocytic Leukemia.	CXCR4
28357672	10.1007/978-1-4939-6872-5_15	2017	Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma.	CXCR4
28366781	10.1016/j.clml.2017.02.028	2017	Waldenstr√∂m Macroglobulinemia: Review of Pathogenesis and Management.	CXCR4
28373366	10.1158/1078-0432.CCR-16-3202	2017	Correction: ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.	CXCR4
28409853	10.1002/pbc.26414	2017	A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).	CXCR4
28533307	10.1182/blood-2017-04-776740	2017	SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.	CXCR4
28577295	10.1186/s13550-017-0294-z	2017	Response assessment with the CXCR4-directed positron emission tomography tracer [<sup>68</sup>Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities.	CXCR4
28617062	10.1080/17474086.2017.1343661	2017	Novel approaches to targeting MYD88 in Waldenstr√∂m macroglobulinemia.	CXCR4
28619846	10.3324/haematol.2016.159517	2017	Acute lymphoblastic leukemia cells create a leukemic niche without affecting the CXCR4/CXCL12 axis.	CXCR4
28641630	10.7534/j.issn.1009-2137.2017.03.021	2017	[SDF-1Œ±/CXCR4 Mediated Drug Resistance Can be Reversed by Ibrutinib in Acute Lymphoblastic Leukemia].	CXCR4
28646116	10.1182/blood-2016-10-747303	2017	Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.	CXCR4
28694325	10.1182/blood-2017-03-770982	2017	TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL.	CXCR4
28699226	10.1111/imm.12792	2017	Epstein-Barr virus (EBV) provides survival factors to EBV<sup>+</sup> diffuse large B-cell lymphoma (DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV<sup>+</sup> ¬†DLBCL.	CXCR4
28744319	10.7150/thno.19119	2017	[<sup>177</sup>Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent.	CXCR4
28877839	10.3881/j.issn.1000-503X.2017.04.019	2017	Significances of MYD88<sup>L265P</sup> and CXCR4<sup>WHIM</sup> Mutations in Waldenstrom Macroglobulinemia.	CXCR4
28903575	10.14735/amko20172S81	2017	Diagnostic Tools of Waldenstr√∂ms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.	CXCR4
28916148	10.1016/j.ymeth.2017.09.002	2017	Chemokine receptor - Directed imaging and therapy.	CXCR4
29025291	10.1556/650.2017.30868	2017	[Waldenstr√∂m's macroglobulinemia and its individualized therapy options].	CXCR4
29117236	10.1371/journal.pone.0187684	2017	Effects of CD49d-targeted antisense-oligonucleotide on Œ±4 integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies.	CXCR4
29153094	10.1016/j.cancergen.2017.09.002	2017	Differences between chronic lymphocytic leukaemia and small lymphocytic lymphoma cells by proteomic profiling and SNP microarray analysis.	CXCR4
29156704	10.18632/oncotarget.18844	2017	ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration.	CXCR4
29222280	10.1182/asheducation-2017.1.365	2017	Toward personalized treatment in Waldenstr√∂m macroglobulinemia.	CXCR4
29296751	10.1182/bloodadvances.2016003921	2017	A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies.	CXCR4
29365396	10.3760/cma.j.issn.0253-2727.2017.12.006	2017	[Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma].	CXCR4
29527563	10.1186/s41181-016-0020-6	2017	[<sup>64</sup>Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model.	CXCR4
26153511	10.1111/ejh.12626	2016	Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.	CXCR4
26303343	10.1159/000435769	2016	Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study.	CXCR4
26350264	10.1158/1078-0432.CCR-15-0987	2016	ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.	CXCR4
26369824	10.2174/1568026615666150915120218	2016	Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.	CXCR4
26554889	10.1097/MOH.0000000000000200	2016	Plerixafor for stem cell mobilization: the current status.	CXCR4
26635033	10.3324/haematol.2015.137265	2016	Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstr√∂m macroglobulinemia.	CXCR4
26659815	10.1111/bjh.13897	2016	Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr√∂m Macroglobulinaemia.	CXCR4
26885608	10.18632/oncotarget.7320	2016	Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment.	CXCR4
26901808	10.1080/10245332.2015.1125078	2016	Angiopoietins in the bone marrow microenvironment of acute lymphoblastic leukemia.	CXCR4
26931577	10.1189/jlb.5MA0915-394R	2016	Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia.	CXCR4
26942591	10.1007/s11864-016-0391-7	2016	Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.	CXCR4
26954567	10.1371/journal.pone.0150585	2016	Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.	CXCR4
26969772	10.1016/j.bjhh.2015.07.011	2016	Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review.	CXCR4
26996301	10.1016/j.canlet.2016.02.033	2016	Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy.	CXCR4
27071778	10.1111/bjh.14075	2016	Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia.	CXCR4
27090170	10.1016/j.blre.2016.02.003	2016	FDG-PET imaging in hematological malignancies.	CXCR4
27135782	10.1002/pbc.26035	2016	CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.	CXCR4
27268124	10.1016/j.clml.2016.04.014	2016	Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.	CXCR4
27297662	10.1038/ncomms11889	2016	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.	CXCR4
27307990	10.1186/s40364-016-0067-2	2016	The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines.	CXCR4
27374031	10.1016/j.medcli.2016.05.019	2016	[Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].	CXCR4
27381622	10.1093/jnci/djw131	2016	Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.	CXCR4
27544389	10.1007/s00432-016-2220-6	2016	Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin.	CXCR4
27598329	10.1080/17460441.2016.1233176	2016	Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.	CXCR4
27655427	10.1186/s13550-016-0227-2	2016	Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo¬†-¬†a comparison to [(68)Ga]pentixafor.	CXCR4
27725861	NA	2016	Suppression of chronic lymphocytic leukemia progression by CXCR4 inhibitor WZ811.	CXCR4
27799525	10.1073/pnas.1615258113	2016	Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice.	CXCR4
27825458	10.1016/j.beha.2016.09.001	2016	Learning from Waldenstrom Macroglobulinemia.	CXCR4
27825462	10.1016/j.beha.2016.08.019	2016	Targeting cell adhesion and homing as strategy to cure Waldenstr√∂m's macroglobulinemia.	CXCR4
27825467	10.1016/j.beha.2016.08.021	2016	Future therapeutic options for patients with Waldenstr√∂m macroglobulinemia.	CXCR4
27890075	10.1016/j.leukres.2016.10.008	2016	Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenstr√∂m macroglobulinemia/lymphoplasmacytic lymphoma.	CXCR4
27905841	10.1089/apc.2016.0245	2016	Cell-Delivered Entry Inhibitors for HIV-1: CCR5 Downregulation and Blocking Virus/Membrane Fusion in Defending the Host Cell Population.	CXCR4
28056298	10.3760/cma.j.issn.0529-5807.2016.12.005	2016	[Significance of CXCL12/CXCR4 expression in T-lymphoblastic lymphoma/leukemia].	CXCR4
30042959	10.18383/j.tom.2016.00130	2016	First <sup>18</sup>F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo.	CXCR4
31360080	10.2147/BLCTT.S84157	2016	Waldenstr√∂m macroglobulinemia: biology, genetics, and therapy.	CXCR4
25231113	10.1002/path.4446	2015	CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival.	CXCR4
25232031	10.1158/1541-7786.MCR-14-0150	2015	Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenstr√∂m macroglobulinemia.	CXCR4
25236359	10.1179/2295333714Y.0000000077	2015	Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium.	CXCR4
25504752	10.1158/1535-7163.MCT-14-0850	2015	Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.	CXCR4
25547652	10.3109/10428194.2014.999328	2015	VLA-4 and CXCR4 overexpression in bone marrow of an aleukemic B-cell acute lymphoblastic leukemia presenting with osteolytic bone lesions.	CXCR4
25571787	10.1016/j.hemonc.2014.11.007	2015	Plerixafor in the treatment of progenitor cell mobilization failure: First experience in Algeria.	CXCR4
25572297	10.1007/s00018-014-1830-x	2015	CXCL12/CXCR4 axis in the pathogenesis of acute lymphoblastic leukemia (ALL): a possible therapeutic target.	CXCR4
25643939	10.1111/bjh.13293	2015	Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma.	CXCR4
25644173	10.1186/s12943-014-0285-x	2015	Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes.	CXCR4
25655610	10.1007/978-3-319-13150-4_7	2015	Biology, prognosis, and therapy of Waldenstr√∂m Macroglobulinemia.	CXCR4
25679974	NA	2015	Waldenstr√∂m macroglobulinemia.	CXCR4
25681335	10.4049/jimmunol.1402610	2015	Bortezomib inhibits expression of TGF-Œ≤1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.	CXCR4
25688243	10.3389/fimmu.2015.00012	2015	Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges.	CXCR4
25704881	10.18632/oncotarget.3343	2015	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.	CXCR4
25819228	10.1111/bjh.13361	2015	MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.	CXCR4
25825601	10.7150/thno.11251	2015	Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.	CXCR4
25853860	10.1371/journal.pone.0122338	2015	Immunophenotyping of Waldenstr√∂ms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications.	CXCR4
25878069	10.1093/glycob/cwv022	2015	Interference with the CXCL12/CXCR4 axis as potential antitumor strategy: superiority of a sulfated galactofucan from the brown alga Saccharina latissima and fucoidan over heparins.	CXCR4
25882617	10.1016/j.blre.2015.03.001	2015	Waldenstr√∂m macroglobulinemia: What a hematologist needs to know.	CXCR4
25938000	10.1186/s40164-015-0004-3	2015	Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins.	CXCR4
26031918	10.1182/blood-2015-02-628677	2015	Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.	CXCR4
26058071	10.1016/j.ccell.2015.05.011	2015	T-ALL: Home Is where the CXCL12 Is.	CXCR4
26058075	10.1016/j.ccell.2015.05.002	2015	CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance.	CXCR4
26058076	10.1016/j.ccell.2015.05.003	2015	CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia.	CXCR4
26138997	10.1586/17474086.2015.1061427	2015	Ibrutinib for the treatment of Waldenstr√∂m macroglobulinemia.	CXCR4
26170971	10.3892/ol.2015.3182	2015	SGK3 (CISK) may induce tumor angiogenesis (Hypothesis).	CXCR4
26175195	10.1016/j.mehy.2015.07.005	2015	Plerixafor may treat intractable post-herpetic neuralgia.	CXCR4
26194765	10.1182/blood-2015-04-640805	2015	Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells.	CXCR4
26320102	10.1182/blood-2015-02-628560	2015	CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling.	CXCR4
26360610	10.18632/oncotarget.5094	2015	POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL.	CXCR4
26755907	10.5114/pdia.2015.48034	2015	Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides.	CXCR4
23713454	10.3109/10428194.2013.809079	2014	Successful and safe stem cell mobilization using plerixafor in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.	CXCR4
23781769	10.1111/trf.12265	2014	Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.	CXCR4
23949965	10.1002/hon.2090	2014	Phenotype profiling of primary testicular diffuse large B-cell lymphomas.	CXCR4
24018164	10.1016/j.semcancer.2013.08.011	2014	The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies.	CXCR4
24117899	10.1111/trf.12429	2014	Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest.	CXCR4
24118008	10.1111/trf.12434	2014	Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.	CXCR4
24128272	10.1111/trf.12459	2014	Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor.	CXCR4
24149438	10.4161/cbt.26607	2014	Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.	CXCR4
24239175	10.1016/j.leukres.2013.10.016	2014	High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia.	CXCR4
24329982	10.1111/trf.12516	2014	High-dose methotrexate in the mobilization of hematopoietic stem cells for patients with non-Hodgkin's lymphoma: a twelve-year study in a single center.	CXCR4
24366360	10.1182/blood-2013-09-525808	2014	The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.	CXCR4
24497931	10.1371/journal.pone.0085926	2014	CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12.	CXCR4
24589157	10.1016/j.clml.2014.01.004	2014	Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge.	CXCR4
24677543	10.1182/blood-2013-12-545954	2014	Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis?	CXCR4
24680978	10.1016/j.bbmt.2014.03.019	2014	Polymorphism of CD44 influences the efficacy of CD34(+) cells mobilization in patients with hematological malignancies.	CXCR4
24697337	10.1111/bjh.12883	2014	Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia.	CXCR4
24711662	10.1182/blood-2014-03-564583	2014	C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.	CXCR4
24725174	10.1111/bjd.13054	2014	Expression dynamics of CXCL12 and CXCR4 during the progression of mycosis fungoides.	CXCR4
24799524	10.1158/1078-0432.CCR-14-0154	2014	Disruption of follicular dendritic cells-follicular lymphoma cross-talk by the pan-PI3K inhibitor BKM120 (Buparlisib).	CXCR4
24859274	10.1371/journal.pone.0098194	2014	Decreased expression of CXCR4 chemokine receptor in bone marrow after chemotherapy in patients with non-Hodgkin lymphomas is a good prognostic factor.	CXCR4
24917186	10.1186/1471-2407-14-418	2014	B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cells.	CXCR4
25066861	10.1016/j.semcancer.2014.07.004	2014	Understanding and exploiting 5T4 oncofoetal glycoprotein expression.	CXCR4
25070183	10.3892/mmr.2014.2425	2014	Administration of a plasmid that expresses SDF-1Œ± affects the oncogenic potential of mouse bcr-abl-transformed cells.	CXCR4
25072364	10.1097/MPH.0000000000000220	2014	Chemotherapy-induced alteration of SDF-1/CXCR4 expression in bone marrow-derived mesenchymal stem cells from adolescents and young adults with acute lymphoblastic leukemia.	CXCR4
25197663	10.1155/2014/835138	2014	New insights in the mobilization of hematopoietic stem cells in lymphoma and multiple myeloma patients.	CXCR4
25201756	10.1016/j.exphem.2014.08.006	2014	Rictor/mammalian target of rapamycin 2 regulates the development of Notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3.	CXCR4
25333254	10.18632/oncotarget.2407	2014	Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.	CXCR4
25378977	10.3904/kjim.2014.29.6.785	2014	Clinical significance of nuclear factor Œ∫B and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.	CXCR4
25550696	10.4110/in.2014.14.6.296	2014	Simultaneous Inhibition of CXCR4 and VLA-4 Exhibits Combinatorial Effect in Overcoming Stroma-Mediated Chemotherapy Resistance in Mantle Cell Lymphoma Cells.	CXCR4
22936065	10.1038/modpathol.2012.134	2013	Chemokine receptors in gastric MALT lymphoma: loss of CXCR4 and upregulation of CXCR7 is associated with progression to diffuse large B-cell lymphoma.	CXCR4
23178377	10.1016/j.exphem.2012.11.004	2013	Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice.	CXCR4
23213054	10.1158/1078-0432.CCR-12-2333	2013	BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.	CXCR4
23238991	10.1007/s10495-012-0787-1	2013	Snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles induce apoptosis and growth arrest in human prostate cancer cells.	CXCR4
23294096	10.1111/bjh.12205	2013	MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism.	CXCR4
23295736	10.1038/leu.2012.358	2013	U-2932: two clones in one cell line, a tool for the study of clonal evolution.	CXCR4
23405135	10.1371/journal.pone.0055324	2013	Horizontal transmission of malignancy: in-vivo fusion of human lymphomas with hamster stroma produces tumors retaining human genes and lymphoid pathology.	CXCR4
23628037	10.7534/j.issn.1009-2137.2013.02.025	2013	[Expressions of VEGF and CXCR4 in diffuse large B cell lymphoma and their clinical significances].	CXCR4
23637121	10.1158/1078-0432.CCR-12-3015	2013	Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.	CXCR4
23698254	10.1097/CAD.0b013e328360cd8c	2013	Plerixafor and autologous stem cell transplantation: impressive result in a chemoresistant testicular cancer patient treated with high-dose chemotherapy.	CXCR4
23754844	10.1158/1541-7786.MCR-13-0114	2013	Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.	CXCR4
23811005	10.1016/j.freeradbiomed.2013.06.018	2013	Therapeutic efficacy and molecular mechanisms of snake (Walterinnesia aegyptia) venom-loaded silica nanoparticles in the treatment of breast cancer- and prostate cancer-bearing experimental mouse models.	CXCR4
23940282	10.1182/blood-2013-02-482125	2013	Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.	CXCR4
23943384	10.1007/s11912-013-0332-6	2013	Therapeutic options for adult T-cell leukemia/lymphoma.	CXCR4
23973876	10.1016/j.cellimm.2013.07.016	2013	Enhanced anticancer efficacy of snake venom combined with silica nanoparticles in a murine model of human multiple myeloma: molecular targets for cell cycle arrest and apoptosis induction.	CXCR4
24035716	10.1016/j.clml.2013.05.013	2013	CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.	CXCR4
24179472	10.1159/000354132	2013	Physiology and pharmacology of plerixafor.	CXCR4
24415962	10.1159/000354229	2013	Current clinical indications for plerixafor.	CXCR4
21740294	10.3109/10428194.2011.601698	2012	Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists.	CXCR4
21827503	10.1111/j.1537-2995.2011.03286.x	2012	Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent.	CXCR4
21830996	10.3109/10428194.2011.613135	2012	Disrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies.	CXCR4
21889797	10.1016/j.leukres.2011.08.001	2012	Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy.	CXCR4
21936770	10.3109/10428194.2011.625578	2012	The G protein-coupled receptor CysLT1 mediates chemokine-like effects and prolongs survival in chronic lymphocytic leukemia.	CXCR4
21981351	10.1111/j.1537-2995.2011.03349.x	2012	Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.	CXCR4
21984373	10.1002/path.3015	2012	Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia.	CXCR4
21992403	10.1111/j.1600-0609.2011.01719.x	2012	Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.	CXCR4
22186993	10.1182/blood-2011-04-347518	2012	Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia.	CXCR4
22202080	10.2741/s288	2012	Optimizing stem cell collection through CXCR4 antagonists.	CXCR4
22231445	10.1038/onc.2011.604	2012	STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.	CXCR4
22264762	10.1016/j.bmc.2011.12.052	2012	Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression.	CXCR4
22304442	10.1111/j.1537-2995.2011.03525.x	2012	Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.	CXCR4
22373785	10.1038/leu.2012.54	2012	Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.	CXCR4
22381519	10.1684/ejd.2012.1639	2012	Decreased expression of homeostatic chemokine receptors in intravascular large B-cell lymphoma.	CXCR4
22420651	10.1186/1750-9378-7-6	2012	HIV Co-receptor usage in HIV-related non-hodgkin's lymphoma.	CXCR4
22465758	10.1016/j.transci.2012.03.011	2012	Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.	CXCR4
22508288	10.1002/hep.25790	2012	Recruitment mechanisms of primary and malignant B cells to the human liver.	CXCR4
22509798	10.1111/j.1365-2141.2012.09123.x	2012	A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential.	CXCR4
22541616	NA	2012	Recent advances in non-small cell lung cancer biology and clinical management.	CXCR4
22586443	10.1371/journal.pone.0033788	2012	Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines.	CXCR4
22608605	10.1016/j.clml.2012.04.003	2012	Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q).	CXCR4
22722314	10.1038/bjc.2012.272	2012	PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.	CXCR4
22740445	10.1182/blood-2012-03-415380	2012	Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas.	CXCR4
22796644	10.1016/j.bbmt.2012.07.002	2012	Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield.	CXCR4
22808135	10.1371/journal.pone.0040332	2012	Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma.	CXCR4
22892553	10.1016/j.bbmt.2012.08.001	2012	Toward a more rational policy for autologous hematopoietic stem cell mobilization.	CXCR4
23009155	10.1186/1750-1172-7-71	2012	Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry.	CXCR4
23170195	10.4084/MJHID.2012.066	2012	New strategies for stem cell mobilization.	CXCR4
23234751	NA	2012	[Hematopoietic cells raising with plerixafor in non-Hodgkin lymphoma].	CXCR4
23251606	10.1371/journal.pone.0051661	2012	Cellular and molecular mechanisms underlie the anti-tumor activities exerted by Walterinnesia aegyptia venom combined with silica nanoparticles against multiple myeloma cancer cell types.	CXCR4
20880037	10.1111/j.1537-2995.2010.02896.x	2011	Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.	CXCR4
20938660	10.1007/s00277-010-1098-7	2011	Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.	CXCR4
20951741	10.1016/j.imlet.2010.09.022	2011	New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas.	CXCR4
20972470	10.1038/bmt.2010.249	2011	Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.	CXCR4
21048156	10.1182/blood-2010-01-262691	2011	Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.	CXCR4
21174490	10.3109/14653249.2010.542461	2011	Transiently redirected T cells for adoptive transfer.	CXCR4
21198864	10.1111/j.1600-0609.2010.01573.x	2011	Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.	CXCR4
21210239	10.1007/s10014-010-0013-1	2011	CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target.	CXCR4
21438839	10.3109/10428194.2011.568649	2011	The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets.	CXCR4
21456010	10.1002/cncr.26113	2011	Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia.	CXCR4
21458858	10.1016/j.leukres.2011.03.011	2011	Rac-1 GTPase controls the capacity of human leukaemic lymphoblasts to migrate on fibronectin in response to SDF-1Œ± (CXCL12).	CXCR4
21468240	10.2147/CE.S7801	2011	Plerixafor for autologous CD34 cell mobilization.	CXCR4
21474836	10.1177/1087057111403480	2011	Imaging-based assay for identification and characterization of inhibitors of CXCR4-tropic HIV-1 envelope-dependent cell-cell fusion.	CXCR4
21483439	10.1038/leu.2011.76	2011	Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist.	CXCR4
21492180	10.1111/j.1537-2995.2011.03136.x	2011	Effectiveness and cost analysis of just-in-time salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.	CXCR4
21518481	NA	2011	[Level of SDF-1/CXCR4 in children with acute leukemia and its significance].	CXCR4
21518888	10.1073/pnas.1103154108	2011	Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation.	CXCR4
21669033	10.3727/096368911X580536	2011	Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.	CXCR4
21672222	10.1186/1476-4598-10-73	2011	The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells.	CXCR4
21729688	10.1016/j.clml.2011.03.035	2011	Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia.	CXCR4
21749860	10.1016/j.bbrc.2011.06.172	2011	A novel 2,6-diisopropylphenyl-docosahexaenoamide conjugate induces apoptosis in T cell acute lymphoblastic leukemia cell lines.	CXCR4
21806478	10.1517/14712598.2011.601737	2011	Novel strategies for blood stem cell mobilization: special focus on plerixafor.	CXCR4
21816850	10.1095/biolreprod.111.091793	2011	Spermatogonial stem cell self-renewal requires ETV5-mediated downstream activation of Brachyury in mice.	CXCR4
21837928	10.2143/ACB.66.3.2062547	2011	Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.	CXCR4
21861545	10.2165/11206040-000000000-00000	2011	Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.	CXCR4
21865343	10.1182/blood-2011-01-333682	2011	ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation.	CXCR4
21955498	10.4161/rna.8.6.16264	2011	Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific.	CXCR4
22069486	10.1371/journal.pone.0027042	2011	Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1/CXCR4 axis.	CXCR4
22174304	10.1182/blood-2011-10-386524	2011	Can we build a better allograft?	CXCR4
24198526	10.2147/SCCAA.S6713	2011	Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.	CXCR4
19483760	10.1038/bmt.2009.119	2010	Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.	CXCR4
19748593	10.1016/j.bbmt.2009.09.003	2010	A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment.	CXCR4
19896878	10.1016/j.jfms.2009.09.008	2010	Differential CXCR4 expression and function in subpopulations of the feline lymphoma cell line 3201 susceptible to feline immunodeficiency virus.	CXCR4
19949101	10.4049/jimmunol.0901980	2010	gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes.	CXCR4
20111071	10.1038/leu.2009.302	2010	Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.	CXCR4
20141446	10.3109/10428190903560180	2010	Am80 inhibits stromal cell-derived factor-1-induced chemotaxis in T-cell acute lymphoblastic leukemia cells.	CXCR4
20153802	10.1016/j.exphem.2010.02.002	2010	Fifth complement cascade protein (C5) cleavage fragments disrupt the SDF-1/CXCR4 axis: further evidence that innate immunity orchestrates the mobilization of hematopoietic stem/progenitor cells.	CXCR4
20360661	NA	2010	Plerixafor (Mozobil).	CXCR4
20397073	10.1007/82_2010_26	2010	CXCR4 in clinical hematology.	CXCR4
20411999	10.1592/phco.30.5.485	2010	Plerixafor: a peripheral blood stem cell mobilizer.	CXCR4
20473162	10.1097/MOH.0b013e328338b7d5	2010	Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.	CXCR4
20530974	10.1159/000315736	2010	FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.	CXCR4
20566945	10.1001/archdermatol.2010.113	2010	A case of intravascular large B-cell lymphoma with atypical clinical manifestations and analysis of CXCL12 and CXCR4 expression.	CXCR4
20568229	10.1002/jcp.22284	2010	Attenuation of CXCR4 responses by CCL18 in acute lymphocytic leukemia B cells.	CXCR4
20685493	10.1016/j.clinthera.2010.05.007	2010	Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.	CXCR4
20689431	10.1097/CCO.0b013e32833d752c	2010	Recent advances of IMiDs in cancer therapy.	CXCR4
20826182	10.1016/j.pharmthera.2010.08.009	2010	Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil‚Ñ¢) and potential of other CXCR4 antagonists as stem cell mobilizers.	CXCR4
20872671	10.1002/ijc.25236	2010	Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells.	CXCR4
20939442	NA	2010	Plerixafor. Only for certain patients when G-CSF stem cell mobilisation fails.	CXCR4
21048105	10.4049/jimmunol.1001373	2010	Methyl gallate exhibits potent antitumor activities by inhibiting tumor infiltration of CD4+CD25+ regulatory T cells.	CXCR4
21098756	10.1345/aph.1P223	2010	Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.	CXCR4
21099212	10.1159/000321509	2010	Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer.	CXCR4
21106070	10.1186/1471-2407-10-644	2010	If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma.	CXCR4
21159639	10.1158/0008-5472.CAN-10-1943	2010	CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells.	CXCR4
18488221	10.1007/s00262-008-0528-z	2009	Expression and function of T cell homing molecules in Hodgkin's lymphoma.	CXCR4
19064997	10.1074/jbc.M804935200	2009	Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and lymphocytic cancer cell lines.	CXCR4
19135941	10.1016/j.bbmt.2008.10.018	2009	Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.	CXCR4
19161986	10.1016/j.bcp.2008.12.014	2009	The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).	CXCR4
19167685	10.1016/j.bbmt.2008.11.028	2009	Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.	CXCR4
19180104	10.1038/nrd2819	2009	Plerixafor.	CXCR4
19228923	10.1182/blood-2008-10-185827	2009	Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.	CXCR4
19242508	10.1038/jid.2009.45	2009	Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors.	CXCR4
19275275	10.2165/00003495-200969030-00007	2009	Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.	CXCR4
19308288	10.1593/neo.81508	2009	Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor cell migration.	CXCR4
19344405	10.1111/j.1365-2141.2009.07648.x	2009	CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK.	CXCR4
19347723	10.1080/10428190902730243	2009	Sensitising leukemic cells by targeting microenvironment.	CXCR4
19391039	10.1080/10428190902893801	2009	Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells.	CXCR4
19557626	10.1080/10428190902991837	2009	The stromal derived factor-1\CXCR4 axis--a legitimate therapeutic target in multiple myeloma?	CXCR4
19657116	10.1182/blood-2008-11-189308	2009	Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice.	CXCR4
19657955	10.1080/10428190903150847	2009	Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.	CXCR4
19720922	10.1200/JCO.2008.20.7209	2009	Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.	CXCR4
19757319	10.1080/10428190903216853	2009	Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.	CXCR4
19834627	10.1358/dot.2009.45.7.1395292	2009	Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells.	CXCR4
19927352	10.1002/jcla.20346	2009	CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.	CXCR4
19929463	10.3109/14653240903121245	2009	A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.	CXCR4
20695076	10.4248/IJOS.09059	2009	CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex.	CXCR4
21076551	10.1159/000235954	2009	Turning CD34 Non-Mobilizers into Mobilizers: A Case Report Involving Plerixafor (AMD3100).	CXCR4
21082960	10.1586/ehm.09.54	2009	Mobilization of hematopoietic stem cells into the peripheral blood.	CXCR4
17914737	10.1002/pbc.21370	2008	Chemokine CXCL12 enhances proliferation in pre-B-ALL via STAT5 activation.	CXCR4
18172310	10.1158/0008-5472.CAN-07-2778	2008	PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.	CXCR4
18277033	10.2169/internalmedicine.47.0500	2008	Peripheral T-cell lymphoma following diffuse large B-cell lymphoma associated with celiac disease.	CXCR4
18322253	10.3324/haematol.12098	2008	Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways.	CXCR4
18374178	10.1016/S0076-6879(07)00427-2	2008	Rho GTPases and regulation of hematopoietic stem cell localization.	CXCR4
18561120	10.1002/path.2372	2008	Distinct signatures of B-cell homeostatic and activation-dependent chemokine receptors in the development and progression of extragastric MALT lymphomas.	CXCR4
18636124	10.1371/journal.pone.0002816	2008	Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.	CXCR4
18847313	10.1517/14712598.8.11.1797	2008	Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.	CXCR4
18940680	10.1016/j.bbmt.2008.08.011	2008	A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.	CXCR4
17064769	10.1016/j.leukres.2006.09.012	2007	CXCR4 expression during tumour cell death.	CXCR4
17198877	10.1016/j.exphem.2006.09.006	2007	Gene-expression profiling during curcumin-induced apoptosis reveals downregulation of CXCR4.	CXCR4
17290476	10.1002/anie.200604295	2007	siRNA delivery into human T cells and primary cells with carbon-nanotube transporters.	CXCR4
17324009	10.2165/00126839-200708020-00006	2007	Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791.	CXCR4
17324341	10.3816/clm.2007.n.009	2007	AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma.	CXCR4
17336267	10.1016/j.bbrc.2007.02.053	2007	Dynamic interplay between the neutral glycosphingolipid CD77/Gb3 and the therapeutic antibody target CD20 within the lipid bilayer of model B lymphoma cells.	CXCR4
17369141	10.1309/NUQHJ79BHWYD9TAF	2007	Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1.	CXCR4
17410186	10.1038/sj.leu.2404684	2007	CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment.	CXCR4
17488655	10.3324/haematol.10621	2007	Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia.	CXCR4
17553309	NA	2007	[The role of stromal cell derived factor-1/CXCR4 biological axis in tumor metastasis of non-Hodgkin lymphoma].	CXCR4
17568820	10.1038/sj.leu.2404769	2007	Focal adhesion kinase is required for CXCL12-induced chemotactic and pro-adhesive responses in hematopoietic precursor cells.	CXCR4
17641901	10.1007/s00401-007-0258-x	2007	Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma.	CXCR4
17697366	10.1186/ar2210	2007	B cells in Sj√∂gren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue.	CXCR4
17784839	10.1089/scd.2006.0087	2007	Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients.	CXCR4
17875700	10.1158/0008-5472.CAN-06-4722	2007	Differential regulation of hypoxia-induced CXCR4 triggering during B-cell development and lymphomagenesis.	CXCR4
18080041	NA	2007	Molecule of the month. Plerixafor hydrochloride.	CXCR4
16118018	10.1016/j.leukres.2005.07.009	2006	Chemokine receptor expression and function in childhood acute lymphoblastic leukemia of B-lineage.	CXCR4
16204308	10.1182/blood-2005-04-1492	2006	Skin homing of S√©zary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV.	CXCR4
16454701	10.2174/138945006775270187	2006	Lymphoproliferative disorders and chemokines.	CXCR4
16476057	10.1111/j.1365-2567.2005.02311.x	2006	Epstein-Barr virus infection negatively impacts the CXCR4-dependent migration of tonsillar B cells.	CXCR4
16584580	NA	2006	[Expression of SDF-1alpha and its receptor CXCR4 in acute leukemias and their relationship with extramedullary infiltration].	CXCR4
16619289	10.1002/eji.200535799	2006	Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing.	CXCR4
16679918	10.1097/01.mph.0000212908.14642.a5	2006	Chemokine IL-8 and chemokine receptor CXCR3 and CXCR4 gene expression in childhood acute lymphoblastic leukemia at first relapse.	CXCR4
16815309	10.1016/j.bcp.2006.05.010	2006	Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4.	CXCR4
16863911	10.1016/j.exphem.2006.06.003	2006	The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics.	CXCR4
16923552	10.1080/10428190600562112	2006	The SDF-1 G &gt; A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia.	CXCR4
16939815	10.1016/j.exphem.2006.05.004	2006	Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.	CXCR4
16990769	10.1038/sj.leu.2404390	2006	T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy.	CXCR4
17005036	10.1186/1742-4690-3-64	2006	Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias.	CXCR4
17049119	10.1111/j.1745-7254.2006.00415.x	2006	Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro.	CXCR4
17058243	10.1002/hep.21365	2006	Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence.	CXCR4
17071491	10.1080/10428190600775599	2006	Survey of chemokine receptor expression reveals frequent co-expression of skin-homing CCR4 and CCR10 in adult T-cell leukemia/lymphoma.	CXCR4
17079483	10.1158/0008-5472.CAN-06-1981	2006	Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma.	CXCR4
15454484	10.1182/blood-2004-03-0799	2005	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation.	CXCR4
15833862	10.1158/0008-5472.CAN-04-3402	2005	Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia.	CXCR4
15833868	10.1158/0008-5472.CAN-04-4280	2005	Construction of a minimal HIV-1 variant that selectively replicates in leukemic derived T-cell lines: towards a new virotherapy approach.	CXCR4
15854291	NA	2005	[Expression of stromal cell derived factor-1(SDF-1) and its receptor CXCR4 in hematologic malignancies].	CXCR4
15923599	10.1200/JCO.2005.55.250	2005	Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma.	CXCR4
15967804	10.1182/blood-2005-01-0324	2005	Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma.	CXCR4
16018941	10.1016/j.urolonc.2005.02.004	2005	Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression.	CXCR4
16038794	10.1016/j.cellsig.2004.12.009	2005	Heterologous regulation of chemokine receptor signaling by the lipid phosphatase SHIP in lymphocytes.	CXCR4
16080846	NA	2005	[The expression and clinical significance of stromal cell-derived factor-1 and CXCR4 in acute leukemia and malignant lymphoma].	CXCR4
16178723	10.2174/1389557054867075	2005	Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.	CXCR4
16211229	NA	2005	Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression.	CXCR4
16236608	10.1080/10428190500215027	2005	CXCR4 chemokine receptors, histone deacetylase inhibitors and acute lymphoblastic leukemia.	CXCR4
16269859	10.1159/000088410	2005	Role of CXCR4 chemokine receptor blockade using AMD3100 for mobilization of autologous hematopoietic progenitor cells.	CXCR4
16373702	10.1158/1535-7163.MCT-05-0146	2005	Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures.	CXCR4
11157475	10.1182/blood.v97.3.608	2001	SHP2 and cbl participate in alpha-chemokine receptor CXCR4-mediated signaling pathways.	CXCR4
33579790	10.1136/gutjnl-2020-322935	2022	Oncogenetic landscape of lymphomagenesis in coeliac disease.	DDX3X
35726023	10.1038/s41684-022-00998-x	2022	The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications.	DDX3X
35794096	10.1038/s41467-022-31355-8	2022	Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.	DDX3X
35815807	10.1158/0008-5472.CAN-21-2454	2022	The X-Linked Helicase DDX3X Is Required for Lymphoid Differentiation and MYC-Driven Lymphomagenesis.	DDX3X
35882439	10.1182/bloodadvances.2022007541	2022	Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association.	DDX3X
36000950	10.1002/pbc.29926	2022	Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic lymphoma.	DDX3X
32732362	10.3324/haematol.2020.254276	2021	Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic roles of PRDM1.	DDX3X
33808787	10.3390/cancers13061414	2021	EBV and the Pathogenesis of NK/T Cell Lymphoma.	DDX3X
34437837	10.1016/j.molcel.2021.07.041	2021	Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis.	DDX3X
34624215	10.1016/j.molcel.2021.09.009	2021	Sex, life, and death in MYC-driven lymphomagenesis.	DDX3X
34654425	10.1186/s12943-021-01437-0	2021	DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.	DDX3X
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	DDX3X
31822801	10.1038/s41379-019-0415-5	2020	Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America.	DDX3X
32363958	10.1177/0300060520918087	2020	CD56-positive diffuse large B-cell lymphoma/leukemia with <i>BCL6/MYC</i> double-hit and multiple gene mutations: an indicator of poor prognosis?	DDX3X
32843425	10.1101/mcs.a004994	2020	Failure of tofacitinib to achieve an objective response in a <i>DDX3X-MLLT10</i> T-lymphoblastic leukemia with activating <i>JAK3</i> mutations.	DDX3X
33376237	10.1038/s41392-020-00331-3	2020	Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.	DDX3X
30563911	10.1101/gr.241141.118	2019	Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.	DDX3X
30664667	10.1038/s41564-018-0334-0	2019	Defective Epstein-Barr virus in chronic active infection and haematological malignancy.	DDX3X
30733272	10.3324/haematol.2018.207928	2019	Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.	DDX3X
31123138	10.1136/jclinpath-2019-205727	2019	Intravascular NK/T-cell lymphoma: clinicopathological and integrated molecular analysis of two cases provides a clue to disease pathogenesis.	DDX3X
31300419	10.1182/bloodadvances.2018029546	2019	Sporadic and endemic Burkitt lymphoma have frequent <i>FOXO1</i> mutations but distinct hotspots in the AKT recognition motif.	DDX3X
31305266	10.1097/PAS.0000000000001324	2019	Chronic Active Epstein-Barr Virus Infection of T/NK-Cell Type Mimicking Classic Hodgkin Lymphoma: Clinicopathologic and Genetic Features of 8 Cases Supporting a Variant With Hodgkin/Reed-Sternberg-like Cells of NK Phenotype.	DDX3X
31311407	10.1080/15384047.2019.1638670	2019	Somatic mutations in <i>KMT2D</i> and <i>TET2</i> associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders.	DDX3X
31391454	10.1038/s41419-019-1825-5	2019	Avenanthramide A triggers potent ROS-mediated anti-tumor effects in colorectal cancer by directly targeting DDX3.	DDX3X
29674644	10.1038/s41467-018-03987-2	2018	Aggressive natural killer-cell leukemia¬†mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.	DDX3X
29896680	10.1007/978-981-10-7230-7_21	2018	EBV in T-/NK-Cell Tumorigenesis.	DDX3X
30134235	10.1159/000492835	2018	Frequent Mutations in Natural Killer/T Cell Lymphoma.	DDX3X
30209976	10.1080/15384101.2018.1522912	2018	PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation.	DDX3X
28033648	10.1002/gcc.22439	2017	Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.	DDX3X
29375552	10.3389/fimmu.2017.01867	2017	Chronic Active Epstein-Barr Virus Disease.	DDX3X
26773734	10.1002/gcc.22348	2016	Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type.	DDX3X
25466511	10.1016/j.ejca.2014.10.017	2015	Differential proteomic analysis of endemic and sporadic Epstein-Barr virus-positive and negative Burkitt lymphoma.	DDX3X
26192917	10.1038/ng.3358	2015	Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.	DDX3X
24584351	10.3324/haematol.2013.101725	2014	DDX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia.	DDX3X
23673860	10.1182/blood-2013-02-487256	2013	New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia.	DDX3X
14729942	10.1074/mcp.D300003-MCP200	2004	Identification of phosphoproteins and their phosphorylation sites in the WEHI-231 B lymphoma cell line.	DDX3X
35937947	10.1155/2022/6441139	2022	Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis.	DTX1
32868912	10.1038/s41423-020-00527-1	2021	Exploring the stage-specific roles of Tcf-1 in T cell development and malignancy at single-cell resolution.	DTX1
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	DTX1
33939500	10.1177/10668969211013402	2021	A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor.	DTX1
33945543	10.1371/journal.pone.0248886	2021	Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.	DTX1
31822496	10.1158/0008-5472.CAN-19-1471	2020	ARRB1-Promoted NOTCH1 Degradation Is Suppressed by OncomiR miR-223 in T-cell Acute Lymphoblastic Leukemia.	DTX1
30802265	10.1371/journal.pone.0212813	2019	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.	DTX1
28183850	10.3324/haematol.2016.157495	2017	Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma.	DTX1
25891013	10.1002/art.39163	2015	The anergy induction of M3 muscarinic acetylcholine receptor-reactive CD4+ T cells suppresses experimental sialadenitis-like Sj√∂gren's syndrome.	DTX1
25000980	10.4049/jimmunol.1301416	2014	Deltex1 promotes protein kinase CŒ∏ degradation and sustains Casitas B-lineage lymphoma expression.	DTX1
25171927	10.1182/blood-2013-12-546309	2014	Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients.	DTX1
22891273	10.1084/jem.20120904	2012	The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.	DTX1
21840596	10.1016/j.leukres.2011.07.024	2011	Cooperation between somatic Ikaros and Notch1 mutations at the inception of T-ALL.	DTX1
20161710	10.1371/journal.pone.0009094	2010	Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.	DTX1
20861909	10.1038/leu.2010.204	2010	NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.	DTX1
19293180	10.1158/0008-5472.CAN-08-4223	2009	Heterozygosity for hypoxia inducible factor 1alpha decreases the incidence of thymic lymphomas in a p53 mutant mouse model.	DTX1
16103065	10.1158/0008-5472.CAN-05-1400	2005	OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1.	DTX1
12670957	10.1074/jbc.M301157200	2003	The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity.	DTX1
34265801	10.1097/PAS.0000000000001780	2022	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.	EP300
34560683	10.1097/PAS.0000000000001813	2022	A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients.	EP300
34649275	10.1182/bloodadvances.2021005316	2022	Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity.	EP300
34971957	10.1016/j.bbrc.2021.12.078	2022	CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.	EP300
35054466	10.3390/life12010073	2022	The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma.	EP300
35205765	10.3390/cancers14041018	2022	Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.	EP300
35317330	10.14740/wjon1436	2022	Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis.	EP300
35646048	10.3389/fgene.2022.878618	2022	Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	EP300
35908982	10.1016/j.blre.2022.100992	2022	Follicular lymphoma: The long and winding road leading to your cure?	EP300
35921545	10.1080/10428194.2022.2095630	2022	Zinc finger protein 384 (<i>ZNF384</i>) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia.	EP300
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	EP300
33145596	10.1093/labmed/lmaa085	2021	Detection of a Cryptic EP300/ZNF384 Gene Fusion by Chromosomal Microarray and Next-Generation Sequencing Studies in a Pediatric Patient with B-Lymphoblastic Leukemia.	EP300
33399078	10.1016/j.esmoop.2020.100012	2021	Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.	EP300
33413063	10.2174/1568009620666210106122750	2021	Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).	EP300
33431788	10.1038/s41392-020-00437-8	2021	CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.	EP300
33560380	10.1182/bloodadvances.2020002469	2021	Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features.	EP300
33829512	10.1111/his.14378	2021	Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma.	EP300
33911074	10.1038/s41419-021-03695-8	2021	Genome-wide CRISPR screens reveal synthetic lethal interaction between CREBBP and EP300 in diffuse large B-cell lymphoma.	EP300
33951889	10.3324/haematol.2020.271957	2021	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.	EP300
33988307	10.1111/ijlh.13580	2021	Systematic application of fluorescence in situ hybridization and immunophenotype profile for the identification of ZNF384 gene rearrangements in B cell acute lymphoblastic leukemia.	EP300
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	EP300
35008340	10.3390/cancers14010176	2021	Recent Advances in the Genetic of MALT Lymphomas.	EP300
35071240	10.3389/fcell.2021.805195	2021	Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.	EP300
31423576	10.1111/bjh.16159	2020	M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.	EP300
31752573	10.1080/10428194.2019.1691200	2020	New murine models of aggressive lymphoma.	EP300
31822509	10.1074/jbc.RA119.008742	2020	Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma.	EP300
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	EP300
32027248	10.19746/j.cnki.issn.1009-2137.2020.01.005	2020	[Analysis of Clinical Characteristics of Acute B Lymphoblastic Leukemia with EP300-ZNF384 Fusion Gene Positive].	EP300
32349779	10.1186/s13073-020-00739-0	2020	CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.	EP300
32553609	10.1016/j.virusres.2020.198066	2020	p300 promotes cell proliferation through suppressing Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation in the infected B-lymphoma cells.	EP300
32576962	10.1038/s41375-020-0908-8	2020	CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.	EP300
32882003	10.1182/bloodadvances.2020001879	2020	Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734.	EP300
32980888	10.1007/s00277-020-04251-8	2020	Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing.	EP300
33045225	10.1016/j.humpath.2020.09.014	2020	The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.	EP300
33097085	10.1186/s13148-020-00948-9	2020	Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.	EP300
33160401	10.1186/s13148-020-00962-x	2020	Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.	EP300
30307363	10.1080/15384047.2018.1523857	2019	Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).	EP300
30563911	10.1101/gr.241141.118	2019	Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.	EP300
30721949	10.1093/carcin/bgz013	2019	Mutational landscape of T-cell lymphoma in mice lacking the DNA mismatch repair gene Mlh1: no synergism with ionizing radiation.	EP300
30733272	10.3324/haematol.2018.207928	2019	Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.	EP300
30979734	10.1158/1078-0432.CCR-18-3989	2019	Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.	EP300
31182547	10.1158/0008-5472.CAN-18-3622	2019	CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms.	EP300
31221981	10.1038/s12276-019-0230-6	2019	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.	EP300
31234226	10.1002/1873-3468.13506	2019	ZNF384-fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities.	EP300
31292115	10.1182/blood.2019001126	2019	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.	EP300
31475375	10.1002/hon.2674	2019	m7FLIPI and targeted sequencing in high-risk follicular lymphoma.	EP300
31489524	10.1007/s11899-019-00541-9	2019	Chromatin-Remodeled State in Lymphoma.	EP300
31519498	10.1016/j.immuni.2019.08.006	2019	Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.	EP300
31533053	10.1016/j.immuni.2019.08.018	2019	Scoring a HAT-Trick against Lymphoma.	EP300
31563285	10.1016/j.prp.2019.152651	2019	Targeted next-generation sequencing revealed distinct clinicopathologic and molecular features of VCL-ALK RCC: A unique case from an older patient without clinical evidence of sickle cell trait.	EP300
31662917	10.1155/2019/4532434	2019	An Unusually Short Latent Period of Therapy-Related Myeloid Neoplasm Harboring a Rare MLL-EP300 Rearrangement: Case Report and Literature Review.	EP300
31669559	10.1016/j.exphem.2019.10.004	2019	Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.	EP300
31735627	10.1016/j.ccell.2019.10.004	2019	The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability.	EP300
29305415	10.3324/haematol.2017.182444	2018	Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.	EP300
29359884	10.1002/ajmg.a.38603	2018	Benign and malignant tumors in Rubinstein-Taybi syndrome.	EP300
29431567	10.1080/10428194.2018.1434885	2018	Deep spontaneous molecular remission in a patient with congenital acute myeloid leukemia expressing a novel MOZ-p300 fusion transcript.	EP300
29467311	10.1128/JVI.02155-17	2018	Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.	EP300
29531323	10.1038/s41416-018-0022-0	2018	Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression.	EP300
29884215	10.1186/s13072-018-0197-x	2018	CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.	EP300
30104217	10.1182/blood-2018-01-824607	2018	North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies.	EP300
30134235	10.1159/000492835	2018	Frequent Mutations in Natural Killer/T Cell Lymphoma.	EP300
30135206	10.1074/jbc.RA118.004084	2018	The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.	EP300
30227405	10.1159/000491013	2018	Microarray-Based Gene Expression Analysis Identifies Potential Diagnostic and Prognostic Biomarkers for Waldenstr√∂m Macroglobulinemia.	EP300
30360879	10.1053/j.seminoncol.2018.07.005	2018	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	EP300
30723478	10.3389/fimmu.2018.03135	2018	CVID-Associated Tumors: Czech Nationwide Study Focused on Epidemiology, Immunology, and Genetic Background in a Cohort of Patients With CVID.	EP300
27634205	10.3324/haematol.2016.151035	2017	ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.	EP300
27717743	10.1016/j.mce.2016.10.002	2017	AKT1 has dual actions on the glucocorticoid receptor by cooperating with 14-3-3.	EP300
27742770	10.3324/haematol.2016.144964	2017	Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.	EP300
27903646	10.1101/gr.209163.116	2017	Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.	EP300
28103279	10.1371/journal.pone.0170282	2017	Aristaless Related Homeobox (ARX) Interacts with Œ≤-Catenin, BCL9, and P300 to Regulate Canonical Wnt Signaling.	EP300
28106467	10.1080/15592294.2017.1282587	2017	Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.	EP300
28270109	10.1186/s12866-017-0946-1	2017	Oral microbe-host interactions: influence of Œ≤-glucans on gene expression of inflammatory cytokines and metabolome profile.	EP300
28302137	10.1186/s13045-017-0438-7	2017	Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.	EP300
28378055	10.1007/s12185-017-2220-6	2017	EP300-ZNF384 fusion gene product up-regulates GATA3 gene expression and induces hematopoietic stem cell gene expression signature in B-cell precursor acute lymphoblastic leukemia cells.	EP300
28425985	10.1038/cddis.2017.164	2017	The cellular senescence of leukemia-initiating cells from acute lymphoblastic leukemia is postponed by Œ≤-Arrestin1 binding with P300-Sp1 to regulate hTERT transcription.	EP300
28551630	10.21873/anticanres.11646	2017	Expression and Prognostic Significance of <i>EP300</i>, <i>TP53</i> and <i>BAX</i> in Clear Cell Renal Cell Carcinoma.	EP300
28725161	10.1186/s12935-017-0439-1	2017	EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP.	EP300
28831000	10.1073/pnas.1619555114	2017	Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.	EP300
29222279	10.1182/asheducation-2017.1.358	2017	Follicular lymphoma: are we ready for a risk-adapted approach?	EP300
29340061	10.18632/oncotarget.22799	2017	Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.	EP300
26698557	10.2217/epi.15.96	2016	Epigenetic dysregulation in follicular lymphoma.	EP300
27003102	10.3109/10428194.2016.1160083	2016	Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.	EP300
27132507	10.1038/onc.2016.126	2016	FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism.	EP300
27181063	10.1016/j.exphem.2016.04.011	2016	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia.	EP300
27392123	10.1002/pbc.26116	2016	Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion.	EP300
27428428	10.1016/j.ebiom.2016.04.038	2016	Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia.	EP300
27590521	10.18632/oncotarget.11773	2016	Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.	EP300
25444907	10.1016/j.canlet.2014.11.024	2015	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	EP300
25943178	10.1038/leu.2015.111	2015	A novel recurrent EP300-ZNF384 gene fusion in B-cell precursor acute lymphoblastic leukemia.	EP300
26189108	10.1016/j.leukres.2015.06.005	2015	Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.	EP300
26192917	10.1038/ng.3358	2015	Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.	EP300
26256760	10.1016/S1470-2045(15)00169-2	2015	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	EP300
26293203	10.1186/s13045-015-0197-2	2015	Establishment and genetic characterization of a novel mixed-phenotype acute leukemia cell line with EP300-ZNF384 fusion.	EP300
26473533	10.1038/bcj.2015.89	2015	Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.	EP300
23728349	10.1038/onc.2013.169	2014	Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.	EP300
24345752	10.1182/blood-2013-10-531509	2014	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.	EP300
24529102	10.1186/1476-4598-13-29	2014	Histone acetyltransferase-deficient p300 mutants in diffuse large B cell lymphoma have altered transcriptional regulatory activities and are required for optimal cell growth.	EP300
24942943	10.3960/jslrt.54.23	2014	Molecular pathogenesis of follicular lymphoma.	EP300
25088465	10.1016/j.mce.2014.07.020	2014	Reciprocal occupancy of BCL6 and STAT5 on Growth Hormone target genes: contrasting transcriptional outcomes and promoter-specific roles of p300 and HDAC3.	EP300
25364581	10.7497/j.issn.2095-3941.2014.03.006	2014	The gene expression patterns of BMPR2, EP300, TGFŒ≤2, and TNFAIP3 in B-Lymphoma cells.	EP300
23985173	10.1186/1755-8166-6-34	2013	Characterization of a case of follicular lymphoma transformed into B-lymphoblastic leukemia.	EP300
22116549	10.1038/leu.2011.340	2012	Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy.	EP300
22237106	10.1038/nature10725	2012	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.	EP300
22287508	10.18632/oncotarget.436	2012	Histone modification defects in developmental disorders and cancer.	EP300
22585168	10.1158/2159-8290.CD-11-0208	2012	Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.	EP300
23342264	10.1002/cam4.29	2012	MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma.	EP300
24371765	10.1016/j.lrr.2012.10.002	2012	Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones.	EP300
21232847	10.1016/j.canlet.2010.12.018	2011	A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity.	EP300
21390126	10.1038/nature09730	2011	Inactivating mutations of acetyltransferase genes in B-cell lymphoma.	EP300
21493871	10.1158/1055-9965.EPI-11-0059	2011	Multilocus association of genetic variants in MLL, CREBBP, EP300, and TOP2A with childhood acute lymphoblastic leukemia in Hispanics from Texas.	EP300
21705495	10.1182/blood-2010-12-326199	2011	HTLV-1 bZIP factor enhances TGF-Œ≤ signaling through p300 coactivator.	EP300
21796119	10.1038/nature10351	2011	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.	EP300
19948376	10.1016/j.canlet.2009.10.018	2010	Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8.	EP300
20101207	10.1038/onc.2009.498	2010	The HTLV-1 tax protein cooperates with phosphorylated CREB, TORC2 and p300 to activate CRE-dependent cyclin D1 transcription.	EP300
21041953	10.1172/JCI42869	2010	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.	EP300
18245479	10.1158/0008-5472.CAN-07-0008	2008	BCL6 represses Smad signaling in transforming growth factor-beta resistance.	EP300
18815299	10.1128/JVI.01356-08	2008	The proto-oncogene Bcl3, induced by Tax, represses Tax-mediated transcription via p300 displacement from the human T-cell leukemia virus type 1 promoter.	EP300
19064921	10.1073/pnas.0810965105	2008	Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.	EP300
16428436	10.1128/MCB.26.3.789-809.2006	2006	Conditional knockout mice reveal distinct functions for the global transcriptional coactivators CBP and p300 in T-cell development.	EP300
16638200	NA	2006	[Regulatory effect of curcumin on p300 and HDAC1 in B-NHL cells].	EP300
15943569	10.1089/aid.2005.21.273	2005	Human T lymphotropic virus type 1 accessory protein p12I modulates calcium-mediated cellular gene expression and enhances p300 expression in T lymphocytes.	EP300
14668346	10.1074/jbc.M309485200	2004	Kaposi's sarcoma-associated herpesvirus-encoded vIRF-3 stimulates the transcriptional activity of cellular IRF-3 and IRF-7.	EP300
15066326	10.1016/j.cancergencyto.2003.09.006	2004	Absence of p300 gene promoter methylation in acute leukemia.	EP300
15315758	10.1016/j.cell.2004.08.007	2004	One nucleotide in a kappaB site can determine cofactor specificity for NF-kappaB dimers.	EP300
12730195	10.1074/jbc.M303518200	2003	Identification and characterization of BCL-3-binding protein: implications for transcription and DNA repair or recombination.	EP300
14635047	10.1002/eji.200324061	2003	p300 cooperates with Smad3/4 and Runx3 in TGFbeta1-induced IgA isotype expression.	EP300
12402037	10.1038/ng1018	2002	Acetylation inactivates the transcriptional repressor BCL6.	EP300
10891508	10.1128/MCB.20.15.5722-5735.2000	2000	Modulation of histone acetyltransferase activity through interaction of epstein-barr nuclear antigen 3C with prothymosin alpha.	EP300
10497212	10.1074/jbc.274.40.28491	1999	Bcl3, an IkappaB protein, stimulates activating protein-1 transactivation and cellular proliferation.	EP300
35675522	10.1182/bloodadvances.2022007725	2022	ETS1 is a novel transcriptional regulator of adult T-cell leukemia/lymphoma of North American descent.	ETS1
33479306	10.1038/s41598-020-80376-0	2021	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.	ETS1
33512466	10.1182/blood.2020010175	2021	OBF1 and Oct factors control the germinal center transcriptional program.	ETS1
33537078	10.7150/thno.52677	2021	Conditioned medium from adipose-derived stem cells attenuates ischemia/reperfusion-induced cardiac injury through the microRNA-221/222/PUMA/ETS-1 pathway.	ETS1
34763718	10.1186/s13046-021-02159-3	2021	ASB2 is a direct target of FLI1 that sustains NF-Œ∫B pathway activation in germinal center-derived diffuse large B-cell lymphoma.	ETS1
32679859	10.3390/cancers12071912	2020	Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type.	ETS1
32924017	10.1158/2643-3230.BCD-20-0026	2020	Combinatorial ETS1-dependent control of oncogenic NOTCH1 enhancers in T-cell leukemia.	ETS1
30733272	10.3324/haematol.2018.207928	2019	Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.	ETS1
30940846	10.1038/s41598-019-41805-x	2019	Insertional mutagenesis using the Sleeping Beauty transposon system identifies drivers of erythroleukemia in mice.	ETS1
31181104	10.1371/journal.pone.0217542	2019	A transcriptional signature associated with non-Hodgkin lymphoma in the blood of patients with Q fever.	ETS1
29512921	10.1111/jcmm.13525	2018	ETS1 and SP1 drive DHX15 expression in acute lymphoblastic leukaemia.	ETS1
28264017	10.1371/journal.pone.0173298	2017	NCOA1 is a novel susceptibility gene for multiple myeloma in the Chinese population: A case-control study.	ETS1
28270453	10.1182/blood-2016-09-742148	2017	Activation of the <i>LMO2</i> oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.	ETS1
25363344	10.3109/10428194.2014.981670	2015	The transcription factor ETS1 in lymphomas: friend or foe?	ETS1
25791160	10.5301/jbm.5000134	2015	Identification of biomarkers for the prognosis of pancreatic ductal adenocarcinoma with miRNA microarray data.	ETS1
25795716	10.3324/haematol.2015.124305	2015	Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern.	ETS1
24398325	10.1182/blood-2013-06-507996	2014	A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.	ETS1
24491024	10.3109/10428194.2014.889824	2014	Long-term effect of curcumin down-regulates expression of tumor necrosis factor-Œ± and interleukin-6 via modulation of E26 transformation-specific protein and nuclear factor-Œ∫B transcription factors in livers of lymphoma bearing mice.	ETS1
25145835	10.1111/bjh.13079	2014	The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.	ETS1
25210949	10.1111/jcmm.12399	2014	HMGB1 mediates hyperglycaemia-induced cardiomyocyte apoptosis via ERK/Ets-1 signalling pathway.	ETS1
25229333	10.18632/oncotarget.2399	2014	Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia.	ETS1
25279986	10.1016/j.ajhg.2014.09.004	2014	Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region.	ETS1
22890838	10.1002/ijc.27774	2013	High-resolution genomic profiling reveals clonal evolution and competition in gastrointestinal marginal zone B-cell lymphoma and its large cell variant.	ETS1
23246696	10.1016/j.gene.2012.12.009	2013	Regulation of the MIR155 host gene in physiological and pathological processes.	ETS1
23522449	10.1016/j.leukres.2013.02.019	2013	MicroRNA profiling reveals aberrant microRNA expression in adult ETP-ALL and functional studies implicate a role for miR-222 in acute leukemia.	ETS1
23926301	10.1182/blood-2013-01-475772	2013	Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma.	ETS1
22150124	10.1111/j.1365-2141.2011.08962.x	2012	Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes.	ETS1
22211287	10.1111/j.1365-2559.2011.04086.x	2012	Intramucosal variant of nasal natural killer (NK)/T cell lymphoma has a better survival than does invasive variant: implication on loss of E26 transformation-specific sequence 1 (ETS-1) and T-box expressed in T cells (T-bet) with invasion.	ETS1
22516263	10.1016/j.ccr.2012.02.013	2012	TLX homeodomain oncogenes mediate T cell maturation arrest in T-ALL via interaction with ETS1 and suppression of TCRŒ± gene expression.	ETS1
22581005	10.3324/haematol.2012.061770	2012	ETS1 encoding a transcription factor involved in B-cell differentiation is recurrently deleted and down-regulated in classical Hodgkin's lymphoma.	ETS1
22920872	10.1051/medsci/2012288012	2012	[Deciphering functional activity of TLX homeodomain oncogenes in T-ALL: a clue for a differentiating therapy?].	ETS1
21329961	10.1016/j.humpath.2009.11.022	2011	Transcription factors engaged in development of NK cells are commonly expressed in nasal NK/T-cell lymphomas.	ETS1
20511667	10.3324/haematol.2009.021428	2010	Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.	ETS1
17397260	10.1371/journal.ppat.0030044	2007	Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus.	ETS1
15889157	10.1038/sj.leu.2403787	2005	Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma.	ETS1
14557674	10.1159/000072964	2004	Regulation of the human leukemia inhibitory factor gene by ETS transcription factors.	ETS1
15369140	10.1111/j.1749-0774.2004.tb00079.x	2004	Transcription factor expression in cell lines derived from natural killer-cell and natural killer-like T-cell leukemia-lymphoma.	ETS1
8891896	10.1002/(sici)1097-4644(19960915)62:4&lt;506::aid-jcb8&gt;3.0.co;2-q	1996	Heat shock inhibits pre-rRNA processing at the primary site in vitro and alters the activity of some rRNA binding proteins.	ETS1
8139017	10.1128/JVI.68.4.2320-2330.1994	1994	Effects of provirus integration in the Tpl-1/Ets-1 locus in Moloney murine leukemia virus-induced rat T-cell lymphomas: levels of expression, polyadenylation, transcriptional initiation, and differential splicing of the Ets-1 mRNA.	ETS1
8280137	10.1006/bbrc.1993.2608	1993	Sequence specific binding of the transcription factor c-Ets1 to the human immunodeficiency virus type I long terminal repeat.	ETS1
8330281	10.1016/0165-4608(93)90071-s	1993	DNA fragments of altered electrophoretic mobility in leukemia samples can arise from double-strand DNA breaks at nuclease hypersensitive sites of active genes.	ETS1
8350410	10.1128/JVI.67.9.5522-5528.1993	1993	Activation of the human T-cell leukemia virus type I enhancer is mediated by binding sites for Elf-1 and the pets factor.	ETS1
8361234	NA	1993	Regulation of human T cell receptor beta gene expression by Ets-1.	ETS1
1742746	NA	1991	Rearrangements on chromosome 11q23 in hematopoietic tumor-associated t(11;14) and t(11;19) translocations.	ETS1
1829960	10.1002/gcc.2870030108	1991	CD3G is within 200 kb of the leukemic t(4;11) translocation breakpoint.	ETS1
2013228	10.1159/000133062	1991	Relationship of the human protooncogene CBL2 on 11q23 to the t(4;11), t(11;22), and t(11;14) breakpoints.	ETS1
2251277	10.1073/pnas.87.23.9358	1990	Mapping chromosome band 11q23 in human acute leukemia with biotinylated probes: identification of 11q23 translocation breakpoints with a yeast artificial chromosome.	ETS1
2528035	10.1016/0145-2126(89)90164-1	1989	Deletion of c-ets1 and T3 gamma loci from the 11q- chromosome in the human monoblastic cell line U937.	ETS1
2461869	10.1007/BF01939909	1988	Restriction fragment length polymorphisms in the ETS-1 proto-oncogene. Comparison of Saudi and Western populations.	ETS1
36045062	10.3343/alm.2023.43.1.92	2023	First Case of <i>ETV6-RUNX1</i> Fusion in Adult <i>De Novo</i> Acute Myeloid Leukemia Detected Using Targeted RNA Sequencing.	ETV6
34448823	10.1182/bloodadvances.2021004212	2022	The molecular hallmarks of primary and secondary vitreoretinal lymphoma.	ETV6
34535762	10.1038/s41375-021-01409-9	2022	ETV6-RUNX1 and RUNX1 directly regulate RAG1 expression: one more step in the understanding of childhood B-cell¬†acute lymphoblastic leukemia leukemogenesis.	ETV6
34591292	10.1007/s12185-021-03229-0	2022	Successful treatment of hepatosplenic T-cell lymphoma with fludarabine, high-dose cytarabine and subsequent unrelated umbilical cord blood transplantation.	ETV6
34597466	10.1002/pbc.29361	2022	Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse.	ETV6
34617433	10.4274/tjh.galenos.2021.2021.0326	2022	Characterization of Immunophenotypic Aberrancies with Respect to Common Fusion Transcripts in B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 986 Indian Patients	ETV6
34624096	10.1182/blood.2020010405	2022	ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells.	ETV6
34657128	10.1038/s41375-021-01448-2	2022	Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.	ETV6
34727170	10.1182/bloodadvances.2021005522	2022	Decreased IL-10 accelerates B-cell leukemia/lymphoma in a mouse model of pediatric lymphoid leukemia.	ETV6
34787376	10.1002/cnr2.1587	2022	Philadelphia-like acute lymphoblastic leukemia: Characterization in a pediatric cohort in a referral center in Colombia.	ETV6
34788984	10.3324/haematol.2021.279177	2022	Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.	ETV6
34819303	10.1101/mcs.a006157	2022	Hi-C detects genomic structural variants in peripheral blood of pediatric leukemia patients.	ETV6
34871373	10.1182/blood.2021012727	2022	Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR¬†T-cell therapy.	ETV6
34933343	10.1182/bloodadvances.2021005634	2022	Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001.	ETV6
34981432	10.1007/s12185-021-03269-6	2022	Newly diagnosed ETV6-RUNX1-positive B-acute lymphoblastic leukemia localized to the left pelvic bone marrow.	ETV6
34982829	10.1182/bloodadvances.2021005703	2022	A somatic UBA2 variant preceded ETV6-RUNX1 in the concordant BCP-ALL of monozygotic twins.	ETV6
34999180	10.1016/j.gene.2021.146132	2022	Identification of diagnosis and prognosis gene markers in B-ALL with ETV6-RUNX1 fusion by integrated bioinformatics analysis.	ETV6
35053500	10.3390/cancers14020338	2022	High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients.	ETV6
35074994	10.4103/IJPM.IJPM_1154_20	2022	Erythrophagocytosis in a patient with B-cell acute lymphoblastic leukemia with t(12;21) (p13.2; q22.1); ETV6-RUNX1: Case report and review of the literature.	ETV6
35084434	10.1001/jamaoncol.2021.6826	2022	Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia.	ETV6
35106936	10.1002/cam4.4550	2022	SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.	ETV6
35258855	10.1007/s12185-022-03315-x	2022	JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia.	ETV6
35294722	10.1007/s11864-022-00963-3	2022	In Utero Development and Immunosurveillance of B Cell Acute Lymphoblastic Leukemia.	ETV6
35300216	10.2147/JIR.S341355	2022	The Mutation of <i>BTG2</i> Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma.	ETV6
35506873	10.1080/10428194.2022.2064991	2022	Apparent coexistence of <i>ETV6::RUNX1</i> and <i>KMT2A::MLLT3</i> fusions due to a nonproductive <i>KMT2A</i> rearrangement in B-ALL.	ETV6
35543076	10.1111/his.14680	2022	Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy.	ETV6
35562965	10.3390/ijms23094574	2022	Multi-Cohort Transcriptomic Subtyping of B-Cell Acute Lymphoblastic Leukemia.	ETV6
35644195	10.7499/j.issn.1008-8830.2111108	2022	[Clinical features and prognosis of childhood B-lineage acute lymphoblastic leukemia expressing the <i>PRAME</i> gene].	ETV6
35646048	10.3389/fgene.2022.878618	2022	Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	ETV6
35720485	10.3892/ol.2022.13348	2022	A unique case of inflammatory myofibroblastic tumor of the liver manifesting with biloma: A case report.	ETV6
35803545	10.1016/j.exphem.2022.06.002	2022	Germline ETV6 mutation promotes inflammation and disrupts lymphoid development of early hematopoietic progenitors.	ETV6
35865523	10.3389/fimmu.2022.868053	2022	Savior Siblings Might Rescue Fetal Lethality But Not Adult Lymphoma in Irf2bp2-Null Mice.	ETV6
35928872	10.3389/fonc.2022.932674	2022	Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma.	ETV6
35995457	10.1080/10428194.2022.2113524	2022	Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients.	ETV6
36011285	10.3390/genes13081374	2022	Commonly Assessed Markers in Childhood BCP-ALL Diagnostic Panels and Their Association with Genetic Aberrations and Outcome Prediction.	ETV6
31894899	10.1002/cyto.b.21865	2021	CD49f protein expression varies among genetic subgroups of B lymphoblastic leukemia and is distinctly low in KMT2A-rearranged cases.	ETV6
32467145	10.3324/haematol.2020.247973	2021	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.	ETV6
32693409	10.1182/blood.2020006164	2021	Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia.	ETV6
32819174	10.1080/09537104.2020.1802416	2021	Functional analysis of germline <i>ETV6 W380R</i> mutation causing inherited thrombocytopenia and secondary acute lymphoblastic leukemia or essential thrombocythemia.	ETV6
32898863	10.1182/blood.2020005622	2021	Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia.	ETV6
33070555	10.4143/crt.2020.507	2021	Differing Outcomes of Patients with High Hyperdiploidy and ETV6-RUNX1 Rearrangement in Korean Pediatric Precursor B Cell Acute Lymphoblastic Leukemia.	ETV6
33078873	10.1002/gcc.22901	2021	Rare and novel RUNX1 fusions in myeloid neoplasms: A single-institute experience.	ETV6
33170547	10.1111/ijlh.13386	2021	The gene expression level of m6A catalytic enzymes is increased in ETV6/RUNX1-positive acute lymphoblastic leukemia.	ETV6
33328584	10.1038/s41568-020-00315-z	2021	Advances in germline predisposition to acute leukaemias and myeloid neoplasms.	ETV6
33368842	10.1002/gcc.22933	2021	Sister chromatid cohesion defects are associated with chromosomal copy number heterogeneity in high hyperdiploid childhood acute lymphoblastic leukemia.	ETV6
33386596	10.1007/s12185-020-03063-w	2021	The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia.	ETV6
33400146	10.1007/s11684-020-0821-6	2021	Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.	ETV6
33475741	10.1182/blood.2020008190	2021	Germline ETV6 variants: not ALL created equally.	ETV6
33526873	10.1038/s41379-021-00739-4	2021	Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group.	ETV6
33634864	10.1002/ijc.33527	2021	Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis.	ETV6
33646306	10.1182/bloodadvances.2020001844	2021	Genome-wide interference of ZNF423 with B-lineage transcriptional circuitries in acute lymphoblastic leukemia.	ETV6
33660258	10.1111/bjh.17271	2021	Management of ETV6-ABL1-positive childhood acute lymphoblastic leukaemia: report of two cases, a literature review and a call for action.	ETV6
33707599	10.1038/s41598-021-85213-6	2021	Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia with kinase fusions in Taiwan.	ETV6
33714976	10.1038/s41375-021-01209-1	2021	Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks.	ETV6
33725318	10.1007/s12185-021-03116-8	2021	Clinical features and chromosomal/genetic aberration in adult acute lymphoblastic leukemia in Japan: results of Fukuoka Blood & Marrow Transplant Group Studies ALL MRD 2002 and 2008.	ETV6
33739852	10.1200/JCO.20.02370	2021	Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331.	ETV6
33743795	10.1186/s13045-021-01051-z	2021	Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia.	ETV6
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	ETV6
33750258	10.1080/0284186X.2021.1900908	2021	Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on <i>BCR-ABL1</i>-like subtype.	ETV6
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	ETV6
33792628	10.1182/bloodadvances.2020003699	2021	ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML.	ETV6
33890726	10.1002/cjp2.211	2021	CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways.	ETV6
33895809	10.1182/blood.2020010144	2021	Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.	ETV6
33987955	10.1002/cam4.3928	2021	RAG1 co-expression signature identifies ETV6-RUNX1-like B-cell precursor acute lymphoblastic leukemia in children.	ETV6
33990705	10.1038/s41379-021-00817-7	2021	Myeloid/lymphoid neoplasms with FLT3 rearrangement.	ETV6
34010407	10.1182/blood.2020009895	2021	Toward prevention of childhood ALL by early-life immune training.	ETV6
34072771	10.3390/ijms22115902	2021	NKL Homeobox Gene VENTX Is Part of a Regulatory Network in Human Conventional Dendritic Cells.	ETV6
34101758	10.1371/journal.pone.0253012	2021	Investigation of lncRNA-mRNA co-expression network in ETV6-RUNX1-positive pediatric B-cell acute lymphoblastic leukemia.	ETV6
34159401	10.1007/s00277-021-04574-0	2021	Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.	ETV6
34250504	10.1158/2643-3230.BCD-20-0229	2021	Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.	ETV6
34266412	10.1186/s12885-021-08545-6	2021	DNA index as prognostic factor in childhood acute lymphoblastic leukemia in the COG-TARGET database.	ETV6
34297047	10.1182/bloodadvances.2021004334	2021	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma.	ETV6
34325057	10.1016/j.jmoldx.2021.07.008	2021	Comparison of Two Quantitative PCR-Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts.	ETV6
34329606	10.1016/S1470-2045(21)00328-4	2021	Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.	ETV6
34348305	10.1159/000518280	2021	Cytogenetic and Fluorescence in situ Hybridization Profile of Pediatric Acute Lymphoblastic Leukemia in a University Hospital in South India.	ETV6
34371436	10.1016/j.leukres.2021.106683	2021	Proposal and clinical application of molecular genetic risk scoring system, MRplus, for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.	ETV6
34511174	10.7499/j.issn.1008-8830.2105004	2021	Clinical features and prognosis of children with acute leukemias of ambiguous lineage under different diagnostic criteria.	ETV6
34547766	10.1182/bloodadvances.2021004895	2021	Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia.	ETV6
34551905	10.1158/1078-0432.CCR-21-1165	2021	Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib.	ETV6
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	ETV6
34732618	10.11406/rinketsu.62.1465	2021	[Down syndrome and acute lymphoblastic leukemia].	ETV6
34753926	10.1038/s41408-021-00570-9	2021	Cancer drivers and clonal dynamics in acute lymphoblastic leukaemia subtypes.	ETV6
34940123	10.3390/cimb43030149	2021	Molecular Genetics of Pre-B Acute Lymphoblastic Leukemia Sister Cell Lines during Disease Progression.	ETV6
35004601	10.3389/fpubh.2021.805757	2021	Risk Factors for Childhood Leukemia: Radiation and Beyond.	ETV6
31482743	10.1080/10428194.2019.1658105	2020	Myeloid neoplasm with eosinophilia and <i>ETV6-JAK2</i> fusion.	ETV6
31602594	10.1007/s13353-019-00524-9	2020	The correction of ETV6/RUNX1 translocation in acute lymphocytic leukemia cells: a new gene targeting system by homologous recombination mechanism.	ETV6
31645680	10.1038/s41417-019-0147-1	2020	The incidence, genetic characteristics, and prognosis of leukemia with concurrent pathogenic fusion genes: a series of 25 cases from a large cohort of leukemia patients.	ETV6
31704777	10.1136/jmedgenet-2019-106339	2020	Novel phenotypes observed in patients with <i>ETV6</i>-linked leukaemia/familial thrombocytopenia syndrome and a biallelic <i>ARID5B</i> risk allele as leukaemogenic cofactor.	ETV6
31902036	10.1007/s10555-019-09841-1	2020	Insights into the prenatal origin of childhood acute lymphoblastic leukemia.	ETV6
31905241	10.1182/bloodadvances.2019000769	2020	Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement.	ETV6
31944572	10.1002/cyto.b.21866	2020	CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.	ETV6
31952221	10.3390/cells9010215	2020	<i>ETV6</i>/<i>RUNX1</i> Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia.	ETV6
32029838	10.1038/s41598-020-58970-z	2020	Clinicopathological features and prognostic value of SOX11 in childhood acute lymphoblastic leukemia.	ETV6
32078009	10.1007/s00277-020-03953-3	2020	Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.	ETV6
32114371	10.1016/j.leukres.2020.106316	2020	Osteopontin-c is overexpressed in KMT2A-AFF1 positive pediatric B-cell lymphoblastic leukemia when compared to those with ETV6-RUNX1.	ETV6
32118299	10.1111/bjh.16523	2020	Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche.	ETV6
32135505	10.1016/j.canep.2020.101693	2020	MTHFR rs1801133 polymorphism is associated with increased risk of B-cell precursor lymphoblastic leukaemia with recurrent genetic aberrations of fetal origin.	ETV6
32150610	10.1182/bloodadvances.2019001008	2020	The application of RNA sequencing for the diagnosis and genomic classification of pediatric acute lymphoblastic leukemia.	ETV6
32201861	10.1093/noajnl/vdaa018	2020	Primary CNS lymphoma commonly expresses immune response biomarkers.	ETV6
32205481	10.1097/PAS.0000000000001471	2020	Salivary Secretory Carcinoma Harboring a Novel ALK Fusion: Expanding the Molecular Characterization of Carcinomas Beyond the ETV6 Gene.	ETV6
32238402	10.1101/mcs.a004937	2020	The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and <i>ZBTB20-JAK2</i> gene fusion presenting as B-lymphoblastic leukemia.	ETV6
32367453	10.1007/s12185-020-02885-y	2020	Functional characterization of a germline ETV6 variant associated with inherited thrombocytopenia, acute lymphoblastic leukemia, and salivary gland carcinoma in childhood.	ETV6
32368831	10.1002/gcc.22858	2020	Impact of immunophenotypic characteristics on genetic subgrouping in childhood acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) study L04-16.	ETV6
32378810	10.1002/cam4.3099	2020	High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.	ETV6
32536138	10.3760/cma.j.issn.0253-2727.2020.05.008	2020	[Clinical characteristics and gene expression profiles in children with ETV6-RUNX1 acute lymphoblastic leukemia].	ETV6
32572036	10.1038/s41598-020-65744-0	2020	Evidence for a role of RUNX1 as recombinase cofactor for TCRŒ≤ rearrangements and pathological deletions in ETV6-RUNX1 ALL.	ETV6
32573712	10.1182/blood.2019004090	2020	Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL.	ETV6
32592278	10.1002/gcc.22882	2020	Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.	ETV6
32661308	10.1038/s41598-020-68311-9	2020	MLPA and DNA index improve the molecular diagnosis of childhood B-cell acute lymphoblastic leukemia.	ETV6
32812094	10.1007/s10561-020-09855-y	2020	Screening for pre-leukemia TEL-AML1 chromosomal translocation in banked cord blood units: cord blood bank perspective.	ETV6
32836179	10.1016/j.anndiagpath.2020.151588	2020	Siblings with ETV6/RUNX1-positive B-lymphoblastic leukemia: A single site experience and review of the literature.	ETV6
32911536	10.1182/blood.2019004381	2020	An intact gut microbiome protects genetically predisposed mice against leukemia.	ETV6
32946981	10.1016/j.exphem.2020.09.184	2020	Human pediatric B-cell acute lymphoblastic leukemias can be classified as B-1 or B-2-like based on a minimal transcriptional signature.	ETV6
33038982	10.1016/j.beha.2020.101193	2020	Molecular markers in ALL: Clinical implications.	ETV6
33074527	10.1007/s11684-020-0759-8	2020	Precision medicine in acute lymphoblastic leukemia.	ETV6
33095873	10.1182/bloodadvances.2019001307	2020	Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia.	ETV6
33113607	10.3760/cma.j.issn.0253-2727.2020.09.008	2020	[Diagnosis of adult Philadelphia chromosome-like acute lymphoblastic leukemia by fluorescence in situ hybridization].	ETV6
33127954	10.1038/s41598-020-75596-3	2020	Nanostring-based screening for tyrosine kinase fusions in inflammatory myofibroblastic tumors.	ETV6
33164984	10.1172/JCI140797	2020	Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo.	ETV6
33166908	10.1016/j.leukres.2020.106460	2020	Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.	ETV6
33245684	10.2217/epi-2020-0152	2020	Role of rs10406069 in miR-5196 in hyperdiploid childhood acute lymphoblastic leukemia.	ETV6
33327998	NA	2020	[Clinical significance of minimal residual disease in B-lineage acute lymphoblastic leukemia pediatric patients with different fusion gene backgrounds].	ETV6
33333691	10.3760/cma.j.issn.0253-2727.2020.11.003	2020	[Efficacy and prognostic factors of the chemotherapy regimen of CCLG-ALL-2008 on pediatric acute lymphoblastic leukemia with ETV6-RUNX1 rearrangement].	ETV6
33355873	10.32471/exp-oncology.2312-8852.vol-42-no-4.15275	2020	Woman with Turner syndrome and her child with acute leukemia (a case report).	ETV6
33369444	10.31557/APJCP.2020.21.12.3493	2020	Frequency and Correlation of Common Genes Copy Number Alterations in Childhood Acute Lymphoblastic Leukemia with Prognosis.	ETV6
29530508	10.1016/j.jim.2018.03.005	2019	Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia.	ETV6
29992858	10.1080/10428194.2018.1480774	2019	Cryptic ETV6-PDGFRB fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome/myeloproliferative neoplasm.	ETV6
30028819	10.1097/MPH.0000000000001249	2019	Cryptic ETV6-ABL1 Fusion and MLL2 Truncation Revealed by Integrative Clinical Sequencing in Multiply Relapsed Acute Lymphoblastic Leukemia.	ETV6
30381299	10.3324/haematol.2018.193631	2019	Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia.	ETV6
30510082	10.1182/blood-2018-07-862946	2019	Novel susceptibility variants at the <i>ERG</i> locus for childhood acute lymphoblastic leukemia in Hispanics.	ETV6
30526151	10.1080/10428194.2018.1529311	2019	Coexpression of ETV6/MDS1/EVI1 and ETV6/EVI1 fusion transcripts in acute myeloid leukemia with t(3;12)(q26.2;p13) and thrombocytosis.	ETV6
30550870	10.1016/j.jtho.2018.12.003	2019	Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.	ETV6
30561492	10.1093/ajcp/aqy160	2019	Application of Fluorescence In Situ Hybridization on Cerebrospinal Fluid Cytospins for the Detection of Residual Leukemic Cells in Patients With Childhood Acute Lymphoblastic Leukemia.	ETV6
30630978	10.3324/haematol.2018.204974	2019	Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort.	ETV6
30634950	10.1186/s12885-019-5277-1	2019	Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review.	ETV6
30689137	10.1007/s12185-019-02599-w	2019	Discontinuation of L-asparaginase and poor response to prednisolone are associated with poor outcome of ETV6-RUNX1-positive pediatric B-cell precursor acute lymphoblastic leukemia.	ETV6
30701458	10.1007/s11033-019-04649-2	2019	Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.	ETV6
30730614	10.1111/ijlh.12983	2019	Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia.	ETV6
30770347	10.1158/1055-9965.EPI-18-0801	2019	Is There Etiologic Heterogeneity between Subtypes of Childhood Acute Lymphoblastic Leukemia? A Review of Variation in Risk by Subtype.	ETV6
30842058	10.1016/S1470-2045(19)30031-2	2019	Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.	ETV6
30874617	10.1038/s41598-019-41078-4	2019	Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.	ETV6
30940639	10.1182/bloodadvances.2018030635	2019	Germline deletion of <i>ETV6</i> in familial acute lymphoblastic leukemia.	ETV6
30944321	10.1038/s41467-019-09469-3	2019	Proteogenomics and Hi-C reveal transcriptional dysregulation in high hyperdiploid childhood acute lymphoblastic leukemia.	ETV6
30986496	10.1016/j.exphem.2019.03.004	2019	ETV6-RUNX1 interacts with a region in SPIB intron 1 to regulate gene expression in pre-B-cell acute lymphoblastic leukemia.	ETV6
31034759	10.1002/pbc.27780	2019	High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia.	ETV6
31035338	10.3390/ijms20092089	2019	Marek's Disease Virus Regulates the Ubiquitylome of Chicken CD4<sup>+</sup> T Cells to Promote Tumorigenesis.	ETV6
31096545	10.3390/ijms20102394	2019	Identification and Characterization of Novel Fusion Genes with Potential Clinical Applications in Mexican Children with Acute Lymphoblastic Leukemia.	ETV6
31102422	10.1002/gcc.22765	2019	Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children.	ETV6
31112375	10.1111/ijlh.13052	2019	Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay.	ETV6
31157932	10.1002/bem.22193	2019	Novel ETV6-RUNX1 Mouse Model to Study the Role of ELF-MF in Childhood B-Acute Lymphoblastic Leukemia: a Pilot Study.	ETV6
31202078	10.1016/j.leukres.2019.05.013	2019	Microarray testing as an efficient tool to redefine hyperdiploid paediatric B-cell precursor acute lymphoblastic leukaemia patients.	ETV6
31228652	10.1016/j.leukres.2019.05.009	2019	Prognostic gene alterations and clonal changes in childhood B-ALL.	ETV6
31243155	10.1126/scitranslmed.aat8549	2019	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8<sup>+</sup> T cell responses.	ETV6
31250485	10.1002/pbc.27902	2019	A newborn case of jejunal ALK-negative inflammatory myofibroblastic tumor with ETV6-NTRK3 fusion.	ETV6
31289210	10.3324/haematol.2018.205849	2019	<i>TP53, ETV6</i> and <i>RUNX1</i> germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia.	ETV6
31311817	10.1182/blood.2018852400	2019	Genetic defects in hematopoietic transcription factors and predisposition to acute lymphoblastic leukemia.	ETV6
31381561	10.1371/journal.pgen.1008280	2019	PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia.	ETV6
31429529	10.1002/mgg3.933	2019	The study of METTL3 and METTL14 expressions in childhood ETV6/RUNX1-positive acute lymphoblastic leukemia.	ETV6
31456164	10.1007/s13353-019-00509-8	2019	MLPA as a complementary tool for diagnosis of chromosome 21 aberrations in childhood BCP-ALL.	ETV6
31506148	NA	2019	[Long-term clinical effect of the CCLG-ALL2008 regimen in treatment of childhood acute lymphoblastic leukemia with different molecular biological features].	ETV6
31519648	10.1182/bloodadvances.2018028795	2019	Predisposition to childhood acute lymphoblastic leukemia caused by a constitutional translocation disrupting <i>ETV6</i>.	ETV6
31629941	10.1016/j.ejca.2019.09.004	2019	Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study.	ETV6
31648321	10.1182/bloodadvances.2019000404	2019	Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.	ETV6
31725893	10.1182/bloodadvances.2019000700	2019	Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.	ETV6
31767839	10.1038/s41467-019-13069-6	2019	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk.	ETV6
31779973	10.1016/j.beha.2019.101095	2019	How advanced are we in targeting novel subtypes of ALL?	ETV6
31817853	10.3390/ijms20246175	2019	SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric <i>ETV6-RUNX1</i> B-Acute Lymphoblastic Leukemia Patients.	ETV6
28272805	10.1111/bjh.14579	2018	Early thymic precursor-like lymphomatous presentation of the ETV6-NCOA2 translocation.	ETV6
28776427	10.1080/10428194.2017.1359742	2018	ETV6 and NOTCH1 germline variants in adult acute leukemia.	ETV6
28819864	10.1007/s00018-017-2620-z	2018	Molecular processes involved in B cell acute lymphoblastic leukaemia.	ETV6
28853218	10.1002/pbc.26786	2018	Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.	ETV6
28972594	10.1038/leu.2017.303	2018	RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.	ETV6
29034503	10.1111/ejh.12981	2018	Detection of a new heterozygous germline ETV6 mutation in a case with hyperdiploid acute lymphoblastic leukemia.	ETV6
29046324	10.1530/EJE-17-0499	2018	<i>ETV6-NTRK3</i> and <i>STRN-ALK</i> kinase fusions are recurrent events in papillary thyroid cancer of adult population.	ETV6
29064485	10.1038/leu.2017.289	2018	Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials.	ETV6
29148893	10.1200/JCO.2017.74.4946	2018	Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).	ETV6
29177615	10.1007/s12185-017-2371-5	2018	ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.	ETV6
29290585	10.1016/j.devcel.2017.12.005	2018	A Human IPS Model Implicates Embryonic B-Myeloid Fate Restriction as Developmental Susceptibility to B¬†Acute Lymphoblastic Leukemia-Associated ETV6-RUNX1.	ETV6
29311095	10.1182/blood-2017-09-808402	2018	Five percent of healthy newborns have an <i>ETV6-RUNX1</i> fusion as revealed by DNA-based GIPFEL screening.	ETV6
29327718	10.1038/modpathol.2017.191	2018	Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases.	ETV6
29348129	10.1182/blood-2017-07-796862	2018	Genomic CDKN2A/2B deletions in adult Ph<sup>+</sup> ALL are adverse despite allogeneic stem cell transplantation.	ETV6
29407587	10.1016/j.leukres.2018.01.012	2018	High frequency of intermediate and poor risk copy number abnormalities in pediatric cohort of B-ALL correlate with high MRD post induction.	ETV6
29432597	10.1093/neuonc/noy019	2018	Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma.	ETV6
29498923	10.1200/JCO.2017.74.3617	2018	IKZF1<sup>plus</sup> Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.	ETV6
29507076	10.1182/bloodadvances.2017014704	2018	Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.	ETV6
29520434	10.1007/s00277-018-3291-z	2018	A patient with B-cell acute lymphoblastic leukemia with PAX5-ETV6 rearrangement with dic(9;12)(p13;p13) identified by chromosomal microarray.	ETV6
29575541	10.1111/ijlh.12805	2018	Simultaneous detection of ABL1 mutation and IKZF1 deletion in Philadelphia chromosome-positive acute lymphoblastic leukemia using a customized target enrichment system panel.	ETV6
29589281	10.1007/s12185-018-2440-4	2018	Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16.	ETV6
29632299	10.1038/s41467-018-03178-z	2018	Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia.	ETV6
29726059	10.1002/gcc.6	2018	Two novel fusion genes, AIF1L-ETV6 and ABL1-AIF1L, result together with ETV6-ABL1 from a single chromosomal rearrangement in acute lymphoblastic leukemia with prenatal origin.	ETV6
29763473	10.1371/journal.pone.0197408	2018	Maternal folate genes and aberrant DNA hypermethylation in pediatric acute lymphoblastic leukemia.	ETV6
29778230	10.1016/j.cancergen.2018.03.001	2018	ETV6/RUNX1-positive childhood acute lymphoblastic leukemia (ALL): The spectrum of clonal heterogeneity and its impact on prognosis.	ETV6
29784935	10.1038/s41568-018-0015-6	2018	A causal mechanism for childhood acute lymphoblastic leukaemia.	ETV6
29786757	10.1007/s12185-018-2474-7	2018	Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.	ETV6
29880614	10.1182/blood-2018-05-849554	2018	ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.	ETV6
29891112	10.1016/j.critrevonc.2018.05.010	2018	Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.	ETV6
29900760	10.1177/0300060518780873	2018	Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.	ETV6
29950197	10.7534/j.issn.1009-2137.2018.03.002	2018	[HER2 Expression in Childhood ETV6/RUNX1<sup>+</sup> Acute Lymphoblastic Leukemia and Its Correlation with Clinical Features].	ETV6
29992138	10.1155/2018/3574534	2018	Identification of Hub Genes and Key Pathways Associated with Two Subtypes of Diffuse Large B-Cell Lymphoma Based on Gene Expression Profiling via Integrated Bioinformatics.	ETV6
29997224	10.1182/blood-2018-04-841676	2018	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.	ETV6
30115129	10.1186/s13052-018-0541-6	2018	ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.	ETV6
30125757	10.1016/j.leukres.2018.08.009	2018	Retrospective analysis of 36 fusion genes in 2479 Chinese patients of de novo acute lymphoblastic leukemia.	ETV6
30139830	10.1182/blood-2018-06-857540	2018	Genomic precision medicine: on the TRK.	ETV6
30168245	10.1002/pbc.27366	2018	A triple-probe FISH screening strategy for risk-stratified therapy of acute lymphoblastic leukaemia in low-resource settings.	ETV6
30203896	10.1002/gcc.22664	2018	Improved cytogenetic characterization and risk stratification of pediatric acute lymphoblastic leukemia using single nucleotide polymorphism array analysis: A single center experience of 296 cases.	ETV6
30341373	10.1038/s41598-018-33947-1	2018	Genome wide mapping of ETV6 binding sites in pre-B leukemic cells.	ETV6
30422774	10.1148/rg.2018180192	2018	Primary Lung Tumors in Children: Radiologic-Pathologic Correlation From the Radiologic Pathology Archives.	ETV6
30487223	10.1073/pnas.1814397115	2018	Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.	ETV6
30559310	10.1101/mcs.a003079	2018	Two myeloid leukemia cases with rare <i>FLT3</i> fusions.	ETV6
30701920	10.26442/terarkh201890730-37	2018	Structure and significance of cytogenetic abnormalities in adult patients with Ph-negative acute lymphoblastic leukemia.	ETV6
27339065	10.1080/10428194.2016.1193855	2017	Gene copy number alteration profile and its clinical correlation in B-cell acute lymphoblastic leukemia.	ETV6
27506214	10.4143/crt.2016.211	2017	Outcome and Prognostic Factors for <i>ETV6/RUNX1</i> Positive Pediatric Acute Lymphoblastic Leukemia Treated at a Single Institution in Korea.	ETV6
27560110	10.1038/leu.2016.234	2017	Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.	ETV6
27683100	10.1002/cncr.30257	2017	The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results.	ETV6
27698447	10.1038/leu.2016.274	2017	Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children.	ETV6
28004528	10.1111/ijlh.12593	2017	Minimal residual disease monitoring in childhood B lymphoblastic leukemia with t(12;21)(p13;q22); ETV6-RUNX1: concordant results using quantitation of fusion transcript and flow cytometry.	ETV6
28063378	10.1016/j.leukres.2016.12.005	2017	Overexpression of PTP4A3 in ETV6-RUNX1 acute lymphoblastic leukemia.	ETV6
28063722	10.1016/j.jfma.2016.12.002	2017	Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.	ETV6
28202519	10.1158/0008-5472.CAN-16-2571	2017	Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia.	ETV6
28219927	10.15252/embj.201695495	2017	Molecular role of the PAX5-ETV6 oncoprotein in promoting B-cell acute lymphoblastic leukemia.	ETV6
28256570	10.1038/modpathol.2017.12	2017	Recurrent BCOR internal tandem duplication and BCOR or BCL6 expression distinguish primitive myxoid mesenchymal tumor of infancy from congenital infantile fibrosarcoma.	ETV6
28299660	10.1007/978-981-10-3233-2_14	2017	ETV6-RUNX1 <sup>+</sup> Acute Lymphoblastic Leukaemia in Identical Twins.	ETV6
28395118	10.1002/gcc.22464	2017	ETV6/RUNX1-like acute lymphoblastic leukemia: A novel B-cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype.	ETV6
28401483	10.1007/s12032-017-0940-3	2017	Molecular profiling of gene copy number abnormalities in key regulatory genes in high-risk B-lineage acute lymphoblastic leukemia: frequency and their association with clinicopathological findings in Indian patients.	ETV6
28408464	10.1182/blood-2016-12-758979	2017	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.	ETV6
28415763	10.18632/oncotarget.16211	2017	Low numbers of pre-leukemic fusion genes are frequently present in umbilical cord blood without affecting DNA damage response.	ETV6
28418909	10.18632/oncotarget.16367	2017	Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse.	ETV6
28487787	10.1155/2017/5083463	2017	EBV-Negative Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder with Marked Morphologic Pleomorphism and Pathogenic Mutations in <i>ASXL1</i>, <i>BCOR</i>, <i>CDKN2A</i>, <i>NF1</i>, and <i>TP53</i>.	ETV6
28500740	10.1002/pbc.26518	2017	Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers.	ETV6
28555414	10.1007/s12185-017-2259-4	2017	Germline ETV6 mutations and predisposition to hematological malignancies.	ETV6
28557976	10.1038/bjc.2017.152	2017	Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.	ETV6
28624474	10.1016/j.tiv.2017.06.013	2017	Exposure to the insecticides permethrin and malathion induces leukemia and lymphoma-associated gene aberrations in vitro.	ETV6
28630052	10.1158/0008-5472.CAN-17-0701	2017	Infection Exposure Promotes <i>ETV6-RUNX1</i> Precursor B-cell Leukemia via Impaired H3K4 Demethylases.	ETV6
28631637	10.4103/IJPM.IJPM_466_16	2017	An integrated genomic profile that includes copy number alterations is highly predictive of minimal residual disease status in childhood precursor B-lineage acute lymphoblastic leukemia.	ETV6
28709134	10.1016/j.ejca.2017.06.012	2017	BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.	ETV6
28724437	10.1186/s12943-017-0692-x	2017	The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia.	ETV6
28778863	10.1182/blood-2017-05-742643	2017	New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia.	ETV6
28806978	10.1186/s13045-017-0515-y	2017	Transcriptome sequencing in pediatric acute lymphoblastic leukemia identifies fusion genes associated with distinct DNA methylation profiles.	ETV6
28810325	10.3760/cma.j.issn.0253-2727.2017.07.006	2017	[Heterogeneity and clonal evolution in pediatric ETV6-RUNX1(+) acute lymphoblastic leukemia by quantitative multigene fluorescence in situ hybridization].	ETV6
28886309	10.14715/cmb/2017.63.8.4	2017	The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.	ETV6
28954346	10.3760/cma.j.issn.0253-2727.2017.08.006	2017	[Clinical significance of monitoring ETV6-RUNX1 fusion gene expression in children with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].	ETV6
29125853	10.1371/journal.pone.0187422	2017	Whole-genome DNA methylation characteristics in pediatric precursor B cell acute lymphoblastic leukemia (BCP ALL).	ETV6
26327566	10.3109/10428194.2015.1088650	2016	Genetic alterations in glucocorticoid signaling pathway components are associated with adverse prognosis in children with relapsed ETV6/RUNX1-positive acute lymphoblastic leukemia.	ETV6
26573422	10.1038/nrclinonc.2015.211	2016	Haematological cancer: ETV6 germline mutation - a risk for ALL.	ETV6
26647767	10.1111/his.12910	2016	ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.	ETV6
26693794	10.3109/10428194.2015.1115041	2016	Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.	ETV6
26711002	10.1002/cam4.579	2016	Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing.	ETV6
26781410	NA	2016	[Detection of copy number variations in pediatric ETV6/RUNX1-positive acute lymphoblastic leukemia with multiplex ligation-dependent probe amplification].	ETV6
26785729	10.1074/mcp.M115.054593	2016	High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells.	ETV6
26852652	10.1016/j.bcmd.2015.11.006	2016	ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia.	ETV6
26883104	10.18632/oncotarget.7356	2016	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.	ETV6
26919255	10.18632/oncotarget.7687	2016	Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice.	ETV6
26957068	10.3760/cma.j.issn.0578-1310.2016.03.011	2016	[Copy number variations in pediatric ETV6/RUNX1 positive acute lymphoblastic leukemia].	ETV6
27033238	10.3324/haematol.2015.141101	2016	New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia.	ETV6
27058227	10.1038/bcj.2016.11	2016	Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusion.	ETV6
27151989	10.3324/haematol.2016.143875	2016	Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia.	ETV6
27161658	10.1016/j.jmoldx.2016.03.004	2016	Genome-Wide Single-Nucleotide Polymorphism Array Analysis Improves Prognostication of Acute Lymphoblastic Leukemia/Lymphoma.	ETV6
27181063	10.1016/j.exphem.2016.04.011	2016	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia.	ETV6
27215399	10.1016/j.yexmp.2016.05.010	2016	Oligo-based aCGH analysis reveals cryptic unbalanced der(6)t(X;6) in pediatric t(12;21)-positive acute lymphoblastic leukemia.	ETV6
27239736	10.1016/j.leukres.2016.05.009	2016	Defining the significance of IGF2BP1 overexpression in t(12;21)(p13;q22)-positive leukemia REH cells.	ETV6
27259007	10.1097/PAS.0000000000000677	2016	ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors.	ETV6
27265895	10.1038/ncomms11790	2016	Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia.	ETV6
27341996	10.1016/j.cancergen.2016.06.004	2016	Chromosomal aberrations in childhood acute lymphoblastic leukemia: 15-year single center experience.	ETV6
27365488	10.3324/haematol.2016.147496	2016	Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia.	ETV6
27374714	10.3343/alm.2016.36.5.475	2016	Frequency and Clinical Characteristics of Intrachromosomal Amplification of Chromosome 21 in Korean Childhood B-lineage Acute Lymphoblastic Leukemia.	ETV6
27393278	10.1007/s12185-016-2034-y	2016	Prognostic impact of RUNX1 and ETV6 gene copy number on pediatric B-cell precursor acute lymphoblastic leukemia with or without hyperdiploidy.	ETV6
27431763	10.7554/eLife.13087	2016	Transcription-coupled genetic instability marks acute lymphoblastic leukemia structural variation hotspots.	ETV6
27498737	10.11406/rinketsu.57.900	2016	Familial acute lymphoblastic leukemia.	ETV6
27536776	10.1371/journal.pone.0161539	2016	Gene Signature of High White Blood Cell Count in B-Precursor Acute Lymphoblastic Leukemia.	ETV6
27540136	10.3324/haematol.2016.149740	2016	CLIC5: a novel ETV6 target gene in childhood acute lymphoblastic leukemia.	ETV6
27590521	10.18632/oncotarget.11773	2016	Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.	ETV6
27611867	10.1371/journal.pone.0162638	2016	The Expression Pattern of the Pre-B Cell Receptor Components Correlates with Cellular Stage and Clinical Outcome in Acute Lymphoblastic Leukemia.	ETV6
27620872	10.1101/gr.193649.115	2016	Genome-wide repression of eRNA and target gene loci by the ETV6-RUNX1 fusion in acute leukemia.	ETV6
27632978	10.1186/s13000-016-0541-z	2016	Multiplexed automated digital quantification of fusion transcripts: comparative study with fluorescent in-situ hybridization (FISH) technique in acute leukemia patients.	ETV6
27650541	10.18632/oncotarget.12063	2016	Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia.	ETV6
27664585	10.1016/j.gene.2016.09.030	2016	Characterization of a novel acquired der(1)del(1)(p13p31)t(1;15)(q42;q15) in a high risk t(12;21)-positive acute lymphoblastic leukemia.	ETV6
27775641	10.3390/ijms17101759	2016	Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma.	ETV6
27802191	10.3233/CBM-160656	2016	Molecular combing: A new tool in diagnosing leukemia.	ETV6
27900092	10.3892/mco.2016.1008	2016	Primary orbital precursor T-cell lymphoblastic lymphoma: Report of a unique case.	ETV6
28476192	10.1016/j.arcmed.2016.12.005	2016	Gene Expression Profiling of Acute Lymphoblastic Leukemia in Children with¬†Very Early Relapse.	ETV6
28476198	10.1016/j.arcmed.2016.12.002	2016	Copy Number Alterations Associated with Acute Lymphoblastic Leukemia in Mexican Children. A report from The Mexican Inter-Institutional Group for the identification of the causes of childhood leukemia.	ETV6
24897505	10.1038/leu.2014.177	2015	Evolutionary trajectories of hyperdiploid ALL in monozygotic twins.	ETV6
24975316	10.3109/10428194.2014.938330	2015	Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene.	ETV6
25150625	10.1016/j.bcmd.2014.07.011	2015	Concordant B-cell precursor acute lymphoblastic leukemia in non-twinned siblings.	ETV6
25261097	10.3324/haematol.2014.112912	2015	Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia.	ETV6
25312094	10.1111/bjh.13142	2015	Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.	ETV6
25355294	10.1002/humu.22719	2015	The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing.	ETV6
25373509	10.3109/10428194.2014.982643	2015	ETV6/ARG oncoprotein confers autonomous cell growth by enhancing c-Myc expression via signal transducer and activator of transcription 5 activation in the acute promyelocytic leukemia cell line HT93A.	ETV6
25388957	10.1038/leu.2014.322	2015	Clonal origins of ETV6-RUNX1‚Å∫ acute lymphoblastic leukemia: studies in monozygotic twins.	ETV6
25595912	10.18632/oncotarget.2807	2015	LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients.	ETV6
25678190	10.1016/j.cancergen.2014.11.003	2015	Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study.	ETV6
25706938	10.1002/gcc.22246	2015	A population-based single nucleotide polymorphism array analysis of genomic aberrations in younger adult acute lymphoblastic leukemia patients.	ETV6
25764068	10.1371/journal.pone.0119256	2015	Neonatal infection with species C adenoviruses confirmed in viable cord blood lymphocytes.	ETV6
25807284	10.1038/ng.3253	2015	Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia.	ETV6
25893288	10.1038/onc.2015.50	2015	The TEL-AML1 fusion protein of acute lymphoblastic leukemia modulates IRF3 activity during early B-cell differentiation.	ETV6
25948177	10.7534/j.issn.1009-2137.2015.02.004	2015	[Cytogenetic characteristics of 163 children with acute lymphoblastic leukemia].	ETV6
25982135	10.1002/pbc.25583	2015	Clinical features and induction outcome of childhood acute lymphoblastic leukemia in a lower/middle income population: A multi-institutional report from Pakistan.	ETV6
26102509	10.1371/journal.pgen.1005262	2015	Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.	ETV6
26137961	10.3324/haematol.2015.126953	2015	CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol.	ETV6
26185316	10.1309/AJCPVY5E5OMMYBFJ	2015	Heterogeneity of Abnormal RUNX1 Leading to Clinicopathologic Variations in Childhood B-Lymphoblastic Leukemia.	ETV6
26237075	10.1080/15592294.2015.1061174	2015	Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia.	ETV6
26266519	10.1007/s40291-015-0149-0	2015	High frequency and poor prognosis of late childhood BCR-ABL-positive and MLL-AF4-positive ALL define the need for advanced molecular diagnostics and improved therapeutic strategies in pediatric B-ALL in Pakistan.	ETV6
26269126	10.1186/s12885-015-1586-1	2015	Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5(+/-) leukemia.	ETV6
26277549	10.1016/j.cancergen.2015.06.003	2015	Frequency of copy number abnormalities in common genes associated with B-cell precursor acute lymphoblastic leukemia cytogenetic subtypes in Brazilian children.	ETV6
26429121	10.4081/pmc.2015.112	2015	Mitotic crossover promotes leukemogenesis in children born with TEL-AML1 via the generation of loss of heterozygosity at 12p.	ETV6
26514535	10.7314/apjcp.2015.16.16.7343	2015	Importance of FISH combined with Morphology, Immunophenotype and Cytogenetic Analysis of Childhood/ Adult Acute Lymphoblastic Leukemia in Omani Patients.	ETV6
26520622	10.1016/j.leukres.2015.10.006	2015	Preserved global histone H4 acetylation linked to ETV6-RUNX1 fusion and PAX5 deletions is associated with favorable outcome in pediatric B-cell progenitor acute lymphoblastic leukemia.	ETV6
26522332	10.1016/S1470-2045(15)00369-1	2015	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study.	ETV6
26580398	10.1371/journal.pone.0142863	2015	A Double Negative Loop Comprising ETV6/RUNX1 and MIR181A1 Contributes to Differentiation Block in t(12;21)-Positive Acute Lymphoblastic Leukemia.	ETV6
26625756	10.7314/apjcp.2015.16.17.7523	2015	Low Frequency of ETV6-RUNX1 (t 12; 21) in Saudi Arabian Pediatric Acute Lymphoblastic Leukemia Patients: Association with Clinical Parameters and Early Remission.	ETV6
23772667	10.3109/10428194.2013.814127	2014	Pathogenetic role of ETV6 fusion gene in leukemic transformation of myelodysplastic syndrome refractory anemia with excess blasts-1 with a new, rare translocation t(11;19)(q24.3;q13.12) and insertion ins(6;12)(p22.3p13).	ETV6
23873282	10.1007/s00277-013-1843-9	2014	Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia.	ETV6
23911702	10.3324/haematol.2013.090225	2014	High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.	ETV6
23940019	10.1002/pbc.24584	2014	Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia in Saudi Arabia: a multi-institutional retrospective national collaborative study.	ETV6
24045615	10.1093/hmg/ddt447	2014	Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia.	ETV6
24166298	10.1038/leu.2013.317	2014	An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome.	ETV6
24188477	10.3109/10428194.2013.861071	2014	Clinical outcome of the coexistence of ETV6/RUNX1 and high hyperdiploidy in pediatric acute lymphoblastic leukemia.	ETV6
24222333	10.1182/blood-2013-06-509463	2014	Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.	ETV6
24231528	10.1016/j.leukres.2013.10.008	2014	Significance of CD66c expression in childhood acute lymphoblastic leukemia.	ETV6
24235135	10.1182/blood-2013-07-453480	2014	How I treat ALL in Down's syndrome: pathobiology and management.	ETV6
24240203	10.1038/leu.2013.345	2014	Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia.	ETV6
24241490	10.3324/haematol.2012.072470	2014	Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia.	ETV6
24318592	10.1007/s00277-013-1975-y	2014	Extramedullary T-lymphoid blast crisis of an ETV6/ABL1-positive myeloproliferative neoplasm with t(9;12)(q34;p13) and t(7;14)(p13;q11.2).	ETV6
24345752	10.1182/blood-2013-10-531509	2014	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.	ETV6
24394348	10.4161/epi.27585	2014	Epigenetic deregulation in pediatric acute lymphoblastic leukemia.	ETV6
24413735	10.1038/ng.2874	2014	RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.	ETV6
24473322	10.1038/ng.2879	2014	A RAG driver on the road to pediatric ALL.	ETV6
24557455	10.1159/000356778	2014	ETV6/RUNX1 rearrangement identified by RT-PCR without evidence on FISH.	ETV6
24577543	10.1097/MPH.0000000000000119	2014	Novel t(2;12)(q31;p13) in a case of pediatric T-cell acute lymphoblastic leukemia.	ETV6
24596209	10.1158/2159-8290.CD-RW2014-018	2014	ETV6-RUNX1-positive ALL may be driven by aberrant RAG activity.	ETV6
24648275	10.1002/pbc.25031	2014	Childhood acute lymphoblastic leukemia in the Middle East and neighboring countries: a prospective multi-institutional international collaborative study (CALLME1) by the Middle East Childhood Cancer Alliance (MECCA).	ETV6
24740533	10.1002/pbc.25050	2014	False positivity of ETV6/RUNX1 detected by FISH in healthy newborns and adults.	ETV6
24790906	10.3343/alm.2014.34.3.198	2014	Diagnostic utility of multiprobe fluorescence in situ hybridization assay for detecting cytogenetic aberrations in acute leukemia.	ETV6
24816234	10.3324/haematol.2014.103820	2014	IGH@ translocations co-exist with other primary rearrangements in B-cell precursor acute lymphoblastic leukemia.	ETV6
24886876	10.1186/1756-8722-7-43	2014	Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding.	ETV6
24913195	10.1111/bjh.12963	2014	Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?	ETV6
24957142	10.1182/blood-2014-03-562918	2014	A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.	ETV6
24970810	10.18632/oncotarget.2080	2014	Mutational analysis of primary central nervous system lymphoma.	ETV6
24998463	10.1016/j.cancergen.2014.05.003	2014	High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.	ETV6
25137060	10.1371/journal.pone.0104419	2014	Genomic inverse PCR for exploration of ligated breakpoints (GIPFEL), a new method to detect translocations in leukemia.	ETV6
25207766	10.1056/NEJMoa1403088	2014	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.	ETV6
25273558	10.1091/mbc.E14-06-1038	2014	Predicting interactome network perturbations in human cancer: application to gene fusions in acute lymphoblastic leukemia.	ETV6
25298122	10.1038/srep06565	2014	Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL.	ETV6
25368826	10.3343/alm.2014.34.6.475	2014	A cryptic ETV6/ABL1 rearrangement represents a unique fluorescence in situ hybridization signal pattern in a patient with B acute lymphoblastic leukemia.	ETV6
25692130	10.1155/2014/210560	2014	Prevalence of gene rearrangements in Mexican children with acute lymphoblastic leukemia: a population study-report from the Mexican Interinstitutional Group for the identification of the causes of childhood leukemia.	ETV6
22528566	10.1007/s12253-012-9533-9	2013	Six cases of rare gene amplifications and multiple copy of fusion gene in childhood acute lymphoblastic leukemia.	ETV6
22699455	10.1038/leu.2012.155	2013	Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.	ETV6
22734863	10.3109/10428194.2012.706288	2013	Identification of NIPBL, a new ETV6 partner gene in t(5;12) (p13;p13)-associated acute megakaryoblastic leukemia.	ETV6
22897724	10.3109/10428194.2012.710330	2013	Gene expression pattern contributing to prognostic factors in childhood acute lymphoblastic leukemia.	ETV6
23077088	10.1002/gcc.22021	2013	Abnormalities of the der(12)t(12;21) in ETV6-RUNX1 acute lymphoblastic leukemia.	ETV6
23135987	10.1002/stem.1277	2013	TEL (ETV6)-AML1 (RUNX1) initiates self-renewing fetal pro-B cells in association with a transcriptional program shared with embryonic stem cells in mice.	ETV6
23171811	10.1159/000342490	2013	Variant of ETV6/ABL1 gene is associated with leukemia phenotype.	ETV6
23190578	10.1111/ijlh.12031	2013	Interphase-FISH screening for eight common rearrangements in pediatric B-cell precursor acute lymphoblastic leukemia.	ETV6
23210573	10.3109/10428194.2012.754888	2013	Detection and clinical significance of gene rearrangements in Chinese patients with adult acute lymphoblastic leukemia.	ETV6
23276184	10.5858/arpa.2011-0429-CR	2013	Burkitt lymphoma arising from lymphoplasmacytic lymphoma following acquisition of MYC translocation and loss of the ETV6 tumor suppressor gene.	ETV6
23382691	10.1371/journal.pgen.1003225	2013	Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers.	ETV6
23443342	10.1038/leu.2013.15	2013	Initially disadvantaged, TEL-AML1 cells expand and initiate leukemia in response to irradiation and cooperating mutations.	ETV6
23488608	10.3109/10428194.2013.786068	2013	The ETV6/RUNX1 fusion transcript is not detected in RNA isolated from neonatal dried blood spots from children later diagnosed with the corresponding leukemia.	ETV6
23491079	10.1016/j.cancergen.2013.01.004	2013	Simultaneous occurrence of ETV6-RUNX1 and BCR-ABL1 (e1a2) transcripts in a child with B-cell acute lymphoblastic leukemia.	ETV6
23603912	10.1182/blood-2012-11-465138	2013	Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.	ETV6
23636228	10.1038/leu.2013.136	2013	Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor.	ETV6
23694795	NA	2013	Hemophagocytosis by leukemic blasts in B lymphoblastic leukemia with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1): a case report.	ETV6
23710385	10.1155/2013/652745	2013	Clonal Hypereosinophilia with ETV6 Rearrangement Evolving to T-Cell Lymphoblastic Lymphoma: A Case Report and Review of the Literature.	ETV6
23716539	10.3324/haematol.2012.080432	2013	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.	ETV6
23722552	10.1158/0008-5472.CAN-12-4367	2013	Integration of high-resolution methylome and transcriptome analyses to dissect epigenomic changes in childhood acute lymphoblastic leukemia.	ETV6
23741012	10.1182/blood-2012-11-465252	2013	STAT3 mediates oncogenic addiction to TEL-AML1 in t(12;21) acute lymphoblastic leukemia.	ETV6
23859904	10.1016/j.cancergen.2013.05.017	2013	Frequency of the ETV6-RUNX1, BCR-ABL1, TCF3-PBX1, and MLL-AFF1 fusion genes in Guatemalan pediatric acute lymphoblastic leukemia patients and their ethnic associations.	ETV6
23915977	10.1016/j.leukres.2013.06.027	2013	MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia.	ETV6
24006408	10.3324/haematol.2013.090860	2013	Clone-specific secondary aberrations are not detected in neonatal blood spots of children with ETV6-RUNX1-positive leukemia.	ETV6
24076604	10.1038/ng.2777	2013	Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.	ETV6
24081948	10.1084/jem.20130497	2013	Aberrant ZNF423 impedes B cell differentiation and is linked to adverse outcome of ETV6-RUNX1 negative B precursor acute lymphoblastic leukemia.	ETV6
24319172	10.1182/asheducation-2013.1.118	2013	Targeting signaling pathways in acute lymphoblastic leukemia: new insights.	ETV6
24339741	10.1593/neo.131310	2013	ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells.	ETV6
21720744	10.1007/s00277-011-1289-x	2012	Phenotypic and genetic characterization of adult T-cell acute lymphoblastic leukemia with del(9)(q34);SET-NUP214 rearrangement.	ETV6
21765475	10.1038/onc.2011.291	2012	Dominant-negative mechanism of leukemogenic PAX5 fusions.	ETV6
21869842	10.1038/leu.2011.227	2012	ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.	ETV6
21877899	10.3109/10428194.2011.618235	2012	Update on cytogenetic and molecular changes in myelodysplastic syndromes.	ETV6
22005784	10.1038/leu.2011.274	2012	High concordance of subtypes of childhood acute lymphoblastic leukemia within families: lessons from sibships with multiple cases of leukemia.	ETV6
22050763	10.1111/j.1365-2141.2011.08918.x	2012	PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.	ETV6
22058208	10.3324/haematol.2011.049593	2012	Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity.	ETV6
22072402	10.1002/gcc.20944	2012	High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with down syndrome.	ETV6
22076464	10.1038/leu.2011.302	2012	Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia.	ETV6
22094584	10.1038/leu.2011.333	2012	Whole-exome sequencing of pediatric acute lymphoblastic leukemia.	ETV6
22094587	10.1038/leu.2011.322	2012	Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.	ETV6
22217495	10.1097/MPH.0b013e3182332268	2012	RT-PCR screening for ETV6-RUNX1-positive clones in cord blood from newborns in the Danish National Birth Cohort.	ETV6
22226019	10.1016/j.leukres.2011.12.003	2012	RT-PCR diagnosis of recurrent rearrangements in pediatric acute lymphoblastic leukemia in Argentina.	ETV6
22237106	10.1038/nature10725	2012	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.	ETV6
22260162	10.3109/10428194.2012.658570	2012	Clinical impact of in vitro cellular drug resistance on childhood acute lymphoblastic leukemia in Taiwan.	ETV6
22359517	10.1371/journal.pgen.1002533	2012	The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution.	ETV6
22373549	10.1007/s00277-012-1431-4	2012	Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia.	ETV6
22382891	10.1038/leu.2012.26	2012	Newly diagnosed acute lymphoblastic leukemia in China (I): abnormal genetic patterns in 1346 childhood and adult cases and their comparison with the reports from Western countries.	ETV6
22404039	10.1111/j.1365-2141.2012.09083.x	2012	Genome-wide analysis of cytogenetic aberrations in ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia.	ETV6
22450142	10.1556/OH.2012.29334	2012	[Leukemia- and lymphoma-associated flow cytometric, cytogenetic, and molecular genetic aberrations in healthy individuals].	ETV6
22521551	10.1016/j.leukres.2012.03.024	2012	Additional aberrations of the ETV6 and RUNX1 genes have no prognostic impact in 229 t(12;21)(p13;q22)-positive B-cell precursor acute lymphoblastic leukaemias treated according to the NOPHO-ALL-2000 protocol.	ETV6
22531296	10.4161/epi.20193	2012	A distinct DNA methylation signature defines pediatric pre-B cell acute lymphoblastic leukemia.	ETV6
22534638	10.1097/DAD.0b013e31824d689c	2012	Alpha-interferon secreting blastic plasmacytoid dendritic cells neoplasm: a case report with histological, molecular genetics and long-term tumor cells culture studies.	ETV6
22580999	10.3324/haematol.2011.059584	2012	Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol.	ETV6
22705992	10.1038/leu.2012.161	2012	Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia.	ETV6
22733019	10.3324/haematol.2012.064659	2012	Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish.	ETV6
22848414	10.1371/journal.pone.0040934	2012	IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia.	ETV6
22851563	10.1200/JCO.2011.40.3907	2012	IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia.	ETV6
22976839	10.1007/s10552-012-0060-5	2012	NQO1 rs1800566 (C609T), PON1 rs662 (Q192R), and PON1 rs854560 (L55M) polymorphisms segregate the risk of childhood acute leukemias according to age range distribution.	ETV6
22994759	10.7314/apjcp.2012.13.7.3349	2012	Prognostically significant fusion oncogenes in Pakistani patients with adult acute lymphoblastic leukemia and their association with disease biology and outcome.	ETV6
23233609	10.1182/asheducation-2012.1.389	2012	The molecular genetic makeup of acute lymphoblastic leukemia.	ETV6
23317202	10.7314/apjcp.2012.13.11.5469	2012	Five most common prognostically important fusion oncogenes are detected in the majority of Pakistani pediatric acute lymphoblastic leukemia patients and are strongly associated with disease biology and treatment outcome.	ETV6
20713965	10.1182/blood-2010-05-282764	2011	Prevalence of t(12;21)[ETV6-RUNX1]-positive cells in healthy neonates.	ETV6
21069786	10.1002/pbc.22679	2011	The dual role of HLXB9 in leukemia.	ETV6
21080443	10.1002/ijc.25769	2011	Exposure to professional pest control treatments and the risk of childhood acute lymphoblastic leukemia.	ETV6
21145270	10.1016/j.bcmd.2010.11.003	2011	Febrile infections in young children do not frequently induce translocation ETV6-RUNX1.	ETV6
21157892	10.1002/pbc.22686	2011	TEL/AML1-positive patients lacking TEL exon 5 resemble canonical TEL/AML1 cases.	ETV6
21160474	10.1038/nature09650	2011	Genetic variegation of clonal architecture and propagating cells in leukaemia.	ETV6
21172890	10.1200/JCO.2010.32.0325	2011	Improved prognosis for older adolescents with acute lymphoblastic leukemia.	ETV6
21212293	10.1182/blood-2010-09-309070	2011	ETV6/RUNX1 (TEL/AML1) is a frequent prenatal first hit in childhood leukemia.	ETV6
21212294	10.1182/blood-2010-09-309351	2011	Fusion genes in cord blood.	ETV6
21224468	10.1182/blood-2010-03-275347	2011	ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling.	ETV6
21312262	10.1002/gepi.20573	2011	LOHAS: loss-of-heterozygosity analysis suite.	ETV6
21414819	10.1016/j.bcmd.2011.02.005	2011	Identification of characteristic IGF2BP expression patterns in distinct B-ALL entities.	ETV6
21444869	10.1200/JCO.2010.32.5340	2011	Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.	ETV6
21482711	10.1182/blood-2010-10-314674	2011	Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia.	ETV6
21527530	10.1182/blood-2011-01-329961	2011	Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia.	ETV6
21549623	10.1016/j.bcmd.2011.04.003	2011	PAX5 deletion is common and concurrently occurs with CDKN2A deletion in B-lineage acute lymphoblastic leukemia.	ETV6
21569007	10.1111/j.1365-2141.2011.08729.x	2011	Native ETV6 deletions accompanied by ETV6-RUNX1 rearrangements are associated with a favourable prognosis in childhood acute lymphoblastic leukaemia: a candidate for prognostic marker.	ETV6
21628403	10.1182/blood-2011-02-338848	2011	Modeling the evolution of ETV6-RUNX1-induced B-cell precursor acute lymphoblastic leukemia in mice.	ETV6
21680795	10.1182/blood-2011-03-341412	2011	Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.	ETV6
21705501	10.1182/blood-2011-03-343426	2011	Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.	ETV6
21822204	10.1038/modpathol.2011.118	2011	Pediatric B-lymphoblastic leukemia with RUNX1 amplification: clinicopathologic study of eight cases.	ETV6
21882283	10.1002/gcc.20919	2011	Microarray-based genomic profiling as a diagnostic tool in acute lymphoblastic leukemia.	ETV6
21914494	10.1016/j.exphem.2011.08.014	2011	hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup.	ETV6
22028862	10.1371/journal.pone.0026348	2011	The leukemia-specific fusion gene ETV6/RUNX1 perturbs distinct key biological functions primarily by gene repression.	ETV6
22162831	10.1084/jem.20112239	2011	ETV6 mutations in early immature human T cell leukemias.	ETV6
19710699	10.1038/leu.2009.170	2010	Characterizing chromosomal break points of t(12;21)[ETV6-RUNX1]-positive leukaemia using multiple tiling PCR on whole-genome-amplified DNA.	ETV6
19713226	10.3324/haematol.2009.011346	2010	Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia.	ETV6
19890372	10.1038/leu.2009.208	2010	Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53.	ETV6
19896186	10.1016/j.leukres.2009.09.033	2010	CD9 expression can be used to predict childhood TEL/AML1-positive acute lymphoblastic leukemia: proposal for an accelerated diagnostic flowchart.	ETV6
19998443	10.1002/gcc.20736	2010	Cytogenetics of long-term survivors of ETV6-RUNX1 fusion positive acute lymphoblastic leukemia.	ETV6
20016529	10.1038/leu.2009.264	2010	Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001.	ETV6
20016538	10.1038/leu.2009.248	2010	Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia.	ETV6
20042721	10.1182/blood-2009-09-235986	2010	Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?	ETV6
20061556	10.1182/blood-2009-10-251413	2010	Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia.	ETV6
20073070	10.1002/gcc.20743	2010	ABL1 rearrangements in T-cell acute lymphoblastic leukemia.	ETV6
20197715	10.3343/kjlm.2010.30.1.1	2010	[Prognostic significance of TEL/AML1 rearrangement and its additional genetic changes in Korean childhood precursor B-acute lymphoblastic leukemia].	ETV6
20211010	10.1186/1755-8794-3-6	2010	Gene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies.	ETV6
20409752	10.1016/S1470-2045(10)70066-8	2010	Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.	ETV6
20442364	10.1182/blood-2009-07-235291	2010	Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.	ETV6
20513752	10.1093/hmg/ddq224	2010	The correlation pattern of acquired copy number changes in 164 ETV6/RUNX1-positive childhood acute lymphoblastic leukemias.	ETV6
20561032	10.1111/j.1600-0609.2010.01493.x	2010	Childhood near-tetraploid acute lymphoblastic leukemia: an EGIL study on 36 cases.	ETV6
20589932	10.1002/gcc.20796	2010	Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis and prenatal origin.	ETV6
20618334	10.1111/j.1365-2141.2010.08323.x	2010	A doctor(s) dilemma: ETV6-ABL1 positive acute lymphoblastic leukaemia.	ETV6
20620598	10.1016/j.cancergencyto.2010.04.010	2010	Distribution of common genetic subgroups in childhood acute lymphoblastic leukemia in four developing countries.	ETV6
20658612	10.1002/pbc.22628	2010	Frequencies of ETV6-RUNX1 fusion and hyperdiploidy in pediatric acute lymphoblastic leukemia are lower in far east than west.	ETV6
20701601	10.1111/j.1365-2141.2010.08314.x	2010	Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankf√ºrt-M√ºnster study group.	ETV6
20804916	10.1016/j.cancergencyto.2010.07.121	2010	ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia.	ETV6
20806817	NA	2010	[ABL1, SRC and other non-receptor protein tyrosine kinases as new targets for specific anticancer therapy].	ETV6
20807887	10.1182/blood-2009-02-206706	2010	TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a.	ETV6
20930648	10.1097/MPH.0b013e3181ed1655	2010	Multiplex reverse transcription-polymerase chain reaction as diagnostic molecular screening of 4 common fusion chimeric genes in Taiwanese children with acute lymphoblastic leukemia.	ETV6
21098271	10.1073/pnas.1006981107	2010	Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.	ETV6
21152005	10.1371/journal.pcbi.1001019	2010	Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.	ETV6
21156245	10.1016/j.cancergencyto.2010.08.004	2010	B lymphoblastic leukemia with ETV6 amplification.	ETV6
18803328	10.1002/gcc.20616	2009	Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks.	ETV6
18838613	10.1182/blood-2008-07-166801	2009	A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups.	ETV6
18927438	10.1182/blood-2008-08-170928	2009	Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.	ETV6
18992913	10.1016/j.humpath.2008.08.012	2009	Diffuse large B-cell lymphoma with TEL/ETV6 translocation.	ETV6
19081626	10.1016/j.leukres.2008.11.001	2009	Cluster analysis of genomic ETV6-RUNX1 (TEL-AML1) fusion sites in childhood acute lymphoblastic leukemia.	ETV6
19100516	10.1016/j.cancergencyto.2008.09.005	2009	ETV6/RUNX1 fusion lacking prognostic effect in pediatric patients with acute lymphoblastic leukemia.	ETV6
19129484	10.1189/jlb.0808469	2009	Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia.	ETV6
19135770	10.1016/j.exphem.2008.11.002	2009	Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors.	ETV6
19147089	10.1016/j.bbmt.2008.10.010	2009	Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.	ETV6
19175693	10.1111/j.1582-4934.2008.00559.x	2009	Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.	ETV6
19264230	10.1016/j.cancergencyto.2008.12.003	2009	Involvement of der(12)t(12;21)(p13;q22) and as well as additional rearrangements of chromosome 12 homolog in ETV6/RUNX1-positive acute lymphoblastic leukemia.	ETV6
19287094	10.1172/JCI36428	2009	The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells.	ETV6
19454491	10.3324/haematol.2008.000299	2009	Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia.	ETV6
19594616	10.1111/j.1600-0609.2009.01315.x	2009	Interphase FISH on TEL/AML1 positive acute lymphoblastic leukemia relapses--analysis of clinical relevance of additional TEL and AML1 copy number changes.	ETV6
19665068	10.1016/j.cancergencyto.2009.04.021	2009	ETV6-RUNX1 fusion gene and additional genetic changes in infant leukemia: a genome-wide analysis.	ETV6
19679565	10.1093/hmg/ddp354	2009	The DNA methylome of pediatric acute lymphoblastic leukemia.	ETV6
19837270	10.1016/j.cancergencyto.2009.06.013	2009	Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.	ETV6
19963112	10.1016/j.cancergencyto.2009.07.002	2009	A complex rearrangement involving cryptic deletion of ETV6 and CDKN1B genes in a case of childhood acute lymphoblastic leukemia.	ETV6
17622527	10.1007/s00262-007-0349-5	2008	HLA-DPB1 supertype-associated protection from childhood leukaemia: relationship to leukaemia karyotype and implications for prevention.	ETV6
17890455	10.1182/blood-2007-05-088310	2008	Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray.	ETV6
17972957	10.1038/sj.leu.2404994	2008	Disruption of ETV6 in intron 2 results in upregulatory and insertional events in childhood acute lymphoblastic leukaemia.	ETV6
18172310	10.1158/0008-5472.CAN-07-2778	2008	PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.	ETV6
18181181	10.1002/gcc.20537	2008	Genetic lesions in a preleukemic aplasia phase in a child with acute lymphoblastic leukemia.	ETV6
18202291	10.1126/science.1150648	2008	Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia.	ETV6
18241254	10.1111/j.1365-2141.2008.06980.x	2008	Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival.	ETV6
18275435	10.1111/j.1365-2141.2007.06917.x	2008	Array-CGH reveals hidden gene dose changes in children with acute lymphoblastic leukaemia and a normal or failed karyotype by G-banding.	ETV6
18281529	10.1158/1078-0432.CCR-07-4022	2008	ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations.	ETV6
18297515	10.1080/10428190801895360	2008	JAK and MPL mutations in myeloid malignancies.	ETV6
18328947	10.1016/j.cancergencyto.2007.12.012	2008	Coexistence of ETV6/RUNX1 and MLL aberrations in B-cell precursor acute lymphoblastic leukemia discloses a small subclass of BCP-ALL.	ETV6
18445843	10.1200/JCO.2007.14.3552	2008	Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.	ETV6
18455790	10.1016/j.leukres.2008.03.021	2008	BCR-ABL, ETV6-RUNX1 and E2A-PBX1: prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients.	ETV6
18458336	10.1073/pnas.0800408105	2008	Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease.	ETV6
18557744	10.1111/j.1365-2141.2008.07280.x	2008	Array comparative genome hybridization analysis of acute lymphoblastic leukaemia and acute megakaryoblastic leukaemia in patients with Down syndrome.	ETV6
18565891	10.1200/JCO.2008.16.1117	2008	Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.	ETV6
18617057	10.1016/j.cancergencyto.2008.04.003	2008	Analysis of gene rearrangements using a fluorescence in situ hybridization method in Mexican patients with acute lymphoblastic leukemia: experience at a single institution.	ETV6
18635414	10.1016/S1607-551X(08)70155-4	2008	TEL/AML1 fusion gene in childhood acute lymphoblastic leukemia in southern Taiwan.	ETV6
18656692	10.1016/j.cancergencyto.2008.05.001	2008	Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement.	ETV6
18656693	10.1016/j.cancergencyto.2008.04.007	2008	Deletion of 14q24.1 approximately q24.3 in a patient with acute lymphoblastic leukemia: a hidden chromosomal anomaly detected by array-based comparative genomic hybridization.	ETV6
18728978	10.1080/08880010802237450	2008	RUNX1 aberrations in ETV6/RUNX1-positive and ETV6/RUNX1-negative patients: its hemato-pathological and prognostic significance in a large cohort (619 cases) of ALL.	ETV6
18767146	10.1002/gcc.20613	2008	The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1.	ETV6
18767247	10.4238/vol7-3gmr486	2008	Leukemia/lymphoma-associated gene fusions in normal individuals.	ETV6
18928518	10.1186/1756-8722-1-17	2008	Persistence of TEL-AML1 fusion gene as minimal residual disease has no additive prognostic value in CD 10 positive B-acute lymphoblastic leukemia: a FISH study.	ETV6
19010836	10.1158/1078-0432.CCR-07-5051	2008	Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia.	ETV6
19047175	10.1158/0008-5472.CAN-08-2139	2008	Chromosome 12p deletions in TEL-AML1 childhood acute lymphoblastic leukemia are associated with retrotransposon elements and occur postnatally.	ETV6
17215856	10.1038/sj.leu.2404507	2007	Deletion of 11q23 is a highly specific nonrandom secondary genetic abnormality of ETV6/RUNX1-rearranged childhood acute lymphoblastic leukemia.	ETV6
17237825	10.1038/sj.onc.1210190	2007	Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization.	ETV6
17284366	10.1016/j.cancergencyto.2006.09.007	2007	Automated detection of residual leukemic cells by consecutive immunolabeling for CD10 and fluorescence in situ hybridization for ETV6/RUNX1 rearrangement in childhood acute lymphoblastic leukemia.	ETV6
17344859	10.1038/nature05690	2007	Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.	ETV6
17374122	10.1111/j.1349-7006.2007.00443.x	2007	Genetic abnormalities involved in t(12;21) TEL-AML1 acute lymphoblastic leukemia: analysis by means of array-based comparative genomic hybridization.	ETV6
17443227	10.1038/sj.leu.2404691	2007	High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.	ETV6
17673463	10.1074/jbc.M706314200	2007	Hepatocyte growth factor receptor c-MET is associated with FAS and when activated enhances drug-induced apoptosis in pediatric B acute lymphoblastic leukemia with TEL-AML1 translocation.	ETV6
17690704	10.1038/sj.leu.2404879	2007	Combined high-resolution array-based comparative genomic hybridization and expression profiling of ETV6/RUNX1-positive acute lymphoblastic leukemias reveal a high incidence of cryptic Xq duplications and identify several putative target genes within the commonly gained region.	ETV6
17854676	10.1016/j.cancergencyto.2007.05.012	2007	Presenting features of 201 children with acute lymphoblastic leukemia: comparison according to presence or absence of ETV6/RUNX1 rearrangement.	ETV6
17889709	10.1016/j.cancergencyto.2007.05.019	2007	Prevalence of ETV6-RUNX1 fusion gene in children with acute lymphoblastic leukemia in China.	ETV6
17897302	10.1111/j.1365-2141.2007.06731.x	2007	Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia.	ETV6
17956600	10.1186/1471-2164-8-385	2007	Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia.	ETV6
17976519	10.1016/j.exphem.2007.08.025	2007	Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V&gt;F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.	ETV6
16307024	10.1038/sj.leu.2404028	2006	Expression of Tel-Aml1 transcript variants in pediatric acute lymphoblastic leukemia.	ETV6
16386788	10.1016/j.leukres.2005.11.007	2006	The incidence of T-cell receptor gene rearrangements in childhood B-lineage acute lymphoblastic leukemia is related to immunophenotype and fusion oncogene expression.	ETV6
16673018	10.1038/sj.leu.2404249	2006	A novel TEL-AML1 fusion transcript involving the pro-apoptotic gene BCL-G in pediatric precursor B acute lymphoblastic leukemia.	ETV6
16914570	10.1158/1078-0432.CCR-05-2592	2006	CpG island methylator phenotype redefines the prognostic effect of t(12;21) in childhood acute lymphoblastic leukemia.	ETV6
17015828	10.1073/pnas.0603349103	2006	TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia.	ETV6
15704129	10.1002/gcc.20158	2005	ETV6/RUNX1 fusion at diagnosis and relapse: some prognostic indications.	ETV6
15970674	10.4161/cc.4.8.1860	2005	TELAML1-positive ALL: a discordant genotype.	ETV6
16278392	10.1158/1078-0432.CCR-05-1239	2005	Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection.	ETV6
15104290	10.1016/j.cancergencyto.2003.07.003	2004	Cloning and sequencing of ETV6/RUNX1 (TEL/AML1) variant in acute lymphoblastic leukemia.	ETV6
15142881	10.1182/blood-2003-12-4306	2004	Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis.	ETV6
15328172	10.1158/1078-0432.CCR-04-0584	2004	TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia.	ETV6
12526921	10.1016/s0145-2126(02)00183-2	2003	TEL-AML1 fusion precedes differentiation to pre-B cells in childhood acute lymphoblastic leukemia.	ETV6
12626745	10.1073/pnas.0637114100	2003	Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor.	ETV6
12091359	10.1182/blood.v100.2.640	2002	Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal.	ETV6
12127395	10.1016/s0165-4608(01)00655-0	2002	Differential expression of TCL1 during pre-B-cell acute lymphoblastic leukemia progression.	ETV6
11731410	NA	2001	Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.	ETV6
11001911	NA	2000	Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein.	ETV6
9695962	10.1046/j.1365-2141.1998.00803.x	1998	Haemopoietic transformation by the TEL/ABL oncogene.	ETV6
9360930	10.1126/science.278.5341.1309	1997	A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.	ETV6
8653712	NA	1996	Biallelic alterations of both ETV6 and CDKN1B genes in a t(12;21) childhood acute lymphoblastic leukemia case.	ETV6
7761424	10.1073/pnas.92.11.4917	1995	Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.	ETV6
7780150	NA	1995	The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion.	ETV6
34162179	10.3324/haematol.2021.278743	2022	Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.	EZH2
34382383	10.3324/haematol.2020.263251	2022	Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma.	EZH2
34601504	10.1038/s41379-021-00938-z	2022	Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation.	EZH2
34655667	10.1016/j.canlet.2021.10.010	2022	EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.	EZH2
34788984	10.3324/haematol.2021.279177	2022	Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.	EZH2
34793663	10.4143/crt.2021.1121	2022	Hypo-trimethylation of Histone H3 Lysine 4 and Hyper-tri/dimethylation of Histone H3 Lysine 27 as Epigenetic Markers of Poor Prognosis in Patients with Primary Central Nervous System Lymphoma.	EZH2
34837284	10.1111/cas.15224	2022	Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.	EZH2
34904909	10.1080/14656566.2021.2014815	2022	Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma.	EZH2
34957565	10.1002/path.5861	2022	Widespread in situ follicular neoplasia in patients who subsequently developed follicular lymphoma.	EZH2
35022084	10.1186/s13046-021-02234-9	2022	The follicular lymphoma epigenome regulates its microenvironment.	EZH2
35031597	10.1038/s41420-022-00819-7	2022	ALKBH5-mediated N<sup>6</sup>-methyladenosine modification of TRERNA1 promotes DLBCL proliferation via p21 downregulation.	EZH2
35034955	10.1038/s41375-021-01494-w	2022	Inhibition of the¬†deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2.	EZH2
35045798	10.1080/10428194.2021.2024821	2022	High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.	EZH2
35082399	10.1038/s41417-021-00415-4	2022	CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma.	EZH2
35086959	10.1158/1535-7163.MCT-21-0216	2022	Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.	EZH2
35151584	10.1016/j.clml.2021.12.014	2022	Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.	EZH2
35157216	10.1007/s12325-022-02054-z	2022	A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.	EZH2
35173526	10.7150/ijbs.64752	2022	SOX8 Affects Tumoral SPARC Expression by Regulating EZH2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC.	EZH2
35180337	10.46883.2022.25920946	2022	Follicular Lymphoma: a Focus on Current and Emerging Therapies	EZH2
35181615	NA	2022	Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications.	EZH2
35236331	10.1186/s12885-022-09237-5	2022	Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.	EZH2
35247900	10.1158/2643-3230.BCD-21-0098	2022	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma.	EZH2
35250278	10.2147/OTT.S267011	2022	Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat.	EZH2
35253299	10.1002/gcc.23036	2022	CRLF2 overexpression defines an immature-like subgroup which is rescued through restoration of the PRC2 function in T-cell precursor acute lymphoblastic leukemia.	EZH2
35357654	10.1007/s13402-022-00663-y	2022	BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.	EZH2
35369397	10.6004/jadpro.2022.13.2.7	2022	Tazemetostat: EZH2 Inhibitor.	EZH2
35379077	10.1080/10428194.2022.2057488	2022	Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.	EZH2
35380993	10.1172/JCI145343	2022	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma.	EZH2
35454811	10.3390/cancers14081904	2022	Deciphering Genetic Alterations of Hairy Cell Leukemia and Hairy Cell Leukemia-like Disorders in 98 Patients.	EZH2
35491222	10.11406/rinketsu.63.313	2022	[Epigenetic modification as a therapeutic approach for B-cell lymphoma].	EZH2
35522148	10.3324/haematol.2021.280005	2022	Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase <i>KDM4C</i> in B cell lymphomas.	EZH2
35561310	10.1182/bloodadvances.2021006069	2022	Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment.	EZH2
35562412	10.1038/s41379-022-01085-9	2022	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia.	EZH2
35574216	10.18632/oncotarget.28229	2022	Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes.	EZH2
35650206	10.1038/s41467-022-30651-7	2022	Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis.	EZH2
35661922	10.1007/s00428-022-03347-y	2022	H3K27m3 overexpression as a new, BCL2 independent diagnostic tool in follicular and cutaneous follicle center lymphomas.	EZH2
35734596	10.3389/fonc.2022.846573	2022	The Clinical Characteristics and Prognosis of AYA and Older Adult ETP-ALL/LBL: A Real-World Multicenter Study in China.	EZH2
35753676	10.1016/j.bbagrm.2022.194840	2022	Chemical biology and pharmacology of histone lysine methylation inhibitors.	EZH2
35772421	10.1016/S2352-3026(22)00169-7	2022	Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma.	EZH2
35772429	10.1016/S2352-3026(22)00134-X	2022	SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial.	EZH2
35795062	10.3389/fonc.2022.870487	2022	Plasma Concentrations and Cancer-Associated Mutations in Cell-Free Circulating DNA of Treatment-Naive Follicular Lymphoma for Improved Non-Invasive Diagnosis and Prognosis.	EZH2
35851487	10.1016/j.blre.2022.100988	2022	Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas.	EZH2
35908982	10.1016/j.blre.2022.100992	2022	Follicular lymphoma: The long and winding road leading to your cure?	EZH2
35941836	10.1080/15384101.2022.2109898	2022	ELK1-Induced upregulation of long non-coding TNK2-AS1 promotes the progression of acute myeloid leukemia by EZH2-mediated epigenetic silencing of CELF2.	EZH2
35959380	10.2147/BLCTT.S282247	2022	A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?	EZH2
35960849	10.1182/blood.2022016428	2022	Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma.	EZH2
35973200	10.1182/bloodadvances.2022008403	2022	Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic stem cell transplantation.	EZH2
36029326	10.1007/s00277-022-04914-8	2022	Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.	EZH2
36055572	10.1016/j.clim.2022.109105	2022	A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.	EZH2
32799209	10.1159/000509159	2021	The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma.	EZH2
32855278	10.3324/haematol.2020.254854	2021	Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype.	EZH2
33094664	10.1080/15476286.2020.1838783	2021	LncRNAs in adaptive immunity: role in physiological and pathological conditions.	EZH2
33226554	10.1007/s12094-020-02504-6	2021	Expression and DNA methylation profiles of EZH2-target genes in plasma exosomes and matched primary tumor tissues of the patients with diffuse large B-cell lymphoma.	EZH2
33263441	10.1080/17474086.2021.1856652	2021	Development of molecular intervention strategies for B-cell lymphoma.	EZH2
33270606	10.1172/JCI135711	2021	Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice.	EZH2
33271120	10.1016/j.immuni.2020.11.002	2021	Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas.	EZH2
33389794	10.1002/jcla.23693	2021	USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B-cell lymphoma.	EZH2
33413063	10.2174/1568009620666210106122750	2021	Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).	EZH2
33414134	10.1158/1078-0432.CCR-20-2378	2021	Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP.	EZH2
33431788	10.1038/s41392-020-00437-8	2021	CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.	EZH2
33436855	10.1038/s41598-020-80613-6	2021	Targeted sequencing to identify genetic alterations and prognostic markers in pediatric T-cell acute lymphoblastic leukemia.	EZH2
33492746	10.1111/cas.14822	2021	Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.	EZH2
33502806	10.1002/biof.1704	2021	BCL-6 promotes the methylation of miR-34a by recruiting EZH2 and upregulating CTRP9 to protect ischemic myocardial injury.	EZH2
33513156	10.1371/journal.pone.0237554	2021	Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development.	EZH2
33529029	10.1021/acs.jmedchem.0c02112	2021	Design and Characterization of a Pyridone-Containing EZH2 Inhibitor Phosphate Prodrug.	EZH2
33560380	10.1182/bloodadvances.2020002469	2021	Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features.	EZH2
33562694	10.3390/cancers13040641	2021	Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention.	EZH2
33616890	10.1007/s40265-020-01446-1	2021	Novel Therapy Approaches to Follicular Lymphoma.	EZH2
33709777	10.2217/fon-2020-1244	2021	EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.	EZH2
33711241	10.1080/14656566.2021.1902988	2021	Novel synthetic drugs for the treatment of non-Hodgkin lymphoma.	EZH2
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	EZH2
33754292	10.1007/s11899-021-00614-8	2021	Targeted Therapies for Follicular Lymphoma.	EZH2
33770460	10.1200/EDBK_320117	2021	Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas.	EZH2
33792119	10.1111/cas.14905	2021	CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.	EZH2
33794893	10.1186/s12935-021-01897-w	2021	Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells.	EZH2
33797691	10.1007/s11899-021-00617-5	2021	When to Use Targeted Therapy for the Treatment of Follicular Lymphoma.	EZH2
33821477	10.1002/ijc.33584	2021	A rare variant in EZH2 is associated with prostate cancer risk.	EZH2
33829512	10.1111/his.14378	2021	Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma.	EZH2
33899787	10.1097/PAS.0000000000001691	2021	The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.	EZH2
33904892	10.1182/bloodadvances.2020002773	2021	Treating lymphoma is now a bit EZ-er.	EZH2
33935039	10.5045/br.2021.2021049	2021	Genomics of diffuse large B cell lymphoma.	EZH2
33937922	10.1007/s11912-021-01076-0	2021	Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.	EZH2
33959502	10.3389/fonc.2021.638897	2021	c-Rel Is the Pivotal NF-Œ∫B Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.	EZH2
33997750	10.1016/j.jhepr.2021.100276	2021	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury.	EZH2
34017197	10.2147/CMAR.S267258	2021	Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma.	EZH2
34044429	10.24875/RIC.21000070	2021	A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma.	EZH2
34065087	10.3390/ijms22095013	2021	The Impact of Epigenetic Modifications in Myeloid Malignancies.	EZH2
34069564	10.3390/ijms22105352	2021	The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential.	EZH2
34094676	NA	2021	HMGA1 induces EZH2 overexpression in human B-cell lymphomas.	EZH2
34104370	10.1177/20406207211015882	2021	The role of tazemetostat in relapsed/refractory follicular lymphoma.	EZH2
34105464	10.19746/j.cnki.issn.1009-2137.2021.03.012	2021	[Analysis of the Predictive Value of EZH2 Expression Level on the Clinical Efficacy and Long-term Prognosis of Patients with Primary Gastrointestinal Diffuse Large B-cell Lymphoma].	EZH2
34159682	10.1111/cas.15040	2021	Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.	EZH2
34168051	10.1158/1078-0432.CCR-20-4027	2021	Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma.	EZH2
34193230	10.1186/s13045-021-01113-2	2021	Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies.	EZH2
34196564	10.1021/acs.jmedchem.1c00460	2021	Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma.	EZH2
34202528	10.3390/cancers13133155	2021	Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types.	EZH2
34204385	10.3390/cancers13123032	2021	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing.	EZH2
34321240	10.1158/0008-5472.CAN-21-1027	2021	Mutant <i>Idh2</i> Cooperates with a <i>NUP98-HOXD13</i> Fusion to Induce Early Immature Thymocyte Precursor ALL.	EZH2
34351144	10.1021/acs.jmedchem.1c00226	2021	Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders.	EZH2
34376807	10.1038/s41379-021-00885-9	2021	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.	EZH2
34449935	10.1111/cas.15122	2021	The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.	EZH2
34455369	10.1016/j.bbrc.2021.08.051	2021	Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.	EZH2
34478526	10.1182/bloodadvances.2021005215	2021	Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.	EZH2
34488340	10.1021/acs.jmedchem.1c01116	2021	Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.	EZH2
34503063	10.3390/cancers13174249	2021	The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma.	EZH2
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	EZH2
34590470	10.52586/4970	2021	Methylation alterations and advance of treatment in lymphoma.	EZH2
34664960	10.1021/acs.jmedchem.1c01154	2021	Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.	EZH2
34671837	10.1007/s00292-021-01011-x	2021	[Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].	EZH2
34781267	10.6004/jnccn.2021.0054	2021	NCCN Guidelines¬Æ Insights: B-Cell Lymphomas, Version 5.2021.	EZH2
34807608	10.1021/acs.jmedchem.1c01161	2021	Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.	EZH2
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	EZH2
34944658	10.3390/biomedicines9121842	2021	Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas.	EZH2
34945856	10.3390/jpm11121384	2021	Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma.	EZH2
35008680	10.3390/ijms23010253	2021	Histone Modifications and Their Targeting in Lymphoid Malignancies.	EZH2
35071240	10.3389/fcell.2021.805195	2021	Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.	EZH2
30842630	10.1038/s41423-019-0219-z	2020	The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection.	EZH2
31289198	10.3324/haematol.2019.222935	2020	EZH2 inhibitors abrogate upregulation of trimethylation of H3K27 by CDK9 inhibitors and potentiate its activity against diffuse large B-cell lymphoma.	EZH2
31423576	10.1111/bjh.16159	2020	M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.	EZH2
31637838	10.1002/cyto.a.23919	2020	Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity.	EZH2
31680297	10.1002/ajh.25673	2020	Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.	EZH2
31685780	10.1248/cpb.c19-00550	2020	Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.	EZH2
31752573	10.1080/10428194.2019.1691200	2020	New murine models of aggressive lymphoma.	EZH2
31819273	10.1038/s41589-019-0421-4	2020	Discovery of a first-in-class EZH2 selective degrader.	EZH2
31831267	10.1016/j.chembiol.2019.11.006	2020	Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.	EZH2
31846764	10.1016/j.jprot.2019.103614	2020	Global characterization of proteome and lysine methylome features in EZH2 wild-type and mutant lymphoma cell lines.	EZH2
31891210	10.1002/hon.2711	2020	Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade.	EZH2
31962268	10.1016/j.molimm.2020.01.006	2020	EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.	EZH2
31991488	10.1111/apm.13029	2020	EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.	EZH2
32027840	10.1016/j.molcel.2020.01.017	2020	Replicational Dilution of H3K27me3 in Mammalian Cells and the Role of Poised Promoters.	EZH2
32122924	10.1158/1078-0432.CCR-19-3741	2020	A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.	EZH2
32138178	10.3390/cancers12030580	2020	Serine Biosynthesis Pathway Supports MYC-miR-494-EZH2 Feed-Forward Circuit Necessary to Maintain Metabolic and Epigenetic Reprogramming of Burkitt Lymphoma Cells.	EZH2
32139296	10.1016/j.clml.2019.11.007	2020	Defining Acute Myeloid Leukemia Ontogeny in Older Patients.	EZH2
32166598	10.1007/s40265-020-01288-x	2020	Tazemetostat: First Approval.	EZH2
32232478	10.1182/bloodadvances.2019001256	2020	Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma.	EZH2
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	EZH2
32349972	10.1158/2159-8290.CD-19-0789	2020	<i>EZH2</i>-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress.	EZH2
32396854	10.1016/j.ccell.2020.04.008	2020	Genetic Alterations Impact Immune Microenvironment Interactions in Follicular Lymphoma.	EZH2
32396861	10.1016/j.ccell.2020.04.004	2020	Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.	EZH2
32408898	10.1186/s12885-020-06937-8	2020	Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model.	EZH2
32421389	10.1200/JOP.19.00691	2020	Potential of Circulating Tumor DNA for the Management of Patients With Lymphoma.	EZH2
32421455	10.1200/EDBK_279043	2020	ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.	EZH2
32512858	10.3390/cancers12061464	2020	The miR-26b-5p/KPNA2 Axis Is an Important Regulator of Burkitt Lymphoma Cell Growth.	EZH2
32525136	10.1358/dot.2020.56.6.3147937	2020	Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors.	EZH2
32533097	10.1038/s41388-020-1347-8	2020	The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma.	EZH2
32546039	10.1080/10428194.2020.1775216	2020	TBLR1 and CREBBP as potential novel prognostic immunohistochemical biomarkers in diffuse large B-cell lymphoma.	EZH2
32552947	10.19746/j.cnki.issn.1009-2137.2020.03.022	2020	[Expression and Clinical Significance of EZH2 in Patients with Diffuse Large B Cell Lymphoma Accompanied by HBV Infection].	EZH2
32580550	10.1021/acs.jmedchem.0c00479	2020	EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development.	EZH2
32601883	10.1007/s11864-020-00761-9	2020	Hypomethylating Agents in Lymphoma.	EZH2
32641029	10.1186/s12906-020-03006-2	2020	Matrine inhibits the growth of natural killer/T-cell lymphoma cells by modulating CaMKIIŒ≥-c-Myc signaling pathway.	EZH2
32668764	10.3390/genes11070785	2020	Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.	EZH2
32715799	10.1080/10428194.2020.1795155	2020	<i>EZH2</i>-activating mutation: no reliable indicator for efficacy of methyltransferase inhibitors.	EZH2
32715803	10.1080/14740338.2020.1802424	2020	Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.	EZH2
32788174	10.1158/1055-9965.EPI-20-0451	2020	Stochastic Epigenetic Mutations Are Associated with Risk of Breast Cancer, Lung Cancer, and Mature B-cell Neoplasms.	EZH2
32816857	10.1158/0008-5472.CAN-20-1259	2020	SUMOylation of E2F1 Regulates Expression of EZH2.	EZH2
32850364	10.3389/fonc.2020.01226	2020	Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of <i>cdkn2b</i>.	EZH2
32853382	10.1182/bloodadvances.2019000938	2020	The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.	EZH2
32906688	10.3390/cancers12092541	2020	Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in <i>EZH2</i> Gain-of-Function Mutant Diffuse Large B-Cell Lymphoma.	EZH2
32978169	10.1158/0008-5472.CAN-20-2147	2020	EZH2-Targeted Therapies in Cancer: Hype or a Reality.	EZH2
33035457	10.1016/S1470-2045(20)30441-1	2020	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.	EZH2
33035458	10.1016/S1470-2045(20)30530-1	2020	EZH2 inhibition for epithelioid sarcoma and follicular lymphoma.	EZH2
33104794	10.1182/bloodadvances.2020002580	2020	Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.	EZH2
33211828	10.1182/bloodadvances.2020002944	2020	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.	EZH2
33233721	10.3390/ijms21228795	2020	Identification of Recurrent Mutations in the microRNA-Binding Sites of B-Cell Lymphoma-Associated Genes in Follicular Lymphoma.	EZH2
33283516	10.1021/acs.jmedchem.0c01344	2020	Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.	EZH2
33288562	10.21873/anticanres.14692	2020	EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment.	EZH2
33374737	10.3390/ijms22010074	2020	Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies.	EZH2
33843893	NA	2020	Refining the management of relapsed or refractory follicular lymphoma.	EZH2
34365354	10.1158/2159-8290.CD-RW2020-150	2020	The EZH2 Inhibitor Tazemetostat Shows Efficacy in Follicular Lymphoma.	EZH2
34667996	10.21037/aol-20-20	2020	Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.	EZH2
30218753	10.1016/j.humpath.2018.08.025	2019	Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis.	EZH2
30371509	10.1097/PAS.0000000000001180	2019	Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas.	EZH2
30588655	10.1111/his.13815	2019	ALK and EGFR expression by immunohistochemistry are associated with Merkel cell polyomavirus status in Merkel cell carcinoma.	EZH2
30608448	10.1097/MD.0000000000014011	2019	Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report.	EZH2
30705065	10.1158/2159-8290.CD-18-1090	2019	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.	EZH2
30719267	10.1177/2040620718820510	2019	Novel treatment approaches and future perspectives in follicular lymphoma.	EZH2
30788082	10.1016/j.csbj.2019.01.006	2019	Bivalent Ligands for Protein Degradation in Drug Discovery.	EZH2
30814291	10.1128/JVI.02143-18	2019	A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.	EZH2
30837715	10.1038/s41571-019-0190-8	2019	Emerging epigenetic-modulating therapies in lymphoma.	EZH2
30885427	10.1016/j.molmed.2019.02.013	2019	The 3D Genome: EZH2 Comes into the Fold.	EZH2
30935402	10.1186/s13045-019-0716-7	2019	Molecular pathogenic pathways in extranodal NK/T cell lymphoma.	EZH2
30936220	10.1158/2159-8290.CD-19-0090	2019	EZH2 Inhibitors: Take It EZy, It Is All About Context.	EZH2
30979734	10.1158/1078-0432.CCR-18-3989	2019	Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.	EZH2
31000418	10.1016/j.ebiom.2019.03.083	2019	Assessment of epigenetic mechanisms and DNA double-strand break repair using laser micro-irradiation technique developed for hematological cells.	EZH2
31139703	NA	2019	Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer immunotherapy.	EZH2
31142679	10.1126/scitranslmed.aau9087	2019	Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.	EZH2
31171828	10.1038/s41401-019-0248-2	2019	AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.	EZH2
31204938	10.19746/j.cnki.issn.1009-2137.2019.03.029	2019	[Expression of MiR101 and EZH2 in Patients with Mantle Cell Lymphoma and Its Clinical Significance].	EZH2
31205561	10.7150/jca.29807	2019	EZH2/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions.	EZH2
31205619	10.1016/j.csbj.2019.03.006	2019	Application of PD-1 Blockade in Cancer Immunotherapy.	EZH2
31219818	10.1097/PAS.0000000000001312	2019	Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases.	EZH2
31287161	10.1002/cncr.32145	2019	Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?	EZH2
31295529	10.1016/j.bbadis.2019.07.001	2019	The regulation of NDRG2 expression during ATLL development after HTLV-1 infection.	EZH2
31322273	10.3892/or.2019.7240	2019	Growth inhibition and transcriptional effects of ribavirin in lymphoma.	EZH2
31366503	10.21873/anticanres.13577	2019	Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma.	EZH2
31419226	10.1371/journal.pone.0220681	2019	DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.	EZH2
31423206	10.3892/ol.2019.10410	2019	Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.	EZH2
31434700	10.1182/blood.2019000381	2019	MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma.	EZH2
31471312	10.1158/1078-0432.CCR-18-4121	2019	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.	EZH2
31492675	10.1182/blood.2019000015	2019	Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.	EZH2
31551170	10.1016/j.clml.2019.08.010	2019	EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms.	EZH2
31565482	10.20892/j.issn.2095-3941.2018.0380	2019	Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57<sup>CDKN1C</sup> and TP53INP1 in mantle cell lymphoma.	EZH2
31631594	NA	2019	[Effects of Histone Methyltransferase Inhibitors on the Survival, Apoptosis and Cell Cycle of Raji Cells].	EZH2
31681423	10.3389/fgene.2019.00986	2019	Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma.	EZH2
31697821	10.1182/blood.2019002067	2019	Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.	EZH2
31740676	10.1038/s41408-019-0249-x	2019	Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.	EZH2
31747604	10.1016/j.celrep.2019.10.083	2019	Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.	EZH2
31752930	10.1186/s13045-019-0814-6	2019	EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.	EZH2
31805195	10.1182/blood.2019003023	2019	The EZ-riding NK/T-cell lymphoma.	EZH2
28641467	10.1080/10428194.2017.1339881	2018	Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells.	EZH2
29122756	10.1182/blood-2017-08-799080	2018	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.	EZH2
29158360	10.1182/blood-2017-08-737361	2018	Chromatin modifying gene mutations in follicular lymphoma.	EZH2
29200404	10.1172/JCI94509	2018	STAT5BN642H is a driver mutation for T cell neoplasia.	EZH2
29248547	10.1016/j.jid.2017.10.036	2018	Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment.	EZH2
29363553	10.1042/BSR20171589	2018	Hematopoietic stem/progenitor cell senescence is associated with altered expression profiles of cellular memory-involved gene.	EZH2
29397836	10.7534/j.issn.1009-2137.2018.01.027	2018	[Significance of H3K27me3 and EZH2 in Predicting the Therapeutic Efficacy of Diffuse Large B-Cell Lymphoma].	EZH2
29456795	10.1021/acsmedchemlett.7b00437	2018	Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma.	EZH2
29473431	10.1080/10428194.2018.1430795	2018	Enhancer of zeste homolog 2 (EZH2) inhibitors.	EZH2
29572378	10.1182/blood-2017-08-804344	2018	Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.	EZH2
29616853	10.1080/10428194.2018.1443452	2018	Clonal shifts in MDS - from SF3B1 to EZH2.	EZH2
29641966	10.1056/NEJMoa1801445	2018	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.	EZH2
29650362	10.1016/S1470-2045(18)30145-1	2018	Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.	EZH2
29650364	10.1016/S1470-2045(18)30149-9	2018	Targeting EZH2 with tazemetostat.	EZH2
29663940	NA	2018	EZH2 Expression in Naturally Occurring Canine Tumors.	EZH2
29669287	10.1016/j.celrep.2018.03.078	2018	ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.	EZH2
29738334	10.1097/MOH.0000000000000437	2018	Precision medicine and lymphoma.	EZH2
29743404	10.11406/rinketsu.59.432	2018	[Epigenetic aberrations in adult T-cell leukemia/lymphoma and development of a novel EZH1/2 inhibitor].	EZH2
29858685	10.1007/s00428-018-2384-3	2018	Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.	EZH2
29895903	10.1038/s41408-018-0089-0	2018	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.	EZH2
29970342	10.1016/j.clml.2018.06.004	2018	Molecular Markers and Prognosis of Myelofibrosis in the Genomic Era: A Meta-analysis.	EZH2
29980507	10.1158/2159-8290.CD-NB2018-088	2018	Positive Results for Tazemetostat in Follicular Lymphoma.	EZH2
29989027	10.18632/oncotarget.25601	2018	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	EZH2
30031020	10.1016/j.yexmp.2018.07.009	2018	EZH2 is upregulated in the proliferation centers of CLL/SLL lymph nodes.	EZH2
30080177	10.1172/JCI94645	2018	Ezh2 loss propagates hypermethylation at T cell differentiation-regulating genes to promote leukemic transformation.	EZH2
30087673	10.3389/fmicb.2018.01686	2018	HTLV-1-Mediated Epigenetic Pathway to Adult T-Cell Leukemia-Lymphoma.	EZH2
30112706	10.1007/s11899-018-0466-6	2018	Emerging EZH2 Inhibitors and Their Application in Lymphoma.	EZH2
30126979	10.1182/blood-2018-03-837252	2018	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.	EZH2
30159126	10.18632/oncotarget.25835	2018	LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL).	EZH2
30176648	NA	2018	[INHIBITORY EZH2 NOWƒÑ OPCJƒÑ TERAPEUTYCZNƒÑ W LECZENIU NAWROTOWEGO LUB OPORNEGO CH≈ÅONIAKA GRUDKOWEGO EZH2 INHIBITORS AS A NEW THERAPEUTIC OPTION FOR THE TREATMENT OF RELAPSED OR RECURRENT FOLLICULAR LYMPHOMA].	EZH2
30258009	10.1128/JVI.00909-18	2018	Long Noncoding RNA ANRIL Supports Proliferation of Adult T-Cell Leukemia Cells through Cooperation with EZH2.	EZH2
30269902	10.1016/j.stem.2018.08.018	2018	Epigenetic Restoration of Fetal-like IGF1 Signaling Inhibits Leukemia Stem Cell Activity.	EZH2
30360879	10.1053/j.seminoncol.2018.07.005	2018	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	EZH2
30404791	10.1084/jem.20180570	2018	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.	EZH2
31938438	NA	2018	Secondary mixed phenotype acute leukemia following chemotherapy for diffuse large B-cell lymphoma: a case report and review of the literature.	EZH2
27184221	10.1080/10428194.2016.1180686	2017	Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma.	EZH2
27389057	10.1038/leu.2016.175	2017	Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.	EZH2
27555605	10.1002/pbc.26218	2017	Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.	EZH2
28092155	10.1021/acs.jmedchem.6b01576	2017	Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.	EZH2
28106467	10.1080/15592294.2017.1282587	2017	Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.	EZH2
28122867	10.1158/2159-8290.CD-16-0330	2017	The Genetic Basis of Hepatosplenic T-cell Lymphoma.	EZH2
28135235	10.1038/nchembio.2304	2017	An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.	EZH2
28167662	10.1182/blood-2016-09-741348	2017	Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.	EZH2
28229364	10.1007/s11864-017-0449-1	2017	Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.	EZH2
28249909	NA	2017	Morphoproteomics Identifies SIRT1 and EZH2 Pathways as Commonalities in B-cell Acute Lymphoblastic Leukemia: Pathogenetic Implications and Opportunities for Therapeutic Intervention.	EZH2
28256832	10.1021/acs.jmedchem.7b00287	2017	Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).	EZH2
28359267	10.1186/s12885-017-3233-5	2017	Aberrant expression of ALK and EZH2 in Merkel cell carcinoma.	EZH2
28411252	10.3324/haematol.2017.165415	2017	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.	EZH2
28412742	10.18632/oncotarget.15453	2017	Association of the long non-coding RNA MALAT1 with the polycomb repressive complex pathway in T and NK cell lymphoma.	EZH2
28430172	10.1038/bcj.2017.32	2017	EZH2 alterations in follicular lymphoma: biological and clinical correlations.	EZH2
28438623	10.1016/j.humpath.2017.04.011	2017	EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.	EZH2
28487787	10.1155/2017/5083463	2017	EBV-Negative Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder with Marked Morphologic Pleomorphism and Pathogenic Mutations in <i>ASXL1</i>, <i>BCOR</i>, <i>CDKN2A</i>, <i>NF1</i>, and <i>TP53</i>.	EZH2
28548121	10.1038/modpathol.2017.37	2017	EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution.	EZH2
28556566	10.1002/pro.3202	2017	Select human cancer mutants of NRMT1 alter its catalytic activity and decrease N-terminal trimethylation.	EZH2
28625826	10.1016/j.addr.2017.06.010	2017	Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.	EZH2
28653353	10.1111/bjh.14803	2017	Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.	EZH2
28655885	10.1038/s41598-017-02800-2	2017	miR-15a/miR-16 down-regulates BMI1, impacting Ub-H2A mediated DNA repair and breast cancer cell sensitivity to doxorubicin.	EZH2
28659443	10.1126/scitranslmed.aak9969	2017	Genetic and epigenetic inactivation of <i>SESTRIN1</i> controls mTORC1 and response to EZH2 inhibition in follicular lymphoma.	EZH2
28741798	10.1111/cas.13326	2017	Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.	EZH2
28747286	10.4274/tjh.2017.0194	2017	Coexistence of EZH2, NOTCH1, IL7R, and PHF6 Mutations in Adult T-cell Acute Lymphoblastic Leukemia.	EZH2
28811957	10.1080/2162402X.2017.1321184	2017	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.	EZH2
28835384	10.1158/1535-7163.MCT-16-0840	2017	EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.	EZH2
28914785	10.3390/ijms18091986	2017	Hsp90Œ± Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.	EZH2
28976514	10.1039/c7fo00263g	2017	Role of epigenetic regulation on the induction of apoptosis in Jurkat leukemia cells by white grape pomace rich in phenolic compounds.	EZH2
28978842	10.11406/rinketsu.58.2004	2017	Molecular pathogenesis and its therapeutic implication for ATL.	EZH2
28993276	10.1016/j.humpath.2017.09.013	2017	A distinctive subgroup of oral EBV+ B-cell neoplasm with polymorphous features is potentially identical to EBV+ mucocutaneous ulcer.	EZH2
29113202	10.3892/ol.2017.6912	2017	EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys<sup>27</sup> acetylation in the <i>BIM</i> gene promoter and enhancers.	EZH2
29113297	10.18632/oncotarget.17956	2017	Long non-coding RNA profile in mantle cell lymphoma identifies a functional lncRNA ROR1-AS1 associated with EZH2/PRC2 complex.	EZH2
29209652	10.1080/23723556.2017.1365107	2017	Sestrin1, a tumor suppressor that can be rescued.	EZH2
29222279	10.1182/asheducation-2017.1.358	2017	Follicular lymphoma: are we ready for a risk-adapted approach?	EZH2
32300390	10.14740/jh320w	2017	Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes.	EZH2
25893294	10.1038/onc.2015.114	2016	Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.	EZH2
26337274	10.1007/s13277-015-3977-y	2016	The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.	EZH2
26659825	10.1158/1541-7786.MCR-15-0313	2016	Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression.	EZH2
26697989	10.1016/j.critrevonc.2015.11.004	2016	Myeloproliferative neoplasms: Current molecular biology and genetics.	EZH2
26698557	10.2217/epi.15.96	2016	Epigenetic dysregulation in follicular lymphoma.	EZH2
26757888	10.3109/10428194.2015.1121261	2016	Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients.	EZH2
26769278	10.1021/acs.jmedchem.5b01501	2016	The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.	EZH2
26773040	10.1182/blood-2015-09-672352	2016	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.	EZH2
26773042	10.1182/blood-2015-08-662593	2016	Polycomb-dependent epigenetic landscape in adult T-cell leukemia.	EZH2
26883583	10.3109/10428194.2016.1139703	2016	Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.	EZH2
26904942	10.1016/j.celrep.2016.01.064	2016	Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia.	EZH2
26917488	10.1111/bjh.13952	2016	Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.	EZH2
26973857	10.18632/oncoscience.288	2016	EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis.	EZH2
27010137	NA	2016	Mutational status of EZH2 and CD79B hot spots in mature B-cell non-Hodgkin's lymphomas: novel CD79B variations have been revealed.	EZH2
27052808	10.1080/15592294.2016.1164375	2016	Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.	EZH2
27055146	10.1097/MOH.0000000000000249	2016	The many layers of epigenetic dysfunction in B-cell lymphomas.	EZH2
27086936	10.3109/10428194.2016.1165816	2016	Rubinstein-Taybi syndrome - a window into follicular lymphoma biology.	EZH2
27098631	NA	2016	Extranodal B Cell Lymphoma with Prominent Spindle Cell Features Arising in Uterus and in Maxillary Sinus: Report of Two Cases and Literature Review.	EZH2
27102345	10.1038/modpathol.2016.79	2016	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.	EZH2
27135738	10.1038/nm.4092	2016	An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.	EZH2
27169594	10.1007/s00432-016-2174-8	2016	EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.	EZH2
27261606	10.1016/j.biopha.2016.04.019	2016	Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.	EZH2
27282353	10.1038/modpathol.2016.114	2016	Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.	EZH2
27289323	10.1016/j.bmcl.2016.05.018	2016	Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays.	EZH2
27297789	10.1182/blood-2016-01-690701	2016	EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.	EZH2
27311868	10.1016/j.pathol.2016.05.002	2016	Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.	EZH2
27322685	10.18632/oncotarget.9982	2016	Deregulation of polycomb repressor complex 1 modifier AUTS2 in T-cell leukemia.	EZH2
27440511	10.1373/clinchem.2016.255315	2016	Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.	EZH2
27490482	10.7554/eLife.18270	2016	MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs.	EZH2
27505670	10.1016/j.ccell.2016.07.006	2016	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.	EZH2
27548656	10.4155/fmc-2016-0096	2016	Recently discovered EZH2 and EHMT2 (G9a) inhibitors.	EZH2
27550047	10.4132/jptm.2016.06.06	2016	Long Non-coding RNA HOTAIR Expression in Diffuse Large B-Cell Lymphoma: In Relation to Polycomb Repressive Complex Pathway Proteins and H3K27 Trimethylation.	EZH2
27739677	10.1021/acs.jmedchem.6b01315	2016	Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.	EZH2
27748863	10.3892/or.2016.5147	2016	Role of HOTAIR in the diagnosis and prognosis of acute leukemia.	EZH2
27807891	10.1111/apm.12623	2016	Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.	EZH2
27888877	10.1016/j.hoc.2016.07.007	2016	Promising Novel Agents for Aggressive B-Cell Lymphoma.	EZH2
27889452	10.1016/j.molcel.2016.10.021	2016	An RB-EZH2 Complex Mediates Silencing of Repetitive DNA Sequences.	EZH2
27980305	10.3960/jslrt.56.71	2016	Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.	EZH2
27998273	10.1186/s12967-016-1100-9	2016	LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.	EZH2
24469040	10.1038/onc.2013.571	2015	Oncogenic Y641 mutations in EZH2 prevent Jak2/Œ≤-TrCP-mediated degradation.	EZH2
25030036	10.3109/10428194.2014.944522	2015	Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.	EZH2
25130477	10.3109/10428194.2014.941836	2015	Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.	EZH2
25263318	10.3109/10428194.2014.968780	2015	Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases.	EZH2
25382618	10.3109/10428194.2014.983099	2015	Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorder in children and young adults has similar molecular signature to extranodal nasal natural killer/T-cell lymphoma but shows distinctive stem cell-like phenotype.	EZH2
25407652	10.3109/10428194.2014.987770	2015	EZH2: a potential new target in T-cell lymphoma?	EZH2
25568352	10.1182/blood-2014-10-606822	2015	Polycomb genes, miRNA, and their deregulation in B-cell malignancies.	EZH2
25586788	10.1002/cncr.29198	2015	EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.	EZH2
25587943	10.1080/15592294.2014.1003746	2015	Epigenetic regulation in human melanoma: past and future.	EZH2
25595890	10.18632/oncotarget.2218	2015	Mutational spectrum of adult T-ALL.	EZH2
25605023	10.18632/oncotarget.3120	2015	HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma.	EZH2
25651430	10.3109/10428194.2015.1006220	2015	Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.	EZH2
25762637	10.18632/oncotarget.3154	2015	Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?	EZH2
25807917	10.1002/cncy.21535	2015	Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation.	EZH2
26004134	10.1517/13543784.2015.1051220	2015	Targeting of cancer stem cells by inhibitors of DNA and histone methylation.	EZH2
26005520	10.1021/acsmedchemlett.5b00037	2015	EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.	EZH2
26027790	10.1016/j.exphem.2015.05.001	2015	Targeting EZH2 and PRC2 dependence as novel anticancer therapy.	EZH2
26062053	10.1002/hon.2215	2015	VII. Are lymphomas driven by epigenetic lesions?	EZH2
26077423	10.2217/epi.15.14	2015	Small molecule inhibitors of EZH2: the emerging translational landscape.	EZH2
26110843	10.1186/1471-2164-16-S8-S5	2015	Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer.	EZH2
26189108	10.1016/j.leukres.2015.06.005	2015	Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.	EZH2
26256760	10.1016/S1470-2045(15)00169-2	2015	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	EZH2
26268310	10.1186/s13046-015-0191-0	2015	EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches.	EZH2
26280220	10.1038/labinvest.2015.104	2015	Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma.	EZH2
26297264	10.1016/j.clml.2015.02.035	2015	Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.	EZH2
26300989	10.1186/s13148-015-0118-9	2015	Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells.	EZH2
26371046	10.3390/genes6030812	2015	Epigenetic Heterogeneity of B-Cell Lymphoma: DNA Methylation, Gene Expression and Chromatin States.	EZH2
26458440	10.11406/rinketsu.56.2015	2015	[Epigenetic therapy for hematologic malignancies].	EZH2
26473533	10.1038/bcj.2015.89	2015	Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.	EZH2
26506391	10.3390/genes6041076	2015	Epigenetic Heterogeneity of B-Cell Lymphoma: Chromatin Modifiers.	EZH2
26517694	10.1172/JCI80325	2015	Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.	EZH2
26637768	10.1182/asheducation-2015.1.522	2015	Advances in therapies for non-Hodgkin lymphoma in children.	EZH2
24097338	10.1038/leu.2013.288	2014	EZH2 in normal and malignant hematopoiesis.	EZH2
24153014	10.1038/leu.2013.307	2014	Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma.	EZH2
24162788	10.3324/haematol.2013.094474	2014	Early lesions of follicular lymphoma: a genetic perspective.	EZH2
24304372	10.3109/10428194.2013.858816	2014	Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.	EZH2
24327543	10.1002/gcc.22126	2014	Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.	EZH2
24355555	10.1016/j.gene.2013.12.006	2014	Identification and characterization of microRNAs in the crab-eating macaque (Macaca fascicularis) using transcriptome analysis.	EZH2
24362818	10.1038/ng.2856	2014	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.	EZH2
24435047	10.1182/blood-2013-05-500264	2014	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	EZH2
24504051	10.18632/oncotarget.1449	2014	ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells.	EZH2
24563539	10.1158/1535-7163.MCT-13-0773	2014	Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.	EZH2
24634383	10.1158/1078-0432.CCR-13-1597	2014	EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations.	EZH2
24697523	10.1111/bph.12708	2014	YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK.	EZH2
24710217	10.1038/ncomms4630	2014	The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes.	EZH2
24736461	10.4161/cc.27757	2014	MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL.	EZH2
24767850	10.1016/j.bmcl.2014.04.010	2014	Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.	EZH2
24785273	NA	2014	[Phenotypic genetic regulation and treatment of malignant lymphoma].	EZH2
24802772	10.1182/blood-2012-12-473439	2014	A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.	EZH2
24811343	10.1038/leu.2014.126	2014	FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.	EZH2
24857928	10.1158/1078-0432.CCR-14-0629	2014	Manipulating the epigenome in germinal center lymphomas: is it getting easier and ezier?	EZH2
24870942	10.1007/s00277-014-2116-y	2014	Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.	EZH2
24900844	10.1021/ml400494b	2014	Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2.	EZH2
24942941	10.3960/jslrt.54.3	2014	Pathology of follicular lymphoma.	EZH2
24942943	10.3960/jslrt.54.23	2014	Molecular pathogenesis of follicular lymphoma.	EZH2
24987060	10.1158/1078-0432.CCR-13-2499	2014	Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination.	EZH2
25149548	10.1016/j.humpath.2014.07.002	2014	Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.	EZH2
25154026	10.1021/cb500548b	2014	Reaction coupling between wild-type and disease-associated mutant EZH2.	EZH2
25179367	10.1093/jb/mvu054	2014	Targeting histone methyltransferase EZH2 as cancer treatment.	EZH2
25253781	10.1158/1535-7163.MCT-13-0876	2014	A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.	EZH2
25266721	10.1074/jbc.M114.574517	2014	c-Rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells.	EZH2
25275047	NA	2014	Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.	EZH2
25369470	10.1021/jm501230c	2014	Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.	EZH2
25457120	10.1016/j.chembiol.2014.11.003	2014	Chemical cryptology of cancer's histone code.	EZH2
25457180	10.1016/j.chembiol.2014.09.017	2014	EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.	EZH2
25493630	10.1371/journal.pone.0111840	2014	Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.	EZH2
25941598	10.4161/21624011.2014.970025	2014	Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma.	EZH2
23298878	10.1097/MOH.0b013e32835d82fe	2013	Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.	EZH2
23361872	10.1002/cncy.21262	2013	EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples.	EZH2
23529930	10.1182/blood-2012-08-450494	2013	EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.	EZH2
23538750	10.1038/leu.2013.94	2013	Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.	EZH2
23614352	10.1021/cb400133j	2013	An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.	EZH2
23680141	10.1016/j.ccr.2013.04.028	2013	EZH2: an epigenetic gatekeeper promoting lymphomagenesis.	EZH2
23759589	10.4161/cc.25163	2013	Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.	EZH2
23948956	10.1007/s00428-013-1428-y	2013	In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2.	EZH2
23982173	10.1182/blood-2013-02-484055	2013	Polycomb repressive complex 2 (PRC2) suppresses EŒº-myc lymphoma.	EZH2
24052547	10.1182/blood-2013-04-496893	2013	EZH2 mutations are frequent and represent an early event in follicular lymphoma.	EZH2
24107828	10.4161/epi.26546	2013	A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma.	EZH2
24122997	NA	2013	Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.	EZH2
24183969	10.1016/j.chembiol.2013.09.013	2013	Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.	EZH2
24200695	10.1172/JCI70626	2013	Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.	EZH2
24349473	10.1371/journal.pone.0083244	2013	Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.	EZH2
24367611	10.1371/journal.pone.0083737	2013	Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.	EZH2
21877899	10.3109/10428194.2011.618235	2012	Update on cytogenetic and molecular changes in myelodysplastic syndromes.	EZH2
22237106	10.1038/nature10725	2012	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.	EZH2
22237151	10.1038/nm.2651	2012	Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.	EZH2
22238326	10.1182/blood-2011-10-388470	2012	Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.	EZH2
22323599	10.1073/pnas.1116418109	2012	Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).	EZH2
22343534	10.1073/pnas.1121343109	2012	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	EZH2
22431509	10.1101/gad.186411.111	2012	A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia.	EZH2
22508723	10.1101/gad.191163.112	2012	A complex Polycomb issue: the two faces of EZH2 in cancer.	EZH2
22520951	10.1016/j.humpath.2011.12.019	2012	Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.	EZH2
22850114	10.1016/j.febslet.2012.07.066	2012	A687V EZH2 is a gain-of-function mutation found in lymphoma patients.	EZH2
22872916	NA	2012	Does the proliferation of human lymphoma cells depend on the mutation of EZH2 and consequential epigenetic modification of H3K27?	EZH2
22932665	10.1158/1078-0432.CCR-12-0873	2012	Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.	EZH2
22956625	10.1258/ebm.2012.012075	2012	Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.	EZH2
23011159	10.3233/CBM-2012-0269	2012	Different expression of EZH2, BMI1 and Ki67 in low and high grade neuroendocrine tumors of the lung.	EZH2
23023262	10.1038/nchembio.1084	2012	A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.	EZH2
23023713	10.1172/JCI63186	2012	Pathogenesis of follicular lymphoma.	EZH2
23051747	10.1038/nature11606	2012	EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.	EZH2
23075734	NA	2012	Overexpression of enhancer of zests homolog 2 in lymphoma.	EZH2
23079660	10.1016/j.ccr.2012.09.003	2012	Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.	EZH2
23086691	10.1634/theoncologist.2012-0218	2012	Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?	EZH2
23153531	10.1016/j.ccr.2012.10.016	2012	Epigenetic therapy leaps ahead with specific targeting of EZH2.	EZH2
23236167	10.1073/pnas.1210371110	2012	Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.	EZH2
20863566	10.1016/j.leukres.2010.08.018	2011	Mutational analysis of EZH2 codon 641 in non-Hodgkin lymphomas and leukemias.	EZH2
21087793	10.1016/j.leukres.2010.10.014	2011	Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma.	EZH2
21190999	10.1182/blood-2010-11-321208	2011	Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.	EZH2
21228036	10.3324/haematol.2010.028605	2011	Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.	EZH2
21233829	10.1038/leu.2010.311	2011	EZH2 Y641 mutations in follicular lymphoma.	EZH2
21275949	10.1111/j.1365-2141.2010.08445.x	2011	Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas.	EZH2
21367748	10.1158/1078-0432.CCR-10-2156	2011	Aberrations of EZH2 in cancer.	EZH2
21856302	10.1016/j.febslet.2011.08.018	2011	The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states.	EZH2
21921784	10.1097/PAS.0b013e318224d2cd	2011	Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins.	EZH2
22194861	10.1371/journal.pone.0028585	2011	EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas.	EZH2
20081860	10.1038/ng.518	2010	Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.	EZH2
20104248	10.1038/ng0210-100	2010	Deregulation of H3K27 methylation in cancer.	EZH2
20558579	10.2353/ajpath.2010.090769	2010	Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma.	EZH2
20565746	10.1186/1476-4598-9-151	2010	Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines.	EZH2
20736451	10.1182/blood-2010-04-280149	2010	EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis.	EZH2
20858097	10.3109/10428194.2010.510897	2010	Somatic mutations altering Tyr641 of EZH2 are rare in primary central nervous system lymphoma.	EZH2
21078963	10.1073/pnas.1012525107	2010	Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.	EZH2
19197161	10.4161/cc.8.4.7599	2009	Repressing the repressor: a new mode of MYC action in lymphomagenesis.	EZH2
19657361	10.1038/leu.2009.161	2009	Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.	EZH2
19749796	10.1038/onc.2009.273	2009	Suppression of lung adenocarcinoma through menin and polycomb gene-mediated repression of growth factor pleiotrophin.	EZH2
20193471	NA	2009	[Recent advances on EZH2 in malignant tumors].	EZH2
18713946	10.1182/blood-2008-03-147645	2008	MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.	EZH2
17563396	10.1200/JCO.2006.08.7999	2007	Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors.	EZH2
16361539	10.1158/1078-0432.CCR-05-1047	2005	Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.	EZH2
14982841	10.1016/S0002-9440(10)63175-6	2004	Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines.	EZH2
14532106	10.1093/emboj/cdg542	2003	EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.	EZH2
11298590	10.1046/j.1365-2141.2001.02641.x	2001	The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma.	EZH2
11389032	10.1182/blood.v97.12.3896	2001	Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma.	EZH2
10980109	10.1016/S0002-9440(10)64583-X	2000	Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease.	EZH2
32393046	10.1080/09603123.2020.1757043	2022	The expression of microRNAs and exposure to environmental contaminants related to human health: a review.	FAS
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	FAS
34417692	10.1007/s11356-021-15985-x	2022	Landfill soil leachates from Nigeria and India induced DNA damage and alterations in genes associated with apoptosis in Jurkat cell.	FAS
34494161	10.1007/s00428-021-03186-3	2022	Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.	FAS
34615417	10.1080/19396368.2021.1980132	2022	The balance between cell survival and death in the placenta: Do neurotrophins have a role?	FAS
34752896	10.1016/j.cbpc.2021.109241	2022	Excessive manganese alters serum biochemical indices, induces histopathological alterations, and activates apoptosis in liver and cerebrum of Jianzhou Da'er goat (Capra hircus).	FAS
34896245	10.1016/j.exphem.2021.12.193	2022	Lipid uptake in chronic lymphocytic leukemia.	FAS
34980830	10.1097/PAS.0000000000001859	2022	Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing.	FAS
34999105	10.1016/j.chemosphere.2022.133550	2022	Exploration of binding mechanism of triclosan towards cancer markers using molecular docking and molecular dynamics.	FAS
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	FAS
35030634	10.1182/bloodadvances.2021006280	2022	Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma.	FAS
35035775	10.18632/oncotarget.28177	2022	GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells.	FAS
35136485	10.18632/oncotarget.28189	2022	GZ17-6.02 and axitinib interact to kill renal carcinoma cells.	FAS
35214193	10.3390/pharmaceutics14020466	2022	Hyaluronic Acid Nanoparticles for Immunogenic Chemotherapy of Leukemia and T-Cell Lymphoma.	FAS
35218445	10.1007/s11033-022-07280-w	2022	Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies.	FAS
35280407	10.21037/atm-22-91	2022	Mechanism of protective role of miR-874-3p in intervertebral disc degeneration.	FAS
35378398	10.1016/j.ecoenv.2022.113471	2022	Complex molecular mechanism of ammonia-induced apoptosis in chicken peripheral blood lymphocytes: miR-27b-3p, heat shock proteins, immunosuppression, death receptor pathway, and mitochondrial pathway.	FAS
35393909	10.1080/09513590.2022.2061454	2022	Effects of clinical and metabolic variables and hormones on the expression of immune protein biomarkers in the endometrium of women with polycystic ovary syndrome and normal-cycling controls.	FAS
35413358	10.1016/j.jad.2022.04.021	2022	Neuroprotective role of Bacopa monnieri extract in modulating depression in an experimental rat model.	FAS
35447282	10.1016/j.canlet.2022.215678	2022	MORTALIN-Ca<sup>2+</sup> axis drives innate rituximab resistance in diffuse large B-cell lymphoma.	FAS
35479087	10.3389/fimmu.2022.841299	2022	Inhibition of O-GlcNAcylation Decreases the Cytotoxic Function of Natural Killer Cells.	FAS
35512184	10.1182/blood.2022015601	2022	Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma.	FAS
35637951	10.7150/ijbs.68016	2022	The Classical Apoptotic Adaptor FADD Regulates Glycolytic Capacity in Acute Lymphoblastic Leukemia.	FAS
35641486	10.1038/s41419-022-04946-y	2022	Hepatocyte Bcl-3 protects from death-receptor mediated apoptosis and subsequent acute liver failure.	FAS
35646685	10.3389/fonc.2022.713476	2022	A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines.	FAS
35687490	10.1182/bloodadvances.2021006654	2022	Genomic characterization of lymphomas in patients with inborn errors of immunity.	FAS
35722364	10.21037/atm-22-2233	2022	Mitochondria-specific peptide amphiphiles induce mitochondrial dysfunction and peripheral T-cell lymphomas (PTCL) damage.	FAS
35789025	10.1002/hon.3045	2022	Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.	FAS
35809312	10.14715/cmb/2022.68.1.24	2022	Effects of 7,12-Dimethylbenz(a)anthracene on Apoptosis of Breast Cancer Cells through Regulating Expressions of FasL and Bcl-2.	FAS
35858181	10.1002/hon.3054	2022	Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera<sup>¬Æ</sup> ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.	FAS
35861049	10.1002/jsfa.12141	2022	Research on apoptotic mechanism and related pathways involving in postmortem grass carp (Ctenopharyngodon idellus) muscle.	FAS
32652549	10.1002/eji.202048584	2021	Bcl-3 inhibits lupus-like phenotypes in BL6/lpr mice.	FAS
32827707	10.1016/j.jcmgh.2020.08.003	2021	TNFSF15 Promotes Antimicrobial Pathways in Human Macrophages and These Are Modulated by TNFSF15 Disease-Risk Variants.	FAS
33237303	10.1084/jem.20201173	2021	Compromised counterselection by FAS creates an aggressive subtype of germinal center lymphoma.	FAS
33356695	10.1080/10408363.2020.1855623	2021	Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS).	FAS
33375216	10.4274/tjh.galenos.2020.2020.0618	2021	Autoimmune Lymphoproliferative Syndrome in Children with Nonmalignant Organomegaly, Chronic Immune Cytopenia, and Newly Diagnosed Lymphoma	FAS
33406104	10.1371/journal.pone.0241091	2021	Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNŒ≥/CXCL10-dependent peripheral T cell recruitment in humanized murine model.	FAS
33436023	10.1186/s13045-021-01033-1	2021	Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).	FAS
33454909	10.1007/s11033-021-06136-z	2021	Deciphering the molecular pathways of apoptosis using purified fractions from leaf extract of Basella alba through studying the regulation of apoptosis related genes.	FAS
33513976	10.3390/ijms22031255	2021	Natural Killer Cell Phenotype and Functionality Affected by Exposure to Extracellular Survivin and Lymphoma-Derived Exosomes.	FAS
33539018	10.1007/978-3-030-49844-3_9	2021	Bile Acid Toxicity and Protein Kinases.	FAS
33666760	10.1007/s00262-021-02895-7	2021	Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.	FAS
33751108	10.1182/blood.2020009088	2021	miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.	FAS
33898103	10.1016/j.omtn.2021.03.011	2021	Cell death pathways and viruses: Role of microRNAs.	FAS
33963613	10.1111/pai.13535	2021	Clinical, immunological, and genetic features in 780 patients with autoimmune lymphoproliferative syndrome (ALPS) and ALPS-like diseases: A systematic review.	FAS
33991612	10.1016/j.cellsig.2021.110042	2021	CTRP3 promotes TNF-Œ±-induced apoptosis and barrier dysfunction in salivary epithelial cells.	FAS
33994507	10.1536/ihj.20-600	2021	MiR-448-5p/VEGFA Axis Protects Cardiomyocytes from Hypoxia Through Regulating the FAS/FAS-L Signaling Pathway.	FAS
33995372	10.3389/fimmu.2021.656356	2021	Next Generation Sequencing for Detecting Somatic <i>FAS</i> Mutations in Patients With Autoimmune Lymphoproliferative Syndrome.	FAS
34192738	10.1093/biolre/ioab126	2021	Chemerin as a modulator of angiogenesis and apoptosis processes in the corpus luteum of pigs: an in vitro study‚Ä†.	FAS
34205588	10.3390/cancers13123084	2021	Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia.	FAS
34384744	10.1016/j.bj.2021.04.005	2021	Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes.	FAS
34400143	10.1016/j.abb.2021.108982	2021	Mangiferin mitigates di-(2-ethylhexyl) phthalate-induced testicular injury in rats by modulating oxidative stress-mediated signals, inflammatory cascades, apoptotic pathways, and steroidogenesis.	FAS
34400859	10.1016/j.jsps.2021.04.027	2021	Effects of neoadjuvant therapies on genetic regulation of targeted pathways in ER+¬†primary ductal breast carcinoma: A meta-analysis of microarray datasets.	FAS
34439744	10.3390/biom11081066	2021	Influence of Galectin-9 Treatment on the Phenotype and Function of NK-92MI Cells in the Presence of Different Serum Supplements.	FAS
34447369	10.3389/fimmu.2021.671755	2021	Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.	FAS
34485291	10.3389/fcell.2021.705690	2021	Vaginal Probiotic <i>Lactobacillus crispatus</i> Seems to Inhibit Sperm Activity and Subsequently Reduces Pregnancies in Rat.	FAS
34508147	10.1038/s41598-021-97545-4	2021	Leukotoxin (LtxA/Leukothera) induces ATP expulsion via pannexin-1 channels and subsequent cell death in malignant lymphocytes.	FAS
34588797	10.2147/JIR.S327858	2021	Transcription Coactivator BCL3 Acts as a Potential Regulator of Lipid Metabolism Through the Effects on Inflammation.	FAS
34627429	10.19746/j.cnki.issn.1009-2137.2021.05.018	2021	[Relationships between CASP8, Fas Gene Polymorphisms and the Prognosis of Patients with Non-Hodgkin's Lymphoma in Han Nationality].	FAS
34831003	10.3390/cancers13225849	2021	AKF-D52, a Synthetic Phenoxypyrimidine-Urea Derivative, Triggers Extrinsic/Intrinsic Apoptosis and Cytoprotective Autophagy in Human Non-Small Cell Lung Cancer Cells.	FAS
34848457	10.21873/anticanres.15422	2021	Characteristics of Human Peripheral Blood Œ≥Œ¥ T Cells Expanded With Zoledronate.	FAS
35036396	10.3389/fped.2021.798959	2021	Case Report: Autoimmune Lymphoproliferative Syndrome vs. Chronic Active Epstein-Barr Virus Infection in Children: A Diagnostic Challenge.	FAS
30958694	10.5858/arpa.2018-0190-RS	2020	Autoimmune Lymphoproliferative Syndrome: An Overview.	FAS
31433522	10.1002/jcb.27445	2020	AT1R¬†knockdown confers cardioprotection against sepsis-induced myocardial injury by inhibiting the MAPK signaling pathway in rats.	FAS
31586690	10.1016/j.jep.2019.112256	2020	Ganoderma lucidum spore oil induces apoptosis of breast cancer cells in vitro and in vivo by activating caspase-3 and caspase-9.	FAS
31758388	10.1007/s12017-019-08578-y	2020	Topiramate Reverses Physiological and Behavioral Alterations by Postoperative Cognitive Dysfunction in Rat Model Through Inhibiting TNF Signaling Pathway.	FAS
31853278	10.3892/etm.2019.8176	2020	Remote ischemic post-conditioning protects against myocardial ischemia/reperfusion injury by inhibiting the Rho-kinase signaling pathway.	FAS
31907700	10.1007/s10616-019-00354-x	2020	Silencing of soluble epoxide hydrolase 2 gene reduces H<sub>2</sub>O<sub>2</sub>-induced oxidative damage in rat intestinal epithelial IEC-6 cells via activating PI3K/Akt/GSK3Œ≤ signaling pathway.	FAS
31908105	10.1111/cas.14296	2020	Efficient recruitment of c-FLIP<sub>L</sub> to the death-inducing signaling complex leads to Fas resistance in natural killer-cell lymphoma.	FAS
31918102	10.1016/j.chemosphere.2019.125794	2020	Antagonistic effect of selenium on lead-induced neutrophil apoptosis in chickens via miR-16-5p targeting of PiK3R1 and IGF1R.	FAS
32058096	10.1016/j.fsi.2020.02.015	2020	Cadmium exposure induces apoptosis, inflammation and immunosuppression through CYPs activation and antioxidant dysfunction in common carp neutrophils.	FAS
32075108	10.3390/ijms21041298	2020	C5, A Cassaine Diterpenoid Amine, Induces Apoptosis via the Extrinsic Pathways in Human Lung Cancer Cells and Human Lymphoma Cells.	FAS
32322022	10.1038/s41379-020-0533-0	2020	Morphologic and genetic heterogeneity in breast fibroepithelial lesions-a comprehensive mapping study.	FAS
32346136	10.1038/s41418-020-0540-1	2020	JNK1 and ERK1/2 modulate lymphocyte homeostasis via BIM and DRP1 upon AICD induction.	FAS
32353704	10.1016/j.critrevonc.2020.102945	2020	Lymphoma in the setting of autoimmune diseases: A review of association and mechanisms.	FAS
32373555	10.3389/fcimb.2020.00162	2020	A New Hope for CD56<sup>neg</sup>CD16<sup>pos</sup> NK Cells as Unconventional Cytotoxic Mediators: An Adaptation to Chronic Diseases.	FAS
32411316	10.1155/2020/1359164	2020	Copper Induces Oxidative Stress and Apoptosis in the Mouse Liver.	FAS
32412348	10.1080/0284186X.2020.1759823	2020	Negative illness perceptions are related to more fatigue among haematological cancer survivors: a PROFILES study.	FAS
32426239	10.1016/j.toxrep.2020.04.010	2020	MicroRNAs and Xenobiotic Toxicity: An Overview.	FAS
32478494	10.1631/jzus.B1900520	2020	Effect of resveratrol treatment on apoptosis and apoptotic pathways during boar semen freezing.	FAS
32499235	10.1158/1078-0432.CCR-20-0514	2020	Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial.	FAS
32518946	10.1182/blood.2020005844	2020	Germline TET2 loss of function causes childhood immunodeficiency and lymphoma.	FAS
32602049	10.1007/s43032-020-00238-y	2020	Strength Training Modulates Prostate of Wistar Rats Submitted to High-Fat Diet.	FAS
32619459	10.1016/j.exphem.2020.06.005	2020	Characterization of resistance to a recombinant hexameric Fas-ligand (APO010) in human cancer cell lines.	FAS
32713953	10.24875/BMHIM.19000187	2020	Yin-Yang-1 decreases Fas-induced apoptosis in acute lymphoblastic leukemia under hypoxic conditions: its implications in immune evasion.	FAS
32784334	10.1097/CM9.0000000000000999	2020	TOSO interacts with SYK and enhances BCR pathway activation in chronic lymphocytic leukemia.	FAS
32928920	10.1158/0008-5472.CAN-19-3993	2020	The Inhibitor of Apoptosis Protein Livin Confers Resistance to Fas-Mediated Immune Cytotoxicity in Refractory Lymphoma.	FAS
33143024	10.3390/ani10111996	2020	Ameliorative Effect of Graviola (<i>Annona muricata</i>) on Mono Sodium Glutamate-Induced Hepatic Injury in Rats: Antioxidant, Apoptotic, Anti-inflammatory, Lipogenesis Markers, and Histopathological Studies.	FAS
33162537	10.11406/rinketsu.61.1365	2020	[Lymphoproliferative disorders and inborn errors of immunity].	FAS
33168041	10.1186/s13046-020-01747-z	2020	MiR-7e-5p downregulation promotes transformation of low-grade follicular lymphoma to aggressive lymphoma by modulating an immunosuppressive stroma through the upregulation of FasL in M1 macrophages.	FAS
33297339	10.3390/nu12123755	2020	Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.	FAS
33328962	10.3389/fnagi.2020.582455	2020	LongShengZhi Capsule Attenuates Alzheimer-Like Pathology in APP/PS1 Double Transgenic Mice by Reducing Neuronal Oxidative Stress and Inflammation.	FAS
30146791	10.1002/jcp.27123	2019	Antrodia salmonea-induced oxidative stress abrogates HER-2 signaling cascade and enhanced apoptosis in ovarian carcinoma cells.	FAS
30467847	10.1002/jcp.27061	2019	TNF-Œ±-TNFR signal pathway inhibits autophagy and promotes apoptosis of alveolar macrophages in coal worker's pneumoconiosis.	FAS
30472609	10.1016/j.chemosphere.2018.11.128	2019	Mechanisms underlying nickel nanoparticle induced reproductive toxicity and chemo-protective effects of vitamin C in male rats.	FAS
30508623	10.1016/j.jep.2018.11.042	2019	Ulmus macrocarpa Hance improves benign prostatic hyperplasia by regulating prostatic cell apoptosis.	FAS
30590156	10.1016/j.fsi.2018.12.049	2019	Impairing of gill health through decreasing immune function and structural integrity of grass carp (Ctenopharyngodon idella) fed graded levels dietary lipids after challenged with Flavobacterium columnare.	FAS
30683910	10.1038/s41375-019-0380-5	2019	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.	FAS
30694585	10.1002/JLB.3A0718-287RR	2019	Interleukin-5 induces apoptotic defects in CD4<sup>+</sup> T cells of patients with allergic rhinitis.	FAS
30697680	10.1007/s12011-018-1623-4	2019	The Protective Role of Selenium Against AFB<sub>1</sub>-Induced Liver Apoptosis by Death Receptor Pathway in Broilers.	FAS
30805584	10.1093/carcin/bgz041	2019	S194-P-FADD as a marker of aggressiveness and poor prognosis in human T-cell lymphoblastic lymphoma.	FAS
30861119	10.1111/joa.12970	2019	Apoptosis and proliferation during human salivary gland development.	FAS
30891776	10.1002/jcp.28446	2019	Scutellarin exerts protective effects against atherosclerosis in rats by regulating the Hippo-FOXO3A and PI3K/AKT signaling pathways.	FAS
30925928	10.1186/s12943-019-0977-3	2019	MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.	FAS
30966844	10.1080/21505594.2019.1605803	2019	The roles of apoptosis, autophagy and unfolded protein response in arbovirus, influenza virus, and HIV infections.	FAS
30971474	10.1128/JVI.00352-19	2019	Replication of Marek's Disease Virus Is Dependent on Synthesis of <i>De Novo</i> Fatty Acid and Prostaglandin E<sub>2</sub>.	FAS
31090237	10.1111/1346-8138.14923	2019	Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: The results of a phase 2 study (B-1201).	FAS
31109948	10.1128/IAI.00309-19	2019	Aggregatibacter actinomycetemcomitans Leukotoxin (LtxA) Requires Death Receptor Fas, in Addition to LFA-1, To Trigger Cell Death in T Lymphocytes.	FAS
31139332	10.18632/oncotarget.26900	2019	Blood transcriptional profiling reveals IL-1 and integrin signaling pathways associated with clinical response to extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma.	FAS
31173173	10.3892/ijmm.2019.4230	2019	Hydroxysafflor Yellow A mitigated myocardial ischemia/reperfusion injury by inhibiting the¬†activation of the JAK2/STAT1 pathway.	FAS
31237178	10.1080/10428194.2019.1581936	2019	High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy.	FAS
31262890	10.21873/anticanres.13512	2019	Amentoflavone Induces Apoptosis and Reduces Expression of Anti-apoptotic and Metastasis-associated Proteins in Bladder Cancer.	FAS
31262977	10.1042/BSR20182274	2019	EPHA3 enhances macrophage autophagy and apoptosis by disrupting the mTOR signaling pathway in mice with endometriosis.	FAS
31301310	10.1016/j.ejphar.2019.172531	2019	MicroRNA Let-7f-1-3p attenuates smoke-induced apoptosis in bronchial and alveolar epithelial cells in vitro by targeting FOXO1.	FAS
31357635	10.3390/biom9080310	2019	Detoxification, Apoptosis, and Immune Transcriptomic Responses of the Gill Tissue of Bay Scallop Following Exposure to the Algicide Thiazolidinedione 49.	FAS
31373906	10.1097/CM9.0000000000000362	2019	Roles of extra-cellular signal-regulated protein kinase 5 signaling pathway in the development of spinal cord injury.	FAS
31410196	10.7150/thno.34001	2019	Regulating Bcl2L12 expression in mast cells inhibits food allergy.	FAS
31411343	10.1002/path.5333	2019	Genomic characterisation of breast fibroepithelial lesions in an international cohort.	FAS
31442446	10.1016/j.yexmp.2019.104299	2019	Possible curative role of curcumin and silymarin against nephrotoxicity induced by gamma-rays in rats.	FAS
31590241	10.3390/cancers11101494	2019	Isorhamnetin Induces Cell Cycle Arrest and Apoptosis Via Reactive Oxygen Species-Mediated AMP-Activated Protein Kinase Signaling Pathway Activation in Human Bladder Cancer Cells.	FAS
31652745	10.3390/v11110974	2019	Influence of Immunogenetic Biomarkers in the Clinical Outcome of HTLV-1 Infected Persons.	FAS
31689275	10.1097/RLU.0000000000002816	2019	18F-FDG PET Imaging Features of Patients With Autoimmune Lymphoproliferative Syndrome.	FAS
31701727	10.12047/j.cjap.5691.2019.080	2019	[The effects of salidroside on the apoptosis pathway of myocardial cells in acute exhausted rats].	FAS
31782491	10.1042/BSR20190597	2019	Prostaglandin E1 protects cardiomyocytes against hypoxia-reperfusion induced injury via the miR-21-5p/FASLG axis.	FAS
31956452	10.1155/2019/2543038	2019	Fatal Hypogammaglobulinemia 3 Years after Rituximab in a Patient with Immune Thrombocytopenia: An Underlying Genetic Predisposition?	FAS
32105427	10.29262/ram.v66i4.646	2019	[Autoimmune lymphoproliferative syndrome. Update and review].	FAS
28509416	10.1002/cyto.b.21533	2018	The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry.	FAS
28982542	10.1016/j.ejphar.2017.09.051	2018	A molecular mechanism on the antiapoptotic effects of zingerone in isoproterenol induced myocardial infarcted rats.	FAS
29027106	10.1007/s12011-017-1176-y	2018	Fas- and Mitochondria-Mediated Signaling Pathway Involved in Osteoblast Apoptosis Induced by AlCl<sub>3</sub>.	FAS
29115483	10.3892/mmr.2017.7979	2018	Hepatocellular toxicity of oxalicumone A via oxidative stress injury and mitochondrial dysfunction in healthy human liver cells.	FAS
29298131	10.1080/13510002.2017.1416773	2018	A systematic review of p53 regulation of oxidative stress in skeletal muscle.	FAS
29339045	10.1016/j.fsi.2018.01.015	2018	Deficiency of dietary pyridoxine disturbed the intestinal physical barrier function of young grass carp (Ctenopharyngodon idella).	FAS
29367005	10.1016/j.fsi.2018.01.027	2018	The impaired immune function and structural integrity by dietary iron deficiency or excess in gill of fish after infection with Flavobacterium columnare: Regulation of NF-Œ∫B, TOR, JNK, p38MAPK, Nrf2 and MLCK signalling.	FAS
29375700	10.3892/etm.2017.5403	2018	Expression of miR-625 and Fas in cervical vertebral cartilage endplate.	FAS
29436625	10.3892/mmr.2018.8552	2018	Allicin induces apoptosis through activation of both intrinsic and extrinsic pathways in glioma cells.	FAS
29481902	10.1016/j.jid.2018.02.015	2018	Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma.	FAS
29483509	10.1038/s41467-018-03028-y	2018	Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL.	FAS
29490300	10.1159/000487673	2018	Palmitic Acid-Induced Podocyte Apoptosis via the Reactive Oxygen Species-Dependent Mitochondrial Pathway.	FAS
29504848	10.1080/08916934.2018.1446525	2018	Signalling pathways identified in salivary glands from primary Sj√∂gren's syndrome patients reveal enhanced adipose tissue development.	FAS
29512699	10.3892/mmr.2018.8658	2018	High expression of active ATF6 aggravates endoplasmic reticulum stress‚Äëinduced vascular endothelial cell apoptosis through the mitochondrial apoptotic pathway.	FAS
29516694	10.13702/j.1000-0607.170526	2018	[Effects of Moxibustion on Ventricular Mass Index and Expression of Apoptosis Related Proteins in Myocardium of Rats with Chronic Heart Failure].	FAS
29538305	10.3390/ijms19030848	2018	Epidermal Growth Factor, through Alleviating Oxidative Stress, Protect IPEC-J2 Cells from Lipopolysaccharides-Induced Apoptosis.	FAS
29617412	10.1371/journal.pone.0195116	2018	Tissue Inhibitor of Metalloproteinase-3 (TIMP-3) induces FAS dependent apoptosis in human vascular smooth muscle cells.	FAS
29635023	10.1016/j.biocel.2018.03.020	2018	Edaravone attenuates neuronal apoptosis in hypoxic-ischemic brain damage rat model via suppression of TRAIL signaling pathway.	FAS
29675945	10.1111/php.12925	2018	Epigenetically Enhanced PDT Induces Significantly Higher Levels of Multiple Extrinsic Pathway Apoptotic Factors than Standard PDT, Resulting in Greater Extrinsic and Overall Apoptosis of Cutaneous T-cell Lymphoma.	FAS
29680307	10.1016/j.arcmed.2018.04.006	2018	Prognostic Value of CD95, Active Caspase-3, and Bcl-2 Expression in Adult Patients with De Novo Acute Lymphoblastic Leukemia.	FAS
29721391	10.1080/2162402X.2018.1426423	2018	A genetic IFN/STAT1/FAS axis determines CD4 T stem cell memory levels and apoptosis in healthy controls and Adult T-cell Leukemia patients.	FAS
29772677	10.3390/ijms19051476	2018	Lambertianic Acid Sensitizes Non-Small Cell Lung Cancers to TRAIL-Induced Apoptosis via Inhibition of XIAP/NF-Œ∫B and Activation of Caspases and Death Receptor 4.	FAS
29863267	10.26355/eurrev_201805_15082	2018	Antagonism of cortistatin against cyclosporine-induced apoptosis in rat myocardial cells and its effect on myocardial apoptosis gene expression.	FAS
29891925	10.1038/s41598-018-27106-9	2018	Cadmium-induced apoptosis in neuronal cells is mediated by Fas/FasL-mediated mitochondrial apoptotic signaling pathway.	FAS
29906621	10.1016/j.fsi.2018.06.013	2018	Deoxynivalenol decreased the growth performance and impaired intestinal physical barrier in juvenile grass carp (Ctenopharyngodon idella).	FAS
29914415	10.1186/s12885-018-4525-0	2018	MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-Œ∫B.	FAS
29928342	10.3892/ol.2018.8584	2018	Quercetin induced apoptosis of human oral cancer SAS cells through mitochondria and endoplasmic reticulum mediated signaling pathways.	FAS
29954133	10.3390/nu10070836	2018	CFTR Deletion Confers Mitochondrial Dysfunction and Disrupts Lipid Homeostasis in Intestinal Epithelial Cells.	FAS
29998174	10.1016/j.bonr.2018.06.003	2018	Expression of pro-apoptotic markers is increased along the osteochondral junction in naturally occurring osteochondrosis.	FAS
30023826	10.1021/acsomega.7b01971	2018	Chlorogenic Acid Improves Intestinal Development via Suppressing Mucosa Inflammation and Cell Apoptosis in Weaned Pigs.	FAS
30092310	10.1016/j.ijbiomac.2018.08.017	2018	Zinc-chitosan nanoparticles induced apoptosis in human acute T-lymphocyte leukemia through activation of tumor necrosis factor receptor CD95 and apoptosis-related genes.	FAS
30097433	10.1158/1078-0432.CCR-18-0426	2018	A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.	FAS
30167641	10.1001/jamadermatol.2018.2756	2018	Analysis of the Effect of Gentian Violet on Apoptosis and Proliferation in Cutaneous T-Cell Lymphoma in an In Vitro Study.	FAS
30196309	10.12659/MSM.909726	2018	Marsdenia Tenacissima Extract Inhibits Proliferation and Promotes Apoptosis in Human Ovarian Cancer Cells.	FAS
30206207	10.1038/s41419-018-0964-4	2018	Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia.	FAS
30272252	10.3892/ijmm.2018.3900	2018	eRF3b-37 inhibits the TGF-Œ≤1-induced activation of hepatic stellate cells by regulating cell proliferation, G0/G1 arrest, apoptosis and migration.	FAS
30386345	10.3389/fimmu.2018.02400	2018	EBV Negative Lymphoma and Autoimmune Lymphoproliferative Syndrome Like Phenotype Extend the Clinical Spectrum of Primary Immunodeficiency Caused by STK4 Deficiency.	FAS
30411191	10.1007/s40199-018-0219-z	2018	Anticancer potential of Ferula hezarlalehzarica Y. Ajani fraction in Raji lymphoma cell line: induction of apoptosis, cell cycle arrest, and changes in mitochondrial membrane potential.	FAS
30515277	10.4162/nrp.2018.12.6.494	2018	Red pepper seed water extract inhibits preadipocyte differentiation and induces mature adipocyte apoptosis in 3T3-L1 cells.	FAS
30571718	10.1371/journal.pone.0208633	2018	Combined effects of 17Œ≤-estradiol and exercise training on cardiac apoptosis in ovariectomized rats.	FAS
30610804	NA	2018	Research on correlations of ERCC-1 with proliferation and apoptosis of ovarian cancer cells.	FAS
32186077	NA	2018	Antioxidative and hepatoprotective activities of the ethyl acetate fraction separated from the fruit of Livistona chinensis.	FAS
27135630	10.1111/and.12580	2017	Dose-dependent protective effect of baicalin against testicular torsion-detorsion in rats.	FAS
27444971	10.1002/tox.22325	2017	Bufalin induces apoptosis in vitro and has Antitumor activity against human lung cancer xenografts in vivo.	FAS
27641442	10.1016/j.bbadis.2016.09.012	2017	CD95-mediated apoptosis in Burkitt's lymphoma B-cells is associated with Pim-1 down-regulation.	FAS
27799292	10.1128/MCB.00254-16	2017	SUMO-Modified FADD Recruits Cytosolic Drp1 and Caspase-10 to Mitochondria for Regulated Necrosis.	FAS
27846610	10.3324/haematol.2015.138081	2017	Bone marrow findings in autoimmune lymphoproliferative syndrome with germline FAS mutation.	FAS
27848183	10.1007/s12185-016-2126-8	2017	An atypical case of late-onset systemic lupus erythematosus with systemic lymphadenopathy and severe autoimmune thrombocytopenia/neutropenia mimicking malignant lymphoma.	FAS
27929746	10.1080/15384101.2016.1261226	2017	Exogenous expression of SAMHD1 inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma-derived HuT78 cells.	FAS
27977511	10.1097/FPC.0000000000000262	2017	Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger.	FAS
28144786	10.1007/s12185-016-2175-z	2017	Serum concentrations of apoptosis-associated molecules in septic children with leukemia, neutropenia and fever.	FAS
28166970	10.1016/j.theriogenology.2016.11.030	2017	Effects of intrauterine growth restriction during late pregnancy on the cell apoptosis and related gene expression in ovine fetal liver.	FAS
28177892	10.18632/oncotarget.15050	2017	Pevonedistat, a Nedd8-activating enzyme inhibitor, sensitizes neoplastic B-cells to death receptor-mediated apoptosis.	FAS
28182009	10.1038/cddis.2017.22	2017	Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling.	FAS
28192254	10.1016/j.fsi.2017.02.007	2017	Effect of dietary phosphorus deficiency on the growth, immune function and structural integrity of head kidney, spleen and skin in young grass carp (Ctenopharyngodon idella).	FAS
28202635	10.3945/jn.116.240804	2017	Short-Term Subclinical Zinc Deficiency in Weaned Piglets Affects Cardiac Redox Metabolism and Zinc Concentration.	FAS
28206666	10.2340/00015555-2632	2017	High Expression of Fas/CD95 on CD4+ Circulating T Cells: An Exclusion Criterion in the Diagnosis of Mycosis Fungoides?	FAS
28260084	10.3892/mmr.2017.6283	2017	Toxicity study of oxalicumone A, derived from a marine-derived fungus Penicillium oxalicum, in cultured renal epithelial cells.	FAS
28356967	10.3892/ol.2016.5517	2017	<i>Trametes robiniophila</i> may induce apoptosis and inhibit MMPs expression in the human gastric carcinoma cell line MKN-45.	FAS
28361387	10.1007/s12011-017-0992-4	2017	Excess Manganese-Induced Apoptosis in Chicken Cerebrums and Embryonic Neurocytes.	FAS
28368239	10.17305/bjbms.2017.1961	2017	Apoptosis of pancreatic Œ≤-cells in Type 1 diabetes.	FAS
28373431	10.21873/anticanres.11501	2017	Caspase-6 Induces 7A6 Antigen Localization to Mitochondria During FAS-induced Apoptosis of Jurkat Cells.	FAS
28428059	10.1016/j.fsi.2017.04.009	2017	The decreased growth performance and impaired immune function and structural integrity by dietary iron deficiency or excess are associated with TOR, NF-Œ∫B, p38MAPK, Nrf2 and MLCK signaling in head kidney, spleen and skin of grass carp (Ctenopharyngodon idella).	FAS
28450936	10.3892/etm.2017.4088	2017	The traditional Korean herbal medicine Ga-Gam-Nai-Go-Hyan suppresses testosterone-induced benign prostatic hyperplasia by regulating inflammatory responses and apoptosis.	FAS
28454103	10.18632/oncotarget.16960	2017	Subchronic arsenism-induced oxidative stress and inflammation contribute to apoptosis through mitochondrial and death receptor dependent pathways in chicken immune organs.	FAS
28454279	10.3892/ol.2016.5547	2017	Anticancer activity of <i>Nelumbo nucifera</i> stamen extract in human colon cancer HCT-116 cells <i>in vitro</i>.	FAS
28489605	10.18632/oncotarget.17383	2017	Genetic rearrangements result in altered gene expression and novel fusion transcripts in S√©zary syndrome.	FAS
28494454	10.1159/000475884	2017	Acceleration of Apoptosis by Extracellular Basic pH in a 3D Human Skin Equivalent System.	FAS
28529565	10.3892/ol.2017.5813	2017	Prodelphinidins isolated from Chinese bayberry leaves induces apoptosis via the p53-dependent signaling pathways in OVCAR-3 human ovarian cancer cells.	FAS
28577176	10.1007/s00125-017-4316-1	2017	Complement C5a induces mesenchymal stem cell apoptosis during the progression of chronic diabetic complications.	FAS
28586001	10.3892/mmr.2017.6678	2017	Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways.	FAS
28595877	10.1016/j.bcp.2017.06.112	2017	Lipoxygenase inhibitors protect acute lymphoblastic leukemia cells from ferroptotic cell death.	FAS
28610850	10.1016/j.fsi.2017.06.032	2017	Dietary myo-inositol deficiency decreased the growth performances and impaired intestinal physical barrier function partly relating to nrf2, jnk, e2f4 and mlck signaling in young grass carp (Ctenopharyngodon idella).	FAS
28610909	10.1016/j.imbio.2017.06.001	2017	RIP1 has a role in CD40-mediated apoptosis in human follicular lymphoma cells.	FAS
28625872	10.1016/j.fsi.2017.06.041	2017	Decreased enteritis resistance ability by dietary low or excess levels of¬†lipids through impairing the intestinal physical and immune barriers function of young grass carp (Ctenopharyngodon idella).	FAS
28627691	10.3892/mmr.2017.6798	2017	Scutellaria¬†baicalensis Georgi induces caspase-dependent apoptosis via mitogen activated protein kinase activation and the generation of reactive oxygen species signaling pathways in MCF-7 breast cancer cells.	FAS
28627735	10.1111/cas.13303	2017	Genetic alterations in adult T-cell leukemia/lymphoma.	FAS
28698127	10.1016/j.fsi.2017.07.019	2017	Dietary protein levels regulated antibacterial activity, inflammatory response and structural integrity in the head kidney, spleen and skin of grass carp (Ctenopharyngodon idella) after challenged with Aeromonas hydrophila.	FAS
28798154	10.1096/fj.201700033R	2017	A novel synthetic analogue of œâ-3 17,18-epoxyeicosatetraenoic acid activates TNF receptor-1/ASK1/JNK signaling to promote apoptosis in human breast cancer cells.	FAS
28814155	10.1080/00480169.2017.1367731	2017	Frequency of a FAS ligand gene variant associated with inherited feline autoimmune lymphoproliferative syndrome in British shorthair cats in New Zealand.	FAS
28849044	10.3892/mmr.2017.7259	2017	Emodin alleviates severe acute pancreatitis-associated acute lung injury by decreasing pre-B-cell colony-enhancing factor expression and promoting polymorphonuclear neutrophil apoptosis.	FAS
28933221	10.1177/0963689717715168	2017	Neural Stem Cell Transplantation Is Associated with Inhibition of Apoptosis, Bcl-xL Upregulation, and Recovery of Neurological Function in a Rat Model of Traumatic Brain Injury.	FAS
28950661	10.1016/j.biopha.2017.08.021	2017	Linarin sensitizes tumor necrosis factor-related apoptosis (TRAIL)-induced ligand-triggered apoptosis in human glioma cells and in xenograft nude mice.	FAS
28962106	10.3892/etm.2017.4769	2017	Effects of celecoxib on cell apoptosis and Fas, FasL and Bcl-2 expression in a BGC-823 human gastric cancer cell line.	FAS
28978471	10.1016/j.celrep.2017.09.015	2017	Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.	FAS
29104666	10.3892/etm.2017.5105	2017	<i>Lactobacillus</i> raises <i>in vitro</i> anticancer effect of geniposide in HSC-3 human oral squamous cell carcinoma cells.	FAS
29142404	10.4103/pm.pm_13_17	2017	Chalepin: A Compound from <i>Ruta angustifolia</i> L. Pers Exhibits Cell Cycle Arrest at S phase, Suppresses Nuclear Factor-Kappa B (NF-Œ∫B) Pathway, Signal Transducer and Activation of Transcription 3 (STAT3) Phosphorylation and Extrinsic Apoptotic Pathway in Non-small Cell Lung Cancer Carcinoma (A549).	FAS
29217160	10.1016/j.biopha.2017.11.122	2017	Interaction between Gallic acid and Asparaginase to potentiate anti-proliferative effect on lymphoblastic leukemia cell line.	FAS
29285062	10.3892/etm.2017.5241	2017	Effects of apigenin on the expression levels of B-cell lymphoma-2, Fas and Fas ligand in renal ischemia-reperfusion injury in rats.	FAS
29960293	10.1016/s0254-6272(17)30046-8	2017	Effect of Icariin on apoptosis and expression of Fas, Fas ligand, B cell lymphoma, and Bcl-2-associated X protein in CD4+ T lymphocytesfrom patients with ankylosing spondylitis.	FAS
25663566	10.1007/s12016-015-8466-y	2016	Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS).	FAS
25927246	10.3109/10428194.2015.1044449	2016	Features of cell death, mitochondrial activation and caspase dependence of rabbit anti-T-lymphocyte globulin signaling in lymphoblastic Jurkat cells are distinct from classical apoptosis signaling of CD95.	FAS
26310832	10.1189/jlb.3A1114-537RR	2016	Staurosporine resistance in inflammatory neutrophils is associated with the inhibition of caspase- and proteasome-mediated Mcl-1 degradation.	FAS
26437781	10.1038/leu.2015.267	2016	A20 targets caspase-8 and FADD to protect HTLV-I-infected cells.	FAS
26479732	10.1080/09168451.2015.1095065	2016	Advanced glycation end-product (AGE) induces apoptosis in human retinal ARPE-19 cells via promoting mitochondrial dysfunction and activating the Fas-FasL signaling.	FAS
26581163	10.1038/mt.2015.209	2016	A Recombinant Bispecific CD20√óCD95 Antibody With Superior Activity Against Normal and Malignant B-cells.	FAS
26724751	10.1016/j.virusres.2015.12.012	2016	Antigen detection and apoptosis in Mongolian gerbil's kidney experimentally intraperitoneally infected by swine hepatitis E virus.	FAS
26767854	10.3904/kjim.2016.31.1.30	2016	The antibacterial effect of fatty acids on Helicobacter pylori infection.	FAS
26769704	10.1007/s12010-015-1970-y	2016	Fermented Brown Rice Extract Causes Apoptotic Death of Human Acute Lymphoblastic Leukemia Cells via Death Receptor Pathway.	FAS
26829127	10.1021/acs.jafc.5b05613	2016	Trace Mineral Overload Induced Hepatic Oxidative Damage and Apoptosis in Pigs with Long-Term High-Level Dietary Mineral Exposure.	FAS
26848681	10.3390/v8020033	2016	Pandemic Influenza A (H1N1) Virus Infection Increases Apoptosis and HIV-1 Replication in HIV-1 Infected Jurkat Cells.	FAS
26885564	10.3109/10428194.2016.1144879	2016	Butyrate production from high-fiber diet protects against lymphoma tumor.	FAS
26905515	10.1007/s00296-016-3443-1	2016	Fas/FasL, Bcl2 and Caspase-8 gene polymorphisms in Chinese patients with rheumatoid arthritis.	FAS
26944716	10.1016/j.fsi.2016.02.033	2016	Dietary vitamin C deficiency depresses the growth, head kidney and spleen immunity and structural integrity by regulating NF-Œ∫B, TOR, Nrf2, apoptosis and MLCK signaling in young grass carp (Ctenopharyngodon idella).	FAS
26950187	10.1002/ajh.24354	2016	A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients.	FAS
26968634	10.1016/j.yexcr.2016.03.006	2016	Dual effect of LPS on murine myeloid leukemia cells: Pro-proliferation and anti-proliferation.	FAS
26985864	10.3892/or.2016.4682	2016	Curcumin inhibits intracellular fatty acid synthase and induces apoptosis in human breast cancer MDA-MB-231 cells.	FAS
27060458	10.1111/cei.12800	2016	Differential regulation of miR-146a/FAS and miR-21/FASLG axes in autoimmune lymphoproliferative syndrome due to FAS mutation (ALPS-FAS).	FAS
27157598	10.1016/j.fsi.2016.03.163	2016	Dietary low or excess levels of lipids reduced growth performance, and impaired immune function and structure of head kidney, spleen and skin in young grass carp (Ctenopharyngodon idella) under the infection of Aeromonas hydrophila.	FAS
27175997	10.3892/mmr.2016.5287	2016	Saponin 6 derived from Anemone¬†taipaiensis induces U87 human malignant glioblastoma cell apoptosis via regulation of Fas and Bcl‚Äë2 family proteins.	FAS
27206675	10.18632/oncotarget.9390	2016	Loss of T-cell quiescence by targeting Slfn2 prevents the development and progression of T-ALL.	FAS
27256594	10.1111/jcmm.12880	2016	Helium-based cold atmospheric plasma-induced reactive oxygen species-mediated apoptotic pathway attenuated by platinum nanoparticles.	FAS
27306897	10.3945/jn.116.231639	2016	Membrane Disordering by Eicosapentaenoic Acid in B Lymphomas Is Reduced by Elongation to Docosapentaenoic Acid as Revealed with Solid-State Nuclear Magnetic Resonance Spectroscopy of Model Membranes.	FAS
27391025	10.1371/journal.pone.0158987	2016	The Interaction of CD154 with the Œ±5Œ≤1 Integrin Inhibits Fas-Induced T Cell Death.	FAS
27444344	10.1016/j.phymed.2016.05.009	2016	Trifolin induces apoptosis via extrinsic and intrinsic pathways in the NCI-H460 human non-small cell lung-cancer cell line.	FAS
27509941	NA	2016	E1/E2 of Hepatitis C Virus Genotype4 and Apoptosis.	FAS
27551529	10.1038/cddiscovery.2016.39	2016	Comparison of biological effects of modulated electro-hyperthermia and conventional heat treatment in human lymphoma U937 cells.	FAS
27556297	10.18632/oncotarget.11370	2016	Deregulated FADD expression and phosphorylation in T-cell lymphoblastic lymphoma.	FAS
27558422	10.1128/JVI.00668-16	2016	CD95 Signaling Inhibits B Cell Receptor-Mediated Gammaherpesvirus Replication in Apoptosis-Resistant B Lymphoma Cells.	FAS
27600729	10.3892/mmr.2016.5712	2016	Curcumin ameliorates high‚Äëfat diet‚Äëinduced spermatogenesis dysfunction.	FAS
27600998	10.3892/mmr.2016.5714	2016	Resveratrol attenuates acute kidney injury by inhibiting death receptor‚Äëmediated apoptotic pathways in a cisplatin‚Äëinduced rat model.	FAS
27603942	10.1371/journal.pone.0162456	2016	A B-Cell Superantigen Induces the Apoptosis of Murine and Human Malignant B Cells.	FAS
27640333	10.1016/j.fsi.2016.09.029	2016	Dietary vitamin C deficiency depressed the gill physical barriers and immune barriers referring to Nrf2, apoptosis, MLCK, NF-Œ∫B and TOR signaling in grass carp (Ctenopharyngodon idella) under infection of Flavobacterium columnare.	FAS
27802519	10.1167/iovs.16-19707	2016	Antiapoptotic Effect of Acetylcholine in Fas-Induced Apoptosis in Human Keratocytes.	FAS
27882126	10.3892/etm.2016.3727	2016	Anticancer activities of alkaloids extracted from the <i>Ba lotus</i> seed in human nasopharyngeal carcinoma CNE-1 cells.	FAS
27893813	10.1371/journal.ppat.1006042	2016	Azidothymidine Sensitizes Primary Effusion Lymphoma Cells to Kaposi Sarcoma-Associated Herpesvirus-Specific CD4+ T Cell Control and Inhibits vIRF3 Function.	FAS
28078002	NA	2016	LncRNA-LINC00152 down-regulated by miR-376c-3p restricts viability and promotes apoptosis of colorectal cancer cells.	FAS
28101220	10.3892/ol.2016.5284	2016	Antitumor effect of forbesione isolated from <i>Garcinia hanburyi</i> on cholangiocarcinoma <i>in vitro</i> and <i>in vivo</i>.	FAS
24716460	10.3109/10428194.2014.913287	2015	Abnormal expression of CD66a promotes proliferation and inhibits apoptosis of human leukemic B cells in vitro.	FAS
24872334	10.1177/1933719114536474	2015	Prenatal exposure to hypoxia induced Beclin 1 signaling-mediated renal autophagy and altered renal development in rat fetuses.	FAS
25140833	10.1038/jid.2014.364	2015	c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death.	FAS
25273173	10.1007/s13277-014-2675-5	2015	Antitumor activity of irradiated riboflavin on human renal carcinoma cell line 786-O.	FAS
25301266	10.14670/HH-30.559	2015	Lymphoid hyperplasia and lymphoma in KSHV K1 transgenic mice.	FAS
25301392	10.1007/s00125-014-3407-5	2015	Autoreactive T cells induce necrosis and not BCL-2-regulated or death receptor-mediated apoptosis or RIPK3-dependent necroptosis of transplanted islets in a mouse model of type 1 diabetes.	FAS
25352238	10.3892/mmr.2014.2779	2015	Salvia miltiorrhiza injection restores apoptosis of fibroblast-like synoviocytes cultured with serum from patients with rheumatoid arthritis.	FAS
25373554	10.3892/mmr.2014.2885	2015	Baicalein induces apoptosis of human cervical cancer HeLa cells in vitro.	FAS
25465296	10.1016/j.jbior.2014.10.003	2015	Lipid rafts as major platforms for signaling regulation in cancer.	FAS
25515142	10.3892/mmr.2014.3096	2015	Iodine-131 induces apoptosis in HTori-3 human thyrocyte cell line and G2/M phase arrest in a p53-independent pathway.	FAS
25552935	10.7150/ijbs.10276	2015	MiR-467a is upregulated in radiation-induced mouse thymic lymphomas and regulates apoptosis by targeting Fas and Bax.	FAS
25578476	10.1038/leu.2015.9	2015	BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma.	FAS
25582824	10.1038/mt.2015.4	2015	Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.	FAS
25624917	10.3892/ol.2014.2756	2015	Induction of apoptosis in HCT-116 colon cancer cells by polysaccharide of <i>Larimichthys crocea</i> swim bladder.	FAS
25642983	10.1371/journal.pgen.1004922	2015	Genome-wide association study identifies shared risk loci common to two malignancies in golden retrievers.	FAS
25647297	10.3892/ijo.2015.2869	2015	(-)-Epigallocatechingallate induces apoptosis in B lymphoma cells via caspase-dependent pathway and Bcl-2 family protein modulation.	FAS
25670364	10.1016/j.jacl.2014.09.014	2015	Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency.	FAS
25678597	10.1158/1541-7786.MCR-14-0241	2015	HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer.	FAS
25690520	10.5507/bp.2015.005	2015	New biomarkers in the selection of patients for talcage of pleural cavity in the palliative therapy of malign pleural exudate.	FAS
25708257	10.1111/aji.12371	2015	Effects of Intrauterine Growth Restriction During Late Pregnancy on the Development of the Ovine Fetal Thymus and the T-Lymphocyte Subpopulation.	FAS
25808868	10.1158/0008-5472.CAN-14-2144	2015	Decoy Receptor DcR1 Is Induced in a p50/Bcl3-Dependent Manner and Attenuates the Efficacy of Temozolomide.	FAS
25850729	10.1016/j.leukres.2015.03.010	2015	LFA-1-targeting Leukotoxin (LtxA; Leukothera¬Æ) causes lymphoma tumor regression in a humanized mouse model and requires caspase-8 and Fas to kill malignant lymphocytes.	FAS
25868101	10.1097/BRS.0000000000000821	2015	Apoptosis in human compressive myelopathy due to metastatic neoplasia.	FAS
25921028	10.1016/j.intimp.2015.04.034	2015	Genipin attenuates sepsis-induced immunosuppression through inhibition of T lymphocyte apoptosis.	FAS
25927598	10.1080/15384101.2015.1038685	2015	Autophagy and apoptosis in liver injury.	FAS
25948224	10.7534/j.issn.1009-2137.2015.02.051	2015	[Research Progress on Expression Regulation, Function and Clinical Significance of CASP8AP2 Gene].	FAS
25951128	10.3390/nu7053200	2015	Anticancer Effect of Ursodeoxycholic Acid in Human Oral Squamous Carcinoma HSC-3 Cells through the Caspases.	FAS
26010871	10.1371/journal.pone.0126526	2015	Death Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells.	FAS
26041772	10.1177/0300985815586224	2015	A Novel and Likely Inherited Lymphoproliferative Disease in British Shorthair Kittens.	FAS
26062198	NA	2015	[Effects of moxibustion with seed-sized moxa cone on apoptosis of myocardial cells after sport fatigue in mice].	FAS
26062544	10.1186/s40659-015-0022-y	2015	Hepato-protective effect of rutin via IL-6/STAT3 pathway in CCl4-induced hepatotoxicity in rats.	FAS
26063084	10.3892/ijmm.2015.2241	2015	Rhodiola rosea suppresses thymus T-lymphocyte apoptosis by downregulating tumor necrosis factor-Œ±-induced protein 8-like-2 in septic rats.	FAS
26081503	NA	2015	[Effects of chronic intermittent hypoxia on regulation of miRNA-214 in myocardial apoptosis in rats].	FAS
26115301	10.2527/jas.2014-8597	2015	Genome wide transcriptomic analysis identifies pathways affected by the infusion of Clostridium perfringens culture supernatant in the duodenum of broilers in situ.	FAS
26142735	10.1007/s13277-015-3720-8	2015	Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.	FAS
26185062	10.1007/s12185-015-1843-8	2015	Analysis of the molecular mechanism underlying bone marrow necrosis with acute lymphoblastic leukemia.	FAS
26190111	10.1016/j.celrep.2015.06.057	2015	Systemic Akt1 Deletion after Tumor Onset in p53(-/-) Mice Increases Lifespan and Regresses Thymic Lymphoma Emulating p53 Restoration.	FAS
26202984	10.4049/jimmunol.1402942	2015	Localized Store-Operated Calcium Influx Represses CD95-Dependent Apoptotic Effects of Rituximab in Non-Hodgkin B Lymphomas.	FAS
26271190	10.1016/j.bbmt.2015.08.008	2015	Apoptosis Susceptibility Prolongs the Lack of Memory B Cells in Acute Leukemic Patients After Allogeneic Hematopoietic Stem Cell Transplantation.	FAS
26302991	10.1111/php.12521	2015	Epigenetically Enhanced Photodynamic Therapy (ePDT) is Superior to Conventional Photodynamic Therapy for Inducing Apoptosis in Cutaneous T-Cell Lymphoma.	FAS
26334989	10.1038/pr.2015.170	2015	Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.	FAS
26389000	10.3831/KPI.2015.18.022	2015	Condurango (Gonolobus condurango) Extract Activates Fas Receptor and Depolarizes Mitochondrial Membrane Potential to Induce ROS-dependent Apoptosis in Cancer Cells in vitro: CE-treatment on HeLa: a ROS-dependent mechanism.	FAS
26398902	10.3892/or.2015.4303	2015	RANKL/RANK interaction promotes the growth of cervical cancer cells by strengthening the dialogue between cervical cancer cells and regulation of IL-8 secretion.	FAS
26422926	NA	2015	[INFLUENCE OF DOXORUBICIN AND ETOPOSIDE ON THE CD 95 MEDIATED APOPTOSIS IN EBV INFECTED LYMPHOMA CELLS BL-41 AND DG-75].	FAS
26446488	10.1038/ncomms9325	2015	LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair.	FAS
26467838	10.1099/jgv.0.000313	2015	Epstein-Barr virus-infected cells release Fas ligand in exosomal fractions and induce apoptosis in recipient cells via the extrinsic pathway.	FAS
26556860	10.18632/oncotarget.5715	2015	The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.	FAS
26599641	10.1371/journal.pone.0143414	2015	Apoptosis-Related Factors in the Luteal Phase of the Domestic Cat and Their Involvement in the Persistence of Corpora Lutea in Lynx.	FAS
26679669	NA	2015	[Autoimmune lymphoproliferative syndrome: a case report and literature review].	FAS
23697878	10.3109/10428194.2013.806802	2014	Apoptotic and proliferative characteristics of proliferation centers in lymph node sections of patients with chronic lymphocytic leukemia.	FAS
23783422	10.1007/s00277-013-1823-0	2014	A diagnostic dilemma in AL(L)PS.	FAS
23832418	10.1002/ijc.28379	2014	The Wilms' tumor suppressor WT1 enhances CD95L expression and promotes activation-induced cell death in leukemic T cells.	FAS
23845452	10.1016/j.remn.2013.05.008	2014	Autoimmune lymphoproliferative syndrome and non-Hodgkin lymphoma: what 18F-fluorodeoxyglucose positron emission tomography/computed tomography can do in the management of these patients? Suggestions from a case report.	FAS
23906016	10.3109/10428194.2013.829573	2014	Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide.	FAS
23963693	10.1002/cbf.2993	2014	Anti-proliferative and apoptosis inducing effect of nimbolide by altering molecules involved in apoptosis and IGF signalling via PI3K/Akt in prostate cancer (PC-3) cell line.	FAS
24140513	10.1016/j.bbadis.2013.10.006	2014	Toll-like receptor 3 plays a role in myocardial infarction and ischemia/reperfusion injury.	FAS
24177179	10.1158/0008-5472.CAN-13-0436	2014	HTLV-1 bZIP factor suppresses apoptosis by attenuating the function of FoxO3a and altering its localization.	FAS
24189145	10.1158/2159-8290.CD-13-0276	2014	Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma.	FAS
24200242	10.1089/scd.2013.0270	2014	Resistance of hematopoietic progenitors to Fas-mediated apoptosis is actively sustained by NFŒ∫B with a characteristic transcriptional signature.	FAS
24212079	10.1016/j.jep.2013.10.045	2014	Total alkaloids of Tripterygium hypoglaucum (levl.) Hutch inhibits tumor growth both in vitro and in vivo.	FAS
24218069	10.1007/s12253-013-9705-2	2014	Fas gene variants in childhood acute lymphoblastic leukemia and association with prognosis.	FAS
24279338	10.3109/09553002.2014.859765	2014	Carcinogenic and inflammatory effects of plutonium-nitrate retention in an exposed nuclear worker and beagle dogs.	FAS
24352466	10.1128/JVI.03025-13	2014	Human T-cell leukemia virus type 1 Tax-deregulated autophagy pathway and c-FLIP expression contribute to resistance against death receptor-mediated apoptosis.	FAS
24353313	10.1124/mol.113.090043	2014	Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells.	FAS
24397922	10.1016/j.mce.2013.10.024	2014	Up-regulation of Bcl-2 during adipogenesis mediates apoptosis resistance in human adipocytes.	FAS
24398331	10.1182/blood-2013-10-535393	2014	Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.	FAS
24417874	10.5732/cjc.013.10131	2014	Resistance to apoptosis should not be taken as a hallmark of cancer.	FAS
24434433	10.1038/bjc.2013.779	2014	Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity.	FAS
24487434	10.1038/nm.3442	2014	Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas.	FAS
24577510	10.1007/s00277-014-2021-4	2014	Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.	FAS
24603338	10.1038/cddis.2014.83	2014	FAS system deregulation in T-cell lymphoblastic lymphoma.	FAS
24646432	10.1111/exd.12374	2014	Quantitative gene analysis of methylation and expression (Q-GAME) in fresh or fixed cells and tissues.	FAS
24682485	10.3892/ijo.2014.2361	2014	Antibody ligation of CM1 on cisplatin-exposed HeLa cells induces apoptosis through reactive oxygen species-dependent Fas ligand expression.	FAS
24687228	10.1007/s10495-014-0972-5	2014	Effects of SOD/catalase mimetic platinum nanoparticles on radiation-induced apoptosis in human lymphoma U937 cells.	FAS
24692054	10.1007/s10495-014-0984-1	2014	Isofraxidin, a potent reactive oxygen species (ROS) scavenger, protects human leukemia cells from radiation-induced apoptosis via ROS/mitochondria pathway in p53-independent manner.	FAS
24706665	10.1158/2159-8290.CD-RW2014-035	2014	T cells prevent the development of spontaneous B-cell lymphomas.	FAS
24811343	10.1038/leu.2014.126	2014	FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.	FAS
24855207	10.1182/blood-2013-05-500918	2014	Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly.	FAS
24862567	10.1016/j.abb.2014.04.019	2014	Methotrexate inhibits the viability of human melanoma cell lines and enhances Fas/Fas-ligand expression, apoptosis and response to interferon-alpha: rationale for its use in combination therapy.	FAS
24989893	10.1111/boc.201400004	2014	Mark4 promotes adipogenesis and triggers apoptosis in 3T3-L1 adipocytes by activating JNK1 and inhibiting p38MAPK pathways.	FAS
25013479	10.3892/ol.2014.2147	2014	Pregnenolone, a cholesterol metabolite, induces glioma cell apoptosis via activating extrinsic and intrinsic apoptotic pathways.	FAS
25048265	10.1538/expanim.63.459	2014	Administration of an antioxidant prevents lymphoma development in transmitochondrial mice overproducing reactive oxygen species.	FAS
25050223	10.4161/onci.28697	2014	T cell immunosurveillance controls B lymphoma development.	FAS
25078973	10.1016/j.cbi.2014.07.004	2014	Spiruchostatin A and B, novel histone deacetylase inhibitors, induce apoptosis through reactive oxygen species-mitochondria pathway in human lymphoma U937 cells.	FAS
25086580	10.1007/s11882-014-0462-4	2014	Autoimmune lymphoproliferative syndrome: an update and review of the literature.	FAS
25187044	10.1007/s10495-014-1032-x	2014	Arbutin, an intracellular hydroxyl radical scavenger, protects radiation-induced apoptosis in human lymphoma U937 cells.	FAS
25197333	NA	2014	Epigallocatechin-3-gallate protects against cisplatin nephrotoxicity by inhibiting the apoptosis in mouse.	FAS
25225399	10.1073/pnas.1414780111	2014	Dysfunction of dendritic cells in aged C57BL/6 mice leads to failure of natural killer cell activation and of tumor eradication.	FAS
25227919	10.1186/s13045-014-0064-6	2014	Highly efficient, in-vivo Fas-mediated apoptosis of B-cell lymphoma by hexameric CTLA4-FasL.	FAS
25232277	10.4137/BMI.S16553	2014	Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas.	FAS
25304249	10.1186/s13046-014-0080-y	2014	CD74 interferes with the expression of fas receptor on the surface of lymphoma cells.	FAS
25470234	10.4161/15548627.2014.981790	2014	Deficiency in the mitochondrial apoptotic pathway reveals the toxic potential of autophagy under ER stress conditions.	FAS
25482930	10.4161/15384047.2014.972183	2014	DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.	FAS
25692234	10.1080/15476286.2014.996462	2014	The role of microRNAs in osteoclasts and osteoporosis.	FAS
22464639	10.1016/j.etp.2012.02.002	2013	Alpha-chymotrypcin ameliorates neuroinflammation and apoptosis characterizing Alzheimer's disease-induced in ovarictomized rats.	FAS
22543586	10.1038/onc.2012.150	2013	Depletion of the receptor for advanced glycation end products (RAGE) sensitizes towards apoptosis via p53 and p73 posttranslational regulation.	FAS
22830613	10.3109/10428194.2012.710331	2013	Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.	FAS
22891763	10.3109/10428194.2012.720979	2013	Fas-associated phosphatase 1 mediates Fas resistance in myeloid progenitor cells expressing the Bcr-abl oncogene.	FAS
22989017	10.3109/10428194.2012.731600	2013	Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils.	FAS
23093495	10.1124/mol.112.080788	2013	Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.	FAS
23173123	NA	2013	Vps41, a protein involved in lysosomal trafficking, interacts with caspase-8.	FAS
23202726	10.1177/1933719112466305	2013	Complete sperm suppression in rats with dienogest plus testosterone undecanoate is facilitated through apoptosis in testicular cells.	FAS
23246696	10.1016/j.gene.2012.12.009	2013	Regulation of the MIR155 host gene in physiological and pathological processes.	FAS
23264653	10.4049/jimmunol.1201554	2013	Granzyme B-mediated damage of CD8+ T cells impairs graft-versus-tumor effect.	FAS
23349502	10.2337/db12-0677	2013	Cbl-b is a critical regulator of macrophage activation associated with obesity-induced insulin resistance in mice.	FAS
23382561	10.4049/jimmunol.1201605	2013	CD4+ T cell-depleted lymphocyte infusion impairs neither the recovery of recipient thymus nor the development of transplanted thymus.	FAS
23415674	10.1016/j.exphem.2013.02.004	2013	Deferasirox shows in¬†vitro and in¬†vivo antileukemic effects on murine leukemic cell lines regardless of iron status.	FAS
23435631	10.1007/s11130-013-0344-2	2013	Micropropagation effect on the anti-carcinogenic activitiy of polyphenolics from Mexican oregano (Poliomintha glabrescens Gray) in human colon cancer cells HT-29.	FAS
23485651	10.1016/j.tox.2013.02.010	2013	Cadmium telluride quantum dots cause oxidative stress leading to extrinsic and intrinsic apoptosis in hepatocellular carcinoma HepG2 cells.	FAS
23530146	10.4049/jimmunol.1202487	2013	Adiponectin deficiency suppresses lymphoma growth in mice by modulating NK cells, CD8 T cells, and myeloid-derived suppressor cells.	FAS
23541070	10.1016/j.critrevonc.2013.02.005	2013	The role of the ubiquitin proteasome system in lymphoma.	FAS
23545938	10.1038/labinvest.2013.50	2013	RIP1 expression is necessary for CD30-mediated cell death induction in anaplastic large-cell lymphoma cells.	FAS
23567332	10.1016/j.trsl.2013.03.004	2013	Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.	FAS
23597460	NA	2013	[Detection of the expression of NK ligands in acute leukemia cell lines by real-time PCR].	FAS
23599269	10.1182/blood-2012-12-471094	2013	Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex.	FAS
23658488	10.2147/IJN.S43508	2013	Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells.	FAS
23665184	10.1016/j.jhep.2013.04.031	2013	Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.	FAS
23727661	10.1038/bcj.2013.15	2013	Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma.	FAS
23727784	10.1038/cmi.2013.14	2013	Toll-like receptor agonists induce apoptosis in mouse B-cell lymphoma cells by altering NF-Œ∫B activation.	FAS
23751424	10.1016/j.tiv.2013.05.016	2013	Apoptotic toxicity of destruxin B in human non-Hodgkin lymphoma cells.	FAS
23755802	10.1016/j.theriogenology.2013.04.002	2013	FasL-induced apoptosis in bovine oocytes via the Bax signal.	FAS
23770045	10.1016/j.bbamcr.2013.06.001	2013	Crosstalk between apoptosis, necrosis and autophagy.	FAS
23770345	10.1016/j.fct.2013.05.045	2013	Proteomic-based identification of multiple pathways underlying n-butylidenephthalide-induced apoptosis in LNCaP human prostate cancer cells.	FAS
23770605	10.1038/ng.2652	2013	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.	FAS
23788110	10.1038/cgt.2013.35	2013	Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.	FAS
23830814	10.1016/j.cbi.2013.06.017	2013	Inhibitory effect of Œ±-lipoic acid on thioacetamide-induced tumor promotion through suppression of inflammatory cell responses in a two-stage hepatocarcinogenesis model in rats.	FAS
23928701	10.1038/cddis.2013.286	2013	Malaria parasite liver stages render host hepatocytes susceptible to mitochondria-initiated apoptosis.	FAS
23934044	10.1177/0300060513490084	2013	Effects of CD40 ligation combined with chemotherapy drugs on human breast cancer cell lines.	FAS
23991993	10.7314/apjcp.2013.14.7.4301	2013	B-cell Lymphoma 2 rs17757541 C&gt;G polymorphism was associated with an increased risk of gastric cardiac adenocarcinoma in a Chinese population.	FAS
24101757	10.1542/peds.2012-2748	2013	Autoimmune lymphoproliferative syndrome misdiagnosed as hemophagocytic lymphohistiocytosis.	FAS
24177013	10.1016/j.bbrc.2013.10.100	2013	Relevance of signaling molecules for apoptosis induction on influenza A virus replication.	FAS
24211713	10.1016/j.clim.2013.08.005	2013	TSPAN33 is a novel marker of activated and malignant B cells.	FAS
24356489	10.1159/000356607	2013	Up-regulated expression of miR-23a/b targeted the pro-apoptotic Fas in radiation-induced thymic lymphoma.	FAS
25374737	10.1155/2013/245893	2013	Autoimmune Lymphoproliferative Syndrome and Epstein-Barr Virus-Associated Lymphoma: An Adjunctive Diagnostic Role for Monitoring EBV Viremia?	FAS
21374789	10.1002/tox.20688	2012	Necrosis and apoptosis of renal tubular epithelial cells in rats exposed to 3-methyl-4-nitrophenol.	FAS
21528407	10.1007/s12032-011-9965-1	2012	Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia.	FAS
21638304	10.1002/hon.996	2012	Cellular (FLICE) like inhibitory protein (cFLIP) expression in diffuse large B-cell lymphoma identifies a poor prognostic subset, but fails to predict the molecular subtype.	FAS
21693768	10.1093/annonc/mdr289	2012	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion.	FAS
21917312	10.1016/j.leukres.2011.08.005	2012	Elevated Fas/FasL system and endothelial cell microparticles are involved in endothelial damage in acute graft-versus-host disease: a clinical analysis.	FAS
21986259	10.1016/j.tiv.2011.09.010	2012	The role of the intrinsic FAS pathway in Titanocene Y apoptosis: The mechanism of overcoming multiple drug resistance in malignant leukemia cells.	FAS
22017300	10.1111/j.1349-7006.2011.02124.x	2012	Alginate encapsulated cells secreting Fas-ligand reduce lymphoma carcinogenicity.	FAS
22086925	10.1074/jbc.M111.286526	2012	Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.	FAS
22108298	10.1016/j.mrrev.2011.11.001	2012	Biological activity of piceatannol: leaving the shadow of resveratrol.	FAS
22156152	10.1177/1538574411422277	2012	p53 gene therapy modulates signal transduction in the apoptotic and cell cycle pathways downregulating neointimal hyperplasia.	FAS
22211272	10.3109/08923973.2011.643313	2012	Differential immunotoxic effects of ethanol on murine EL-4 lymphoma and normal lymphocytes is mediated through increased ROS production and activation of p38MAPK.	FAS
22211869	10.3109/10428194.2011.654117	2012	Functional polymorphisms in FAS, FASL and CASP8 genes and risk of childhood acute lymphoblastic leukemia: a case-control study.	FAS
22289617	10.1016/j.biochi.2012.01.015	2012	Effect of ursolic acid treatment on apoptosis and DNA damage in isoproterenol-induced myocardial infarction.	FAS
22308310	10.4049/jimmunol.1102065	2012	Removal of syndecan-1 promotes TRAIL-induced apoptosis in myeloma cells.	FAS
22311471	10.1007/s10495-012-0698-1	2012	Molecular mechanisms of apoptosis induction by 2-dodecylcyclobutanone, a radiolytic product of palmitic acid, in human lymphoma U937 cells.	FAS
22350416	10.1158/0008-5472.CAN-11-2432	2012	Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics.	FAS
22411956	10.1093/carcin/bgs118	2012	ECRG4 is a negative regulator of caspase-8-mediated apoptosis in human T-leukemia cells.	FAS
22414163	10.1111/j.1468-1293.2012.00999.x	2012	Long-term beneficial effect of protease inhibitors on the intrinsic apoptosis of peripheral blood mononuclear cells in HIV-infected patients.	FAS
22652939	10.1097/WON.0b013e318259c47e	2012	Effectiveness of apoptotic factors expressed on the wounds of patients with stage III pressure ulcers.	FAS
22653339	10.1038/cdd.2012.67	2012	C/EBP homologous protein contributes to cytokine-induced pro-inflammatory responses and apoptosis in Œ≤-cells.	FAS
22686190	10.1111/j.1365-2141.2012.09178.x	2012	In non-follicular lymphoproliferative disorders, IGH/BCL2-fusion is not restricted to chronic lymphocytic leukaemia.	FAS
22732457	10.1016/j.jprot.2012.06.009	2012	RNASET2--an autoantigen in anaplastic large cell lymphoma identified by protein array analysis.	FAS
22735740	10.1039/c2mb25120e	2012	Impaired JAK2-induced activation of STAT3 in failing human myocytes.	FAS
22752304	10.1073/pnas.1205995109	2012	Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma.	FAS
22771207	10.1016/j.vetmic.2012.06.009	2012	Ability of Clostridium butyricum to inhibit Escherichia coli-induced apoptosis in chicken embryo intestinal cells.	FAS
22789925	10.1167/iovs.11-8719	2012	Immune mediators in vitreous fluids from patients with vitreoretinal B-cell lymphoma.	FAS
22824744	NA	2012	New insights on the role of T cells in the pathogenesis of celiac disease.	FAS
22884443	10.1016/j.jaad.2012.05.035	2012	The Fas apoptotic pathway in cutaneous T-cell lymphomas: frequent expression of phenotypes associated with resistance to apoptosis.	FAS
22898211	10.1016/j.cbi.2012.07.005	2012	Apoptotic cell death by the novel natural compound, cinobufotalin.	FAS
22904309	10.4049/jimmunol.1101988	2012	Immune surveillance properties of human NK cell-derived exosomes.	FAS
22929310	10.1186/1756-9966-31-69	2012	The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematological cancer cells.	FAS
22945289	10.1002/eji.201242530	2012	ZNF385B is characteristically expressed in germinal center B cells and involved in B-cell apoptosis.	FAS
23109725	10.4049/jimmunol.1102937	2012	Differential expression of neurotensin and specific receptors, NTSR1 and NTSR2, in normal and malignant human B lymphocytes.	FAS
24710548	10.3390/cells1041156	2012	Apoptotic Volume Decrease (AVD) Is Independent of Mitochondrial Dysfunction and Initiator Caspase Activation.	FAS
20706274	10.1038/cdd.2010.99	2011	Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression.	FAS
20872776	10.1002/hep.23987	2011	Tumor necrosis factor Œ± sensitizes primary murine hepatocytes to Fas/CD95-induced apoptosis in a Bim- and Bid-dependent manner.	FAS
20958220	10.3109/09553002.2010.518208	2011	Different radiosensitivity of CD4(+)CD25(+) regulatory T cells and effector T cells to low dose gamma irradiation in¬†vitro.	FAS
21036138	10.1016/j.abb.2010.10.020	2011	Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL).	FAS
21102324	10.1097/MOH.0b013e3283414edf	2011	Neutropenia associated with rituximab therapy.	FAS
21173302	10.1001/archdermatol.2010.376	2011	Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma.	FAS
21190961	10.1210/en.2010-0790	2011	The transcription factor B-cell lymphoma (BCL)-6 modulates pancreatic {beta}-cell inflammatory responses.	FAS
21196202	10.2741/3719	2011	Understanding rituximab function and resistance: implications for tailored therapy.	FAS
21198858	10.1111/j.1600-0609.2010.01567.x	2011	Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL).	FAS
21264287	10.1371/journal.pone.0014527	2011	TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro.	FAS
21270445	10.1182/blood-2010-07-294819	2011	Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription.	FAS
21315423	10.1016/j.humpath.2010.11.002	2011	Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin lymphomas.	FAS
21381869	10.3109/08880018.2011.557261	2011	Hodgkin disease and the role of the immune system.	FAS
21382445	10.1016/j.bbagen.2011.02.010	2011	Agaritine from Agaricus blazei Murrill induces apoptosis in the leukemic cell line U937.	FAS
21447005	10.1111/j.1600-0609.2011.01617.x	2011	Advances in autoimmune lymphoproliferative syndromes.	FAS
21464892	10.1371/journal.pone.0018376	2011	Functional role of kallikrein 6 in regulating immune cell survival.	FAS
21509038	10.1038/cddis.2011.33	2011	Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.	FAS
21520490	10.1002/mnfr.201000576	2011	Resveratrol (trans-3,5,4'-trihydroxystilbene) suppresses EL4 tumor growth by induction of apoptosis involving reciprocal regulation of SIRT1 and NF-Œ∫B.	FAS
21526201	10.1371/journal.pone.0018933	2011	Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement.	FAS
21610152	10.1158/1078-0432.CCR-11-0479	2011	Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.	FAS
21616012	NA	2011	[Signaling pathways in pathogenesis of diffuse large B-cell lymphoma].	FAS
21683516	10.1016/j.canlet.2011.05.014	2011	Resveratrol enhances the expression of death receptor Fas/CD95 and induces differentiation and apoptosis in anaplastic large-cell lymphoma cells.	FAS
21701267	10.1097/AAP.0b013e318217a6c7	2011	Midazolam activates the intrinsic pathway of apoptosis independent of benzodiazepine and death receptor signaling.	FAS
21716208	NA	2011	Quantitative real time PCR analysis of apoptosis-related gene expression in leukemias in Ukrainian patients.	FAS
21774779	10.2174/138161211796957463	2011	Œ≥-Tocotrienol induces apoptosis in human T cell lymphoma through activation of both intrinsic and extrinsic pathways.	FAS
21793801	10.1042/BJ20110125	2011	Phosphoinositide phosphatase SHIP-1 regulates apoptosis induced by edelfosine, Fas ligation and DNA damage in mouse lymphoma cells.	FAS
21803845	10.1182/blood-2011-04-349670	2011	PMLRARŒ± binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo.	FAS
21808017	10.1073/pnas.1100898108	2011	Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers.	FAS
21809546	NA	2011	[Effect and mechanism of matrine on apoptosis of Raji cells].	FAS
21868575	10.1182/blood-2011-04-345181	2011	A novel inhibitor of focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma.	FAS
21885601	10.1182/blood-2011-07-325217	2011	How I treat autoimmune lymphoproliferative syndrome.	FAS
21885602	10.1182/blood-2011-04-347641	2011	A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation.	FAS
22084121	10.1073/pnas.1114799108	2011	Constitutive exposure of phosphatidylserine on viable cells.	FAS
22152244	10.3760/cma.j.issn.1007-3418.2011.07.013	2011	[Peroxisome proliferator activated receptor gamma activation and overexpression prevent hepatocellular apoptosis of nutritional fibrotic steatohepatitis in mice].	FAS
19759548	10.1038/jid.2009.301	2010	Downregulation of Fas gene expression in S√©zary syndrome is associated with promoter hypermethylation.	FAS
19886912	10.1111/j.1349-7006.2009.01377.x	2010	Modulation of innate immunity system by Epstein-Barr virus-encoded non-coding RNA and oncogenesis.	FAS
19890350	10.1038/jid.2009.299	2010	Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP.	FAS
19968579	10.1517/13543780903463854	2010	Milatuzumab - a promising new immunotherapeutic agent.	FAS
20001229	10.3109/10428190903383419	2010	Cytotoxic effects of novel phytosphingosine derivatives, including N,N-dimethylphytosphingosine and N-monomethylphytosphingosine, in human leukemia cell line HL60.	FAS
20147977	10.1038/leu.2010.9	2010	SHIP-1 inhibits CD95/APO-1/Fas-induced apoptosis in primary T lymphocytes and T leukemic cells by promoting CD95 glycosylation independently of its phosphatase activity.	FAS
20162683	10.1002/pbc.22445	2010	Accessory spleen: differential diagnosis for lymphoma in autoimmune lymphoproliferative syndrome.	FAS
20170754	10.1016/j.autrev.2010.02.007	2010	The autoimmune lymphoproliferative syndrome: A rare disorder providing clues about normal tolerance.	FAS
20203691	10.1038/cdd.2010.19	2010	TNF-alpha-induced ROS production triggering apoptosis is directly linked to Romo1 and Bcl-X(L).	FAS
20216376	10.1097/PAS.0b013e3181d5ddf8	2010	Development of disseminated histiocytic sarcoma in a patient with autoimmune lymphoproliferative syndrome and associated Rosai-Dorfman disease.	FAS
20231830	10.1038/jid.2009.427	2010	Epigenetic causes of apoptosis resistance in cutaneous T-cell lymphomas.	FAS
20232432	10.1002/pbc.22463	2010	Low mRNA expression of the apoptosis-related genes CASP3, CASP8, and FAS is associated with low induction treatment response in childhood acute lymphoblastic leukemia (ALL).	FAS
20233887	10.1158/1078-0432.CCR-09-2456	2010	In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.	FAS
20352431	10.1007/s00277-010-0945-x	2010	Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.	FAS
20360470	10.1182/blood-2010-01-263145	2010	Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome.	FAS
20393185	10.1074/mcp.M000153-MCP201	2010	Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.	FAS
20418899	10.1038/cmi.2010.15	2010	Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effect.	FAS
20422450	10.1007/s10495-010-0494-8	2010	Ouabain-induced perturbations in intracellular ionic homeostasis regulate death receptor-mediated apoptosis.	FAS
20428773	10.3892/ijo_00000635	2010	Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis.	FAS
20435142	10.1016/j.jsbmb.2010.04.019	2010	PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia, interferes with glucocorticoid-induced apoptosis.	FAS
20615965	10.1073/pnas.1004594107	2010	The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.	FAS
20617132	10.1155/2010/104918	2010	Cytotoxic T cells in H. pylori-related gastric autoimmunity and gastric lymphoma.	FAS
20617141	10.1155/2010/234540	2010	Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells.	FAS
20659914	10.1093/bja/aeq169	2010	Ketamine induces apoptosis via the mitochondrial pathway in human lymphocytes and neuronal cells.	FAS
20669965	10.1021/jm100459k	2010	[NiII(3-OMe-salophene)]: a potent agent with antitumor activity.	FAS
20670671	10.1016/j.exphem.2010.06.014	2010	Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.	FAS
20673483	10.3779/j.issn.1009-3419.2010.07.05	2010	[Immune evasion of human lung carcinoma cell A549 suppressed by human lymphoma cell Jurkat via Fas/FasL pathway].	FAS
20709103	10.1016/j.imlet.2010.08.005	2010	Expression of IFNŒ≥R2 mutated in a dileucine internalization motif reinstates IFNŒ≥ signaling and apoptosis in human T lymphocytes.	FAS
20812013	10.1007/s00292-010-1372-4	2010	[cFLIP diminishes CD95-induced apoptosis of CD30-stimulated cutaneous anaplastic large T cell lymphoma (cALCL) cells].	FAS
20815894	10.1186/1756-9966-29-121	2010	Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells.	FAS
20882745	NA	2010	Autoimmune lymphoproliferative syndrome (ALPS). Case report and family history.	FAS
20884685	10.1093/carcin/bgq200	2010	Cutaneous HPV5 E6 causes increased expression of Osteoprotegerin and Interleukin 6 which contribute to evasion of UV-induced apoptosis.	FAS
20889682	10.1093/carcin/bgq201	2010	Modulation of the Fas-apoptosis-signalling pathway by functional polymorphisms at Fas, FasL and Fadd and their implication in T-cell lymphoblastic lymphoma susceptibility.	FAS
20937806	10.1074/jbc.M110.159681	2010	Tumor necrosis factor alpha-induced inflammation is increased but apoptosis is inhibited by common food additive carrageenan.	FAS
20981665	10.1002/chem.201000785	2010	Mitochondrial mode of action of a thymidine-based cisplatin analogue breaks resistance in cancer cells.	FAS
21036702	NA	2010	Synergistic effects of topoisomerase I inhibitor, SN38, on Fas-mediated apoptosis.	FAS
21088216	10.2353/ajpath.2010.100301	2010	CD40¬∑FasL and CTLA-4¬∑FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling.	FAS
21131755	10.4103/0019-509X.73576	2010	Detection of B cell lymphoma 2, tumor protein 53, and FAS gene transcripts in blood cells of patients with breast cancer.	FAS
21182165	10.1002/jbt.20344	2010	Monitoring treatment response of childhood acute lymphocytic leukemia with certain molecular and biochemical markers.	FAS
21203530	10.1371/journal.pone.0015694	2010	Superantigens increase the survival of mice bearing T cell lymphomas by inducing apoptosis of neoplastic cells.	FAS
18923451	10.1038/jid.2008.309	2009	Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.	FAS
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	FAS
19751723	10.1016/j.yexcr.2009.09.008	2009	Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma.	FAS
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	FAS
19890783	10.1055/s-0029-1241178	2009	Growth control of normal and malignant lymphocytes--cell death research from basic concepts to signal pathways and translation into the clinic.	FAS
19906200	10.1111/j.1365-3083.2009.02331.x	2009	Feedback regulation of mitochondria by caspase-9 in the B cell receptor-mediated apoptosis.	FAS
19996270	10.1158/1535-7163.MCT-09-0408	2009	Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells.	FAS
20021969	NA	2009	[Immunophenotype analysis on neoplastic cells in bone marrow and peripheral blood of angioimmunoblastic T-cell lymphoma].	FAS
20032398	NA	2009	Aloe-emodin induces cell death through S-phase arrest and caspase-dependent pathways in human tongue squamous cancer SCC-4 cells.	FAS
17932249	10.1182/blood-2007-04-085399	2008	ATM kinase activity modulates Fas sensitivity through the regulation of FLIP in lymphoid cells.	FAS
17962369	10.1189/jlb.0407198	2008	Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia.	FAS
18552209	10.1182/blood-2007-11-123315	2008	High expression of CD40 on B-cell precursor acute lymphoblastic leukemia blasts is an independent risk factor associated with improved survival and enhanced capacity to up-regulate the death receptor CD95.	FAS
19669200	10.1007/s12308-008-0003-y	2008	Analysis of single nucleotide polymorphisms in the FAS and CTLA-4 genes of peripheral T-cell lymphomas.	FAS
17376892	10.1182/blood-2006-08-038398	2007	Up-regulation of c-FLIPS+R upon CD40 stimulation is associated with inhibition of CD95-induced apoptosis in primary precursor B-ALL.	FAS
17487740	10.1080/10428190701230858	2007	Mutations within the 5' region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma.	FAS
17545588	10.1158/0008-5472.CAN-06-4006	2007	A role for the Fas/FasL system in modulating genetic susceptibility to T-cell lymphoblastic lymphomas.	FAS
16304056	10.1182/blood-2005-06-2601	2006	c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma.	FAS
16403915	10.1182/blood-2005-06-2567	2006	HTLV-1 Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP).	FAS
16914910	10.1159/000093645	2006	Associations between soluble APO-1 (Fas/CD95) concentrations and hematopoietic activity in healthy women.	FAS
15816832	10.1111/j.0022-202X.2005.23657.x	2005	Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas.	FAS
15078899	10.1084/jem.20031080	2004	c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis.	FAS
15160902	10.1080/10428190310001593166	2004	Development of lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its relationship to Fas gene mutations.	FAS
15203866	10.1080/1024533042000205496	2004	Assessment of bcl-2 expression as modulator of fas mediated apoptosis in acute leukemia.	FAS
15514680	10.1038/sj.embor.7400280	2004	Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds.	FAS
12952224	10.1080/1042819031000090228	2003	Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma.	FAS
11830507	10.1182/blood.v99.4.1492	2002	Germline FAS gene mutation in a case of ALPS and NLP Hodgkin lymphoma.	FAS
12060388	10.1046/j.1523-1747.2002.01794.x	2002	Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin.	FAS
12096347	10.1038/sj.onc.1205571	2002	Frequent mutations of Fas gene in nasal NK/T cell lymphoma.	FAS
12163388	10.1016/S0002-9440(10)64219-8	2002	Frequent Fas gene mutations in testicular germ cell tumors.	FAS
12415011	10.1242/jcs.00153	2002	Caspase-dependent initiation of apoptosis and necrosis by the Fas receptor in lymphoid cells: onset of necrosis is associated with delayed ceramide increase.	FAS
12466128	10.1016/S0002-9440(10)64490-2	2002	Frequent deletion of Fas gene sequences encoding death and transmembrane domains in nasal natural killer/T-cell lymphoma.	FAS
11418480	10.1182/blood.v98.1.194	2001	The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis.	FAS
11483955	10.1038/35087019	2001	TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation.	FAS
10340403	10.1016/s0301-472x(99)00033-8	1999	Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma, and Hodgkin's disease.	FAS
9787134	NA	1998	Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity.	FAS
9821419	10.1016/s0022-3476(98)70102-7	1998	The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis.	FAS
8598453	NA	1996	Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis.	FAS
8976184	10.1084/jem.184.6.2287	1996	Cross-linking of Fas by antibodies to a peculiar domain of gp120 V3 loop can enhance T cell apoptosis in HIV-1-infected patients.	FAS
1375228	NA	1992	Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.	FAS
1713127	10.1016/0092-8674(91)90614-5	1991	The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.	FAS
2787530	10.1126/science.2787530	1989	Monoclonal antibody-mediated tumor regression by induction of apoptosis.	FAS
35876323	10.1080/08880018.2022.2101723	2022	Whole genome sequencing and inheritance-based variant filtering as a tool for unraveling missing heritability in pediatric cancer.	FAT4
34166375	10.1371/journal.pone.0251272	2021	Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma.	FAT4
26773734	10.1002/gcc.22348	2016	Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type.	FAT4
24349473	10.1371/journal.pone.0083244	2013	Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.	FAT4
35504885	10.1038/s41419-022-04873-y	2022	Somatic FOXC1 insertion mutation remodels the immune microenvironment and promotes the progression of childhood acute lymphoblastic leukemia.	FOXC1
32733009	10.1038/s41375-020-0999-2	2021	Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination.	FOXC1
34807923	10.1371/journal.pone.0259674	2021	Establishment of the TBX-code reveals aberrantly activated T-box gene TBX3 in Hodgkin lymphoma.	FOXC1
32632082	10.4143/crt.2020.032	2020	Forkhead Box C1 (FOXC1) Expression in Stromal Cells within the Microenvironment of T and NK Cell Lymphomas: Association with Tumor Dormancy and Activation.	FOXC1
29328384	10.3892/mmr.2018.8423	2018	Forkhead box protein C1 promotes cell proliferation and invasion in human cervical cancer.	FOXC1
29487724	10.18632/oncotarget.22742	2018	FOXC1, the new player in the cancer sandbox.	FOXC1
30209976	10.1080/15384101.2018.1522912	2018	PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation.	FOXC1
27505670	10.1016/j.ccell.2016.07.006	2016	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.	FOXC1
24844359	10.3109/10428194.2014.924119	2015	Repressed BMP signaling reactivates NKL homeobox gene MSX1 in a T-ALL subset.	FOXC1
25533033	10.1182/blood-2014-04-568188	2015	Jun-regulated genes promote interaction of diffuse large B-cell lymphoma with the microenvironment.	FOXC1
26406991	10.1371/journal.pone.0138416	2015	Aberrantly Expressed OTX Homeobox Genes Deregulate B-Cell Differentiation in Hodgkin Lymphoma.	FOXC1
24237447	10.3109/10428194.2013.864762	2014	Oncogenic deregulation of NKL homeobox gene MSX1 in mantle cell lymphoma.	FOXC1
25043849	10.1002/gcc.22204	2014	Deregulated FOX genes in Hodgkin lymphoma.	FOXC1
22586443	10.1371/journal.pone.0033788	2012	Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines.	FOXC1
33327711	10.3324/haematol.2020.263194	2022	Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma.	FOXO1
34265801	10.1097/PAS.0000000000001780	2022	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.	FOXO1
34341476	10.1038/s10038-021-00965-3	2022	PAX3/7-FOXO1 fusion-negative alveolar rhabdomyosarcoma in Schuurs-Hoeijmakers syndrome.	FOXO1
34617271	10.1111/bjh.17874	2022	Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.	FOXO1
34894199	10.1002/mnfr.202100564	2022	Green Alga Enteromorpha prolifera Oligosaccharide Ameliorates Ageing and Hyperglycemia through Gut-Brain Axis in Age-Matched Diabetic Mice.	FOXO1
35045798	10.1080/10428194.2021.2024821	2022	High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.	FOXO1
35079069	10.1038/s41598-022-05334-4	2022	FOXO1 forkhead domain mutants in B-cell lymphoma lack transcriptional activity.	FOXO1
35176466	10.1016/j.jep.2022.115095	2022	Cinobufagin induces FOXO1-regulated apoptosis, proliferation, migration, and invasion by inhibiting G9a in non-small-cell lung cancer A549¬†cells.	FOXO1
35330543	10.4274/balkanmedj.galenos.2021.2021-8-62	2022	Deacetylated-poly-N-acetylglucosamine-folic Acid as a Nanocarrier for Delivering miR-196a Inhibitor to Anticancer Activity.	FOXO1
35477814	10.1007/s10637-022-01250-6	2022	Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia.	FOXO1
35511481	10.1080/09553002.2022.2074164	2022	<i>BAG1, MGMT, FOXO1</i>, and <i>DNAJA1</i> as potential drug targets for radiosensitizing cancer cell lines.	FOXO1
35578798	10.1002/jcp.30777	2022	Neddylation inactivation affects cell cycle and apoptosis in sheep follicular granulosa cells.	FOXO1
35774848	10.1155/2022/3276925	2022	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.	FOXO1
35895105	10.1021/acs.biochem.2c00224	2022	Oncogenic Mutations in the DNA-Binding Domain of FOXO1 that Disrupt Folding: Quantitative Insights from Experiments and Molecular Simulations.	FOXO1
35910796	10.7150/thno.72786	2022	Inhibition of acylglycerol kinase sensitizes DLBCL to venetoclax via upregulation of FOXO1-mediated BCL-2 expression.	FOXO1
33152216	10.5713/ajas.20.0444	2021	Role of stearyl-coenzyme A desaturase 1 in mediating the effects of palmitic acid on endoplasmic reticulum stress, inflammation, and apoptosis in goose primary hepatocytes.	FOXO1
33393492	10.1172/JCI142627	2021	Doubling up on function: dual-specificity tyrosine-regulated kinase 1A (DYRK1A) in B cell acute lymphoblastic leukemia.	FOXO1
33393494	10.1172/JCI135937	2021	DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.	FOXO1
33416167	10.3892/or.2020.7888	2021	Involvement of Blnk and Foxo1 in tumor suppression in BCR‚ÄëABL1‚Äëtransformed pro‚ÄëB cells.	FOXO1
33508992	10.1080/10428194.2021.1876857	2021	Tamoxifen enhances romidepsin-induced apoptosis in T-cell malignant cells via activation of FOXO1 signaling pathway.	FOXO1
33821300	10.1007/s00540-021-02909-9	2021	Dexmedetomidine ameliorates lipopolysaccharide-induced acute lung injury by inhibiting the PI3K/Akt/FoxO1 signaling pathway.	FOXO1
34140493	10.1038/s41467-021-24037-4	2021	Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified.	FOXO1
34374220	10.1002/cjp2.223	2021	c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.	FOXO1
34380064	10.1016/j.immuni.2021.07.009	2021	Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis.	FOXO1
34419260	10.1016/S1875-5364(21)60060-2	2021	Seed oil of Brucea javanica induces apoptosis through the PI3K/Akt signaling pathway in acute lymphocytic leukemia Jurkat cells.	FOXO1
34506757	10.1016/j.abb.2021.109026	2021	SMC4 knockdown inhibits malignant biological behaviors of endometrial cancer cells by regulation of FoxO1 activity.	FOXO1
34599153	10.1038/s41419-021-04187-5	2021	Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.	FOXO1
34679437	10.3390/diagnostics11101739	2021	Dysregulation of miRNAs in DLBCL: Causative Factor for Pathogenesis, Diagnosis and Prognosis.	FOXO1
34948236	10.3390/ijms222413441	2021	Akt Signaling Pathway Is Activated in the Minor Salivary Glands of Patients with Primary Sj√∂gren's Syndrome.	FOXO1
31423576	10.1111/bjh.16159	2020	M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.	FOXO1
31872845	10.1039/c9fo02491c	2020	Calcium relieves fluoride-induced bone damage through the PI3K/AKT pathway.	FOXO1
32296592	10.20892/j.issn.2095-3941.2019.0374	2020	Erratum to Inactivation of FOXO1 induces T follicular cell polarization and involves angioimmunoblastic T cell lymphoma.	FOXO1
32342940	NA	2020	Metastatic alveolar rhabdomyosarcoma on the fine-needle aspiration cytology of cervical lymph node in an elderly patient, with FISH confirmation: A case report.	FOXO1
32373978	10.26355/eurrev_202004_21022	2020	MiRNA-584 suppresses the progression of NK/T-cell lymphoma by targeting FOXO1.	FOXO1
32581241	10.1038/s41467-020-16927-w	2020	Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.	FOXO1
32905193	10.1093/toxres/tfaa059	2020	Alogliptin: a novel approach against cyclophosphamide-induced hepatic injury via modulating SIRT1/FoxO1 pathway.	FOXO1
32964916	10.1042/BSR20200485	2020	MicroRNA-223 decreases cell proliferation, migration, invasion, and enhances cell apoptosis in childhood acute lymphoblastic leukemia via targeting Forkhead box O 1.	FOXO1
33038355	10.1016/j.neuro.2020.10.001	2020	Quercetin provides protection against the peripheral nerve damage caused by vincristine in rats by suppressing caspase 3, NF-Œ∫B, ATF-6 pathways and activating Nrf2, Akt pathways.	FOXO1
33045225	10.1016/j.humpath.2020.09.014	2020	The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.	FOXO1
33207194	10.1016/j.celrep.2020.108403	2020	Cyclin D3 Governs Clonal Expansion of Dark Zone Germinal Center B Cells.	FOXO1
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	FOXO1
30520026	10.1111/bjh.15702	2019	Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.	FOXO1
30628689	10.3892/mmr.2019.9827	2019	Low‚Äëdose lipopolysaccharide inhibits neuronal apoptosis induced by cerebral ischemia/reperfusion injury via the PI3K/Akt/FoxO1 signaling pathway in rats.	FOXO1
30998151	10.19746/j.cnki.issn.1009-2137.2019.02.021	2019	[Exploration of the Role of Tumor Suppressor Genes Foxo1 and PTEN in the Tumorigenesis of Mouse Natural Killer-Cell Lymphoma].	FOXO1
31203134	10.1016/j.biopha.2019.109092	2019	Estradiol promotes trophoblast viability and invasion by activating SGK1.	FOXO1
31300419	10.1182/bloodadvances.2018029546	2019	Sporadic and endemic Burkitt lymphoma have frequent <i>FOXO1</i> mutations but distinct hotspots in the AKT recognition motif.	FOXO1
31301310	10.1016/j.ejphar.2019.172531	2019	MicroRNA Let-7f-1-3p attenuates smoke-induced apoptosis in bronchial and alveolar epithelial cells in vitro by targeting FOXO1.	FOXO1
31557894	10.3390/cancers11101427	2019	FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma.	FOXO1
31669559	10.1016/j.exphem.2019.10.004	2019	Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies.	FOXO1
31908892	10.20892/j.issn.2095-3941.2019.0115	2019	Inactivation of FOXO1 induces T follicular cell polarization and involves angioimmunoblastic T cell lymphoma.	FOXO1
28774833	10.1016/j.semcancer.2017.07.008	2018	FOXO in B-cell lymphopoiesis and B cell neoplasia.	FOXO1
29399633	10.1126/sciadv.aar5701	2018	Discrete roles and bifurcation of PTEN signaling and mTORC1-mediated anabolic metabolism underlie IL-7-driven B lymphopoiesis.	FOXO1
29439954	10.1182/blood-2017-07-795278	2018	Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation.	FOXO1
29545328	10.1182/blood-2017-11-817601	2018	Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.	FOXO1
29545835	10.3892/etm.2018.5853	2018	Expression and phosphorylation of FOXO1 influences cell proliferation and apoptosis in the gastrointestinal stromal tumor cell line GIST-T1.	FOXO1
29567632	10.1016/j.ejca.2018.02.011	2018	The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.	FOXO1
29622548	10.1182/blood-2017-10-813576	2018	Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia.	FOXO1
29721381	10.1080/2162402X.2017.1423183	2018	FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.	FOXO1
29937999	10.18632/oncotarget.25463	2018	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma.	FOXO1
30020823	10.1080/08880018.2018.1467986	2018	Epigenetic silencing of the tumor suppressor genes SPI1, PRDX2, KLF4, DLEC1, and DAPK1 in childhood and adolescent lymphomas.	FOXO1
30259128	10.1007/s00702-018-1927-8	2018	Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.	FOXO1
30272279	10.3892/ijo.2018.4577	2018	Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.	FOXO1
30333121	10.1182/blood-2018-06-856203	2018	Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells.	FOXO1
30360879	10.1053/j.seminoncol.2018.07.005	2018	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	FOXO1
30462731	10.1371/journal.ppat.1007440	2018	Neddylation contributes to CD4+ T cell-mediated protective immunity against blood-stage Plasmodium infection.	FOXO1
30524445	10.3389/fimmu.2018.02715	2018	The c-Myc/miR17-92/PTEN Axis Tunes PI3K Activity to Control Expression of Recombination Activating Genes in Early B Cell Development.	FOXO1
27707884	10.1189/jlb.2A0116-040RR	2017	Ikaros 6 protects acute lymphoblastic leukemia cells against daunorubicin-induced apoptosis by activating the Akt-FoxO1 pathway.	FOXO1
28465297	10.1158/1541-7786.MCR-16-0305	2017	Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type-Specific Differences.	FOXO1
28550734	10.1016/j.intimp.2017.05.022	2017	Pterostilbene alleviates polymicrobial sepsis-induced liver injury: Possible role of SIRT1 signaling.	FOXO1
28691928	10.1172/JCI92026	2017	Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis.	FOXO1
29113202	10.3892/ol.2017.6912	2017	EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys<sup>27</sup> acetylation in the <i>BIM</i> gene promoter and enhancers.	FOXO1
29212954	10.1172/jci.insight.95103	2017	Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.	FOXO1
26033966	10.1136/gutjnl-2014-308270	2016	BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling.	FOXO1
26475987	10.1111/exd.12878	2016	Differential T-cell subset representation in cutaneous squamous cell carcinoma arising in immunosuppressed versus immunocompetent individuals.	FOXO1
26585955	10.1182/blood-2015-06-654111	2016	FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.	FOXO1
26647218	10.1158/1078-0432.CCR-15-2123	2016	Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.	FOXO1
26686861	10.1007/s00018-015-2112-y	2016	FOXO transcription factors in cancer development and therapy.	FOXO1
26764572	10.1038/cddis.2015.396	2016	FoxO3 suppresses Myc-driven lymphomagenesis.	FOXO1
26787462	10.1002/1873-3468.12045	2016	Enhanced cytotoxic T-cell function and inhibition of tumor progression by Mst1 deficiency.	FOXO1
26847027	10.1038/leu.2016.9	2016	Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.	FOXO1
27132507	10.1038/onc.2016.126	2016	FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism.	FOXO1
27160160	10.1159/000443119	2016	Huang Qi Huai Granules Induce Apoptosis in Acute Lymphoblastic Leukemia Cells through the Akt/FoxO1 Pathway.	FOXO1
27166193	10.18632/oncotarget.9210	2016	Repression of TCF3/E2A contributes to Hodgkin lymphomagenesis.	FOXO1
27385213	10.18632/oncotarget.10368	2016	Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma.	FOXO1
27559048	10.4049/jimmunol.1501989	2016	The DNA Damage Response Regulates RAG1/2 Expression in Pre-B Cells through ATM-FOXO1 Signaling.	FOXO1
27661108	10.18632/oncotarget.12132	2016	Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells.	FOXO1
27779675	10.3892/mmr.2016.5861	2016	Resveratrol alleviates sepsis‚Äëinduced myocardial injury in rats by suppressing neutrophil accumulation, the induction of TNF‚ÄëŒ± and myocardial apoptosis via activation of Sirt1.	FOXO1
27933060	10.3389/fimmu.2016.00520	2016	Regulators of Tfh Cell Differentiation.	FOXO1
25430416	10.3109/10428194.2014.990900	2015	Dissecting chronic lymphocytic leukemia microenvironment signals in patients with unmutated disease: microRNA-22 regulates phosphatase and tensin homolog/AKT/FOXO1 pathway in proliferative leukemic cells.	FOXO1
25691468	10.1101/gad.255331.114	2015	The E-Id protein axis modulates the activities of the PI3K-AKT-mTORC1-Hif1a and c-myc/p19Arf pathways to suppress innate variant TFH cell development, thymocyte expansion, and lymphomagenesis.	FOXO1
25769609	10.1016/j.immuni.2015.02.006	2015	Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function.	FOXO1
25909227	10.18632/oncotarget.3729	2015	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.	FOXO1
25951043	10.1080/15548627.2015.1017192	2015	The role of STAT3 in autophagy.	FOXO1
26027540	10.1016/j.clml.2015.03.018	2015	Genomic and Clinicopathologic Features of Primary Myelofibrosis With Isolated 13q Deletion.	FOXO1
26153519	10.1182/blood-2015-01-621623	2015	NF-Œ∫B and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity.	FOXO1
26256760	10.1016/S1470-2045(15)00169-2	2015	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	FOXO1
26314988	10.1038/bcj.2015.69	2015	Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.	FOXO1
26398583	10.3892/or.2015.4287	2015	SIRT1 downregulation enhances chemosensitivity and survival of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand repair.	FOXO1
24427371	NA	2014	Nasopharyngeal alveolar rhabdomyosarcoma expressing CD56: a mimicker of extranodal natural killer/T-cell lymphoma.	FOXO1
24614102	10.1172/JCI63139	2014	CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis.	FOXO1
24977668	10.18632/oncotarget.2107	2014	FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma.	FOXO1
25043849	10.1002/gcc.22204	2014	Deregulated FOX genes in Hodgkin lymphoma.	FOXO1
25232062	10.1182/blood-2014-07-590570	2014	FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma.	FOXO1
25347953	10.1038/ncomms6217	2014	RNAi-based functional selection identifies novel cell migration determinants dependent on PI3K and AKT pathways.	FOXO1
23174882	10.1038/leu.2012.280	2013	Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma.	FOXO1
23307059	10.1038/modpathol.2012.222	2013	Anaplastic lymphoma kinase status in rhabdomyosarcomas.	FOXO1
23460611	10.1182/blood-2013-01-479865	2013	Analysis of FOXO1 mutations in diffuse large B-cell lymphoma.	FOXO1
23665105	10.1016/j.ygcen.2013.04.033	2013	Transcriptomic profiling of progesterone in the male fathead minnow (Pimephales promelas) testis.	FOXO1
23714564	10.14694/EdBook_AM.2013.33.420	2013	Emerging molecular-targeted therapies in early-phase clinical trials and preclinical models.	FOXO1
23764004	10.1016/j.ccr.2013.05.002	2013	SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.	FOXO1
23770045	10.1016/j.bbamcr.2013.06.001	2013	Crosstalk between apoptosis, necrosis and autophagy.	FOXO1
23772809	10.1111/joim.12099	2013	miR-223: infection, inflammation and cancer.	FOXO1
23791885	10.1016/j.canlet.2013.06.012	2013	MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention.	FOXO1
24149177	10.1038/bjc.2013.653	2013	High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma.	FOXO1
22185211	10.3109/10428194.2011.649478	2012	Curcumin potentiates antitumor activity of L-asparaginase via inhibition of the AKT signaling pathway in acute lymphoblastic leukemia.	FOXO1
22197543	10.1016/j.anndiagpath.2011.09.004	2012	Detection of PAX3/PAX7-FKHR fusion transcripts in rhabdomyosarcoma and other small round cell tumors by 1-step reverse transcriptase polymerase chain reaction: a novel tool for diagnosis and differentiation.	FOXO1
22343918	10.1182/blood-2011-09-381905	2012	FOXO1 is a tumor suppressor in classical Hodgkin lymphoma.	FOXO1
22473959	10.1084/jem.20111470	2012	Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia.	FOXO1
22570335	10.1210/me.2011-1276	2012	FOXO1 mediates the autocrine effect of endothelin-1 on endothelial cell survival.	FOXO1
22966017	10.1158/1078-0432.CCR-12-0397	2012	Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.	FOXO1
21245099	10.1158/0008-5472.CAN-10-2203	2011	Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a FoxO1-dependent manner.	FOXO1
21423089	NA	2011	CD150-mediated Akt signalling pathway in normal and malignant B cells.	FOXO1
22042699	10.1182/blood-2011-05-354654	2011	miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.	FOXO1
22110774	10.4161/derm.3.3.15331	2011	Isotretinoin and FoxO1: A scientific hypothesis.	FOXO1
19757185	10.1007/s11033-009-9748-3	2010	Role of dephosphorylation of FOXO1 on apoptosis induced by wortmannin for non-Hodgkin's lymphoma cells.	FOXO1
20709952	10.4049/jimmunol.1001430	2010	The MAPK/ERK and PI3K pathways additively coordinate the transcription of recombination-activating genes in B lineage cells.	FOXO1
18788887	10.2350/08-03-0434.1	2009	ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.	FOXO1
19198627	10.1038/onc.2008.502	2009	Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.	FOXO1
17254960	10.1016/j.cell.2007.01.009	2007	FoxOs in tumor suppression and stem cell maintenance.	FOXO1
17254969	10.1016/j.cell.2006.12.029	2007	FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis.	FOXO1
17502057	10.1051/medsci/2007235466	2007	[FoxO: stress or eternal life].	FOXO1
17974917	10.1101/gad.453107	2007	FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf.	FOXO1
16943287	10.1128/JVI.00983-06	2006	Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A.	FOXO1
15668399	10.1073/pnas.0406789102	2005	Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation.	FOXO1
15837766	10.1158/1078-0432.CCR-04-1857	2005	Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.	FOXO1
14747556	10.1128/jvi.78.4.1918-1927.2004	2004	The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway.	FOXO1
14962911	10.1182/blood-2003-03-0820	2004	NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.	FOXO1
15353558	10.1084/jem.20040789	2004	Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.	FOXO1
12930690	NA	2003	[Detection of PAX3/PAX7-FKHR fusion transcript in rhabdomyosarcoma by one-step RT-PCR].	FOXO1
9823299	NA	1998	Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.	FOXO1
34617271	10.1111/bjh.17874	2022	Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.	GNA13
35075971	10.1080/10428194.2021.2010060	2022	Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study.	GNA13
35611992	10.1002/gcc.23069	2022	Primary mediastinal large B-cell lymphoma is characterized by large-scale copy-neutral loss of heterozygosity.	GNA13
35885481	10.3390/diagnostics12071575	2022	Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma.	GNA13
32079702	10.3324/haematol.2019.237719	2021	Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study.	GNA13
32961552	10.1182/blood.2020007507	2021	Mutational landscape of gray zone lymphoma.	GNA13
33423045	10.1038/s41419-020-03311-1	2021	GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner.	GNA13
33945543	10.1371/journal.pone.0248886	2021	Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.	GNA13
34312841	10.1111/bjh.17719	2021	Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.	GNA13
34405005	10.7150/jca.60390	2021	Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.	GNA13
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	GNA13
35116576	10.21037/tcr-20-2525	2021	Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database.	GNA13
32363958	10.1177/0300060520918087	2020	CD56-positive diffuse large B-cell lymphoma/leukemia with <i>BCL6/MYC</i> double-hit and multiple gene mutations: an indicator of poor prognosis?	GNA13
30567752	10.1182/blood-2018-07-864025	2019	The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.	GNA13
30733272	10.3324/haematol.2018.207928	2019	Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.	GNA13
30802265	10.1371/journal.pone.0212813	2019	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.	GNA13
31324389	10.1016/j.prp.2019.152528	2019	Quantitative proteomics analysis of differentially expressed proteins in activated B-cell-like diffuse large B-cell lymphoma using quantitative proteomics.	GNA13
31816062	10.1182/bloodadvances.2019001012	2019	Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.	GNA13
29650799	10.1182/blood-2017-11-814913	2018	Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.	GNA13
30024968	10.1371/journal.ppat.1007111	2018	Hepatitis C virus enters liver cells using the CD81 receptor complex proteins calpain-5 and CBLB.	GNA13
30227305	10.1016/j.neo.2018.08.012	2018	Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.	GNA13
30307409	10.1097/PAS.0000000000000969	2018	Analysis of GNA13 Protein in Follicular Lymphoma and its Association With Poor Prognosis.	GNA13
28302137	10.1186/s13045-017-0438-7	2017	Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.	GNA13
26567765	10.1111/bjh.13849	2016	The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.	GNA13
26603838	10.1182/blood-2015-07-658781	2016	Active IKKŒ≤ promotes the stability of GLI1 oncogene in diffuse large B-cell lymphoma.	GNA13
26608593	10.1002/gcc.22328	2016	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.	GNA13
26616858	10.1038/onc.2015.442	2016	Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the GŒ±13/RhoA axis in B cells.	GNA13
26773040	10.1182/blood-2015-09-672352	2016	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.	GNA13
26819451	10.1158/1078-0432.CCR-15-2305	2016	Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.	GNA13
26989201	10.1182/blood-2015-07-659938	2016	GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo.	GNA13
27959929	10.1371/journal.pmed.1002197	2016	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.	GNA13
27980305	10.3960/jslrt.56.71	2016	Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.	GNA13
25991819	10.1158/1078-0432.CCR-14-2116	2015	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.	GNA13
24867287	10.1097/MOH.0000000000000059	2014	New clues to the molecular pathogenesis of Burkitt lymphoma revealed through next-generation sequencing.	GNA13
25274307	10.1038/nature13765	2014	Loss of signalling via GŒ±13 in germinal centre B-cell-derived lymphoma.	GNA13
23292937	10.1073/pnas.1205299110	2013	Genetic heterogeneity of diffuse large B-cell lymphoma.	GNA13
23699601	10.1182/blood-2013-02-483727	2013	Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.	GNA13
22343534	10.1073/pnas.1121343109	2012	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	GNA13
23143597	10.1038/ng.2468	2012	The genetic landscape of mutations in Burkitt lymphoma.	GNA13
12738680	10.1182/blood-2002-08-2482	2003	BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma.	GRHPR
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	HIST1H1C
35583604	10.1158/1078-0432.CCR-21-3347	2022	Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL.	HIST1H1C
36055572	10.1016/j.clim.2022.109105	2022	A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.	HIST1H1C
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	HIST1H1C
26473533	10.1038/bcj.2015.89	2015	Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.	HIST1H1C
24435047	10.1182/blood-2013-05-500264	2014	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	HIST1H1C
19806355	10.1007/s00277-009-0839-y	2010	An extensive analysis of the hereditary hemochromatosis gene HFE and neighboring histone genes: associations with childhood leukemia.	HIST1H1C
35038193	10.1111/his.14617	2022	Incidence, clinicopathological features and genetics of in-situ follicular neoplasia: a comprehensive screening study in a Japanese cohort.	HIST1H1E
35583604	10.1158/1078-0432.CCR-21-3347	2022	Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL.	HIST1H1E
35646048	10.3389/fgene.2022.878618	2022	Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	HIST1H1E
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	HIST1H1E
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	HIST1H1E
32469082	10.1002/cncr.32866	2020	Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.	HIST1H1E
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	HIST1H1E
30802265	10.1371/journal.pone.0212813	2019	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.	HIST1H1E
31221981	10.1038/s12276-019-0230-6	2019	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.	HIST1H1E
30209976	10.1080/15384101.2018.1522912	2018	PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation.	HIST1H1E
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	HIST1H1E
24435047	10.1182/blood-2013-05-500264	2014	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	HIST1H1E
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	HIST1H2BK
30209976	10.1080/15384101.2018.1522912	2018	PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation.	HIST1H2BK
35358442	10.1016/S2352-3026(22)00036-9	2022	In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.	HLA-B
35759244	10.1002/iid3.666	2022	EBV protection- and susceptibility-related HLA alleles and EBV status in the Chinese population: A single-center study.	HLA-B
35953408	10.1016/j.humimm.2022.08.002	2022	HLA homozygosity is associated with Non-Hodgkin lymphoma.	HLA-B
33512416	10.1182/blood.2020007245	2021	Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.	HLA-B
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	HLA-B
33899124	10.1007/s00894-021-04754-9	2021	Deciphering the selective binding mechanisms of anaplastic lymphoma kinase-derived neuroblastoma tumor neoepitopes to human leukocyte antigen.	HLA-B
33964277	10.1016/j.humpath.2021.04.014	2021	Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma.	HLA-B
34330762	10.1136/jitc-2021-002410	2021	High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.	HLA-B
34717720	10.1186/s13045-021-01201-3	2021	HLA alleles associated with asparaginase hypersensitivity in Chinese children.	HLA-B
34830986	10.3390/cancers13225833	2021	HLA Expression in Relation to HLA Type in Classic Hodgkin Lymphoma Patients.	HLA-B
34925382	10.3389/fimmu.2021.796584	2021	The HLA Ligandome Comprises a Limited Repertoire of O-GlcNAcylated Antigens Preferentially Associated With HLA-B*07:02.	HLA-B
34926267	10.3389/fonc.2021.765544	2021	<i>SEPT6</i>_<i>TRIM33</i> Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.	HLA-B
31958417	10.1016/S2352-3026(19)30220-0	2020	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.	HLA-B
32072624	10.1111/bjh.16398	2020	Variation in the Human Leukocyte Antigen system and risk for endemic Burkitt lymphoma in northern Uganda.	HLA-B
32883310	10.1186/s12977-020-00536-y	2020	HLA-B*35 as a new marker for susceptibility to human T-cell lymphotropic virus type 1 (HTLV-1) Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in patients living in Argentina.	HLA-B
30396848	10.1016/j.jcyt.2018.08.001	2019	Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.	HLA-B
30715139	10.1093/asj/sjz021	2019	Differences in Human Leukocyte Antigen Expression Between Breast Implant-Associated Anaplastic Large Cell Lymphoma Patients and the General Population.	HLA-B
30871628	10.1186/s40425-019-0538-8	2019	Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.	HLA-B
31026237	10.1097/QAI.0000000000002027	2019	Increasing Levels of Serum Heat Shock Protein 70 Precede the Development of AIDS-Defining Non-Hodgkin Lymphoma Among Carriers of HLA-B8-DR3.	HLA-B
31066027	10.1002/cpt.1493	2019	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions.	HLA-B
31101215	10.1016/j.transproceed.2019.04.014	2019	Non-Hodgkin Lymphoma in a Kidney Transplant Patient: A Case Report.	HLA-B
31215275	10.1080/10428194.2019.1617858	2019	The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population.	HLA-B
31325731	10.1016/j.leukres.2019.106193	2019	Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada.	HLA-B
31428523	10.1080/2162402X.2019.1625688	2019	NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma.	HLA-B
29080718	10.1016/j.humimm.2017.10.010	2018	Sex-specific survival difference in association with HLA-DRB1‚àó04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies.	HLA-B
29441070	10.3389/fimmu.2018.00099	2018	A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.	HLA-B
29735552	10.1158/0008-5472.CAN-17-2900	2018	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes.	HLA-B
30032036	10.1016/j.neo.2018.07.001	2018	Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma.	HLA-B
27696192	10.1007/s12185-016-2101-4	2017	Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma.	HLA-B
27987385	10.1016/j.bbmt.2016.11.021	2017	MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study.	HLA-B
28053195	10.1182/blood-2016-09-737536	2017	TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.	HLA-B
28126967	10.3324/haematol.2016.158584	2017	The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia.	HLA-B
28405493	10.1080/2162402X.2016.1219825	2017	HLA class I-restricted <i>MYD88</i> L265P-derived peptides as specific targets for lymphoma immunotherapy.	HLA-B
28659916	10.3389/fimmu.2017.00675	2017	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.	HLA-B
28811957	10.1080/2162402X.2017.1321184	2017	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.	HLA-B
28948342	10.1007/s00403-017-1783-7	2017	Pediatric mycosis fungoides: a study of the human leukocyte antigen system among Israeli Jewish patients.	HLA-B
28980457	10.1111/tan.13151	2017	The novel HLA-B*08:183 allele identified by sequence-based typing in a Caucasian leukemia patient.	HLA-B
28981945	10.3760/cma.j.issn.1003-9406.2017.05.026	2017	[Association of HLA-A, -B, -DRB1 alleles and haplotypes with acute lymphoblastic leukemia among ethnic Hans from northern China].	HLA-B
29147614	10.1080/2162402X.2017.1356964	2017	Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.	HLA-B
25753140	10.1111/jdv.13083	2016	Mycosis fungoides: association of KIR ligands and HLA-DQB1*05 with bad prognosis of the disease.	HLA-B
26472014	10.1016/j.humimm.2015.10.009	2016	Genetic associations of killer immunoglobulin like receptors and class I human leukocyte antigens on childhood acute lymphoblastic leukemia among north Indians.	HLA-B
26841353	10.1002/art.39515	2016	Activation-Induced Killer Cell Immunoglobulin-like Receptor 3DL2 Binding to HLA-B27 Licenses Pathogenic T Cell Differentiation in Spondyloarthritis.	HLA-B
27063556	10.1016/j.gene.2016.04.017	2016	The associations of HLA-A, -B, DRB1 alleles and haplotypes in Turkish lymphoma patients.	HLA-B
27095065	10.4274/tjh.2016.0102	2016	The Frequency of HLA-A, HLA-B, and HLA-DRB1 Alleles in Patients with Acute Lymphoblastic Leukemia in the Turkish Population: A Case-Control Study.	HLA-B
27104753	10.3109/10428194.2016.1173209	2016	Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.	HLA-B
27273744	10.1111/tan.12829	2016	The effect of missing KIR ligands, activating KIR genotype and haplotype on the outcome of T-cell-replete hematopoietic stem cell transplantation from HLA-identical siblings in Thai patients.	HLA-B
27602742	10.1038/537S60a	2016	Pharmacogenetics: The right drug for you.	HLA-B
27689397	10.18632/oncotarget.12247	2016	A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.	HLA-B
27776339	10.18632/oncotarget.12778	2016	Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.	HLA-B
25414443	10.1182/blood-2014-07-587840	2015	Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.	HLA-B
25545232	10.1016/j.trim.2014.12.003	2015	Donors with HLA-B*58:01/TNFŒ± ‚àí 308A haplotype are unfavorable to haploidentical hematopoietic stem cell transplantation in acute lymphoblastic leukemia.	HLA-B
25569183	10.1038/ncomms6751	2015	A genome-wide association study of marginal zone lymphoma shows association to the HLA region.	HLA-B
25611436	10.1111/ejh.12513	2015	Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations.	HLA-B
25648508	10.1002/ijc.29467	2015	Modeling HLA associations with EBV-positive and -negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis.	HLA-B
25672859	10.5692/clinicalneurol.55.13	2015	[Neuro-neutrophilic disease suspected by human leukocyte antigen (HLA) typing and brain biopsy: a case report].	HLA-B
26040094	NA	2015	A coincidence of HLA-B27 negative spondyloarthritis and paravertebral non-Hodgkin's lymphoma--a lesson to be learnt from the past experience.	HLA-B
26189878	10.1111/tan.12604	2015	Human leukocyte antigens and genetic susceptibility to lymphoma.	HLA-B
26334430	10.1097/MPH.0000000000000419	2015	HLA Polymorphism in Algerian Children With Lymphomas.	HLA-B
24518758	10.1182/blood-2013-11-540625	2014	The role of KIR genes and their cognate HLA class I ligands in childhood acute lymphoblastic leukemia.	HLA-B
24533560	10.1111/jdv.12391	2014	Immunogenetic factors in mycosis fungoides: can the HLA system influence the susceptibility and prognosis of the disease? Long-term follow-up study of 46 patients.	HLA-B
24755352	10.1016/j.humimm.2014.04.004	2014	Killer cell immunoglobulin-like receptors in Thai patients with leukemia and diffuse large B-cell lymphoma.	HLA-B
24963477	10.1155/2014/231236	2014	The association of HLA-class I and class II with Hodgkin's lymphoma in Iranian patients.	HLA-B
25261932	10.1038/ng.3105	2014	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.	HLA-B
25549594	IJIv11i4A5	2014	HLA-A*26 and susceptility of iranian patients with non-Hodgkin lymphoma.	HLA-B
23326239	10.1371/journal.pgen.1003147	2013	A genome-wide integrative genomic study localizes genetic factors influencing antibodies against Epstein-Barr virus nuclear antigen 1 (EBNA-1).	HLA-B
23376818	10.1038/bmt.2013.4	2013	The role of HLA-matched unrelated transplantation in adult patients with Ph chromosome-negative ALL in first remission. A decision analysis.	HLA-B
23843497	10.1182/blood-2013-02-483420	2013	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.	HLA-B
24032727	10.1111/tan.12175	2013	A novel HLA-B allele, HLA-B*39:01:16, identified by super high-resolution single-molecule sequence-based typing in a Japanese individual.	HLA-B
24364037	10.1155/2013/705862	2013	HLA-B*40 allele plays a role in the development of acute leukemia in Mexican population: a case-control study.	HLA-B
22340965	10.1016/S1470-2045(12)70004-9	2012	Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study.	HLA-B
22350167	10.1007/s00251-012-0605-5	2012	Spectrum of HLA associations: the case of medically refractory pediatric acute lymphoblastic leukemia.	HLA-B
22489945	10.1111/j.1399-0039.2012.01868.x	2012	Somatic mutations in the HLA genes of patients with hematological malignancy.	HLA-B
22781790	NA	2012	[The impact of HLA high resolution typing mismatching of donor-recipient pairs on outcome of unrelated donor hematopoietic stem cell transplantation].	HLA-B
23092091	NA	2012	[Incidence of uveitis in the northern Kyushu region of Japan --comparison between the periods of 1996-2001 and 2003-2008].	HLA-B
20870028	10.1016/j.bbmt.2010.09.012	2011	HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.	HLA-B
21059899	10.1182/blood-2010-08-301598	2011	MHC variation and risk of childhood B-cell precursor acute lymphoblastic leukemia.	HLA-B
21481192	10.1111/j.1744-313X.2011.01007.x	2011	Detection of A B acute lymphoblastic leukaemia blast-specific mutation in HLA-B*39:01.	HLA-B
21982422	10.1016/S1470-2045(11)70260-1	2011	Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis.	HLA-B
22125456	10.1100/2011/373876	2011	Human leukocyte antigen class I and II alleles and overall survival in diffuse large B-cell lymphoma and follicular lymphoma.	HLA-B
20110857	10.1097/TP.0b013e3181c69855	2010	Impact of HLA mismatching on incidence of posttransplant non-hodgkin lymphoma after kidney transplantation.	HLA-B
20147981	10.1038/leu.2010.17	2010	Human leukocyte antigen (HLA) A1-B8-DR3 (8.1) haplotype, tumor necrosis factor (TNF) G-308A, and risk of non-Hodgkin lymphoma.	HLA-B
20385791	10.1182/blood-2010-01-266775	2010	Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology.	HLA-B
20388056	10.3109/10428191003802340	2010	Human leukocyte antigen class I alleles and the risk of chronic myelogenous leukemia: a meta-analysis.	HLA-B
20522710	10.1182/blood-2010-02-270199	2010	Comparative analysis of predicted HLA binding of immunoglobulin idiotype sequences indicates T cell-mediated immunosurveillance in follicular lymphoma.	HLA-B
20536911	10.1111/j.1432-2277.2010.01117.x	2010	Impact of amino acid substitution at residue 9 of HLA-A2 on the development of acute GVHD in Korean pediatric patients receiving unrelated hematopoietic stem cell transplantation.	HLA-B
20558104	10.1016/S1470-2045(10)70127-3	2010	Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.	HLA-B
21041953	10.1172/JCI42869	2010	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.	HLA-B
18841361	10.1007/s00262-008-0601-7	2009	Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.	HLA-B
19032105	10.1086/594373	2009	The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children.	HLA-B
19167686	10.1016/j.bbmt.2008.11.025	2009	Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.	HLA-B
19199259	10.3760/cma.j.issn.1003-9406.2009.01.019	2009	[Analysis of HLA haplotype frequency and linkage disequilibrium in patients with acute lymphoblastic leukemia from Northern Chinese Han].	HLA-B
19235017	10.1080/10428190802668873	2009	HLA risk markers for chronic myelogenous leukemia in Eastern Canada.	HLA-B
19265139	10.4049/jimmunol.0802316	2009	Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells.	HLA-B
19493232	10.1111/j.1399-0039.2009.01235.x	2009	Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia.	HLA-B
19654554	10.1097/QAI.0b013e3181b017d5	2009	The major histocompatibility complex conserved extended haplotype 8.1 in AIDS-related non-Hodgkin lymphoma.	HLA-B
17971052	10.1111/j.1399-0039.2007.00954.x	2008	Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome.	HLA-B
18301962	10.1007/s12185-008-0040-4	2008	Association of HLA alleles with non-Hodgkin's lymphoma in Korean population.	HLA-B
18544086	10.1111/j.1365-2141.2008.07177.x	2008	Impact of HLA-DPB1 allelic and single amino acid mismatches on HSCT.	HLA-B
18583252	NA	2008	[Association of HLA-A, B and DRB1 alleles with leukemia in Han population in Hunan Province].	HLA-B
18587537	10.1007/s11060-008-9630-5	2008	Primary CNS lymphoma and HLA class I and II alleles in a German cohort of immunocompetent patients.	HLA-B
18724291	10.1038/bmt.2008.145	2008	Current status of hematopoietic stem cell transplantations in Vietnam.	HLA-B
17302780	10.1111/j.1537-2995.2007.01109.x	2007	A possible role for the production of multiple HLA antibodies in fatal platelet transfusion refractoriness after peripheral blood progenitor cell transplantation from the mother in a patient with relapsed leukemia.	HLA-B
17311253	10.1002/gcc.20436	2007	Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma.	HLA-B
17437273	10.1002/ijc.22767	2007	Risk of human T-lymphotropic virus type I-associated diseases in Jamaica with common HLA types.	HLA-B
17493332	NA	2007	[Single nucleotide polymorphism in the promoter region of asparagine synthetase and its impact on the gene expression].	HLA-B
17560447	10.1016/S0140-6736(07)60915-5	2007	Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.	HLA-B
17589290	10.1097/CJI.0b013e3180336771	2007	Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.	HLA-B
17665074	10.1590/s0104-42302007000300024	2007	[Association between HLA and leukemia in a mixed Brazilian population].	HLA-B
17909631	10.1172/JCI32377	2007	HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection.	HLA-B
18005680	10.1016/j.chom.2007.01.001	2007	A two-pronged mechanism for HIV-1 Nef-mediated endocytosis of immune costimulatory molecules CD80 and CD86.	HLA-B
16257267	10.1016/j.clim.2005.09.006	2006	HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia).	HLA-B
16710717	10.1007/s00277-006-0118-0	2006	HLA-B67 may be a male-specific HLA marker of susceptibility to relapsed childhood ALL in Hong Kong Chinese and HLA-A33 or HLA-B17 signifies a higher presentation leukocytosis: A retrospective analysis on 53 transplant candidates (1989-2003).	HLA-B
16933987	10.1371/journal.ppat.0020079	2006	KIR/HLA pleiotropism: protection against both HIV and opportunistic infections.	HLA-B
17145860	10.1158/0008-5472.CAN-06-2326	2006	Isolation of germ cells from leukemia and lymphoma cells in a human in vitro model: potential clinical application for restoring human fertility after anticancer therapy.	HLA-B
17194665	NA	2006	Paraneoplastic stiff-person syndrome, heterotopic soft tissue ossification and gonarthritis in a HLA B27-positive woman preceding the diagnosis of Hodgkin's lymphoma.	HLA-B
15621808	10.1080/10428190400013589	2005	Two new cases of familial hairy cell leukemia associated with HLA haplotypes A2, B7, Bw4, Bw6.	HLA-B
15731175	10.1182/blood-2004-12-4825	2005	Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.	HLA-B
15854278	NA	2005	[Study on the correlation between acute lymphoblastic leukemia and HLA genes in southern China Han population].	HLA-B
15916683	10.1111/j.1365-2141.2005.05499.x	2005	Epstein-Barr virus-associated familial Hodgkin lymphoma: paediatric onset in three of five siblings.	HLA-B
14634793	10.1007/s00277-003-0809-8	2004	Decreased frequency of HLA-B35 in patients with gastric MALT lymphoma.	HLA-B
15202948	10.1186/1471-2407-4-25	2004	Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).	HLA-B
15786697	NA	2004	Impact of standardization on clinical cell analysis by flow cytometry.	HLA-B
12842998	10.1182/blood-2002-11-3584	2003	Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy.	HLA-B
13130260	NA	2003	[Characteristics of uveitis presenting de novo in the elderly].	HLA-B
14515258	10.1002/eji.200324182	2003	Differential effects of US2, US6 and US11 human cytomegalovirus proteins on HLA class Ia and HLA-E expression: impact on target susceptibility to NK cell subsets.	HLA-B
14727382	NA	2003	[Association of HLA class I and leukemia in mestizo patients of the state of Zulia, Venezuela].	HLA-B
11869956	NA	2002	Keratoderma blenorrhagica, balanitis and uveitis after HLA-B15 mismatched bone marrow transplantation.	HLA-B
11872238	10.1016/s0198-8859(01)00381-0	2002	Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon.	HLA-B
11917131	10.1073/pnas.072495599	2002	MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.	HLA-B
12010826	10.1182/blood.v99.11.4200	2002	The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors.	HLA-B
12148880	10.1080/10428190290021588	2002	Increased frequency of homozygosity for HLA class II loci in female patients with chronic lymphocytic leukemia.	HLA-B
12352909	10.1097/00007890-200208270-00012	2002	Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients.	HLA-B
12399966	10.1038/sj.leu.2402690	2002	Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors.	HLA-B
11169449	10.1002/1521-4141(200101)31:1&lt;156::aid-immu156&gt;3.0.co;2-p	2001	Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries.	HLA-B
11485622	10.1089/088922201300343735	2001	HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA-B*4801 alleles predispose to adult T cell leukemia: the limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8(+) cytotoxic T lymphocytes.	HLA-B
10715516	10.1016/s0198-8859(99)00186-x	2000	Differential expression of human major histocompatibility class I loci: HLA-A, -B, and -C.	HLA-B
10717799	10.1016/s0198-8859(99)00147-0	2000	Unrelated donors selected prospectively by block-matching have superior bone marrow transplant outcome.	HLA-B
11035374	10.1038/sj.bmt.1702565	2000	First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients.	HLA-B
11122133	NA	2000	Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.	HLA-B
10566592	10.1016/s0198-8859(99)00076-2	1999	Acquisition of a stimulatory activity for Vgamma9/Vdelta2 T cells by a Burkitt's lymphoma cell line without loss of HLA class I expression.	HLA-B
10622558	10.1016/s0168-8278(99)80372-9	1999	Autoimmunity and extrahepatic manifestations in hepatitis C virus infection.	HLA-B
9892612	10.1084/jem.189.2.301	1999	A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia.	HLA-B
10026877	10.1007/978-1-4615-5357-1_36	1998	Identification of epitopes for CTCL-specific cytotoxic T lymphocytes.	HLA-B
9490691	NA	1998	Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia.	HLA-B
9508175	10.1200/JCO.1998.16.3.931	1998	Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia.	HLA-B
9535555	10.1007/s001090050211	1998	Immunotherapy of acute lymphoblastic leukemia by vaccination with autologous leukemic cells transfected with a cDNA expression plasmid coding for an allogeneic HLA class I antigen combined with interleukin-2 treatment.	HLA-B
9577643	NA	1998	[Post-transplant EBV-associated lymphoproliferative disorders--report of two cases].	HLA-B
9753343	10.1097/00007890-199809150-00013	1998	Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies.	HLA-B
9780337	10.1056/NEJM199810223391701	1998	Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program.	HLA-B
8992968	NA	1997	Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL.	HLA-B
9120290	NA	1997	Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.	HLA-B
9123502	10.1016/s0041-1345(96)00444-7	1997	A low incidence of grade II to IV acute GVHD, but high mortality from infection using HLA-A, -B, and -DR-identical unrelated donors and immunosuppression with ATG, cyclosporine, and methotrexate.	HLA-B
7744880	10.1074/jbc.270.20.12276	1995	The human leukocyte antigen A2 interferon-stimulated response element consensus sequence binds a nuclear factor required for constitutive expression.	HLA-B
7761977	10.1111/j.1399-0039.1995.tb02437.x	1995	The HLA-A,B,C genotype of the class I negative cell line Daudi reveals novel HLA-A and -B alleles.	HLA-B
7820055	NA	1994	HLA typing in hairy cell leukemia.	HLA-B
7909466	10.3109/10428199409059592	1994	Human major histocompatibility complex contains several leukemia susceptibility genes.	HLA-B
8065158	10.1016/0145-2126(94)90037-x	1994	Increased incidence of HLA antigen B35 in patients with chronic lymphocytic leukemia.	HLA-B
8107207	10.1128/JVI.68.3.1442-1448.1994	1994	Down-regulation of HLA antigens by the adenovirus type 2 E3/19K protein in a T-lymphoma cell line.	HLA-B
8302299	10.1016/0161-5890(94)90138-4	1994	Generation of HLA-B55 restricted T lymphocyte mediated cytotoxicity against autologous LCL.	HLA-B
8220228	10.1016/0248-4900(93)90117-w	1993	Clinical applications of flow cytometry in hematology and immunology.	HLA-B
1285893	10.1111/j.1600-0897.1992.tb00806.x	1992	Diffuse infiltrative lymphocytosis syndrome in children and adults infected with HIV-1: a model of rheumatic illness caused by acquired viral infection.	HLA-B
1738086	NA	1992	HLA-B35 is associated with accelerated progression to AIDS.	HLA-B
1655115	NA	1991	Cell phenotype dependent expression of MHC class I antigens in Burkitt's lymphoma cell lines.	HLA-B
1899854	10.1002/ijc.2910470412	1991	Aberrant expression of HLA class-I antigens in Burkitt lymphoma cells.	HLA-B
2066181	10.1002/ijc.2910470703	1991	Differential transcription inducibility by interferon of the HLA-A3 and HLA-B7 class-I genes.	HLA-B
2251046	NA	1990	[Histocompatibility antigens in children with acute lymphoblastic leukemia].	HLA-B
2266272	10.1111/j.1744-313x.1990.tb00868.x	1990	Altered expression of HLA-A,B specificities on acute lymphoid and myeloid leukaemia blasts.	HLA-B
2290171	NA	1990	Lymphoma presenting as a popliteal mass in a patient with rheumatoid arthritis.	HLA-B
2395381	NA	1990	Immunophenotypic and HLA studies in childhood acute lymphoblastic leukemia in Trinidad, West Indies.	HLA-B
2535859	NA	1989	IFN-mediated differential regulation of the expression of HLA-B7 and HLA-A3 class I genes.	HLA-B
2561749	NA	1989	[Cluster headache, Epstein-Barr and Burkitt's lymphoma virus infections].	HLA-B
2643045	10.1056/NEJM198901263200401	1989	Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma.	HLA-B
2744385	NA	1989	[Class I and II HLA antigens in children with acute lymphoblastic leukemia].	HLA-B
2788584	NA	1989	Study of HLA antigens in patients with Hodgkin's disease.	HLA-B
2804917	10.1002/1097-0142(19891201)64:11&lt;2259::aid-cncr2820641113&gt;3.0.co;2-0	1989	Possible disorder of B-cell-related surveillance and malignant lymphoma of the thyroid.	HLA-B
2450918	NA	1988	Specific associations of fluorescent beta-2-microglobulin with cell surfaces. The affinity of different H-2 and HLA antigens for beta-2-microglobulin.	HLA-B
2894907	NA	1988	HLA and adult T cell leukaemia: HLA-linked genes controlling susceptibility to human T cell leukaemia virus type I.	HLA-B
3131426	NA	1988	Isolation and nucleotide sequence of a cDNA clone encoding a novel HLA class I gene.	HLA-B
3199882	NA	1988	HLA-A11 is associated with poor prognosis in childhood acute lymphoblastic leukemia (ALL).	HLA-B
3259347	NA	1988	[Does the presence of HLA-B5 and B35 antigen signify a worse prognosis for Hodgkin's disease? Preliminary report].	HLA-B
2423453	10.3109/08820138609042018	1986	Study on the association of HLA with malignant lymphoma.	HLA-B
3092030	10.1016/0161-5890(86)90115-x	1986	The synthesis and expression of HLA-A and -B antigens in Xenopus laevis oocytes.	HLA-B
2578520	NA	1985	Delineation of three subsets of class I human T antigens (HTA) on Molt-4 cells: serologic and regulatory relationship to HLA class I antigens.	HLA-B
3872893	10.1016/s0190-9622(85)70075-8	1985	Human leukocyte antigens in cutaneous T cell lymphoma.	HLA-B
3971646	10.1177/000992288502400315	1985	Hodgkin's disease in siblings.	HLA-B
6197461	NA	1984	Cytotoxic T lymphocyte recognition of HLA-A/B antigens introduced into EL4 cells by cell-liposome fusion.	HLA-B
6334992	10.1097/00000441-198412000-00005	1984	Graves' disease with ophthalmopathy following radiotherapy for Hodgkin's disease.	HLA-B
6361126	NA	1984	Introduction of HLA-A/B antigens into lymphoid cell membranes by cell-liposome fusion.	HLA-B
6376119	10.1002/j.1460-2075.1984.tb01915.x	1984	Autogenous production of interferon-beta switches on HLA genes during differentiation of histiocytic lymphoma U937 cells.	HLA-B
6390442	10.1073/pnas.81.23.7549	1984	Recognition of HLA-A2 and -B7 antigens by cloned cytotoxic T lymphocytes after gene transfer into human and monkey, but not mouse, cells.	HLA-B
6420131	10.1016/0011-5029(84)90005-1	1984	Lymphocyte markers in health and disease.	HLA-B
6303316	10.1042/bj2100079	1983	Human class I histocompatibility antigens (HLA-A,B,C). A small proportion only is phosphorylated.	HLA-B
6875280	10.1111/j.1744-313x.1983.tb00801.x	1983	HLA in familial Hodgkin's disease.	HLA-B
6888549	10.1038/305058a0	1983	Cell lines producing human T-cell lymphoma virus show altered HLA expression.	HLA-B
6888550	10.1038/305060a0	1983	Homology of human T-cell leukaemia virus envelope gene with class I HLA gene.	HLA-B
6181407	NA	1982	Lack of expression of HLA-ABC antigens in choriocarcinoma and other human tumor cell lines.	HLA-B
6187075	10.1007/BF01543018	1982	HLA antigen expression at the single cell level on a K562 X B cell hybrid: an analysis with monoclonal antibodies using bacterial binding assays.	HLA-B
6760459	10.1111/j.1399-0039.1982.tb02252.x	1982	HLA typing in non-Hodgkin's lymphomas. Comparative study in Caucasoids, Mexican-Americans and Negroids.	HLA-B
6951167	10.1073/pnas.79.4.1190	1982	Introduction of a human X-6 translocation chromosome into a mouse teratocarcinoma: investigation of control of HLA-A, B, C expression.	HLA-B
6960462	NA	1982	[Detection of HLA-A, B and C antigens on various normal and pathologic cells using the monoclonal antibody W6/32].	HLA-B
7000762	NA	1980	Biosynthesis of HLA-A and HLA-B antigens in vivo.	HLA-B
24959916	10.1371/journal.pone.0100480	2014	Differences in meiotic recombination rates in childhood acute lymphoblastic leukemia at an MHC class II hotspot close to disease associated haplotypes.	HLA-DMB
16191436	10.1016/j.leukres.2005.08.013	2006	HLA-DM expression is elevated in ETV6-AML1 translocation-positive pediatric acute lymphoblastic leukemia.	HLA-DMB
9712021	NA	1998	Antigen processing of two H2-IEd-restricted epitopes is differentially influenced by the structural changes in a viral glycoprotein.	HLA-DMB
9103423	NA	1997	Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4+ EBV-specific CTLs.	HLA-DMB
9352359	10.1093/intimm/9.10.1537	1997	Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.	HLA-DMB
33767152	10.1038/s41419-021-03594-y	2021	A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes.	HNRNPD
30681073	10.12659/MSM.912082	2019	Berberine Promotes Apoptosis of Colorectal Cancer via Regulation of the Long Non-Coding RNA (lncRNA) Cancer Susceptibility Candidate 2 (CASC2)/AU-Binding Factor 1 (AUF1)/B-Cell CLL/Lymphoma 2 (Bcl-2) Axis.	HNRNPD
30209976	10.1080/15384101.2018.1522912	2018	PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation.	HNRNPD
30210700	NA	2018	Survival associated alternative splicing events in diffuse large B-cell lymphoma.	HNRNPD
27578251	10.1038/srep32189	2016	The long noncoding RNA ASNR regulates degradation of Bcl-2 mRNA through its interaction with AUF1.	HNRNPD
22159912	10.1007/s00125-011-2399-7	2012	Involvement of the RNA-binding protein ARE/poly(U)-binding factor 1 (AUF1) in the cytotoxic effects of proinflammatory cytokines on pancreatic beta cells.	HNRNPD
19520857	10.1074/jbc.M109.023721	2009	B cell lymphoma (Bcl)-2 protein is the major determinant in bcl-2 adenine-uridine-rich element turnover overcoming HuR activity.	HNRNPD
16835382	10.1182/blood-2006-04-014902	2006	A liaison dangereuse between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK.	HNRNPD
34256839	10.1186/s40164-021-00232-3	2021	Progress in molecular feature of smoldering mantle cell lymphoma.	HNRNPH1
32160292	10.1182/blood.2019002385	2020	Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing.	HNRNPH1
32449435	10.1080/15476286.2020.1772559	2020	Burkitt lymphoma-related <i>TCF3</i> mutations alter TCF3 alternative splicing by disrupting hnRNPH1 binding.	HNRNPH1
32584970	10.1182/blood.2020005289	2020	Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.	HNRNPH1
30171027	10.3324/haematol.2017.186320	2019	Clinical and molecular characteristics of <i>MEF2D</i> fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in <i>MEF2D-HNRNPH1</i> gene fusion.	HNRNPH1
30209976	10.1080/15384101.2018.1522912	2018	PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation.	HNRNPH1
26446488	10.1038/ncomms9325	2015	LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair.	HNRNPH1
23673860	10.1182/blood-2013-02-487256	2013	New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia.	HNRNPH1
35583604	10.1158/1078-0432.CCR-21-3347	2022	Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL.	HNRNPU
30209976	10.1080/15384101.2018.1522912	2018	PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation.	HNRNPU
26446488	10.1038/ncomms9325	2015	LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair.	HNRNPU
27980386	10.4137/CIN.S30563	2015	Quantitative Proteomic Approach for MicroRNA Target Prediction Based on <sup>18</sup>O/<sup>16</sup>O Labeling.	HNRNPU
7753047	10.1016/0161-5890(95)00005-y	1995	Binding sites of the Epstein-Barr virus and C3d receptor (CR2, CD21) for its three intracellular ligands, the p53 anti-oncoprotein, the p68 calcium binding protein and the nuclear p120 ribonucleoprotein.	HNRNPU
30126979	10.1182/blood-2018-03-837252	2018	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.	HVCN1
28064239	10.1182/blood-2016-07-729954	2017	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.	HVCN1
25425665	10.1073/pnas.1411390111	2014	Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells.	HVCN1
20346427	10.1016/j.jprot.2010.03.010	2010	Proteomic analysis of B-cell malignancies.	HVCN1
33941102	10.1186/s12885-021-08142-7	2021	Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.	IL16
32735617	10.1371/journal.ppat.1008701	2020	Interleukin 16 contributes to gammaherpesvirus pathogenesis by inhibiting viral reactivation.	IL16
28574850	10.18632/oncotarget.17959	2017	Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.	IL16
24794807	10.3109/10428194.2014.919634	2015	CCR4+T cell recruitment to the skin in mycosis fungoides: potential contributions by thymic stromal lymphopoietin and interleukin-16.	IL16
23893766	10.1002/jcp.24441	2014	Regulation of cellular processes by interleukin-16 in homeostasis and cancer.	IL16
23297678	10.1111/sji.12026	2013	Pro-IL-16 is associated with MHC class II-mediated negative regulation of mouse resting B cell activation through MAP kinases, NF-Œ∫B and Skp2-dependent p27kip regulation.	IL16
20878214	10.1007/s10875-010-9464-8	2011	Interleukin-16 as a marker of S√©zary syndrome onset and stage.	IL16
21818556	10.1007/s00432-011-1017-x	2011	Introduction of pro-interleukin-16 inhibits T-lymphoblastic leukemia growth in mice.	IL16
22080865	10.1172/JCI41769	2011	Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.	IL16
20802378	10.1097/FPC.0b013e32833deb16	2010	A multiplex MALDI-TOF MS approach facilitates genotyping of DNA from formalin-fixed paraffin-embedded tumour specimens.	IL16
19066394	10.1182/blood-2008-04-153858	2009	Organochlorine exposure, immune gene variation, and risk of non-Hodgkin lymphoma.	IL16
18633131	10.1182/blood-2007-09-111658	2008	Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.	IL16
17577790	10.1080/10428190701268767	2007	Serum levels of interleukin-16 in lymphoid malignancies.	IL16
16709867	10.4049/jimmunol.176.11.7051	2006	Leukotriene A4 hydrolase expression in PEL cells is regulated at the transcriptional level and leads to increased leukotriene B4 production.	IL16
12769791	10.2174/1568005033481178	2003	Current perspectives on cytokines for anti-retroviral therapy in AIDS related B-cell lymphomas.	IL16
11967309	10.1128/jvi.76.10.4919-4927.2002	2002	Expression of transcription factor AML-2 (RUNX3, CBF(alpha)-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell activation phenotype.	IL16
11298554	10.1046/j.1365-2133.2001.04150.x	2001	Angioimmunoblastic lymphadenopathy-type peripheral T-cell lymphoma with cutaneous infiltration: report of a case and its gene expression profile.	IL16
10692046	10.1046/j.1365-2567.2000.00959.x	2000	Human B-cell lines constitutively express and secrete interleukin-16.	IL16
10949545	10.1034/j.1600-0625.2000.009004248.x	2000	IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression.	IL16
11064099	10.1016/s0165-2478(00)00258-3	2000	CXCR4 and CCR5 expression by H9 T-cells is downregulated by a peptide-nucleic acid immunomodulator.	IL16
11154979	10.1159/000039756	2000	The cellular immune system of patients with acute leukemia and severe chemotherapy-induced leukopenia: characterization of T lymphocyte subsets responsive to IL-16 and IL-17.	IL16
10504456	10.1046/j.1523-1747.1999.00717.x	1999	Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides.	IL16
3286773	NA	1988	Functional analysis of mononuclear cells infiltrating into tumors. III. Soluble factors involved in the regulation of T lymphocyte infiltration into tumors.	IL16
34662484	10.1002/pbc.29402	2022	Allergies, genetic polymorphisms of Th2 interleukins, and childhood acute lymphoblastic leukemia: The ESTELLE study.	IL4R
33684939	10.1182/blood.2020007683	2021	Characterization of DLBCL with a PMBL gene expression signature.	IL4R
31141539	10.1371/journal.pone.0216898	2019	Epstein-Barr virus (EBV) activates NKL homeobox gene HLX in DLBCL.	IL4R
29253230	10.3382/ps/pex343	2018	Correlation between miRNAs and target genes in response to Campylobacter jejuni inoculation in chicken.	IL4R
29467182	10.1182/blood-2017-09-808907	2018	Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation.	IL4R
29883839	10.1016/j.canep.2018.05.004	2018	Genetic polymorphisms of Th2 interleukins, history of asthma or eczema and childhood acute lymphoid leukaemia: Findings from the ESCALE study (SFCE).	IL4R
28134252	10.1038/ncomms14290	2017	THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.	IL4R
27268263	10.1182/blood-2015-11-683003	2016	Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.	IL4R
27407063	10.1002/ijc.30263	2016	Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.	IL4R
26448050	10.1371/journal.pone.0139329	2015	Inherited Inflammatory Response Genes Are Associated with B-Cell Non-Hodgkin's Lymphoma Risk and Survival.	IL4R
24960198	10.1016/j.bbrc.2014.06.069	2014	IL-4 receptor Œ± in non-lipid rafts is the target molecule of strictinin in inhibiting STAT6 activation.	IL4R
22102710	10.3324/haematol.2011.048132	2012	MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response.	IL4R
22902050	10.1016/j.leukres.2012.07.014	2012	Using haplotype analysis to elucidate significant associations between genes and Hodgkin lymphoma.	IL4R
21061265	10.1002/mc.20688	2011	Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes.	IL4R
21421840	10.1182/blood-2010-10-312942	2011	Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset.	IL4R
20299965	10.1097/QAD.0b013e328332d5b1	2010	Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study.	IL4R
20716621	10.1158/1055-9965.EPI-10-0389	2010	Genetic polymorphisms in adaptive immunity genes and childhood acute lymphoblastic leukemia.	IL4R
19508433	10.1111/j.1600-0609.2009.01288.x	2009	Genetic variants in immunoregulatory genes and risk for childhood lymphomas.	IL4R
19515749	10.1093/annonc/mdp110	2009	Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial.	IL4R
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	IL4R
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	IL4R
18633131	10.1182/blood-2007-09-111658	2008	Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.	IL4R
18636124	10.1371/journal.pone.0002816	2008	Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.	IL4R
12154046	NA	2002	Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells.	IL4R
11513543	10.1006/clim.2001.5082	2001	Analysis of the Ser786Pro interleukin-4 receptor alpha allelic variant in allergic and nonallergic asthma and its functional consequences.	IL4R
11697499	10.3109/10428190109099331	2001	Expression and production of interleukin 4 in B-cell chronic lymphocytic leukaemia.	IL4R
10652211	10.1006/bbrc.2000.2080	2000	Possible involvement of Shc in IL-4-induced germline epsilon transcription in a human B cell line.	IL4R
10856136	10.1067/mai.2000.107604	2000	IL-4/IL-13 signaling beyond JAK/STAT.	IL4R
9545332	10.1074/jbc.273.16.9898	1998	A role for the insulin-interleukin (IL)-4 receptor motif of the IL-4 receptor alpha-chain in regulating activation of the insulin receptor substrate 2 and signal transducer and activator of transcription 6 pathways. Analysis by mutagenesis.	IL4R
9761767	10.1165/ajrcmb.19.4.3208	1998	Human eosinophils constitutively express a functional interleukin-4 receptor: interleukin-4 -induced priming of chemotactic responses and induction of PI-3 kinase activity.	IL4R
8624803	10.1016/s1074-7613(00)80677-9	1996	Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor.	IL4R
34310368	10.1097/PAS.0000000000001785	2022	Reactive Intralymphovascular Immunoblastic Proliferations Mimicking Aggressive Lymphomas.	IRF4
34560683	10.1097/PAS.0000000000001813	2022	A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients.	IRF4
34622970	10.1111/cup.14147	2022	Primary cutaneous anaplastic large-cell lymphoma with DUSP22-IRF4 rearrangement following insect bites.	IRF4
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	IRF4
34699105	10.1111/cup.14156	2022	Patch/plaque mycosis-fungoides-like presentations of DUSP22-translocated T-cell lymphomas.	IRF4
34705295	10.1111/cup.14157	2022	Primary cutaneous anaplastic large-cell lymphoma with aberrant cytokeratin expression: An unusual mimicker of poorly differentiated carcinomas.	IRF4
34775495	10.1038/s41374-021-00638-x	2022	microRNA-155-5p initiates childhood acute lymphoblastic leukemia by regulating the IRF4/CDK6/CBL axis.	IRF4
34791573	10.1007/s10014-021-00415-0	2022	Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement.	IRF4
34801601	10.1016/j.humpath.2021.11.007	2022	Clinicopathological features of syncytial variant nodular sclerosis Hodgkin lymphoma.	IRF4
34913532	10.1002/pro.4260	2022	The molecular basis for the development of adult T-cell leukemia/lymphoma in patients with an IRF4<sup>K59R</sup> mutation.	IRF4
34952945	10.1038/s41379-021-01002-6	2022	Genomic landscape of Epstein-Barr virus-positive extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue.	IRF4
34962700	10.1002/pbc.29527	2022	Importance of clinical correlation in the diagnosis of pediatric B-cell lymphomas.	IRF4
35001425	10.1111/cup.14199	2022	Primary cutaneous CD8+ cytotoxic T-cell lymphoma of the face with intraoral involvement, resulting in facial nerve palsy after chemotherapy.	IRF4
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	IRF4
35142151	10.3324/haematol.2021.279908	2022	A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas.	IRF4
35183824	10.1016/j.prp.2022.153804	2022	Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma.	IRF4
35255429	10.1016/j.anndiagpath.2021.151886	2022	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.	IRF4
35338347	10.1038/s41417-022-00450-9	2022	SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide.	IRF4
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	IRF4
35472072	10.1371/journal.ppat.1010453	2022	Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells.	IRF4
35504924	10.1038/s41467-022-30053-9	2022	IRF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma.	IRF4
35560037	10.1111/1346-8138.16424	2022	Primary cutaneous anaplastic large cell lymphoma with DUSP22-IRF4 rearrangement demonstrating a biphasic histopathologic pattern and a complete natural regression.	IRF4
35675522	10.1182/bloodadvances.2022007725	2022	ETS1 is a novel transcriptional regulator of adult T-cell leukemia/lymphoma of North American descent.	IRF4
35759728	10.1182/blood.2022015926	2022	Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma.	IRF4
35884496	10.3390/cancers14143434	2022	Classifying Germinal Center Derived Lymphomas-Navigate a Complex Transcriptional Landscape.	IRF4
35884913	10.3390/biomedicines10071608	2022	Downregulation of STAT3 in Epstein-Barr Virus-Positive Hodgkin Lymphoma.	IRF4
35928872	10.3389/fonc.2022.932674	2022	Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma.	IRF4
35968590	10.3760/cma.j.issn.0253-2727.2022.06.006	2022	[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review].	IRF4
35983077	10.1155/2022/9544827	2022	Immunogenomic-Based Analysis of Hierarchical Clustering of Diffuse Large Cell Lymphoma.	IRF4
35984488	10.1007/s00428-022-03385-6	2022	Primary effusion anaplastic large cell lymphoma with indolent clinical course and IRF4/DUSP22 rearrangement: a case report expanding the spectrum of effusion-based lymphoma.	IRF4
36009586	10.3390/biomedicines10082038	2022	Genomic Aberrations Generate Fusion Gene FOXK2::TP63 and Activate NFKB1 in Cutaneous T-Cell Lymphoma.	IRF4
36047964	10.1111/cas.15550	2022	Alvocidib inhibits IRF4 expression via super-enhancer suppression and adult T-cell leukemia/lymphoma cell growth.	IRF4
32139889	10.1038/s41375-020-0766-4	2021	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.	IRF4
32749698	10.1002/jcp.29953	2021	Roles of BATF/JUN/IRF4 complex in tacrolimus mediated immunosuppression on Tfh cells in acute rejection after liver transplantation.	IRF4
33150420	10.1182/blood.2020005083	2021	Plasmablasts derive from CD23- activated B cells after the extinction of IL-4/STAT6 signaling and IRF4 induction.	IRF4
33406405	10.1016/j.cmet.2020.12.011	2021	Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma.	IRF4
33411730	10.1371/journal.ppat.1009091	2021	Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.	IRF4
33503299	10.1111/pin.13067	2021	B cell lymphoma with IRF4 rearrangement: A clinicopathological study of 13 cases.	IRF4
33512466	10.1182/blood.2020010175	2021	OBF1 and Oct factors control the germinal center transcriptional program.	IRF4
33597573	10.1038/s41598-021-83352-4	2021	Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous T-cell lymphoma.	IRF4
33629212	10.1007/s12032-021-01470-5	2021	Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.	IRF4
33654205	10.1038/s41375-021-01181-w	2021	BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.	IRF4
33685720	10.1016/j.pathol.2021.01.002	2021	New developments in non-Hodgkin lymphoid malignancies.	IRF4
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	IRF4
34078047	10.3760/cma.j.cn112151-20210204-00127	2021	[Clinicopathological and molecular genetic features of Burkitt-like lymphoma with 11q aberration].	IRF4
34164830	10.1111/cup.14089	2021	Primary cutaneous anaplastic large-cell lymphoma with 6p25.3 rearrangement exhibits a biphasic histopathologic pattern: Two case reports and literature review.	IRF4
34304770	10.1016/j.cll.2021.03.018	2021	Update on Pediatric and Young Adult Mature Lymphomas.	IRF4
34455369	10.1016/j.bbrc.2021.08.051	2021	Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.	IRF4
34465776	10.1038/s41467-021-25405-w	2021	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.	IRF4
34477080	NA	2021	Indurated Plaques on the Legs: Think Lymphoma.	IRF4
34484219	10.3389/fimmu.2021.716240	2021	Coupled Antigen and BLIMP1 Asymmetric Division With a Large Segregation Between Daughter Cells Recapitulates the Temporal Transition From Memory B Cells to Plasma Cells and a DZ-to-LZ Ratio in the Germinal Center.	IRF4
34707037	10.3960/jslrt.21025	2021	t(9;14)(p13;q32)/PAX5-IGH translocation as a secondary cytogenetic abnormality in diffuse large B-cell lymphoma.	IRF4
34944796	10.3390/cancers13246174	2021	RNA Sequencing of Primary Cutaneous and Breast-Implant Associated Anaplastic Large Cell Lymphomas Reveals Infrequent Fusion Transcripts and Upregulation of PI3K/AKT Signaling via Neurotrophin Pathway Genes.	IRF4
31324665	10.1136/jclinpath-2019-205915	2020	Tonsillar follicular large B-cell lymphoma with <i>IRF4</i> rearrangement causing sleep apnoea.	IRF4
31361906	10.1111/his.13964	2020	Extraoral plasmablastic lymphomas in a high human immunodeficiency virus endemic area.	IRF4
31631721	10.1177/1066896919883013	2020	Primary Low-Grade B-Cell Lymphoma of Skull With Translocation Between Immunoglobulin and Interferon Regulatory Factor 4 Genes.	IRF4
31688142	10.1097/PAS.0000000000001399	2020	Unusual Variants of Follicular Lymphoma: Case-based Review.	IRF4
31725418	10.1097/PAP.0000000000000253	2020	Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches.	IRF4
31735345	10.1016/j.pathol.2019.08.013	2020	Diffuse large B-cell lymphoma variants: an update.	IRF4
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	IRF4
31773249	10.1007/s00428-019-02704-8	2020	Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas.	IRF4
31882178	10.1053/j.semdp.2019.12.002	2020	Pathology and genetics of anaplastic large cell lymphoma.	IRF4
31914056	10.1097/MD.0000000000018670	2020	Clinicopathologic features and prognostic analysis of Waldeyer ring B-cell lymphoma.	IRF4
31964683	10.1136/jclinpath-2019-206267	2020	Application of 2016 WHO classification in the diagnosis of paediatric high-grade <i>MYC</i>-negative mature B-cell lymphoma with Burkitt-like morphological features.	IRF4
31972002	10.1182/blood.2019002639	2020	Feed-forward regulatory loop driven by IRF4 and NF-Œ∫B in adult T-cell leukemia/lymphoma.	IRF4
32100965	10.1111/ddg.14041	2020	Lymphomatoid papulosis.	IRF4
32202225	10.1177/0300985820913265	2020	Spectrum of Posttransplant Lymphoproliferations in NSG Mice and Their Association With EBV Infection After Engraftment of Pediatric Solid Tumors.	IRF4
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	IRF4
32239695	10.1111/bjh.16578	2020	Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group.	IRF4
32349466	10.4274/tjh.galenos.2020.2020.0086	2020	<i>IRF4</i>-Rearranged Large B-Cell Lymphoma on Waldeyer‚Äôs Ring: A Case Report	IRF4
32585984	10.3390/cancers12061669	2020	Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma.	IRF4
32610392	10.3760/cma.j.cn112151-20200213-00089	2020	[Large B-cell lymphoma with atypical IRF4 rearrangement: report of a case].	IRF4
32753663	10.1038/s41598-020-69884-1	2020	Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma.	IRF4
32761226	10.1182/blood.2020006406	2020	Early pattern of large B-cell lymphoma with IRF4 rearrangement.	IRF4
32771332	10.1016/j.oraloncology.2020.104910	2020	Primary intraosseous CD9-positive B-cell lymphoblastic lymphoma of the maxilla affecting a pediatric patient: Immunohistochemical and in situ hybridization analysis.	IRF4
32779615	10.3960/jslrt.20019	2020	Clinical application of genomic aberrations in adult T-cell leukemia/lymphoma.	IRF4
32817485	10.1073/pnas.1922216117	2020	Global epigenomic analysis of KSHV-infected primary effusion lymphoma identifies functional <i>MYC</i> superenhancers and enhancer RNAs.	IRF4
32843547	10.1128/mBio.01457-20	2020	Kaposi's Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma.	IRF4
32859220	10.1186/s12977-020-00535-z	2020	Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma.	IRF4
32889849	10.1097/QAD.0000000000002590	2020	HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients.	IRF4
32909092	10.1007/s00292-020-00816-6	2020	[Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas].	IRF4
32914098	10.1158/2643-3230.BCD-20-0009	2020	Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma.	IRF4
32921221	10.1080/10428194.2020.1815017	2020	Clinicopathological and prognostic significance of <i>BCL2</i>, <i>BCL6</i>, <i>MYC</i>, and <i>IRF4</i> copy number gains and translocations in follicular lymphoma: a study by FISH analysis.	IRF4
32922661	10.18632/oncotarget.27683	2020	The NKL-code for innate lymphoid cells reveals deregulated expression of NKL homeobox genes HHEX and HLX in anaplastic large cell lymphoma (ALCL).	IRF4
32992413	10.3760/cma.j.cn112151-20200601-00433	2020	[Clinicopathological study of large B-cell lymphoma with IRF4 rearrangement].	IRF4
33017467	10.1182/bloodadvances.2020002049	2020	The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1.	IRF4
33298918	10.1038/s41467-020-20136-w	2020	Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors.	IRF4
33357426	10.1016/j.celrep.2020.108517	2020	Chromatin Protein PC4 Orchestrates B Cell Differentiation by Collaborating with IKAROS and IRF4.	IRF4
33613551	10.3389/fimmu.2020.620716	2020	Multiscale Modeling of Germinal Center Recapitulates the Temporal Transition From Memory B Cells to Plasma Cells Differentiation as Regulated by Antigen Affinity-Based Tfh Cell Help.	IRF4
29718735	10.1080/10428194.2018.1466290	2019	Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.	IRF4
30016448	10.1093/labmed/lmy035	2019	Anaplastic Large Cell Lymphoma Manifesting as Pleural Effusion in a Patient with Long-Standing Eosinophilia.	IRF4
30019203	10.1007/s00292-018-0456-4	2019	[Revised version of the 4th edition of the WHO classification of malignant lymphomas : What is new?]	IRF4
30068263	10.1080/10428194.2018.1485915	2019	Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.	IRF4
30277089	10.1080/10428194.2018.1508669	2019	A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL).	IRF4
30380402	10.1016/j.anndiagpath.2018.09.014	2019	Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues.	IRF4
30457169	10.1111/his.13794	2019	Biphasic pathological pattern in transformed mycosis fungoides not associated with DUSP22-IRF4 translocation.	IRF4
30664244	10.1002/eji.201847855	2019	Transformation of mature mouse B cells into malignant plasma cells in vitro via introduction of defined genetic elements.	IRF4
30695866	10.3760/cma.j.issn.0529-5807.2019.02.011	2019	[Clinicopathological features of follicular lymphoma in children].	IRF4
30732171	10.1097/MD.0000000000014367	2019	Diffuse large B-cell lymphoma of the central nervous system presenting as lymphomatosis cerebri and dementia in elderly man: Case report and review of the literature.	IRF4
30792929	10.1155/2019/3730915	2019	CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type.	IRF4
30802809	10.1016/j.anndiagpath.2019.02.001	2019	American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.	IRF4
30907723	10.1099/jgv.0.001249	2019	IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.	IRF4
30962205	10.1182/blood.2018880138	2019	Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells.	IRF4
31012208	10.1002/pbc.27770	2019	IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children's Oncology Group trials.	IRF4
31039827	10.1186/s13073-019-0637-7	2019	A modular transcriptome map of mature B cell lymphomas.	IRF4
31101622	10.1182/blood.2019000626	2019	Recurrent <i>MSC</i> <sup>E116K</sup> mutations in ALK-negative anaplastic large cell lymphoma.	IRF4
31102405	10.1093/neuonc/noz088	2019	A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study.	IRF4
31104675	10.3760/cma.j.issn.0529-5807.2019.05.006	2019	[Clinicopathological features and molecular genetics of paediatric-type follicular lymphoma: report of eight cases].	IRF4
31151983	10.1182/blood.2019001043	2019	A novel model of controlling PD-L1 expression in ALK<sup>+</sup> anaplastic large cell lymphoma revealed by CRISPR screening.	IRF4
31187530	10.1002/hon.2585	2019	Rare mature B-cell lymphomas in children and adolescents.	IRF4
31278738	10.1093/ajcp/aqz078	2019	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms.	IRF4
31292115	10.1182/blood.2019001126	2019	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.	IRF4
31331250	10.2217/pme-2018-0068	2019	Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma.	IRF4
31363108	10.1038/s41598-019-47343-w	2019	A bioinformatic analysis identifies circadian expression of splicing factors and time-dependent alternative splicing events in the HD-MY-Z cell line.	IRF4
31570354	10.1136/bcr-2019-230641	2019	<i>DUSP22-IRF4</i> rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma.	IRF4
31584842	10.5858/arpa.2019-0331-RA	2019	Ancillary Studies in the Diagnostic Evaluation of Large B-Cell Lymphoma.	IRF4
31594013	10.1055/a-0597-7606	2019	[Current standard in diagnostic and therapy of peripheral T-cell lymphoma].	IRF4
31837029	10.1111/vcp.12816	2019	Lymphoma with Mott cell differentiation and validation of immunohistochemical lymphoid markers in an African pygmy hedgehog (Atelerix albiventris).	IRF4
29084771	10.1182/blood-2017-01-761874	2018	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.	IRF4
29097500	10.3324/haematol.2017.179309	2018	A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.	IRF4
29122756	10.1182/blood-2017-08-799080	2018	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.	IRF4
29154209	10.1016/j.molimm.2017.11.011	2018	External signals regulate germinal center fate-determining transcription factors in the A20 lymphoma cell line.	IRF4
29251015	10.1080/10428194.2017.1410884	2018	Prognostic impact of activation-induced cytidine deaminase expression for patients with diffuse large B-cell lymphoma.	IRF4
29253230	10.3382/ps/pex343	2018	Correlation between miRNAs and target genes in response to Campylobacter jejuni inoculation in chicken.	IRF4
29346274	10.3390/cancers10010021	2018	IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.	IRF4
29397940	10.1016/j.bbrc.2018.01.154	2018	KSHV vIRF4 enhances BCL6 transcription via downregulation of IRF4 expression.	IRF4
29467311	10.1128/JVI.02155-17	2018	Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.	IRF4
29540473	10.1074/jbc.RA117.000164	2018	An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia.	IRF4
29555645	10.1182/blood-2018-01-824540	2018	Epigenetic silencing of miR-125b is required for normal B-cell development.	IRF4
29567771	10.3324/haematol.2017.181024	2018	Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2.	IRF4
29588546	10.1038/s41375-018-0045-9	2018	The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.	IRF4
29616088	10.3892/ol.2018.8014	2018	Retrospective screening of microarray data to identify candidate IFN-inducible genes in a HTLV-1 transformed model.	IRF4
29666157	10.1136/jclinpath-2018-205039	2018	CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.	IRF4
29676376	10.4103/IJPM.IJPM_194_17	2018	An unusual presentation of large B-cell lymphoma with interferon regulatory factor 4 gene rearrangement.	IRF4
29684346	10.1016/j.bbrc.2018.04.159	2018	MicroRNA-3662 expression correlates with antiviral drug resistance in adult T-cell leukemia/lymphoma cells.	IRF4
29738359	10.1097/PAS.0000000000001071	2018	Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients.	IRF4
29937999	10.18632/oncotarget.25463	2018	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma.	IRF4
29954751	10.1182/blood-2018-01-828418	2018	CK1Œ± and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.	IRF4
29992063	10.1155/2018/5320590	2018	A Rare Case of ALK-Positive Large B-Cell Lymphoma with CD33 Expression.	IRF4
29992138	10.1155/2018/3574534	2018	Identification of Hub Genes and Key Pathways Associated with Two Subtypes of Diffuse Large B-Cell Lymphoma Based on Gene Expression Profiling via Integrated Bioinformatics.	IRF4
30021904	10.1128/JVI.00716-18	2018	Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.	IRF4
30032036	10.1016/j.neo.2018.07.001	2018	Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma.	IRF4
30057145	10.1016/j.ccell.2018.06.014	2018	Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma.	IRF4
30111411	10.7534/j.issn.1009-2137.2018.04.023	2018	[Prognostic Value of Morphology and Hans Classification in Diffuse Large B Cell Lymphoma].	IRF4
30111820	10.1038/s41467-018-05506-9	2018	Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma.	IRF4
30125329	10.1371/journal.ppat.1007221	2018	An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model.	IRF4
30207048	10.1002/pbc.27399	2018	Burkitt lymphoma in Iraqi children: A distinctive form of sporadic disease with high incidence of EBV<sup>+</sup> cases and more frequent expression of MUM1/IRF4 protein in cases with head and neck presentation.	IRF4
30305518	10.11406/rinketsu.59.2127	2018	[Genetic analysis and its clinical implication in adult T-cell leukemia/lymphoma].	IRF4
30305637	10.1038/s41467-018-06541-2	2018	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenstr√∂m macroglobulinemia.	IRF4
30348505	10.1016/j.pathol.2018.08.008	2018	Mycosis fungoides in Taiwan shows a relatively high frequency of large cell transformation and CD56 expression.	IRF4
30522172	10.3760/cma.j.issn.0529-5807.2018.12.005	2018	[Diagnostic and therapeutic values of interphase fluorescence in situ hybridization in B-cell lymphomas: a clinicopathologic analysis of 604 cases].	IRF4
30701929	10.26442/terarkh201890796-101	2018	Successful experience of treatment of a patient with generalized non-GCB- DLBCL using the R-mNHL-BFM-90 protocol with lenalidomide: case report and review of literature.	IRF4
31360094	10.2147/BLCTT.S142814	2018	Plasmablastic lymphoma: current perspectives.	IRF4
27616053	10.1002/pbc.26236	2017	IFR4/MUM1-positive lymphoma in Waldeyer ring with co-expression of CD5 and CD10.	IRF4
28079574	10.1097/PAS.0000000000000804	2017	Prognostic Impact of MUM1/IRF4 Expression in Burkitt Lymphoma (BL): A Reappraisal of 88 BL Patients in Japan.	IRF4
28263097	10.1080/08916934.2017.1284821	2017	Transcriptional and epigenetic regulation of follicular T-helper cells and their role in autoimmunity.	IRF4
28357165	10.7759/cureus.1033	2017	Persistent Afebrile Abdominal Pain: An Unusual Case of Segmental Colitis in an Immunocompromised Host.	IRF4
28368397	10.1038/onc.2017.90	2017	Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.	IRF4
28368411	10.1038/onc.2017.79	2017	PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.	IRF4
28369050	10.1038/ni.3716	2017	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.	IRF4
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	IRF4
28494239	10.1016/j.chom.2017.04.005	2017	CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors.	IRF4
28529614	10.7150/jca.17358	2017	IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma.	IRF4
28600336	10.1182/blood-2017-02-734541	2017	Diagnosis and classification of hematologic malignancies on the basis of genetics.	IRF4
28627735	10.1111/cas.13303	2017	Genetic alterations in adult T-cell leukemia/lymphoma.	IRF4
28693749	10.1016/j.pathol.2017.05.007	2017	Primary gastrointestinal anaplastic large cell lymphoma.	IRF4
28910419	10.1371/journal.ppat.1006597	2017	IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways.	IRF4
29056123	2721	2017	Immunohistochemical Expression of CD10, BCL6 and MUM1 in Differentiating Diffuse Large B Cell Lymphoma Subtypes.	IRF4
29070116	10.7534/j.issn.1009-2137.2017.05.022	2017	[Effect of B Cell Differentiation Markers on the Prognosis of Primary Central Nervous System Lymphoma].	IRF4
26119939	10.1038/onc.2015.245	2016	Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.	IRF4
26414904	10.1002/cncy.21626	2016	CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.	IRF4
26416032	10.1007/s00428-015-1855-z	2016	Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia.	IRF4
26526666	10.1007/s00431-015-2660-z	2016	Hodgkin lymphoma as a novel presentation of familial DICER1 syndrome.	IRF4
26608593	10.1002/gcc.22328	2016	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.	IRF4
26762526	10.1007/s00428-015-1902-9	2016	Intrafollicular Epstein-Barr virus-positive large B cell lymphoma. A variant of germinotropic lymphoproliferative disorder.	IRF4
26851186	10.1158/1078-0432.CCR-15-1784	2016	STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides.	IRF4
26869285	10.1002/cam4.650	2016	Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles.	IRF4
26878872	10.18632/aging.100898	2016	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.	IRF4
26910115	10.18632/oncotarget.7495	2016	Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.	IRF4
26932576	10.1038/leu.2016.27	2016	PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia.	IRF4
27102442	10.18632/oncotarget.8836	2016	JMJD3 promotes survival of diffuse large B-cell lymphoma subtypes via distinct mechanisms.	IRF4
27169444	10.11406/rinketsu.57.417	2016	[Genetic landscape of adult T-cell leukemia/lymphoma].	IRF4
27408374	10.1007/s12288-015-0549-7	2016	Plasmablastic Lymphoma of Small Intestine: A Rare Case Report with Review of Literature.	IRF4
27419920	10.1002/ajh.24485	2016	The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.	IRF4
27664237	10.1101/gad.283762.116	2016	Superenhancer reprogramming drives a B-cell-epithelial transition and high-risk leukemia.	IRF4
27799566	10.1073/pnas.1610970113	2016	Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.	IRF4
25131361	10.1111/his.12529	2015	Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features.	IRF4
25252151	10.3109/08880018.2014.954071	2015	Pediatric Hodgkin lymphoma in a South Indian regional cancer center: its immunomorphology, tumor-associated macrophages, and association with Epstein-Barr virus.	IRF4
25359993	10.1182/blood-2014-08-594507	2015	Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.	IRF4
25687653	10.1038/leu.2015.43	2015	Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.	IRF4
25817328	10.1093/neuonc/nov046	2015	Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.	IRF4
25828391	10.1097/PAS.0000000000000434	2015	Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.	IRF4
25833963	10.1182/blood-2014-05-578575	2015	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-Œ∫B positive feedback loop in peripheral T-cell lymphoma.	IRF4
26034867	10.1097/PAS.0000000000000445	2015	Skin Involvement of Mantle Cell Lymphoma May Mimic Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type.	IRF4
26056791	10.1097/MPH.0000000000000368	2015	Cytotoxic Molecule-positive Epstein-Barr Virus-associated Peripheral T-cell Lymphoma in a 20-Month-old Child: A Case Report and Review of the Literature.	IRF4
26173642	10.1002/gcc.22268	2015	The PCBP1 gene encoding poly(rC) binding protein I is recurrently mutated in Burkitt lymphoma.	IRF4
26284337	10.1038/bjc.2015.274	2015	Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas.	IRF4
26289642	10.1182/blood-2015-02-626176	2015	The forkhead transcription factor FOXP1 represses human plasma cell differentiation.	IRF4
26299509	10.1016/j.humpath.2015.06.020	2015	Rare variants in the spectrum of human herpesvirus 8/Epstein-Barr virus-copositive lymphoproliferations.	IRF4
26307535	10.1182/blood-2015-06-649905	2015	Cell of origin of transformed follicular lymphoma.	IRF4
26360498	10.1038/modpathol.2015.99	2015	Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype.	IRF4
26376702	10.1136/bcr-2015-211960	2015	Rare presentation of orbital plasmablastic lymphoma with oral cavity involvement in an HIV-negative patient.	IRF4
26437031	10.1038/ng.3415	2015	Integrated molecular analysis of adult T cell leukemia/lymphoma.	IRF4
26604798	10.2147/OTT.S90057	2015	Novel prognostic genes of diffuse large B-cell lymphoma revealed by survival analysis of gene expression data.	IRF4
26617862	NA	2015	MUM-1 expression differentiates AITL with HRS-like cells from cHL.	IRF4
26960478	10.4103/0019-509X.178437	2015	Plasmablastic lymphoma in HIV patients: Experience at a tertiary care hospital in eastern India.	IRF4
23647062	10.3109/10428194.2013.800196	2014	Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts.	IRF4
23989669	10.1007/s00277-013-1889-8	2014	Refractory IGŒ∫/IRF4-positive DLBCL with CDKN2A/2B deletion.	IRF4
24030746	10.1038/modpathol.2013.156	2014	Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma.	IRF4
24153013	10.1038/leu.2013.308	2014	Altered expression of miR-24, miR-126 and miR-365 does not affect viability of childhood TCF3-rearranged leukemia cells.	IRF4
24265352	10.1093/annonc/mdt385	2014	Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma.	IRF4
24335298	10.1128/JVI.02106-13	2014	Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets expression of cellular IRF4 and the Myc gene to facilitate lytic replication.	IRF4
24344258	10.1073/pnas.1321704111	2014	Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A.	IRF4
24604141	10.1007/s00428-014-1560-3	2014	Peripheral T-cell lymphoma with t(6;14)(p25;q11.2) translocation presenting with massive splenomegaly.	IRF4
24704296	10.1016/j.canlet.2014.03.030	2014	The NF-Œ∫B inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.	IRF4
24721791	10.1038/leu.2014.106	2014	Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.	IRF4
24805854	10.1097/PAS.0000000000000217	2014	Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders.	IRF4
24805861	10.1097/PAS.0000000000000225	2014	Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: A clinicopathologic and immunophenotypical study of 10 cases.	IRF4
24875472	10.1093/nar/gku451	2014	SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.	IRF4
24928034	10.1016/j.virol.2014.04.020	2014	Downregulation of IRF4 induces lytic reactivation of KSHV in primary effusion lymphoma cells.	IRF4
24970810	10.18632/oncotarget.2080	2014	Mutational analysis of primary central nervous system lymphoma.	IRF4
25149549	10.1016/j.humpath.2014.06.019	2014	Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis.	IRF4
25207815	10.1371/journal.pone.0106788	2014	Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies.	IRF4
25232062	10.1182/blood-2014-07-590570	2014	FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma.	IRF4
25236575	10.1016/j.yexmp.2014.09.014	2014	Analysis of biological and technical variability in gene expression assays from formalin-fixed paraffin-embedded classical Hodgkin lymphomas.	IRF4
25265348	NA	2014	Intrinsic defect in B-lymphoblastoid cell lines from patients with X-linked lymphoproliferative disease type 1. II. receptor-mediated Akt/PKB and ERK1/2 activation and transcription factors expression profile.	IRF4
25282160	10.1038/ni.3008	2014	Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(H)17 differentiation.	IRF4
25439346	10.1016/j.humpath.2014.09.002	2014	Diffuse large B-cell lymphoma occurring in an ovarian cystic teratoma: expanding the spectrum of large B-cell lymphoma associated with chronic inflammation.	IRF4
22966948	10.3109/10428194.2012.728597	2013	Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.	IRF4
23073988	10.1002/gcc.22014	2013	High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas.	IRF4
23108024	10.1097/PAS.0b013e31826b9b57	2013	Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma.	IRF4
23252516	10.1111/bjh.12172	2013	Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.	IRF4
23255160	10.1007/s12185-012-1244-1	2013	Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.	IRF4
23269792	10.1128/JVI.03003-12	2013	Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature.	IRF4
23300175	10.3324/haematol.2012.076851	2013	A low-grade B-cell lymphoma with prolymphocytic/paraimmunoblastic proliferation and IRF4 rearrangement.	IRF4
23332472	10.1016/j.leukres.2012.12.001	2013	The significance of MUM1/IRF4 protein expression and IRF4 translocation of CD30(+) cutaneous T-cell lymphoproliferative disorders: a study of 53 cases.	IRF4
23348205	10.1097/PAS.0b013e31826cebad	2013	Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.	IRF4
23355206	10.1309/AJCP0YGM8BLFYHJY	2013	Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia.	IRF4
23445872	10.3324/haematol.2012.073916	2013	Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas.	IRF4
23449597	10.3324/haematol.2013.084582	2013	Reply to A combination treatment approach and cord blood stem cell transplant for blastic plasmacytoid dendritic cell neoplasm and to A low-grade B-cell lymphoma with prolymphocytic/paraimmunoblastic proliferation and IRF4 rearrangement dendritic cell leukemia.	IRF4
23455380	10.1093/carcin/bgt082	2013	Risk of genome-wide association study-identified genetic variants for non-Hodgkin lymphoma in a Chinese population.	IRF4
23599146	10.1038/modpathol.2013.50	2013	Follicular lymphoma in young adults: a clinicopathological and molecular study of 200 patients.	IRF4
23648461	10.1097/PAS.0b013e318282d01e	2013	Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis.	IRF4
23726928	10.1016/j.prp.2013.04.014	2013	Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.	IRF4
23770605	10.1038/ng.2652	2013	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.	IRF4
23783577	10.1158/0008-5472.CAN-12-3546	2013	Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL.	IRF4
23804715	10.4049/jimmunol.1202514	2013	Role of IRF4 in IFN-stimulated gene induction and maintenance of Kaposi sarcoma-associated herpesvirus latency in primary effusion lymphoma cells.	IRF4
23977280	10.1371/journal.pone.0072326	2013	Implication of IRF4 aberrant gene expression in the acute leukemias of childhood.	IRF4
23980171	10.1073/pnas.1309378110	2013	The transcription factor Interferon Regulatory Factor 4 is required for the generation of protective effector CD8+ T cells.	IRF4
23995111	10.3960/jslrt.53.141	2013	Double-hit lymphoma demonstrating t(6;14;18)(p25;q32;q21), suggesting two independent dual-hit translocations, MYC/BCL-2 and IRF4/BCL-2.	IRF4
24121164	10.1038/bcj.2013.49	2013	Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma.	IRF4
21756027	10.3109/10428194.2011.605190	2012	The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment.	IRF4
22024108	10.1016/j.exphem.2011.10.004	2012	Bortezomib-resistant nuclear factor Œ∫B expression in stem-like cells in mantle cell lymphoma.	IRF4
22102710	10.3324/haematol.2011.048132	2012	MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response.	IRF4
22213394	10.1002/cncr.27396	2012	Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.	IRF4
22238326	10.1182/blood-2011-10-388470	2012	Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.	IRF4
22251943	10.1097/PAS.0b013e31823ea106	2012	Primary bone marrow lymphoma: an uncommon extranodal presentation of aggressive non-hodgkin lymphomas.	IRF4
22308355	10.1073/pnas.1113019109	2012	Quantitative modeling of the terminal differentiation of B cells and mechanisms of lymphomagenesis.	IRF4
22314189	10.1097/PAS.0b013e31824433d8	2012	Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and Œ±Œ≤, Œ≥Œ¥, and Œ±Œ≤/Œ≥Œ¥ T-cell origin: a comprehensive clinicopathologic and phenotypic study.	IRF4
22372911	10.5858/arpa.2010-0747-RS	2012	Intravascular large B-cell lymphoma.	IRF4
22388754	10.1038/modpathol.2012.38	2012	Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders.	IRF4
22409820	10.1016/j.beha.2012.01.004	2012	New biomarkers in T-cell lymphomas.	IRF4
22422878	10.4049/jimmunol.1103302	2012	p110Œ¥ phosphoinositide 3-kinase represses IgE switch by potentiating BCL6 expression.	IRF4
22442255	10.1074/mcp.M111.015362	2012	Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles.	IRF4
22552227	10.1073/pnas.1205834109	2012	Transcription factor IRF4 determines germinal center formation through follicular T-helper cell differentiation.	IRF4
22627742	10.1038/modpathol.2012.70	2012	Infectious mononucleosis mimicking lymphoma: distinguishing morphological and immunophenotypic features.	IRF4
22698399	10.1016/j.ccr.2012.05.024	2012	Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.	IRF4
22700993	10.1093/annonc/mds150	2012	Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.	IRF4
22762030	NA	2012	Subtle bone marrow involvement by large B-cell lymphoma with pronormoblast-like morphology and prominent but not exclusive sinusoidal distribution.	IRF4
22955914	10.1182/blood-2012-05-428896	2012	Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.	IRF4
22994707	10.7314/apjcp.2012.13.7.3037	2012	Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.	IRF4
23009111	10.1111/j.1600-0463.2012.02915.x	2012	Expression of Toll-like receptor9 in diffuse large B-cell lymphoma: further exploring CpG oligodeoxynucleotide in NFŒ∫B pathway.	IRF4
23149704	NA	2012	Indolent cutaneous B-cell lymphoma: diagnosis and treatment 2012.	IRF4
20956803	10.1182/blood-2010-02-269514	2011	Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.	IRF4
21114485	10.1111/j.1365-2141.2010.08497.x	2011	IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion.	IRF4
21131593	10.1182/blood-2010-08-303123	2011	A role for Blimp1 in the transcriptional network controlling natural killer cell maturation.	IRF4
21169992	10.1038/modpathol.2010.225	2011	Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.	IRF4
21393330	10.3324/haematol.2010.031138	2011	Classical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation.	IRF4
21424034	NA	2011	B-cell transcription factors Pax-5, Oct-2, BOB.1, Bcl-6, and MUM1 are useful markers for the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma.	IRF4
21441466	10.1182/blood-2010-12-322362	2011	Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.	IRF4
21487109	10.1182/blood-2011-01-330795	2011	Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults.	IRF4
21569705	NA	2011	[Correlation between the expressions of CARMA1 gene and MUM1 and its significance in diffuse large B cell lymphoma].	IRF4
21623692	10.3109/10428194.2011.573032	2011	Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma.	IRF4
21659362	10.3324/haematol.2011.042531	2011	Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles.	IRF4
21680528	10.1128/JVI.00570-11	2011	Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression.	IRF4
21761432	10.1002/ajh.22078	2011	EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.	IRF4
21867533	10.1186/1746-1596-6-79	2011	Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand.	IRF4
21890374	10.1016/j.cyto.2011.08.014	2011	Interferon regulatory factor-4 activates IL-2 and IL-4 promoters in cooperation with c-Rel.	IRF4
21915363	NA	2011	Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era.	IRF4
21934230	10.4103/0377-4929.85104	2011	Primary cardiac diffuse large B-cell lymphoma with activated B-cell-like phenotype.	IRF4
21997689	10.1097/PAS.0b013e31822bd8a8	2011	Clinicopathologic and genetic characterization of follicular lymphomas presenting in the ovary reveals 2 distinct subgroups.	IRF4
22041376	10.2169/internalmedicine.50.5815	2011	Double-hit lymphoma with t(8;14)(q24;q32) and t(12;14)(q24;q32) chromosomal translocations.	IRF4
22158496	10.1700/989.10724	2011	Immunohistochemical expression of Mum-1, Oct-2 and Bcl-6 in systemic anaplastic large cell lymphomas.	IRF4
22169641	NA	2011	[Significance of MUM-1/IRF4 protein expression in follicular lymphoma].	IRF4
18815567	10.1097/PAI.0b013e31817fa43c	2010	Translocations involving MUM1 are rare in diffuse large B-cell lymphoma.	IRF4
19710685	10.1038/jid.2009.270	2010	Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators.	IRF4
19804451	10.1111/j.1365-2141.2009.07946.x	2010	IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma.	IRF4
19812605	10.1038/jid.2009.314	2010	IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases.	IRF4
19821826	10.1111/j.1365-2141.2009.07945.x	2010	IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma.	IRF4
19897031	10.1016/j.bbadis.2009.10.015	2010	An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males.	IRF4
19925052	10.3109/10428190903370338	2010	Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores.	IRF4
20054341	10.1038/jid.2009.418	2010	IRF4 expression without IRF4 rearrangement is a general feature of primary cutaneous diffuse large B-cell lymphoma, leg type.	IRF4
20080768	10.1073/pnas.0912920107	2010	IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter.	IRF4
20118770	10.1097/PAS.0b013e3181cd3aeb	2010	B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.	IRF4
20182347	10.1097/PAI.0b013e3181cf1126	2010	MUM1/IRF4: A Review.	IRF4
20185248	10.1016/j.prp.2010.01.003	2010	Mediastinal lymphomas: primary mediastinal (thymic) large B-cell lymphoma versus classical Hodgkin lymphoma, histopathologic dilemma solved?	IRF4
20408839	10.1111/j.1365-2141.2010.08199.x	2010	A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma.	IRF4
20736456	10.1182/blood-2010-03-276766	2010	Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.	IRF4
18987657	10.1038/leu.2008.320	2009	Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.	IRF4
19047678	10.1182/blood-2008-10-184077	2009	Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas.	IRF4
19103865	10.1136/jcp.2008.059519	2009	p63 protein expression in high risk diffuse large B-cell lymphoma.	IRF4
19144381	10.1016/j.humpath.2008.07.021	2009	Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma.	IRF4
19287457	10.1038/modpathol.2009.36	2009	HHV8-positive, EBV-positive Hodgkin lymphoma-like large B-cell lymphoma and HHV8-positive intravascular large B-cell lymphoma.	IRF4
19377508	10.1038/onc.2009.74	2009	Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile.	IRF4
19390683	10.1371/journal.pone.0005360	2009	Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk.	IRF4
19396635	10.1007/s10552-009-9348-5	2009	Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma.	IRF4
19448593	10.1038/modpathol.2009.73	2009	Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.	IRF4
19484731	10.1002/ajh.21434	2009	Differentiating germinal center-derived lymphomas through their cellular microenvironment.	IRF4
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	IRF4
19656156	10.1111/j.1349-7006.2009.01268.x	2009	Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.	IRF4
19669219	10.1007/s12308-009-0021-4	2009	Prognostic impact of C-REL expression in diffuse large B-cell lymphoma.	IRF4
19717648	10.1182/blood-2009-01-201111	2009	C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.	IRF4
19769942	10.1016/j.bbrc.2009.09.059	2009	Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation.	IRF4
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	IRF4
19786664	10.1200/JCO.2009.22.7058	2009	Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.	IRF4
19787248	10.3892/ijo_00000409	2009	Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics.	IRF4
19880780	10.3324/haematol.2009.008862	2009	Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials.	IRF4
19917431	10.1016/j.annder.2009.02.005	2009	[Cutaneous large B-cell leg-type lymphoma occurring on a leg burn].	IRF4
20003543	10.1186/1472-6890-9-11	2009	Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda.	IRF4
20309427	10.1007/s12308-009-0044-x	2009	A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score.	IRF4
18231914	10.1080/10428190701760037	2008	MUM1/IRF4 expression in the circulating compartment of chronic lymphocytic leukemia.	IRF4
18235046	10.1182/blood-2007-08-108654	2008	PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.	IRF4
18324968	10.1111/j.1365-2141.2008.07011.x	2008	Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis.	IRF4
18436278	10.1016/j.humpath.2007.10.025	2008	B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray.	IRF4
18580679	10.1097/PAS.0b013e318166f46a	2008	Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker.	IRF4
18925696	10.3325/cmj.2008.5.625	2008	Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.	IRF4
18983461	10.1111/j.1365-2559.2008.03144.x	2008	Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD).	IRF4
16954503	10.1182/blood-2006-04-014977	2007	Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival.	IRF4
17038524	10.1182/blood-2006-08-039024	2007	The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas.	IRF4
17098231	10.1016/j.yexcr.2006.10.015	2007	B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages.	IRF4
17296566	10.3324/haematol.10724	2007	Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms.	IRF4
17296585	10.3324/haematol.10682	2007	MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes.	IRF4
17356384	10.1097/01.jnen.0000248553.45456.96	2007	Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression.	IRF4
17614857	10.1111/j.1600-0463.2007.apm_631.x	2007	Plasmablastic microlymphoma occurring in human herpesvirus 8 (HHV-8)-positive multicentric Castleman's disease and featuring a follicular growth pattern.	IRF4
17635238	10.1111/j.1600-0609.2007.00892.x	2007	Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.	IRF4
17651861	10.1016/j.ejcb.2007.05.006	2007	IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells.	IRF4
17768115	10.3324/haematol.11523	2007	A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4.	IRF4
17785200	10.1016/j.ccr.2007.08.012	2007	The endless complexity of lymphocyte differentiation and lymphomagenesis: IRF-4 downregulates BCL6 expression.	IRF4
17785208	10.1016/j.ccr.2007.08.011	2007	A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.	IRF4
18039900	10.1354/vp.44-6-875	2007	Immunohistochemical detection of multiple myeloma 1/interferon regulatory factor 4 (MUM1/IRF-4) in canine plasmacytoma: comparison with CD79a and CD20.	IRF4
19455257	NA	2007	Germinal center B cell-like (GCB) and activated B cell-like (ABC) type of diffuse large B cell lymphoma (DLBCL): analysis of molecular predictors, signatures, cell cycle state and patient survival.	IRF4
16323006	10.1007/s00428-005-0122-0	2006	Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases.	IRF4
16396779	10.1080/10428190500144680	2006	Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis.	IRF4
16426914	10.1016/j.humpath.2005.09.029	2006	The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma.	IRF4
16585013	NA	2006	PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma.	IRF4
16778825	10.1038/modpathol.3800650	2006	Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma.	IRF4
16943530	10.1200/JCO.2006.05.5897	2006	Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.	IRF4
17056545	10.4049/jimmunol.177.9.6165	2006	Epigenetic histone modifications do not control Igkappa locus contraction and intranuclear localization in cells with dual B cell-macrophage potential.	IRF4
17082608	10.4049/jimmunol.177.10.6930	2006	Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance.	IRF4
17149956	10.5858/2006-130-1819-ICODNT	2006	Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.	IRF4
15308563	10.1182/blood-2004-04-1594	2005	Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling.	IRF4
15510210	10.1038/sj.leu.2403543	2005	Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in unmutated B-CLL.	IRF4
15578069	10.1038/modpathol.3800355	2005	Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles.	IRF4
15611260	10.4049/jimmunol.174.1.367	2005	Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement.	IRF4
15677569	10.1182/blood-2004-08-3112	2005	Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation.	IRF4
15701085	10.1111/j.0303-6987.2005.00298.x	2005	Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study.	IRF4
15710572	NA	2005	Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup.	IRF4
15722318	10.1136/bjo.2004.047092	2005	Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: an analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases.	IRF4
15735858	10.1177/106689690501300110	2005	Follicular colonization of nodal marginal-zone B-cell lymphoma resembling follicular lymphoma: report of 6 cases.	IRF4
15749666	NA	2005	Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.	IRF4
15832089	10.1097/01.pas.0000157937.01624.1d	2005	HHV-8-associated T-cell lymphoma in a lymph node with concurrent peritoneal effusion in an HIV-positive man.	IRF4
15905193	10.1182/blood-2004-12-4631	2005	AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping.	IRF4
15959530	10.1038/sj.leu.2403833	2005	Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy.	IRF4
16249468	10.1167/iovs.05-0318	2005	Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma.	IRF4
16342298	10.1002/hon.764	2005	Evidence of abortive plasma cell differentiation in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.	IRF4
14685876	10.1007/s00417-003-0831-5	2004	Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases.	IRF4
15087665	10.1097/00000478-200404000-00005	2004	Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma.	IRF4
15220833	10.1016/s0242-6498(04)93937-5	2004	[Nodular lymphocyte predominance Hodgkin's disease and its differential diagnosis].	IRF4
12507907	10.1016/s0002-9440(10)63815-1	2003	Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins.	IRF4
15202521	10.1080/10428190310001623810	2003	Pathobiology of primary mediastinal B-cell lymphoma.	IRF4
11781220	10.1182/blood.v99.2.409	2002	Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry.	IRF4
11846984	10.1089/107999002753452746	2002	IRF-4 activities in HTLV-I-induced T cell leukemogenesis.	IRF4
11972519	10.1046/j.1365-2141.2002.03456.x	2002	Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease.	IRF4
12079517	10.1111/j.1349-7006.2002.tb01307.x	2002	MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).	IRF4
12200383	10.1182/blood-2002-01-0008	2002	A molecular compendium of genes expressed in multiple myeloma.	IRF4
12379751	10.1097/01.MP.0000027624.08159.19	2002	CD5+ T-cell/histiocyte-rich large B-cell lymphoma.	IRF4
11157493	10.1182/blood.v97.3.744	2001	Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas.	IRF4
11299818	NA	2001	Quantitation of multiple myeloma oncogene 1/interferon-regulatory factor 4 gene expression in malignant B-cell proliferations and normal leukocytes.	IRF4
11455001	10.1038/modpathol.3880373	2001	Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry.	IRF4
11520558	10.1016/s0165-4608(01)00436-8	2001	Interphase detection of immunoglobulin heavy chain gene translocations with specific oncogene loci in 173 patients with B-cell lymphoma.	IRF4
11749693	10.1111/j.1349-7006.2001.tb02151.x	2001	Possible involvement of interferon regulatory factor 4 (IRF4) in a clinical subtype of adult T-cell leukemia.	IRF4
10706878	NA	2000	A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells.	IRF4
10720141	10.1038/sj.leu.2401696	2000	MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies.	IRF4
11013272	10.1200/JCO.2000.18.19.3331	2000	Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.	IRF4
11067898	10.4049/jimmunol.165.10.5462	2000	Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo.	IRF4
11091208	10.1046/j.1365-2141.2000.02329.x	2000	Expression of MUM1/IRF4 selectively clusters with primary effusion lymphoma among lymphomatous effusions: implications for disease histogenesis and pathogenesis.	IRF4
34952945	10.1038/s41379-021-01002-6	2022	Genomic landscape of Epstein-Barr virus-positive extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue.	IRF8
35086136	10.1182/bloodadvances.2021004366	2022	IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma.	IRF8
35460405	10.1093/ajcp/aqac044	2022	IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas.	IRF8
35609565	10.1182/bloodadvances.2022007322	2022	A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile.	IRF8
35834399	10.1097/PAS.0000000000001932	2022	Pediatric-Type Indolent B-Cell Lymphomas With Overlapping Clinical, Pathologic, and Genetic Features.	IRF8
36030374	10.1002/eji.202250037	2022	IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies.	IRF8
33751038	10.1093/hmg/ddab066	2021	Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes.	IRF8
33939500	10.1177/10668969211013402	2021	A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor.	IRF8
34478526	10.1182/bloodadvances.2021005215	2021	Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.	IRF8
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	IRF8
32535543	10.1016/j.cancergen.2020.05.002	2020	Generation and characterization of the E¬µ-Irf8 mouse model.	IRF8
32546039	10.1080/10428194.2020.1775216	2020	TBLR1 and CREBBP as potential novel prognostic immunohistochemical biomarkers in diffuse large B-cell lymphoma.	IRF8
33017467	10.1182/bloodadvances.2020002049	2020	The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1.	IRF8
30105896	10.1002/jcp.27045	2019	Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).	IRF8
31000603	10.1073/pnas.1901258116	2019	Transcription factors IRF8 and PU.1 are required for follicular B cell development and BCL6-driven germinal center responses.	IRF8
31024321	10.3389/fphar.2019.00367	2019	Inhibitory Effect of KP-A038 on Osteoclastogenesis and Inflammatory Bone Loss Is Associated With Downregulation of Blimp1.	IRF8
31292115	10.1182/blood.2019001126	2019	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.	IRF8
31444033	10.1016/j.jaut.2019.102317	2019	Genetic contributors and soluble mediators in prediction of autoimmune comorbidity.	IRF8
29463002	10.3390/ijms19020601	2018	Inhibitory Effect of Purpurogallin on Osteoclast Differentiation in Vitro through the Downregulation of c-Fos and NFATc1.	IRF8
29899297	10.3390/ijms19061758	2018	Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.	IRF8
28533310	10.1182/blood-2017-03-776278	2017	Mutations of <i>MAP2K1</i> are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation.	IRF8
28537908	10.18632/oncotarget.17693	2017	Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.	IRF8
26932576	10.1038/leu.2016.27	2016	PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia.	IRF8
27098631	NA	2016	Extranodal B Cell Lymphoma with Prominent Spindle Cell Features Arising in Uterus and in Maxillary Sinus: Report of Two Cases and Literature Review.	IRF8
27338637	10.1038/modpathol.2016.102	2016	A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma.	IRF8
27559096	10.1126/scitranslmed.aad8949	2016	Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma.	IRF8
26316891	10.7150/jca.12067	2015	Loss of IRF8 Inhibits the Growth of Diffuse Large B-cell Lymphoma.	IRF8
23573829	10.3109/10428194.2013.793324	2014	IRF8 is associated with germinal center B-cell-like type of diffuse large B-cell lymphoma and exceptionally involved in translocation t(14;16)(q32.33;q24.1).	IRF8
24435047	10.1182/blood-2013-05-500264	2014	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	IRF8
24886876	10.1186/1756-8722-7-43	2014	Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding.	IRF8
25265348	NA	2014	Intrinsic defect in B-lymphoblastoid cell lines from patients with X-linked lymphoproliferative disease type 1. II. receptor-mediated Akt/PKB and ERK1/2 activation and transcription factors expression profile.	IRF8
25331958	10.1074/jbc.M114.571182	2014	Interferon regulatory factor 8 (IRF8) interacts with the B cell lymphoma 6 (BCL6) corepressor BCOR.	IRF8
23292937	10.1073/pnas.1205299110	2013	Genetic heterogeneity of diffuse large B-cell lymphoma.	IRF8
23307532	10.1158/1055-9965.EPI-12-1217	2013	Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypes.	IRF8
23770605	10.1038/ng.2652	2013	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.	IRF8
23775715	10.1182/blood-2013-04-495804	2013	A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma.	IRF8
19648273	10.4049/jimmunol.0803693	2009	IFN regulatory factor 8 regulates MDM2 in germinal center B cells.	IRF8
19814688	10.3109/10428190903296913	2009	Loss of Irf8 does not co-operate with overexpression of BCL-2 in the induction of leukemias in vivo.	IRF8
18580679	10.1097/PAS.0b013e318166f46a	2008	Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: a novel germinal center marker.	IRF8
16380510	10.1084/jem.20051450	2006	Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein.	IRF8
16780917	10.1016/j.virol.2006.05.006	2006	The Icsbp locus is a common proviral insertion site in mature B-cell lymphomas/plasmacytomas induced by exogenous murine leukemia virus.	IRF8
17082608	10.4049/jimmunol.177.10.6930	2006	Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance.	IRF8
12916872	10.1080/1042819031000090273	2003	Transcriptional profiling during the early differentiation of granulocyte and monocyte progenitors controlled by conditional versions of the E2a-Pbx1 oncoprotein.	IRF8
35977101	10.1182/blood.2022016056	2022	Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma.	KDR
32997825	10.1111/ejh.13526	2021	VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B-cell lymphoma.	KDR
33410241	10.1111/cas.14801	2021	VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.	KDR
34219681	10.3233/TUB-211510	2021	Angiogenesis' related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients.	KDR
34471499	10.1016/j.csbj.2021.08.003	2021	A data-driven methodology towards evaluating the potential of drug repurposing hypotheses.	KDR
32158186	10.2147/DDDT.S227477	2020	Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.	KDR
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	KDR
30423319	10.1016/j.ejphar.2018.11.012	2019	Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway.	KDR
30896872	10.3892/mmr.2019.10074	2019	Umbilical cord blood‚Äëderived Helios‚Äëpositive regulatory T¬†cells promote angiogenesis in acute lymphoblastic leukemia in mice via CCL22 and the VEGFA‚ÄëVEGFR2 pathway.	KDR
31126146	10.3390/cells8050498	2019	c-Cbl: An Important Regulator and a Target in Angiogenesis and Tumorigenesis.	KDR
31211886	10.1111/ejh.13279	2019	Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B-cell non-Hodgkin's lymphoma.	KDR
29345176	10.1080/10428194.2017.1422858	2018	Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.	KDR
29455107	10.1016/j.leukres.2018.02.007	2018	Helios expression in regulatory T cells promotes immunosuppression, angiogenesis and the growth of leukemia cells in pediatric acute lymphoblastic leukemia.	KDR
29588308	10.1158/1078-0432.CCR-18-0103	2018	Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.	KDR
29636358	10.1158/1078-0432.CCR-17-2452	2018	Resistance Mechanisms to Targeted Therapies in <i>ROS1</i><sup>+</sup> and <i>ALK</i><sup>+</sup> Non-small Cell Lung Cancer.	KDR
29854308	10.18632/oncotarget.25209	2018	Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel.	KDR
29864401	10.1016/j.yexcr.2018.05.038	2018	CS2164 exerts an antitumor effect against human Non-Hodgkin's lymphomas in vitro and in vivo.	KDR
30005850	10.1016/j.cancergen.2018.04.119	2018	Challenges in next generation sequencing analysis of somatic mutations in transplant patients.	KDR
30074936	10.1097/CAD.0000000000000667	2018	Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.	KDR
30144594	10.1016/j.wneu.2018.08.080	2018	Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.	KDR
27774879	10.2174/1570163813666161019143740	2017	Strong Anti-tumorous Potential of Nardostachys jatamansi Rhizome Extract on Glioblastoma and In Silico Analysis of its Molecular Drug Targets.	KDR
26879230	10.1161/CIRCRESAHA.115.307679	2016	Selective Targeting of a Novel Epsin-VEGFR2 Interaction Promotes VEGF-Mediated Angiogenesis.	KDR
26970956	10.1186/s40792-016-0152-7	2016	Dynamic computed tomography findings of an accessory spleen in the pelvis: a case report.	KDR
27365461	10.3324/haematol.2015.135475	2016	Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene.	KDR
27806094	10.1371/journal.pone.0165876	2016	EGF-Induced VEGF Exerts a PI3K-Dependent Positive Feedback on ERK and AKT through VEGFR2 in Hematological In Vitro Models.	KDR
25329007	10.3109/10428194.2014.977886	2015	A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.	KDR
25444907	10.1016/j.canlet.2014.11.024	2015	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	KDR
25689789	10.1016/j.bbmt.2014.12.027	2015	Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma.	KDR
25951043	10.1080/15548627.2015.1017192	2015	The role of STAT3 in autophagy.	KDR
23772669	10.3109/10428194.2013.813629	2014	Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma.	KDR
25233367	10.1021/ci500414b	2014	Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility.	KDR
25289059	10.3892/etm.2014.1930	2014	Effect of a heat shock protein 90-specific inhibitor on the proliferation and apoptosis induced by VEGF-C in cervical cancer cells.	KDR
23624620	10.2340/00015555-1589	2013	Microvessel density and expression of vascular endothelial growth factor and its receptors in different subtypes of primary cutaneous B-cell lymphoma.	KDR
23991993	10.7314/apjcp.2013.14.7.4301	2013	B-cell Lymphoma 2 rs17757541 C&gt;G polymorphism was associated with an increased risk of gastric cardiac adenocarcinoma in a Chinese population.	KDR
22129133	10.1111/j.1349-7006.2011.02168.x	2012	VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma.	KDR
22251800	10.1186/1471-2407-12-19	2012	DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4).	KDR
19211267	10.1016/j.carpath.2008.11.001	2010	Atrial fibrillation is associated with cardiac hypoxia.	KDR
19120365	10.1111/j.1365-2141.2008.07534.x	2009	Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma.	KDR
19419943	10.2478/v10042-009-0004-4	2009	Soluble angiogenesis markers in gastric tumor patients.	KDR
19701853	10.1080/10428190903156729	2009	Expression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomas.	KDR
19707156	10.1097/MPH.0b013e3181b258df	2009	Expression of VEGF and VEGF receptors in childhood precursor B-cell acute lymphoblastic leukemia evaluated by immunohistochemistry.	KDR
19860625	10.3109/10428190903275586	2009	Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression.	KDR
20011623	10.1007/s12195-009-0069-3	2009	Shear Stress Regulates the Flk-1/Cbl/PI3K/NF-Œ∫B Pathway Via Actin and Tyrosine Kinases.	KDR
18461646	10.1002/hon.861	2008	Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation.	KDR
19021062	10.1080/10428190802450629	2008	Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins.	KDR
17372230	10.1073/pnas.0700809104	2007	A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis.	KDR
17488657	10.3324/haematol.10723	2007	Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients.	KDR
17577783	10.1080/10428190701340616	2007	Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia.	KDR
17917967	10.1080/10428190701534424	2007	Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2.	KDR
17169805	10.1080/10428190600948253	2006	Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416.	KDR
17169806	10.1080/10428190600948048	2006	The investigation of mutation and single nucleotide polymorphism of receptor tyrosine kinases and downstream scaffold molecules in acute myeloid leukemia.	KDR
15693894	10.1111/j.1365-2559.2005.02081.x	2005	The expression and cellular localization of phosphorylated VEGFR2 in lymphoma and non-neoplastic lymphadenopathy: an immunohistochemical study.	KDR
16305489	10.2174/156652405774641106	2005	Kinases as drug discovery targets in hematologic malignancies.	KDR
16383242	NA	2005	[Preliminary study of VEGF and its receptor expression on childhood acute lymphoblastic leukemia and its relativity to clinical manifestations].	KDR
14654077	10.1016/s0145-2126(03)00188-7	2004	Immature B cell malignancies synthesize VEGF, VEGFR-1 (Flt-1) and VEGFR-2 (KDR).	KDR
14996703	10.1182/blood-2003-08-2763	2004	VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia.	KDR
15223651	10.1080/10428190410001712225	2004	Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2.	KDR
15634546	NA	2004	[Dynamic observation of vascular endothelial growth factor (VEGF)/VEGF-receptors expression in acute leukemia].	KDR
12607599	10.1097/00129039-200212000-00005	2002	Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma.	KDR
11378536	10.3109/10428190109057978	2001	Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas.	KDR
10623771	10.1128/jvi.74.2.1038-1044.2000	2000	The human herpesvirus 8 homolog of Epstein-Barr virus SM protein (KS-SM) is a posttranscriptional activator of gene expression.	KDR
10905767	10.1016/s1083-8791(00)70055-3	2000	Donor origin of circulating endothelial progenitors after allogeneic bone marrow transplantation.	KDR
9973224	NA	1999	Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.	KDR
33395752	10.1016/j.tranon.2020.100977	2021	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.	KLHL14
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	KLHL14
32127472	10.1073/pnas.1921187117	2020	Regulation of B cell receptor-dependent NF-Œ∫B signaling by the tumor suppressor KLHL14.	KLHL14
25189415	10.1038/leu.2014.264	2015	The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.	KLHL14
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	KLHL6
32059783	10.1016/j.cell.2020.01.029	2020	Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody.	KLHL6
30646831	10.1080/15384101.2019.1568765	2019	KLHL6 is a tumor suppressor gene in diffuse large B-cell lymphoma.	KLHL6
29695787	10.1038/s41556-018-0084-5	2018	Loss of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing the mRNA decay factor roquin2.	KLHL6
29738359	10.1097/PAS.0000000000001071	2018	Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients.	KLHL6
30209976	10.1080/15384101.2018.1522912	2018	PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation.	KLHL6
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	KLHL6
28807996	10.4049/jimmunol.1700708	2017	Klhl6 Deficiency Impairs Transitional B Cell Survival and Differentiation.	KLHL6
29140403	10.1093/ajcp/aqx099	2017	KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas.	KLHL6
27248180	10.18632/oncotarget.9678	2016	The genetic landscape of dural marginal zone lymphomas.	KLHL6
23531283	10.1186/1752-0509-7-25	2013	MutComFocal: an integrative approach to identifying recurrent and focal genomic alterations in tumor samples.	KLHL6
22585168	10.1158/2159-8290.CD-11-0208	2012	Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.	KLHL6
19465900	10.1038/modpathol.2009.54	2009	Lymphocyte-rich classical Hodgkin's lymphoma: distinctive tumor and microenvironment markers.	KLHL6
33579790	10.1136/gutjnl-2020-322935	2022	Oncogenetic landscape of lymphomagenesis in coeliac disease.	KMT2D
34265801	10.1097/PAS.0000000000001780	2022	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.	KMT2D
34325497	10.4143/crt.2021.752	2022	Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma.	KMT2D
34494161	10.1007/s00428-021-03186-3	2022	Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.	KMT2D
34515044	10.1159/000518227	2022	A Patient with Kabuki Syndrome Mutation Presenting with Very Severe Aplastic Anemia.	KMT2D
34553842	10.1002/cnr2.1559	2022	Genetic features of B-cell lymphoblastic lymphoma with TCF3-PBX1.	KMT2D
34601504	10.1038/s41379-021-00938-z	2022	Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation.	KMT2D
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	KMT2D
34664256	10.1111/bjh.17894	2022	Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.	KMT2D
34837284	10.1111/cas.15224	2022	Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.	KMT2D
34957565	10.1002/path.5861	2022	Widespread in situ follicular neoplasia in patients who subsequently developed follicular lymphoma.	KMT2D
34967008	10.1111/bjh.17990	2022	The molecular ontogeny of follicular lymphoma: gene mutations succeeding the BCL2 translocation define common precursor cells.	KMT2D
34977845	10.1016/j.xjidi.2021.100068	2022	Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders.	KMT2D
34980601	10.1158/1078-0432.CCR-21-2949	2022	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.	KMT2D
35022084	10.1186/s13046-021-02234-9	2022	The follicular lymphoma epigenome regulates its microenvironment.	KMT2D
35038193	10.1111/his.14617	2022	Incidence, clinicopathological features and genetics of in-situ follicular neoplasia: a comprehensive screening study in a Japanese cohort.	KMT2D
35045798	10.1080/10428194.2021.2024821	2022	High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.	KMT2D
35058282	10.1101/mcs.a006156	2022	Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report.	KMT2D
35240014	10.4143/crt.2022.017	2022	Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.	KMT2D
35266562	10.1002/ajh.26523	2022	Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.	KMT2D
35300216	10.2147/JIR.S341355	2022	The Mutation of <i>BTG2</i> Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma.	KMT2D
35317330	10.14740/wjon1436	2022	Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis.	KMT2D
35363872	10.1182/bloodadvances.2021005284	2022	Molecular subclusters of follicular lymphoma: a report from the UK's Haematological Malignancy Research Network.	KMT2D
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	KMT2D
35522148	10.3324/haematol.2021.280005	2022	Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase <i>KDM4C</i> in B cell lymphomas.	KMT2D
35646048	10.3389/fgene.2022.878618	2022	Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	KMT2D
35816682	10.1182/bloodadvances.2022008355	2022	Genomic and microenvironmental landscape of stage I follicular lymphoma, compared to stage III/IV.	KMT2D
35879731	10.1186/s40364-022-00401-4	2022	Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma.	KMT2D
35882439	10.1182/bloodadvances.2022007541	2022	Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association.	KMT2D
35908982	10.1016/j.blre.2022.100992	2022	Follicular lymphoma: The long and winding road leading to your cure?	KMT2D
35937947	10.1155/2022/6441139	2022	Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis.	KMT2D
36048893	10.1093/ajcp/aqac104	2022	Systemic Presentation of Somatic TET2 Mutated B-Cell Lymphoma in a Child With Kabuki Syndrome and a Germline KMT2D Variant.	KMT2D
36055572	10.1016/j.clim.2022.109105	2022	A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.	KMT2D
36081566	10.3389/fonc.2022.941347	2022	Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.	KMT2D
32855278	10.3324/haematol.2020.254854	2021	Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype.	KMT2D
32929178	10.1038/s41379-020-00673-x	2021	The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy.	KMT2D
32973328	10.1038/s41379-020-00685-7	2021	The clinicopathological and molecular features of sinusoidal large B-cell lymphoma.	KMT2D
33152759	10.1182/blood.2020005381	2021	Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance.	KMT2D
33413063	10.2174/1568009620666210106122750	2021	Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).	KMT2D
33431788	10.1038/s41392-020-00437-8	2021	CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.	KMT2D
33432228	10.1038/s41590-020-00827-8	2021	Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.	KMT2D
33436855	10.1038/s41598-020-80613-6	2021	Targeted sequencing to identify genetic alterations and prognostic markers in pediatric T-cell acute lymphoblastic leukemia.	KMT2D
33479306	10.1038/s41598-020-80376-0	2021	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.	KMT2D
33544565	10.1097/PAS.0000000000001658	2021	Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II.	KMT2D
33560380	10.1182/bloodadvances.2020002469	2021	Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features.	KMT2D
33562694	10.3390/cancers13040641	2021	Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention.	KMT2D
33569430	10.21037/atm-20-7574	2021	Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity.	KMT2D
33581493	10.1016/j.ctarc.2021.100310	2021	Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients.	KMT2D
33655698	10.1002/cam4.3649	2021	Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.	KMT2D
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	KMT2D
33786580	10.1182/blood.2020008743	2021	KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.	KMT2D
33809641	10.3390/cancers13061340	2021	Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms.	KMT2D
33829512	10.1111/his.14378	2021	Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma.	KMT2D
33881803	10.1111/ijlh.13534	2021	A lineage switch from NPM1-mutant acute myeloid leukemia to acute T-cell lymphoblastic leukemia with KMT2D and ARID2 mutant.	KMT2D
33939500	10.1177/10668969211013402	2021	A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor.	KMT2D
33945543	10.1371/journal.pone.0248886	2021	Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.	KMT2D
33964277	10.1016/j.humpath.2021.04.014	2021	Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma.	KMT2D
34039950	10.1038/s41408-021-00493-5	2021	Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.	KMT2D
34080947	10.1080/10428194.2021.1933480	2021	Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.	KMT2D
34256839	10.1186/s40164-021-00232-3	2021	Progress in molecular feature of smoldering mantle cell lymphoma.	KMT2D
34334687	10.1097/PAS.0000000000001726	2021	High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B.	KMT2D
34350060	10.1080/2162402X.2021.1928365	2021	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.	KMT2D
34535012	10.1182/bloodadvances.2021004562	2021	Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations.	KMT2D
34558064	10.1111/bjh.17824	2021	Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases.	KMT2D
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	KMT2D
34590470	10.52586/4970	2021	Methylation alterations and advance of treatment in lymphoma.	KMT2D
34621263	10.3389/fimmu.2021.688493	2021	Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes.	KMT2D
34671837	10.1007/s00292-021-01011-x	2021	[Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].	KMT2D
34745101	10.3389/fimmu.2021.732006	2021	International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.	KMT2D
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	KMT2D
35008340	10.3390/cancers14010176	2021	Recent Advances in the Genetic of MALT Lymphomas.	KMT2D
35071240	10.3389/fcell.2021.805195	2021	Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.	KMT2D
35846093	10.1002/jha2.131	2021	Liquid biopsy for disease monitoring after anti-CD19 chimeric antigen receptor T cell in diffuse large B-cell lymphoma.	KMT2D
31028364	10.1038/s41379-019-0279-8	2020	Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.	KMT2D
31537689	10.3324/haematol.2018.214056	2020	<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.	KMT2D
31705772	10.1002/gcc.22825	2020	Molecular characteristics of terminal deoxynucleotidyl transferase negative precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.	KMT2D
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	KMT2D
31752573	10.1080/10428194.2019.1691200	2020	New murine models of aggressive lymphoma.	KMT2D
31774495	10.1182/blood.2019001904	2020	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.	KMT2D
31776129	10.1101/mcs.a004614	2020	Dramatic increase in gene mutational burden after transformation of follicular lymphoma into TdT<sup>+</sup> B-lymphoblastic leukemia/lymphoma.	KMT2D
31807922	10.1007/s00428-019-02691-w	2020	Subsequent development of histiocytic sarcoma and follicular lymphoma: cytogenetics and next-generation sequencing analyses provide evidence for transdifferentiation of early common lymphoid precursor-a case report and review of literature.	KMT2D
31886867	10.1093/jnen/nlz125	2020	Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma.	KMT2D
31980558	10.1136/jclinpath-2019-206282	2020	Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenstr√∂m macroglobulinaemia and description of its mutational profiles by targeted NGS.	KMT2D
32010998	10.1002/hon.2720	2020	Refractory celiac disease type II: An atypical case highlighting limitations of the current classification system.	KMT2D
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	KMT2D
32064880	10.4149/neo_2020_190307N194	2020	KMT2D and TP53 mutation status improve the prognostic value of the International Prognostic Index (IPI) stratification in ENKTL patients.	KMT2D
32127923	10.1177/1758835919900856	2020	Epigenetic aberrations in natural killer/T-cell lymphoma: diagnostic, prognostic and therapeutic implications.	KMT2D
32164600	10.1186/s12885-020-6709-7	2020	Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing.	KMT2D
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	KMT2D
32239765	10.1002/ajh.25796	2020	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.	KMT2D
32349779	10.1186/s13073-020-00739-0	2020	CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.	KMT2D
32350066	10.1158/0008-5472.CAN-19-2247	2020	FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.	KMT2D
32399964	10.1002/ijc.33049	2020	Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.	KMT2D
32459397	10.1111/jcmm.15425	2020	Establishment and characterization of a novel 'double-hit' follicular lymphoma cell line, FL-SJC.	KMT2D
32469082	10.1002/cncr.32866	2020	Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.	KMT2D
32589730	10.1182/bloodadvances.2020001696	2020	Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.	KMT2D
32682634	10.1016/j.jdermsci.2020.06.013	2020	Hydroa vacciniforme-like lymphoproliferative disorder: A study of clinicopathology and whole-exome sequencing in Chinese patients.	KMT2D
32695399	10.1186/s40364-020-00205-4	2020	Plasma circulating tumor DNA assessment reveals <i>KMT2D</i> as a potential poor prognostic factor in extranodal NK/T-cell lymphoma.	KMT2D
32770099	10.1038/s41598-020-70310-9	2020	Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.	KMT2D
32871937	10.1097/MD.0000000000021938	2020	Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.	KMT2D
33045225	10.1016/j.humpath.2020.09.014	2020	The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.	KMT2D
33188997	10.1016/j.ctarc.2020.100235	2020	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.	KMT2D
33211828	10.1182/bloodadvances.2020002944	2020	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.	KMT2D
33376237	10.1038/s41392-020-00331-3	2020	Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.	KMT2D
29629950	10.1097/PAI.0000000000000644	2019	A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification.	KMT2D
30028819	10.1097/MPH.0000000000001249	2019	Cryptic ETV6-ABL1 Fusion and MLL2 Truncation Revealed by Integrative Clinical Sequencing in Multiply Relapsed Acute Lymphoblastic Leukemia.	KMT2D
30282051	10.1016/j.clim.2018.09.013	2019	Exome sequencing confirms diagnosis of kabuki syndrome in an-adult with hodgkin lymphoma and unusually severe multisystem phenotype.	KMT2D
30309852	10.3324/haematol.2018.198572	2019	Targeted next generation sequencing reveals high mutation frequency of <i>CREBBP, BCL2</i> and <i>KMT2D</i> in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements.	KMT2D
30563911	10.1101/gr.241141.118	2019	Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.	KMT2D
30567752	10.1182/blood-2018-07-864025	2019	The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.	KMT2D
30569626	10.1002/ajmg.a.60674	2019	Burkitt lymphoma in a patient with Kabuki syndrome carrying a novel KMT2D mutation.	KMT2D
30721949	10.1093/carcin/bgz013	2019	Mutational landscape of T-cell lymphoma in mice lacking the DNA mismatch repair gene Mlh1: no synergism with ionizing radiation.	KMT2D
31221981	10.1038/s12276-019-0230-6	2019	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.	KMT2D
31305266	10.1097/PAS.0000000000001324	2019	Chronic Active Epstein-Barr Virus Infection of T/NK-Cell Type Mimicking Classic Hodgkin Lymphoma: Clinicopathologic and Genetic Features of 8 Cases Supporting a Variant With Hodgkin/Reed-Sternberg-like Cells of NK Phenotype.	KMT2D
31311407	10.1080/15384047.2019.1638670	2019	Somatic mutations in <i>KMT2D</i> and <i>TET2</i> associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders.	KMT2D
31320741	10.1038/s41598-019-46906-1	2019	Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma.	KMT2D
31334109	10.3389/fonc.2019.00568	2019	Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma Cells.	KMT2D
31378966	10.1002/ajh.25600	2019	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.	KMT2D
31403034	10.3389/fonc.2019.00683	2019	Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.	KMT2D
31489524	10.1007/s11899-019-00541-9	2019	Chromatin-Remodeled State in Lymphoma.	KMT2D
31702703	10.1097/PAI.0000000000000683	2019	High-throughput Sequencing of Subcutaneous Panniculitis-like T-Cell Lymphoma Reveals Candidate Pathogenic Mutations.	KMT2D
31747604	10.1016/j.celrep.2019.10.083	2019	Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.	KMT2D
29158360	10.1182/blood-2017-08-737361	2018	Chromatin modifying gene mutations in follicular lymphoma.	KMT2D
29305415	10.3324/haematol.2017.182444	2018	Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.	KMT2D
29452662	10.1016/j.beha.2017.10.006	2018	Pathogenesis of follicular lymphoma.	KMT2D
29937999	10.18632/oncotarget.25463	2018	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma.	KMT2D
30126979	10.1182/blood-2018-03-837252	2018	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.	KMT2D
30134235	10.1159/000492835	2018	Frequent Mutations in Natural Killer/T Cell Lymphoma.	KMT2D
30227305	10.1016/j.neo.2018.08.012	2018	Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.	KMT2D
30360879	10.1053/j.seminoncol.2018.07.005	2018	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	KMT2D
30401751	10.1182/bloodadvances.2018022962	2018	Insights into the genomic landscape of MYD88 wild-type Waldenstr√∂m macroglobulinemia.	KMT2D
27389057	10.1038/leu.2016.175	2017	Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.	KMT2D
28106467	10.1080/15592294.2017.1282587	2017	Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.	KMT2D
28152507	10.18632/oncotarget.14928	2017	The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.	KMT2D
28302137	10.1186/s13045-017-0438-7	2017	Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.	KMT2D
28801451	10.1182/blood-2017-02-767335	2017	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets.	KMT2D
28805986	10.1002/cncy.21851	2017	Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics.	KMT2D
29262531	10.18632/oncotarget.21986	2017	Mutational profile of primary breast diffuse large B-cell lymphoma.	KMT2D
26698557	10.2217/epi.15.96	2016	Epigenetic dysregulation in follicular lymphoma.	KMT2D
27055146	10.1097/MOH.0000000000000249	2016	The many layers of epigenetic dysfunction in B-cell lymphomas.	KMT2D
27121112	10.3109/10428194.2016.1173212	2016	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.	KMT2D
27198204	10.1038/leu.2016.135	2016	Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.	KMT2D
27203213	10.18632/oncotarget.9400	2016	Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders.	KMT2D
27257180	10.1182/blood-2016-03-703819	2016	Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene.	KMT2D
27325104	10.1182/blood-2015-12-682591	2016	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations.	KMT2D
27335277	10.1182/blood-2016-02-696757	2016	The genetics of nodal marginal zone lymphoma.	KMT2D
27449094	10.18632/oncotarget.10716	2016	Gene mutations and actionable genetic lesions in mantle cell lymphoma.	KMT2D
27566587	10.18632/oncotarget.11548	2016	Recurrent mutations in NF-Œ∫B pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.	KMT2D
27663730	10.1073/pnas.1613836113	2016	Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.	KMT2D
27729836	10.5808/GI.2016.14.3.78	2016	Mutational Analysis of Extranodal NK/T-Cell Lymphoma Using Targeted Sequencing with a Comprehensive Cancer Panel.	KMT2D
27750045	10.1016/j.ajpath.2016.07.027	2016	B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains.	KMT2D
25355294	10.1002/humu.22719	2015	The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing.	KMT2D
25779943	10.1158/1078-0432.CCR-14-2759	2015	Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.	KMT2D
26062053	10.1002/hon.2215	2015	VII. Are lymphomas driven by epigenetic lesions?	KMT2D
26366710	10.1038/nm.3943	2015	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.	KMT2D
26366712	10.1038/nm.3940	2015	Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.	KMT2D
26415585	10.1038/ncomms9470	2015	Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in S√©zary syndrome.	KMT2D
26463831	10.1158/2159-8290.CD-NB2015-141	2015	Studies Identify Non-Hodgkin Lymphoma Suppressor.	KMT2D
26551667	10.1038/ng.3442	2015	The mutational landscape of cutaneous T cell lymphoma and S√©zary syndrome.	KMT2D
26722499	NA	2015	MLL2 protein is a prognostic marker for gastrointestinal diffuse large B-cell lymphoma.	KMT2D
24362818	10.1038/ng.2856	2014	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.	KMT2D
24435047	10.1182/blood-2013-05-500264	2014	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	KMT2D
24682267	10.1182/blood-2013-07-517177	2014	The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.	KMT2D
25123191	10.1186/s13059-014-0432-0	2014	Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas.	KMT2D
24240169	10.18632/oncotarget.1555	2013	KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.	KMT2D
21796119	10.1038/nature10351	2011	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.	KMT2D
19219072	10.1038/onc.2009.6	2009	Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes.	KMT2D
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	KRAS
33509945	10.1136/jclinpath-2020-207339	2022	Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.	KRAS
33722842	10.1136/jclinpath-2020-207205	2022	Clinicopathological characteristic of ciliated muconodular papillary tumour of the lung.	KRAS
33730843	10.3324/haematol.2020.269431	2022	Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia.	KRAS
34015890	10.4143/crt.2021.218	2022	Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations.	KRAS
34193976	10.1038/s41375-021-01326-x	2022	Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.	KRAS
34472720	10.1002/cnr2.1545	2022	Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.	KRAS
34799485	10.1097/PAS.0000000000001834	2022	Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation.	KRAS
34998786	10.1016/j.clml.2021.12.008	2022	The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.	KRAS
35004079	10.7759/cureus.20914	2022	The Role of Tissue and Liquid Biopsy in the Clinical Management of Adult Lung Cancer Patients in King Abdul-Aziz Medical City in Riyadh, Saudi Arabia.	KRAS
35012520	10.1186/s12890-021-01803-0	2022	Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study.	KRAS
35039569	10.1038/s41598-021-04736-0	2022	Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma.	KRAS
35065344	10.1016/j.lungcan.2022.01.005	2022	A whole-slide image (WSI)-based immunohistochemical feature prediction system improves the subtyping of lung cancer.	KRAS
35091678	10.1038/s41388-021-02162-0	2022	An mRNA expression-based signature for oncogene-induced replication-stress.	KRAS
35092381	10.31557/APJCP.2022.23.1.131	2022	Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.	KRAS
35123209	10.1016/j.esmoop.2021.100337	2022	Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.	KRAS
35133871	10.1200/JCO.21.01648	2022	Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.	KRAS
35138919	10.1200/PO.21.00424	2022	Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.	KRAS
35172382	10.1002/JLB.5A0721-361R	2022	Genomic heterogeneity contributed to different prognosis between adult and pediatric acute lymphoblastic.	KRAS
35198656	10.1016/j.ejro.2022.100400	2022	Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: A systematic literature review and meta-analysis.	KRAS
35231988	10.3760/cma.j.issn.0253-2727.2022.01.005	2022	[Mutational spectrum and its prognostic significance in childhood acute lymphoblastic leukemia based on next-generation sequencing technology].	KRAS
35240014	10.4143/crt.2022.017	2022	Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.	KRAS
35280362	10.21037/atm-22-412	2022	Genomic landscape and prognosis of patients with <i>TP53</i>-mutated non-small cell lung cancer.	KRAS
35351263	10.7499/j.issn.1008-8830.2109141	2022	Detection of <i>RAS</i> gene mutation and its clinical significance in children with acute lymphoblastic leukemia.	KRAS
35353542	10.1126/scitranslmed.abc7480	2022	Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.	KRAS
35359041	10.3760/cma.j.cn112151-20211028-00781	2022	[Characteristics of fusion gene expression in acute lymphoblastic leukemia].	KRAS
35363510	10.1200/JCO.21.02840	2022	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.	KRAS
35484682	10.3324/haematol.2021.280557	2022	Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement.	KRAS
35510120	10.25259/Cytojournal_18_2021	2022	Adequacy of pleural fluid cytology for comprehensive molecular analysis of lung adenocarcinoma: Experience of a large health-care system.	KRAS
35517800	10.3389/fphar.2022.875330	2022	Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives.	KRAS
35582532	10.20517/cdr.2021.85	2022	Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study.	KRAS
35646685	10.3389/fonc.2022.713476	2022	A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines.	KRAS
35669427	10.3389/fonc.2022.873111	2022	Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Na√Øve Metastatic Lung Adenocarcinoma.	KRAS
35723561	10.1002/cncy.22609	2022	Machine learning-based gene alteration prediction model for primary lung cancer using cytologic images.	KRAS
35727053	10.1002/cncr.34348	2022	Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.	KRAS
35739536	10.1186/s12920-022-01291-z	2022	A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.	KRAS
35748237	10.2217/pme-2021-0059	2022	Targeting molecular alterations in non-small-cell lung cancer: what's next?	KRAS
35806042	10.3390/ijms23137037	2022	State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan.	KRAS
35870258	10.1016/j.lungcan.2022.07.011	2022	Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.	KRAS
35892000	10.5114/kitp.2022.117498	2022	Computed tomography-guided lung biopsy for molecular tests: a meta-analysis.	KRAS
35895495	10.1002/1878-0261.13295	2022	Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model.	KRAS
35899444	10.3779/j.issn.1009-3419.2022.102.19	2022	[Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy].	KRAS
35920299	10.1096/fj.202200061RR	2022	Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context.	KRAS
35980949	10.1371/journal.pone.0273207	2022	Various impacts of driver mutations on the PD-L1 expression of NSCLC.	KRAS
35981360	10.19746/j.cnki.issn.1009-2137.2022.04.011	2022	[The Effect of KRAS on Proliferation and Apoptosis of T-ALL Cell Lines].	KRAS
36017149	10.1155/2022/7904293	2022	Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia.	KRAS
36077521	10.3390/ijms231710117	2022	Small RNA-Seq Reveals Similar miRNA Transcriptome in Children and Young Adults with T-ALL and Indicates miR-143-3p as Novel Candidate Tumor Suppressor in This Leukemia.	KRAS
32414848	10.3324/haematol.2019.241729	2021	Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.	KRAS
32693409	10.1182/blood.2020006164	2021	Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia.	KRAS
32852896	10.1002/cjp2.177	2021	Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.	KRAS
32918044	10.1038/s41375-020-01036-w	2021	An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance.	KRAS
32929178	10.1038/s41379-020-00673-x	2021	The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy.	KRAS
33147938	10.3324/haematol.2020.259226	2021	Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations	KRAS
33277443	10.1158/1535-7163.MCT-19-0987	2021	A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.	KRAS
33393503	10.1172/JCI133090	2021	BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.	KRAS
33397922	10.1038/s41467-020-20255-4	2021	A RAC-GEF network critical for early intestinal tumourigenesis.	KRAS
33469311	10.2147/OTT.S276912	2021	Case Report: Myeloid Sarcoma Development During Treatment for B Cell Lymphoblastic Lymphoma in a Boy with KRAS/NRAS Gene Mutations.	KRAS
33475256	10.1111/1759-7714.13829	2021	Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report.	KRAS
33494549	10.3390/ph14020080	2021	Therapeutic Sequencing in ALK<sup>+</sup> NSCLC.	KRAS
33506327	10.1007/s00428-021-03032-6	2021	Undifferentiated large cell/rhabdoid carcinoma presenting in the intestines of patients with concurrent or recent non-small cell lung cancer (NSCLC): clinicopathologic and molecular analysis of 14 cases indicates an unusual pattern of dedifferentiated metastases.	KRAS
33512434	10.1182/blood.2020009082	2021	Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.	KRAS
33532178	10.1016/j.apsb.2020.07.010	2021	Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.	KRAS
33552685	10.1080/2162402X.2020.1865653	2021	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ‚â•50%: real-world data.	KRAS
33569430	10.21037/atm-20-7574	2021	Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity.	KRAS
33572152	10.3390/cancers13040694	2021	Dual Targeting Oncoproteins MYC and HIF1Œ± Regresses Tumor Growth of Lung Cancer and Lymphoma.	KRAS
33655698	10.1002/cam4.3649	2021	Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.	KRAS
33656807	10.1002/cam4.3769	2021	Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.	KRAS
33671873	10.3390/cancers13040804	2021	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.	KRAS
33685866	10.1158/1078-0432.CCR-21-0032	2021	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer.	KRAS
33749383	10.1177/10935266211001308	2021	Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23); <i>KMT2A/EPS15</i>, Following Blinatumomab Therapy.	KRAS
33750258	10.1080/0284186X.2021.1900908	2021	Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on <i>BCR-ABL1</i>-like subtype.	KRAS
33807876	10.3390/ijms22052625	2021	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.	KRAS
33847923	10.1007/s12094-021-02579-9	2021	Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).	KRAS
33889526	10.21037/tlcr-20-1290	2021	High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations.	KRAS
33889527	10.21037/tlcr-21-160	2021	Concomitant mutation status of <i>ALK</i>-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib.	KRAS
33898318	10.3389/fonc.2021.647598	2021	Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.	KRAS
33902046	10.1159/000514648	2021	Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.	KRAS
34024223	10.1080/10428194.2021.1919660	2021	Co-occurrence of <i>KIT</i> and <i>NRAS</i> mutations defines an adverse prognostic core-binding factor acute myeloid leukemia.	KRAS
34035082	10.1158/0008-5472.CAN-20-2823	2021	Whole-Exome Sequencing of Radiation-Induced Thymic Lymphoma in Mouse Models Identifies Notch1 Activation as a Driver of p53 Wild-Type Lymphoma.	KRAS
34074758	10.1073/pnas.2019740118	2021	Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration.	KRAS
34094825	10.1016/j.apsb.2020.10.019	2021	New possible silver lining for pancreatic cancer therapy: Hydrogen sulfide and its donors.	KRAS
34164626	10.1158/2643-3230.BCD-20-0203	2021	Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients.	KRAS
34230493	10.1038/s41467-021-24442-9	2021	Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires Œ≤-catenin activity to drive T-cell acute lymphoblastic leukemia.	KRAS
34277785	10.21037/atm-21-2256	2021	Integration of clinicopathological and mutational data offers insight into lung cancer with tumor spread through air spaces.	KRAS
34298439	10.1016/j.prp.2021.153551	2021	Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis.	KRAS
34299796	10.3390/ijerph18147345	2021	The Genomic Landscape of a Restricted ALL Cohort from Patients Residing on the U.S./Mexico Border.	KRAS
34302028	10.1038/s41598-021-94566-x	2021	Development of thymic tumor in [LSL:Kras<sup>G12D</sup>; Pdx1-CRE] mice, an adverse effect associated with accelerated pancreatic carcinogenesis.	KRAS
34321240	10.1158/0008-5472.CAN-21-1027	2021	Mutant <i>Idh2</i> Cooperates with a <i>NUP98-HOXD13</i> Fusion to Induce Early Immature Thymocyte Precursor ALL.	KRAS
34337566	10.1016/j.xcrm.2021.100350	2021	ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.	KRAS
34343999	10.1159/000514821	2021	Multigene Combined Detection by RT-qPCR Using Cytological Specimens.	KRAS
34353680	10.1016/j.lungcan.2021.06.002	2021	The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.	KRAS
34412631	10.1186/s12935-021-02143-z	2021	Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-Œ∫B-related signaling.	KRAS
34428672	10.1016/j.bios.2021.113568	2021	Multiplexed electrokinetic sensor for detection and therapy monitoring of extracellular vesicles from liquid biopsies of non-small-cell lung cancer patients.	KRAS
34434995	10.12998/wjcc.v9.i22.6287	2021	Diagnostic and prognostic value of secreted protein acidic and rich in cysteine in the diffuse large B-cell lymphoma.	KRAS
34447369	10.3389/fimmu.2021.671755	2021	Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.	KRAS
34479175	10.1016/j.lungcan.2021.08.012	2021	Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.	KRAS
34548910	10.18632/oncotarget.28062	2021	Polyclonal on- and off-target resistance mutations in an <i>EML4-ALK</i> positive non-small cell lung cancer patient under ALK inhibition.	KRAS
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	KRAS
34584457	10.2147/CMAR.S317319	2021	Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma.	KRAS
34600407	10.1016/j.lungcan.2021.09.011	2021	Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.	KRAS
34638488	10.3390/cancers13195004	2021	The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer.	KRAS
34703756	10.1016/j.jbo.2021.100394	2021	Estimating survival and clinical outcome in advanced non-small cell lung cancer with bone-only metastasis using molecular markers.	KRAS
34722241	10.3389/fonc.2021.692788	2021	Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.	KRAS
34749754	10.1186/s13000-021-01166-4	2021	Primary breast CD20-positive extranodal NK/T cell lymphoma with stomach involvement: a case report and literature review.	KRAS
34940123	10.3390/cimb43030149	2021	Molecular Genetics of Pre-B Acute Lymphoblastic Leukemia Sister Cell Lines during Disease Progression.	KRAS
35116717	10.21037/tcr-21-1037	2021	Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects.	KRAS
35845190	10.1002/jha2.315	2021	Mutation profiles of diffuse large B-cell lymphoma transformation of splenic B-cell lymphoma/leukemia, unclassifiable on whole-exome sequencing.	KRAS
30225784	10.1007/s12253-018-0469-6	2020	The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.	KRAS
30854949	10.2174/0929867326666190222183219	2020	Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy.	KRAS
31439678	10.3324/haematol.2019.230375	2020	Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.	KRAS
31804006	10.1002/cam4.2757	2020	RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.	KRAS
31807922	10.1007/s00428-019-02691-w	2020	Subsequent development of histiocytic sarcoma and follicular lymphoma: cytogenetics and next-generation sequencing analyses provide evidence for transdifferentiation of early common lymphoid precursor-a case report and review of literature.	KRAS
31822503	10.1074/jbc.RA119.011443	2020	Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.	KRAS
31864154	10.1016/j.thromres.2019.12.009	2020	Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study.	KRAS
31989260	10.1007/s00428-020-02756-1	2020	Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.	KRAS
32047266	10.1038/s41388-020-1195-6	2020	RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice.	KRAS
32066856	10.1038/s41598-020-59744-3	2020	Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.	KRAS
32072746	10.1111/1759-7714.13359	2020	Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.	KRAS
32077636	10.1111/1759-7714.13361	2020	Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.	KRAS
32164600	10.1186/s12885-020-6709-7	2020	Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing.	KRAS
32179095	10.1016/j.mri.2020.03.002	2020	Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases.	KRAS
32186929	10.1080/14737140.2020.1744439	2020	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.	KRAS
32209330	10.1016/j.clml.2020.02.003	2020	RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.	KRAS
32283823	10.3390/ijms21072623	2020	Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with <i>ALK</i> Rearrangement.	KRAS
32312912	10.26508/lsa.201900601	2020	Oncogenic <i>ALK</i> <sup><i>F1174L</i></sup> drives tumorigenesis in cutaneous squamous cell carcinoma.	KRAS
32315234	10.1200/GO.20.00030	2020	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.	KRAS
32316711	10.3779/j.issn.1009-3419.2020.101.17	2020	[Genetic Profile of Young Chinese Patients with Lung Adenocarcinoma].	KRAS
32327174	10.1016/j.thorsurg.2020.01.004	2020	Molecular Targets Beyond the Big 3.	KRAS
32336065	10.3779/j.issn.1009-3419.2020.101.25	2020	[Analysis of Clinical Characteristics and Driver Genes in 405 Patients with Lung Cancer Complicated with Tuberculosis].	KRAS
32373977	10.26355/eurrev_202004_21021	2020	Association between C-myc and K-ras gene polymorphisms and non-Hodgkin lymphoma.	KRAS
32416585	10.1016/j.resmer.2020.01.003	2020	Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study.	KRAS
32427409	10.1002/gcc.22861	2020	Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.	KRAS
32450595	10.1055/s-0039-1700994	2020	Targeted Therapy for Non-Small Cell Lung Cancer.	KRAS
32527129	10.21037/apm-19-430b	2020	Glans metastatic extra-nodal natural killer/T-cell lymphoma, nasal-type with HDAC inhibitor as maintenance therapy: a rare case report with literature review.	KRAS
32586982	10.1158/0008-5472.CAN-19-3822	2020	<i>NRAS</i> Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma.	KRAS
32636302	10.1074/jbc.RA120.012915	2020	The molecular basis for immune dysregulation by the hyperactivated E62K mutant of the GTPase RAC2.	KRAS
32747568	10.1073/pnas.2005052117	2020	Activating <i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.	KRAS
32756609	10.1371/journal.pone.0236580	2020	Molecular profiling of non-small cell lung cancer.	KRAS
32918521	10.1002/pbc.28704	2020	Aggressive Langerhans cell histiocytosis following T-cell acute lymphoblastic leukemia.	KRAS
32944405	10.20892/j.issn.2095-3941.2020.0121	2020	Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.	KRAS
32957736	10.3390/cancers12092658	2020	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review.	KRAS
32989257	10.1038/s41388-020-01469-8	2020	Increased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis.	KRAS
32991719	10.1182/bloodadvances.2020002457	2020	Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.	KRAS
33053439	10.1016/j.critrevonc.2020.103119	2020	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.	KRAS
33067202	NA	2020	Chemical Pathology of Homocysteine VIII. Effects of Tocotrienol, Geranylgeraniol, and Squalene on Thioretinaco Ozonide, Mitochondrial Permeability, and Oxidative Phosphorylation in Arteriosclerosis, Cancer, Neurodegeneration and Aging.	KRAS
33079606	10.1200/GO.20.00265	2020	Patterns of Biomarker Use in Cancer Treatment Among Medical Oncologists in the Philippines.	KRAS
33209369	10.21037/jtd-20-1716	2020	Clinicoradiopathological features and prognosis according to genomic alterations in patients with resected lung adenocarcinoma.	KRAS
33225311	10.1158/2643-3230.BCD-20-0051	2020	Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway.	KRAS
33269250	10.12998/wjcc.v8.i21.5139	2020	Accuracy of endoscopic ultrasound-guided needle aspiration specimens for molecular diagnosis of non-small-cell lung carcinoma.	KRAS
35117356	10.21037/tcr-20-1675	2020	Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study.	KRAS
27898263	10.1080/21541248.2016.1263718	2019	Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas.	KRAS
30048416	10.1097/LBR.0000000000000534	2019	Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.	KRAS
30190342	10.3324/haematol.2018.196055	2019	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.	KRAS
30355676	10.1158/1541-7786.MCR-18-0582	2019	<i>Sleeping Beauty</i> Screen Identifies <i>RREB1</i> and Other Genetic Drivers in Human B-cell Lymphoma.	KRAS
30467824	10.14670/HH-18-067	2019	Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient.	KRAS
30515612	10.1007/s10495-018-1498-z	2019	NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.	KRAS
30543838	10.1016/j.jtho.2018.12.001	2019	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events.	KRAS
30548240	10.1002/cncr.31871	2019	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.	KRAS
30581133	10.1016/j.chembiol.2018.10.026	2019	Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme.	KRAS
30634950	10.1186/s12885-019-5277-1	2019	Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review.	KRAS
30635233	10.1016/j.clml.2018.12.009	2019	Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.	KRAS
30636374	10.1111/resp.13463	2019	Somatic mutations and immune checkpoint biomarkers.	KRAS
30662526	10.7150/jca.26947	2019	Comparison of Clinicopathological Features and Prognosis between <i>ALK</i> Rearrangements and <i>EGFR</i> Mutations in Surgically Resected Early-stage Lung Adenocarcinoma.	KRAS
30677225	10.1002/smll.201805285	2019	Developing a New qPCR-Based System for Screening Mutation.	KRAS
30741488	10.1002/dc.24154	2019	Genotyping and cytomorphological subtyping of lung adenocarcinoma based on liquid-based cytology.	KRAS
30741758	10.1097/COC.0000000000000508	2019	Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.	KRAS
30885850	10.1016/j.athoracsur.2019.02.010	2019	Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer.	KRAS
30902917	10.1634/theoncologist.2018-0572	2019	Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.	KRAS
30953094	10.1007/s00018-019-03089-2	2019	The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients.	KRAS
31016879	10.1002/cam4.2183	2019	Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.	KRAS
31025831	10.1002/cncy.22140	2019	Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.	KRAS
31028135	10.1042/BSR20190389	2019	ssExpression level of GAS6-mRNA influences the prognosis of acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation.	KRAS
31037966	10.2217/fon-2018-0939	2019	Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer.	KRAS
31093306	10.1155/2019/5451290	2019	Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis.	KRAS
31141932	10.3390/cells8060514	2019	Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma.	KRAS
31186809	10.3892/ol.2019.10250	2019	High expression of microRNA-500 is associated with poor prognosis in patients with acute myeloid leukemia receiving allogeneic hematopoietic stem cell transplantation.	KRAS
31199785	10.1371/journal.pgen.1008168	2019	Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias.	KRAS
31277422	10.3390/genes10070505	2019	Activating Mutations in <i>PTPN11</i> and <i>KRAS</i> in Canine Histiocytic Sarcomas.	KRAS
31343834	10.1111/crj.13063	2019	Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer.	KRAS
31406302	10.1038/s41568-019-0179-8	2019	Co-occurring genomic alterations in¬†non-small-cell lung cancer biology and therapy.	KRAS
31412611	10.3390/ijms20163939	2019	Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (<i>ALK</i>) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects.	KRAS
31439588	10.1158/1078-0432.CCR-19-1176	2019	Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <i>ALK</i>-Rearranged Non-Small-Cell Lung Cancer.	KRAS
31443309	10.3390/medicina55080490	2019	Malignant Pleural Effusion and Its Current Management: A Review.	KRAS
31443496	10.3390/cancers11091229	2019	Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation.	KRAS
31455365	10.1186/s13000-019-0864-7	2019	ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma.	KRAS
31551170	10.1016/j.clml.2019.08.010	2019	EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms.	KRAS
31555515	10.21037/tlcr.2019.08.13	2019	Quantitative features of dual-energy spectral computed tomography for solid lung adenocarcinoma with <i>EGFR</i> and <i>KRAS</i> mutations, and <i>ALK</i> rearrangement: a preliminary study.	KRAS
31611441	10.4103/IJPM.IJPM_69_19	2019	Morphological characterization and molecular profiling of malignant pericardial effusion in patients with pulmonary adenocarcinoma.	KRAS
31655619	10.1186/s13287-019-1419-2	2019	Protective mechanism of artemisinin on rat bone marrow-derived mesenchymal stem cells against apoptosis induced by hydrogen peroxide via activation of c-Raf-Erk1/2-p90<sup>rsk</sup>-CREB pathway.	KRAS
31711449	10.1186/s12890-019-0964-x	2019	EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.	KRAS
31910789	10.1177/0300891620902334	2019	Relationship of radiometabolic biomarkers to KRAS mutation status and ALK rearrangements in cases of lung adenocarcinoma.	KRAS
35116853	10.21037/tcr.2019.06.22	2019	Lung cancer in young patients: tumour characteristics and treatment in an Irish population.	KRAS
35116907	10.21037/tcr.2019.06.23	2019	Dual drive coexistence of <i>ALK</i> rearrangement and <i>KRAS</i> mutation advanced lung adenocarcinoma and response to crizotinib.	KRAS
28280984	10.1007/s00595-017-1497-7	2018	Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.	KRAS
28332047	10.1007/164_2017_16	2018	Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.	KRAS
28544061	10.1111/imj.13491	2018	Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma.	KRAS
28756651	10.1111/crj.12670	2018	Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao.	KRAS
28757336	10.1016/j.cllc.2017.06.010	2018	Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.	KRAS
28780976	10.1016/j.cllc.2017.06.008	2018	Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.	KRAS
28843358	10.1016/j.jtho.2017.08.005	2018	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.	KRAS
28853218	10.1002/pbc.26786	2018	Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic/cytogenetic features in children with B-precursor acute lymphoblastic leukemia.	KRAS
28914263	10.1038/modpathol.2017.109	2018	Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.	KRAS
28919190	10.1016/j.cllc.2017.08.005	2018	ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas.	KRAS
29027108	10.1007/s12185-017-2340-z	2018	Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.	KRAS
29186353	10.1093/annonc/mdx629	2018	Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.	KRAS
29198034	10.1007/s00428-017-2268-y	2018	Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study.	KRAS
29361134	10.1093/annonc/mdx631	2018	Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice.	KRAS
29371584	10.12659/ajcr.906803	2018	Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung.	KRAS
29382756	10.1073/pnas.1716452115	2018	Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma.	KRAS
29398453	10.1016/j.jmoldx.2017.11.004	2018	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.	KRAS
29439113	10.1136/gutjnl-2016-312608	2018	Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.	KRAS
29486633	10.1177/1533034618754475	2018	Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma.	KRAS
29507487	10.3747/co.25.3867	2018	Standardizing biomarker testing for Canadian patients with advanced lung cancer.	KRAS
29516752	10.1080/13696998.2018.1450261	2018	Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.	KRAS
29535536	10.2147/OTT.S148363	2018	Response to crizotinib in a non-small-cell lung cancer patient harboring an <i>EML4-ALK</i> fusion with an atypical <i>LTBP1</i> insertion.	KRAS
29541220	10.3892/ol.2018.7859	2018	Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases.	KRAS
29545318	10.1183/13993003.01467-2017	2018	Cost-effectiveness of <i>KRAS</i>, <i>EGFR</i> and <i>ALK</i> testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.	KRAS
29600072	10.21037/jtd.2017.12.68	2018	Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.	KRAS
29631966	10.1016/j.cllc.2018.03.010	2018	MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.	KRAS
29636358	10.1158/1078-0432.CCR-17-2452	2018	Resistance Mechanisms to Targeted Therapies in <i>ROS1</i><sup>+</sup> and <i>ALK</i><sup>+</sup> Non-small Cell Lung Cancer.	KRAS
29652780	10.1097/BRS.0000000000002683	2018	Implication of Biomarker Mutations for Predicting Survival in Patients With Metastatic Lung Cancer to the Spine.	KRAS
29697418	10.1097/MCP.0000000000000493	2018	Recent progress in systemic treatment for lung cancer.	KRAS
29707333	10.21037/jtd.2018.01.148	2018	Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer.	KRAS
29708356	10.14735/amko2018130	2018	MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.	KRAS
29735551	10.1158/0008-5472.CAN-17-4004	2018	Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.	KRAS
29741520	10.4997/JRCPE.2018.104	2018	ALK immunohistochemistry is highly sensitive and specific for the detection of ALK translocated lung adenocarcinomas: lessons from an audit of lung cancer molecular testing.	KRAS
29755699	10.18632/oncotarget.25037	2018	Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.	KRAS
29764594	10.3779/j.issn.1009-3419.2018.05.11	2018	[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].	KRAS
29764596	10.3779/j.issn.1009-3419.2018.05.13	2018	[A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib].	KRAS
29786757	10.1007/s12185-018-2474-7	2018	Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.	KRAS
29792386	10.1177/1010428318771472	2018	Disparate effects of Shb gene deficiency on disease characteristics in murine models of myeloid, B-cell, and T-cell leukemia.	KRAS
29807803	10.1016/j.clml.2018.05.008	2018	Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients.	KRAS
29856861	10.1371/journal.pone.0198634	2018	Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.	KRAS
29858031	10.1016/j.lungcan.2018.05.006	2018	Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer.	KRAS
29911108	10.21037/atm.2018.05.02	2018	Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.	KRAS
29947237	10.4149/BLL_2018_068	2018	Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia.	KRAS
29970498	10.21873/anticanres.12662	2018	Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.	KRAS
29978950	10.1111/1759-7714.12791	2018	Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.	KRAS
29997224	10.1182/blood-2018-04-841676	2018	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.	KRAS
30005850	10.1016/j.cancergen.2018.04.119	2018	Challenges in next generation sequencing analysis of somatic mutations in transplant patients.	KRAS
30032847	10.1016/j.lungcan.2018.05.020	2018	Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.	KRAS
30037374	10.3779/j.issn.1009-3419.2018.07.06	2018	[Association between EGFR, ALK and KRAS Gene Status and Synchronous Distant Organ Metastasis in Non-small Cell Lung Cancer].	KRAS
30050322	10.2147/CMAR.S147569	2018	Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with <i>ALK</i> rearrangement.	KRAS
30092236	10.1016/j.humpath.2018.07.029	2018	So-called non-classic ciliated muconodular papillary tumors: a comprehensive comparison of the clinicopathological and molecular features with classic ciliated muconodular papillary tumors.	KRAS
30120912	10.1002/cncr.31589	2018	Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.	KRAS
30199148	10.1002/cncy.22048	2018	Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.	KRAS
30257940	10.1073/pnas.1721678115	2018	PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.	KRAS
30282799	10.1182/blood-2018-03-842088	2018	IG-<i>MYC</i> <sup>+</sup> neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.	KRAS
30322385	10.1186/s13000-018-0758-0	2018	KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma.	KRAS
30327151	10.1016/j.prp.2018.09.028	2018	Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.	KRAS
30334450	10.4149/neo_2018_171225N843	2018	PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center experience.	KRAS
30359792	10.1016/j.ctrv.2018.10.006	2018	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?	KRAS
30477470	10.1186/s12885-018-5078-y	2018	Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.	KRAS
30504104	NA	2018	Distribution of molecular subtypes of advanced lung adenocarcinoma and clinical outcomes in a center of Argentina.	KRAS
30546443	10.3892/ol.2018.9560	2018	ALK expression favorably impacts the prognosis of <i>NRAS</i>-mutated metastatic melanomas.	KRAS
30570921	NA	2018	[National variation in molecular diagnostics in metastatic lung cancer].	KRAS
30680072	10.18632/oncotarget.26428	2018	Targeted therapies for advanced non-small cell lung cancer.	KRAS
30948995	10.1080/08998280.2018.1479579	2018	Early T-cell precursor acute lymphoblastic leukemia with <i>KRAS</i> and <i>DNMT3A</i> mutations and unexpected monosomy 7.	KRAS
27575422	10.1016/j.jtho.2016.08.137	2017	High Prevalence of Concomitant Oncogene Mutations¬†in Prospectively Identified Patients with¬†ROS1-Positive Metastatic Lung Cancer.	KRAS
27588400	10.18632/oncotarget.11730	2017	MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.	KRAS
27717083	10.1002/gcc.22423	2017	T-cell acute lymphoblastic leukemia in infants has distinct genetic and epigenetic features compared to childhood cases.	KRAS
27737534	10.4143/crt.2016.365	2017	ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.	KRAS
27912827	10.1016/j.hoc.2016.08.010	2017	New Targets in Non-Small Cell Lung Cancer.	KRAS
27979926	10.3324/haematol.2016.145177	2017	CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.	KRAS
28007627	10.1016/j.jtho.2016.12.003	2017	Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).	KRAS
28024701	10.1016/j.lungcan.2016.12.001	2017	A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.	KRAS
28035073	10.18632/oncotarget.14298	2017	MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.	KRAS
28078910	10.1080/10428194.2016.1260126	2017	Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.	KRAS
28088512	10.1016/j.jtho.2017.01.004	2017	ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.	KRAS
28103968	10.3779/j.issn.1009-3419.2017.01.02	2017	[Gene Expression and Clinical Characteristics of Molecular Targeted Therapy in Non-small Cell Lung Cancer Patients in Shandong].	KRAS
28122867	10.1158/2159-8290.CD-16-0330	2017	The Genetic Basis of Hepatosplenic T-cell Lymphoma.	KRAS
28132868	10.1016/j.jtho.2017.01.019	2017	LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.	KRAS
28146588	10.1371/journal.pone.0171280	2017	The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.	KRAS
28157215	10.1038/bcj.2017.3	2017	Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia.	KRAS
28167572	10.1634/theoncologist.2016-0194	2017	An Oncogenic <i>ALK</i> Fusion and an <i>RRAS</i> Mutation in <i>KRAS</i> Mutation-Negative Pancreatic Ductal Adenocarcinoma.	KRAS
28177518	10.1002/cncr.30539	2017	Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.	KRAS
28179026	10.1186/s40880-017-0187-6	2017	Proportion and clinical features of never-smokers with non-small cell lung cancer.	KRAS
28189832	10.1016/j.jtho.2017.02.001	2017	Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.	KRAS
28212996	10.1016/j.lungcan.2016.12.005	2017	Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).	KRAS
28218040	10.1177/1010428317691413	2017	Comprehensive profiling and quantitation of oncogenic mutations in non-small cell lung carcinoma using single-molecule amplification and re-sequencing technology.	KRAS
28222308	10.1016/j.ejca.2017.01.004	2017	Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.	KRAS
28235199	10.1016/j.cell.2017.02.006	2017	Multivalent Small-Molecule Pan-RAS Inhibitors.	KRAS
28237660	10.1016/j.yexmp.2017.02.014	2017	Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis.	KRAS
28246485	10.3748/wjg.v23.i6.1106	2017	Coexisting tubular adenoma with a neuroendocrine carcinoma of colon allowing early surgical intervention and implicating a shared stem cell origin.	KRAS
28259530	10.1016/j.ejso.2017.02.008	2017	Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis.	KRAS
28262675	10.1038/ncomms14581	2017	Genomic characterisation of EŒº-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.	KRAS
28280620	10.21037/jgo.2017.01.14	2017	Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.	KRAS
28285687	10.1016/j.lungcan.2017.02.008	2017	MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.	KRAS
28331826	10.21037/tlcr.2017.01.02	2017	Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology.	KRAS
28350094	10.3892/ijo.2017.3935	2017	Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing.	KRAS
28377205	10.1016/j.cllc.2017.03.001	2017	Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical¬†Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.	KRAS
28399384	10.1200/JOP.2016.019182	2017	Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.	KRAS
28401006	NA	2017	Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.	KRAS
28407465	10.3904/kjim.2015.299	2017	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.	KRAS
28408464	10.1182/blood-2016-12-758979	2017	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.	KRAS
28415793	10.18632/oncotarget.16276	2017	Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.	KRAS
28423587	10.18632/oncotarget.15627	2017	The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.	KRAS
28424246	10.1084/jem.20160894	2017	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.	KRAS
28425994	10.1038/nature22056	2017	Modulating the therapeutic response of tumours to dietary serine and glycine starvation.	KRAS
28433077	10.1016/j.jmoldx.2016.11.004	2017	Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma.	KRAS
28468034	10.3760/cma.j.issn.0529-5807.2017.05.004	2017	[To evaluate the clinicopathologic characteristics and outcome of tumor cells spreading through air spaces in patients with adenocarcinoma of lung].	KRAS
28476735	10.6004/jnccn.2017.0058	2017	Identification of Targetable <i>ALK</i> Rearrangements in Pancreatic Ductal Adenocarcinoma.	KRAS
28502721	10.1016/j.jtho.2017.04.031	2017	MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.	KRAS
28507204	10.1634/theoncologist.2016-0376	2017	Detection of an <i>ALK</i> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA.	KRAS
28507793	10.1080/2162402X.2017.1286437	2017	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.	KRAS
28510280	10.1111/ajt.14360	2017	Modeling the Iatrogenic Pancreatic Cancer Risk After Islet Autotransplantation in Mouse.	KRAS
28544751	10.1002/pbc.26647	2017	Constitutional abnormalities of IDH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia.	KRAS
28550959	10.1016/j.cllc.2017.04.006	2017	Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a¬†Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.	KRAS
28576746	10.1016/j.jtho.2017.05.018	2017	A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R.	KRAS
28601386	10.1016/j.cllc.2017.04.013	2017	Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.	KRAS
28608966	10.1002/cncr.30794	2017	Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.	KRAS
28609002	10.1002/cncy.21866	2017	Analytic inquiry: Molecular testing in lung cancer.	KRAS
28633480	10.1093/annonc/mdx156	2017	A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.	KRAS
28687222	10.1016/j.clml.2017.06.003	2017	TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.	KRAS
28754405	10.1016/j.jdermsci.2017.07.013	2017	Comprehensive cancer-related gene analysis reveals that active KRAS mutation is a prognostic mutation in mycosis fungoides.	KRAS
28762087	10.1007/s11523-017-0520-7	2017	Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study).	KRAS
28838992	10.3324/haematol.2017.169870	2017	The role of constitutive activation of FMS-related tyrosine kinase-3 and <i>NRas/KRas</i> mutational status in infants with <i>KMT2A</i>-rearranged acute lymphoblastic leukemia.	KRAS
28840016	10.21037/jtd.2017.06.20	2017	Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.	KRAS
28852126	10.1038/s41598-017-10366-2	2017	Decrease of FSTL1-BMP4-Smad signaling predicts poor prognosis in lung adenocarcinoma but not in squamous cell carcinoma.	KRAS
28855972	10.1186/s13148-017-0393-8	2017	Epigenetic response of imprinted domains during carcinogenesis.	KRAS
28856790	10.1111/ped.13365	2017	MSH2 deletion with CREBBP and KRAS mutations in pediatric high-hyperdiploid acute lymphoblastic leukemia.	KRAS
28866095	10.1016/j.canlet.2017.08.034	2017	Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.	KRAS
28885734	10.1111/cup.13039	2017	Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.	KRAS
28894396	10.2147/POR.S140579	2017	A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data.	KRAS
28932588	10.21037/jtd.2017.07.11	2017	<i>KRAS</i> mutation-positive mucinous adenocarcinoma originating in the thymus.	KRAS
29143897	10.1007/s11864-017-0513-x	2017	Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.	KRAS
29167001	10.3779/j.issn.1009-3419.2017.11.02	2017	[Association between the ALK Gene Status and the Efficacy of First-line Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].	KRAS
29167009	10.3779/j.issn.1009-3419.2017.11.10	2017	[Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].	KRAS
29184034	10.1126/scisignal.aam7550	2017	MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.	KRAS
29199670	10.4103/ijc.IJC_258_17	2017	Targeted therapy in nonsmall cell lung cancer.	KRAS
29296886	10.1182/bloodadvances.2017012211	2017	Constitutive Ras signaling and <i>Ink4a/Arf</i> inactivation cooperate during the development of B-ALL in mice.	KRAS
25663566	10.1007/s12016-015-8466-y	2016	Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS).	KRAS
25809997	10.1111/ejh.12549	2016	Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation.	KRAS
25947035	10.3109/10428194.2015.1046863	2016	Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective.	KRAS
25956936	10.1007/s00330-015-3814-0	2016	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.	KRAS
26254613	10.1007/s13277-015-3869-1	2016	Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study.	KRAS
26381283	10.1016/j.cllc.2015.08.001	2016	EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.	KRAS
26414189	10.3109/10428194.2015.1099648	2016	Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support.	KRAS
26469326	10.1097/PAI.0000000000000250	2016	CDX-2 Expression in Primary Lung Adenocarcinoma.	KRAS
26527318	10.18632/oncotarget.6259	2016	Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.	KRAS
26549032	10.1038/onc.2015.431	2016	RasGRP1 overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines.	KRAS
26618563	10.1586/14737140.2016.1126514	2016	Emerging targeted therapies in non-small cell lung cancer.	KRAS
26620497	10.1177/1753465815617871	2016	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.	KRAS
26646246	10.1007/s00432-015-2081-4	2016	Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations.	KRAS
26695526	10.1002/cncr.29812	2016	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.	KRAS
26712101	10.1016/j.cllc.2015.11.004	2016	Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.	KRAS
26720421	10.1001/jamaoncol.2015.4482	2016	Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.	KRAS
26777916	10.1016/S0140-6736(16)00004-0	2016	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).	KRAS
26789109	10.18632/oncotarget.6671	2016	Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.	KRAS
26808549	10.1172/JCI84014	2016	Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.	KRAS
26829311	10.1016/j.jtho.2016.01.010	2016	KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.	KRAS
26848526	10.18632/oncotarget.7134	2016	Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.	KRAS
26852652	10.1016/j.bcmd.2015.11.006	2016	ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia.	KRAS
26883104	10.18632/oncotarget.7356	2016	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.	KRAS
26893860	10.3892/mco.2015.690	2016	Genetic alterations in lung adenocarcinoma with a micropapillary component.	KRAS
26898615	10.1016/j.lungcan.2016.01.002	2016	K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.	KRAS
26901614	10.1016/j.ejca.2015.12.033	2016	Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.	KRAS
26933125	10.1158/1078-0432.CCR-15-3000	2016	Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.	KRAS
26951514	10.1007/s13277-016-4840-5	2016	Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro.	KRAS
26964771	10.1016/j.jtho.2016.02.018	2016	Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.	KRAS
26968843	10.1186/s12885-016-2249-6	2016	Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.	KRAS
26992209	10.18632/oncotarget.8074	2016	Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.	KRAS
27013922	10.2174/1389202916666151014221954	2016	Genetics of Bladder Malignant Tumors in Childhood.	KRAS
27033383	10.3760/cma.j.issn.0529-5807.2016.04.002	2016	[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].	KRAS
27034005	10.18632/oncotarget.8427	2016	Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.	KRAS
27040858	10.1016/j.lungcan.2016.03.005	2016	EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient.	KRAS
27055865	10.1038/leu.2016.40	2016	Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.	KRAS
27056998	10.1093/annonc/mdw163	2016	Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.	KRAS
27073482	10.3892/ol.2016.4235	2016	<i>EGFR</i>, <i>ALK</i>, <i>RET</i>, <i>KRAS</i> and <i>BRAF</i> alterations in never-smokers with non-small cell lung cancer.	KRAS
27073516	10.3892/ol.2016.4233	2016	Association between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification.	KRAS
27080983	10.1038/modpathol.2016.66	2016	Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging.	KRAS
27086595	10.4132/jptm.2016.03.09	2016	Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases.	KRAS
27094798	10.1016/j.jtho.2016.03.022	2016	Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.	KRAS
27099101	10.1111/resp.12737	2016	Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.	KRAS
27100677	10.1371/journal.pone.0154186	2016	Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.	KRAS
27107327	10.1016/j.ejca.2016.03.012	2016	High co-expression of PD-L1 and HIF-1Œ± correlates with tumour necrosis in pulmonary pleomorphic carcinoma.	KRAS
27114375	10.1016/j.pathol.2016.02.016	2016	ALK-rearranged adenocarcinoma with extensive mucin production can mimic mucinous adenocarcinoma: clinicopathological analysis and comprehensive histological comparison with KRAS-mutated mucinous adenocarcinoma.	KRAS
27141364	10.1080/2162402X.2015.1108514	2016	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1Œ± and STAT3.	KRAS
27164089	10.3390/ijms17050683	2016	Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses.	KRAS
27229929	10.1186/s12885-016-2374-2	2016	Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor.	KRAS
27237031	10.1016/j.lungcan.2016.05.001	2016	Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.	KRAS
27262212	10.1016/j.jtho.2016.04.033	2016	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.	KRAS
27266901	10.1016/j.rmr.2016.01.007	2016	[Molecular epidemiology of the lung cancer].	KRAS
27298405	10.1200/JCO.2016.67.2410	2016	Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.	KRAS
27379696	NA	2016	HSP90 inhibitors in lung cancer: promise still unfulfilled.	KRAS
27402797	10.1093/jjco/hyw094	2016	Impact of the oncogenic status on the mode of recurrence in resected non-small cell lung cancer.	KRAS
27409166	10.18632/oncotarget.10464	2016	Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.	KRAS
27434036	10.1038/bjc.2016.208	2016	Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study.	KRAS
27453951	10.1172/jci.insight.86698	2016	An extra copy of <i>p53</i> suppresses development of spontaneous Kras-driven but not radiation-induced cancer.	KRAS
27460205	10.3892/or.2016.4962	2016	ALK ambiguous-positive non-small cell lung cancers are tumors challenged by diagnostic and therapeutic issues.	KRAS
27488117	10.1007/s13277-016-5283-8	2016	IQGAP1 gene silencing induces apoptosis and decreases the invasive capacity of human hepatocellular carcinoma cells.	KRAS
27518729	10.1371/journal.pone.0161081	2016	Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Na√Øve Patients with Advanced Lung Adenocarcinoma.	KRAS
27544536	10.1002/cam4.809	2016	Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.	KRAS
27554588	10.1002/cam4.852	2016	Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma.	KRAS
27598807	10.1016/j.ijrobp.2016.06.006	2016	The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases.	KRAS
27600764	10.1038/ncomms12602	2016	Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.	KRAS
27615396	10.1016/j.jtho.2016.08.142	2016	Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma.	KRAS
27623943	10.1007/s13277-016-5357-7	2016	Tumour biology of obesity-related cancers: understanding the molecular concept for better diagnosis and treatment.	KRAS
27627705	10.1111/cas.13080	2016	EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway.	KRAS
27655895	10.1073/pnas.1608420113	2016	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.	KRAS
27663730	10.1073/pnas.1613836113	2016	Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.	KRAS
27670423	10.1182/blood-2016-01-692855	2016	High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.	KRAS
27672108	10.1093/annonc/mdw282	2016	First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.	KRAS
27683039	10.18632/oncotarget.12238	2016	Clonal and microclonal mutational heterogeneity in high hyperdiploid acute lymphoblastic leukemia.	KRAS
27696251	10.1007/s12020-016-1080-9	2016	Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.	KRAS
27760592	10.3779/j.issn.1009-3419.2016.10.02	2016	[Driven Gene in Patients with Lung Squamous Cell Carcinoma: Analysis of Clinicopathologic Characteristics and Prognosis].	KRAS
27769042	10.18632/oncotarget.12705	2016	ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.	KRAS
27803402	10.2169/internalmedicine.55.6794	2016	Triple Gene Analysis Using Samples Obtained by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration.	KRAS
27835869	10.18632/oncotarget.13181	2016	OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.	KRAS
27867542	10.21037/jtd.2016.09.64	2016	The expression of <i>SALL4</i> is significantly associated with <i>EGFR</i>, but not <i>KRAS</i> or <i>EML4-ALK</i> mutations in lung cancer.	KRAS
27987580	10.1016/j.lungcan.2016.10.010	2016	Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.	KRAS
27997540	10.1371/journal.pmed.1002200	2016	IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.	KRAS
28101165	10.3892/etm.2016.3847	2016	Functions of microRNA-143 in the apoptosis, invasion and migration of nasopharyngeal carcinoma.	KRAS
28476195	10.1016/j.arcmed.2016.11.016	2016	Tobacco Smoke and Ras Mutations Among Latino and Non-Latino Children with Acute Lymphoblastic Leukemia.	KRAS
31042492	10.1016/j.jasc.2015.11.003	2016	Fine-needle aspiration of small pulmonary nodules yields material for reliable molecular analysis of adenocarcinomas.	KRAS
24897505	10.1038/leu.2014.177	2015	Evolutionary trajectories of hyperdiploid ALL in monozygotic twins.	KRAS
25053852	10.1093/neuonc/nou146	2015	Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.	KRAS
25110823	10.3109/10428194.2014.953152	2015	Aggressive congenital juvenile myelomonocytic leukemia associated with somatic KRAS p.G13D mutation and concurrent germline IGF1R duplication.	KRAS
25243942	10.1097/RLU.0000000000000581	2015	Role of imaging biomarkers in predicting anaplastic lymphoma kinase-positive lung adenocarcinoma.	KRAS
25273224	10.1002/cncr.29042	2015	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.	KRAS
25344360	10.1093/annonc/mdu484	2015	Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.	KRAS
25361983	10.1093/annonc/mdu505	2015	Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth.	KRAS
25371176	10.1038/leu.2014.315	2015	Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.	KRAS
25444907	10.1016/j.canlet.2014.11.024	2015	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	KRAS
25549722	10.1158/1078-0432.CCR-14-1589	2015	Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.	KRAS
25557162	10.1002/cncy.21507	2015	Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.	KRAS
25588859	10.5301/jbm.5000127	2015	Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.	KRAS
25596245	10.1309/AJCPMY8UI7WSFSYY	2015	Adequacy of core needle biopsy specimens and fine-needle aspirates for molecular testing of lung adenocarcinomas.	KRAS
25615851	10.3109/07357907.2014.1000494	2015	Mutational profiling of second primary lung cancers in patients who have received radiation for the treatment of Hodgkin's disease.	KRAS
25629635	10.1097/JTO.0000000000000487	2015	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	KRAS
25657019	10.1183/09031936.00097214	2015	BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.	KRAS
25665893	10.1016/j.cllc.2014.12.009	2015	Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.	KRAS
25676841	10.1159/000369860	2015	Feasibility and accuracy of molecular testing in specimens obtained with small biopsy forceps: comparison with the results of surgical specimens.	KRAS
25682546	10.1016/j.cllc.2015.01.003	2015	Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.	KRAS
25689095	10.1111/resp.12490	2015	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).	KRAS
25704901	10.1016/j.rmr.2014.08.014	2015	[Targeted therapies in non-small cell lung cancer in 2014].	KRAS
25706305	10.1371/journal.pone.0117333	2015	Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.	KRAS
25711901	10.1002/cncy.21527	2015	FNA, core biopsy, or both for the diagnosis of lung carcinoma: Obtaining sufficient tissue for a specific diagnosis and molecular testing.	KRAS
25738220	10.1097/JTO.0000000000000516	2015	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	KRAS
25745045	10.1183/09031936.00097314	2015	No impact of passive smoke on the somatic profile of lung cancers in never-smokers.	KRAS
25773866	10.1016/j.lungcan.2015.02.018	2015	Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.	KRAS
25776025	10.1016/j.humpath.2014.10.032	2015	An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung.	KRAS
25813151	10.1007/s13277-015-3331-4	2015	The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.	KRAS
25819217	10.1016/j.bulcan.2015.02.016	2015	[Second generation ALK inhibitors in non-small cell lung cancer: systemic review].	KRAS
25833149	10.1159/000376552	2015	Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.	KRAS
25842168	10.1016/j.ctrv.2015.03.009	2015	Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.	KRAS
25862146	10.1016/j.lungcan.2015.03.017	2015	PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.	KRAS
25910841	10.1093/neuonc/nov043	2015	Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?	KRAS
25917266	10.1038/leu.2015.107	2015	KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia.	KRAS
25925381	10.1016/j.neo.2015.03.004	2015	Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.	KRAS
25964588	NA	2015	Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer.	KRAS
25973127	NA	2015	ALK-rearranged squamous cell lung cancer: a case report.	KRAS
26028064	10.7314/apjcp.2015.16.10.4147	2015	Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.	KRAS
26045026	10.1159/000430852	2015	Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data.	KRAS
26045865	NA	2015	Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer.	KRAS
26056079	10.1016/j.lungcan.2015.05.012	2015	Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.	KRAS
26095438	10.4132/jptm.2015.05.13	2015	Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma.	KRAS
26121087	10.1038/ng.3333	2015	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.	KRAS
26130140	10.3892/mmr.2015.4001	2015	A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review.	KRAS
26155992	10.1002/cam4.492	2015	Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.	KRAS
26189108	10.1016/j.leukres.2015.06.005	2015	Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.	KRAS
26215190	10.1245/s10434-015-4704-z	2015	Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.	KRAS
26222068	10.1002/pbc.25683	2015	Analysis of KRAS and NRAS Gene Mutations in Arab Asian Children With Acute Leukemia: High Frequency of RAS Mutations in Acute Lymphoblastic Leukemia.	KRAS
26245900	10.1074/jbc.M115.657833	2015	The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.	KRAS
26273395	10.1111/1759-7714.12191	2015	Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements.	KRAS
26297264	10.1016/j.clml.2015.02.035	2015	Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.	KRAS
26301689	10.1038/nm.3930	2015	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.	KRAS
26331813	10.1002/cncr.29531	2015	Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population.	KRAS
26332764	10.1371/journal.pone.0136659	2015	Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger.	KRAS
26339915	NA	2015	[Molecular diagnostics of lung cancer].	KRAS
26358176	10.1038/cgt.2015.39	2015	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	KRAS
26360058	10.1371/journal.pone.0137917	2015	Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia.	KRAS
26373952	10.1186/s13000-015-0409-7	2015	Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and DDR2 in primary pulmonary adenoid cystic carcinoma.	KRAS
26379152	10.1097/PAS.0000000000000503	2015	Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis.	KRAS
26399548	10.1038/ncomms9477	2015	Acute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphoma.	KRAS
26483338	10.3779/j.issn.1009-3419.2015.10.08	2015	[Role of HER2 in NSCLC].	KRAS
26507119	10.1080/15592294.2015.1110672	2015	Epigenetic instability at imprinting control regions in a Kras(G12D)-induced T-cell neoplasm.	KRAS
26517679	10.18632/oncotarget.5434	2015	Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.	KRAS
26536196	10.1097/JTO.0000000000000665	2015	Clinical Implications of Variant ALK FISH Rearrangement Patterns.	KRAS
26555338	10.1371/journal.pone.0142306	2015	Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations.	KRAS
26581482	10.1186/s13104-015-1675-x	2015	Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice.	KRAS
26627242	10.1073/pnas.1520329112	2015	microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.	KRAS
26677401	10.1186/s13148-015-0162-5	2015	MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy.	KRAS
26995877	NA	2015	[Companion Diagnostics for Solid Tumors].	KRAS
23988776	10.1183/09031936.00018013	2014	EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.	KRAS
24067137	10.3109/10428194.2013.847934	2014	Impact of mutations in FLT3, PTPN11 and RAS genes on the overall survival of pediatric B cell precursor acute lymphoblastic leukemia in Brazil.	KRAS
24139827	10.1016/j.cllc.2013.08.002	2014	Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.	KRAS
24397598	10.3109/10428194.2013.878461	2014	Absence of BRAF and KRAS hotspot mutations in primary mediastinal B-cell lymphoma.	KRAS
24505083	10.1182/blood-2013-01-477620	2014	Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy.	KRAS
24610751	10.1002/pbc.24797	2014	Concurrent juvenile myelomonocytic leukemia and T-lymphoblastic lymphoma with a shared missense mutation in NRAS.	KRAS
24691006	10.1371/journal.pone.0092147	2014	Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.	KRAS
24729716	10.2147/OTT.S60122	2014	Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients.	KRAS
24799949	10.4103/1742-6413.129183	2014	Utility of molecular tests in cytopathology.	KRAS
24809777	10.1038/bjc.2014.218	2014	Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.	KRAS
24828667	10.1097/JTO.0000000000000142	2014	Small-cell lung cancers in patients who never smoked cigarettes.	KRAS
24857124	10.14694/EdBook_AM.2014.34.e353	2014	Management and future directions in non-small cell lung cancer with known activating mutations.	KRAS
24885803	10.5858/arpa.2013-0388-OA	2014	ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.	KRAS
24885982	10.1148/radiol.14140789	2014	ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization.	KRAS
24888607	10.1002/jso.23646	2014	Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.	KRAS
24903964	10.1007/s00432-014-1715-2	2014	Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study.	KRAS
24913807	10.1007/s12032-014-0034-4	2014	Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.	KRAS
24925809	10.1016/j.cllc.2014.04.004	2014	Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.	KRAS
24982390	NA	2014	Rare co-existence of mutation in KRAS and ALK gene re-arrangement in an adenocarcinoma patient--a case report.	KRAS
25010763	NA	2014	[Criteria of the molecular pathology testing of lung cancer].	KRAS
25043004	10.1038/nature13495	2014	Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.	KRAS
25105841	10.1038/ncomms5654	2014	Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations.	KRAS
25131476	NA	2014	[Anaplastic lymphoma kinase fusion gene expression, clinical pathological characteristics and prognosis in 95 Chinese patients with non-small cell lung cancer].	KRAS
25189939	10.3892/mmr.2014.2533	2014	Learning curve for endobronchial ultrasound‚Äëguided transbronchial needle aspiration: experience of a community‚Äëbased teaching hospital.	KRAS
25193384	10.1158/0008-5472.CAN-14-0268	2014	ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.	KRAS
25204082	NA	2014	NRAS mutations in de novo acute leukemia: prevalence and clinical significance.	KRAS
25217578	10.1093/jnci/dju256	2014	Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.	KRAS
25253770	10.1182/blood-2014-04-531871	2014	Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.	KRAS
25275049	NA	2014	Mixed adenoneuroendocrine carcinoma of the colon: molecular pathogenesis and treatment.	KRAS
25288236	10.1016/j.humpath.2014.08.005	2014	Molecular alterations in non-small cell lung carcinomas of the young.	KRAS
25342991	10.1177/1758834014532510	2014	Novel agents in development for advanced non-small cell lung cancer.	KRAS
25364578	10.7497/j.issn.2095-3941.2014.03.003	2014	Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.	KRAS
25425670	10.1073/pnas.1420822111	2014	Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics.	KRAS
25563851	10.2174/187446720701150105171219	2014	Molecular testing and personalized treatment of lung cancer.	KRAS
26767032	10.1111/1759-7714.12111	2014	Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma.	KRAS
23392229	10.1097/JTO.0b013e318283558e	2013	Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.	KRAS
23403319	10.3324/haematol.2012.067983	2013	Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.	KRAS
23495083	10.1002/cncy.21288	2013	Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.	KRAS
23729361	10.1158/1078-0432.CCR-13-0318	2013	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.	KRAS
23841470	10.1164/rccm.201305-0843PP	2013	The impact of genomic changes on treatment of lung cancer.	KRAS
23919423	10.3109/01902148.2013.819535	2013	Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.	KRAS
23932486	10.1016/j.lungcan.2013.07.013	2013	Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.	KRAS
24166518	10.1200/JCO.2012.48.5292	2013	Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.	KRAS
24192124	10.2217/pgs.13.177	2013	EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.	KRAS
24200637	10.1016/j.cancergen.2013.09.004	2013	Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.	KRAS
21720997	10.1002/cncr.26311	2012	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.	KRAS
22080568	10.1158/0008-5472.CAN-11-1403	2012	Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.	KRAS
22135231	10.1158/1535-7163.MCT-11-0692	2012	Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.	KRAS
22317764	10.1158/1078-0432.CCR-11-2511	2012	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.	KRAS
21209378	10.1182/blood-2010-09-305128	2011	High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.	KRAS
21311557	10.1038/leu.2011.15	2011	Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model.	KRAS
21586752	10.1182/blood-2010-12-326058	2011	Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.	KRAS
20183914	10.1245/s10434-009-0808-7	2010	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.	KRAS
20237506	10.1038/leu.2010.39	2010	Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations.	KRAS
20624322	10.1186/1476-4598-9-188	2010	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.	KRAS
20688547	10.1016/j.bcmd.2010.07.007	2010	Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia.	KRAS
19164213	10.1200/JCO.2008.18.0463	2009	Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.	KRAS
19234440	10.1038/modpathol.2009.2	2009	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	KRAS
19551857	10.1002/ijc.24681	2009	The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms.	KRAS
19667264	10.1200/JCO.2009.22.6993	2009	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	KRAS
17910045	10.1002/gcc.20502	2008	Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia.	KRAS
18663146	10.1182/blood-2008-03-147587	2008	K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.	KRAS
18701506	10.1158/0008-5472.CAN-08-0101	2008	Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.	KRAS
18006851	10.1158/0008-5472.CAN-07-0986	2007	16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway.	KRAS
16533526	10.1016/j.leukres.2006.02.004	2006	PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia.	KRAS
16923573	10.1080/10428190600565925	2006	Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations.	KRAS
16969076	10.4161/cbt.5.8.3251	2006	Recurrent KRAS codon 146 mutations in human colorectal cancer.	KRAS
12824925	10.1111/j.1349-7006.2003.tb01436.x	2003	Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China.	KRAS
3057505	10.1073/pnas.85.23.9268	1988	Analysis of RAS oncogene mutations in human lymphoid malignancies.	KRAS
29449437	10.3324/haematol.2017.172304	2018	Dynamic clonal progression in xenografts of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21.	LCOR
34837284	10.1111/cas.15224	2022	Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.	MEF2B
35240014	10.4143/crt.2022.017	2022	Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.	MEF2B
35317330	10.14740/wjon1436	2022	Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis.	MEF2B
35322462	10.1111/his.14652	2022	Epstein-Barr virus infection patterns in nodular lymphocyte-predominant Hodgkin lymphoma.	MEF2B
36055572	10.1016/j.clim.2022.109105	2022	A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.	MEF2B
33959502	10.3389/fonc.2021.638897	2021	c-Rel Is the Pivotal NF-Œ∫B Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.	MEF2B
34418874	10.1016/j.jmgm.2021.108009	2021	Systematic transition modeling analysis in the MEF2B-DNA binding interface due to Y69H and K4E variants.	MEF2B
35528192	10.1158/2767-9764.crc-21-0022	2021	The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways.	MEF2B
31423576	10.1111/bjh.16159	2020	M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.	MEF2B
31850910	10.1097/PAI.0000000000000813	2020	Correlation Analysis Between the Expression of MEF2B, and Germinal Center and Nongerminal Center Markers in Diffuse Large B-Cell Lymphoma.	MEF2B
31914533	10.3760/cma.j.issn.0529-5807.2020.01.008	2020	[Expression of myocyte enhancer factor 2B in mantle cell lymphoma and its clinical significance].	MEF2B
32738045	10.1093/nar/gkaa642	2020	Landscape of DNA binding signatures of myocyte enhancer factor-2B reveals a unique interplay of base and shape readout.	MEF2B
33045225	10.1016/j.humpath.2020.09.014	2020	The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.	MEF2B
33211828	10.1182/bloodadvances.2020002944	2020	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.	MEF2B
33232656	10.1016/j.molcel.2020.10.036	2020	Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage.	MEF2B
30446717	10.1038/s41374-018-0152-2	2019	MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.	MEF2B
31403034	10.3389/fonc.2019.00683	2019	Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.	MEF2B
29122756	10.1182/blood-2017-08-799080	2018	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.	MEF2B
29309299	10.1097/PAS.0000000000001015	2018	Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas.	MEF2B
29477338	10.1016/j.jmb.2018.02.012	2018	The Cancer Mutation D83V Induces an Œ±-Helix to Œ≤-Strand Conformation Switch in MEF2B.	MEF2B
30006595	10.1038/s41598-018-25712-1	2018	Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients.	MEF2B
30205047	10.1016/j.ccell.2018.08.006	2018	MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis.	MEF2B
27389057	10.1038/leu.2016.175	2017	Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.	MEF2B
28116089	10.1186/s40425-016-0207-0	2017	It's a long way to the top (if you want to personalize immunotherapy).	MEF2B
28851661	10.1016/j.humpath.2017.08.015	2017	J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.	MEF2B
29222279	10.1182/asheducation-2017.1.358	2017	Follicular lymphoma: are we ready for a risk-adapted approach?	MEF2B
26468528	10.1128/JVI.02318-15	2016	Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.	MEF2B
26631611	10.1158/1078-0432.CCR-15-2023	2016	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells.	MEF2B
27166360	10.1182/blood-2016-02-699520	2016	Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.	MEF2B
27198204	10.1038/leu.2016.135	2016	Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.	MEF2B
27224912	10.18632/oncotarget.9500	2016	Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.	MEF2B
25769544	10.3324/haematol.2014.120048	2015	BCL6--regulated by AhR/ARNT and wild-type MEF2B--drives expression of germinal center markers MYBL1 and LMO2.	MEF2B
26089142	10.1007/s00428-015-1796-6	2015	Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas.	MEF2B
26229090	10.1158/2159-8290.CD-15-0370	2015	Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma.	MEF2B
26245647	10.1038/ncomms8953	2015	MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation.	MEF2B
26256760	10.1016/S1470-2045(15)00169-2	2015	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.	MEF2B
24942943	10.3960/jslrt.54.23	2014	Molecular pathogenesis of follicular lymphoma.	MEF2B
23292937	10.1073/pnas.1205299110	2013	Genetic heterogeneity of diffuse large B-cell lymphoma.	MEF2B
23382691	10.1371/journal.pgen.1003225	2013	Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers.	MEF2B
23407552	10.1182/blood-2013-01-478834	2013	The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.	MEF2B
23974956	10.1038/ni.2688	2013	MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma.	MEF2B
24052547	10.1182/blood-2013-04-496893	2013	EZH2 mutations are frequent and represent an early event in follicular lymphoma.	MEF2B
24145436	10.1073/pnas.1314608110	2013	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.	MEF2B
22343534	10.1073/pnas.1121343109	2012	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	MEF2B
21796119	10.1038/nature10351	2011	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.	MEF2B
34624096	10.1182/blood.2020010405	2022	ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells.	MEF2C
33150819	10.1080/08880018.2020.1838013	2021	<i>KMT2A</i>-rearranged diffuse large B-cell lymphoma in a child: a case report and molecular characterization.	MEF2C
34440292	10.3390/genes12081118	2021	T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness.	MEF2C
31900516	10.1007/s00210-019-01764-6	2020	A novel MEF2C mutation in lymphoid neoplasm diffuse large B-cell lymphoma promotes tumorigenesis by increasing c-JUN expression.	MEF2C
32142900	10.1016/j.jmoldx.2020.02.004	2020	Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia.	MEF2C
32913188	10.1038/s41419-020-02949-1	2020	A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1<sup>-</sup> pre-B-ALL.	MEF2C
33094287	10.1093/narcan/zcaa029	2020	Activation-induced cytidine deaminase localizes to G-quadruplex motifs at mutation hotspots in lymphoma.	MEF2C
33298918	10.1038/s41467-020-20136-w	2020	Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors.	MEF2C
30171027	10.3324/haematol.2017.186320	2019	Clinical and molecular characteristics of <i>MEF2D</i> fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in <i>MEF2D-HNRNPH1</i> gene fusion.	MEF2C
30190342	10.3324/haematol.2018.196055	2019	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.	MEF2C
29279377	10.1073/pnas.1717125115	2018	Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia.	MEF2C
28482719	10.1080/10428194.2017.1312383	2017	MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.	MEF2C
26957223	10.1038/mt.2016.55	2016	Evaluating the Safety of Retroviral Vectors Based on Insertional Oncogene Activation and Blocked Differentiation in Cultured Thymocytes.	MEF2C
27322685	10.18632/oncotarget.9982	2016	Deregulation of polycomb repressor complex 1 modifier AUTS2 in T-cell leukemia.	MEF2C
25675295	10.1038/cddis.2014.594	2015	The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.	MEF2C
25716962	NA	2015	Analysis of microRNA expression in canine mammary cancer stem-like cells indicates epigenetic regulation of transforming growth factor-beta signaling.	MEF2C
26172269	10.1371/journal.pone.0132926	2015	BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?	MEF2C
26245647	10.1038/ncomms8953	2015	MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation.	MEF2C
26473286	10.18632/oncotarget.5556	2015	Aberrant expression of homeobox gene SIX1 in Hodgkin lymphoma.	MEF2C
26670384	10.1128/mBio.01863-15	2015	Common Viral Integration Sites Identified in Avian Leukosis Virus-Induced B-Cell Lymphomas.	MEF2C
23975177	10.3324/haematol.2013.090233	2014	Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors.	MEF2C
24304814	10.1038/jid.2013.461	2014	miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.	MEF2C
22997707	10.1134/s1068162012030089	2012	[The functional analysis of polymorphic insertions of Alu retroelements at acute lymphoblastic leukemia].	MEF2C
21261500	10.3109/10428194.2010.537003	2011	Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.	MEF2C
21425961	10.3109/10428194.2011.566391	2011	Activation of Paired-homeobox gene PITX1 by del(5)(q31) in T-cell acute lymphoblastic leukemia.	MEF2C
21481790	10.1016/j.ccr.2011.02.008	2011	Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.	MEF2C
19056693	10.1182/blood-2007-09-113597	2009	HOXA9 is required for survival in human MLL-rearranged acute leukemias.	MEF2C
18079734	10.1038/sj.leu.2405067	2008	MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines.	MEF2C
16455055	10.1016/j.bbrc.2006.01.036	2006	Evidence for the interaction of the regulatory protein Ki-1/57 with p53 and its interacting proteins.	MEF2C
35241462	10.1136/bmjopen-2020-041961	2022	Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis.	MKI67
35248490	10.1016/j.clbc.2022.02.001	2022	Changes in Ki-67 in Residual Tumor and Outcome of Primary Inflammatory Breast Cancer Treated With Trimodality Therapy.	MKI67
35393909	10.1080/09513590.2022.2061454	2022	Effects of clinical and metabolic variables and hormones on the expression of immune protein biomarkers in the endometrium of women with polycystic ovary syndrome and normal-cycling controls.	MKI67
35583604	10.1158/1078-0432.CCR-21-3347	2022	Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL.	MKI67
32873701	10.1136/jclinpath-2020-206956	2021	Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody.	MKI67
33136585	10.1097/PAS.0000000000001609	2021	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.	MKI67
33404293	10.1080/15548627.2020.1871204	2021	BNIP3L-mediated mitophagy is required for mitochondrial remodeling during the differentiation of optic nerve oligodendrocytes.	MKI67
33723149	10.4103/jcrt.JCRT_311_19	2021	Role of WT1, B-cell lymphoma 2, Ki-67 (Mib1), and Her2/Neu as diagnostic and prognostic immunomarkers in ovarian serous and endometroid carcinoma.	MKI67
33737021	10.1016/j.taap.2021.115491	2021	Pyrazole (1, 2-diazole) induce apoptosis in lymphoma cells by targeting BCL-2 and BCL-XL genes and mitigate murine solid tumour development by regulating cyclin-D1 and Ki-67 expression.	MKI67
33788720	10.21873/anticanres.14886	2021	Tumor Cell Microenvironment and Microvessel Density Analysis in MALT Type Lymphoma.	MKI67
33941102	10.1186/s12885-021-08142-7	2021	Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma.	MKI67
33991204	10.1007/s00277-021-04473-4	2021	Elevated expression of HMGB1 is prognostic of poor survival in patients with relapsed/refractory T/NK-CL.	MKI67
34258959	10.7754/Clin.Lab.2021.201132	2021	Prognostic Values of MicroRNA-21 and Ki-67 in Diffuse Large B-Cell Lymphoma Patients: Egyptian Experience.	MKI67
34339560	10.1111/pin.13148	2021	Diagnostic utility and prognostic significance of the Ki-67 labeling index in diffuse large B-cell lymphoma transformed from follicular lymphoma: a study of 76 patients.	MKI67
34535585	10.1159/000518452	2021	Efficacy of the Antigenicity-Retaining Ability of Fixative Solutions for Liquid-Based Cytology: Immunocytochemistry of Long-Term Storage.	MKI67
34898577	10.3390/curroncol28060383	2021	Evaluation of Ki-67 as a Prognostic Marker in Diffuse Large B-Cell Lymphoma-A Single-Center Retrospective Cohort Study.	MKI67
31698053	10.1016/j.micpath.2019.103845	2020	Epigenetics evaluation of the oncogenic mechanisms of two closely related bovine and human deltaretroviruses: A system biology study.	MKI67
32059385	10.3390/medicina56020072	2020	Bmi-1 Immunohistochemical Expression in Endometrial Carcinoma is Correlated with Prognostic Activity.	MKI67
32443328	10.1097/MD.0000000000020140	2020	Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography.	MKI67
32556361	10.2340/00015555-3578	2020	Stage-dependent Increase in Expression of miR-155 and Ki-67 and Number of Tumour-associated Inflammatory Cells in Folliculotropic Mycosis Fungoides.	MKI67
32727513	10.1186/s12885-020-07200-w	2020	Comprehensive analysis of spread through air spaces in lung adenocarcinoma and squamous cell carcinoma using the 8th edition AJCC/UICC staging system.	MKI67
32767162	10.1007/s10637-020-00979-2	2020	Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo.	MKI67
32843697	10.1038/s41598-020-71058-y	2020	Activation-induced cytidine deaminase overexpression in double-hit lymphoma: potential target for novel anticancer therapy.	MKI67
30224636	10.1038/s41401-018-0108-5	2019	CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.	MKI67
30328119	10.1111/cup.13375	2019	Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation.	MKI67
30446982	10.1007/s10753-018-0930-4	2019	Breast Implant Texturization Does Not Affect the Crosstalk Between MSC and ALCL Cells.	MKI67
30467824	10.14670/HH-18-067	2019	Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient.	MKI67
30768440	10.1097/PAS.0000000000001233	2019	SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.	MKI67
30964854	10.12659/MSM.914934	2019	The Signal Transducer and Activator of Transcription 5B (STAT5B) Gene Promotes Proliferation and Drug Resistance of Human Mantle Cell Lymphoma Cells by Activating the Akt Signaling Pathway.	MKI67
31219818	10.1097/PAS.0000000000001312	2019	Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases.	MKI67
31259656	10.1080/10428194.2019.1633629	2019	The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma.	MKI67
31492883	10.1038/s41598-019-49326-3	2019	Classification of aggressive and classic mantle cell lymphomas using synchrotron Fourier Transform Infrared microspectroscopy.	MKI67
27490760	10.1097/PAI.0000000000000424	2018	Prognostic Significance of High Ki-67 Index and Histogenetic Subclassification in Primary Central Nervous System Lymphoma.	MKI67
28868942	10.1080/10428194.2017.1370547	2018	MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes.	MKI67
29196411	10.1182/blood-2017-07-797019	2018	Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.	MKI67
29319177	10.1111/cei.13099	2018	Characterization of ectopic lymphoid structures in different types of acute renal allograft rejection.	MKI67
29579328	10.1002/cncr.31328	2018	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.	MKI67
29785709	10.1111/bjh.15411	2018	Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).	MKI67
30272319	10.3892/or.2018.6743	2018	Effects of 60¬†kDa prolactin and estradiol on metabolism and cell survival in cervical cancer: Co‚Äëexpression of their hormonal receptors during cancer progression.	MKI67
30385732	10.1172/jci.insight.120974	2018	Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.	MKI67
28270020	10.1080/10428194.2017.1298754	2017	18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation.	MKI67
26272457	10.1111/his.12808	2016	Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas.	MKI67
26926679	10.1200/JCO.2015.63.8387	2016	Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.	MKI67
27959929	10.1371/journal.pmed.1002197	2016	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.	MKI67
25381338	10.1158/1078-0432.CCR-14-1913	2015	Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.	MKI67
25431344	10.1111/his.12624	2015	Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma.	MKI67
25504496	10.1007/s12185-014-1719-3	2015	High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy.	MKI67
25573205	10.3109/10428194.2015.1004169	2015	Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.	MKI67
25648135	10.1007/s10549-015-3288-4	2015	Bcl2 and Ki67 refine prognostication in luminal breast cancers.	MKI67
25712457	10.1093/annonc/mdv074	2015	Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL).	MKI67
26107196	10.7314/apjcp.2015.16.11.4515	2015	Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma.	MKI67
26546525	NA	2015	Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor Proliferation.	MKI67
24013721	10.1038/cdd.2013.123	2014	The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.	MKI67
24597851	10.1186/1471-2407-14-153	2014	Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis.	MKI67
24684350	10.1111/bjh.12854	2014	SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.	MKI67
25204411	10.1007/s12032-014-0218-y	2014	Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type.	MKI67
25374203	10.7314/apjcp.2014.15.20.8759	2014	Distribution of Ki67 proliferative indices among WHO subtypes of non-Hodgkin's lymphoma: association with other clinical parameters.	MKI67
23240716	10.1111/his.12009	2013	Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression.	MKI67
24471040	10.5125/jkaoms.2013.39.4.182	2013	Expansile keratocystic odontogenic tumor in the maxilla: immunohistochemical studies and review of literature.	MKI67
22531522	10.4103/0973-1482.95182	2012	Correlation of fluorodeoxyglucose uptake and tumor-proliferating antigen Ki-67 in lymphomas.	MKI67
21738398	NA	2011	Expression of cell proliferation and apoptosis biomarkers in pterygia and normal conjunctiva.	MKI67
20038236	10.3109/10428190903440953	2010	SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma.	MKI67
20181625	NA	2010	Molecular profiling using tissue microarrays as a tool to identify predictive biomarkers in laryngeal cancer treated with radiotherapy.	MKI67
20369488	NA	2010	[Expression and significance of P53 and P21 in nasal NK/T-cell lymphoma].	MKI67
20530581	10.1158/1541-7786.MCR-10-0131	2010	PRDM1 is required for mantle cell lymphoma response to bortezomib.	MKI67
20882047	10.1038/leu.2010.221	2010	COX-2 is a novel target in therapy of mycosis fungoides.	MKI67
18778369	10.1111/j.1600-0609.2008.01152.x	2009	Expression levels of apoptosis-related proteins and Ki-67 in nasal NK / T-cell lymphoma.	MKI67
19452712	NA	2009	[Expressions of p53 and p21 in nasal NK/T-cell lymphoma and their relationship with the proliferation and apoptosis of cells].	MKI67
20001925	10.2174/092986609789353646	2009	Proteomic analysis of mitochondria in Raji cells following exposure to radiation: implications for radiotherapy response.	MKI67
18077791	10.1182/blood-2007-10-117010	2008	Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.	MKI67
18612102	10.1182/blood-2008-03-145128	2008	A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).	MKI67
18766962	10.1080/10428190802140055	2008	Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma.	MKI67
17296585	10.3324/haematol.10682	2007	MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes.	MKI67
17693651	10.1093/annonc/mdm183	2007	Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type.	MKI67
16623776	10.1111/j.1365-2559.2006.02378.x	2006	Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders.	MKI67
17225522	NA	2006	[Expression and its significance of STAT3, STAT5, Survivin and Ki67 in nasal NK/T cell lymphoma].	MKI67
15931389	10.1172/JCI23412	2005	Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer.	MKI67
16295759	NA	2005	[Expression of proliferation marker Ki 67 in chronic lymphocytic leukemia].	MKI67
35106936	10.1002/cam4.4550	2022	SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.	MPEG1
34557402	10.3389/fonc.2021.638757	2021	Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma.	MPEG1
32373555	10.3389/fcimb.2020.00162	2020	A New Hope for CD56<sup>neg</sup>CD16<sup>pos</sup> NK Cells as Unconventional Cytotoxic Mediators: An Adaptation to Chronic Diseases.	MPEG1
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	MPEG1
31866476	10.1016/j.semcancer.2019.12.008	2022	Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy.	MTOR
33782541	10.1038/s41401-021-00644-1	2022	SAF-248, a novel PI3KŒ¥-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.	MTOR
33850273	10.1038/s41401-021-00643-2	2022	P300/CBP inhibition sensitizes mantle cell lymphoma to PI3KŒ¥ inhibitor idelalisib.	MTOR
34074205	10.1080/15548627.2021.1936932	2022	Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance.	MTOR
34162179	10.3324/haematol.2021.278743	2022	Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.	MTOR
34193976	10.1038/s41375-021-01326-x	2022	Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.	MTOR
34320785	10.3324/haematol.2021.278853	2022	Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.	MTOR
34528236	10.1111/bjd.20760	2022	Transcriptomic changes during stage progression of mycosis fungoides.	MTOR
34624079	10.1182/blood.2021012081	2022	SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.	MTOR
34670357	10.3324/haematol.2021.278796	2022	Either IL-7 activation of JAK-STAT or BEZ inhibition of PI3K-AKT-mTOR pathways dominates the single-cell phosphosignature of <i>ex vivo</i> treated pediatric T-cell acute lymphoblastic leukemia cells.	MTOR
34673128	10.1016/j.canlet.2021.10.018	2022	Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds.	MTOR
34714908	10.1182/bloodadvances.2021005486	2022	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.	MTOR
34791836	10.1002/cam4.4422	2022	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.	MTOR
34796518	10.1002/hon.2948	2022	Downregulation of FAPP2 gene induces cell autophagy and inhibits PI3K/AKT/mTOR pathway in T-cell acute lymphoblastic leukemia.	MTOR
34836490	10.1080/15548627.2021.1997053	2022	HYPK coordinates degradation of polyneddylated proteins by autophagy.	MTOR
34877904	10.1080/10428194.2021.2008382	2022	Inhibition of pyrimidine biosynthesis by strobilurin derivatives induces differentiation of acute myeloid leukemia cells.	MTOR
34913612	10.1002/cam4.4466	2022	miR-155-regulated mTOR and Toll-like receptor 5 in gastric diffuse large B-cell lymphoma.	MTOR
35019715	10.1128/jvi.01941-21	2022	Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties.	MTOR
35031886	10.1186/s43556-021-00066-9	2022	Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma.	MTOR
35033818	10.1016/j.bioorg.2022.105607	2022	Anti-leukemic effect and molecular mechanism of 11-methoxytabersonine from Melodinus cochinchinensis via network pharmacology, ROS-mediated mitochondrial dysfunction and PI3K/Akt signaling pathway.	MTOR
35035775	10.18632/oncotarget.28177	2022	GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells.	MTOR
35038545	10.1016/j.exphem.2022.01.004	2022	hnRNPK/Beclin1 signaling regulates autophagy to promote imatinib resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia cells.	MTOR
35053972	10.3390/foods11020240	2022	Protective Effect of <i>Ganoderma atrum</i> Polysaccharide on Acrolein-Induced Apoptosis and Autophagic Flux in IEC-6 Cells.	MTOR
35058488	10.1038/s41598-022-04916-6	2022	Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.	MTOR
35064010	10.1136/jitc-2021-003766	2022	JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy.	MTOR
35068379	10.1080/16078454.2021.2019363	2022	Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma.	MTOR
35091546	10.1038/s41420-022-00833-9	2022	Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma.	MTOR
35091949	10.1007/s11356-022-18863-2	2022	Cadmium induces apoptosis and autophagy in swine small intestine by downregulating the PI3K/Akt pathway.	MTOR
35105670	10.1158/1541-7786.MCR-21-0729	2022	PARK2 regulates eIF4B-driven lymphomagenesis.	MTOR
35156211	10.1111/jfbc.14111	2022	Evaluation of the protective effects of morin against acrylamide-induced lung toxicity by biomarkers of oxidative stress, inflammation, apoptosis, and autophagy.	MTOR
35163615	10.3390/ijms23031693	2022	Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential.	MTOR
35174346	10.5187/jast.2021.e128	2022	Effect of hyperthermia on cell viability, amino acid transfer, and milk protein synthesis in bovine mammary epithelial cells.	MTOR
35184749	10.1186/s12885-022-09275-z	2022	The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.	MTOR
35188042	10.1080/10428194.2022.2042689	2022	Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells.	MTOR
35191952	10.1158/1541-7786.MCR-21-0729	2022	PARK2 regulates eIF4B-driven lymphomagenesis.	MTOR
35219693	10.1016/j.exer.2022.109004	2022	Casein kinase I inhibitor D4476 influences autophagy and apoptosis in chloroquine-induced adult retinal pigment epithelial-19¬†cells.	MTOR
35220934	10.2174/1568009622666220225121009	2022	ND-16: A Novel Compound for Inhibiting the Growth of Cutaneous T Cell Lymphoma by Targeting JAK2.	MTOR
35237397	10.1177/20406207221080743	2022	Mantle cell lymphoma management trends and novel agents: where are we going?	MTOR
35248829	10.1016/j.redox.2022.102268	2022	mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells.	MTOR
35257981	10.1016/j.drup.2022.100822	2022	Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma.	MTOR
35259456	10.1016/j.cellsig.2022.110301	2022	Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL).	MTOR
35291908	10.1080/21655979.2022.2042142	2022	Protective effect of phillyrin against cerebral ischemia/reperfusion injury in rats and oxidative stress-induced cell apoptosis and autophagy in neurons.	MTOR
35304656	10.1007/s10565-022-09708-2	2022	Chemokine (C-X-C motif) ligand 1 maintains the immune surveillance function of natural killer cells via the PDK2/mTOR signaling pathway.	MTOR
35306048	10.1016/j.exphem.2022.03.005	2022	CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome.	MTOR
35321703	10.1186/s12906-022-03568-3	2022	Polyphenols in Ilex latifolia Thunb. inhibit human lung cancer cell line A549 by regulation of the PI3K-Akt signaling pathway.	MTOR
35336821	10.3390/biology11030449	2022	Post-Irradiation Thymic Regeneration in B6C3F1 Mice Is Age Dependent and Modulated by Activation of the PI3K-AKT-mTOR Pathway.	MTOR
35381283	10.1016/j.ijbiomac.2022.03.212	2022	Molecular characterization, expression and anti-tumor function analysis of yak IFITM2 gene.	MTOR
35397422	10.1016/j.bbrc.2022.03.105	2022	Poricoic acid A (PAA) inhibits T-cell acute lymphoblastic leukemia through inducing autophagic cell death and ferroptosis.	MTOR
35467473	10.1080/17474086.2022.2061455	2022	Advances in therapeutic strategies for primary CNS B-cell lymphomas.	MTOR
35483878	10.1101/mcs.a006188	2022	The utility of cerebrospinal fluid-derived cell-free DNA in molecular diagnostics for the <i>PIK3CA</i>-related megalencephaly-capillary malformation (MCAP) syndrome: a case report.	MTOR
35510955	10.15252/emmm.202215816	2022	A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.	MTOR
35517800	10.3389/fphar.2022.875330	2022	Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives.	MTOR
35558005	10.1177/17588359221093745	2022	Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.	MTOR
35571080	10.3389/fphar.2022.875016	2022	Anticancer Activities of <i>Polygonum odoratum</i> Lour.: A Systematic Review.	MTOR
35614940	10.3389/fphar.2022.875372	2022	Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment.	MTOR
35625998	10.3390/cancers14102392	2022	Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality.	MTOR
35626685	10.3390/cells11101648	2022	SMER28 Attenuates PI3K/mTOR Signaling by Direct Inhibition of PI3K p110 Delta.	MTOR
35640776	10.1016/j.lfs.2022.120675	2022	Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-Œ∫B pathways and LncRNA-AF085935/GPC3 axis.	MTOR
35671182	10.1097/CM9.0000000000001916	2022	Hepatocyte growth factor protects pulmonary endothelial barrier against oxidative stress and mitochondria-dependent apoptosis.	MTOR
35674939	10.1007/s12032-022-01707-x	2022	Pentacyclic triterpenoid ursolic acid induces apoptosis with mitochondrial dysfunction in adult T-cell leukemia MT-4 cells to promote surrounding cell growth.	MTOR
35688904	10.1007/s00277-022-04876-x	2022	Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis.	MTOR
35713434	10.1097/MD.0000000000029312	2022	KIF23 is a potential biomarker of diffuse large B cell lymphoma: Analysis based on bioinformatics and immunohistochemistry.	MTOR
35730922	10.1080/10428194.2022.2086247	2022	SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma.	MTOR
35740513	10.3390/cancers14122847	2022	Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in S√©zary Syndrome.	MTOR
35743211	10.3390/ijms23126773	2022	Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF).	MTOR
35757978	10.1002/jbt.23117	2022	l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.	MTOR
35774599	10.3389/fphar.2022.914733	2022	UPLC-MS/MS Technology for the Quantitative Methodology and Pharmacokinetic Analysis of Voxtalisib in Rat Plasma.	MTOR
35774848	10.1155/2022/3276925	2022	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.	MTOR
35785030	10.1155/2022/2253436	2022	Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.	MTOR
35810594	10.1016/j.bbrc.2022.06.089	2022	RHEB is a potential therapeutic target in T cell acute lymphoblastic leukemia.	MTOR
35857791	10.1080/15548627.2022.2100105	2022	Lack of COL6/collagen VI causes megakaryocyte dysfunction by impairing autophagy and inducing apoptosis.	MTOR
35864538	10.1186/s13045-022-01315-2	2022	hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype.	MTOR
35875136	10.3389/fonc.2022.913487	2022	Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia.	MTOR
35908982	10.1016/j.blre.2022.100992	2022	Follicular lymphoma: The long and winding road leading to your cure?	MTOR
35929918	10.1080/01443615.2022.2106834	2022	The effects of REG4 expression on chemoresistance of ovarian cancer.	MTOR
35981361	10.19746/j.cnki.issn.1009-2137.2022.04.012	2022	[Effect of Netrin-1 on VEGFA Expression in T-ALL Cells and Its Related Mechanism].	MTOR
36029491	10.14715/cmb/2022.68.5.21	2022	Effects of Atractylon on Proliferation and Apoptosis of Intestinal Cancer Cells Through PI3K/AKT/mTOR Signaling Pathway.	MTOR
36051080	10.1002/jha2.535	2022	Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma.	MTOR
32749680	10.1002/jcp.29943	2021	Light-emitting diode irradiation induces AKT/mTOR-mediated apoptosis in human pancreatic cancer cells and xenograft mouse model.	MTOR
32763229	10.1016/j.hemonc.2020.07.007	2021	Molecular events and cytotoxic effects of a novel thiosemicarbazone derivative in human leukemia and lymphoma cell lines.	MTOR
32800789	10.1016/j.pharmthera.2020.107659	2021	Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases.	MTOR
32898863	10.1182/blood.2020005622	2021	Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia.	MTOR
32970929	10.1111/ajco.13449	2021	Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance.	MTOR
33037136	10.1158/1535-7163.MCT-19-0973	2021	Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.	MTOR
33044904	10.1080/15548627.2020.1821548	2021	BNIP3L/Nix-induced mitochondrial fission, mitophagy, and impaired myocyte glucose uptake are abrogated by PRKA/PKA phosphorylation.	MTOR
33154093	10.1158/1541-7786.MCR-20-0466	2021	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.	MTOR
33206174	10.1093/carcin/bgaa119	2021	Synergistic targeting of CHK1 and mTOR in MYC-driven tumors.	MTOR
33246167	10.1016/j.phrs.2020.105302	2021	Cannabis and its constituents for cancer: History, biogenesis, chemistry and pharmacological activities.	MTOR
33251904	10.1080/10428194.2020.1849679	2021	The regulation of bcr-abl in hypoxia is through the mTOR pathway.	MTOR
33300153	10.1002/hon.2831	2021	Growth inhibition and suppression of the mTOR and Wnt/Œ≤-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion.	MTOR
33311569	10.1038/s41417-020-00267-4	2021	LncRNA LINC01857 promotes cell growth and diminishes apoptosis via PI3K/mTOR pathway and EMT process by regulating miR-141-3p/MAP4K4 axis in diffuse large B-cell lymphoma.	MTOR
33318657	10.1038/s41416-020-01205-9	2021	Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax.	MTOR
33391513	10.7150/thno.46655	2021	LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma.	MTOR
33393503	10.1172/JCI133090	2021	BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.	MTOR
33412518	10.18632/aging.202462	2021	Function of Deptor and its roles in hematological malignancies.	MTOR
33450375	10.1016/j.freeradbiomed.2020.12.452	2021	Oxygen sensing, mitochondrial biology and experimental therapeutics for pulmonary hypertension and cancer.	MTOR
33475938	10.1007/s10637-021-01066-w	2021	AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis.	MTOR
33484281	10.1007/s00109-020-02020-8	2021	3D culture conditions support Kaposi's sarcoma herpesvirus (KSHV) maintenance and viral spread in endothelial cells.	MTOR
33496749	10.1182/bloodadvances.2020002832	2021	Hypoxia favors chemoresistance in T-ALL through an HIF1Œ±-mediated mTORC1 inhibition loop.	MTOR
33506273	10.1007/s00520-021-06016-z	2021	Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.	MTOR
33530027	10.1016/j.tranon.2021.101027	2021	STRN-ALK rearranged pediatric malignant peritoneal mesothelioma - Functional testing of 527 cancer drugs in patient-derived cancer cells.	MTOR
33531656	10.1038/s41375-021-01132-5	2021	Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.	MTOR
33559856	10.1007/978-3-030-55617-4_5	2021	IL-22 Signaling in the Tumor Microenvironment.	MTOR
33567641	10.3390/cancers13040682	2021	Genomic Landscape of Hodgkin Lymphoma.	MTOR
33570607	10.1182/blood.2020008465	2021	Synergy of MALT1 and mTOR inhibition in DLBCL.	MTOR
33605486	10.1113/EP089328	2021	Endogenous production of n-3 polyunsaturated fatty acids protects mice from carbon tetrachloride-induced liver fibrosis by regulating mTOR and Bcl-2/Bax signalling pathways.	MTOR
33611674	10.1007/s11010-021-04098-1	2021	Long non-coding RNA GAS5 suppresses rheumatoid arthritis progression via miR-128-3p/HDAC4 axis.	MTOR
33615686	10.1002/kjm2.12352	2021	The depletion of Circ-PRKDC enhances autophagy and apoptosis in T-cell acute lymphoblastic leukemia via microRNA-653-5p/Reelin mediation of the PI3K/AKT/mTOR signaling pathway.	MTOR
33619116	10.1158/0008-5472.CAN-20-2297	2021	NPM-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation.	MTOR
33641344	10.1139/cjpp-2020-0487	2021	mTOR inhibition as a possible pharmacological target in the management of systemic inflammatory response and associated neuroinflammation by lipopolysaccharide challenge in rats.	MTOR
33641784	10.1016/S1875-5364(21)60014-6	2021	Artemisia kruhsiana leaf extract induces autophagic cell death in human prostate cancer cells.	MTOR
33664464	10.1038/s41375-021-01191-8	2021	Targeted based therapy in nodal T-cell lymphomas.	MTOR
33668434	10.3390/molecules26040987	2021	Anti-Cancer Properties of Theaflavins.	MTOR
33705488	10.1371/journal.pone.0248298	2021	Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.	MTOR
33729497	10.1042/CS20201296	2021	Brain angiotensin system: a new promise in the management of epilepsy?	MTOR
33730679	10.1016/j.tranon.2021.101068	2021	MicroRNA-181a suppresses norethisterone-promoted tumorigenesis of breast epithelial MCF10A cells through the PGRMC1/EGFR-PI3K/Akt/mTOR signaling pathway.	MTOR
33747367	10.4081/oncol.2021.514	2021	Metformin - its anti-cancer effects in hematologic malignancies.	MTOR
33774181	10.1016/j.phrs.2021.105579	2021	Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.	MTOR
33777762	10.3389/fonc.2021.618908	2021	CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With <i>MYC</i> and <i>BCL2</i> Rearrangements.	MTOR
33784031	10.1002/cnr2.1372	2021	Mixed phenotype acute leukemia in a child associated with a NUP98-NSD1 fusion and NRAS p.Gly61Arg mutation.	MTOR
33787984	10.1007/s00277-021-04493-0	2021	High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.	MTOR
33790574	10.2147/OTT.S189032	2021	Oral PI3K-Œ¥,Œ≥ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib.	MTOR
33793811	10.1093/jpp/rgaa011	2021	Eupafolin induces autophagy and apoptosis in B-cell non-Hodgkin lymphomas.	MTOR
33793828	10.1093/jpp/rgaa018	2021	Hypericin-mediated photodynamic therapy for the treatment of cancer: a review.	MTOR
33812443	10.19746/j.cnki.issn.1009-2137.2021.02.052	2021	[New Advances in the Treatment of Primary Central Nervous System Lymphoma--Review].	MTOR
33821934	10.1093/abbs/gmab031	2021	Anti-DLBCL efficacy of DCZ0825 in vitro and in vivo: involvement of the PI3K‚ÄíAKT‚ÄímTOR/JNK pathway.	MTOR
33838212	10.1016/j.brainresbull.2021.04.003	2021	Hydrogen-saturated saline mediated neuroprotection through autophagy via PI3K/AKT/mTOR pathway in early and medium stages of rotenone-induced Parkinson's disease rats.	MTOR
33876224	10.1182/blood.2020008955	2021	A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia.	MTOR
33890833	10.1080/1744666X.2021.1919085	2021	Novel therapeutic approaches for cutaneous T cell lymphomas.	MTOR
33907223	10.1038/s41598-021-87966-6	2021	ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells.	MTOR
33923420	10.3390/ncrna7020026	2021	Exon-Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation.	MTOR
33939091	10.1007/s11356-021-14049-4	2021	Morin protects against acrylamide-induced neurotoxicity in rats: an investigation into different signal pathways.	MTOR
33954056	10.7717/peerj.11264	2021	Melatonin ameliorates myocardial injury by reducing apoptosis and autophagy of cardiomyocytes in a rat cardiopulmonary bypass model.	MTOR
33970999	10.1182/blood.2019000553	2021	Overexpression of wild-type IL-7RŒ± promotes T-cell acute lymphoblastic leukemia/lymphoma.	MTOR
33994361	10.21873/cgp.20265	2021	Clear Cell Renal Carcinoma: MicroRNAs With Efficacy in Preclinical <i>In Vivo</i> Models.	MTOR
34014537	10.1007/978-3-030-65768-0_7	2021	Non-Hodgkin Lymphoma Metabolism.	MTOR
34043588	10.1172/JCI139675	2021	Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming.	MTOR
34070951	10.3390/diagnostics11060999	2021	Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma.	MTOR
34080325	10.1002/cam4.4024	2021	The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia.	MTOR
34115902	10.1111/ced.14798	2021	The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth.	MTOR
34116237	10.1016/j.jshs.2021.06.002	2021	Exercise attenuates angiotensin‚Ö°-induced muscle atrophy by targeting PPARŒ≥/miR-29b.	MTOR
34119916	10.1016/j.intimp.2021.107829	2021	Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma.	MTOR
34132378	10.3892/ijo.2021.5232	2021	Traditional and emerging therapies for anaplastic large cell lymphoma (Review).	MTOR
34139193	10.1016/j.ajpath.2021.06.004	2021	Rictor/Mammalian Target of Rapamycin Complex 2 Signaling Protects Colonocytes from Apoptosis and Prevents Epithelial Barrier Breakdown.	MTOR
34159086	10.21037/tau-21-280	2021	The protective effects of exogenous spermine on renal ischemia-reperfusion injury in rats.	MTOR
34162911	10.1038/s41598-021-92448-w	2021	Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia.	MTOR
34219464	10.1139/bcb-2021-0045	2021	Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway.	MTOR
34221985	10.3389/fonc.2021.670275	2021	Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas.	MTOR
34260908	10.1016/j.celrep.2021.109372	2021	Inhibition of Rag GTPase signaling in mice suppresses B cell responses and lymphomagenesis with minimal detrimental trade-offs.	MTOR
34277771	10.21037/atm-21-2360	2021	Norcantharidin triggers apoptotic cell death in non-small cell lung cancer via a mitophagy-mediated autophagy pathway.	MTOR
34277781	10.21037/atm-21-2574	2021	A novel peptide promotes human trophoblast proliferation and migration through PI3K/Akt/mTOR signaling pathway.	MTOR
34311319	10.1016/j.jinorgbio.2021.111550	2021	Iridium(III)-BBIP complexes induce apoptosis via PI3K/AKT/mTOR pathway and inhibit A549 lung tumor growth in vivo.	MTOR
34386317	10.1016/j.apsb.2020.10.018	2021	Natural compounds modulate the autophagy with potential implication of stroke.	MTOR
34403880	10.1016/j.neo.2021.07.009	2021	Oncogene-independent resistance in Philadelphia chromosome - positive (Ph<sup>+</sup>) acute lymphoblastic leukemia (ALL) is mediated by activation of AKT/mTOR pathway.	MTOR
34410900	10.1080/13880209.2021.1961825	2021	Anticancer effect of myristicin on hepatic carcinoma and related molecular mechanism.	MTOR
34426436	10.1158/1078-0432.CCR-21-0573	2021	Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma.	MTOR
34439483	10.3390/antiox10081235	2021	Anthocyanins Promote Learning through Modulation of Synaptic Plasticity Related Proteins in an Animal Model of Ageing.	MTOR
34540765	10.3389/fped.2021.703853	2021	Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up.	MTOR
34557659	10.1016/j.isci.2021.102931	2021	The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma.	MTOR
34579773	10.1186/s13578-021-00688-0	2021	Metabolic reprogramming and metabolic sensors in KSHV-induced cancers and KSHV infection.	MTOR
34589395	10.1016/j.apsb.2020.12.020	2021	Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.	MTOR
34589671	10.1097/HS9.0000000000000636	2021	The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial.	MTOR
34606736	10.1080/14728222.2021.1988927	2021	Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma.	MTOR
34643126	10.1080/07357907.2021.1983584	2021	Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.	MTOR
34651869	10.1002/hon.2933	2021	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.	MTOR
34658308	10.1080/21655979.2021.1977557	2021	Transcription factor 3 (TCF3) combined with histone deacetylase 3 (HDAC3) down-regulates microRNA-101 to promote Burkitt lymphoma cell proliferation and inhibit apoptosis.	MTOR
34659910	NA	2021	Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature.	MTOR
34669944	10.1093/mtomcs/mfab058	2021	Maternal selenium deficiency suppresses proliferation, induces autophagy dysfunction and apoptosis in the placenta of mice.	MTOR
34692691	10.3389/fcell.2021.734818	2021	TEOA Promotes Autophagic Cell Death via ROS-Mediated Inhibition of mTOR/p70S6k Signaling Pathway in Pancreatic Cancer Cells.	MTOR
34700229	10.1016/j.biopha.2021.112349	2021	Rapamycin attenuates PLA2R activation-mediated podocyte apoptosis via the PI3K/AKT/mTOR pathway.	MTOR
34710755	10.1016/j.phymed.2021.153802	2021	Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo.	MTOR
34729938	10.1111/1759-7714.14184	2021	Hexokinases II-mediated glycolysis governs susceptibility to crizotinib in ALK-positive non-small cell lung cancer.	MTOR
34736967	10.1016/j.ejphar.2021.174612	2021	Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells.	MTOR
34737376	10.1038/s41598-021-00950-y	2021	Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.	MTOR
34745769	10.1080/2162402X.2021.1995999	2021	Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner.	MTOR
34750354	10.1038/s41419-021-04353-9	2021	Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies.	MTOR
34796352	10.5187/jast.2021.e93	2021	Enhanced supply of methionine regulates protein synthesis in bovine mammary epithelial cells under hyperthermia condition.	MTOR
34859142	10.1080/23723556.2021.1979370	2021	From mouse genetics to targeting the Rag GTPase pathway.	MTOR
34893112	10.19746/j.cnki.issn.1009-2137.2021.06.017	2021	[Inhibition Effect of Eriodictyol to Growth of DG-75 Cells and the Related Action Mechanism].	MTOR
34900714	10.3389/fonc.2021.766298	2021	Zotatifin, an eIF4A-Selective Inhibitor, Blocks Tumor Growth in Receptor Tyrosine Kinase Driven Tumors.	MTOR
34907175	10.1038/s41467-021-27197-5	2021	Interleukin-7 receptor Œ± mutational activation can initiate precursor B-cell acute lymphoblastic leukemia.	MTOR
35045655	10.3760/cma.j.issn.0253-2727.2021.11.008	2021	[Effects of L-asparaginase on proliferation, cell cycle and apoptosis of Burkitt lymphoma cell lines].	MTOR
30990357	10.1080/15548627.2019.1607694	2020	Cell quality control mechanisms maintain stemness and differentiation potential of P19 embryonic carcinoma cells.	MTOR
31148590	10.1038/s41375-019-0486-9	2020	The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation.	MTOR
31242129	10.1080/15548627.2019.1635380	2020	<i>MIR145-3p</i> promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting <i>HDAC4</i>.	MTOR
31286804	10.1080/15548627.2019.1635384	2020	New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.	MTOR
31297833	10.1002/jcp.29060	2020	Long noncoding RNA PVT1: A highly dysregulated gene in malignancy.	MTOR
31332784	10.1002/jcp.28984	2020	Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway.	MTOR
31448672	10.1080/15548627.2019.1659654	2020	PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.	MTOR
31464204	10.4103/aja.aja_89_19	2020	Effect of probucol on autophagy and apoptosis in the penile tissue of streptozotocin-induced diabetic rats.	MTOR
31585938	10.1158/1078-0432.CCR-19-1104	2020	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.	MTOR
31587272	10.1002/jcp.29218	2020	Organic anion transporters and PI3K-AKT-mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein.	MTOR
31636099	10.1158/1078-0432.CCR-19-1486	2020	Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.	MTOR
31676945	10.1007/s00403-019-02000-0	2020	Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma.	MTOR
31682844	10.1016/j.jid.2019.08.454	2020	Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell¬†Lymphoma.	MTOR
31712222	10.1101/cshperspect.a036244	2020	PTEN in Regulating Hematopoiesis and Leukemogenesis.	MTOR
31714156	10.1080/14712598.2020.1688298	2020	NK cell-based therapeutics for lung cancer.	MTOR
31742861	10.1111/jcmm.14810	2020	TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway.	MTOR
31772298	10.1038/s41375-019-0663-x	2020	Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.	MTOR
31774199	10.15252/embj.2019102030	2020	Paracaspase MALT1 regulates glioma cell survival by controlling endo-lysosome homeostasis.	MTOR
31774495	10.1182/blood.2019001904	2020	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.	MTOR
31881325	10.1016/j.cellsig.2019.109518	2020	Apoptosis and autophagy in polycystic kidney disease (PKD).	MTOR
31883669	10.1016/j.pathol.2019.09.014	2020	The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.	MTOR
31894340	10.3892/or.2019.7453	2020	Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‚Äë152 in¬†vivo and in¬†vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.	MTOR
31904116	10.1002/jcp.29429	2020	Targeting Wnt/Œ≤-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.	MTOR
31912905	10.1002/jcp.29443	2020	Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling.	MTOR
31950225	10.1007/s00262-020-02482-2	2020	CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to Œ≥<sub>c</sub> cytokine stimulation via PI3K/mTOR axis.	MTOR
31980182	10.1016/j.bbrc.2019.12.129	2020	Curcumin exerts anti-tumor effects on diffuse large B cell lymphoma via regulating PPARŒ≥ expression.	MTOR
32014673	10.1016/j.critrevonc.2020.102886	2020	Mechanisms of resistance to mTOR inhibitors.	MTOR
32033478	10.3390/ijms21031060	2020	Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?	MTOR
32047535	10.1177/1758835919895756	2020	Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.	MTOR
32064003	10.1177/1758835919897546	2020	Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer.	MTOR
32074729	10.3760/cma.j.issn.0529-5807.2020.02.010	2020	[Expression of p-AKT and p-mTOR in pediatric Burkitt lymphoma and their correlation with prognosis].	MTOR
32098126	10.3390/molecules25040971	2020	Benzoxazole Derivative K313 Induces Cell Cycle Arrest, Apoptosis and Autophagy Blockage and Suppresses mTOR/p70S6K Pathway in Nalm-6 and Daudi Cells.	MTOR
32104214	10.3892/etm.2019.8398	2020	Ghrelin inhibits cisplatin-induced MDA-MB-231 breast cancer cell apoptosis via PI3K/Akt/mTOR signaling.	MTOR
32108030	10.1158/1078-0432.CCR-18-3851	2020	Metabolome Analysis Reveals Excessive Glycolysis via PI3K/AKT/mTOR and RAS/MAPK Signaling in Methotrexate-Resistant Primary CNS Lymphoma-Derived Cells.	MTOR
32127939	10.7150/jca.34981	2020	Apigenin and Abivertinib, a novel BTK inhibitor synergize to inhibit diffuse large B-cell lymphoma <i>in vivo and vitro</i>.	MTOR
32131560	10.3390/nu12030679	2020	Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer.	MTOR
32132036	10.21873/anticanres.14081	2020	Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.	MTOR
32140387	10.1016/j.apsb.2019.06.005	2020	Disturbed Yin-Yang balance: stress increases the susceptibility to primary and recurrent infections of herpes simplex virus type 1.	MTOR
32145384	10.1016/j.exphem.2020.02.004	2020	Tumor-specific transcript variants of cyclin D1 in mantle cell lymphoma and multiple myeloma with chromosome 11q13 abnormalities.	MTOR
32145743	10.1186/s12906-020-2865-1	2020	Germacrone protects against oxygen-glucose deprivation/reperfusion injury by inhibiting autophagy processes in PC12 cells.	MTOR
32149078	10.1155/2020/1520651	2020	Autophagy Inhibition Potentiates the Anticancer Effects of a Bendamustine Derivative NL-101 in Acute T Lymphocytic Leukemia.	MTOR
32154751	10.1080/10428194.2020.1734594	2020	IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.	MTOR
32164676	10.1186/s12906-020-2846-4	2020	Total flavones of Dracocephalum moldavica L. protect astrocytes against H<sub>2</sub>O<sub>2</sub>-induced apoptosis through a mitochondria-dependent pathway.	MTOR
32171983	10.1016/j.bioorg.2020.103724	2020	Synthesis and biological evaluation of 6-phenylpurine linked hydroxamates as novel histone deacetylase inhibitors.	MTOR
32179489	10.1016/j.cancergen.2020.02.005	2020	Integrating transcriptome-wide association study and copy number variation study identifies candidate genes and pathways for diffuse non-Hodgkin's lymphoma.	MTOR
32185137	10.3389/fonc.2020.00273	2020	The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects.	MTOR
32206779	10.1182/blood.2019002792	2020	Increased mTOR activation in idiopathic multicentric Castleman disease.	MTOR
32219060	10.3389/fonc.2020.00217	2020	Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway.	MTOR
32231197	10.32471/exp-oncology.2312-8852.vol-42-no-1.14067	2020	Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia.	MTOR
32235787	10.3390/ijms21062193	2020	The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia.	MTOR
32240637	10.1016/j.abb.2020.108352	2020	Rab1A knockdown represses proliferation and promotes apoptosis in gastric cancer cells by inhibition of mTOR/p70S6K pathway.	MTOR
32255708	10.1080/10428194.2020.1747068	2020	Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.	MTOR
32270047	10.1126/sciadv.aaz9798	2020	Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma.	MTOR
32334988	10.1016/j.idc.2020.02.005	2020	Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors.	MTOR
32356174	10.1007/s11864-020-00746-8	2020	PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma.	MTOR
32359574	10.1016/j.psj.2019.10.034	2020	Gut microbiota mediates the protective role of Lactobacillus plantarum in ameliorating deoxynivalenol-induced apoptosis and intestinal inflammation of broiler chickens.	MTOR
32416683	10.2174/1871527319666200517112252	2020	Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects.	MTOR
32427409	10.1002/gcc.22861	2020	Targeted next generation sequencing of MLH1-deficient, MLH1 promoter hypermethylated, and BRAF/RAS-wild-type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions.	MTOR
32468878	10.1177/0300060520926093	2020	BI6727, a polo-like kinase 1 inhibitor with promising efficacy on Burkitt lymphoma cells.	MTOR
32479694	10.1002/cyto.b.21882	2020	Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.	MTOR
32487610	10.21873/anticanres.14297	2020	Sirtuin 1 Activation Suppresses the Growth of T-lymphoblastic Leukemia Cells by Inhibiting NOTCH and NF-Œ∫B Pathways.	MTOR
32495867	10.26355/eurrev_202005_21316	2020	Metformin reduces pancreatic cancer cell proliferation and increases apoptosis through MTOR signaling pathway and its dose-effect relationship.	MTOR
32508655	10.3389/fphar.2020.00737	2020	CCT020312 Inhibits Triple-Negative Breast Cancer Through PERK Pathway-Mediated G1 Phase Cell Cycle Arrest and Apoptosis.	MTOR
32546661	10.1158/1535-7163.MCT-19-1111	2020	A Novel Approach to Safer Glucocorticoid Receptor-Targeted Anti-lymphoma Therapy via REDD1 (Regulated in Development and DNA Damage 1) Inhibition.	MTOR
32566584	10.21037/atm-20-3768	2020	Beta carotene protects H9c2 cardiomyocytes from advanced glycation end product-induced endoplasmic reticulum stress, apoptosis, and autophagy via the PI3K/Akt/mTOR signaling pathway.	MTOR
32586008	10.3390/biomedicines8060170	2020	ROR1 Is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells.	MTOR
32601796	10.1007/s00277-020-04159-3	2020	Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T<sup>3</sup> phase IB trial of the LYSA.	MTOR
32615949	10.1186/s12885-020-07102-x	2020	Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization.	MTOR
32627816	10.1042/BSR20193738	2020	Ma xing shi gan decoction eliminates PM2.5-induced lung injury by reducing pulmonary cell apoptosis through Akt/mTOR/p70S6K pathway in rats.	MTOR
32665551	10.1038/s41467-020-17064-0	2020	PRDM15 is a key regulator of metabolism critical to sustain B-cell lymphomagenesis.	MTOR
32671779	10.1007/978-981-15-4272-5_44	2020	Autophagy and Lymphoma.	MTOR
32682197	10.1016/j.ejmech.2020.112582	2020	New insight into 20(S)-ginsenoside Rh2 against T-cell acute lymphoblastic leukemia associated with the gut microbiota and the immune system.	MTOR
32702393	10.1016/j.exphem.2020.07.005	2020	DEPTOR is a microRNA-155 target regulating migration and cytokine production in diffuse large B-cell lymphoma cells.	MTOR
32731591	10.3390/cancers12082099	2020	Oxidative Stress and Apoptotic Responses Elicited by <i>Nostoc</i>-Synthesized Silver Nanoparticles against Different Cancer Cell Lines.	MTOR
32733473	10.3389/fimmu.2020.01423	2020	From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment.	MTOR
32747423	10.1158/1535-7163.MCT-19-0671	2020	Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis.	MTOR
32753387	10.1158/1535-7163.MCT-20-0160	2020	PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.	MTOR
32776229	10.1007/s00280-020-04122-z	2020	miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway.	MTOR
32803259	10.1042/CS20200514	2020	Antiepileptic effects of long-term intracerebroventricular infusion of angiotensin-(1-7) in an animal model of temporal lobe epilepsy.	MTOR
32804454	10.1097/PAS.0000000000001512	2020	Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature.	MTOR
32835548	10.1080/10428194.2020.1804560	2020	SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome.	MTOR
32913370	10.1371/journal.pone.0239102	2020	Retraction: Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells.	MTOR
32915799	10.1371/journal.pone.0238379	2020	Proteomic and transcriptomic studies of BGC823 cells stimulated with Helicobacter pylori isolates from gastric MALT lymphoma.	MTOR
32926124	10.1182/bloodadvances.2020001685	2020	Targeting phosphatidylinositol 3 kinase-Œ≤ and -Œ¥ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.	MTOR
32943998	10.1186/s12935-020-01539-7	2020	HKDC1 promotes the tumorigenesis and glycolysis in lung adenocarcinoma via regulating AMPK/mTOR signaling pathway.	MTOR
32961236	10.1016/j.lfs.2020.118467	2020	Retinoprotective effect of donepezil in diabetic mice involves mitigation of excitotoxicity and activation of PI3K/mTOR/BCl<sub>2</sub> pathway.	MTOR
32989257	10.1038/s41388-020-01469-8	2020	Increased baseline RASGRP1 signals enhance stem cell fitness during native hematopoiesis.	MTOR
32999755	10.1186/s40164-020-00182-2	2020	miR-100 inhibits cell proliferation in mantle cell lymphoma by targeting mTOR.	MTOR
33020261	10.1073/pnas.2008883117	2020	The transcription factor C/EBPŒ≤ orchestrates dendritic cell maturation and functionality under homeostatic and malignant conditions.	MTOR
33029053	10.1016/j.jceh.2020.02.001	2020	De Novo Malignancy After Living Donor Liver Transplantation: A Large Volume Experience.	MTOR
33049974	10.3390/antiox9100961	2020	Anticancer Properties of Carnosol: A Summary of in Vitro and In Vivo Evidence.	MTOR
33053749	10.3390/cancers12102936	2020	The In Vitro and In Vivo Anticancer Properties of Chalcone Flavokawain B through Induction of ROS-Mediated Apoptotic and Autophagic Cell Death in Human Melanoma Cells.	MTOR
33055173	10.1158/1078-0432.CCR-20-1215	2020	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.	MTOR
33109547	10.21873/anticanres.14630	2020	Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.	MTOR
33154951	10.3389/fonc.2020.591577	2020	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	MTOR
33191863	10.1080/16078454.2020.1845501	2020	Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-Œ∫B signal pathway.	MTOR
33304974	10.1016/j.jdcr.2020.08.041	2020	Primary cutaneous peripheral T-cell lymphoma, not otherwise specified with mammalian target of rapamycin mutation: A novel finding for targeted treatment.	MTOR
33489922	10.3389/fonc.2020.611690	2020	The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside.	MTOR
35356005	10.31491/apt.2020.03.009	2020	Thioredoxin overexpression in mitochondria showed minimum effects on aging and age-related diseases in male C57BL/6 mice.	MTOR
35753740	10.11817/j.issn.1672-7347.2020.190291	2020	Effect of salvianolic acid A on the proliferation and apoptosis in esophageal cancer cells and the underlying mechanisms.	MTOR
29383700	10.1111/bjh.15079	2019	Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.	MTOR
29668543	10.1097/MPH.0000000000001179	2019	Multiple Epstein-Barr Virus-associated Smooth Muscle Sarcomas of the Gut in a Child Treated for Acute Lymphoblastic Leukemia.	MTOR
30198569	10.1111/bjh.15591	2019	The miR-17~92 cluster activates mTORC1 in mantle cell lymphoma by targeting multiple regulators in the STK11/AMPK/TSC/mTOR pathway.	MTOR
30216478	10.1002/hon.2561	2019	The role of maintenance therapy in patients with diffuse large B cell lymphoma: A systematic review and meta-analysis.	MTOR
30224339	10.1158/1078-0432.CCR-18-0867	2019	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.	MTOR
30244168	10.1016/j.cellsig.2018.09.012	2019	BAFF inhibits autophagy promoting cell proliferation and survival by activating Ca<sup>2+</sup>-CaMKII-dependent Akt/mTOR signaling pathway in normal and neoplastic B-lymphoid cells.	MTOR
30249539	10.1016/j.jbior.2018.09.012	2019	IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update.	MTOR
30355676	10.1158/1541-7786.MCR-18-0582	2019	<i>Sleeping Beauty</i> Screen Identifies <i>RREB1</i> and Other Genetic Drivers in Human B-cell Lymphoma.	MTOR
30359076	10.1152/ajpheart.00487.2018	2019	BMI1 promotes cardiac fibrosis in ischemia-induced heart failure via the PTEN-PI3K/Akt-mTOR signaling pathway.	MTOR
30413649	10.1158/1535-7163.MCT-18-0478	2019	Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.	MTOR
30431059	10.3892/ijmm.2018.3982	2019	Overexpression of microRNA-183 promotes apoptosis of substantia nigra neurons via the inhibition of OSMR in a mouse model of Parkinson's disease.	MTOR
30518812	10.1038/s41375-018-0305-8	2019	Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance.	MTOR
30528730	10.1016/j.bbrc.2018.12.004	2019	Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.	MTOR
30535452	10.3892/or.2018.6917	2019	Potential efficacy and prognosis of silencing the CRLF2‚Äëmediated AKT/mTOR pathway in pediatric acute B‚Äëcell lymphoblastic leukemia.	MTOR
30549430	10.1111/ajt.15216	2019	Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.	MTOR
30563887	10.1158/0008-5472.CAN-18-1617	2019	Inhibition of Notch Signaling Enhances Chemosensitivity in B-cell Precursor Acute Lymphoblastic Leukemia.	MTOR
30569126	10.3892/mmr.2018.9737	2019	Ferulic acid ameliorates cerebral infarction by activating Akt/mTOR/4E‚ÄëBP1/Bcl‚Äë2 anti‚Äëapoptotic signaling in the penumbral cortex following permanent cerebral ischemia in rats.	MTOR
30642353	10.1186/s13045-018-0692-3	2019	Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia.	MTOR
30649751	10.1007/s40264-018-0778-4	2019	Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.	MTOR
30684308	10.1111/vco.12460	2019	Canine CD4+ T-cell lymphoma identified by flow cytometry exhibits a consistent histomorphology and gene expression profile.	MTOR
30688831	10.1097/MPH.0000000000001425	2019	Evaluation of Insulin-mediated Regulation of AKT Signaling in Childhood Acute Lymphoblastic Leukemia.	MTOR
30702500	10.1097/CAD.0000000000000756	2019	Sinensetin induces apoptosis and autophagy in the treatment of human T-cell lymphoma.	MTOR
30718665	10.1038/s41598-018-37666-5	2019	Oxo-aglaiastatin-Mediated Inhibition of Translation Initiation.	MTOR
30720463	10.1172/JCI98288	2019	Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR.	MTOR
30733891	10.1186/s40164-019-0126-0	2019	Mantle cell lymphoma and its management: where are we now?	MTOR
30763910	10.1016/j.neo.2019.01.004	2019	Comprehensive Investigation of miRNome Identifies Novel Candidate miRNA-mRNA Interactions Implicated in T-Cell Acute Lymphoblastic Leukemia.	MTOR
30782609	10.1182/blood-2018-09-872549	2019	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.	MTOR
30782662	10.1128/mBio.02871-18	2019	Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma.	MTOR
30795552	10.3390/cells8020190	2019	Targeting mTOR in Acute Lymphoblastic Leukemia.	MTOR
30798134	10.1016/j.biopha.2019.108599	2019	Tanshinone IIA protects against heart failure post-myocardial infarction via AMPKs/mTOR-dependent autophagy pathway.	MTOR
30801854	10.1002/biof.1498	2019	ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway.	MTOR
30806286	10.1615/JEnvironPatholToxicolOncol.2018027885	2019	Autophagy is Required to Regulate Mitochondria Renewal, Cell Attachment, and All-trans-Retinoic Acid-Induced Differentiation in NB4 Acute Promyelocytic Leukemia Cells.	MTOR
30808136	10.13201/j.issn.1001-1781.2019.02.008	2019	[Expression of mTOR and 4E-BP1 in extranodal Nasal-type NK/T-cell Lymphoma and implication for prognosis].	MTOR
30827861	10.1016/j.cmet.2019.02.002	2019	GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors.	MTOR
30845773	10.3390/biom9030092	2019	[Pt(<i>O,O</i>'-acac)(Œ≥-acac)(DMS)] Induces Autophagy in Caki-1 Renal Cancer Cells.	MTOR
30854075	10.3892/ol.2019.9890	2019	UNBS5162 inhibits SKOV3 ovarian cancer cell proliferation by regulating the PI3K/AKT signalling pathway.	MTOR
30864685	10.3892/ijmm.2019.4129	2019	GNG7 silencing promotes the proliferation and differentiation of placental cytotrophoblasts in preeclampsia rats through activation of the mTOR signaling pathway.	MTOR
30864709	10.3892/mmr.2019.10002	2019	Butyrate inhibits the proliferation and induces the apoptosis of colorectal cancer HCT116 cells via the deactivation of mTOR/S6K1 signaling mediated partly by SIRT1 downregulation.	MTOR
30867372	10.5582/bst.2019.01006	2019	Effects of BENC-511, a novel PI3K inhibitor, on the proliferation and apoptosis of A549 human lung adenocarcinoma cells.	MTOR
30880359	10.1007/s11899-019-00501-3	2019	Relapsed T Cell ALL: Current Approaches and New Directions.	MTOR
30896824	10.3892/or.2019.7072	2019	Timosaponin¬†A‚ÄëIII induces autophagy of T‚Äëcell acute lymphoblastic leukemia Jurkat cells via inhibition of the PI3K/Akt/mTOR pathway.	MTOR
30896875	10.3892/mmr.2019.10021	2019	Knockdown of serpin peptidase inhibitor clade C member¬†1 inhibits the growth of nasopharyngeal carcinoma cells.	MTOR
30914027	10.2174/1568009619666190326120833	2019	Inhibition of PI3K/mTOR Pathways with GDC-0980 in Pediatric Leukemia: Impact on Abnormal FLT-3 Activity and Cooperation with Intracellular Signaling Targets.	MTOR
30973085	10.1080/01616412.2019.1596206	2019	Rutin hydrate inhibits apoptosis in the brains of cadmium chloride-treated rats via preserving the mitochondrial integrity and inhibiting endoplasmic reticulum stress.	MTOR
30988770	10.3892/etm.2019.7402	2019	BOS-93, a novel bromophenol derivative, induces apoptosis and autophagy in human A549 lung cancer cells via PI3K/Akt/mTOR and MAPK signaling pathway.	MTOR
30995847	10.14735/amko201990	2019	Therapy of Relapsed/Refractory Acute Lymphoblastic Leukemia Today and Tomorrow.	MTOR
31018830	10.1177/1010428319846803	2019	Mesenchymal stem cells targeting PI3K/AKT pathway in leukemic model.	MTOR
31028199	10.21873/invivo.11541	2019	CCL21 Induces mTOR-dependent MALAT1 Expression, Leading to Cell Migration in Cutaneous T-Cell Lymphoma.	MTOR
31036508	10.1016/j.clml.2019.03.017	2019	Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.	MTOR
31042587	10.1016/j.canlet.2019.04.030	2019	IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.	MTOR
31056348	10.1016/j.clml.2019.03.015	2019	Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.	MTOR
31058559	10.1080/10428194.2019.1607330	2019	Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway.	MTOR
31101621	10.1182/blood.2018874560	2019	Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma.	MTOR
31114980	10.26355/eurrev_201905_17778	2019	MiR-29 regulates retinopathy in diabetic mice via the AMPK signaling pathway.	MTOR
31135975	10.1111/bjh.15997	2019	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma.	MTOR
31166253	10.1097/HJH.0000000000002139	2019	Dysfunction of B-cell lymphoma 2/adenovirus E1B 19KD interacting protein 3 in decidua is involved in the pathogenesis of preeclampsia.	MTOR
31167506	10.3390/cancers11060775	2019	The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.	MTOR
31173255	10.3892/mmr.2019.10369	2019	Effect of metformin on cell proliferation, apoptosis, migration and invasion in A172 glioma cells and its mechanisms.	MTOR
31181779	10.3390/molecules24112165	2019	A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways.	MTOR
31189740	10.1042/BSR20182196	2019	microRNA-613 exerts anti-angiogenic effect on nasopharyngeal carcinoma cells through inactivating the AKT signaling pathway by down-regulating FN1.	MTOR
31202171	10.1016/j.biopha.2019.109071	2019	Huaier extract enhances the treatment efficacy of imatinib in Ik6<sup>+</sup> Ph<sup>+</sup> acute lymphoblastic leukemia.	MTOR
31214498	10.3389/fonc.2019.00443	2019	Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas.	MTOR
31226848	10.3390/ijms20123021	2019	Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia.	MTOR
31238062	10.1016/j.ejphar.2019.172494	2019	Comparative transcriptome analysis of peripheral blood mononuclear cells in renal transplant recipients in everolimus- and tacrolimus-based immunosuppressive therapy.	MTOR
31255635	10.1016/j.cbi.2019.108726	2019	Tetrandrine and cepharanthine induce apoptosis through caspase cascade regulation, cell cycle arrest, MAPK activation and PI3K/Akt/mTOR signal modification in glucocorticoid resistant human leukemia Jurkat T cells.	MTOR
31258692	10.3892/etm.2019.7589	2019	Puerarin suppresses cell growth and migration in HPV-positive cervical cancer cells by inhibiting the PI3K/mTOR signaling pathway.	MTOR
31262977	10.1042/BSR20182274	2019	EPHA3 enhances macrophage autophagy and apoptosis by disrupting the mTOR signaling pathway in mice with endometriosis.	MTOR
31281438	10.3892/etm.2019.7629	2019	Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway.	MTOR
31310849	10.1016/j.fsi.2019.07.022	2019	Chlorpyrifos induced oxidative stress to promote apoptosis and autophagy through the regulation of miR-19a-AMPK axis in common carp.	MTOR
31334109	10.3389/fonc.2019.00568	2019	Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma Cells.	MTOR
31351435	10.1016/j.biopha.2019.109241	2019	Huachansu Capsule inhibits the proliferation of human gastric cancer cells via Akt/mTOR pathway.	MTOR
31391255	10.1074/jbc.RA119.009551	2019	Coordinated regulation of scaffold opening and enzymatic activity during CARD11 signaling.	MTOR
31411791	10.1111/jog.14079	2019	Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance.	MTOR
31492675	10.1182/blood.2019000015	2019	Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.	MTOR
31497243	10.18632/oncotarget.27154	2019	Walking the tightrope: UCH-L1 as an mTOR inhibitor and B-cell oncogene.	MTOR
31498006	10.1080/21691401.2019.1645151	2019	Long noncoding RNA HAGLROS promotes the process of mantle cell lymphoma by regulating miR-100/ATG5 axis and involving in PI3K/AKT/mTOR signal.	MTOR
31508518	10.1016/j.heliyon.2019.e02290	2019	Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.	MTOR
31524260	10.3892/mmr.2019.10514	2019	Complement factor H‚Äërelated 3 overexpression affects hepatocellular carcinoma proliferation and apoptosis.	MTOR
31533276	10.3390/genes10090718	2019	Allele-Specific Expression of CD4<sup>+</sup> T Cells in Response to Marek's Disease Virus Infection.	MTOR
31552092	10.3389/fgene.2019.00780	2019	Transcriptional Analysis of Lennert Lymphoma Reveals a Unique Profile and Identifies Novel Therapeutic Targets.	MTOR
31579886	10.1038/s42255-019-0098-8	2019	Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR.	MTOR
31619091	10.1080/17474086.2020.1681962	2019	Contemporary management of nodal and primary splenic marginal zone lymphoma.	MTOR
31628323	10.1038/s41467-019-12656-x	2019	A kinase-independent role for CDK8 in BCR-ABL1<sup>+</sup> leukemia.	MTOR
31638226	10.3892/mmr.2019.10756	2019	Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line.	MTOR
31679027	10.1093/jas/skz339	2019	Dietary supplementation with free methionine or methionine dipeptide improves environment intestinal of broilers challenged with Eimeria spp.	MTOR
31698306	10.1016/j.leukres.2019.106229	2019	Gene expression profiling by mRNA sequencing reveals dysregulation of core genes in Rictor deficient T-ALL mouse model.	MTOR
31827702	10.1155/2019/7989276	2019	Enhancement of Quercetin-Induced Apoptosis by Cotreatment with Autophagy Inhibitor Is Associated with Augmentation of BAK-Dependent Mitochondrial Pathway in Jurkat T Cells.	MTOR
31827726	10.18632/oncotarget.27309	2019	Correction: Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1.	MTOR
31839994	10.1038/s41420-019-0231-1	2019	A cysteine near the C-terminus of UCH-L1 is dispensable for catalytic activity but is required to promote AKT phosphorylation, eIF4F assembly, and malignant B-cell survival.	MTOR
31853198	10.2147/CMAR.S208720	2019	First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.	MTOR
31934105	NA	2019	EBV-associated myoid tumor with lipoblast-like cells in a patient with normal immunity.	MTOR
32009599	10.2174/1871520619666190925143216	2019	Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma.	MTOR
28905990	10.1002/ijc.31044	2018	The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.	MTOR
28952842	10.1080/10428194.2017.1379077	2018	Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.	MTOR
29066507	10.1158/1078-0432.CCR-17-1041	2018	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.	MTOR
29076004	10.1007/s10238-017-0478-x	2018	High mTOR expression independently prognosticates poor clinical outcome to induction chemotherapy in acute lymphoblastic leukemia.	MTOR
29077243	10.1111/cas.13431	2018	Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.	MTOR
29115419	10.3892/mmr.2017.7840	2018	Effect of Œ≤‚Äëecdysterone on glucocorticoid‚Äëinduced apoptosis and autophagy in osteoblasts.	MTOR
29115429	10.3892/mmr.2017.7868	2018	Resveratrol-mediated apoptosis in renal cell carcinoma via the p53/AMP‚Äëactivated protein kinase/mammalian target of rapamycin autophagy signaling pathway.	MTOR
29172833	10.1080/0284186X.2017.1404634	2018	A systematic review of targeted agents for non-small cell lung cancer.	MTOR
29185784	10.1089/dna.2017.3922	2018	miR-21 Inhibitors Modulate Biological Functions of Gastric Cancer Cells via PTEN/PI3K/mTOR Pathway.	MTOR
29207056	10.3892/ijmm.2017.3285	2018	Different roles of Akt and mechanistic target of rapamycin in serum‚Äëdependent chondroprotection of human osteoarthritic chondrocytes.	MTOR
29234922	10.1007/s00280-017-3499-y	2018	Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients.	MTOR
29247643	10.1016/j.cbi.2017.12.017	2018	Traditional herbal medicine-derived sulforaphene promotes mitophagic cell death in lymphoma cells through CRM1-mediated p62/SQSTM1 accumulation and AMPK activation.	MTOR
29322846	10.1080/10428194.2017.1421760	2018	PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.	MTOR
29344647	10.3892/ijmm.2018.3393	2018	Autophagy regulates the degeneration of the auditory cortex through the AMPK-mTOR-ULK1 signaling pathway.	MTOR
29355544	10.1016/j.lfs.2018.01.014	2018	Quercetin suppresses breast cancer stem cells (CD44<sup>+</sup>/CD24<sup>-</sup>) by inhibiting the PI3K/Akt/mTOR-signaling pathway.	MTOR
29360358	10.1021/acs.jmedchem.7b01465	2018	Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.	MTOR
29361117	10.1093/jnen/nlx121	2018	Discrepancy Between Low Levels of mTOR Activity and High Levels of P-S6 in Primary Central Nervous System Lymphoma May Be Explained by PAS Domain-Containing Serine/Threonine-Protein Kinase-Mediated Phosphorylation.	MTOR
29370086	10.3390/cancers10020031	2018	Cell-Penetrating CaCO‚ÇÉ Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma.	MTOR
29384404	10.1080/10428194.2018.1427855	2018	A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).	MTOR
29386059	10.1186/s13046-017-0639-5	2018	MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell lymphoma.	MTOR
29387218	10.3892/ol.2017.7341	2018	<i>Celastrus orbiculatus</i> extracts induce apoptosis and inhibit invasion by targeting the maspin gene in human gastric adenocarcinoma cells.	MTOR
29399197	10.3892/ol.2017.7451	2018	Licochalcone A inhibits PI3K/Akt/mTOR signaling pathway activation and promotes autophagy in breast cancer cells.	MTOR
29399633	10.1126/sciadv.aar5701	2018	Discrete roles and bifurcation of PTEN signaling and mTORC1-mediated anabolic metabolism underlie IL-7-driven B lymphopoiesis.	MTOR
29456744	10.3892/ol.2018.7743	2018	Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer.	MTOR
29463831	10.1038/s41598-018-21570-z	2018	Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.	MTOR
29483509	10.1038/s41467-018-03028-y	2018	Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL.	MTOR
29483777	10.2147/OTT.S149788	2018	Antitumor effect of triptolide in T-cell lymphoblastic lymphoma by inhibiting cell viability, invasion, and epithelial-mesenchymal transition via regulating the PI3K/AKT/mTOR pathway.	MTOR
29485914	10.1089/dna.2017.3874	2018	Streptozotocin-Induced Autophagy Reduces Intracellular Insulin in Insulinoma INS-1E Cells.	MTOR
29504068	10.1007/s10637-017-0552-y	2018	Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling¬†pathway.	MTOR
29505032	10.1038/nm.4505	2018	Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse.	MTOR
29515122	10.1038/s41419-018-0413-4	2018	Pan-class I¬† PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.	MTOR
29545863	10.3892/etm.2018.5830	2018	Triptolide induces autophagy and apoptosis through ERK activation in human breast cancer MCF-7 cells.	MTOR
29550382	10.1016/S2352-3026(18)30030-9	2018	Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.	MTOR
29552123	10.3892/ol.2018.7971	2018	Expression profiling analysis of autophagy-related genes in perineural invasion of cutaneous squamous cell carcinoma.	MTOR
29556265	10.3892/etm.2018.5875	2018	Advanced oxidation protein products inhibit the autophagy of renal tubular epithelial cells.	MTOR
29568883	10.3892/mmr.2018.8769	2018	Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.	MTOR
29569971	10.1080/10428194.2018.1452213	2018	Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.	MTOR
29570671	10.3390/ijms19040966	2018	St. John's Wort Regulates Proliferation and Apoptosis in MCF-7 Human Breast Cancer Cells by Inhibiting AMPK/mTOR and Activating the Mitochondrial Pathway.	MTOR
29574283	10.1016/j.biopha.2018.03.009	2018	VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-Œ∫B activity in B cell precursor-acute lymphoblastic leukemia.	MTOR
29578162	10.4103/0973-1482.172111	2018	The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells.	MTOR
29603593	10.1002/pbc.27062	2018	Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.	MTOR
29616118	10.3892/ol.2018.8089	2018	Adenosine induces intrinsic apoptosis via the PI3K/Akt/mTOR signaling pathway in human pharyngeal squamous carcinoma FaDu cells.	MTOR
29620191	10.3892/ijo.2018.4357	2018	Arsenic disulfide‚Äëinduced apoptosis and its potential mechanism in two‚Äë and three‚Äëdimensionally cultured human breast cancer MCF‚Äë7 cells.	MTOR
29658590	10.3892/or.2018.6361	2018	Cucurbitacin D impedes gastric cancer cell survival via activation of the iNOS/NO and inhibition of the Akt signalling pathway.	MTOR
29666061	10.1158/0008-5472.CAN-17-3107	2018	Deptor Is a Novel Target of Wnt/Œ≤-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.	MTOR
29667769	10.1002/jcp.26539	2018	Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.	MTOR
29710456	10.1016/j.biopha.2018.01.067	2018	Vitexin reverses the autophagy dysfunction to attenuate MCAO-induced cerebral ischemic stroke via mTOR/Ulk1 pathway.	MTOR
29716528	10.1186/s12885-018-4391-9	2018	PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways.	MTOR
29719377	10.2147/DDDT.S160557	2018	Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells.	MTOR
29731854	10.3892/ol.2018.8141	2018	Cantharidin suppresses cell growth and migration, and activates autophagy in human non-small cell lung cancer cells.	MTOR
29734016	10.1016/j.neo.2018.03.002	2018	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.	MTOR
29750888	10.33549/physiolres.933738	2018	Adiponectin enhances biological functions of vascular endothelial progenitor cells through the mTOR-STAT3 signaling pathway.	MTOR
29765528	10.18632/oncotarget.24989	2018	Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells.	MTOR
29769264	10.1182/blood-2017-11-818617	2018	RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice.	MTOR
29774105	10.18632/oncotarget.25072	2018	Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.	MTOR
29774169	10.1186/s40164-018-0103-z	2018	Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma.	MTOR
29802156	10.1042/BSR20171691	2018	Curcumin improves age-related and surgically induced osteoarthritis by promoting autophagy in mice.	MTOR
29907126	10.1186/s13045-018-0621-5	2018	NF-Œ∫B signaling and its relevance to the treatment of mantle cell lymphoma.	MTOR
29916537	10.3892/mmr.2018.9180	2018	Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats.	MTOR
29925955	10.1038/s41586-018-0290-0	2018	A multiprotein supercomplex controlling oncogenic signalling in lymphoma.	MTOR
29932870	10.1096/fj.201701386	2018	ERŒ±36 gene silencing promotes tau protein phosphorylation, inhibits cell proliferation, and induces apoptosis in human neuroblastoma SH-SY5Y cells.	MTOR
29937999	10.18632/oncotarget.25463	2018	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma.	MTOR
29946778	10.1007/978-3-319-77736-8_7	2018	Non-Hodgkin Lymphoma Metabolism.	MTOR
29949919	10.3390/ijms19071878	2018	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update.	MTOR
29950132	10.1080/15548627.2018.1466013	2018	Role of the MAPK/cJun NH<sub>2</sub>-terminal kinase signaling pathway in starvation-induced autophagy.	MTOR
29950218	10.7534/j.issn.1009-2137.2018.03.023	2018	[Effects of Silencing NSD2 Gene by shRNA on Proliferation, Apoptosis and Akt /mTOR Signal Pathway in OCI-Ly3 Cells].	MTOR
29951132	10.1186/s13148-018-0516-x	2018	Acute leukemia cells resistant to PI3K/mTOR inhibition display upregulation of P2RY14 expression.	MTOR
29956761	10.3892/mmr.2018.9220	2018	Aclidinium bromide inhibits the growth and metastasis of gastric cancer MKN‚Äë28 cells via the PI3K signaling pathway.	MTOR
29961897	10.1093/abbs/gmy070	2018	Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression.	MTOR
29987212	10.3390/ijms19071997	2018	Senescence Induces Dysfunctions in Endothelial Progenitor Cells and Osteoblasts by Interfering Translational Machinery and Bioenergetic Homeostasis.	MTOR
30002430	10.1038/s41598-018-28619-z	2018	Angelica gigas Nakai and Decursin Downregulate Myc Expression to Promote Cell Death in B-cell Lymphoma.	MTOR
30021906	10.1128/JVI.01138-18	2018	Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections.	MTOR
30025393	10.1159/000491899	2018	Function of SLC7A7 in T-Cell Acute Lymphoblastic Leukemia.	MTOR
30025915	10.1016/j.mce.2018.07.007	2018	Metformin suppresses growth and adrenocorticotrophic hormone secretion in mouse pituitary corticotroph tumor AtT20‚ÄØcells.	MTOR
30049438	10.1016/j.bbrc.2018.07.019	2018	ZKSCAN3 promotes breast cancer cell proliferation, migration and invasion.	MTOR
30066877	10.3892/mmr.2018.9321	2018	UNBS5162 inhibits proliferation of human melanoma cells by inducing apoptosis via the PI3K/Akt pathway.	MTOR
30067771	10.1371/journal.pone.0200725	2018	The phosphoinositide-3 kinase (PI3K)-Œ¥,Œ≥ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies.	MTOR
30104685	10.1038/s41598-018-30509-3	2018	Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma.	MTOR
30116377	10.3892/etm.2018.6345	2018	Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells.	MTOR
30123222	10.3389/fimmu.2018.01799	2018	Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.	MTOR
30147333	10.2147/OTT.S142264	2018	Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.	MTOR
30156609	10.1590/1414-431X20186839	2018	Knockdown of long non-coding RNA ANRIL inhibits tumorigenesis in human gastric cancer cells via microRNA-99a-mediated down-regulation of BMI1.	MTOR
30193222	10.1016/j.envpol.2018.08.070	2018	Atrazine hinders PMA-induced neutrophil extracellular traps in carp via the promotion of apoptosis and inhibition of ROS burst, autophagy and glycolysis.	MTOR
30196309	10.12659/MSM.909726	2018	Marsdenia Tenacissima Extract Inhibits Proliferation and Promotes Apoptosis in Human Ovarian Cancer Cells.	MTOR
30198340	10.1080/21691401.2018.1478844	2018	Rituximab (anti-CD20)-modified AZD-2014-encapsulated nanoparticles killing of B lymphoma cells.	MTOR
30221690	10.3892/ijmm.2018.3868	2018	Astragalus polysaccharide combined with 10-hydroxycamptothecin inhibits metastasis in non-small cell lung carcinoma cell lines via the MAP4K3/mTOR signaling pathway.	MTOR
30231317	10.1200/EDBK_200829	2018	Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.	MTOR
30257881	10.1182/blood-2018-05-848515	2018	UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice.	MTOR
30269036	10.1016/j.leukres.2018.09.009	2018	Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line.	MTOR
30279524	10.1038/s41598-018-32965-3	2018	Microgravity induces autophagy via mitochondrial dysfunction in human Hodgkin's lymphoma cells.	MTOR
30297804	10.1038/s41401-018-0161-0	2018	MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.	MTOR
30305939	10.1136/esmoopen-2018-000387	2018	BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance.	MTOR
30360879	10.1053/j.seminoncol.2018.07.005	2018	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	MTOR
30446641	10.1038/s41467-018-07215-9	2018	Cellular metabolism constrains innate immune responses in early human ontogeny.	MTOR
30450663	10.1002/jcb.28038	2018	Activation of the mammalian target of rapamycin signaling pathway underlies a novel inhibitory role of ring finger protein 182 in ventricular remodeling after myocardial ischemia-reperfusion injury.	MTOR
30524948	10.1002/2211-5463.12538	2018	Establishment and characterization of a novel vincristine-resistant diffuse large B-cell lymphoma cell line containing the 8q24 homogeneously staining region.	MTOR
30556337	10.1002/jcb.28093	2018	MEG3 affects the progression and chemoresistance of T-cell lymphoblastic lymphoma by suppressing epithelial-mesenchymal transition via the PI3K/mTOR pathway.	MTOR
30564554	10.3389/fonc.2018.00556	2018	Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies.	MTOR
30594149	10.1186/s12868-018-0482-4	2018	Rapamycin treatment increases hippocampal cell viability in an mTOR-independent manner during exposure to hypoxia mimetic, cobalt chloride.	MTOR
30680072	10.18632/oncotarget.26428	2018	Targeted therapies for advanced non-small cell lung cancer.	MTOR
27939840	10.1016/j.antiviral.2016.12.002	2017	Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation.	MTOR
28082737	10.1038/leu.2017.13	2017	Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL.	MTOR
28151717	10.1158/1078-0432.CCR-15-2869	2017	Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.	MTOR
28159681	10.1016/j.canlet.2017.01.035	2017	The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).	MTOR
28192480	10.1371/journal.pone.0170771	2017	mTOR activity in AIDS-related diffuse large B-cell lymphoma.	MTOR
28703366	10.1002/ptr.5866	2017	Synergistic Effect of TPD7 and Berberine against Leukemia Jurkat Cell Growth through Regulating Ephrin-B2 Signaling.	MTOR
28713965	10.3892/mmr.2017.6989	2017	Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.	MTOR
28724379	10.1186/s12967-017-1258-9	2017	Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.	MTOR
28731147	10.3892/mmr.2017.7064	2017	Beclin 1 overexpression inhibits chondrocyte apoptosis and downregulates extracellular matrix metabolism in osteoarthritis.	MTOR
28829592	10.1021/acs.jmedchem.7b00930	2017	5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.	MTOR
28845578	10.1111/1759-7714.12496	2017	Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review.	MTOR
28854163	10.12659/msm.906389	2017	Decreasing Eukaryotic Initiation Factor 3C (EIF3C) Suppresses Proliferation and Stimulates Apoptosis in Breast Cancer Cell Lines Through Mammalian Target of Rapamycin (mTOR) Pathway.	MTOR
28860565	10.1038/s41598-017-10684-5	2017	Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets.	MTOR
28864640	10.1158/2159-8290.CD-17-0714	2017	Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.	MTOR
28927098	10.3892/ol.2017.6587	2017	Notch 1 is a valuable therapeutic target against cell survival and proliferation in clear cell renal cell carcinoma.	MTOR
28964970	10.1016/j.cellsig.2017.09.020	2017	Metformin triggers apoptosis in PEL cells and alters bortezomib-induced Unfolded Protein Response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation.	MTOR
29046392	10.1042/BCJ20170386	2017	Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.	MTOR
29050265	10.18632/oncotarget.19592	2017	Reactive oxygen species dependent phosphorylation of the liver kinase B1/AMP activated protein kinase/ acetyl-CoA carboxylase signaling is critically involved in apoptotic effect of lambertianic acid in hepatocellular carcinoma cells.	MTOR
29061796	10.21873/anticanres.12064	2017	Differential Anticancer Activity of Pterostilbene Against Three Subtypes of Human Breast Cancer Cells.	MTOR
29070114	10.7534/j.issn.1009-2137.2017.05.020	2017	[Effects of mTOR Inhibitor Rapamycin on Burkitt's Lymphoma Cells].	MTOR
29093603	10.1055/s-0043-118907	2017	PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?	MTOR
29113237	10.3892/ol.2017.6930	2017	MicroRNA-10a suppresses breast cancer progression via PI3K/Akt/mTOR pathway.	MTOR
29156828	10.18632/oncotarget.21411	2017	The Œ≤-glucan from <i>Lentinus edodes</i> suppresses cell proliferation and promotes apoptosis in estrogen receptor positive breast cancers.	MTOR
29157834	10.1016/j.phymed.2017.09.021	2017	16-Hydroxycleroda-3, 13-dien-15, 16-olide inhibits the proliferation and induces mitochondrial-dependent apoptosis through Akt, mTOR, and MEK-ERK pathways in human renal carcinoma cells.	MTOR
29228628	10.18632/oncotarget.22178	2017	Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling.	MTOR
29234489	10.18632/genesandcancer.154	2017	Molecular insights: Suppression of EGFR and AKT activation by a small molecule in non-small cell lung cancer.	MTOR
29262896	10.7534/j.issn.1009-2137.2017.06.017	2017	[Effects of Sinomenine on Proliferation and Apoptosis of MCL Jeko-1 Cell Line and Its Mechanism].	MTOR
29311820	10.3389/fnmol.2017.00432	2017	Activation of Autophagy Contributes to Sevoflurane-Induced Neurotoxicity in Fetal Rats.	MTOR
29383130	10.18632/oncotarget.22414	2017	GSK-3Œ≤ inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents.	MTOR
29387064	10.3389/fimmu.2017.02005	2017	Epstein-Barr Virus Susceptibility in Activated PI3KŒ¥ Syndrome (APDS) Immunodeficiency.	MTOR
32300390	10.14740/jh320w	2017	Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes.	MTOR
26549638	10.3892/ijo.2015.3231	2016	PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.	MTOR
26722032	NA	2016	Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.	MTOR
26892465	10.1186/s13045-016-0241-x	2016	Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.	MTOR
26917778	10.1182/blood-2015-02-629485	2016	4EBP1/c-MYC/PUMA and NF-Œ∫B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.	MTOR
27018341	10.1002/jcb.25559	2016	Targeting the mTOR Pathway in Leukemia.	MTOR
27147575	10.18632/oncotarget.9061	2016	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.	MTOR
27235137	10.1182/blood-2016-02-700328	2016	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.	MTOR
27267853	10.1158/1078-0432.CCR-16-0609	2016	Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma.	MTOR
27473087	10.1007/s13277-016-5272-y	2016	Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.	MTOR
27693556	10.1016/j.canlet.2016.09.016	2016	Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.	MTOR
27756877	10.18632/oncotarget.12654	2016	Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.	MTOR
25729885	10.1080/15384047.2015.1019184	2015	Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking.	MTOR
25747970	10.3109/10428194.2015.1026816	2015	Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents.	MTOR
25849580	10.1186/s12964-015-0091-0	2015	Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma.	MTOR
25909227	10.18632/oncotarget.3729	2015	MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.	MTOR
25915427	10.18632/oncotarget.3802	2015	MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.	MTOR
26043155	10.1080/15548627.2015.1055439	2015	TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy.	MTOR
26362858	10.1007/s12185-015-1858-1	2015	Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.	MTOR
24970801	10.18632/oncotarget.2071	2014	Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.	MTOR
25124033	10.1074/jbc.M114.575571	2014	Degradation of Tiam1 by casein kinase 1 and the SCFŒ≤TrCP ubiquitin ligase controls the duration of mTOR-S6K signaling.	MTOR
25208880	10.1158/1078-0432.CCR-13-3172	2014	mTOR inhibitors induce cell-cycle arrest and inhibit tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells.	MTOR
25215588	10.3390/molecules190914304	2014	Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance.	MTOR
25228590	10.18632/oncotarget.2372	2014	Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.	MTOR
23573198	10.1371/journal.pone.0059335	2013	Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL).	MTOR
23693095	10.1186/1471-2407-13-250	2013	Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.	MTOR
23963361	10.1158/1535-7163.MCT-13-0239	2013	Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-Œ∫B and mTOR dual-targeting approach.	MTOR
24112608	10.1186/1471-2407-13-471	2013	Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.	MTOR
20960030	10.1007/s10637-010-9558-4	2012	Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.	MTOR
21926965	10.1038/leu.2011.248	2012	Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis.	MTOR
21943204	10.1111/j.1600-0714.2011.01083.x	2012	High mTOR expression is associated with a worse oncological outcome in laryngeal carcinoma treated with postoperative radiotherapy: a pilot study.	MTOR
21973240	10.3109/10428194.2011.628062	2012	Association of genetic variations in mTOR with risk of childhood acute lymphoblastic leukemia in a Chinese population.	MTOR
22094587	10.1038/leu.2011.322	2012	Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.	MTOR
22473959	10.1084/jem.20111470	2012	Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia.	MTOR
22895079	10.4161/cbt.21460	2012	Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.	MTOR
22899290	10.1038/modpathol.2012.141	2012	Activity and complexes of mTOR in diffuse large B-cell lymphomas--a tissue microarray study.	MTOR
22902049	10.1016/j.leukres.2012.07.016	2012	Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: a clinicopathological study.	MTOR
21277936	10.1016/j.exphem.2011.01.005	2011	Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.	MTOR
21334199	10.1016/j.ejca.2011.01.003	2011	Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001.	MTOR
21631271	10.5858/2009-0691-OA.1	2011	Uniform expression of Notch1, suppressor of B-cell-specific gene expression, in plasmablastic lymphoma.	MTOR
21861134	10.1007/s00432-011-1037-6	2011	Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway.	MTOR
20354178	10.1158/0008-5472.CAN-09-4072	2010	The antidepressant sertraline inhibits translation initiation by curtailing mammalian target of rapamycin signaling.	MTOR
18596736	10.1038/leu.2008.178	2009	Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling.	MTOR
19225536	10.1038/leu.2008.348	2009	Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.	MTOR
19293424	10.1182/blood-2008-11-191783	2009	Alcohol consumption and decreased risk of non-Hodgkin lymphoma: role of mTOR dysfunction.	MTOR
19321861	10.1182/blood-2008-09-179762	2009	A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation.	MTOR
19373664	10.1080/10428190802709446	2009	mTOR inhibition and adult T-cell leukemia.	MTOR
19489223	NA	2009	[Activation and clinicopathologic significance of AKT/mTOR signaling pathway in diffuse large B-cell lymphoma].	MTOR
19608873	10.2353/ajpath.2009.080451	2009	Activation of mTORC1 signaling pathway in AIDS-related lymphomas.	MTOR
19757306	10.3109/10428190903207548	2009	Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.	MTOR
18339899	10.1182/blood-2007-07-103481	2008	Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma.	MTOR
18704194	10.1172/JCI33337	2008	Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.	MTOR
18769147	10.4161/cc.7.18.6733	2008	GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma.	MTOR
19176054	NA	2008	[Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma].	MTOR
17110454	10.1182/blood-2006-08-042192	2007	mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets.	MTOR
17363738	10.1182/blood-2006-08-039883	2007	Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia.	MTOR
16141350	10.1182/blood-2005-06-2208	2006	Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB.	MTOR
17148679	10.2353/ajpath.2006.051078	2006	Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.	MTOR
7822316	10.1074/jbc.270.2.815	1995	Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.	MTOR
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	MYC
33779481	10.1080/01676830.2021.1904426	2022	Double-hit and triple-hit high-grade B-cell lymphoma of the ocular adnexa.	MYC
33782541	10.1038/s41401-021-00644-1	2022	SAF-248, a novel PI3KŒ¥-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.	MYC
33908607	10.1182/blood.2020007932	2022	MondoA drives malignancy in B-ALL through enhanced adaptation to metabolic stress.	MYC
34131801	10.1007/s00432-021-03691-7	2022	Aberrant expression and genetic alteration of c-MYC in anaplastic large cell lymphoma.	MYC
34162177	10.3324/haematol.2020.267096	2022	Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma.	MYC
34162179	10.3324/haematol.2021.278743	2022	Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.	MYC
34219494	10.1177/00031348211029854	2022	Burkitt Lymphoma Presenting as Perforated Appendicitis.	MYC
34289655	10.3324/haematol.2021.278638	2022	Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.	MYC
34304248	10.1038/s41375-021-01347-6	2022	Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.	MYC
34359075	10.1182/blood.2021012805	2022	Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice.	MYC
34392269	10.1097/PAS.0000000000001750	2022	Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity.	MYC
34456240	10.1097/PAI.0000000000000967	2022	Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting.	MYC
34471258	10.1038/s41416-021-01538-z	2022	Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma.	MYC
34472720	10.1002/cnr2.1545	2022	Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.	MYC
34476551	10.1007/s00259-021-05498-7	2022	Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements.	MYC
34493477	10.1016/j.clml.2021.07.017	2022	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.	MYC
34510996	10.1080/10428194.2021.1975189	2022	<i>BCL2</i> translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival.	MYC
34519021	10.1111/bjh.17815	2022	Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.	MYC
34525177	10.1182/blood.2020008374	2022	Defining and treating high-grade B-cell lymphoma, NOS.	MYC
34528662	10.1093/ajcp/aqab105	2022	MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma.	MYC
34535296	10.1016/j.pathol.2021.06.121	2022	High-grade B-cell lymphoma with concurrent expression of CD5 and cyclin D1 and MYC rearrangement.	MYC
34536035	10.1111/cup.14135	2022	Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee.	MYC
34559466	10.1111/ijlh.13709	2022	Discordant high-grade B-cell lymphoma with MYC and BCL6 rearrangements presenting as a pericardial effusion.	MYC
34601571	10.1182/blood.2021013156	2022	Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.	MYC
34608246	10.1038/s41379-021-00909-4	2022	Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge.	MYC
34612761	10.1080/10428194.2021.1986218	2022	Plasmablastic lymphomas show restricted EBV latency profile and <i>MYC</i> gene aberrations.	MYC
34617271	10.1111/bjh.17874	2022	Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.	MYC
34632715	10.1002/1878-0261.13115	2022	Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma.	MYC
34637146	10.1111/his.14585	2022	EBV<sup>+</sup> high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi-institutional study.	MYC
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	MYC
34668039	10.1007/s00262-021-03057-5	2022	CD4¬†+¬†T cells are found within endemic Burkitt lymphoma and modulate Burkitt lymphoma precursor cell viability and expression of pathogenically relevant Epstein-Barr virus genes.	MYC
34668583	10.1002/eji.202149355	2022	MALT1 protease function in regulatory T cells induces MYC activity to promote mitochondrial function and cellular expansion.	MYC
34669156	10.1007/s11684-021-0877-y	2022	Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.	MYC
34688842	10.1016/j.canlet.2021.10.022	2022	Repressing MYC by targeting BET synergizes with selective inhibition of PI3KŒ± against B cell lymphoma.	MYC
34698964	10.1007/s10637-021-01196-1	2022	FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells.	MYC
34706126	10.1111/cas.15179	2022	High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.	MYC
34711640	10.1158/2159-8290.CD-21-0551	2022	Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia.	MYC
34714908	10.1182/bloodadvances.2021005486	2022	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.	MYC
34727403	10.1111/pin.13182	2022	AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.	MYC
34727830	10.1080/10428194.2021.1998480	2022	Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma.	MYC
34728235	10.1016/j.bbamcr.2021.119168	2022	DNA damage triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and Kaposi sarcoma herpesvirus replication.	MYC
34739417	10.1097/PAS.0000000000001830	2022	Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined With Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma.	MYC
34764434	10.1038/s41379-021-00962-z	2022	BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.	MYC
34788985	10.3324/haematol.2021.279631	2022	Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing.	MYC
34842019	10.1080/10428194.2021.2008383	2022	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?	MYC
34861448	10.1016/j.wneu.2021.11.108	2022	Combined Detection of Copy Number Variations of MYCN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma.	MYC
34872752	10.1016/j.pathol.2021.09.009	2022	EBV-positive low-grade follicular lymphoma transforming to EBV-negative high-grade B-cell lymphoma with MYC and BCL2 rearrangements.	MYC
34875555	10.1016/j.leukres.2021.106769	2022	MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1).	MYC
34882582	10.1172/JCI153283	2022	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.	MYC
34903527	10.1101/gr.275911.121	2022	Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers.	MYC
34910327	10.1111/jop.13269	2022	Oral versus extra-oral plasmablastic lymphoma: A comparative analysis of 101 cases.	MYC
34951009	10.1111/bjh.17971	2022	Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.	MYC
34954522	10.1016/j.bbrc.2021.12.063	2022	The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.	MYC
34962105	10.1002/dc.24922	2022	Primary thyroid high-grade B-cell lymphoma with MYC and BCL2 rearrangements in Hashimoto's thyroiditis.	MYC
34971957	10.1016/j.bbrc.2021.12.078	2022	CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.	MYC
34975070	10.4103/aja2021114	2022	Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-Œ± from M1 macrophages and promotes proliferation of prostate stromal cells.	MYC
34980601	10.1158/1078-0432.CCR-21-2949	2022	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.	MYC
34983615	10.1186/s13046-021-02226-9	2022	SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma.	MYC
34997652	10.1111/ejh.13736	2022	Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.	MYC
35013138	10.1038/s41420-021-00622-w	2022	Knockdown of NRMT enhances sensitivity of retinoblastoma cells to cisplatin through upregulation of the CENPA/Myc/Bcl2 axis.	MYC
35019715	10.1128/jvi.01941-21	2022	Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties.	MYC
35020836	10.1182/blood.2021012077	2022	Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL.	MYC
35022408	10.1038/s41467-021-27704-8	2022	Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma.	MYC
35030628	10.1182/bloodadvances.2021005948	2022	Triple combination of BET plus PI3K and NF-Œ∫B inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma.	MYC
35031886	10.1186/s43556-021-00066-9	2022	Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma.	MYC
35036912	10.1177/2632010X211070774	2022	Rare but Potentially Fatal Presentations of Diffuse Large B-cell Lymphoma: Leukemic Phase or Hemophagocytic Syndrome in Bone Marrow.	MYC
35045798	10.1080/10428194.2021.2024821	2022	High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.	MYC
35046056	10.1158/1078-0432.CCR-21-3617	2022	First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.	MYC
35054466	10.3390/life12010073	2022	The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma.	MYC
35069971	10.1155/2022/3334522	2022	Identification of Aging-Related Genes Associated with Prognostic Value and Immune Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.	MYC
35075986	10.1080/10428194.2021.2008381	2022	RNA-binding proteins as drivers of AML and novel therapeutic targets.	MYC
35078195	10.1159/000520723	2022	The Expression of the RUVBL1 Component of the R2TP Complex Correlates with Poor Prognosis in DLBCL.	MYC
35082399	10.1038/s41417-021-00415-4	2022	CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma.	MYC
35091546	10.1038/s41420-022-00833-9	2022	Pharmacological targeting PIKfyve and tubulin as an effective treatment strategy for double-hit lymphoma.	MYC
35091678	10.1038/s41388-021-02162-0	2022	An mRNA expression-based signature for oncogene-induced replication-stress.	MYC
35114276	10.1016/j.gene.2022.146234	2022	Oncogenic Runx1-Myc axis in p53-deficient thymic lymphoma.	MYC
35123209	10.1016/j.esmoop.2021.100337	2022	Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.	MYC
35125708	10.1007/s12288-021-01427-8	2022	Comparison Between CHOP and DAEPOCH with or Without Rituximab in Adult High Grade B Cell Lymphoma, Not Otherwise Specified; A Retrospective Study From a Tertiary Cancer Hospital in South India.	MYC
35126914	10.1155/2022/2842066	2022	Targeting AraC-Resistant Acute Myeloid Leukemia by Dual Inhibition of CDK9 and Bcl-2: A Systematic Review and Meta-Analysis.	MYC
35132576	10.1007/s12519-022-00517-5	2022	ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma.	MYC
35135797	10.1136/bcr-2021-246687	2022	Burkitt lymphoma: interpreting FISH testing for <i>MYC</i> gene rearrangements.	MYC
35139388	10.1016/j.celrep.2022.110338	2022	The spliceosome component Usp39 controls B cell development by regulating immunoglobulin gene rearrangement.	MYC
35145347	10.1016/j.jsps.2021.12.009	2022	Reposition of the anti-inflammatory drug diacerein in an <i>in-vivo</i> colorectal cancer model.	MYC
35149590	10.1158/0008-5472.CAN-21-1168	2022	Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy.	MYC
35152630	10.3760/cma.j.cn112151-20210826-00604	2022	[Clinicopathological features and prognosis of high-grade B-cell lymphoma with MYC and bcl-2 and/or bcl-6 rearrangements].	MYC
35167621	10.1371/journal.pone.0263980	2022	Cryptic MYC insertions in Burkitt lymphoma: New data and a review of the literature.	MYC
35169547	10.4102/ajlm.v11i1.1355	2022	Extranodal presentation of a lymphoma with precursor B-cell phenotype and translocation t(8;14) in South Africa.	MYC
35171885	10.1097/DAD.0000000000002077	2022	A Case of CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type Secondary to Chronic Lymphedema.	MYC
35173274	10.1038/s41375-022-01516-1	2022	Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL.	MYC
35174018	10.7759/cureus.21208	2022	A Conservative Approach to the Treatment of a Rare Case of Cervical Spine Double Expressor Diffuse Large B-cell Lymphoma: A Case Report.	MYC
35183824	10.1016/j.prp.2022.153804	2022	Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma.	MYC
35185889	10.3389/fimmu.2022.797244	2022	Calcium Signaling Is Impaired in PTEN-Deficient T Cell Acute Lymphoblastic Leukemia.	MYC
35198451	10.3389/fonc.2022.834288	2022	Prognostic Value of Radiomic Features of <sup>18</sup>F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells.	MYC
35205272	10.3390/genes13020227	2022	The Role of the MYC/miR-150/MYB/ZDHHC11 Network in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.	MYC
35216159	10.3390/ijms23042044	2022	IBtkŒ± Activates the Œ≤-Catenin-Dependent Transcription of <i>MYC</i> through Ubiquitylation and Proteasomal Degradation of GSK3Œ≤ in Cancerous B Cells.	MYC
35223507	10.3389/fonc.2022.824632	2022	<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS.	MYC
35231992	10.3760/cma.j.issn.0253-2727.2022.01.009	2022	[MYC and BCL-2 protein co-expression and prognosis of patients with diffuse large B-cell lymphoma: a propensity score matching analysis].	MYC
35245453	10.1016/j.molcel.2022.02.015	2022	How to resist Notch-targeted T-leukemia therapy: Lineage- and MYC enhancer switch.	MYC
35246617	10.1038/s41388-022-02257-2	2022	Alcohol-driven metabolic reprogramming promotes development of RORŒ≥t-deficient thymic lymphoma.	MYC
35247891	10.1158/2159-8290.CD-21-1207	2022	Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma.	MYC
35255429	10.1016/j.anndiagpath.2021.151886	2022	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.	MYC
35260179	10.1186/s13046-022-02276-7	2022	A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing.	MYC
35266562	10.1002/ajh.26523	2022	Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.	MYC
35267654	10.3390/cancers14051346	2022	Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma.	MYC
35277463	10.1136/jitc-2020-002029corr1	2022	Correction: MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	MYC
35279534	10.1016/j.theriogenology.2022.02.028	2022	Ascorbic acid regulates mouse spermatogonial stem cell proliferation in a Wnt/Œ≤-catenin/ROS signaling dependent manner.	MYC
35289116	10.1002/cjp2.266	2022	CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma.	MYC
35295953	10.3389/fgene.2022.825901	2022	<i>MCTS1</i> as a Novel Prognostic Biomarker and Its Correlation With Immune Infiltrates in Breast Cancer.	MYC
35296646	10.1038/s41419-022-04684-1	2022	Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.	MYC
35297566	10.1111/pin.13223	2022	Clinicopathological analysis of follicular lymphoma with BCL2, BCL6, and MYC rearrangements.	MYC
35299080	10.1016/j.anndiagpath.2022.151913	2022	HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridisation to assess MYC gene copies.	MYC
35303910	10.1186/s13045-022-01249-9	2022	Altered pathways and targeted therapy in double hit lymphoma.	MYC
35306137	10.1016/j.cellsig.2022.110311	2022	B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells.	MYC
35309974	10.1016/j.rmcr.2022.101625	2022	A case of lung intravascular large B cell lymphoma developed with respiratory failure rescued by corticosteroid prior to definite diagnosis.	MYC
35316216	10.1172/JCI153436	2022	PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.	MYC
35321274	10.4251/wjgo.v14.i3.746	2022	Re: Association between intestinal neoplasms and celiac disease - beyond celiac disease and more.	MYC
35328502	10.3390/ijms23063079	2022	Mono a Mano: ZBP1's Love-Hate Relationship with the Kissing Virus.	MYC
35332847	10.1080/15384047.2022.2055421	2022	Cyclin-dependent kinase 7/9 inhibitor SNS-032 induces apoptosis in diffuse large B-cell lymphoma cells.	MYC
35338347	10.1038/s41417-022-00450-9	2022	SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide.	MYC
35380701	10.1158/1541-7786.MCR-21-0560	2022	T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62.	MYC
35395974	10.19746/j.cnki.issn.1009-2137.2022.02.017	2022	[Expression Level and Correlation of miR-211, miR-155, C-myc in Acute T Lymphocytic Leukemia].	MYC
35398498	10.1016/j.jep.2022.115267	2022	Isolation and characterization of anti-inflammatory and anti-proliferative compound, for B-cell Non-Hodgkin lymphoma, from Nyctanthes arbor-tristis Linn.	MYC
35411936	10.1111/bjh.18196	2022	Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1Œ± intersect to regulate angiogenesis in B-cell lymphoma.	MYC
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	MYC
35414839	NA	2022	Primary ovarian Burkitt lymphoma: report of a case and review of literature.	MYC
35429891	10.1016/j.prp.2022.153860	2022	The genetic deletion and protein expression of PRDM1 and its clinical implications in diffuse large B cell lymphoma: A retrospective cohort study in China.	MYC
35443279	10.1158/2159-8290.CD-21-1514	2022	SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis.	MYC
35444774	10.4084/MJHID.2022.018	2022	TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment.	MYC
35447911	10.3390/md20040235	2022	5-<i>O</i>-(<i>N</i>-Boc-l-Alanine)-Renieramycin T Induces Cancer Stem Cell Apoptosis via Targeting Akt Signaling.	MYC
35453482	10.3390/biomedicines10040731	2022	Targeting c-Myc Unbalances UPR towards Cell Death and Impairs DDR in Lymphoma and Multiple Myeloma Cells.	MYC
35454765	10.3390/cancers14081857	2022	Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach.	MYC
35477814	10.1007/s10637-022-01250-6	2022	Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia.	MYC
35481444	10.1080/10428194.2022.2064988	2022	Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.	MYC
35481805	10.1080/10428194.2022.2064989	2022	Homozygous iMycCŒ± transgenic mice as a model of plasma B-cell lymphomas.	MYC
35482553	10.1002/hon.3010	2022	Targeting MYC and BCL2 by a natural compound for double-hit lymphoma.	MYC
35484682	10.3324/haematol.2021.280557	2022	Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement.	MYC
35486832	10.1182/blood.2021013990	2022	Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment.	MYC
35489963	10.1016/j.blre.2022.100967	2022	ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma.	MYC
35498426	10.3389/fendo.2022.846357	2022	Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.	MYC
35503708	10.1080/10428194.2022.2064981	2022	Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL.	MYC
35503749	10.1002/eji.202249820	2022	Epstein-Barr virus and malaria upregulate AID and APOBEC3 enzymes, but only¬†AID seems to play a major mutagenic role in Burkitt lymphoma.	MYC
35510016	10.7759/cureus.23681	2022	Incidental Pathogenic Fibrin-Associated Diffuse Large B-cell Lymphoma Found During Aorto-Biiliac Bypass.	MYC
35510955	10.15252/emmm.202215816	2022	A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.	MYC
35511691	10.1093/ajcp/aqac047	2022	A Combined Biomarker of Bright CD38 and MYC ‚â•55% Is Highly Predictive of Double-/Triple-Hit High-Grade B-Cell Lymphoma.	MYC
35512442	10.1016/j.leukres.2022.106843	2022	Multiple cells of origin in common with various types of mouse N-Myc acute leukemia.	MYC
35523507	10.1136/bcr-2021-247430	2022	Epstein-Barr virus-positive mucocutaneous ulcer, plasmablastic type, associated with nodal CD4+ angioimmunoblastic T-cell lymphoma and generalised pruritus: a self-limiting lymphoproliferative disorder resembling cutaneous plasmablastic lymphoma.	MYC
35534379	10.1016/j.clml.2022.04.009	2022	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.	MYC
35538643	10.1002/cam4.4742	2022	Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.	MYC
35539018	10.1016/j.lrr.2022.100318	2022	A very rare case of extranodal B-cell non-Hodgkin lymphoma presenting with adrenal and heart involvement.	MYC
35562413	10.1038/s41379-022-01091-x	2022	Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics.	MYC
35563017	10.3390/ijms23094624	2022	Enhancer RNA AL928768.3 from the IGH Locus Regulates MYC Expression and Controls the Proliferation and Chemoresistance of Burkitt Lymphoma Cells with IGH/MYC Translocation.	MYC
35578798	10.1002/jcp.30777	2022	Neddylation inactivation affects cell cycle and apoptosis in sheep follicular granulosa cells.	MYC
35580327	10.1182/bloodadvances.2022007475	2022	Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.	MYC
35581375	10.1038/s41375-022-01590-5	2022	Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia.	MYC
35583405	10.1097/DAD.0000000000002053	2022	Histological Transformation and Clonal Relationship of Subcutaneous Marginal Zone B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma.	MYC
35591851	10.3389/fgene.2022.873840	2022	Suberoylanilide Hydroxamic Acid (SAHA) Treatment Reveals Crosstalk Among Proteome, Phosphoproteome, and Acetylome in Nasopharyngeal Carcinoma Cells.	MYC
35595618	10.1016/j.clml.2022.04.010	2022	Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA.	MYC
35605249	10.1182/bloodadvances.2022007695	2022	Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis.	MYC
35620830	10.1111/bjh.18280	2022	Favourable outcomes of double-hit/double-expressor lymphoma and high-grade B-cell lymphoma, not otherwise specified after early dose-intensive treatment and up-front autologous stem cell transplantation: a single-centre retrospective experience.	MYC
35622737	10.3390/vetsci9050209	2022	<i>IL-1R8</i> Downregulation and Concomitant <i>TLR7</i> and <i>TLR9</i> Upregulation Are Related to the Pathogenesis of Canine Diffuse Large B-Cell Lymphoma.	MYC
35650679	10.1097/PAS.0000000000001923	2022	Clinicopathologic and Molecular Characterization of Epstein-Barr Virus-positive Plasmacytoma.	MYC
35652622	10.4149/neo_2022_220318N300	2022	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry.	MYC
35657404	10.1007/s00428-022-03342-3	2022	Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.	MYC
35670760	10.1002/pbc.29804	2022	Discordance between detection of MYC rearrangement by immunohistochemistry versus fluorescent in situ hybridization in Burkitt lymphoma.	MYC
35673721	10.3760/cma.j.cn112151-20211117-00836	2022	[ALK-positive large B-cell lymphoma with EBV infection or cyclin D1 expression: a clinicopathological analysis of 3 cases].	MYC
35681778	10.3390/cancers14112799	2022	The Role of NOTCH1, GATA3, and c-MYC in T Cell Non-Hodgkin Lymphomas.	MYC
35696785	10.1016/j.biomaterials.2022.121607	2022	Double-drug loading upconversion nanoparticles for monitoring and therapy of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma.	MYC
35705274	10.2169/internalmedicine.9711-22	2022	Biclonal diffuse large B-cell lymphoma commonly characterized by partial trisomy 18q involving MALT1 and BCL2.	MYC
35708139	10.3324/haematol.2022.281226	2022	Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.	MYC
35715938	10.1002/cjp2.283	2022	Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.	MYC
35726023	10.1038/s41684-022-00998-x	2022	The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications.	MYC
35740961	10.3390/biom12060836	2022	Alternative <i>c-MYC</i> mRNA Transcripts as an Additional Tool for c-Myc2 and c-MycS Production in BL60 Tumors.	MYC
35757978	10.1002/jbt.23117	2022	l-Asparaginase synergizes with etoposide via the PI3K/Akt/mTOR pathway in Epstein-Barr virus-positive Burkitt lymphoma.	MYC
35761419	10.1186/s40164-022-00292-z	2022	Targeting metabolic reprogramming in chronic lymphocytic leukemia.	MYC
35766067	10.1684/abc.2022.1713	2022	Looking for the truth: an IGH-MYC+ lymphoid neoplasm with immature B-cell phenotype (CD34 positivity) successfully treated with Burkitt lymphoma protocol.	MYC
35774514	10.3389/fgene.2022.827840	2022	A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma.	MYC
35774848	10.1155/2022/3276925	2022	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.	MYC
35777795	NA	2022	PLAGL2 Promotes the Proliferation and Migration of Diffuse Large B-cell Lymphoma Cells via Wnt/Œ≤-catenin Pathway.	MYC
35787399	10.1016/j.jid.2022.06.005	2022	The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in Cutaneous T-Cell Lymphoma Can Be Reproduced by ŒîNp73 Depletion.	MYC
35789258	10.1182/blood.2022015674	2022	Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B cell malignancy.	MYC
35790817	10.1038/s41375-022-01626-w	2022	Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia.	MYC
35794797	10.4062/biomolther.2022.022	2022	CKD-581 Downregulates Wnt/Œ≤-Catenin Pathway by DACT3 Induction in Hematologic Malignancy.	MYC
35800829	10.7759/cureus.25547	2022	Diagnosis of Primary Hepatic Lymphoma in a 55-Year-Old Male Patient Presented With Pain in the Right Hypochondrium: A Very Rare Case.	MYC
35815807	10.1158/0008-5472.CAN-21-2454	2022	The X-Linked Helicase DDX3X Is Required for Lymphoid Differentiation and MYC-Driven Lymphomagenesis.	MYC
35829664	10.1111/bjh.18352	2022	Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.	MYC
35836517	10.21037/tcr-21-1692	2022	Effects of heavy ions (<sup>12</sup>C<sup>6+</sup>) on malignant melanoma B16F10 cells.	MYC
35846201	10.1002/jha2.310	2022	Redefining the high-grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report.	MYC
35846216	10.1002/jha2.364	2022	Primary cutaneous diffuse large B-cell lymphoma, leg type with <i>MYC/BCL2/BCL6</i> overexpression.	MYC
35847943	10.3389/fonc.2022.925666	2022	Glutor, a Glucose Transporter Inhibitor, Exerts Antineoplastic Action on Tumor Cells of Thymic Origin: Implication of Modulated Metabolism, Survival, Oxidative Stress, Mitochondrial Membrane Potential, pH Homeostasis, and Chemosensitivity.	MYC
35851125	10.19540/j.cnki.cjcmm.20220309.401	2022	[Paeoniflorin induces apoptosis and cycle arrest in B-cell acute lymphoblastic leukemia cells by inhibiting SENP1/c-Myc signaling pathway].	MYC
35866590	10.1093/hmg/ddac159	2022	The lncRNA KTN1-AS1 co-regulates a variety of Myc-target genes and enhances proliferation of Burkitt lymphoma cells.	MYC
35869021	10.1016/j.clml.2022.06.011	2022	Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.	MYC
35878052	10.18388/abp.2020_5833	2022	The clinicopathological characteristics of C-MYC protein in angioimmunoblastic T-cell lymphoma.	MYC
35879400	10.1038/s41598-022-16943-4	2022	Promising anti-leukemic effect of Zataria multiflora extract in combination with doxorubicin to combat acute lymphoblastic leukemia cells (Nalm-6) (in vitro and in silico).	MYC
35882439	10.1182/bloodadvances.2022007541	2022	Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association.	MYC
35884496	10.3390/cancers14143434	2022	Classifying Germinal Center Derived Lymphomas-Navigate a Complex Transcriptional Landscape.	MYC
35885931	10.3390/genes13071144	2022	Targeting a Novel G-Quadruplex in the <i>CARD11</i> Oncogene Promoter with Naptho(2,1-b)furan-1-ethanol,2-nitro- Requires the Nitro Group.	MYC
35897737	10.3390/ijms23158161	2022	The Pt(<i>S</i>-pr-thiosal)2 and BCL1 Leukemia Lymphoma: Antitumor Activity In Vitro and In Vivo.	MYC
35899960	10.2174/1871520622666220722105802	2022	Galbanic acid improves accumulation and toxicity of arsenic trioxide in MT-2 cells.	MYC
35900784	10.1182/blood.2022016280	2022	EBV-positive high-grade B-cell lymphoma with MYC and BCL6 rearrangements.	MYC
35911113	10.3389/fnut.2022.907386	2022	Selenium Nanoparticles Improved Intestinal Health Through Modulation of the NLRP3 Signaling Pathway.	MYC
35912172	10.3389/fonc.2022.896858	2022	Recurrent Novel <i>P2RY8/IGH</i> Translocations in B-Lymphoblastic Leukemia/Lymphoma.	MYC
35916333	10.1002/dc.25027	2022	HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.	MYC
35916644	10.1097/QAI.0000000000003069	2022	Diffuse Large B-cell Lymphoma in the public-sector of Johannesburg, South Africa, in the era of widescale Anti-retroviral therapy use.	MYC
35918411	10.1038/s41401-022-00936-0	2022	Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain.	MYC
35920412	10.1002/jbt.23185	2022	Inhibiting AKT signaling pathway with cilostazol and meloxicam synergism for suppressing K562 cells in vitro.	MYC
35921443	10.1073/pnas.2201493119	2022	Tcf-1 promotes genomic instability and T cell transformation in response to aberrant Œ≤-catenin activation.	MYC
35932211	10.1002/hon.3061	2022	Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification.	MYC
35932292	10.1002/cncr.34405	2022	Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group.	MYC
35943680	10.1007/s11596-022-2612-6	2022	PHOSPHO1 Serves as a Key Metabolism-Related Biomarker in the Tumorigenesis of Diffuse Large B-cell Lymphoma.	MYC
35945217	10.1038/s41467-022-32368-z	2022	MYC sensitises cells to apoptosis by driving energetic demand.	MYC
35952327	10.1200/JCO.22.00597	2022	Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.	MYC
35952646	10.1016/j.chom.2022.07.003	2022	Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-Œ∫B axis.	MYC
35953760	10.1631/jzus.B2200016	2022	HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.	MYC
35960849	10.1182/blood.2022016428	2022	Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T cell lymphoma.	MYC
35961968	10.1038/s41467-022-32485-9	2022	Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance.	MYC
35963941	10.1038/s41375-022-01658-2	2022	Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.	MYC
35968590	10.3760/cma.j.issn.0253-2727.2022.06.006	2022	[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review].	MYC
35969234	10.1158/2326-6066.CIR-21-0813	2022	TCR-independent metabolic reprogramming precedes lymphoma-driven changes in T-cell fate.	MYC
35975515	10.7754/Clin.Lab.2021.211028	2022	Disparity Analysis of Clinicopathologic Hallmarks between Transformed DLBCL and Primary DLBCL.	MYC
35978743	10.7759/cureus.26860	2022	Sporadic Burkitt Lymphoma of the Thoracic and Lumbar Spinal Canal in an Adult: Oncogenicity and a Literature Review.	MYC
35981367	10.19746/j.cnki.issn.1009-2137.2022.04.018	2022	[Effects of BET Bromodomain Inhibitor JQ1 on Double-Expressor Lymphoma Cell Lines and Its Mechanism].	MYC
36001789	10.46883/2022.25920970	2022	Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas.	MYC
36006771	10.1097/PAS.0000000000001957	2022	Clinicopathologic Features and Genomic Signature of De Novo CD5+ Diffuse Large B-Cell Lymphoma: A Multicenter Collaborative Study.	MYC
36012375	10.3390/ijms23169113	2022	Concomitant Inhibition of IRE1Œ±/XBP1 Axis of UPR and PARP: A Promising Therapeutic Approach against c-Myc and Gammaherpesvirus-Driven B-Cell Lymphomas.	MYC
36040107	10.1002/JLB.6MA0822-720RR	2022	Single-cell phenotypic profiling to identify a set of immune cell protein biomarkers for relapsed and refractory diffuse large B cell lymphoma: A single-center study.	MYC
36051032	10.1002/jha2.451	2022	An artificial intelligence system applied to recurrent cytogenetic aberrations and genetic progression scores predicts <i>MYC</i> rearrangements in large B-cell lymphoma.	MYC
36051037	10.1002/jha2.475	2022	B-cell receptors of EBV-negative Burkitt lymphoma bind modified isoforms of autoantigens.	MYC
36051039	10.1002/jha2.513	2022	Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement.	MYC
36051055	10.1002/jha2.457	2022	An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.	MYC
36057749	10.1007/s00428-022-03404-6	2022	Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma.	MYC
36068335	10.1038/s41388-022-02450-3	2022	Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition.	MYC
36069512	10.1080/00015458.2022.2122320	2022	Diffuse large B-cell lymphoma presenting as an inguinal hernia - case report.	MYC
36074710	10.1111/ijlh.13863	2022	Plasmablastic lymphoma: An update.	MYC
36075025	10.1182/bloodadvances.2022007849	2022	Proinflammatory microenvironment promotes lymphoma progression in mice with high megakaryocyte and TPO levels.	MYC
36081566	10.3389/fonc.2022.941347	2022	Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.	MYC
36088477	10.1038/s41379-022-01150-3	2022	Double/triple hit lymphoma in the gastrointestinal tract: clinicopathological features, PD-L1 expression and screening strategy.	MYC
32273477	10.3324/haematol.2019.243071	2021	<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma.	MYC
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	MYC
33120427	10.1182/blood.2020007193	2021	The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC.	MYC
33300153	10.1002/hon.2831	2021	Growth inhibition and suppression of the mTOR and Wnt/Œ≤-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion.	MYC
33303632	10.1074/jbc.RA120.015285	2021	A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation.	MYC
33306213	10.1002/ajh.26068	2021	First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study.	MYC
33310759	10.26508/lsa.202000794	2021	Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK-driven lymphomagenesis.	MYC
33311588	10.1038/s41416-020-01180-1	2021	A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.	MYC
33340851	10.1016/j.leukres.2020.106491	2021	Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia.	MYC
33360122	10.1016/j.cancergen.2020.12.004	2021	RNA-Based next generation sequencing complements but does not replace fluorescence in situ hybridization studies for the classification of aggressive B-Cell lymphomas.	MYC
33380460	10.1136/jclinpath-2020-207121	2021	Role of MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study.	MYC
33392349	10.22038/AOJNMB.2020.48887.1332	2021	Incremental Value of FDG PET/CT in Aggressive High Grade B Cell lymphoma with TdT Expression.	MYC
33393079	10.1111/his.14327	2021	Radiologically guided percutaneous core needle biopsy of the spleen: a reliable and safe diagnostic procedure for neoplastic and reactive conditions.	MYC
33399078	10.1016/j.esmoop.2020.100012	2021	Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.	MYC
33400146	10.1007/s11684-020-0821-6	2021	Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia.	MYC
33409483	10.1016/j.metop.2020.100075	2021	Oxidative stress-mediated induction of pulmonary oncogenes, inflammatory, and apoptotic markers following time-course exposure to ethylene glycol monomethyl ether in rats.	MYC
33411331	10.15252/embj.2020105784	2021	ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.	MYC
33416496	10.7554/eLife.60191	2021	MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor-1.	MYC
33418509	10.1016/j.ebiom.2020.103191	2021	Dnmt3b catalytic activity is critical for its tumour suppressor function in lymphomagenesis and is associated with c-Met oncogenic signalling.	MYC
33419818	10.21873/anticanres.14770	2021	Activation-Induced Cytidine Deaminase Promotes Proliferation and Enhances Chemoresistance and Migration in B-cell Lymphoma.	MYC
33430343	10.3390/cancers13020181	2021	Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent.	MYC
33441389	10.1136/jitc-2020-001660	2021	Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence.	MYC
33444684	10.1016/j.gene.2021.145421	2021	Super-enhancers for RUNX3 are required for cell proliferation in EBV-infected B cell lines.	MYC
33446671	10.1038/s41598-020-78947-2	2021	A mathematical model of tumor regression and recurrence after therapeutic oncogene inactivation.	MYC
33448716	10.1097/MPH.0000000000002051	2021	Precursor B-Cell Acute Lymphoblastic Leukemia With MYC and BCL2 Rearrangements Presenting as Extensive Extranodal Disease in an Adolescent.	MYC
33450085	10.1111/his.14336	2021	MYC status in HIV-associated plasmablastic lymphoma: dual-colour CISH, FISH and immunohistochemistry.	MYC
33480087	10.1002/hon.2839	2021	High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup.	MYC
33480830	10.1080/10428194.2020.1869965	2021	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy.	MYC
33494394	10.3390/cancers13030396	2021	Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma.	MYC
33509883	10.1136/bcr-2020-239014	2021	Extranodal blastoid/pleomorphic variant of mantle cell lymphoma involving the testis and skin.	MYC
33512431	10.1182/blood.2020007452	2021	Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.	MYC
33514657	10.1158/1541-7786.MCR-20-0738	2021	Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells.	MYC
33521119	10.12998/wjcc.v9.i2.482	2021	Double-hit lymphoma (rearrangements of MYC, BCL-2) during pregnancy: A case report.	MYC
33524501	10.1016/j.canlet.2021.01.022	2021	Interleukin-10 counteracts T-helper type 1 responses in B-cell lymphoma and is a target for tumor immunotherapy.	MYC
33528622	10.1007/s00428-021-03022-8	2021	Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.	MYC
33530253	10.1097/MD.0000000000024449	2021	Prognostic value of lymphocyte-to-monocyte ratio and histone methyltransferase G9a histone methyltransferase in patients with double expression lymphoma: A retrospective observational study.	MYC
33537096	10.7150/thno.53561	2021	Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.	MYC
33538798	10.1182/blood.2020005734	2021	Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.	MYC
33548250	10.1016/j.humpath.2021.01.006	2021	Double expressor and double/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes.	MYC
33551436	10.3960/jslrt.20043	2021	DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.	MYC
33562682	10.3390/cancers13040639	2021	NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy.	MYC
33566253	10.1007/s10637-021-01079-5	2021	Histone deacetylase inhibitor chidamide regulates the Wnt/Œ≤-catenin pathway by MYCN/DKK3 in B-ALL.	MYC
33572152	10.3390/cancers13040694	2021	Dual Targeting Oncoproteins MYC and HIF1Œ± Regresses Tumor Growth of Lung Cancer and Lymphoma.	MYC
33591648	10.1002/brb3.2061	2021	New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL).	MYC
33610538	10.1016/j.oooo.2020.11.005	2021	Oral and oropharyngeal diffuse large B-cell lymphoma and high-grade B-cell lymphoma: A clinicopathologic and prognostic study of 69 cases.	MYC
33615197	10.1016/j.isci.2021.102089	2021	Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways.	MYC
33619116	10.1158/0008-5472.CAN-20-2297	2021	NPM-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation.	MYC
33619557	10.1182/blood.2020009564	2021	EBF1 and PAX5 control pro-B cell expansion via opposing regulation of the Myc gene.	MYC
33636392	10.1016/j.jmoldx.2021.02.005	2021	Validation of the Double-Hit Gene Expression Signature (DLBCL90) in an Independent Cohort of Patients with Diffuse Large B-Cell Lymphoma of Germinal Center Origin.	MYC
33637566	10.1158/0008-5472.CAN-20-3351	2021	Activated ALK Cooperates with N-Myc via Wnt/Œ≤-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.	MYC
33651821	10.1371/journal.pone.0247394	2021	IL-6 promotes MYC-induced B cell lymphomagenesis independent of STAT3.	MYC
33654205	10.1038/s41375-021-01181-w	2021	BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.	MYC
33655392	10.1007/s00428-021-03050-4	2021	The Burkitt-like immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.	MYC
33657257	10.1111/pin.13085	2021	Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.	MYC
33660007	10.1007/s00432-021-03580-z	2021	Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation.	MYC
33661537	10.1002/ajh.26151	2021	2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.	MYC
33664809	10.3892/ol.2021.12506	2021	Upregulation of fatty acid synthase in MYC and BCL-2 double-expressor lymphoma.	MYC
33668434	10.3390/molecules26040987	2021	Anti-Cancer Properties of Theaflavins.	MYC
33670870	10.3390/cancers13051002	2021	Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling.	MYC
33672644	10.3390/cancers13040887	2021	Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements.	MYC
33683983	10.1177/1093526621999022	2021	EBV-Positive Plasmacytomas Involving a Nasopharyngeal Angiofibroma in an Adolescent.	MYC
33685720	10.1016/j.pathol.2021.01.002	2021	New developments in non-Hodgkin lymphoid malignancies.	MYC
33689920	10.1016/j.leukres.2021.106552	2021	Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.	MYC
33692924	10.7759/cureus.13155	2021	Double-Expressor Phenotype (BCL-2/c-MYC Co-expression) of Diffuse Large B-Cell Lymphoma and Its Clinicopathological Correlation.	MYC
33717748	10.7759/cureus.13209	2021	CD30-Positive Anaplastic Variant of Diffuse Large B-cell Lymphoma: Frequency and Association With Clinicopathological Parameters.	MYC
33728138	10.7759/cureus.13120	2021	Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma.	MYC
33732356	10.3892/ol.2021.12541	2021	Triptolide inhibits human telomerase reverse transcriptase by downregulating translation factors SP1 and c-Myc in Epstein-Barr virus-positive B lymphocytes.	MYC
33754004	10.7150/jca.52958	2021	R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with <i>MYC</i> rearrangement or double expression of <i>MYC</i> and <i>BCL-2</i>.	MYC
33763601	10.1515/med-2021-0246	2021	Burkitt-like lymphoma with 11q aberration in a patient with AIDS and a patient without AIDS: Two cases reports and literature review.	MYC
33768318	10.1007/s00428-021-03084-8	2021	High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.	MYC
33771538	10.1016/j.humpath.2021.03.006	2021	MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.	MYC
33774953	NA	2021	Frequency Of Double Expressor Lymphoma In A Tertiary Care Hospital.	MYC
33775465	10.1016/j.blre.2021.100824	2021	Revisiting Richter transformation in the era of novel CLL agents.	MYC
33777762	10.3389/fonc.2021.618908	2021	CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With <i>MYC</i> and <i>BCL2</i> Rearrangements.	MYC
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	MYC
33786583	10.1182/blood.2020010187	2021	Synergistic efficacy of the dual PI3K-Œ¥/Œ≥ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models.	MYC
33799592	10.3390/ijms22062841	2021	Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer.	MYC
33801599	10.3390/ijms22073458	2021	Gene Transactivation and Transrepression in MYC-Driven Cancers.	MYC
33807449	10.3390/cancers13071620	2021	High-Grade B-Cell Lymphoma (HGBL) with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan.	MYC
33809641	10.3390/cancers13061340	2021	Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms.	MYC
33811533	10.1007/s00428-021-03091-9	2021	Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas.	MYC
33812418	10.19746/j.cnki.issn.1009-2137.2021.02.027	2021	[Effects of Emodin Derivative on Cell Cycle, Apoptosis and NF-Œ∫B Pathway in Burkitt Lymphoma Cells].	MYC
33812419	10.19746/j.cnki.issn.1009-2137.2021.02.028	2021	[Up-Regulation of Bax/BCL-2 Ratio by 2-Methoxyestradiol Induces Apoptosis in Lymphoma Raji Cells].	MYC
33816589	10.3389/fvets.2021.647009	2021	Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma.	MYC
33827367	10.1080/10428194.2021.1907375	2021	Is acute lymphoblastic leukemia with mature B-cell phenotype and <i>KMT2A</i> rearrangements a new entity? A systematic review and meta-analysis.	MYC
33852185	10.1002/ardp.202000450	2021	Design, synthesis, and antiproliferative effect of 2,9-bis[4-(pyridinylalkylaminomethyl)phenyl]-1,10-phenanthroline derivatives on human leukemic cells by targeting G-quadruplex.	MYC
33858042	10.3760/cma.j.issn.0253-2727.2021.02.006	2021	[The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma].	MYC
33863812	10.1158/1541-7786.MCR-20-0791	2021	CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors.	MYC
33870741	10.1177/00220345211007855	2021	Role of Mechanotransduction in Periodontal Homeostasis and Disease.	MYC
33879463	10.1136/bcr-2020-240925	2021	Early-stage Burkitt lymphoma remained in remission 7 years from diagnosis after only one cycle of chemoimmunotherapy.	MYC
33884195	10.3892/br.2021.1428	2021	Regulation of gene transcription of B lymphoma Mo-MLV insertion region 1 homolog (Review).	MYC
33893987	10.1007/s12185-021-03145-3	2021	Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era.	MYC
33894159	10.1016/j.ab.2021.114206	2021	Uncovering metabolic reservoir cycles in MYC-transformed lymphoma B cells using stable isotope resolved metabolomics.	MYC
33895809	10.1182/blood.2020010144	2021	Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.	MYC
33899787	10.1097/PAS.0000000000001691	2021	The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.	MYC
33900450	10.1007/s00277-021-04535-7	2021	Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.	MYC
33904352	10.1080/10428194.2021.1919663	2021	Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype, <i>TP53</i> deletion, and <i>TP53</i> mutations.	MYC
33912162	10.3389/fimmu.2021.634584	2021	The E¬µ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies.	MYC
33921029	10.3390/cancers13081907	2021	Minimal Disease Monitoring in Pediatric Non-Hodgkin's Lymphoma: Current Clinical Application and Future Challenges.	MYC
33930347	10.1016/j.bcp.2021.114576	2021	Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis.	MYC
33942298	10.1111/bjh.17255	2021	A novel MYC-non-IG fusion in refractory diffuse large B-cell lymphoma.	MYC
33951889	10.3324/haematol.2020.271957	2021	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.	MYC
33964277	10.1016/j.humpath.2021.04.014	2021	Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma.	MYC
33980611	10.1158/1541-7786.MCR-21-0267	2021	EGR1 Addiction in Diffuse Large B-cell Lymphoma.	MYC
33982372	10.1002/gcc.22971	2021	Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias.	MYC
33988072	10.1080/10428194.2021.1927020	2021	Low LIM-domain only 2 (LMO2) expression in aggressive B cell lymphoma correlates with <i>MYC</i> and <i>MYC</i>/<i>BCL2</i> rearrangements, especially in germinal center cell-type tumors.	MYC
33994432	10.3960/jslrt.21001	2021	Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2<sup>V617F</sup>-myeloproliferative neoplasm.	MYC
34007370	10.14740/jh818	2021	<i>MYC</i>-Positive Diffuse Large B-Cell Lymphoma in Leukemic Phase at Presentation: A Diagnostic and Therapeutic Challenge.	MYC
34017010	10.1038/s41597-021-00915-w	2021	DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set.	MYC
34019298	10.1007/978-1-0716-1476-1_16	2021	Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia.	MYC
34051685	10.1016/j.ejrad.2021.109784	2021	Differentiation between primary CNS lymphoma and atypical glioblastoma according to major genomic alterations using diffusion and susceptibility-weighted MR imaging.	MYC
34058070	10.1002/1878-0261.13033	2021	NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.	MYC
34059753	10.1038/s41598-021-90596-7	2021	Association of killer cell immunoglobulin-like receptors with endemic Burkitt lymphoma in Kenyan children.	MYC
34078046	10.3760/cma.j.cn112151-20201223-00953	2021	[Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma].	MYC
34078047	10.3760/cma.j.cn112151-20210204-00127	2021	[Clinicopathological and molecular genetic features of Burkitt-like lymphoma with 11q aberration].	MYC
34078654	10.1136/jitc-2020-002029	2021	MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	MYC
34079590	10.3892/ol.2021.12792	2021	MCTS1 promotes the development of lung adenocarcinoma by regulating E2F1 expression.	MYC
34088288	10.1186/s12906-021-03315-0	2021	Matrine suppresses cell growth of diffuse large B-cell lymphoma via inhibiting CaMKIIŒ≥/c-Myc/CDK6 signaling pathway.	MYC
34091974	10.1111/jop.13209	2021	Burkitt lymphoma of the head and neck: An international collaborative study.	MYC
34097157	10.1007/s11864-021-00857-w	2021	Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma.	MYC
34099699	10.1038/s41467-021-23695-8	2021	Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing.	MYC
34101913	10.1111/jop.13208	2021	Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: A systematic review with meta-analysis.	MYC
34105464	10.19746/j.cnki.issn.1009-2137.2021.03.012	2021	[Analysis of the Predictive Value of EZH2 Expression Level on the Clinical Efficacy and Long-term Prognosis of Patients with Primary Gastrointestinal Diffuse Large B-cell Lymphoma].	MYC
34105893	10.1002/cam4.4062	2021	Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.	MYC
34113336	10.3389/fimmu.2021.599493	2021	<i>PiggyBac</i>-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.	MYC
34114734	10.1111/jcmm.16554	2021	Loss of MYSM1 inhibits the oncogenic activity of cMYC in B cell lymphoma.	MYC
34115544	10.1200/JCO.21.00086	2021	Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).	MYC
34123811	10.3389/fonc.2021.656219	2021	Case Report: Concurrent Occurrence of Abdominal Double Expressor Lymphoma and Jejunum Follicular Lymphoma.	MYC
34137847	10.1182/blood.2020010620	2021	Blocking RiBi to suppress MYC lymphomagenesis.	MYC
34151703	10.1080/10428194.2021.1941929	2021	Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK‚Äâ+‚ÄâLBCL): a systematic review of clinicopathological features and management.	MYC
34155628	10.1111/bjh.17550	2021	Adverse outcome in follicular lymphoma is associated with MYC rearrangements but not MYC extra copies.	MYC
34162911	10.1038/s41598-021-92448-w	2021	Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia.	MYC
34165048	10.1080/10428194.2021.1907374	2021	Molecular characterization of Burkitt lymphoma in the breast or ovary.	MYC
34171161	10.1111/pin.13131	2021	Fluorescent nanoparticle-mediated semiquantitative MYC protein expression analysis in morphologically diffuse large B-cell lymphoma.	MYC
34176698	10.1053/j.semdp.2021.06.005	2021	NUT carcinoma of the lung.	MYC
34204385	10.3390/cancers13123032	2021	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing.	MYC
34221962	10.3389/fonc.2021.638154	2021	Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.	MYC
34223928	10.1007/s00109-021-02101-2	2021	CARMA1 is required for Notch1-induced NF-Œ∫B activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia.	MYC
34229208	10.1016/j.tranon.2021.101170	2021	Immune checkpoint blockade impairs immunosuppressive mechanisms of regulatory T cells in B-cell lymphoma.	MYC
34232987	10.1182/blood.2021011079	2021	CYB561A3 is the key lysosomal iron reductase required for Burkitt B-cell growth and survival.	MYC
34252226	10.1111/cas.15061	2021	Bromodomain-containing protein 4 inhibitor JQ1 promotes melanoma cell apoptosis by regulating mitochondrial dynamics.	MYC
34255748	10.1172/JCI143119	2021	Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia.	MYC
34256839	10.1186/s40164-021-00232-3	2021	Progress in molecular feature of smoldering mantle cell lymphoma.	MYC
34263697	10.1080/10428194.2021.1948030	2021	Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).	MYC
34266887	10.1101/gad.348319.121	2021	Transient genomic instability drives tumorigenesis through accelerated clonal evolution.	MYC
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	MYC
34277639	10.3389/fcell.2021.693706	2021	HIV-1 Transactivator of Transcription (Tat) Co-operates With AP-1 Factors to Enhance <i>c-MYC</i> Transcription.	MYC
34280172	10.1097/CCO.0000000000000765	2021	Targeting SUMOylation in cancer.	MYC
34280258	10.1182/blood.2021011787	2021	BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway.	MYC
34280359	10.1016/j.abb.2021.108998	2021	GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/Œ≤-catenin signaling pathway.	MYC
34282799	10.3390/cancers13133369	2021	The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.	MYC
34283887	10.1182/blood.2021011711	2021	Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes.	MYC
34284686	10.1080/10428194.2021.1953010	2021	CD5+ diffuse large B-cell lymphoma: a narrative review.	MYC
34287231	10.3390/cimb43020041	2021	Identification and Characterization of Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma Using the SORE6 Reporter.	MYC
34297745	10.1371/journal.ppat.1009764	2021	Inhibition of polo-like kinase 1 (PLK1) facilitates reactivation of gamma-herpesviruses and their elimination.	MYC
34299194	10.3390/ijms22147576	2021	Expression of RUNX1-JAK2 in Human Induced Pluripotent Stem Cell-Derived Hematopoietic Cells Activates the JAK-STAT and MYC Pathways.	MYC
34303663	10.1016/j.ejphar.2021.174373	2021	The antipsychotic drug pimozide is effective against human T-cell leukemia virus type 1-infected T cells.	MYC
34307232	10.4322/acr.2021.278	2021	De novo double-hit B-cell precursor leukemia/lymphoma - an unusual presentation as peritoneal lymphomatosis.	MYC
34318932	10.1111/bjh.17734	2021	MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.	MYC
34330316	10.1186/s13023-021-01972-5	2021	Mature B cell acute lymphoblastic leukaemia with KMT2A-MLLT3 transcripts in children: three case reports and literature reviews.	MYC
34333327	10.1016/j.phymed.2021.153674	2021	Physciosporin suppresses mitochondrial respiration, aerobic glycolysis, and tumorigenesis in breast cancer.	MYC
34334687	10.1097/PAS.0000000000001726	2021	High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B.	MYC
34339901	10.1016/j.clineuro.2021.106838	2021	MYC, BCL2, and BCL6 expression as prognostic indicators in primary central nervous system lymphoma: A systematic review and meta-analysis.	MYC
34341990	10.1111/bjh.17730	2021	Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.	MYC
34347909	10.1002/hon.2902	2021	Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis.	MYC
34354779	10.1016/j.jccase.2020.12.010	2021	Complete remission from post-heart transplant lymphoproliferative disorder: A case report.	MYC
34362497	10.19746/j.cnki.issn.1009-2137.2021.04.022	2021	[Clinical Efficacy of Autologous Hematopoietic Stem Cell Transplantation for Patients with Diffuse Large B-Cell Lymphoma].	MYC
34362532	10.19746/j.cnki.issn.1009-2137.2021.04.057	2021	[Research Advances in the Mechanisms of BRD4 and Its Inhibitors in Hematologic Malignancies--Review].	MYC
34363012	10.1038/s41375-021-01376-1	2021	CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.	MYC
34374220	10.1002/cjp2.223	2021	c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.	MYC
34380369	10.1080/10428194.2021.1964021	2021	Whole genome sequencing demonstrates substantial pathophysiological differences of <i>MYC</i> rearrangements in patients with plasma cell myeloma and B-cell lymphoma.	MYC
34384155	10.3760/cma.j.issn.0253-2727.2021.06.008	2021	[Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].	MYC
34388250	10.1093/jnen/nlab080	2021	Expression of STAT6 and Phosphorylated STAT6 in Primary Central Nervous System Lymphomas.	MYC
34396983	10.1172/JCI151295	2021	All in for nuclear PFKP-induced CXCR4 metastasis: a T cell acute lymphoblastic leukemia prognostic marker.	MYC
34399819	10.1186/s40170-021-00263-8	2021	Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies.	MYC
34404436	10.1186/s13027-021-00396-x	2021	Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China.	MYC
34405615	10.3760/cma.j.cn112151-20201207-00908	2021	[Translocations of MYC, bcl-2 and bcl-6 genes and Epstein-Barr virus infection in primary cardiac large B-cell lymphoma].	MYC
34407842	10.1186/s13046-021-02071-w	2021	SIRT1 regulates the phosphorylation and degradation of P27 by deacetylating CDK2 to promote T-cell acute lymphoblastic leukemia progression.	MYC
34412631	10.1186/s12935-021-02143-z	2021	Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-Œ∫B-related signaling.	MYC
34419613	10.1016/j.micpath.2021.105153	2021	Identification of joint gene players implicated in the pathogenesis of HTLV-1 and BLV through a comprehensive system biology analysis.	MYC
34424958	10.1182/blood.2021012052	2021	Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior.	MYC
34430143	10.7759/cureus.16534	2021	Clinicopathological and Immunohistochemical Profile of Mantle Cell Lymphoma: An Institutional Experience.	MYC
34437837	10.1016/j.molcel.2021.07.041	2021	Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis.	MYC
34438040	10.1016/j.annonc.2021.08.1991	2021	SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status.	MYC
34440920	10.3390/cells10082151	2021	Inhibition of STAT3/PD-L1 and Activation of miR193a-5p Are Critically Involved in Apoptotic Effect of Compound K in Prostate Cancer Cells.	MYC
34455369	10.1016/j.bbrc.2021.08.051	2021	Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.	MYC
34456919	10.3389/fimmu.2021.710711	2021	Mouse Models of Germinal Center Derived B-Cell Lymphomas.	MYC
34465776	10.1038/s41467-021-25405-w	2021	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma.	MYC
34477080	NA	2021	Indurated Plaques on the Legs: Think Lymphoma.	MYC
34479963	10.1158/0008-5472.CAN-21-2734	2021	Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.	MYC
34500469	10.1182/bloodadvances.2021004635	2021	Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma.	MYC
34511544	10.3960/jslrt.20025	2021	Increased MYC expression without MYC gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders.	MYC
34521752	10.1073/pnas.2105440118	2021	DNA damage-induced phosphorylation of CtIP at a conserved ATM/ATR site T855 promotes lymphomagenesis in mice.	MYC
34528238	10.1111/bjh.17729	2021	Quadruple-hit pleomorphic mantle cell lymphoma with MYC, BCL2, BCL6, and CCND1 gene rearrangements.	MYC
34534532	10.1016/j.ejphar.2021.174505	2021	7-[[(4-methyl-2-pyridinyl)amino](2-pyridinyl)methyl]-8-quinolinol (compound 30666) inhibits enhancer activity and reduces B-cell lymphoma growth - A question of specificity.	MYC
34535769	10.1038/s41388-021-02012-z	2021	Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia.	MYC
34551904	10.1158/1078-0432.CCR-21-1067	2021	Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma.	MYC
34557659	10.1016/j.isci.2021.102931	2021	The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma.	MYC
34559254	10.1007/s00018-021-03940-5	2021	Assessing eukaryotic initiation factor 4F subunit essentiality by CRISPR-induced gene ablation in the mouse.	MYC
34572031	10.3390/cells10092382	2021	The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity.	MYC
34581757	10.1182/bloodadvances.2021004619	2021	Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.	MYC
34584457	10.2147/CMAR.S317319	2021	Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma.	MYC
34588837	10.2147/BLCTT.S330008	2021	Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission.	MYC
34588860	10.1016/j.sjbs.2021.08.020	2021	Characterization and phytochemical constituents of Periploca hydaspidis Falc crude extract and its anticancer activities.	MYC
34601505	10.1038/s41388-021-02031-w	2021	USP29 coordinates MYC and HIF1Œ± stabilization to promote tumor metabolism and progression.	MYC
34603598	10.1155/2021/5529518	2021	One-Two Punch Therapy for the Treatment of T-Cell Malignancies Involving p53-Dependent Cellular Senescence.	MYC
34624215	10.1016/j.molcel.2021.09.009	2021	Sex, life, and death in MYC-driven lymphomagenesis.	MYC
34625423	10.1158/0008-5472.CAN-21-1023	2021	Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.	MYC
34625792	10.1182/bloodadvances.2021005682	2021	Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.	MYC
34627430	10.19746/j.cnki.issn.1009-2137.2021.05.019	2021	[Clinical Characteristics and Prognosis Affecting-Factors of the Patients with Burkitt Lymphoma].	MYC
34630126	10.3389/fphar.2021.759267	2021	LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis.	MYC
34638508	10.3390/cancers13195024	2021	RAS Mediates BET Inhibitor-Endued Repression of Lymphoma Migration and Prognosticates a Novel Proteomics-Based Subgroup of DLBCL through Its Negative Regulator IQGAP3.	MYC
34638774	10.3390/ijms221910433	2021	Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments.	MYC
34651869	10.1002/hon.2933	2021	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.	MYC
34671837	10.1007/s00292-021-01011-x	2021	[Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].	MYC
34679437	10.3390/diagnostics11101739	2021	Dysregulation of miRNAs in DLBCL: Causative Factor for Pathogenesis, Diagnosis and Prognosis.	MYC
34680290	10.3390/cancers13205141	2021	Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents.	MYC
34698437	10.1111/jcmm.16999	2021	Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma.	MYC
34706861	10.1136/bjophthalmol-2021-319580	2021	Prevalence and prognostic value of <i>MYD88</i> and <i>CD79B</i> mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.	MYC
34707037	10.3960/jslrt.21025	2021	t(9;14)(p13;q32)/PAX5-IGH translocation as a secondary cytogenetic abnormality in diffuse large B-cell lymphoma.	MYC
34732441	10.21873/anticanres.15384	2021	Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell Lymphoma.	MYC
34742294	10.1186/s13000-021-01163-7	2021	Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers.	MYC
34748616	10.1371/journal.ppat.1010045	2021	ŒîNp63Œ± promotes Epstein-Barr virus latency in undifferentiated epithelial cells.	MYC
34757246	10.1016/j.cancergen.2021.10.006	2021	A new dual translocation of chromosome 14 in a pediatric Burkitt lymphoma/leukemia patient: t(8;14) and t(14;15).	MYC
34763718	10.1186/s13046-021-02159-3	2021	ASB2 is a direct target of FLI1 that sustains NF-Œ∫B pathway activation in germinal center-derived diffuse large B-cell lymphoma.	MYC
34782660	10.1038/s41598-021-01693-6	2021	Primary central nervous system lymphomas express immunohistochemical factors of autophagy.	MYC
34785569	10.1136/lupus-2021-000561	2021	Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases.	MYC
34804437	10.4084/MJHID.2021.063	2021	Treatment Outcomes and Clinical Relevance in Patients with Double Expressor DLBCL.	MYC
34804942	10.3389/fonc.2021.754180	2021	Development and Validation of a Novel Prognostic Nomogram for CD5-Positive Diffuse Large B-Cell Lymphoma: A Retrospective Multicenter Study in China.	MYC
34806851	10.20892/j.issn.2095-3941.2021.0193	2021	Prognostic value of <i>BCL2</i> and <i>TP53</i> genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP.	MYC
34819491	10.1038/s41408-021-00578-1	2021	MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma.	MYC
34821060	10.1002/cam4.4394	2021	Development of a novel cell line-derived xenograft model of primary herpesvirus 8-unrelated effusion large B-cell lymphoma and antitumor activity of birabresib in vitro and in vivo.	MYC
34821091	10.12047/j.cjap.6159.2021.095	2021	[Effects of miR-155-3p on the degradation rate of EAF1 mRNA and malignant proliferation in HANK1 cells].	MYC
34830747	10.3390/cancers13225592	2021	Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era.	MYC
34837933	10.31557/APJCP.2021.22.11.3723	2021	Investigation the Cytotoxicity of 5-AZA on Acute Lymphoblastic Leukemia Cell Line In Vitro and Characterization the Underlying Molecular Mechanisms of Cell Death and Motility.	MYC
34857874	10.1038/s42003-021-02853-0	2021	KSHV transactivator-derived small peptide traps coactivators to attenuate MYC and inhibits leukemia and lymphoma cell growth.	MYC
34858727	10.1080/2162402X.2021.2003533	2021	Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma.	MYC
34868769	10.7759/cureus.19130	2021	Adult Nodal Burkitt Lymphoma Forming Nodular Architectures.	MYC
34885010	10.3390/cancers13235900	2021	CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL.	MYC
34885204	10.3390/cancers13236093	2021	Differential Transcriptional Reprogramming by Wild Type and Lymphoma-Associated Mutant MYC Proteins as B-Cells Convert to a Lymphoma Phenotype.	MYC
34888589	10.21037/aol-21-18	2021	Reframing Burkitt lymphoma: virology not epidemiology defines clinical variants.	MYC
34889402	10.1182/hematology.2021000247	2021	Double-hit lymphoma: optimizing therapy.	MYC
34893113	10.19746/j.cnki.issn.1009-2137.2021.06.018	2021	[The Effect of Bcl-6 Expression on the Prognosis of Newly Treated Double-Expressing Lymphoma Treated with R-CHOP Regimen].	MYC
34898570	10.3390/curroncol28060393	2021	Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-Center Experience with 87 Patients.	MYC
34907175	10.1038/s41467-021-27197-5	2021	Interleukin-7 receptor Œ± mutational activation can initiate precursor B-cell acute lymphoblastic leukemia.	MYC
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	MYC
34945004	10.3390/cancers13246384	2021	Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel.	MYC
34956871	10.3389/fonc.2021.746577	2021	Clinical Features and Prognostic Significance of <i>NOTCH1</i> Mutations in Diffuse Large B-Cell Lymphoma.	MYC
34967583	10.31557/APJCP.2021.22.12.4011	2021	Association between c-Myc Expression with Clinicopathological Features in T And NK Cell Lymphomas.	MYC
35004320	10.3389/fonc.2021.795330	2021	Case Report: Phenotypic Switch in High-Grade B-Cell Lymphoma With <i>MYC</i> and <i>BCL6</i> Rearrangements: A Potential Mechanism of Therapeutic Resistance in Lymphoma?	MYC
35008547	10.3390/ijms23010122	2021	Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform.	MYC
35045655	10.3760/cma.j.issn.0253-2727.2021.11.008	2021	[Effects of L-asparaginase on proliferation, cell cycle and apoptosis of Burkitt lymphoma cell lines].	MYC
35116484	10.21037/tcr-20-2748	2021	Double hit B-lymphoblastic lymphoma with concurrent <i>IGH</i>/<i>BCL2</i> and 8q24/<i>MYC</i> translocations: a case report.	MYC
35432798	10.22038/IJBMS.2021.58633.13025	2021	Combination of auraptene and arsenic trioxide induces apoptosis and cellular accumulation in the subG1 phase in adult T-cell leukemia cells.	MYC
35582389	10.20517/cdr.2021.55	2021	MYC inhibitors in multiple myeloma.	MYC
31348551	10.1111/his.13959	2020	High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma.	MYC
31399522	10.3324/haematol.2019.223891	2020	An increase in <i>MYC</i> copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens.	MYC
31462708	10.1038/s41388-019-0973-5	2020	ALK<sup>ATI</sup> interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma.	MYC
31706988	10.1016/j.yexmp.2019.104326	2020	CD5<sup>+</sup>MYC<sup>+</sup> predicts worse prognosis in diffuse large B-cell lymphoma.	MYC
31776900	10.1007/s11060-019-03348-z	2020	cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.	MYC
31844144	10.1038/s41375-019-0691-6	2020	Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.	MYC
31932576	10.1038/s41408-019-0271-z	2020	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?	MYC
31991488	10.1111/apm.13029	2020	EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.	MYC
32011831	10.17219/acem/112608	2020	Analysis of the rRNA methylation complex components in pediatric B-cell precursor acute lymphoblastic leukemia: A pilot study.	MYC
32074595	10.1159/000505892	2020	The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.	MYC
32101329	10.1002/hon.2727	2020	Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.	MYC
32101699	10.1016/j.chembiol.2020.02.002	2020	MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome.	MYC
32334477	10.31557/APJCP.2020.21.4.1103	2020	The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.	MYC
32350066	10.1158/0008-5472.CAN-19-2247	2020	FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells.	MYC
32373977	10.26355/eurrev_202004_21021	2020	Association between C-myc and K-ras gene polymorphisms and non-Hodgkin lymphoma.	MYC
32391636	10.1111/jcmm.15322	2020	Molecular mechanism of c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma.	MYC
32420596	10.1042/CS20200032	2020	Deregulation of miRNAs-cMYC circuits is a key event in refractory celiac disease type-2 lymphomagenesis.	MYC
32432756	10.26355/eurrev_202005_21182	2020	GPAA1 promotes progression of childhood acute lymphoblastic leukemia through regulating c-myc.	MYC
32497402	10.1002/cyto.b.21887	2020	Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.	MYC
32503978	10.1038/s41467-020-16447-7	2020	MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies.	MYC
32549409	10.3390/ijms21124265	2020	Insights about MYC and Apoptosis in B-Lymphomagenesis: An Update from Murine Models.	MYC
32566654	10.1155/2020/1350820	2020	Prognostic Value of Concurrent Expression of C-MYC and BCL2 in Intravascular Large B-Cell Lymphoma: A 10-Year Retrospective Study.	MYC
32632092	10.1038/s41392-020-00236-1	2020	YL064 activates proteasomal-dependent degradation of c-Myc and synergistically enhances the anti-tumor activity of ABT-199 in diffuse large B cell lymphoma.	MYC
32659596	10.1016/j.molimm.2020.06.029	2020	The c-Rel-c-Myc axis controls metabolism and proliferation of human T leukemia cells.	MYC
32722781	10.1182/bloodadvances.2020001551	2020	Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.	MYC
32728938	10.1007/s00277-020-04200-5	2020	The prognostic value of 25-hydroxy vitamin D deficiency and its interaction with c-Myc expression in diffuse large B cell lymphoma.	MYC
32833271	10.1002/ajh.25980	2020	Double hit anaplastic large cell lymphoma with concurrent ALK and MYC rearrangements.	MYC
32889391	10.1016/j.anndiagpath.2020.151610	2020	Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.	MYC
32921221	10.1080/10428194.2020.1815017	2020	Clinicopathological and prognostic significance of <i>BCL2</i>, <i>BCL6</i>, <i>MYC</i>, and <i>IRF4</i> copy number gains and translocations in follicular lymphoma: a study by FISH analysis.	MYC
32981916	10.3960/jslrt.20021	2020	Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma.	MYC
32991338	10.1097/PAS.0000000000001577	2020	High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.	MYC
33168821	10.1038/s41408-020-00382-3	2020	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients.	MYC
33298911	10.1038/s41467-020-20107-1	2020	TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation.	MYC
33298918	10.1038/s41467-020-20136-w	2020	Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors.	MYC
33300052	10.3892/ijo.2020.5128	2020	lncRNA LUNAR1 accelerates colorectal cancer progression by targeting the miR‚Äë495‚Äë3p/MYCBP axis.	MYC
33333886	10.3390/cells9122692	2020	Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.	MYC
33335784	10.1155/2020/8876567	2020	Clonally Related Plasmablastic Lymphoma Simultaneously Occurring with Diffuse Large B-Cell Lymphoma.	MYC
33339535	10.1186/s13256-020-02526-2	2020	Double-hit lymphoma of the male breast: a case report.	MYC
33344238	10.3389/fonc.2020.584095	2020	DNA Copy Number Changes in Diffuse Large B Cell Lymphomas.	MYC
33365186	10.25259/SNI_314_2020	2020	Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India.	MYC
33489398	10.1155/2020/8875547	2020	Plasmablastic Lymphoma Associated with Adjacent Mature Plasma Cell Population Exhibiting Opposite Light Chain Restriction.	MYC
29741984	10.1080/10428194.2018.1464158	2019	MYC protein expression is an important prognostic factor in acute myeloid leukemia.	MYC
29954940	10.3324/haematol.2018.195958	2019	MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.	MYC
29974930	10.1111/bjh.15431	2019	Pleural effusion at diagnosis predicts extremely poor outcomes in patients with diffuse large B-cell lymphoma harbouring MYC rearrangement.	MYC
30306208	10.1007/s00277-018-3498-z	2019	MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.	MYC
30460680	10.1111/bjh.15653	2019	Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.	MYC
30737994	10.1111/ejh.13219	2019	Stratification by MYC expression has prognostic impact in MYC translocated B-cell lymphoma-Identifies a subgroup of patients with poor outcome.	MYC
30739786	10.1016/j.bbrc.2019.01.105	2019	LncRNA FIRRE is activated by MYC and promotes the development of diffuse large B-cell lymphoma via Wnt/Œ≤-catenin signaling pathway.	MYC
30825244	10.1002/jcb.28529	2019	c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma.	MYC
30912195	10.1111/iep.12307	2019	Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large B-cell lymphoma.	MYC
30953469	10.1186/s12885-019-5537-0	2019	Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.	MYC
31127282	10.1093/nar/gkz462	2019	Acute depletion of CTCF directly affects MYC regulation through loss of enhancer-promoter looping.	MYC
31127909	10.31557/APJCP.2019.20.5.1463	2019	C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma	MYC
31138843	10.1038/s41375-019-0492-y	2019	Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.	MYC
31142587	10.1084/jem.20181726	2019	c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma.	MYC
31173259	10.3892/or.2019.7183	2019	miR‚Äë29 promoter and enhancer methylation identified by pyrosequencing in Burkitt lymhoma cells: Interplay between MYC and miR‚Äë29 regulation.	MYC
31257571	10.1111/bjh.16082	2019	Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement.	MYC
31259656	10.1080/10428194.2019.1633629	2019	The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma.	MYC
31266538	10.1186/s13072-019-0278-5	2019	MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.	MYC
31266772	10.1158/0008-5472.CAN-18-2847	2019	<i>MYC</i> Regulates the <i>HIF2Œ±</i> Stemness Pathway via <i>Nanog</i> and <i>Sox2</i> to Maintain Self-Renewal in Cancer Stem Cells versus Non-Stem Cancer Cells.	MYC
31315646	10.1186/s13000-019-0856-7	2019	Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.	MYC
31498031	10.1200/JCO.19.00743	2019	Prognostic Significance of <i>MYC</i> Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.	MYC
31767764	10.1073/pnas.1910391116	2019	Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance.	MYC
28838257	10.1080/10428194.2017.1365851	2018	Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC.	MYC
28868942	10.1080/10428194.2017.1370547	2018	MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes.	MYC
29112016	10.1097/PAS.0000000000000982	2018	B Lymphoblastic Leukemia/Lymphoma With Burkitt-like Morphology and IGH/MYC Rearrangement: Report of 3 Cases in Adult Patients.	MYC
29118124	10.1128/JVI.01178-17	2018	c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.	MYC
29180471	10.1158/0008-5472.CAN-17-0815	2018	MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.	MYC
29229300	10.1016/j.bbagen.2017.12.002	2018	c-MYC G-quadruplex binding by the RNA polymerase I inhibitor BMH-21 and analogues revealed by a combined NMR and biochemical Approach.	MYC
29284789	10.1038/s41388-017-0055-5	2018	Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis.	MYC
29289266	10.1016/j.amjms.2017.06.007	2018	Is Myc an Important Biomarker? Myc Expression in Immune Disorders and Cancer.	MYC
29314290	10.1002/mc.22781	2018	Oncogene RNA helicase DDX6 promotes the process of c-Myc expression in gastric cancer cells.	MYC
29367285	10.15252/embr.201744871	2018	Che-1 is targeted by c-Myc to sustain proliferation in pre-B-cell acute lymphoblastic leukemia.	MYC
29666061	10.1158/0008-5472.CAN-17-3107	2018	Deptor Is a Novel Target of Wnt/Œ≤-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.	MYC
29666157	10.1136/jclinpath-2018-205039	2018	CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.	MYC
29708579	10.5146/tjpath.2018.01430	2018	Evaluation of the Prognostic Importance of c-Myc and Bcl-2 Expressions and the Presence of Epstein-Barr Virus in Classical Hodgkin Lymphoma.	MYC
29749488	10.3892/mmr.2018.8935	2018	C‚ÄëMyc inhibitor 10058‚ÄëF4 increases the efficacy of dexamethasone on acute lymphoblastic leukaemia cells.	MYC
29801406	10.22034/APJCP.2018.19.5.1229	2018	Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience	MYC
29885057	10.1002/path.5110	2018	Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.	MYC
30015962	10.3892/or.2018.6581	2018	Knockdown of metadherin inhibits cell proliferation and migration in colorectal cancer.	MYC
30043475	10.1002/dc.24038	2018	Triple hit lymphomas: A retrospective cytology case series of an uncommon high grade B-cell malignancy with C-MYC, BCL-2 and BCL-6 rearrangements.	MYC
30099568	10.1007/s00277-018-3439-x	2018	Novel synthetic 4-chlorobenzoyl berbamine inhibits c-Myc expression and induces apoptosis of diffuse large B cell lymphoma cells.	MYC
30113335	10.1097/PAS.0000000000001132	2018	High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.	MYC
30115641	10.1182/bloodadvances.2018016048	2018	Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.	MYC
30237309	10.15252/embj.201798589	2018	Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.	MYC
30260324	10.1172/JCI122533	2018	PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.	MYC
30282799	10.1182/blood-2018-03-842088	2018	IG-<i>MYC</i> <sup>+</sup> neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.	MYC
27687004	10.1038/modpathol.2016.162	2017	Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1.	MYC
27687005	10.1038/modpathol.2016.56	2017	Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.	MYC
27729620	10.18632/oncotarget.12535	2017	The IgH 3' regulatory region and c-myc-induced B-cell lymphomagenesis.	MYC
27776009	10.1097/PAS.0000000000000758	2017	Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients.	MYC
27987331	10.1002/jcb.25845	2017	IRS1/Œ≤-Catenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells.	MYC
27993575	10.1016/j.humpath.2016.12.007	2017	B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry.	MYC
28055963	10.18632/oncotarget.14393	2017	Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism.	MYC
28119527	10.1038/leu.2017.40	2017	RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC.	MYC
28212447	10.1371/journal.pone.0172364	2017	Diffuse large B-cell lymphoma with concurrent high MYC and BCL2 expression shows evidence of active B-cell receptor signaling by quantitative immunofluorescence.	MYC
28232371	10.3324/haematol.2016.156281	2017	c-Myc dysregulation is a co-transforming event for nuclear factor-Œ∫B activated B cells.	MYC
28280048	10.1182/blood-2016-10-745620	2017	A CD34-negative <i>MYC</i>-rearranged B-lymphoblastic lymphoma aberrantly expresses CD3 and CD5.	MYC
28291124	10.1097/PAS.0000000000000799	2017	MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.	MYC
28327893	10.1093/annonc/mdx022	2017	BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial.	MYC
28344317	10.1038/leu.2017.99	2017	Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia.	MYC
28344319	10.1038/leu.2017.103	2017	PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.	MYC
28351934	10.1182/blood-2016-11-747022	2017	Genetic profiling of <i>MYC</i> and <i>BCL2</i> in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.	MYC
28368423	10.1038/onc.2017.95	2017	Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.	MYC
28498285	10.1097/PAS.0000000000000871	2017	C-MYC and Its Main Ubiquitin Ligase, FBXW7, Influence Cell Proliferation and Prognosis in Adult T-cell Leukemia/Lymphoma.	MYC
28498893	10.1093/carcin/bgx041	2017	Role of DHX33 in c-Myc-induced cancers.	MYC
28521631	10.1177/1093526616689642	2017	Immunohistochemical Profile of MYC Protein in Pediatric Small Round Blue Cell Tumors.	MYC
28614202	10.1097/PAS.0000000000000818	2017	Further Exploration of the Complexities of Large B-Cell Lymphomas With MYC Abnormalities and the Importance of a Blastoid Morphology.	MYC
28639315	10.1111/his.13287	2017	MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma.	MYC
28665415	10.1038/bcj.2017.59	2017	Cryptic t(3;8)(q27;q24) and/or MYC-BCL6 linkage associated with MYC expression by immunohistochemistry is frequent in multiple-hit B-cell lymphomas.	MYC
28686226	10.1038/bcj.2017.61	2017	MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma.	MYC
28776574	10.1038/modpathol.2017.93	2017	Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.	MYC
28790107	10.1182/blood-2017-03-775536	2017	RUNX1 is required for oncogenic <i>Myb</i> and <i>Myc</i> enhancer activity in T-cell acute lymphoblastic leukemia.	MYC
28800143	10.1111/cup.13025	2017	Immunohistochemistry reveals an increased proportion of MYC-positive cells in subcutaneous panniculitis-like T-cell lymphoma compared with lupus panniculitis.	MYC
28914785	10.3390/ijms18091986	2017	Hsp90Œ± Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.	MYC
28952038	10.1007/s11912-017-0629-y	2017	Double-Hit Large B Cell Lymphoma.	MYC
29044419	10.1093/jnen/nlx083	2017	MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL.	MYC
29088292	10.1371/journal.pone.0186983	2017	Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.	MYC
29198442	10.1016/j.trecan.2017.09.008	2017	Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma.	MYC
29209623	10.1155/2017/1967648	2017	<i>MYC</i> Gene Rearrangements Are Closely Associated with Poor Survival of Diffuse Large B Cell Lymphoma with Hepatitis B Virus Infection.	MYC
25982280	10.1038/onc.2015.167	2016	Scribble acts as an oncogene in EŒº-myc-driven lymphoma.	MYC
26119939	10.1038/onc.2015.245	2016	Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.	MYC
26307073	10.1136/jclinpath-2015-203002	2016	Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases.	MYC
26340843	10.1111/ejh.12680	2016	CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma.	MYC
26390147	10.3109/10428194.2015.1096352	2016	Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.	MYC
26421520	10.3109/10428194.2015.1101099	2016	Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma.	MYC
26448193	10.1097/PAS.0000000000000542	2016	High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.	MYC
26565895	10.1002/cncr.29781	2016	Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.	MYC
26568397	10.1111/bjh.13844	2016	Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene.	MYC
26573234	10.18632/oncotarget.6262	2016	Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.	MYC
26820684	10.1016/j.ejca.2015.12.001	2016	Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.	MYC
26848526	10.18632/oncotarget.7134	2016	Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.	MYC
26873538	10.1002/jcb.25516	2016	Distinct Patterns of Colocalization of the CCND1 and CMYC Genes With Their Potential Translocation Partner IGH at Successive Stages of B-Cell Differentiation.	MYC
26916070	10.1038/modpathol.2016.35	2016	The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia.	MYC
26917778	10.1182/blood-2015-02-629485	2016	4EBP1/c-MYC/PUMA and NF-Œ∫B/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.	MYC
26966191	10.1126/science.aac9935	2016	MYC regulates the antitumor immune response through CD47 and PD-L1.	MYC
26988986	10.1158/0008-5472.CAN-15-2477	2016	Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.	MYC
27071312	10.3109/10428194.2016.1167205	2016	Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.	MYC
27125356	10.1038/modpathol.2016.71	2016	Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression.	MYC
27151990	10.3324/haematol.2016.143768	2016	C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas.	MYC
27239040	10.1016/j.celrep.2016.05.015	2016	PIAS1 Promotes Lymphomagenesis through MYC Upregulation.	MYC
27243588	10.1080/10428194.2016.1187275	2016	Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma.	MYC
27282353	10.1038/modpathol.2016.114	2016	Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas.	MYC
27286976	10.1186/s12885-016-2397-8	2016	MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.	MYC
27339797	10.1038/ncomms11807	2016	MYC/MIZ1-dependent gene repression inversely coordinates the circadian clock with cell cycle and proliferation.	MYC
27341130	10.18632/oncotarget.10187	2016	p63Œ± modulates c-Myc activity via direct interaction and regulation of MM1 protein stability.	MYC
27391453	10.1097/DAD.0000000000000607	2016	Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.	MYC
27448819	10.1007/s13277-016-5225-5	2016	PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.	MYC
27469075	10.1111/bjh.14282	2016	Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.	MYC
27490482	10.7554/eLife.18270	2016	MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs.	MYC
27544800	10.1016/j.humpath.2016.07.025	2016	Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature.	MYC
27590350	10.18632/oncotarget.11718	2016	Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer.	MYC
27633159	10.1016/j.clml.2016.08.017	2016	Clinical and Pathologic Correlation of Increased MYC Gene Copy Number in Diffuse Large B-Cell Lymphoma.	MYC
27635472	10.18632/oncotarget.11719	2016	The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas.	MYC
27748879	10.3892/mmr.2016.5818	2016	Quercetin-induced apoptosis of HT-29¬†colon cancer cells via inhibition of the Akt-CSN6-Myc signaling axis.	MYC
27810071	10.1016/j.cancergen.2016.08.007	2016	MYC rearranged B-cell neoplasms: Impact of genetics on classification.	MYC
27821172	10.1186/s13045-016-0349-z	2016	A positive feedback loop involving the Wnt/Œ≤-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma.	MYC
27840026	10.1016/j.molcel.2016.10.012	2016	CRY2 and FBXL3 Cooperatively Degrade c-MYC.	MYC
27886239	10.1038/srep37772	2016	Histone deacetylase 1 plays a predominant pro-oncogenic role in EŒº-myc driven B cell lymphoma.	MYC
24679006	10.3109/10428194.2014.907896	2015	TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.	MYC
24731854	10.1016/j.bbagrm.2014.04.004	2015	The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis.	MYC
24844357	10.3109/10428194.2014.924116	2015	Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.	MYC
24998853	10.1038/onc.2014.186	2015	A common functional consequence of tumor-derived mutations within c-MYC.	MYC
25103070	10.1038/modpathol.2014.95	2015	B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas.	MYC
25219592	10.3109/10428194.2014.963575	2015	Glycolytic inhibitor 2-deoxy-d-glucose suppresses cell proliferation and enhances methylprednisolone sensitivity in non-Hodgkin lymphoma cells through down-regulation of HIF-1Œ± and c-MYC.	MYC
25229766	10.1097/PAS.0000000000000319	2015	Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations.	MYC
25284491	10.3109/10428194.2014.970550	2015	Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.	MYC
25311243	10.1038/leu.2014.302	2015	A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies.	MYC
25359993	10.1182/blood-2014-08-594507	2015	Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.	MYC
25373509	10.3109/10428194.2014.982643	2015	ETV6/ARG oncoprotein confers autonomous cell growth by enhancing c-Myc expression via signal transducer and activator of transcription 5 activation in the acute promyelocytic leukemia cell line HT93A.	MYC
25468432	10.1016/j.jmoldx.2014.08.006	2015	Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.	MYC
25487600	10.1016/j.clml.2014.10.003	2015	Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.	MYC
25531321	10.1038/onc.2014.427	2015	c-MYC is a radiosensitive locus in human breast cells.	MYC
25581730	10.1097/PAS.0000000000000365	2015	Expression profiles of MYC protein and MYC gene rearrangement in lymphomas.	MYC
25595783	10.4049/jimmunol.1402382	2015	Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors.	MYC
25621564	10.7554/eLife.04024	2015	Registered report: transcriptional amplification in tumor cells with elevated c-Myc.	MYC
25673238	10.1038/leu.2015.34	2015	The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum.	MYC
25690653	10.1096/fj.14-263889	2015	Long noncoding RNAs as a novel component of the Myc transcriptional network.	MYC
25692307	10.1080/15384047.2014.1002698	2015	Inauhzin(c) inactivates c-Myc independently of p53.	MYC
25739120	10.18632/oncotarget.3245	2015	Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.	MYC
25741152	10.3748/wjg.v21.i8.2433	2015	Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.	MYC
25784651	10.18632/oncotarget.2969	2015	p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia.	MYC
25827211	10.3109/10428194.2015.1034699	2015	Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome.	MYC
25828389	10.1097/PAS.0000000000000433	2015	MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.	MYC
25828391	10.1097/PAS.0000000000000434	2015	Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.	MYC
26010683	10.1111/apm.12390	2015	MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.	MYC
26062055	10.1002/hon.2217	2015	IX. Is it only about MYC? How to approach the diagnosis of diffuse large B-cell lymphomas.	MYC
26158410	10.18632/oncotarget.4073	2015	MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma.	MYC
26261666	NA	2015	Richter transformation with c-MYC overexpression: report of three cases.	MYC
26261669	NA	2015	Utility of immunohistochemistry with an antibody against MYC at the initial diagnosis of follicular lymphoma, grade 3A, for predicting a more aggressive clinical course: a case report and review of the literature.	MYC
26317903	10.18632/oncotarget.4620	2015	Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.	MYC
26327622	10.1371/journal.ppat.1005135	2015	KSHV Latency Locus Cooperates with Myc to Drive Lymphoma in Mice.	MYC
26453442	10.1186/s12885-015-1661-7	2015	Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation.	MYC
26515759	10.1186/s13045-015-0218-1	2015	Establishment and characterization of a novel MYC/BCL2 double-hit diffuse large B cell lymphoma cell line, RC.	MYC
26517351	10.18632/oncotarget.5982	2015	Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia.	MYC
26517511	10.18632/oncotarget.5705	2015	High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival.	MYC
26558423	10.3109/08880018.2015.1087611	2015	De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis.	MYC
26634708	10.1007/s11864-015-0374-0	2015	Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.	MYC
26717387	10.1097/MD.0000000000002388	2015	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.	MYC
23416976	10.1038/onc.2013.28	2014	Sensitisation of c-MYC-induced B-lymphoma cells to apoptosis by ATF2.	MYC
24118498	10.1111/ejh.12212	2014	MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations.	MYC
24249258	10.1002/gcc.22117	2014	MYC fails to efficiently shape malignant transformation in T-cell acute lymphoblastic leukemia.	MYC
24368766	10.1074/jbc.M113.525949	2014	SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma.	MYC
24394663	10.1182/blood-2013-08-522698	2014	c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.	MYC
24397618	10.3109/10428194.2013.879714	2014	Antigen expression patterns of MYC-rearranged versus non-MYC-rearranged B-cell lymphomas by flow cytometry.	MYC
24398325	10.1182/blood-2013-06-507996	2014	A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.	MYC
24503701	10.1371/journal.pone.0087456	2014	Immunohistochemistry for myc predicts survival in colorectal cancer.	MYC
24552990	10.1038/leu.2014.78	2014	Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.	MYC
24586197	10.1371/journal.pgen.1004167	2014	Insertional mutagenesis and deep profiling reveals gene hierarchies and a Myc/p53-dependent bottleneck in lymphomagenesis.	MYC
24614102	10.1172/JCI63139	2014	CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis.	MYC
24614699	10.1097/PAT.0000000000000076	2014	Detection of MYC rearrangement in high grade B cell lymphomas: correlation of MYC immunohistochemistry and FISH analysis.	MYC
24619762	10.1309/AJCPPHMZ6VHF0WQV	2014	p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.	MYC
24625415	10.1097/PAS.0000000000000147	2014	Clinical significance of MYC expression and/or high-grade morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study.	MYC
24642368	10.1016/j.prp.2014.02.004	2014	Both c-Myc and Ki-67 expression are predictive markers in patients with extranodal NK/T-cell lymphoma, nasal type: a retrospective study in China.	MYC
24675470	10.1038/cddis.2014.112	2014	Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers.	MYC
24686171	10.1158/0008-5472.CAN-13-2732	2014	Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression.	MYC
24705315	10.1097/PAS.0000000000000213	2014	MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).	MYC
24713985	10.1097/PAP.0b013e3182a92cde	2014	Burkitt lymphoma and MYC: what else is new?	MYC
24719189	10.1007/s13277-014-1907-z	2014	MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy.	MYC
24740248	10.1371/journal.pone.0095020	2014	C-MYC aberrations as prognostic factors in diffuse large B-cell lymphoma: a meta-analysis of epidemiological studies.	MYC
24809777	10.1038/bjc.2014.218	2014	Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.	MYC
24913718	10.1158/2326-6066.CIR-14-0090	2014	Mechanisms that can promote peripheral B-cell lymphoma in ATM-deficient mice.	MYC
24994904	10.1073/pnas.1409778111	2014	Alteration of the lipid profile in lymphomas induced by MYC overexpression.	MYC
25034145	10.1038/leu.2014.224	2014	Synergy of Myc, cell cycle regulators and the Akt pathway in the development of aggressive B-cell lymphoma in a mouse model.	MYC
25060305	10.1016/j.leukres.2014.06.022	2014	C-myc protein expression in B-cell acute lymphoblastic leukemia, prognostic significance?	MYC
25060588	10.1002/cncr.28899	2014	MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.	MYC
25090026	10.1371/journal.pone.0104068	2014	MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.	MYC
25125624	10.1309/AJCPBWVHTF7RRSA4	2014	Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics.	MYC
25125625	10.1309/AJCPUBHM8U7ZFLOB	2014	Aberrations of MYC are a common event in B-cell prolymphocytic leukemia.	MYC
25194570	10.1038/nm.3665	2014	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.	MYC
25261932	10.1038/ng.3105	2014	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma.	MYC
25270907	10.1182/blood-2014-06-578856	2014	Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations.	MYC
25297597	10.3760/cma.j.issn.1003-9406.2014.01.020	2014	[Significance of BCL6, MYC, P53 genes abnormalities for the prognosis of diffuse large B-cell lymphoma].	MYC
25337204	NA	2014	C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas.	MYC
25369933	10.1073/pnas.1407079111	2014	Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia.	MYC
25479599	10.1371/journal.pone.0114398	2014	MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system.	MYC
26016222	NA	2014	[Clinical features in DLBCL and translocation BCL2/c-MYC double hit lymphoma].	MYC
22484426	10.1038/onc.2012.117	2013	Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.	MYC
22957790	10.3109/10428194.2012.704034	2013	Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells.	MYC
22967991	10.1093/annonc/mds209	2013	A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome.	MYC
23012230	10.1002/gcc.22008	2013	Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement.	MYC
23178486	10.1038/onc.2012.543	2013	STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma.	MYC
23237560	10.1016/j.leukres.2012.11.010	2013	c-Myc and E2F1 drive PBK/TOPK expression in high-grade malignant lymphomas.	MYC
23243310	10.1074/jbc.M112.410274	2013	Transforming growth factor-Œ≤ directly induces p53-up-regulated modulator of apoptosis (PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas.	MYC
23330001	NA	2013	Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature.	MYC
23335369	10.1182/blood-2012-06-435842	2013	MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.	MYC
23341364	10.1002/path.4164	2013	Decitabine represses translocated MYC oncogene in Burkitt lymphoma.	MYC
23355209	10.1309/AJCP2Z0TAGMUYJEB	2013	Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large B-cell lymphoma.	MYC
23363269	10.3109/10428194.2013.771398	2013	MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma.	MYC
23449635	10.1182/blood-2012-10-460063	2013	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.	MYC
23525267	10.1158/1541-7786.MCR-12-0441	2013	Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma.	MYC
23538750	10.1038/leu.2013.94	2013	Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.	MYC
23589839	10.1073/pnas.1208530110	2013	Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis.	MYC
23599149	10.1038/modpathol.2013.73	2013	ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements.	MYC
23601184	10.1111/febs.12299	2013	Sp1 and c-Myc regulate transcription of BMI1 in nasopharyngeal carcinoma.	MYC
23716551	10.3324/haematol.2013.086173	2013	MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.	MYC
23770605	10.1038/ng.2652	2013	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.	MYC
23791182	10.1016/j.cell.2013.05.041	2013	The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability.	MYC
23795946	10.1111/his.12178	2013	MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection.	MYC
23797802	10.1097/CAD.0b013e328363ae50	2013	Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.	MYC
23821202	10.1167/iovs.13-12272	2013	MicroRNA profiling in ocular adnexal lymphoma: a role for MYC and NFKB1 mediated dysregulation of microRNA expression in aggressive disease.	MYC
23926923	10.1111/his.12207	2013	Immunohistochemical evaluation of MYC expression in mantle cell lymphoma.	MYC
23933736	10.1093/hmg/ddt381	2013	Myc inhibition impairs autophagosome formation.	MYC
23939148	10.1097/PAP.0b013e3182a289f2	2013	MYC/BCL2 double-hit high-grade B-cell lymphoma.	MYC
23982173	10.1182/blood-2013-02-484055	2013	Polycomb repressive complex 2 (PRC2) suppresses EŒº-myc lymphoma.	MYC
24009228	10.1182/blood-2013-05-498329	2013	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.	MYC
24040459	NA	2013	Primary sacral non-germinal center type diffuse large B-cell lymphoma with MYC translocation: a case report and a review of the literature.	MYC
24140063	10.1016/j.bbrc.2013.10.034	2013	C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells.	MYC
24152439	10.3390/ijms141020236	2013	Acidosis decreases c-Myc oncogene expression in human lymphoma cells: a role for the proton-sensing G protein-coupled receptor TDAG8.	MYC
24169826	10.1182/blood-2012-12-473090	2013	The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop.	MYC
24216476	10.1172/JCI64210	2013	A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.	MYC
24319234	10.1182/asheducation-2013.1.575	2013	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.	MYC
20981461	10.1007/s10006-010-0254-5	2012	Diffuse swelling of the buccal mucosa and palate as first and only manifestation of an extranodal non-Hodgkin 'double-hit' lymphoma: report of a case.	MYC
21882178	10.1002/cncr.26433	2012	Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.	MYC
21913186	10.1002/ijc.26423	2012	High Myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas.	MYC
22002311	10.1038/onc.2011.470	2012	Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.	MYC
22002575	10.1038/modpathol.2011.147	2012	B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.	MYC
22081066	10.1038/onc.2011.507	2012	Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency.	MYC
22120970	10.1002/gcc.21915	2012	Molecular analysis of the t(2;8)/MYC-IGK translocation in high-grade lymphoma/leukemia by long-distance inverse PCR.	MYC
22168746	10.1111/j.1349-7006.2011.02186.x	2012	Role of activation-induced cytidine deaminase in the progression of follicular lymphoma.	MYC
22314191	10.1097/PAS.0b013e318244e2ba	2012	High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma.	MYC
22333947	10.1016/S0140-6736(11)61177-X	2012	Burkitt's lymphoma.	MYC
22393362	10.1371/journal.pone.0031366	2012	Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia.	MYC
22453922	10.1074/jbc.M111.335216	2012	Kaposi sarcoma-associated herpesvirus vIRF-3 protein binds to F-box of Skp2 protein and acts as a regulator of c-Myc protein function and stability.	MYC
22615405	10.1073/pnas.1203244109	2012	Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC.	MYC
22661084	10.4049/jimmunol.1102277	2012	B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels.	MYC
22665537	10.1200/JCO.2011.41.4342	2012	Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	MYC
22804688	10.1111/j.1365-2559.2012.04301.x	2012	High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis.	MYC
22826319	10.4049/jimmunol.1201000	2012	A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice.	MYC
22844532	10.1371/journal.pone.0041891	2012	Rabring7 degrades c-Myc through complex formation with MM-1.	MYC
22851565	10.1200/JCO.2011.41.0985	2012	Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.	MYC
22863009	10.1016/j.cell.2012.06.033	2012	Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state.	MYC
22897848	10.1016/j.ccr.2012.06.012	2012	Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis.	MYC
22949148	10.1200/JCO.2012.44.4729	2012	Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.	MYC
23018644	10.1182/blood-2012-05-428466	2012	Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.	MYC
23042398	10.3760/cma.j.issn.1003-9406.2012.05.017	2012	[Correlation of BCL-6, MYC and p53 gene abnormalities with immunological subtypes and prognosis of diffuse large B-cell lymphoma].	MYC
23079660	10.1016/j.ccr.2012.09.003	2012	Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.	MYC
23143306	10.1172/JCI62973	2012	ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth.	MYC
23175515	10.18632/oncotarget.748	2012	Epigenetics, c-Myc and aggressive B-cell lymphomas.	MYC
20661666	10.1007/s12032-010-9614-0	2011	Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement.	MYC
21217079	10.1182/blood-2010-05-286351	2011	Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia.	MYC
21245140	10.1074/jbc.M110.165977	2011	SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27(KIP1) through SKP2 in human leukemia cells.	MYC
21478429	10.1182/blood-2010-10-315432	2011	Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway.	MYC
21527520	10.1182/blood-2011-02-336842	2011	Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia.	MYC
21628855	10.3960/jslrt.51.7	2011	BCL2 and MYC dual-hit lymphoma/leukemia.	MYC
21640157	10.1016/j.exphem.2011.05.002	2011	Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent¬†Bcl-2 and c-Myc overexpression.	MYC
21646687	10.18632/oncotarget.283	2011	The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas.	MYC
21692100	10.1002/hon.991	2011	Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma.	MYC
21783402	10.1016/j.oraloncology.2011.06.506	2011	Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas.	MYC
21878679	10.1126/scisignal.2001754	2011	AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.	MYC
21949397	10.1073/pnas.1108190108	2011	Targeting MYC dependence in cancer by inhibiting BET bromodomains.	MYC
22022427	10.1371/journal.pone.0025645	2011	Notch ankyrin repeat domain variation influences leukemogenesis and Myc transactivation.	MYC
19881537	10.1038/onc.2009.377	2010	c-Myc overexpression promotes a germinal center-like program in Burkitt's lymphoma.	MYC
20087644	10.1007/s10552-010-9504-y	2010	Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma.	MYC
20118770	10.1097/PAS.0b013e3181cd3aeb	2010	B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.	MYC
20133585	10.1073/pnas.0901230107	2010	Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model.	MYC
20378577	10.3324/haematol.2009.012864	2010	Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma.	MYC
20442643	10.1097/PAS.0b013e3181db83af	2010	Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation.	MYC
20498406	10.1200/JCO.2009.26.3947	2010	Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.	MYC
20573831	10.1128/JVI.00244-10	2010	Myc is required for the maintenance of Kaposi's sarcoma-associated herpesvirus latency.	MYC
20598117	10.1186/1471-2407-10-348	2010	Myc suppression of Nfkb2 accelerates lymphomagenesis.	MYC
20737197	10.1007/s11010-010-0536-0	2010	The impact of C-MYC gene expression on gastric cancer cell.	MYC
20823132	10.3324/haematol.2010.025767	2010	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.	MYC
20823134	10.3324/haematol.2010.026831	2010	Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis.	MYC
20962620	10.1097/PAS.0b013e3181f3e29f	2010	IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.	MYC
19022773	10.1074/jbc.M808080200	2009	TGF-beta induces growth arrest in Burkitt lymphoma cells via transcriptional repression of E2F-1.	MYC
19038003	10.1111/j.1349-7006.2008.01035.x	2009	Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma.	MYC
19179467	10.1182/blood-2008-10-183475	2009	Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine.	MYC
19219026	10.1038/nature07823	2009	c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.	MYC
19336552	10.1158/1055-9965.EPI-08-1037	2009	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.	MYC
19497851	10.1074/jbc.M109.021477	2009	DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC.	MYC
19535347	10.3324/haematol.2008.005355	2009	Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations.	MYC
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	MYC
19594747	10.1111/j.1365-2141.2009.07791.x	2009	Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.	MYC
19597184	10.1182/blood-2009-03-212191	2009	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.	MYC
19704118	10.1182/blood-2009-05-220095	2009	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.	MYC
19755676	10.1182/blood-2008-12-196709	2009	TC-PTP is required for the maintenance of MYC-driven B-cell lymphomas.	MYC
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	MYC
19815507	10.1073/pnas.0907994106	2009	Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis.	MYC
19996270	10.1158/1535-7163.MCT-09-0408	2009	Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells.	MYC
17989722	10.1038/sj.leu.2404999	2008	Characterization of three t(3;8)(q27;q24) translocations from diffuse large B-cell lymphomas.	MYC
18066065	10.1038/ng.2007.30	2008	Widespread microRNA repression by Myc contributes to tumorigenesis.	MYC
18085637	10.1002/cncr.23196	2008	The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.	MYC
18089500	10.1309/NKK3FEX2BE5L7EKB	2008	Transformation of follicular lymphoma to precursor B-cell lymphoblastic lymphoma with c-myc gene rearrangement as a critical event.	MYC
18235046	10.1182/blood-2007-08-108654	2008	PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.	MYC
18297523	10.1080/10428190701836845	2008	C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator?	MYC
18393360	10.1002/jcb.21765	2008	c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27(Kip1) cyclin dependent kinase inhibitor.	MYC
18426731	10.1309/CMPGPYTMFRM6RVQR	2008	Primary diffuse large B-cell lymphoma of bone displays preferential rearrangements of the c-MYC or BCL2 gene.	MYC
18460403	10.1016/j.leukres.2007.10.006	2008	Characterization of de novo diffuse large B-cell lymphoma with a translocation of c-myc and immunoglobulin genes.	MYC
18535662	10.1371/journal.pgen.1000090	2008	Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis.	MYC
18628958	10.1371/journal.pone.0002722	2008	Global regulation of nucleotide biosynthetic genes by c-Myc.	MYC
18713946	10.1182/blood-2008-03-147645	2008	MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.	MYC
18752503	10.1111/j.1365-2559.2008.03076.x	2008	MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.	MYC
18754028	10.1038/leu.2008.230	2008	Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).	MYC
17310999	10.1038/sj.onc.1210299	2007	Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen.	MYC
17363738	10.1182/blood-2006-08-039883	2007	Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia.	MYC
17419945	10.1016/S0065-230X(06)97007-9	2007	c-MYC impairs immunogenicity of human B cells.	MYC
17541401	10.1038/sj.leu.2404753	2007	Identification of two distinct MYC breakpoint clusters and their association with various IGH breakpoint regions in the t(8;14) translocations in sporadic Burkitt-lymphoma.	MYC
17613764	10.1080/10428190701402903	2007	Characterization of genetic changes in MCL by interphase FISH on tissue sections.	MYC
17622571	10.1182/blood-2006-09-048033	2007	Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.	MYC
17634226	10.1128/JVI.00804-07	2007	The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc.	MYC
17646408	10.1084/jem.20070872	2007	The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.	MYC
17728244	10.1074/jbc.M706430200	2007	Stimulation of c-Myc transcriptional activity by vIRF-3 of Kaposi sarcoma-associated herpesvirus.	MYC
17785433	10.1128/MCB.00440-07	2007	Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1.	MYC
18024371	10.3324/haematol.11305	2007	The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.	MYC
16432227	10.1073/pnas.0507367103	2006	ATM promotes apoptosis and suppresses tumorigenesis in response to Myc.	MYC
16466700	10.1016/j.bbrc.2006.01.097	2006	c-Myc over-expression in Ramos Burkitt's lymphoma cell line predisposes to iron homeostasis disruption in vitro.	MYC
16508012	10.1128/MCB.26.6.2373-2386.2006	2006	Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.	MYC
16537801	10.1182/blood-2006-01-0172	2006	MYC levels govern hematopoietic tumor type and latency in transgenic mice.	MYC
16541139	10.1038/sj.leu.2404183	2006	Richter's and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation.	MYC
16675879	10.1155/2006/695262	2006	The CT-element of the c-myc gene does not predispose to chromosomal breakpoints in Burkitt's lymphoma.	MYC
16690525	10.1080/10428190500361128	2006	Expression of ice, bcl-2, c-myc and p53 in different bone marrow cell populations from patients with diffuse large B-cell lymphoma.	MYC
17001014	10.1073/pnas.0509988103	2006	Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.	MYC
15468060	10.1002/jcp.20229	2005	Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression.	MYC
15716988	10.1038/sj.leu.2403661	2005	Concurrent translocation of BCL2 and MYC with a single immunoglobulin locus in high-grade B-cell lymphomas.	MYC
15800668	10.1038/sj.leu.2403729	2005	G1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression.	MYC
16094360	10.1038/nature03845	2005	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.	MYC
16140957	10.1158/0008-5472.CAN-05-1581	2005	Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation.	MYC
16169462	10.1016/j.ccr.2005.08.005	2005	The great MYC escape in tumorigenesis.	MYC
14697225	10.1016/j.bbrc.2003.12.002	2004	Defective RNA-mediated c-myc gene silencing pathway in Burkitt's lymphoma.	MYC
15098029	10.1038/nm1042	2004	The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis.	MYC
15150404	10.1073/pnas.0402770101	2004	The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation.	MYC
15160911	10.1080/10428190310001607151	2004	The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome.	MYC
15191563	10.1111/j.0022-202X.2004.22720.x	2004	Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas.	MYC
15287031	10.1002/gcc.20063	2004	Level of MYC overexpression in pediatric Burkitt's lymphoma is strongly dependent on genomic breakpoint location within the MYC locus.	MYC
12446731	10.1074/jbc.M206733200	2003	Guanine nucleotide exchange factor, Tiam1, directly binds to c-Myc and interferes with c-Myc-mediated apoptosis in rat-1 fibroblasts.	MYC
12553908	10.1016/s0092-8674(02)01284-9	2003	X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors.	MYC
12562237	10.5858/2003-127-208-EOPMOB	2003	Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.	MYC
12688321	10.1080/1042819021000047010	2003	Activation of protein kinase C enhances TNF-alpha-induced differentiation by preventing apoptosis via rapid up-regulation of c-Myc protein expression in HL-60 cells.	MYC
12808131	10.1073/pnas.1332764100	2003	A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.	MYC
11777933	10.1074/jbc.M111426200	2002	A Myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt's lymphoma.	MYC
12036888	10.1182/blood.v99.12.4554	2002	Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.	MYC
12149649	10.1038/sj.onc.1205640	2002	Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis.	MYC
12213716	10.1016/S0002-9440(10)64248-4	2002	The nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomas.	MYC
11182042	10.3892/or.8.2.289	2001	c-myc gene mutation in gastric mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B-cell lymphoma.	MYC
11443860	10.1007/978-3-642-56515-1_10	2001	EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma.	MYC
11567024	10.1074/jbc.M106127200	2001	MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer.	MYC
9689053	10.1073/pnas.95.16.9172	1998	Identification of a large Myc-binding protein that contains RCC1-like repeats.	MYC
7642555	10.1074/jbc.270.32.18961	1995	c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas.	MYC
8220424	10.1038/ng0993-56	1993	Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.	MYC
8247524	NA	1993	Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential.	MYC
1597196	10.1111/j.1432-1033.1992.tb16964.x	1992	DNA-activated protein kinase in Raji Burkitt's lymphoma cells. Phosphorylation of c-Myc oncoprotein.	MYC
3277717	10.1016/0092-8674(88)90507-7	1988	A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas.	MYC
3033665	10.1073/pnas.84.9.2824	1987	MYC oncogene involved in a t(8;22) chromosome translocation is not altered in its putative regulatory regions.	MYC
3540591	10.1128/mcb.6.10.3481-3489.1986	1986	Novel promoter upstream of the human c-myc gene and regulation of c-myc expression in B-cell lymphomas.	MYC
6419122	10.1038/306760a0	1984	Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma.	MYC
6547209	10.1038/309592a0	1984	Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma.	MYC
6304538	10.1038/303725a0	1983	Nucleotide sequence of cloned cDNA of human c-myc oncogene.	MYC
6321164	10.1002/j.1460-2075.1983.tb01749.x	1983	Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumours.	MYC
6324175	10.1073/pnas.80.24.7476	1983	Activation of the c-myc gene by translocation: a model for translational control.	MYC
6414718	10.1016/0092-8674(83)90534-2	1983	The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma.	MYC
33634586	10.1002/cyto.b.21995	2022	Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenstr√∂m macroglobulinemia.	MYD88
33682304	10.1002/cyto.b.22000	2022	VS38 staining contributes to a novel gating strategy in flow cytometry for small B cell lymphoma, especially in lymphoplasmacytic lymphoma/Waldenstr√∂m macroglobulinemia.	MYD88
34325497	10.4143/crt.2021.752	2022	Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma.	MYD88
34411492	10.1139/cjpp-2021-0007	2022	Colchicine attenuates renal ischemia-reperfusion-induced liver damage: implication of TLR4/NF-Œ∫B, TGF-Œ≤, and <i>BAX</i> and <i>Bcl-2</i> gene expression.	MYD88
34448823	10.1182/bloodadvances.2021004212	2022	The molecular hallmarks of primary and secondary vitreoretinal lymphoma.	MYD88
34638136	10.1182/bloodadvances.2020003698	2022	Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.	MYD88
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	MYD88
34674984	10.1016/j.clml.2021.09.014	2022	Bing-Neel Syndrome: Update on the Diagnosis and Treatment.	MYD88
34793256	10.1200/JCO.21.01194	2022	Venetoclax in Previously Treated Waldenstr√∂m Macroglobulinemia.	MYD88
34802044	10.1038/s41379-021-00954-z	2022	A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform.	MYD88
34895930	10.1016/j.pathol.2021.09.018	2022	Cutaneous lymphoplasmacytic lymphoma with MYD88 L265P mutation, bone marrow involvement, and paraproteinaemia.	MYD88
34961399	10.1080/10428194.2021.2018584	2022	Discriminating between Waldenstr√∂m macroglobulinemia and marginal zone lymphoma using logistic LASSO regression.	MYD88
34980578	10.1016/j.clml.2021.11.014	2022	SOHO State of the Art Updates and Next Questions: Waldenstr√∂m Macroglobulinemia - 2021 Update on Management and Future Directions.	MYD88
34997652	10.1111/ejh.13736	2022	Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.	MYD88
35020191	10.1111/bjh.18036	2022	Diagnosis and management of Waldenstr√∂m macroglobulinaemia-A British Society for Haematology guideline.	MYD88
35028710	10.1007/s00428-021-03265-5	2022	Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.	MYD88
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	MYD88
35044826	10.1126/sciadv.abl4644	2022	Preneoplastic somatic mutations including <i>MYD88</i><sup>L265P</sup> in lymphoplasmacytic lymphoma.	MYD88
35073397	10.1039/d1lc01055g	2022	Direct MYD88<sup>L265P</sup> gene detection for diffuse large B-cell lymphoma (DLBCL) <i>via</i> a miniaturised CRISPR/dCas9-based sensing chip.	MYD88
35096069	10.1155/2022/1182384	2022	Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenstr√∂m's Macroglobulinemia).	MYD88
35106936	10.1002/cam4.4550	2022	SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.	MYD88
35126963	10.1177/20406207211072839	2022	MYD88<sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy.	MYD88
35142151	10.3324/haematol.2021.279908	2022	A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas.	MYD88
35149375	10.1016/j.ctarc.2022.100527	2022	Current approach to Waldenstr√∂m Macroglobulinemia.	MYD88
35154721	10.1002/ccr3.5372	2022	Successful treatment with bortezomib for refractory fever associated with myelodysplastic syndrome with underlying lymphoplasmacytic lymphoma.	MYD88
35156897	10.1080/21655979.2022.2032939	2022	MicroRNA-885-3p alleviates bronchial epithelial cell injury induced by lipopolysaccharide via toll-like receptor 4.	MYD88
35158867	10.3390/cancers14030598	2022	Diagnosing Vitreoretinal Lymphomas-An Analysis of the Sensitivity of Existing Tools.	MYD88
35169086	10.11477/mf.1436204531	2022	[Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].	MYD88
35200564	10.3390/curroncol29020065	2022	Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology.	MYD88
35210172	10.1016/j.preteyeres.2022.101053	2022	Challenges in the diagnosis and management of vitreoretinal lymphoma - Clinical and basic approaches.	MYD88
35223507	10.3389/fonc.2022.824632	2022	<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS.	MYD88
35236331	10.1186/s12885-022-09237-5	2022	Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.	MYD88
35255429	10.1016/j.anndiagpath.2021.151886	2022	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.	MYD88
35255496	10.1182/bloodadvances.2021006147	2022	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.	MYD88
35265542	10.12890/2022_003106	2022	Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression.	MYD88
35267569	10.3390/cancers14051264	2022	The Biology of Ocular Adnexal Marginal Zone Lymphomas.	MYD88
35281910	10.3389/fphar.2022.857869	2022	Engineered Bacteria EcN-MT Alleviate Liver Injury in Cadmium-Exposed Mice <i>via</i> its Probiotics Characteristics and Expressing of Metallothionein.	MYD88
35300216	10.2147/JIR.S341355	2022	The Mutation of <i>BTG2</i> Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma.	MYD88
35339405	10.1016/j.clml.2022.02.005	2022	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenstr√∂m Macroglobulinemia.	MYD88
35339566	10.1016/j.humpath.2022.03.008	2022	Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation.	MYD88
35340094	10.1111/vco.12816	2022	Anticancer activity of IRAK-4 inhibitors against canine lymphoid malignancies.	MYD88
35358350	10.1002/ajh.26552	2022	First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenstr√∂m's Macroglobulinemia: A systematic review and meta-analysis.	MYD88
35359040	10.3760/cma.j.cn112151-20211220-00915	2022	[Clinicopathological features and BRAF V600E and MYD88 L265P mutation status of nodal marginal zone lymphoma].	MYD88
35370644	10.3389/fphar.2022.842723	2022	Baicalein Ameliorates Myocardial Ischemia Through Reduction of Oxidative Stress, Inflammation and Apoptosis via TLR4/MyD88/MAPK<sub>S</sub>/NF-Œ∫B Pathway and Regulation of Ca<sup>2+</sup> Homeostasis by L-type Ca<sup>2+</sup> Channels.	MYD88
35401516	10.3389/fimmu.2022.842439	2022	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.	MYD88
35454017	10.3390/diagnostics12040969	2022	Nucleic Acid Biomarkers in Waldenstr√∂m Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.	MYD88
35506035	10.5114/wo.2022.115675	2022	Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (Œ≤)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell non-Hodgkin lymphoma patients - an immunohistochemical study.	MYD88
35510210	10.1177/20406207221093962	2022	Treatment paradigm in Waldenstr√∂m macroglobulinemia: frontline therapy and beyond.	MYD88
35514998	10.3389/fimmu.2022.894464	2022	Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome.	MYD88
35537114	10.1182/bloodadvances.2022007279	2022	Landscape of immunoglobulin heavy chain gene repertoire and its¬†clinical relevance to LPL/WM.	MYD88
35538064	10.1038/s41467-022-30050-y	2022	The genomic and transcriptional landscape of primary central nervous system lymphoma.	MYD88
35554927	10.1002/eji.202149746	2022	Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched diffuse large B-cell lymphomas.	MYD88
35628381	10.3390/ijms23105570	2022	<i>MYD88</i> Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies.	MYD88
35646048	10.3389/fgene.2022.878618	2022	Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	MYD88
35680596	10.3760/cma.j.issn.0253-2727.2022.05.007	2022	[Exploring the detection of MYD88 mutation in patients with Waldenstr√∂m macroglobulinemia by different methods and specimens].	MYD88
35759728	10.1182/blood.2022015926	2022	Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma.	MYD88
35761836	10.1155/2022/3864863	2022	Mesenchymal Stem Cell Exosomal miR-146a Mediates the Regulation of the TLR4/MyD88/NF-<i>Œ∫</i>B Signaling Pathway in Inflammation due to Diabetic Retinopathy.	MYD88
35794278	10.1007/s00277-022-04910-y	2022	First Latin America report on the diagnostic utility of the study of the MYD88 L265P gene mutation in patients with Waldenstr√∂m Macroglobulinemia.	MYD88
35813102	10.1097/HS9.0000000000000746	2022	Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenstr√∂m's Macroglobulinemia Before and After the Implementation of a National Guideline.	MYD88
35877223	10.3390/curroncol29070363	2022	Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation.	MYD88
35879731	10.1186/s40364-022-00401-4	2022	Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma.	MYD88
35903524	10.1016/j.jsps.2022.05.009	2022	Genistein promotes M1 macrophage apoptosis and reduces inflammatory response by disrupting miR-21/TIPE2 pathway.	MYD88
35911113	10.3389/fnut.2022.907386	2022	Selenium Nanoparticles Improved Intestinal Health Through Modulation of the NLRP3 Signaling Pathway.	MYD88
35928872	10.3389/fonc.2022.932674	2022	Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma.	MYD88
35932039	10.1186/s13000-022-01244-1	2022	Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma.	MYD88
35937947	10.1155/2022/6441139	2022	Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis.	MYD88
35939775	10.1200/GO.21.00380	2022	Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study.	MYD88
35949601	10.3892/ol.2022.13418	2022	Hemophagocytic lymphohistiocytosis as an onset of diffuse large B-cell lymphoma: A case report.	MYD88
35952646	10.1016/j.chom.2022.07.003	2022	Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-Œ∫B axis.	MYD88
35952929	10.1016/j.oret.2022.08.005	2022	Aqueous Humor-Derived MYD88 L265P Mutation Analysis in Vitreoretinal Lymphoma: A potential less-invasive method for diagnosis and treatment response assessment.	MYD88
35968590	10.3760/cma.j.issn.0253-2727.2022.06.006	2022	[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review].	MYD88
35973369	10.1016/j.intimp.2022.109138	2022	Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization.	MYD88
36003901	10.2147/BLCTT.S259860	2022	Differential Diagnosis of Waldenstr√∂m's Macroglobulinemia and Early Management: Perspectives from Clinical Practice.	MYD88
36006771	10.1097/PAS.0000000000001957	2022	Clinicopathologic Features and Genomic Signature of De Novo CD5+ Diffuse Large B-Cell Lymphoma: A Multicenter Collaborative Study.	MYD88
36051079	10.1002/jha2.428	2022	Targetable alterations in primary extranodal diffuse large B-cell lymphoma.	MYD88
36053490	10.1002/hon.3073	2022	Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.	MYD88
36055572	10.1016/j.clim.2022.109105	2022	A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.	MYD88
36059608	10.3389/fonc.2022.955080	2022	Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis.	MYD88
36081566	10.3389/fonc.2022.941347	2022	Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.	MYD88
31418635	10.1080/09273948.2019.1636093	2021	PreservCyt Is an Optimal Fixative that Permits Cytologic and Molecular Analyses of Vitreoretinal Lymphoma Biopsies.	MYD88
31603365	10.1080/09273948.2019.1657903	2021	Clinical Relevance of the High Prevalence of MYD88 L265P Mutated Vitreoretinal Lymphoma Identified by Droplet Digital Polymerase Chain Reaction.	MYD88
32139889	10.1038/s41375-020-0766-4	2021	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.	MYD88
32447345	10.1038/s41375-020-0874-1	2021	Cytokine IL-36Œ≥ improves CAR T-cell functionality and induces endogenous antitumor response.	MYD88
32583848	10.1093/neuonc/noaa145	2021	Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.	MYD88
32591642	10.1038/s41375-020-0934-6	2021	Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma.	MYD88
32810857	10.1159/000509286	2021	Current and Emerging Treatments for Waldenstr√∂m Macroglobulinemia.	MYD88
32845738	10.1080/09273948.2020.1787460	2021	Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center.	MYD88
32965155	10.1080/09273948.2020.1802488	2021	Serial Detection of <i>MYD88</i> L265P Mutation in the Aqueous Humor of a Patient with Vitreoretinal Lymphoma for Disease Monitoring.	MYD88
32970964	10.1165/rcmb.2020-0083OC	2021	<i>Aspergillus</i> <i>fumigatus</i> Recognition by Dendritic Cells Negatively Regulates Allergic Lung Inflammation through a TLR2/MyD88 Pathway.	MYD88
32973328	10.1038/s41379-020-00685-7	2021	The clinicopathological and molecular features of sinusoidal large B-cell lymphoma.	MYD88
33025009	10.1182/blood.2020004918	2021	MYD88 L265P elicits mutation-specific ubiquitination to drive NF-Œ∫B activation and lymphomagenesis.	MYD88
33079297	10.1007/s10014-020-00386-8	2021	Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas.	MYD88
33202420	10.1182/blood.2020008520	2021	EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.	MYD88
33217360	10.1016/j.hemonc.2020.10.003	2021	Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.	MYD88
33221324	10.1016/j.ophtha.2020.11.018	2021	Single B-Cell Genomic Analyses Differentiate Vitreoretinal Lymphoma from Chronic Inflammation.	MYD88
33222046	10.1007/s12185-020-03038-x	2021	Monitoring of MYD88 L265P mutation by droplet digital polymerase chain reaction for prediction of early relapse in a patient with Bing-Neel syndrome.	MYD88
33232972	10.1182/blood.2020005244	2021	Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.	MYD88
33263441	10.1080/17474086.2021.1856652	2021	Development of molecular intervention strategies for B-cell lymphoma.	MYD88
33311649	10.1038/s41379-020-00720-7	2021	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.	MYD88
33368476	10.1002/ajh.26082	2021	Waldenstr√∂m macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.	MYD88
33395752	10.1016/j.tranon.2020.100977	2021	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.	MYD88
33447829	10.1158/2643-3230.BCD-19-0059	2021	An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities.	MYD88
33455071	10.1111/ijlh.13467	2021	The relative expression levels of CD148 and CD180 on clonal B cells and CD148/CD180 median fluorescence intensity ratios are useful in the characterization of mature B cell lymphoid neoplasms infiltrating blood and bone marrow - Results from a single centre pilot study.	MYD88
33488968	10.1021/acsmedchemlett.0c00474	2021	Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs.	MYD88
33512416	10.1182/blood.2020007245	2021	Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.	MYD88
33569985	10.1080/10428194.2021.1881514	2021	Clinical application of genomics in Waldenstr√∂m macroglobulinemia.	MYD88
33581493	10.1016/j.ctarc.2021.100310	2021	Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients.	MYD88
33620087	10.1111/bjh.17357	2021	MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.	MYD88
33622752	10.1136/bcr-2020-240242	2021	IgM paraprotein and anti-MAG sensory polyneuropathy associated with Waldenstrom's macroglobulinaemia and medullary carcinoma of the thyroid.	MYD88
33643507	10.14740/jh767	2021	Histologic Transformation in an Untreated Waldenstrom's Macroglobulinemia After 14 Years: Case Report and Review of the Literature.	MYD88
33677885	10.3760/cma.j.cn112151-20200513-00383	2021	[Clinicopathological features and MYD88 L265P mutation status of intravascular large B cell lymphoma].	MYD88
33685720	10.1016/j.pathol.2021.01.002	2021	New developments in non-Hodgkin lymphoid malignancies.	MYD88
33724154	10.1080/21505594.2021.1899674	2021	Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.	MYD88
33735664	10.1016/j.neo.2021.02.002	2021	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr√∂m macroglobulinemia.	MYD88
33735913	10.1182/blood.2020010137	2021	A rapid genotyping panel for detection of primary central nervous system lymphoma.	MYD88
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	MYD88
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	MYD88
33899787	10.1097/PAS.0000000000001691	2021	The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.	MYD88
33907976	10.1007/s12185-021-03157-z	2021	Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenstr√∂m macroglobulinemia/lymphoplasmacytic lymphoma.	MYD88
33909933	10.1002/ajh.26210	2021	Assessment of fixed-duration therapies for treatment-na√Øve Waldenstr√∂m macroglobulinemia.	MYD88
33962927	10.1136/bcr-2021-241707	2021	Chylothorax as a complication of Waldenstr√∂m macroglobulinaemia with a patient's perspective.	MYD88
33979991	10.3324/haematol.2020.278258	2021	Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-Œ∫B blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with <i>MYD88</i> L265P mutation.	MYD88
34009095	10.1080/09273948.2021.1878233	2021	Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma.	MYD88
34017329	10.3389/fimmu.2021.641692	2021	Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells.	MYD88
34038803	10.1016/j.carpath.2021.107348	2021	Endomyocardial biopsy with co-localization of a lymphoplasmacytic lymphoma and AL amyloidosis.	MYD88
34071407	10.3390/cancers13112665	2021	Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL.	MYD88
34078045	10.3760/cma.j.cn112151-20201201-00882	2021	[Nodal lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia: a clinicopathological and prognostical study].	MYD88
34105469	10.19746/j.cnki.issn.1009-2137.2021.03.017	2021	[Relationship between Polymorphism of miR-155 and Its Target Gene MyD88 and Clinicopathological Features of Diffuse Large B-cell Lymphoma].	MYD88
34113355	10.3389/fimmu.2021.684424	2021	Hippo Pathway Counter-Regulates Innate Immunity in Hepatitis B Virus Infection.	MYD88
34132782	10.1182/blood.2021011405	2021	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.	MYD88
34163463	10.3389/fimmu.2021.616451	2021	Absence of Non-Canonical, Inhibitory <i>MYD88</i> Splice Variants in B Cell Lymphomas Correlates With Sustained NF-Œ∫B Signaling.	MYD88
34173362	10.1097/IAE.0000000000003241	2021	CLINICAL FEATURES, DIAGNOSTIC SIGNIFICANCE, AND PROGNOSIS OF VITREORETINAL LYMPHOMA IN YOUNG PATIENTS.	MYD88
34201186	10.3390/medicina57060592	2021	Frostbite and Cold Agglutinin Disease: Coexistence of Two Entities Leading to Poor Clinical Outcomes.	MYD88
34204385	10.3390/cancers13123032	2021	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing.	MYD88
34236648	10.1007/978-1-0716-1669-7_20	2021	Generation and Surgical Analysis of Genetic Mouse Models to Study NF-Œ∫B-Driven Pathogenesis of Diffuse Large B Cell Lymphoma.	MYD88
34254378	10.1111/neup.12739	2021	Primary central nervous system lymphomas with massive intratumoral hemorrhage: Clinical, radiological, pathological, and molecular features of six cases.	MYD88
34255584	10.1080/09273948.2021.1916040	2021	A Case of Spontaneous Regression and Recurrence of Primary Vitreoretinal Lymphoma.	MYD88
34277756	10.3389/fvets.2021.683863	2021	<i>Clostridium butyricum</i> Helps to Alleviate Inflammation in Weaned Piglets Challenged With Enterotoxigenic <i>Escherichia coli</i> K88.	MYD88
34279092	10.1021/acs.jmedchem.1c00103	2021	Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL.	MYD88
34327781	10.1111/cas.15091	2021	Current progress and future perspectives of research on intravascular large B-cell lymphoma.	MYD88
34330762	10.1136/jitc-2021-002410	2021	High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.	MYD88
34340248	10.1111/bjh.17691	2021	Disease outcomes and biomarkers of progression in smouldering Waldenstr√∂m macroglobulinaemia.	MYD88
34362495	10.19746/j.cnki.issn.1009-2137.2021.04.020	2021	[The Types and Laboratory Characteristics of Non-Hodgkin Lymphoma with Bone Marrow Invasion as the First Manifestation].	MYD88
34377990	10.1093/noajnl/vdab090	2021	MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience.	MYD88
34378195	10.1111/bjh.17765	2021	Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.	MYD88
34405609	10.3760/cma.j.cn112151-20210110-00023	2021	[Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation].	MYD88
34439078	10.3390/cancers13163921	2021	Vitreoretinal Lymphoma.	MYD88
34497201	10.11406/rinketsu.62.1139	2021	[Therapeutic algorithm of Waldenstr√∂m's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].	MYD88
34523186	10.1111/cas.15133	2021	Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma.	MYD88
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	MYD88
34576156	10.3390/ijms22189992	2021	Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy.	MYD88
34589395	10.1016/j.apsb.2020.12.020	2021	Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.	MYD88
34606736	10.1080/14728222.2021.1988927	2021	Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma.	MYD88
34651869	10.1002/hon.2933	2021	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.	MYD88
34657049	NA	2021	[Circulating Tumor DNA Analysis in Lymphomas].	MYD88
34706861	10.1136/bjophthalmol-2021-319580	2021	Prevalence and prognostic value of <i>MYD88</i> and <i>CD79B</i> mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.	MYD88
34732622	10.11406/rinketsu.62.1493	2021	[IgG-variant Bing-Neel syndrome diagnosed by detecting MYD88 L265P mutation in the cerebrospinal fluid cells].	MYD88
34739844	10.1016/j.ccell.2021.10.006	2021	Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.	MYD88
34849377	10.14309/crj.0000000000000689	2021	A Rare Case of Waldenstrom Macroglobulinemia of the Rectosigmoid Colon.	MYD88
34865422	10.3760/cma.j.cn112151-20210316-00208	2021	[Lymphoplasmacytic lymphoma: a clinicopathological and prognostic analysis of 27 cases].	MYD88
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	MYD88
34940069	10.3390/curroncol28060430	2021	CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen.	MYD88
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	MYD88
34945004	10.3390/cancers13246384	2021	Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel.	MYD88
35087759	10.3389/fonc.2021.801124	2021	Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenstr√∂m Macroglobulinemia.	MYD88
35116576	10.21037/tcr-20-2525	2021	Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database.	MYD88
29629945	10.1097/PAI.0000000000000655	2020	Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	MYD88
30335535	10.1080/09273948.2018.1533984	2020	Immunohistochemical and Immunocytochemical Analyses in Patients with Vitreoretinal Lymphoma.	MYD88
31123031	10.3324/haematol.2018.214122	2020	<i>MYD88</i> mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.	MYD88
31286804	10.1080/15548627.2019.1635384	2020	New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.	MYD88
31588566	10.1111/bjh.16210	2020	IgM paraprotein-associated peripheral neuropathy: small CD20-positive B-cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness.	MYD88
31609782	10.1097/PAS.0000000000001386	2020	Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.	MYD88
31630277	10.1007/s10014-019-00354-x	2020	Ventricle-predominant primary CNS lymphomas: clinical, radiological and pathological evaluation of five cases and review of the literature.	MYD88
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	MYD88
31767130	10.1016/j.pathol.2019.09.009	2020	Lymphoplasmacytic lymphoma and Waldenstr√∂m macroglobulinaemia: clinicopathological features and differential diagnosis.	MYD88
31776466	10.1038/s41375-019-0661-z	2020	CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-Œ∫B signaling.	MYD88
31814157	10.1002/ajh.25697	2020	Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenstr√∂m Macroglobulinemia.	MYD88
31863183	10.1007/s00428-019-02698-3	2020	Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.	MYD88
31866281	10.1016/S2352-3026(19)30210-8	2020	Acalabrutinib monotherapy in patients with Waldenstr√∂m macroglobulinemia: a single-arm, multicentre, phase 2 study.	MYD88
31886867	10.1093/jnen/nlz125	2020	Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma.	MYD88
31902622	10.1016/j.pathol.2019.11.002	2020	A practical guide to laboratory investigations at diagnosis and follow up in Waldenstr√∂m macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.	MYD88
31935288	10.1182/bloodadvances.2019000947	2020	Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.	MYD88
31960730	10.1080/10428194.2020.1711901	2020	Waldenstrom's macroglobulinemia in the era of immunotherapy.	MYD88
31964218	10.1177/1078155219895079	2020	Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level.	MYD88
31992103	10.1080/10428194.2020.1719100	2020	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenstr√∂m macroglobulinemia.	MYD88
32005797	10.1038/s41408-020-0277-6	2020	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.	MYD88
32006301	10.1007/s11899-020-00559-4	2020	Novel Treatment Strategies in the Management of Waldenstr√∂m Macroglobulinemia.	MYD88
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	MYD88
32014679	10.1016/j.ejmech.2020.112092	2020	Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.	MYD88
32016162	10.1016/j.ajoc.2020.100597	2020	Lymphoplasmacytic lymphoma infiltrating both lacrimal glands in a patient with Waldenstr√∂m's macroglobulinemia.	MYD88
32056332	10.1111/cas.14347	2020	Gene expression profiling of primary vitreoretinal lymphoma.	MYD88
32083995	10.1200/JCO.19.02314	2020	Genomic Landscape of Waldenstr√∂m Macroglobulinemia and Its Impact on Treatment Strategies.	MYD88
32103491	10.1111/bjh.16463	2020	Genomic evolution of ibrutinib-resistant clones in Waldenstr√∂m macroglobulinaemia.	MYD88
32127472	10.1073/pnas.1921187117	2020	Regulation of B cell receptor-dependent NF-Œ∫B signaling by the tumor suppressor KLHL14.	MYD88
32161170	10.1128/JVI.02123-19	2020	Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.	MYD88
32170099	10.1038/s41408-020-0305-6	2020	Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice.	MYD88
32173361	10.1016/j.exphem.2020.03.001	2020	Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma.	MYD88
32187361	10.1182/blood.2019003535	2020	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.	MYD88
32201861	10.1093/noajnl/vdaa018	2020	Primary CNS lymphoma commonly expresses immune response biomarkers.	MYD88
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	MYD88
32249238	10.3960/jslrt.19041	2020	Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma.	MYD88
32267931	10.1182/bloodadvances.2019000980	2020	Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire.	MYD88
32272395	10.1016/j.intimp.2020.106445	2020	4-hydroxybenzo[d]oxazol-2(3H)-one ameliorates LPS/D-GalN-induced acute liver injury by inhibiting TLR4/NF-Œ∫B and MAPK signaling pathways in mice.	MYD88
32322395	10.1186/s40364-020-00189-1	2020	TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients.	MYD88
32323419	10.1111/pin.12937	2020	Composite monoclonal B-cell lymphocytosis and MYD88 L265P-positive lymphoplasmacytic lymphoma in a patient with IgM light chain amyloidosis: Case report.	MYD88
32325488	10.1182/blood.2019002654	2020	LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells.	MYD88
32335928	10.1111/cup.13722	2020	An unusual case of cutaneous Waldenstr√∂m macroglobulinemia with the MYD88 L265P mutation.	MYD88
32374309	10.1039/d0fo00019a	2020	Dietary supplementation of l-arginine and N-carbamylglutamate enhances duodenal barrier and mitochondrial functions and suppresses duodenal inflammation and mitophagy in suckling lambs suffering from intrauterine-growth-restriction.	MYD88
32391356	10.3389/fcell.2020.00262	2020	A Dual TLR7/TLR9 Inhibitor HJ901 Inhibits ABC-DLBCL Expressing the MyD88 L265P Mutation.	MYD88
32399964	10.1002/ijc.33049	2020	Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.	MYD88
32468019	10.3892/mmr.2020.11186	2020	Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.	MYD88
32469082	10.1002/cncr.32866	2020	Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.	MYD88
32488284	10.2340/00015555-3535	2020	Cutaneous Involvement in Waldenstr√∂m's Macroglobulinaemia.	MYD88
32510610	10.1002/hon.2761	2020	On point in primary CNS lymphoma.	MYD88
32536998	10.3892/etm.2020.8695	2020	Effectiveness of digital PCR for MYD88<sup>L265P</sup> detection in vitreous fluid for primary central nervous system lymphoma diagnosis.	MYD88
32566435	10.7759/cureus.8651	2020	Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: A Case Report.	MYD88
32572944	10.26355/eurrev_202006_21545	2020	Propofol improves intestinal ischemia-reperfusion injury in rats through NF-Œ∫B pathway.	MYD88
32578872	10.1111/bjh.16917	2020	Two independent consecutive lymphoma cases carry an identical MYD88 mutation but differ in their IGVH rearrangement.	MYD88
32603202	10.1080/14656566.2020.1770727	2020	An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.	MYD88
32630470	10.3390/cancers12061688	2020	Immunoglobulin M Paraproteinaemias.	MYD88
32654665	10.1186/s13256-020-02404-x	2020	Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a¬†case report.	MYD88
32660905	10.1016/j.clml.2020.06.006	2020	Light Chain Deposition Disease in a Patient With MYD88 L265P Mutation-positive Low-grade B-cell Lymphoma and Monoclonal Immunoglobulin G Œ∫.	MYD88
32695560	10.2176/nmccrj.cr.2019-0241	2020	Primary Central Nervous System Methotrexate-associated Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis: Case Report and Review of Literature.	MYD88
32723621	10.1016/j.clml.2020.06.025	2020	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis.	MYD88
32736575	10.1186/s12885-020-07198-1	2020	Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.	MYD88
32738175	10.1002/hon.2784	2020	Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis.	MYD88
32745612	10.1016/j.jmoldx.2020.07.002	2020	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.	MYD88
32780869	10.1111/bjh.17038	2020	Indolent clinical behaviour of primary cutaneous diffuse large B-cell lymphoma, leg type, with double MYC and BCL6 gene rearrangement.	MYD88
32781214	10.1016/j.leukres.2020.106426	2020	MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.	MYD88
32789566	10.1007/s12185-020-02970-2	2020	Lymphoplasmacytic lymphoma in a patient with Birt-Hogg-Dub√© syndrome.	MYD88
32790920	10.1111/bjh.17036	2020	Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responses.	MYD88
32848129	10.1038/s41408-020-00351-w	2020	Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.	MYD88
32854650	10.1186/s12885-020-07293-3	2020	DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.	MYD88
32858764	10.1111/jcmm.15774	2020	IKKŒµ and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKKŒµ/TBK1 inhibitor to repress NF-Œ∫B and IL-10 signalling.	MYD88
32888499	10.1016/j.chembiol.2020.08.010	2020	Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.	MYD88
32932517	10.1182/blood.2020005857	2020	The dangers of d√©j√† vu: memory B cells as the cells of origin of ABC-DLBCLs.	MYD88
32947237	10.1016/j.tranon.2020.100855	2020	Identification of clinical molecular targets for childhood Burkitt lymphoma.	MYD88
32955949	10.1080/14728214.2020.1822816	2020	Emerging drugs for the treatment of Waldenstr√∂m macroglobulinemia.	MYD88
32971631	10.4103/ijo.IJO_1712_19	2020	<i>MYD88</i> L265P mutation in intraocular lymphoma: A potential diagnostic marker.	MYD88
33050534	10.3390/cancers12102913	2020	Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice.	MYD88
33067267	10.1158/0008-5472.CAN-20-2425	2020	A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.	MYD88
33091850	10.1016/j.bmc.2020.115815	2020	Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.	MYD88
33154951	10.3389/fonc.2020.591577	2020	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	MYD88
33180881	10.1371/journal.pone.0241634	2020	Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?	MYD88
33182056	10.1016/j.intimp.2020.106974	2020	Echinacea polysaccharide alleviates LPS-induced lung injury via inhibiting inflammation, apoptosis and activation of the TLR4/NF-Œ∫B signal pathway.	MYD88
33188997	10.1016/j.ctarc.2020.100235	2020	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.	MYD88
33211828	10.1182/bloodadvances.2020002944	2020	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.	MYD88
33214835	10.1021/acsmedchemlett.0c00378	2020	Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma.	MYD88
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	MYD88
33275726	10.1182/hematology.2020000121	2020	Management of Waldenstr√∂m macroglobulinemia in 2020.	MYD88
33297772	10.1080/17474086.2020.1851184	2020	Zanubrutinib for the treatment of Waldenstr√∂m Macroglobulinemia.	MYD88
33318921	10.1016/j.rmcr.2020.101313	2020	Lymphoplasmacytic lymphoma involving the mediastinum and the lung, followed by amyloidosis: A surgically and genetically proven case.	MYD88
33343574	10.3389/fimmu.2020.602868	2020	B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS.	MYD88
33445850	10.3760/cma.j.issn.0253-2727.2020.12.009	2020	[Clinical characteristics and prognosis of Waldenstr√∂m's macroglobulinemia: a clinical data report from a single center].	MYD88
34667996	10.21037/aol-20-20	2020	Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.	MYD88
29734251	10.1097/PAI.0000000000000585	2019	MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.	MYD88
30038380	10.1038/s41375-018-0215-9	2019	Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.	MYD88
30113125	10.1111/aos.13808	2019	Clinical spectrum of vitreoretinal lymphoma and its association with MyD88 L265P mutation.	MYD88
30198568	10.1111/bjh.15584	2019	CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.	MYD88
30204732	10.1097/IAE.0000000000002319	2019	MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA.	MYD88
30324684	10.1002/jcb.27854	2019	Protective effects and mechanism of curcumin on myocardial injury induced by coronary microembolization.	MYD88
30328142	10.1002/ajh.25292	2019	Waldenstr√∂m macroglobulinemia: 2019 update on diagnosis, risk stratification, and management.	MYD88
30338525	10.1111/bjh.15610	2019	Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenstr√∂m Macroglobulinaemia reveals different patterns of clonal evolution.	MYD88
30342054	10.1016/j.humpath.2018.09.021	2019	Prolymphocytic transformation of lymphoplasmacytic lymphoma: an extremely unusual event.	MYD88
30353605	10.1111/cas.13848	2019	Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.	MYD88
30360939	10.1016/j.leukres.2018.10.003	2019	Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns.	MYD88
30390359	10.1111/ejh.13191	2019	CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.	MYD88
30408153	10.1111/bjh.15674	2019	MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma.	MYD88
30426157	10.1007/s00277-018-3545-9	2019	Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis.	MYD88
30444439	10.5858/arpa.2018-0092-OA	2019	High Frequency of MYD88 L265P Mutation in Primary Ocular Adnexal Marginal Zone Lymphoma and Its Clinicopathologic Correlation: A Study From a Single Institution.	MYD88
30501537	10.1080/10428194.2018.1537487	2019	Modulating the conformation of the TIR domain by a neoteric MyD88 inhibitor leads to the separation of GVHD from GVT.	MYD88
30604315	10.1007/s12185-018-02585-8	2019	Is clinicopathological distinction of mucosa-associated lymphoid tissue lymphoma from Waldenstr√∂m macroglobulinemia essential in MYD88 L265P mutation-positive cases?	MYD88
30608918	10.12659/MSM.912490	2019	Protective Effect of Hesperidin Against Sepsis-Induced Lung Injury by Inducing the Heat-Stable Protein 70 (Hsp70)/Toll-Like Receptor 4 (TLR4)/ Myeloid Differentiation Primary Response 88 (MyD88) Pathway.	MYD88
30623224	10.1007/s00347-018-0840-8	2019	[New molecular pathological strategies for malignant iris tumors].	MYD88
30663686	10.3791/58439	2019	Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity.	MYD88
30680453	10.1007/s00428-019-02527-7	2019	AL amyloidosis with a localized B cell neoplasia.	MYD88
30683910	10.1038/s41375-019-0380-5	2019	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.	MYD88
30715765	10.1111/his.13832	2019	Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases.	MYD88
30723112	10.1182/bloodadvances.2018027672	2019	<i>MYD88</i> L265P mutation and <i>CDKN2A</i> loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.	MYD88
30763982	10.1111/bjh.15792	2019	Digital PCR in bone marrow trephine biopsies is highly sensitive for MYD88<sup>L265P</sup> detection in lymphomas with plasmacytic/plasmacytoid differentiation.	MYD88
30772517	10.1016/j.gene.2019.02.030	2019	The inhibition of microRNA-203 on ischemic reperfusion injury after total knee arthroplasty via suppressing MYD88-mdiated toll-like receptor signaling pathway.	MYD88
30793105	10.1016/j.htct.2018.05.014	2019	Prognostic impact of <i>MYD88</i> mutation, proliferative index and cell origin in diffuse large B cell lymphoma.	MYD88
30815927	10.1111/cas.13983	2019	Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.	MYD88
30828149	10.1007/s12288-018-0978-1	2019	MYD88 and CXCR4 Mutation Profiling in Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinaemia.	MYD88
30989098	10.1016/j.jdcr.2019.02.002	2019	Schnitzler syndrome associated with <i>MYD88</i> L265P mutation.	MYD88
31000522	10.1158/0008-5472.CAN-18-3438	2019	MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.	MYD88
31033057	10.1111/cyt.12711	2019	Cytological diagnosis of vitreoretinal lymphomas: A case series.	MYD88
31107988	10.1111/his.13921	2019	MYD88L265P mutated IgA lymphoplasmacytic lymphoma.	MYD88
31109360	10.1186/s13000-019-0826-0	2019	Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.	MYD88
31115023	10.26355/eurrev_201905_17824	2019	A study of regulatory effects of TLR4 and NF-Œ∫B on primary biliary cholangitis.	MYD88
31150604	10.1016/j.jid.2019.05.008	2019	Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.	MYD88
31184237	10.1080/10428194.2019.1620942	2019	Clinicopathologic correlates of <i>MYD88</i> L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.	MYD88
31202483	10.1016/j.pathol.2019.03.005	2019	MALT lymphoma with IgM paraprotein and bone marrow involvement mimicking Waldenstr√∂m macroglobulinaemia.	MYD88
31221512	10.1016/j.clml.2019.03.009	2019	Characteristics of Waldenstr√∂m Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.	MYD88
31229160	10.1016/j.hoc.2019.03.004	2019	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.	MYD88
31243026	10.1136/bcr-2019-230067	2019	Rare case of Bing-Neel syndrome treated successfully with ibrutinib.	MYD88
31255931	10.1016/j.jss.2019.05.036	2019	Posttreatment With LYRM03 Protects Rats From¬†Acute Lung Inflammation Induced by Lipopolysaccharide via Suppressing the NF-Œ∫B/MyD88/TLR4 Axis.	MYD88
31276195	10.1111/bjh.16086	2019	A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenstr√∂m macroglobulinaemia or other lymphoproliferative disorders.	MYD88
31278738	10.1093/ajcp/aqz078	2019	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms.	MYD88
31292111	10.1182/blood.2019000022	2019	Single-cell MYD88 sequencing of isolated B cells from vitreous biopsies aids vitreoretinal lymphoma diagnosis.	MYD88
31305194	10.1080/10428194.2019.1639169	2019	Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma.	MYD88
31378966	10.1002/ajh.25600	2019	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.	MYD88
31391404	10.3960/jslrt.19009	2019	IgA-producing lymphoplasmacytic lymphoma carrying the chromosomal abnormality t(8;14).	MYD88
31402495	10.1111/imr.12792	2019	Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.	MYD88
31403034	10.3389/fonc.2019.00683	2019	Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.	MYD88
31432184	10.3892/or.2019.7282	2019	Disrupting myddosome assembly in diffuse large B‚Äëcell lymphoma cells using the MYD88 dimerization inhibitor ST2825.	MYD88
31436356	10.1111/cas.14176	2019	Mutations found in cell-free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis.	MYD88
31464711	10.1097/PAS.0000000000001363	2019	Class-switched Primary Cutaneous Marginal Zone Lymphomas Are Frequently IgG4-positive and Have Features Distinct From IgM-positive Cases.	MYD88
31484887	10.11406/rinketsu.60.903	2019	[Successful detection of MYD88 L265P mutation in Waldenstr√∂m's macroglobulinemia complicated with myelofibrosis using highly sensitive digital PCR].	MYD88
31488111	10.1186/s12906-019-2656-8	2019	The protective effect and mechanism of catalpol on high glucose-induced podocyte injury.	MYD88
31527073	10.1182/blood.2019000725	2019	How I treat Waldenstr√∂m macroglobulinemia.	MYD88
31528323	10.4084/MJHID.2019.057	2019	Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the <i>MYD88</i> L265P Gene Mutation.	MYD88
31556196	10.1111/pin.12854	2019	MYD88 L265P mutation analysis is a useful diagnostic adjunct for lymphoplasmacytic lymphoma with pleural effusion.	MYD88
31576141	10.2147/OTT.S211436	2019	Follicular Lymphoma Presenting With Monoclonal IgM And MYD88 Mutation: A Case Report And Review Of The Literature.	MYD88
31589186	10.1097/ICU.0000000000000620	2019	Primary vitreoretinal lymphoma: empowering our clinical suspicion.	MYD88
31591468	10.1038/s41375-019-0592-8	2019	What is new in the treatment of Waldenstrom macroglobulinemia?	MYD88
31592789	10.1097/WCO.0000000000000759	2019	Molecular profiling of primary central nervous system lymphomas - predictive and prognostic value?	MYD88
31695539	10.2147/JBM.S183997	2019	Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.	MYD88
31698464	10.1182/bloodadvances.2019000588	2019	Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.	MYD88
31699794	10.3324/haematol.2019.227272	2019	MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.	MYD88
31806993	10.2147/OTT.S227122	2019	Genomic Alterations In Primary Cardiac Diffuse Large B Cell Lymphoma: A Case Report And Literature Review.	MYD88
32063711	10.2147/OTT.S222189	2019	Prevalence And Clinical Significance Of Oncogenic <i>CD79B</i> And <i>MYD88</i> Mutations In Primary Testicular Diffuse Large B-Cell Lymphoma: A Retrospective Study In China.	MYD88
35100686	10.1200/PO.18.00308	2019	High Detection Rate of <i>MYD88</i> Mutations in Cerebrospinal Fluid From Patients With CNS Lymphomas.	MYD88
28815730	10.1002/jcb.26353	2018	Loss of BMI-1 dampens migration and EMT of colorectal cancer in inflammatory microenvironment through TLR4/MD-2/MyD88-mediated NF-Œ∫B signaling.	MYD88
28868954	10.1080/10428194.2017.1370546	2018	Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.	MYD88
29018161	10.1136/jnnp-2017-316689	2018	High prevalence of the <i>MYD88 L265P</i> mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy.	MYD88
29043881	10.1080/10428194.2017.1387903	2018	Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines.	MYD88
29080258	10.1002/ajh.24955	2018	MYD88 mutation status does not impact overall survival in Waldenstr√∂m macroglobulinemia.	MYD88
29122821	10.1136/bjophthalmol-2017-311151	2018	Metagenomic deep sequencing of aqueous fluid detects intraocular lymphomas.	MYD88
29151258	10.1111/cas.13450	2018	Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.	MYD88
29181840	10.1111/bjh.15049	2018	MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and¬†overall survival.	MYD88
29210102	10.1002/hon.2489	2018	The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid.	MYD88
29258950	10.1016/j.wneu.2017.12.028	2018	MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.	MYD88
29289361	10.1016/j.blre.2017.12.001	2018	The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.	MYD88
29358175	10.1182/blood-2017-09-805499	2018	Extracellular vesicle-mediated transfer of constitutively active MyD88<sup>L265P</sup> engages MyD88<sup>wt</sup> and activates signaling.	MYD88
29375693	10.3892/etm.2017.5349	2018	Simvastatin improves intracerebral hemorrhage through NF-Œ∫B-mediated apoptosis via the MyD88/TRIF signaling pathway.	MYD88
29398441	10.1016/j.bmc.2018.01.008	2018	Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.	MYD88
29403563	10.3892/ol.2017.7472	2018	High frequency and prognostic value of <i>MYD88</i> L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment.	MYD88
29433938	10.1016/j.ymthe.2018.01.007	2018	B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.	MYD88
29482770	10.1016/j.jmoldx.2017.11.006	2018	MYD88 Mutations and Sensitivity to Ibrutinib Therapy.	MYD88
29496671	10.1182/blood-2017-10-811752	2018	BTK<sup>Cys481Ser</sup> drives ibrutinib resistance via ERK1/2 and protects BTK<sup>wild-type</sup> MYD88-mutated cells by a paracrine mechanism.	MYD88
29514783	10.1182/blood-2017-12-822817	2018	High prevalence of <i>MYD88</i> and <i>CD79B</i> mutations in intravascular large B-cell lymphoma.	MYD88
29567768	10.3324/haematol.2017.186528	2018	Highly sensitive <i>MYD88</i><sup>L265P</sup> mutation detection by droplet digital polymerase chain reaction in Waldenstr√∂m macroglobulinemia.	MYD88
29587428	10.3390/biomedicines6020038	2018	NF-Œ∫B Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy.	MYD88
29596904	10.1016/j.jid.2018.03.1516	2018	A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg¬†Type.	MYD88
29610969	10.1007/s00277-018-3311-z	2018	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstr√∂m macroglobulinemia.	MYD88
29637541	10.1111/bjh.15202	2018	How we manage patients with Waldenstr√∂m macroglobulinaemia.	MYD88
29641966	10.1056/NEJMoa1801445	2018	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.	MYD88
29703722	10.1158/0008-5472.CAN-18-0215	2018	<i>MYD88</i> L265P Mutation in Lymphoid Malignancies.	MYD88
29712895	10.1038/s41408-018-0076-5	2018	Waldenstr√∂m macroglobulinemia treatment algorithm 2018.	MYD88
29760948	10.1186/s40942-018-0120-4	2018	The diagnosis and treatment of primary vitreoretinal lymphoma: a review.	MYD88
29856685	10.1056/NEJMoa1802917	2018	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstr√∂m's Macroglobulinemia.	MYD88
29857068	10.1016/j.jid.2018.04.038	2018	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.	MYD88
29868855	10.1093/ajcp/aqy041	2018	Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?	MYD88
29869471	10.30637/2018.17-090	2018	[Diagnostic approach of an IgM monoclonal gammopathy and clinical importance of gene MYD88 L265P mutation].	MYD88
29871863	10.1182/blood-2017-12-819706	2018	HSP110 sustains chronic NF-Œ∫B signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.	MYD88
29878045	10.1093/annonc/mdy133	2018	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.	MYD88
29891112	10.1016/j.critrevonc.2018.05.010	2018	Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.	MYD88
29895903	10.1038/s41408-018-0089-0	2018	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.	MYD88
29899297	10.3390/ijms19061758	2018	Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.	MYD88
29925955	10.1038/s41586-018-0290-0	2018	A multiprotein supercomplex controlling oncogenic signalling in lymphoma.	MYD88
29931605	10.1007/s11864-018-0555-8	2018	Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.	MYD88
29937999	10.18632/oncotarget.25463	2018	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma.	MYD88
29957733	10.1097/PAS.0000000000001113	2018	Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas: A Lesion Associated With Diverse Immunodeficiency Settings.	MYD88
29973445	10.11406/rinketsu.59.695	2018	[Successful diagnosis of lymphoplasmacytic lymphoma with IgG paraprotein using MYD88 L265P mutation analysis].	MYD88
29982402	10.1093/annonc/mdy146	2018	Waldenstr√∂m's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.	MYD88
29989027	10.18632/oncotarget.25601	2018	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	MYD88
30027272	10.1001/jamaophthalmol.2018.2887	2018	Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction.	MYD88
30027276	10.1001/jamaophthalmol.2018.2894	2018	Detection of MYD88 Mutations in Vitreoretinal Lymphoma and Its Implications.	MYD88
30072412	10.1182/blood-2018-06-857532	2018	HSP110 and MYD88: blame the chaperone.	MYD88
30086464	10.1016/j.biopha.2018.07.139	2018	Dual functional roles of the MyD88 signaling in colorectal cancer development.	MYD88
30126942	10.1158/1078-0432.CCR-17-3265	2018	Targeting Myddosome Signaling in Waldenstr√∂m's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.	MYD88
30171453	10.1007/s11060-018-2990-6	2018	Characterization of genomic alterations in primary central nervous system lymphomas.	MYD88
30190015	10.1016/j.hoc.2018.05.007	2018	Working Toward a Genomic Prognostic Classification of Waldenstr√∂m Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.	MYD88
30203262	10.1007/s00262-018-2242-9	2018	Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.	MYD88
30227305	10.1016/j.neo.2018.08.012	2018	Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.	MYD88
30238920	10.1684/abc.2018.1384	2018	IgG lymphoplasmacytic lymphoma: a case report.	MYD88
30253331	10.1016/j.intimp.2018.09.024	2018	MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade.	MYD88
30294590	10.3389/fonc.2018.00382	2018	Detection of the <i>MYD88</i> p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma.	MYD88
30301877	10.1038/s41408-018-0130-3	2018	Loss of TNFAIP3 enhances MYD88<sub>L265P</sub>-driven signaling in non-Hodgkin lymphoma.	MYD88
30360879	10.1053/j.seminoncol.2018.07.005	2018	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	MYD88
30401751	10.1182/bloodadvances.2018022962	2018	Insights into the genomic landscape of MYD88 wild-type Waldenstr√∂m macroglobulinemia.	MYD88
30429379	10.1172/jci.insight.125568	2018	Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.	MYD88
30501701	10.7534/j.issn.1009-2137.2018.06.014	2018	[ARMS-PCR combined with capillary electrophoresis can be a sensitive and quantitative method for detection of MYD88-L265P mutation in lymphoma].	MYD88
30626796	10.11406/rinketsu.59.2600	2018	[MALT lymphoma accompanied by elevated serum IgM levels mimicking Waldenstr√∂m's macroglobulinemia].	MYD88
27161435	10.1111/bjh.14080	2017	MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma.	MYD88
27347751	10.1080/10428194.2016.1196813	2017	Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies.	MYD88
27687087	10.1080/10428194.2016.1213836	2017	Nodal marginal zone lymphoma: mutation status analyses of CD79A, CD79B, and MYD88 reveal no specific recurrent lesions.	MYD88
27734522	10.1002/hon.2361	2017	Detection of L265P MYD-88 mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ).	MYD88
27840426	10.1038/leu.2016.330	2017	Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.	MYD88
27861728	10.1111/bjd.15183	2017	Myeloid differentiation primary response 88 mutations in a distinct type of cutaneous marginal-zone lymphoma with a nonclass-switched immunoglobulin M immunophenotype.	MYD88
27915469	10.1002/cncr.30404	2017	MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.	MYD88
27923841	10.1158/1078-0432.CCR-16-1922	2017	Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.	MYD88
28002793	10.18632/oncotarget.14008	2017	Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.	MYD88
28042684	10.1111/ijlh.12598	2017	Detection of the MYD88 mutation by the combination of the allele-specific PCR and quenching probe methods.	MYD88
28056114	10.1001/jamaoncol.2016.5763	2017	Diagnosis and Management of Waldenstr√∂m Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.	MYD88
28073005	10.1016/j.ccell.2016.12.003	2017	Simultaneous Inhibition of PI3KŒ¥ and PI3KŒ± Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-Œ∫B and AKT.	MYD88
28076910	10.1111/imj.13311	2017	Treatment of patients with Waldenstr√∂m macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.	MYD88
28094456	10.1002/ajh.24557	2017	Waldenstr√∂m macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.	MYD88
28147336	10.18632/oncotarget.14876	2017	Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.	MYD88
28153771	10.1016/j.ebiom.2017.01.027	2017	B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.	MYD88
28232371	10.3324/haematol.2016.156281	2017	c-Myc dysregulation is a co-transforming event for nuclear factor-Œ∫B activated B cells.	MYD88
28235842	10.1182/blood-2017-01-761726	2017	Acquired mutations associated with ibrutinib resistance in Waldenstr√∂m macroglobulinemia.	MYD88
28241765	10.1186/s12967-017-1152-5	2017	Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.	MYD88
28273183	NA	2017	[The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenstr√∂m macroglobulinaemia].	MYD88
28280994	10.1007/s00277-017-2968-z	2017	Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.	MYD88
28286680	10.1155/2017/5183646	2017	Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom's Macroglobulinemia.	MYD88
28319526	10.1097/PAS.0000000000000836	2017	Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features.	MYD88
28321094	10.11406/rinketsu.58.155	2017	Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88<sup>L265P</sup> mutation.	MYD88
28331368	10.2147/CMAR.S94059	2017	New developments in the management of Waldenstr√∂m macroglobulinemia.	MYD88
28341730	10.3324/haematol.2016.161893	2017	Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant <i>MYD88</i> and wildtype <i>CD79</i>.	MYD88
28352655	10.1172/jci.insight.90196	2017	Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.	MYD88
28366781	10.1016/j.clml.2017.02.028	2017	Waldenstr√∂m Macroglobulinemia: Review of Pathogenesis and Management.	MYD88
28368397	10.1038/onc.2017.90	2017	Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.	MYD88
28370087	10.1111/cup.12944	2017	MYD88 L265P mutation in cutaneous involvement by Waldenstr√∂m macroglobulinemia.	MYD88
28381754	10.2169/internalmedicine.56.7340	2017	Lymphoplasmacytic Lymphoma Presenting with Diarrhea and Joint Pain Which was Successfully Diagnosed by an MYD88 Mutation Analysis.	MYD88
28405493	10.1080/2162402X.2016.1219825	2017	HLA class I-restricted <i>MYD88</i> L265P-derived peptides as specific targets for lymphoma immunotherapy.	MYD88
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	MYD88
28483372	10.1016/j.pathol.2017.02.004	2017	Role of plasma cells in Waldenstr√∂m macroglobulinaemia.	MYD88
28496180	10.1038/s41598-017-01998-5	2017	Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.	MYD88
28533926	NA	2017	Concomitant lymphoplasmacytic lymphoma and plasma cell myeloma, a diagnostic challenge.	MYD88
28552327	10.1016/j.ccell.2017.04.012	2017	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.	MYD88
28558176	10.22608/APO.2017150	2017	Primary Vitreoretinal Lymphoma -- A Review.	MYD88
28592763	10.11406/rinketsu.58.480	2017	Malignant lymphoma: pathophysiology and current therapy.	MYD88
28617062	10.1080/17474086.2017.1343661	2017	Novel approaches to targeting MYD88 in Waldenstr√∂m macroglobulinemia.	MYD88
28636991	10.18632/oncotarget.18325	2017	Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.	MYD88
28664939	10.1038/modpathol.2017.58	2017	Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.	MYD88
28679988	10.11406/rinketsu.58.595	2017	Follicular lymphoma with plasmacytic differentiation accompanied by monoclonal IgG gammopathy.	MYD88
28682481	10.1002/path.4933	2017	Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma.	MYD88
28690525	10.1159/000477489	2017	Primary Type3 (Non-ABC, Non-GCB) Subtype of Extranodal Diffuse Large B-Cell Lymphoma of the Thyroid Bearing No <i>MYD88</i> Mutation by Padlock Probe Hybridization.	MYD88
28701369	10.1084/jem.20161454	2017	Synergistic cooperation and crosstalk between <i>MYD88<sup>L265P</sup></i> and mutations that dysregulate CD79B and surface IgM.	MYD88
28751561	10.3324/haematol.2016.160192	2017	Exome sequencing identifies recurrent <i>BCOR</i> alterations and the absence of <i>KLF2</i>, <i>TNFAIP3</i> and <i>MYD88</i> mutations in splenic diffuse red pulp small B-cell lymphoma.	MYD88
28786474	10.1111/bjh.14826	2017	Dexamethasone, rituximab and cyclophosphamide for relapsed¬†and/or refractory and treatment-na√Øve patients with Waldenstrom macroglobulinemia.	MYD88
28803429	10.1007/s00277-017-3094-7	2017	Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.	MYD88
28811957	10.1080/2162402X.2017.1321184	2017	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.	MYD88
28847710	10.1016/j.bbmt.2017.08.022	2017	Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.	MYD88
28856744	10.1111/neup.12405	2017	Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.	MYD88
28877839	10.3881/j.issn.1000-503X.2017.04.019	2017	Significances of MYD88<sup>L265P</sup> and CXCR4<sup>WHIM</sup> Mutations in Waldenstrom Macroglobulinemia.	MYD88
28892161	10.1002/path.4982	2017	A gene is known by the company it keeps: enrichment of TNFAIP3 gene aberrations in MALT lymphomas expressing IGHV4-34 antigen receptors.	MYD88
28903575	10.14735/amko20172S81	2017	Diagnostic Tools of Waldenstr√∂ms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.	MYD88
28922238	10.1097/WCO.0000000000000492	2017	Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies?	MYD88
28987624	10.1016/j.micpath.2017.10.004	2017	Toll like receptor 4 signaling pathway participated in Salmonella lipopolysaccharide-induced spleen injury in young chicks.	MYD88
28993276	10.1016/j.humpath.2017.09.013	2017	A distinctive subgroup of oral EBV+ B-cell neoplasm with polymorphous features is potentially identical to EBV+ mucocutaneous ulcer.	MYD88
28993856	10.1007/s00292-017-0378-6	2017	[Malignant lymphomas of the eye].	MYD88
29025291	10.1556/650.2017.30868	2017	[Waldenstr√∂m's macroglobulinemia and its individualized therapy options].	MYD88
29029457	10.18632/oncotarget.19936	2017	Prognostic relevance of protein expression, clinical factors, and <i>MYD88</i> mutation in primary bone lymphoma.	MYD88
29054399	10.1016/j.jmoldx.2017.07.007	2017	Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study.	MYD88
29061802	10.21873/anticanres.12070	2017	MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells.	MYD88
29070995	10.1159/000480292	2017	Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88<sup>L265P</sup> Mutation.	MYD88
29081197	10.3760/cma.j.issn.0253-2727.2017.09.011	2017	[Clinical features and prognosis of 17 patients with primary cold agglutinin disease].	MYD88
29088270	10.1371/journal.pone.0186614	2017	IRAK4 is essential for TLR9-induced suppression of Epstein-Barr virus BZLF1 transcription in Akata Burkitt's lymphoma cells.	MYD88
29172502	10.1021/acs.jmedchem.7b01290	2017	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell Lymphoma.	MYD88
29222280	10.1182/asheducation-2017.1.365	2017	Toward personalized treatment in Waldenstr√∂m macroglobulinemia.	MYD88
29245897	10.18632/oncotarget.18502	2017	Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum.	MYD88
29262531	10.18632/oncotarget.21986	2017	Mutational profile of primary breast diffuse large B-cell lymphoma.	MYD88
32064225	10.1016/j.ehpc.2017.06.006	2017	Persistent indolent pancolonic marginal zone lymphoma of MALT-type with plasmacytic differentiation - A rare post-transplant lymphoma?	MYD88
26111727	10.1111/nan.12259	2016	Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.	MYD88
26747248	10.1182/blood-2015-07-655647	2016	CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.	MYD88
26752547	10.1097/PAS.0000000000000592	2016	Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.	MYD88
26757737	10.1007/s00401-016-1536-2	2016	Genomic characterization of primary central nervous system lymphoma.	MYD88
26773040	10.1182/blood-2015-09-672352	2016	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.	MYD88
26787899	10.1073/pnas.1524677113	2016	Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.	MYD88
26792260	10.1158/1078-0432.CCR-15-1525	2016	MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.	MYD88
26797804	10.1111/ijlh.12456	2016	Positive selection and high sensitivity test for MYD88 mutations using locked nucleic acid.	MYD88
26800678	10.1007/s00108-015-0006-6	2016	[Classification of malignant lymphomas. Current situation].	MYD88
26841176	10.1055/s-0041-107960	2016	[New developments in Waldenstr√∂m's macroglobulinemia].	MYD88
26867669	10.1038/leu.2016.8	2016	Clonal B cells in Waldenstr√∂m's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling.	MYD88
26883583	10.3109/10428194.2016.1139703	2016	Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.	MYD88
26900675	10.1097/IAE.0000000000000996	2016	PREVALENCE OF MYD88 L265P MUTATION IN HISTOLOGICALLY PROVEN, DIFFUSE LARGE B-CELL VITREORETINAL LYMPHOMA.	MYD88
26942591	10.1007/s11864-016-0391-7	2016	Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.	MYD88
26980069	10.3109/10428194.2016.1157875	2016	Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.	MYD88
27048211	10.1182/blood-2015-11-684183	2016	B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.	MYD88
27102345	10.1038/modpathol.2016.79	2016	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.	MYD88
27121112	10.3109/10428194.2016.1173212	2016	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.	MYD88
27143257	10.1182/blood-2016-01-695098	2016	HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.	MYD88
27189828	10.1016/j.jid.2016.04.018	2016	MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell¬†Lymphoma.	MYD88
27198204	10.1038/leu.2016.135	2016	Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.	MYD88
27262792	10.1016/j.semcancer.2016.05.002	2016	Mechanisms of NF-Œ∫B deregulation in lymphoid malignancies.	MYD88
27268124	10.1016/j.clml.2016.04.014	2016	Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.	MYD88
27329639	10.1093/ajcp/aqw072	2016	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.	MYD88
27402288	10.1016/j.semcancer.2016.07.001	2016	Toll-like receptors signaling: A complex network for NF-Œ∫B activation in B-cell lymphoid malignancies.	MYD88
27439595	10.1111/pin.12439	2016	Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.	MYD88
27440511	10.1373/clinchem.2016.255315	2016	Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.	MYD88
27452667	10.1016/j.semcancer.2016.07.003	2016	MALT lymphoma: A paradigm of NF-Œ∫B dysregulation.	MYD88
27458005	10.1182/blood-2016-03-708065	2016	Inhibiting TLR9 and other UNC93B1-dependent TLRs paradoxically increases accumulation of MYD88L265P plasmablasts in vivo.	MYD88
27503954	10.1093/protein/gzw033	2016	Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization.	MYD88
27526684	10.1111/ejh.12792	2016	Rewired NFŒ∫B signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.	MYD88
27566587	10.18632/oncotarget.11548	2016	Recurrent mutations in NF-Œ∫B pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.	MYD88
27707672	10.1684/abc.2016.1179	2016	Cytogenetics in the management of lymphomas and lymphoproliferative disorders in adults and children: an update by the Groupe francophone de cytog√©n√©tique h√©matologique (GFCH).	MYD88
27722129	10.5045/br.2016.51.3.181	2016	Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas.	MYD88
27733371	10.1158/0008-5472.CAN-16-0504	2016	TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism.	MYD88
27795509	10.11406/rinketsu.57.2013	2016	Diffuse large B-cell lymphoma: current standard treatment and future perspectives.	MYD88
27799566	10.1073/pnas.1610970113	2016	Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.	MYD88
27825110	10.18632/oncotarget.13065	2016	Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.	MYD88
27825459	10.1016/j.beha.2016.08.024	2016	Origin of Waldenstrom's macroglobulinaemia.	MYD88
27825467	10.1016/j.beha.2016.08.021	2016	Future therapeutic options for patients with Waldenstr√∂m macroglobulinemia.	MYD88
27835906	10.18632/oncotarget.13239	2016	Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.	MYD88
27837631	NA	2016	The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.	MYD88
27890075	10.1016/j.leukres.2016.10.008	2016	Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenstr√∂m macroglobulinemia/lymphoplasmacytic lymphoma.	MYD88
27980305	10.3960/jslrt.56.71	2016	Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.	MYD88
28088969	10.3760/cma.j.issn.0253-2727.2016.12.009	2016	[The clinical features of patients with lymphoplasmacytic diseases harboring MyD88 L265P mutation].	MYD88
31360080	10.2147/BLCTT.S84157	2016	Waldenstr√∂m macroglobulinemia: biology, genetics, and therapy.	MYD88
24828863	10.3109/10428194.2014.924123	2015	MYD88 mutant lymphoplasmacytic lymphoma/Waldenstr√∂m macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.	MYD88
25216226	10.1038/modpathol.2014.120	2015	MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.	MYD88
25247317	10.1159/000358914	2015	Oncogenic MYD88 mutations are rare events in double-hit B-cell lymphomas.	MYD88
25347427	10.3109/10428194.2014.979413	2015	Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.	MYD88
25723115	10.1097/PAS.0000000000000411	2015	MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.	MYD88
25768255	10.1097/IAE.0000000000000589	2015	MyD-88 L265P mutations are present in some cases of vitreoretinal lymphoma.	MYD88
25816840	10.1111/bjh.13369	2015	Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples.	MYD88
25819228	10.1111/bjh.13361	2015	MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.	MYD88
25900979	10.1182/blood-2015-01-620518	2015	High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates.	MYD88
25978699	10.1089/gtmb.2015.0041	2015	MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.	MYD88
26099629	10.1111/bjd.13960	2015	Lack of myeloid differentiation primary response protein MyD88 L265P mutation in primary cutaneous marginal zone lymphoma.	MYD88
26159625	10.1016/j.jns.2015.06.026	2015	Bing-Neel syndrome: Two unexpected cases and a review of the literature.	MYD88
26230596	10.5858/arpa.2014-0322-OA	2015	Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.	MYD88
26388135	10.1111/pin.12336	2015	High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.	MYD88
24153350	10.1038/gene.2013.54	2014	Absence of somatic MYD88 L265P mutations in patients with primary Sjogren's syndrome.	MYD88
24253023	10.1038/leu.2013.348	2014	High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.	MYD88
24366360	10.1182/blood-2013-09-525808	2014	The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.	MYD88
24444466	10.1016/j.humpath.2013.10.023	2014	CD79B and MYD88 mutations in diffuse large B-cell lymphoma.	MYD88
24859878	10.3324/haematol.2014.108688	2014	Gamma heavy chain disease lacks the MYD88 L265p mutation associated with lymphoplasmacytic lymphoma.	MYD88
24903481	10.1038/leu.2014.184	2014	MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.	MYD88
25055137	10.1001/jamadermatol.2014.821	2014	High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.	MYD88
25359991	10.1182/blood-2014-05-573188	2014	Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization.	MYD88
25501023	10.1038/bcj.2014.87	2014	Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.	MYD88
22944768	10.1038/leu.2012.257	2013	IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstr√∂m macroglobulinemia/lymphoplasmacytic lymphomas.	MYD88
23321251	10.1182/blood-2012-09-454355	2013	MYD88 L265P in Waldenstr√∂m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.	MYD88
23355535	10.1182/blood-2012-09-457101	2013	Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.	MYD88
23380077	10.1016/j.humpath.2012.10.026	2013	MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.	MYD88
23532735	10.1182/blood-2012-06-436329	2013	MYD88 L265P mutation in Waldenstrom macroglobulinemia.	MYD88
23666053	10.1007/s11033-013-2513-7	2013	Polymorphisms and haplotypes in MyD88 are associated with the development of sarcoidosis: a candidate-gene association study.	MYD88
23955458	10.1309/AJCP10ZCLFZGYZIP	2013	MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.	MYD88
24224040	10.1371/journal.pone.0080088	2013	L265P mutation of the MYD88 gene is frequent in Waldenstr√∂m's macroglobulinemia and its absence in myeloma.	MYD88
22495176	10.1038/jid.2012.102	2012	MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type.	MYD88
22640364	10.1111/j.1365-2141.2012.09176.x	2012	MYD88 somatic mutations in MALT lymphomas.	MYD88
22808296	NA	2012	Mutation analysis of NF-Œ∫B signal pathway-related genes in ocular MALT lymphoma.	MYD88
22837180	10.1158/1078-0432.CCR-12-0845	2012	Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.	MYD88
22931316	10.1056/NEJMoa1200710	2012	MYD88 L265P somatic mutation in Waldenstr√∂m's macroglobulinemia.	MYD88
21179087	10.1038/nature09671	2011	Oncogenically active MYD88 mutations in human lymphoma.	MYD88
22020631	10.1007/s00401-011-0891-2	2011	Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.	MYD88
20438785	10.1016/j.humimm.2010.04.004	2010	Polymorphisms in innate immunity genes and risk of childhood leukemia.	MYD88
19745833	10.1038/jhg.2009.90	2009	Polymorphisms and haplotypes in TLR9 and MYD88 are associated with the development of Hodgkin's lymphoma: a candidate-gene association study.	MYD88
35021606	10.3324/haematol.2021.280003	2022	Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS.	NFKB1
35089437	10.1007/s00018-022-04139-y	2022	A20 undermines alternative NF-Œ∫B activity and expression of anti-apoptotic genes in Helicobacter pylori infection.	NFKB1
36009586	10.3390/biomedicines10082038	2022	Genomic Aberrations Generate Fusion Gene FOXK2::TP63 and Activate NFKB1 in Cutaneous T-Cell Lymphoma.	NFKB1
33025009	10.1182/blood.2020004918	2021	MYD88 L265P elicits mutation-specific ubiquitination to drive NF-Œ∫B activation and lymphomagenesis.	NFKB1
33684151	10.1371/journal.pone.0248259	2021	SNPs in genes encoding for IL-10, TNF-Œ±, and NFŒ∫B p105/p50 are associated with clinical prognostic factors for patients with Hodgkin lymphoma.	NFKB1
33707466	10.1038/s41598-021-84912-4	2021	CDK1 is up-regulated by temozolomide in an NF-Œ∫B dependent manner in glioblastoma.	NFKB1
34364837	10.1016/j.cbi.2021.109619	2021	Anticancer effects of oleanolic acid on human melanoma cells.	NFKB1
34401669	10.1016/j.isci.2021.102888	2021	Bisphenol A-induced DNA damages promote to lymphoma progression in human lymphoblastoid cells through aberrant CTNNB1 signaling pathway.	NFKB1
31957805	10.1093/carcin/bgaa005	2020	Bcl-3 promotes multi-modal tumour cell migration via NF-Œ∫B1 mediated regulation of Cdc42.	NFKB1
32452133	10.1111/jcmm.15383	2020	MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF-Œ∫B activation.	NFKB1
32712875	10.1007/s11064-020-03096-x	2020	miR-29c-3p Increases Cell Viability and Suppresses Apoptosis by Regulating the TNFAIP1/NF-Œ∫B Signaling Pathway via TNFAIP1 in AŒ≤-Treated Neuroblastoma Cells.	NFKB1
32912211	10.1186/s12977-020-00538-w	2020	A novel positive feedback-loop between the HTLV-1 oncoprotein Tax and NF-Œ∫B activity in T-cells.	NFKB1
33202260	10.1016/j.ajhg.2020.10.015	2020	Multiplexed Functional Assessment of Genetic Variants in CARD11.	NFKB1
30696620	10.1182/blood-2018-08-871293	2019	Autocrine LTA signaling drives NF-Œ∫B and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma.	NFKB1
30711173	10.1016/j.joen.2018.10.006	2019	Inhibition of Nuclear Factor Kappa B Prevents the Development of Experimental Periapical Lesions.	NFKB1
30711250	10.1016/j.bbrc.2019.01.089	2019	NF-Œ∫B-dependent RANKL expression in a mouse model of immature T-cell leukemia.	NFKB1
30787019	10.1182/bloodadvances.2018029322	2019	Cells of adult T-cell leukemia evade HTLV-1 Tax/NF-Œ∫B hyperactivation-induced senescence.	NFKB1
30885361	10.1016/bs.acr.2019.01.004	2019	HVEM network signaling in cancer.	NFKB1
30887112	10.1007/s00109-019-01777-x	2019	Activation of NF-Œ∫B in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IŒ∫B-Œ±.	NFKB1
31344550	10.1016/j.virol.2019.07.011	2019	Association of polymorphisms in NFŒ∫B1 promoter and NFŒ∫BIA gene with the development of antibodies against HHV-8 in HIV-infected individuals.	NFKB1
31497245	10.18632/oncotarget.27098	2019	Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma.	NFKB1
31574234	10.1096/fj.201900101RR	2019	Long intergenic noncoding RNA LINC00284 knockdown reduces angiogenesis in ovarian cancer cells <i>via</i> up-regulation of MEST through NF-Œ∫B1.	NFKB1
31803180	10.3389/fimmu.2019.02618	2019	Late-Onset Antibody Deficiency Due to Monoallelic Alterations in <i>NFKB1</i>.	NFKB1
29020881	10.1080/10245332.2017.1385194	2018	Knockdown of REGŒ≥ inhibits the proliferation and migration and promotes the apoptosis of multiple myeloma cells by downregulating NF-Œ∫B signal pathway.	NFKB1
29449436	10.3324/haematol.2017.182048	2018	Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients.	NFKB1
29593668	10.3389/fmicb.2018.00380	2018	Simulation Study of cDNA Dataset to Investigate Possible Association of Differentially Expressed Genes of Human THP1-Monocytic Cells in Cancer Progression Affected by Bacterial Shiga Toxins.	NFKB1
29698475	10.1371/journal.ppat.1006968	2018	CADM1 is essential for KSHV-encoded vGPCR-and vFLIP-mediated chronic NF-Œ∫B activation.	NFKB1
29976660	10.1128/JVI.00580-18	2018	Upregulation of MicroRNA 711 Mediates HIV-1 Vpr Promotion of Kaposi's Sarcoma-Associated Herpesvirus Latency and Induction of Pro-proliferation and Pro-survival Cytokines by Targeting the Notch/NF-Œ∫B-Signaling Axis.	NFKB1
30116272	10.1186/s11658-018-0102-4	2018	The notch pathway promotes NF-Œ∫B activation through Asb2 in T cell acute lymphoblastic leukemia cells.	NFKB1
30127896	10.3892/ol.2018.9010	2018	Burkitt lymphoma-associated network construction and important network motif analysis.	NFKB1
27840321	10.1016/j.freeradbiomed.2016.11.010	2017	Pro-apoptotic effects of lipid oxidation products: HNE at the crossroads of NF-Œ∫B pathway and anti-apoptotic Bcl-2.	NFKB1
28152513	10.18632/oncotarget.14934	2017	Propiece IL-1Œ± facilitates the growth of acute T-lymphocytic leukemia cells through the activation of NF-Œ∫B and SP1.	NFKB1
28232371	10.3324/haematol.2016.156281	2017	c-Myc dysregulation is a co-transforming event for nuclear factor-Œ∫B activated B cells.	NFKB1
28281555	10.1038/modpathol.2017.5	2017	NF-Œ∫B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.	NFKB1
28346502	10.1371/journal.pone.0174136	2017	EBV induces persistent NF-Œ∫B activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.	NFKB1
28368397	10.1038/onc.2017.90	2017	Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.	NFKB1
28369050	10.1038/ni.3716	2017	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.	NFKB1
28672935	10.3892/etm.2017.4464	2017	Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.	NFKB1
28684863	10.1038/emm.2017.89	2017	Bcl3: a regulator of NF-Œ∫B inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells.	NFKB1
28689659	10.1016/j.molcel.2017.06.011	2017	Bcl3 Phosphorylation by Akt, Erk2, and IKK Is Required for Its Transcriptional Activity.	NFKB1
29333957	10.1177/1533034617745761	2017	MiR-98 Promotes Apoptosis of Glioma Cells via Suppressing IKBKE/NF-Œ∫B Pathway.	NFKB1
25912249	10.4274/tjh.2014.0190	2016	Deregulated Levels of the NF-Œ∫B1, NF-Œ∫B2, and Rel Genes in Ukrainian Patients with Leukemia and Lymphoma in the Post-Chernobyl Period.	NFKB1
26275874	10.1007/82_2015_479	2016	Roles of the NF-Œ∫B Pathway in B-Lymphocyte Biology.	NFKB1
26526716	10.1053/j.gastro.2015.10.017	2016	BCL3 Reduces the Sterile Inflammatory Response in Pancreatic and Biliary Tissues.	NFKB1
26573110	10.3892/ijo.2015.3238	2016	Involvement of cyclic-nucleotide response element-binding family members in the radiation response of Ramos B lymphoma cells.	NFKB1
26648441	10.3892/mmr.2015.4606	2016	Effects of miR‚Äë590 on oxLDL‚Äëinduced endothelial cell apoptosis: Roles of p53 and NF‚ÄëŒ∫B.	NFKB1
26767426	10.1016/j.jid.2015.12.027	2016	MALT1 Protease Activity Controls the Expression of Inflammatory Genes in Keratinocytes upon Zymosan Stimulation.	NFKB1
26776161	10.1038/onc.2015.493	2016	Oncogenic CARMA1 couples NF-Œ∫B and Œ≤-catenin signaling in diffuse large B-cell lymphomas.	NFKB1
26792751	10.1128/JVI.03000-15	2016	The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-Œ∫B by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein.	NFKB1
27221964	10.1016/j.semcancer.2016.05.001	2016	NF-Œ∫B deregulation in Hodgkin lymphoma.	NFKB1
27262792	10.1016/j.semcancer.2016.05.002	2016	Mechanisms of NF-Œ∫B deregulation in lymphoid malignancies.	NFKB1
27338827	10.1007/s10875-016-0306-1	2016	NF-Œ∫B1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation.	NFKB1
27402288	10.1016/j.semcancer.2016.07.001	2016	Toll-like receptors signaling: A complex network for NF-Œ∫B activation in B-cell lymphoid malignancies.	NFKB1
27440900	10.1128/JVI.00797-16	2016	HIV-1 Vpr Inhibits Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Inducing MicroRNA miR-942-5p and Activating NF-Œ∫B Signaling.	NFKB1
27452667	10.1016/j.semcancer.2016.07.003	2016	MALT lymphoma: A paradigm of NF-Œ∫B dysregulation.	NFKB1
27488529	10.1158/0008-5472.CAN-16-0595	2016	TG2 and NF-Œ∫B Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy.	NFKB1
27489104	10.1074/jbc.M116.719302	2016	The Nuclear Protein IŒ∫BŒ∂ Forms a Transcriptionally Active Complex with Nuclear Factor-Œ∫B (NF-Œ∫B) p50 and the Lcn2 Promoter via the N- and C-terminal Ankyrin Repeat Motifs.	NFKB1
27503810	10.1016/j.semcancer.2016.08.002	2016	NF-Œ∫B deregulation in splenic marginal zone lymphoma.	NFKB1
27546290	10.1016/j.semcancer.2016.08.001	2016	Genetic drivers of NF-Œ∫B deregulation in diffuse large B-cell lymphoma.	NFKB1
28028966	10.17219/acem/63752	2016	Glycogen Synthase Kinase-3Œ≤ (GSK-3Œ≤) and Nuclear Factor Kappa-B (NFKB) in Childhood Acute Lymphoblastic Leukemia.	NFKB1
25394713	10.1038/leu.2014.324	2015	GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF-Œ∫B-dependent induction of HIF-1Œ±.	NFKB1
25541152	10.1038/leu.2014.351	2015	MicroRNAs in B-cell lymphomas: how a complex biology gets more complex.	NFKB1
25572145	10.1042/BSR20140160	2015	Re-expression of HPV16 E2 in SiHa (human cervical cancer) cells potentiates NF-Œ∫B activation induced by TNF-Œ± concurrently increasing senescence and survival.	NFKB1
25636172	10.1016/j.humpath.2014.06.032	2015	Clinicopathological implications of nuclear factor Œ∫B signal pathway activation in diffuse large B-cell lymphoma.	NFKB1
25837675	10.1158/1535-7163.MCT-14-1053	2015	MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFŒ∫B Activation in Breast Cancer.	NFKB1
25922067	10.1074/jbc.M115.643700	2015	Mapping the Interaction of B Cell Leukemia 3 (BCL-3) and Nuclear Factor Œ∫B (NF-Œ∫B) p50 Identifies a BCL-3-mimetic Anti-inflammatory Peptide.	NFKB1
25951043	10.1080/15548627.2015.1017192	2015	The role of STAT3 in autophagy.	NFKB1
25960206	10.1002/gcc.22253	2015	NFkB is activated by multiple mechanisms in hairy cell leukemia.	NFKB1
25987724	10.1084/jem.20142009	2015	Functional loss of IŒ∫BŒµ leads to NF-Œ∫B deregulation in aggressive chronic lymphocytic leukemia.	NFKB1
25996250	10.1111/febs.13325	2015	MALT1--a universal soldier: multiple strategies to ensure NF-Œ∫B activation and target gene expression.	NFKB1
26043790	10.1080/15548627.2015.1052205	2015	Cocaine-mediated microglial activation involves the ER stress-autophagy axis.	NFKB1
26049760	10.1097/MOH.0000000000000160	2015	Unexpected functions of nuclear factor-Œ∫B during germinal center B-cell development: implications for lymphomagenesis.	NFKB1
26060405	10.2147/OTT.S82936	2015	Oral treatment with the herbal formula B307 alleviates cardiac toxicity in doxorubicin-treated mice via suppressing oxidative stress, inflammation, and apoptosis.	NFKB1
26112410	10.1074/jbc.M114.630061	2015	The Transitional Endoplasmic Reticulum ATPase p97 Regulates the Alternative Nuclear Factor NF-Œ∫B Signaling via Partial Degradation of the NF-Œ∫B Subunit p100.	NFKB1
26391888	10.1038/srep14315	2015	Genome-wide homozygosity signature and risk of Hodgkin lymphoma.	NFKB1
26477771	10.3760/cma.j.issn.0253-2727.2015.10.016	2015	[Clinical significance of NF-Œ∫B/p65 expression in patients with diffuse large B-cell lymphoma].	NFKB1
26487345	10.1038/srep15215	2015	Transcription factor and miRNA co-regulatory network reveals shared and specific regulators in the development of B cell and T cell.	NFKB1
26606782	NA	2015	[PROGNOSTIC ROLE OF NF-Œ∫B EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA SUBGROUPS].	NFKB1
26612043	10.1007/s11427-015-4977-2	2015	Molecular pathogenesis of lymphomas of mucosa-associated lymphoid tissue--from (auto)antigen driven selection to the activation of NF-Œ∫B signaling.	NFKB1
26668357	10.1073/pnas.1507459112	2015	Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-Œ∫B and JNK activation.	NFKB1
27308399	10.4161/23723548.2014.968073	2015	Nfkb1 suppresses DNA alkylation-induced tumor formation.	NFKB1
23886693	10.1016/j.imbio.2013.06.013	2014	Activation of NF-Œ∫B and respiratory burst following Aspergillus fumigatus stimulation of macrophages.	NFKB1
24200242	10.1089/scd.2013.0270	2014	Resistance of hematopoietic progenitors to Fas-mediated apoptosis is actively sustained by NFŒ∫B with a characteristic transcriptional signature.	NFKB1
24292677	10.1038/onc.2013.503	2014	YGLF motif in the Kaposi sarcoma herpes virus G-protein-coupled receptor adjusts NF-Œ∫B activation and paracrine actions.	NFKB1
24296945	10.1038/leu.2013.365	2014	Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation.	NFKB1
24393203	10.1186/1476-4598-13-5	2014	NF-kappa B mediated up-regulation of CCCTC-binding factor in pediatric acute lymphoblastic leukemia.	NFKB1
24419302	10.1007/s00018-013-1545-4	2014	NF-Œ∫B pathways in hematological malignancies.	NFKB1
24459141	10.1074/jbc.M114.551986	2014	Inhibition of transcription by B cell Leukemia 3 (Bcl-3) protein requires interaction with nuclear factor Œ∫B (NF-Œ∫B) p50.	NFKB1
24548923	10.1016/j.molimm.2014.01.011	2014	Phosphorylation of Carma1, but not Bcl10, by Akt regulates TCR/CD28-mediated NF-Œ∫B induction and cytokine production.	NFKB1
24704296	10.1016/j.canlet.2014.03.030	2014	The NF-Œ∫B inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.	NFKB1
24867094	10.1007/s13277-014-1998-6	2014	Crebanine, an aporphine alkaloid, sensitizes TNF-Œ±-induced apoptosis and suppressed invasion of human lung adenocarcinoma cells A549 by blocking NF-Œ∫B-regulated gene products.	NFKB1
24971370	10.1155/2014/492872	2014	Alternative expression pattern of MALT1-A20-NF-Œ∫B in patients with rheumatoid arthritis.	NFKB1
23328932	10.1007/s00428-013-1372-x	2013	Nuclear factor-Œ∫B activation in primary lymphoma of bone.	NFKB1
23360303	10.1111/bjh.12206	2013	The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.	NFKB1
23441730	10.1042/BJ20121651	2013	The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system.	NFKB1
23603894	10.1254/jphs.12149fp	2013	Inhibition of the PI3K/AKT-NF-Œ∫B pathway with curcumin enhanced radiation-induced apoptosis in human Burkitt's lymphoma.	NFKB1
23752607	10.5604/17322693.1052449	2013	Expression of PIM-2 and NF-Œ∫B genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival.	NFKB1
23821202	10.1167/iovs.13-12272	2013	MicroRNA profiling in ocular adnexal lymphoma: a role for MYC and NFKB1 mediated dysregulation of microRNA expression in aggressive disease.	NFKB1
23868181	10.1002/path.4239	2013	Constitutive activation of distinct NF-Œ∫B signals in EBV-associated nasopharyngeal carcinoma.	NFKB1
23869088	10.1182/blood-2013-06-508028	2013	IŒ∫B-Œ∂ controls the constitutive NF-Œ∫B target gene network and survival of ABC DLBCL.	NFKB1
24027435	10.1593/neo.131140	2013	Human T cell leukemia virus type I tax-induced IŒ∫B-Œ∂ modulates tax-dependent and tax-independent gene expression in T cells.	NFKB1
24059932	10.1186/1471-2199-14-24	2013	Identification of an NF-Œ∫B p50/p65-responsive site in the human MIR155HG promoter.	NFKB1
21902578	10.3109/10428194.2011.621566	2012	Interleukin-6 plasma levels are modulated by a polymorphism in the NF-Œ∫B1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.	NFKB1
22267549	10.1158/1535-7163.MCT-11-0635	2012	Galiximab signals B-NHL cells and inhibits the activities of NF-Œ∫B-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs.	NFKB1
22362744	10.1093/nar/gks175	2012	MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia.	NFKB1
22384168	10.1371/journal.pone.0032168	2012	Genetic diversity of EBV-encoded LMP1 in the Swiss HIV Cohort Study and implication for NF-Œöb activation.	NFKB1
22394598	10.1182/blood-2011-10-386011	2012	ALK+ALCLs induce cutaneous, HMGB-1-dependent IL-8/CXCL8 production by keratinocytes through NF-Œ∫B activation.	NFKB1
22435562	10.1111/j.1600-065X.2012.01094.x	2012	Dynamic roles for NF-Œ∫B in HTLV-I and HIV-1 retroviral pathogenesis.	NFKB1
22538516	10.1038/modpathol.2012.52	2012	EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation.	NFKB1
22553204	10.1074/jbc.M112.340992	2012	Tax protein-induced expression of antiapoptotic Bfl-1 protein contributes to survival of human T-cell leukemia virus type 1 (HTLV-1)-infected T-cells.	NFKB1
22768179	10.1371/journal.pone.0039945	2012	Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis.	NFKB1
23028875	10.1371/journal.pone.0045244	2012	Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-Œ∫B signaling.	NFKB1
21061265	10.1002/mc.20688	2011	Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes.	NFKB1
21189087	10.1902/jop.2010.100312	2011	Real-time quantitative polymerase chain reaction analysis of patients with refractory chronic periodontitis.	NFKB1
21249144	10.1371/journal.pone.0016171	2011	Identification of genes that elicit disuse muscle atrophy via the transcription factors p50 and Bcl-3.	NFKB1
21273489	10.1126/science.1198946	2011	Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.	NFKB1
21406399	10.1158/0008-5472.CAN-10-3626	2011	CARMA3 is crucial for EGFR-Induced activation of NF-Œ∫B and tumor progression.	NFKB1
21417823	10.3109/10428194.2011.565437	2011	The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival.	NFKB1
21531730	10.1074/jbc.M111.224048	2011	A20 is induced by Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 and blocks K13-induced nuclear factor-kappaB in a negative feedback manner.	NFKB1
21574100	NA	2011	Activation of NF-ƒ∏B in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukaemia: relation to other prognostic factors.	NFKB1
21674474	10.1002/eji.201041052	2011	Dephosphorylation of Bcl-10 by calcineurin is essential for canonical NF-Œ∫B activation in Th cells.	NFKB1
21743832	10.3390/v3060714	2011	Human T-cell lymphotropic virus: a model of NF-Œ∫B-associated tumorigenesis.	NFKB1
21873235	10.1073/pnas.1105020108	2011	Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines.	NFKB1
21979374	10.1101/gad.17620611	2011	Opposing roles of NF-Œ∫B in anti-cancer treatment outcome unveiled by cross-species investigations.	NFKB1
21979375	10.1101/gad.17276711	2011	Control of the senescence-associated secretory phenotype by NF-Œ∫B promotes senescence and enhances chemosensitivity.	NFKB1
21987722	10.1158/0008-5472.CAN-11-1715	2011	IKKŒ≤ and NF-Œ∫B transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1.	NFKB1
21994759	10.3390/v3060886	2011	Targeting HTLV-1 activation of NFŒ∫B in mouse models and ATLL patients.	NFKB1
19897484	10.1074/jbc.M109.050815	2010	B-cell CLL/lymphoma 10 (BCL10) is required for NF-kappaB production by both canonical and noncanonical pathways and for NF-kappaB-inducing kinase (NIK) phosphorylation.	NFKB1
20106524	10.1016/j.leukres.2009.12.014	2010	NFkappaB modulators in a model of glucocorticoid resistant, childhood acute lymphoblastic leukemia.	NFKB1
20226764	10.1016/j.bbrc.2010.03.054	2010	Insulin receptor substrate-3, interacting with Bcl-3, enhances p50 NF-kappaB activity.	NFKB1
20391111	10.1080/15287390903578521	2010	Granuloma formation induced by low-dose chronic silica inhalation is associated with an anti-apoptotic response in Lewis rats.	NFKB1
20410275	10.1128/JVI.00344-10	2010	Epstein-Barr virus latent membrane protein 1 modulates distinctive NF- kappaB pathways through C-terminus-activating region 1 to regulate epidermal growth factor receptor expression.	NFKB1
20414006	10.1159/000313697	2010	NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer.	NFKB1
20438785	10.1016/j.humimm.2010.04.004	2010	Polymorphisms in innate immunity genes and risk of childhood leukemia.	NFKB1
20439115	10.1016/j.molimm.2010.04.005	2010	Interaction of calmodulin with Bcl10 modulates NF-kappaB activation.	NFKB1
20507572	10.1186/1471-2172-11-26	2010	Differential cytokine regulation by NF-kappaB and AP-1 in Jurkat T-cells.	NFKB1
20547759	10.1128/MCB.01600-09	2010	The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1.	NFKB1
20558726	10.1074/jbc.M110.112128	2010	BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit PSMB1.	NFKB1
20716621	10.1158/1055-9965.EPI-10-0389	2010	Genetic polymorphisms in adaptive immunity genes and childhood acute lymphoblastic leukemia.	NFKB1
20800578	10.1016/j.bbrc.2010.08.084	2010	Bcl3-dependent stabilization of CtBP1 is crucial for the inhibition of apoptosis and tumor progression in breast cancer.	NFKB1
20813154	10.1016/j.exphem.2010.08.007	2010	NF-Œ∫B mediates aberrant activation of HIF-1 in malignant lymphoma.	NFKB1
21110852	10.1186/1756-9966-29-154	2010	Glycogen synthase kinase-3Œ≤ inhibition induces nuclear factor-Œ∫B-mediated apoptosis in pediatric acute lymphocyte leukemia cells.	NFKB1
18640717	10.1016/j.leukres.2008.06.010	2009	PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines.	NFKB1
18668140	10.1038/jid.2008.205	2009	NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma.	NFKB1
18796561	10.1096/fj.07-104109	2009	Oxidative, multistep activation of the noncanonical NF-kappaB pathway via disulfide Bcl-3/p50 complex.	NFKB1
19129458	10.1128/JVI.01512-08	2009	A systems biology approach to identify the combination effects of human herpesvirus 8 genes on NF-kappaB activation.	NFKB1
19223558	10.1158/1055-9965.EPI-08-1130	2009	Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma.	NFKB1
19234489	10.1038/onc.2009.17	2009	TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB.	NFKB1
19243308	10.1042/BJ20082140	2009	Two distinct signalling cascades target the NF-kappaB regulatory factor c-IAP1 for degradation.	NFKB1
19258598	10.1182/blood-2008-08-174110	2009	The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.	NFKB1
19279104	10.1128/JVI.00097-09	2009	The LMP1 promoter can be transactivated directly by NF-kappaB.	NFKB1
19412164	10.1038/nature07968	2009	Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.	NFKB1
19469019	10.1111/j.1349-7006.2009.01083.x	2009	Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation.	NFKB1
19540595	10.1016/j.molimm.2009.05.178	2009	TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells.	NFKB1
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	NFKB1
19709433	10.1186/1476-4598-8-67	2009	STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells.	NFKB1
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	NFKB1
19885551	10.3892/ijo_00000446	2009	Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.	NFKB1
19954665	NA	2009	[The action mechanisms of unclassical NF-kappaB activity and TRAF3 expression in Hodgkin's lymphoma cells].	NFKB1
17963943	10.1016/j.virusres.2007.09.003	2008	The latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus induces expression of the putative oncogene Bcl-3 through activation of the nuclear factor-kappaB.	NFKB1
18252714	10.1074/jbc.M708833200	2008	Toll-like receptor 4 mediates induction of the Bcl10-NFkappaB-interleukin-8 inflammatory pathway by carrageenan in human intestinal epithelial cells.	NFKB1
18287044	10.1073/pnas.0712313105	2008	NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-kappaB activation.	NFKB1
18316375	10.1074/jbc.M707988200	2008	Sequestration of NF-kappaB signaling complexes in lipid rafts contributes to repression of NF-kappaB in T lymphocytes under hyperthermia stress.	NFKB1
18344086	NA	2008	[Protein expression and clinical significance of cyclooxygenase 2 and nuclear factor kappa B in gastric mucosa-associated lymphoid tissue lymphoma].	NFKB1
18398749	10.1080/10428190801910912	2008	Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.	NFKB1
18596915	10.1371/journal.pone.0002555	2008	RelB-dependent stromal cells promote T-cell leukemogenesis.	NFKB1
18625728	10.1128/MCB.00418-08	2008	The protein kinase C-responsive inhibitory domain of CARD11 functions in NF-kappaB activation to regulate the association of multiple signaling cofactors that differentially depend on Bcl10 and MALT1 for association.	NFKB1
18636124	10.1371/journal.pone.0002816	2008	Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.	NFKB1
18661398	10.1080/10428190802216723	2008	CD40L-mediated inhibition of NF-kappaB in CA46 Burkitt lymphoma cells promotes apoptosis.	NFKB1
18928599	NA	2008	[Expression of survivin and NF-kappaB in peripheral T-cell lymphoma and its significance].	NFKB1
18983609	10.1111/j.1365-2559.2008.03139.x	2008	Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications.	NFKB1
18990758	10.1158/1055-9965.EPI-08-0536	2008	Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma.	NFKB1
19021048	10.1080/10428190802444176	2008	Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies.	NFKB1
16979925	10.1016/j.oraloncology.2006.04.011	2007	Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy.	NFKB1
17356384	10.1097/01.jnen.0000248553.45456.96	2007	Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression.	NFKB1
17502353	10.1128/MCB.01645-06	2007	Phosphorylation of Bcl10 negatively regulates T-cell receptor-mediated NF-kappaB activation.	NFKB1
17555878	10.1016/j.bbagen.2007.04.011	2007	Nitric oxide induces apoptosis in cutaneous T cell lymphoma (HuT-78) by downregulating constitutive NF-kappaB.	NFKB1
17573907	10.1111/j.1462-5822.2007.00950.x	2007	Alteration of NF-kappaB activity leads to mitochondrial apoptosis after infection with pathological prion protein.	NFKB1
17577783	10.1080/10428190701340616	2007	Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia.	NFKB1
17626072	10.1128/JVI.02241-06	2007	Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.	NFKB1
17641042	10.4049/jimmunol.179.3.1760	2007	OX40 gene expression is up-regulated by chromatin remodeling in its promoter region containing Sp1/Sp3, YY1, and NF-kappa B binding sites.	NFKB1
18006812	10.1158/0008-5472.CAN-07-1708	2007	Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation.	NFKB1
18006844	10.1158/0008-5472.CAN-07-0519	2007	Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappaB inhibition and the rapid generation of other selenium species.	NFKB1
18025803	10.1159/000111116	2007	Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas.	NFKB1
16219794	10.1182/blood-2005-06-2536	2006	Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.	NFKB1
16288225	10.1038/sj.onc.1209178	2006	Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas.	NFKB1
16439988	10.1038/sj.cdd.4401856	2006	Deciphering the pathway from the TCR to NF-kappaB.	NFKB1
16497967	10.1182/blood-2005-10-4042	2006	Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas.	NFKB1
16751281	10.1073/pnas.0507809103	2006	The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas.	NFKB1
16778171	10.1158/0008-5472.CAN-06-0194	2006	NFKB1 is a direct target of the TAL1 oncoprotein in human T leukemia cells.	NFKB1
16891304	10.1074/jbc.M605116200	2006	The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 AND TRAF2.	NFKB1
15802604	10.1126/science.1107107	2005	PDK1 nucleates T cell receptor-induced signaling complex for NF-kappaB activation.	NFKB1
15870177	10.1182/blood-2004-12-4901	2005	NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.	NFKB1
15876358	10.1186/1742-4690-2-29	2005	Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-kappaB activation.	NFKB1
15940251	10.1038/sj.onc.1208779	2005	Nfkb 1 is dispensable for Myc-induced lymphomagenesis.	NFKB1
15979856	10.1016/j.bbadis.2005.05.003	2005	Relationship between constitutive nuclear factor-kappaB (NF-kappaB) and inhibitor kappaB-alpha (IkappaB-alpha) in an interferon-alpha-sensitive human Burkitt lymphoma cell line.	NFKB1
15982633	10.1016/j.bbrc.2005.06.058	2005	API2-MALT1 fusion protein induces transcriptional activation of the API2 gene through NF-kappaB binding elements: evidence for a positive feed-back loop pathway resulting in unremitting NF-kappaB activation.	NFKB1
16037393	10.1182/blood-2004-12-4965	2005	Distinct roles for the NF-kappaB1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals.	NFKB1
16108830	10.1111/j.1349-7006.2005.00078.x	2005	Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3.	NFKB1
16123212	10.1182/blood-2004-09-3620	2005	Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas.	NFKB1
16270046	10.1038/sj.leu.2403960	2005	Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas.	NFKB1
16299251	10.1158/1078-0432.CCR-05-0224	2005	Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.	NFKB1
16306601	10.1128/JVI.79.24.15302-15313.2005	2005	Respiratory syncytial virus-inducible BCL-3 expression antagonizes the STAT/IRF and NF-kappaB signaling pathways by inducing histone deacetylase 1 recruitment to the interleukin-8 promoter.	NFKB1
14747545	10.1128/jvi.78.4.1800-1816.2004	2004	Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor.	NFKB1
15147743	10.1016/j.biocel.2004.02.004	2004	Tissue inhibitor of metalloproteinases-2 growth-stimulatory activity is mediated by nuclear factor-kappa B in A549 lung epithelial cells.	NFKB1
15153339	10.1593/neo.3388	2004	Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells.	NFKB1
15184390	10.1074/jbc.M402244200	2004	Physical and functional interaction of CARMA1 and CARMA3 with Ikappa kinase gamma-NFkappaB essential modulator.	NFKB1
15190178	10.1073/pnas.0308016101	2004	Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP).	NFKB1
15231650	10.1158/0008-5472.CAN-03-3885	2004	High-throughput retroviral tagging for identification of genes involved in initiation and progression of mouse splenic marginal zone lymphomas.	NFKB1
15315758	10.1016/j.cell.2004.08.007	2004	One nucleotide in a kappaB site can determine cofactor specificity for NF-kappaB dimers.	NFKB1
15469820	10.1016/j.molcel.2004.09.004	2004	GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity.	NFKB1
15514680	10.1038/sj.embor.7400280	2004	Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds.	NFKB1
15546001	10.1172/JCI21696	2004	Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy.	NFKB1
12972607	10.1128/MCB.23.19.6887-6900.2003	2003	Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence.	NFKB1
14678988	NA	2003	Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma.	NFKB1
15068390	10.1007/BF03260037	2003	Monitoring NF-kappa B transactivation potential via real-time PCR quantification of I kappa B-alpha gene expression.	NFKB1
11830587	10.1074/jbc.M110480200	2002	The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex.	NFKB1
12032828	10.1038/sj.onc.1205483	2002	NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells.	NFKB1
12058256	10.1038/sj.gene.6363846	2002	Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations.	NFKB1
12145210	10.1093/emboj/cdf389	2002	Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B.	NFKB1
10670837	10.1097/00024382-200013020-00001	2000	NF-kappaB regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome.	NFKB1
10931834	10.1074/jbc.M004148200	2000	NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.	NFKB1
10023675	10.1038/sj.onc.1202374	1999	Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105.	NFKB1
10362352	10.1038/sj.onc.1202717	1999	The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators.	NFKB1
10390192	10.1016/s0301-472x(99)00053-3	1999	NF-kappaB involvement in the activation of primary adult T-cell leukemia cells and its clinical implications.	NFKB1
10469655	10.1093/emboj/18.17.4766	1999	NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes.	NFKB1
9480976	10.1084/jem.187.5.663	1998	B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells.	NFKB1
9572494	10.1038/sj.onc.1201735	1998	Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB.	NFKB1
9584180	10.1128/MCB.18.6.3395	1998	Interaction of stat6 and NF-kappaB: direct association and synergistic activation of interleukin-4-induced transcription.	NFKB1
9218802	10.1093/emboj/16.12.3609	1997	Regulation of NFKB1 proteins by the candidate oncoprotein BCL-3: generation of NF-kappaB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation.	NFKB1
9223487	10.1128/JVI.71.8.5972-5981.1997	1997	VBP and RelA regulate avian leukosis virus long terminal repeat-enhanced transcription in B cells.	NFKB1
9250404	10.1379/1466-1268(1997)002&lt;0132:msphiw&gt;2.3.co;2	1997	Major stress protein Hsp70 interacts with NF-kB regulatory complex in human T-lymphoma cells.	NFKB1
9021684	10.3109/10428199609054800	1996	The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies.	NFKB1
8113688	10.1084/jem.179.3.961	1994	The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein.	NFKB1
8196632	10.1128/mcb.14.6.3915-3926.1994	1994	BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins.	NFKB1
7692229	10.1128/mcb.13.10.6283-6289.1993	1993	Differential regulation of vascular cell adhesion molecule 1 gene expression by specific NF-kappa B subunits in endothelial and epithelial cells.	NFKB1
8378093	NA	1993	Structural alterations of the NF-kappa B transcription factor lyt-10 in lymphoid malignancies.	NFKB1
8428580	10.1002/j.1460-2075.1993.tb05647.x	1993	The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B.	NFKB1
1612589	10.1016/0888-7543(92)90244-m	1992	Related subunits of NF-kappa B map to two distinct loci associated with translocations in leukemia, NFKB1 and NFKB2.	NFKB1
35296646	10.1038/s41419-022-04684-1	2022	Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.	NFKBIA
35600392	10.3389/fonc.2022.881801	2022	SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer.	NFKBIA
35885481	10.3390/diagnostics12071575	2022	Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma.	NFKBIA
32817282	10.3324/haematol.2019.236455	2021	A three-gene signature based on <i>MYC</i>, <i>BCL-2</i> and <i>NFKBIA</i> improves risk stratification in diffuse large B-cell lymphoma.	NFKBIA
32961552	10.1182/blood.2020007507	2021	Mutational landscape of gray zone lymphoma.	NFKBIA
33757561	10.1186/s13104-021-05521-y	2021	HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) versus adult T-cell leukemia/lymphoma (ATLL).	NFKBIA
33824284	10.1038/s41419-021-03638-3	2021	Single loss of a Trp53 allele triggers an increased oxidative, DNA damage and cytokine inflammatory responses through deregulation of IŒ∫BŒ± expression.	NFKBIA
33847741	10.1182/bloodadvances.2020003431	2021	Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen.	NFKBIA
34113355	10.3389/fimmu.2021.684424	2021	Hippo Pathway Counter-Regulates Innate Immunity in Hepatitis B Virus Infection.	NFKBIA
34405005	10.7150/jca.60390	2021	Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.	NFKBIA
32065117	10.12659/MSM.921649	2020	Huai Qi Huang Potentiates Dexamethasone-Mediated Lethality in Acute Lymphoblastic Leukemia Cells by Upregulating Glucocorticoid Receptor Œ±.	NFKBIA
32246052	10.1038/s42003-020-0882-8	2020	Molecular bases for HOIPINs-mediated inhibition of LUBAC and innate immune responses.	NFKBIA
30563911	10.1101/gr.241141.118	2019	Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.	NFKBIA
30887112	10.1007/s00109-019-01777-x	2019	Activation of NF-Œ∫B in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IŒ∫B-Œ±.	NFKBIA
31344550	10.1016/j.virol.2019.07.011	2019	Association of polymorphisms in NFŒ∫B1 promoter and NFŒ∫BIA gene with the development of antibodies against HHV-8 in HIV-infected individuals.	NFKBIA
30116272	10.1186/s11658-018-0102-4	2018	The notch pathway promotes NF-Œ∫B activation through Asb2 in T cell acute lymphoblastic leukemia cells.	NFKBIA
26247921	10.1002/jcp.25122	2016	Nuclear Translocation of p65 is Controlled by Sec6 via the Degradation of IŒ∫BŒ±.	NFKBIA
26526716	10.1053/j.gastro.2015.10.017	2016	BCL3 Reduces the Sterile Inflammatory Response in Pancreatic and Biliary Tissues.	NFKBIA
26647777	10.3892/ijo.2015.3247	2016	Diallyl trisulfide induces apoptosis by suppressing NF-Œ∫B signaling through destabilization of TRAF6 in primary effusion lymphoma.	NFKBIA
26727576	10.1038/oncsis.2015.44	2016	A mix of S and ŒîS variants of STAT3 enable survival of activated B-cell-like diffuse large B-cell lymphoma cells in culture.	NFKBIA
26740240	10.1038/srep18934	2016	Inhibition of Canonical NF-Œ∫B Signaling by a Small Molecule Targeting NEMO-Ubiquitin Interaction.	NFKBIA
27221964	10.1016/j.semcancer.2016.05.001	2016	NF-Œ∫B deregulation in Hodgkin lymphoma.	NFKBIA
27563822	10.18632/oncotarget.11507	2016	The BCR-ABL/NF-Œ∫B signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.	NFKBIA
27566587	10.18632/oncotarget.11548	2016	Recurrent mutations in NF-Œ∫B pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.	NFKBIA
25333578	10.3892/mmr.2014.2704	2015	An enzymatically fortified ginseng extract inhibits proliferation and induces apoptosis of KATO3 human gastric cancer cells via modulation of Bax, mTOR, PKB and IŒ∫BŒ±.	NFKBIA
25394713	10.1038/leu.2014.324	2015	GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin's B lymphomas via NF-Œ∫B-dependent induction of HIF-1Œ±.	NFKBIA
25916485	10.1007/s13346-015-0230-6	2015	TAT cell-penetrating peptide modulates inflammatory response and apoptosis in human lung epithelial cells.	NFKBIA
25985447	10.1055/s-0034-1398628	2015	Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines.	NFKBIA
26237500	10.1097/CAD.0000000000000274	2015	Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IŒ∫BŒ± kinase downregulation.	NFKBIA
26488500	10.12659/msm.895257	2015	Common Polymorphisms in the NFKBIA Gene and Cancer Susceptibility: A Meta-Analysis.	NFKBIA
26492364	10.1038/cddis.2015.260	2015	The RCAN1 inhibits NF-Œ∫B and suppresses lymphoma growth in mice.	NFKBIA
23697845	10.3109/10428194.2013.806799	2014	Bortezomib inhibits proteasomal degradation of IŒ∫BŒ± and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.	NFKBIA
24992336	10.1371/journal.pone.0101314	2014	Guanylyl cyclase-G modulates jejunal apoptosis and inflammation in mice with intestinal ischemia and reperfusion.	NFKBIA
25280822	10.1016/j.jstrokecerebrovasdis.2014.05.032	2014	Anti-inflammatory and antiapoptotic effects of mesenchymal stem cells transplantation in rat brain with cerebral ischemia.	NFKBIA
22889356	10.3109/10428194.2012.720371	2013	Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.	NFKBIA
23441730	10.1042/BJ20121651	2013	The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system.	NFKBIA
23526666	10.1002/cbin.10101	2013	Genistein induces apoptotic cell death associated with inhibition of the NF-Œ∫B pathway in adult T-cell leukemia cells.	NFKBIA
23555990	10.1371/journal.pone.0060540	2013	Phosphorylated IŒ∫BŒ± predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release.	NFKBIA
23633516	10.1093/carcin/bgt144	2013	p53 dysfunction precedes the activation of nuclear factor-Œ∫B during disease progression in mice expressing Tax, a human T-cell leukemia virus type 1 oncoprotein.	NFKBIA
23665105	10.1016/j.ygcen.2013.04.033	2013	Transcriptomic profiling of progesterone in the male fathead minnow (Pimephales promelas) testis.	NFKBIA
23868181	10.1002/path.4239	2013	Constitutive activation of distinct NF-Œ∫B signals in EBV-associated nasopharyngeal carcinoma.	NFKBIA
22065599	10.1182/blood-2011-08-374561	2012	Tcl1 interacts with Atm and enhances NF-Œ∫B activation in hematologic malignancies.	NFKBIA
22297640	10.1038/jid.2011.470	2012	Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma.	NFKBIA
22393418	10.1371/journal.pone.0032584	2012	Blocking autophagy prevents bortezomib-induced NF-Œ∫B activation by reducing I-Œ∫BŒ± degradation in lymphoma cells.	NFKBIA
22649101	10.1182/blood-2011-07-369397	2012	Essential role of TAK1 in regulating mantle cell lymphoma survival.	NFKBIA
22768179	10.1371/journal.pone.0039945	2012	Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis.	NFKBIA
20889926	10.1182/blood-2010-06-290437	2011	Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-Œ∫B-inducing kinase while activating both canonical and alternative nuclear factor-Œ∫B pathways.	NFKBIA
21224428	10.1158/1541-7786.MCR-10-0368	2011	Bortezomib induces nuclear translocation of IŒ∫BŒ± resulting in gene-specific suppression of NF-Œ∫B--dependent transcription and induction of apoptosis in CTCL.	NFKBIA
21228035	10.3324/haematol.2010.030577	2011	Polymorphisms of nuclear factor-Œ∫B family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.	NFKBIA
21406399	10.1158/0008-5472.CAN-10-3626	2011	CARMA3 is crucial for EGFR-Induced activation of NF-Œ∫B and tumor progression.	NFKBIA
21526201	10.1371/journal.pone.0018933	2011	Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement.	NFKBIA
21701779	10.3892/mmr.2011.515	2011	Analysis of CCL5 expression in classical Hodgkin's lymphoma L428 cell line.	NFKBIA
21896478	10.1074/jbc.M111.263384	2011	The E3 ubiquitin ligase mind bomb-2 (MIB2) protein controls B-cell CLL/lymphoma 10 (BCL10)-dependent NF-Œ∫B activation.	NFKBIA
19648161	10.3324/haematol.2009.010157	2010	Mutations in the genes coding for the NF-Œ∫B regulating factors IŒ∫BŒ± and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma.	NFKBIA
19857958	10.1016/j.ejca.2009.10.008	2010	Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients.	NFKBIA
19966855	10.1038/onc.2009.431	2010	TCEAL7, a putative tumor suppressor gene, negatively regulates NF-kappaB pathway.	NFKBIA
20081837	10.1038/ncb2019	2010	Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA.	NFKBIA
20106524	10.1016/j.leukres.2009.12.014	2010	NFkappaB modulators in a model of glucocorticoid resistant, childhood acute lymphoblastic leukemia.	NFKBIA
20193848	10.1016/j.cancergencyto.2009.11.005	2010	Mutations of NFKBIA in biopsy specimens from Hodgkin lymphoma.	NFKBIA
20359517	10.1016/j.tox.2010.03.014	2010	Gene expression profiles of human promyelocytic leukemia cell lines exposed to volatile organic compounds.	NFKBIA
20393484	10.1038/jid.2010.86	2010	Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling.	NFKBIA
20466000	10.1016/j.yexcr.2010.05.004	2010	Lipopolysaccharide-induced activation of NF-Œ∫B non-canonical pathway requires BCL10 serine 138 and NIK phosphorylations.	NFKBIA
20551178	10.1242/jcs.069476	2010	Interplay between BCL10, MALT1 and IkappaBalpha during T-cell-receptor-mediated NFkappaB activation.	NFKBIA
20558726	10.1074/jbc.M110.112128	2010	BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit PSMB1.	NFKBIA
20607853	10.1002/gcc.20789	2010	Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma.	NFKBIA
20716621	10.1158/1055-9965.EPI-10-0389	2010	Genetic polymorphisms in adaptive immunity genes and childhood acute lymphoblastic leukemia.	NFKBIA
20937806	10.1074/jbc.M110.159681	2010	Tumor necrosis factor alpha-induced inflammation is increased but apoptosis is inhibited by common food additive carrageenan.	NFKBIA
18992741	10.1016/j.yexcr.2008.10.010	2009	Role for protein geranylgeranylation in adult T-cell leukemia cell survival.	NFKBIA
19085995	10.1002/ibd.20821	2009	ROS, Hsp27, and IKKbeta mediate dextran sodium sulfate (DSS) activation of IkappaBa, NFkappaB, and IL-8.	NFKBIA
19219072	10.1038/onc.2009.6	2009	Matrix Metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes.	NFKBIA
19223558	10.1158/1055-9965.EPI-08-1130	2009	Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma.	NFKBIA
19507254	10.1002/ijc.24502	2009	Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases.	NFKBIA
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	NFKBIA
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	NFKBIA
20695076	10.4248/IJOS.09059	2009	CXCL12/SDF-1 alpha activates NF-kappaB and promotes oral cancer invasion through the Carma3/Bcl10/Malt1 complex.	NFKBIA
18235046	10.1182/blood-2007-08-108654	2008	PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.	NFKBIA
18574738	10.1080/08830180801939272	2008	Current topics in prevention of human T-cell leukemia virus type i infection: NF-kappa B inhibitors and APOBEC3.	NFKBIA
18636124	10.1371/journal.pone.0002816	2008	Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.	NFKBIA
18728964	10.1080/10428190802304966	2008	Growth control of multiple myeloma cells through inhibition of glycogen synthase kinase-3.	NFKBIA
18852135	10.1158/1535-7163.MCT-08-0541	2008	Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines.	NFKBIA
16778832	10.1038/sj.cdd.4401996	2007	Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner.	NFKBIA
17095757	10.1152/ajpgi.00380.2006	2007	Carrageenan induces interleukin-8 production through distinct Bcl10 pathway in normal human colonic epithelial cells.	NFKBIA
17310217	10.1038/labinvest.3700528	2007	IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells.	NFKBIA
17355202	10.1089/adt.2006.048	2007	A cell-based assay for IkappaBalpha stabilization using a two-color dual luciferase-based sensor.	NFKBIA
17363905	10.1038/sj.emboj.7601622	2007	Phosphorylation and ubiquitination of the IkappaB kinase complex by two distinct signaling pathways.	NFKBIA
17367755	10.1016/j.bbrc.2007.03.002	2007	Induction of the nuclear IkappaB protein IkappaB-zeta upon stimulation of B cell antigen receptor.	NFKBIA
17540779	10.1152/ajpgi.00149.2007	2007	Bcl10 mediates LPS-induced activation of NF-kappaB and IL-8 in human intestinal epithelial cells.	NFKBIA
17550372	10.1111/j.1365-2249.2007.03427.x	2007	Interleukin-13-induced type II polarization of inflammatory macrophages is mediated through suppression of nuclear factor-kappaB and preservation of IkappaBalpha in a T cell lymphoma.	NFKBIA
17555878	10.1016/j.bbagen.2007.04.011	2007	Nitric oxide induces apoptosis in cutaneous T cell lymphoma (HuT-78) by downregulating constitutive NF-kappaB.	NFKBIA
17681786	10.1016/j.phrs.2007.06.003	2007	Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells.	NFKBIA
17899540	10.1002/eji.200636759	2007	Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells.	NFKBIA
16289774	10.1016/j.canlet.2005.10.004	2006	The synthetic epoxyquinoids jesterone dimer and epoxyquinone A monomer induce apoptosis and inhibit REL (human c-Rel) DNA binding in an IkappaBalpha-deficient diffuse large B-cell lymphoma cell line.	NFKBIA
16388856	10.1016/j.imlet.2005.10.019	2006	In vivo and in vitro sensitization of leukemic cells to adriamycin-induced apoptosis by pentoxifylline. Involvement of caspase cascades and IkappaBalpha phosphorylation.	NFKBIA
16401828	10.1182/blood-2005-07-2827	2006	Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma.	NFKBIA
16498412	10.1038/sj.emboj.7600996	2006	Notch3 and pre-TCR interaction unveils distinct NF-kappaB pathways in T-cell development and leukemia.	NFKBIA
16539850	10.1111/j.1745-7254.2006.00284.x	2006	Deguelin inhibits expression of IkappaBalpha protein in Raji and U937 cells.	NFKBIA
16751281	10.1073/pnas.0507809103	2006	The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas.	NFKBIA
15778364	10.4049/jimmunol.174.7.4060	2005	CD40 engagement prevents peroxisome proliferator-activated receptor gamma agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-kappaB-dependent mechanism.	NFKBIA
15782119	10.1038/sj.onc.1208564	2005	Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts.	NFKBIA
15858823	10.1002/ijc.21036	2005	Germline mutations and polymorphisms in the NFKBIA gene in Hodgkin lymphoma.	NFKBIA
15909110	10.1007/s10495-005-1877-0	2005	Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity.	NFKBIA
15922723	10.1016/j.yexcr.2005.02.015	2005	Evidence for a phosphorylation-independent role for Ser 32 and 36 in proteasome inhibitor-resistant (PIR) IkappaBalpha degradation in B cells.	NFKBIA
15969767	10.1186/1471-2172-6-12	2005	Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors.	NFKBIA
15973455	10.1038/sj.leu.2403841	2005	Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin's and non-Hodgkin's lymphomas.	NFKBIA
15979856	10.1016/j.bbadis.2005.05.003	2005	Relationship between constitutive nuclear factor-kappaB (NF-kappaB) and inhibitor kappaB-alpha (IkappaB-alpha) in an interferon-alpha-sensitive human Burkitt lymphoma cell line.	NFKBIA
16023083	10.1016/j.bcp.2005.04.043	2005	Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.	NFKBIA
16185501	NA	2005	[Preliminary analysis of mutations in exon 5 of IkappaBalpha gene in Hodgkin lymphoma].	NFKBIA
16299251	10.1158/1078-0432.CCR-05-0224	2005	Inhibition of nuclear translocation of nuclear factor-kappaB despite lack of functional IkappaBalpha protein overcomes multiple defects in apoptosis signaling in human B-cell malignancies.	NFKBIA
16464740	NA	2005	Differential effects of tumor necrosis factor-alpha and CD40L on NF-kappa B inhibitory proteins I kappa B alpha, beta and epsilon and on the induction of the Jun amino-terminal kinase pathway in Ramos Burkitt lymphoma cells.	NFKBIA
14668329	10.1074/jbc.M312398200	2004	Bcl-3 and NFkappaB p50-p50 homodimers act as transcriptional repressors in tolerant CD4+ T cells.	NFKBIA
14763901	10.1042/BJ20031796	2004	A mechanistic insight into a proteasome-independent constitutive inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor kappaB (NF-kappaB) activation pathway in WEHI-231 B-cells.	NFKBIA
15125833	10.1016/s1097-2765(04)00236-9	2004	The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes.	NFKBIA
15131062	10.1158/1078-0432.ccr-03-0494	2004	Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.	NFKBIA
15147743	10.1016/j.biocel.2004.02.004	2004	Tissue inhibitor of metalloproteinases-2 growth-stimulatory activity is mediated by nuclear factor-kappa B in A549 lung epithelial cells.	NFKBIA
15198731	10.1111/j.1365-2141.2004.05000.x	2004	Mutational analysis of the IkappaBalpha gene in activated B cell-like diffuse large B-cell lymphoma.	NFKBIA
12406882	10.1182/blood-2002-08-2525	2003	Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B.	NFKBIA
12525885	NA	2003	Mutational analysis of IkappaBalpha in hematologic malignancies.	NFKBIA
12537981	10.1016/s0145-2126(02)00164-9	2003	Capsaicin inhibits growth of adult T-cell leukemia cells.	NFKBIA
12745547	10.1080/0962935031000096953	2003	Dexamethasone prevents interleukin-1beta-induced nuclear factor-kappaB activation by upregulating IkappaB-alpha synthesis, in lymphoblastic cells.	NFKBIA
12815168	10.1124/mol.64.1.123	2003	Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor kappaB by inhibiting the inhibitor of kappaB kinase.	NFKBIA
12816986	10.4049/jimmunol.171.1.88	2003	Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.	NFKBIA
12902482	10.4049/jimmunol.171.4.1816	2003	T cell-intrinsic requirement for NF-kappa B induction in postdifferentiation IFN-gamma production and clonal expansion in a Th1 response.	NFKBIA
12963487	10.1016/s0006-2952(03)00415-5	2003	Genistein reduces NF-kappa B in T lymphoma cells via a caspase-mediated cleavage of I kappa B alpha.	NFKBIA
15068390	10.1007/BF03260037	2003	Monitoring NF-kappa B transactivation potential via real-time PCR quantification of I kappa B-alpha gene expression.	NFKBIA
11830587	10.1074/jbc.M110480200	2002	The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex.	NFKBIA
11861386	NA	2002	Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.	NFKBIA
12058256	10.1038/sj.gene.6363846	2002	Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations.	NFKBIA
12189195	10.1093/carcin/23.9.1511	2002	Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2.	NFKBIA
12377412	10.1016/s0165-4608(02)00541-1	2002	Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma.	NFKBIA
12413886	10.1006/excr.2002.5640	2002	CD40-mediated apoptosis in murine B-lymphoma lines containing mutated p53.	NFKBIA
11707390	10.1093/emboj/20.22.6180	2001	Crystal structure of the ankyrin repeat domain of Bcl-3: a unique member of the IkappaB protein family.	NFKBIA
11739184	10.1182/blood.v98.13.3762	2001	Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage.	NFKBIA
11781710	10.1038/sj.gene.6363803	2001	Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway.	NFKBIA
10637284	10.1084/jem.191.2.395	2000	Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma.	NFKBIA
10670837	10.1097/00024382-200013020-00001	2000	NF-kappaB regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome.	NFKBIA
10720133	10.1038/sj.leu.2401705	2000	Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.	NFKBIA
10781932	10.1016/s0898-6568(00)00062-0	2000	Role and regulation of Rel/NF-kappaB activity in anti-immunoglobulin-induced apoptosis in WEHI-231 B lymphoma cells.	NFKBIA
10880446	10.1093/emboj/19.13.3337	2000	Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice.	NFKBIA
10930537	10.1016/s0006-2952(00)00387-7	2000	Prevention of etoposide-induced apoptosis by proteasome inhibitors in a human leukemic cell line but not in fresh acute leukemia blasts. A differential role of NF-kappab activation.	NFKBIA
10931834	10.1074/jbc.M004148200	2000	NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.	NFKBIA
11023521	NA	2000	Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation.	NFKBIA
11110706	NA	2000	Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells.	NFKBIA
10023675	10.1038/sj.onc.1202374	1999	Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105.	NFKBIA
10090947	NA	1999	Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells.	NFKBIA
10202013	NA	1999	An 11-amino acid sequence in the cytoplasmic domain of CD40 is sufficient for activation of c-Jun N-terminal kinase, activation of MAPKAP kinase-2, phosphorylation of I kappa B alpha, and protection of WEHI-231 cells from anti-IgM-induced growth arrest.	NFKBIA
10340377	10.1038/sj.onc.1202893	1999	Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha.	NFKBIA
10362352	10.1038/sj.onc.1202717	1999	The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators.	NFKBIA
10384125	NA	1999	Constitutive nuclear translocation of NF-kappa B in B cells in the absence of I kappa B degradation.	NFKBIA
10515890	NA	1999	Expression of human inducible nitric oxide synthase gene in T-cell lines infected with human T-cell leukemia virus type-I and primary adult T-cell leukemia cells.	NFKBIA
10564680	10.1093/jnci/91.22.1956	1999	Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells.	NFKBIA
9973408	NA	1999	Lipopolysaccharide inhibits TNF-induced apoptosis: role of nuclear factor-kappaB activation and reactive oxygen intermediates.	NFKBIA
9512545	10.1093/nar/26.7.1724	1998	Signal-dependent degradation of IkappaBalpha is mediated by an inducible destruction box that can be transferred to NF-kappaB, bcl-3 or p53.	NFKBIA
9570540	NA	1998	CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of nuclear factor-kappa B/c-Rel.	NFKBIA
9572494	10.1038/sj.onc.1201735	1998	Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB.	NFKBIA
9624136	10.1074/jbc.273.25.15494	1998	Ceramide activates NFkappaB by inducing the processing of p105.	NFKBIA
9221757	10.1084/jem.186.2.279	1997	IkappaBalpha overexpression delays tumor formation in v-rel transgenic mice.	NFKBIA
9252555	10.1152/ajplung.1997.273.1.L185	1997	Systemic blood loss affects NF-kappa B regulatory mechanisms in the lungs.	NFKBIA
8683159	NA	1996	Maintenance of nuclear factor-kappa B/Rel and c-myc expression during CD40 ligand rescue of WEHI 231 early B cells from receptor-mediated apoptosis through modulation of I kappa B proteins.	NFKBIA
8654782	10.1042/bst023597s	1995	Sustained activation of NF kappa B and transient I kappa B alpha degradation induced by tumour necrosis factor in 1321N1 human astrocytoma.	NFKBIA
7692229	10.1128/mcb.13.10.6283-6289.1993	1993	Differential regulation of vascular cell adhesion molecule 1 gene expression by specific NF-kappa B subunits in endothelial and epithelial cells.	NFKBIA
35885481	10.3390/diagnostics12071575	2022	Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma.	NFKBIE
35964234	10.1093/ajcp/aqac087	2022	Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma.	NFKBIE
32079702	10.3324/haematol.2019.237719	2021	Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study.	NFKBIE
32961552	10.1182/blood.2020007507	2021	Mutational landscape of gray zone lymphoma.	NFKBIE
34405005	10.7150/jca.60390	2021	Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.	NFKBIE
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	NFKBIE
32170099	10.1038/s41408-020-0305-6	2020	Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice.	NFKBIE
32585984	10.3390/cancers12061669	2020	Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma.	NFKBIE
32947237	10.1016/j.tranon.2020.100855	2020	Identification of clinical molecular targets for childhood Burkitt lymphoma.	NFKBIE
29449436	10.3324/haematol.2017.182048	2018	Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients.	NFKBIE
29857068	10.1016/j.jid.2018.04.038	2018	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.	NFKBIE
29899297	10.3390/ijms19061758	2018	Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.	NFKBIE
26647218	10.1158/1078-0432.CCR-15-2123	2016	Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.	NFKBIE
27489104	10.1074/jbc.M116.719302	2016	The Nuclear Protein IŒ∫BŒ∂ Forms a Transcriptionally Active Complex with Nuclear Factor-Œ∫B (NF-Œ∫B) p50 and the Lcn2 Promoter via the N- and C-terminal Ankyrin Repeat Motifs.	NFKBIE
27670424	10.1182/blood-2016-03-704528	2016	Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.	NFKBIE
25987724	10.1084/jem.20142009	2015	Functional loss of IŒ∫BŒµ leads to NF-Œ∫B deregulation in aggressive chronic lymphocytic leukemia.	NFKBIE
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	NFKBIE
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	NFKBIE
16360644	10.1016/j.bcp.2005.11.013	2006	Inhibition of transcription factor NF-kappaB signaling proteins IKKbeta and p65 through specific cysteine residues by epoxyquinone A monomer: correlation with its anti-cancer cell growth activity.	NFKBIE
16464740	NA	2005	Differential effects of tumor necrosis factor-alpha and CD40L on NF-kappa B inhibitory proteins I kappa B alpha, beta and epsilon and on the induction of the Jun amino-terminal kinase pathway in Ramos Burkitt lymphoma cells.	NFKBIE
14595753	10.1002/path.1454	2003	Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.	NFKBIE
10384125	NA	1999	Constitutive nuclear translocation of NF-kappa B in B cells in the absence of I kappa B degradation.	NFKBIE
9223487	10.1128/JVI.71.8.5972-5981.1997	1997	VBP and RelA regulate avian leukosis virus long terminal repeat-enhanced transcription in B cells.	NFKBIE
33232972	10.1182/blood.2020005244	2021	Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.	NFKBIZ
29289361	10.1016/j.blre.2017.12.001	2018	The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.	NFKBIZ
30275490	10.1038/s41467-018-06354-3	2018	Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma.	NFKBIZ
30401751	10.1182/bloodadvances.2018022962	2018	Insights into the genomic landscape of MYD88 wild-type Waldenstr√∂m macroglobulinemia.	NFKBIZ
26647218	10.1158/1078-0432.CCR-15-2123	2016	Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.	NFKBIZ
26702065	10.1182/blood-2015-10-673236	2016	Targetable genetic features of primary testicular and primary central nervous system lymphomas.	NFKBIZ
26727576	10.1038/oncsis.2015.44	2016	A mix of S and ŒîS variants of STAT3 enable survival of activated B-cell-like diffuse large B-cell lymphoma cells in culture.	NFKBIZ
26869285	10.1002/cam4.650	2016	Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles.	NFKBIZ
27793034	10.18632/oncotarget.12876	2016	Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.	NFKBIZ
25282160	10.1038/ni.3008	2014	Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(H)17 differentiation.	NFKBIZ
23869088	10.1182/blood-2013-06-508028	2013	IŒ∫B-Œ∂ controls the constitutive NF-Œ∫B target gene network and survival of ABC DLBCL.	NFKBIZ
24027435	10.1593/neo.131140	2013	Human T cell leukemia virus type I tax-induced IŒ∫B-Œ∂ modulates tax-dependent and tax-independent gene expression in T cells.	NFKBIZ
24072847	10.1182/blood-2013-08-516864	2013	Shaping oncogenic NF-Œ∫B activity in the nucleus.	NFKBIZ
22513784	10.1038/jid.2012.117	2012	A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides.	NFKBIZ
19586995	10.1177/1753425909103738	2009	Interleukin (IL)-10 attenuates lipopolysaccharide-induced IL-6 production via inhibition of IkappaB-zeta activity by Bcl-3.	NFKBIZ
18647318	10.1111/j.1365-2222.2008.03030.x	2008	Up-regulated cytokine-inducible SH2-containing protein expression in allergen-stimulated T cells from hen's egg-allergic patients.	NFKBIZ
17367755	10.1016/j.bbrc.2007.03.002	2007	Induction of the nuclear IkappaB protein IkappaB-zeta upon stimulation of B cell antigen receptor.	NFKBIZ
32169428	10.1053/j.gastro.2020.03.009	2020	Innate Immune Molecule NLRC5 Protects Mice From Helicobacter-induced Formation of Gastric Lymphoid Tissue.	NLRC5
35845006	10.1002/jha2.116	2020	Genetic aberrations of <i>NLRC5</i> are associated with downregulated MHC-I antigen presentation and impaired T-cell immunity in follicular lymphoma.	NLRC5
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	NOTCH1
34624096	10.1182/blood.2020010405	2022	ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells.	NOTCH1
34669156	10.1007/s11684-021-0877-y	2022	Chidamide inhibits the NOTCH1-MYC signaling axis in T-cell acute lymphoblastic leukemia.	NOTCH1
34814054	10.1016/j.tice.2021.101674	2022	Mechanism of IDH1-R132H mutation in T cell acute lymphoblastic leukemia mouse model via the Notch1 pathway.	NOTCH1
34882582	10.1172/JCI153283	2022	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.	NOTCH1
34937946	10.1038/s41586-021-04244-1	2022	Valine tRNA levels and availability regulate complex I assembly in leukaemia.	NOTCH1
35014081	10.1002/ddr.21911	2022	Mitoquinone intravitreal injection ameliorates retinal ischemia-reperfusion injury in rats involving SIRT1/Notch1/NADPH axis.	NOTCH1
35014928	10.1080/10428194.2021.2020779	2022	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.	NOTCH1
35020836	10.1182/blood.2021012077	2022	Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL.	NOTCH1
35106936	10.1002/cam4.4550	2022	SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.	NOTCH1
35129045	10.1080/10428194.2022.2032033	2022	Prognostic significance of <i>NOTCH1/FBXW7</i> mutations in pediatric T cell acute lymphoblastic leukemia: a study of minimal residual disease risk-directed CCLG-ALL 2008 treatment protocol.	NOTCH1
35173274	10.1038/s41375-022-01516-1	2022	Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL.	NOTCH1
35231988	10.3760/cma.j.issn.0253-2727.2022.01.005	2022	[Mutational spectrum and its prognostic significance in childhood acute lymphoblastic leukemia based on next-generation sequencing technology].	NOTCH1
35240234	10.1016/j.canlet.2022.215608	2022	DT7 peptide-modified lecithin nanoparticles co-loaded with Œ≥-secretase inhibitor and dexamethasone efficiently inhibit T-cell acute lymphoblastic leukemia and reduce gastrointestinal toxicity.	NOTCH1
35245453	10.1016/j.molcel.2022.02.015	2022	How to resist Notch-targeted T-leukemia therapy: Lineage- and MYC enhancer switch.	NOTCH1
35279479	10.1016/j.imbio.2022.152205	2022	Optimized outcome prediction of oncogenetic mutations in non-early T-cell precursor acute lymphoblastic leukemia.	NOTCH1
35280829	10.3389/fonc.2022.811151	2022	Prognostic Significance of Comprehensive Gene Mutations and Clinical Characteristics in Adult T-Cell Acute Lymphoblastic Leukemia Based on Next-Generation Sequencing.	NOTCH1
35280868	10.3389/fmed.2022.826705	2022	Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring <i>EML4-ALK</i> Fusion Gene: Study of Two Typical Cases and Review of Literature.	NOTCH1
35300216	10.2147/JIR.S341355	2022	The Mutation of <i>BTG2</i> Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma.	NOTCH1
35401501	10.3389/fimmu.2022.867443	2022	Monoallelic <i>Heb/Tcf12</i> Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.	NOTCH1
35589701	10.1038/s41467-022-30396-3	2022	Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia.	NOTCH1
35592856	10.3389/fmed.2022.808378	2022	A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer.	NOTCH1
35605191	10.1182/blood.2021015144	2022	NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness.	NOTCH1
35680792	10.19746/j.cnki.issn.1009-2137.2022.03.006	2022	[Effect of Curcumin on Apoptosis of Acute T-Lymphoblastic Leukemia Cells induced by UMI-77 and Its Related Mechanism].	NOTCH1
35681778	10.3390/cancers14112799	2022	The Role of NOTCH1, GATA3, and c-MYC in T Cell Non-Hodgkin Lymphomas.	NOTCH1
35685993	10.21147/j.issn.1000-9604.2022.02.03	2022	Genomic landscape of T-cell lymphoblastic lymphoma.	NOTCH1
35734596	10.3389/fonc.2022.846573	2022	The Clinical Characteristics and Prognosis of AYA and Older Adult ETP-ALL/LBL: A Real-World Multicenter Study in China.	NOTCH1
35767640	10.1073/pnas.2118529119	2022	Early expression of mature Œ±Œ≤ TCR in CD4<sup>-</sup>CD8<sup>-</sup> T cell progenitors enables MHC to drive development of T-ALL bearing NOTCH mutations.	NOTCH1
35768390	10.3760/cma.j.cn112137-20211025-02358	2022	[Characteristics and prognostic effects of NOTCH1/FBXW7 gene mutations in T-cell acute lymphoblastic leukemia patients].	NOTCH1
35774848	10.1155/2022/3276925	2022	Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.	NOTCH1
35829664	10.1111/bjh.18352	2022	Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.	NOTCH1
35852337	10.1128/spectrum.01478-22	2022	BET-Independent Murine Leukemia Virus Integration Is Retargeted <i>In Vivo</i> and Selects Distinct Genomic Elements for Lymphomagenesis.	NOTCH1
35910501	10.6004/jadpro.2022.13.5.7	2022	An Approach to Diagnosis of Richter Transformation in Chronic Lymphocytic Leukemia.	NOTCH1
35915142	10.1038/s41375-022-01651-9	2022	Inhibition of the m<sup>6</sup>A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia.	NOTCH1
36000950	10.1002/pbc.29926	2022	Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic lymphoma.	NOTCH1
36090975	10.3389/fimmu.2022.987298	2022	Targeting the Cbl-b-Notch1 axis as a novel immunotherapeutic strategy to boost CD8+ T-cell responses.	NOTCH1
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	NOTCH1
32327503	10.3324/haematol.2019.238766	2021	Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target.	NOTCH1
32382081	10.1038/s41375-020-0845-6	2021	SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia.	NOTCH1
32415821	10.17305/bjbms.2020.4687	2021	Progress in research on childhood T-cell acute lymphocytic leukemia, Notch1 signaling pathway, and its inhibitors: A review.	NOTCH1
32733009	10.1038/s41375-020-0999-2	2021	Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination.	NOTCH1
32812017	10.1182/blood.2020006996	2021	Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia.	NOTCH1
33068240	10.1007/s11845-020-02386-1	2021	Biclonal lymphoproliferative disorders: another association with NOTCH1-mutated chronic lymphocytic leukaemias.	NOTCH1
33152759	10.1182/blood.2020005381	2021	Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance.	NOTCH1
33191568	10.1002/onco.13595	2021	More Insights on the Use of Œ≥-Secretase Inhibitors in Cancer Treatment.	NOTCH1
33227818	10.1182/blood.2019004547	2021	Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL.	NOTCH1
33310759	10.26508/lsa.202000794	2021	Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK-driven lymphomagenesis.	NOTCH1
33314742	10.1002/1878-0261.12877	2021	Downregulation of Glutamine Synthetase, not glutaminolysis, is responsible for glutamine addiction in Notch1-driven acute lymphoblastic leukemia.	NOTCH1
33316538	10.1016/j.neo.2020.11.010	2021	U-RT1 - A new model for Richter transformation.	NOTCH1
33407740	10.1186/s13045-020-01015-9	2021	Targeting oncogenic Notch signaling with SERCA inhibitors.	NOTCH1
33436855	10.1038/s41598-020-80613-6	2021	Targeted sequencing to identify genetic alterations and prognostic markers in pediatric T-cell acute lymphoblastic leukemia.	NOTCH1
33458694	10.1158/2643-3230.BCD-20-0201	2021	A Tumor Suppressor Enhancer of <i>PTEN</i> in T-cell development and leukemia.	NOTCH1
33479306	10.1038/s41598-020-80376-0	2021	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.	NOTCH1
33526873	10.1038/s41379-021-00739-4	2021	Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group.	NOTCH1
33538669	10.2174/1389450122666210203192752	2021	Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia.	NOTCH1
33538798	10.1182/blood.2020005734	2021	Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.	NOTCH1
33569430	10.21037/atm-20-7574	2021	Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity.	NOTCH1
33570635	10.1182/bloodadvances.2020002995	2021	Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors.	NOTCH1
33571115	10.1126/sciadv.abc9781	2021	NOTCH1-driven UBR7 stimulates nucleotide biosynthesis to promote T cell acute lymphoblastic leukemia.	NOTCH1
33578108	10.1016/j.jbior.2021.100788	2021	Mutations that collaborate with IL-7Ra signaling pathways to drive ALL.	NOTCH1
33611795	10.1002/gcc.22943	2021	MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia.	NOTCH1
33615197	10.1016/j.isci.2021.102089	2021	Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways.	NOTCH1
33634864	10.1002/ijc.33527	2021	Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis.	NOTCH1
33775465	10.1016/j.blre.2021.100824	2021	Revisiting Richter transformation in the era of novel CLL agents.	NOTCH1
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	NOTCH1
33858050	10.3760/cma.j.issn.0253-2727.2021.02.014	2021	[The role and research progress of NOTCH1 in T-cell acute lymphoblastic leukemia].	NOTCH1
33876224	10.1182/blood.2020008955	2021	A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia.	NOTCH1
33925883	10.3390/ijms22094502	2021	The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.	NOTCH1
33941203	10.1186/s13045-021-01068-4	2021	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL.	NOTCH1
33942287	10.1111/bjh.17310	2021	Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.	NOTCH1
33947863	10.1038/s41467-021-22787-9	2021	Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures.	NOTCH1
33972504	10.1038/s41408-021-00477-5	2021	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.	NOTCH1
34035082	10.1158/0008-5472.CAN-20-2823	2021	Whole-Exome Sequencing of Radiation-Induced Thymic Lymphoma in Mouse Models Identifies Notch1 Activation as a Driver of p53 Wild-Type Lymphoma.	NOTCH1
34080325	10.1002/cam4.4024	2021	The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia.	NOTCH1
34167562	10.1186/s13045-021-01114-1	2021	PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.	NOTCH1
34188174	10.1038/s42003-021-02330-8	2021	NOTCH-ing up nucleotide metabolism in T-cell acute lymphoblastic leukemia.	NOTCH1
34203994	10.3390/cancers13123005	2021	<i>DLX</i> Genes: Roles in Development and Cancer.	NOTCH1
34218589	10.3760/cma.j.issn.0253-2727.2021.05.015	2021	[The characteristics and prognostic impact of NOTCH1/FBXW7 mutation and CDKN2A/B deletion in adult T-cell acute lymphoblastic leukemia patients].	NOTCH1
34223928	10.1007/s00109-021-02101-2	2021	CARMA1 is required for Notch1-induced NF-Œ∫B activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia.	NOTCH1
34256839	10.1186/s40164-021-00232-3	2021	Progress in molecular feature of smoldering mantle cell lymphoma.	NOTCH1
34376672	10.1038/s41467-021-25101-9	2021	Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma.	NOTCH1
34407842	10.1186/s13046-021-02071-w	2021	SIRT1 regulates the phosphorylation and degradation of P27 by deacetylating CDK2 to promote T-cell acute lymphoblastic leukemia progression.	NOTCH1
34440292	10.3390/genes12081118	2021	T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness.	NOTCH1
34506616	10.1371/journal.pone.0257353	2021	Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).	NOTCH1
34514345	10.1097/HS9.0000000000000641	2021	Toward Pediatric T Lymphoblastic Lymphoma Stratification Based on Minimal Disseminated Disease and <i>NOTCH1/FBXW7</i> Status.	NOTCH1
34573936	10.3390/diagnostics11091594	2021	Prognostic Role of Minimal Disseminated Disease and <i>NOTCH1/FBXW7</i> Mutational Status in Children with Lymphoblastic Lymphoma: The AIEOP Experience.	NOTCH1
34680290	10.3390/cancers13205141	2021	Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents.	NOTCH1
34698884	10.1007/s00018-021-03979-4	2021	MicroRNA-34a: the bad guy in age-related vascular diseases.	NOTCH1
34735923	10.1016/j.imbio.2021.152149	2021	Upregulation of leukemia-induced non-coding activator RNA (LUNAR1) predicts poor outcome in pediatric T-acute lymphoblastic leukemia.	NOTCH1
34739844	10.1016/j.ccell.2021.10.006	2021	Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.	NOTCH1
34753401	10.1080/16078454.2021.1997197	2021	Circ_0000745 regulates NOTCH1-mediated cell proliferation and apoptosis in pediatric T-cell acute lymphoblastic leukemia through adsorbing miR-193b-3p.	NOTCH1
34771656	10.3390/cancers13215493	2021	High Expression of <i>PPM1D</i> Induces Tumors Phenotypically Similar to <i>TP53</i> Loss-of-Function Mutations in Mice.	NOTCH1
34956871	10.3389/fonc.2021.746577	2021	Clinical Features and Prognostic Significance of <i>NOTCH1</i> Mutations in Diffuse Large B-Cell Lymphoma.	NOTCH1
34956898	10.3389/fonc.2021.780085	2021	Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.	NOTCH1
35008340	10.3390/cancers14010176	2021	Recent Advances in the Genetic of MALT Lymphomas.	NOTCH1
35111674	10.3389/fonc.2021.790481	2021	Mutations in <i>JAK/STAT</i> and <i>NOTCH1</i> Genes Are Enriched in Post-Transplant Lymphoproliferative Disorders.	NOTCH1
29313423	10.1080/21541248.2018.1423851	2020	Rho guanosine nucleotide exchange factors are not such bad guys after all in cancer<sup>a</sup>.	NOTCH1
31467126	10.3324/haematol.2019.217687	2020	Dissecting molecular mechanisms of resistance to NOTCH1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts.	NOTCH1
31570389	10.1101/cshperspect.a035246	2020	The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia.	NOTCH1
31586130	10.1038/s41388-019-1042-9	2020	NRARP displays either pro- or anti-tumoral roles in T-cell acute lymphoblastic leukemia depending on Notch and Wnt signaling.	NOTCH1
31739126	10.1016/j.cancergen.2019.11.002	2020	Molecular and phenotypic characterization of an early T-cell precursor acute lymphoblastic lymphoma harboring PICALM-MLLT10 fusion with aberrant expression of B-cell antigens.	NOTCH1
31785807	10.1016/j.bbrc.2019.11.148	2020	Flavone inhibited proliferation of T-ALL by promoting c-Cbl-induced ubiquitinylation and degradation of Notch1.	NOTCH1
31796666	10.3233/CBM-190967	2020	Significance of NOTCH1 mutations d√©tections in T-acute lymphoblastic leukemia patients.	NOTCH1
31804006	10.1002/cam4.2757	2020	RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.	NOTCH1
31822496	10.1158/0008-5472.CAN-19-1471	2020	ARRB1-Promoted NOTCH1 Degradation Is Suppressed by OncomiR miR-223 in T-cell Acute Lymphoblastic Leukemia.	NOTCH1
31852326	10.1080/08880018.2019.1701160	2020	Mutation analysis in Korean patients with T-cell acute lymphoblastic leukemia.	NOTCH1
31853322	10.3892/etm.2019.8228	2020	miR-9 inhibition of neuronal apoptosis and expression levels of apoptosis genes Bcl-2 and Bax in depression model rats through Notch pathway.	NOTCH1
31894255	10.3892/ijmm.2019.4418	2020	Precision medicine for human cancers with Notch signaling dysregulation (Review).	NOTCH1
31930426	10.2340/00015555-3402	2020	Increased Expression of Delta-like Ligand 4 in Mycosis Fungoides.	NOTCH1
32027255	10.19746/j.cnki.issn.1009-2137.2020.01.012	2020	[Analysis of Clinical Characteristics and Therapeutic Efficacy of Patients with Adult Acute Lymphoblastic Leukemia].	NOTCH1
32080345	10.1038/s41375-020-0757-5	2020	A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: a multicenter study.	NOTCH1
32143838	10.1016/j.cellimm.2020.104081	2020	NK cells prevent T cell lymphoma development in T cell receptor-transgenic mice.	NOTCH1
32160292	10.1182/blood.2019002385	2020	Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing.	NOTCH1
32164600	10.1186/s12885-020-6709-7	2020	Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing.	NOTCH1
32173361	10.1016/j.exphem.2020.03.001	2020	Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma.	NOTCH1
32179411	10.1016/j.bcmd.2020.102419	2020	PEST domain NOTCH mutations confer a poor relapse free survival in pediatric T-ALL: Data from a tertiary care centre in India.	NOTCH1
32185137	10.3389/fonc.2020.00273	2020	The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects.	NOTCH1
32187361	10.1182/blood.2019003535	2020	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.	NOTCH1
32191807	10.1182/bloodadvances.2019001396	2020	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.	NOTCH1
32234760	10.1158/1078-0432.CCR-19-4207	2020	A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma.	NOTCH1
32245383	10.1186/s12920-020-0709-y	2020	Comprehensive chromosomal aberrations in a case of a patient with TCF3-HLF-positive BCP-ALL.	NOTCH1
32272636	10.3390/cancers12040894	2020	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.	NOTCH1
32277542	10.1002/gcc.22849	2020	Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.	NOTCH1
32277947	10.1016/j.taap.2020.115001	2020	Mebendazole is a potent inhibitor to chemoresistant T cell acute lymphoblastic leukemia cells.	NOTCH1
32317694	10.1038/s41598-020-63434-5	2020	Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.	NOTCH1
32386594	10.1016/j.chembiol.2020.04.002	2020	Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.	NOTCH1
32431543	10.2147/CMAR.S242903	2020	Clinicopathological Characteristics and Mutational Profiling of Adult T-Cell Lymphoblastic Lymphoma in a Chinese Population.	NOTCH1
32432760	10.26355/eurrev_202005_21188	2020	MiR-210 suppresses neuronal apoptosis in rats with cerebral infarction through regulating VEGF-notch signaling pathway.	NOTCH1
32432776	10.26355/eurrev_202005_21205	2020	Effect of atorvastatin on pulmonary hypertension rats through regulating notch signaling pathway.	NOTCH1
32487610	10.21873/anticanres.14297	2020	Sirtuin 1 Activation Suppresses the Growth of T-lymphoblastic Leukemia Cells by Inhibiting NOTCH and NF-Œ∫B Pathways.	NOTCH1
32526730	NA	2020	T-Cell Acute Lymphoblastic Leukemia: A Cytogenomic Update.	NOTCH1
32604737	10.3390/microorganisms8060958	2020	Variable Expression of Notch1 and Pax5 in Classical Hodgkin Lymphoma and Infection with Epstein-Barr in Pediatric Patients.	NOTCH1
32651260	10.1158/0008-5472.CAN-20-0034	2020	Monocyte-Derived Leukemia-Associated Macrophages Facilitate Extramedullary Distribution of T-cell Acute Lymphoblastic Leukemia Cells.	NOTCH1
32677544	10.1080/15384101.2020.1792686	2020	A Gli inhibitor GANT61 suppresses cell proliferation, promotes cell apoptosis and induces G1/G0 cycle retardation with a dose- and time-dependent manner through inhibiting Notch pathway in multiple myeloma.	NOTCH1
32695399	10.1186/s40364-020-00205-4	2020	Plasma circulating tumor DNA assessment reveals <i>KMT2D</i> as a potential poor prognostic factor in extranodal NK/T-cell lymphoma.	NOTCH1
32708470	10.3390/cells9071726	2020	miR-22-3p Negatively Affects Tumor Progression in T-Cell Acute Lymphoblastic Leukemia.	NOTCH1
32732220	10.1158/0008-5472.CAN-20-0486	2020	Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice.	NOTCH1
32738175	10.1002/hon.2784	2020	Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis.	NOTCH1
32793890	10.1158/0008-5472.BCD-19-0041	2020	Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia.	NOTCH1
32828943	10.1016/j.lfs.2020.118306	2020	Ranolazine protects against diabetic cardiomyopathy by activating the NOTCH1/NRG1 pathway.	NOTCH1
32848129	10.1038/s41408-020-00351-w	2020	Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.	NOTCH1
32894532	10.26355/eurrev_202008_22622	2020	MiR-145 targeting BNIP3 reduces apoptosis of chondrocytes in osteoarthritis through Notch signaling pathway.	NOTCH1
32907612	10.1186/s12943-020-01254-x	2020	Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells.	NOTCH1
32918521	10.1002/pbc.28704	2020	Aggressive Langerhans cell histiocytosis following T-cell acute lymphoblastic leukemia.	NOTCH1
32924017	10.1158/2643-3230.BCD-20-0026	2020	Combinatorial ETS1-dependent control of oncogenic NOTCH1 enhancers in T-cell leukemia.	NOTCH1
32939265	10.1186/s40364-020-00222-3	2020	Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia.	NOTCH1
32963611	10.3892/ol.2020.12068	2020	Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing.	NOTCH1
33010698	10.1016/j.prp.2020.153212	2020	LncRNA-NEAT1 promotes proliferation of T-ALL cells via miR-146b-5p/NOTCH1 signaling pathway.	NOTCH1
33017398	10.1371/journal.pbio.3000850	2020	Notch dimerization and gene dosage are important for normal heart development, intestinal stem cell maintenance, and splenic marginal zone B-cell homeostasis during mite infestation.	NOTCH1
33072583	10.3389/fonc.2020.558339	2020	MALT1 Inhibition as a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia by Blocking Notch1-Induced NF-Œ∫B Activation.	NOTCH1
33283700	10.19746/j.cnki.issn.1009-2137.2020.06.001	2020	[Gene Mutation in Acute Lymphoblastic Leukemia by DNA Sequencing].	NOTCH1
33585446	10.3389/fcell.2020.606448	2020	Vascular Notch Signaling in Stress Hematopoiesis.	NOTCH1
34865381	10.3760/cma.j.cn112138-20190924-00652	2020	[Clonal heterogeneity and its prognostic significance in acute lymphoblastic leukemia].	NOTCH1
30224339	10.1158/1078-0432.CCR-18-0867	2019	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.	NOTCH1
30280491	10.1002/pbc.27496	2019	Clinical and biological relevance of genetic alterations in pediatric T-cell acute lymphoblastic leukemia in Taiwan.	NOTCH1
30365070	10.3892/ijmm.2018.3957	2019	MicroRNA-98 reduces amyloid Œ≤-protein production and improves oxidative stress and mitochondrial dysfunction through the Notch signaling pathway via HEY2 in Alzheimer's disease mice.	NOTCH1
30370525	10.1002/jcp.27323	2019	Knockdown of MAML1 inhibits proliferation and induces apoptosis of T-cell acute lymphoblastic leukemia cells through SP1-dependent inactivation of TRIM59.	NOTCH1
30387229	10.1111/cas.13859	2019	NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia.	NOTCH1
30431086	10.3892/mmr.2018.9637	2019	Activation of the Notch‚ÄëNox4‚Äëreactive oxygen species signaling pathway induces cell death in high glucose‚Äëtreated human retinal endothelial cells.	NOTCH1
30467824	10.14670/HH-18-067	2019	Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient.	NOTCH1
30482776	10.1158/0008-5472.CAN-18-1987	2019	Ribosomal Lesions Promote Oncogenic Mutagenesis.	NOTCH1
30514801	10.3324/haematol.2018.198424	2019	T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development.	NOTCH1
30563887	10.1158/0008-5472.CAN-18-1617	2019	Inhibition of Notch Signaling Enhances Chemosensitivity in B-cell Precursor Acute Lymphoblastic Leukemia.	NOTCH1
30567843	10.1158/2159-8290.CD-18-1005	2019	<i>Phf6</i> Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL.	NOTCH1
30578688	10.1002/gcc.22723	2019	CRLF2 expression associates with ICN1 stabilization in T-cell acute lymphoblastic leukemia.	NOTCH1
30635552	10.1038/s12276-018-0195-x	2019	CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia.	NOTCH1
30718223	10.1016/j.anndiagpath.2019.01.004	2019	The frequency of NOTCH1 variants in T-acute lymphoblastic leukemia/lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma among Jordanian patients.	NOTCH1
30721949	10.1093/carcin/bgz013	2019	Mutational landscape of T-cell lymphoma in mice lacking the DNA mismatch repair gene Mlh1: no synergism with ionizing radiation.	NOTCH1
30734052	10.2340/00015555-3141	2019	Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.	NOTCH1
30777096	10.1186/s13046-019-1076-4	2019	Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.	NOTCH1
30839226	10.1089/dna.2018.4396	2019	Mechanism of Low Expression of miR-30a-5p on Epithelial-Mesenchymal Transition and Metastasis in Ovarian Cancer.	NOTCH1
30914196	10.1016/j.bbrc.2019.03.094	2019	Activation of Notch1 signaling by HTLV-1 Tax promotes proliferation of adult T-cell leukemia cells.	NOTCH1
30940846	10.1038/s41598-019-41805-x	2019	Insertional mutagenesis using the Sleeping Beauty transposon system identifies drivers of erythroleukemia in mice.	NOTCH1
30950667	10.1080/10428194.2019.1597270	2019	Gene mutations and pretransplant minimal residual disease predict risk of relapse in adult patients after allogeneic hematopoietic stem-cell transplantation for T cell acute lymphoblastic leukemia.	NOTCH1
30953029	10.1038/s41375-019-0466-0	2019	Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma.	NOTCH1
30967635	10.1038/s41388-019-0802-x	2019	The anti-malarial drug chloroquine sensitizes oncogenic NOTCH1 driven human T-ALL to Œ≥-secretase inhibition.	NOTCH1
31023700	10.1182/blood.2018882555	2019	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.	NOTCH1
31132650	10.1016/j.anndiagpath.2019.05.004	2019	TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.	NOTCH1
31142678	10.1126/scitranslmed.aau6246	2019	Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition.	NOTCH1
31226848	10.3390/ijms20123021	2019	Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia.	NOTCH1
31285322	10.1073/pnas.1905305116	2019	Nbn-Mre11 interaction is required for tumor suppression and genomic integrity.	NOTCH1
31298359	10.26355/eurrev_201906_18168	2019	MiR-9 facilitates cartilage regeneration of osteoarthritis in rabbits through regulating Notch signaling pathway.	NOTCH1
31308913	10.4084/MJHID.2019.037	2019	Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies.	NOTCH1
31311407	10.1080/15384047.2019.1638670	2019	Somatic mutations in <i>KMT2D</i> and <i>TET2</i> associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders.	NOTCH1
31322185	10.3892/mmr.2019.10451	2019	miR‚Äë338‚Äë3p suppresses the malignancy of T‚Äëcell lymphoblastic lymphoma by downregulating HOXA3.	NOTCH1
31344256	10.1111/bjh.16117	2019	The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.	NOTCH1
31346528	10.1155/2019/5601396	2019	Notch/CXCR4 Partnership in Acute Lymphoblastic Leukemia Progression.	NOTCH1
31399482	10.1242/dmm.040931	2019	Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically heterogeneous mouse model of T-cell acute lymphoblastic leukemia.	NOTCH1
31476403	10.1016/j.gene.2019.144095	2019	Penehyclidine hydrochloride defends against LPS-induced ALI in rats by mitigating endoplasmic reticulum stress and promoting the Hes1/Notch1 pathway.	NOTCH1
31530562	10.1182/blood.2019000982	2019	IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.	NOTCH1
31543360	10.1016/j.jbior.2019.100652	2019	Insulin-like growth factor (IGF) signaling in T-cell acute lymphoblastic leukemia.	NOTCH1
31622281	10.1172/jci.insight.131434	2019	A unique mutator phenotype reveals complementary oncogenic lesions leading to acute leukemia.	NOTCH1
31655559	10.1186/s12885-019-6209-9	2019	The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.	NOTCH1
31676012	10.1186/s13046-019-1458-7	2019	Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy.	NOTCH1
31690634	10.1126/scisignal.aay2369	2019	Extension of the Notch intracellular domain ankyrin repeat stack by NRARP promotes feedback inhibition of Notch signaling.	NOTCH1
31712410	10.1073/pnas.1913919116	2019	Mutant p53 antagonizes p63/p73-mediated tumor suppression via Notch1.	NOTCH1
31717324	10.3390/cancers11111755	2019	The Role of Nrf2 Activity in Cancer Development and Progression.	NOTCH1
31752447	10.3390/cancers11111820	2019	Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications.	NOTCH1
31799679	10.26355/eurrev_201911_19576	2019	Effect of lncRNA GAS5 on the apoptosis of neurons via the notch1 signaling pathway in rats with cerebral infarction.	NOTCH1
31819653	10.2147/CMAR.S232075	2019	CircCDYL Serves as a New Biomarker in Mantle Cell Lymphoma and Promotes Cell Proliferation.	NOTCH1
31824864	10.3389/fonc.2019.01304	2019	Myeloid/Lymphoid Neoplasm With FGFR1 Rearrangement Accompanying <i>RUNX1</i> and <i>NOTCH1</i> Gene Mutations.	NOTCH1
35117001	10.21037/tcr.2019.10.04	2019	Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.	NOTCH1
28776427	10.1080/10428194.2017.1359742	2018	ETV6 and NOTCH1 germline variants in adult acute leukemia.	NOTCH1
28914259	10.1038/leu.2017.282	2018	Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia.	NOTCH1
28925785	10.1080/10428194.2017.1376746	2018	Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.	NOTCH1
29051182	10.1182/blood-2017-04-778829	2018	Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.	NOTCH1
29115891	10.1080/10428194.2017.1397660	2018	The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.	NOTCH1
29151585	10.1038/leu.2017.328	2018	Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system.	NOTCH1
29158376	10.1084/jem.20151778	2018	Leukemia-specific delivery of mutant NOTCH1 targeted therapy.	NOTCH1
29180399	10.1182/blood-2017-09-805663	2018	Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.	NOTCH1
29200162	10.1097/MPH.0000000000001006	2018	Study of NOTCH1 and FBXW7 Mutations and Its Prognostic Significance in South Indian T-Cell Acute Lymphoblastic Leukemia.	NOTCH1
29330145	10.1158/0008-5472.CAN-17-1434	2018	MBD2 Ablation Impairs Lymphopoiesis and Impedes Progression and Maintenance of T-ALL.	NOTCH1
29342136	10.1038/nature25186	2018	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.	NOTCH1
29382756	10.1073/pnas.1716452115	2018	Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma.	NOTCH1
29484684	10.1002/hon.2502	2018	Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia.	NOTCH1
29514083	10.1016/j.celrep.2018.02.049	2018	PI3K/Akt Cooperates with Oncogenic Notch by Inducing Nitric Oxide-Dependent Inflammation.	NOTCH1
29556024	10.1038/s41375-018-0046-8	2018	The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia.	NOTCH1
29599840	10.3892/etm.2018.5784	2018	Effect of dihydroarteminin combined with siRNA targeting Notch1 on Notch1/c-Myc signaling in T-cell lymphoma cells.	NOTCH1
29641966	10.1056/NEJMoa1801445	2018	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.	NOTCH1
29643474	10.1038/s41388-018-0234-z	2018	Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.	NOTCH1
29654263	10.1038/s41375-018-0097-x	2018	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.	NOTCH1
29666622	10.3389/fimmu.2018.00633	2018	Chemotactic Cues for NOTCH1-Dependent Leukemia.	NOTCH1
29674500	10.3324/haematol.2018.191601	2018	Novel <i>GPR34</i> and <i>CCR6</i> mutation and distinct genetic profiles in MALT lymphomas of different sites.	NOTCH1
29692342	10.1182/blood-2018-01-791376	2018	Biology and treatment of Richter syndrome.	NOTCH1
29725418	10.3892/ol.2018.8193	2018	Differential regulation of AKT1 contributes to survival and proliferation in hepatocellular carcinoma cells by mediating Notch1 expression.	NOTCH1
29733873	10.1016/j.exphem.2018.04.008	2018	RUNX1 promotes cell growth in human T-cell acute lymphoblastic leukemia by transcriptional regulation of key target genes.	NOTCH1
29735551	10.1158/0008-5472.CAN-17-4004	2018	Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.	NOTCH1
29740158	10.1038/s41375-018-0127-8	2018	Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia.	NOTCH1
29765142	10.1038/s41379-018-0064-0	2018	Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement.	NOTCH1
29781813	10.1172/JCI92981	2018	The NOTCH1/CD44 axis drives pathogenesis in a T cell acute lymphoblastic leukemia model.	NOTCH1
29845231	10.3892/mmr.2018.9029	2018	Identification of key gene networks associated with fracture healing using Œ±SMA‚Äëlabeled progenitor cells.	NOTCH1
29877249	10.11406/rinketsu.59.574	2018	[The microenvironment and immune status of peripheral T-cell lymphoma: focusing on AITL and ATLL].	NOTCH1
29908894	10.1016/j.brainresbull.2018.06.005	2018	MicroRNA-499a decelerates glioma cell proliferation while accelerating apoptosis through the suppression of Notch1 and the MAPK signaling pathway.	NOTCH1
29938780	10.1111/bjh.15449	2018	The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols.	NOTCH1
29948644	10.1007/s11899-018-0455-9	2018	Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia.	NOTCH1
29976660	10.1128/JVI.00580-18	2018	Upregulation of MicroRNA 711 Mediates HIV-1 Vpr Promotion of Kaposi's Sarcoma-Associated Herpesvirus Latency and Induction of Pro-proliferation and Pro-survival Cytokines by Targeting the Notch/NF-Œ∫B-Signaling Axis.	NOTCH1
29989027	10.18632/oncotarget.25601	2018	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	NOTCH1
30030836	10.1007/978-3-319-89512-3_18	2018	Notch in Leukemia.	NOTCH1
30032036	10.1016/j.neo.2018.07.001	2018	Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma.	NOTCH1
30038221	10.1038/s41591-018-0105-8	2018	Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia.	NOTCH1
30103821	10.1186/s13104-018-3700-3	2018	FOXP3 knockdown inhibits the proliferation and reduces NOTCH1 expression of T cell acute lymphoblastic leukemia cells.	NOTCH1
30111389	10.7534/j.issn.1009-2137.2018.04.001	2018	[Study on Immunophenotypes and Gene of Acute Lymphoblastic Leukemia].	NOTCH1
30116272	10.1186/s11658-018-0102-4	2018	The notch pathway promotes NF-Œ∫B activation through Asb2 in T cell acute lymphoblastic leukemia cells.	NOTCH1
30208327	10.1016/j.celrep.2018.08.030	2018	STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia.	NOTCH1
30213787	10.1182/bloodadvances.2018019919	2018	B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33.	NOTCH1
30231940	10.1186/s13045-018-0665-6	2018	JAG1 overexpression contributes to Notch1 signaling and the migration of HTLV-1-transformed ATL cells.	NOTCH1
30250888	10.1080/23723556.2018.1432257	2018	An unexpected tumor suppressor role for VAV1<sup>a</sup>.	NOTCH1
30266814	10.1158/2159-8290.CD-17-0831	2018	Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation.	NOTCH1
30269902	10.1016/j.stem.2018.08.018	2018	Epigenetic Restoration of Fetal-like IGF1 Signaling Inhibits Leukemia Stem Cell Activity.	NOTCH1
30295241	10.7534/j.issn.1009-2137.2018.05.007	2018	[Effect of FBXW7 and NOTCH1 Mutations on Prognosis of Patients with Adult Acute T Lymphoblastic Leukemia].	NOTCH1
30370255	10.15430/JCP.2018.23.3.109	2018	PIM Kinase as an Executional Target in Cancer.	NOTCH1
30466748	10.1016/j.beha.2018.10.001	2018	Can one target T-cell ALL?	NOTCH1
30574752	NA	2018	miR-200b promotes cell proliferation and invasion in t-cell acute Lymphoblastic leukemia through NOTCH1.	NOTCH1
30788923	10.12047/j.cjap.5674.2018.097	2018	[Effects of irbesartan on Notch1 signaling pathway in diabetic rats with myocardial injury].	NOTCH1
27181628	10.1080/10428194.2016.1180681	2017	Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma.	NOTCH1
27499002	10.1080/10428194.2016.1213829	2017	Biallelic ATM alterations detected at diagnosis identify a subset of treatment-na√Øve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.	NOTCH1
27686521	10.1080/10428194.2016.1211278	2017	NOTCH1 mutation in type II Hodgkin transformation of chronic lymphocytic leukemia.	NOTCH1
27730468	10.1007/s12015-016-9691-3	2017	Eliminating Cancer Stem Cells by Targeting Embryonic Signaling Pathways.	NOTCH1
27758824	10.3324/haematol.2016.154013	2017	CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.	NOTCH1
27759908	10.1002/pbc.26266	2017	Translocation t(8;14)(q24;q11) with concurrent PTEN alterations and deletions of STIL/TAL1 and CDKN2A/B in a pediatric case of acute T-lymphoblastic leukemia: A genetic profile associated with adverse prognosis.	NOTCH1
27872496	10.1038/leu.2016.339	2017	Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.	NOTCH1
27872499	10.1038/leu.2016.340	2017	Phosphatase PRL2 promotes oncogenic NOTCH1-Induced T-cell leukemia.	NOTCH1
27888718	10.1016/j.molimm.2016.11.014	2017	Characterization of peritoneal leukemia-associated macrophages in Notch1-induced mouse T cell acute lymphoblastic leukemia.	NOTCH1
27936980	10.1080/17474086.2017.1270203	2017	Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.	NOTCH1
28004113	10.3892/or.2016.5281	2017	Suberoyl bis-hydroxamic acid activates Notch1 signaling and induces apoptosis in anaplastic thyroid carcinoma through p53.	NOTCH1
28096536	10.1038/leu.2017.25	2017	Germline IKAROS mutation associated with primary immunodeficiency that progressed to T-cell acute lymphoblastic leukemia.	NOTCH1
28115368	10.1182/blood-2016-09-692582	2017	The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia.	NOTCH1
28115373	10.1182/blood-2016-10-706465	2017	The genetics and molecular biology of T-ALL.	NOTCH1
28122332	10.18632/oncotarget.14784	2017	The homeoprotein Dlx5 drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling.	NOTCH1
28143869	10.1158/1078-0432.CCR-16-2880	2017	Stabilization of Notch1 by the Hsp90 Chaperone Is Crucial for T-Cell Leukemogenesis.	NOTCH1
28151717	10.1158/1078-0432.CCR-15-2869	2017	Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.	NOTCH1
28157189	10.1038/bcj.2016.122	2017	Identification of cell-type-specific mutations in nodal T-cell lymphomas.	NOTCH1
28174276	10.1073/pnas.1611831114	2017	Synergistic antileukemic therapies in <i>NOTCH1</i>-induced T-ALL.	NOTCH1
28245838	10.1186/s13045-017-0431-1	2017	Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia.	NOTCH1
28314854	10.1073/pnas.1702564114	2017	Common nonmutational <i>NOTCH1</i> activation in chronic lymphocytic leukemia.	NOTCH1
28321121	10.1038/leu.2017.89	2017	Dnmt3a regulates T-cell development and suppresses T-ALL transformation.	NOTCH1
28359267	10.1186/s12885-017-3233-5	2017	Aberrant expression of ALK and EZH2 in Merkel cell carcinoma.	NOTCH1
28360149	10.3324/haematol.2016.157792	2017	<i>NOTCH1</i> mutation, <i>TP53</i> alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia.	NOTCH1
28446316	10.7534/j.issn.1009-2137.2017.02.050	2017	[Prognostic Value of Recurrent Molecular Genetics and Epigenetics Abnormity in T Lymphoblastic Lymphoma / Leukemia -Review].	NOTCH1
28487945	10.3892/mmr.2017.6516	2017	Nox4 is involved in high glucose-induced apoptosis in renal tubular epithelial cells via Notch pathway.	NOTCH1
28505169	10.1371/journal.pone.0177524	2017	Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines.	NOTCH1
28664939	10.1038/modpathol.2017.58	2017	Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.	NOTCH1
28671688	10.1038/ng.3909	2017	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.	NOTCH1
28716817	10.1158/1535-7163.MCT-17-0141	2017	PI3KŒ≥/Œ¥ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature.	NOTCH1
28747286	10.4274/tjh.2017.0194	2017	Coexistence of EZH2, NOTCH1, IL7R, and PHF6 Mutations in Adult T-cell Acute Lymphoblastic Leukemia.	NOTCH1
28790107	10.1182/blood-2017-03-775536	2017	RUNX1 is required for oncogenic <i>Myb</i> and <i>Myc</i> enhancer activity in T-cell acute lymphoblastic leukemia.	NOTCH1
28819011	10.1182/blood-2017-04-779736	2017	<i>TP53</i> mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.	NOTCH1
28827447	10.1084/jem.20170167	2017	Internal deletion of BCOR reveals a tumor suppressor function for BCOR in T lymphocyte malignancies.	NOTCH1
28870926	10.21873/anticanres.11914	2017	Hedgehog Stimulation Suppresses Clonogenicity and Activates NOTCH Signalling in T-lymphoblastic Leukaemia Jurkat Cells.	NOTCH1
28892521	10.1371/journal.pone.0183969	2017	A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma.	NOTCH1
29023469	10.1371/journal.pone.0185762	2017	The common oncogenomic program of NOTCH1 and NOTCH3 signaling in T-cell acute lymphoblastic leukemia.	NOTCH1
29045517	10.1093/annonc/mdx407	2017	Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma.	NOTCH1
29136506	10.1016/j.ccell.2017.10.004	2017	A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia.	NOTCH1
29138297	10.1126/scisignal.aam6846	2017	MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.	NOTCH1
29246179	10.1186/s13046-017-0652-8	2017	Smoldering mantle cell lymphoma.	NOTCH1
31966505	NA	2017	Curcumin combined with cis-platinum promote the apoptosis of human colorectal cancer HT29 cells and mechanism.	NOTCH1
26220040	10.1038/leu.2015.206	2016	Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial.	NOTCH1
26239199	10.1038/leu.2015.210	2016	Altered mesenchymal niche cells impede generation of normal hematopoietic progenitor cells in leukemic bone marrow.	NOTCH1
26292904	10.3109/10428194.2015.1080366	2016	Complexity of NOTCH1 juxtamembrane insertion mutations in T-cell acute lymphoblastic leukemia.	NOTCH1
26426381	10.1097/PAS.0000000000000523	2016	NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease.	NOTCH1
26589915	10.3324/haematol.2015.137695	2016	FGFR1OP2-FGFR1 induced myeloid leukemia and T-cell lymphoma in a mouse model.	NOTCH1
26644537	10.1200/JCO.2015.61.5385	2016	Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.	NOTCH1
26707936	10.1038/leu.2015.353	2016	CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia.	NOTCH1
26753883	10.1038/ncomms10087	2016	Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress.	NOTCH1
26787889	10.1073/pnas.1525354113	2016	Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered mice.	NOTCH1
26797410	10.1136/jclinpath-2015-203403	2016	Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases.	NOTCH1
26801976	10.1158/0008-5472.CAN-15-2092	2016	Aberrant Notch Signaling in the Bone Marrow Microenvironment of Acute Lymphoid Leukemia Suppresses Osteoblast-Mediated Support of Hematopoietic Niche Function.	NOTCH1
26816546	10.1111/1759-7714.12297	2016	Notch1 controls cell chemoresistance in small cell lung carcinoma cells.	NOTCH1
26821066	10.1038/cddis.2015.413	2016	The clerodane diterpene casearin J induces apoptosis of T-ALL cells through SERCA inhibition, oxidative stress, and interference with Notch1 signaling.	NOTCH1
26864725	10.1080/15384101.2015.1128191	2016	Targeting NOTCH1 in T-ALL: Starving the dragon.	NOTCH1
26931577	10.1189/jlb.5MA0915-394R	2016	Role of CXCR4-mediated bone marrow colonization in CNS infiltration by T cell acute lymphoblastic leukemia.	NOTCH1
26934331	10.18632/oncotarget.7772	2016	Notch signaling: its roles and therapeutic potential in hematological malignancies.	NOTCH1
26985716	10.3892/ijmm.2016.2525	2016	Valsartan ameliorates podocyte loss in diabetic mice through the Notch pathway.	NOTCH1
27040710	10.1053/j.seminoncol.2016.02.012	2016	Richter syndrome: pathogenesis and management.	NOTCH1
27070758	10.1016/j.leukres.2016.03.002	2016	Risk stratification of T-cell Acute Lymphoblastic Leukemia patients based on gene expression, mutations and copy number variation.	NOTCH1
27121112	10.3109/10428194.2016.1173212	2016	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.	NOTCH1
27125305	10.1038/leu.2016.106	2016	Œ≤-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1.	NOTCH1
27151993	10.3324/haematol.2015.139410	2016	RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.	NOTCH1
27157619	10.1038/onc.2016.133	2016	Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies.	NOTCH1
27206675	10.18632/oncotarget.9390	2016	Loss of T-cell quiescence by targeting Slfn2 prevents the development and progression of T-ALL.	NOTCH1
27229929	10.1186/s12885-016-2374-2	2016	Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor.	NOTCH1
27235137	10.1182/blood-2016-02-700328	2016	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.	NOTCH1
27247421	10.1073/pnas.1601537113	2016	Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients.	NOTCH1
27342483	10.7534/j.issn.1009-2137.2016.03.001	2016	[Effect of PDK1 on Notch1-Induced Mouse T-cell Acute Lymphoblastic Leukemia].	NOTCH1
27342484	10.7534/j.issn.1009-2137.2016.03.002	2016	[ADAR1 Knockout Inhibits Notch1-induced T-ALL in Mice].	NOTCH1
27351634	10.1080/17474086.2016.1199948	2016	Richter transformation of CLL.	NOTCH1
27391576	10.1038/bcj.2016.57	2016	Reprogramming of Notch1-induced acute lymphoblastic leukemia cells into pluripotent stem cells in mice.	NOTCH1
27449094	10.18632/oncotarget.10716	2016	Gene mutations and actionable genetic lesions in mantle cell lymphoma.	NOTCH1
27451956	10.1038/nrc.2016.63	2016	The genetics and mechanisms of T cell acute lymphoblastic leukaemia.	NOTCH1
27473087	10.1007/s13277-016-5272-y	2016	Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.	NOTCH1
27531766	10.7534/j.issn.1009-2137.2016.04.010	2016	[Mutation of IL-7R in Adult Patients with T-cell Acute Lymphoblastic Leukemia and Its Clinical Significance].	NOTCH1
27566587	10.18632/oncotarget.11548	2016	Recurrent mutations in NF-Œ∫B pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.	NOTCH1
27582570	10.3324/haematol.2016.146381	2016	The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.	NOTCH1
27602765	10.18632/oncotarget.11796	2016	Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations.	NOTCH1
27612641	10.1016/j.immuni.2016.07.018	2016	Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease.	NOTCH1
27666896	10.3892/or.2016.5117	2016	MicroRNA-101 regulates T-cell acute lymphoblastic leukemia progression and chemotherapeutic sensitivity by targeting Notch1.	NOTCH1
27670423	10.1182/blood-2016-01-692855	2016	High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.	NOTCH1
27742070	10.1016/j.beha.2016.08.006	2016	Richter's syndrome: Novel and promising therapeutic alternatives.	NOTCH1
27797342	10.1172/JCI86489	2016	High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells.	NOTCH1
27900092	10.3892/mco.2016.1008	2016	Primary orbital precursor T-cell lymphoblastic lymphoma: Report of a unique case.	NOTCH1
24844362	10.3109/10428194.2014.917638	2015	Jagged-1: a new promising factor associated with favorable prognosis in patients with acute myeloid leukemia.	NOTCH1
25118879	10.1038/leu.2014.241	2015	Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model.	NOTCH1
25248094	10.5858/arpa.2014-0086-RA	2015	Clinical prognostic biomarkers in chronic lymphocytic leukemia and diffuse large B-cell lymphoma.	NOTCH1
25281505	10.3324/haematol.2014.110742	2015	Focused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute lymphoblastic leukemia.	NOTCH1
25311243	10.1038/leu.2014.302	2015	A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies.	NOTCH1
25355291	10.1093/carcin/bgu223	2015	DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice.	NOTCH1
25371176	10.1038/leu.2014.315	2015	Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.	NOTCH1
25371178	10.1038/leu.2014.318	2015	The impact of SF3B1 mutations in CLL on the DNA-damage response.	NOTCH1
25381127	10.3324/haematol.2014.116855	2015	The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.	NOTCH1
25393162	10.1002/cyto.a.22582	2015	Notch affects the prodifferentiating effect of retinoic acid and PMA on leukemic cells.	NOTCH1
25412322	10.3892/mmr.2014.2976	2015	Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression.	NOTCH1
25493453	10.1097/MPH.0000000000000290	2015	NOTCH1 and FBXW7 mutations favor better outcome in pediatric South Indian T-cell acute lymphoblastic leukemia.	NOTCH1
25502893	10.1097/MOP.0000000000000171	2015	Update on biology and treatment of T-cell acute lymphoblastic leukaemia.	NOTCH1
25517959	10.1097/PAS.0000000000000358	2015	NOTCH1 intracellular domain immunohistochemistry as a diagnostic tool to distinguish T-lymphoblastic lymphoma from thymoma.	NOTCH1
25582697	10.1158/2159-8290.CD-14-0625	2015	PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers.	NOTCH1
25584678	10.4161/15384101.2014.989129	2015	An oncogenic enhancer enemy (N-Me) in T-ALL.	NOTCH1
25595890	10.18632/oncotarget.2218	2015	Mutational spectrum of adult T-ALL.	NOTCH1
25637217	10.1016/j.yexcr.2015.01.008	2015	Role of stromal cells-mediated Notch-1 in the invasion of T-ALL cells.	NOTCH1
25644173	10.1186/s12943-014-0285-x	2015	Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes.	NOTCH1
25655195	10.1038/leu.2015.27	2015	Activated Notch counteracts Ikaros tumor suppression in mouse and human T-cell acute lymphoblastic leukemia.	NOTCH1
25662994	10.4049/jimmunol.1400451	2015	Organ-specific microenvironment modifies diverse functional and phenotypic characteristics of leukemia-associated macrophages in mouse T cell acute lymphoblastic leukemia.	NOTCH1
25663545	10.1007/s10549-015-3279-5	2015	The role of polycomb group protein Bmi-1 and Notch4 in breast cancer stem cell inhibition by benzyl isothiocyanate.	NOTCH1
25671302	10.18632/oncotarget.3244	2015	Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.	NOTCH1
25700513	10.1126/science.1261093	2015	Structural biology. Structural basis for Notch1 engagement of Delta-like 4.	NOTCH1
25710912	10.4049/jimmunol.1402443	2015	Repression of Ccr9 transcription in mouse T lymphocyte progenitors by the Notch signaling pathway.	NOTCH1
25721902	10.3109/10428194.2015.1023800	2015	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.	NOTCH1
25740104	10.3324/haematol.2014.118562	2015	T-ALL: ALL a matter of Translation?	NOTCH1
25784680	10.1182/blood-2014-10-608448	2015	Therapeutic targeting of HES1 transcriptional programs in T-ALL.	NOTCH1
25860243	10.3109/10428194.2015.1028051	2015	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia.	NOTCH1
25879451	10.18632/oncotarget.3621	2015	Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.	NOTCH1
25903014	10.1186/s13045-015-0138-0	2015	Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A.	NOTCH1
25930743	10.1002/gcc.22252	2015	Unique clonal relationship between T-cell acute lymphoblastic leukemia and subsequent Langerhans cell histiocytosis with TCR rearrangement and NOTCH1 mutation.	NOTCH1
25942645	10.1371/journal.pone.0125429	2015	Characterization of LEF1 High Expression and Novel Mutations in Adult Acute Lymphoblastic Leukemia.	NOTCH1
25966987	10.1182/blood-2014-10-551895	2015	How I treat T-cell acute lymphoblastic leukemia in adults.	NOTCH1
26002977	10.4049/jimmunol.1402639	2015	Cutting Edge: Codeletion of the Ras GTPase-Activating Proteins (RasGAPs) Neurofibromin 1 and p120 RasGAP in T Cells Results in the Development of T Cell Acute Lymphoblastic Leukemia.	NOTCH1
26018266	NA	2015	[Triptolide induces apoptosis of human acute T lymphocytic leukemia Jurkat cells via inhibiting transcription of human endogenous retrovirus HERV-K Np9 gene].	NOTCH1
26046801	10.1038/srep11012	2015	A novel Monoclonal Antibody against Notch1 Targets Leukemia-associated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors.	NOTCH1
26056302	10.1073/pnas.1424104112	2015	Disregulated expression of the transcription factor ThPOK during T-cell development leads to high incidence of T-cell lymphomas.	NOTCH1
26058076	10.1016/j.ccell.2015.05.003	2015	CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia.	NOTCH1
26077240	10.1200/JCO.2014.60.6327	2015	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.	NOTCH1
26108691	10.1038/leu.2015.162	2015	Characterization of the genome-wide TLX1 binding profile in T-cell acute lymphoblastic leukemia.	NOTCH1
26117003	10.7534/j.issn.1009-2137.2015.03.002	2015	[Mutations of FBXW7 in Adult T-Cell Acute Lymphocytic Leukemia].	NOTCH1
26117016	10.7534/j.issn.1009-2137.2015.03.015	2015	[Effects of Silencing AKT Gene by shRNA on Proliferation, Apoptosis and Notch1 Signal Pathway in Jeko-1 Cells].	NOTCH1
26125582	10.1371/journal.pone.0130666	2015	Genetic Analysis of T Cell Lymphomas in Carbon Ion-Irradiated Mice Reveals Frequent Interstitial Chromosome Deletions: Implications for Second Cancer Induction in Normal Tissues during Carbon Ion Radiotherapy.	NOTCH1
26160878	10.3324/haematol.2015.127498	2015	Potential role of hypoxia in early stages of Hodgkin lymphoma pathogenesis.	NOTCH1
26205622	10.1111/bjh.13613	2015	Distinctive genotypes in infants with T-cell acute lymphoblastic leukaemia.	NOTCH1
26206799	10.3324/haematol.2015.130179	2015	Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia.	NOTCH1
26229090	10.1158/2159-8290.CD-15-0370	2015	Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma.	NOTCH1
26302069	10.1038/jid.2015.328	2015	Notch1 Pathway Activation Results from the Epigenetic Abrogation of Notch-Related MicroRNAs in Mycosis Fungoides.	NOTCH1
26314424	10.7534/j.issn.1009-2137.2015.04.008	2015	[Effect of ADAM10 Inhibitor GI254023X on Proliferation and Apoptosis of Acute T-Lymphoblastic Leukemia Jurkat Cells In Vitro and Its Possible Mechanisms].	NOTCH1
26330272	10.1038/srep13749	2015	LncRNA NALT interaction with NOTCH1 promoted cell proliferation in pediatric T cell acute lymphoblastic leukemia.	NOTCH1
26341754	10.1007/s00277-015-2474-0	2015	Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival.	NOTCH1
26365182	10.1016/j.celrep.2015.08.034	2015	Off-Target V(D)J Recombination Drives Lymphomagenesis and Is Escalated by Loss of the Rag2 C Terminus.	NOTCH1
26390244	10.1038/nm.3955	2015	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.	NOTCH1
26407235	10.1038/bcj.2015.80	2015	A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.	NOTCH1
26450156	10.1186/s12885-015-1677-z	2015	Inhibition of IGF1-R overcomes IGFBP7-induced chemotherapy resistance in T-ALL.	NOTCH1
26588464	10.1371/journal.pone.0143275	2015	The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies.	NOTCH1
23697875	10.3109/10428194.2013.807510	2014	The importance of Notch signaling in peripheral T-cell lymphomas.	NOTCH1
23774673	10.1038/leu.2013.183	2014	Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.	NOTCH1
23841506	10.3109/10428194.2013.823493	2014	Novel targeted therapies in acute lymphoblastic leukemia.	NOTCH1
24047107	10.3109/10428194.2013.834054	2014	Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?	NOTCH1
24047479	10.3109/10428194.2013.845882	2014	Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia.	NOTCH1
24140475	10.1016/j.cellsig.2013.09.021	2014	New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of Œ≥-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.	NOTCH1
24249312	10.1002/pbc.24852	2014	Identification of novel NOTCH1 mutations: increasing our knowledge of the NOTCH signaling pathway.	NOTCH1
24301524	10.1038/leu.2013.366	2014	Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.	NOTCH1
24326827	10.1177/1066896913513833	2014	Utility of LRF/Pokemon and NOTCH1 protein expression in the distinction between nodular lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma.	NOTCH1
24329526	10.1089/dna.2013.2199	2014	The TCR Œ≥Œ¥ repertoire and relative gene expression characteristics of T-ALL cases with biclonal malignant VŒ¥1 and VŒ¥2 T cells.	NOTCH1
24384093	10.1016/j.canlet.2013.12.027	2014	Murine Pten(-/-) T-ALL requires non-redundant PI3K/mTOR and DLL4/Notch1 signals for maintenance and Œ≥c/TCR signals for thymic exit.	NOTCH1
24394663	10.1182/blood-2013-08-522698	2014	c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.	NOTCH1
24401270	10.1172/JCI65093	2014	Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia.	NOTCH1
24421328	10.1182/blood-2013-11-516229	2014	How we treat Richter syndrome.	NOTCH1
24424791	10.1002/pbc.24803	2014	Prognostic implications of mutations in NOTCH1 and FBXW7 in childhood T-ALL treated according to the NOPHO ALL-1992 and ALL-2000 protocols.	NOTCH1
24465765	10.1371/journal.pone.0085883	2014	LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.	NOTCH1
24485662	10.1016/j.celrep.2014.01.007	2014	ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemia.	NOTCH1
24505083	10.1182/blood-2013-01-477620	2014	Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy.	NOTCH1
24530429	10.1016/j.mrfmmm.2014.01.007	2014	Illegitimate V(D)J recombination-mediated deletions in Notch1 and Bcl11b are not sufficient for extensive clonal expansion and show minimal age or sex bias in frequency or junctional processing.	NOTCH1
24548608	10.1016/j.clml.2013.12.016	2014	Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice.	NOTCH1
24584072	10.1038/ng.2913	2014	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.	NOTCH1
24584351	10.3324/haematol.2013.101725	2014	DDX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia.	NOTCH1
24586197	10.1371/journal.pgen.1004167	2014	Insertional mutagenesis and deep profiling reveals gene hierarchies and a Myc/p53-dependent bottleneck in lymphomagenesis.	NOTCH1
24596208	10.1158/2159-8290.CD-RW2014-017	2014	Activation of PP2A by perphenazine induces apoptosis in T-ALL.	NOTCH1
24597984	10.3109/10428194.2014.898760	2014	NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.	NOTCH1
24619868	10.1002/gcc.22163	2014	Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.	NOTCH1
24661878	10.1016/j.bbrc.2014.03.048	2014	Functional expression of P2X family receptors in macrophages is affected by microenvironment in mouse T cell acute lymphoblastic leukemia.	NOTCH1
24687960	10.1084/jem.20122727	2014	Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential.	NOTCH1
24690100	10.1111/bjh.12866	2014	NOTCH1 mutations are associated with favourable long-term prognosis in paediatric T-cell acute lymphoblastic leukaemia: a retrospective study of patients treated on BCH-2003 and CCLG-2008 protocol in China.	NOTCH1
24710376	10.1038/nm.3528	2014	Cancer therapy resistance: chasing epigenetics.	NOTCH1
24726647	10.1016/j.bbrc.2014.04.003	2014	Activation of Notch1 promotes development of human CD8(+) single positive T cells in humanized mice.	NOTCH1
24727675	10.1038/leu.2014.134	2014	An aberrant microRNA signature in childhood T-cell lymphoblastic lymphoma affecting CDKN1B expression, NOTCH1 and growth factor signaling pathways.	NOTCH1
24729385	10.1002/gcc.22176	2014	14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphoma.	NOTCH1
24740809	10.1182/blood-2014-01-547695	2014	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.	NOTCH1
24795015	10.1158/2159-8290.CD-RW2014-060	2014	Epigenetic mechanisms underlie resistance to NOTCH inhibition in T-ALL.	NOTCH1
24819383	10.1016/j.jbior.2014.04.004	2014	Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.	NOTCH1
24828041	10.1038/nature13317	2014	Cell competition is a tumour suppressor mechanism in the thymus.	NOTCH1
24857884	10.1097/MOH.0000000000000057	2014	Do mantle cell lymphomas have an 'Achilles heel'?	NOTCH1
24857886	10.1097/MOH.0000000000000058	2014	The clonal evolution of leukemic stem cells in T-cell acute lymphoblastic leukemia.	NOTCH1
24895337	10.3324/haematol.2013.099515	2014	MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia.	NOTCH1
24952875	10.1186/1471-2407-14-463	2014	FHL1C induces apoptosis in Notch1-dependent T-ALL cells through an interaction with RBP-J.	NOTCH1
24959528	10.3389/fped.2014.00054	2014	The challenge of targeting notch in hematologic malignancies.	NOTCH1
24989265	10.7534/j.issn.1009-2137.2014.03.009	2014	[Expression of P2X family receptors in peritoneal macrophages of mouse with acute T lymphoblastic leukemia].	NOTCH1
25043004	10.1038/nature13495	2014	Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.	NOTCH1
25083870	10.1016/j.cell.2014.05.049	2014	Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia.	NOTCH1
25141821	10.1002/path.4428	2014	Recurrent mutations of NOTCH genes in follicular lymphoma identify a distinctive subset of tumours.	NOTCH1
25156146	10.1007/s10495-014-1029-5	2014	Gamma secretase inhibitors enhance vincristine-induced apoptosis in T-ALL in a NOTCH-independent manner.	NOTCH1
25185196	10.1158/2159-8290.CD-RW2014-162	2014	NOTCH1 downregulation contributes to PI3K inhibitor resistance in T-ALL.	NOTCH1
25194570	10.1038/nm.3665	2014	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia.	NOTCH1
25201756	10.1016/j.exphem.2014.08.006	2014	Rictor/mammalian target of rapamycin 2 regulates the development of Notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3.	NOTCH1
25218362	10.1007/s11899-014-0223-4	2014	Risk factors for Richter syndrome in chronic lymphocytic leukemia.	NOTCH1
25238756	10.4049/jimmunol.1300337	2014	Requirement for ssbp2 in hematopoietic stem cell maintenance and stress response.	NOTCH1
25295936	10.1038/nm.3711	2014	Thymocyte transformation enhanced.	NOTCH1
25344525	10.3324/haematol.2014.115683	2014	The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.	NOTCH1
25344755	10.1038/ncb3046	2014	Cyclin C is a haploinsufficient tumour suppressor.	NOTCH1
25358351	10.1038/ncb3055	2014	Cyclin C surprises in tumour suppression.	NOTCH1
25366136	10.1186/s13045-014-0071-7	2014	Notch1-induced T cell leukemia can be potentiated by microenvironmental cues in the spleen.	NOTCH1
25367958	10.1158/2159-8290.CD-RW2014-196	2014	T-ALL pathogenesis requires a NOTCH1-driven MYC enhancer.	NOTCH1
25369933	10.1073/pnas.1407079111	2014	Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia.	NOTCH1
25404153	10.1615/critrevoncog.2014011794	2014	Friend or foe: can activating mutations in NOTCH1 contribute to a favorable treatment outcome in patients with T-ALL?	NOTCH1
25471034	10.2217/fon.14.81	2014	Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development.	NOTCH1
25483078	10.4161/15384101.2014.964118	2014	KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo.	NOTCH1
25522233	10.1371/journal.pgen.1004768	2014	SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.	NOTCH1
25543484	10.7534/j.issn.1009-2137.2014.06.021	2014	[Effect of silencing NOTCH1 gene by shRNA interference on AKT/mTOR pathway in mantle cell lymphoma].	NOTCH1
22349824	10.1038/onc.2012.42	2013	Analysis of Rho GTPase expression in T-ALL identifies RhoU as a target for Notch involved in T-ALL cell migration.	NOTCH1
22814294	10.1038/leu.2012.176	2013	Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.	NOTCH1
22846929	10.1038/leu.2012.192	2013	Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression.	NOTCH1
22968660	10.1007/s00277-012-1561-8	2013	Notch1 signaling is irresponsible to the anti-leukemic effect of HDACis in B-ALL Nalm-6 cells.	NOTCH1
23040356	10.1016/j.bcmd.2012.09.001	2013	BCL11B, FLT3, NOTCH1 and FBXW7 mutation status in T-cell acute lymphoblastic leukemia patients.	NOTCH1
23108395	10.1038/onc.2012.482	2013	DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia.	NOTCH1
23161489	10.1158/0008-5472.CAN-12-1389	2013	Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias.	NOTCH1
23289374	10.1186/1756-8722-6-3	2013	Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells.	NOTCH1
23295735	10.1038/leu.2012.357	2013	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.	NOTCH1
23341344	10.1002/gcc.22039	2013	The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.	NOTCH1
23343182	10.3109/10428194.2013.769049	2013	New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works.	NOTCH1
23349303	10.3324/haematol.2012.073585	2013	NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.	NOTCH1
23354995	10.1007/s00277-012-1664-2	2013	Gene mutation profiles and prognostic implications in Korean patients with T-lymphoblastic leukemia.	NOTCH1
23359050	10.1371/journal.pone.0053190	2013	FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.	NOTCH1
23359069	10.1084/jem.20121527	2013	Notch activation inhibits AML growth and survival: a potential therapeutic approach.	NOTCH1
23373539	10.1111/bjh.12231	2013	KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.	NOTCH1
23396305	10.1182/blood-2012-12-474148	2013	Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence.	NOTCH1
23407552	10.1182/blood-2013-01-478834	2013	The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.	NOTCH1
23410974	10.1016/j.ccr.2013.01.011	2013	Growth factor independence 1 antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemia.	NOTCH1
23435313	10.1016/j.exphem.2013.02.006	2013	Isolated Hoxa9 overexpression predisposes to the development of lymphoid but not myeloid leukemia.	NOTCH1
23445313	10.1111/bjd.12071	2013	Proteasome inhibition as a novel mechanism of the proapoptotic activity of Œ≥-secretase inhibitor I in cutaneous T-cell lymphoma.	NOTCH1
23480493	10.3109/10428194.2013.783913	2013	Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?	NOTCH1
23603912	10.1182/blood-2012-11-465138	2013	Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations.	NOTCH1
23667468	10.1371/journal.pone.0062346	2013	Fli-1 overexpression in hematopoietic progenitors deregulates T cell development and induces pre-T cell lymphoblastic leukaemia/lymphoma.	NOTCH1
23673656	10.1074/jbc.M113.475376	2013	Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.	NOTCH1
23685026	10.1016/j.jaad.2013.04.027	2013	A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.	NOTCH1
23687089	10.1182/blood-2013-03-491092	2013	Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia.	NOTCH1
23692084	10.1111/cpr.12037	2013	Overexpression of hCLP46 enhances Notch activation and regulates cell proliferation in a cell type-dependent manner.	NOTCH1
23695450	10.1097/MOH.0b013e3283623c61	2013	Early T-cell precursor acute lymphoblastic leukaemia.	NOTCH1
23730497	10.1177/2040620712471368	2013	The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy.	NOTCH1
23788636	10.1074/jbc.M113.451625	2013	Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells.	NOTCH1
23791182	10.1016/j.cell.2013.05.041	2013	The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability.	NOTCH1
23825651	10.1371/journal.pone.0067306	2013	Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.	NOTCH1
23827704	10.1016/j.stem.2013.06.008	2013	Notching up MYC gives a LIC.	NOTCH1
23857984	10.1084/jem.20122516	2013	The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.	NOTCH1
23873701	10.1002/gcc.22088	2013	BMI1, the polycomb-group gene, is recurrently targeted by genomic rearrangements in progressive B-cell leukemia/lymphoma.	NOTCH1
23898065	NA	2013	Effects of the HIF1 inhibitor, echinomycin, on growth and NOTCH signalling in leukaemia cells.	NOTCH1
23908464	10.1182/blood-2013-05-500850	2013	Genetic loss of SH2B3 in acute lymphoblastic leukemia.	NOTCH1
23982259	10.1007/s11033-013-2654-8	2013	Investigation of deregulated genes of Notch signaling pathway in human T cell acute lymphoblastic leukemia cell lines and clinical samples.	NOTCH1
24014297	10.1007/978-1-4614-8051-8_8	2013	Richter syndrome.	NOTCH1
24041576	10.1182/blood-2013-08-460311	2013	Genome sequencing of lymphoid malignancies.	NOTCH1
24046360	10.1242/dmm.012575	2013	A mouse model for inducible overexpression of Prdm14 results in rapid-onset and highly penetrant T-cell acute lymphoblastic leukemia (T-ALL).	NOTCH1
24090996	10.1016/j.leukres.2013.09.007	2013	Distinct sensitivity of CD8+ CD4- and CD8+ CD4+ leukemic cell subpopulations to cyclophosphamide and rapamycin in Notch1-induced T-ALL mouse model.	NOTCH1
24127483	10.1084/jem.20131448	2013	Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.	NOTCH1
24145436	10.1073/pnas.1314608110	2013	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.	NOTCH1
24166518	10.1200/JCO.2012.48.5292	2013	Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.	NOTCH1
24174626	10.1182/blood-2012-08-451278	2013	In vivo leukemogenic potential of an interleukin 7 receptor Œ± chain mutant in hematopoietic stem and progenitor cells.	NOTCH1
24370020	10.7534/j.issn.1009-2137.2013.06.008	2013	[Characteristics of NOTCH1 mutation in adult T-cell acute lymphoblastic leukemia].	NOTCH1
24386421	10.1371/journal.pone.0084841	2013	Characterization of two distinct lymphoproliferative diseases caused by ectopic expression of the Notch ligand DLL4 on T cells.	NOTCH1
21984373	10.1002/path.3015	2012	Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia.	NOTCH1
22116551	10.1038/leu.2011.328	2012	Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis.	NOTCH1
22171922	10.1111/j.1365-2141.2011.08980.x	2012	Absence of NOTCH1 gene mutations in MALT lymphomas.	NOTCH1
22210878	10.1182/blood-2011-11-391474	2012	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.	NOTCH1
22311010	10.1007/s11033-011-1424-8	2012	The indicative effect of Notch1 expression for the prognosis of T-cell acute lymphocytic leukemia: a systematic review.	NOTCH1
22348144	10.1371/journal.pone.0032047	2012	The translation factor eIF6 is a Notch-dependent regulator of cell migration and invasion.	NOTCH1
22357466	NA	2012	[Gene expression of Notch1 and Jagged1 in children with acute leukemia].	NOTCH1
22393458	10.1371/journal.pone.0032944	2012	Enhanced Notch activation is advantageous but not essential for T cell lymphomagenesis in Id1 transgenic mice.	NOTCH1
22424712	10.1016/j.leukres.2012.02.013	2012	Notch-mediated repression of miR-223 contributes to IGF1R regulation in T-ALL.	NOTCH1
22491738	10.3324/haematol.2011.059030	2012	The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.	NOTCH1
22510873	10.1182/blood-2011-10-388504	2012	An activating intragenic deletion in NOTCH1 in human T-ALL.	NOTCH1
22571487	10.1111/j.1365-2141.2012.09155.x	2012	Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome.	NOTCH1
22673746	10.1007/82_2012_232	2012	Recent advances on NOTCH signaling in T-ALL.	NOTCH1
22695916	10.1007/82_2012_231	2012	Notch1 and IL-7 receptor signalling in early T-cell development and leukaemia.	NOTCH1
22718117	10.1038/jid.2012.203	2012	NOTCH1 signaling as a therapeutic target in S√©zary syndrome.	NOTCH1
22768113	10.1371/journal.pone.0039725	2012	NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches.	NOTCH1
23022380	10.1016/j.molcel.2012.08.022	2012	NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function.	NOTCH1
23086478	10.1038/nm.2960	2012	NOTCH1 promotes T cell leukemia-initiating activity by RUNX-mediated regulation of PKC-Œ∏ and reactive oxygen species.	NOTCH1
20965628	10.1016/j.blre.2010.09.004	2011	Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.	NOTCH1
21052088	10.1038/leu.2010.255	2011	Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic Œ≥Œ¥ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro.	NOTCH1
21326611	10.1371/journal.pone.0016761	2011	Transient responses to NOTCH and TLX1/HOX11 inhibition in T-cell acute lymphoblastic leukemia/lymphoma.	NOTCH1
21464222	10.1084/jem.20102384	2011	Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL.	NOTCH1
21556011	10.1038/leu.2011.96	2011	Occurrence of identical NOTCH1 mutation in non-twinned sisters with T-cell acute lymphoblastic leukemia.	NOTCH1
21625236	10.1038/leu.2011.130	2011	Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL.	NOTCH1
21631271	10.5858/2009-0691-OA.1	2011	Uniform expression of Notch1, suppressor of B-cell-specific gene expression, in plasmablastic lymphoma.	NOTCH1
21775206	10.1016/j.it.2011.06.005	2011	Notch in T-ALL: new players in a complex disease.	NOTCH1
21807868	10.1084/jem.20110121	2011	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling.	NOTCH1
21835957	10.1182/blood-2011-02-334219	2011	Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study.	NOTCH1
21880637	10.3324/haematol.2011.043083	2011	Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia.	NOTCH1
21979940	10.1182/blood-2011-08-376061	2011	Notch signaling in acute lymphoblastic leukemia: any role for stromal microenvironment?	NOTCH1
22006338	10.1073/pnas.1114669108	2011	Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.	NOTCH1
22022427	10.1371/journal.pone.0025645	2011	Notch ankyrin repeat domain variation influences leukemogenesis and Myc transactivation.	NOTCH1
19631984	10.1016/j.leukres.2009.06.026	2010	T-cell lymphoblastic leukemia in early childhood presents NOTCH1 mutations and MLL rearrangements.	NOTCH1
19847202	10.1038/leu.2009.221	2010	Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies.	NOTCH1
20348880	10.1038/modpathol.2010.67	2010	Notch1 in primary effusion lymphoma: a clinicopathological study.	NOTCH1
20538790	10.1182/blood-2009-12-260216	2010	Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma.	NOTCH1
20683149	10.3233/DMA-2010-0715	2010	Prognostic significance of NOTCH1 and FBXW7 mutations in pediatric T-ALL.	NOTCH1
20823234	10.1073/pnas.1010722107	2010	Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia.	NOTCH1
20861909	10.1038/leu.2010.204	2010	NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.	NOTCH1
20861920	10.1038/leu.2010.205	2010	NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.	NOTCH1
20944675	10.1038/leu.2010.203	2010	The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function.	NOTCH1
21302811	10.3727/096504010x12864748215007	2010	Mutations in the HD and PEST domain of Notch-1 receptor in T-cell acute lymphoblastic leukemia: report of novel mutations from Indian population.	NOTCH1
18984862	10.1182/blood-2008-02-138172	2009	NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity.	NOTCH1
19057901	10.1007/s00277-008-0646-x	2009	Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines.	NOTCH1
19091404	10.1016/j.leukres.2008.10.026	2009	Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines.	NOTCH1
19109228	10.1182/blood-2008-10-184069	2009	NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.	NOTCH1
19151773	10.1038/leu.2008.366	2009	A second NOTCH1 chromosome rearrangement: t(9;14)(q34.3;q11.2) in T-cell neoplasia.	NOTCH1
19160126	10.1080/10428190802553257	2009	Down-regulation of Notch-1 increases co-cultured Jurkat cell sensitivity to chemotherapy.	NOTCH1
19239437	10.1111/j.1600-0463.2008.00023.x	2009	Analysis of NOTCH1 extracellular juxtamembrane expansion mutations in acute leukemias and multiple myelomas.	NOTCH1
19245433	10.1111/j.1365-2141.2009.07607.x	2009	FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma.	NOTCH1
19339697	10.1182/blood-2008-11-190090	2009	Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells.	NOTCH1
19340001	10.1038/leu.2009.64	2009	The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.	NOTCH1
19635999	10.1200/JCO.2009.22.0996	2009	Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.	NOTCH1
19704010	10.1128/MCB.00406-09	2009	Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling.	NOTCH1
19778842	10.3816/CLM.2009.s.013	2009	Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.	NOTCH1
19794083	10.3324/haematol.2008.005272	2009	Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.	NOTCH1
19907488	10.1038/nature08543	2009	Direct inhibition of the NOTCH transcription factor complex.	NOTCH1
20008221	10.1182/asheducation-2009.1.353	2009	The role of NOTCH1 signaling in T-ALL.	NOTCH1
17874453	10.1002/ajh.21044	2008	Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1.	NOTCH1
17901244	10.1182/blood-2007-02-074690	2008	NOTCH1 mutation can be an early, prenatal genetic event in T-ALL.	NOTCH1
17980397	10.1016/j.virol.2007.10.009	2008	An auto-regulatory loop for EBV LMP2A involves activation of Notch.	NOTCH1
18411416	10.1182/blood-2007-12-130096	2008	NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL.	NOTCH1
18449208	10.1038/leu.2008.101	2008	Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma.	NOTCH1
18663146	10.1182/blood-2008-03-147587	2008	K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.	NOTCH1
17252014	10.1038/sj.leu.2404546	2007	NOTCH1-induced T-cell leukemia in transgenic zebrafish.	NOTCH1
17560996	10.1016/j.yexcr.2007.04.027	2007	Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines.	NOTCH1
17646408	10.1084/jem.20070872	2007	The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia.	NOTCH1
17671232	10.1182/blood-2007-02-073486	2007	Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1.	NOTCH1
18056171	10.1158/1078-0432.CCR-07-1474	2007	Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia.	NOTCH1
18184405	10.1111/j.1600-0463.2007.00751.x	2007	Mutational analysis of NOTCH1, 2, 3 and 4 genes in common solid cancers and acute leukemias.	NOTCH1
16449526	10.1182/blood-2005-09-3551	2006	Notch1 promotes survival of E2A-deficient T cell lymphomas through pre-T cell receptor-dependent and -independent mechanisms.	NOTCH1
16651424	10.1158/0008-5472.CAN-05-3830	2006	Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.	NOTCH1
16688224	10.1038/sj.leu.2404258	2006	CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors.	NOTCH1
16707600	10.1158/1078-0432.CCR-05-2832	2006	NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis.	NOTCH1
16738328	10.1128/MCB.01655-05	2006	Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.	NOTCH1
16880534	10.1128/MCB.02478-05	2006	Identification of a conserved negative regulatory sequence that influences the leukemogenic activity of NOTCH1.	NOTCH1
16887975	10.4049/jimmunol.177.4.2153	2006	Structurally distinct ligand-binding or ligand-independent Notch1 mutants are leukemogenic but affect thymocyte development, apoptosis, and metastasis differently.	NOTCH1
17107915	10.1080/10428190600773339	2006	NOTCH1 mutations are rare in acute myeloid leukemia.	NOTCH1
15756589	10.1007/s00428-005-1214-6	2005	Amplification of NOTCH1 and ABL1 gene loci is a frequent aberration in enteropathy-type T-cell lymphoma.	NOTCH1
16079893	10.1038/sj.leu.2403896	2005	Mutations of the Notch1 gene in T-cell acute lymphoblastic leukemia: analysis in adults and children.	NOTCH1
16298817	10.1532/IJH97.05096	2005	Deregulated NOTCH signaling in acute T-cell lymphoblastic leukemia/lymphoma: new insights, questions, and opportunities.	NOTCH1
15472075	10.1126/science.1102160	2004	Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.	NOTCH1
12509463	10.1128/MCB.23.2.655-664.2003	2003	Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling.	NOTCH1
12532332	10.1002/jcb.10383	2003	Differential regulation of Notch signal transduction in leukaemia and lymphoma cells in culture.	NOTCH1
11964309	10.1182/blood.v99.9.3398	2002	Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma.	NOTCH1
11739188	10.1182/blood.v98.13.3793	2001	A novel Notch ligand, Dll4, induces T-cell leukemia/lymphoma when overexpressed in mice by retroviral-mediated gene transfer.	NOTCH1
9111040	10.1074/jbc.272.17.11336	1997	Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription.	NOTCH1
1831692	10.1016/0092-8674(91)90111-b	1991	TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms.	NOTCH1
34407041	10.1097/CAD.0000000000001165	2022	Risk-tailored treatment of splenic marginal zone lymphoma.	NOTCH2
34435359	10.1111/imm.13408	2022	LncRNA00492 is required for marginal zone B-cell development.	NOTCH2
34494161	10.1007/s00428-021-03186-3	2022	Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.	NOTCH2
34586000	10.1080/10428194.2021.1984452	2022	NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma-opportunities for therapy.	NOTCH2
34632572	10.1111/bjh.17858	2022	Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.	NOTCH2
34821038	10.1111/ijlh.13769	2022	T cell lymphoblastic lymphoma with uncommon CD20 expression.	NOTCH2
35236331	10.1186/s12885-022-09237-5	2022	Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.	NOTCH2
35317330	10.14740/wjon1436	2022	Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis.	NOTCH2
35339566	10.1016/j.humpath.2022.03.008	2022	Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation.	NOTCH2
35834399	10.1097/PAS.0000000000001932	2022	Pediatric-Type Indolent B-Cell Lymphomas With Overlapping Clinical, Pathologic, and Genetic Features.	NOTCH2
35964234	10.1093/ajcp/aqac087	2022	Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma.	NOTCH2
35967131	10.7759/cureus.26738	2022	Splenic Marginal Zone Lymphoma With Histological Transformation to Hodgkin's Lymphoma.	NOTCH2
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	NOTCH2
33111346	10.1002/jcp.30115	2021	PTN-PTPRZ signalling is involved in deer antler stem cell regulation during tissue regeneration.	NOTCH2
33311649	10.1038/s41379-020-00720-7	2021	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.	NOTCH2
33314017	10.1111/bjh.17141	2021	Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.	NOTCH2
33570635	10.1182/bloodadvances.2020002995	2021	Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors.	NOTCH2
34039950	10.1038/s41408-021-00493-5	2021	Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.	NOTCH2
34204385	10.3390/cancers13123032	2021	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing.	NOTCH2
34299796	10.3390/ijerph18147345	2021	The Genomic Landscape of a Restricted ALL Cohort from Patients Residing on the U.S./Mexico Border.	NOTCH2
34378195	10.1111/bjh.17765	2021	Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.	NOTCH2
35008340	10.3390/cancers14010176	2021	Recent Advances in the Genetic of MALT Lymphomas.	NOTCH2
31433838	10.1093/ajcp/aqz133	2020	An Uncommon Case of Double-Hit Mantle Cell Lymphoma That Demonstrates a Transformation Process.	NOTCH2
31894255	10.3892/ijmm.2019.4418	2020	Precision medicine for human cancers with Notch signaling dysregulation (Review).	NOTCH2
32187361	10.1182/blood.2019003535	2020	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.	NOTCH2
32191807	10.1182/bloodadvances.2019001396	2020	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.	NOTCH2
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	NOTCH2
32239765	10.1002/ajh.25796	2020	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.	NOTCH2
32277542	10.1002/gcc.22849	2020	Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.	NOTCH2
32585984	10.3390/cancers12061669	2020	Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma.	NOTCH2
32598477	10.1182/bloodadvances.2019001350	2020	Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.	NOTCH2
32871937	10.1097/MD.0000000000021938	2020	Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.	NOTCH2
33017398	10.1371/journal.pbio.3000850	2020	Notch dimerization and gene dosage are important for normal heart development, intestinal stem cell maintenance, and splenic marginal zone B-cell homeostasis during mite infestation.	NOTCH2
33211828	10.1182/bloodadvances.2020002944	2020	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.	NOTCH2
33224395	10.14740/jh760	2020	Molecular Genetic Analysis With Flow Cytometry Sorting Identifies Angioimmunoblastic T-Cell Lymphoma and Concomitant <i>De Novo</i> Myelodysplastic Syndrome Arising From the Same Hematopoietic Progenitor.	NOTCH2
33400727	10.18632/oncotarget.27805	2020	RNA sequencing analyses reveal differentially expressed genes and pathways as Notch2 targets in B-cell lymphoma.	NOTCH2
30802265	10.1371/journal.pone.0212813	2019	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.	NOTCH2
30963600	10.1002/ajh.25487	2019	Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management.	NOTCH2
31320741	10.1038/s41598-019-46906-1	2019	Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma.	NOTCH2
31378966	10.1002/ajh.25600	2019	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.	NOTCH2
31395597	10.1101/mcs.a004259	2019	Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma.	NOTCH2
29641966	10.1056/NEJMoa1801445	2018	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.	NOTCH2
29735551	10.1158/0008-5472.CAN-17-4004	2018	Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.	NOTCH2
29755111	10.1038/s41417-018-0022-5	2018	Genomic landscape and prognostic analysis of mantle cell lymphoma.	NOTCH2
29955182	10.1038/s41591-018-0097-4	2018	Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.	NOTCH2
29989027	10.18632/oncotarget.25601	2018	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	NOTCH2
30073422	10.1007/s12032-018-1183-7	2018	Splenic marginal zone lymphomas in acquired C1-inhibitor deficiency: clinical and molecular characterization.	NOTCH2
27347751	10.1080/10428194.2016.1196813	2017	Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies.	NOTCH2
27717083	10.1002/gcc.22423	2017	T-cell acute lymphoblastic leukemia in infants has distinct genetic and epigenetic features compared to childhood cases.	NOTCH2
27874290	10.1080/10428194.2016.1260124	2017	Impact of clinical factors on outcome of leukemia patients with TLS-ERG fusion gene.	NOTCH2
28232365	10.1158/2159-8290.CD-16-1189	2017	BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.	NOTCH2
28288718	10.1016/j.beha.2016.09.005	2017	Splenic marginal zone lymphoma.	NOTCH2
28522570	10.3324/haematol.2016.161711	2017	Clinical and diagnostic relevance of <i>NOTCH2</i>-and <i>KLF2</i>-mutations in splenic marginal zone lymphoma.	NOTCH2
26426381	10.1097/PAS.0000000000000523	2016	NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease.	NOTCH2
26989207	10.1182/blood-2015-11-624312	2016	Splenic marginal zone lymphoma: from genetics to management.	NOTCH2
27121112	10.3109/10428194.2016.1173212	2016	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.	NOTCH2
27148583	10.1101/mcs.a000679	2016	Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing.	NOTCH2
27248180	10.18632/oncotarget.9678	2016	The genetic landscape of dural marginal zone lymphomas.	NOTCH2
27335277	10.1182/blood-2016-02-696757	2016	The genetics of nodal marginal zone lymphoma.	NOTCH2
27566587	10.18632/oncotarget.11548	2016	Recurrent mutations in NF-Œ∫B pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.	NOTCH2
27572051	10.3892/mmr.2016.5688	2016	Notch 2 signaling contributes to cell growth, anti-apoptosis and metastasis in laryngeal squamous cell carcinoma.	NOTCH2
25023849	10.1016/j.medcli.2014.04.025	2015	[Mantle cell lymphoma: Towards a personalized therapeutic strategy?].	NOTCH2
25311243	10.1038/leu.2014.302	2015	A microRNA-mediated regulatory loop modulates NOTCH and MYC oncogenic signals in B- and T-cell malignancies.	NOTCH2
25355291	10.1093/carcin/bgu223	2015	DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice.	NOTCH2
25381127	10.3324/haematol.2014.116855	2015	The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.	NOTCH2
25428260	10.1038/leu.2014.330	2015	KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.	NOTCH2
25595890	10.18632/oncotarget.2218	2015	Mutational spectrum of adult T-ALL.	NOTCH2
25612624	10.1182/blood-2014-08-596247	2015	DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features.	NOTCH2
25663545	10.1007/s10549-015-3279-5	2015	The role of polycomb group protein Bmi-1 and Notch4 in breast cancer stem cell inhibition by benzyl isothiocyanate.	NOTCH2
25779943	10.1158/1078-0432.CCR-14-2759	2015	Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.	NOTCH2
26498442	10.1186/s12885-015-1766-z	2015	Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations.	NOTCH2
24116381	10.1111/bph.12442	2014	Involvement of midkine in neuroblastoma tumourigenesis.	NOTCH2
24317268	10.1292/jvms.13-0344	2014	Notch2 transduction by feline leukemia virus in a naturally infected cat.	NOTCH2
24651005	10.1016/j.ccr.2014.03.001	2014	A jagged road to lymphoma aggressiveness.	NOTCH2
24651014	10.1016/j.ccr.2014.02.005	2014	Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance.	NOTCH2
24689848	10.1111/cas.12408	2014	Disease-specific mutations in mature lymphoid neoplasms: recent advances.	NOTCH2
24722428	10.1038/nrc3730	2014	Microenvironment: Endothelial cells create a niche.	NOTCH2
25088352	10.1111/bjh.13052	2014	Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features.	NOTCH2
25141821	10.1002/path.4428	2014	Recurrent mutations of NOTCH genes in follicular lymphoma identify a distinctive subset of tumours.	NOTCH2
25314575	10.1371/journal.pone.0108747	2014	The truncate mutation of Notch2 enhances cell proliferation through activating the NF-Œ∫B signal pathway in the diffuse large B-cell lymphomas.	NOTCH2
23359069	10.1084/jem.20121527	2013	Notch activation inhibits AML growth and survival: a potential therapeutic approach.	NOTCH2
23625998	10.1093/jb/mvt035	2013	The heparin-binding growth factor midkine: the biological activities and candidate receptors.	NOTCH2
23665546	10.1016/j.semcancer.2013.04.002	2013	Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies.	NOTCH2
24145436	10.1073/pnas.1314608110	2013	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.	NOTCH2
24168526	10.1586/17474086.2013.845522	2013	Splenic marginal zone lymphoma: disease features and management.	NOTCH2
24349473	10.1371/journal.pone.0083244	2013	Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.	NOTCH2
22391171	NA	2012	[Expression of Notch signal molecules in human lymphoma cells and its significance].	NOTCH2
22695918	10.1007/82_2012_235	2012	Notch2 and immune function.	NOTCH2
22891273	10.1084/jem.20120904	2012	The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.	NOTCH2
22891276	10.1084/jem.20120910	2012	Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma.	NOTCH2
23022380	10.1016/j.molcel.2012.08.022	2012	NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function.	NOTCH2
21332343	10.3109/0886022X.2011.553979	2011	Notch2/Hes-1 pathway plays an important role in renal ischemia and reperfusion injury-associated inflammation and apoptosis and the Œ≥-secretase inhibitor DAPT has a nephroprotective effect.	NOTCH2
21494254	10.1038/leu.2011.50	2011	GSI-I (Z-LLNle-CHO) inhibits Œ≥-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.	NOTCH2
22006338	10.1073/pnas.1114669108	2011	Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.	NOTCH2
22128846	10.1186/1471-2407-11-502	2011	Current views on the role of Notch signaling and the pathogenesis of human leukemia.	NOTCH2
20393564	10.1038/nature08878	2010	Therapeutic antibody targeting of individual Notch receptors.	NOTCH2
20538790	10.1182/blood-2009-12-260216	2010	Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma.	NOTCH2
19001083	10.1182/blood-2008-03-147967	2009	Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases.	NOTCH2
19075186	10.1182/blood-2008-08-174748	2009	Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL.	NOTCH2
19339697	10.1182/blood-2008-11-190090	2009	Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells.	NOTCH2
19445024	10.1111/j.1349-7006.2009.01130.x	2009	Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma.	NOTCH2
18508802	10.3324/haematol.11635	2008	NOTCH2 mutations in marginal zone lymphoma.	NOTCH2
17456054	10.1111/j.1365-2141.2007.06576.x	2007	Identification of novel molecular prognostic markers for paediatric T-cell acute lymphoblastic leukaemia.	NOTCH2
18184405	10.1111/j.1600-0463.2007.00751.x	2007	Mutational analysis of NOTCH1, 2, 3 and 4 genes in common solid cancers and acute leukemias.	NOTCH2
16780947	10.1016/j.leukres.2006.05.003	2006	Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors.	NOTCH2
15621797	10.1080/10428190400010742	2005	Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia.	NOTCH2
14976135	10.1093/carcin/bgh124	2004	Defective expression of Notch1 and Notch2 in connection to alterations of c-Myc and Ikaros in gamma-radiation-induced mouse thymic lymphomas.	NOTCH2
15507668	10.1016/S1525-1578(10)60525-9	2004	Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma.	NOTCH2
11561162	10.1097/00062752-200107000-00010	2001	Notch signaling in leukemia.	NOTCH2
11699411	10.3109/10428190109064603	2001	Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells.	NOTCH2
10507363	10.1016/s0165-2427(99)00075-6	1999	Lymphokines modulate the growth and survival of thymic tumor cells containing a novel feline leukemia virus/Notch2 variant.	NOTCH2
9343387	10.1128/MCB.17.11.6265	1997	Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2.	NOTCH2
8892932	10.1128/JVI.70.11.8071-8080.1996	1996	Transduction of Notch2 in feline leukemia virus-induced thymic lymphoma.	NOTCH2
8946923	NA	1996	Viral genetic variation, AIDS, and the multistep nature of carcinogenesis: the feline leukemia virus model.	NOTCH2
29731965	10.18632/oncotarget.24656	2018	<i>TP53</i> and <i>OSBPL10</i> alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosis.	OSBPL10
25189415	10.1038/leu.2014.264	2015	The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.	OSBPL10
34857887	10.1038/s41388-021-02126-4	2022	HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort.	P2RY8
35484080	10.1016/j.clml.2022.03.007	2022	Clinico-hematological and Outcome Profile of Pediatric B-other-ALL and BCR::ABL1-like pre-B-ALL: An Integrated Genomic Study From North India.	P2RY8
35537330	10.1016/j.cyto.2022.155896	2022	High occurrence of CRLF2 abnormalities in Mexican children with B-cell acute lymphoblastic leukemia.	P2RY8
35912172	10.3389/fonc.2022.896858	2022	Recurrent Novel <i>P2RY8/IGH</i> Translocations in B-Lymphoblastic Leukemia/Lymphoma.	P2RY8
36076986	10.3390/ijms23179587	2022	Characterization of Philadelphia-like Pre-B Acute Lymphoblastic Leukemia: Experiences in Mexican Pediatric Patients.	P2RY8
33615710	10.1111/ijlh.13419	2021	Effects of different aberrations in the CRLF2 gene on the biological¬†characteristics and drug sensitivities of Nalm6 cells.	P2RY8
33707599	10.1038/s41598-021-85213-6	2021	Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia with kinase fusions in Taiwan.	P2RY8
33750258	10.1080/0284186X.2021.1900908	2021	Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on <i>BCR-ABL1</i>-like subtype.	P2RY8
33781217	10.1186/s12885-020-07781-6	2021	Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach - a population-based study.	P2RY8
33812392	10.19746/j.cnki.issn.1009-2137.2021.02.001	2021	[Clinical Features and Prognosis of Acute Lymphoblastic Leukemia Children with P2RY8-CRLF2 Gene Rearrangement].	P2RY8
33890726	10.1002/cjp2.211	2021	CRLF2 and IKZF1 abnormalities in Mexican children with acute lymphoblastic leukemia and recurrent gene fusions: exploring surrogate markers of signaling pathways.	P2RY8
34159401	10.1007/s00277-021-04574-0	2021	Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.	P2RY8
34732618	10.11406/rinketsu.62.1465	2021	[Down syndrome and acute lymphoblastic leukemia].	P2RY8
33113607	10.3760/cma.j.issn.0253-2727.2020.09.008	2020	[Diagnosis of adult Philadelphia chromosome-like acute lymphoblastic leukemia by fluorescence in situ hybridization].	P2RY8
30842656	10.1038/s41586-019-1003-z	2019	S-Geranylgeranyl-L-glutathione is a ligand for human B cell-confinement receptor P2RY8.	P2RY8
30859636	10.1002/gcc.22748	2019	GATA3 germline variant is associated with CRLF2 expression and predicts outcome in pediatric B-cell precursor acute lymphoblastic leukemia.	P2RY8
29194562	10.1111/bjh.15056	2018	A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.	P2RY8
29407587	10.1016/j.leukres.2018.01.012	2018	High frequency of intermediate and poor risk copy number abnormalities in pediatric cohort of B-ALL correlate with high MRD post induction.	P2RY8
29507076	10.1182/bloodadvances.2017014704	2018	Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.	P2RY8
29786757	10.1007/s12185-018-2474-7	2018	Copy number abnormality of acute lymphoblastic leukemia cell lines based on their genetic subtypes.	P2RY8
29982439	10.1093/gigascience/giy079	2018	Clinker: visualizing fusion genes detected in RNA-seq data.	P2RY8
27637012	10.1002/gcc.22421	2017	Prognostic significance of P2RY8-CRLF2 and CRLF2 overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia.	P2RY8
27855558	10.1080/10428194.2016.1219902	2017	Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL).	P2RY8
27899802	10.1038/leu.2016.365	2017	Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia.	P2RY8
28033648	10.1002/gcc.22439	2017	Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.	P2RY8
28371317	10.1002/pbc.26539	2017	Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhood.	P2RY8
28395118	10.1002/gcc.22464	2017	ETV6/RUNX1-like acute lymphoblastic leukemia: A novel B-cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype.	P2RY8
28408464	10.1182/blood-2016-12-758979	2017	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.	P2RY8
28866095	10.1016/j.canlet.2017.08.034	2017	Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.	P2RY8
29140408	10.1093/ajcp/aqx111	2017	Philadelphia Chromosome-like Mixed-Phenotype Acute Leukemia Demonstrating P2RY8-CRLF2 Fusion and JAK1 Mutation.	P2RY8
26754556	10.1016/j.leukres.2015.11.018	2016	CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.	P2RY8
27161658	10.1016/j.jmoldx.2016.03.004	2016	Genome-Wide Single-Nucleotide Polymorphism Array Analysis Improves Prognostication of Acute Lymphoblastic Leukemia/Lymphoma.	P2RY8
27959929	10.1371/journal.pmed.1002197	2016	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.	P2RY8
26018335	10.1111/bjh.13514	2015	The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.	P2RY8
23911702	10.3324/haematol.2013.090225	2014	High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.	P2RY8
24935070	10.1002/gcc.22190	2014	An overall characterization of pediatric acute lymphoblastic leukemia with CRLF2 overexpression.	P2RY8
25044358	10.1002/gcc.22201	2014	Gene alterations involving the CRLF2-JAK pathway and recurrent gene deletions in Down syndrome-associated acute lymphoblastic leukemia in Japan.	P2RY8
25105841	10.1038/ncomms5654	2014	Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations.	P2RY8
25274307	10.1038/nature13765	2014	Loss of signalling via GŒ±13 in germinal centre B-cell-derived lymphoma.	P2RY8
22875627	10.3324/haematol.2011.056135	2013	IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.	P2RY8
23145900	10.1111/bjh.12130	2013	No prognostic impact of P2RY8-CRLF2 fusion in intermediate cytogenetic risk childhood B-cell acute lymphoblastic leukaemia.	P2RY8
23212523	10.1182/blood-2012-04-422691	2013	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.	P2RY8
23930217	10.1002/cam4.87	2013	IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan.	P2RY8
22072402	10.1002/gcc.20944	2012	High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with down syndrome.	P2RY8
22343534	10.1073/pnas.1121343109	2012	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	P2RY8
22368272	10.1182/blood-2011-11-394221	2012	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.	P2RY8
22484421	10.1038/leu.2012.101	2012	Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia.	P2RY8
22816614	10.1111/j.1365-2141.2012.09221.x	2012	Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups.	P2RY8
22851563	10.1200/JCO.2011.40.3907	2012	IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia.	P2RY8
23091296	10.1182/blood-2012-07-443218	2012	Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL.	P2RY8
21106984	10.1182/blood-2010-07-297135	2011	Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial.	P2RY8
21527530	10.1182/blood-2011-01-329961	2011	Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia.	P2RY8
19965641	10.1182/blood-2009-08-235408	2010	Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.	P2RY8
20139093	10.1182/blood-2009-09-245944	2010	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.	P2RY8
20378752	10.1182/blood-2009-11-256131	2010	Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol.	P2RY8
20847213	10.1182/blood-2010-05-286492	2010	t(X;14)(p22;q32)/t(Y;14)(p11;q32) CRLF2-IGH translocations from human B-lineage ALLs involve CpG-type breaks at CRLF2, but CRLF2/P2RY8 intrachromosomal deletions do not.	P2RY8
19838194	10.1038/ng.469	2009	Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.	P2RY8
17487742	10.1080/10428190701225882	2007	Transforming activity of purinergic receptor P2Y, G protein coupled, 8 revealed by retroviral expression screening.	P2RY8
17554380	10.1038/sj.leu.2404784	2007	Upregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic follicular lymphoma.	P2RY8
34997652	10.1111/ejh.13736	2022	Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.	PCLO
35646048	10.3389/fgene.2022.878618	2022	Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	PCLO
33546774	10.1186/s40164-021-00200-x	2021	Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas.	PCLO
26608593	10.1002/gcc.22328	2016	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.	PCLO
22343534	10.1073/pnas.1121343109	2012	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	PCLO
34325497	10.4143/crt.2021.752	2022	Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma.	PIM1
34448823	10.1182/bloodadvances.2021004212	2022	The molecular hallmarks of primary and secondary vitreoretinal lymphoma.	PIM1
34714908	10.1182/bloodadvances.2021005486	2022	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.	PIM1
34979782	10.3760/cma.j.cn112138-20210124-00066	2022	[Mucosal associated lymphoid tissue lymphoma with positive PIM1 expression: a case report].	PIM1
34997652	10.1111/ejh.13736	2022	Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.	PIM1
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	PIM1
35106936	10.1002/cam4.4550	2022	SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.	PIM1
35223507	10.3389/fonc.2022.824632	2022	<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS.	PIM1
35300216	10.2147/JIR.S341355	2022	The Mutation of <i>BTG2</i> Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma.	PIM1
35401516	10.3389/fimmu.2022.842439	2022	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.	PIM1
35415904	10.1002/ctm2.808	2022	PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B-cell lymphoma.	PIM1
35646048	10.3389/fgene.2022.878618	2022	Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	PIM1
35928872	10.3389/fonc.2022.932674	2022	Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma.	PIM1
35937947	10.1155/2022/6441139	2022	Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis.	PIM1
36053490	10.1002/hon.3073	2022	Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.	PIM1
36081566	10.3389/fonc.2022.941347	2022	Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.	PIM1
32139889	10.1038/s41375-020-0766-4	2021	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.	PIM1
32973328	10.1038/s41379-020-00685-7	2021	The clinicopathological and molecular features of sinusoidal large B-cell lymphoma.	PIM1
33202420	10.1182/blood.2020008520	2021	EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.	PIM1
33307035	10.1016/j.ajpath.2020.12.001	2021	PIM Kinases Promote Survival and Immune Escape in Primary Mediastinal Large B-Cell Lymphoma through Modulation of JAK-STAT and NF-Œ∫B Activity.	PIM1
33479306	10.1038/s41598-020-80376-0	2021	Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.	PIM1
33581493	10.1016/j.ctarc.2021.100310	2021	Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients.	PIM1
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	PIM1
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	PIM1
33945543	10.1371/journal.pone.0248886	2021	Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.	PIM1
34267815	10.3892/ol.2021.12883	2021	<i>In vitro</i> assessment of the efficiency of the PIM-1 kinase pharmacological inhibitor as a potential treatment for Burkitt's lymphoma.	PIM1
34374220	10.1002/cjp2.223	2021	c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.	PIM1
34625423	10.1158/0008-5472.CAN-21-1023	2021	Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.	PIM1
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	PIM1
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	PIM1
35116576	10.21037/tcr-20-2525	2021	Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database.	PIM1
31886867	10.1093/jnen/nlz125	2020	Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma.	PIM1
31958486	10.1016/j.canlet.2020.01.012	2020	Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma.	PIM1
32146726	10.1002/1878-0261.12662	2020	PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.	PIM1
32201861	10.1093/noajnl/vdaa018	2020	Primary CNS lymphoma commonly expresses immune response biomarkers.	PIM1
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	PIM1
32315407	10.1182/blood.2019003880	2020	Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.	PIM1
32379874	10.1182/blood.2020005142	2020	A targetable cue in T-cell malignancy.	PIM1
32399964	10.1002/ijc.33049	2020	Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.	PIM1
32469082	10.1002/cncr.32866	2020	Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.	PIM1
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	PIM1
32753387	10.1158/1535-7163.MCT-20-0160	2020	PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.	PIM1
32864130	10.1186/s40364-020-00214-3	2020	A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression.	PIM1
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	PIM1
30076176	10.3324/haematol.2018.199257	2019	Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.	PIM1
30658101	10.1016/j.lfs.2019.01.022	2019	PIM inhibitor SMI-4a induces cell apoptosis in B-cell acute lymphocytic leukemia cells via the HO-1-mediated JAK2/STAT3 pathway.	PIM1
30829648	10.1172/JCI120654	2019	BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment.	PIM1
31403034	10.3389/fonc.2019.00683	2019	Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.	PIM1
31483572	10.1111/jcmm.14601	2019	Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting miR-497-5p/PIM1 axis.	PIM1
31780656	10.1038/s41467-019-13315-x	2019	The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.	PIM1
31806993	10.2147/OTT.S227122	2019	Genomic Alterations In Primary Cardiac Diffuse Large B Cell Lymphoma: A Case Report And Literature Review.	PIM1
32245312	10.18502/ijaai.v18i6.2181	2019	Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.	PIM1
29444501	10.1159/000486361	2018	Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study.	PIM1
29479063	10.1038/s41375-018-0031-2	2018	High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement.	PIM1
29496663	10.1158/2159-8290.CD-17-0583	2018	HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.	PIM1
29891112	10.1016/j.critrevonc.2018.05.010	2018	Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.	PIM1
29937999	10.18632/oncotarget.25463	2018	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma.	PIM1
30020405	10.1093/abbs/gmy076	2018	PIM1 overexpression in T-cell lymphomas protects tumor cells from apoptosis and confers doxorubicin resistance by upregulating c-myc expression.	PIM1
30185437	10.1182/bloodadvances.2018021063	2018	STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.	PIM1
30209976	10.1080/15384101.2018.1522912	2018	PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation.	PIM1
30227305	10.1016/j.neo.2018.08.012	2018	Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.	PIM1
30370255	10.15430/JCP.2018.23.3.109	2018	PIM Kinase as an Executional Target in Cancer.	PIM1
30463380	10.3390/cancers10110459	2018	Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma.	PIM1
27641442	10.1016/j.bbadis.2016.09.012	2017	CD95-mediated apoptosis in Burkitt's lymphoma B-cells is associated with Pim-1 down-regulation.	PIM1
28134252	10.1038/ncomms14290	2017	THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.	PIM1
28368397	10.1038/onc.2017.90	2017	Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.	PIM1
28415816	10.18632/oncotarget.16320	2017	Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.	PIM1
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	PIM1
28698206	10.1182/blood-2017-01-760702	2017	Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.	PIM1
28729093	10.1016/j.yexcr.2017.07.019	2017	PIM kinases 1, 2 and 3 in intracellular LIF signaling, proliferation and apoptosis in trophoblastic cells.	PIM1
28841204	10.1038/bcj.2017.72	2017	From Waldenstr√∂m's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.	PIM1
29245897	10.18632/oncotarget.18502	2017	Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum.	PIM1
29262531	10.18632/oncotarget.21986	2017	Mutational profile of primary breast diffuse large B-cell lymphoma.	PIM1
26757737	10.1007/s00401-016-1536-2	2016	Genomic characterization of primary central nervous system lymphoma.	PIM1
26773040	10.1182/blood-2015-09-672352	2016	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.	PIM1
26813676	10.1182/blood-2015-11-685032	2016	Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia.	PIM1
27030389	10.1182/blood-2015-12-686550	2016	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.	PIM1
27088431	10.1111/cas.12945	2016	Identification of cooperative genes for E2A-PBX1 to develop acute lymphoblastic leukemia.	PIM1
27198204	10.1038/leu.2016.135	2016	Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.	PIM1
27556513	10.18632/oncotarget.11457	2016	Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.	PIM1
27904766	NA	2016	The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.	PIM1
25189415	10.1038/leu.2014.264	2015	The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.	PIM1
25553374	10.2741/E728	2015	Understanding the functional discrepancy of Pim-1 in cancer.	PIM1
26340096	10.1371/journal.pone.0137210	2015	Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.	PIM1
26643319	10.1186/s12943-015-0477-z	2015	Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.	PIM1
23910958	10.1016/j.bcmd.2013.07.003	2014	GFI1B, EVI5, MYB--additional genes that cooperate with the human BCL6 gene to promote the development of lymphomas.	PIM1
24131033	10.1517/13543776.2014.848196	2014	Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.	PIM1
24240734	10.1007/s00401-013-1202-x	2014	Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.	PIM1
24474669	10.1158/1078-0432.CCR-13-2062	2014	Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.	PIM1
24547709	10.3109/10428194.2014.893303	2014	Expression of PIM1 protein in chronic lymphocytic leukemia/small lymphocytic lymphoma.	PIM1
24605938	10.3109/10428194.2014.900762	2014	A new model of LMP1-MYC interaction in B cell lymphoma.	PIM1
24756111	10.1038/jid.2014.199	2014	Exploring the IL-21-STAT3 axis as therapeutic target for S√©zary syndrome.	PIM1
24970810	10.18632/oncotarget.2080	2014	Mutational analysis of primary central nervous system lymphoma.	PIM1
23360755	10.1186/1756-8722-6-12	2013	Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice.	PIM1
23872419	10.1016/j.bbamcr.2013.07.010	2013	Calix[6]arene bypasses human pancreatic cancer aggressiveness: downregulation of receptor tyrosine kinases and induction of cell death by reticulum stress and autophagy.	PIM1
24900629	10.1021/ml400307j	2013	Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.	PIM1
21743487	10.1038/onc.2011.278	2012	The proto-oncogene Pim-1 is a target of miR-33a.	PIM1
22101984	10.1002/eji.201141987	2012	Pim1 and Myc reversibly transform murine precursor B lymphocytes but not mature B lymphocytes.	PIM1
22282239	10.1007/s11596-012-0003-0	2012	PI3K-like kinases restrain Pim gene expression in endothelial cells.	PIM1
22385356	10.1111/j.1399-6576.2012.02657.x	2012	Desflurane-induced and ischaemic postconditioning against myocardial infarction are mediated by Pim-1 kinase.	PIM1
22451912	10.1073/pnas.1201168109	2012	PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas.	PIM1
22722314	10.1038/bjc.2012.272	2012	PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.	PIM1
22955922	10.1182/blood-2012-02-412643	2012	Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.	PIM1
21474815	10.1161/CIRCRESAHA.110.239111	2011	Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling.	PIM1
21741249	10.1016/j.bmc.2011.06.013	2011	Arthrinins A-D: novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp.	PIM1
21859846	10.1084/jem.20110846	2011	Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.	PIM1
19965690	10.1182/blood-2009-07-233445	2010	A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.	PIM1
20670681	10.1016/j.cellsig.2010.07.013	2010	Epstein-Barr virus latent membrane protein 1 increases chemo-resistance of cancer cells via cytoplasmic sequestration of Pim-1.	PIM1
18704108	10.1038/jid.2008.243	2009	Primary cutaneous marginal zone B-cell lymphomas are targeted by aberrant somatic hypermutation.	PIM1
19336552	10.1158/1055-9965.EPI-08-1037	2009	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.	PIM1
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	PIM1
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	PIM1
18180034	10.1016/j.leukres.2007.11.028	2008	Quantifying the role of aberrant somatic hypermutation in transformation of follicular lymphoma.	PIM1
18467333	10.1074/jbc.M709695200	2008	Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma.	PIM1
18715779	10.1016/j.ejca.2008.06.044	2008	Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.	PIM1
19021050	10.1080/10428190802419640	2008	Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.	PIM1
19688129	10.4143/crt.2008.40.4.190	2008	Association of single nucleotide polymorphisms in PIM-1 gene with the risk of Korean lung cancer.	PIM1
17197434	10.1182/blood-2006-06-030494	2007	MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation.	PIM1
17251349	10.1073/pnas.0610732104	2007	Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice.	PIM1
17289214	10.1016/j.jaad.2006.12.026	2007	New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas.	PIM1
17363577	10.1158/0008-5472.CAN-06-2419	2007	G-rich proto-oncogenes are targeted for genomic instability in B-cell lymphomas.	PIM1
17476282	10.1038/sj.leu.2404706	2007	Analysis of BCL-6, CD95, PIM1, RHO/TTF and PAX5 mutations in splenic and nodal marginal zone B-cell lymphomas suggests a particular B-cell origin.	PIM1
17545590	10.1158/0008-5472.CAN-07-0433	2007	Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas.	PIM1
17560648	10.1016/j.leukres.2007.04.015	2007	Association of PIM gene translocation and TEL/AML1 rearrangement.	PIM1
17876297	10.1038/labinvest.3700672	2007	Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed-Sternberg cells by LC-MS/MS.	PIM1
16437153	10.1038/sj.leu.2404094	2006	Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas.	PIM1
16614247	10.1182/blood-2005-10-3949	2006	Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma.	PIM1
16647097	10.1016/j.virol.2006.03.037	2006	KSHV encoded LANA upregulates Pim-1 and is a substrate for its kinase activity.	PIM1
15721354	10.1016/j.virol.2005.01.001	2005	Pim kinases are upregulated during Epstein-Barr virus infection and enhance EBNA2 activity.	PIM1
15767564	10.1073/pnas.0500830102	2005	A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression.	PIM1
15808862	10.1016/j.jmb.2005.02.039	2005	Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.	PIM1
15809970	10.1002/path.1754	2005	Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection.	PIM1
16373702	10.1158/1535-7163.MCT-05-0146	2005	Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures.	PIM1
14592832	10.1182/blood-2003-05-1465	2004	Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation.	PIM1
12537534	10.1667/0033-7587(2003)159[0274:colteo]2.0.co;2	2003	Comments on """"Long-term exposure of Emicro-Pim1 transgenic mice to 898.4 MHz microwaves does not increase lymphoma incidence"""" by Utteridge et al., Radiat. Res. 158, 357-364 (2002).	PIM1
12537535	10.1667/0033-7587(2003)159[0275:colteo]2.0.co;2	2003	Comments on """"Long-term exposure of Emicro-Pim1 transgenic mice to 898.4 MHz microwaves does not increase lymphoma incidence"""" by Utteridge et al., Radiat. Res. 158, 357-364 (2002).	PIM1
12537536	10.1667/0033-7587(2003)159[0276:cotrpo]2.0.co;2	2003	Comments on the recent publication on microwave effects on Emicro-Pim1 transgenic mice (Utteridge et al., Radiat. Res. 158, 357-364, 2002).	PIM1
12605034	10.1097/00019606-200303000-00005	2003	Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV.	PIM1
12668877	10.1385/endo:20:1-2:123	2003	Prolactin-regulated pim-1 transcription: identification of critical promoter elements and Akt signaling.	PIM1
12680209	NA	2003	Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects.	PIM1
12714522	10.1182/blood-2002-11-3606	2003	Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma.	PIM1
12751966	10.1667/0033-7587(2003)159[0835:fcoleo]2.0.co;2	2003	Further comments on """"Long-term exposure of Emu-Pim1 transgenic mice to 898.4 MHz microwaves does not increase lymphoma incidence"""" by Utteridge et al. (Radiat. Res. 158, 357-364 2002).	PIM1
12111331	10.1007/s00412-002-0192-6	2002	Pim-1 associates with protein complexes necessary for mitosis.	PIM1
12175314	10.1667/0033-7587(2002)158[0357:lteoep]2.0.co;2	2002	Long-term exposure of E-mu-Pim1 transgenic mice to 898.4 MHz microwaves does not increase lymphoma incidence.	PIM1
12185366	10.1038/ng950	2002	High-throughput retroviral tagging to identify components of specific signaling pathways in cancer.	PIM1
12472567	10.1046/j.1365-2141.2002.03931.x	2002	Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma.	PIM1
11164909	10.1016/s0165-5728(00)00430-6	2001	Prolactin signaling to pim-1 expression: a role for phosphatidylinositol 3-kinase.	PIM1
11237709	10.1006/bbrc.2001.4405	2001	Regulation of Pim-1 by Hsp90.	PIM1
11313958	10.1038/sj.onc.1204090	2001	Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging.	PIM1
11460166	10.1038/35085588	2001	Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas.	PIM1
12441685	NA	2001	Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis.	PIM1
10790285	10.1667/0033-7587(2000)153[0627:laliir]2.0.co;2	2000	Leukemia and lymphoma incidence in rodents exposed to low-frequency magnetic fields.	PIM1
10523604	10.1084/jem.190.8.1059	1999	PIM1 reconstitutes thymus cellularity in interleukin 7- and common gamma chain-mutant mice and permits thymocyte maturation in Rag- but not CD3gamma-deficient mice.	PIM1
10557087	10.1038/sj.onc.1202995	1999	Overexpression of Frat1 in transgenic mice leads to glomerulosclerosis and nephrotic syndrome, and provides direct evidence for the involvement of Frat1 in lymphoma progression.	PIM1
10579330	10.1210/endo.140.12.7215	1999	Prolactin regulation of pim-1 expression: positive and negative promoter elements.	PIM1
9496894	NA	1998	A test of lymphoma induction by long-term exposure of E mu-Pim1 transgenic mice to 50 Hz magnetic fields.	PIM1
9635873	10.1093/carcin/19.5.847	1998	X-ray-induced lymphomagenesis in E mu-pim-1 transgenic mice: an investigation of the co-operating molecular events.	PIM1
9727621	10.1046/j.1525-1500.1998.00059.x	1998	Expression of lymphomagenic oncogenes in T-cell lymphomas of HPV 16 transgenic mice.	PIM1
9771937	10.1093/carcin/19.9.1649	1998	Exposure to 60 Hz magnetic fields and risk of lymphoma in PIM transgenic and TSG-p53 (p53 knockout) mice.	PIM1
9840930	10.1038/sj.onc.1202191	1998	Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis.	PIM1
9864091	10.1177/019262339802600606	1998	Evaluation of the Emu-pim-1 transgenic mouse model for short-term carcinogenicity testing.	PIM1
9867250	10.1385/ENDO:9:2:163	1998	Prolactin-regulated apoptosis of Nb2 lymphoma cells: pim-1, bcl-2, and bax expression.	PIM1
8985317	10.1128/JVI.71.1.9-16.1997	1997	Characterization of pal-1, a common proviral insertion site in murine leukemia virus-induced lymphomas of c-myc and Pim-1 transgenic mice.	PIM1
9034327	10.1093/emboj/16.3.441	1997	Activation of a novel proto-oncogene, Frat1, contributes to progression of mouse T-cell lymphomas.	PIM1
9079225	10.1007/978-3-642-60682-3_36	1997	Lymphoma induction by heterocyclic amines in E mu-pim-1 transgenic mice.	PIM1
9146709	NA	1997	Lymphomas in E mu-Pim1 transgenic mice exposed to pulsed 900 MHZ electromagnetic fields.	PIM1
9163683	10.1093/carcin/18.5.975	1997	Use of E mu-PIM-1 transgenic mice short-term in vivo carcinogenicity testing: lymphoma induction by benzo[a]pyrene, but not by TPA.	PIM1
9171354	10.1093/emboj/16.9.2408	1997	An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice.	PIM1
9401000	10.1038/sj.onc.1201670	1997	Pim1 cooperates with E2a-Pbx1 to facilitate the progression of thymic lymphomas in transgenic mice.	PIM1
8543805	NA	1996	pim-1 proto-oncogene expression in anti-CD3-mediated T cell activation is associated with protein kinase C activation and is independent of Raf-1.	PIM1
8622900	NA	1996	Zinc finger protein GFI-1 cooperates with myc and pim-1 in T-cell lymphomagenesis by reducing the requirements for IL-2.	PIM1
8642629	10.1128/JVI.70.4.2095-2100.1996	1996	Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development?	PIM1
8648744	10.1128/JVI.70.6.4063-4070.1996	1996	Sequence tags of provirus integration sites in DNAs of tumors induced by the murine retrovirus SL3-3.	PIM1
8692692	10.1093/nar/24.13.2528	1996	MoMuLV proviral integrations identified by Sup-F selection in tumors from infected myc/pim bitransgenic mice correlate with activation of the gfi-1 gene.	PIM1
8847898	NA	1996	Elevated pim-1 and c-myc proto-oncogene induction in B lymphocytes from BLV-infected cows with persistent B lymphocytosis.	PIM1
8895492	10.1093/carcin/17.10.2221	1996	Short-term carcinogenicity testing of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in E(mu)-pim-1 transgenic mice.	PIM1
8959340	NA	1996	Alterations in pim-1 and c-myc expression associated with sodium butyrate-induced growth factor dependency in autonomous rat Nb2 lymphoma cells.	PIM1
7588268	10.1210/endo.136.12.7588268	1995	Rapid induction of pim-1 expression by prolactin and interleukin-2 in rat Nb2 lymphoma cells.	PIM1
7781606	10.1002/j.1460-2075.1995.tb07251.x	1995	Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2.	PIM1
7844555	10.1099/0022-1317-76-2-347	1995	Leukaemogenesis by the delta Mo + SV Moloney murine leukaemia virus (M-MuLV) variant in E mu pim-1 transgenic mice: high frequency of recombination with a solo endogenous M-MuLV LTR in vivo.	PIM1
7859360	10.1093/carcin/16.2.285	1995	Short-term carcinogenesis bioassay of genotoxic procarcinogens in PIM transgenic mice.	PIM1
7587098	10.1101/sqb.1994.059.01.049	1994	Mouse model systems to study multistep tumorigenesis.	PIM1
7683108	10.1016/0165-7992(93)90091-9	1993	Micronuclei induced in peripheral blood of E mu-PIM-1 transgenic mice by chronic oral treatment with 2-acetylaminofluorene or benzene but not with diethyl-nitrosamine or 1,2-dichloroethane.	PIM1
1658705	NA	1991	E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.	PIM1
2537153	10.1016/0092-8674(89)90589-8	1989	Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.	PIM1
2681009	10.1002/ijc.2910440706	1989	Transgenic mice as a means to study synergism between oncogenes.	PIM1
35053500	10.3390/cancers14020338	2022	High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients.	PIM2
34625423	10.1158/0008-5472.CAN-21-1023	2021	Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.	PIM2
30658101	10.1016/j.lfs.2019.01.022	2019	PIM inhibitor SMI-4a induces cell apoptosis in B-cell acute lymphocytic leukemia cells via the HO-1-mediated JAK2/STAT3 pathway.	PIM2
30340823	10.1016/j.bbrc.2018.09.062	2018	Proviral insertion in murine lymphomas 2 promotes stomach cancer progression by regulating apoptosis via reactive oxygen species-triggered endoplasmic reticulum stress.	PIM2
30370255	10.15430/JCP.2018.23.3.109	2018	PIM Kinase as an Executional Target in Cancer.	PIM2
28698206	10.1182/blood-2017-01-760702	2017	Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.	PIM2
28729093	10.1016/j.yexcr.2017.07.019	2017	PIM kinases 1, 2 and 3 in intracellular LIF signaling, proliferation and apoptosis in trophoblastic cells.	PIM2
26764044	10.3109/10428194.2015.1124991	2016	Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia.	PIM2
26824321	10.18632/oncotarget.7036	2016	Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.	PIM2
26340096	10.1371/journal.pone.0137210	2015	Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.	PIM2
26643319	10.1186/s12943-015-0477-z	2015	Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.	PIM2
24131033	10.1517/13543776.2014.848196	2014	Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.	PIM2
24474669	10.1158/1078-0432.CCR-13-2062	2014	Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.	PIM2
25207815	10.1371/journal.pone.0106788	2014	Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies.	PIM2
23135987	10.1002/stem.1277	2013	TEL (ETV6)-AML1 (RUNX1) initiates self-renewing fetal pro-B cells in association with a transcriptional program shared with embryonic stem cells in mice.	PIM2
23360755	10.1186/1756-8722-6-12	2013	Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice.	PIM2
23752607	10.5604/17322693.1052449	2013	Expression of PIM-2 and NF-Œ∫B genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival.	PIM2
24009772	10.1371/journal.pone.0074420	2013	Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts.	PIM2
24900629	10.1021/ml400307j	2013	Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.	PIM2
22722314	10.1038/bjc.2012.272	2012	PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.	PIM2
22808135	10.1371/journal.pone.0040332	2012	Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma.	PIM2
22843119	10.1007/s10059-012-0142-y	2012	MYC and PIM2 co-expression in mouse bone marrow cells readily establishes permanent myeloid cell lines that can induce lethal myeloid sarcoma in vivo.	PIM2
22955922	10.1182/blood-2012-02-412643	2012	Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.	PIM2
21273489	10.1126/science.1198946	2011	Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.	PIM2
21299464	10.3109/10428194.2011.553001	2011	Paired box gene 5 may modulate Proviral Integration of Moloney virus 2 gene and protein expression in mature B-cells.	PIM2
21859846	10.1084/jem.20110846	2011	Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.	PIM2
21937691	10.1182/blood-2011-03-344374	2011	PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.	PIM2
19965690	10.1182/blood-2009-07-233445	2010	A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.	PIM2
20215640	10.1182/blood-2009-03-210070	2010	Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model.	PIM2
17289214	10.1016/j.jaad.2006.12.026	2007	New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas.	PIM2
17395733	10.1196/annals.1392.003	2007	Insertional mutagenesis by replication-deficient retroviral vectors encoding the large T oncogene.	PIM2
17696935	10.1111/j.1478-3231.2007.01542.x	2007	Up-regulation of proproliferative genes and the ligand/receptor pair placental growth factor and vascular endothelial growth factor receptor 1 in hepatitis C cirrhosis.	PIM2
15721354	10.1016/j.virol.2005.01.001	2005	Pim kinases are upregulated during Epstein-Barr virus infection and enhance EBNA2 activity.	PIM2
16373702	10.1158/1535-7163.MCT-05-0146	2005	Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures.	PIM2
15291354	10.1080/10428190310001641251	2004	Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma.	PIM2
15548703	10.1158/0008-5472.CAN-04-2284	2004	Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation.	PIM2
12605034	10.1097/00019606-200303000-00005	2003	Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV.	PIM2
12185366	10.1038/ng950	2002	High-throughput retroviral tagging to identify components of specific signaling pathways in cancer.	PIM2
12200383	10.1182/blood-2002-01-0008	2002	A molecular compendium of genes expressed in multiple myeloma.	PIM2
11313958	10.1038/sj.onc.1204090	2001	Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging.	PIM2
9804974	10.1016/s0167-4781(98)00185-7	1998	The human Pim-2 proto-oncogene and its testicular expression.	PIM2
9294606	10.1038/sj.onc.1201288	1997	Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc.	PIM2
9401000	10.1038/sj.onc.1201670	1997	Pim1 cooperates with E2a-Pbx1 to facilitate the progression of thymic lymphomas in transgenic mice.	PIM2
8786139	10.1006/geno.1996.0301	1996	Genomic structure and precise mapping of a thymic regulatory region on mouse chromosome 17 revealed by a c-myc transgene insertion.	PIM2
7781606	10.1002/j.1460-2075.1995.tb07251.x	1995	Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2.	PIM2
7587098	10.1101/sqb.1994.059.01.049	1994	Mouse model systems to study multistep tumorigenesis.	PIM2
33512466	10.1182/blood.2020010175	2021	OBF1 and Oct factors control the germinal center transcriptional program.	POU2F2
34461601	10.1016/j.ebiom.2021.103559	2021	Loss of synergistic transcriptional feedback loops drives diverse B-cell cancers.	POU2F2
26993806	10.1073/pnas.1600557113	2016	Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2.	POU2F2
27009953	10.1128/JVI.00239-16	2016	HCF1 and OCT2 Cooperate with EBNA1 To Enhance OriP-Dependent Transcription and Episome Maintenance of Latent Epstein-Barr Virus.	POU2F2
25765478	10.1186/s12864-015-1303-0	2015	Genome-wide comparison of PU.1 and Spi-B binding sites in a mouse B lymphoma cell line.	POU2F2
24344258	10.1073/pnas.1321704111	2014	Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A.	POU2F2
24435047	10.1182/blood-2013-05-500264	2014	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	POU2F2
23292937	10.1073/pnas.1205299110	2013	Genetic heterogeneity of diffuse large B-cell lymphoma.	POU2F2
22346751	10.1371/journal.ppat.1002516	2012	The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.	POU2F2
21424034	NA	2011	B-cell transcription factors Pax-5, Oct-2, BOB.1, Bcl-6, and MUM1 are useful markers for the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma.	POU2F2
22158496	10.1700/989.10724	2011	Immunohistochemical expression of Mum-1, Oct-2 and Bcl-6 in systemic anaplastic large cell lymphomas.	POU2F2
20141429	10.3109/10428191003592735	2010	OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia.	POU2F2
18695675	10.1038/onc.2008.286	2008	Functional long-range interactions of the IgH 3' enhancers with the bcl-2 promoter region in t(14;18) lymphoma cells.	POU2F2
16186795	10.1038/sj.onc.1209127	2006	Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression.	POU2F2
15796964	10.1016/j.cancergencyto.2004.09.005	2005	Alterations of loci encoding PU.1, BOB1, and OCT2 transcription regulators do not correlate with their suppressed expression in Hodgkin lymphoma.	POU2F2
14707079	10.4049/jimmunol.172.2.1054	2004	NF-kappa B and Oct-2 synergize to activate the human 3' Igh hs4 enhancer in B cells.	POU2F2
15257313	10.1038/modpathol.3800227	2004	Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma.	POU2F2
12507907	10.1016/s0002-9440(10)63815-1	2003	Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins.	POU2F2
12592383	10.1038/sj.onc.1206270	2003	Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines.	POU2F2
12598320	10.1016/S0002-9440(10)63882-5	2003	Expression of B-lymphocyte-associated transcription factors in human T-cell neoplasms.	POU2F2
12647220	10.1007/s00428-002-0735-5	2003	Expression patterns of transcription factors in progressively transformed germinal centers and Hodgkin lymphoma.	POU2F2
12848851	10.1046/j.0818-9641.2003.01172.x	2003	Knockout B lymphoma cell lines as biochemical tools to explore multiple signalling pathways.	POU2F2
14608905	10.1309/YCH8-DWUF-FQBK-GPVB	2003	The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma.	POU2F2
14662861	10.4049/jimmunol.171.12.6589	2003	Critical role for the Oct-2/OCA-B partnership in Ig-secreting cells.	POU2F2
11929801	10.1182/blood.v99.8.3060	2002	Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease.	POU2F2
11154228	10.1182/blood.v97.2.496	2001	Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription.	POU2F2
11280769	NA	2001	Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells.	POU2F2
11696441	10.1016/S0002-9440(10)63027-1	2001	The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease.	POU2F2
10727398	NA	2000	Phosphorylation of Oct-2 at sites located in the POU domain induces differential down-regulation of Oct-2 DNA-binding ability.	POU2F2
9925930	10.1159/000015128	1998	Transcription factor effects on chromosome constitution of cell hybrids.	POU2F2
8537118	10.1007/BF00186600	1996	The function of the octamer-binding site in the DRA promoter.	POU2F2
8639794	NA	1996	High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells.	POU2F2
7486513	10.1111/j.1749-6632.1995.tb55817.x	1995	Role of Oct-2 in immunoglobulin gene silencing.	POU2F2
7868225	10.1128/iai.63.3.1040-1046.1995	1995	Diphosphoryl lipid A from Rhodobacter sphaeroides transiently activates NF-kappa B but inhibits lipopolysaccharide induction of kappa light chain and Oct-2 in the B-cell lymphoma line 70Z/3.	POU2F2
7600290	10.1016/1074-7613(94)90034-5	1994	Constitutively expressed Oct-2 prevents immunoglobulin gene silencing in myeloma x T cell hybrids.	POU2F2
7813434	10.1002/j.1460-2075.1994.tb06942.x	1994	Transformation by homeobox genes can be mediated by selective transcriptional repression.	POU2F2
8039828	10.1007/BF00167080	1994	Two different IFN-gamma nonresponsive variants derived from the B-cell lymphoma 70Z/3.	POU2F2
8121549	NA	1994	Primary brain tumors differ in their expression of octamer deoxyribonucleic acid-binding transcription factors from long-term cultured glioma cell lines.	POU2F2
1937571	NA	1991	Differentiation of human B-cell malignant lymphomas is independent of the octamer lymphoid specific binding factor (Oct-2).	POU2F2
1689272	10.1007/BF00661216	1990	1.3E2, a variant of the B lymphoma 70Z/3, defective in activation of NF-kappa B and OTF-2.	POU2F2
21670604	10.4161/cc.10.12.15798	2011	Spinophilin loss contributes to tumorigenesis in vivo.	PPP1R9B
20360004	10.1074/jbc.M109.051490	2010	Scaffold proteins IRSp53 and spinophilin regulate localized Rac activation by T-lymphocyte invasion and metastasis protein 1 (TIAM1).	PPP1R9B
12531897	10.1074/jbc.M207876200	2003	Regulation of p70 S6 kinase by complex formation between the Rac guanine nucleotide exchange factor (Rac-GEF) Tiam1 and the scaffold spinophilin.	PPP1R9B
34382383	10.3324/haematol.2020.263251	2022	Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma.	PRDM1
34844236	10.1159/000520070	2022	Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.	PRDM1
34980830	10.1097/PAS.0000000000001859	2022	Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing.	PRDM1
35429891	10.1016/j.prp.2022.153860	2022	The genetic deletion and protein expression of PRDM1 and its clinical implications in diffuse large B cell lymphoma: A retrospective cohort study in China.	PRDM1
35444638	10.3389/fimmu.2022.871096	2022	Labial Gland Mesenchymal Stem Cell Derived Exosomes-Mediated miRNA-125b Attenuates Experimental Sjogren's Syndrome by Targeting PRDM1 and Suppressing Plasma Cells.	PRDM1
35697790	10.1038/s41375-022-01623-z	2022	Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma.	PRDM1
35759728	10.1182/blood.2022015926	2022	Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma.	PRDM1
35794478	10.1038/s41586-022-04906-8	2022	Super-enhancer hypermutation alters oncogene expression in B cell lymphoma.	PRDM1
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	PRDM1
32732362	10.3324/haematol.2020.254276	2021	Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic roles of PRDM1.	PRDM1
33199235	10.1016/j.intimp.2020.107137	2021	Agrimophol suppresses RANKL-mediated osteoclastogenesis through Blimp1-Bcl6 axis and prevents inflammatory bone loss in mice.	PRDM1
33426772	10.1111/cas.14806	2021	Genetic profile of adult T-cell leukemia/lymphoma in Okinawa: Association with prognosis, ethnicity, and HTLV-1 strains.	PRDM1
33569430	10.21037/atm-20-7574	2021	Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity.	PRDM1
33629212	10.1007/s12032-021-01470-5	2021	Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.	PRDM1
34236648	10.1007/978-1-0716-1669-7_20	2021	Generation and Surgical Analysis of Genetic Mouse Models to Study NF-Œ∫B-Driven Pathogenesis of Diffuse Large B Cell Lymphoma.	PRDM1
34484219	10.3389/fimmu.2021.716240	2021	Coupled Antigen and BLIMP1 Asymmetric Division With a Large Segregation Between Daughter Cells Recapitulates the Temporal Transition From Memory B Cells to Plasma Cells and a DZ-to-LZ Ratio in the Germinal Center.	PRDM1
35008340	10.3390/cancers14010176	2021	Recent Advances in the Genetic of MALT Lymphomas.	PRDM1
31725418	10.1097/PAP.0000000000000253	2020	Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches.	PRDM1
31980558	10.1136/jclinpath-2019-206282	2020	Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenstr√∂m macroglobulinaemia and description of its mutational profiles by targeted NGS.	PRDM1
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	PRDM1
32127923	10.1177/1758835919900856	2020	Epigenetic aberrations in natural killer/T-cell lymphoma: diagnostic, prognostic and therapeutic implications.	PRDM1
32533097	10.1038/s41388-020-1347-8	2020	The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma.	PRDM1
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	PRDM1
32679859	10.3390/cancers12071912	2020	Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type.	PRDM1
33017467	10.1182/bloodadvances.2020002049	2020	The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1.	PRDM1
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	PRDM1
33463110	10.18502/ijaai.v19i4.4118	2020	Increased Expression of B Lymphocyte Induced Maturation Protein 1 (BLIMP1) in Patients with Common Variable Immunodeficiency (CVID).	PRDM1
33613551	10.3389/fimmu.2020.620716	2020	Multiscale Modeling of Germinal Center Recapitulates the Temporal Transition From Memory B Cells to Plasma Cells Differentiation as Regulated by Antigen Affinity-Based Tfh Cell Help.	PRDM1
30348636	10.1158/1078-0432.CCR-18-1153	2019	Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma.	PRDM1
30894186	10.1186/s12920-018-0437-8	2019	Analyzing the 3D chromatin organization coordinating with gene expression regulation in B-cell lymphoma.	PRDM1
30935402	10.1186/s13045-019-0716-7	2019	Molecular pathogenic pathways in extranodal NK/T cell lymphoma.	PRDM1
31002364	10.3892/or.2019.7112	2019	JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T‚Äëcell lymphoma, nasal type.	PRDM1
31024321	10.3389/fphar.2019.00367	2019	Inhibitory Effect of KP-A038 on Osteoclastogenesis and Inflammatory Bone Loss Is Associated With Downregulation of Blimp1.	PRDM1
31378966	10.1002/ajh.25600	2019	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.	PRDM1
31607324	10.19746/j.cnki.issn.1009-2137.2019.05.042	2019	[Deubiquitinase MYSM1 Regulates Differentiation of Human B Cells to Plasma Cells].	PRDM1
31806993	10.2147/OTT.S227122	2019	Genomic Alterations In Primary Cardiac Diffuse Large B Cell Lymphoma: A Case Report And Literature Review.	PRDM1
28573896	10.1080/10428194.2017.1330470	2018	Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia.	PRDM1
29325247	10.3760/cma.j.issn.0529-5807.2018.01.006	2018	[Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].	PRDM1
29463002	10.3390/ijms19020601	2018	Inhibitory Effect of Purpurogallin on Osteoclast Differentiation in Vitro through the Downregulation of c-Fos and NFATc1.	PRDM1
29781221	10.1002/art.40556	2018	Aberrant Expansion and Function of Follicular Helper T Cell Subsets in IgG4-Related Disease.	PRDM1
29891112	10.1016/j.critrevonc.2018.05.010	2018	Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.	PRDM1
29966370	10.3390/ijms19071931	2018	The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation.	PRDM1
30274972	10.1158/2159-8290.CD-18-0657	2018	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.	PRDM1
30612403	10.3760/cma.j.issn.0253-2727.2018.12.008	2018	[PRDM1 expression and its relationship with PI3K/AKT pathway activation in extranodal NK/T cell lymphoma-nasal type].	PRDM1
27568520	10.1038/leu.2016.243	2017	Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.	PRDM1
27687004	10.1038/modpathol.2016.162	2017	Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1.	PRDM1
27704586	10.1002/hon.2362	2017	Hypermethylation of PRDM1/Blimp-1 promoter in extranodal NK/T-cell lymphoma, nasal type: an evidence of predominant role in its downregulation.	PRDM1
27775850	10.1111/his.13106	2017	Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).	PRDM1
27924626	10.14670/HH-11-852	2017	Expression of the activation markers Blimp1, Foxp1 and pStat3 in extranodal diffuse large B-cell lymphomas.	PRDM1
27941793	10.1038/nm.4252	2017	Fasting selectively blocks development of acute lymphoblastic leukemia via leptin-receptor upregulation.	PRDM1
28378641	10.1177/1010428317695929	2017	Downregulation of PRDM1 promotes cellular invasion and lung cancer metastasis.	PRDM1
28412245	10.1016/j.yexcr.2017.04.014	2017	CXCR5<sup>+</sup>CD8<sup>+</sup> T cells infiltrate the colorectal tumors and nearby lymph nodes, and are associated with enhanced IgG response in B cells.	PRDM1
28468592	10.1177/1010428317701648	2017	Whole transcriptome analysis reveals dysregulated oncogenic lncRNAs in natural killer/T-cell lymphoma and establishes MIR155HG as a target of PRDM1.	PRDM1
28474779	10.1002/ajh.24778	2017	A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation.	PRDM1
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	PRDM1
28494239	10.1016/j.chom.2017.04.005	2017	CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors.	PRDM1
28554762	10.1016/j.prp.2017.04.003	2017	Effect of plasma-activated medium on the decrease of tumorigenic population in lymphoma.	PRDM1
28835384	10.1158/1535-7163.MCT-16-0840	2017	EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL.	PRDM1
28842558	10.1038/s41467-017-00476-w	2017	HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells.	PRDM1
28858629	10.1016/j.molimm.2017.08.016	2017	Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival.	PRDM1
29262531	10.18632/oncotarget.21986	2017	Mutational profile of primary breast diffuse large B-cell lymphoma.	PRDM1
31966717	NA	2017	PRDM1 expression levels in marginal zone lymphoma and lymphoplasmacytic lymphoma.	PRDM1
26111727	10.1111/nan.12259	2016	Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.	PRDM1
26530011	10.1038/leu.2015.285	2016	EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis.	PRDM1
26625717	10.1016/j.ejpb.2015.11.007	2016	PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity.	PRDM1
26727971	10.1002/pbc.25854	2016	Successful Treatment of Genetically Profiled Pediatric Extranodal NK/T-Cell Lymphoma Targeting Oncogenic STAT3 Mutation.	PRDM1
27098601	10.1038/gene.2016.18	2016	Downregulation of ZBTB24 hampers the G0/1- to S-phase cell-cycle transition via upregulating the expression of IRF-4 in human B cells.	PRDM1
27363279	NA	2016	[Increased expressions of Blimp-1 and Bcl-6 in the deciduas of patients with unexplained recurrent spontaneous abortion].	PRDM1
27436361	10.1126/scisignal.aad8953	2016	ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.	PRDM1
27539853	10.1074/jbc.M116.738617	2016	Kruppel-like Factor 6 Promotes Macrophage-mediated Inflammation by Suppressing B Cell Leukemia/Lymphoma 6 Expression.	PRDM1
27764808	10.18632/oncotarget.12680	2016	The feedback loop of LITAF and BCL6 is involved in regulating apoptosis in B cell non-Hodgkin's-lymphoma.	PRDM1
28056297	10.3760/cma.j.issn.0529-5807.2016.12.004	2016	[Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].	PRDM1
25115512	10.3109/10428194.2014.953155	2015	PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas.	PRDM1
25487076	10.3109/10428194.2014.994181	2015	Methylation contributes to imbalance of PRDM1Œ±/PRDM1bŒ≤ expression in diffuse large B-cell lymphoma.	PRDM1
25533804	10.1038/leu.2014.347	2015	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.	PRDM1
25559471	10.1111/bjh.13265	2015	Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.	PRDM1
25991819	10.1158/1078-0432.CCR-14-2116	2015	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.	PRDM1
26054109	NA	2015	Decreased Bcl-6 and increased Blimp-1 in the peritoneal cavity of patients with endometriosis.	PRDM1
26206802	10.3324/haematol.2015.126854	2015	Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma.	PRDM1
26221594	10.1155/2015/435423	2015	The Genetic Deletion of 6q21 and PRDM1 and Clinical Implications in Extranodal NK/T Cell Lymphoma, Nasal Type.	PRDM1
26289642	10.1182/blood-2015-02-626176	2015	The forkhead transcription factor FOXP1 represses human plasma cell differentiation.	PRDM1
26431332	10.1371/journal.ppat.1005195	2015	Differentiation-Dependent KLF4 Expression Promotes Lytic Epstein-Barr Virus Infection in Epithelial Cells.	PRDM1
26460037	10.1073/pnas.1507312112	2015	Bcl6 middle domain repressor function is required for T follicular helper cell differentiation and utilizes the corepressor MTA3.	PRDM1
24030746	10.1038/modpathol.2013.156	2014	Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma.	PRDM1
24240734	10.1007/s00401-013-1202-x	2014	Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.	PRDM1
24306881	10.1007/s12253-013-9724-z	2014	Hodgkin disease therapy induced second malignancy susceptibility 6q21 functional variants in roma and hungarian population samples.	PRDM1
24376268	10.4049/jimmunol.1300420	2014	Premature terminal differentiation protects from deregulated lymphocyte activation by ITK-Syk.	PRDM1
24438193	10.1186/1756-9966-33-7	2014	The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK/T-cell lymphoma, nasal type.	PRDM1
24487434	10.1038/nm.3442	2014	Fas ligand-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas.	PRDM1
24821775	10.1073/pnas.1400958111	2014	Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.	PRDM1
25203537	10.1016/j.ajpath.2014.07.011	2014	HACE1, a potential tumor suppressor gene on 6q21, is not involved in extranodal natural killer/T-cell lymphoma pathophysiology.	PRDM1
25205514	10.1158/1055-9965.EPI-14-0683	2014	Genetic associations in classical hodgkin lymphoma: a systematic review and insights into susceptibility mechanisms.	PRDM1
25232062	10.1182/blood-2014-07-590570	2014	FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma.	PRDM1
25382611	10.1038/bcj.2014.75	2014	Hypermethylation of the tumor suppressor gene PRDM1/Blimp-1 supports a pathogenetic role in EBV-positive Burkitt lymphoma.	PRDM1
23269792	10.1128/JVI.03003-12	2013	Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature.	PRDM1
23355206	10.1309/AJCP0YGM8BLFYHJY	2013	Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia.	PRDM1
23599149	10.1038/modpathol.2013.73	2013	ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements.	PRDM1
23768641	10.1016/j.beha.2013.04.006	2013	Molecular underpinning of extranodal NK/T-cell lymphoma.	PRDM1
23980171	10.1073/pnas.1309378110	2013	The transcription factor Interferon Regulatory Factor 4 is required for the generation of protective effector CD8+ T cells.	PRDM1
24004669	10.1182/blood-2013-04-497933	2013	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma.	PRDM1
24009228	10.1182/blood-2013-05-498329	2013	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.	PRDM1
24200695	10.1172/JCI70626	2013	Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis.	PRDM1
24319234	10.1182/asheducation-2013.1.575	2013	Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification.	PRDM1
24370060	10.7534/j.issn.1009-2137.2013.06.048	2013	[Research progress on B lymphocyte-induced maturation protein 1 and its relationship with the development of lymphoma].	PRDM1
21812534	10.3109/10428194.2011.608447	2012	Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge.	PRDM1
21894172	10.1038/icb.2011.73	2012	Immunoglobulin light chain, Blimp-1 and cytochrome P4501B1 peptides as potential vaccines for AL amyloidosis.	PRDM1
22020966	10.1002/ijc.26503	2012	CD99 triggers upregulation of miR-9-modulated PRDM1/BLIMP1 in Hodgkin/Reed-Sternberg cells and induces redifferentiation.	PRDM1
22167754	10.1182/blood-2011-07-363820	2012	Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.	PRDM1
22318729	10.1074/jbc.M111.324046	2012	STAT5 protein negatively regulates T follicular helper (Tfh) cell generation and function.	PRDM1
22321048	10.1111/j.1365-2559.2011.04160.x	2012	Bcl-2 and BLIMP-1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCBL) while other markers for nodal DLBCL are not useful.	PRDM1
22491065	10.1038/icb.2012.17	2012	IL-6 triggers IL-21 production by human CD4+ T cells to drive STAT3-dependent plasma cell differentiation in B cells.	PRDM1
22580854	10.5507/bp.2012.003	2012	BLIMP1Œ±, the master regulator of plasma cell differentiation is a tumor supressor gene in B cell lymphomas.	PRDM1
22585398	10.1002/eji.201142203	2012	miR-9 enhances IL-2 production in activated human CD4(+) T cells by repressing Blimp-1.	PRDM1
22593617	10.4049/jimmunol.1103039	2012	B cell receptor-ERK1/2 signal cancels PAX5-dependent repression of BLIMP1 through PAX5 phosphorylation: a mechanism of antigen-triggering plasma cell differentiation.	PRDM1
22711707	10.1158/1078-0432.CCR-11-3169	2012	Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell Lymphoma.	PRDM1
22780928	10.3760/cma.j.issn.0253-3766.2012.02.007	2012	[Analysis of the immunohistochemical subtypes and prognosis of primary diffuse large B cell lymphoma of the central nervous system].	PRDM1
22922206	10.1016/j.exphem.2012.08.005	2012	Lineage-specific growth inhibition of NK cell lines by FOXO3 in association with Akt activation status.	PRDM1
23027925	10.1084/jem.20112744	2012	Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production.	PRDM1
23089009	10.1016/j.icrp.2012.06.030	2012	Genetic predisposition to radiation-related cancer and potential implications for risk assessment.	PRDM1
20966935	10.1038/leu.2010.230	2011	Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas.	PRDM1
21083654	10.1111/j.1365-2141.2010.08420.x	2011	The role of BCL6 in lymphomas and routes to therapy.	PRDM1
21131593	10.1182/blood-2010-08-303123	2011	A role for Blimp1 in the transcriptional network controlling natural killer cell maturation.	PRDM1
21325069	10.1158/1078-0432.CCR-10-2945	2011	Identification of loss of p16 expression and upregulation of MDR-1 as genetic events resulting from two novel chromosomal translocations found in a plasmablastic lymphoma of the uterus.	PRDM1
21411757	10.1182/blood-2010-09-307710	2011	Down-regulation of BLIMP1Œ± by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas.	PRDM1
21487109	10.1182/blood-2011-01-330795	2011	Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults.	PRDM1
21616012	NA	2011	[Signaling pathways in pathogenesis of diffuse large B-cell lymphoma].	PRDM1
21690554	10.1182/blood-2011-04-346890	2011	Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms by genomic and functional analyses.	PRDM1
21722313	10.1111/j.1742-4658.2011.08227.x	2011	PRDM1/Blimp1 downregulates expression of germinal center genes LMO2 and HGAL.	PRDM1
21785431	10.1038/nm.2407	2011	Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma.	PRDM1
21792874	10.1002/eji.201141891	2011	Bcl6: where too much complexity is barely enough.	PRDM1
21818085	10.1038/nm.2428	2011	A step toward slaying the hydra of second cancers.	PRDM1
21940827	10.1182/blood-2011-07-364364	2011	Fox and Blimp in NK-cell lymphoma.	PRDM1
22143801	10.1073/pnas.1115128108	2011	PRDM1 is a tumor suppressor gene in natural killer cell malignancies.	PRDM1
19530237	10.1002/ijc.24655	2010	B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression.	PRDM1
20014148	10.1002/hon.932	2010	Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas.	PRDM1
20047096	10.1007/s12185-009-0472-5	2010	Blimp-1 is a tumor suppressor gene in lymphoid malignancies.	PRDM1
20123757	10.1093/toxsci/kfq035	2010	A bistable switch underlying B-cell differentiation and its disruption by the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin.	PRDM1
20368579	10.1084/jem.20091957	2010	The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis.	PRDM1
20418245	10.3324/haematol.2009.016113	2010	Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype.	PRDM1
20530581	10.1158/1541-7786.MCR-10-0131	2010	PRDM1 is required for mantle cell lymphoma response to bortezomib.	PRDM1
20651244	10.2353/ajpath.2010.091291	2010	Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7.	PRDM1
20800019	10.5732/cjc.010.10082	2010	Blimp-1 protein and Hans classification on prognosis of diffuse large B-cell lymphoma and their interrelation.	PRDM1
20859709	10.1007/s12185-010-0689-3	2010	Loss of promoter methylation contributes to the expression of functionally impaired PRDM1Œ≤ isoform in diffuse large B-cell lymphoma.	PRDM1
21156281	10.1016/j.ccr.2010.10.030	2010	BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma.	PRDM1
21156282	10.1016/j.ccr.2010.11.024	2010	Constitutive canonical NF-Œ∫B activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma.	PRDM1
19018532	10.1007/s00262-008-0625-z	2009	Peroxisome proliferator-activated receptor gamma overexpression and knockdown: impact on human B cell lymphoma proliferation and survival.	PRDM1
19047678	10.1182/blood-2008-10-184077	2009	Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas.	PRDM1
19194464	10.1038/leu.2009.3	2009	Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies.	PRDM1
19202128	10.1182/blood-2008-09-178186	2009	Patterns of microRNA expression characterize stages of human B-cell differentiation.	PRDM1
19237549	10.1093/toxsci/kfp028	2009	Involvement of Blimp-1 and AP-1 dysregulation in the 2,3,7,8-Tetrachlorodibenzo-p-dioxin-mediated suppression of the IgM response by B cells.	PRDM1
19329782	10.1182/blood-2008-08-172866	2009	Blimp1 is limiting for transformation in a mouse plasmacytoma model.	PRDM1
19380033	10.1016/j.cancergencyto.2009.01.003	2009	A novel missense mutation of the XBP1 gene in diffuse large B-cell lymphoma.	PRDM1
19494841	10.1038/leu.2009.120	2009	Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma.	PRDM1
19717648	10.1182/blood-2009-01-201111	2009	C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.	PRDM1
19752343	10.1200/JCO.2008.20.5450	2009	Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034.	PRDM1
19828640	10.4049/jimmunol.0901120	2009	PU.1 regulates positive regulatory domain I-binding factor 1/Blimp-1 transcription in lymphoma cells.	PRDM1
18235046	10.1182/blood-2007-08-108654	2008	PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.	PRDM1
18256039	10.1093/intimm/dxn005	2008	Regulation of the plasma cell transcription factor Blimp-1 gene by Bach2 and Bcl6.	PRDM1
18263789	10.1182/blood-2007-09-111385	2008	Significance of PRDM1beta expression as a prognostic marker in diffuse large B-cell lymphomas.	PRDM1
18297524	10.1080/10428190701817282	2008	Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia.	PRDM1
18354204	10.4049/jimmunol.180.7.4805	2008	STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation.	PRDM1
18400362	10.1016/j.exphem.2008.02.014	2008	Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs.	PRDM1
18583325	10.2353/ajpath.2008.080009	2008	MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas.	PRDM1
18596541	10.1097/NEN.0b013e31817dd02d	2008	Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma.	PRDM1
18845144	10.1016/j.yexcr.2008.09.008	2008	Blimp-1Deltaexon7: a naturally occurring Blimp-1 deletion mutant with auto-regulatory potential.	PRDM1
18983461	10.1111/j.1365-2559.2008.03144.x	2008	Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-infected B cells in HIV+ multicentric Castleman disease (MCD).	PRDM1
19021048	10.1080/10428190802444176	2008	Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies.	PRDM1
16954503	10.1182/blood-2006-04-014977	2007	Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival.	PRDM1
17213024	10.1016/j.cancergencyto.2006.08.005	2007	Novel BLIMP1/PRDM1 gene mutations in B-cell lymphoma.	PRDM1
17291741	10.1016/j.coi.2007.01.003	2007	Terminal differentiation of lymphocytes depends on Blimp-1.	PRDM1
17379744	10.1182/blood-2006-09-049189	2007	Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma.	PRDM1
17545502	10.1182/blood-2007-01-069575	2007	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.	PRDM1
17573669	10.1002/path.2199	2007	The BCL6-associated transcriptional co-repressor, MTA3, is selectively expressed by germinal centre B cells and lymphomas of putative germinal centre derivation.	PRDM1
17651861	10.1016/j.ejcb.2007.05.006	2007	IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells.	PRDM1
16331266	10.1038/sj.onc.1209252	2006	A peptide aptamer to antagonize BCL-6 function.	PRDM1
16424392	10.1182/blood-2005-09-3778	2006	Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas.	PRDM1
16492805	10.1084/jem.20052204	2006	Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.	PRDM1
16585013	NA	2006	PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma.	PRDM1
15749846	10.4049/jimmunol.174.6.3173	2005	Spontaneously Ig-secreting B-1 cells violate the accepted paradigm for expression of differentiation-associated transcription factors.	PRDM1
15772984	10.1002/path.1752	2005	PRDM1/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage.	PRDM1
15100284	10.4049/jimmunol.172.9.5427	2004	Modular nature of Blimp-1 in the regulation of gene expression during B cell maturation.	PRDM1
15231650	10.1158/0008-5472.CAN-03-3885	2004	High-throughput retroviral tagging for identification of genes involved in initiation and progression of mouse splenic marginal zone lymphomas.	PRDM1
15496906	10.1038/431919a	2004	Cancer: negative feedback for B cells.	PRDM1
12511417	10.1182/blood-2002-08-2424	2003	Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas.	PRDM1
12695118	10.1016/s0161-5890(03)00029-4	2003	Activation of terminal B cell differentiation by inhibition of histone deacetylation.	PRDM1
12165517	10.4049/jimmunol.169.4.1922	2002	Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene.	PRDM1
11067898	10.4049/jimmunol.165.10.5462	2000	Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo.	PRDM1
10508273	10.1002/(SICI)1521-4141(199909)29:09&lt;2988::AID-IMMU2988&gt;3.0.CO;2-T	1999	Reversal of Blimp-1-mediated apoptosis by A1, a member of the Bcl-2 family.	PRDM1
9110979	10.1126/science.276.5312.596	1997	Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation.	PRDM1
8921366	10.1006/geno.1996.0516	1996	The B-lymphocyte maturation promoting transcription factor BLIMP1/PRDI-BF1 maps to D6S447 on human chromosome 6q21-q22.1 and the syntenic region of mouse chromosome 10.	PRDM1
8168136	10.1016/0092-8674(94)90321-2	1994	Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells.	PRDM1
35806064	10.3390/ijms23137060	Biochemical, Enzymatic, and Computational Characterization of Recurrent Somatic Mutations of the Human Protein Tyrosine Phosphatase PTP1B in Primary Mediastinal B Cell Lymphoma.	PTPN1	NA
34657149	10.1182/blood.2020008136	Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.	PTPN1	NA
34606417	10.1080/21655979.2021.1988376	Protein tyrosine phosphatase 1B(PTP1B) promotes melanoma cells progression through Src activation.	PTPN1	NA
33382412	10.1093/carcin/bgaa144	The PTP1B mutant PTP1B‚àÜ2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma.	PTPN1	NA
32079702	10.3324/haematol.2019.237719	Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study.	PTPN1	NA
31774495	10.1182/blood.2019001904	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.	PTPN1	NA
31622281	10.1172/jci.insight.131434	A unique mutator phenotype reveals complementary oncogenic lesions leading to acute leukemia.	PTPN1	NA
31331250	10.2217/pme-2018-0068	Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma.	PTPN1	NA
29650799	10.1182/blood-2017-11-814913	Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.	PTPN1	NA
28245838	10.1186/s13045-017-0431-1	Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia.	PTPN1	NA
28082443	10.1182/blood-2016-06-720516	A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.	PTPN1	NA
27268263	10.1182/blood-2015-11-683003	Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.	PTPN1	NA
26817397	10.1016/j.cyto.2015.12.025	TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.	PTPN1	NA
26599546	10.1371/journal.pone.0139663	Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines.	PTPN1	NA
25617799	10.1016/j.canlet.2015.01.020	PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.	PTPN1	NA
25057888	10.1042/BJ20140712	The molecular regulation of Janus kinase (JAK) activation.	PTPN1	NA
24706663	10.1158/2159-8290.CD-RW2014-048	PTPN1 is recurrently mutated in lymphoid cancers.	PTPN1	NA
24531327	10.1038/ng.2900	Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.	PTPN1	NA
23274914	10.1007/s11418-012-0735-y	A polybromodiphenyl ether from an Indonesian marine sponge Lamellodysidea herbacea and its chemical derivatives inhibit protein tyrosine phosphatase 1B, an important target for diabetes treatment.	PTPN1	NA
22890838	10.1002/ijc.27774	High-resolution genomic profiling reveals clonal evolution and competition in gastrointestinal marginal zone B-cell lymphoma and its large cell variant.	PTPN1	NA
21144060	10.1186/1471-2121-11-99	3D nuclear organization of telomeres in the Hodgkin cell lines U-HO1 and U-HO1-PTPN1: PTPN1 expression prevents the formation of very short telomeres including """"t-stumps"""".	PTPN1	NA
18716132	10.1182/blood-2008-03-148726	PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling.	PTPN1	NA
16267035	10.1158/0008-5472.CAN-05-1353	Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development.	PTPN1	NA
15591113	10.1182/blood-2004-10-3820	Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.	PTPN1	NA
11832424	10.1152/ajprenal.00184.2001	Altered regulation of SHP-2 and PTP 1B tyrosine phosphatases in cystic kidneys from bcl-2 -/- mice.	PTPN1	NA
28082443	10.1182/blood-2016-06-720516	A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.	PTPN1	NA
25617799	10.1016/j.canlet.2015.01.020	PTP1B promotes cell proliferation and metastasis through activating src and ERK1/2 in non-small cell lung cancer.	PTPN1	NA
24706663	10.1158/2159-8290.CD-RW2014-048	PTPN1 is recurrently mutated in lymphoid cancers.	PTPN1	NA
24531327	10.1038/ng.2900	Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.	PTPN1	NA
23499906	10.1016/j.cellsig.2013.02.020	Control of ALK (wild type and mutated forms) phosphorylation: specific role of the phosphatase PTP1B.	PTPN1	NA
26817397	10.1016/j.cyto.2015.12.025	TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.	PTPN1	NA
18716132	10.1182/blood-2008-03-148726	PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling.	PTPN1	NA
18636124	10.1371/journal.pone.0002816	Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.	PTPN1	NA
35982972	10.3389/fonc.2022.835965	Retinoblastoma¬†in¬†Adults: Clinical Features, Gene Mutations and Treatment Outcomes: <i>A Study of Six Cases</i>.	RB1	NA
35896160	10.1111/1759-7714.14592	Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis.	RB1	NA
35609408	10.1016/j.lungcan.2022.05.002	Neuroendocrine transformation from EGFR/ALK-wild type or TKI-na√Øve non-small cell lung cancer: An under-recognized phenomenon.	RB1	NA
34729013	10.2147/OTT.S323700	<i>ALK</i> Rearrangement in Small-Cell Lung Cancer and Durable Response to Alectinib: A Case Report.	RB1	NA
34657128	10.1038/s41375-021-01448-2	Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.	RB1	NA
34551361	10.1016/j.jep.2021.114656	Chinese patent medicine Aidi injection for cancer care: An overview of systematic reviews and meta-analyses.	RB1	NA
34440292	10.3390/genes12081118	T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness.	RB1	NA
34371436	10.1016/j.leukres.2021.106683	Proposal and clinical application of molecular genetic risk scoring system, """"MRplus"""", for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.	RB1	NA
34340673	10.1186/s12885-021-08635-5	Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia.	RB1	NA
34232939	10.1097/CAD.0000000000001094	Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.	RB1	NA
34226971	10.1007/s00428-021-03148-9	Transdifferentiation of mantle cell lymphoma into sarcoma with limited neuromuscular differentiation after conventional chemotherapy.	RB1	NA
33563892	10.1038/s41392-020-00412-3	Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.	RB1	NA
33541390	10.1186/s13039-020-00526-x	Bi-allelic amplification of ATM gene in blastoid variant of mantle cell lymphoma: a novel mechanism of inactivation due to chromoanagenesis?	RB1	NA
33369444	10.31557/APJCP.2020.21.12.3493	Frequency and Correlation of Common Genes Copy Number Alterations in Childhood Acute Lymphoblastic Leukemia with Prognosis.	RB1	NA
33324635	10.3389/fcell.2020.577784	Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells <i>via</i> Quantitative Phosphoproteomics.	RB1	NA
33020271	10.1073/pnas.2007946117	Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A.	RB1	NA
32908255	10.1038/s41379-020-00669-7	The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.	RB1	NA
32661308	10.1038/s41598-020-68311-9	MLPA and DNA index improve the molecular diagnosis of childhood B-cell acute lymphoblastic leukemia.	RB1	NA
32592278	10.1002/gcc.22882	Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocol.	RB1	NA
32345961	10.1038/s41408-020-0310-9	DNA methylation and copy number variation profiling of T-cell lymphoblastic leukemia and lymphoma.	RB1	NA
32245383	10.1186/s12920-020-0709-y	Comprehensive chromosomal aberrations in a case of a patient with TCF3-HLF-positive BCP-ALL.	RB1	NA
31992242	10.1186/s12887-020-1923-7	Survival and ocular preservation in a long-term cohort of Japanese patients with retinoblastoma.	RB1	NA
31931161	10.1016/j.jep.2019.112536	Baoyuan decoction ameliorates apoptosis via AT1-CARP signaling pathway in H9C2 cells and heart failure post-acute myocardial infarction rats.	RB1	NA
31885322	10.1080/15384101.2019.1706903	The double dealing of cyclin D1.	RB1	NA
31411343	10.1002/path.5333	Genomic characterisation of breast fibroepithelial lesions in an international cohort.	RB1	NA
31228652	10.1016/j.leukres.2019.05.009	Prognostic gene alterations and clonal changes in childhood B-ALL.	RB1	NA
31202078	10.1016/j.leukres.2019.05.013	Microarray testing as an efficient tool to redefine hyperdiploid paediatric B-cell precursor acute lymphoblastic leukaemia patients.	RB1	NA
31112375	10.1111/ijlh.13052	Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay.	RB1	NA
30988756	10.3892/etm.2019.7330	Ginsenoside Rb1 protects cardiomyocytes from oxygen-glucose deprivation injuries by targeting microRNA-21.	RB1	NA
30938769	10.1093/labmed/lmz008	BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use.	RB1	NA
30926971	10.1038/s41588-019-0375-1	Genomic subtyping and therapeutic targeting of acute erythroleukemia.	RB1	NA
30874617	10.1038/s41598-019-41078-4	Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia.	RB1	NA
30563911	10.1101/gr.241141.118	Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.	RB1	NA
30538135	10.1182/blood-2018-07-862151	<i>CCND2</i> and <i>CCND3</i> hijack immunoglobulin light-chain enhancers in cyclin D1<sup>-</sup> mantle cell lymphoma.	RB1	NA
30518749	10.1038/s41419-018-1212-7	Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in S√©zary syndrome.	RB1	NA
30203896	10.1002/gcc.22664	Improved cytogenetic characterization and risk stratification of pediatric acute lymphoblastic leukemia using single nucleotide polymorphism array analysis: A single center experience of 296 cases.	RB1	NA
30154667	10.2147/OTT.S172124	<i>ALK</i>-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literature.	RB1	NA
29636869	NA	Ginsenoside Rb1 inhibit apoptosis in rat model of Alzheimer's disease induced by AŒ≤<sub>1-40</sub>.	RB1	NA
29575541	10.1111/ijlh.12805	Simultaneous detection of ABL1 mutation and IKZF1 deletion in Philadelphia chromosome-positive acute lymphoblastic leukemia using a customized target enrichment system panel.	RB1	NA
29498923	10.1200/JCO.2017.74.3617	IKZF1<sup>plus</sup> Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.	RB1	NA
29407587	10.1016/j.leukres.2018.01.012	High frequency of intermediate and poor risk copy number abnormalities in pediatric cohort of B-ALL correlate with high MRD post induction.	RB1	NA
29270859	10.1007/s12105-017-0876-0	Sinonasal Leiomyosarcoma: Clinicopathological Analysis of Nine Cases with Emphasis on Common Association with Other Malignancies and Late Distant Metastasis.	RB1	NA
28886309	10.14715/cmb/2017.63.8.4	The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.	RB1	NA
28674118	10.1158/1078-0432.CCR-17-0652	Retinoblastoma and Neuroblastoma Predisposition and Surveillance.	RB1	NA
28631637	10.4103/IJPM.IJPM_466_16	An integrated genomic profile that includes copy number alterations is highly predictive of minimal residual disease status in childhood precursor B-lineage acute lymphoblastic leukemia.	RB1	NA
28439887	10.1111/bjh.14721	Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts.	RB1	NA
28418845	10.18632/oncotarget.16216	Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.	RB1	NA
28401483	10.1007/s12032-017-0940-3	Molecular profiling of gene copy number abnormalities in key regulatory genes in high-risk B-lineage acute lymphoblastic leukemia: frequency and their association with clinicopathological findings in Indian patients.	RB1	NA
28285684	10.1016/j.lungcan.2017.02.005	Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?	RB1	NA
28281554	10.1038/modpathol.2017.3	Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.	RB1	NA
28202519	10.1158/0008-5472.CAN-16-2571	Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia.	RB1	NA
28126143	10.1016/j.medcli.2016.07.035	[Copy number alterations in adult patients with mature B acute lymphoblastic leukemia treated with specific immunochemotherapy].	RB1	NA
28089441	10.1016/j.clml.2016.12.001	Prognostic Implications of Monosomies in Patients With Multiple Myeloma.	RB1	NA
27979924	10.3324/haematol.2016.153023	Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.	RB1	NA
27960642	10.1080/08880018.2016.1251518	The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia.	RB1	NA
27889452	10.1016/j.molcel.2016.10.021	An RB-EZH2 Complex Mediates Silencing of Repetitive DNA Sequences.	RB1	NA
27835869	10.18632/oncotarget.13181	OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.	RB1	NA
27036041	10.18632/oncotarget.8414	miR-590 promotes cell proliferation and invasion in T-cell acute lymphoblastic leukaemia by inhibiting RB1.	RB1	NA
27652204	10.21037/tlcr.2016.07.10	Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors.	RB1	NA
27399693	10.3390/ijms17071092	miR-494-3p Induces Cellular Senescence and Enhances Radiosensitivity in Human Oral Squamous Carcinoma Cells.	RB1	NA
27339065	10.1080/10428194.2016.1193855	Gene copy number alteration profile and its clinical correlation in B-cell acute lymphoblastic leukemia.	RB1	NA
27235019	10.1016/j.jep.2016.05.055	The combination effects of Shen-Ling-Bai-Zhu on promoting apoptosis of transplanted H22 hepatocellular carcinoma in mice receiving chemotherapy.	RB1	NA
27181063	10.1016/j.exphem.2016.04.011	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia.	RB1	NA
26781410	NA	[Detection of copy number variations in pediatric ETV6/RUNX1-positive acute lymphoblastic leukemia with multiplex ligation-dependent probe amplification].	RB1	NA
26740820	10.1186/s13039-015-0212-x	Monoallelic and biallelic deletions of 13q14 in a group of CLL/SLL patients investigated by CGH Haematological Cancer and SNP array (8x60K).	RB1	NA
26709271	10.3343/alm.2016.36.2.185	B-cell Acute Lymphoblastic Leukemia With t(9;22)(q34;q11) Translocation and Clonal Divergence Through ider(22) Chromosome and t(13;17)(q14;q25) Translocation.	RB1	NA
26551667	10.1038/ng.3442	The mutational landscape of cutaneous T cell lymphoma and S√©zary syndrome.	RB1	NA
26297264	10.1016/j.clml.2015.02.035	Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.	RB1	NA
26280220	10.1038/labinvest.2015.104	Characterization and pharmacologic targeting of EZH2, a fetal retinal protein and epigenetic regulator, in human retinoblastoma.	RB1	NA
26277549	10.1016/j.cancergen.2015.06.003	Frequency of copy number abnormalities in common genes associated with B-cell precursor acute lymphoblastic leukemia cytogenetic subtypes in Brazilian children.	RB1	NA
26205622	10.1111/bjh.13613	Distinctive genotypes in infants with T-cell acute lymphoblastic leukaemia.	RB1	NA
26027540	10.1016/j.clml.2015.03.018	Genomic and Clinicopathologic Features of Primary Myelofibrosis With Isolated 13q Deletion.	RB1	NA
26022239	10.1182/blood-2015-02-628792	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.	RB1	NA
25706938	10.1002/gcc.22246	A population-based single nucleotide polymorphism array analysis of genomic aberrations in younger adult acute lymphoblastic leukemia patients.	RB1	NA
25676421	10.1038/leu.2015.41	Early B-cell-specific inactivation of ATM synergizes with ectopic CyclinD1 expression to promote pre-germinal center B-cell lymphomas in mice.	RB1	NA
25261097	10.3324/haematol.2014.112912	Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia.	RB1	NA
25126481	10.1089/biores.2014.0011	Establishment and characterization of a singaporean chinese lung adenocarcinoma cell line with four copies of the epidermal growth factor receptor gene.	RB1	NA
24913233	10.1084/jem.20132120	Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy.	RB1	NA
24828667	10.1097/JTO.0000000000000142	Small-cell lung cancers in patients who never smoked cigarettes.	RB1	NA
24682267	10.1182/blood-2013-07-517177	The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.	RB1	NA
24678689	10.5858/arpa.2013-0101-RS	Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review.	RB1	NA
24633422	10.1007/s00268-014-2485-3	Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.	RB1	NA
24189068	10.1074/jbc.M113.510669	Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.	RB1	NA
24166298	10.1038/leu.2013.317	An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome.	RB1	NA
23989127	10.1159/000351058	Radiation therapy: retinal tumors.	RB1	NA
23961875	10.1111/bjh.12515	Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma.	RB1	NA
23950931	10.1371/journal.pone.0070422	RNAi mediated Tiam1 gene knockdown inhibits invasion of retinoblastoma.	RB1	NA
23900870	10.5114/pjp.2013.36199	Allelic loss of selected tumor suppressor genes in acute lymphoblastic leukemia in children.	RB1	NA
23676220	10.4161/cc.24928	Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3KŒ¥ inhibition through PIK3IP1.	RB1	NA
23508010	10.3324/haematol.2013.085175	Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: association with cytogenetics and clinical features.	RB1	NA
23483089	10.3343/alm.2013.33.2.130	A rare case of transformation of childhood myelodysplastic syndrome to acute lymphoblastic leukemia.	RB1	NA
23334668	10.1038/ng.2532	The genomic landscape of hypodiploid acute lymphoblastic leukemia.	RB1	NA
22851563	10.1200/JCO.2011.40.3907	IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia.	RB1	NA
22834783	10.3109/09273948.2012.702843	Genetics of primary intraocular tumors.	RB1	NA
22812491	10.3109/10428194.2012.713481	Development and characterization of a novel human Waldenstr√∂m macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenstr√∂m Macroglobulinemia 1.	RB1	NA
22072402	10.1002/gcc.20944	High frequency of BTG1 deletions in acute lymphoblastic leukemia in children with down syndrome.	RB1	NA
21900200	10.1182/blood-2011-03-337501	Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion.	RB1	NA
21693768	10.1093/annonc/mdr289	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion.	RB1	NA
21527530	10.1182/blood-2011-01-329961	Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia.	RB1	NA
20435884	10.1182/blood-2009-10-247122	Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.	RB1	NA
20435627	10.3324/haematol.2009.011114	Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia.	RB1	NA
20193845	10.1016/j.cancergencyto.2009.11.018	Array comparative genomic hybridization analysis of adult acute leukemia patients.	RB1	NA
19594747	10.1111/j.1365-2141.2009.07791.x	Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.	RB1	NA
19389505	10.1016/j.cancergencyto.2009.01.002	High-resolution genomic profiling of pediatric lymphoblastic lymphomas reveals subtle differences with pediatric acute lymphoblastic leukemias in the B-lineage.	RB1	NA
19387079	10.1167/iovs.09-3517	Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.	RB1	NA
19083825	10.1016/j.fsigen.2008.02.008	Comparison of five DNA quantification methods.	RB1	NA
18984860	10.1182/blood-2008-07-170183	Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling.	RB1	NA
18832135	10.1182/blood-2008-04-153031	Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome.	RB1	NA
18694959	10.1128/MCB.00923-08	Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells.	RB1	NA
18539616	10.1093/annonc/mdn374	Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas.	RB1	NA
18458336	10.1073/pnas.0800408105	Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease.	RB1	NA
18410453	10.1111/j.1365-2141.2008.07124.x	Advances in the understanding of mantle cell lymphoma.	RB1	NA
18391076	10.1182/blood-2007-10-118794	Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas.	RB1	NA
17900658	10.1016/j.humpath.2007.05.009	Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma.	RB1	NA
17724719	10.1002/ijc.23038	Presence of simian virus 40 DNA sequences in diffuse large B-cell lymphomas in Tunisia correlates with aberrant promoter hypermethylation of multiple tumor suppressor genes.	RB1	NA
17563396	10.1200/JCO.2006.08.7999	Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors.	RB1	NA
17443227	10.1038/sj.leu.2404691	High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.	RB1	NA
17332242	10.1182/blood-2006-11-057208	Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis.	RB1	NA
16858686	10.1002/ijc.22124	Epigenetic silencing of multiple genes in primary CNS lymphoma.	RB1	NA
16809940	10.1159/000094322	Defective expression of HRK is associated with promoter methylation in primary central nervous system lymphomas.	RB1	NA
16614728	10.1038/sj.jid.5700224	Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis.	RB1	NA
15832092	10.1097/01.pas.0000155163.40668.e7	Genetic aberrations in primary cutaneous large B-cell lymphoma: a fluorescence in situ hybridization study of 25 cases.	RB1	NA
15572583	10.1182/blood-2004-09-3701	Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line.	RB1	NA
15315804	10.1016/j.ejca.2004.06.007	Understanding cancer at the chromosome level: 40 years of progress.	RB1	NA
15172754	10.1016/j.cancergencyto.2003.09.022	Aberrations involving 13q12 approximately q14 are frequent secondary events in childhood acute lymphoblastic leukemia.	RB1	NA
15061196	10.1080/1042819031000151112	Altered apoptosis pathways in mantle cell lymphoma.	RB1	NA
15034294	10.4161/cbt.3.5.838	Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo.	RB1	NA
12925224	10.1046/j.1523-1747.2003.12406.x	Genomic alterations in blastic natural killer/extranodal natural killer-like T cell lymphoma with cutaneous involvement.	RB1	NA
12874790	10.1002/gcc.10234	Multipoint methylation analysis indicates a distinctive epigenetic phenotype among testicular germ cell tumors and testicular malignant lymphomas.	RB1	NA
12812137	NA	Molecular control of the cell cycle in cancer: biological and clinical aspects.	RB1	NA
12759925	10.1002/gcc.10200	Cytogenetic, spectral karyotyping, fluorescence in situ hybridization, and comparative genomic hybridization characterization of two new secondary leukemia cell lines with 5q deletions, and MYC and MLL amplification.	RB1	NA
12660028	10.1016/s0165-4608(02)00799-9	CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients.	RB1	NA
12647795	10.14670/HH-18.449	Expression of cyclin D3 and cyclin E and identification of distinct clusters of proliferation and apoptosis in diffuse large B-cell lymphomas.	RB1	NA
12145697	10.1038/sj.leu.2402644	Proliferation-dependent expression and phosphorylation of pRB in B cell non-Hodgkin's lymphomas: dependence on RB1 copy number.	RB1	NA
12036888	10.1182/blood.v99.12.4554	Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.	RB1	NA
12010815	10.1182/blood.v99.11.4116	Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia.	RB1	NA
11706071	10.1038/modpathol.3880444	Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas.	RB1	NA
11522621	NA	Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.	RB1	NA
11347338	NA	Cytogenetic abnormalities in chronic lymphocytic leukemia.	RB1	NA
11237059	10.1038/sj.leu.2402052	Deletion of chromosomal region 13q14.3 in childhood acute lymphoblastic leukemia.	RB1	NA
10938405	10.3892/ijo.17.3.603	Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells; clinical and pathological implications in patients with Hodgkin's disease.	RB1	NA
10862046	10.1002/1098-2264(200008)28:4&lt;380::aid-gcc3&gt;3.0.co;2-4	Marginal zone B-cell lymphomas (MZBL) arising at different sites represent different biological entities.	RB1	NA
10810367	NA	Membrane associated antitumor effects of crocine-, ginsenoside- and cannabinoid derivates.	RB1	NA
10803523	10.1038/sj.leu.2401761	Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.	RB1	NA
10784395	10.3109/10428190009148398	Simultaneous detection of BCL-2 protein, trisomy 12, retinoblastoma and P53 monoallelic gene deletions in B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization (FISH): relation to disease status.	RB1	NA
10773403	10.1016/s0304-3835(99)00447-4	Mutation analysis of the pRb pathway in 2',3'-dideoxycytidine- and 1, 3-butadiene-induced mouse lymphomas.	RB1	NA
10745626	NA	Delineation of the frequently deleted region on chromosome arm 13q in B-cell non-Hodgkin's lymphoma.	RB1	NA
10502318	10.1002/(sici)1098-2264(199911)26:3&lt;210::aid-gcc4&gt;3.0.co;2-j	A biological role for deletions in chromosomal band 13q14 in mantle cell and peripheral t-cell lymphomas?	RB1	NA
10379868	10.1002/(sici)1098-2264(199907)25:3&lt;222::aid-gcc4&gt;3.0.co;2-c	Myeloid- and lymphoid-specific breakpoint cluster regions in chromosome band 13q14 in acute leukemia.	RB1	NA
10374885	10.1038/sj.leu.2401395	Frequent chromosome arm 13q deletion in aggressive non-Hodgkin's lymphoma.	RB1	NA
10086736	10.1038/sj.leu.2401315	Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma.	RB1	NA
10049044	10.1038/sj.leu.2401208	Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization.	RB1	NA
9583687	10.1038/sj.onc.1201764	Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.	RB1	NA
9563492	NA	Molecular cytogenetic analysis in splenic lymphoma with villous lymphocytes: frequent allelic imbalance of the RB1 gene but not the D13S25 locus on chromosome 13q14.	RB1	NA
9546285	10.1111/j.1750-3639.1998.tb00152.x	Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL.	RB1	NA
9130611	10.3109/10428199709042493	Inactivation of cyclin-dependent kinase inhibitor genes and development of human acute leukemias.	RB1	NA
8724537	10.3109/10428199609051737	Allele imbalance at tumour suppressor loci during the indolent phase of follicle centre cell lymphoma.	RB1	NA
8611453	10.1046/j.1365-2141.1996.456994.x	Microsatellite instability in follicle centre cell lymphoma.	RB1	NA
8647524	NA	Cell cycle regulation and human leukemias: the role of p16INK4 gene inactivation in the development of human acute lymphoblastic leukemia.	RB1	NA
7655020	NA	13q deletions in lymphoid malignancies.	RB1	NA
7785662	10.1093/ajcp/103.6.748	Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin.	RB1	NA
7507704	10.1002/gcc.2870090113	Multiple genetic events involving RB1 gene deletion and amplification of chromosome 21 in a case of acute lymphocytic leukemia.	RB1	NA
8391274	10.1001/archotol.1993.01880190031006	Genetics of tumors of the head and neck.	RB1	NA
8380252	NA	Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma.	RB1	NA
1886710	NA	Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells.	RB1	NA
1884351	10.1016/0165-4608(91)90207-b	Hemizygous deletion of the 3' end of the RB1 gene in a case of Philadelphia positive-acute lymphoblastic leukemia.	RB1	NA
2397469	10.1016/0165-4608(90)90159-8	Structural alterations at the putative retinoblastoma locus in some human leukemias and preleukemia.	RB1	NA
185057	10.1002/eji.1830050402	Primary and secondary in vitro generation of cytolytic T lymphocytes in the murine sarcoma virus system.	RB1	NA
28674118	10.1158/1078-0432.CCR-17-0652	Retinoblastoma and Neuroblastoma Predisposition and Surveillance.	RB1	NA
25550786	NA	Epstein-Barr virus infection is inversely correlated with the expression of retinoblastoma protein in Reed-Sternberg cells in classic Hodgkin lymphoma.	RB1	NA
20157766	10.1007/s11010-010-0394-9	Notch signaling maintains proliferation and survival of the HL60 human promyelocytic leukemia cell line and promotes the phosphorylation of the Rb protein.	RB1	NA
17332242	10.1182/blood-2006-11-057208	Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis.	RB1	NA
15161658	10.1016/S0002-9440(10)63782-0	Retinoblastoma protein is frequently absent or phosphorylated in anaplastic large-cell lymphoma.	RB1	NA
12145697	10.1038/sj.leu.2402644	Proliferation-dependent expression and phosphorylation of pRB in B cell non-Hodgkin's lymphomas: dependence on RB1 copy number.	RB1	NA
27377594	10.1002/mc.22523	Rb silencing mediated by the down-regulation of MeCP2 is involved in cell transformation induced by long-term exposure to hydroquinone.	RB1	NA
27036041	10.18632/oncotarget.8414	miR-590 promotes cell proliferation and invasion in T-cell acute lymphoblastic leukaemia by inhibiting RB1.	RB1	NA
24913233	10.1084/jem.20132120	Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy.	RB1	NA
23900870	10.5114/pjp.2013.36199	Allelic loss of selected tumor suppressor genes in acute lymphoblastic leukemia in children.	RB1	NA
18694959	10.1128/MCB.00923-08	Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells.	RB1	NA
17428253	10.1111/j.1349-7006.2007.00482.x	Telomere dysfunction and inactivation of the p16(INK4a)/Rb pathway in pyothorax-associated lymphoma.	RB1	NA
16614728	10.1038/sj.jid.5700224	Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis.	RB1	NA
16352731	10.1073/pnas.0503886102	Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase.	RB1	NA
9395244	10.1038/sj.onc.1201431	Phosphorylated retinoblastoma protein stimulates DNA polymerase alpha.	RB1	NA
8552662	10.1073/pnas.93.1.465	Retinoblastoma protein directly interacts with and activates the transcription factor NF-IL6.	RB1	NA
33563892	10.1038/s41392-020-00412-3	Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.	RB1	NA
17900658	10.1016/j.humpath.2007.05.009	Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma.	RB1	NA
17695524	NA	Alterations of the p53, Rb and p27 tumor suppressor pathways in diffuse large B-cell lymphomas.	RB1	NA
10197586	NA	The partial homeodomain of the transcription factor Pax-5 (BSAP) is an interaction motif for the retinoblastoma and TATA-binding proteins.	RB1	NA
25675863	10.1016/j.leukres.2015.01.008	The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome.	RB1	NA
15878620	10.1016/j.leukres.2005.04.006	Aberrant expression of tumor suppressor genes and their association with chimeric oncogenes in pediatric acute lymphoblastic leukemia.	RB1	NA
21518927	10.1182/blood-2010-08-301135	The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway.	RB1	NA
17287852	10.1038/sj.leu.2404583	Activation of the c-myc p1 promoter in Burkitt's lymphoma by the hs3 immunoglobulin heavy-chain gene enhancer.	RB1	NA
24189068	10.1074/jbc.M113.510669	Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.	RB1	NA
20435627	10.3324/haematol.2009.011114	Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia.	RB1	NA
15695403	NA	Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma.	RB1	NA
19594747	10.1111/j.1365-2141.2009.07791.x	Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.	RB1	NA
12036888	10.1182/blood.v99.12.4554	Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.	RB1	NA
23022380	10.1016/j.molcel.2012.08.022	NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function.	RB1	NA
28694326	10.1182/blood-2017-02-768234	2017	Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).	RFXAP
20024540	10.1007/s00251-009-0418-3	2010	Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP.	RFXAP
16337482	10.1016/j.molimm.2005.03.008	2006	Conserved residues of the bare lymphocyte syndrome transcription factor RFXAP determine coordinate MHC class II expression.	RFXAP
34260908	10.1016/j.celrep.2021.109372	2021	Inhibition of Rag GTPase signaling in mice suppresses B cell responses and lymphomagenesis with minimal detrimental trade-offs.	RRAGC
31579886	10.1038/s42255-019-0098-8	2019	Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR.	RRAGC
28659443	10.1126/scitranslmed.aak9969	2017	Genetic and epigenetic inactivation of <i>SESTRIN1</i> controls mTORC1 and response to EZH2 inhibition in follicular lymphoma.	RRAGC
26691987	10.1038/ng.3473	2016	Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.	RRAGC
27230687	10.1038/ng0616-700b	2016	Corrigendum: Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.	RRAGC
27267853	10.1158/1078-0432.CCR-16-0609	2016	Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma.	RRAGC
35353559	10.1126/sciadv.abn0067	Structure of S1PR2-heterotrimeric G<sub>13</sub> signaling complex.	S1PR2	NA
34218556	10.3760/cma.j.cn121094-20201116-00633	[Chlorpromazine hydrochloride plays a tumor suppressive role in diffuse large B lymphoma by promoting the expression of S1PR2].	S1PR2	NA
33945543	10.1371/journal.pone.0248886	Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.	S1PR2	NA
31648327	10.1182/bloodadvances.2019000210	Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma.	S1PR2	NA
31404445	10.1007/s12308-019-00354-y	Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.	S1PR2	NA
30666658	10.1002/path.5237	Regulation of S1PR2 by the EBV oncogene LMP1 in aggressive ABC-subtype diffuse large B-cell lymphoma.	S1PR2	NA
29615404	10.1182/blood-2017-10-810630	The tumor suppressive TGF-Œ≤/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma.	S1PR2	NA
28878352	10.1038/leu.2017.275	S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells.	S1PR2	NA
27980305	10.3960/jslrt.56.71	Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.	S1PR2	NA
27959929	10.1371/journal.pmed.1002197	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.	S1PR2	NA
27389057	10.1038/leu.2016.175	Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.	S1PR2	NA
26989186	10.1182/blood-2016-01-692129	S1PR2 deficiency in DLBCL: a FOXy connection.	S1PR2	NA
26729899	10.1182/blood-2015-08-662635	The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.	S1PR2	NA
25938000	10.1186/s40164-015-0004-3	Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins.	S1PR2	NA
25274307	10.1038/nature13765	Loss of signalling via GŒ±13 in germinal centre B-cell-derived lymphoma.	S1PR2	NA
23419711	10.1038/labinvest.2013.7	Sphingosine-1-phosphate receptor 1 in classical Hodgkin lymphoma: assessment of expression and role in cell migration.	S1PR2	NA
19903857	10.1158/0008-5472.CAN-09-1110	Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation.	S1PR2	NA
35522148	10.3324/haematol.2021.280005	Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase <i>KDM4C</i> in B cell lymphomas.	SETD1B	NA
33512416	10.1182/blood.2020007245	Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.	SETD1B	NA
31092896	10.1038/s41375-019-0473-1	Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling.	SETD1B	NA
29967129	10.1182/blood-2018-02-832253	Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.	SETD1B	NA
22158038	10.1038/onc.2011.566	Mcm2 deficiency results in short deletions allowing high resolution identification of genes contributing to lymphoblastic lymphoma.	SETD1B	NA
34977845	10.1016/j.xjidi.2021.100068	2022	Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders.	SETD2
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	SETD2
35443279	10.1158/2159-8290.CD-21-1514	2022	SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis.	SETD2
35459873	10.1038/s41375-022-01571-8	2022	Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.	SETD2
35522148	10.3324/haematol.2021.280005	2022	Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase <i>KDM4C</i> in B cell lymphomas.	SETD2
35551151	10.1097/PAS.0000000000001914	2022	Targeted Next-generation Sequencing Reveals a Wide Morphologic and Immunophenotypic Spectrum of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma.	SETD2
35708139	10.3324/haematol.2022.281226	2022	Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.	SETD2
35726023	10.1038/s41684-022-00998-x	2022	The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications.	SETD2
35895386	10.1111/bjd.21791	2022	Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.	SETD2
35979577	10.3960/jslrt.22005	2022	Surface CD3-negative monomorphic epitheliotropic intestinal T-cell lymphoma.	SETD2
34406703	10.1002/ajh.26324	2021	The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study.	SETD2
34576156	10.3390/ijms22189992	2021	Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy.	SETD2
34895266	10.1186/s13000-021-01173-5	2021	Clinicopathological and molecular genomic features of monomorphic epitheliotropic intestinal T-cell lymphoma in the Chinese population: a study of 20 cases.	SETD2
31028364	10.1038/s41379-019-0279-8	2020	Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.	SETD2
31599770	10.1097/CCO.0000000000000590	2020	Novel molecular targets for the treatment of lung cancer.	SETD2
31914529	10.3760/cma.j.issn.0529-5807.2020.01.004	2020	[Monomorphic epitheliotropic intestinal T-cell lymphoma: a clinicopathological analysis of twelve cases].	SETD2
32271188	10.1097/PAS.0000000000001470	2020	Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders: A Clinical, Pathologic, and Molecular Study of 60 Cases Presenting With a Single Lesion: A Multicenter Study of the French Cutaneous Lymphoma Study Group.	SETD2
32349779	10.1186/s13073-020-00739-0	2020	CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.	SETD2
32469082	10.1002/cncr.32866	2020	Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.	SETD2
32695399	10.1186/s40364-020-00205-4	2020	Plasma circulating tumor DNA assessment reveals <i>KMT2D</i> as a potential poor prognostic factor in extranodal NK/T-cell lymphoma.	SETD2
32853382	10.1182/bloodadvances.2019000938	2020	The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL.	SETD2
33260897	10.3390/cancers12123539	2020	Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma in Asia Frequently Shows <i>SETD2</i> Alterations.	SETD2
30307363	10.1080/15384047.2018.1523857	2019	Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).	SETD2
31221981	10.1038/s12276-019-0230-6	2019	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.	SETD2
31344256	10.1111/bjh.16117	2019	The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype.	SETD2
31411343	10.1002/path.5333	2019	Genomic characterisation of breast fibroepithelial lesions in an international cohort.	SETD2
28910456	10.1001/jamaoncol.2017.2918	2018	Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.	SETD2
29305415	10.3324/haematol.2017.182444	2018	Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.	SETD2
29337025	10.1016/j.humpath.2018.01.005	2018	Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors.	SETD2
29694893	10.1016/j.celrep.2018.03.124	2018	SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression.	SETD2
28122867	10.1158/2159-8290.CD-16-0330	2017	The Genetic Basis of Hepatosplenic T-cell Lymphoma.	SETD2
28373165	10.1158/2159-8290.CD-17-0160	2017	It Takes a Village to Unmask HSTL.	SETD2
28424246	10.1084/jem.20160894	2017	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.	SETD2
28612716	10.1051/medsci/20173305004	2017	[Molecular oncogenesis of lymphomas: role of the SETD2 gene in intestinal T-cell lymphomas].	SETD2
26527318	10.18632/oncotarget.6259	2016	Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.	SETD2
26829311	10.1016/j.jtho.2016.01.010	2016	KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.	SETD2
26839360	10.1136/thoraxjnl-2015-207950	2016	A patient with complex multiple genomic ALK alterations.	SETD2
27181063	10.1016/j.exphem.2016.04.011	2016	Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia.	SETD2
27218135	10.1080/1062936X.2016.1186112	2016	Investigation of the inhibitors of histone-lysine N-methyltransferase SETD2 for acute lymphoblastic leukaemia from traditional Chinese medicine.	SETD2
27505670	10.1016/j.ccell.2016.07.006	2016	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.	SETD2
27600764	10.1038/ncomms12602	2016	Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.	SETD2
25444907	10.1016/j.canlet.2014.11.024	2015	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	SETD2
24662245	10.1038/ncomms4469	2014	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.	SETD2
24710217	10.1038/ncomms4630	2014	The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes.	SETD2
23065515	10.3324/haematol.2012.066977	2013	The role of a newly identified SET domain-containing protein, SETD3, in oncogenesis.	SETD2
22237106	10.1038/nature10725	2012	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.	SETD2
35106936	10.1002/cam4.4550	2022	SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.	SGK1
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	SGK1
33988691	10.1182/blood.2020010432	2021	SGK1 mutations in DLBCL generate hyperstable protein neoisoforms that promote AKT independence.	SGK1
34132431	10.1002/ptr.7157	2021	Suppression of phosphoinositide 3-kinase/phosphoinositide-dependent kinase-1/serum and glucocorticoid-induced protein kinase pathway.	SGK1
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	SGK1
34378195	10.1111/bjh.17765	2021	Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.	SGK1
31958764	10.1016/j.biopha.2020.109835	2020	Clinical characteristics of colorectal cancer patients and anti-neoplasm activity of genistein.	SGK1
32187361	10.1182/blood.2019003535	2020	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.	SGK1
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	SGK1
33584271	10.3389/fphar.2020.594038	2020	Piperazine-Derived Œ±<sub>1D/1A</sub> Antagonist 1- Benzyl-N- (3-(4- (2-Methoxyphenyl) Piperazine-1-yl) Propyl) -1H- Indole-2- Carboxamide Induces Apoptosis in Benign Prostatic Hyperplasia Independently of Œ±1-Adrenoceptor Blocking.	SGK1
30213827	10.3324/haematol.2018.203224	2019	<i>JUNB</i>, <i>DUSP2</i>, <i>SGK1</i>, <i>SOCS1</i> and <i>CREBBP</i> are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma.	SGK1
30694908	10.1097/WNR.0000000000001180	2019	Leonurine promotes neurite outgrowth and neurotrophic activity by modulating the GR/SGK1 signaling pathway in cultured PC12 cells.	SGK1
30926771	10.1038/s41408-019-0203-y	2019	Inhibition of the STAT3 target SGK1 sensitizes diffuse large B cell lymphoma cells to AKT inhibitors.	SGK1
31203134	10.1016/j.biopha.2019.109092	2019	Estradiol promotes trophoblast viability and invasion by activating SGK1.	SGK1
35540673	10.1039/c9ra07900a	2019	Retracted Article: Circular RNA hsa_circ_0000467 modulates SGK1 to facilitate cell migration, metastasis, and EMT while repressing apoptosis in colorectal cancer by sponging miR-383-5p.	SGK1
28905990	10.1002/ijc.31044	2018	The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.	SGK1
30613266	10.7150/thno.26888	2018	Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages.	SGK1
28879465	10.1007/s00292-017-0335-4	2017	[Nodular lymphocyte-dominant Hodgkin's lymphoma : LP cells show recurrent mutations in DUSP2, SGK1 and JUNB].	SGK1
26658840	10.1038/leu.2015.328	2016	Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.	SGK1
26229090	10.1158/2159-8290.CD-15-0370	2015	Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma.	SGK1
26380811	10.1016/j.fob.2015.08.001	2015	NDRG2 promotes myoblast proliferation and caspase 3/7 activities during differentiation, and attenuates hydrogen peroxide - But not palmitate-induced toxicity.	SGK1
34140493	10.1038/s41467-021-24037-4	Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified.	SIN3A	NA
32363958	10.1177/0300060520918087	CD56-positive diffuse large B-cell lymphoma/leukemia with <i>BCL6/MYC</i> double-hit and multiple gene mutations: an indicator of poor prognosis?	SIN3A	NA
31558468	10.1182/blood.2019001880	The whole-genome landscape of Burkitt lymphoma subtypes.	SIN3A	NA
31555365	10.3892/etm.2019.7867	miR-210-3p regulates the proliferation and apoptosis of non-small cell lung cancer cells by targeting SIN3A.	SIN3A	NA
31221981	10.1038/s12276-019-0230-6	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.	SIN3A	NA
30692217	10.1158/0008-5472.CAN-18-0359	The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3.	SIN3A	NA
30617194	10.1182/blood-2018-09-871418	Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma.	SIN3A	NA
24344258	10.1073/pnas.1321704111	Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A.	SIN3A	NA
23633923	10.1593/neo.121784	Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.	SIN3A	NA
19769942	10.1016/j.bbrc.2009.09.059	Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation.	SIN3A	NA
12634383	10.1128/jvi.77.7.4261-4272.2003	Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines.	SIN3A	NA
11884454	10.4049/jimmunol.168.6.2847	The ubiquitously expressed DNA-binding protein late SV40 factor binds Ig switch regions and represses class switching to IgA.	SIN3A	NA
10611298	10.1073/pnas.96.26.14831	Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B.	SIN3A	NA
10490596	10.1128/MCB.19.10.6566	Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.	SIN3A	NA
23633923	10.1593/neo.121784	Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.	SIN3A	NA
11719366	10.1182/blood.v98.12.3290	The acute promyelocytic leukemia-associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D(3)-induced monocytic differentiation of U937 cells through a physical interaction with vitamin D(3) receptor.	SIN3A	NA
11000236	10.1128/jvi.74.20.9637-9645.2000	Human herpesvirus 8 LANA interacts with proteins of the mSin3 corepressor complex and negatively regulates Epstein-Barr virus gene expression in dually infected PEL cells.	SIN3A	NA
17287852	10.1038/sj.leu.2404583	Activation of the c-myc p1 promoter in Burkitt's lymphoma by the hs3 immunoglobulin heavy-chain gene enhancer.	SIN3A	NA
11884454	10.4049/jimmunol.168.6.2847	The ubiquitously expressed DNA-binding protein late SV40 factor binds Ig switch regions and represses class switching to IgA.	SIN3A	NA
12634383	10.1128/jvi.77.7.4261-4272.2003	Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines.	SIN3A	NA
16147992	10.1074/mcp.M500112-MCP200	Analysis of BCL6-interacting proteins by tandem mass spectrometry.	SIN3A	NA
35885481	10.3390/diagnostics12071575	2022	Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma.	SOCS1
35879731	10.1186/s40364-022-00401-4	2022	Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma.	SOCS1
35790291	10.21873/anticanres.15823	2022	SOCS1 Gene Therapy for Head and Neck Cancers: An Experimental Study.	SOCS1
35600392	10.3389/fonc.2022.881801	2022	SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer.	SOCS1
35240014	10.4143/crt.2022.017	2022	Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.	SOCS1
35205765	10.3390/cancers14041018	2022	Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study.	SOCS1
35075971	10.1080/10428194.2021.2010060	2022	Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study.	SOCS1
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	SOCS1
34854137	10.1111/ejh.13730	2022	Combination of two monoclonal antibodies with SOCS1 N- and C-terminal binding sites to address SOCS1 status in B cells and B-cell lymphoma.	SOCS1
34791836	10.1002/cam4.4422	2022	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.	SOCS1
34714908	10.1182/bloodadvances.2021005486	2022	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.	SOCS1
34405005	10.7150/jca.60390	2021	Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.	SOCS1
34362488	10.19746/j.cnki.issn.1009-2137.2021.04.013	2021	[Second-generation Sequencing Analysis of Ph<sup>+</sup> and Ph-like Childhood T-cell Acute Lymphoblastic Leukemia].	SOCS1
34312841	10.1111/bjh.17719	2021	Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.	SOCS1
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	SOCS1
34265801	10.1097/PAS.0000000000001780	2022	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.	SOCS1
34248938	10.3389/fimmu.2021.650977	2021	T Cell-Intrinsic CDK6 Is Dispensable for Anti-Viral and Anti-Tumor Responses <i>In Vivo</i>.	SOCS1
34039950	10.1038/s41408-021-00493-5	2021	Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.	SOCS1
33951889	10.3324/haematol.2020.271957	2021	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.	SOCS1
33899787	10.1097/PAS.0000000000001691	2021	The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.	SOCS1
33714214	10.1111/ejh.13620	2021	A new reliable and highly specific monoclonal antibody to detect the C-terminal region of silencer of cytokine signaling 1.	SOCS1
33684939	10.1182/blood.2020007683	2021	Characterization of DLBCL with a PMBL gene expression signature.	SOCS1
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	SOCS1
33225311	10.1158/2643-3230.BCD-20-0051	2020	Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway.	SOCS1
33223115	10.1016/j.jep.2020.113514	2021	Ethyl acetate extract of Tibetan medicine Rhamnella gilgitica ameliorated type II collagen-induced arthritis in rats via regulating JAK-STAT signaling pathway.	SOCS1
33045225	10.1016/j.humpath.2020.09.014	2020	The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.	SOCS1
32961552	10.1182/blood.2020007507	2021	Mutational landscape of gray zone lymphoma.	SOCS1
32947237	10.1016/j.tranon.2020.100855	2020	Identification of clinical molecular targets for childhood Burkitt lymphoma.	SOCS1
32555149	10.1038/s41408-020-0335-0	2020	CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma.	SOCS1
32495891	10.26355/eurrev_202005_21342	2020	Gene polymorphisms of SOCS1 and SOCS2 and acute lymphoblastic leukemia.	SOCS1
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	SOCS1
32187361	10.1182/blood.2019003535	2020	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.	SOCS1
32079702	10.3324/haematol.2019.237719	2021	Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study.	SOCS1
31948699	10.1016/j.annpat.2019.12.006	2020	[Low-grade dural extranodal marginal zone lymphoma].	SOCS1
31774495	10.1182/blood.2019001904	2020	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.	SOCS1
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	SOCS1
31515941	10.15252/emmm.201910576	2019	The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma.	SOCS1
31431735	10.1038/s41375-019-0541-6	2020	Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma.	SOCS1
31407320	10.1111/bjh.16147	2019	The impact of SOCS1 mutations in diffuse large B-cell lymphoma.	SOCS1
31305266	10.1097/PAS.0000000000001324	2019	Chronic Active Epstein-Barr Virus Infection of T/NK-Cell Type Mimicking Classic Hodgkin Lymphoma: Clinicopathologic and Genetic Features of 8 Cases Supporting a Variant With """"Hodgkin/Reed-Sternberg-like"""" Cells of NK Phenotype.	SOCS1
31101761	10.1158/0008-5472.CAN-18-1503	2019	Phosphorylation of SOCS1 Inhibits the SOCS1-p53 Tumor Suppressor Axis.	SOCS1
30972748	10.1002/jcp.28410	2019	microRNA-30a inhibits the liver cell proliferation and promotes cell apoptosis through the JAK/STAT signaling pathway by targeting SOCS-1 in rats with sepsis.	SOCS1
30463380	10.3390/cancers10110459	2018	Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma.	SOCS1
30213827	10.3324/haematol.2018.203224	2019	<i>JUNB</i>, <i>DUSP2</i>, <i>SGK1</i>, <i>SOCS1</i> and <i>CREBBP</i> are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma.	SOCS1
30211726	10.1097/PAS.0000000000001154	2019	Cyclin D1-positive Mediastinal Large B-Cell Lymphoma With Copy Number Gains of CCND1 Gene: A Study of 3 Cases With Nonmediastinal Disease.	SOCS1
30144205	10.1002/gcc.22679	2018	Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HNRNPK and SOCS1 in mycosis fungoides.	SOCS1
30087457	10.1038/s41374-018-0096-6	2018	Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues.	SOCS1
30054295	10.1182/blood-2018-01-829424	2018	Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.	SOCS1
29911923	10.1080/10428194.2018.1461861	2019	MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia.	SOCS1
29650799	10.1182/blood-2017-11-814913	2018	Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.	SOCS1
29415891	10.1172/jci.insight.98368	2018	Efficacy of intracellular immune checkpoint-silenced DC vaccine.	SOCS1
28866095	10.1016/j.canlet.2017.08.034	2017	Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.	SOCS1
28739740	10.21873/anticanres.11841	2017	Global Analysis of miRNA-mRNA Interaction Network in Breast Cancer with Brain Metastasis.	SOCS1
28424246	10.1084/jem.20160894	2017	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.	SOCS1
28302137	10.1186/s13045-017-0438-7	2017	Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.	SOCS1
28295300	10.1002/eji.201646806	2017	IFN-Œ≥ directly inhibits murine B-cell precursor leukemia-initiating cell proliferation early in life.	SOCS1
28082443	10.1182/blood-2016-06-720516	2017	A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.	SOCS1
27859003	10.1111/bjh.14431	2018	Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A.	SOCS1
27356265	10.1002/gcc.22391	2016	Novel IGH and MYC Translocation Partners in Diffuse Large B-Cell Lymphomas.	SOCS1
27198204	10.1038/leu.2016.135	2016	Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.	SOCS1
27144517	10.18632/oncotarget.9077	2016	Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.	SOCS1
26885984	10.1007/s11010-016-2665-6	2016	Response of the JAK-STAT pathway to mammalian hibernation in 13-lined ground squirrel striated muscle.	SOCS1
26820519	10.1016/j.jconrel.2016.01.042	2016	A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells.	SOCS1
26633718	10.1038/cddis.2015.342	2015	Socs1 and Socs3 degrades Traf6 via polyubiquitination in LPS-induced acute necrotizing pancreatitis.	SOCS1
26599546	10.1371/journal.pone.0139663	2015	Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines.	SOCS1
26462859	10.1111/cei.12732	2016	Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?	SOCS1
26336985	10.18632/oncotarget.4829	2015	Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma.	SOCS1
25820993	10.1002/path.4539	2015	Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.	SOCS1
24641245	10.1111/bjd.12717	2014	A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert-Bazin type) mycosis fungoides.	SOCS1
23768868	10.1016/j.leukres.2013.05.003	2013	Polymorphisms in JAK/STAT signaling pathway genes and risk of non-Hodgkin lymphoma.	SOCS1
23296022	10.18632/oncotarget.774	2013	SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients.	SOCS1
23246696	10.1016/j.gene.2012.12.009	2013	Regulation of the MIR155 host gene in physiological and pathological processes.	SOCS1
22488585	10.1002/hon.2010	2013	Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.	SOCS1
22000024	10.1016/j.smim.2011.09.001	2011	The role of the transcription factor Miz-1 in lymphocyte development and lymphomagenesis-Binding Myc makes the difference.	SOCS1
21418178	10.1111/j.1365-2141.2011.08632.x	2011	Association of JAK-STAT pathway related genes with lymphoma risk: results of a European case-control study (EpiLymph).	SOCS1
19734449	10.1182/blood-2009-06-225839	2009	Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities.	SOCS1
18416826	10.1186/1471-2407-8-106	2008	Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis.	SOCS1
18401415	10.1038/leu.2008.85	2008	STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-cell lymphoma.	SOCS1
18035697	NA	2005	[Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in MedB-1 mediastinal lymphoma line].	SOCS1
17934639	10.1590/s0100-879x2007001100003	2007	miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia.	SOCS1
17867599	NA	2006	[Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation].	SOCS1
17764563	10.1186/1471-2164-8-302	2007	Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia.	SOCS1
17652621	10.1182/blood-2007-03-082511	2007	Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6.	SOCS1
17169806	10.1080/10428190600948048	2006	The investigation of mutation and single nucleotide polymorphism of receptor tyrosine kinases and downstream scaffold molecules in acute myeloid leukemia.	SOCS1
16782810	10.1073/pnas.0603728103	2006	Gene expression patterns define novel roles for E47 in cell cycle progression, cytokine-mediated signaling, and T lineage development.	SOCS1
16598306	10.1038/sj.leu.2404206	2006	JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.	SOCS1
16532038	10.1038/sj.onc.1209151	2006	Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.	SOCS1
16287070	10.1002/ijc.21485	2006	Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein.	SOCS1
16206268	10.1002/ijc.21539	2006	Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells.	SOCS1
16125365	10.1016/j.cellsig.2005.07.013	2006	Characterization of STAT5B phosphorylation correlating with expression of cytokine-inducible SH2-containing protein (CIS).	SOCS1
15815722	10.1038/sj.leu.2403741	2005	Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays.	SOCS1
15580314	10.1038/sj.onc.1208032	2005	Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors.	SOCS1
15572583	10.1182/blood-2004-09-3701	2005	Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line.	SOCS1
14630083	10.1016/s0145-2126(03)00158-9	2004	Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells.	SOCS1
14614518	10.1038/sj.leu.2403216	2004	SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway.	SOCS1
14551136	10.1182/blood-2003-07-2617	2004	A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling.	SOCS1
10856136	10.1067/mai.2000.107604	2000	IL-4/IL-13 signaling beyond JAK/STAT.	SOCS1
10811447	10.3109/10428190009060318	2000	The janus kinase inhibitor, Jab/SOCS-1, is an interferon-gamma inducible gene and determines the sensitivity to interferons.	SOCS1
21291295	10.3109/08820139.2010.534218	2011	Differential regulation of T and B lymphocytes by PD-1 and SOCS-1 signaling in hepatitis C virus-associated non-Hodgkin's lymphoma.	SOCS1
22387553	10.4049/jimmunol.1102899	2012	Downregulation of inflammatory microRNAs by Ig-like transcript 3 is essential for the differentiation of human CD8(+) T suppressor cells.	SOCS1
20438785	10.1016/j.humimm.2010.04.004	2010	Polymorphisms in innate immunity genes and risk of childhood leukemia.	SOCS1
14968112	10.1038/sj.onc.1207398	2004	Identification of NPM-ALK interacting proteins by tandem mass spectrometry.	SOCS1
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	SPEN
35106936	10.1002/cam4.4550	2022	SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.	SPEN
32139889	10.1038/s41375-020-0766-4	2021	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.	SPEN
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	SPEN
34256839	10.1186/s40164-021-00232-3	2021	Progress in molecular feature of smoldering mantle cell lymphoma.	SPEN
35008340	10.3390/cancers14010176	2021	Recent Advances in the Genetic of MALT Lymphomas.	SPEN
32173361	10.1016/j.exphem.2020.03.001	2020	Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma.	SPEN
32191807	10.1182/bloodadvances.2019001396	2020	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.	SPEN
32598477	10.1182/bloodadvances.2019001350	2020	Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.	SPEN
31132650	10.1016/j.anndiagpath.2019.05.004	2019	TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.	SPEN
29481902	10.1016/j.jid.2018.02.015	2018	Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma.	SPEN
30209976	10.1080/15384101.2018.1522912	2018	PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation.	SPEN
25381127	10.3324/haematol.2014.116855	2015	The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection.	SPEN
24486720	10.1016/j.jmr.2013.12.013	2014	In vivo single-shot 13C spectroscopic imaging of hyperpolarized metabolites by spatiotemporal encoding.	SPEN
23744182	10.1007/s00247-013-2721-2	2013	Imaging features of pancreatic tumors in children: 13-year experience at a pediatric tertiary hospital.	SPEN
24349473	10.1371/journal.pone.0083244	2013	Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.	SPEN
22497198	10.3109/10428194.2012.684350	2012	Biological effects of decreasing RBM15 on chronic myelogenous leukemia cells.	SPEN
22891273	10.1084/jem.20120904	2012	The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.	SPEN
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	STAT3
33579790	10.1136/gutjnl-2020-322935	2022	Oncogenetic landscape of lymphomagenesis in coeliac disease.	STAT3
33944901	10.1093/asj/sjab215	2022	Nonmalignant CD30+ Cells in Contralateral Peri-Implant Capsule of Patient With BIA-ALCL: A Premalignant Step?	STAT3
34380908	10.4103/1673-5374.320991	2022	Kr√ºppel-like factor 7 attenuates hippocampal neuronal injury after traumatic brain injury.	STAT3
34503423	10.2174/1871520621666210908103306	2022	The Acetyltransferase KAT5 Inhibitor NU 9056 Promotes Apoptosis and Inhibits JAK2/STAT3 Pathway in Extranodal NK/T Cell Lymphoma.	STAT3
34520436	10.1097/CAD.0000000000001249	2022	Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells.	STAT3
34528236	10.1111/bjd.20760	2022	Transcriptomic changes during stage progression of mycosis fungoides.	STAT3
34587248	10.1182/blood.2021012976	2022	Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.	STAT3
34657149	10.1182/blood.2020008136	2022	Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma.	STAT3
34687742	10.1016/j.jid.2021.09.024	2022	PLCŒ≥1/PKCŒ∏ Downstream Signaling Controls Cutaneous T-Cell Lymphoma Development and Progression.	STAT3
34714908	10.1182/bloodadvances.2021005486	2022	Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways.	STAT3
34743203	10.1038/s41418-021-00880-2	2022	Glycoprotein PTGDS promotes tumorigenesis of diffuse large B-cell lymphoma by MYH9-mediated regulation of Wnt-Œ≤-catenin-STAT3 signaling.	STAT3
34818414	10.1182/blood.2021012734	2022	Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.	STAT3
34862350	10.1097/MPH.0000000000002364	2022	Management of Peripheral T-Cell Lymphoma in Children and Adolescents Including STAT 3 Mutation Hyper-IgE Syndrome: One Size Does Not Fit All.	STAT3
34915482	10.1159/000521445	2022	STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma.	STAT3
34917911	10.1016/j.jhepr.2021.100386	2022	ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis.	STAT3
34922904	10.1016/j.cbi.2021.109779	2022	Diffuse large B-cell lymphoma-derived exosomes push macrophage polarization toward M2 phenotype via GP130/STAT3 signaling pathway.	STAT3
34977845	10.1016/j.xjidi.2021.100068	2022	Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders.	STAT3
35014680	10.3892/mmr.2022.12592	2022	Role of TGM2 in T‚Äëcell lymphoblastic lymphoma via regulation of IL‚Äë6/JAK/STAT3 signalling.	STAT3
35021606	10.3324/haematol.2021.280003	2022	Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS.	STAT3
35059947	10.1007/s10875-021-01197-y	2022	Malignancy in STAT3 Deficient Hyper IgE Syndrome.	STAT3
35085771	10.1016/j.cellsig.2022.110264	2022	EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.	STAT3
35100463	10.1111/cas.15277	2022	Inhibition of adult T-cell leukemia cell proliferation by polymerized proanthocyanidin from blueberry leaves through JAK proteolysis.	STAT3
35133054	10.1111/cas.15296	2022	Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.	STAT3
35136485	10.18632/oncotarget.28189	2022	GZ17-6.02 and axitinib interact to kill renal carcinoma cells.	STAT3
35189357	10.1016/j.phrs.2022.106134	2022	Expanding the armory for treating lymphoma: Targeting redox cellular status through thioredoxin reductase inhibition.	STAT3
35199089	10.1016/j.xjidi.2021.100084	2022	Malignant T Cell Activation by a <i>Bacillus</i> Species Isolated from Cutaneous T-Cell Lymphoma Lesions.	STAT3
35228642	10.1038/s41698-022-00254-y	2022	STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis.	STAT3
35249489	10.2174/1568009622666220304202116	2022	Novel Compound, ND-17, Regulates the JAK/STAT, PI3K/AKT, and MAPK Pathways and Restrains Human T-lymphoid Leukemia Development.	STAT3
35279012	10.1016/j.biopha.2022.112800	2022	The multifaceted mechanisms of Paeoniflorin in the treatment of tumors: State-of-the-Art.	STAT3
35340094	10.1111/vco.12816	2022	Anticancer activity of IRAK-4 inhibitors against canine lymphoid malignancies.	STAT3
35359405	10.3389/fonc.2022.842356	2022	Fbw7 Inhibits the Progression of Activated B-Cell Like Diffuse Large B-Cell Lymphoma by Targeting the Positive Feedback Loop of the LDHA/lactate/miR-223 Axis.	STAT3
35366115	10.1007/s00428-022-03309-4	2022	Cutaneous presentation of enteropathy-associated T-cell lymphoma masquerading as a DUSP22-rearranged CD30+‚Äâlymphoproliferation.	STAT3
35395970	10.19746/j.cnki.issn.1009-2137.2022.02.013	2022	[Expression Level of SOCS3 in Acute Lymphoblastic Leukemia Cells Affects the Cytotoxicity of NK Cells].	STAT3
35411036	10.1038/s41388-022-02301-1	2022	Novel TENM3-ALK fusion is an alternate mechanism for ALK activation in neuroblastoma.	STAT3
35438417	10.1007/s10875-022-01269-7	2022	Correction to: Malignancy in STAT3 Deficient Hyper IgE Syndrome.	STAT3
35439335	10.1002/hon.3007	2022	The potential efficacy and mechanism of bendamustine in entra-nodal NK/T cell lymphoma.	STAT3
35474053	10.1007/s11033-022-07399-w	2022	STAT signaling as a target for intervention: from cancer inflammation and angiogenesis to non-coding RNAs modulation.	STAT3
35477814	10.1007/s10637-022-01250-6	2022	Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia.	STAT3
35484662	10.3324/haematol.2021.279957	2022	Resistance to PI3Œ∫Œ¥ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis.	STAT3
35489748	10.21873/anticanres.15709	2022	Dimethyl Fumarate Induces Apoptosis <i>via</i> Inhibiting NF-Œ∫B and STAT3 Signaling in Adult T-cell Leukemia/Lymphoma Cells.	STAT3
35501257	10.1016/j.clml.2022.04.002	2022	Indolent Lymphoproliferative T-Cell Disorders Associated With Gastrointestional Disease: Diagnostic Challenges and Outcomes.	STAT3
35557592	10.21037/jgo-22-237	2022	miRNA-320 inhibits colitis-associated colorectal cancer by regulating the IL-6R/STAT3 pathway in mice.	STAT3
35578798	10.1002/jcp.30777	2022	Neddylation inactivation affects cell cycle and apoptosis in sheep follicular granulosa cells.	STAT3
35579082	10.1111/cas.15402	2022	CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a/b to disinhibit PD-L1.	STAT3
35600392	10.3389/fonc.2022.881801	2022	SOCS3 Acts as an Onco-immunological Biomarker With Value in Assessing the Tumor Microenvironment, Pathological Staging, Histological Subtypes, Therapeutic Effect, and Prognoses of Several Types of Cancer.	STAT3
35640677	10.1016/j.ajpath.2022.05.005	2022	Induction of Transcriptional Inhibitor HES1 and the Related Repression of Tumor-Suppressor TXNIP Are Important Components of Cell-Transformation Program Imposed by Oncogenic Kinase NPM-ALK.	STAT3
35642002	10.1186/s12967-022-03451-2	2022	Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.	STAT3
35651609	10.3389/fimmu.2022.878989	2022	Hyper-IgE and Carcinoma in CADINS Disease.	STAT3
35671182	10.1097/CM9.0000000000001916	2022	Hepatocyte growth factor protects pulmonary endothelial barrier against oxidative stress and mitochondria-dependent apoptosis.	STAT3
35697790	10.1038/s41375-022-01623-z	2022	Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma.	STAT3
35743211	10.3390/ijms23126773	2022	Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF).	STAT3
35752777	10.1186/s12860-022-00422-9	2022	Evaluation of the putative lymphoma-associated point mutation D427H in the STAT3 transcription factor.	STAT3
35790291	10.21873/anticanres.15823	2022	SOCS1 Gene Therapy for Head and Neck Cancers: An Experimental Study.	STAT3
35803438	10.1016/j.taap.2022.116156	2022	1-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-(2-(dimethylamino)ethyl)imidazolidin-2-one (ZX-42) inhibits cell proliferation and induces apoptosis via inhibiting ALK and its downstream pathways in Karpas299 cells.	STAT3
35805156	10.3390/cells11132072	2022	Phospho-Specific Flow Cytometry Reveals Signaling Heterogeneity in T-Cell Acute Lymphoblastic Leukemia Cell Lines.	STAT3
35879049	10.1136/gutjnl-2021-326257	2022	Immunopathogenesis and environmental triggers in coeliac disease.	STAT3
35882439	10.1182/bloodadvances.2022007541	2022	Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association.	STAT3
35884913	10.3390/biomedicines10071608	2022	Downregulation of STAT3 in Epstein-Barr Virus-Positive Hodgkin Lymphoma.	STAT3
35897737	10.3390/ijms23158161	2022	The Pt(<i>S</i>-pr-thiosal)2 and BCL1 Leukemia Lymphoma: Antitumor Activity In Vitro and In Vivo.	STAT3
35903524	10.1016/j.jsps.2022.05.009	2022	Genistein promotes M1 macrophage apoptosis and reduces inflammatory response by disrupting miR-21/TIPE2 pathway.	STAT3
35917766	10.1016/j.bmc.2022.116936	2022	Design, synthesis and in vitro biological evaluation of marine phidianidine derivatives as potential anti-inflammatory agents.	STAT3
35973920	10.1016/j.jcyt.2022.06.007	2022	Human gingival mesenchymal stem cells improve movement disorders and tyrosine hydroxylase neuronal damage in Parkinson disease rats.	STAT3
35990641	10.3389/fimmu.2022.937872	2022	Genomic crossroads between non-Hodgkin's lymphoma and common variable immunodeficiency.	STAT3
35994220	10.1007/s12013-022-01088-y	2022	Effects of STAT3 Inhibitor BP-1-102 on The Proliferation, Invasiveness, Apoptosis and Neurosphere Formation of Glioma Cells in Vitro.	STAT3
36035991	10.3389/fcell.2022.935023	2022	Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.	STAT3
36045346	10.1186/s12943-022-01640-7	2022	PDGFRŒ≤ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma.	STAT3
36064579	10.1038/s41388-022-02453-0	2022	ALK fusion promotes metabolic reprogramming of cancer cells by transcriptionally upregulating PFKFB3.	STAT3
36086962	10.15586/aei.v50i5.626	2022	Deoxyelephantopin alleviates lipopolysaccharide-induced septic lung injury through inhibiting NF-ƒ∏B/STAT3 axis.	STAT3
32270320	10.1007/s00403-020-02062-5	2021	The polymorphisms of IL-6/STAT3 signaling pathway may contribute to cutaneous T-cell lymphomas susceptibility.	STAT3
32273478	10.3324/haematol.2020.251579	2021	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.	STAT3
32327503	10.3324/haematol.2019.238766	2021	Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target.	STAT3
32619110	10.1080/10520295.2020.1770332	2021	Silencing Stat3 inhibits viability and induces apoptosis in BGC-823 human gastric cancer cell line.	STAT3
32780548	10.1111/cbdd.13778	2021	Alantolactone induces apoptosis in THP-1 cells through STAT3, survivin inhibition, and intrinsic apoptosis pathway.	STAT3
32822082	10.1002/ptr.6842	2021	MicroRNA216b mediated downregulation of HSP27/STAT3/AKT signaling is critically involved in lambertianic acid induced apoptosis in human cervical cancers.	STAT3
32961552	10.1182/blood.2020007507	2021	Mutational landscape of gray zone lymphoma.	STAT3
32985300	10.1080/10428194.2020.1817431	2021	Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway.	STAT3
33079297	10.1007/s10014-020-00386-8	2021	Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas.	STAT3
33080566	10.1016/j.phymed.2020.153366	2021	Effect of the isoflavone corylin from cullen corylifolium on colorectal cancer growth, by targeting the STAT3 signaling pathway.	STAT3
33158639	10.1016/j.ejso.2020.10.029	2021	Biological and genetic landscape of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).	STAT3
33184494	10.1038/s41375-020-01088-y	2021	A novel model of alternative NF-Œ∫B pathway activation in anaplastic large cell lymphoma.	STAT3
33223115	10.1016/j.jep.2020.113514	2021	Ethyl acetate extract of Tibetan medicine Rhamnella gilgitica ameliorated type II collagen-induced arthritis in rats via regulating JAK-STAT signaling pathway.	STAT3
33247178	10.1038/s41375-020-01093-1	2021	STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.	STAT3
33247999	10.1111/cas.14752	2021	Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.	STAT3
33307035	10.1016/j.ajpath.2020.12.001	2021	PIM Kinases Promote Survival and Immune Escape in Primary Mediastinal Large B-Cell Lymphoma through Modulation of JAK-STAT and NF-Œ∫B Activity.	STAT3
33310759	10.26508/lsa.202000794	2021	Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK-driven lymphomagenesis.	STAT3
33333215	10.1016/j.gene.2020.145354	2021	Puerarin alleviates coronary heart disease via suppressing inflammation in a rat model.	STAT3
33367520	10.1093/asj/sjaa398	2021	Analysis of the Molecular Signature of Breast Implant-Associated Anaplastic Large Cell Lymphoma in an Asian Patient.	STAT3
33370049	10.1097/PRS.0000000000007423	2021	Cellular and Molecular Mechanisms of Breast Implant-Associated Anaplastic Large Cell Lymphoma.	STAT3
33389078	10.1007/s00432-020-03446-w	2021	Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma.	STAT3
33393492	10.1172/JCI142627	2021	Doubling up on function: dual-specificity tyrosine-regulated kinase 1A (DYRK1A) in B cell acute lymphoblastic leukemia.	STAT3
33393494	10.1172/JCI135937	2021	DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.	STAT3
33410350	10.1080/10428194.2020.1869964	2021	<i>STAT3</i> and <i>STAT5B</i> mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms.	STAT3
33418509	10.1016/j.ebiom.2020.103191	2021	Dnmt3b catalytic activity is critical for its tumour suppressor function in lymphomagenesis and is associated with c-Met oncogenic signalling.	STAT3
33466582	10.3390/cancers13020280	2021	JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL).	STAT3
33512408	10.1182/blood.2020005964	2021	TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.	STAT3
33512451	10.1182/blood.2020006721	2021	Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.	STAT3
33513694	10.3390/biomedicines9020118	2021	IRE1 Alpha/XBP1 Axis Sustains Primary Effusion Lymphoma Cell Survival by Promoting Cytokine Release and STAT3 Activation.	STAT3
33529679	10.1016/j.fct.2021.112031	2021	Methylgerambullin derived from plant Glyccsmis pentaphylla (Retz) correa. Mediates anti-hepatocellular carcinoma cancer effect by activating mitochondrial and endoplasmic reticulum stress signaling and inhibiting AKT and STAT3 pathways.	STAT3
33544565	10.1097/PAS.0000000000001658	2021	Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II.	STAT3
33550887	10.1080/10428194.2021.1881511	2021	PD-L1 expression in peripheral T-cell lymphomas is not related to either <i>PD-L1</i> gene amplification or rearrangements.	STAT3
33632668	10.1016/j.clml.2020.12.012	2021	A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.	STAT3
33641239	10.1111/gbb.12729	2021	Binge-like ethanol drinking activates anaplastic lymphoma kinase signaling and increases the expression of STAT3 target genes in the mouse hippocampus and prefrontal cortex.	STAT3
33649847	10.3892/mmr.2021.11947	2021	Chidamide induces apoptosis in DLBCL cells by¬†suppressing the HDACs/STAT3/Bcl‚Äë2 pathway.	STAT3
33651821	10.1371/journal.pone.0247394	2021	IL-6 promotes MYC-induced B cell lymphomagenesis independent of STAT3.	STAT3
33660353	10.1111/tbj.14205	2021	Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway.	STAT3
33664848	10.7150/thno.54343	2021	The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling.	STAT3
33667957	10.1016/j.archoralbio.2021.105085	2021	Gold nanoparticles conjugated with programmed death-ligand 1 antibodies induce apoptosis of SCC-25 oral squamous cell carcinoma cells via programmed death-ligand 1/signal transducer and transcription 3 pathway.	STAT3
33687890	10.2174/1871529X21666210308111546	2021	Preclinical Studies of PROTACs in Hematological Malignancies.	STAT3
33692440	10.1038/s41374-021-00581-x	2021	Feline low-grade intestinal T cell lymphoma: a unique natural model of human indolent T cell lymphoproliferative disorder of the gastrointestinal tract.	STAT3
33705488	10.1371/journal.pone.0248298	2021	Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.	STAT3
33714841	10.1016/j.coi.2021.02.008	2021	Human MALT1 deficiency and predisposition to infections.	STAT3
33715582	10.1080/10428194.2021.1894642	2021	miR-145-5p exerts anti-tumor effects in diffuse large B-cell lymphoma by regulating S1PR1/STAT3/AKT pathway.	STAT3
33728771	10.1111/cas.14885	2021	The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death.	STAT3
33757561	10.1186/s13104-021-05521-y	2021	HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) versus adult T-cell leukemia/lymphoma (ATLL).	STAT3
33758275	10.1038/s41598-021-86021-8	2021	Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines.	STAT3
33761896	10.1186/s12885-021-07905-6	2021	EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells.	STAT3
33771682	10.1016/j.etap.2021.103639	2021	Interleukin-6 reverses Adriamycin resistance in nasal NK/T-cell lymphoma via downregulation of ABCC4 and inactivation of the JAK2/STAT3/NF-Œ∫B/P65 pathway.	STAT3
33777671	10.1016/j.apsb.2020.10.022	2021	Hedgehog signaling in gastrointestinal carcinogenesis and the gastrointestinal tumor microenvironment.	STAT3
33799222	10.1016/j.phymed.2021.153545	2021	Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization.	STAT3
33828027	10.1248/bpb.b21-00163	2021	MicroRNA-221 Upregulates the Expression of P-gp and Bcl-2 by Activating the Stat3 Pathway to Promote Doxorubicin Resistance in Osteosarcoma Cells.	STAT3
33841008	10.1016/j.jgr.2019.12.007	2021	Anti-tumor activities of <i>Panax quinquefolius</i> saponins and potential biomarkers in prostate cancer.	STAT3
33876201	10.1182/blood.2020009404	2021	Dimethyl fumarate induces ferroptosis and impairs NF-Œ∫B/STAT3 signaling in DLBCL.	STAT3
33883905	10.2147/OTT.S292388	2021	Calycosin Induces Gastric Cancer Cell Apoptosis via the ROS-Mediated MAPK/STAT3/NF-Œ∫B Pathway.	STAT3
33889291	10.4239/wjd.v12.i4.466	2021	Elevated retinol binding protein 4 levels are associated with atherosclerosis in diabetic rats <i>via</i> JAK2/STAT3 signaling pathway.	STAT3
33899787	10.1097/PAS.0000000000001691	2021	The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.	STAT3
33901030	10.1097/PAI.0000000000000936	2021	ALK-Negative Anaplastic Large Cell Lymphoma (ALCL): Prognostic Implications of Molecular Subtyping and JAK-STAT Pathway.	STAT3
33928032	10.3389/fonc.2021.643620	2021	Cytoskeleton Dynamics in Peripheral T Cell Lymphomas: An Intricate Network Sustaining Lymphomagenesis.	STAT3
33932101	10.1002/1878-0261.12969	2021	Tumour-derived substrate-adherent cells promote neuroblastoma survival through secreted trophic factors.	STAT3
33951889	10.3324/haematol.2020.271957	2021	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.	STAT3
33954056	10.7717/peerj.11264	2021	Melatonin ameliorates myocardial injury by reducing apoptosis and autophagy of cardiomyocytes in a rat cardiopulmonary bypass model.	STAT3
33987937	10.1002/iub.2503	2021	Lovastatin reduces PEL cell survival by phosphorylating ERK1/2 that blocks the autophagic flux and engages a cross-talk with p53 to activate p21.	STAT3
34039950	10.1038/s41408-021-00493-5	2021	Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing.	STAT3
34090412	10.1186/s12890-021-01553-z	2021	EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.	STAT3
34128135	10.1007/s10689-021-00266-w	2021	The paradigm of hematological malignant versus non-malignant manifestations, driven by primary immunodeficiencies: a complex interplay.	STAT3
34151703	10.1080/10428194.2021.1941929	2021	Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK‚Äâ+‚ÄâLBCL): a systematic review of clinicopathological features and management.	STAT3
34208159	10.3390/ijms22126291	2021	Functional Analysis of the Promoter Regions of Two Apoptosis-Related Genes (<i>Bcl-2</i> and <i>Cycs</i>) and Their Regulation by Zn in Yellow Catfish.	STAT3
34242968	10.1016/j.esmoop.2021.100172	2021	Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.	STAT3
34244887	10.1007/s11033-021-06528-1	2021	Atiprimod triggered apoptotic cell death via acting on PERK/eIF2Œ±/ATF4/CHOP and STAT3/NF-ŒöB axis in MDA-MB-231 and MDA-MB-468 breast cancer cells.	STAT3
34258755	10.1111/bjh.17639	2021	Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).	STAT3
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	STAT3
34282785	10.3390/cancers13133367	2021	Potent Anticancer Effects of Epidithiodiketopiperazine NT1721 in Cutaneous T Cell Lymphoma.	STAT3
34295778	10.21037/tp-21-39	2021	Effect of SOCS3 on apoptosis of human trophoblasts via adjustment of the JAK2/STAT3 signaling pathway in preterm birth.	STAT3
34297745	10.1371/journal.ppat.1009764	2021	Inhibition of polo-like kinase 1 (PLK1) facilitates reactivation of gamma-herpesviruses and their elimination.	STAT3
34303663	10.1016/j.ejphar.2021.174373	2021	The antipsychotic drug pimozide is effective against human T-cell leukemia virus type 1-infected T cells.	STAT3
34322285	NA	2021	The non-leukemic T cell large granular lymphocytic leukemia variant with marked splenomegaly and neutropenia in the setting of rheumatoid arthritis - Felty syndrome and hepatosplenic T cell lymphoma mask.	STAT3
34349069	10.11406/rinketsu.62.835	2021	[The road to treating chronic active Epstein-Barr viral infection].	STAT3
34355652	10.1080/10428194.2021.1961231	2021	Trametinib enhances ATRA-induced differentiation in AML cells.	STAT3
34376672	10.1038/s41467-021-25101-9	2021	Chronological genome and single-cell transcriptome integration characterizes the evolutionary process of adult T cell leukemia-lymphoma.	STAT3
34384156	10.3760/cma.j.issn.0253-2727.2021.06.009	2021	[Clinical characteristics of T-cell large granular lymphoblastic leukemia with STAT3 gene mutation].	STAT3
34395444	10.3389/fcell.2021.714298	2021	Functional and Clinical Characteristics of Cell Adhesion Molecule CADM1 in Cancer.	STAT3
34440920	10.3390/cells10082151	2021	Inhibition of STAT3/PD-L1 and Activation of miR193a-5p Are Critically Involved in Apoptotic Effect of Compound K in Prostate Cancer Cells.	STAT3
34447369	10.3389/fimmu.2021.671755	2021	Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.	STAT3
34455369	10.1016/j.bbrc.2021.08.051	2021	Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.	STAT3
34466072	10.1016/j.sjbs.2021.07.072	2021	Chemical composition and pharmacological bio-efficacy of <i>Parrotiopsis jacquemontiana</i> (Decne) Rehder for anticancer activity.	STAT3
34489160	10.1016/j.jjcc.2021.08.018	2021	LncRNA MIAT knockdown alleviates oxygen-glucose deprivation‚Äëinduced cardiomyocyte injury by regulating JAK2/STAT3 pathway via miR-181a-5p.	STAT3
34504101	10.1038/s41467-021-25622-3	2021	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth.	STAT3
34508914	10.1016/j.bj.2021.08.012	2021	We refuse to die - T cells causing havoc.	STAT3
34535012	10.1182/bloodadvances.2021004562	2021	Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations.	STAT3
34563576	10.1016/j.ijbiomac.2021.09.095	2021	The crystal structure of the domain-swapped dimer of onconase highlights some catalytic and antitumor activity features of the enzyme.	STAT3
34572418	10.3390/biomedicines9091233	2021	Overexpression of Neuron-Derived Orphan Receptor 1 (NOR-1) Rescues Cardiomyocytes from Cell Death and Improves Viability after Doxorubicin Induced Stress.	STAT3
34572893	10.3390/cancers13184667	2021	ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas.	STAT3
34588425	10.1038/s41420-021-00655-1	2021	The JAK2 inhibitor TG101209 exhibits anti-tumor and chemotherapeutic sensitizing effects on Burkitt lymphoma cells by inhibiting the JAK2/STAT3/c-MYB signaling axis.	STAT3
34628002	10.1016/j.cellsig.2021.110167	2021	Artesunate induces apoptosis, autophagy and ferroptosis in diffuse large B cell lymphoma cells by impairing STAT3 signaling.	STAT3
34638962	10.3390/ijms221910623	2021	Acetaminophen-Induced Liver Injury Exposes Murine IL-22 as Sex-Related Gene Product.	STAT3
34654425	10.1186/s12943-021-01437-0	2021	DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.	STAT3
34680385	10.3390/cancers13205238	2021	A Recurrent <i>STAT5B<sup>N642H</sup></i> Driver Mutation in Feline Alimentary T Cell Lymphoma.	STAT3
34710755	10.1016/j.phymed.2021.153802	2021	Myricetin exhibit selective anti-lymphoma activity by targeting BTK and is effective via oral administration in vivo.	STAT3
34736477	10.1186/s12935-021-02296-x	2021	CircADARB1 serves as a new biomarker in natural killer T-cell lymphoma and a potential regulator of p-Stat3.	STAT3
34837676	10.22074/cellj.2021.7302	2021	AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines.	STAT3
34853180	10.1136/jitc-2021-003176	2021	Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells.	STAT3
34858727	10.1080/2162402X.2021.2003533	2021	Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma.	STAT3
34900688	10.3389/fonc.2021.738085	2021	Combination of Auranofin and ICG-001 Suppress the Proliferation and Metastasis of Colon Cancer.	STAT3
34906296	NA	2021	[Naringin inhibits the proliferation and invasion of Eca109 esophageal cancer cells and promotes its apoptosis by blocking JAK/STAT signal pathway].	STAT3
35116524	10.21037/tcr-20-3018	2021	Procyanidins mediates antineoplastic effects against non-small cell lung cancer via the JAK2/STAT3 pathway.	STAT3
28609201	10.1080/21541248.2017.1341365	2020	Opposite functions of STAT3 and Smad3 in regulating Tiam1 expression in Th17 cells.	STAT3
31049933	10.1111/bjd.18098	2020	Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-Œ∫B and nuclear factor of activated T cells pathways.	STAT3
31383967	10.1038/s41379-019-0336-3	2020	PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.	STAT3
31390055	10.1111/bjd.18353	2020	Deregulated signalling and inflammation in cutaneous T-cell lymphoma.	STAT3
31441360	10.1080/10428194.2019.1654096	2020	Identification of microRNAs modulated by DNA hypomethylating drugs in extranodal NK/T-cell lymphoma.	STAT3
31610171	10.1016/j.ajpath.2019.09.005	2020	Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.	STAT3
31623480	10.1080/10428194.2019.1678154	2020	STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas.	STAT3
31663116	10.1002/jcp.29338	2020	miR-22-3p enhances the intrinsic regenerative abilities of primary sensory neurons via the CBL/p-EGFR/p-STAT3/GAP43/p-GAP43 axis.	STAT3
31736340	10.1152/ajpgi.00130.2019	2020	Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.	STAT3
31773249	10.1007/s00428-019-02704-8	2020	Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas.	STAT3
31774495	10.1182/blood.2019001904	2020	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.	STAT3
31778838	10.1016/j.wneu.2019.11.100	2020	STAT3 Activation Is Associated with Interleukin-10 Expression and Survival in Primary Central Nervous System Lymphoma.	STAT3
31801855	10.1128/JVI.01384-19	2020	Kaposi's Sarcoma-Associated Herpesvirus Viral Interleukin-6 Signaling Upregulates Integrin Œ≤3 Levels and Is Dependent on STAT3.	STAT3
31804622	10.1038/s41388-019-1136-4	2020	The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma.	STAT3
31822801	10.1038/s41379-019-0415-5	2020	Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America.	STAT3
31836854	10.1038/s41375-019-0678-3	2020	Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract.	STAT3
31845004	10.1007/s00418-019-01834-z	2020	RNAscope dual ISH-IHC technology to study angiogenesis in diffuse large B-cell lymphomas.	STAT3
31889428	10.1002/kjm2.12181	2020	miR-636 represses cell survival by targeting CDK6/Bcl-2 in cervical cancer.	STAT3
31896810	10.1038/s41379-019-0448-9	2020	PD-L1 expression in anaplastic large cell lymphoma.	STAT3
31918398	10.1016/j.bioorg.2019.103542	2020	JAK3 inhibitors based on thieno[3,2-d]pyrimidine scaffold: design, synthesis and bioactivity evaluation for the treatment of B-cell lymphoma.	STAT3
31935288	10.1182/bloodadvances.2019000947	2020	Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.	STAT3
31956933	10.1007/s10637-020-00896-4	2020	KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth.	STAT3
31957855	10.26355/eurrev_202001_19939	2020	Losartan promotes myocardial apoptosis after acute myocardial infarction in rats through inhibiting Ang II-induced JAK/STAT pathway.	STAT3
31961925	10.1182/blood.2019001815	2020	Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions.	STAT3
32004387	10.1111/bjh.16435	2020	Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma.	STAT3
32005797	10.1038/s41408-020-0277-6	2020	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.	STAT3
32010998	10.1002/hon.2720	2020	Refractory celiac disease type II: An atypical case highlighting limitations of the current classification system.	STAT3
32021103	10.2147/DDDT.S228610	2020	Curcumin Combined with Thalidomide Reduces Expression of <i>STAT3</i> and <i>Bcl-xL</i>, Leading to Apoptosis in Acute Myeloid Leukemia Cell Lines.	STAT3
32044149	10.1016/j.imbio.2020.151907	2020	Natural Killer cell transcriptome during primary EBV infection and EBV associated Hodgkin Lymphoma in children-A preliminary observation.	STAT3
32110041	10.2147/OTT.S209312	2020	Embelin Promotes Oncolytic Vaccinia Virus-Mediated Antitumor Immunity Through Disruption of IL-6/STAT3 Signaling in Lymphoma.	STAT3
32120334	10.1016/j.tranon.2020.100744	2020	Inflammatory Infiltrate and Angiogenesis in Mantle Cell Lymphoma.	STAT3
32123306	10.1038/s41375-020-0754-8	2020	The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK<sup>-</sup> anaplastic large cell lymphoma by regulating the DNA helicase HELLS.	STAT3
32141561	10.26355/eurrev_202002_20370	2020	MicroRNA-29b promotes cell sensitivity to Temozolomide by targeting STAT3 in glioma.	STAT3
32183146	10.3390/molecules25061320	2020	Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells.	STAT3
32185560	10.1007/s11894-020-0756-8	2020	Refractory Celiac Disease.	STAT3
32188095	10.3390/cancers12030702	2020	<i>STAT3</i> Mutation Is Associated with STAT3 Activation in CD30<sup>+</sup> ALK<sup>-</sup> ALCL.	STAT3
32194752	10.3892/ol.2020.11315	2020	Inhibiting the Src/STAT3 signaling pathway contributes to the anti-melanoma mechanisms of dioscin.	STAT3
32196559	10.1182/bloodadvances.2019001429	2020	Proteomic profiling of HTLV-1 carriers and ATL patients reveals sTNFR2 as a novel diagnostic biomarker for acute ATL.	STAT3
32203093	10.1038/s41379-020-0522-3	2020	Reply to """"PD-L1 expression in anaplastic large cell lymphoma"""".	STAT3
32271188	10.1097/PAS.0000000000001470	2020	Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders: A Clinical, Pathologic, and Molecular Study of 60 Cases Presenting With a Single Lesion: A Multicenter Study of the French Cutaneous Lymphoma Study Group.	STAT3
32296013	10.1038/s41392-020-0123-0	2020	A novel silicone derivative of natural osalmid (DCZ0858) induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2/STAT3 pathway.	STAT3
32312912	10.26508/lsa.201900601	2020	Oncogenic <i>ALK</i> <sup><i>F1174L</i></sup> drives tumorigenesis in cutaneous squamous cell carcinoma.	STAT3
32352029	10.1038/s41523-020-0157-z	2020	BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression.	STAT3
32391356	10.3389/fcell.2020.00262	2020	A Dual TLR7/TLR9 Inhibitor HJ901 Inhibits ABC-DLBCL Expressing the MyD88 L265P Mutation.	STAT3
32394008	10.1007/s10495-020-01607-3	2020	Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination.	STAT3
32420596	10.1042/CS20200032	2020	Deregulation of miRNAs-cMYC circuits is a key event in refractory celiac disease type-2 lymphomagenesis.	STAT3
32463472	10.1042/BSR20190318	2020	Effect of hnRNPA2/B1 on the proliferation and apoptosis of glioma U251 cells via the regulation of AKT and STAT3 pathways.	STAT3
32466622	10.3390/vaccines8020250	2020	Cloning and Expression of the Tibetan Pig Interleukin-23 Gene and Its Promotion of Immunity of Pigs to PCV2 Vaccine.	STAT3
32471947	10.1073/pnas.1922884117	2020	HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling.	STAT3
32484926	10.1002/cncr.32985	2020	Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition.	STAT3
32554052	10.1016/j.imlet.2020.06.008	2020	Eomesodermin promotes interaction of RelA and NFATc2 with the Ifng promoter and multiple conserved noncoding sequences across the Ifng locus in mouse lymphoma BW5147 cells.	STAT3
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	STAT3
32573700	10.1182/blood.2019003793	2020	IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.	STAT3
32637355	10.3389/fonc.2020.00898	2020	Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine.	STAT3
32641029	10.1186/s12906-020-03006-2	2020	Matrine inhibits the growth of natural killer/T-cell lymphoma cells by modulating CaMKIIŒ≥-c-Myc signaling pathway.	STAT3
32643174	10.1111/ijd.15036	2020	Mapping signal transducer and activator of transcription (STAT) activity in different stages of mycosis fungoides and Sezary syndrome.	STAT3
32658867	10.18632/aging.103490	2020	CAMKIIŒ≥ is a targetable driver of multiple myeloma through CaMKIIŒ≥/ Stat3 axis.	STAT3
32668392	10.1016/j.omtn.2020.06.016	2020	The Role and Underlying Mechanism of Exosomal CA1 in Chemotherapy Resistance in Diffuse Large B Cell Lymphoma.	STAT3
32671511	10.1007/s10528-020-09982-x	2020	TIAM1 Upregulation Confers NVP-BEZ235 Resistance to Breast Cancer Cells Through FGFR/STAT3 Pathway.	STAT3
32682634	10.1016/j.jdermsci.2020.06.013	2020	Hydroa vacciniforme-like lymphoproliferative disorder: A study of clinicopathology and whole-exome sequencing in Chinese patients.	STAT3
32704112	10.1038/s41598-020-69227-0	2020	IL-21 Stimulates the expression and activation of cell cycle regulators and promotes cell proliferation in EBV-positive diffuse large B cell lymphoma.	STAT3
32708974	10.3390/genes11070816	2020	BCL2L15 Depletion Inhibits Endometrial Receptivity via the STAT1 Signaling Pathway.	STAT3
32714471	10.1016/j.curtheres.2020.100589	2020	Cell Death by Gallotannin Is Associated with Inhibition of the JAK/STAT Pathway in Human Colon Cancer Cells.	STAT3
32735617	10.1371/journal.ppat.1008701	2020	Interleukin 16 contributes to gammaherpesvirus pathogenesis by inhibiting viral reactivation.	STAT3
32744682	10.26355/eurrev_202007_22251	2020	MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway.	STAT3
32779615	10.3960/jslrt.20019	2020	Clinical application of genomic aberrations in adult T-cell leukemia/lymphoma.	STAT3
32798587	10.1016/j.canlet.2020.07.032	2020	Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.	STAT3
32850389	10.3389/fonc.2020.01276	2020	Indolent T-Cell Lymphoproliferative Disease of the GI Tract: Insights for Better Diagnosis, Prognosis, and Appropriate Therapy.	STAT3
32858764	10.1111/jcmm.15774	2020	IKKŒµ and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKKŒµ/TBK1 inhibitor to repress NF-Œ∫B and IL-10 signalling.	STAT3
32859630	10.21873/cgp.20208	2020	Combination of ERK2 and STAT3 Inhibitors Promotes Anticancer Effects on Acute Lymphoblastic Leukemia Cells.	STAT3
32865519	10.1172/JCI133283	2020	Beclin 2 negatively regulates innate immune signaling and tumor development.	STAT3
32865793	10.1007/978-1-0716-0771-8_15	2020	Targeted Gene Silencing in Malignant Hematolymphoid Cells Using GapmeR.	STAT3
32866816	10.1016/j.jns.2020.117102	2020	Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.	STAT3
32876369	10.1111/cas.14638	2020	Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.	STAT3
32922661	10.18632/oncotarget.27683	2020	The NKL-code for innate lymphoid cells reveals deregulated expression of NKL homeobox genes HHEX and HLX in anaplastic large cell lymphoma (ALCL).	STAT3
32966974	10.1159/000500713	2020	HDAC3 Silencing Enhances Acute B Lymphoblastic Leukaemia Cells Sensitivity to MG-132 by Inhibiting the JAK/Signal Transducer and Activator of Transcription 3 Signaling Pathway.	STAT3
32992412	10.3760/cma.j.cn112151-20200205-00066	2020	[Expression of pSTAT3 and PD-L1 in extranodal NK/T cell lymphoma and its clinical significance].	STAT3
33002095	10.1371/journal.ppat.1008849	2020	STAT3 imparts BRCAness¬†by impairing homologous recombination repair in Epstein-Barr virus-transformed B lymphocytes.	STAT3
33102814	10.1016/j.bbrep.2020.100832	2020	Cucurbitacin E and I target the JAK/STAT pathway and induce apoptosis in S√©zary cells.	STAT3
33113625	10.3760/cma.j.cn112152-20200220-00107	2020	[Silencing PBX1 expression induces apoptosis and ROS production of lung cancer cells].	STAT3
33123290	10.7150/jca.47816	2020	Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients.	STAT3
33141118	10.1172/JCI134990	2020	ALK-transformed mature T lymphocytes restore early thymus progenitor features.	STAT3
33212804	10.3390/ph13110397	2020	Small-Dose Sunitinib Modulates p53, Bcl-2, STAT3, and ERK1/2 Pathways and Protects against Adenine-Induced Nephrotoxicity.	STAT3
33225311	10.1158/2643-3230.BCD-20-0051	2020	Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway.	STAT3
33228022	10.3390/cancers12113435	2020	Carcinoma-Associated Fibroblasts Promote Growth of Sox2-Expressing Breast Cancer Cells.	STAT3
33260630	10.3390/genes11121434	2020	TYK2 Variants in B-Acute Lymphoblastic Leukaemia.	STAT3
33318172	10.1073/pnas.2013194117	2020	HIV proviral DNA integration can drive T cell growth ex vivo.	STAT3
33322712	10.3390/molecules25245881	2020	The Anti-Cancer Effect of Linusorb B3 from Flaxseed Oil through the Promotion of Apoptosis, Inhibition of Actin Polymerization, and Suppression of Src Activity in Glioblastoma Cells.	STAT3
33323828	10.1097/CM9.0000000000001294	2020	R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms.	STAT3
33331925	10.1182/blood.2020005372	2020	Chromosome 20 loss is characteristic of breast implant-associated anaplastic large cell lymphoma.	STAT3
33333886	10.3390/cells9122692	2020	Epigenetic Silencing of Tumor Suppressor miR-124 Directly Supports STAT3 Activation in Cutaneous T-Cell Lymphoma.	STAT3
33376237	10.1038/s41392-020-00331-3	2020	Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.	STAT3
34661140	10.1158/2643-3249.BCD-20-0075	2020	The Genomic Landscape of HIV-Associated Plasmablastic Lymphoma.	STAT3
35117335	10.21037/tcr-20-2151	2020	Primary pulmonary extranodal NK/T-cell lymphoma: a case report and literature review.	STAT3
29792338	10.1177/0960327118777869	2019	Molecular mechanism for the influence of gender dimorphism on alcoholic liver injury in mice.	STAT3
29911923	10.1080/10428194.2018.1461861	2019	MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia.	STAT3
30030006	10.1016/j.jaci.2018.06.036	2019	Human T<sub>H</sub>9 differentiation is dependent on signal transducer and activator of transcription (STAT) 3 to restrain STAT1-mediated inhibition.	STAT3
30131584	10.1038/s41375-018-0239-1	2019	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.	STAT3
30198914	10.1097/CAD.0000000000000692	2019	Effects of 9-cis-retinoic acid on the proliferation and apoptosis of cutaneous T-cell lymphoma cells.	STAT3
30206415	10.1038/s41379-018-0130-7	2019	Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas.	STAT3
30218753	10.1016/j.humpath.2018.08.025	2019	Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis.	STAT3
30299211	10.1080/15384047.2018.1504721	2019	MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1.	STAT3
30348636	10.1158/1078-0432.CCR-18-1153	2019	Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma.	STAT3
30365149	10.3892/or.2018.6798	2019	I157172, a novel inhibitor of cystathionine Œ≥-lyase, inhibits growth and migration of breast cancer cells via SIRT1-mediated deacetylation of STAT3.	STAT3
30370578	10.1002/jcp.27398	2019	microRNA-874 inhibition targeting STAT3 protects the heart from ischemia-reperfusion injury by attenuating cardiomyocyte apoptosis in a mouse model.	STAT3
30371509	10.1097/PAS.0000000000001180	2019	Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas.	STAT3
30381301	10.3324/haematol.2018.201590	2019	TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation <i>via</i> NF-Œ∫B mediated signaling in B-cells.	STAT3
30387321	10.1111/jcmm.13945	2019	Dynein axonemal intermediate chain 2 plays a role in gametogenesis by activation of Stat3.	STAT3
30395862	10.1016/j.athoracsur.2018.09.031	2019	Pretreatment With Diazoxide Attenuates Spinal Cord Ischemia-Reperfusion Injury Through Signaling Transducer and Activator of Transcription 3 Pathway.	STAT3
30431687	10.1002/jbt.22243	2019	Evaluation of the renoprotective effect of nano turmeric against toxic dose of copper sulfate: Role of vascular cell adhesion molecule-1, kidney injury molecule-1, and signal transducer and activator of transcription 3 protein expressions.	STAT3
30446590	10.1158/1078-0432.CCR-18-1226	2019	Neutrophil Extracellular Traps Induced by IL8 Promote Diffuse Large B-cell Lymphoma Progression via the TLR9 Signaling.	STAT3
30450688	10.1111/1346-8138.14702	2019	Papuloerythroderma-like cutaneous involvement of a CD62L<sup>-</sup> subclone of T-cell prolymphocytic leukemia.	STAT3
30510251	10.1038/s41591-018-0262-9	2019	Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.	STAT3
30529073	10.1016/j.neo.2018.11.006	2019	Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.	STAT3
30530749	10.1182/blood-2018-05-851667	2019	Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.	STAT3
30535477	10.3892/ijmm.2018.4012	2019	Cryptotanshinone induces reactive oxygen species‚Äëmediated apoptosis in human rheumatoid arthritis fibroblast‚Äëlike synoviocytes.	STAT3
30567732	10.4049/jimmunol.1800876	2019	BCL6-Mediated Silencing of PD-1 Ligands in Germinal Center B Cells Maintains Follicular T Cell Population.	STAT3
30623224	10.1007/s00347-018-0840-8	2019	[New molecular pathological strategies for malignant iris tumors].	STAT3
30631148	10.1038/s41388-018-0670-9	2019	Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.	STAT3
30639963	10.1016/j.tranon.2018.12.008	2019	STAT-3 RNAscope Determination in Human Diffuse Large B-Cell Lymphoma.	STAT3
30658101	10.1016/j.lfs.2019.01.022	2019	PIM inhibitor SMI-4a induces cell apoptosis in B-cell acute lymphocytic leukemia cells via the HO-1-mediated JAK2/STAT3 pathway.	STAT3
30675310	10.3892/ol.2018.9838	2019	MicroRNA-543 suppresses liver cancer growth and induces apoptosis via the JAK2/STAT3 signaling pathway.	STAT3
30692217	10.1158/0008-5472.CAN-18-0359	2019	The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3.	STAT3
30715169	10.1093/asj/sjy311	2019	Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).	STAT3
30715174	10.1093/asj/sjy250	2019	What Cytokines Can Tell Us About the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).	STAT3
30726736	10.1016/j.celrep.2019.01.034	2019	Bone Marrow Mesenchymal Stromal Cell-Derived Periostin Promotes B-ALL Progression by Modulating CCL2 in Leukemia Cells.	STAT3
30741923	10.1038/s41467-019-08605-3	2019	Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation.	STAT3
30745139	10.1016/j.clml.2018.12.020	2019	Prognostic Significance of Serum Copper in Patients With Cutaneous T-cell Lymphoma.	STAT3
30747218	10.3892/or.2019.6976	2019	Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non‚Äësmall cell lung cancer A549 cells via the JAK/STAT3 signaling pathway.	STAT3
30755239	10.1186/s13046-019-1081-7	2019	Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels.	STAT3
30770362	10.1182/bloodadvances.2018020602	2019	PD-L1 and tumor-associated macrophages in de novo DLBCL.	STAT3
30782609	10.1182/blood-2018-09-872549	2019	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.	STAT3
30787154	10.1128/JVI.02290-18	2019	Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.	STAT3
30805320	10.3389/fped.2019.00014	2019	Advances in the Study of Chronic Active Epstein-Barr Virus Infection: Clinical Features Under the 2016 WHO Classification and Mechanisms of Development.	STAT3
30837035	10.3727/096504018X15439207752093	2019	miR-101 Represses T-Cell Acute Lymphoblastic Leukemia by Targeting CXCR7/STAT3 Axis.	STAT3
30864721	10.3892/mmr.2019.10011	2019	CircRNA‚Äë0044073 is upregulated in atherosclerosis and increases the proliferation and invasion of cells by targeting miR‚Äë107.	STAT3
30910759	10.1016/j.jid.2019.03.1130	2019	Contribution of STAT3 and RAD23B in Primary S√©zary Cells to Histone Deacetylase Inhibitor FK228 Resistance.	STAT3
30926771	10.1038/s41408-019-0203-y	2019	Inhibition of the STAT3 target SGK1 sensitizes diffuse large B cell lymphoma cells to AKT inhibitors.	STAT3
30935402	10.1186/s13045-019-0716-7	2019	Molecular pathogenic pathways in extranodal NK/T cell lymphoma.	STAT3
30953147	10.1007/s00428-019-02570-4	2019	Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior.	STAT3
30962205	10.1182/blood.2018880138	2019	Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells.	STAT3
30972748	10.1002/jcp.28410	2019	microRNA-30a inhibits the liver cell proliferation and promotes cell apoptosis through the JAK/STAT signaling pathway by targeting SOCS-1 in rats with sepsis.	STAT3
30988279	10.1038/s41419-019-1563-8	2019	Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma.	STAT3
31002169	10.26355/eurrev_201904_17586	2019	Effect of IL-6-mediated STAT3 signaling pathway on myocardial apoptosis in mice with dilated cardiomyopathy.	STAT3
31002364	10.3892/or.2019.7112	2019	JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T‚Äëcell lymphoma, nasal type.	STAT3
31032347	10.1155/2019/4860268	2019	Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy.	STAT3
31038184	10.5114/fn.2019.83827	2019	Ginkgetin aglycone attenuates neuroinflammation and neuronal injury in the rats with ischemic stroke by modulating STAT3/JAK2/SIRT1.	STAT3
31044025	10.4081/oncol.2019.400	2019	Prognostic significance of aberrant CD5 expression in B-cell leukemia.	STAT3
31054507	10.1016/j.biopha.2019.108913	2019	Promoter methylation and expression of SOCS3 affect the clinical outcome of pediatric acute lymphoblastic leukemia by JAK/STAT pathway.	STAT3
31098955	10.1007/s12539-019-00331-0	2019	PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation.	STAT3
31108175	10.1016/j.fsi.2019.05.034	2019	Ctenopharyngodon Idella STAT3 alleviates autophagy by up-regulating BCL-2 expression.	STAT3
31125630	10.1016/j.humpath.2019.05.007	2019	Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas.	STAT3
31141539	10.1371/journal.pone.0216898	2019	Epstein-Barr virus (EBV) activates NKL homeobox gene HLX in DLBCL.	STAT3
31151983	10.1182/blood.2019001043	2019	A novel model of controlling PD-L1 expression in ALK<sup>+</sup> anaplastic large cell lymphoma revealed by CRISPR screening.	STAT3
31155767	10.1111/jpn.13110	2019	Dietary l-arginine supplementation influences growth performance and B-cell secretion of immunoglobulin in broiler chickens.	STAT3
31213131	10.1080/15384101.2019.1629789	2019	miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.	STAT3
31237072	10.1111/cas.14114	2019	Phosphorylated STAT3 expression predicts better prognosis in smoldering type of adult T-cell leukemia/lymphoma.	STAT3
31311407	10.1080/15384047.2019.1638670	2019	Somatic mutations in <i>KMT2D</i> and <i>TET2</i> associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders.	STAT3
31313387	10.1002/JLB.5RU0519-145R	2019	JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy.	STAT3
31321184	10.1097/GOX.0000000000002188	2019	Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.	STAT3
31331920	10.1182/blood.2018888107	2019	Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma.	STAT3
31364140	10.26355/eurrev_201907_18456	2019	Effect of propofol on myocardial ischemia/reperfusion injury in rats through JAK/STAT signaling pathway.	STAT3
31364141	10.26355/eurrev_201907_18457	2019	Effects of propofol on myocardial ischemia reperfusion injury through inhibiting the JAK/STAT pathway.	STAT3
31364493	10.1161/JAHA.119.012047	2019	Systems Network Genomic Analysis Reveals Cardioprotective Effect of MURC/Cavin-4 Deletion Against Ischemia/Reperfusion Injury.	STAT3
31390744	10.3390/cancers11081119	2019	NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma.	STAT3
31391340	10.1172/jci.insight.128435	2019	Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma.	STAT3
31394087	10.1016/j.yexmp.2019.104294	2019	RHOA G17V mutation in angioimmunoblastic T-cell lymphoma: A potential biomarker for cytological assessment.	STAT3
31404445	10.1007/s12308-019-00354-y	2019	Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas.	STAT3
31503548	10.1172/JCI127721	2019	Myeloid loss of Beclin 1 promotes PD-L1hi precursor B cell lymphoma development.	STAT3
31515941	10.15252/emmm.201910576	2019	The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma.	STAT3
31568628	10.1111/jcmm.14653	2019	Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.	STAT3
31585620	10.1016/j.beha.2019.06.003	2019	Genomics of LGL leukemia and select other rare leukemia/lymphomas.	STAT3
31601188	10.1186/s12885-019-6057-7	2019	Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.	STAT3
31627175	10.1016/j.pharep.2019.05.021	2019	N-Acetyl cysteine prevents activities of STAT3 inhibitors, Stattic and BP-1-102 independently of its antioxidant properties.	STAT3
31654627	10.1016/j.bcp.2019.113666	2019	Methotrexate significantly induces apoptosis by inhibiting STAT3 activation in NPM-ALK-positive ALCL cells.	STAT3
31684088	10.3390/cancers11111711	2019	STAT3 Dysregulation in Mature T and NK Cell Lymphomas.	STAT3
31693087	10.1042/BSR20182376	2019	Emerging roles of the long non-coding RNA 01296/microRNA-143-3p/MSI2 axis in development of thyroid cancer.	STAT3
31701713	10.12047/j.cjap.5799.2019.066	2019	[Effects of 2-12alkyl-6-methoxycyclohexa-2, 5-diene-1, 4-dione(DMDD)on diffuse large B lymphoma and its mechanism].	STAT3
31715132	10.1016/j.ccell.2019.10.002	2019	A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In¬†Vivo.	STAT3
31718693	10.1186/s13046-019-1428-0	2019	Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6.	STAT3
31747516	10.1021/acs.jmedchem.9b01530	2019	Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.	STAT3
31752432	10.3390/ijms20225816	2019	In Vitro Effects of Vaspin on Porcine Granulosa Cell Proliferation, Cell Cycle Progression, and Apoptosis by Activation of GRP78 Receptor and Several Kinase Signaling Pathways Including MAP3/1, AKT, and STAT3.	STAT3
31754348	10.1186/s12935-019-1011-y	2019	Circ_ZNF124 promotes non-small cell lung cancer progression by abolishing miR-337-3p mediated downregulation of JAK2/STAT3 signaling pathway.	STAT3
31772601	10.1155/2019/8128170	2019	Uncovering the Anticancer Mechanism of Compound Sophorae Decoction against Ulcerative Colitis-Related Colorectal Cancer in Mice.	STAT3
31777595	10.7150/jca.30361	2019	The Effects and Mechanisms by which Saikosaponin-D Enhances the Sensitivity of Human Non-small Cell Lung Cancer Cells to Gefitinib.	STAT3
31779213	10.3390/biom9120787	2019	Betulinic Acid Attenuates T-2-Toxin-Induced Testis Oxidative Damage Through Regulation of the JAK2/STAT3 Signaling Pathway in Mice.	STAT3
31783811	10.1186/s12885-019-6381-y	2019	Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells.	STAT3
31861597	10.3390/cancers12010019	2019	STAT3 Activation and Oncogenesis in Lymphoma.	STAT3
31901912	NA	2019	pSTAT3 and MYC in Epstein-Barr virus-positive diffuse large B-cell lymphoma.	STAT3
32063711	10.2147/OTT.S222189	2019	Prevalence And Clinical Significance Of Oncogenic <i>CD79B</i> And <i>MYD88</i> Mutations In Primary Testicular Diffuse Large B-Cell Lymphoma: A Retrospective Study In China.	STAT3
32186040	NA	2019	Efficacy of Zhonglun'a-decoction-containing serum on fibroblast-like synoviocyte apoptosis in rats with collagen-induced arthritis via inhibiting Janus kinase/signal transducer and activator of transcription signaling pathway.	STAT3
28633612	10.1080/10428194.2017.1339880	2018	Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL).	STAT3
28665006	10.1002/hon.2455	2018	Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma.	STAT3
28835002	10.4062/biomolther.2017.099	2018	Cripto Enhances Proliferation and Survival of Mesenchymal Stem Cells by Up-Regulating JAK2/STAT3 Pathway in a GRP78-Dependent Manner.	STAT3
28901004	10.1002/eji.201747017	2018	Bcl-3 induced by IL-22 via STAT3 activation acts as a potentiator of psoriasis-related gene expression in epidermal keratinocytes.	STAT3
28905990	10.1002/ijc.31044	2018	The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.	STAT3
28940360	10.1111/cei.13054	2018	Lys63-polyubiquitination by the E3 ligase casitas B-lineage lymphoma-b (Cbl-b) modulates peripheral regulatory T cell tolerance in patients with systemic lupus erythematosus.	STAT3
29084771	10.1182/blood-2017-01-761874	2018	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.	STAT3
29097500	10.3324/haematol.2017.179309	2018	A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.	STAT3
29115552	10.3892/mmr.2017.8008	2018	Effects of daphnetin combined with Bcl2‚ÄësiRNA on antiapoptotic genes in synovial fibroblasts of rats with collagen‚Äëinduced arthritis.	STAT3
29119628	10.1111/jvim.14860	2018	STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs.	STAT3
29128259	10.1016/j.jid.2017.10.028	2018	Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of¬†Cutaneous T-Cell Lymphoma.	STAT3
29164994	10.1080/10428194.2017.1397668	2018	STAT3 inhibition as a therapeutic strategy for leukemia.	STAT3
29207064	10.3892/mmr.2017.8110	2018	Quinalizarin exerts an anti-tumour effect on lung cancer A549 cells by modulating the Akt, MAPK, STAT3 and p53 signalling pathways.	STAT3
29258893	10.1016/j.jid.2017.12.010	2018	LMO4 Is a Disease-Provocative Transcription Coregulator Activated by IL-23 in Psoriatic Keratinocytes.	STAT3
29286137	10.3892/mmr.2017.8348	2018	MicroRNA-124a inhibits cell proliferation and migration in liver cancer by regulating interleukin-11.	STAT3
29295936	10.1073/pnas.1715118115	2018	Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.	STAT3
29304536	10.1160/TH17-04-0275	2018	Defibrotide Stimulates Angiogenesis and Protects Endothelial Cells from Calcineurin Inhibitor-Induced Apoptosis via Upregulation of AKT/Bcl-xL.	STAT3
29337025	10.1016/j.humpath.2018.01.005	2018	Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors.	STAT3
29346274	10.3390/cancers10010021	2018	IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.	STAT3
29353075	10.1016/j.exphem.2018.01.003	2018	BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints.	STAT3
29393473	10.3892/mmr.2018.8543	2018	Protective effects of N(2)‚ÄëL‚Äëalanyl‚ÄëL‚Äëglutamine mediated by the JAK2/STAT3 signaling pathway on myocardial ischemia reperfusion.	STAT3
29399062	10.3892/etm.2017.5414	2018	The effect of hydroxy safflower yellow A on coronary heart disease through Bcl-2/Bax and PPAR-Œ≥.	STAT3
29399699	10.3892/or.2018.6220	2018	The role of aldehyde dehydrogenase 1A1 in B-cell non-Hodgkin's lymphoma.	STAT3
29433938	10.1016/j.ymthe.2018.01.007	2018	B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.	STAT3
29434770	10.3892/etm.2017.5600	2018	MicroRNA-519a inhibits the proliferation and promotes the apoptosis of ovarian cancer cells through targeting signal transducer and activator of transcription 3.	STAT3
29434895	10.3892/ol.2017.7502	2018	Dihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling.	STAT3
29434967	10.3892/ol.2017.7593	2018	Celastrol suppresses the proliferation of lung adenocarcinoma cells by regulating microRNA-24 and microRNA-181b.	STAT3
29444468	10.1016/j.ejphar.2018.02.012	2018	A major component of vitamin E, Œ±-tocopherol inhibits the anti-tumor activity of crizotinib against cells transformed by EML4-ALK.	STAT3
29463696	10.1073/pnas.1713889115	2018	Genetic rescue of lineage-balanced blood cell production reveals a crucial role for STAT3 antiinflammatory activity in hematopoiesis.	STAT3
29464048	10.18632/oncotarget.23192	2018	Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action.	STAT3
29475733	10.1016/j.ymthe.2018.02.006	2018	Decoy-Based, Targeted Inhibition of STAT3: A New Step forward for B Cell Lymphoma Immunotherapy.	STAT3
29477912	10.1016/j.biopha.2018.02.019	2018	Bavachin induces the apoptosis of multiple myeloma cell lines by inhibiting the activation of nuclear factor kappa B and signal transducer and activator of transcription 3.	STAT3
29490645	10.1186/s12967-018-1421-y	2018	Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia.	STAT3
29496539	10.1016/j.canlet.2018.02.036	2018	Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer.	STAT3
29511132	10.1634/theoncologist.2017-0325	2018	A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.	STAT3
29531812	10.1038/s41420-017-0012-7	2018	Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells.	STAT3
29541181	10.3892/ol.2018.7830	2018	Effects of purified <i>Omphalia lapidescens</i> protein on metastasis, cell cycle, apoptosis and the JAK-STAT signaling pathway in SGC-7901 human gastric cells.	STAT3
29581848	10.18632/oncotarget.24512	2018	Aberrant expression of NKL homeobox gene HLX in Hodgkin lymphoma.	STAT3
29595984	10.1021/acs.molpharmaceut.8b00059	2018	Exosomes from Irradiated Nonsmall Cell Lung Cancer Cells Reduced Sensitivity of Recipient Cells to Anaplastic Lymphoma Kinase Inhibitors.	STAT3
29619509	10.1007/s00262-018-2156-6	2018	Interferon-Œ±2b-induced STAT3 suppression in myeloid-derived suppressor cells in mycosis fungoides.	STAT3
29637270	10.1007/s00428-018-2352-y	2018	Dual JAK1 and STAT3 mutations in a breast implant-associated anaplastic large cell lymphoma.	STAT3
29641255	10.1089/cbr.2017.2386	2018	MiR-17 Regulates Prostate Cancer Cell Proliferation and Apoptosis Through Inhibiting JAK-STAT3 Signaling Pathway.	STAT3
29650799	10.1182/blood-2017-11-814913	2018	Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.	STAT3
29666362	10.1038/s41467-018-03803-x	2018	Cooperative STAT/NF-Œ∫B signaling regulates lymphoma metabolic reprogramming and aberrant GOT2 expression.	STAT3
29674644	10.1038/s41467-018-03987-2	2018	Aggressive natural killer-cell leukemia¬†mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.	STAT3
29681389	10.1016/j.jid.2017.12.022	2018	A Microbiota-Dependent, STAT3-Driven Mouse Model of Cutaneous T-Cell Lymphoma.	STAT3
29689246	10.1016/j.humpath.2018.04.007	2018	IL-13 is produced by tumor cells in breast implant-associated anaplastic large cell lymphoma: implications for pathogenesis.	STAT3
29695237	10.1186/s12885-018-4266-0	2018	Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation.	STAT3
29702481	10.2478/acph-2018-0013	2018	Paeoniflorin inhibits the growth of bladder carcinoma via deactivation of STAT3.	STAT3
29740433	10.3389/fimmu.2018.00787	2018	SYK Inhibition Induces Apoptosis in Germinal Center-Like B Cells by Modulating the Antiapoptotic Protein Myeloid Cell Leukemia-1, Affecting B-Cell Activation and Antibody Production.	STAT3
29750888	10.33549/physiolres.933738	2018	Adiponectin enhances biological functions of vascular endothelial progenitor cells through the mTOR-STAT3 signaling pathway.	STAT3
29752696	10.1007/s11655-018-2563-8	2018	Total Saponins of Rubus Parvifolius L. Exhibited Anti-Leukemia Effect in vivo through STAT3 and eIF4E Signaling Pathways.	STAT3
29794468	10.1159/000490019	2018	Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma.	STAT3
29805643	10.3892/ol.2018.8522	2018	Chrysin induces cell growth arrest, apoptosis, and ER stress and inhibits the activation of STAT3 through the generation of ROS in bladder cancer cells.	STAT3
29857068	10.1016/j.jid.2018.04.038	2018	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.	STAT3
29898964	10.4049/jimmunol.1800400	2018	Early Generated B-1-Derived B Cells Have the Capacity To Progress To Become Mantle Cell Lymphoma-like Neoplasia in Aged Mice.	STAT3
29928398	10.3892/ol.2018.8639	2018	Hydrogen-rich solution attenuates myocardial injury caused by cardiopulmonary bypass in rats via the Janus-activated kinase 2/signal transducer and activator of transcription 3 signaling pathway.	STAT3
29992138	10.1155/2018/3574534	2018	Identification of Hub Genes and Key Pathways Associated with Two Subtypes of Diffuse Large B-Cell Lymphoma Based on Gene Expression Profiling via Integrated Bioinformatics.	STAT3
30013646	10.3892/ol.2018.8899	2018	Pachymic acid inhibits growth and induces cell cycle arrest and apoptosis in gastric cancer SGC-7901 cells.	STAT3
30020405	10.1093/abbs/gmy076	2018	PIM1 overexpression in T-cell lymphomas protects tumor cells from apoptosis and confers doxorubicin resistance by upregulating c-myc expression.	STAT3
30054295	10.1182/blood-2018-01-829424	2018	Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.	STAT3
30093402	10.1182/blood-2018-03-838524	2018	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with <i>DUSP22</i> rearrangements.	STAT3
30099568	10.1007/s00277-018-3439-x	2018	Novel synthetic 4-chlorobenzoyl berbamine inhibits c-Myc expression and induces apoptosis of diffuse large B cell lymphoma cells.	STAT3
30132572	10.3892/mmr.2018.9420	2018	Alpinetin inhibits proliferation and migration of ovarian cancer cells via suppression of STAT3 signaling.	STAT3
30194286	10.12659/MSM.910170	2018	Inhibition of JAK2/STAT3 Signaling Pathway Suppresses Proliferation of Burkitt's Lymphoma Raji Cells via Cell Cycle Progression, Apoptosis, and Oxidative Stress by Modulating HSP70.	STAT3
30209121	10.1182/blood-2018-03-841015	2018	B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.	STAT3
30209389	10.1038/s41467-018-06134-z	2018	STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas.	STAT3
30214513	10.3892/etm.2018.6562	2018	Tanshinone IIA inhibits cell proliferation and tumor growth by downregulating STAT3 in human gastric cancer.	STAT3
30217007	10.3390/cancers10090327	2018	The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies.	STAT3
30217447	10.1016/j.bbrc.2018.09.019	2018	Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression.	STAT3
30231940	10.1186/s13045-018-0665-6	2018	JAG1 overexpression contributes to Notch1 signaling and the migration of HTLV-1-transformed ATL cells.	STAT3
30250636	10.18632/oncotarget.26054	2018	JAK inhibitors for refractory lymphoma.	STAT3
30253331	10.1016/j.intimp.2018.09.024	2018	MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade.	STAT3
30257404	10.1016/j.biopha.2018.08.091	2018	The relationship between lncRNA PCGEM1 and STAT3 during the occurrence and development of endometrial carcinoma.	STAT3
30272302	10.3892/or.2018.6711	2018	Taurolidine promotes cell apoptosis by enhancing GRIM‚Äë19 expression in liver cancer.	STAT3
30305518	10.11406/rinketsu.59.2127	2018	[Genetic analysis and its clinical implication in adult T-cell leukemia/lymphoma].	STAT3
30334451	10.4149/neo_2018_180121N44	2018	miR-451a induced apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells by targeting IL-6R.	STAT3
30335863	10.1371/journal.pone.0206014	2018	Oncogenic mutations in IKKŒ≤ function through global changes induced by K63-linked ubiquitination and result in autocrine stimulation.	STAT3
30360879	10.1053/j.seminoncol.2018.07.005	2018	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	STAT3
30384495	10.3390/v10110599	2018	EBV and KSHV Infection Dysregulates Autophagy to Optimize Viral Replication, Prevent Immune Recognition and Promote Tumorigenesis.	STAT3
30390336	10.1002/jcb.28000	2018	Icaritin inhibits glioblastoma cell viability and glycolysis by blocking the IL-6/Stat3 pathway.	STAT3
30405790	10.3892/ol.2018.9475	2018	Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.	STAT3
30410493	10.3389/fimmu.2018.02470	2018	Molecular Control of Follicular Helper T cell Development and Differentiation.	STAT3
30420593	10.1038/s41408-018-0138-8	2018	Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.	STAT3
30446007	10.1186/s40425-018-0436-5	2018	STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.	STAT3
30458835	10.1186/s12967-018-1689-y	2018	Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.	STAT3
30501694	10.7534/j.issn.1009-2137.2018.06.007	2018	[Effect of IL-8 on the Immune Function of Patients with Acute -Lymphoblastic Leukemia and Its Mechanism].	STAT3
30534553	10.1155/2018/1042597	2018	Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.	STAT3
30546832	10.18632/oncotarget.26308	2018	Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma.	STAT3
30619766	10.3389/fonc.2018.00632	2018	Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion.	STAT3
30704352	10.1080/25785826.2018.1556030	2018	Chronic active Epstein-Barr virus infection: a bi-faceted disease with inflammatory and neoplastic elements.	STAT3
31949637	NA	2018	Aggressive natural killer cell leukemia mimicking interstitial lung diseases with the activation of the mitogen-activated protein kinase pathway.	STAT3
35547965	10.1039/c8ra05224g	2018	Screening of ferrocenyl-phosphines identifies a gold-coordinated derivative as a novel anticancer agent for hematological malignancies.	STAT3
27924626	10.14670/HH-11-852	2017	Expression of the activation markers Blimp1, Foxp1 and pStat3 in extranodal diffuse large B-cell lymphomas.	STAT3
28009988	10.18632/oncotarget.14032	2017	A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway.	STAT3
28069035	10.1186/s13046-016-0476-y	2017	Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.	STAT3
28082737	10.1038/leu.2017.13	2017	Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL.	STAT3
28344319	10.1038/leu.2017.103	2017	PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.	STAT3
28356514	10.1073/pnas.1700682114	2017	Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.	STAT3
28414323	10.1038/labinvest.2017.39	2017	Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma.	STAT3
28483518	10.1016/j.bbrc.2017.05.031	2017	STAT3 mediates multidrug resistance of Burkitt lymphoma cells by promoting antioxidant feedback.	STAT3
28522550	10.1042/BSR20170186	2017	Suppression of microRNA-135b-5p protects against myocardial ischemia/reperfusion injury by activating JAK2/STAT3 signaling pathway in mice during sevoflurane anesthesia.	STAT3
28529032	10.1016/j.ebiom.2017.04.037	2017	Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis.	STAT3
28534932	10.3892/mmr.2017.6583	2017	Inhibition of prostate cancer RM1 cell growth in¬†vitro by hydroxyapatite nanoparticle‚Äëdelivered short hairpin RNAs against Stat3.	STAT3
28535087	10.1080/10428194.2017.1324154	2017	Cytotoxic T cells in chronic idiopathic neutropenia express restricted antigen receptors.	STAT3
28599489	10.3892/ol.2017.6073	2017	Maslinic acid suppresses the growth of human gastric cells by inducing apoptosis via inhibition of the interleukin-6 mediated Janus kinase/signal transducer and activator of transcription 3 signaling pathway.	STAT3
28617558	NA	2017	Up-regulation of miR-124 inhibits invasion and proliferation of prostate cancer cells through mediating JAK-STAT3 signaling pathway.	STAT3
28619949	10.1189/jlb.5MA1116-453RR	2017	Expansion and activation of granulocytic, myeloid-derived suppressor cells in childhood precursor B cell acute lymphoblastic leukemia.	STAT3
28623282	10.1038/s41598-017-03967-4	2017	A Nationwide Study of Severe and Protracted Diarrhoea in Patients with Primary Immunodeficiency Diseases.	STAT3
28640256	10.1038/cddis.2017.291	2017	MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.	STAT3
28644106	10.1902/jop.2017.170116	2017	Viability and Osteogenic Differentiation of Human Periodontal Ligament Progenitor Cells Are Maintained After Incubation With Porphyromonas gingivalis Protein Extract.	STAT3
28653223	10.1007/s10495-017-1391-1	2017	Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma.	STAT3
28656237	10.3892/mmr.2017.6865	2017	Matrine increases the inhibitory effects of afatinib on H1975 cells via the IL‚Äë6/JAK1/STAT3 signaling pathway.	STAT3
28713965	10.3892/mmr.2017.6989	2017	Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.	STAT3
28716895	10.1158/0008-5472.CAN-16-0342	2017	CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity.	STAT3
28756223	10.1016/j.bbrc.2017.07.139	2017	BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.	STAT3
28806414	10.1371/journal.pone.0183003	2017	Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.	STAT3
28811825	10.1155/2017/4218468	2017	Ethanol Extract of <i>Mylabris phalerata</i> Inhibits M2 Polarization Induced by Recombinant IL-4 and IL-13 in Murine Macrophages.	STAT3
28837676	10.1371/journal.pone.0183516	2017	ALK signaling cascade confers multiple advantages to glioblastoma cells through neovascularization and cell proliferation.	STAT3
28842424	10.1096/fj.201700120RR	2017	Gab2 mediates hepatocellular carcinogenesis by integrating multiple signaling pathways.	STAT3
28848064	10.4049/jimmunol.1700106	2017	Integrated STAT3 and Ikaros Zinc Finger Transcription Factor Activities Regulate Bcl-6 Expression in CD4<sup>+</sup> Th Cells.	STAT3
28870600	10.1016/j.yexcr.2017.08.036	2017	Interleukin 10 enhanced CD8+ T cell activity and reduced CD8<sup>+</sup> T cell apoptosis in patients with diffuse large B cell lymphoma.	STAT3
28910419	10.1371/journal.ppat.1006597	2017	IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways.	STAT3
28950914	10.1186/s13046-017-0601-6	2017	Resveratrol inhibits Extranodal NK/T cell lymphoma through activation of DNA damage response pathway.	STAT3
28964970	10.1016/j.cellsig.2017.09.020	2017	Metformin triggers apoptosis in PEL cells and alters bortezomib-induced Unfolded Protein Response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation.	STAT3
29022919	10.1038/cddis.2017.472	2017	DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.	STAT3
29029457	10.18632/oncotarget.19936	2017	Prognostic relevance of protein expression, clinical factors, and <i>MYD88</i> mutation in primary bone lymphoma.	STAT3
29033545	10.2147/DDDT.S135993	2017	Downregulation of A20 increases the cytotoxicity of IFN-Œ≥ in hepatocellular carcinoma cells.	STAT3
29039526	10.3892/mmr.2017.7771	2017	Promoting effects of IL‚Äë23 on myocardial ischemia and reperfusion are associated with increased expression of IL‚Äë17A and upregulation of the JAK2‚ÄëSTAT3 signaling pathway.	STAT3
29043002	10.3892/etm.2017.4934	2017	Humanin analogue, S14G-humanin, has neuroprotective effects against oxygen glucose deprivation/reoxygenation by reactivating Jak2/Stat3 signaling through the PI3K/AKT pathway.	STAT3
29045271	10.1097/CAD.0000000000000552	2017	Rhabdomyosarcoma cells are susceptible to cell death by LDK378 alone or in combination with sorafenib independently of anaplastic lymphoma kinase status.	STAT3
29131834	10.1371/journal.pone.0187722	2017	Plasma microRNA profiling: Exploring better biomarkers for lymphoma surveillance.	STAT3
29133756	10.4103/0366-6999.218016	2017	Signal Transducer and Activator of Transcription 3 for the Differentiation of Hepatocellular Carcinoma from Cirrhosis.	STAT3
29142404	10.4103/pm.pm_13_17	2017	Chalepin: A Compound from <i>Ruta angustifolia</i> L. Pers Exhibits Cell Cycle Arrest at S phase, Suppresses Nuclear Factor-Kappa B (NF-Œ∫B) Pathway, Signal Transducer and Activation of Transcription 3 (STAT3) Phosphorylation and Extrinsic Apoptotic Pathway in Non-small Cell Lung Cancer Carcinoma (A549).	STAT3
29179721	10.1186/s13046-017-0632-z	2017	Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death.	STAT3
29228427	10.26355/eurrev_201711_13832	2017	MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway.	STAT3
29228628	10.18632/oncotarget.22178	2017	Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling.	STAT3
29262599	10.18632/oncotarget.21790	2017	Fusion of the genes ataxin 2 like, <i>ATXN2L</i>, and Janus kinase 2, <i>JAK2</i>, in cutaneous CD4 positive T-cell lymphoma.	STAT3
29279550	10.3960/jslrt.17023	2017	Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.	STAT3
29285175	10.3892/etm.2017.5329	2017	Quercetin prevents alcohol-induced liver injury through targeting of PI3K/Akt/nuclear factor-Œ∫B and STAT3 signaling pathway.	STAT3
29340070	10.18632/oncotarget.22847	2017	A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models.	STAT3
26738536	10.1182/blood-2015-08-662353	2016	Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.	STAT3
26789110	10.18632/oncotarget.6916	2016	Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma.	STAT3
26815506	10.1007/s13277-016-4861-0	2016	Curcumin analogue, A13, exhibits anti-leukemia effect via inhibiting STAT3.	STAT3
26983850	10.1182/blood-2015-10-678706	2016	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.	STAT3
27132469	10.1016/j.ccell.2016.03.026	2016	Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.	STAT3
27198716	10.3324/haematol.2016.146118	2016	Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma.	STAT3
27268052	10.1074/jbc.M116.736868	2016	Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.	STAT3
27371847	NA	2016	[Astaxanthin inhibits proliferation and promotes apoptosis of A549 lung cancer cells via blocking JAK1/STAT3 pathway].	STAT3
27436361	10.1126/scisignal.aad8953	2016	ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.	STAT3
27564404	10.1111/cas.13065	2016	An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.	STAT3
27633398	10.3892/or.2016.5091	2016	WP1066 exhibits antitumor efficacy in nasal‚Äëtype natural killer/T-cell lymphoma cells through downregulation of the STAT3 signaling pathway.	STAT3
24793791	10.1038/onc.2014.109	2015	Phosphorylated STAT3 physically interacts with NPM and transcriptionally enhances its expression in cancer.	STAT3
25586472	10.1038/ncomms7025	2015	Activating mutations of STAT5B and STAT3 in lymphomas derived from Œ≥Œ¥-T or NK cells.	STAT3
25612622	10.1182/blood-2014-07-588970	2015	Receptor-type tyrosine-protein phosphatase Œ∫ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma.	STAT3
25684945	10.3748/wjg.v21.i6.1804	2015	Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.	STAT3
25704763	10.1002/ijc.29494	2015	A natural HIV p17 protein variant up-regulates the LMP-1 EBV oncoprotein and promotes the growth of EBV-infected B-lymphocytes: implications for EBV-driven lymphomagenesis in the HIV setting.	STAT3
25717101	10.1128/JVI.00121-15	2015	Cellular STAT3 functions via PCBP2 to restrain Epstein-Barr Virus lytic activation in B lymphocytes.	STAT3
25977172	NA	2015	Effect of STAT3 inhibition on the metabolic switch in a highly STAT3-activated lymphoma cell line.	STAT3
25984943	10.1371/journal.pone.0127243	2015	Ratios of Four STAT3 Splice Variants in Human Eosinophils and Diffuse Large B Cell Lymphoma Cells.	STAT3
26080800	10.1007/s11060-015-1843-9	2015	STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.	STAT3
26184999	10.1016/j.canlet.2015.07.006	2015	Tyrosine kinase inhibitor tyrphostin AG490 triggers both apoptosis and autophagy by reducing HSF1 and Mcl-1 in PEL cells.	STAT3
26244872	10.18632/oncotarget.4111	2015	Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.	STAT3
26245900	10.1074/jbc.M115.657833	2015	The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.	STAT3
26255115	10.1016/j.biocel.2015.08.002	2015	Downregulation of STAT3 phosphorylation enhances tumoricidal effect of IL-15-activated dendritic cell against doxorubicin-resistant lymphoma and leukemia via TNF-Œ±.	STAT3
26430964	10.18632/oncotarget.5763	2015	Overexpression of Bcl-2 induces STAT-3 activation via an increase in mitochondrial superoxide.	STAT3
26500281	10.1042/BSR20150165	2015	Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells.	STAT3
26565811	10.18632/oncotarget.6300	2015	Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.	STAT3
26582900	10.1126/scitranslmed.aac5272	2015	AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.	STAT3
26675719	10.1038/nature16449	2015	Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site.	STAT3
23841503	10.3109/10428194.2013.824077	2014	Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas.	STAT3
23975180	10.3324/haematol.2013.088286	2014	STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.	STAT3
24497534	10.1182/blood-2013-12-544809	2014	GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.	STAT3
24892807	10.1172/JCI73174	2014	CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.	STAT3
25070240	10.1186/1476-4598-13-181	2014	ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex.	STAT3
25110240	10.5146/tjpath.2014.01269	2014	The expression of STAT3, BCL-XL and MMP-2 proteins in colon adenocarcinomas and their relationship with prognostic factors.	STAT3
25242136	10.3892/mmr.2014.2581	2014	Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells.	STAT3
25275020	NA	2014	STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides.	STAT3
22967991	10.1093/annonc/mds209	2013	A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome.	STAT3
23563237	10.1038/leu.2013.104	2013	STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia.	STAT3
23599149	10.1038/modpathol.2013.73	2013	ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements.	STAT3
23681230	10.1038/cddis.2013.159	2013	SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-Œ∫B/STAT3 complex to its promoter in malignant lymphoid cells.	STAT3
23716595	10.1128/MCB.01620-12	2013	STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.	STAT3
23740979	10.1128/JVI.02976-12	2013	Kaposi's sarcoma-associated herpesvirus kaposin B induces unique monophosphorylation of STAT3 at serine 727 and MK2-mediated inactivation of the STAT3 transcriptional repressor TRIM28.	STAT3
23741012	10.1182/blood-2012-11-465252	2013	STAT3 mediates oncogenic addiction to TEL-AML1 in t(12;21) acute lymphoblastic leukemia.	STAT3
23750211	10.1371/journal.pone.0064678	2013	Signal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemia.	STAT3
23768868	10.1016/j.leukres.2013.05.003	2013	Polymorphisms in JAK/STAT signaling pathway genes and risk of non-Hodgkin lymphoma.	STAT3
23830147	10.1016/j.jaci.2013.05.029	2013	Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8(+) T-cell memory formation and function.	STAT3
23861822	10.1371/journal.pone.0067851	2013	A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.	STAT3
23966384	10.1128/JVI.01762-13	2013	Signal transducer and activator of transcription 3 limits Epstein-Barr virus lytic activation in B lymphocytes.	STAT3
23995109	10.3960/jslrt.53.127	2013	Role of Stat3 activation in cell-cell interaction between B-cell lymphoma and macrophages: the in vitro study.	STAT3
24142927	10.1534/g3.113.007674	2013	STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-cell lymphoma.	STAT3
21818116	10.1038/leu.2011.198	2012	Constitutive activation of STAT3 in S√©zary syndrome is independent of SHP-1.	STAT3
21938013	10.1038/jid.2011.293	2012	Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in S√©zary syndrome.	STAT3
22116549	10.1038/leu.2011.340	2012	Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy.	STAT3
22126101	10.3109/10428194.2011.645212	2012	Investigation and analysis of single nucleotide polymorphisms in Janus kinase/signal transducer and activator of transcription genes with leukemia.	STAT3
22491065	10.1038/icb.2012.17	2012	IL-6 triggers IL-21 production by human CD4+ T cells to drive STAT3-dependent plasma cell differentiation in B cells.	STAT3
22656398	10.1016/j.jfma.2010.10.002	2012	Interleukin-27 and interleukin-12 augment activation of distinct cord blood natural killer cells responses via STAT3 pathways.	STAT3
22735740	10.1039/c2mb25120e	2012	Impaired JAK2-induced activation of STAT3 in failing human myocytes.	STAT3
22745305	10.1182/blood-2011-12-399030	2012	S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma.	STAT3
22751495	10.1097/MD.0b013e31825f95b9	2012	Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey.	STAT3
23018644	10.1182/blood-2012-05-428466	2012	Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.	STAT3
21085192	10.1038/jid.2010.349	2011	MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in S√©zary syndrome.	STAT3
21346774	10.1038/jid.2011.27	2011	Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway.	STAT3
21415216	10.1158/1078-0432.CCR-10-2798	2011	Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.	STAT3
21806788	10.1186/1756-8722-4-31	2011	High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma.	STAT3
22104307	10.3960/jslrt.51.93	2011	M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma.	STAT3
19889776	10.1128/JVI.01745-09	2010	Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors.	STAT3
19968719	10.1111/j.1751-553X.2009.01204.x	2010	Frequent STAT3 activation is associated with Mcl-1 expression in nasal NK-cell lymphoma.	STAT3
20015877	10.3324/haematol.2009.014050	2010	C/EBPŒ≤ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.	STAT3
20133729	10.1073/pnas.0909086107	2010	STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress.	STAT3
20213502	10.2478/s11658-010-0008-2	2010	STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL.	STAT3
20438785	10.1016/j.humimm.2010.04.004	2010	Polymorphisms in innate immunity genes and risk of childhood leukemia.	STAT3
20446017	10.1007/s11060-010-0188-7	2010	Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.	STAT3
20663948	10.3324/haematol.2009.019745	2010	Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.	STAT3
20716621	10.1158/1055-9965.EPI-10-0389	2010	Genetic polymorphisms in adaptive immunity genes and childhood acute lymphoblastic leukemia.	STAT3
20802378	10.1097/FPC.0b013e32833deb16	2010	A multiplex MALDI-TOF MS approach facilitates genotyping of DNA from formalin-fixed paraffin-embedded tumour specimens.	STAT3
20974051	NA	2010	Gene regulation by BCL3 in a cervical cancer cell line.	STAT3
18755494	10.1016/j.humpath.2008.06.009	2009	Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.	STAT3
19251695	10.1074/jbc.M807761200	2009	STAT3-stathmin interactions control microtubule dynamics in migrating T-cells.	STAT3
19421230	10.1038/leu.2009.91	2009	STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma.	STAT3
19608866	10.2353/ajpath.2009.080982	2009	IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.	STAT3
19626047	10.1038/leu.2009.139	2009	IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing.	STAT3
17951530	10.1182/blood-2007-04-087734	2008	Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.	STAT3
18160665	10.1182/blood-2007-09-111948	2008	Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.	STAT3
18354204	10.4049/jimmunol.180.7.4805	2008	STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation.	STAT3
18483262	10.1158/0008-5472.CAN-07-6091	2008	Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.	STAT3
18636124	10.1371/journal.pone.0002816	2008	Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.	STAT3
18684866	10.1182/blood-2008-01-134783	2008	Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha.	STAT3
19074878	10.1158/0008-5472.CAN-08-2121	2008	The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies?	STAT3
19088198	10.1073/pnas.0810958105	2008	Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).	STAT3
17151100	10.1128/JVI.01769-06	2007	Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells.	STAT3
18024124	10.1016/j.micinf.2007.09.008	2007	Integration of HIV-1 caused STAT3-associated B cell lymphoma in an AIDS patient.	STAT3
16364321	10.1016/j.febslet.2005.11.057	2006	Physical and functional interactions between STAT3 and Kaposi's sarcoma-associated herpesvirus-encoded LANA.	STAT3
16732314	10.1038/sj.onc.1209711	2006	BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription.	STAT3
16825495	10.1182/blood-2006-04-017434	2006	Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.	STAT3
16861352	10.1182/blood-2005-08-007377	2006	STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes.	STAT3
17015686	10.4049/jimmunol.177.8.5032	2006	A preferential role for STAT5, not constitutively active STAT3, in promoting survival of a human lymphoid tumor.	STAT3
17225522	NA	2006	[Expression and its significance of STAT3, STAT5, Survivin and Ki67 in nasal NK/T cell lymphoma].	STAT3
15870198	10.1073/pnas.0501959102	2005	STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes.	STAT3
15895073	10.1038/nm1249	2005	Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.	STAT3
15912144	10.1038/sj.leu.2403750	2005	STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis.	STAT3
16306601	10.1128/JVI.79.24.15302-15313.2005	2005	Respiratory syncytial virus-inducible BCL-3 expression antagonizes the STAT/IRF and NF-kappaB signaling pathways by inducing histone deacetylase 1 recruitment to the interleukin-8 promoter.	STAT3
12969979	10.1182/blood-2003-04-1048	2004	Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation.	STAT3
14968112	10.1038/sj.onc.1207398	2004	Identification of NPM-ALK interacting proteins by tandem mass spectrometry.	STAT3
15141228	10.1038/sj.leu.2403385	2004	In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3.	STAT3
15161657	10.1016/S0002-9440(10)63781-9	2004	Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.	STAT3
15163742	10.1128/JVI.78.12.6489-6497.2004	2004	Activation of Stat3 transcription factor by Herpesvirus saimiri STP-A oncoprotein.	STAT3
15207733	10.1016/j.bbrc.2004.05.162	2004	Herpesvirus saimiri STP A11 protein interacts with STAT3 and stimulates its transcriptional activity.	STAT3
12393476	10.1182/blood-2002-07-2130	2003	Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma.	STAT3
11751994	10.4049/jimmunol.168.1.466	2002	Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.	STAT3
12389630	10.1080/1042819022386716	2002	Role of the leukemia-associated transcription factor STAT3 in platelet physiology.	STAT3
11021801	10.1126/science.290.5489.144	2000	Regulation of STAT3 by direct binding to the Rac1 GTPase.	STAT3
10037026	10.3109/10428199909167389	1999	Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery.	STAT3
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	STAT6
34528236	10.1111/bjd.20760	2022	Transcriptomic changes during stage progression of mycosis fungoides.	STAT6
34839096	10.1016/j.prp.2021.153697	2022	STAT6 and phosphorylated STAT6 are differentially expressed in lymphomas.	STAT6
34957565	10.1002/path.5861	2022	Widespread in situ follicular neoplasia in patients who subsequently developed follicular lymphoma.	STAT6
35045920	10.1691/ph.2022.1670	2022	Anti-TIM1 suppresses airway inflammation and hyperresponsiveness via the STAT6 /STAT1 pathways in mice with allergic asthma.	STAT6
35121362	10.1016/j.prp.2022.153781	2022	Expression and prognostic analysis of STAT6(YE361) in Hodgkin lymphoma.	STAT6
35363872	10.1182/bloodadvances.2021005284	2022	Molecular subclusters of follicular lymphoma: a report from the UK's Haematological Malignancy Research Network.	STAT6
35403270	10.1111/his.14660	2022	Intraindividual variability of CD30 expression in mycosis fungoides -implications for diagnostic evaluation and therapy.	STAT6
35795062	10.3389/fonc.2022.870487	2022	Plasma Concentrations and Cancer-Associated Mutations in Cell-Free Circulating DNA of Treatment-Naive Follicular Lymphoma for Improved Non-Invasive Diagnosis and Prognosis.	STAT6
35816682	10.1182/bloodadvances.2022008355	2022	Genomic and microenvironmental landscape of stage I follicular lymphoma, compared to stage III/IV.	STAT6
35851155	10.1038/s41375-022-01641-x	2022	PARP14 is a novel target in STAT6 mutant follicular lymphoma.	STAT6
35885481	10.3390/diagnostics12071575	2022	Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma.	STAT6
35973369	10.1016/j.intimp.2022.109138	2022	Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization.	STAT6
35989611	10.1080/13685538.2022.2110232	2022	Solitary fibrous tumors in prostate: a case report with review of the literature.	STAT6
35999655	10.1093/asj/sjac234	2022	CD30 Regulation of IL-13-STAT6 Pathway in Breast Implant Associated Anaplastic Large Cell Lymphoma.	STAT6
36001451	10.1097/PAS.0000000000001956	2022	Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.	STAT6
36074181	10.1007/s00277-022-04949-x	2022	Circulating tumor DNA in Hodgkin lymphoma.	STAT6
32079702	10.3324/haematol.2019.237719	2021	Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study.	STAT6
32600091	10.1080/15592294.2020.1786317	2021	Epigenetic regulation of miR-518a-5p-CCR6 feedback loop promotes both proliferation and invasion in diffuse large B cell lymphoma.	STAT6
32954856	10.1080/17425247.2021.1825376	2021	Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.	STAT6
33150420	10.1182/blood.2020005083	2021	Plasmablasts derive from CD23- activated B cells after the extinction of IL-4/STAT6 signaling and IRF4 induction.	STAT6
33507341	10.1007/s00262-020-02835-x	2021	Support of BCP-ALL-cells by autologous bone marrow Th-cells involves induction of AID expression but not widespread AID off-target mutagenesis.	STAT6
33672548	10.3390/cancers13040884	2021	Biology and Clinical Applicability of Plasma Thymus and Activation-Regulated Chemokine (TARC) in Classical Hodgkin Lymphoma.	STAT6
33684939	10.1182/blood.2020007683	2021	Characterization of DLBCL with a PMBL gene expression signature.	STAT6
33777766	10.3389/fonc.2021.620435	2021	Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma.	STAT6
33945543	10.1371/journal.pone.0248886	2021	Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.	STAT6
33991851	10.1016/j.prp.2021.153477	2021	STAT6: A review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology.	STAT6
34090412	10.1186/s12890-021-01553-z	2021	EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.	STAT6
34312841	10.1111/bjh.17719	2021	Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.	STAT6
34359628	10.3390/cancers13153724	2021	Ruxolitinib as a Novel Therapeutic Option for Poor Prognosis T-LBL Pediatric Patients.	STAT6
34388250	10.1093/jnen/nlab080	2021	Expression of STAT6 and Phosphorylated STAT6 in Primary Central Nervous System Lymphomas.	STAT6
34778251	10.3389/fcell.2021.735855	2021	A miR-129-5P/ARID3A Negative Feedback Loop Modulates Diffuse Large B Cell Lymphoma Progression and Immune Evasion Through Regulating the PD-1/PD-L1 Checkpoint.	STAT6
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	STAT6
34926078	10.7759/cureus.19614	2021	Gastric Desmoid Fibromatosis - Report of a Rare Mimic of Gastrointestinal Stromal Tumor.	STAT6
34945004	10.3390/cancers13246384	2021	Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel.	STAT6
31524297	10.1002/hon.2679	2020	STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma.	STAT6
31688142	10.1097/PAS.0000000000001399	2020	Unusual Variants of Follicular Lymphoma: Case-based Review.	STAT6
31822802	10.1038/s41379-019-0428-0	2020	Diagnostic utility of STAT6<sup>YE361</sup> expression in classical Hodgkin lymphoma and related entities.	STAT6
32438399	10.1182/blood.2019004725	2020	Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma.	STAT6
32506320	10.1007/s12185-020-02901-1	2020	Diffuse follicular lymphoma variant with a typical diagnostic pattern and an unusually aggressive clinical presentation.	STAT6
32514881	10.1007/s11748-020-01396-1	2020	A case of long-term unchanged calcifying fibrous tumor.	STAT6
32555149	10.1038/s41408-020-0335-0	2020	CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma.	STAT6
32643174	10.1111/ijd.15036	2020	Mapping signal transducer and activator of transcription (STAT) activity in different stages of mycosis fungoides and Sezary syndrome.	STAT6
33045225	10.1016/j.humpath.2020.09.014	2020	The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.	STAT6
33144480	10.21873/invivo.12211	2020	Solitary Fibrous Tumor of the Orbit: A Clinicopathologic Study of Two Cases With Review of the Literature.	STAT6
33149660	10.2147/IJGM.S279483	2020	Intracranial Primary Malignant Solitary Fibrous Tumor/Hemangiopericytoma Masquerading as Meningioma: Report of a Rare Case.	STAT6
33188464	10.1186/s40792-020-01067-6	2020	Malignant solitary fibrous tumor of the pancreas: a case report.	STAT6
33211828	10.1182/bloodadvances.2020002944	2020	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.	STAT6
30338340	10.1007/s00125-018-4750-8	2019	The transcription factor STAT6 plays a critical role in promoting beta cell viability and is depleted in islets of individuals with type 1 diabetes.	STAT6
30381301	10.3324/haematol.2018.201590	2019	TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation <i>via</i> NF-Œ∫B mediated signaling in B-cells.	STAT6
30696620	10.1182/blood-2018-08-871293	2019	Autocrine LTA signaling drives NF-Œ∫B and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma.	STAT6
30962205	10.1182/blood.2018880138	2019	Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells.	STAT6
31568628	10.1111/jcmm.14653	2019	Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.	STAT6
31718693	10.1186/s13046-019-1428-0	2019	Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6.	STAT6
31816062	10.1182/bloodadvances.2019001012	2019	Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.	STAT6
29193015	10.1111/bjh.15041	2018	The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion.	STAT6
29238954	10.1111/bjd.16237	2018	Interleukin-25 is involved in cutaneous T-cell lymphoma progression by establishing a T helper 2-dominant microenvironment.	STAT6
29449275	10.1182/blood-2017-11-812073	2018	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.	STAT6
29501729	10.1016/j.cellsig.2018.02.016	2018	STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma.	STAT6
29650799	10.1182/blood-2017-11-814913	2018	Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.	STAT6
29651360	10.1186/s40164-018-0100-2	2018	Phosphatase of regenerating liver-3 (PRL-3) is overexpressed in classical Hodgkin lymphoma and promotes survival and migration.	STAT6
29656114	10.1016/j.exphem.2018.04.002	2018	Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1.	STAT6
29695237	10.1186/s12885-018-4266-0	2018	Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation.	STAT6
30087457	10.1038/s41374-018-0096-6	2018	Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues.	STAT6
30107911	10.1016/j.bbrc.2018.08.030	2018	IL-13 and IL-13RŒ±1 are overexpressed in extranodal natural killer/T cell lymphoma and mediate tumor cell proliferation.	STAT6
28082443	10.1182/blood-2016-06-720516	2017	A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.	STAT6
28099521	10.1371/journal.ppat.1006124	2017	Nuclear Localization and Cleavage of STAT6 Is Induced by Kaposi's Sarcoma-Associated Herpesvirus for Viral Latency.	STAT6
28875978	10.1038/icb.2017.71	2017	IL4 and IL21 cooperate to induce the high Bcl6 protein level required for germinal center formation.	STAT6
26474728	10.1002/eji.201545673	2016	Specialized proresolving mediators (SPMs) inhibit human B-cell IgE production.	STAT6
26647218	10.1158/1078-0432.CCR-15-2123	2016	Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.	STAT6
26811457	10.1073/pnas.1524668113	2016	Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.	STAT6
26965583	10.1038/modpathol.2016.51	2016	Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations.	STAT6
27398157	NA	2016	Flagellin modulates IgE expression in B cells to initiate food allergy in mice.	STAT6
27440511	10.1373/clinchem.2016.255315	2016	Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.	STAT6
25428220	10.1182/blood-2014-06-582650	2015	Activating STAT6 mutations in follicular lymphoma.	STAT6
25614636	10.1182/blood-2014-12-615294	2015	Mutations and microenvironment collude in FL.	STAT6
26112603	10.1016/j.febslet.2015.06.015	2015	E3 ubiquitin ligase Cbl-b suppresses human ORMDL3 expression through STAT6 mediation.	STAT6
26123794	10.1016/j.blre.2015.06.002	2015	Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies.	STAT6
26246572	10.1128/JVI.01525-15	2015	Constitutive Activation of Interleukin-13/STAT6 Contributes to Kaposi's Sarcoma-Associated Herpesvirus-Related Primary Effusion Lymphoma Cell Proliferation and Survival.	STAT6
26438862	10.1073/pnas.1407075112	2015	Effects of lymphocyte profile on development of EBV-induced lymphoma subtypes in humanized mice.	STAT6
26461141	10.3892/mmr.2015.4411	2015	MicroRNA‚Äë361‚Äë5p suppresses cancer progression by targeting signal transducer and activator of transcription 6 in non‚Äësmall cell lung cancer.	STAT6
26565811	10.18632/oncotarget.6300	2015	Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.	STAT6
24491557	10.1016/j.bbrc.2014.01.140	2014	MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6).	STAT6
24550509	10.1073/pnas.1301138111	2014	Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression.	STAT6
24610827	10.1158/1078-0432.CCR-13-3007	2014	Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo.	STAT6
24886089	10.1186/1476-4598-13-125	2014	DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells.	STAT6
24908303	10.1007/978-1-4939-0928-5_14	2014	Evaluation of the adverse effect of low concentration of cadmium on interleukin-4 induced class switch recombination in Burkett's lymphoma Raji cell line.	STAT6
24960198	10.1016/j.bbrc.2014.06.069	2014	IL-4 receptor Œ± in non-lipid rafts is the target molecule of strictinin in inhibiting STAT6 activation.	STAT6
24965443	10.1111/bjh.12997	2014	Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma--a matched pair analysis from the German Hodgkin Study Group (GHSG).	STAT6
25193702	10.1016/j.bbrc.2014.08.131	2014	Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance.	STAT6
25277174	10.18632/oncotarget.2447	2014	Targeting STAT6 in PMBL.	STAT6
25485578	10.4161/15384101.2014.965061	2014	Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.	STAT6
25486484	10.4161/15384101.2014.947759	2014	Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.	STAT6
25594020	10.18632/oncoscience.35	2014	Knock-down of BCL6 / STAT6 sensitizes primary B cell lymphoma cells for treatment with current therapeutic agents.	STAT6
23297127	10.1182/blood-2012-04-421826	2013	High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.	STAT6
23553437	10.1002/ijc.28189	2013	Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs.	STAT6
23768868	10.1016/j.leukres.2013.05.003	2013	Polymorphisms in JAK/STAT signaling pathway genes and risk of non-Hodgkin lymphoma.	STAT6
23852366	10.18632/oncotarget.1149	2013	STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL).	STAT6
23940785	10.1371/journal.pone.0071754	2013	Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.	STAT6
22012462	10.1099/vir.0.036087-0	2012	Activation of the STAT6 transcription factor in Jurkat T-cells by the herpesvirus saimiri Tip protein.	STAT6
22094113	10.1016/j.yexcr.2011.10.017	2012	Epigenetic and transcriptional control of the 15-lipoxygenase-1 gene in a Hodgkin lymphoma cell line.	STAT6
22408261	10.1182/blood-2011-01-331421	2012	The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.	STAT6
23072591	10.1186/1471-2407-12-478	2012	Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.	STAT6
23285160	10.1371/journal.pone.0052703	2012	Transcriptional regulation of 15-lipoxygenase expression by histone h3 lysine 4 methylation/demethylation.	STAT6
20876453	10.1182/blood-2010-01-265272	2011	STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma.	STAT6
21127196	10.1158/0008-5472.CAN-10-2987	2011	Dynamic mathematical modeling of IL13-induced signaling in Hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets.	STAT6
21268278	10.1002/pmic.201000569	2011	One-source peptide/phosphopeptide standards for accurate phosphorylation degree determination.	STAT6
21418178	10.1111/j.1365-2141.2011.08632.x	2011	Association of JAK-STAT pathway related genes with lymphoma risk: results of a European case-control study (EpiLymph).	STAT6
21828071	10.1093/dnares/dsr025	2011	Characterization of STAT6 target genes in human B cells and lung epithelial cells.	STAT6
21911376	10.1073/pnas.1017082108	2011	Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family.	STAT6
22032493	10.1186/1471-2180-11-240	2011	Activation of PI3K/AKT and ERK MAPK signal pathways is required for the induction of lytic cycle replication of Kaposi's sarcoma-associated herpesvirus by herpes simplex virus type 1.	STAT6
22042699	10.1182/blood-2011-05-354654	2011	miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.	STAT6
22179211	10.1159/000332967	2011	Contribution of gut microbiota to colonic and extracolonic cancer development.	STAT6
20393449	10.3791/1904	2010	Using an automated cell counter to simplify gene expression studies: siRNA knockdown of IL-4 dependent gene expression in Namalwa cells.	STAT6
20438785	10.1016/j.humimm.2010.04.004	2010	Polymorphisms in innate immunity genes and risk of childhood leukemia.	STAT6
20716621	10.1158/1055-9965.EPI-10-0389	2010	Genetic polymorphisms in adaptive immunity genes and childhood acute lymphoblastic leukemia.	STAT6
20719954	10.1128/JVI.01293-10	2010	Kaposi's sarcoma-associated herpesvirus inhibits interleukin-4-mediated STAT6 phosphorylation to regulate apoptosis and maintain latency.	STAT6
20944673	10.1038/leu.2010.223	2010	Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis.	STAT6
19030780	10.1007/s11060-008-9736-9	2009	Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant.	STAT6
19147789	10.1182/blood-2008-03-144121	2009	PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells.	STAT6
19276270	10.1158/1078-0432.CCR-08-2054	2009	Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model.	STAT6
19423726	10.1182/blood-2009-03-209759	2009	Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.	STAT6
19440213	10.1038/leu.2009.103	2009	STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line.	STAT6
19494841	10.1038/leu.2009.120	2009	Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma.	STAT6
18401415	10.1038/leu.2008.85	2008	STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-cell lymphoma.	STAT6
18541724	10.1182/blood-2008-01-133769	2008	Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines.	STAT6
18602072	10.1016/j.intimp.2008.05.007	2008	Differential gene expression in murine large cell B-cell lymphoma metastatic variants.	STAT6
18636124	10.1371/journal.pone.0002816	2008	Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.	STAT6
18641027	10.3324/haematol.12875	2008	Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization.	STAT6
18682601	10.1182/blood-2008-02-138933	2008	IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma.	STAT6
18716132	10.1182/blood-2008-03-148726	2008	PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling.	STAT6
16954503	10.1182/blood-2006-04-014977	2007	Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival.	STAT6
17210636	10.1128/MCB.01234-06	2007	T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6.	STAT6
17478423	10.1074/jbc.M611283200	2007	Collaborator of Stat6 (CoaSt6)-associated poly(ADP-ribose) polymerase activity modulates Stat6-dependent gene transcription.	STAT6
17606441	10.3324/haematol.11073	2007	A detailed inventory of DNA copy number alterations in four commonly used Hodgkin's lymphoma cell lines.	STAT6
17652621	10.1182/blood-2007-03-082511	2007	Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6.	STAT6
17968425	10.1038/sj.cr.2007.90	2007	IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contribution of the PI-3 kinase/AKT pathway.	STAT6
17997602	10.1371/journal.ppat.0030166	2007	EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas.	STAT6
16213149	10.1016/j.critrevonc.2005.08.005	2006	The role of constitutively active Stat6 in leukemia and lymphoma.	STAT6
16418334	10.1182/blood-2005-03-0897	2006	Gene expression and angiotropism in primary CNS lymphoma.	STAT6
16732981	NA	2006	Apoptosis induced by short hairpin RNA-mediated STAT6 gene silencing in human colon cancer cells.	STAT6
17023392	10.1096/fj.06-5995fje	2006	N-linked glycosylation of IL-13R alpha2 is essential for optimal IL-13 inhibitory activity.	STAT6
15591113	10.1182/blood-2004-10-3820	2005	Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.	STAT6
15817683	10.1182/blood-2005-01-0201	2005	Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma.	STAT6
15899923	10.1093/intimm/dxh260	2005	Induction and activation of the aryl hydrocarbon receptor by IL-4 in B cells.	STAT6
16297208	10.1111/j.0022-202X.2005.23925.x	2005	Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.	STAT6
15044251	10.1182/blood-2003-10-3545	2004	Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma.	STAT6
15126369	10.1158/0008-5472.can-03-3764	2004	Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo.	STAT6
15163701	10.1128/JVI.78.12.6081-6090.2004	2004	Interleukin-13 overexpression by tax transactivation: a potential autocrine stimulus in human T-cell leukemia virus-infected lymphocytes.	STAT6
15231650	10.1158/0008-5472.CAN-03-3885	2004	High-throughput retroviral tagging for identification of genes involved in initiation and progression of mouse splenic marginal zone lymphomas.	STAT6
15381729	10.1084/jem.20031816	2004	The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascades.	STAT6
15606748	10.1111/j.1432-1033.2004.04424.x	2004	Regulation of STAT signalling by proteolytic processing.	STAT6
12594267	10.4049/jimmunol.170.5.2435	2003	Inhibition of Th2 differentiation and GATA-3 expression by BCL-6.	STAT6
12778491	10.1002/eji.200323680	2003	PU.1 is required for transcriptional activation of the Stat6 response element in the Igepsilon promoter.	STAT6
12848851	10.1046/j.0818-9641.2003.01172.x	2003	Knockout B lymphoma cell lines as biochemical tools to explore multiple signalling pathways.	STAT6
11781246	10.1182/blood.v99.2.618	2002	Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.	STAT6
12152987	10.1080/10428190290026259	2002	The role of interleukin 13 in classical Hodgkin lymphoma.	STAT6
12225394	10.1034/j.1600-0609.2002.00653.x	2002	Multiple gammac-receptor expression in adult T-cell leukemia.	STAT6
12230500	10.1046/j.1523-1747.2002.01864.x	2002	Ketoconazole suppresses interleukin-4 plus anti-CD40-induced IgE class switching in surface IgE negative B cells from patients with atopic dermatitis.	STAT6
12477975	NA	2002	Transcriptional regulation of the BCL-6 gene: mechanistic dissection using mutant cell lines.	STAT6
11162477	10.1006/bbrc.2000.4069	2001	Identification of an inhibitor for interleukin 4-induced epsilon germline transcription and antigen-specific IgE production in vivo.	STAT6
11513543	10.1006/clim.2001.5082	2001	Analysis of the Ser786Pro interleukin-4 receptor alpha allelic variant in allergic and nonallergic asthma and its functional consequences.	STAT6
11564163	10.1046/j.0022-202x.2001.01436.x	2001	Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells.	STAT6
11591117	10.1006/cimm.2001.1829	2001	Differential effect of IL-4 and IL-13 on CD44 expression in the Burkitt's lymphoma B cell line BL30/B95-8 and in Epstein-Barr virus (EBV) transformed human B cells: loss of IL-13 receptors on Burkitt's lymphoma B cells.	STAT6
11594748	10.1006/bbrc.2001.5723	2001	PKCdelta and zeta mediate IL-4/IL-13-induced germline epsilon transcription in human B cells: a putative regulation via PU.1 phosphorylation.	STAT6
11675351	10.1182/blood.v98.9.2778	2001	Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells.	STAT6
11708812	10.1006/bbrc.2001.5968	2001	CD40 employs p38 MAP kinase in IgE isotype switching.	STAT6
11815733	10.1159/000049523	2001	Interleukin 13: a growth factor in hodgkin lymphoma.	STAT6
10744706	10.1074/jbc.275.14.10212	2000	Interleukin-4 mediates cell growth inhibition through activation of Stat1.	STAT6
10856136	10.1067/mai.2000.107604	2000	IL-4/IL-13 signaling beyond JAK/STAT.	STAT6
10369418	10.1016/s0161-5890(98)00114-x	1999	Regulation of the germline immunoglobulin Cgamma1 promoter by CD40 ligand and IL-4: dual role for tandem NF-kappaB binding sites.	STAT6
10572070	10.1165/ajrcmb.21.6.3709	1999	Homologous human and murine antisense oligonucleotides targeting stat6. Functional effects on germline cepsilon transcript.	STAT6
10626250	10.3109/08830189909088490	1999	Regulation of lymphocyte cell fate decisions and lymphomagenesis by BCL-6.	STAT6
9545332	10.1074/jbc.273.16.9898	1998	A role for the insulin-interleukin (IL)-4 receptor motif of the IL-4 receptor alpha-chain in regulating activation of the insulin receptor substrate 2 and signal transducer and activator of transcription 6 pathways. Analysis by mutagenesis.	STAT6
9584180	10.1128/MCB.18.6.3395	1998	Interaction of stat6 and NF-kappaB: direct association and synergistic activation of interleukin-4-induced transcription.	STAT6
9110977	10.1126/science.276.5312.589	1997	Control of inflammation, cytokine expression, and germinal center formation by BCL-6.	STAT6
9144491	NA	1997	CD40 cross-linking induces Ig epsilon germline transcripts in B cells via activation of NF-kappaB: synergy with IL-4 induction.	STAT6
9159166	10.1073/pnas.94.11.5866	1997	Homodimerization of the human interleukin 4 receptor alpha chain induces Cepsilon germline transcripts in B cells in the absence of the interleukin 2 receptor gamma chain.	STAT6
9192639	10.1073/pnas.94.13.6764	1997	Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines.	STAT6
9317131	NA	1997	Cooperation of binding sites for STAT6 and NF kappa B/rel in the IL-4-induced up-regulation of the human IgE germline promoter.	STAT6
9440542	10.1016/s0091-6749(97)70002-2	1997	A thiol antioxidant regulates IgE isotype switching by inhibiting activation of nuclear factor-kappaB.	STAT6
8624802	10.1016/s1074-7613(00)80676-7	1996	IL-4 function can be transferred to the IL-2 receptor by tyrosine containing sequences found in the IL-4 receptor alpha chain.	STAT6
8624803	10.1016/s1074-7613(00)80677-9	1996	Growth and gene expression are predominantly controlled by distinct regions of the human IL-4 receptor.	STAT6
32964767	10.1080/10428194.2020.1821011	2021	Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas.	TAP1
35845006	10.1002/jha2.116	2020	Genetic aberrations of <i>NLRC5</i> are associated with downregulated MHC-I antigen presentation and impaired T-cell immunity in follicular lymphoma.	TAP1
29107940	10.1038/nature24627	2017	Structure of the human MHC-I peptide-loading complex.	TAP1
26910071	10.1007/978-1-4939-3347-1_7	2016	Fluorimetric Methods for Analysis of Permeability, Drug Transport Kinetics, and Inhibition of the ABCB1 Membrane Transporter.	TAP1
23302045	10.3109/10428194.2013.764417	2013	Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis.	TAP1
22419807	10.1128/JVI.07216-11	2012	Identification of host-chromosome binding sites and candidate gene targets for Kaposi's sarcoma-associated herpesvirus LANA.	TAP1
20020123	10.1007/s00262-009-0805-5	2010	Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells.	TAP1
17285277	10.1007/s00277-007-0256-z	2007	Upregulation of antigen-processing machinery components at mRNA level in acute lymphoblastic leukemia cells after CD40 stimulation.	TAP1
16585582	10.4049/jimmunol.176.8.4869	2006	Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/lymphoma, carcinoma, and melanoma cell lines.	TAP1
15905524	10.4049/jimmunol.174.11.6829	2005	Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.	TAP1
16103103	10.1158/0008-5472.CAN-03-3734	2005	Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas.	TAP1
15265880	10.4049/jimmunol.173.3.1526	2004	Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells.	TAP1
14558951	NA	2003	[Expression of transporter associated with antigen processing (TAP) in childhood acute leukemia and its clinical significance].	TAP1
11781255	10.1182/blood.v99.2.690	2002	HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease.	TAP1
11169961	10.1002/1097-0215(200002)9999:9999&lt;::aid-ijc1056&gt;3.0.co;2-k	2001	Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence.	TAP1
11340574	10.1002/1097-0215(20010601)92:5&lt;692::aid-ijc1237&gt;3.0.co;2-z	2001	Expression of HLA class I, beta(2)-microglobulin, TAP1 and IL-10 in Epstein-Barr virus-associated nasal NK/T-cell lymphoma: Implications for tumor immune escape mechanism.	TAP1
10760797	10.1002/(SICI)1521-4141(200004)30:4&lt;1088::AID-IMMU1088&gt;3.0.CO;2-O	2000	Innate and adaptive immunity to tumors: IL-12 is required for optimal responses.	TAP1
10597194	10.1002/(sici)1097-0215(19991210)83:6&lt;772::aid-ijc13&gt;3.0.co;2-g	1999	CD40 cross-linking enhances the immunogenicity of Burkitt's-lymphoma cell lines.	TAP1
9443401	NA	1998	Mouse models for hereditary nonpolyposis colorectal cancer.	TAP1
9443410	NA	1998	Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells.	TAP1
9531330	10.1046/j.1365-2141.1998.00631.x	1998	Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course.	TAP1
9551890	NA	1998	Rejection of allogeneic and syngeneic but not MHC class I-deficient tumor grafts by MHC class I-deficient mice.	TAP1
9562372	10.1016/s0165-2478(97)00157-0	1998	Peptide transport in human lymphoblastoid and tumor cells: effect of transporter associated with antigen presentation (TAP) polymorphism.	TAP1
9680372	NA	1998	Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.	TAP1
9725200	NA	1998	Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1.	TAP1
9746788	NA	1998	Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.	TAP1
9764810	10.1097/00008390-199808000-00008	1998	TAP prefers to transport melanoma antigenic peptides which are longer than the optimal T-cell epitope: evidence for further processing in the endoplasmic reticulum.	TAP1
9129970	10.1016/S0198-8859(97)00001-3	1997	Localization of class I histocompatibility molecule assembly by subfractionation of the early secretory pathway.	TAP1
9278330	NA	1997	Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination.	TAP1
9317117	NA	1997	Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10.	TAP1
9550373	NA	1997	Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells.	TAP1
8764046	10.1128/JVI.70.8.5357-5362.1996	1996	Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.	TAP1
8765034	10.1002/eji.1830260831	1996	Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2.	TAP1
8900437	10.1002/(SICI)1097-0215(19961009)68:2&lt;251::AID-IJC19&gt;3.0.CO;2-D	1996	Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.	TAP1
7565411	10.1128/mr.59.3.387-405.1995	1995	Immune regulation in Epstein-Barr virus-associated diseases.	TAP1
7774641	10.1002/eji.1830250536	1995	Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.	TAP1
7517178	10.1093/intimm/6.4.639	1994	Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line.	TAP1
7796675	10.1002/9780470514672.ch2	1994	Potential antigenic targets on Epstein-Barr virus-associated tumours and the host response.	TAP1
7972022	10.1073/pnas.91.23.11128	1994	Abnormal class I assembly and peptide presentation in the nonobese diabetic mouse.	TAP1
34448823	10.1182/bloodadvances.2021004212	2022	The molecular hallmarks of primary and secondary vitreoretinal lymphoma.	TBL1XR1
34494161	10.1007/s00428-021-03186-3	2022	Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.	TBL1XR1
34791836	10.1002/cam4.4422	2022	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.	TBL1XR1
34799485	10.1097/PAS.0000000000001834	2022	Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation.	TBL1XR1
35205758	10.3390/cancers14041010	2022	Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren's Syndrome.	TBL1XR1
35300216	10.2147/JIR.S341355	2022	The Mutation of <i>BTG2</i> Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma.	TBL1XR1
35401516	10.3389/fimmu.2022.842439	2022	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.	TBL1XR1
35583604	10.1158/1078-0432.CCR-21-3347	2022	Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL.	TBL1XR1
35726023	10.1038/s41684-022-00998-x	2022	The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications.	TBL1XR1
33777766	10.3389/fonc.2021.620435	2021	Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma.	TBL1XR1
34147695	10.1016/j.jmoldx.2021.04.013	2021	Detection of Gene Fusion Transcripts in Peripheral T-Cell Lymphoma Using a Multiplexed Targeted Sequencing Assay.	TBL1XR1
35528192	10.1158/2767-9764.crc-21-0022	2021	The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways.	TBL1XR1
31557339	10.1111/his.14005	2020	Fluorescence in-situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing.	TBL1XR1
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	TBL1XR1
32316399	10.3390/cancers12040986	2020	Identifying Genetic Lesions in Ocular Adnexal Extranodal Marginal Zone Lymphomas of the MALT Subtype by Whole Genome, Whole Exome and Targeted Sequencing.	TBL1XR1
32322395	10.1186/s40364-020-00189-1	2020	TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients.	TBL1XR1
32339039	10.1080/02713683.2020.1762228	2020	<i>TBL1XR1</i> Mutations in Primary Marginal Zone Lymphomas of Ocular Adnexa are Associated with Unique Morphometric Phenotypes.	TBL1XR1
32546039	10.1080/10428194.2020.1775216	2020	TBLR1 and CREBBP as potential novel prognostic immunohistochemical biomarkers in diffuse large B-cell lymphoma.	TBL1XR1
32619424	10.1016/j.cell.2020.05.049	2020	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.	TBL1XR1
32932517	10.1182/blood.2020005857	2020	The dangers of d√©j√† vu: memory B cells as the cells of origin of ABC-DLBCLs.	TBL1XR1
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	TBL1XR1
31648321	10.1182/bloodadvances.2019000404	2019	Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.	TBL1XR1
31806993	10.2147/OTT.S227122	2019	Genomic Alterations In Primary Cardiac Diffuse Large B Cell Lymphoma: A Case Report And Literature Review.	TBL1XR1
29674500	10.3324/haematol.2018.191601	2018	Novel <i>GPR34</i> and <i>CCR6</i> mutation and distinct genetic profiles in MALT lymphomas of different sites.	TBL1XR1
29891112	10.1016/j.critrevonc.2018.05.010	2018	Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.	TBL1XR1
30214692	10.18632/oncotarget.26080	2018	Correction: The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in <i>TNFAIP3</i> followed by mutations in <i>TBL1XR1</i> and <i>CREBBP</i>.	TBL1XR1
30401751	10.1182/bloodadvances.2018022962	2018	Insights into the genomic landscape of MYD88 wild-type Waldenstr√∂m macroglobulinemia.	TBL1XR1
28152507	10.18632/oncotarget.14928	2017	The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.	TBL1XR1
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	TBL1XR1
28509585	10.1080/10428194.2017.1318437	2017	Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.	TBL1XR1
26111727	10.1111/nan.12259	2016	Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.	TBL1XR1
26608593	10.1002/gcc.22328	2016	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.	TBL1XR1
27248180	10.18632/oncotarget.9678	2016	The genetic landscape of dural marginal zone lymphomas.	TBL1XR1
25991819	10.1158/1078-0432.CCR-14-2116	2015	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.	TBL1XR1
26189108	10.1016/j.leukres.2015.06.005	2015	Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.	TBL1XR1
23823658	10.1038/leu.2013.206	2014	Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011.	TBL1XR1
24689486	10.1111/exd.12405	2014	Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing.	TBL1XR1
24895125	10.1074/jbc.M114.569889	2014	Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model.	TBL1XR1
24970810	10.18632/oncotarget.2080	2014	Mutational analysis of primary central nervous system lymphoma.	TBL1XR1
22496164	10.1182/blood-2012-02-414441	2012	TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma.	TBL1XR1
22837180	10.1158/1078-0432.CCR-12-0845	2012	Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.	TBL1XR1
23022380	10.1016/j.molcel.2012.08.022	2012	NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function.	TBL1XR1
21562036	10.1158/1078-0432.CCR-11-0395	2011	Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens.	TBL1XR1
21680795	10.1182/blood-2011-03-341412	2011	Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.	TBL1XR1
20547759	10.1128/MCB.01600-09	2010	The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1.	TBL1XR1
18767146	10.1002/gcc.20613	2008	The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1.	TBL1XR1
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	TET2
33579790	10.1136/gutjnl-2020-322935	2022	Oncogenetic landscape of lymphomagenesis in coeliac disease.	TET2
34494161	10.1007/s00428-021-03186-3	2022	Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.	TET2
34840089	10.1016/j.clml.2021.10.015	2022	Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.	TET2
34847227	10.1182/bloodadvances.2021004926	2022	Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenstr√∂m macroglobulinemia.	TET2
34937926	10.1038/s41590-021-01087-w	2022	TET deficiency perturbs mature B cell homeostasis and promotes oncogenesis associated with accumulation of G-quadruplex and R-loop structures.	TET2
34980830	10.1097/PAS.0000000000001859	2022	Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing.	TET2
34998786	10.1016/j.clml.2021.12.008	2022	The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.	TET2
35021606	10.3324/haematol.2021.280003	2022	Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS.	TET2
35064935	10.1111/his.14619	2022	Parallel evolution of two distinct lymphoid proliferations in clonal haematopoiesis.	TET2
35255774	10.1080/15548627.2022.2048432	2022	TET2 regulates osteoclastogenesis by modulating autophagy in OVX-induced bone loss.	TET2
35256801	10.1038/s41591-022-01708-3	2022	High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster.	TET2
35301414	10.1038/s41379-022-01022-w	2022	Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations.	TET2
35380239	10.1007/s00277-022-04806-x	2022	The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation.	TET2
35401516	10.3389/fimmu.2022.842439	2022	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.	TET2
35459873	10.1038/s41375-022-01571-8	2022	Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.	TET2
35492814	10.1016/j.jaccao.2022.01.098	2022	<i>TET2</i> Clonal Hematopoiesis Is Associated With Anthracycline-Induced Cardiotoxicity in Patients With Lymphoma.	TET2
35533245	10.1158/2643-3230.BCD-21-0177	2022	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.	TET2
35543621	10.1080/10428194.2022.2070913	2022	Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis.	TET2
35577752	10.1016/j.clml.2022.04.015	2022	Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma.	TET2
35590059	10.1038/s43018-022-00370-5	2022	Acute lymphoblastic leukemia displays a distinct highly methylated genome.	TET2
35625998	10.3390/cancers14102392	2022	Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality.	TET2
35652795	10.1080/10428194.2022.2081323	2022	The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.	TET2
35835912	10.1038/s41588-022-01121-z	2022	Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis.	TET2
35846192	10.1002/jha2.354	2022	T-cell lymphoma, B-cell lymphoma, and myelodysplastic syndrome harboring common mutations: Trilineage tumorigenesis from a common founder clone.	TET2
35895386	10.1111/bjd.21791	2022	Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.	TET2
35921527	10.1182/blood.2022015451	2022	Clonal germinal center B cells function as a niche for T-cell lymphoma.	TET2
35995702	10.1016/j.clml.2022.07.009	2022	Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma.	TET2
36012614	10.3390/ijms23169349	2022	Angioimmunoblastic T-Cell Lymphoma with Exuberant CD30-Positive Follicular Dendritic Cell Proliferation in a SARS-CoV-2 Patient: The Role of Mutational Analysis to Exclude an Associated Follicular Dendritic Cell Sarcoma.	TET2
36048893	10.1093/ajcp/aqac104	2022	Systemic Presentation of Somatic TET2 Mutated B-Cell Lymphoma in a Child With Kabuki Syndrome and a Germline KMT2D Variant.	TET2
36059252	10.1080/10428194.2022.2116932	2022	MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.	TET2
36066697	10.1007/s10875-022-01361-y	2022	Novel Germline TET2 Mutations in Two Unrelated Patients with Autoimmune Lymphoproliferative Syndrome-Like Phenotype and Hematologic Malignancy.	TET2
33413063	10.2174/1568009620666210106122750	2021	Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).	TET2
33431788	10.1038/s41392-020-00437-8	2021	CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.	TET2
33432228	10.1038/s41590-020-00827-8	2021	Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.	TET2
33496747	10.1182/bloodadvances.2020003081	2021	Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.	TET2
33512451	10.1182/blood.2020006721	2021	Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.	TET2
33544565	10.1097/PAS.0000000000001658	2021	Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II.	TET2
33546774	10.1186/s40164-021-00200-x	2021	Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas.	TET2
33569430	10.21037/atm-20-7574	2021	Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity.	TET2
33650043	10.1007/s00428-021-03071-z	2021	Clinicopathological characterization of follicular helper T-cell-derived peripheral T-cell lymphoma involving Waldeyer's ring.	TET2
33708776	10.3389/fmed.2021.584507	2021	Case Report: Refusal of an Veno-Arterial Extracorporeal Membrane Oxygenation Due to Malignant Disease? - An Extremely Rare Form of Cardiac Involvement in Acute Myeloid Leukemia.	TET2
33711909	10.1080/10428194.2021.1894650	2021	Mutational spectrum of <i>de novo NPM1</i>-mutated acute myeloid leukemia patients older than 75 years.	TET2
33739791	10.1097/PAS.0000000000001646	2021	Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Novel Form of Composite Lymphoma Potentially Mimicking Richter Syndrome.	TET2
33829512	10.1111/his.14378	2021	Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma.	TET2
33849798	10.1016/j.clml.2021.03.002	2021	Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphoma: A Meta-analysis: RHOA mutations in AITL.	TET2
33876209	10.1182/blood.2020010510	2021	14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia.	TET2
33928261	10.1038/s43018-020-00161-w	2021	<i>FYN-TRAF3IP2</i> induces NF-Œ∫B signaling-driven peripheral T cell lymphoma.	TET2
33939500	10.1177/10668969211013402	2021	A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor.	TET2
33941203	10.1186/s13045-021-01068-4	2021	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL.	TET2
33951889	10.3324/haematol.2020.271957	2021	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.	TET2
33990228	10.1186/s40164-021-00224-3	2021	Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas.	TET2
34021249	10.1038/s41375-021-01289-z	2021	Thyroid MALT lymphoma: self-harm to gain potential T-cell help.	TET2
34065087	10.3390/ijms22095013	2021	The Impact of Epigenetic Modifications in Myeloid Malignancies.	TET2
34078586	10.1016/j.clml.2021.04.014	2021	Genetic Heterogeneity in Chronic Myeloid Leukemia: How Clonal Hematopoiesis and Clonal Evolution May Influence Prognosis, Treatment Outcome, and Risk of Cardiovascular Events.	TET2
34108263	10.1158/1535-7163.MCT-20-0377	2021	Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways.	TET2
34164626	10.1158/2643-3230.BCD-20-0203	2021	Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients.	TET2
34230442	10.1097/CCO.0000000000000773	2021	Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment.	TET2
34258755	10.1111/bjh.17639	2021	Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).	TET2
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	TET2
34390161	10.1002/pbc.29285	2021	Molecular features of non-anaplastic peripheral T-cell lymphoma in children and adolescents.	TET2
34413196	10.1073/pnas.2110758118	2021	TET2 as a tumor suppressor and therapeutic target in T-cell acute lymphoblastic leukemia.	TET2
34424323	10.1182/bloodadvances.2021004653	2021	B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations.	TET2
34447369	10.3389/fimmu.2021.671755	2021	Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.	TET2
34449978	10.1002/dc.24861	2021	Angioimmunoblastic T-cell lymphoma diagnosed from pleural fluid by integration of morphologic, immunophenotypic, and molecular findings.	TET2
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	TET2
34581268	10.7554/eLife.66395	2021	Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking.	TET2
34590470	10.52586/4970	2021	Methylation alterations and advance of treatment in lymphoma.	TET2
34615796	10.11406/rinketsu.62.1367	2021	[Epigenetic abnormalities in non-Hodgkin lymphomas].	TET2
34621263	10.3389/fimmu.2021.688493	2021	Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes.	TET2
34899857	10.3389/fgene.2021.768913	2021	Epigenetic Regulation of miR-92a and TET2 and Their Association in Non-Hodgkin Lymphoma.	TET2
35008340	10.3390/cancers14010176	2021	Recent Advances in the Genetic of MALT Lymphomas.	TET2
35027991	NA	2021	Update on recurrent mutations in angioimmunoblastic T-cell lymphoma.	TET2
31028364	10.1038/s41379-019-0279-8	2020	Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.	TET2
31827242	10.1038/s41375-019-0675-6	2020	Familial myeloid malignancies with germline TET2 mutation.	TET2
31859368	10.1002/path.5376	2020	Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell.	TET2
31870198	10.1080/10428194.2019.1702179	2020	Angioimmunoblastic T-cell lymphoma in Taiwan reveals worse progression-free survival for <i>RHOA</i> G17V mutated subtype.	TET2
31896782	10.1038/s41375-019-0697-0	2020	The clinical mutatome of core binding factor leukemia.	TET2
32077355	10.1080/10428194.2020.1728751	2020	Longitudinal clonal architecture of acute myeloid leukemia with <i>NPM1</i> driver insertion, early <i>TET2</i> mutations and secondary e6a2 <i>BCR-ABL1</i> rearrangement.	TET2
32091281	10.1080/10428194.2020.1723016	2020	Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated <i>RUNX1</i> versus acute myeloid leukemia with myelodysplasia-related changes with mutated <i>RUNX1</i>.	TET2
32107212	10.1158/0008-5472.CAN-19-2787	2020	Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma.	TET2
32114498	10.1136/jitc-2019-000104	2020	T-cell lymphoma secondary to checkpoint inhibitor therapy.	TET2
32127923	10.1177/1758835919900856	2020	Epigenetic aberrations in natural killer/T-cell lymphoma: diagnostic, prognostic and therapeutic implications.	TET2
32187361	10.1182/blood.2019003535	2020	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.	TET2
32203209	10.1038/s41416-020-0788-8	2020	Decreased vitamin C uptake mediated by SLC2A3 promotes leukaemia progression and impedes TET2 restoration.	TET2
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	TET2
32271188	10.1097/PAS.0000000000001470	2020	Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders: A Clinical, Pathologic, and Molecular Study of 60 Cases Presenting With a Single Lesion: A Multicenter Study of the French Cutaneous Lymphoma Study Group.	TET2
32397113	10.3390/ijms21093323	2020	Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.	TET2
32442302	10.1182/bloodadvances.2020001636	2020	Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms.	TET2
32469082	10.1002/cncr.32866	2020	Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.	TET2
32518946	10.1182/blood.2020005844	2020	Germline TET2 loss of function causes childhood immunodeficiency and lymphoma.	TET2
32598477	10.1182/bloodadvances.2019001350	2020	Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.	TET2
32853377	10.1182/blood.2020006881	2020	Human TET2 bridges cancer and immunity.	TET2
32945366	10.3892/ijmm.2020.4686	2020	A comprehensive analysis of RHOA mutation positive and negative angioimmunoblastic T-cell¬†lymphomas by targeted deep sequencing, expression profiling and single cell digital image analysis.	TET2
33106431	10.1073/pnas.2014308117	2020	A mosaic analysis system with Cre or Tomato expression in the mouse.	TET2
33160401	10.1186/s13148-020-00962-x	2020	Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.	TET2
33167720	10.1080/10428194.2020.1779255	2020	Venetoclax induced complete remission in extramedullary relapse of AML co-harboring <i>NPM1</i>, <i>TET2</i>, and <i>NRAS</i> mutations after haploidentical hematopoietic stem cell transplantation.	TET2
33224395	10.14740/jh760	2020	Molecular Genetic Analysis With Flow Cytometry Sorting Identifies Angioimmunoblastic T-Cell Lymphoma and Concomitant <i>De Novo</i> Myelodysplastic Syndrome Arising From the Same Hematopoietic Progenitor.	TET2
33363958	10.1002/ccr3.3430	2020	Angioimmunoblastic T-cell lymphoma after acute myeloid leukemia: Alleged common pathogenesis. A case report and literature review.	TET2
33376237	10.1038/s41392-020-00331-3	2020	Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.	TET2
34667996	10.21037/aol-20-20	2020	Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.	TET2
29629950	10.1097/PAI.0000000000000644	2019	A Survey of Somatic Mutations in 41 Genes in a Cohort of T-Cell Lymphomas Identifies Frequent Mutations in Genes Involved in Epigenetic Modification.	TET2
30097855	10.1007/s10689-018-0099-x	2019	Candidate susceptibility variants in angioimmunoblastic T-cell lymphoma.	TET2
30143831	10.1007/s00277-018-3482-7	2019	Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies.	TET2
30357811	10.1111/cei.13227	2019	AID and TET2 co-operation modulates FANCA expression by active demethylation in diffuse large B cell lymphoma.	TET2
30596212	10.1007/978-3-319-99716-2_2	2019	Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma.	TET2
30623224	10.1007/s00347-018-0840-8	2019	[New molecular pathological strategies for malignant iris tumors].	TET2
30632835	10.1080/10428194.2018.1516878	2019	Descriptive analysis of genetic aberrations and cell of origin in Richter transformation.	TET2
30683910	10.1038/s41375-019-0380-5	2019	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.	TET2
30726915	10.1093/intimm/dxz008	2019	Loss of TET proteins in regulatory T cells promotes abnormal proliferation, Foxp3 destabilization and IL-17 expression.	TET2
30782038	10.1080/17474086.2019.1583102	2019	New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.	TET2
30829413	10.1002/ajh.25450	2019	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.	TET2
30890702	10.1038/s41467-019-09198-7	2019	Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans.	TET2
30952970	10.1038/s41379-019-0254-4	2019	The pathological features of angioimmunoblastic T-cell lymphomas with IDH2<sup>R172</sup> mutations.	TET2
31097631	10.3324/haematol.2018.215327	2019	Clonal sequence tracking reveals <i>TET2</i>-mutated extranodal NK/T-cell lymphoma disseminated independent of Epstein Barr virus.	TET2
31123138	10.1136/jclinpath-2019-205727	2019	Intravascular NK/T-cell lymphoma: clinicopathological and integrated molecular analysis of two cases provides a clue to disease pathogenesis.	TET2
31184232	10.1080/10428194.2019.1627539	2019	Common clonal origin of an EBV-positive diffuse large B cell lymphoma and a chronic myelomonocytic leukemia.	TET2
31204875	10.1080/10428194.2019.1627541	2019	Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in <i>TET2</i>, <i>DNMT3</i> and <i>CUX1</i> - azacitidine induces only lymphoma remission.	TET2
31266538	10.1186/s13072-019-0278-5	2019	MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.	TET2
31311407	10.1080/15384047.2019.1638670	2019	Somatic mutations in <i>KMT2D</i> and <i>TET2</i> associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders.	TET2
31371502	10.1073/pnas.1903059116	2019	Paradoxical association of TET loss of function with genome-wide DNA hypomethylation.	TET2
31394087	10.1016/j.yexmp.2019.104294	2019	RHOA G17V mutation in angioimmunoblastic T-cell lymphoma: A potential biomarker for cytological assessment.	TET2
31441600	10.1111/ijlh.13099	2019	Low expression of TET2 gene in pediatric acute lymphoblastic leukemia is associated with poor clinical outcome.	TET2
31467227	10.21873/cgp.20138	2019	Association of Leukemia Target Genes <i>Tet2, Bcl2</i>, and <i>Slc23a2</i> in Vitamin C Pathways.	TET2
31594013	10.1055/a-0597-7606	2019	[Current standard in diagnostic and therapy of peripheral T-cell lymphoma].	TET2
31594043	10.3760/cma.j.issn.0529-5807.2019.10.007	2019	[Angioimmunoblastic T-cell lymphoma: histopathological grading and prognosis].	TET2
31597847	10.11406/rinketsu.60.1221	2019	[Diagnosis and treatment of angioimmunoblastic T-cell lymphoma and related cancers].	TET2
31902816	10.11406/rinketsu.60.1652	2019	[Relapsed acute myeloid leukemia concomitant with TET2-mutated peripheral T-cell lymphoma, not otherwise specified].	TET2
28718760	10.1080/10428194.2017.1352089	2018	CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.	TET2
28889481	10.1111/cas.13393	2018	Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma.	TET2
29052597	10.1038/modpathol.2017.145	2018	SYK expression in monomorphic epitheliotropic intestinal T-cell lymphoma.	TET2
29199511	10.1080/10428194.2017.1406087	2018	Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response.	TET2
29321428	10.2169/internalmedicine.9668-17	2018	Synchronous Occurrence of Mycosis Fungoides, Diffuse Large B Cell Lymphoma and Acute Myeloid Leukemia.	TET2
29368535	10.1080/10428194.2018.1427857	2018	Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia.	TET2
29397528	10.1007/s11899-018-0432-3	2018	The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL).	TET2
29398449	10.1016/j.ccell.2018.01.001	2018	RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis.	TET2
29491461	10.1038/s41417-018-0013-6	2018	Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5.	TET2
29581109	10.1182/bloodadvances.2017014118	2018	B-cell tumor development in <i>Tet2</i>-deficient mice.	TET2
29662631	10.18632/oncotarget.24592	2018	Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features.	TET2
29666007	10.1016/j.cancergen.2018.02.006	2018	Mutation analysis of therapy-related myeloid neoplasms.	TET2
29666117	10.1182/blood-2017-11-764357	2018	Novel insights into the pathogenesis of T-cell lymphomas.	TET2
29674500	10.3324/haematol.2018.191601	2018	Novel <i>GPR34</i> and <i>CCR6</i> mutation and distinct genetic profiles in MALT lymphomas of different sites.	TET2
29769264	10.1182/blood-2017-11-818617	2018	RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice.	TET2
29793312	10.1016/j.biopha.2017.11.033	2018	Aberrant DNA methylation of key genes and Acute Lymphoblastic Leukemia.	TET2
29877249	10.11406/rinketsu.59.574	2018	[The microenvironment and immune status of peripheral T-cell lymphoma: focusing on AITL and ATLL].	TET2
29895903	10.1038/s41408-018-0089-0	2018	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.	TET2
29904089	10.1038/s41417-018-0028-z	2018	Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia.	TET2
29947237	10.4149/BLL_2018_068	2018	Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia.	TET2
29961066	10.1159/000491065	2018	Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.	TET2
30001986	10.1016/j.clml.2018.06.011	2018	A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome.	TET2
30032569	10.3760/cma.j.issn.0253-2727.2018.06.013	2018	[Targeted sequencing analysis of hyper-eosinophilic syndrome and chronic eosinophilic leukemia].	TET2
30111389	10.7534/j.issn.1009-2137.2018.04.001	2018	[Study on Immunophenotypes and Gene of Acute Lymphoblastic Leukemia].	TET2
30228234	10.1182/blood-2018-01-827964	2018	<i>Bcor</i> insufficiency promotes initiation and progression of myelodysplastic syndrome.	TET2
30274972	10.1158/2159-8290.CD-18-0657	2018	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.	TET2
30510015	10.1158/2159-8290.CD-18-1143	2018	TET2 Deficiency Sets the Stage for B-cell Lymphoma.	TET2
30583461	10.3390/cancers11010011	2018	Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.	TET2
31938438	NA	2018	Secondary mixed phenotype acute leukemia following chemotherapy for diffuse large B-cell lymphoma: a case report and review of the literature.	TET2
27353473	10.1002/hon.2319	2017	Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.	TET2
27848178	10.1007/s12185-016-2122-z	2017	Dysregulation of TET2 in hematologic malignancies.	TET2
27874290	10.1080/10428194.2016.1260124	2017	Impact of clinical factors on outcome of leukemia patients with TLS-ERG fusion gene.	TET2
27921272	10.1007/s12185-016-2159-z	2017	BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma.	TET2
28068180	10.1200/JCO.2016.71.6712	2017	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.	TET2
28082343	10.3324/haematol.2016.158428	2017	Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin.	TET2
28148900	10.18632/oncotarget.14846	2017	Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling.	TET2
28157189	10.1038/bcj.2016.122	2017	Identification of cell-type-specific mutations in nodal T-cell lymphomas.	TET2
28193779	10.1158/2159-8290.CD-16-1049	2017	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in <i>IDH2</i>- and <i>TET2</i>-Mutant Acute Myeloid Leukemia.	TET2
28245838	10.1186/s13045-017-0431-1	2017	Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia.	TET2
28331128	10.3960/jslrt.56.145	2017	TET2 mutation in diffuse large B-cell lymphoma.	TET2
28337768	10.1002/path.4898	2017	TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma.	TET2
28394181	10.1080/10428194.2017.1292357	2017	A novel recurrent copy number loss region on 6q23.3 in MDS-related myeloid malignancy patients with stable survival conditions.	TET2
28487787	10.1155/2017/5083463	2017	EBV-Negative Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder with Marked Morphologic Pleomorphism and Pathogenic Mutations in <i>ASXL1</i>, <i>BCOR</i>, <i>CDKN2A</i>, <i>NF1</i>, and <i>TP53</i>.	TET2
28543514	10.1002/path.4920	2017	Angioimmunoblastic T-cell lymphoma: more than a disease of T follicular helper cells.	TET2
28634614	10.1007/s00277-017-3038-2	2017	Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma.	TET2
28691928	10.1172/JCI92026	2017	Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis.	TET2
28731140	10.3892/mmr.2017.7058	2017	Integrated analysis of genome‚Äëwide gene expression and DNA methylation microarray of diffuse large B‚Äëcell lymphoma with TET mutations.	TET2
28881727	10.18632/oncotarget.13665	2017	Adult T cell leukemia aggressivenness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression.	TET2
28978861	10.11406/rinketsu.58.2160	2017	Acute leukemia in adolescents and young adults.	TET2
29190698	10.1371/journal.pone.0188856	2017	Profiles of a broad spectrum of epigenetic DNA modifications in normal and malignant human cell lines: Proliferation rate is not the major factor responsible for the 5-hydroxymethyl-2'-deoxycytidine level in cultured cancerous cell lines.	TET2
29279549	10.3960/jslrt.17019	2017	Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma.	TET2
25809997	10.1111/ejh.12549	2016	Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation.	TET2
26384468	10.1111/bjd.14174	2016	Decreased expression of ten-eleven translocation 2 protein is associated with progressive disease and death in patients with mycosis fungoides.	TET2
26697989	10.1016/j.critrevonc.2015.11.004	2016	Myeloproliferative neoplasms: Current molecular biology and genetics.	TET2
26700872	10.3109/10428194.2015.1122785	2016	DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia.	TET2
26719098	10.1038/leu.2015.357	2016	Recurrent activating mutations of CD28 in peripheral T-cell lymphomas.	TET2
26880370	10.1186/s12943-016-0500-z	2016	Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia.	TET2
26917488	10.1111/bjh.13952	2016	Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.	TET2
27055146	10.1097/MOH.0000000000000249	2016	The many layers of epigenetic dysfunction in B-cell lymphomas.	TET2
27169594	10.1007/s00432-016-2174-8	2016	EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.	TET2
27177312	10.1097/MOH.0000000000000261	2016	The curious origins of angioimmunoblastic T-cell lymphoma.	TET2
27203213	10.18632/oncotarget.9400	2016	Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders.	TET2
27384850	10.11406/rinketsu.57.715	2016	Significance of TET2 mutations in myeloid and lymphoid neoplasms.	TET2
27428748	10.1038/ng.3610	2016	DNMT3A and TET2 compete and cooperate to repress lineage-specific transcription factors in hematopoietic stem cells.	TET2
27644645	NA	2016	TET2 Promoter DNA Methylation and Expression in Childhood Acute Lymphoblastic Leukemia.	TET2
27818202	10.1016/j.clim.2016.10.017	2016	The expression of Bcl-6 in circulating follicular helper-like T cells positively correlates with the disease activity in systemic lupus erythematosus.	TET2
24844363	10.3109/10428194.2014.924120	2015	Myelodysplastic syndrome with extramedullary erythroid hyperplasia induced by loss of Tet2 in mice.	TET2
25312805	10.1111/bjh.13170	2015	Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma.	TET2
25614448	10.1158/1078-0432.CCR-14-1216	2015	Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma.	TET2
25628103	10.1007/s12185-015-1738-8	2015	Multistep tumorigenesis in peripheral T cell lymphoma.	TET2
25645650	10.1111/ejh.12515	2015	The molecular pathogenesis of the myelodysplastic syndromes.	TET2
25671252	10.1056/NEJMoa1412098	2015	Effect of mutation order on myeloproliferative neoplasms.	TET2
25687841	10.1007/s00277-015-2332-0	2015	Double somatic mosaic mutations in TET2 and DNMT3A--origin of peripheral T cell lymphoma in a case.	TET2
25876776	10.11406/rinketsu.56.246	2015	[Molecular mechanisms of angioimmunoblastic T-cell lymphoma].	TET2
26256875	10.11406/rinketsu.56.651	2015	[TET2 as a gatekeeper for hematologic malignancies].	TET2
26268241	10.1182/blood-2015-05-644591	2015	IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.	TET2
26297264	10.1016/j.clml.2015.02.035	2015	Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.	TET2
26297278	10.1016/j.clml.2015.03.005	2015	Transformation of the Clinical Management of CMML Patients Through In-Depth Molecular Characterization.	TET2
26345566	10.11406/rinketsu.56.1053	2015	[Mutations in epigenetic and metabolic regulators in peripheral T-cell lymphoma].	TET2
26379152	10.1097/PAS.0000000000000503	2015	Primary CNS T-cell Lymphomas: A Clinical, Morphologic, Immunophenotypic, and Molecular Analysis.	TET2
26551667	10.1038/ng.3442	2015	The mutational landscape of cutaneous T cell lymphoma and S√©zary syndrome.	TET2
26586431	10.1016/j.celrep.2015.10.037	2015	Combined Loss of Tet1 and Tet2 Promotes B Cell, but Not Myeloid Malignancies, in Mice.	TET2
26617922	NA	2015	Discordant intracellular and plasma D-2-hydroxyglutarate levels in a patient with IDH2 mutated angioimmunoblastic T-cell lymphoma.	TET2
26763362	10.3960/jslrt.55.145	2015	TET2 Mutation in Adult T-Cell Leukemia/Lymphoma.	TET2
24072100	10.1038/leu.2013.283	2014	Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm.	TET2
24345752	10.1182/blood-2013-10-531509	2014	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.	TET2
24413734	10.1038/ng.2873	2014	Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.	TET2
24413737	10.1038/ng.2872	2014	Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.	TET2
24524305	10.3109/10428194.2014.893308	2014	Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.	TET2
24598796	10.1371/journal.pone.0089791	2014	Pleiotropy of cancer susceptibility variants on the risk of non-Hodgkin lymphoma: the PAGE consortium.	TET2
24635575	10.3109/10428194.2014.891024	2014	Myeloid neoplasms with der(1)t(1;19) may constitute a specific entity characterized by a cytogenetic biomarker and gene mutations involved in DNA methylation.	TET2
24788138	10.1371/journal.pone.0096209	2014	Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.	TET2
24815671	10.1111/bjh.12941	2014	Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment.	TET2
24989305	10.7534/j.issn.1009-2137.2014.03.049	2014	[TET2 gene in hematological diseases].	TET2
25040794	10.1111/cas.12484	2014	TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.	TET2
25326804	10.1038/nm.3733	2014	Age-related mutations associated with clonal hematopoietic expansion and malignancies.	TET2
25501021	10.1038/bcj.2014.83	2014	Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice.	TET2
23298878	10.1097/MOH.0b013e32835d82fe	2013	Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.	TET2
23407552	10.1182/blood-2013-01-478834	2013	The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.	TET2
23432690	10.3109/10428194.2013.778408	2013	Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.	TET2
23831920	10.3324/haematol.2013.088740	2013	Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma.	TET2
23940084	10.1002/ajh.23567	2013	TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.	TET2
21877899	10.3109/10428194.2011.618235	2012	Update on cytogenetic and molecular changes in myelodysplastic syndromes.	TET2
22080757	10.3109/10428194.2011.639878	2012	A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.	TET2
22215888	10.1182/blood-2011-11-391748	2012	IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.	TET2
22216861	10.1056/NEJMc1111708	2012	TET2 and DNMT3A mutations in human T-cell lymphoma.	TET2
22733026	10.3324/haematol.2012.065375	2012	Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.	TET2
22760778	10.1182/blood-2012-02-408542	2012	Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.	TET2
21042320	10.1038/leu.2010.243	2011	TET2 mutations in childhood leukemia.	TET2
21723201	10.1016/j.ccr.2011.06.003	2011	TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.	TET2
21779006	10.1038/nrc3115	2011	Leukaemia and lymphoma: The expansive reach of TET2.	TET2
20195608	10.1007/s00277-010-0920-6	2010	Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.	TET2
20214447	10.3109/10428191003605313	2010	Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.	TET2
20428194	10.1038/leu.2010.69	2010	Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.	TET2
34511583	10.3960/jslrt.21015	2021	The biology of the tumor microenvironment in DLBCL: Targeting the """"don't eat me"""" signal.	TMEM30A
32094924	10.1038/s41591-020-0757-z	2020	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma.	TMEM30A
25991819	10.1158/1078-0432.CCR-14-2116	2015	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.	TMEM30A
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	TMSB4X
35955786	10.3390/ijms23158651	2022	Effect of CB2 Stimulation on Gene Expression in Pediatric B-Acute Lymphoblastic Leukemia: New Possible Targets.	TMSB4X
31806993	10.2147/OTT.S227122	2019	Genomic Alterations In Primary Cardiac Diffuse Large B Cell Lymphoma: A Case Report And Literature Review.	TMSB4X
25171927	10.1182/blood-2013-12-546309	2014	Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients.	TMSB4X
33579790	10.1136/gutjnl-2020-322935	2022	Oncogenetic landscape of lymphomagenesis in coeliac disease.	TNFAIP3
34494161	10.1007/s00428-021-03186-3	2022	Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.	TNFAIP3
34560683	10.1097/PAS.0000000000001813	2022	A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients.	TNFAIP3
34605949	10.1007/s00277-021-04671-0	2022	Characterization of molecular genetics and clinicopathology in thymic MALT lymphoma.	TNFAIP3
34664256	10.1111/bjh.17894	2022	Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.	TNFAIP3
34840214	10.1272/jnms.JNMS.2022_89-305	2022	Clinicopathologic Characteristics and A20 Mutation in Primary Thyroid Lymphoma.	TNFAIP3
34853447	10.1038/s41418-021-00908-7	2022	Bcl-3 promotes TNF-induced hepatocyte apoptosis by regulating the deubiquitination of RIP1.	TNFAIP3
34952945	10.1038/s41379-021-01002-6	2022	Genomic landscape of Epstein-Barr virus-positive extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue.	TNFAIP3
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	TNFAIP3
35075971	10.1080/10428194.2021.2010060	2022	Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study.	TNFAIP3
35089437	10.1007/s00018-022-04139-y	2022	A20 undermines alternative NF-Œ∫B activity and expression of anti-apoptotic genes in Helicobacter pylori infection.	TNFAIP3
35099607	10.1007/s00018-022-04154-z	2022	A20 and ABIN-1 cooperate in balancing CBM complex-triggered NF-Œ∫B signaling in activated T cells.	TNFAIP3
35236331	10.1186/s12885-022-09237-5	2022	Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.	TNFAIP3
35267569	10.3390/cancers14051264	2022	The Biology of Ocular Adnexal Marginal Zone Lymphomas.	TNFAIP3
35490943	10.1016/j.jbspin.2022.105390	2022	Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma.	TNFAIP3
35937947	10.1155/2022/6441139	2022	Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis.	TNFAIP3
36001451	10.1097/PAS.0000000000001956	2022	Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.	TNFAIP3
32079702	10.3324/haematol.2019.237719	2021	Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study.	TNFAIP3
32785655	10.1182/blood.2019004713	2021	Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.	TNFAIP3
32808859	10.1080/10799893.2020.1808678	2021	Regulation of cell activation by A20 through STAT signaling in acute lymphoblastic leukemia.	TNFAIP3
32961552	10.1182/blood.2020007507	2021	Mutational landscape of gray zone lymphoma.	TNFAIP3
33263441	10.1080/17474086.2021.1856652	2021	Development of molecular intervention strategies for B-cell lymphoma.	TNFAIP3
33311649	10.1038/s41379-020-00720-7	2021	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.	TNFAIP3
33544565	10.1097/PAS.0000000000001658	2021	Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II.	TNFAIP3
33724154	10.1080/21505594.2021.1899674	2021	Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.	TNFAIP3
33814335	10.1016/j.clml.2021.02.010	2021	A Case of EBV-Negative Aggressive NK-cell Leukemia: Use of Next-Generation Sequencing in Demystifying a Diagnostic Dilemma and Guiding Clinical Care.	TNFAIP3
33887878	10.3892/ijo.2021.5211	2021	Potential of the tumor‚Äëderived extracellular vesicles carrying the miR‚Äë125b‚Äë5p target TNFAIP3 in reducing the sensitivity of diffuse large B cell lymphoma to rituximab.	TNFAIP3
33933552	10.1016/j.canlet.2021.04.017	2021	The dual roles of A20 in cancer.	TNFAIP3
34021249	10.1038/s41375-021-01289-z	2021	Thyroid MALT lymphoma: self-harm to gain potential T-cell help.	TNFAIP3
34201504	10.3390/cancers13133131	2021	Deregulated miRNAs Contribute to Silencing of B-Cell Specific Transcription Factors and Activation of NF-Œ∫B in Classical Hodgkin Lymphoma.	TNFAIP3
34203889	10.3390/cancers13122993	2021	Genetic Characterization and Clinical Features of <i>Helicobacter pylori</i> Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.	TNFAIP3
34312841	10.1111/bjh.17719	2021	Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.	TNFAIP3
34405005	10.7150/jca.60390	2021	Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.	TNFAIP3
34447369	10.3389/fimmu.2021.671755	2021	Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.	TNFAIP3
34526012	10.1186/s12935-021-02191-5	2021	TNFAIP3 mutation may be associated with favorable overall survival for patients with T-cell lymphoma.	TNFAIP3
34558064	10.1111/bjh.17824	2021	Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases.	TNFAIP3
35008340	10.3390/cancers14010176	2021	Recent Advances in the Genetic of MALT Lymphomas.	TNFAIP3
35528192	10.1158/2767-9764.crc-21-0022	2021	The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways.	TNFAIP3
31807922	10.1007/s00428-019-02691-w	2020	Subsequent development of histiocytic sarcoma and follicular lymphoma: cytogenetics and next-generation sequencing analyses provide evidence for transdifferentiation of early common lymphoid precursor-a case report and review of literature.	TNFAIP3
31948699	10.1016/j.annpat.2019.12.006	2020	[Low-grade dural extranodal marginal zone lymphoma].	TNFAIP3
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	TNFAIP3
32059783	10.1016/j.cell.2020.01.029	2020	Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody.	TNFAIP3
32299816	10.1158/1078-0432.CCR-19-4137	2020	A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.	TNFAIP3
32316399	10.3390/cancers12040986	2020	Identifying Genetic Lesions in Ocular Adnexal Extranodal Marginal Zone Lymphomas of the MALT Subtype by Whole Genome, Whole Exome and Targeted Sequencing.	TNFAIP3
32443356	10.1097/MD.0000000000020232	2020	Genetic heterogeneity of pediatric systemic lupus erythematosus with lymphoproliferation.	TNFAIP3
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	TNFAIP3
32738175	10.1002/hon.2784	2020	Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis.	TNFAIP3
33045225	10.1016/j.humpath.2020.09.014	2020	The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.	TNFAIP3
33139544	10.1073/pnas.2014470117	2020	Essential role of the linear ubiquitin chain assembly complex and TAK1 kinase in A20 mutant Hodgkin lymphoma.	TNFAIP3
33154951	10.3389/fonc.2020.591577	2020	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	TNFAIP3
30211726	10.1097/PAS.0000000000001154	2019	Cyclin D1-positive Mediastinal Large B-Cell Lymphoma With Copy Number Gains of CCND1 Gene: A Study of 3 Cases With Nonmediastinal Disease.	TNFAIP3
30488325	10.1007/s00277-018-3565-5	2019	Primary hepatic marginal B cell lymphoma of mucosa-associated lymphoid tissue (MALT) and non-alcoholic steatohepatitis (NASH): more than a coincidence?	TNFAIP3
30738453	10.7534/j.issn.1009-2137.2019.01.015	2019	[Correlation of EBV Infection with Expression of TNF-Œ±-Inducing Protein 3 Gene and A20 Protein in Hodgkin's Lmphoma].	TNFAIP3
31140551	10.1093/ajcp/aqz041	2019	Activation of the NF-Œ∫B Pathway and Heterozygous Deletion of TNFAIP3 (A20) Confer Superior Survival in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.	TNFAIP3
31320741	10.1038/s41598-019-46906-1	2019	Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma.	TNFAIP3
31378966	10.1002/ajh.25600	2019	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.	TNFAIP3
31403034	10.3389/fonc.2019.00683	2019	Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.	TNFAIP3
31444033	10.1016/j.jaut.2019.102317	2019	Genetic contributors and soluble mediators in prediction of autoimmune comorbidity.	TNFAIP3
31534975	10.1155/2019/6728694	2019	TNFAIP3 Gene Polymorphisms in Three Common Autoimmune Diseases: Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Primary Sjogren Syndrome-Association with Disease Susceptibility and Clinical Phenotypes in Italian Patients.	TNFAIP3
31816062	10.1182/bloodadvances.2019001012	2019	Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.	TNFAIP3
28296250	10.1111/ajco.12672	2018	Different genetic alteration of A20 in a S√©zary syndrome case with VŒ±2-JŒ±22 T cell clone.	TNFAIP3
29380463	10.1002/gcc.22524	2018	Clinicopathologic implications of TNFAIP3/A20 deletions in extranodal NK/T-cell lymphoma.	TNFAIP3
29463935	10.18926/AMO/55659	2018	A20 (TNFAIP3) Alterations in Primary Intestinal Diffuse Large B-cell Lymphoma.	TNFAIP3
29674500	10.3324/haematol.2018.191601	2018	Novel <i>GPR34</i> and <i>CCR6</i> mutation and distinct genetic profiles in MALT lymphomas of different sites.	TNFAIP3
29695787	10.1038/s41556-018-0084-5	2018	Loss of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing the mRNA decay factor roquin2.	TNFAIP3
29765142	10.1038/s41379-018-0064-0	2018	Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement.	TNFAIP3
29891112	10.1016/j.critrevonc.2018.05.010	2018	Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.	TNFAIP3
30087457	10.1038/s41374-018-0096-6	2018	Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues.	TNFAIP3
30214692	10.18632/oncotarget.26080	2018	Correction: The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in <i>TNFAIP3</i> followed by mutations in <i>TBL1XR1</i> and <i>CREBBP</i>.	TNFAIP3
30301877	10.1038/s41408-018-0130-3	2018	Loss of TNFAIP3 enhances MYD88<sub>L265P</sub>-driven signaling in non-Hodgkin lymphoma.	TNFAIP3
30662920	10.1155/2018/6923213	2018	TNFAIP3 F127C Coding Variation in Greek Primary Sjogren's Syndrome Patients.	TNFAIP3
27297871	10.1111/his.13015	2017	Recurrent mutations in genes involved in nuclear factor-Œ∫B signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.	TNFAIP3
28073005	10.1016/j.ccell.2016.12.003	2017	Simultaneous Inhibition of PI3KŒ¥ and PI3KŒ± Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-Œ∫B and AKT.	TNFAIP3
28152507	10.18632/oncotarget.14928	2017	The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP.	TNFAIP3
28153771	10.1016/j.ebiom.2017.01.027	2017	B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.	TNFAIP3
28178345	10.1371/journal.pone.0171221	2017	PI3KŒ¥ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3KŒ¥ and BTK inhibitors.	TNFAIP3
28189285	10.1016/j.prp.2016.11.001	2017	Mutation analysis of tumor necrosis factor alpha-induced protein 3 gene in Hodgkin lymphoma.	TNFAIP3
28288707	10.1016/j.beha.2016.09.002	2017	MALT lymphoma: Genetic abnormalities, immunological stimulation and molecular mechanism.	TNFAIP3
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	TNFAIP3
28682481	10.1002/path.4933	2017	Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma.	TNFAIP3
28751561	10.3324/haematol.2016.160192	2017	Exome sequencing identifies recurrent <i>BCOR</i> alterations and the absence of <i>KLF2</i>, <i>TNFAIP3</i> and <i>MYD88</i> mutations in splenic diffuse red pulp small B-cell lymphoma.	TNFAIP3
28892161	10.1002/path.4982	2017	A gene is known by the company it keeps: enrichment of TNFAIP3 gene aberrations in MALT lymphomas expressing IGHV4-34 antigen receptors.	TNFAIP3
29033545	10.2147/DDDT.S135993	2017	Downregulation of A20 increases the cytotoxicity of IFN-Œ≥ in hepatocellular carcinoma cells.	TNFAIP3
26338037	10.1136/annrheumdis-2015-207731	2016	Germline variation of TNFAIP3 in primary Sj√∂gren's syndrome-associated lymphoma.	TNFAIP3
26437781	10.1038/leu.2015.267	2016	A20 targets caspase-8 and FADD to protect HTLV-I-infected cells.	TNFAIP3
26518771	10.1007/s13277-015-4322-1	2016	Higher incidence of the SNP Met 788 Ile in the coding region of A20 in diffuse large B cell lymphomas.	TNFAIP3
26650888	10.1002/gcc.22331	2016	Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma.	TNFAIP3
26679293	10.1111/sji.12405	2016	Low Protein A20 in Minor Salivary Glands is Associated with Lymphoma in Primary Sj√∂gren's Syndrome.	TNFAIP3
26752547	10.1097/PAS.0000000000000592	2016	Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.	TNFAIP3
26780579	10.1111/ajt.13558	2016	EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features.	TNFAIP3
26819451	10.1158/1078-0432.CCR-15-2305	2016	Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.	TNFAIP3
26986245	10.3892/or.2016.4662	2016	Development of a high-resolution melting method for the screening of TNFAIP3 gene mutations.	TNFAIP3
27050077	10.18632/oncotarget.8537	2016	Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma.	TNFAIP3
27221964	10.1016/j.semcancer.2016.05.001	2016	NF-Œ∫B deregulation in Hodgkin lymphoma.	TNFAIP3
27248180	10.18632/oncotarget.9678	2016	The genetic landscape of dural marginal zone lymphomas.	TNFAIP3
27349720	10.3892/or.2016.4899	2016	PMA/IONO affects diffuse large B-cell lymphoma cell growth through upregulation of A20 expression.	TNFAIP3
27435953	10.1111/ajco.12577	2016	A20 SNP rs77191406 may be related to secondary cancer for rheumatoid arthritis and systemic lupus erythematosus patients.	TNFAIP3
27452667	10.1016/j.semcancer.2016.07.003	2016	MALT lymphoma: A paradigm of NF-Œ∫B dysregulation.	TNFAIP3
27551157	10.1084/jem.20151065	2016	NKT sublineage specification and survival requires the ubiquitin-modifying enzyme TNFAIP3/A20.	TNFAIP3
27566587	10.18632/oncotarget.11548	2016	Recurrent mutations in NF-Œ∫B pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.	TNFAIP3
27637078	10.18632/oncotarget.12018	2016	miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20.	TNFAIP3
28088970	10.3760/cma.j.issn.0253-2727.2016.12.010	2016	[TNFAIP3 deletion status in classical Hodgkin lymphoma and its relation to Epstein-Barr virus].	TNFAIP3
25316606	10.1111/bjh.13192	2015	Sj√∂gren Syndrome-associated lymphomas: an update on pathogenesis and management.	TNFAIP3
25428260	10.1038/leu.2014.330	2015	KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.	TNFAIP3
25779943	10.1158/1078-0432.CCR-14-2759	2015	Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.	TNFAIP3
25991819	10.1158/1078-0432.CCR-14-2116	2015	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.	TNFAIP3
26043155	10.1080/15548627.2015.1055439	2015	TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy.	TNFAIP3
26159495	10.1016/j.leukres.2015.06.004	2015	Up-regulated A20 promotes proliferation, regulates cell cycle progression and induces chemotherapy resistance of acute lymphoblastic leukemia cells.	TNFAIP3
26366710	10.1038/nm.3943	2015	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.	TNFAIP3
26599546	10.1371/journal.pone.0139663	2015	Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines.	TNFAIP3
26716984	10.1371/journal.pone.0145037	2015	A20 Mutation Is Not a Prognostic Marker for Activated B-Cell-Like Diffuse Large B-Cell Lymphoma.	TNFAIP3
24362818	10.1038/ng.2856	2014	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.	TNFAIP3
24491438	10.1158/2159-8290.CD-13-0915	2014	Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.	TNFAIP3
24534189	10.1084/jem.20131424	2014	Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance.	TNFAIP3
24611736	10.1179/1607845414Y.0000000160	2014	Characteristics of A20 gene polymorphisms in T-cell acute lymphocytic leukemia.	TNFAIP3
24867288	10.1097/MOH.0000000000000051	2014	The origin and targeting of mucosa-associated lymphoid tissue lymphomas.	TNFAIP3
24870942	10.1007/s00277-014-2116-y	2014	Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.	TNFAIP3
24971370	10.1155/2014/492872	2014	Alternative expression pattern of MALT1-A20-NF-Œ∫B in patients with rheumatoid arthritis.	TNFAIP3
25364581	10.7497/j.issn.2095-3941.2014.03.006	2014	The gene expression patterns of BMPR2, EP300, TGFŒ≤2, and TNFAIP3 in B-Lymphoma cells.	TNFAIP3
25384343	10.1186/s40001-014-0062-8	2014	Characteristics of CARMA1-BCL10-MALT1-A20-NF-Œ∫B expression in T cell-acute lymphocytic leukemia.	TNFAIP3
23292937	10.1073/pnas.1205299110	2013	Genetic heterogeneity of diffuse large B-cell lymphoma.	TNFAIP3
23327292	10.3109/10428194.2012.762511	2013	Clinicopathologic implication of A20/TNFAIP3 deletion in diffuse large B-cell lymphoma: an analysis according to immunohistochemical subgroups and rituximab treatment.	TNFAIP3
23418597	10.1371/journal.pone.0056741	2013	A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.	TNFAIP3
23677497	10.1007/s13105-013-0259-2	2013	Bcl10 is an essential regulator for A20 gene expression.	TNFAIP3
23720088	10.1002/ajh.23490	2013	Molecular and genomic aberrations in Chlamydophila psittaci negative ocular adnexal marginal zone lymphomas.	TNFAIP3
24159176	10.1182/blood-2013-05-503383	2013	Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome.	TNFAIP3
24349473	10.1371/journal.pone.0083244	2013	Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.	TNFAIP3
22052242	10.1038/gt.2011.160	2012	Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs.	TNFAIP3
22102703	10.3324/haematol.2011.054080	2012	BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.	TNFAIP3
22207688	10.3324/haematol.2010.036798	2012	A20 inactivation in ocular adnexal MALT lymphoma.	TNFAIP3
22285182	10.1016/j.bbrc.2012.01.056	2012	Targeting A20 enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells.	TNFAIP3
22301699	10.1038/modpathol.2011.213	2012	Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities.	TNFAIP3
22343828	10.1038/cmi.2011.59	2012	Regulation of NF-Œ∫B signaling by the A20 deubiquitinase.	TNFAIP3
22382892	10.1038/leu.2012.28	2012	Chlamydia psittaci-negative ocular adnexal marginal zone B-cell lymphomas have biased VH4-34 immunoglobulin gene expression and proliferate in a distinct inflammatory environment.	TNFAIP3
22393903	10.1111/j.1365-2559.2012.04181.x	2012	A novel A20 (TNFAIP3) antibody (Ber-A20) can be used to detect unmutated A20 by immunohistology.	TNFAIP3
22397314	10.3109/10428194.2012.668286	2012	Role of nuclear factor-Œ∫B regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma.	TNFAIP3
22550173	10.1073/pnas.1200081109	2012	MicroRNAs miR-125a and miR-125b constitutively activate the NF-Œ∫B pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20).	TNFAIP3
22808296	NA	2012	Mutation analysis of NF-Œ∫B signal pathway-related genes in ocular MALT lymphoma.	TNFAIP3
23032187	10.1038/emboj.2012.241	2012	Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-Œ∫B regulation.	TNFAIP3
23039325	10.1186/1471-2407-12-457	2012	Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma.	TNFAIP3
21115979	10.1182/blood-2010-01-264275	2011	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome.	TNFAIP3
21266526	10.1158/1078-0432.CCR-10-1859	2011	A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma.	TNFAIP3
21324920	10.1158/0008-5472.CAN-10-2525	2011	Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.	TNFAIP3
21406721	10.1182/blood-2010-10-310995	2011	A20 (TNFAIP3) genetic alterations in EBV-associated AIDS-related lymphoma.	TNFAIP3
21454205	10.3816/CLML.2011.n.021	2011	High-throughput genomic analysis in Waldenstr√∂m's macroglobulinemia.	TNFAIP3
21518331	10.1111/j.1365-2141.2011.08624.x	2011	TNFAIP3 abnormalities in MALT lymphoma with autoimmunity.	TNFAIP3
21531730	10.1074/jbc.M111.224048	2011	A20 is induced by Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 and blocks K13-induced nuclear factor-kappaB in a negative feedback manner.	TNFAIP3
21566404	NA	2011	[Significance of A20 in B-cell lymphomas].	TNFAIP3
21625233	10.1038/leu.2011.101	2011	Tumor suppressor TNFAIP3 (A20) is frequently deleted in S√©zary syndrome.	TNFAIP3
21737982	NA	2011	[Frequent inactivation of A20 through gene mutation in B-cell lymphomas].	TNFAIP3
21745165	10.3109/10428194.2011.596968	2011	Thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a clinicopathological and genetic analysis of six cases.	TNFAIP3
21881048	10.1182/blood-2011-06-359166	2011	Alteration of BIRC3 and multiple other NF-Œ∫B pathway genes in splenic marginal zone lymphoma.	TNFAIP3
22099304	10.1016/j.molcel.2011.09.015	2011	Direct, noncatalytic mechanism of IKK inhibition by A20.	TNFAIP3
19648161	10.3324/haematol.2009.010157	2010	Mutations in the genes coding for the NF-Œ∫B regulating factors IŒ∫BŒ± and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma.	TNFAIP3
19907439	10.1038/leu.2009.234	2010	A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma.	TNFAIP3
20014148	10.1002/hon.932	2010	Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas.	TNFAIP3
20186265	10.1371/journal.pbio.1000319	2010	Targeting A20 decreases glioma stem cell survival and tumor growth.	TNFAIP3
20359517	10.1016/j.tox.2010.03.014	2010	Gene expression profiles of human promyelocytic leukemia cell lines exposed to volatile organic compounds.	TNFAIP3
20544211	10.1007/s00401-010-0709-7	2010	Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma.	TNFAIP3
20599425	10.1016/j.bcp.2010.06.044	2010	Expression, biological activities and mechanisms of action of A20 (TNFAIP3).	TNFAIP3
20607853	10.1002/gcc.20789	2010	Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma.	TNFAIP3
20804738	10.1016/j.bbrc.2010.08.091	2010	Cleavage by MALT1 induces cytosolic release of A20.	TNFAIP3
19006194	10.1002/path.2466	2009	A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands.	TNFAIP3
19258598	10.1182/blood-2008-08-174110	2009	The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.	TNFAIP3
19380636	10.1084/jem.20090765	2009	A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme.	TNFAIP3
19380639	10.1084/jem.20090528	2009	TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.	TNFAIP3
19412163	10.1038/nature07969	2009	Frequent inactivation of A20 in B-cell lymphomas.	TNFAIP3
19412164	10.1038/nature07968	2009	Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.	TNFAIP3
19494296	10.4049/jimmunol.0803313	2009	A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains.	TNFAIP3
19507254	10.1002/ijc.24502	2009	Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases.	TNFAIP3
19608751	10.1182/blood-2008-12-194852	2009	TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.	TNFAIP3
19617629	10.1074/jbc.M109.019786	2009	Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of interleukin-10.	TNFAIP3
19826422	10.1038/sj.bjc.6605352	2009	Impaired TNFalpha-induced A20 expression in E1A/Ras-transformed cells.	TNFAIP3
20008234	10.1182/asheducation-2009.1.491	2009	Molecular biology of Hodgkin lymphoma.	TNFAIP3
17886247	10.1002/gcc.20499	2008	TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma.	TNFAIP3
18223652	10.1038/ni1561	2008	T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20.	TNFAIP3
18297524	10.1080/10428190701817282	2008	Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia.	TNFAIP3
18349075	10.1242/jcs.021105	2008	A20 is a negative regulator of BCL10- and CARMA3-mediated activation of NF-kappaB.	TNFAIP3
17953374	NA	2007	[Expressions of cytoprotective proteins for human renal allografts].	TNFAIP3
15359998	10.1080/10428190310001657326	2004	Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).	TNFAIP3
12754742	10.1002/path.1351	2003	Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation.	TNFAIP3
8970991	10.1128/JVI.70.12.8653-8659.1996	1996	Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene.	TNFAIP3
34265801	10.1097/PAS.0000000000001780	2022	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.	TNFRSF14
34382383	10.3324/haematol.2020.263251	2022	Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma.	TNFRSF14
35038193	10.1111/his.14617	2022	Incidence, clinicopathological features and genetics of in-situ follicular neoplasia: a comprehensive screening study in a Japanese cohort.	TNFRSF14
35106936	10.1002/cam4.4550	2022	SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.	TNFRSF14
35609565	10.1182/bloodadvances.2022007322	2022	A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile.	TNFRSF14
35734168	10.3389/fimmu.2022.922471	2022	m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment.	TNFRSF14
35834399	10.1097/PAS.0000000000001932	2022	Pediatric-Type Indolent B-Cell Lymphomas With Overlapping Clinical, Pathologic, and Genetic Features.	TNFRSF14
32855278	10.3324/haematol.2020.254854	2021	Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype.	TNFRSF14
33311649	10.1038/s41379-020-00720-7	2021	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.	TNFRSF14
33395752	10.1016/j.tranon.2020.100977	2021	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.	TNFRSF14
33560380	10.1182/bloodadvances.2020002469	2021	Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features.	TNFRSF14
33562694	10.3390/cancers13040641	2021	Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention.	TNFRSF14
33945543	10.1371/journal.pone.0248886	2021	Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.	TNFRSF14
33959502	10.3389/fonc.2021.638897	2021	c-Rel Is the Pivotal NF-Œ∫B Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.	TNFRSF14
33964277	10.1016/j.humpath.2021.04.014	2021	Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma.	TNFRSF14
33968070	10.3389/fimmu.2021.666935	2021	Single-Cell RNA Sequencing Reveals Tissue Compartment-Specific Plasticity of Mycosis Fungoides Tumor Cells.	TNFRSF14
34021249	10.1038/s41375-021-01289-z	2021	Thyroid MALT lymphoma: self-harm to gain potential T-cell help.	TNFRSF14
34069564	10.3390/ijms22105352	2021	The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential.	TNFRSF14
34374220	10.1002/cjp2.223	2021	c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.	TNFRSF14
34478526	10.1182/bloodadvances.2021005215	2021	Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.	TNFRSF14
34558064	10.1111/bjh.17824	2021	Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases.	TNFRSF14
34671837	10.1007/s00292-021-01011-x	2021	[Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].	TNFRSF14
35008340	10.3390/cancers14010176	2021	Recent Advances in the Genetic of MALT Lymphomas.	TNFRSF14
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	TNFRSF14
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	TNFRSF14
32304999	10.1016/j.ebiom.2020.102731	2020	Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab.	TNFRSF14
33045225	10.1016/j.humpath.2020.09.014	2020	The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma.	TNFRSF14
33188997	10.1016/j.ctarc.2020.100235	2020	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.	TNFRSF14
33211828	10.1182/bloodadvances.2020002944	2020	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.	TNFRSF14
30696620	10.1182/blood-2018-08-871293	2019	Autocrine LTA signaling drives NF-Œ∫B and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma.	TNFRSF14
30819919	10.3324/haematol.2018.211631	2019	A high definition picture of key genes and pathways mutated in pediatric follicular lymphoma.	TNFRSF14
30885361	10.1016/bs.acr.2019.01.004	2019	HVEM network signaling in cancer.	TNFRSF14
30918139	10.3960/jslrt.19003	2019	High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation.	TNFRSF14
31368914	10.1097/PAS.0000000000001338	2019	Indolent In Situ B-Cell Neoplasms With MYC Rearrangements Show Somatic Mutations in MYC and TNFRSF14 by Next-generation Sequencing.	TNFRSF14
29674500	10.3324/haematol.2018.191601	2018	Novel <i>GPR34</i> and <i>CCR6</i> mutation and distinct genetic profiles in MALT lymphomas of different sites.	TNFRSF14
29738359	10.1097/PAS.0000000000001071	2018	Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients.	TNFRSF14
29858685	10.1007/s00428-018-2384-3	2018	Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.	TNFRSF14
30126979	10.1182/blood-2018-03-837252	2018	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.	TNFRSF14
27297871	10.1111/his.13015	2017	Recurrent mutations in genes involved in nuclear factor-Œ∫B signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.	TNFRSF14
28533310	10.1182/blood-2017-03-776278	2017	Mutations of <i>MAP2K1</i> are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation.	TNFRSF14
26650888	10.1002/gcc.22331	2016	Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma.	TNFRSF14
26965583	10.1038/modpathol.2016.51	2016	Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations.	TNFRSF14
27086936	10.3109/10428194.2016.1165816	2016	Rubinstein-Taybi syndrome - a window into follicular lymphoma biology.	TNFRSF14
27098631	NA	2016	Extranodal B Cell Lymphoma with Prominent Spindle Cell Features Arising in Uterus and in Maxillary Sinus: Report of Two Cases and Literature Review.	TNFRSF14
27103745	10.1182/blood-2015-10-679191	2016	TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.	TNFRSF14
27257180	10.1182/blood-2016-03-703819	2016	Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene.	TNFRSF14
27325104	10.1182/blood-2015-12-682591	2016	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations.	TNFRSF14
27693350	10.1016/j.cell.2016.08.032	2016	Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.	TNFRSF14
27750045	10.1016/j.ajpath.2016.07.027	2016	B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains.	TNFRSF14
26366710	10.1038/nm.3943	2015	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.	TNFRSF14
24162788	10.3324/haematol.2013.094474	2014	Early lesions of follicular lymphoma: a genetic perspective.	TNFRSF14
24435047	10.1182/blood-2013-05-500264	2014	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.	TNFRSF14
24942943	10.3960/jslrt.54.23	2014	Molecular pathogenesis of follicular lymphoma.	TNFRSF14
25277889	10.1016/j.bbrc.2014.09.084	2014	CD160 expression defines a uniquely exhausted subset of T lymphocytes in HTLV-1 infection.	TNFRSF14
23297126	10.1182/blood-2012-09-457283	2013	Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.	TNFRSF14
23306973	10.2340/00015555-1523	2013	Serum-soluble herpes virus entry mediator levels reflect disease severity and Th2 environment in cutaneous T-cell lymphoma.	TNFRSF14
23445872	10.3324/haematol.2012.073916	2013	Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas.	TNFRSF14
24052547	10.1182/blood-2013-04-496893	2013	EZH2 mutations are frequent and represent an early event in follicular lymphoma.	TNFRSF14
21941365	10.1038/leu.2011.266	2012	High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis.	TNFRSF14
22297640	10.1038/jid.2011.470	2012	Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma.	TNFRSF14
22343534	10.1073/pnas.1121343109	2012	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing.	TNFRSF14
22634623	10.4049/jimmunol.1102807	2012	B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.	TNFRSF14
23023713	10.1172/JCI63186	2012	Pathogenesis of follicular lymphoma.	TNFRSF14
20946916	10.1016/j.imlet.2010.10.007	2011	Immunohistochemical analysis of HLDA9 Workshop antibodies against cell-surface molecules in reactive and neoplastic lymphoid tissues.	TNFRSF14
20884631	10.1158/0008-5472.CAN-10-2460	2010	Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis.	TNFRSF14
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	TNFRSF14
19762537	10.1309/AJCPPHKGYYGGL39C	2009	High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.	TNFRSF14
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	TNFRSF14
14562115	10.1038/sj.leu.2403175	2003	Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity.	TNFRSF14
31307539	10.1186/s40425-019-0664-3	2019	Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody.	TNFSF9
30194255	10.1182/blood-2018-04-845834	2018	Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.	TNFSF9
27756788	10.1158/1078-0432.CCR-16-1272	2017	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.	TNFSF9
25710169	10.1371/journal.ppat.1004652	2015	HITS-CLIP analysis uncovers a link between the Kaposi's sarcoma-associated herpesvirus ORF57 protein and host pre-mRNA metabolism.	TNFSF9
23095505	10.1097/PAS.0b013e318268c6ea	2013	CD137 ligand is expressed in primary and secondary lymphoid follicles and in B-cell lymphomas: diagnostic and therapeutic implications.	TNFSF9
23204227	10.1158/0008-5472.CAN-12-3849	2013	Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression.	TNFSF9
23716461	10.1002/gcc.22072	2013	The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma.	TNFSF9
22213068	10.1002/ijc.27416	2012	Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas.	TNFSF9
20438785	10.1016/j.humimm.2010.04.004	2010	Polymorphisms in innate immunity genes and risk of childhood leukemia.	TNFSF9
20520765	10.1371/journal.pone.0010845	2010	Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling.	TNFSF9
19225975	10.1080/10428190802709453	2009	The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders.	TNFSF9
19382019	10.1080/09553000902838541	2009	Effect of (211)At alpha-particle irradiation on expression of selected radiation responsive genes in human lymphocytes.	TNFSF9
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	TNFSF9
19608748	10.1182/blood-2009-03-208215	2009	Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma.	TNFSF9
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	TNFSF9
16287062	10.1002/ijc.21579	2006	Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival.	TNFSF9
16800841	10.1111/j.1600-0609.2006.00679.x	2006	Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.	TNFSF9
14648705	10.1002/ijc.11574	2004	CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival.	TNFSF9
11485353	10.1006/cimm.2001.1804	2001	4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.	TNFSF9
10202049	NA	1999	4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.	TNFSF9
7532686	10.1084/jem.181.3.985	1995	Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP.	TNFSF9
7622190	10.1016/0165-2478(94)00227-i	1995	Characterization of human homologue of 4-1BB and its ligand.	TNFSF9
32393046	10.1080/09603123.2020.1757043	2022	The expression of microRNAs and exposure to environmental contaminants related to human health: a review.	TP53
33297669	10.3324/haematol.2020.267294	2022	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas.	TP53
33954816	10.1007/s00277-021-04530-y	2022	Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.	TP53
34092056	10.3324/haematol.2021.278304	2022	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation.	TP53
34226971	10.1007/s00428-021-03148-9	2022	Transdifferentiation of mantle cell lymphoma into sarcoma with limited neuromuscular differentiation after conventional chemotherapy.	TP53
34244612	10.1038/s41375-021-01311-4	2022	Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.	TP53
34289655	10.3324/haematol.2021.278638	2022	Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.	TP53
34319003	10.1002/cnr2.1524	2022	Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma.	TP53
34332791	10.1016/j.pathol.2021.04.008	2022	Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.	TP53
34365516	10.1007/s00262-021-03009-z	2022	Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.	TP53
34467833	10.1080/10428194.2021.1973670	2022	CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.	TP53
34528662	10.1093/ajcp/aqab105	2022	MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma.	TP53
34560683	10.1097/PAS.0000000000001813	2022	A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients.	TP53
34592901	10.1080/10428194.2021.1983568	2022	Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.	TP53
34597466	10.1002/pbc.29361	2022	Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse.	TP53
34608246	10.1038/s41379-021-00909-4	2022	Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge.	TP53
34664256	10.1111/bjh.17894	2022	Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.	TP53
34673251	10.1016/j.cbpc.2021.109215	2022	Environmentally relevant lead (Pb) water concentration induce toxicity in zebrafish (Danio rerio) larvae.	TP53
34675373	10.1038/s41375-021-01444-6	2022	Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma.	TP53
34687488	10.1002/gcc.23005	2022	Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.	TP53
34687742	10.1016/j.jid.2021.09.024	2022	PLCŒ≥1/PKCŒ∏ Downstream Signaling Controls Cutaneous T-Cell Lymphoma Development and Progression.	TP53
34690091	10.1016/j.clml.2021.09.013	2022	Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes.	TP53
34699592	10.1182/blood.2021011895	2022	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.	TP53
34710245	10.1002/ajh.26392	2022	Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B-cell lymphoma.	TP53
34728235	10.1016/j.bbamcr.2021.119168	2022	DNA damage triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and Kaposi sarcoma herpesvirus replication.	TP53
34764434	10.1038/s41379-021-00962-z	2022	BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis.	TP53
34788985	10.3324/haematol.2021.279631	2022	Mutational landscape of high-grade B-cell lymphoma with <i>MYC-</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements characterized by whole-exome sequencing.	TP53
34791836	10.1002/cam4.4422	2022	Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.	TP53
34799485	10.1097/PAS.0000000000001834	2022	Resistance of B-Cell Lymphomas to CAR T-Cell Therapy Is Associated With Genomic Tumor Changes Which Can Result in Transdifferentiation.	TP53
34808593	10.1016/j.cancergen.2021.10.003	2022	Clinical utility of chromosomal microarray in establishing clonality and high risk features in patients with Richter transformation.	TP53
34818414	10.1182/blood.2021012734	2022	Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.	TP53
34842019	10.1080/10428194.2021.2008383	2022	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?	TP53
34860572	10.1200/JCO.21.02143	2022	Impact of <i>TP53</i> Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.	TP53
34861096	10.1002/1878-0261.13153	2022	Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.	TP53
34861697	10.1182/bloodadvances.2021006156	2022	Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo.	TP53
34882582	10.1172/JCI153283	2022	Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.	TP53
34907000	10.1124/molpharm.121.000354	2022	Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin.	TP53
34928233	10.5152/balkanmedj.2021.21068	2022	HOXD3 Up-regulating KDM5C Promotes Malignant Progression of Diffuse Large B-Cell Lymphoma by Decreasing p53 Expression	TP53
34933652	10.1080/10428194.2021.2018579	2022	Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile.	TP53
34941996	10.1182/bloodadvances.2021005954	2022	Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.	TP53
34951009	10.1111/bjh.17971	2022	Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.	TP53
34980830	10.1097/PAS.0000000000001859	2022	Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System: An Analysis of 11 Cases Using Targeted Gene Sequencing.	TP53
34998786	10.1016/j.clml.2021.12.008	2022	The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.	TP53
35004079	10.7759/cureus.20914	2022	The Role of Tissue and Liquid Biopsy in the Clinical Management of Adult Lung Cancer Patients in King Abdul-Aziz Medical City in Riyadh, Saudi Arabia.	TP53
35014928	10.1080/10428194.2021.2020779	2022	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.	TP53
35030036	10.1200/JCO.21.02321	2022	Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.	TP53
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	TP53
35042152	10.1016/j.esmoop.2021.100333	2022	Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.	TP53
35047863	10.1016/j.xhgg.2021.100078	2022	A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk.	TP53
35071774	10.1515/med-2021-0409	2022	The biomarkers of key miRNAs and gene targets associated with extranodal NK/T-cell lymphoma.	TP53
35072373	10.1097/PPO.0000000000000573	2022	Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia.	TP53
35091682	10.1038/s41388-022-02196-y	2022	Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax.	TP53
35101379	10.1016/j.clml.2022.01.002	2022	Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).	TP53
35105854	10.1038/s41408-022-00617-5	2022	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.	TP53
35106936	10.1002/cam4.4550	2022	SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.	TP53
35123209	10.1016/j.esmoop.2021.100337	2022	Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.	TP53
35130959	10.1186/s40364-022-00352-w	2022	Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma.	TP53
35132678	10.1002/ajh.26490	2022	High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.	TP53
35151528	10.1016/j.blre.2022.100930	2022	CLL update 2022: A continuing evolution in care.	TP53
35184869	10.1016/j.revmed.2022.01.010	2022	[Chronic lymphocytic leukemia].	TP53
35203244	10.3390/cells11040593	2022	Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.	TP53
35231988	10.3760/cma.j.issn.0253-2727.2022.01.005	2022	[Mutational spectrum and its prognostic significance in childhood acute lymphoblastic leukemia based on next-generation sequencing technology].	TP53
35232479	10.1186/s13046-022-02269-6	2022	Partial p53 reactivation is sufficient to induce cancer regression.	TP53
35237397	10.1177/20406207221080743	2022	Mantle cell lymphoma management trends and novel agents: where are we going?	TP53
35240014	10.4143/crt.2022.017	2022	Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.	TP53
35264779	10.1038/s41418-022-00964-7	2022	Flow cytometric single cell-based assay to simultaneously detect cell death, cell cycling, DNA content and cell senescence.	TP53
35266562	10.1002/ajh.26523	2022	Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.	TP53
35277463	10.1136/jitc-2020-002029corr1	2022	Correction: MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	TP53
35280362	10.21037/atm-22-412	2022	Genomic landscape and prognosis of patients with <i>TP53</i>-mutated non-small cell lung cancer.	TP53
35280829	10.3389/fonc.2022.811151	2022	Prognostic Significance of Comprehensive Gene Mutations and Clinical Characteristics in Adult T-Cell Acute Lymphoblastic Leukemia Based on Next-Generation Sequencing.	TP53
35301414	10.1038/s41379-022-01022-w	2022	Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations.	TP53
35327381	10.3390/biomedicines10030579	2022	Macrophage Infiltration Correlates with Genomic Instability in Classic Hodgkin Lymphoma.	TP53
35344582	10.1182/blood.2021014007	2022	Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies.	TP53
35356636	10.14740/jh942	2022	Concurrent Presentation of Hairy Cell Leukemia and Mantle Cell Lymphoma (Leukemic Non-Nodal Variant): An Extremely Rare Composite Lymphoma.	TP53
35371098	10.3389/fimmu.2022.858590	2022	Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy.	TP53
35380239	10.1007/s00277-022-04806-x	2022	The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation.	TP53
35399106	10.1038/s41392-022-00924-0	2022	Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.	TP53
35417939	10.3324/haematol.2021.280352	2022	Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.	TP53
35426613	10.1007/s00432-022-04022-0	2022	Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma.	TP53
35435617	10.1007/s11864-022-00953-5	2022	Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.	TP53
35437610	10.1007/s00277-022-04795-x	2022	Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.	TP53
35437925	10.1002/cam4.4663	2022	Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.	TP53
35452696	10.1016/j.humpath.2022.04.002	2022	B-cell lymphoma-2 downregulation is a useful feature supporting a neoplastic phenotype in mature T-cell lymphomas.	TP53
35459873	10.1038/s41375-022-01571-8	2022	Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.	TP53
35486574	10.1371/journal.pone.0267543	2022	Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.	TP53
35490155	10.1016/j.clml.2022.04.001	2022	Beyond BCL-2 Inhibition in Acute Myloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway.	TP53
35503707	10.1080/10428194.2022.2070911	2022	Rare case of leptomeningeal small lymphocytic lymphoma with <i>TP53</i> mutation detected by deep next-generation sequencing.	TP53
35511481	10.1080/09553002.2022.2074164	2022	<i>BAG1, MGMT, FOXO1</i>, and <i>DNAJA1</i> as potential drug targets for radiosensitizing cancer cell lines.	TP53
35533245	10.1158/2643-3230.BCD-21-0177	2022	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.	TP53
35543621	10.1080/10428194.2022.2070913	2022	Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis.	TP53
35551107	10.5045/br.2022.2020113	2022	Smudge cells in CD200<sup>+</sup>, <i>TP53</i> mutated leukemic mantle cell lymphoma.	TP53
35551110	10.5045/br.2022.2022052	2022	Enrichment of TP53 alterations within GCB-like DNA subclassifications of diffuse large B-cell lymphoma after transition from de-novo to relapsed or refractory disease.	TP53
35561299	10.1200/EDBK_349509	2022	New Directions for Mantle Cell Lymphoma in 2022.	TP53
35561314	10.1182/bloodadvances.2022007247	2022	Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.	TP53
35562412	10.1038/s41379-022-01085-9	2022	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia.	TP53
35577753	10.1016/j.clml.2022.04.017	2022	SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.	TP53
35579989	10.1002/ijc.34123	2022	Special issue """"The advance of solid tumor research in China"""": Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China.	TP53
35585141	10.1038/s41375-022-01587-0	2022	Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution.	TP53
35592333	10.3389/fimmu.2022.888250	2022	Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma.	TP53
35592856	10.3389/fmed.2022.808378	2022	A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer.	TP53
35598475	10.1016/j.leukres.2022.106857	2022	De Novo myelodysplastic syndromes in patients 20-50 years old are enriched for adverse risk features.	TP53
35609408	10.1016/j.lungcan.2022.05.002	2022	Neuroendocrine transformation from EGFR/ALK-wild type or TKI-na√Øve non-small cell lung cancer: An under-recognized phenomenon.	TP53
35616090	10.1002/cam4.4834	2022	Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidence.	TP53
35624058	10.1016/j.clml.2022.04.007	2022	Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany.	TP53
35628297	10.3390/ijms23105486	2022	Role of miRNAs in Human T Cell Leukemia Virus Type 1 Induced T Cell Leukemia: A Literature Review and Bioinformatics Approach.	TP53
35635647	10.1007/s10534-022-00397-2	2022	TPEN selectively eliminates lymphoblastic B cells from bone marrow pediatric acute lymphoblastic leukemia patients.	TP53
35657404	10.1007/s00428-022-03342-3	2022	Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.	TP53
35671390	10.1182/blood.2021015135	2022	The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms.	TP53
35674998	10.1007/s11899-022-00663-7	2022	Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.	TP53
35681513	10.3390/cells11111818	2022	A Unique Spectrum of Spontaneous Tumors in <i>Dino</i> Knockout Mice Identifies Tissue-Specific Requirements for Tumor Suppression.	TP53
35681698	10.3390/cancers14112720	2022	Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib.	TP53
35705773	10.1007/s11033-022-07643-3	2022	Association of TP53 gene polymorphisms with the risk of acute lymphoblastic leukemia in Moroccan children.	TP53
35708139	10.3324/haematol.2022.281226	2022	Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.	TP53
35719104	10.1080/10428194.2022.2087070	2022	TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression.	TP53
35726023	10.1038/s41684-022-00998-x	2022	The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications.	TP53
35727053	10.1002/cncr.34348	2022	Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.	TP53
35757723	10.3389/fimmu.2022.894787	2022	Case Report: Dual Inhibition of HDAC and BTK for Diffuse Large B-Cell Lymphoma After Failure to CD19-Targeted CAR-T Therapy.	TP53
35760783	10.1038/s41419-022-05021-2	2022	IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma.	TP53
35761419	10.1186/s40164-022-00292-z	2022	Targeting metabolic reprogramming in chronic lymphocytic leukemia.	TP53
35779323	10.1016/j.tranon.2022.101471	2022	Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations.	TP53
35785159	10.3389/fonc.2022.813158	2022	Genomic Features of Solid Tumor Patients Harboring <i>ALK/ROS1/NTRK</i> Gene Fusions.	TP53
35794096	10.1038/s41467-022-31355-8	2022	Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.	TP53
35829664	10.1111/bjh.18352	2022	Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.	TP53
35835991	10.1038/s41375-022-01634-w	2022	APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.	TP53
35846192	10.1002/jha2.354	2022	T-cell lymphoma, B-cell lymphoma, and myelodysplastic syndrome harboring common mutations: Trilineage tumorigenesis from a common founder clone.	TP53
35852680	10.1007/s12094-022-02884-x	2022	Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.	TP53
35870258	10.1016/j.lungcan.2022.07.011	2022	Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.	TP53
35872366	10.1016/j.prp.2022.154033	2022	Association of ATG16L1 rs2241880 and TP53 rs1042522 with characteristics and course of diffuse large B-cell lymphoma.	TP53
35879233	10.1111/imj.15851	2022	Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.	TP53
35882439	10.1182/bloodadvances.2022007541	2022	Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association.	TP53
35895495	10.1002/1878-0261.13295	2022	Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model.	TP53
35908104	10.1038/s41375-022-01655-5	2022	Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia.	TP53
35910501	10.6004/jadpro.2022.13.5.7	2022	An Approach to Diagnosis of Richter Transformation in Chronic Lymphocytic Leukemia.	TP53
35940055	10.1016/j.ejca.2022.06.037	2022	First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements.	TP53
35941212	10.1038/s41375-022-01649-3	2022	A phase two study of high dose blinatumomab in Richter's syndrome.	TP53
35953760	10.1631/jzus.B2200016	2022	HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.	TP53
35963941	10.1038/s41375-022-01658-2	2022	Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.	TP53
35964234	10.1093/ajcp/aqac087	2022	Histiocytic Sarcoma With CCND1 Gene Rearrangement Clonally Related and Transdifferentiated From Mantle Cell Lymphoma.	TP53
35967131	10.7759/cureus.26738	2022	Splenic Marginal Zone Lymphoma With Histological Transformation to Hodgkin's Lymphoma.	TP53
35968590	10.3760/cma.j.issn.0253-2727.2022.06.006	2022	[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review].	TP53
36017149	10.1155/2022/7904293	2022	Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia.	TP53
36029002	10.1111/bjh.18419	2022	Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.	TP53
36029326	10.1007/s00277-022-04914-8	2022	Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis.	TP53
36055572	10.1016/j.clim.2022.109105	2022	A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.	TP53
36059252	10.1080/10428194.2022.2116932	2022	MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.	TP53
36059262	10.1080/10428194.2022.2118529	2022	p53 immunohistochemistry must be confirmed by TP53 next generation sequencing for accurate risk stratification of patients with mantle cell lymphoma.	TP53
36059700	10.3389/fonc.2022.976762	2022	Integrated driver mutations profile of chinese gastrointestinal-natural killer/T-cell lymphoma.	TP53
36065483	10.1111/cas.15522	2022	Association between germline pathogenic variants in cancer-predisposing genes and lymphoma risk.	TP53
36075047	10.1080/10428194.2022.2118532	2022	A nomogram using cytogenetics, TP53, and NPM1 mutational status can predict responses to induction chemotherapy in AML.	TP53
36089905	10.1080/10428194.2022.2118533	2022	Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of <i>TP53</i> alterations and venetoclax treatment.	TP53
32193631	10.1007/s00277-020-03974-y	2021	Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation.	TP53
32356355	10.1002/ajh.25848	2021	Triple hit"" SOX11<sup>-</sup> , MME<sup>+</sup> , TP53 mutated high-grade pleomorphic mantle cell lymphoma.	TP53
32488603	10.1007/s00277-020-04094-3	2021	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.	TP53
32732362	10.3324/haematol.2020.254276	2021	Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic roles of PRDM1.	TP53
32908255	10.1038/s41379-020-00669-7	2021	The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.	TP53
32924682	10.1080/10428194.2020.1817441	2021	The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.	TP53
32946634	10.1111/his.14256	2021	Prevalence and potential biological role of TERT amplifications in ALK translocated adenocarcinoma of the lung.	TP53
32958587	10.1158/1940-6207.CAPR-20-0368	2021	Reducing Fatty Acid Oxidation Improves Cancer-free Survival in a Mouse Model of Li-Fraumeni Syndrome.	TP53
32961552	10.1182/blood.2020007507	2021	Mutational landscape of gray zone lymphoma.	TP53
32973328	10.1038/s41379-020-00685-7	2021	The clinicopathological and molecular features of sinusoidal large B-cell lymphoma.	TP53
33040459	10.1002/1878-0261.12822	2021	EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.	TP53
33087830	10.1038/s41375-020-01061-9	2021	Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome.	TP53
33147938	10.3324/haematol.2020.259226	2021	Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations	TP53
33154093	10.1158/1541-7786.MCR-20-0466	2021	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.	TP53
33179373	10.1002/iub.2407	2021	Mitochondria and nucleus cross-talk: Signaling in metabolism, apoptosis, and differentiation, and function in cancer.	TP53
33183999	10.1016/j.cancergen.2020.10.003	2021	FANCA, TP53, and del(5q)/RPS14 alterations in a patient with T-cell non-Hodgkin lymphoma and concomitant Fanconi anemia and Li-Fraumeni syndrome.	TP53
33199185	10.1016/j.clml.2020.10.012	2021	Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.	TP53
33237469	10.1007/s00428-020-02971-w	2021	ALK alterations in salivary gland carcinomas.	TP53
33241658	10.1111/jcmm.16117	2021	Anti-coronavirus disease 2019 (COVID-19) targets and mechanisms of puerarin.	TP53
33247178	10.1038/s41375-020-01093-1	2021	STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.	TP53
33263441	10.1080/17474086.2021.1856652	2021	Development of molecular intervention strategies for B-cell lymphoma.	TP53
33277788	10.1002/gcc.22925	2021	Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia-variant.	TP53
33303420	10.1016/j.clml.2020.10.009	2021	Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study.	TP53
33306126	10.1093/jmcb/mjaa065	2021	BCL7C suppresses ovarian cancer growth by inactivating mutant p53.	TP53
33310890	10.1158/1078-0432.CCR-20-2853	2021	Proteasome Inhibition Overcomes ALK-TKI Resistance in <i>ALK</i>-Rearranged/<i>TP53</i>-Mutant NSCLC via Noxa Expression.	TP53
33311649	10.1038/s41379-020-00720-7	2021	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.	TP53
33314017	10.1111/bjh.17141	2021	Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.	TP53
33316538	10.1016/j.neo.2020.11.010	2021	U-RT1 - A new model for Richter transformation.	TP53
33328584	10.1038/s41568-020-00315-z	2021	Advances in germline predisposition to acute leukaemias and myeloid neoplasms.	TP53
33364550	10.1097/HS9.0000000000000510	2021	Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3.	TP53
33395752	10.1016/j.tranon.2020.100977	2021	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.	TP53
33399480	10.1080/10428194.2020.1864354	2021	Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of <i>TP53</i> mutations - a registry based analysis.	TP53
33414134	10.1158/1078-0432.CCR-20-2378	2021	Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP.	TP53
33414171	10.1158/0008-5472.CAN-20-1504	2021	CDK2-Mediated Upregulation of TNFŒ± as a Mechanism of Selective Cytotoxicity in Acute Leukemia.	TP53
33454909	10.1007/s11033-021-06136-z	2021	Deciphering the molecular pathways of apoptosis using purified fractions from leaf extract of Basella alba through studying the regulation of apoptosis related genes.	TP53
33486679	10.1007/s11060-020-03676-5	2021	Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma.	TP53
33494549	10.3390/ph14020080	2021	Therapeutic Sequencing in ALK<sup>+</sup> NSCLC.	TP53
33495922	10.1007/s00277-021-04419-w	2021	Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.	TP53
33507515	10.1007/s11899-021-00605-9	2021	High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.	TP53
33509276	10.1186/s13148-021-01011-x	2021	Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia.	TP53
33528622	10.1007/s00428-021-03022-8	2021	Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.	TP53
33538798	10.1182/blood.2020005734	2021	Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1.	TP53
33542453	10.1038/s41598-021-82867-0	2021	Significance of abnormal 53BP1 expression as a novel molecular pathologic parameter of follicular-shaped B-cell lymphoid lesions in human digestive tract.	TP53
33546774	10.1186/s40164-021-00200-x	2021	Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas.	TP53
33561953	10.3390/cancers13040650	2021	Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies.	TP53
33563892	10.1038/s41392-020-00412-3	2021	Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.	TP53
33569430	10.21037/atm-20-7574	2021	Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity.	TP53
33569988	10.1080/10428194.2021.1876871	2021	MDMX/MDM4 is highly expressed and contributes to cell growth and survival in anaplastic large cell lymphoma.	TP53
33588113	10.1016/j.jtho.2021.01.1615	2021	Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.	TP53
33615665	10.1002/iub.2453	2021	Mitochondrial-nuclear p53 trafficking controls neuronal susceptibility in stroke.	TP53
33618247	10.1016/j.prp.2021.153370	2021	Prognostic value of Bcl2 and p53 in Hodgkin lymphoma: A systematic review and meta-analysis.	TP53
33631112	10.1016/S2352-3026(20)30433-6	2021	Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.	TP53
33631963	10.1177/0963689721996649	2021	Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.	TP53
33634864	10.1002/ijc.33527	2021	Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis.	TP53
33655698	10.1002/cam4.3649	2021	Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.	TP53
33660365	10.1111/acel.13331	2021	A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition.	TP53
33679144	10.1177/2634853521994094	2021	A Clinical Triad with Fatal Implications: Recrudescent Diffuse Large B-cell Non-Hodgkin Lymphoma Presenting in the Leukemic Phase with an Elevated Serum Lactic Acid Level and Dysregulation of the TP53 Tumor Suppressor Gene - A Case Report and Literature Review.	TP53
33687951	10.1158/0008-5472.CAN-21-0033	2021	Hypothermia Effectively Treats Tumors with Temperature-Sensitive p53 Mutations.	TP53
33735664	10.1016/j.neo.2021.02.002	2021	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr√∂m macroglobulinemia.	TP53
33742045	10.1038/s41598-021-85354-8	2021	Short and long-read genome sequencing methodologies for somatic variant detection; genomic analysis of a patient with diffuse large B-cell lymphoma.	TP53
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	TP53
33750258	10.1080/0284186X.2021.1900908	2021	Genomic landscape of B-other acute lymphoblastic leukemia in an adult retrospective cohort with a focus on <i>BCR-ABL1</i>-like subtype.	TP53
33757561	10.1186/s13104-021-05521-y	2021	HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) versus adult T-cell leukemia/lymphoma (ATLL).	TP53
33759673	10.1080/17474086.2021.1908121	2021	Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?	TP53
33775465	10.1016/j.blre.2021.100824	2021	Revisiting Richter transformation in the era of novel CLL agents.	TP53
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	TP53
33808787	10.3390/cancers13061414	2021	EBV and the Pathogenesis of NK/T Cell Lymphoma.	TP53
33851417	10.1111/bjh.17394	2021	Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.	TP53
33867306	10.1016/j.clml.2021.03.003	2021	Concurrent TP53 Mutation and Deletion in Refractory Low-grade Follicular Lymphoma.	TP53
33872109	10.1177/10935266211007254	2021	Distinctive Clinicopathologic Features of Monomorphic B-cell Post-transplant Lymphoproliferative Disorders in Children.	TP53
33889527	10.21037/tlcr-21-160	2021	Concomitant mutation status of <i>ALK</i>-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib.	TP53
33895809	10.1182/blood.2020010144	2021	Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.	TP53
33902046	10.1159/000514648	2021	Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.	TP53
33902665	10.1186/s13045-021-01054-w	2021	Current and future treatment strategies in chronic lymphocytic leukemia.	TP53
33903686	10.1038/s41598-021-88449-4	2021	Recurrent somatic mutations and low germline predisposition mutations in Korean ALL patients.	TP53
33904352	10.1080/10428194.2021.1919663	2021	Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype, <i>TP53</i> deletion, and <i>TP53</i> mutations.	TP53
33918002	10.3390/genes12040539	2021	Kr√ºppel-Like Factor 4 and Its Activator APTO-253 Induce NOXA-Mediated, p53-Independent Apoptosis in Triple-Negative Breast Cancer Cells.	TP53
33938069	10.1002/gcc.22956	2021	Single nucleotide polymorphism array-based signature of low hypodiploidy in acute lymphoblastic leukemia.	TP53
33945543	10.1371/journal.pone.0248886	2021	Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.	TP53
33946435	10.3390/cancers13092167	2021	Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma.	TP53
33951889	10.3324/haematol.2020.271957	2021	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.	TP53
33972504	10.1038/s41408-021-00477-5	2021	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.	TP53
33981772	10.1155/2021/7463867	2021	Circular RNA circPVT1 Contributes to Doxorubicin (DXR) Resistance of Osteosarcoma Cells by Regulating TRIAP1 via miR-137.	TP53
33987937	10.1002/iub.2503	2021	Lovastatin reduces PEL cell survival by phosphorylating ERK1/2 that blocks the autophagic flux and engages a cross-talk with p53 to activate p21.	TP53
33988304	10.1111/ijlh.13577	2021	Karyotypic complexity, TP53 pathogenic variants, and increased number of variants on Next-Generation Sequencing are associated with disease progression in a North American Adult T-Cell Leukemia/Lymphoma cohort.	TP53
34010787	10.1016/j.ejca.2021.03.034	2021	Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials.	TP53
34049842	10.1016/j.clml.2020.10.001	2021	Case Report of an Unusual Tumor in an Adult With a TP53 Germline Mutation.	TP53
34058070	10.1002/1878-0261.13033	2021	NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.	TP53
34066756	10.3390/diagnostics11050844	2021	<i>TP53</i>-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy.	TP53
34074652	10.1101/mcs.a006089	2021	Twists and turns from """"tumor in tumor"""" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis.	TP53
34078654	10.1136/jitc-2020-002029	2021	MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.	TP53
34080325	10.1002/cam4.4024	2021	The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia.	TP53
34080947	10.1080/10428194.2021.1933480	2021	Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.	TP53
34088885	10.18632/aging.203098	2021	Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology.	TP53
34099776	10.1038/s41598-021-91433-7	2021	Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.	TP53
34110383	10.1001/jamaoncol.2021.1649	2021	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.	TP53
34113336	10.3389/fimmu.2021.599493	2021	<i>PiggyBac</i>-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report.	TP53
34115827	10.1182/blood.2020009655	2021	Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity.	TP53
34150491	10.1016/j.lrr.2021.100255	2021	Distal chromosome 1q aberrations and initial response to ibrutinib in central nervous system relapsed mantle cell lymphoma.	TP53
34164264	10.21037/tlcr-21-32	2021	Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.	TP53
34174984	10.1016/j.hoc.2021.04.001	2021	The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.	TP53
34175504	10.1016/j.lungcan.2021.06.012	2021	Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.	TP53
34195328	10.1016/j.jdcr.2021.05.014	2021	Bilateral auricular nodules: A peculiar presentation of systemic mantle cell lymphoma.	TP53
34218582	10.3760/cma.j.issn.0253-2727.2021.05.008	2021	[Clinical and prognostic values of TP53 mutation in patients with B-lineage acute lymphoblastic leukemia].	TP53
34221962	10.3389/fonc.2021.638154	2021	Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.	TP53
34226168	10.1016/j.clml.2021.06.006	2021	Survival Benefit and Efficiency of Low Dose Decitabine With CEG Regimen Compared to Decitabine Alone in the Elderly MDS - A Multicenter, Retrospective Study.	TP53
34232939	10.1097/CAD.0000000000001094	2021	Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.	TP53
34233959	10.1158/1078-0432.CCR-21-0464	2021	Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a <i>TP53-</i> and <i>BAX-</i>Dependent Manner.	TP53
34248972	10.3389/fimmu.2021.687458	2021	Targeting Bruton's Tyrosine Kinase in CLL.	TP53
34253131	10.1080/17474086.2021.1950529	2021	Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma.	TP53
34256839	10.1186/s40164-021-00232-3	2021	Progress in molecular feature of smoldering mantle cell lymphoma.	TP53
34258755	10.1111/bjh.17639	2021	Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).	TP53
34261406	10.1080/10428194.2021.1950710	2021	Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of <i>TP53</i> mutation and genetic complexity.	TP53
34267184	10.1038/s41419-021-03988-y	2021	Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.	TP53
34269910	10.1007/s11912-021-01094-y	2021	Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.	TP53
34272731	10.1111/bjh.17708	2021	EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.	TP53
34277785	10.21037/atm-21-2256	2021	Integration of clinicopathological and mutational data offers insight into lung cancer with tumor spread through air spaces.	TP53
34285380	10.1038/s41409-021-01418-3	2021	T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease.	TP53
34298439	10.1016/j.prp.2021.153551	2021	Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis.	TP53
34301750	10.1158/1078-0432.CCR-21-0715	2021	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53.	TP53
34308104	10.1093/jncics/pkab007	2021	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.	TP53
34320163	10.1182/blood.2020006783	2021	Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.	TP53
34323164	10.1080/10428194.2021.1950706	2021	A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.	TP53
34339834	10.1016/j.critrevonc.2021.103430	2021	Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review.	TP53
34345533	10.1080/2162402X.2021.1951019	2021	Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer.	TP53
34349054	10.11406/rinketsu.62.721	2021	[Lineage switch from T-lymphoblastic leukemia to myeloid leukemia at relapse].	TP53
34350060	10.1080/2162402X.2021.1928365	2021	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.	TP53
34361036	10.3390/ijms22158268	2021	Hinokitiol Exhibits Antitumor Properties through Induction of ROS-Mediated Apoptosis and p53-Driven Cell-Cycle Arrest in Endometrial Cancer Cell Lines (Ishikawa, HEC-1A, KLE).	TP53
34365011	10.1016/j.jmoldx.2021.07.013	2021	Practical Considerations for Using RNA Sequencing in Management of B-Lymphoblastic Leukemia: Malaysia-Singapore Acute Lymphoblastic Leukemia 2020 Implementation Strategy.	TP53
34374220	10.1002/cjp2.223	2021	c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.	TP53
34376372	10.1016/j.clml.2021.07.007	2021	Molecular Characterization and Clinical Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients With TP53 Mutation.	TP53
34381423	10.3389/fendo.2021.673908	2021	Case Report: Identification of Potential Prognosis-Related <i>TP53</i> Mutation and <i>BCL6-LPP</i> Fusion in Primary Pituitary Lymphoma by Next Generation Sequencing: Two Cases.	TP53
34386317	10.1016/j.apsb.2020.10.018	2021	Natural compounds modulate the autophagy with potential implication of stroke.	TP53
34390161	10.1002/pbc.29285	2021	Molecular features of non-anaplastic peripheral T-cell lymphoma in children and adolescents.	TP53
34405395	10.1111/bjh.17749	2021	Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.	TP53
34406703	10.1002/ajh.26324	2021	The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study.	TP53
34430143	10.7759/cureus.16534	2021	Clinicopathological and Immunohistochemical Profile of Mantle Cell Lymphoma: An Institutional Experience.	TP53
34440292	10.3390/genes12081118	2021	T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness.	TP53
34478505	10.1182/bloodadvances.2021005083	2021	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.	TP53
34496723	10.1080/10428194.2021.1957869	2021	Clinico-genomic profiling and clonal dynamic modeling of <i>TP53</i>-aberrant myelodysplastic syndrome and acute myeloid leukemia.	TP53
34497195	10.11406/rinketsu.62.1085	2021	[Molecular pathogenesis and treatment of chronic lymphocytic leukemia].	TP53
34500472	10.1182/bloodadvances.2021004528	2021	Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.	TP53
34500495	10.1111/bjh.17830	2021	Adult T-cell leukaemia/lymphoma and the trouble with TP53.	TP53
34503286	10.3390/cancers13174476	2021	Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma.	TP53
34506616	10.1371/journal.pone.0257353	2021	Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM).	TP53
34511320	10.1016/j.clml.2021.07.022	2021	Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).	TP53
34521752	10.1073/pnas.2105440118	2021	DNA damage-induced phosphorylation of CtIP at a conserved ATM/ATR site T855 promotes lymphomagenesis in mice.	TP53
34523970	10.1128/JVI.01459-21	2021	The ORF45 Protein of Kaposi Sarcoma-Associated Herpesvirus Is an Inhibitor of p53 Signaling during Viral Reactivation.	TP53
34537440	10.1016/j.jtho.2021.07.035	2021	Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.	TP53
34568060	10.3389/fonc.2021.729106	2021	Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia.	TP53
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	TP53
34576319	10.3390/ijms221810157	2021	BH3 Mimetics in Hematologic Malignancies.	TP53
34589661	10.1200/PO.21.00112	2021	Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma.	TP53
34603753	10.17691/stm2021.13.3.04	2021	Asynchronous DNA Replication of Biallelically Expressed Genes in Human Peripheral Blood Lymphocytes as a Prognostic Sign of Cancer.	TP53
34625994	10.1002/ajh.26367	2021	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.	TP53
34626359	10.1007/978-3-030-78311-2_8	2021	Chronic Lymphocytic Leukemia (CLL): Biology and Therapy.	TP53
34627430	10.19746/j.cnki.issn.1009-2137.2021.05.019	2021	[Clinical Characteristics and Prognosis Affecting-Factors of the Patients with Burkitt Lymphoma].	TP53
34634383	10.1016/j.canlet.2021.10.006	2021	IGFBP7-AS1 is a p53-responsive long noncoding RNA downregulated by Epstein-Barr virus that contributes to viral tumorigenesis.	TP53
34635181	10.1186/s40364-021-00330-8	2021	Deciphering genes associated with diffuse large B-cell lymphoma with lymphomatous effusions: A mutational accumulation scoring approach.	TP53
34646650	10.7759/cureus.17598	2021	An Aggressive Presentation of Mantle Cell Lymphoma With Unique Molecular Features.	TP53
34680290	10.3390/cancers13205141	2021	Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents.	TP53
34711913	10.1038/s41698-021-00235-7	2021	Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers.	TP53
34729013	10.2147/OTT.S323700	2021	<i>ALK</i> Rearrangement in Small-Cell Lung Cancer and Durable Response to Alectinib: A Case Report.	TP53
34754447	10.3892/mco.2021.2422	2021	Epstein-Barr virus infection mediated TP53 and Bcl-2 expression in nasopharyngeal carcinoma pathogenesis.	TP53
34771656	10.3390/cancers13215493	2021	High Expression of <i>PPM1D</i> Induces Tumors Phenotypically Similar to <i>TP53</i> Loss-of-Function Mutations in Mice.	TP53
34781193	10.1016/j.vetmic.2021.109269	2021	Mutations in the tumor suppressor gene p53 in cattle are associated with enzootic bovine leukosis.	TP53
34806851	10.20892/j.issn.2095-3941.2021.0193	2021	Prognostic value of <i>BCL2</i> and <i>TP53</i> genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP.	TP53
34826411	10.1016/S2352-3026(21)00307-0	2021	Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.	TP53
34830747	10.3390/cancers13225592	2021	Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era.	TP53
34885220	10.3390/cancers13236111	2021	Newborn Screening for the Detection of the <i>TP53</i> R337H Variant and Surveillance for Early Diagnosis of Pediatric Adrenocortical Tumors: Lessons Learned and Way Forward.	TP53
34893110	10.19746/j.cnki.issn.1009-2137.2021.06.015	2021	[Effect of RITA on TP53 Mutant Human Mantle Cell Lymphoma Cell Line and Its Mechanism].	TP53
34895266	10.1186/s13000-021-01173-5	2021	Clinicopathological and molecular genomic features of monomorphic epitheliotropic intestinal T-cell lymphoma in the Chinese population: a study of 20 cases.	TP53
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	TP53
34926267	10.3389/fonc.2021.765544	2021	<i>SEPT6</i>_<i>TRIM33</i> Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.	TP53
34944936	10.3390/cancers13246316	2021	The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, <i>TP53</i> Deletion, and a Poor Prognosis.	TP53
34956898	10.3389/fonc.2021.780085	2021	Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.	TP53
35116331	10.21037/tcr-21-882	2021	Clinical and biological features of mantle cell lymphoma patients with co-expression of CD10 and BCL-6: a retrospective study.	TP53
35122027	10.1038/s43018-021-00230-8	2021	Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse.	TP53
35126471	10.3389/fgene.2021.815679	2021	Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma.	TP53
35844699	10.1002/jha2.261	2021	Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia.	TP53
31296581	10.3324/haematol.2019.219543	2020	Highly sensitive and specific <i>in situ</i> hybridization assay for quantification of <i>SOX11</i> mRNA in mantle cell lymphoma reveals association of <i>TP53</i> mutations with negative and low <i>SOX11</i> expression.	TP53
31433838	10.1093/ajcp/aqz133	2020	An Uncommon Case of Double-Hit Mantle Cell Lymphoma That Demonstrates a Transformation Process.	TP53
31462704	10.1038/s41388-019-0979-z	2020	Tumor-derived CK1Œ± mutations enhance MDMX inhibition of p53.	TP53
31490284	10.1097/CAD.0000000000000824	2020	EX527, a Sirt-1 inhibitor, induces apoptosis in glioma via activating the p53 signaling pathway.	TP53
31522287	10.1007/s00428-019-02658-x	2020	Lineage-negative lymphoma with a helper innate lymphoid cell phenotype.	TP53
31537689	10.3324/haematol.2018.214056	2020	<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.	TP53
31559875	10.1177/1066896919878804	2020	Recurrent Pleomorphic Myxoid Liposarcoma in a Patient With Li-Fraumeni Syndrome.	TP53
31628428	10.1038/s41375-019-0602-x	2020	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.	TP53
31666375	10.1128/JVI.01553-19	2020	USP7-Dependent Regulation of TRAF Activation and Signaling by a Viral Interferon Regulatory Factor Homologue.	TP53
31697823	10.1182/blood.2019002220	2020	Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.	TP53
31701788	10.1080/17474086.2020.1690987	2020	Histological transformation in malignant lymphoma: a possible role of PET/CT and circulating tumor DNA as noninvasive diagnostic tools.	TP53
31729120	10.1111/cas.14238	2020	TP53 alterations in relapsed childhood acute lymphoblastic leukemia.	TP53
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	TP53
31760435	10.1007/s00204-019-02623-2	2020	Mitotic catastrophe and p53-dependent senescence induction in T-cell malignancies exposed to nonlethal dosage of GL-V9.	TP53
31774495	10.1182/blood.2019001904	2020	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL.	TP53
31794893	10.1016/j.dnarep.2019.102754	2020	Loss of Setd4 delays radiation-induced thymic lymphoma in mice.	TP53
31804006	10.1002/cam4.2757	2020	RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.	TP53
31822801	10.1038/s41379-019-0415-5	2020	Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America.	TP53
31842651	10.1080/10428194.2019.1702177	2020	Combining gene variants with clinical characteristics improves outcome prediction in Chinese patients with myelodysplastic syndromes.	TP53
31894386	10.1007/s00432-019-03116-6	2020	Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.	TP53
31894535	10.1007/s12185-019-02810-y	2020	Histologic transformation of t(11;18)-positive MALT lymphoma presented with aberrant T-cell marker expression.	TP53
31914529	10.3760/cma.j.issn.0529-5807.2020.01.004	2020	[Monomorphic epitheliotropic intestinal T-cell lymphoma: a clinicopathological analysis of twelve cases].	TP53
31918102	10.1016/j.chemosphere.2019.125794	2020	Antagonistic effect of selenium on lead-induced neutrophil apoptosis in chickens via miR-16-5p targeting of PiK3R1 and IGF1R.	TP53
31964785	10.1158/1078-0432.CCR-19-3061	2020	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study.	TP53
31965269	10.1007/s00277-020-03911-z	2020	Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.	TP53
31975037	10.1007/s00428-020-02750-7	2020	Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11.	TP53
31991488	10.1111/apm.13029	2020	EZH2 expression is dependent on MYC and TP53 regulation in diffuse large B-cell lymphoma.	TP53
32013644	10.1080/10428194.2020.1719089	2020	Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes.	TP53
32016852	10.1007/s43440-019-00004-1	2020	Effect of new olivacine derivatives on p53 protein level.	TP53
32027255	10.19746/j.cnki.issn.1009-2137.2020.01.012	2020	[Analysis of Clinical Characteristics and Therapeutic Efficacy of Patients with Adult Acute Lymphoblastic Leukemia].	TP53
32033927	10.1016/j.clml.2019.10.009	2020	Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry.	TP53
32041553	10.1186/s12885-020-6599-8	2020	Expression of p53 N-terminal isoforms in B-cell precursor acute lymphoblastic leukemia and its correlation with clinicopathological profiles.	TP53
32044274	10.1016/j.clml.2020.01.003	2020	Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.	TP53
32064880	10.4149/neo_2020_190307N194	2020	KMT2D and TP53 mutation status improve the prognostic value of the International Prognostic Index (IPI) stratification in ENKTL patients.	TP53
32075226	10.3390/ijms21041309	2020	Mdm2 and MdmX RING Domains Play Distinct Roles in the Regulation of p53 Responses: A Comparative Study of Mdm2 and MdmX RING Domains in U2OS Cells.	TP53
32077636	10.1111/1759-7714.13361	2020	Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.	TP53
32103174	10.1038/s41586-020-2041-2	2020	DNA-PKcs has KU-dependent function in rRNA processing and haematopoiesis.	TP53
32119867	10.1016/j.jid.2019.12.041	2020	Involvement of p53 Acetylation in Growth Suppression of Cutaneous T-Cell Lymphomas Induced by HDAC Inhibition.	TP53
32139108	10.1016/j.arcmed.2020.02.005	2020	CpG Oligodeoxynucleotides Induces Apoptosis of Human Bladder Cancer Cells via Caspase-3-Bax/Bcl-2-p53 Axis.	TP53
32139296	10.1016/j.clml.2019.11.007	2020	Defining Acute Myeloid Leukemia Ontogeny in Older Patients.	TP53
32142900	10.1016/j.jmoldx.2020.02.004	2020	Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia.	TP53
32160292	10.1182/blood.2019002385	2020	Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing.	TP53
32161460	10.2147/IJN.S225142	2020	Synergistic Treatment of Tumor by Targeted Biotherapy and Chemotherapy via Site-Specific Anchoring of Aptamers on DNA Nanotubes.	TP53
32164276	10.3390/cancers12030642	2020	Precision Medicine Management of Chronic Lymphocytic Leukemia.	TP53
32173361	10.1016/j.exphem.2020.03.001	2020	Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma.	TP53
32187361	10.1182/blood.2019003535	2020	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.	TP53
32191807	10.1182/bloodadvances.2019001396	2020	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.	TP53
32203146	10.1038/s41375-020-0795-z	2020	Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study.	TP53
32223488	10.1080/10428194.2020.1742905	2020	Cytogenetically masked <i>CBFB-MYH11</i> fusion and concomitant <i>TP53</i> deletion in a case of acute myeloid leukemia with a complex karyotype.	TP53
32230928	10.3390/biom10040510	2020	An Extract of Transgenic Senna obtusifolia L. Hairy Roots with Overexpression of PgSS1 Gene in Combination with Chemotherapeutic Agent Induces Apoptosis in the Leukemia Cell Line.	TP53
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	TP53
32239765	10.1002/ajh.25796	2020	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.	TP53
32253666	10.1007/s12185-020-02867-0	2020	Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?	TP53
32255708	10.1080/10428194.2020.1747068	2020	Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.	TP53
32257467	10.1155/2020/9185432	2020	Non-Nodal CD5-Negative Mantle Cell Lymphoma with Secondary TP53 Deletion.	TP53
32272636	10.3390/cancers12040894	2020	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.	TP53
32277542	10.1002/gcc.22849	2020	Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.	TP53
32299384	10.1186/s12885-020-06805-5	2020	Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.	TP53
32311893	10.3760/cma.j.issn.0253-2727.2020.03.008	2020	[The prognostic significance of POD24 in 106 cases with splenic marginal lymphoma with bone marrow invasion].	TP53
32316711	10.3779/j.issn.1009-3419.2020.101.17	2020	[Genetic Profile of Young Chinese Patients with Lung Adenocarcinoma].	TP53
32317694	10.1038/s41598-020-63434-5	2020	Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.	TP53
32321318	10.1080/13543784.2020.1760245	2020	Novel agents for mantle cell lymphoma: molecular rational and clinical data.	TP53
32322022	10.1038/s41379-020-0533-0	2020	Morphologic and genetic heterogeneity in breast fibroepithelial lesions-a comprehensive mapping study.	TP53
32345625	10.1136/jitc-2019-000364	2020	CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.	TP53
32362171	10.1080/10428194.2020.1759051	2020	Clinical outcomes and characteristics of patients with <i>TP53</i>-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.	TP53
32399964	10.1002/ijc.33049	2020	Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.	TP53
32419250	10.1111/cpr.12826	2020	B-cell lymphoma 2 family genes show a molecular pattern of spatiotemporal heterogeneity in gynaecologic and breast cancer.	TP53
32426239	10.1016/j.toxrep.2020.04.010	2020	MicroRNAs and Xenobiotic Toxicity: An Overview.	TP53
32431543	10.2147/CMAR.S242903	2020	Clinicopathological Characteristics and Mutational Profiling of Adult T-Cell Lymphoblastic Lymphoma in a Chinese Population.	TP53
32453841	10.1182/bloodadvances.2020001466	2020	Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features.	TP53
32457845	10.3389/fonc.2020.00726	2020	The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients.	TP53
32472610	10.1002/hon.2750	2020	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.	TP53
32515564	10.36233/0507-4088-2020-65-2-87-94	2020	[Interferon-regulating activity of the CelAgrip drug and its influence on the formation of reactive oxygen species and expression of innate immunity genes in Burkitt's lymphome cells cultures.]	TP53
32519351	10.1111/bjh.16748	2020	Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).	TP53
32563740	10.1016/j.lungcan.2020.05.026	2020	Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.	TP53
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	TP53
32580907	10.1016/j.clbc.2020.05.005	2020	p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.	TP53
32581054	10.1136/jitc-2019-000218	2020	CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.	TP53
32584970	10.1182/blood.2020005289	2020	Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes.	TP53
32589730	10.1182/bloodadvances.2020001696	2020	Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma.	TP53
32598477	10.1182/bloodadvances.2019001350	2020	Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.	TP53
32602002	10.1007/s12253-020-00864-6	2020	The Role of Immunohistochemical Overexpression of p53 as Adverse Prognostic Factor in Primary Testicular Diffuse Large B Cell Lymphoma.	TP53
32620919	10.1038/s41379-020-0616-y	2020	Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers.	TP53
32627089	10.1007/s10014-020-00373-z	2020	Primary central nervous system lymphomas associated with chronic inflammation: diagnostic pitfalls of central nervous system lymphomas.	TP53
32632752	10.1007/s00109-020-01943-6	2020	The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.	TP53
32649656	NA	2020	Richter transformation of chronic lymphocytic leukemia in the era of novel agents.	TP53
32649887	10.1016/j.ccell.2020.06.002	2020	Immunogenomic Landscape of Hematological Malignancies.	TP53
32659728	10.1016/j.advms.2020.06.002	2020	Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.	TP53
32695399	10.1186/s40364-020-00205-4	2020	Plasma circulating tumor DNA assessment reveals <i>KMT2D</i> as a potential poor prognostic factor in extranodal NK/T-cell lymphoma.	TP53
32748433	10.1111/bjh.17023	2020	p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.	TP53
32751805	10.3390/cancers12082120	2020	Concurrent <i>TP53</i> and <i>CDKN2A</i> Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy.	TP53
32770099	10.1038/s41598-020-70310-9	2020	Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study.	TP53
32779615	10.3960/jslrt.20019	2020	Clinical application of genomic aberrations in adult T-cell leukemia/lymphoma.	TP53
32780847	10.1182/bloodadvances.2020001727	2020	Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma.	TP53
32804454	10.1097/PAS.0000000000001512	2020	Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature.	TP53
32825230	10.3390/genes11090960	2020	Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying <i>TP53</i> Molecular Alterations.	TP53
32838487	10.3779/j.issn.1009-3419.2020.102.14	2020	[Different Gene Mutation Spectrum of the Paired CSF and Plasma Samples in Lung Adenocarcinoma with Leptomeningeal Metastases: the Liquid Biopsy Based on Circulating Tumor DNA].	TP53
32861280	10.1016/j.hoc.2020.06.001	2020	What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes?	TP53
32862455	10.1111/bjh.17063	2020	A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.	TP53
32862873	10.1016/S2152-2650(20)30465-1	2020	The Problem of TP53-Mutant MDS/AML.	TP53
32862879	10.1016/S2152-2650(20)30470-5	2020	Management of Frail Older Adults with Newly Diagnosed Multiple Myeloma - Moving Toward a Personalized Approach.	TP53
32871937	10.1097/MD.0000000000021938	2020	Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report.	TP53
32872120	10.3390/jpm10030107	2020	Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, <i>ALK</i>-Positive, <i>TP53</i>-Mutant NSCLC.	TP53
32889036	10.1016/j.tiv.2020.104992	2020	Epigenetic priming by EHMT1/EHMT2 in acute lymphoblastic leukemia induces TP53 and TP73 overexpression and promotes cell death.	TP53
32890601	10.1016/j.humpath.2020.08.008	2020	Comprehensive molecular genetic studies of Epstein-Barr virus-negative aggressive Natural killer-cell leukemia/lymphoma.	TP53
32939265	10.1186/s40364-020-00222-3	2020	Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia.	TP53
32981916	10.3960/jslrt.20021	2020	Integrative genomic analysis focused on cell cycle genes for MYC-driven aggressive mature B-cell lymphoma.	TP53
32988392	10.1186/s13000-020-01022-x	2020	Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports.	TP53
32999452	10.1038/s41434-020-00194-x	2020	Easy and robust electrotransfection protocol for efficient ectopic gene expression and genome editing in human B cells.	TP53
33017727	10.1016/j.lungcan.2020.09.012	2020	Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.	TP53
33060089	10.1136/bmjopen-2020-039168	2020	Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ‚â•30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations.	TP53
33061576	10.2147/CMAR.S260583	2020	The Anti-Apoptotic Role of EBV-LMP1 in Lymphoma Cells.	TP53
33093445	10.1038/s41419-020-03115-3	2020	BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity.	TP53
33095873	10.1182/bloodadvances.2019001307	2020	Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia.	TP53
33116627	10.2147/OTT.S253758	2020	MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma.	TP53
33127875	10.1038/s41408-020-00376-1	2020	New directions for emerging therapies in acute myeloid leukemia: the next chapter.	TP53
33148342	10.1186/s13045-020-00982-3	2020	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.	TP53
33188997	10.1016/j.ctarc.2020.100235	2020	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.	TP53
33204162	10.2147/CMAR.S269624	2020	Characteristics and Management of <i>TP53</i>-Mutated Diffuse Large B-Cell Lymphoma Patients.	TP53
33240649	10.7717/peerj.10335	2020	The rs78378222 prevalence and the copy loss of the protective allele A in the tumor tissue of diffuse large B-cell lymphoma.	TP53
33283700	10.19746/j.cnki.issn.1009-2137.2020.06.001	2020	[Gene Mutation in Acute Lymphoblastic Leukemia by DNA Sequencing].	TP53
33290262	10.18632/aging.202146	2020	The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development.	TP53
33333693	10.3760/cma.j.issn.0253-2727.2020.11.005	2020	[The effect of TP53 mutations on the clinical outcomes of Ph-negative B-acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation].	TP53
33344238	10.3389/fonc.2020.584095	2020	DNA Copy Number Changes in Diffuse Large B Cell Lymphomas.	TP53
33380880	10.3747/co.27.6795	2020	Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.	TP53
33533212	10.36233/0507-4088-2020-65-5-5	2020	[Interferon-regulating activity of the celagrip antiviral drug and its influence on formation of reactive oxygen species and expression of innate immunity genes in the follicular lymphoma patients].	TP53
33585229	10.3389/fonc.2020.609409	2020	The Effect of <i>SF3B1</i> Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer.	TP53
30255938	10.1002/ijc.31893	2019	Identification of a highly lethal V3<sup>+</sup> TP53<sup>+</sup> subset in ALK<sup>+</sup> lung adenocarcinoma.	TP53
30592281	10.3892/mmr.2018.9793	2019	LncRNA BANCR participates in polycystic ovary syndrome by promoting cell apoptosis.	TP53
30702927	10.1096/fj.201801559RR	2019	AICAr suppresses cell proliferation by inducing NTP and dNTP pool imbalances in acute lymphoblastic leukemia cells.	TP53
30843662	10.1002/cam4.2043	2019	Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.	TP53
30955249	10.1111/petr.13408	2019	Strong expression of p53 protein in bone marrow samples after hematopoietic stem cell transplantation indicates risk of relapse in pediatric acute lymphoblastic leukemia patients.	TP53
30962574	10.1038/s41556-019-0305-6	2019	ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway.	TP53
31056984	10.1080/10428194.2019.1608528	2019	MicroRNA-661 upregulation in myelodysplastic syndromes induces apoptosis through p53 activation and associates with decreased overall survival.	TP53
31101761	10.1158/0008-5472.CAN-18-1503	2019	Phosphorylation of SOCS1 Inhibits the SOCS1-p53 Tumor Suppressor Axis.	TP53
31128065	10.31557/APJCP.2019.20.5.1579	2019	TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population	TP53
31132650	10.1016/j.anndiagpath.2019.05.004	2019	TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.	TP53
31207703	10.3760/cma.j.issn.0253-2727.2019.05.008	2019	[High-dose methylprednisolone with Rituximab and fresh frozen plasma in the treatment of six patients with B-cell lymphoproliferative disorders harboring TP53 abnormalities].	TP53
31208944	10.1016/S2352-3026(19)30104-8	2019	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.	TP53
31229158	10.1016/j.hoc.2019.03.002	2019	Mantle Cell Lymphoma: Current and Emerging Treatment Strategies and Unanswered Questions.	TP53
31230491	10.1080/10428194.2019.1630619	2019	Myelodysplastic/myeloproliferative neoplasm with eosinophilia as a manifestation of Li Fraumeni Syndrome.	TP53
31243098	10.1158/1535-7163.MCT-19-0105	2019	Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes.	TP53
31257681	10.1002/jcb.29143	2019	Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.	TP53
31268728	10.1080/17474086.2019.1639501	2019	Optimal management of mantle cell lymphoma in the primary setting.	TP53
31281315	10.3389/fimmu.2019.01382	2019	The Molecular Evolution and Functional Divergence of Lamprey Programmed Cell Death Genes.	TP53
31285322	10.1073/pnas.1905305116	2019	Nbn-Mre11 interaction is required for tumor suppression and genomic integrity.	TP53
31289210	10.3324/haematol.2018.205849	2019	<i>TP53, ETV6</i> and <i>RUNX1</i> germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia.	TP53
31316614	10.3892/etm.2019.7674	2019	miRNA-125a-5p inhibits hepatocellular carcinoma cell proliferation and induces apoptosis by targeting TP53 regulated inhibitor of apoptosis 1 and Bcl-2-like-2 protein.	TP53
31317311	10.1007/s00428-019-02608-7	2019	Clonal evolution of chronic lymphocytic leukemia to Langerhans cell histiocytosis: a case report.	TP53
31320741	10.1038/s41598-019-46906-1	2019	Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma.	TP53
31339741	10.1089/dna.2018.4520	2019	Recombinant Pierisin-5 Induces Apoptosis and Differential Expression of Bcl-2, Bax, and p53 in Human Cancer Cells.	TP53
31343754	10.1002/ddr.21573	2019	Anticancer activity of newly synthesized 1,1-disubstituted cyclohexane-1-carboxamides: in vitro caspases mediated apoptosis activators in human cancer cell lines and their molecular modeling.	TP53
31352982	10.1016/j.path.2019.03.012	2019	Prognostic and Predictive Biomarkers in Diffuse Large B-cell Lymphoma.	TP53
31359442	10.1002/hon.2657	2019	CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.	TP53
31371221	10.1016/j.clml.2019.03.002	2019	Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.	TP53
31378966	10.1002/ajh.25600	2019	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.	TP53
31406302	10.1038/s41568-019-0179-8	2019	Co-occurring genomic alterations in¬†non-small-cell lung cancer biology and therapy.	TP53
31411343	10.1002/path.5333	2019	Genomic characterisation of breast fibroepithelial lesions in an international cohort.	TP53
31433581	10.3349/ymj.2019.60.9.832	2019	miR-1301/TRIAP1 Axis Participates in Epirubicin-Mediated Anti-Proliferation and Pro-Apoptosis in Osteosarcoma.	TP53
31436356	10.1111/cas.14176	2019	Mutations found in cell-free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis.	TP53
31439588	10.1158/1078-0432.CCR-19-1176	2019	Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in <i>ALK</i>-Rearranged Non-Small-Cell Lung Cancer.	TP53
31443496	10.3390/cancers11091229	2019	Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation.	TP53
31444835	10.1111/cas.14177	2019	Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.	TP53
31473630	10.1136/jclinpath-2019-205895	2019	Somatic <i>SF3B1</i> mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia.	TP53
31475375	10.1002/hon.2674	2019	m7FLIPI and targeted sequencing in high-risk follicular lymphoma.	TP53
31512258	10.1002/ajh.25638	2019	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.	TP53
31542870	10.1007/s11523-019-00673-1	2019	Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia.	TP53
31551170	10.1016/j.clml.2019.08.010	2019	EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms.	TP53
31607305	10.19746/j.cnki.issn.1009-2137.2019.05.023	2019	[Effect of P53 Expression on Prognosis of Patients with Double Expressor Lymphoma].	TP53
31644328	10.1200/JCO.19.01694	2019	Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.	TP53
31648313	10.1182/bloodadvances.2019000051	2019	Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.	TP53
31648477	10.3760/cma.j.issn.0253-2727.2019.09.008	2019	[Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review].	TP53
31652456	10.1042/BSR20191357	2019	The inhibition of tumor protein p53 by microRNA-151a-3p induced cell proliferation, migration and invasion in nasopharyngeal carcinoma.	TP53
31693904	10.1016/j.celrep.2019.09.071	2019	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design.	TP53
31699989	10.1038/s41467-019-13002-x	2019	Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant.	TP53
31753813	10.1101/mcs.a004630	2019	Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in <i>KLC1-ALK</i>-rearranged lung cancer.	TP53
31776787	10.1007/s11864-019-0684-8	2019	Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment.	TP53
31780660	10.1038/s41408-019-0259-8	2019	Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma.	TP53
31808882	10.1182/hematology.2019000011	2019	Molecular profiling and management of mantle cell lymphoma.	TP53
31839919	10.1177/2040620719891356	2019	Emerging treatment options for patients with p53-pathway-deficient CLL.	TP53
31856440	10.3760/cma.j.issn.0253-2727.2019.11.006	2019	[Clinical prognosis analysis of patients with """"double hit"""" multiple myeloma].	TP53
31891126	10.1016/j.cdtm.2019.08.001	2019	Cross-talk between Myc and p53 in B-cell lymphomas.	TP53
32397023	10.3760/cma.j.issn.0253-2727.2019.07.010	2019	[Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL].	TP53
27859003	10.1111/bjh.14431	2018	Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A.	TP53
28902083	10.1097/MPH.0000000000000948	2018	Nodular Lymphocyte-predominant Hodgkin Lymphoma in a 15-Year-Old Boy With Li-Fraumeni Syndrome Having a Germline TP53 D49H Mutation.	TP53
29115375	10.3892/ijmm.2017.3205	2018	Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.	TP53
29196411	10.1182/blood-2017-07-797019	2018	Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.	TP53
29300620	10.1200/JCO.2017.75.5215	2018	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.	TP53
29336471	10.3892/ijmm.2018.3392	2018	Neuroprotective effects of p53/microRNA‚Äë22 regulate inflammation and apoptosis in subarachnoid hemorrhage.	TP53
29338567	10.1080/10428194.2017.1422864	2018	Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.	TP53
29346503	10.1093/carcin/bgy001	2018	p53Œ≤: a new prognostic marker for patients with clear-cell renal cell carcinoma from 5.3 years of median follow-up.	TP53
29653964	10.1182/blood-2017-09-806679	2018	TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.	TP53
29661169	10.1186/s12885-018-4304-y	2018	RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas.	TP53
29789628	10.1038/s41467-018-04356-9	2018	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.	TP53
29790592	10.1002/hep.30098	2018	Hepatitis B Virus-Upregulated LNC-HUR1 Promotes Cell Proliferation and Tumorigenesis by Blocking p53 Activity.	TP53
29794145	10.3324/haematol.2018.194399	2018	Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of <i>TP53</i> mutations in mantle cell lymphoma.	TP53
29885057	10.1002/path.5110	2018	Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.	TP53
29885407	10.1016/j.humpath.2018.05.026	2018	TP53 mutations in peripheral mature T and NK cell lymphomas: a whole-exome sequencing study with correlation to p53 expression.	TP53
30086334	10.1016/j.humpath.2018.07.030	2018	Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption.	TP53
30165392	10.1093/annonc/mdy333	2018	Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.	TP53
30297390	10.1136/jim-2018-000804	2018	Prostate cancer aggressiveness and age: Impact of p53, BCL-2 and microvessel density.	TP53
27268868	10.1080/10428194.2016.1187276	2017	Ability to downregulate the level of cyclin-dependent kinase inhibitor p27<sup>Kip1</sup> after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway.	TP53
27619989	10.1007/s10689-016-9931-3	2017	Mutational analysis of TP53 gene in Tunisian familial hematological malignancies and sporadic acute leukemia cases.	TP53
27721412	10.1038/onc.2016.360	2017	Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.	TP53
27739436	10.1038/modpathol.2016.178	2017	P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.	TP53
27993575	10.1016/j.humpath.2016.12.007	2017	B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry.	TP53
28003275	10.1101/cshperspect.a026286	2017	<i>TP53</i> Mutations in Hypodiploid Acute Lymphoblastic Leukemia.	TP53
28251968	10.7868/S0026898416060227	2017	[Frequency, spectrum, and functional significance of TP53 mutations in patients with diffuse large B-cell lymphoma].	TP53
28281555	10.1038/modpathol.2017.5	2017	NF-Œ∫B p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.	TP53
28284458	10.1016/j.blre.2017.03.001	2017	p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell.	TP53
28301507	10.1371/journal.pone.0173171	2017	TP53 alterations in primary and secondary S√©zary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma.	TP53
28369138	10.1371/journal.pone.0174809	2017	TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis.	TP53
28474779	10.1002/ajh.24778	2017	A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation.	TP53
28484276	10.1038/s41598-017-01800-6	2017	Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.	TP53
28551630	10.21873/anticanres.11646	2017	Expression and Prognostic Significance of <i>EP300</i>, <i>TP53</i> and <i>BAX</i> in Clear Cell Renal Cell Carcinoma.	TP53
28557976	10.1038/bjc.2017.152	2017	Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.	TP53
28614910	10.1002/ijc.30838	2017	TP53 mutation and survival in aggressive B cell lymphoma.	TP53
28654064	10.3791/55703	2017	Detection and Visualization of DNA Damage-induced Protein Complexes in Suspension Cell Cultures Using the Proximity Ligation Assay.	TP53
28687222	10.1016/j.clml.2017.06.003	2017	TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.	TP53
28791403	10.3892/or.2017.5891	2017	Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.	TP53
28819011	10.1182/blood-2017-04-779736	2017	<i>TP53</i> mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.	TP53
28901386	10.3892/mmr.2017.7379	2017	Aloin promotes A549 cell apoptosis via the reactive oxygen species‚Äëmitogen activated protein kinase signaling pathway and p53 phosphorylation.	TP53
29126407	10.1186/s12885-017-3760-0	2017	TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.	TP53
25915849	10.1038/onc.2015.88	2016	Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma.	TP53
26209050	10.1007/s12094-015-1338-3	2016	Potential impact of (rs 4645878) BAX promoter -248G&gt;A and (rs 1042522) TP53 72Arg&gt;pro polymorphisms on epithelial ovarian cancer patients.	TP53
26315382	10.1016/j.critrevonc.2015.08.006	2016	TP53 dysfunction in diffuse large B-cell lymphoma.	TP53
26426381	10.1097/PAS.0000000000000523	2016	NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease.	TP53
26448193	10.1097/PAS.0000000000000542	2016	High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.	TP53
26648441	10.3892/mmr.2015.4606	2016	Effects of miR‚Äë590 on oxLDL‚Äëinduced endothelial cell apoptosis: Roles of p53 and NF‚ÄëŒ∫B.	TP53
26709646	10.2741/E751	2016	The emerging role of CD30 and p53 as novel targets for therapy in anaplastic large cell lymphoma.	TP53
26754533	10.3109/10428194.2015.1124992	2016	The leukemic oncoprotein NPM1-RARA inhibits TP53 activity.	TP53
26904937	10.1016/j.celrep.2016.01.059	2016	Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.	TP53
26909609	10.18632/oncotarget.7539	2016	Aryl hydrocarbon receptor nuclear translocator (ARNT) isoforms control lymphoid cancer cell proliferation through differentially regulating tumor suppressor p53 activity.	TP53
26982726	10.1038/nature17157	2016	Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.	TP53
26992948	10.3324/haematol.2015.137059	2016	Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.	TP53
27101868	10.1186/s40478-016-0307-6	2016	TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.	TP53
27229929	10.1186/s12885-016-2374-2	2016	Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor.	TP53
27284738	10.1038/bcj.2016.41	2016	p53-independent ibrutinib responses in an EŒº-TCL1 mouse model demonstrates efficacy in high-risk CLL.	TP53
27351221	10.18632/oncotarget.10268	2016	Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma.	TP53
27542204	10.18632/oncotarget.11297	2016	Nucks1 synergizes with Trp53 to promote radiation lymphomagenesis in mice.	TP53
27559048	10.4049/jimmunol.1501989	2016	The DNA Damage Response Regulates RAG1/2 Expression in Pre-B Cells through ATM-FOXO1 Signaling.	TP53
27622827	10.1016/j.clml.2016.08.016	2016	Aberrant p15, p16, p53, and DAPK Gene Methylation in Myelomagenesis: Clinical and Prognostic Implications.	TP53
27627705	10.1111/cas.13080	2016	EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway.	TP53
27698449	10.1038/srep34578	2016	Cr(VI) induces premature senescence through ROS-mediated p53 pathway in L-02 hepatocytes.	TP53
27825110	10.18632/oncotarget.13065	2016	Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.	TP53
27906186	10.1038/cddis.2016.382	2016	Preimplantation factor is an anti-apoptotic effector in human trophoblasts involving p53 signaling pathway.	TP53
28005077	10.1038/cddis.2016.430	2016	Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2.	TP53
24679006	10.3109/10428194.2014.907896	2015	TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.	TP53
24898668	10.3109/10428194.2014.929673	2015	Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage.	TP53
24925209	10.3109/10428194.2014.930850	2015	Functional p53 can modulate the relationship between E2F-1 expression and tumor kinetics in Hodgkin lymphoma.	TP53
25284491	10.3109/10428194.2014.970550	2015	Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.	TP53
25430047	10.1111/bjh.13237	2015	Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients.	TP53
25573202	10.3109/10428194.2014.1003559	2015	Point mutations in TP53 but not in p15(Ink4b) and p16(Ink4a) genes represent poor prognosis factors in acute adult T cell leukemia/lymphoma.	TP53
25589462	10.1007/s13277-014-3035-1	2015	Indole-3-carbinol suppresses NF-Œ∫B activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells.	TP53
25590240	10.1080/15384101.2015.1004935	2015	PCDH10, a novel p53 transcriptional target in regulating cell migration.	TP53
25641428	10.3109/10428194.2015.1011641	2015	How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?	TP53
25646413	10.1073/pnas.1500010112	2015	TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.	TP53
25692307	10.1080/15384047.2014.1002698	2015	Inauhzin(c) inactivates c-Myc independently of p53.	TP53
25695150	10.3892/mmr.2015.3370	2015	Role of p53Œ≤ in the inhibition of proliferation of gastric cancer cells expressing wild-type or mutated p53.	TP53
25775024	10.1186/s12885-015-1048-9	2015	Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter's syndrome.	TP53
25915824	10.1038/leu.2015.101	2015	MicroRNA-124 links p53 to the NF-Œ∫B pathway in B-cell lymphomas.	TP53
26022239	10.1182/blood-2015-02-628792	2015	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.	TP53
26082451	10.1182/blood-2014-11-611194	2015	Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.	TP53
26106001	10.3960/jslrt.55.13	2015	Mutation Analysis for TP53 in Chronic-Type Adult T-Cell Leukemia/Lymphoma.	TP53
26185311	10.1309/AJCPW83OXPYKPEEN	2015	Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients.	TP53
26232254	10.1016/j.mrgentox.2015.05.011	2015	Relationships between p53 status, apoptosis and induction of micronuclei in different human and mouse cell lines in vitro: Implications for improving existing assays.	TP53
26324762	10.18632/oncotarget.4319	2015	Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.	TP53
26556860	10.18632/oncotarget.5715	2015	The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.	TP53
26638586	NA	2015	The Expressions of P53, Bcl-2, and P-Glycoprotein and Prognostic Impact in Patients with Peripheral T-Cell Lymphoma (PTCL).	TP53
26717387	10.1097/MD.0000000000002388	2015	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.	TP53
26720344	10.1038/cddis.2015.358	2015	Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells.	TP53
24232982	10.1007/s10120-013-0313-3	2014	Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.	TP53
24240203	10.1038/leu.2013.345	2014	Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia.	TP53
24248600	10.1128/MCB.01011-13	2014	p53 tumor suppressor protein stability and transcriptional activity are targeted by Kaposi's sarcoma-associated herpesvirus-encoded viral interferon regulatory factor 3.	TP53
24619762	10.1309/AJCPPHMZ6VHF0WQV	2014	p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.	TP53
24619868	10.1002/gcc.22163	2014	Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.	TP53
24628257	10.1179/1607845414Y.0000000153	2014	Nucleostemin knocking-down causes cell cycle arrest and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells via p53 and p21Waf1/Cip1 up-regulation.	TP53
24642368	10.1016/j.prp.2014.02.004	2014	Both c-Myc and Ki-67 expression are predictive markers in patients with extranodal NK/T-cell lymphoma, nasal type: a retrospective study in China.	TP53
24652995	10.1182/blood-2013-10-532390	2014	p57 regulates T-cell development and prevents lymphomagenesis by balancing p53 activity and pre-TCR signaling.	TP53
24787013	10.1038/cddis.2014.150	2014	Reversion of apoptotic resistance of TP53-mutated Burkitt lymphoma B-cells to spindle poisons by exogenous activation of JNK and p38 MAP kinases.	TP53
24829203	10.1182/blood-2014-02-558833	2014	TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis.	TP53
24852242	10.1016/j.anndiagpath.2014.03.006	2014	Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14.	TP53
24911057	10.1371/journal.pone.0099255	2014	Assessment of the potential diagnostic value of serum p53 antibody for cancer: a meta-analysis.	TP53
25070816	NA	2014	L-arginine enhances arginine deiminase induced human lymphoma cell growth inhibition through NF-kBp65 and p53 expression in vitro.	TP53
25203442	10.1371/journal.pone.0107047	2014	The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to Non-Hodgkin lymphoma risk.	TP53
25297597	10.3760/cma.j.issn.1003-9406.2014.01.020	2014	[Significance of BCL6, MYC, P53 genes abnormalities for the prognosis of diffuse large B-cell lymphoma].	TP53
25842861	NA	2014	[Linkage disequilibrium and haplotypes of rs1042522, rs1625895 and rs17878362 gene TP53 markers in patients with diffuse large B-cell lymphoma].	TP53
22699455	10.1038/leu.2012.155	2013	Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.	TP53
22801382	10.1038/leu.2012.198	2013	Partial 17q gain resulting from isochromosomes, unbalanced translocations and complex rearrangements is associated with gene overexpression, older age and shorter overall survival in high hyperdiploid childhood acute lymphoblastic leukemia.	TP53
23121011	10.3109/10428194.2012.745527	2013	TP53 mutation is rare in primary myelofibrosis.	TP53
23255406	10.1002/pbc.24417	2013	Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing.	TP53
23269799	10.1128/JVI.03081-12	2013	B cells in chronically hepatitis C virus-infected individuals lack a virus-induced mutation signature in the TP53, CTNNB1, and BCL6 genes.	TP53
23358872	10.1593/neo.121362	2013	The HECTD3 E3 ubiquitin ligase suppresses cisplatin-induced apoptosis via stabilizing MALT1.	TP53
23403321	10.3324/haematol.2012.076786	2013	TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.	TP53
23483263	10.3892/ijo.2013.1853	2013	cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases.	TP53
23487038	10.1242/jcs.118174	2013	BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNŒ≥-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.	TP53
23515929	10.1182/blood-2012-12-471722	2013	Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.	TP53
23528269	10.18632/oncotarget.933	2013	Growth factor independence 1 (Gfi1) as a regulator of p53 activity and a new therapeutical target for ALL.	TP53
23589839	10.1073/pnas.1208530110	2013	Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis.	TP53
23608226	10.1016/j.ajpath.2013.01.025	2013	Epstein-Barr virus-encoded miR-BART20-5p inhibits T-bet translation with secondary suppression of p53 in invasive nasal NK/T-cell lymphoma.	TP53
23626008	10.1136/jclinpath-2013-201454	2013	p63 and p53 expression in extranodal NK/T cell lymphoma, nasal type.	TP53
23653000	10.1007/s11033-013-2551-1	2013	CXCL12 and TP53 genetic polymorphisms as markers of susceptibility in a Brazilian children population with acute lymphoblastic leukemia (ALL).	TP53
23733769	10.1200/JCO.2012.46.3711	2013	Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors.	TP53
23745682	10.1089/dna.2012.1900	2013	Genetic variations in MDM2 and P53 genes confer risk for adult acute lymphoblastic leukemia in a Chinese population.	TP53
23852341	10.1038/nm.3247	2013	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint.	TP53
23982177	10.1182/blood-2012-12-473702	2013	MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.	TP53
23991992	10.7314/apjcp.2013.14.7.4295	2013	Clinical significance of serum p53 and epidermal growth factor receptor in patients with acute leukemia.	TP53
24036547	10.4161/cc.26299	2013	Somatic inactivation of Tp53 in hematopoietic stem cells or thymocytes predisposes mice to thymic lymphomas with clonal translocations.	TP53
24122997	NA	2013	Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.	TP53
24294363	NA	2013	Epstein-Barr virus infection correlates with the expression of COX-2, p16(INK4A) and p53 in classic Hodgkin lymphoma.	TP53
21804610	10.1038/onc.2011.331	2012	The proto-oncoprotein KR-POK represses transcriptional activation of CDKN1A by MIZ-1 through competitive binding.	TP53
21823831	10.3109/10428194.2011.608453	2012	Monosomal karyotype routinely defines a poor prognosis subgroup in acute myeloid leukemia and is frequently associated with TP53 deletion.	TP53
22047081	10.1089/dna.2011.1314	2012	Analysis of p53 tumor suppressor pathway genes in chronic lymphocytic leukemia.	TP53
22057359	10.1007/s12032-011-0096-5	2012	TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.	TP53
22156152	10.1177/1538574411422277	2012	p53 gene therapy modulates signal transduction in the apoptotic and cell cycle pathways downregulating neointimal hyperplasia.	TP53
22220854	10.3109/10428194.2011.654115	2012	p53 protein expression in chronic lymphocytic leukemia.	TP53
22235305	10.1371/journal.pone.0029541	2012	miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.	TP53
22263566	10.3109/10428194.2012.658794	2012	Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia.	TP53
22266868	10.1038/onc.2011.648	2012	Angiogenin functionally interacts with p53 and regulates p53-mediated apoptosis and cell survival.	TP53
22275381	10.1182/blood-2011-11-366062	2012	Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.	TP53
22280536	10.3109/10428194.2012.660630	2012	Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia.	TP53
22315488	10.3324/haematol.2011.055715	2012	The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.	TP53
22323293	10.1091/mbc.E11-06-0524	2012	Intermediate progenitors are increased by lengthening of the cell cycle through calcium signaling and p53 expression in human neural progenitors.	TP53
22384858	10.1111/j.1365-2133.2012.10918.x	2012	The tumour suppressor p53 is frequently nonfunctional in S√©zary syndrome.	TP53
22502699	10.7314/apjcp.2012.13.1.349	2012	TP53 codon 72 polymorphism and risk of acute leukemia.	TP53
22607702	10.1016/j.humpath.2012.02.010	2012	Immunohistochemical and oncogenetic analyses of the esophageal basaloid squamous cell carcinoma in comparison with conventional squamous cell carcinomas.	TP53
22845047	10.1111/j.1365-2141.2012.09243.x	2012	TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases.	TP53
22855598	10.1182/blood-2012-03-419937	2012	Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.	TP53
22927405	10.1073/pnas.1205664109	2012	Pathogenic bacterium Helicobacter pylori alters the expression profile of p53 protein isoforms and p53 response to cellular stresses.	TP53
22933706	10.1158/1535-7163.MCT-12-0135	2012	Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.	TP53
22945289	10.1002/eji.201242530	2012	ZNF385B is characteristically expressed in germinal center B cells and involved in B-cell apoptosis.	TP53
22955915	10.1182/blood-2012-05-433334	2012	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.	TP53
22965953	10.1200/JCO.2011.40.7783	2012	Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.	TP53
23029260	10.1371/journal.pone.0045820	2012	p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis.	TP53
23042398	10.3760/cma.j.issn.1003-9406.2012.05.017	2012	[Correlation of BCL-6, MYC and p53 gene abnormalities with immunological subtypes and prognosis of diffuse large B-cell lymphoma].	TP53
23053979	10.1007/s11033-012-1978-0	2012	p53 Codon 72 arginine/proline polymorphism and cancer in Sudan.	TP53
21127431	10.1097/MPH.0b013e3181edf543	2011	The RB (pRb2/p16) and p53 (p14/p53/p21) tumor-suppressor pathways in endemic Burkitt lymphoma.	TP53
21174181	10.1007/s12253-010-9335-x	2011	Aberrant cytoplasmic expression of cyclin B1 protein and its correlation with EBV-LMP1, P53 and P16(INK4A) in classical Hodgkin lymphoma in China.	TP53
21192060	10.1002/cncr.25826	2011	Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil.	TP53
21205967	10.1001/jama.2010.1919	2011	Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.	TP53
21345471	10.1016/j.medcli.2010.11.011	2011	[Li-Fraumeni syndrome].	TP53
21386967	10.1371/journal.pone.0017012	2011	Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia.	TP53
21390126	10.1038/nature09730	2011	Inactivating mutations of acetyltransferase genes in B-cell lymphoma.	TP53
21463115	10.3109/10428194.2011.557454	2011	Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population.	TP53
21487039	10.1158/0008-5472.CAN-10-4300	2011	Cytoplasmic CUL9/PARC ubiquitin ligase is a tumor suppressor and promotes p53-dependent apoptosis.	TP53
21546086	10.1016/j.leukres.2011.04.001	2011	No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma.	TP53
21619452	10.3109/10799893.2011.578140	2011	Cyclic AMP-induced p53 destabilization is independent of EPAC in pre-B acute lymphoblastic leukemia cells in vitro.	TP53
21720382	10.1038/leu.2011.162	2011	Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.	TP53
21738398	NA	2011	Expression of cell proliferation and apoptosis biomarkers in pterygia and normal conjunctiva.	TP53
21747090	10.1200/JCO.2011.34.8144	2011	Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.	TP53
21750659	10.1593/neo.11542	2011	Activation of cAMP signaling interferes with stress-induced p53 accumulation in ALL-derived cells by promoting the interaction between p53 and HDM2.	TP53
21764855	10.1101/gad.2069311	2011	Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas.	TP53
21852537	10.1101/gad.16722111	2011	Validation of MdmX as a therapeutic target for reactivating p53 in tumors.	TP53
21888455	006	2011	Molecular cytogenetic analysis of chemoresistant non-Hodgkin's lymphoma patients with p53 abnormalities using fluorescence in situ hybridisation and comparative genomic hybridisation.	TP53
21903579	10.1074/jbc.M111.272336	2011	p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.	TP53
22056774	10.1038/nsmb.2142	2011	Bilateral inhibition of HAUSP deubiquitinase by a viral interferon regulatory factor protein.	TP53
19586936	10.3324/haematol.2009.007526	2010	Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia.	TP53
20126990	10.3892/ijo_00000545	2010	Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma.	TP53
20130056	10.1128/JVI.01321-09	2010	Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas.	TP53
20181625	NA	2010	Molecular profiling using tissue microarrays as a tool to identify predictive biomarkers in laryngeal cancer treated with radiotherapy.	TP53
20346139	10.1186/1746-1596-5-19	2010	Expression and prognostic significance of Cox-2 and p-53 in Hodgkin lymphomas: a retrospective study.	TP53
20352431	10.1007/s00277-010-0945-x	2010	Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.	TP53
20369488	NA	2010	[Expression and significance of P53 and P21 in nasal NK/T-cell lymphoma].	TP53
20457152	10.1016/j.yexcr.2010.04.030	2010	Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells.	TP53
20575032	10.1002/ajh.21738	2010	A specific linkage between the incidence of TP53 mutations and type of chromosomal translocations in B-precursor acute lymphoblastic leukemia cell lines.	TP53
20734458	10.1002/ajh.21834	2010	Association with TP53 codon 72 polymorphism and the risk of non-Hodgkin lymphoma.	TP53
20807096	10.3109/10428194.2010.502584	2010	PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma.	TP53
20811663	10.3892/or.2010.851	2010	p53 mutation, but not in vitro predictor genes of therapeutic efficacy of cisplatin, is clinically relevant in comparing partial and complete responder cases of maxillary squamous cell carcinoma.	TP53
21131755	10.4103/0019-509X.73576	2010	Detection of B cell lymphoma 2, tumor protein 53, and FAS gene transcripts in blood cells of patients with breast cancer.	TP53
18540692	10.2350/07-11-0378.1	2009	Low frequency of Epstein Barr virus association and high frequency of p53 overexpression in an Argentinean pediatric T-cell lymphoma series.	TP53
18706692	10.1016/j.leukres.2008.06.022	2009	TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype.	TP53
18830263	10.1038/leu.2008.240	2009	Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma.	TP53
18972317	10.1080/00313020802441683	2009	Expression of the multidrug resistance protein MRP and the lung-resistance protein LRP in nasal NK/T cell lymphoma: further exploring the role of P53 and WT1 gene.	TP53
19029147	10.3324/haematol.13533	2009	Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma.	TP53
19046801	10.1016/j.canlet.2008.10.029	2009	TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.	TP53
19225536	10.1038/leu.2008.348	2009	Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.	TP53
19234440	10.1038/modpathol.2009.2	2009	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	TP53
19286999	10.1182/blood-2008-06-160168	2009	NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner.	TP53
19336552	10.1158/1055-9965.EPI-08-1037	2009	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development.	TP53
19347736	10.1080/10428190902763517	2009	MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes.	TP53
19347737	10.1080/10428190902763533	2009	Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.	TP53
19451550	10.1182/blood-2009-02-204883	2009	Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation.	TP53
19452712	NA	2009	[Expressions of p53 and p21 in nasal NK/T-cell lymphoma and their relationship with the proliferation and apoptosis of cells].	TP53
19500100	10.1111/j.1365-2141.2009.07739.x	2009	The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target.	TP53
19573080	10.1111/j.1365-2141.2009.07790.x	2009	Common genetic variants in candidate genes and risk of familial lymphoid malignancies.	TP53
19589272	10.1177/147323000903700332	2009	Comparison of the clinical and immunohistochemical features, including anaplastic lymphoma kinase (ALK) and p53, in inflammatory myofibroblastic tumours.	TP53
19594747	10.1111/j.1365-2141.2009.07791.x	2009	Detection of gene copy number aberrations in mantle cell lymphoma by a single quantitative multiplex PCR assay: clinicopathological relevance and prognosis value.	TP53
19608668	10.3324/haematol.2009.007260	2009	Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma.	TP53
19650989	NA	2009	[Relationship between p53 gene and chromosome 13q14 variations and prognosis in primary intestinal lymphoma].	TP53
19723045	10.1111/j.1749-6632.2009.04686.x	2009	Transforming growth factor-beta1 and regulators of apoptosis.	TP53
19773279	10.1136/oem.2008.044024	2009	Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity.	TP53
19799083	NA	2009	[Expression and significance of p53-related proteins and LMP-1 in nasal NK/T-cell lymphoma].	TP53
19837266	10.1016/j.cancergencyto.2009.05.009	2009	TP53 R72P and MDM2 SNP309 polymorphisms in modification of childhood acute lymphoblastic leukemia susceptibility.	TP53
19941740	10.1179/102453309X12473408860389	2009	Frequency and prognostic significance of murine double minute protein-2 overexpression and p53 gene mutations in childhood acute lymphoblastic leukemia.	TP53
20160358	10.4103/0973-1482.59901	2009	Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma.	TP53
17728781	10.1038/sj.leu.2404929	2008	Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine.	TP53
17982487	10.1038/sj.onc.1210901	2008	Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma.	TP53
18165800	10.1038/modpathol.3800993	2008	Presence of simian virus 40 in diffuse large B-cell lymphomas in Tunisia correlates with germinal center B-cell immunophenotype, t(14;18) translocation, and P53 accumulation.	TP53
18297513	10.1080/10428190801950041	2008	Accumulating evidence for a role of p53 in multiple drug resistant acute myeloid leukemia.	TP53
18433491	10.1186/1471-2407-8-116	2008	MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians.	TP53
18467333	10.1074/jbc.M709695200	2008	Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma.	TP53
18559976	10.1182/blood-2008-01-129783	2008	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.	TP53
18593934	10.1158/0008-5472.CAN-07-5876	2008	c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.	TP53
18616513	10.1111/j.1600-0609.2008.01113.x	2008	Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.	TP53
18628487	10.1182/blood-2008-05-154013	2008	The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.	TP53
18669630	10.1074/jbc.M804433200	2008	A central role for CK1 in catalyzing phosphorylation of the p53 transactivation domain at serine 20 after HHV-6B viral infection.	TP53
18813817	NA	2008	An unusual p53 mutation detected in Burkitt's lymphoma: 30 bp duplication.	TP53
18949611	10.1080/10428190802345902	2008	Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation.	TP53
16988840	10.1007/s00432-006-0152-2	2007	Analysis of p53 and Bak gene mutations in lymphoproliferative disorders developing in rheumatoid arthritis.	TP53
17364023	10.1172/JCI30945	2007	Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.	TP53
17545546	10.1158/1078-0432.CCR-06-2581	2007	Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.	TP53
17587242	10.1111/j.1440-1827.2007.02119.x	2007	Missense mutation with/without nonsense mutation of the p53 gene is associated with large cell morphology in human malignant lymphoma.	TP53
17609875	10.1007/s10238-007-0124-0	2007	Mutation of the p53 tumour suppressor gene and overexpression of its protein in 62 Japanese non-Hodgkin's lymphomas.	TP53
17613764	10.1080/10428190701402903	2007	Characterization of genetic changes in MCL by interphase FISH on tissue sections.	TP53
17692879	10.1016/j.toxicon.2007.06.018	2007	A crystalline compound (BM-ANF1) from the Indian toad (Bufo melanostictus, Schneider) skin extract, induced antiproliferation and apoptosis in leukemic and hepatoma cell line involving cell cycle proteins.	TP53
17693666	10.1093/carcin/bgm172	2007	Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck.	TP53
17695524	NA	2007	Alterations of the p53, Rb and p27 tumor suppressor pathways in diffuse large B-cell lymphomas.	TP53
17881637	10.1182/blood-2007-02-072082	2007	Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.	TP53
17890905	10.4161/cc.6.18.4730	2007	p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas.	TP53
17990259	10.1002/elps.200600831	2007	Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma.	TP53
18365550	NA	2007	Detection of t(14;18), P53 and RAS gene mutations and quantification of residual disease in patients with B-cell non-Hodgkin's lymphoma.	TP53
16249378	10.1182/blood-2005-04-1629	2006	BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma.	TP53
16331255	10.1038/sj.onc.1209282	2006	Hodgkin's lymphoma cells express alternatively spliced forms of HDM2 with multiple effects on cell cycle control.	TP53
16432227	10.1073/pnas.0507367103	2006	ATM promotes apoptosis and suppresses tumorigenesis in response to Myc.	TP53
16455055	10.1016/j.bbrc.2006.01.036	2006	Evidence for the interaction of the regulatory protein Ki-1/57 with p53 and its interacting proteins.	TP53
16532027	10.1038/sj.onc.1209480	2006	Constitutive STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis.	TP53
16569765	10.1182/blood-2006-01-0067	2006	Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence.	TP53
16595680	10.1074/jbc.M513810200	2006	KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia.	TP53
16690525	10.1080/10428190500361128	2006	Expression of ice, bcl-2, c-myc and p53 in different bone marrow cell populations from patients with diffuse large B-cell lymphoma.	TP53
16773719	10.3748/wjg.v12.i22.3602	2006	Roles of syndecan-1, bcl6 and p53 in diagnosis and prognostication of immunoproliferative small intestinal disease.	TP53
17065008	10.1080/10428190600667721	2006	Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma.	TP53
17069461	10.1371/journal.ppat.0020116	2006	EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors.	TP53
17107393	10.1111/j.1365-2133.2006.07527.x	2006	Association of p53 Arg72Pro polymorphism and beta-catenin accumulation in mycosis fungoides.	TP53
15632067	10.1128/MCB.25.2.661-670.2005	2005	Functional interaction of H2AX, NBS1, and p53 in ATM-dependent DNA damage responses and tumor suppression.	TP53
15713979	NA	2005	The role of p53 and anaplastic lymphoma kinase genes in the progression of cutaneous CD30(+) lymphoproliferative diseases.	TP53
15878620	10.1016/j.leukres.2005.04.006	2005	Aberrant expression of tumor suppressor genes and their association with chimeric oncogenes in pediatric acute lymphoblastic leukemia.	TP53
15902285	10.1038/sj.leu.2403802	2005	A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.	TP53
15969767	10.1186/1471-2172-6-12	2005	Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors.	TP53
16094360	10.1038/nature03845	2005	Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.	TP53
16112647	10.1016/j.bbrc.2005.08.026	2005	Transcriptional repression of the eukaryotic initiation factor 4E gene by wild type p53.	TP53
16131817	10.1159/000087980	2005	TP53 gene mutation, an unfavorable prognostic factor for malignant lymphomas in autoimmune diseases.	TP53
14994997	10.1615/jenvpathtoxoncol.v23.i1.70	2004	p53 binding to target sites is dynamically regulated before and after ionizing radiation-mediated DNA damage.	TP53
15061204	10.1080/1042819031000147009	2004	Lack of prognostic significance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry.	TP53
15291355	10.1080/10428190310001638878	2004	Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese.	TP53
15351976	10.1002/cyto.b.20013	2004	Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.	TP53
15378026	10.1038/sj.onc.1207908	2004	Wild-type p53 activates SAP expression in lymphoid cells.	TP53
15577913	10.1038/nature03147	2004	The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.	TP53
12562237	10.5858/2003-127-208-EOPMOB	2003	Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals.	TP53
12592393	10.1038/sj.onc.1206236	2003	Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients.	TP53
12749011	10.1002/ajh.10333	2003	Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.	TP53
12808109	10.1128/MCB.23.13.4713-4727.2003	2003	p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1.	TP53
12824925	10.1111/j.1349-7006.2003.tb01436.x	2003	Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China.	TP53
12854888	10.1080/1042819031000067620	2003	Configuration of the TP53 gene as an independent prognostic parameter of myelodysplastic syndrome.	TP53
12901974	10.1016/s0301-472x(03)00159-0	2003	Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth.	TP53
14559824	NA	2003	PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.	TP53
14673037	10.1200/JCO.2003.12.042	2003	TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.	TP53
14689061	NA	2003	Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.	TP53
11818669	10.1159/000046626	2002	Apoptosis-regulating proteins and prognosis in diffuse large B cell non-Hodgkin's lymphomas.	TP53
11839577	10.1016/S0002-9440(10)64876-6	2002	Nucleolar p14(ARF) overexpression in Reed-Sternberg cells in Hodgkin's lymphoma: absence of p14(ARF)/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts.	TP53
11914273	10.1101/gad.929302	2002	A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling.	TP53
11999565	10.1080/1042819029000611610	2002	Expression of P53 and bcl-2 proteins in T-cell lymphoblastic lymphoma: prognostic implications.	TP53
12036888	10.1182/blood.v99.12.4554	2002	Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.	TP53
12217802	NA	2002	Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement.	TP53
12235242	10.1124/jpet.102.037192	2002	DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells.	TP53
12421820	10.1074/jbc.C200578200	2002	Acetylation of p53 inhibits its ubiquitination by Mdm2.	TP53
11733360	10.1016/S0002-9440(10)63061-1	2001	p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease.	TP53
11764099	10.1080/088800101753328466	2001	MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors.	TP53
11949843	NA	2001	Expression of p53 and bcl-2 proteins in acute leukemias: an immunocytochemical study.	TP53
9419979	10.1038/sj.onc.1201668	1997	Drastic genetic instability of tumors and normal tissues in Turcot syndrome.	TP53
9444950	10.1038/sj.onc.1201492	1997	Identification of RB18A, a 205 kDa new p53 regulatory protein which shares antigenic and functional properties with p53.	TP53
7753047	10.1016/0161-5890(95)00005-y	1995	Binding sites of the Epstein-Barr virus and C3d receptor (CR2, CD21) for its three intracellular ligands, the p53 anti-oncoprotein, the p68 calcium binding protein and the nuclear p120 ribonucleoprotein.	TP53
8221626	10.1016/0304-3835(93)90256-9	1993	Alternative splicing of the p53 tumor suppressor gene in the Molt-4 T-lymphoblastic leukemia cell line.	TP53
1303181	10.1093/hmg/1.3.207	1992	A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.	TP53
1437144	NA	1992	p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas.	TP53
1737852	10.1172/JCI115630	1992	Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia.	TP53
1915267	10.1002/j.1460-2075.1991.tb07837.x	1991	p53 is frequently mutated in Burkitt's lymphoma cell lines.	TP53
35089437	10.1007/s00018-022-04139-y	2022	A20 undermines alternative NF-Œ∫B activity and expression of anti-apoptotic genes in Helicobacter pylori infection.	TRAF3
35332215	10.1038/s41598-022-09112-0	2022	Evaluation of 41 single nucleotide polymorphisms in canine diffuse large B-cell lymphomas using MassARRAY.	TRAF3
35726023	10.1038/s41684-022-00998-x	2022	The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications.	TRAF3
35789025	10.1002/hon.3045	2022	Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.	TRAF3
33184494	10.1038/s41375-020-01088-y	2021	A novel model of alternative NF-Œ∫B pathway activation in anaplastic large cell lymphoma.	TRAF3
33206936	10.1182/blood.2020005650	2021	Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.	TRAF3
33503336	10.1002/cnr2.1335	2021	Novel germline TRAF3IP3 mutation in a dyad with familial acute B lymphoblastic leukemia.	TRAF3
33639170	10.1016/j.jbc.2021.100465	2021	TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells.	TRAF3
33847741	10.1182/bloodadvances.2020003431	2021	Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen.	TRAF3
34202989	10.3390/pharmaceutics13060911	2021	ChoK-Full of Potential: Choline Kinase in B Cell and T Cell Malignancies.	TRAF3
34255829	10.1182/blood.2021011247	2021	DYRK1a mediates BAFF-induced noncanonical NF-Œ∫B activation to promote autoimmunity and B-cell leukemogenesis.	TRAF3
34651869	10.1002/hon.2933	2021	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.	TRAF3
31666375	10.1128/JVI.01553-19	2020	USP7-Dependent Regulation of TRAF Activation and Signaling by a Viral Interferon Regulatory Factor Homologue.	TRAF3
32038991	10.3389/fonc.2020.00023	2020	The Genetic and Molecular Basis for Canine Models of Human Leukemia and Lymphoma.	TRAF3
32773475	10.1097/QAD.0000000000002653	2020	Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV.	TRAF3
33154951	10.3389/fonc.2020.591577	2020	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	TRAF3
33323169	10.1016/j.tvjl.2020.105575	2020	The prevalence and characterisation of TRAF3 and POT1 mutations in canine B-cell lymphoma.	TRAF3
30563911	10.1101/gr.241141.118	2019	Human papillomavirus and the landscape of secondary genetic alterations in oral cancers.	TRAF3
31320741	10.1038/s41598-019-46906-1	2019	Systematic Review of Somatic Mutations in Splenic Marginal Zone Lymphoma.	TRAF3
31378966	10.1002/ajh.25600	2019	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.	TRAF3
29765142	10.1038/s41379-018-0064-0	2018	Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement.	TRAF3
30018073	10.1084/jem.20180210	2018	CRL4<sup>DCAF2</sup> negatively regulates IL-23 production in dendritic cells and limits the development of psoriasis.	TRAF3
30687320	10.3389/fimmu.2018.03114	2018	Dysregulated TRAF3 and BCL2 Expression Promotes Multiple Classes of Mature Non-hodgkin B Cell Lymphoma in Mice.	TRAF3
28682481	10.1002/path.4933	2017	Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma.	TRAF3
29296923	10.1182/bloodadvances.2017009670	2017	The oncogenic membrane protein LMP1 sequesters TRAF3 in B-cell lymphoma cells to produce functional TRAF3 deficiency.	TRAF3
26740054	10.1016/j.leukres.2015.12.005	2016	Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.	TRAF3
26755589	10.1073/pnas.1514586113	2016	Nuclear TRAF3 is a negative regulator of CREB in B cells.	TRAF3
27752131	10.1038/srep35349	2016	TRAF3 deficiency promotes metabolic reprogramming in B cells.	TRAF3
25428260	10.1038/leu.2014.330	2015	KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.	TRAF3
25468570	10.1182/blood-2014-10-602714	2015	Genetic inactivation of TRAF3 in canine and human B-cell lymphoma.	TRAF3
25921526	10.1016/j.celrep.2015.03.059	2015	An oncogenic role for alternative NF-Œ∫B signaling in DLBCL revealed upon deregulated BCL6 expression.	TRAF3
25960828	10.4172/1948-5956.1000327	2015	Targeting TRAF3 Downstream Signaling Pathways in B cell Neoplasms.	TRAF3
26308964	10.1080/15592294.2015.1078050	2015	Integrated methylome and transcriptome analysis reveals novel regulatory elements in pediatric acute lymphoblastic leukemia.	TRAF3
26377837	10.1101/gr.194449.115	2015	Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background.	TRAF3
24362935	10.1038/nm.3435	2014	Pharmacological and genomic profiling identifies NF-Œ∫B-targeted treatment strategies for mantle cell lymphoma.	TRAF3
24418753	10.1016/j.leukres.2013.12.016	2014	Expression and function of a novel isoform of Sox5 in malignant B cells.	TRAF3
24739416	10.4161/cc.28895	2014	The TRAF3 adaptor protein drives proliferation of anaplastic large cell lymphoma cells by regulating multiple signaling pathways.	TRAF3
25200342	10.1186/s13045-014-0056-6	2014	Mutated in colorectal cancer (MCC) is a novel oncogene in B lymphocytes.	TRAF3
23333941	10.1016/j.gene.2012.12.026	2013	Identification and characterization of receptor-interacting protein 2 as a TNFR-associated factor 3 binding partner.	TRAF3
23868181	10.1002/path.4239	2013	Constitutive activation of distinct NF-Œ∫B signals in EBV-associated nasopharyngeal carcinoma.	TRAF3
24131623	10.1186/1471-2407-13-481	2013	N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.	TRAF3
24239354	10.1016/j.celrep.2013.10.022	2013	Context-specific BAFF-R signaling by the NF-Œ∫B and PI3K pathways.	TRAF3
24260396	10.1371/journal.pone.0080470	2013	SUMOylation is required for optimal TRAF3 signaling capacity.	TRAF3
22033491	10.1038/leu.2011.309	2012	Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice.	TRAF3
22469134	10.1111/j.1365-2141.2012.09113.x	2012	Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma.	TRAF3
22711886	10.4049/jimmunol.1200814	2012	TNFR-associated factor 2 deficiency in B lymphocytes predisposes to chronic lymphocytic leukemia/small lymphocytic lymphoma in mice.	TRAF3
20889926	10.1182/blood-2010-06-290437	2011	Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-Œ∫B-inducing kinase while activating both canonical and alternative nuclear factor-Œ∫B pathways.	TRAF3
21228035	10.3324/haematol.2010.030577	2011	Polymorphisms of nuclear factor-Œ∫B family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.	TRAF3
21454205	10.3816/CLML.2011.n.021	2011	High-throughput genomic analysis in Waldenstr√∂m's macroglobulinemia.	TRAF3
21881048	10.1182/blood-2011-06-359166	2011	Alteration of BIRC3 and multiple other NF-Œ∫B pathway genes in splenic marginal zone lymphoma.	TRAF3
20410275	10.1128/JVI.00344-10	2010	Epstein-Barr virus latent membrane protein 1 modulates distinctive NF- kappaB pathways through C-terminus-activating region 1 to regulate epidermal growth factor receptor expression.	TRAF3
21041452	10.1084/jem.20100857	2010	A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling.	TRAF3
19540595	10.1016/j.molimm.2009.05.178	2009	TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells.	TRAF3
19667091	10.4049/jimmunol.0900442	2009	Roles of the TRAF2/3 binding site in differential B cell signaling by CD40 and its viral oncogenic mimic, LMP1.	TRAF3
19693093	10.1038/leu.2009.149	2009	Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33).	TRAF3
19698991	10.1016/j.molimm.2009.07.029	2009	TNF receptor-associated factor 1 is a positive regulator of the NF-kappaB alternative pathway.	TRAF3
19917778	10.1084/jem.20091802	2009	Differential requirement of MALT1 for BAFF-induced outcomes in B cell subsets.	TRAF3
19954665	NA	2009	[The action mechanisms of unclassical NF-kappaB activity and TRAF3 expression in Hodgkin's lymphoma cells].	TRAF3
18042799	10.1182/blood-2007-07-100032	2008	The LMP1 oncogene of EBV activates PERK and the unfolded protein response to drive its own synthesis.	TRAF3
17878343	10.4049/jimmunol.179.7.4473	2007	Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B.	TRAF3
16247482	10.1038/sj.onc.1209023	2006	LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice.	TRAF3
15386359	10.1002/ijc.20503	2005	TRAF interactions with raft-like buoyant complexes, better than TRAF rates of degradation, differentiate signaling by CD40 and EBV latent membrane protein 1.	TRAF3
15514968	10.1002/ijc.20654	2005	In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2.	TRAF3
15914563	10.1182/blood-2004-10-3898	2005	Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis.	TRAF3
16227255	10.1128/JVI.79.21.13326-13337.2005	2005	In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin.	TRAF3
15663562	10.1111/j.1365-2222.2004.02119.x	2004	Biological effects of montelukast, a cysteinyl-leukotriene receptor-antagonist, on T lymphocytes.	TRAF3
12972530	10.1200/JCO.2003.09.037	2003	Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.	TRAF3
12220533	10.1016/s0003-9861(02)00369-7	2002	CD40-mediated tumor necrosis factor receptor-associated factor 3 signaling upregulates IL-4-induced germline Cepsilon transcription in a human B cell line.	TRAF3
12471121	10.4049/jimmunol.169.12.6883	2002	TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production.	TRAF3
11600226	10.1016/s0198-8859(01)00284-1	2001	Expression and function of TRAF-3 splice-variant isoforms in human lymphoma cell lines.	TRAF3
11023520	NA	2000	Hodgkin disease: pharmacologic intervention of the CD40-NF kappa B pathway by a protease inhibitor.	TRAF3
11046039	10.4049/jimmunol.165.9.5084	2000	TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies.	TRAF3
11144929	10.1038/modpathol.3880243	2000	Expression of the tumor necrosis factor receptor-associated factors (TRAFs) 1 and 2 is a characteristic feature of Hodgkin and Reed-Sternberg cells.	TRAF3
10187771	10.1074/jbc.274.15.9962	1999	Equine herpesvirus-2 E10 gene product, but not its cellular homologue, activates NF-kappaB transcription factor and c-Jun N-terminal kinase.	TRAF3
10202013	NA	1999	An 11-amino acid sequence in the cytoplasmic domain of CD40 is sufficient for activation of c-Jun N-terminal kinase, activation of MAPKAP kinase-2, phosphorylation of I kappa B alpha, and protection of WEHI-231 cells from anti-IgM-induced growth arrest.	TRAF3
10225457	10.1002/(sici)1097-0215(19990517)81:4&lt;645::aid-ijc22&gt;3.0.co;2-0	1999	Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells.	TRAF3
10400794	10.1128/JVI.73.8.6953-6963.1999	1999	Identification of a spliced gene from Kaposi's sarcoma-associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein-Barr virus.	TRAF3
10509816	10.1016/s0161-5890(99)00079-6	1999	TRAF-3 mRNA splice-deletion variants encode isoforms that induce NF-kappaB activation.	TRAF3
9990039	10.1073/pnas.96.4.1421	1999	Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation.	TRAF3
9516144	NA	1998	Gene expression by single Reed-Sternberg cells: pathways of apoptosis and activation.	TRAF3
9580648	10.1056/NEJM199805143382003	1998	Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients.	TRAF3
9686578	NA	1998	TNF receptor-associated factor-3 signaling mediates activation of p38 and Jun N-terminal kinase, cytokine secretion, and Ig production following ligation of CD40 on human B cells.	TRAF3
9032281	10.1128/MCB.17.3.1535	1997	Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2.	TRAF3
9037073	10.1073/pnas.94.4.1447	1997	The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation.	TRAF3
9168896	10.1006/bbrc.1997.6509	1997	Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily.	TRAF3
9366415	NA	1997	Characterization of CD40 signaling determinants regulating nuclear factor-kappa B activation in B lymphocytes.	TRAF3
8663299	10.1074/jbc.271.25.14661	1996	TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor.	TRAF3
35938041	10.3389/fgene.2022.940513	2022	Case Report: Immune Microenvironment and Mutation Features in a Patient With Epstein-Barr Virus Positive Large B-Cell Lymphoma Secondary to Angioimmunoblastic T-Cell Lymphoma.	TRIP12
31648321	10.1182/bloodadvances.2019000404	2019	Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.	TRIP12
35151693	10.1016/j.jbc.2022.101714	2022	Interaction of transcription factor FoxO3 with histone acetyltransferase complex subunit TRRAP modulates gene expression and apoptosis.	TRRAP
31563285	10.1016/j.prp.2019.152651	2019	Targeted next-generation sequencing revealed distinct clinicopathologic and molecular features of VCL-ALK RCC: A unique case from an older patient without clinical evidence of sickle cell trait.	TRRAP
29653964	10.1182/blood-2017-09-806679	2018	TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.	TRRAP
30401751	10.1182/bloodadvances.2018022962	2018	Insights into the genomic landscape of MYD88 wild-type Waldenstr√∂m macroglobulinemia.	TRRAP
28694326	10.1182/blood-2017-02-768234	2017	Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).	TRRAP
27835906	10.18632/oncotarget.13239	2016	Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.	TRRAP
23044487	10.1038/leu.2012.265	2013	GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia.	TRRAP
24349473	10.1371/journal.pone.0083244	2013	Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.	TRRAP
30802265	10.1371/journal.pone.0212813	2019	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.	UBE2A
26124562	10.6026/97320630011207	2015	Identification of collaborative activities with oxidative phosphorylation in bipolar disorder.	UBE2A
25171927	10.1182/blood-2013-12-546309	2014	Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients.	UBE2A
32325489	10.1182/blood.2019002102	2020	UBR5 HECT domain mutations identified in mantle cell lymphoma control maturation of B cells.	UBR5
32934672	10.3892/etm.2020.9135	2020	UBR5 oncogene as an indicator of poor prognosis in gastric cancer.	UBR5
29441057	10.3389/fmicb.2018.00080	2018	Stability of the HTLV-1 Antisense-Derived Protein, HBZ, Is Regulated by the E3 Ubiquitin-Protein Ligase, UBR5.	UBR5
28707666	10.7868/S0026898417030132	2017	[Identification of proteins associated with transcription factors HOXA9 and E2A-PBX1 by tandem affinity purification].	UBR5
26446488	10.1038/ncomms9325	2015	LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair.	UBR5
26464214	10.1158/1541-7786.MCR-15-0383	2015	Functional Roles of the E3 Ubiquitin Ligase UBR5 in Cancer.	UBR5
24857884	10.1097/MOH.0000000000000057	2014	Do mantle cell lymphomas have an 'Achilles heel'?	UBR5
23407552	10.1182/blood-2013-01-478834	2013	The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.	UBR5
20544796	10.1002/jcb.22624	2010	alpha4 phosphoprotein interacts with EDD E3 ubiquitin ligase and poly(A)-binding protein.	UBR5
35411950	10.1002/cbf.3702	2022	USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.	USP7
33634864	10.1002/ijc.33527	2021	Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis.	USP7
33650720	10.1111/jvim.16082	2021	Ubiquitin-specific protease 7 as a potential therapeutic target in dogs with hematopoietic malignancies.	USP7
33664368	10.1038/s41598-021-84647-2	2021	Integrative network analysis reveals USP7 haploinsufficiency inhibits E-protein activity in pediatric T-lineage acute lymphoblastic leukemia (T-ALL).	USP7
34061780	10.1172/JCI146893	2021	TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.	USP7
34454635	10.1186/s40364-021-00320-w	2021	Deubiquitinases in hematological malignancies.	USP7
34523970	10.1128/JVI.01459-21	2021	The ORF45 Protein of Kaposi Sarcoma-Associated Herpesvirus Is an Inhibitor of p53 Signaling during Viral Reactivation.	USP7
31666375	10.1128/JVI.01553-19	2020	USP7-Dependent Regulation of TRAF Activation and Signaling by a Viral Interferon Regulatory Factor Homologue.	USP7
32444465	10.1158/2159-8290.CD-19-1436	2020	Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia.	USP7
30617194	10.1182/blood-2018-09-871418	2019	Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma.	USP7
30938820	10.1093/jnci/djz043	2019	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children.	USP7
29343584	10.1128/JVI.02003-17	2018	Human Herpesvirus 8 Interferon Regulatory Factors 1 and 3 Mediate Replication and Latency Activities via Interactions with USP7 Deubiquitinase.	USP7
28157215	10.1038/bcj.2017.3	2017	Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia.	USP7
24710217	10.1038/ncomms4630	2014	The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes.	USP7
23665184	10.1016/j.jhep.2013.04.031	2013	Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.	USP7
22514345	10.1128/JVI.06840-11	2012	The ubiquitin-specific protease USP7 modulates the replication of Kaposi's sarcoma-associated herpesvirus latent episomal DNA.	USP7
23022380	10.1016/j.molcel.2012.08.022	2012	NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function.	USP7
22056774	10.1038/nsmb.2142	2011	Bilateral inhibition of HAUSP deubiquitinase by a viral interferon regulatory factor protein.	USP7
20074048	10.1042/BST0380137	2010	The therapeutic potential of deubiquitinating enzyme inhibitors.	USP7
15359630	10.1080/10428190410001663635	2004	Ubiquitin ligases in malignant lymphoma.	USP7
35301414	10.1038/s41379-022-01022-w	2022	Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations.	VAV1
35326399	10.3390/cells11060949	2022	Vav1 Promotes B-Cell Lymphoma Development.	VAV1
35443168	10.1016/j.celrep.2022.110695	2022	Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T¬†cell lymphoma.	VAV1
35895495	10.1002/1878-0261.13295	2022	Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model.	VAV1
35954378	10.3390/cancers14153716	2022	Mutations Affecting Genes in the Proximal T-Cell Receptor Signaling Pathway in Peripheral T-Cell Lymphoma.	VAV1
32606318	10.1038/s41375-020-0937-3	2021	PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis.	VAV1
34147695	10.1016/j.jmoldx.2021.04.013	2021	Detection of Gene Fusion Transcripts in Peripheral T-Cell Lymphoma Using a Multiplexed Targeted Sequencing Assay.	VAV1
34258755	10.1111/bjh.17639	2021	Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).	VAV1
34417435	10.1038/s41392-021-00730-0	2021	BCL9 regulates CD226 and CD96 checkpoints in CD8<sup>+</sup> T cells to improve PD-1 response in cancer.	VAV1
34617326	10.15252/embj.2021108125	2021	Cancer-associated mutations in VAV1 trigger variegated signaling outputs and T-cell lymphomagenesis.	VAV1
29313423	10.1080/21541248.2018.1423851	2020	Rho guanosine nucleotide exchange factors are not such bad guys after all in cancer<sup>a</sup>.	VAV1
31859368	10.1002/path.5376	2020	Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell.	VAV1
32107212	10.1158/0008-5472.CAN-19-2787	2020	Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma.	VAV1
32992343	10.1182/blood.2020006513	2020	VAV1 mutations contribute to development of T-cell neoplasms in mice.	VAV1
27898263	10.1080/21541248.2016.1263718	2019	Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas.	VAV1
30833082	10.1016/j.bbrc.2019.02.108	2019	The interaction between Vav1 and EBNA1 promotes survival of Burkitt's lymphoma cells by down-regulating the expression of Bim.	VAV1
28832024	10.1038/leu.2017.273	2018	Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.	VAV1
29200404	10.1172/JCI94509	2018	STAT5BN642H is a driver mutation for T cell neoplasia.	VAV1
29682742	10.1111/eci.12939	2018	Rac-GTPases and Rac-GEFs in neutrophil adhesion, migration and recruitment.	VAV1
30250888	10.1080/23723556.2018.1432257	2018	An unexpected tumor suppressor role for VAV1<sup>a</sup>.	VAV1
28062691	10.1073/pnas.1608839114	2017	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.	VAV1
28627735	10.1111/cas.13303	2017	Genetic alterations in adult T-cell leukemia/lymphoma.	VAV1
28694326	10.1182/blood-2017-02-768234	2017	Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E).	VAV1
29136506	10.1016/j.ccell.2017.10.004	2017	A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia.	VAV1
27169444	10.11406/rinketsu.57.417	2016	[Genetic landscape of adult T-cell leukemia/lymphoma].	VAV1
27297792	10.1182/blood-2016-03-707141	2016	Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.	VAV1
27669408	10.1371/journal.pone.0163011	2016	Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.	VAV1
26338970	10.18632/oncotarget.5009	2015	Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis.	VAV1
26437031	10.1038/ng.3415	2015	Integrated molecular analysis of adult T cell leukemia/lymphoma.	VAV1
24501217	10.1182/blood-2013-08-523563	2014	Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells.	VAV1
24534189	10.1084/jem.20131424	2014	Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance.	VAV1
23757206	10.1016/j.bmc.2013.05.021	2013	RNA-aptamers that modulate the RhoGEF activity of Tiam1.	VAV1
22432082	NA	2012	Vav1 in hematologic neoplasms, a mini review.	VAV1
22683124	10.1016/j.immuni.2012.03.023	2012	The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells.	VAV1
22692505	10.1182/blood-2011-06-361709	2012	Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.	VAV1
22717125	10.1016/j.ejcb.2012.04.006	2012	Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells.	VAV1
23022380	10.1016/j.molcel.2012.08.022	2012	NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function.	VAV1
20007546	10.1182/blood-2009-04-216184	2010	Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice.	VAV1
20155735	10.1002/hon.935	2010	Vav-1 expression correlates with NFŒ∫B activation and CD40-mediated cell death in diffuse large B-cell lymphoma cell lines.	VAV1
20011522	10.1371/journal.pone.0008229	2009	The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasis.	VAV1
18227156	10.1128/MCB.01505-07	2008	T-cell receptor-induced NF-kappaB activation is negatively regulated by E3 ubiquitin ligase Cbl-b.	VAV1
18974134	10.1158/0008-5472.CAN-08-2568	2008	The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.	VAV1
16289966	10.1016/j.cellsig.2005.10.001	2006	Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human B lymphoma cell surface triggers Cbl tyrosine phosphorylation, its association with p85 subunit, Crk-L and Syk and its dissociation with Vav.	VAV1
15345594	10.1182/blood-2003-08-2965	2005	The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor.	VAV1
15661896	10.4049/jimmunol.174.3.1385	2005	Kinase-independent functions for Itk in TCR-induced regulation of Vav and the actin cytoskeleton.	VAV1
15661906	10.4049/jimmunol.174.3.1472	2005	Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b.	VAV1
15964830	10.1128/MCB.25.13.5777-5785.2005	2005	Generation of rac3 null mutant mice: role of Rac3 in Bcr/Abl-caused lymphoblastic leukemia.	VAV1
14630790	10.1182/blood-2003-07-2469	2004	VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia.	VAV1
14673152	10.1128/MCB.24.1.164-171.2003	2004	CD3/CD28 costimulation-induced NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkappaB kinase beta to the immunological synapse through CARMA1.	VAV1
12848851	10.1046/j.0818-9641.2003.01172.x	2003	Knockout B lymphoma cell lines as biochemical tools to explore multiple signalling pathways.	VAV1
14586401	10.1038/sj.onc.1207048	2003	Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.	VAV1
11846804	10.1046/j.0014-2956.2001.02741.x	2002	Transient activation of the c-Jun N-terminal kinase (JNK) activity by ligation of the tetraspan CD53 antigen in different cell types.	VAV1
12353912	10.1385/MB:22:1:025	2002	Functional cloning using pFB retroviral cDNA expression libraries.	VAV1
10232389	10.1016/s0165-2478(98)00142-4	1999	Apoptosis of thymic lymphoma clones by thymic epithelial cells: a putative model for 'death by neglect'.	VAV1
9886379	NA	1999	Signaling through the EBV/C3d receptor (CR2, CD21) in human B lymphocytes: activation of phosphatidylinositol 3-kinase via a CD19-independent pathway.	VAV1
10221598	10.1385/ENDO:9:3:313	1998	Prolactin receptor signaling: shared components with the T-cell antigen receptor in Nb2 lymphoma cells.	VAV1
9040011	10.1093/intimm/9.2.291	1997	Targets of p56(lck) activity in immature thymoblasts: stimulation of the Ras/Raf/MAPK pathway.	VAV1
9168816	10.1006/excr.1997.3535	1997	Expression of the vav oncogene in somatic cell hybrids.	VAV1
9178638	10.1006/cimm.1997.1102	1997	CD40-triggered protein tyrosine phosphorylation on Vav and on phosphatidylinositol 3-kinase correlates with survival of the Ramos-Burkitt lymphoma B cell line.	VAV1
9341187	10.1074/jbc.272.43.27362	1997	Identification of two tyrosine phosphoproteins, pp70 and pp68, which interact with phospholipase Cgamma, Grb2, and Vav after B cell antigen receptor activation.	VAV1
8632004	10.1074/jbc.271.7.3856	1996	The tyrosine phosphatase PTP1C associates with Vav, Grb2, and mSos1 in hematopoietic cells.	VAV1
7508909	NA	1994	Interferon alpha induces rapid tyrosine phosphorylation of the vav proto-oncogene product in hematopoietic cells.	VAV1
7689723	NA	1993	Selective association of the p59fyn tyrosine kinase with murine T lymphoma membrane phosphoproteins.	VAV1
7690544	10.1042/bj2940339	1993	Interleukin-2 induces tyrosine phosphorylation of the vav proto-oncogene product in human T cells: lack of requirement for the tyrosine kinase lck.	VAV1
33883344	10.3960/jslrt.20033	2021	Detection of novel and recurrent conjoined genes in non-Hodgkin B-cell lymphoma.	VPS13B
30510251	10.1038/s41591-018-0262-9	2019	Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.	WAS
27694894	10.1038/onc.2016.366	2017	NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma.	WAS
23684068	10.1016/j.jaci.2013.03.046	2013	T-cell receptor ligation causes Wiskott-Aldrich syndrome protein degradation and F-actin assembly downregulation.	WAS
10068673	NA	1999	Involvement of wiskott-aldrich syndrome protein in B-cell cytoplasmic tyrosine kinase pathway.	WAS
8892607	NA	1996	Evidence that the Wiskott-Aldrich syndrome protein may be involved in lymphoid cell signaling pathways.	WAS
35398086	10.1016/j.envres.2022.113245	2022	Molecular docking and optical sensor studies based on 2,4-diamino pyrimidine-5-carbonitriles for detection of Hg<sup>2</sup>.	WEE1
35578798	10.1002/jcp.30777	2022	Neddylation inactivation affects cell cycle and apoptosis in sheep follicular granulosa cells.	WEE1
31919076	10.3324/haematol.2019.231126	2021	WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia.	WEE1
33414171	10.1158/0008-5472.CAN-20-1504	2021	CDK2-Mediated Upregulation of TNFŒ± as a Mechanism of Selective Cytotoxicity in Acute Leukemia.	WEE1
34390915	10.1016/j.dnarep.2021.103203	2021	Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies.	WEE1
32010435	10.1177/2040620719898373	2020	WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma.	WEE1
32314355	10.1111/bjh.16614	2020	The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma.	WEE1
32601814	10.1007/s11864-020-00763-7	2020	Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.	WEE1
32892059	10.1016/j.ctrv.2020.102090	2020	Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.	WEE1
33374413	10.3390/ijms22010122	2020	Tracking the Genetic Susceptibility Background of B-Cell Non-Hodgkin's Lymphomas from Genome-Wide Association Studies.	WEE1
30601995	10.1093/jn/nxy224	2019	Treatment with DHA Modifies the Response of MDA-MB-231 Breast Cancer Cells and Tumors from nu/nu Mice to Doxorubicin through Apoptosis and Cell Cycle Arrest.	WEE1
30967394	10.1182/bloodadvances.2018029660	2019	MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.	WEE1
31064869	10.1158/1535-7163.MCT-18-0919	2019	DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas.	WEE1
31123088	10.1158/0008-5472.CAN-18-2480	2019	Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.	WEE1
31341363	10.3748/wjg.v25.i26.3380	2019	Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells.	WEE1
31590241	10.3390/cancers11101494	2019	Isorhamnetin Induces Cell Cycle Arrest and Apoptosis Via Reactive Oxygen Species-Mediated AMP-Activated Protein Kinase Signaling Pathway Activation in Human Bladder Cancer Cells.	WEE1
31703356	10.3390/cancers11111743	2019	WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage.	WEE1
28025833	10.1111/bjh.14506	2018	Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.	WEE1
29175378	10.1016/j.leukres.2017.11.004	2018	Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.	WEE1
29217775	10.3324/haematol.2017.175992	2018	Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition.	WEE1
29367434	10.1074/mcp.RA117.000539	2018	Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation.	WEE1
29489886	10.1371/journal.pone.0193098	2018	Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.	WEE1
29617859	10.1093/femspd/fty013	2018	Human lung epithelial cells support human metapneumovirus persistence by overcoming apoptosis.	WEE1
30068368	10.1186/s13045-018-0641-1	2018	Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.	WEE1
27072241	10.4103/0973-1482.165861	2016	Tumour suppressive effects of WEE1 gene silencing in neuroblastomas.	WEE1
25428911	10.18632/oncotarget.2583	2015	Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.	WEE1
25594541	10.1667/RR13784.1	2015	The miR-15 family enhances the radiosensitivity of breast cancer cells by targeting G2 checkpoints.	WEE1
25744022	10.1038/cdd.2015.13	2015	The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs.	WEE1
26334102	10.18632/oncotarget.4830	2015	AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair.	WEE1
26439697	10.18632/oncotarget.5954	2015	Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.	WEE1
22333592	10.4161/cc.11.5.19519	2012	Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition.	WEE1
18416826	10.1186/1471-2407-8-106	2008	Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis.	WEE1
12406077	10.1046/j.1365-2141.2002.03834.x	2002	Monensin-mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis.	WEE1
9699647	NA	1998	Negative regulation of Wee1 expression and Cdc2 phosphorylation during p53-mediated growth arrest and apoptosis.	WEE1
8833397	10.3109/10428199609052423	1996	Role of tyrosine phosphorylation in radiation-induced cell cycle-arrest of leukemic B-cell precursors at the G2-M transition checkpoint.	WEE1
7531277	10.1007/BF00926071	1994	Changes of cell cycle-regulating genes in interferon-treated Daudi cells.	WEE1
34597466	10.1002/pbc.29361	2022	Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse.	WHSC1
35124168	10.1016/j.jsbmb.2022.106068	2022	Glucocorticoid receptor gene mutations confer glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.	WHSC1
33147938	10.3324/haematol.2020.259226	2021	Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations	WHSC1
33469000	10.1038/s41420-021-00402-6	2021	Histone methyltransferase WHSC1 inhibits colorectal cancer cell apoptosis via targeting anti-apoptotic BCL2.	WHSC1
31697823	10.1182/blood.2019002220	2020	Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.	WHSC1
32332049	10.1158/1541-7786.MCR-20-0092	2020	The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.	WHSC1
32826945	10.1038/s42003-020-01186-8	2020	Proteosomal degradation of NSD2 by BRCA1 promotes leukemia cell differentiation.	WHSC1
30171259	10.1038/s41388-018-0474-y	2019	An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.	WHSC1
30471851	10.1016/j.bbrc.2018.11.037	2019	Identification of LEM-14 inhibitor of the oncoprotein NSD2.	WHSC1
31221981	10.1038/s12276-019-0230-6	2019	The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.	WHSC1
29755111	10.1038/s41417-018-0022-5	2018	Genomic landscape and prognostic analysis of mantle cell lymphoma.	WHSC1
27872090	10.1158/0008-5472.CAN-16-1303	2017	Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia.	WHSC1
25790293	10.1038/ncomms7604	2015	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.	WHSC1
26294725	10.3324/haematol.2015.129692	2015	Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation.	WHSC1
23823660	10.1038/leu.2013.204	2014	Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies.	WHSC1
24682267	10.1182/blood-2013-07-517177	2014	The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.	WHSC1
24145436	10.1073/pnas.1314608110	2013	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.	WHSC1
35151098	10.1016/j.jinorgbio.2022.111750	2022	Toxicological mechanism of large amount of copper supplementation: Effects on endoplasmic reticulum stress and mitochondria-mediated apoptosis by Nrf2/HO-1 pathway-induced oxidative stress in the porcine myocardium.	XBP1
35453482	10.3390/biomedicines10040731	2022	Targeting c-Myc Unbalances UPR towards Cell Death and Impairs DDR in Lymphoma and Multiple Myeloma Cells.	XBP1
35626128	10.3390/cancers14102526	2022	IRE1Œ± Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies.	XBP1
35857791	10.1080/15548627.2022.2100105	2022	Lack of COL6/collagen VI causes megakaryocyte dysfunction by impairing autophagy and inducing apoptosis.	XBP1
36012375	10.3390/ijms23169113	2022	Concomitant Inhibition of IRE1Œ±/XBP1 Axis of UPR and PARP: A Promising Therapeutic Approach against c-Myc and Gammaherpesvirus-Driven B-Cell Lymphomas.	XBP1
32855532	10.1038/s41401-020-00505-3	2021	Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.	XBP1
32915195	10.1093/carcin/bgaa095	2021	Targeting of BCR-ABL1 and IRE1Œ± induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia.	XBP1
33513694	10.3390/biomedicines9020118	2021	IRE1 Alpha/XBP1 Axis Sustains Primary Effusion Lymphoma Cell Survival by Promoting Cytokine Release and STAT3 Activation.	XBP1
34093792	10.7150/jca.54952	2021	Aggregative Perivascular Tumor Cell Growth Pattern of Primary Central Nervous System Lymphomas Is Associated with Hypoxia-Related Endoplasmic Reticulum Stress.	XBP1
34112145	10.1186/s12935-021-01992-y	2021	The regulation of miR-320a/XBP1 axis through LINC00963 for endoplasmic reticulum stress and autophagy in diffuse large B-cell lymphoma.	XBP1
34514754	10.1631/jzus.B2100053	2021	Endoplasmic reticulum stress is involved in retinal injury induced by repeated transient spikes of intraocular pressure.	XBP1
34831075	10.3390/cells10112853	2021	High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors.	XBP1
35288480	10.26402/jpp.2021.5.13	2021	Does endoplasmic reticulum stress stimulate the apoptosis of granulosa cells in polycystic ovary syndrome?	XBP1
31286804	10.1080/15548627.2019.1635384	2020	New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.	XBP1
31725418	10.1097/PAP.0000000000000253	2020	Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches.	XBP1
31801863	10.1128/JVI.01555-19	2020	Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Thymidine Kinase (ORF21) by X-Box Binding Protein 1.	XBP1
32005067	10.21037/apm.2019.11.31	2020	Emulsified isoflurane protects beta cells against high glucose-induced apoptosis via inhibiting endoplasmic reticulum stress.	XBP1
32376649	10.4049/jimmunol.2000172	2020	Rapid Death of Follicular B Cells and Burkitt Lymphoma Cells Effectuated by Xbp1s.	XBP1
30068263	10.1080/10428194.2018.1485915	2019	Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.	XBP1
30348636	10.1158/1078-0432.CCR-18-1153	2019	Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma.	XBP1
30966844	10.1080/21505594.2019.1605803	2019	The roles of apoptosis, autophagy and unfolded protein response in arbovirus, influenza virus, and HIV infections.	XBP1
31453810	10.7554/eLife.47084	2019	Caspase-mediated cleavage of IRE1 controls apoptotic cell commitment during endoplasmic reticulum stress.	XBP1
31607324	10.19746/j.cnki.issn.1009-2137.2019.05.042	2019	[Deubiquitinase MYSM1 Regulates Differentiation of Human B Cells to Plasma Cells].	XBP1
29381485	10.1172/JCI95864	2018	IRE1Œ± RNase-dependent lipid homeostasis promotes survival in Myc-transformed cancers.	XBP1
29457838	10.1002/hep.29847	2018	Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.	XBP1
29474123	10.1089/jmf.2017.4103	2018	Neuroprotective Effects of the Methanol Extract of Kimchi, a Korean Fermented Vegetable Food, Mediated Via Suppression of Endoplasmic Reticulum Stress and Caspase Cascade Pathways in High-Cholesterol Diet-Fed Mice.	XBP1
29552625	10.1016/j.jcmgh.2017.11.016	2018	Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are¬†Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).	XBP1
29752433	10.1038/s41419-018-0593-y	2018	Palmitic acid, but not high-glucose, induced myocardial apoptosis is alleviated by N‚Äëacetylcysteine due to attenuated mitochondrial-derived ROS accumulation-induced endoplasmic reticulum stress.	XBP1
30038718	10.18632/oncotarget.25707	2018	MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways.	XBP1
31360094	10.2147/BLCTT.S142814	2018	Plasmablastic lymphoma: current perspectives.	XBP1
28167662	10.1182/blood-2016-09-741348	2017	Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth.	XBP1
28368397	10.1038/onc.2017.90	2017	Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.	XBP1
28843399	10.1016/j.neo.2017.08.001	2017	Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia.	XBP1
26491160	10.1128/JVI.01192-15	2016	Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1.	XBP1
26926179	10.1016/j.phymed.2015.12.011	2016	Cryptotanshinone deregulates unfolded protein response and eukaryotic initiation factor signaling in acute lymphoblastic leukemia cells.	XBP1
26993806	10.1073/pnas.1600557113	2016	Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2.	XBP1
27959929	10.1371/journal.pmed.1002197	2016	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.	XBP1
24356728	10.1007/s10238-013-0269-y	2015	Unfolded protein response inducers tunicamycin and dithiothreitol promote myeloma cell differentiation mediated by XBP-1.	XBP1
25670156	10.1016/j.drup.2014.12.001	2015	Molecular basis of resistance to proteasome inhibitors in hematological malignancies.	XBP1
25906181	10.1080/15548627.2015.1017187	2015	ATG16L1: A multifunctional susceptibility factor in Crohn disease.	XBP1
25984893	10.1080/15548627.2015.1034402	2015	The GST-BHMT assay reveals a distinct mechanism underlying proteasome inhibition-induced macroautophagy in mammalian cells.	XBP1
26289642	10.1182/blood-2015-02-626176	2015	The forkhead transcription factor FOXP1 represses human plasma cell differentiation.	XBP1
26360498	10.1038/modpathol.2015.99	2015	Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype.	XBP1
26497741	10.3892/ijmm.2015.2387	2015	Bushen Zhuangjin decoction inhibits TM-induced chondrocyte apoptosis mediated by endoplasmic reticulum stress.	XBP1
24143001	10.3324/haematol.2013.091702	2014	Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma.	XBP1
24496016	10.4161/cbt.27820	2014	Targeting the unfolded protein response, XBP1, and the NLRP3 inflammasome in fibrosis and cancer.	XBP1
24812669	10.1172/JCI73448	2014	Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival.	XBP1
24821775	10.1073/pnas.1400958111	2014	Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.	XBP1
24951965	10.1016/j.phrs.2014.06.003	2014	Protection afforded by pre- or post-treatment with 4-phenylbutyrate against liver injury induced by acetaminophen overdose in mice.	XBP1
24980813	10.18632/oncotarget.2027	2014	A novel copper(I) complex induces ER-stress-mediated apoptosis and sensitizes B-acute lymphoblastic leukemia cells to chemotherapeutic agents.	XBP1
25941621	10.4161/21624011.2014.955691	2014	Consensus guidelines for the detection of immunogenic cell death.	XBP1
23482670	10.1093/neuonc/not012	2013	Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma.	XBP1
23599149	10.1038/modpathol.2013.73	2013	ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements.	XBP1
23678173	10.1128/JVI.00506-13	2013	Activation of the B cell antigen receptor triggers reactivation of latent Kaposi's sarcoma-associated herpesvirus in B cells.	XBP1
23828564	10.1038/cddis.2013.236	2013	Endoplasmic reticulum stress sensitizes pancreatic beta cells to interleukin-1Œ≤-induced apoptosis via Bim/A1 imbalance.	XBP1
24029222	10.1016/j.ccr.2013.08.014	2013	Why proteasome inhibitors cannot ERADicate multiple myeloma.	XBP1
24035931	10.1016/j.gene.2013.09.005	2013	Mmu-miR-702 functions as an anti-apoptotic mirtron by mediating ATF6 inhibition in mice.	XBP1
24357799	10.1038/cddis.2013.502	2013	ERO1Œ±-dependent endoplasmic reticulum-mitochondrial calcium flux contributes to ER stress and mitochondrial permeabilization by procaspase-activating compound-1 (PAC-1).	XBP1
22078940	10.1016/j.leukres.2011.10.019	2012	Transcriptional deregulation of homeobox gene ZHX2 in Hodgkin lymphoma.	XBP1
22167754	10.1182/blood-2011-07-363820	2012	Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.	XBP1
22422988	10.1158/0008-5472.CAN-11-3213	2012	Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate.	XBP1
20980528	10.1099/vir.0.025494-0	2011	X-box binding protein 1 induces the expression of the lytic cycle transactivator of Kaposi's sarcoma-associated herpesvirus but not Epstein-Barr virus in co-infected primary effusion lymphoma.	XBP1
21062387	10.1111/j.1349-7006.2010.01765.x	2011	Dominant expression of survival signals of endoplasmic reticulum stress response in Hodgkin lymphoma.	XBP1
21325069	10.1158/1078-0432.CCR-10-2945	2011	Identification of loss of p16 expression and upregulation of MDR-1 as genetic events resulting from two novel chromosomal translocations found in a plasmablastic lymphoma of the uterus.	XBP1
21447826	10.1182/blood-2011-01-332379	2011	Bortezomib induction of C/EBPŒ≤ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma.	XBP1
21468264	10.3346/jkms.2011.26.4.551	2011	Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma.	XBP1
19530237	10.1002/ijc.24655	2010	B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression.	XBP1
19923262	10.1099/vir.0.017277-0	2010	Regulation of the Epstein-Barr virus Zp promoter in B lymphocytes during reactivation from latency.	XBP1
20723265	10.1186/1471-2407-10-445	2010	Resveratrol-induced cytotoxicity in human Burkitt's lymphoma cells is coupled to the unfolded protein response.	XBP1
19176362	10.3324/haematol.2008.001156	2009	Expression pattern of XBP1(S) in human B-cell lymphomas.	XBP1
19380033	10.1016/j.cancergencyto.2009.01.003	2009	A novel missense mutation of the XBP1 gene in diffuse large B-cell lymphoma.	XBP1
19389935	10.2353/ajpath.2009.080848	2009	Activation of the endoplasmic reticulum stress-associated transcription factor x box-binding protein-1 occurs in a subset of normal germinal-center B cells and in aggressive B-cell lymphomas with prognostic implications.	XBP1
19391038	10.1080/10428190902895780	2009	Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells.	XBP1
19403667	10.1128/JVI.00076-09	2009	X-box binding protein 1 contributes to induction of the Kaposi's sarcoma-associated herpesvirus lytic cycle under hypoxic conditions.	XBP1
19717648	10.1182/blood-2009-01-201111	2009	C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells.	XBP1
19846911	NA	2009	Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia.	XBP1
17312329	10.1200/JCO.2006.09.3534	2007	Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.	XBP1
17487741	10.1080/10428190701216360	2007	Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway.	XBP1
17651861	10.1016/j.ejcb.2007.05.006	2007	IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells.	XBP1
17928342	10.1128/JVI.01663-07	2007	X box binding protein XBP-1s transactivates the Kaposi's sarcoma-associated herpesvirus (KSHV) ORF50 promoter, linking plasma cell differentiation to KSHV reactivation from latency.	XBP1
16396777	10.1080/10428190500312196	2006	Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells.	XBP1
16418334	10.1182/blood-2005-03-0897	2006	Gene expression and angiotropism in primary CNS lymphoma.	XBP1
16782810	10.1073/pnas.0603728103	2006	Gene expression patterns define novel roles for E47 in cell cycle progression, cytokine-mediated signaling, and T lineage development.	XBP1
16102574	10.1016/S0065-2776(05)87005-1	2005	The biology of human lymphoid malignancies revealed by gene expression profiling.	XBP1
12200383	10.1182/blood-2002-01-0008	2002	A molecular compendium of genes expressed in multiple myeloma.	XBP1
34265801	10.1097/PAS.0000000000001780	2022	Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation.	XPO1
34493477	10.1016/j.clml.2021.07.017	2022	Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.	XPO1
35014928	10.1080/10428194.2021.2020779	2022	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.	XPO1
35078739	10.1016/j.clml.2021.12.016	2022	Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.	XPO1
35263209	10.1080/10428194.2022.2047674	2022	Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor - a retrospective, single center study.	XPO1
35361554	10.1016/j.clml.2022.01.014	2022	Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.	XPO1
35367710	10.1016/j.ejmech.2022.114257	2022	Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells.	XPO1
35432603	10.1177/17588359221087555	2022	A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies.	XPO1
35477814	10.1007/s10637-022-01250-6	2022	Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia.	XPO1
35489384	10.1016/j.yexcr.2022.113180	2022	Prognostic and therapeutic significance of XPO1 in T-cell lymphoma.	XPO1
35668193	10.1038/s43018-022-00394-x	2022	P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.	XPO1
36001451	10.1097/PAS.0000000000001956	2022	Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.	XPO1
32079702	10.3324/haematol.2019.237719	2021	Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study.	XPO1
32961552	10.1182/blood.2020007507	2021	Mutational landscape of gray zone lymphoma.	XPO1
32972802	10.1016/j.blre.2020.100758	2021	Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.	XPO1
33173198	10.1038/s41571-020-00442-4	2021	The nuclear export protein XPO1 - from biology to targeted therapy.	XPO1
33263441	10.1080/17474086.2021.1856652	2021	Development of molecular intervention strategies for B-cell lymphoma.	XPO1
33563902	10.1038/s41408-021-00409-3	2021	XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis.	XPO1
33785483	10.1158/1078-0432.CCR-20-4929	2021	Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.	XPO1
33928519	10.1007/s40262-021-01016-y	2021	Pharmacokinetics of Selinexor: The First-in-Class Selective Inhibitor of Nuclear Export.	XPO1
33959502	10.3389/fonc.2021.638897	2021	c-Rel Is the Pivotal NF-Œ∫B Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.	XPO1
34051651	10.1016/j.jchromb.2021.122781	2021	Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS.	XPO1
34405005	10.7150/jca.60390	2021	Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.	XPO1
34669417	10.1021/acs.jmedchem.1c01145	2021	Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor.	XPO1
34926302	10.3389/fonc.2021.785635	2021	Selinexor Enhances NK Cell Activation Against Malignant B Cells <i>via</i> Downregulation of HLA-E.	XPO1
31789821	10.1097/PAI.0000000000000820	2020	EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas.	XPO1
31822802	10.1038/s41379-019-0428-0	2020	Diagnostic utility of STAT6<sup>YE361</sup> expression in classical Hodgkin lymphoma and related entities.	XPO1
31847605	10.1080/13543784.2020.1706087	2020	Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL).	XPO1
31885322	10.1080/15384101.2019.1706903	2020	The double dealing of cyclin D1.	XPO1
32045477	10.1182/bloodadvances.2019000359	2020	Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies.	XPO1
32527129	10.21037/apm-19-430b	2020	Glans metastatic extra-nodal natural killer/T-cell lymphoma, nasal-type with HDAC inhibitor as maintenance therapy: a rare case report with literature review.	XPO1
32536290	10.1080/10428194.2020.1775210	2020	Selinexor for advanced hematologic malignancies.	XPO1
32565964	10.3892/ol.2020.11552	2020	Comprehensive characterization of driver genes in diffuse large B cell lymphoma.	XPO1
32691208	10.1007/s11060-020-03580-y	2020	Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition.	XPO1
32826328	10.1158/1078-0432.CCR-20-1315	2020	The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia.	XPO1
33007990	10.3390/cancers12102829	2020	<i>XPO1</i><sup>E571K</sup> Mutation Modifies Exportin 1 Localisation and Interactome in B-cell Lymphoma.	XPO1
33148342	10.1186/s13045-020-00982-3	2020	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.	XPO1
33154951	10.3389/fonc.2020.591577	2020	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	XPO1
33202794	10.3390/ijms21228553	2020	Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.	XPO1
33224395	10.14740/jh760	2020	Molecular Genetic Analysis With Flow Cytometry Sorting Identifies Angioimmunoblastic T-Cell Lymphoma and Concomitant <i>De Novo</i> Myelodysplastic Syndrome Arising From the Same Hematopoietic Progenitor.	XPO1
30108156	10.1634/theoncologist.2018-0058	2019	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.	XPO1
30211726	10.1097/PAS.0000000000001154	2019	Cyclin D1-positive Mediastinal Large B-Cell Lymphoma With Copy Number Gains of CCND1 Gene: A Study of 3 Cases With Nonmediastinal Disease.	XPO1
30548996	10.1002/hon.2570	2019	Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma.	XPO1
31125526	10.1080/17474086.2019.1624158	2019	Novel targets for the treatment of relapsing multiple myeloma.	XPO1
31296529	10.1158/1078-0432.CCR-19-0273	2019	EŒº-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.	XPO1
31543372	10.1016/j.clml.2019.08.011	2019	Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies.	XPO1
31752970	10.1186/s13045-019-0803-9	2019	Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma.	XPO1
31816062	10.1182/bloodadvances.2019001012	2019	Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion.	XPO1
31850145	10.2217/ijh-2019-0009	2019	Rational targeted therapeutics for double-hit lymphoma.	XPO1
28750570	10.1080/10428194.2017.1349899	2018	Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.	XPO1
29501729	10.1016/j.cellsig.2018.02.016	2018	STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma.	XPO1
29610030	10.1016/j.clml.2018.03.003	2018	Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.	XPO1
29650799	10.1182/blood-2017-11-814913	2018	Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.	XPO1
29653964	10.1182/blood-2017-09-806679	2018	TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.	XPO1
29989027	10.18632/oncotarget.25601	2018	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	XPO1
30510142	10.1158/1535-7163.MCT-17-0789-ATR	2018	XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IŒ∫B.	XPO1
31949642	NA	2018	Expression of exportin-1 in diffuse large B-cell lymphoma: immunohistochemistry and TCGA analyses.	XPO1
27780859	10.1158/1078-0432.CCR-16-1580	2017	The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.	XPO1
28196522	10.1186/s13045-017-0412-4	2017	XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy.	XPO1
28388555	10.18632/oncotarget.16602	2017	Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1.	XPO1
28468797	10.1182/blood-2016-11-750174	2017	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.	XPO1
26608593	10.1002/gcc.22328	2016	Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.	XPO1
26819451	10.1158/1078-0432.CCR-15-2305	2016	Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.	XPO1
26883583	10.3109/10428194.2016.1139703	2016	Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.	XPO1
27312795	10.1002/ajh.24451	2016	Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.	XPO1
27479820	10.3324/haematol.2016.145102	2016	Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.	XPO1
27693556	10.1016/j.canlet.2016.09.016	2016	Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.	XPO1
25466285	10.1016/j.leukres.2014.10.003	2015	CRM1 as a new therapeutic target for non-Hodgkin lymphoma.	XPO1
25951043	10.1080/15548627.2015.1017192	2015	The role of STAT3 in autophagy.	XPO1
26340096	10.1371/journal.pone.0137210	2015	Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.	XPO1
26501108	10.1016/j.ebiom.2015.07.041	2015	Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.	XPO1
24503695	10.1371/journal.pone.0087585	2014	Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.	XPO1
24766216	10.1111/cas.12430	2014	Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.	XPO1
25377562	10.1182/blood-2014-04-567636	2014	Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL.	XPO1
23373539	10.1111/bjh.12231	2013	KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.	XPO1
23970380	10.1182/blood-2013-04-495374	2013	Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.	XPO1
24159164	10.1182/blood-2013-09-523670	2013	Redirecting traffic using the XPO1 police.	XPO1
18246793	NA	2007	[Expression and relationship of p27(kip1) and its related molecules Jab1 and CRM1 during proliferation of lymphoma cells U937].	XPO1
29913212	10.1016/j.cellsig.2018.05.009	2018	Pharmacological inhibition of MALT1 protease activity suppresses endothelial activation via enhancing MCPIP1 expression.	ZC3H12A
26728103	10.1089/AID.2015.0343	2016	Short Communication: Preferential Killing of HIV Latently Infected CD4(+) T Cells by MALT1 Inhibitor.	ZC3H12A
24415781	10.4049/jimmunol.1301619	2014	Posttranscriptional modulation of cytokine production in T cells for the regulation of excessive inflammation by TFL.	ZC3H12A
23706741	10.1016/j.cell.2013.04.034	2013	Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation.	ZC3H12A
29545328	10.1182/blood-2017-11-817601	2018	Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.	ZFP36L1
28142295	10.1080/10428194.2017.1283029	2017	Identification of a tumor suppressor network in T-cell leukemia.	ZFP36L1
20622884	10.1038/ni.1901	2010	Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia.	ZFP36L1
11156427	NA	2000	Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.	ZFP36L1
9191350	10.1042/bst025306s	1997	Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signalling through CD40 and interleukin-4 receptor: role for inhibition of an early response gene, Berg36.	ZFP36L1
8898945	10.1002/eji.1830261013	1996	Distinct mechanisms for rescue from apoptosis in Ramos human B cells by signaling through CD40 and interleukin-4 receptor: role for inhibition of an early response gene, Berg36.	ZFP36L1
34997652	10.1111/ejh.13736	2022	Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.	ZNF292
